PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	ELHAYEK, R; LOKUTA, AJ; AREVALO, C; VALDIVIA, HH				ELHAYEK, R; LOKUTA, AJ; AREVALO, C; VALDIVIA, HH			PEPTIDE PROBE OF RYANODINE RECEPTOR FUNCTION - IMPERATOXIN-A, A PEPTIDE FROM THE VENOM OF THE SCORPION PANDINUS-IMPERATOR, SELECTIVELY ACTIVATES SKELETAL-TYPE RYANODINE RECEPTOR ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM RELEASE CHANNEL; CA-2+ RELEASE; CA2+ RELEASE; CARDIAC-MUSCLE; ADENINE-NUCLEOTIDE; MOLECULAR-CLONING; BINDING; MECHANISM; CAFFEINE	We have used [H-3]ryanodine binding experiments and single channel recordings to provide convergent descriptions of the effect of imperatoxin A (IpTx(a)), a similar to 5-kDa peptide from the venom of the scorpion Pandinus imperator (Valdivia, H. H., Kirby, M. S., Lederer, W. J., and Coronado, R. (1992) Proc. Ntl, Acad. Sc. U.S.A. 89, 12185-12189) on Ca2+ release channels/ryanodine receptors (RyR) of sarcoplasmic reticulum (SR). At nanomolar concentrations, IpTx(a) increased the binding of [H-3]ryanodine to skeletal SR and, to a lesser extent, to cerebellum microsomes. The activating effect of IpTx(a) on skeletal SR was Ca2+-dependent, synergized by caffeine, and independent of other modulators of RyRs. However, IpTx(a) had negligible effects on tissues where the expression of skeletal-type RyR isoforms (RyR1) is small or altogether absent, i.e. cardiac, cerebrum, and liver microsomes. Thus, IpTx(a) may be used as a ligand capable of discriminating between RyR isoforms with nanomolar affinity, IpTx(a) increased the open probability (P-o) of rabbit skeletal muscle RyRs by increasing the frequency of open events and decreasing the duration of the closed lifetimes. This activating effect was dose-dependent (ED(50) = 10 mM), had a fast onset, and was fully reversible, Purified RyR from solubilized skeletal SR displayed high affinity for [H-3]ryanodine with a K-D of 6.1 nM and B-max of similar to 30 pmol/mg of protein. IpTx(a) increased [H-3]ryanodine binding noncompetitively by increasing B-max to similar to 60 pmol/mg of protein. These results suggested the presence of an IpX(a)-binding site on the RyR or a closely associated regulatory protein, This site appears to be distinct from the caffeine- and adenine nucleotide-regulatory sites, IpTx(a) may prove a useful tool to identify regulatory domains critical for channel gating and to dissect the contribution of skeletal-type RyRs to intracellular Ca2+ waveforms generated by stimulation of different RyR isoforms.	UNIV WISCONSIN,SCH MED,DEPT PHYSIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								BERS DM, 1991, EXCITATION CONTRACTI; BUCK E, 1992, J BIOL CHEM, V267, P23560; BULL R, 1989, BIOPHYS J, V56, P749, DOI 10.1016/S0006-3495(89)82722-5; CHENG HP, 1995, SCIENCE, V267, P2009, DOI 10.1126/science.7701326; CHU A, 1993, J MEMBRANE BIOL, V135, P49; CHU A, 1990, MOL PHARMACOL, V37, P735; CORONADO R, 1994, AM J PHYSIOL, V35, pC1485; DIAZMUNOZ M, 1990, J BIOL CHEM, V265, P15894; ELHAYEK R, 1993, BIOPHYS J, V65, P779, DOI 10.1016/S0006-3495(93)81101-9; ELLISMAN MH, 1990, NEURON, V5, P135, DOI 10.1016/0896-6273(90)90304-X; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; FILL M, 1990, BIOPHYS J, V60, P471; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HAIN J, 1994, BIOPHYS J, V67, P1823, DOI 10.1016/S0006-3495(94)80664-2; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HERRMANNFRANK A, 1991, PFLUG ARCH EUR J PHY, V418, P353, DOI 10.1007/BF00550873; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P15637; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KNOX BE, 1986, P NATL ACAD SCI USA, V83, P2345, DOI 10.1073/pnas.83.8.2345; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LAMB GD, 1993, J MUSCLE RES CELL M, V14, P554, DOI 10.1007/BF00141551; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LINDSAY ARG, 1994, J GEN PHYSIOL, V104, P425, DOI 10.1085/jgp.104.3.425; MCGARRY SJ, 1994, J MEMBRANE BIOL, V137, P169; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; OTSU K, 1990, J BIOL CHEM, V265, P13472; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; PESSAH IN, 1990, MOL PHARMACOL, V37, P503; RARDON DP, 1992, ADV EXP MED BIOL, V311, P405; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; SABBADINI RA, 1992, J BIOL CHEM, V267, P15475; SEINO A, 1991, J PHARMACOL EXP THER, V256, P861; SHOSHANBARMATZ V, 1990, BIOCHEM J, V268, P699, DOI 10.1042/bj2680699; SMITH JS, 1989, J GEN PHYSIOL, V92, P1; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; VALDIVIA HH, 1991, J BIOL CHEM, V266, P19135; VALDIVIA HH, 1992, P NATL ACAD SCI USA, V89, P12185, DOI 10.1073/pnas.89.24.12185; VALDIVIA HH, 1994, J BIOCHEM, V116, P1383, DOI 10.1093/oxfordjournals.jbchem.a124691; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; VALDIVIA HH, 1991, AM J PHYSIOL, V261, pC237, DOI 10.1152/ajpcell.1991.261.2.C237; VALDIVIA HH, 1994, BIOPHYS J, V66, pA418; XU L, 1994, P NATL ACAD SCI USA, V91, P3294, DOI 10.1073/pnas.91.8.3294; ZORZATO F, 1990, J BIOL CHEM, V265, P2244; ZYMANYI I, 1991, J PHARMACOL EXP THER, V256, P938	50	77	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28696	28704		10.1074/jbc.270.48.28696	http://dx.doi.org/10.1074/jbc.270.48.28696			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499390	hybrid			2022-12-27	WOS:A1995TH05600034
J	JOHNSTON, JA; WANG, LM; HANSON, EP; SUN, XJ; WHITE, MF; OAKES, SA; PIERCE, JH; OSHEA, JJ				JOHNSTON, JA; WANG, LM; HANSON, EP; SUN, XJ; WHITE, MF; OAKES, SA; PIERCE, JH; OSHEA, JJ			INTERLEUKIN-2, INTERLEUKIN-4, INTERLEUKIN-7, AND INTERLEUKIN-15 STIMULATE TYROSINE PHOSPHORYLATION OF INSULIN-RECEPTOR SUBSTRATE-1 AND SUBSTRATE-2 IN T-CELLS - POTENTIAL ROLE OF JAK KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IL-2 RECEPTOR; GAMMA-CHAIN	The signaling molecules insulin receptor substrate (IRS)-1 and the newly described IRS-2 (4PS) molecule are major insulin and interleukin 4 (IL-4)-dependent phosphoproteins. We report here that IL-2, IL-7, and IL-15, as well as IL-4, rapidly stimulate the tyrosine phosphorylation of IRS-1 and IRS-2 in human peripheral blood T cells, NK cells, and in lymphoid cell lines. In addition, we show that the Janus kinases, JAK1 and JAK3, associate with IRS-1 and IRS-2 in T cells. Coexpression studies demonstrate that these kinases can tyrosine-phosphorylate IRS-2, suggesting a possible mechanism by which cytokine receptors may induce the tyrosine phosphorylation of IRS-1 and IRS-2. We further demonstrate that the p85 subunit of phosphoinositol 3-kinase associates with IRS-1 in response to IL-2 and IL-4 in T cells. Therefore, these data indicate that IRS-1 and IRS-2 may have important roles in T lymphocyte activation not only in response to IL-4, but also in response to IL-2, IL-7, and IL-15.	NCI,CELL & MOLEC BIOL LAB,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02115; NIH,HOWARD HUGHES MED INST,RES SCHOLARS PROGRAM,BETHESDA,MD 20814	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA	JOHNSTON, JA (corresponding author), NIAMS,ARTHRIT & RHEUMATISM BRANCH,LYMPHOCYTE CELL BIOL SECT,BLDG 10,ROOM 9N262,BETHESDA,MD 20892, USA.		Hanson, Eric/AAE-5511-2022	Hanson, Eric/0000-0002-0318-4779				ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; AUSUBEL FM, 1992, SHORT PROTOCOLS MOL, P97; BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; FERRIS DK, 1989, J IMMUNOL, V143, P870; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5282; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MERIDA I, 1991, J IMMUNOL, V147, P2202; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; PAUL WE, 1991, BLOOD, V77, P1859; RIDDERSTRALE M, 1994, J BIOL CHEM, V270, P3471; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7218; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; WANG LM, 1995, STEM CELLS, V13, P360, DOI 10.1002/stem.5530130407; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 1994, J BIOL CHEM, V269, P1; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YIN T, 1994, J BIOL CHEM, P26614; ZHU XY, 1994, J BIOL CHEM, V269, P5518	37	128	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28527	28530		10.1074/jbc.270.48.28527	http://dx.doi.org/10.1074/jbc.270.48.28527			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499365	hybrid			2022-12-27	WOS:A1995TH05600009
J	NEWTON, AC				NEWTON, AC			PROTEIN-KINASE-C - STRUCTURE, FUNCTION, AND REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MYELIN BASIC-PROTEIN; SUBSTRATE-SPECIFICITY; RAT-BRAIN; CATALYTIC SUBUNIT; PHORBOL ESTERS; ACTIVATION; CALCIUM; BINDING; AUTOPHOSPHORYLATION; PHOSPHATIDYLSERINE				NEWTON, AC (corresponding author), UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA.				NIGMS NIH HHS [GM 43154] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043154, R01GM043154] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BELL RM, 1991, J BIOL CHEM, V266, P4661; BORNER C, 1989, J BIOL CHEM, V264, P13902; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; CONRAD R, 1994, J BIOL CHEM, V269, P32051; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; ELLER M, 1993, J BIOCHEM-TOKYO, V114, P177, DOI 10.1093/oxfordjournals.jbchem.a124151; EPAND RM, 1990, TRENDS PHARMACOL SCI, V11, P317, DOI 10.1016/0165-6147(90)90234-Y; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; GODSON C, 1993, J BIOL CHEM, V268, P11946; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; HOUSE C, 1987, J BIOL CHEM, V262, P772; HOUSE C, 1994, SCIENCE, V2, P345; HUANG KP, 1986, J BIOL CHEM, V261, P2134; HUBBARD SR, 1991, SCIENCE, V254, P1776; INOUE M, 1977, J BIOL CHEM, V252, P7610; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P14679, DOI 10.1074/jbc.270.24.14679; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KERANEN LM, 1995, IN PRESS CURR BIOL; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; KWON YG, 1994, J BIOL CHEM, V269, P4839; LEVENTHAL PS, 1993, J BIOL CHEM, V268, P13906; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; MOSIOR M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P185, DOI 10.1016/0005-2736(92)90178-O; MOSIOR M, 1994, J BIOL CHEM, V269, P13798; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NEWTON AC, 1994, BIOPHYS J, V66, pA344; NEWTON AC, 1987, J BIOL CHEM, V262, P10185; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OBRIAN CA, 1984, BIOCHEM BIOPH RES CO, V124, P296, DOI 10.1016/0006-291X(84)90951-3; OBRIAN CA, 1991, BIOCHEMISTRY-US, V30, P2549, DOI 10.1021/bi00223a036; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ORR JW, 1994, J BIOL CHEM, V269, P27715; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; QUEST AFG, 1994, J BIOL CHEM, V269, P20000; RANDO RR, 1992, BIOCHEMISTRY-US, V31, P2211, DOI 10.1021/bi00123a001; SANDO JJ, 1992, CELL SIGNAL, V4, P595, DOI 10.1016/0898-6568(92)90041-6; SOSSIN WS, 1993, TRENDS BIOCHEM SCI, V18, P207, DOI 10.1016/0968-0004(93)90189-T; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TSUTAKAWA SE, 1995, IN PRESS J BIOL CHEM; TURNER RS, 1985, J BIOL CHEM, V260, P1503; WALKER JM, 1988, J BIOL CHEM, V263, P4537; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937; WILKINSON SE, 1994, TRENDS PHARMACOL SCI, V15, P53, DOI 10.1016/0165-6147(94)90110-4; WOLF M, 1985, NATURE, V317, P546, DOI 10.1038/317546a0; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	77	1415	1485	1	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28495	28498		10.1074/jbc.270.43.25526	http://dx.doi.org/10.1074/jbc.270.43.25526			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499357	hybrid			2022-12-27	WOS:A1995TH05600001
J	TAMURA, S; NELSON, H; TAMURA, A; NELSON, N				TAMURA, S; NELSON, H; TAMURA, A; NELSON, N			SHORT EXTERNAL LOOPS AS POTENTIAL SUBSTRATE-BINDING SITE OF GAMMA-AMINOBUTYRIC-ACID TRANSPORTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN GABA TRANSPORTER; RAT-BRAIN; MOUSE-BRAIN; EXPRESSION; CLONING; PERMEASE	While the gamma-aminobutyric acid (GABA) transporter GAT1 exclusively transports GABA, GAT2, -3, and 4 also transport beta-alanine, Cross-mutations in the external loops IV, V, and VI among the various GABA transporters were performed by site-directed mutagenesis. The affinity of GABA transport as well as inhibitor sensitivity of the modified transporters was analyzed, Kinetic analysis revealed that a cross-mutation in which loop IV of GAT1 was modified to resemble GAT4 resulted in increased affinity to GABA from K-m = 8.7 to 2.0 mu M without changing the V-max. A cross mutation in loop VI, which swapped the amino acid sequence of GATE for GAT1, decreased the affinity to GABA (K-m, 35 mu M). These results suggest that loops TV and VI contribute to the binding affinity of GABA transporters, A substitution of three amino acids in loop V of GAT1 by the corresponding sequence of GAT3 resulted in beta-alanine sensitivity of its GABA uptake activity, These three amino acids in loop V seem to participate in the beta-alanine binding domain of GAT3. It is suggested that those three external loops (IV, V, and VI) form a pocket in which the substrate binds to the GABA transporters.	ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110; TEL AVIV UNIV,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL	Roche Holding; Tel Aviv University								AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; GIROS B, 1994, J BIOL CHEM, V269, P15985; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IVERSEN LL, 1975, BIOCHEM PHARMACOL, V24, P933, DOI 10.1016/0006-2952(75)90422-0; JURSKY F, 1994, J EXP BIOL, V196, P283; Kanner BI, 1989, CURR OPIN CELL BIOL, V1, P735, DOI 10.1016/0955-0674(89)90042-2; KANNER BI, 1990, P NATL ACAD SCI USA, V87, P2550, DOI 10.1073/pnas.87.7.2550; KLEINBERGERDORO.N, 1994, J BIOL CHEM, V269, P3063; LIU QR, 1993, J BIOL CHEM, V268, P2106; LOPEZCORCUERA B, 1992, J BIOL CHEM, V267, P17491; MARTIN D, 1976, GABA NERVOUS SYSTEM, P357; NELSON H, 1990, FEBS LETT, V269, P181, DOI 10.1016/0014-5793(90)81149-I; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; PUTTNER IB, 1988, P NATL ACAD SCI USA, V85, P1467, DOI 10.1073/pnas.85.5.1467; RADIAN R, 1990, J NEUROSCI, V10, P1319; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VANIWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595, DOI 10.1021/bi00104a005; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; WRIGHT EM, 1994, J EXP BIOL, V196, P197	24	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28712	28715		10.1074/jbc.270.48.28712	http://dx.doi.org/10.1074/jbc.270.48.28712			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499392	hybrid			2022-12-27	WOS:A1995TH05600036
J	HARUTA, T; MORRIS, AJ; ROSE, DW; NELSON, JG; MUECKLER, M; OLEFSKY, JM				HARUTA, T; MORRIS, AJ; ROSE, DW; NELSON, JG; MUECKLER, M; OLEFSKY, JM			INSULIN-STIMULATED GLUT4 TRANSLOCATION IS MEDIATED BY A DIVERGENT INTRACELLULAR SIGNALING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLUCOSE-TRANSPORT; PLASMA-MEMBRANE; PROTEIN; RECEPTOR; PHOSPHORYLATION; ACTIVATION; MECHANISM; ONCOGENE; CELLS	Insulin stimulates glucose transport largely by mediating translocation of the insulin-sensitive glucose transporter (GLUT4) from an intracellular compartment to the plasma membrane. Using single cell microinjection of 3T3-L1 adipocytes, coupled with immunofluorescence detection of GLUT4 proteins, we have determined that inhibition of endogenous p21(ras) or injection of oncogenic p21(ras) has no effect on insulin-stimulated GLUT4 translocation. On the other hand, micro injection of anti-phosphotyrosine antibodies or inhibition of endogenous phosphatidylinositol 3-kinase by microinjection of a GST-p85 SH2 fusion protein markedly inhibits this biologic effect of insulin. These data suggest that the p21(ras)/mitogen-activated protein kinase pathway is not involved in this metabolic effect of insulin, whereas tyrosine phosphorylation and stimulation of phosphatidylinositol 3-kinase activity are critical components of this signaling pathway.	UNIV CALIF SAN DIEGO, DEPT MED 0673, LA JOLLA, CA 92093 USA; WASHINGTON UNIV, DEPT MED, ST LOUIS, MO 63110 USA; VET ADM RES SERV, SAN DIEGO, CA 92161 USA	University of California System; University of California San Diego; Washington University (WUSTL)			Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R01DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FINGAR DC, 1994, ENDOCRINOLOGY, V134, P728, DOI 10.1210/en.134.2.728; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; HELLERHARRISON R, 1995, DIABETES S1, V44, P31; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JHUN BH, 1994, J BIOL CHEM, V269, P5699; JHUN BH, 1994, MOL CELL BIOL, V14, P7486; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANCHESTER J, 1994, P NATL ACAD SCI USA, V91, P4644, DOI 10.1073/pnas.91.11.4644; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; OKADA T, 1994, J BIOL CHEM, V269, P3568; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; OLEFSKY JM, 1994, ELLENBERG RIFKINS DI, P121; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; REUSCH JEB, 1995, J BIOL CHEM, V270, P2036, DOI 10.1074/jbc.270.5.2036; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; STACEY DW, 1991, ONCOGENE, V6, P2297; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDENBERGHE N, 1994, MOL CELL BIOL, V14, P2372, DOI 10.1128/MCB.14.4.2372; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; XIAO S, 1994, J BIOL CHEM, V269, P21244	38	132	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					27991	27994						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499278				2022-12-27	WOS:A1995TG21000003
J	KATAGIRI, T; OGIMOTO, M; HASEGAWA, K; MIZUNO, K; YAKURA, H				KATAGIRI, T; OGIMOTO, M; HASEGAWA, K; MIZUNO, K; YAKURA, H			SELECTIVE REGULATION OF LYN TYROSINE KINASE BY CD45 IN IMMATURE B-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LEUKOCYTE-COMMON ANTIGEN; PROTEIN-KINASE; LYMPHOCYTES-B; PHOSPHOTYROSINE PHOSPHATASE; MEMBRANE IMMUNOGLOBULIN; PHOSPHORYLATION; ACTIVATION; RECEPTOR; ASSOCIATION; EXPRESSION	It has been well established that protein-tyrosine phosphatase CD45 is critically involved in the regulation of initial tyrosine phosphorylation and effector functions of T and B cells, However, the signaling pathway governed by CD45 is not completely understood. In B cells, it has not been unequivocally resolved as to which protein-tyrosine kinases (PTKs) associated with B cell antigen receptor are regulated by CD45 in intact cells. As a first step toward the elucidation of CD45-initiated signaling events, we have tried to identify physiological substrates for CD45 by analyzing PTK activity in CD45-deficient clones recently generated from the immature B cell line WEHI-231. The results clearly demonstrated that among PTKs examined (Lyn, Lck, and Syk), only Lyn kinase is dysregulated in the absence of CD45 such that without B cell antigen receptor ligation, Lyn is hyperphosphorylated and activated in CD45-negative clones. Thus, Lyn seems to be a selective in vivo substrate for CD45 in immature B cells.	TOKYO METROPOLITAN INST NEUROSCI, DEPT MICROBIOL & IMMUNOL, FUCHU, TOKYO 183, JAPAN	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science								BIFFEN M, 1994, EMBO J, V13, P1920, DOI 10.1002/j.1460-2075.1994.tb06461.x; BROWN VK, 1994, J BIOL CHEM, V269, P17238; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BURNS CM, 1994, J BIOL CHEM, V269, P13594; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOLD MR, 1994, J IMMUNOL, V152, P42; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, ONCOGENE, V5, P809; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; OGIMOTO M, 1995, EUR J IMMUNOL, V25, P2265, DOI 10.1002/eji.1830250823; OGIMOTO M, 1994, INT IMMUNOL, V6, P647, DOI 10.1093/intimm/6.4.647; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WECHSLER RJ, 1995, J IMMUNOL, V154, P1919; YAKURA H, 1994, CRIT REV IMMUNOL, V14, P311, DOI 10.1615/CritRevImmunol.v14.i3-4.50; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YAO XR, 1993, IMMUNOL REV, V132, P163, DOI 10.1111/j.1600-065X.1993.tb00842.x	44	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					27987	27990						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499277				2022-12-27	WOS:A1995TG21000002
J	MEZNA, M; MICHELANGELI, F				MEZNA, M; MICHELANGELI, F			ALKALI-METAL ION DEPENDENCE OF INOSITOL 1,4,5-TRISPHOSPHATE-INDUCED CALCIUM-RELEASE FROM RAT CEREBELLAR MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILIZED HEPATOCYTES; CHANNEL BLOCKERS; CA-2+ RELEASE; TRISPHOSPHATE; RECEPTOR; TRANSPORT; RETICULUM; KINETICS; EXCHANGE; STORES	The effects of the alkali metal ions Na+, K+, Rb+, and Cs+ on ATP dependent Ca2+ uptake, [H-3]Inositol 1,4,5-trisphosphate (InsP(3)) binding, and quantal InsP(3)-induced Ca2+ release were investigated using rat cerebellar microsomes. Both the ion species and concentration affected the ability of the microsomes to support Ca2+ uptake with K+ being most effective (3.8 nmol of Ca2+/min/mg at 100 mM K+), The order of efficacy of the other ions was as follows: K+ > Na+ > Rb+ = Cs+ much greater than Li+. The binding of [H-3]InsP(3) to cerebellar microsomes was, however, affected little by the presence of these ions, All these alkali metal ions (except Li+) supported InsP(3) induced Ca2+ release at concentrations above 25 mM; however, the extent of Ca2+ release (expressed as a percent Ca2+ release compared with that released by the ionophore A23187) was dependent upon the ion species present. Again K+ was more potent than the other ions at facilitating InsP(3)-induced Ca2+ release (order of efficacy: K+ > Rb+ > Na+ > Cs+), although the concentration of InsP(3) required to induce half-maximal Ca2+ release (IC50) was not significantly altered, Over the ion concentration range tested (25-100 mM), the extent of InsP(3)-induced Ca2+ release with both K+ and Rb+ increased in a linear fashion, while Na+ showed only a slight increase and Cs+ showed no increase over this range. The effect of K+ concentration on quantal Ca2+ release was to alter the extent of release rather than the IC50 InsP(3) concentration, Using stopped-flow techniques, the effects of InsP(3) and K+ concentrations on the kinetics of InsP(3)-induced Ca2+ release were shown to exhibit a monoexponential process in this microsomal preparation. The rate constants for Ca2+ release increased with InsP(3) concentration (0.11 s(-1) at 0.02 mu M InsP(3) to 0.5 s(-1) at 40 mu M InsP(3)); however, the relationship between the fractional extent of release and rate constants for release did not change in a similar way with InsP, concentration. Although the fractional extent of Ca2+ release increased with K+ concentration, the rate constants for release over this K+ concentration range were unaffected. This observation leads us to question the role of K+ as a counter ion required for Ca2+ release, and we therefore postulate a role for K+ (and the other alkali metal ions) as a ''co-factor'' required for channel opening.	UNIV BIRMINGHAM, SCH BIOCHEM, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND	University of Birmingham								BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BROWN GR, 1992, BIOCHEM J, V282, P309, DOI 10.1042/bj2820309; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; FABIATO A, 1980, METHOD ENZYMOL, V157, P378; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HANNAERTMERAH Z, 1994, J BIOL CHEM, V269, P29642; HIROSE K, 1994, NATURE, V372, P791; JOSEPH SK, 1986, J BIOL CHEM, V261, P4658; KAO JPY, 1989, J BIOL CHEM, V264, P8179; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MAYRLEITNER M, 1991, CELL CALCIUM, V12, P505, DOI 10.1016/0143-4160(91)90032-A; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEZNA M, 1995, NATURE, V376, P300, DOI 10.1038/376300a0; MEZNA M, 1995, BIOCHEM SOC T, V23, pS428, DOI 10.1042/bst023428s; Michelangeli F, 1991, J Fluoresc, V1, P203, DOI 10.1007/BF00865367; MICHELANGELI F, 1995, NEUROPHARMACOLOGY, V34, P1111, DOI 10.1016/0028-3908(95)00053-9; MICHELANGELI F, 1990, BIOCHEM J, V267, P423, DOI 10.1042/bj2670423; MICHELANGELI F, 1993, CELL SIGNAL, V5, P33, DOI 10.1016/0898-6568(93)90005-7; MICHELANGELI F, 1991, BIOCHEM J, V275, P555, DOI 10.1042/bj2750555; MINTA A, 1989, J BIOL CHEM, V264, P8171; MUALLEM S, 1985, P NATL ACAD SCI USA, V82, P4433, DOI 10.1073/pnas.82.13.4433; NAKADE S, 1994, J BIOL CHEM, V269, P6735; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; OROURKE F, 1994, BIOCHEM J, V300, P673, DOI 10.1042/bj3000673; PALADE P, 1989, MOL PHARMACOL, V36, P664; PERRY RJ, 1993, J PHYSIOL-LONDON, V466, P443; POWIS DA, 1991, CELL CALCIUM, V12, P493, DOI 10.1016/0143-4160(91)90031-9; SAYERS LG, 1993, BIOCHIM BIOPHYS ACTA, V1152, P177, DOI 10.1016/0005-2736(93)90245-U; SAYERS LG, 1993, BIOCHEM J, V289, P883, DOI 10.1042/bj2890883; SHAH J, 1988, BIOCHEM J, V250, P617, DOI 10.1042/bj2500617; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678	33	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28097	28102						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499297				2022-12-27	WOS:A1995TG21000022
J	MONIAKIS, J; COUKELL, MB; FORER, A				MONIAKIS, J; COUKELL, MB; FORER, A			MOLECULAR-CLONING OF AN INTRACELLULAR P-TYPE ATPASE FROM DICTYOSTELIUM THAT IS UP-REGULATED IN CALCIUM-ADAPTED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR SLIME-MOLD; CONTRACTILE VACUOLE COMPLEX; PLASMA-MEMBRANE; CYCLIC-AMP; ENDOPLASMIC-RETICULUM; CA-2+ PUMP; DISCOIDEUM; CA-2+-ATPASE; CALMODULIN; GENE	Results from a number of laboratories suggest that intracellular Ca2+ is involved in the regulation of Dictyostelium discoideum growth and development, To learn more about the regulation and function of intracellular Ca2+ in this organism, we have cloned and sequenced cDNAs that encode a putative P-type Ca2+ ATPase designated patA. The deduced protein product of this gene (PAT1) has a calculated molecular mass of 120,718 daltons. It exhibits about 46% amino acid identity with Ca2+ ATPases of the plasma membrane Ca2+ ATPase family and lower identity with sarco(endo)plasmic reticulum Ca2+ ATPase family members and mono valent cation pumps, However, PAT1 lacks the highly conserved calmodulin-binding domain present in the C-terminal region of most plasma membrane Ca2+ ATPase-type enzymes, When Dictyostelium amoebae are adapted to grow in the presence of 80 mM CaCl2, both the patA message and protein product are up-regulated substantially. These cells also exhibit an increase in the rate and magnitude of intracellular P-type Ca2+ uptake activity, Immunofluorescence analysis indicates that PAT1 colocalizes with bound calmodulin to intracellular membranes, probably components of the contractile vacuole complex. The presence of PAT1 on the contractile vacuole suggests that in Dictyostelium this organelle might function in Ca2+ homeostasis as well as in water regulation.	YORK UNIV, DEPT BIOL, N YORK, ON M3J 1P3, CANADA	York University - Canada								ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; BLUMBERG DD, 1989, DIFFERENTIATION, V41, P14, DOI 10.1111/j.1432-0436.1989.tb00727.x; BOHME R, 1987, BIOCHIM BIOPHYS ACTA, V904, P125, DOI 10.1016/0005-2736(87)90093-9; BONNER JT, 1947, J EXP ZOOL, V106, P1, DOI 10.1002/jez.1401060102; BUMANN J, 1984, J CELL BIOL, V98, P173, DOI 10.1083/jcb.98.1.173; Campbell A.K, 1983, INTRACELLULAR CALCIU; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CHEN FH, 1993, PLANT PHYSIOL, V102, P651, DOI 10.1104/pp.102.2.651; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COCUCCI SM, 1970, J CELL BIOL, V45, P399, DOI 10.1083/jcb.45.2.399; COUKELL B, 1995, FEBS LETT, V362, P342, DOI 10.1016/0014-5793(95)00272-B; COUKELL MB, 1990, J CELL SCI, V97, P649; COUKELL MB, 1992, J CELL SCI, V103, P371; COX JA, 1985, J BIOL CHEM, V260, P2527; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; EUROPEFINNER GN, 1984, FEMS MICROBIOL LETT, V21, P21, DOI 10.1111/j.1574-6968.1984.tb00179.x; EUROPEFINNER GN, 1986, BIOCHIM BIOPHYS ACTA, V887, P335, DOI 10.1016/0167-4889(86)90163-1; FIRTEL RA, 1991, TRENDS GENET, V7, P381, DOI 10.1016/0168-9525(91)90260-W; FLAADT H, 1993, J CELL SCI, V105, P1131; FLAADT H, 1993, J CELL SCI, V105, P255; FRANKE J, 1987, DEV BIOL, V124, P504, DOI 10.1016/0012-1606(87)90503-3; HARLOW E, 1988, ANTIBODIES LABORATOR; HEUSER J, 1993, J CELL BIOL, V121, P1311, DOI 10.1083/jcb.121.6.1311; HULEN D, 1991, CELL MOTIL CYTOSKEL, V18, P113, DOI 10.1002/cm.970180206; HUSSAIN A, 1995, J BIOL CHEM, V270, P12140, DOI 10.1074/jbc.270.20.12140; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; JAMES P, 1989, J BIOL CHEM, V264, P8289; JAMIESON GA, 1981, J CELL BIOL, V91, P36; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; Loomis W., 2012, DEV DICTYOSTELIUM DI; LYTTON J, 1989, J BIOL CHEM, V264, P7059; MAEDA Y, 1973, EXP CELL RES, V82, P125, DOI 10.1016/0014-4827(73)90253-X; MAEDA Y, 1970, DEV GROWTH DIFFER, V12, P217; MILNE JL, 1991, J CELL BIOL, V112, P103, DOI 10.1083/jcb.112.1.103; MILNE JL, 1989, EXP CELL RES, V185, P21, DOI 10.1016/0014-4827(89)90033-5; MILNE JL, 1988, BIOCHEM J, V249, P223, DOI 10.1042/bj2490223; MILNE JL, 1993, MOL BIOL CELL, V4, P283, DOI 10.1091/mbc.4.3.283; NOLTA KV, 1993, J CELL SCI, V105, P849; NOLTA KV, 1994, J BIOL CHEM, V269, P2225; O'Day D., 1990, CALCIUM INTRACELLULA; PATTERSON DJ, 1980, BIOL REV, V55, P1, DOI 10.1111/j.1469-185X.1980.tb00686.x; ROONEY EK, 1992, P NATL ACAD SCI USA, V89, P8025, DOI 10.1073/pnas.89.17.8025; ROONEY EK, 1994, CELL CALCIUM, V16, P509, DOI 10.1016/0143-4160(94)90081-7; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sambrook J, 1989, MOL CLONING LABORATO; SCHAAP P, 1986, DEV BIOL, V118, P52, DOI 10.1016/0012-1606(86)90072-2; SCHATZLE J, 1992, J BIOL CHEM, V267, P4000; SCHLESSER A, 1988, J BIOL CHEM, V263, P19480; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; THOMSON LJ, 1993, PLANT PHYSIOL, V102, P553, DOI 10.1104/pp.102.2.553; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V260, P696, DOI 10.1016/0003-9861(88)90498-5; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WELKER DL, 1985, MOL CELL BIOL, V5, P273, DOI 10.1128/MCB.5.2.273; ZHU QL, 1993, J CELL SCI, V104, P1119; ZHU QL, 1992, J CELL BIOL, V118, P347, DOI 10.1083/jcb.118.2.347	61	42	44	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28276	28281						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499325				2022-12-27	WOS:A1995TG21000050
J	DICKINSON, JL; BATES, EJ; FERRANTE, A; ANTALIS, TM				DICKINSON, JL; BATES, EJ; FERRANTE, A; ANTALIS, TM			PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-2 INHIBITS TUMOR-NECROSIS-FACTOR-ALPHA-INDUCED APOPTOSIS - EVIDENCE FOR AN ALTERNATE BIOLOGICAL FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE-SUPEROXIDE-DISMUTASE; FACTOR-MEDIATED CYTOTOXICITY; CYTO-TOXICITY; VIRUS ENCODES; TNF RECEPTOR; UROKINASE; EXPRESSION; CELLS; PROTEASE; INTERLEUKIN-1-BETA	Plasminogen activator inhibitor type 2 (PAI-2) is a serine proteinase inhibitor or serpin that is a major product of macrophages in response to endotoxin and inflammatory cytokines. We have explored the role of PAI-2 in apoptotic cell death initiated by tumor necrosis factor alpha (TNF). HeLa cells stably transfected with PAI-2 cDNA were protected from TNF-induced apoptosis, whereas cells transfected with antisense PAI-2 cDNA, a control gene, or the plasmid vector alone remained susceptible, The level of PAI-2 expressed by different HeLa cell clones was inversely correlated with their sensitivity to TNF. Loss of TNF sensitivity was not a result of loss of TNF receptor binding. In contrast, PAI-2 expression did not confer protection against apoptosis induced by ultraviolet or ionizing radiation. The serine proteinase urokinase-type plasminogen activator was not demonstrated to be the target of PAI-2 action. The P-1-Arg amino acid residue of PAI-2 was determined to be required for protection, because cells expressing PAI-2 with an Ala in this position were not protected from TNF-mediated cell death. The results suggest that intracellular PAI-2 might be an important factor in regulating cell death in TNF-mediated inflammatory processes through inhibition of a proteinase involved in TNF-induced apoptosis.	QUEENSLAND INST MED RES,QUEENSLAND CANC FUND EXPTL ONCOL UNIT,BRISBANE,QLD 4029,AUSTRALIA; WOMENS & CHILDRENS HOSP,DEPT IMMUNOL,ADELAIDE,SA 5006,AUSTRALIA	QIMR Berghofer Medical Research Institute; Womens & Childrens Hospital Australia			Dickinson, Joanne/J-7728-2014	Dickinson, Joanne/0000-0003-4621-1703				ANTALIS TM, 1992, EUR J BIOCHEM, V205, P203, DOI 10.1111/j.1432-1033.1992.tb16769.x; ANTALIS TM, 1988, P NATL ACAD SCI USA, V85, P985, DOI 10.1073/pnas.85.4.985; BOSWELL DR, 1988, BIOESSAYS, V8, P83, DOI 10.1002/bies.950080209; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN RL, 1989, J BIOL CHEM, V264, P8375; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEPETRO G, 1994, EXP CELL RES, V213, P286, DOI 10.1006/excr.1994.1200; DEVRIES TJ, 1994, AM J PATHOL, V144, P70; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FUJII J, 1991, J BIOL CHEM, V266, P23142; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; GOLDER JP, 1984, EUR J BIOCHEM, V139, P253; GYETKO MR, 1992, J LEUKOCYTE BIOL, V51, P256, DOI 10.1002/jlb.51.3.256; HENNET T, 1993, CANCER RES, V53, P1456; HIGUCHI M, 1991, MOL IMMUNOL, V28, P1039; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JENSEN PH, 1994, BRIT J CANCER, V70, P834, DOI 10.1038/bjc.1994.407; KAWANO T, 1970, J BIOCHEM-TOKYO, V67, P333, DOI 10.1093/oxfordjournals.jbchem.a129257; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KETTNER C, 1979, BIOCHIM BIOPHYS ACTA, V569, P31, DOI 10.1016/0005-2744(79)90078-0; KIRCHHEIMER JC, 1987, FASEB J, V1, P125, DOI 10.1096/fasebj.1.2.3038646; KISO U, 1988, FEBS LETT, V230, P51, DOI 10.1016/0014-5793(88)80640-9; KUMAR S, 1991, J BIOL CHEM, V266, P20960; LASTER SM, 1993, J IMMUNOL, V141, P2629; LOMAS DA, 1993, J BIOL CHEM, V268, P516; LYONSGIORDANO B, 1994, HISTOCHEMISTRY, V101, P105, DOI 10.1007/BF00269356; MIURA Y, 1994, J BIOL CHEM, V269, P542; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUIRA M, 1993, CELL, V75, P653; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; OLSSON I, 1993, EUR CYTOKINE NETW, V4, P169; POWERS JC, 1993, PROTEASES PROTEASE I, P3; PYTEL BA, 1990, J CELL PHYSIOL, V144, P416, DOI 10.1002/jcp.1041440308; RAGNO P, 1993, FEBS LETT, V323, P279, DOI 10.1016/0014-5793(93)81357-6; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RUGGIERO V, 1987, CELL IMMUNOL, V107, P317, DOI 10.1016/0008-8749(87)90240-1; SCHERRER A, 1991, LEUKEMIA, V5, P479; SCHLEUNING WD, 1987, MOL CELL BIOL, V12, P4564; SCHWARTZ BS, 1988, BLOOD, V71, P734; SHAW WV, 1984, METHOD ENZYMOL, V43, P2464; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; SMITH DM, 1994, J BIOL CHEM, V269, P9898; SMITH GL, 1989, J GEN VIROL, V70, P2333, DOI 10.1099/0022-1317-70-9-2333; SUFFYS P, 1988, EUR J BIOCHEM, V178, P257, DOI 10.1111/j.1432-1033.1988.tb14451.x; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; SUGARMAN BJ, 1987, CANCER RES, V47, P780; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; Vassalli J D, 1992, Curr Top Microbiol Immunol, V181, P65; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VONHEIJNE G, 1991, J BIOL CHEM, V266, P15240; WALLACH D, 1984, J IMMUNOL, V132, P2464; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILSON KP, 1994, NATURE, V37, P270; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZIEGLERHEITBROC.HW, 1987, INT J CANCER, V41, P456; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	68	221	227	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27894	27904		10.1074/jbc.270.46.27894	http://dx.doi.org/10.1074/jbc.270.46.27894			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499264	hybrid			2022-12-27	WOS:A1995TE73600075
J	JUCKER, M; FELDMAN, RA				JUCKER, M; FELDMAN, RA			IDENTIFICATION OF A NEW ADAPTER PROTEIN THAT MAY LINK THE COMMON BETA-SUBUNIT OF THE RECEPTOR FOR GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR, INTERLEUKIN (IL)-3, AND IL-5 TO PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; GM-CSF RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; SH2 DOMAIN; DEPENDENT TRANSFORMATION; EXPRESSION CLONING; CELLULAR PROTEINS; HIGH-AFFINITY; BINDING	Binding of human granulocyte/macrophage colony-stimulating factor (hGM-CSF) to its receptor induces the rapid activation of phosphatidylinositol-3 kinase (PI 3-kinase). As hGM-CSF receptor (hGMR) does not contain a consensus sequence for binding of PI 3-kinase, hGMR must use a distinct mechanism for its association with and activation of PI 3-kinase. Here, we describe the identification of a tyrosine phosphorylated protein of 76-85 kDa (p80) that associates with the common beta subunit of hGMR and with the SH2 domains of the p85 subunit of PI 3-kinase in hGM-CSF stimulated cells. Src/Yes and Lyn were tightly associated with the p80 PI 3-kinase complex, suggesting that p80 and other phosphotyrosyl proteins present in the complex were phosphorylated by Src family kinases. Tyrosine phosphorylation of p80 was only detected in hGM-CSF or human interleukin-3-stimulated cells, suggesting that activation of p80 might be specific for signaling via the common beta subunit. We postulate that p80 functions as an adapter protein that may participate in linking the hGM-CSF receptor to the PI 3-kinase signaling pathway.	UNIV MARYLAND, SCH MED, DEPT MICROBIOL & IMMUNOL, BALTIMORE, MD 21201 USA; UNIV MARYLAND, MARYLAND BIOTECHNOL INST, CTR MED BIOTECHNOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore				Feldman, Ricardo A./0000-0001-6090-0439	NATIONAL CANCER INSTITUTE [R29CA055293] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA 55293-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; ARECES LB, 1993, P NATL ACAD SCI USA, V90, P3963, DOI 10.1073/pnas.90.9.3963; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FELDMAN RA, 1989, J VIROL, V63, P5469, DOI 10.1128/JVI.63.12.5469-5474.1989; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; JUCKER M, UNPUB; KANAKURA Y, 1990, BLOOD, V76, P706; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MURATA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1102, DOI 10.1016/S0006-291X(05)80899-X; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TORIGOE T, 1992, BLOOD, V80, P617; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WATANABE Y, 1992, BLOOD, V80, P2215; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	48	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27817	27822						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499252				2022-12-27	WOS:A1995TE73600063
J	KISSIL, JL; DEISS, LP; BAYEWITCH, M; RAVEH, T; KHASPEKOV, G; KIMCHI, A				KISSIL, JL; DEISS, LP; BAYEWITCH, M; RAVEH, T; KHASPEKOV, G; KIMCHI, A			ISOLATION OF DAP3, A NOVEL MEDIATOR OF INTERFERON-GAMMA-INDUCED CELL-DEATH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS; PROTEIN; GENE; PATHWAYS; ENCODES; TOOL; P53	Interaction of certain cytokines with their corresponding cell-surface receptors induces programed cell death. Interferon-gamma induces in HeLa cells a type of cell death with features characteristic of programed cell death. Here, we report the isolation of a novel gene, DAP3 (death-associated protein-3), involved in mediating interferon-gamma-induced cell death. The rescue of this gene was performed by a functional selection approach of gene cloning that is based on transfection with an antisense cDNA expression library, The antisense RNA-mediated inactivation of the DAPS gene protected the cells from interferon-gamma-induced cell death. This property endowed the cells expressing it with a growth advantage in an environment restrictive due to the continuous presence of interferon-gamma and thus provided the basis of its selection, The gene is transcribed into a single 1.7-kilobase mRNA, which is ubiquitously expressed in different tissues and codes for a 46-kDa protein carrying a potential P-loop motif. Ectopic expression of DAP3 in HeLa cells was not compatible with cell growth, resulting in a 16 fold reduction in the number of drug-resistant stable clones. The data presented suggest that DAP3 is a positive mediator of cell death induced by interferon-gamma.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHENCHIK AA, 1993, FEBS LETT, V324, P98; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GABIG TG, 1994, J BIOL CHEM, V269, P29515; GRAWUNDER U, 1993, EUR J IMMUNOL, V23, P544, DOI 10.1002/eji.1830230237; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HARLOW E, 1988, ANTIBODIES LABORATOR; HENIKOFF S, 1991, NUCLEIC ACIDS RES, V19, P6565, DOI 10.1093/nar/19.23.6565; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LIU Y, 1990, Journal of Experimental Medicine, V172, P1735, DOI 10.1084/jem.172.6.1735; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WALLACH D, 1984, J IMMUNOL, V132, P2464; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; YARDEN A, 1986, SCIENCE, V234, P1419, DOI 10.1126/science.3097823; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	31	83	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27932	27936		10.1074/jbc.270.46.27932	http://dx.doi.org/10.1074/jbc.270.46.27932			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499268	hybrid			2022-12-27	WOS:A1995TE73600079
J	MORISHITA, K; JOHNSON, DE; WILLIAMS, LT				MORISHITA, K; JOHNSON, DE; WILLIAMS, LT			A NOVEL PROMOTER FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR RECEPTOR (FLT-1) THAT CONFERS ENDOTHELIAL-SPECIFIC GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; TYROSINE KINASE; FUNCTIONAL-ANALYSIS; TRANSCRIPTION; ANGIOGENESIS; BINDING; FAMILY; IDENTIFICATION; PROTEINS; MUSCLE	The human transmembrane fms-like receptor tyrosine kinase Flt-1 is one of the receptors for vascular endothelial growth factor, a growth factor which induces endothelial proliferation and vascular permeability. Flt-1 is expressed specifically in endothelium and is likely to play a role in tumor angiogenesis and embryonic vascularization. To elucidate the molecular basis for the endothelial specific expression of Flt-1, the promoter region has been isolated and functionally characterized. The promoter region contains a TATA box, a GC-rich region, and putative transcription factor binding elements such as cAMP response element binding protein/activating transcription factor (CREB/ATF) and ets. Adenovirus-mediated transient expression of the flt-1 promoter/luciferase fusion gene in endothelial cells and other cell types demonstrated that a 1-kilobase fragment of the 5'-flanking region of flt-1 is involved in the endothelial-specific expression. A CREB/ATF element was found to be essential for basal transcription of the flt-1 expression. In addition, we also showed that the first intron negatively regulates flt-1 promoter activity. The flt-1 promoter will be useful in functional studies on the regulation of endothelial-specific gene expression and also as a tool in targeting the expression of exogenously introduced genes to the endothelium.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43821] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BOTHWELL ALM, 1981, CELL, V24, P625, DOI 10.1016/0092-8674(81)90089-1; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; IADEMARCO MF, 1993, P NATL ACAD SCI USA, V90, P3943, DOI 10.1073/pnas.90.9.3943; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; KASH SF, 1993, MOL CELL BIOL, V13, P2718, DOI 10.1128/MCB.13.5.2718; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LEE ME, 1990, J BIOL CHEM, V265, P10446; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; NAKAMURA Y, 1994, CANCER RES, V54, P5757; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OREILLY MA, 1992, J BIOL CHEM, V267, P19938; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAN JL, 1993, J BIOL CHEM, V268, P22600; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; VONDERAHE D, 1993, NUCLEIC ACIDS RES, V21, P5636, DOI 10.1093/nar/21.24.5636; WERNERT N, 1992, AM J PATHOL, V140, P119	33	102	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27948	27953		10.1074/jbc.270.46.27948	http://dx.doi.org/10.1074/jbc.270.46.27948			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499271	hybrid			2022-12-27	WOS:A1995TE73600082
J	WENGER, RH; ROLFS, A; MARTI, HH; BAUER, C; GASSMANN, M				WENGER, RH; ROLFS, A; MARTI, HH; BAUER, C; GASSMANN, M			HYPOXIA, A NOVEL INDUCER OF ACUTE-PHASE GENE-EXPRESSION IN A HUMAN HEPATOMA-CELL LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; ALZHEIMERS-DISEASE; ERYTHROPOIETIN GENE; MAMMALIAN-CELLS; IRON-ABSORPTION; MESSENGER-RNA; PROTEIN; TRANSCRIPTION; SEQUENCE; ALPHA-1-ANTICHYMOTRYPSIN	Transcriptional regulation of gene expression by hypoxia is an important, but yet only marginally characterized mechanism by which organisms adapt to low oxygen concentrations, The human hepatoma cell line HepG2 is a widely used model for studying hypoxic induction of the hematopoietic growth factor erythropoietin, In an attempt to identify additional genes expressed in HepG2 cells during hypoxia, we differentially screened a cDNA library derived from hypoxic (1% O-2) HepG2 cells using probes isolated from either normoxic (21% O-2) or hypoxic cells, Two genes were identified, one encoding aldolase, a member of the glycolytic enzymes, and the other encoding alpha(1)-antitrypsin which belongs to the family of the acute phase (AP) responsive proteins, Whereas hypoxic induction of glycolytic enzymes is well established, oxygen-dependent regulation of AP genes has not been reported so far, AP proteins are liver-derived plasma proteins whose production during inflammation is either up regulated (positive AP reactants) or down-regulated (negative AP reactants). In the present study, we demonstrate that on the mRNA level hypoxic stimulation of HepG2 cells led to (i) an induction of the positive AP reactants alpha(1)-antitrypsin, alpha(1)-antichymotrypsin, complement C3, haptoglobin, and alpha(1)-acid glycoprotein; (ii) a down-regulation of the negative AP reactant albumin; (iii) an up-regulation of the negative AP reactant transferrin; and (iv) unchanged levels of the positive AP reactants alpha- and beta-fibrinogen as well as hemopexin, Cycloheximide inhibited hypoxic up-regulation of AP mRNAs demonstrating that de novo protein synthesis is required for hypoxic induction, Nuclear run on assays indicate that the hypoxic increase in AP mRNAs is mainly due to transcriptional regulation, The hypoxic response was compared to AP stimulation by interleukin 6, The results suggest that the adaptive response to hypoxia overlaps with, but is not identical with, the AP response mediated by interleukin 6.			WENGER, RH (corresponding author), UNIV ZURICH, INST PHYSIOL, WINTERTHURERSTR 190, CH-8057 ZURICH, SWITZERLAND.		Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839; Marti, Hugo/0000-0002-8456-334X				ABRAHAM CR, 1992, RES IMMUNOL, V143, P631, DOI 10.1016/0923-2494(92)80047-O; ACKER H, 1994, RESP PHYSIOL, V95, P1, DOI 10.1016/0034-5687(94)90043-4; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BENJAMIN IJ, 1990, P NATL ACAD SCI USA, V87, P6263, DOI 10.1073/pnas.87.16.6263; CABIN DE, 1990, SURGERY, V108, P902; CHALDAKOV GN, 1992, IMMUNOL TODAY, V13, P237, DOI 10.1016/0167-5699(92)90162-Z; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; COLAU B, 1984, DNA-J MOLEC CELL BIO, V3, P327, DOI 10.1089/dna.1.1984.3.327; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; ECKARDT KU, 1988, KLIN WOCHENSCHR, V66, P241, DOI 10.1007/BF01748163; EIKELENBOOM P, 1992, RES IMMUNOL, V143, P617, DOI 10.1016/0923-2494(92)80044-L; Fey G H, 1990, Prog Liver Dis, V9, P89; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; FISHELSON Z, 1991, MOL IMMUNOL, V28, P545, DOI 10.1016/0161-5890(91)90169-K; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; GAULDIE J, 1990, J IMMUNOL, V144, P3804; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1991, BLOOD, V77, P271; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HELFMAN T, 1993, AM J MED SCI, V306, P37, DOI 10.1097/00000441-199307000-00010; HOLERS VM, 1992, IMMUNOL TODAY, V13, P231; HUBER P, 1990, J BIOL CHEM, V265, P5695; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; JUNGERMANN K, 1989, PHYSIOL REV, V69, P708, DOI 10.1152/physrev.1989.69.3.708; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; KRANTZ SB, 1991, BLOOD, V77, P419; KURACHI K, 1981, P NATL ACAD SCI-BIOL, V78, P6826, DOI 10.1073/pnas.78.11.6826; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; MASUDA S, 1994, J BIOL CHEM, V269, P19488; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MITANI K, 1992, BLOOD, V79, P1255; NIELSEN OJ, 1987, BLOOD, V70, P1904; OSTERLOH KRS, 1987, BLUT, V55, P421, DOI 10.1007/BF00367458; PERLMUTTER DH, 1989, AM J PHYSIOL, V257, pL147, DOI 10.1152/ajplung.1989.257.4.L147; POTTER H, 1992, PROG BRAIN RES, V94, P447; ROBIN ED, 1984, J CELL PHYSIOL, V118, P287, DOI 10.1002/jcp.1041180311; RUBIN H, 1992, BIOL CHEM H-S, V373, P497, DOI 10.1515/bchm3.1992.373.2.497; SAAD B, 1995, EUR J BIOCHEM, V229, P349, DOI 10.1111/j.1432-1033.1995.0349k.x; SAKAKIBARA M, 1985, BIOCHEM BIOPH RES CO, V131, P413, DOI 10.1016/0006-291X(85)91818-2; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUSTER SJ, 1989, BLOOD, V73, P13; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SIMPSON RJ, 1992, ANN HEMATOL, V65, P260, DOI 10.1007/BF01836070; VANDENABEELE P, 1991, IMMUNOL TODAY, V12, P217, DOI 10.1016/0167-5699(91)90032-O; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WEBSTER KA, 1987, MOL CELL BIOCHEM, V77, P19; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; WENGER RH, 1993, J BIOL CHEM, V268, P23345; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463	61	111	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27865	27870		10.1074/jbc.270.46.27865	http://dx.doi.org/10.1074/jbc.270.46.27865			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499259	hybrid, Green Accepted			2022-12-27	WOS:A1995TE73600070
J	HATTORI, Y; CAMPBELL, EB; GROSS, SS				HATTORI, Y; CAMPBELL, EB; GROSS, SS			ARGININOSUCCINATE SYNTHETASE MESSENGER-RNA AND ACTIVITY ARE INDUCED BY IMMUNOSTIMULANTS IN VASCULAR SMOOTH-MUSCLE - ROLE IN THE REGENERATION OF ARGININE FOR NITRIC-OXIDE SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ENDOTHELIAL-CELLS; NUCLEOTIDE-SEQUENCE; RELAXING FACTOR; SYNTHASE; MACROPHAGES; IDENTIFICATION; INTERLEUKIN-1; HYPOTENSION; METABOLISM; CITRULLINE	Nitric oxide synthase produces NO, citrulline, water, and NADP at the expense of arginine, NADPH, and dioxygen. While citrulline has been considered to be an inert by-product of the high output inducible isoform of NO synthase (iNOS), we show here that immunostimulants induce a metabolic pathway in vascular smooth muscle cells, which enables them to regenerate arginine from citrulline. Regeneration of arginine from citrulline is accomplished by two urea cycle enzymes: argininosuccinate synthetase (AS) and argininosuccinate lyase (AL). Whereas AL is constitutive to vascular smooth muscle cells, AS mRNA and enzyme activity is markedly induced in cells by treatment with bacterial lipopolysaccharide (LPS). The induction of AS mRNA and activity by LPS follows a time course which mirrors that for iNOS but lags 1-2 h behind. As shown for iNOS, interferon-gamma does not itself induce AS but is synergistic with LPS. AS induction is suppressed by glucocorticoids, actinomycin D, and, to a lesser extent, cycloheximide. On the other hand, AS induction is unaffected by an excess of citrulline or the inhibitor of iNOS, N(omega)-methyl-L-arginine. Our results show the urea cycle enzymes AS and AL confer cells with the capacity to produce NO without a need for exogenous arginine. In conjunction with NOS, citric acid cycle enzymes that covert fumarate to oxaloacetate (fumarase and malate dehydrogenase) and oxaloacetate to aspartate (aspartate transaminase), AS and AL form a novel arginine-citrulline cycle that enables high output NO production by cells.	CORNELL UNIV, MED CTR, COLL MED, DEPT PHARMACOL, 1300 YORK AVE, NEW YORK, NY 10021 USA	Cornell University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046403] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46403] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AISAKA K, 1989, BIOCHEM BIOPH RES CO, V160, P881, DOI 10.1016/0006-291X(89)92517-5; AMAYA Y, 1988, J BIOCHEM-TOKYO, V103, P177, DOI 10.1093/oxfordjournals.jbchem.a122227; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BILLIAR TR, 1992, J LEUKOCYTE BIOL   S, V52, P18; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEUNG CW, 1989, J BIOL CHEM, V264, P4038; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HATTORI Y, 1993, BIOCHEM BIOPH RES CO, V195, P435, DOI 10.1006/bbrc.1993.2062; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; JACKSON MJ, 1986, ANNU REV GENET, V20, P431, DOI 10.1146/annurev.ge.20.120186.002243; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; LOCKRIDGE O, 1977, BIOCHEM GENET, V15, P395, DOI 10.1007/BF00484469; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MEIJER AJ, 1990, PHYSIOL REV, V70, P701, DOI 10.1152/physrev.1990.70.3.701; MITCHELL JA, 1990, EUR J PHARMACOL, V176, P253, DOI 10.1016/0014-2999(90)90541-D; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; OBRIEN WE, 1979, BIOCHEMISTRY-US, V18, P5353, DOI 10.1021/bi00591a015; RATNER S, 1985, METHOD ENZYMOL, V34, P298; STUEHR DJ, 1992, ADV ENZYMOL RELAT AR, V65, P287; SURH LC, 1988, NUCLEIC ACIDS RES, V16, P9352, DOI 10.1093/nar/16.19.9352; TERADA Y, 1992, J CLIN INVEST, V90, P659, DOI 10.1172/JCI115908; THIEMERMANN C, 1990, EUR J PHARMACOL, V182, P591, DOI 10.1016/0014-2999(90)90062-B; WU GY, 1992, BIOCHEM J, V281, P45, DOI 10.1042/bj2810045; XI QW, 1993, J EXP MED, V177, P1779; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	33	149	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9405	9408						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511585				2022-12-27	WOS:A1994NE05300003
J	VANNIER, E; DINARELLO, CA				VANNIER, E; DINARELLO, CA			HISTAMINE ENHANCES INTERLEUKIN (IL)-1-INDUCED IL-6 GENE-EXPRESSION AND PROTEIN-SYNTHESIS VIA H-2 RECEPTORS IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; NECROSIS-FACTOR-ALPHA; SIGNAL TRANSDUCTION; ENDOTHELIAL-CELLS; KAPOSI-SARCOMA; MONOCYTES; IL1	The regulation of interleukin (IL)-6 synthesis by cAMP-increasing agents remains an unresolved issue. Since an increase in cAMP levels via activation of histamine H-2 receptors does not induce IL-1beta synthesis but enhances self-induction of IL-1 (Vannier, E., and Dinarello, C. A. (1993) J. Clin. Invest. 92, 281-287), we investigated whether histamine regulates IL-6 synthesis. Human peripheral blood mononuclear cells were stimulated with IL-1alpha in the absence or presence of histamine (1 nm to 100 muM). IL-6 was measured using a specific radioimmunoassay. Histamine alone did not induce protein synthesis or mRNA accumulation for IL-6. Histamine (1-100 muM) enhanced IL-1alpha1-induced synthesis of IL-6 (p < 0.001). Cimetidine and ranitidine, H-2 receptor antagonists structurally unrelated to each other, completely reversed the histamine-mediated increase in IL-1alpha-induced IL-6 synthesis. However, diphenhydramine, an H-1 receptor antagonist, did not reverse this effect. Prostaglandin E2, an activator of adenylate cyclase, also enhanced IL-1alpha-induced synthesis of IL-6. Histamine increased and sustained steady-state levels of IL-6 mRNA in IL-1alpha-stimulated cells, but reduced IL-6 mRNA half-life (3.5 h versus 1.8 h). Our results indicate that cAMP-increasing agents, such as histamine or prostaglandin E2, fail to induce IL-6 synthesis but rather enhance IL-1-induced IL-6 synthesis.	TUFTS UNIV NEW ENGLAND MED CTR,750 WASHINGTON ST,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University					NIAID NIH HHS [AI-15614] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015614, R01AI015614] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; BAUER J, 1988, BLOOD, V72, P1134; CAMERON W, 1986, J IMMUNOL, V136, P2116; CARLSSON R, 1985, CELL IMMUNOL, V96, P104, DOI 10.1016/0008-8749(85)90343-0; CASALE TB, 1985, INT J IMMUNOPHARMACO, V7, P639, DOI 10.1016/0192-0561(85)90147-X; FONG YM, 1989, J IMMUNOL, V142, P2321; GESPACH C, 1986, AGENTS ACTIONS, V18, P124, DOI 10.1007/BF01988001; GILLITZER R, 1991, J INVEST DERMATOL, V96, P598; HACK CE, 1989, BLOOD, V74, P1704; HELLSTRAND K, 1990, SCAND J IMMUNOL, V31, P631, DOI 10.1111/j.1365-3083.1990.tb02814.x; HELLSTRAND K, 1990, J IMMUNOL, V145, P4365; HIRANO T, 1988, EUR J IMMUNOL, V18, P1797, DOI 10.1002/eji.1830181122; KASAHARA T, 1990, BIOCHEM BIOPH RES CO, V167, P1242, DOI 10.1016/0006-291X(90)90657-9; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LOPPNOW H, 1989, CELL IMMUNOL, V122, P493, DOI 10.1016/0008-8749(89)90095-6; LOPPNOW H, 1990, J CLIN INVEST, V85, P731, DOI 10.1172/JCI114498; LU C, 1993, J CELL BIOL, V120, P1281, DOI 10.1083/jcb.120.5.1281; MANIATIS T, 1987, MOL CLONING LABORATO, P187; MAY LT, 1988, J BIOL CHEM, V263, P7760; MERTENS WC, 1992, LANCET, V340, P397, DOI 10.1016/0140-6736(92)91474-M; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; PRESN EP, 1990, J INVEST DERMATOL, V95, pS121; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; ROSZKOWSKI W, 1977, SCIENCE, V195, P683, DOI 10.1126/science.190677; SCHINDLER R, 1990, BLOOD, V75, P40; SHALABY MR, 1989, CELL IMMUNOL, V121, P372, DOI 10.1016/0008-8749(89)90036-1; SMITH TJ, 1991, J NATL CANCER I, V83, P139, DOI 10.1093/jnci/83.2.139-a; VANDERMEER JWM, 1988, J LEUKOCYTE BIOL, V43, P216, DOI 10.1002/jlb.43.3.216; VANKOOTEN C, 1992, NEUROIMMUNOLOGY FEVE, P49; VANNIER E, 1991, J EXP MED, V174, P281, DOI 10.1084/jem.174.1.281; VANNIER E, 1993, J CLIN INVEST, V92, P281, DOI 10.1172/JCI116562; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802; ZHANG YH, 1988, J BIOL CHEM, V263, P6177; ZITNIK RJ, 1993, AM J PHYSIOL, V264, pL253, DOI 10.1152/ajplung.1993.264.3.L253	36	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9952	9956						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511596				2022-12-27	WOS:A1994NE05300085
J	SEUFFERLEIN, T; ROZENGURT, E				SEUFFERLEIN, T; ROZENGURT, E			LYSOPHOSPHATIDIC ACID STIMULATES TYROSINE PHOSPHORYLATION OF FOCAL ADHESION KINASE, PAXILLIN, AND P130 - SIGNALING PATHWAYS AND CROSS-TALK WITH PLATELET-DERIVED GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; BOMBESIN STIMULATION; ANGIOTENSIN-II; INTACT-CELLS; PROTEIN; VASOPRESSIN; ENDOTHELIN; IDENTIFICATION; ACTIVATION; RECEPTOR	Addition of 1-oleoyl-lysophosphatidic acid (LPA) induces tyrosine phosphorylation of multiple substrates in Swiss 3T3 cells including bands of M(r) 110,000-130,000 and M(r) 70,000-80,000. An increase in tyrosine phosphorylation of the M(r) 110,000-130,000 cluster of bands was detected as soon as 30 s after LPA stimulation reaching a maximum within 1 min. LPA stimulated tyrosine phosphorylation of all bands in a concentration-dependent fashion; a half-maximal effect occurred at 30 nM. Immunoprecipitation of lysates of LPA-treated cells with monoclonal antibodies that specifically recognize focal adhesion kinase (p125(FAK)), paxillin, and p130 revealed that these proteins are prominent substrates for LPA-stimulated tyrosine phosphorylation. Down-regulation of protein kinase C (PKC) by prolonged pretreatment with phorbol 12,13-dibutyrate, selective inhibition of PKC by GF109203X, or depletion of the intracellular Ca2+ pool by thapsigargin had no effect on LPA-stimulated tyrosine phosphorylation. Thus, protein tyrosine phosphorylation by LPA is largely independent of either the PKC or Ca2+ pathways. In contrast, pretreatment of the cells with cytochalasin D, which selectively disrupts the network of the actin filaments, completely inhibited LPA-induced tyrosine phosphorylation. Furthermore, tyrosine phosphorylation of p125(FAR) induced by LPA was completely prevented when cells were stimulated in the presence of platelet-derived growth factor at a concentration (30 ng/ml) that causes disruption of actin stress fibers. This suggests that the integrity of the actin cytoskeleton is essential for LPA-induced tyrosine phosphorylation and reveals a novel cross-talk between LPA and platelet-derived growth factor on p125(FAK) tyrosine phosphorylation.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Seufferlein, Thomas TW/P-7147-2018					BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BENTON AM, 1982, BLOOD, V60, P642; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; FORCE T, 1991, J BIOL CHEM, V266, P6650; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; JALINK K, 1990, J BIOL CHEM, V265, P12232; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MARGLIN A, 1970, ANNU REV BIOCHEM, V39, P841, DOI 10.1146/annurev.bi.39.070170.004205; MIURA Y, 1993, J BIOL CHEM, V268, P510; MOOLENAAR WH, 1985, NATURE, V32, P171; MOOLENAAR WH, 1992, REV PHYSL BIOCH PHAR, V119, P48; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; RANKIN S, 1994, J BIOL CHEM, V269, P704; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1990, PHILOS T ROY SOC B, V327, P209, DOI 10.1098/rstb.1990.0055; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SECKL M, 1993, J BIOL CHEM, V268, P9548; SINNETTSMITH J, 1988, J CELL BIOCHEM, V38, P237, DOI 10.1002/jcb.240380403; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; STADDON JM, 1991, J CELL BIOL, V115, P949, DOI 10.1083/jcb.115.4.949; TBULLEC D, 1991, J BIOL CHEM, V266, P15771; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; TOKUMURA A, 1980, ARCH INT PHARMACOD T, V245, P74; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	55	260	263	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9345	9351						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510708				2022-12-27	WOS:A1994NB41100105
J	YIN, TG; YANG, YC				YIN, TG; YANG, YC			MITOGEN-ACTIVATED PROTEIN-KINASES AND RIBOSOMAL-S6 PROTEIN-KINASES ARE INVOLVED IN SIGNALING PATHWAYS SHARED BY INTERLEUKIN-11, INTERLEUKIN-6, LEUKEMIA INHIBITORY FACTOR, AND ONCOSTATIN-M IN MOUSE 3T3-L1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA STAR OOCYTES; MAP KINASE; TYROSINE PHOSPHORYLATION; S6 KINASE; MOLECULAR-CLONING; THREONINE; PP90RSK; RECEPTOR; INVITRO; RSK	The mechanisms of signaling pathways shared by interleukin (IL)-11, IL-6, leukemia inhibitory factor (LIF), and oncostatin M (ONC) remain elusive. We report here that treatment of 3T3-Ll cells with IL-11, IL-6, LIF, and ONC induces overlapping but distinct patterns of tyrosine phosphorylation and activates indistinguishable primary response genes. We further demonstrate for the first time that IL-11, IL-6, LIF, and ONC can trigger the activation of mitogen-activated protein kinases and the 85-92-kDa ribosomal S6 protein kinases (pp90rsk). In addition, our data also show that preincubation of cells with a tyrosine kinase inhibitor herbimycin A, but not with a serine/threonine kinase inhibitor H7, blocks activation of mitogen-activated protein kinases and pp90rsk. Interestingly, H7, but not herbimycin A, inhibits pp90rsk activity in the in vitro kinase assays. These results suggest that pp90rsk is one of the potential candidates for the H7-sensitive protein kinase(s), which is critical for the activation of primary response genes by these cytokines.	INDIANA UNIV,SCH MED,DEPT MED HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis					NHLBI NIH HHS [R01HL48819] Funding Source: Medline; NIDDK NIH HHS [R01DK43105] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043105] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ANDERSON KC, 1992, BLOOD, V80, P2797; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; ERIKSON E, 1987, MOL CELL BIOL, V7, P3147, DOI 10.1128/MCB.7.9.3147; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HANGOC G, 1993, BLOOD, V81, P965; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KAWASHIMA I, 1991, FEBS LETT, V283, P199, DOI 10.1016/0014-5793(91)80587-S; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LIU JW, 1992, J BIOL CHEM, V267, P16763; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NEBEN TY, 1993, BLOOD, V81, P901; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; QUESNIAUX VFJ, 1992, BLOOD, V80, P1218; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; Sambrook J, 1989, MOL CLONING LABORATO; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SEGER R, 1992, J BIOL CHEM, V267, P14373; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VIK TA, 1990, P NATL ACAD SCI USA, V87, P2685, DOI 10.1073/pnas.87.7.2685; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YIN TG, 1992, J EXP MED, V175, P211, DOI 10.1084/jem.175.1.211; YIN TG, 1992, J BIOL CHEM, V267, P8347; YIN TG, 1993, J IMMUNOL, V151, P2555; YIN TG, 1993, CELL GROWTH DIFFER, V4, P603	56	100	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3731	3738						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508917				2022-12-27	WOS:A1994MV63100088
J	JIA, R; HANAFUSA, H				JIA, R; HANAFUSA, H			THE PROTOONCOGENE OF V-EYK (V-RYK) IS A NOVEL RECEPTOR-TYPE PROTEIN-TYROSINE KINASE WITH EXTRACELLULAR IG/FN-III DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; SIGNAL TRANSDUCTION; GENE; FAMILY; FIBRONECTIN; CLONING; ENCODES; VIRUS; RNA	v-ryk is the oncogene in the avian acute oncogenic retrovirus RPL30, its cellular counterpart, c-ryk, is described in this report. To avoid the confusion caused by another gene with the same name, we renamed v-ryk to be v-eyk, thereby changing the proto-oncogene's name to c-eyk. c-eyk is expressed highly in chicken spleen and moderately in many other tissues including embryonic tissues. Its cDNA is 3061 base pairs encoding a receptor-type protein tyrosine kinase (PTK) of 974 amino acids. Compared to c-Eyk, v-Eyk is a truncated PTK lacking the extracellular and transmembrane regions of c-Eyk in addition to two amino acid changes. c-Eyk has two C2-type Ig domains and two FN-III domains in its extra-cellular region, forming a new subfamily of receptor-type PTK together with UFO/Axl/Ark. As suggested by Ig/FN-III domains in many cell adhesion molecules, this subfamily of PTK may mediate cell-cell interaction.	ROCKEFELLER UNIV,BOX 288,1230 YORK AVE,NEW YORK,NY 10021	Rockefeller University					NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NCI NIH HHS [CA44356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BRUMMENDORF T, 1993, NEURON, V10, P711; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; FAUST M, 1992, ONCOGENE, V7, P1287; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FREDRICKSON TN, 1964, NATL CANCER I MONOGR, V17, P1; FREI T, 1992, J CELL BIOL, V118, P177, DOI 10.1083/jcb.118.1.177; HORTSCH M, 1991, TRENDS BIOCHEM SCI, V16, P283, DOI 10.1016/0968-0004(91)90116-D; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1992, J VIROL, V66, P5975, DOI 10.1128/JVI.66.10.5975-5987.1992; KELMAN Z, 1993, ONCOGENE, V8, P37; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PAUL SR, 1992, INT J CELL CLONING, V10, P309, DOI 10.1002/stem.5530100509; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; Rathjen F. G, 1991, SEMIN NEUROSCI, V3, P297, DOI 10.1016/1044-5765(91)90047-R; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SAJJADI FG, 1993, ONCOGENE, V8, P1807; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; TYAGI JS, 1983, J BIOL CHEM, V258, P5787; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; ZHANG JY, 1993, J VIROL, V67, P1747, DOI 10.1128/JVI.67.4.1747-1751.1993	36	92	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1839	1844						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507487				2022-12-27	WOS:A1994MR98800046
J	WHITEHALL, SK; BARDELEBEN, C; KASSAVETIS, GA				WHITEHALL, SK; BARDELEBEN, C; KASSAVETIS, GA			HYDROLYTIC CLEAVAGE OF NASCENT RNA IN RNA POLYMERASE-III TERNARY TRANSCRIPTION COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-SII; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; INVITRO; GENE; DNA; INITIATION; PROTEIN; INHIBITION; TEMPLATES	Highly purified yeast RNA polymerase III ternary complexes were found to possess a hydrolytic chain retracting activity that cleaves nascent RNA from its 3'-OH end. Most of the shortened transcripts were capable of resuming RNA chain elongation, indicating that they remain stably associated with the enzyme-DNA complex. Analysis of the products of cleavage indicated that retraction primarily occurred in dinucleotide increments, but that mononucleotides were also excised at lower frequency. The ribonuclease activity was totally dependent on the presence of a divalent cation and was stimulated by the addition of non-cognate ribonucleotides. The inclusion of ATP in the reaction enhanced both the rate and extent of transcript cleavage. Evidence suggesting that the hydrolytic activity is intrinsic to RNA polymerase III and factor-independent is also presented. Transcript cleavage by RNA polymerase III ternary complexes appears to be more closely related to the intrinsic nucleolytic activity of vaccinia virus RNA polymerase ternary complexes than to TFIIS-dependent cleavage that has been described for RNA polymerase II ternary complexes.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018386, R37GM018386] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18386] Funding Source: Medline; PHS HHS [07317] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; BAKER RE, 1984, EMBO J, V3, P2793, DOI 10.1002/j.1460-2075.1984.tb02211.x; BARDELEBEN C, 1994, IN PRESS J MOL BIOL; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BURNOL AF, 1993, NATURE, V362, P475, DOI 10.1038/362475a0; DEUSCHLE U, 1990, SCIENCE, V248, P40; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; ESCHENLAUER JB, 1993, MOL CELL BIOL, V13, P3015, DOI 10.1128/MCB.13.5.3015; FELTS SJ, 1990, MOL CELL BIOL, V10, P2390, DOI 10.1128/MCB.10.5.2390; GUO HL, 1993, J BIOL CHEM, V268, P18762; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HORIKOSHI M, 1984, J BIOL CHEM, V259, P608; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; LEVEILLARD T, 1993, J BIOL CHEM, V268, P3594; MATSUZAKI H, 1994, IN PRESS J MOL BIOL; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; MORSE RH, 1992, MOL CELL BIOL, V12, P4015, DOI 10.1128/MCB.12.9.4015; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; RAPPAPORT J, 1988, MOL CELL BIOL, V8, P3136, DOI 10.1128/MCB.8.8.3136; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; Sentenac A., 1992, TRANSCRIPTIONAL REGU, V1, P27; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SPENCER CA, 1990, ONCOGENE, V5, P777; STEINBERG TH, 1992, J BIOL CHEM, V267, P20204; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; YAGER TD, 1987, ESCHERICHIA COLI SAL, V2, P1241	44	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2299	2306						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507490				2022-12-27	WOS:A1994MR98800111
J	SMITH, JW; PIOTROWICZ, RS; MATHIS, D				SMITH, JW; PIOTROWICZ, RS; MATHIS, D			A MECHANISM FOR DIVALENT-CATION REGULATION OF BETA-3-INTEGRINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; PLATELET GLYCOPROTEIN-IIB; CALCIUM-BINDING SITES; VITRONECTIN RECEPTOR; BONE-RESORPTION; CELL ATTACHMENT; LIGAND-BINDING; VONWILLEBRAND-FACTOR; ADHESION RECEPTORS; BETA-3 INTEGRIN	Integrins alpha(IIb)beta3 and alpha(V)beta3 mediate numerous cell-matrix and cell-cell contacts. Both integrins contain multiple divalent cation-binding motifs that regulate ligand binding. Here, we elucidate a major difference in the regulation of alpha(IIb)beta3 and alpha(V)beta3 by divalent ions. Fibrinogen binding to alpha(IIb)beta3 in Ca2+-containing buffer is rapid, with an apparent association rate constant (k1app) of 8.2 x 10(5) M-1 s-1, but Ca2+ does not support association between fibrinogen and alpha(V)beta3. Interestingly, Mn2+ supports fibrinogen binding to both integrins, albeit with a relatively slow association rate (k1app = 10(4) M-1 s-1). This influence of divalent ions on ligand association rates accounts for the opposite divalent ion requirements for platelet aggregation and tumor cell adhesion to fibrinogen. Furthermore, the regulation of fibrinogen binding to alpha(V)beta3 is complex when both Ca2+ and Mn2+ are present. Physiological concentrations of Ca2+ completely ablated adhesion. Kinetic analysis demonstrated that Ca2+ is a mixed-type inhibitor of Mn2+-supported fibrinogen binding to alpha(V)beta3. Consequently, the data presented here suggest a mechanism in which two separate cation-binding sites regulate ligand binding to beta3-integrins.			SMITH, JW (corresponding author), SCRIPPS RES INST, COMM VASC BIOL CVB1, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NCI NIH HHS [CA 56468] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, CANCER RES, V50, P6756; ALTIERI DC, 1991, J IMMUNOL, V147, P1891; ANDRAS V, 1986, BIOCHEMISTRY-US, V25, P519; Brandt M, 1986, MANGANESE METABOLISM, P3; CHAMBERS TJ, 1986, BONE MINER, V1, P127; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; COTZIAS GC, 1958, PHYSIOL REV, V38, P505; Creighton T. E., 1984, PROTEINS STRUCTURES, V2nd; DANG CV, 1985, J BIOL CHEM, V260, P9713; DANG CV, 1989, J BIOL CHEM, V264, P15104; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; EDWARDS JG, 1988, J CELL SCI, V89, P507; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GARTNER TK, 1990, THROMB RES, V60, P291, DOI 10.1016/0049-3848(90)90108-O; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; GULINO D, 1992, J BIOL CHEM, V267, P1001; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; HOGSAN K, 1992, J BIOL CHEM, V267, P23076; HORTON MA, 1989, J BONE MINER RES, V4, P803; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACOBS S, 1976, BIOCHIM BIOPHYS ACTA, V433, P482, DOI 10.1016/0005-2736(76)90275-3; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; LAKKAKORPI PT, 1991, J CELL BIOL, V115, P1179, DOI 10.1083/jcb.115.4.1179; LAM SCT, 1987, J BIOL CHEM, V262, P947; LAMPUGNANI MG, 1991, LAB INVEST, V65, P96; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MULLER B, 1993, J BIOL CHEM, V268, P6800; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PHILLIPS DR, 1988, BLOOD, V71, P831; POLLET RJ, 1977, J BIOL CHEM, V252, P5828; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; RIVAS GA, 1991, BIOCHEM J, V276, P35, DOI 10.1042/bj2760035; SCHRAMM VL, 1986, MANGANESE METABOLISM, P109; SCHROEDER HA, 1966, J CHRON DIS, V19, P545, DOI 10.1016/0021-9681(66)90094-4; SEGAL IH, 1975, ENZYME KINETICS; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SMITH JW, 1991, J BIOL CHEM, V266, P11429; SMTH JW, 1988, J BIOL CHEM, V263, P18726; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; STRYNADKA NCJ, 1990, PROTEINS, V7, P234, DOI 10.1002/prot.340070305; TAYLOR DB, 1992, J BIOL CHEM, V267, P11729; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325	62	172	176	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					960	967						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507113				2022-12-27	WOS:A1994MR22000031
J	NIMPF, J; STIFANI, S; BILOUS, PT; SCHNEIDER, WJ				NIMPF, J; STIFANI, S; BILOUS, PT; SCHNEIDER, WJ			THE SOMATIC CELL-SPECIFIC LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN OF THE CHICKEN - CLOSE KINSHIP TO MAMMALIAN LOW-DENSITY-LIPOPROTEIN RECEPTOR GENE FAMILY MEMBERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR TYPE-1; PREGNANCY ZONE PROTEIN; LDL-RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; HEYMANN NEPHRITIS; OOCYTE RECEPTOR; MESSENGER-RNA; PLASMINOGEN-ACTIVATOR; MEDIATED ENDOCYTOSIS; REGULATED EXPRESSION	Recently, the family of mammalian genes homologous to that for the low density lipoprotein (LDL) receptor has grown. One of the new family members, termed LDL receptor-related protein/alpha2-macroglobulin receptor (LRP/alpha2MR), is one of the largest cell surface proteins characterized to date. Its functions have been hypothesized to include the plasma clearance of chylomicron remnants and activated alpha2-macroglobulin, as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. Here we describe the molecular characterization of an LRP/alpha2MR expressed in chickens, which do not metabolize chylomicron remnants. This chicken protein is expressed in somatic tissues and is different from a second LRP/alpha2MR exclusively expressed in growing ovarian follicles. The sequence of the somatic cell-specific chicken LRP/alpha2MR, deduced from cloned full-length cDNA, shows 83% overall identity with human LRP/alpha2MR. Important characteristic features of the modular protein are completely conserved; in particular, all cysteine residues align perfectly. The avian LRP/alpha2MR is post-translationally cleaved in the same fashion as its human counterpart, and the resulting 515-kDa extracellular subunit binds Ca2+, alpha2-macroglobulin, and vitellogenin. The results indicate that avian LRP/alpha2MR genes have emerged from an ancestor designed to ensure a pivotal event in the reproduction of oviparous species, i.e. vitellogenesis, and that mammalian LRP/alpha2MRs have acquired features required for functioning in plasma clearance of certain non-yolk proteins.	BIOCTR,DEPT MOLEC GENET,DR BOHRGASSE 9-2,A-1030 VIENNA,AUSTRIA; UNIV VIENNA,A-1030 VIENNA,AUSTRIA	University of Vienna				Nimpf, Johannes/0000-0002-9273-3492; Stifani, Stefano/0000-0002-2376-7701				AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BARAKAT HA, 1985, J LIPID RES, V26, P1252; BARBER DL, 1991, J BIOL CHEM, V266, P18761; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BENSADOUN A, 1972, P SOC EXP BIOL MED, V41, P814; BORRAS T, 1985, EMBO J, V4, P445, DOI 10.1002/j.1460-2075.1985.tb03649.x; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DAVIS MM, 1980, SCIENCE, V209, P1360, DOI 10.1126/science.6774415; DEVRIENDT K, 1991, BIOCHIM BIOPHYS ACTA, V1088, P95, DOI 10.1016/0167-4781(91)90157-H; ENGHILD JJ, 1989, J BIOL CHEM, V264, P8779; ESSER V, 1988, J BIOL CHEM, V263, P13282; GAFVELS ME, 1992, J BIOL CHEM, V267, P21230; GEORGE R, 1987, J BIOL CHEM, V262, P16838; GLIEMANN J, 1986, BIOCHIM BIOPHYS ACTA, V883, P400, DOI 10.1016/0304-4165(86)90276-X; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAYASHI K, 1989, J BIOL CHEM, V264, P3131; HEINRICH P, 1989, CURRENT PROTOCOLS MO, V1; HERZ J, 1993, CELL, V73, P428, DOI 10.1016/0092-8674(93)90130-I; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; KANALAS JJ, 1991, J BIOL CHEM, V266, P10825; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; KERJASCHKI D, 1990, VIRCHOWS ARCH B, V58, P253; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; KUTT H, 1989, BIOCHIM BIOPHYS ACTA, V1009, P229, DOI 10.1016/0167-4781(89)90107-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUVEN FV, 1986, J BIOL CHEM, V261, P11369; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAGASE H, 1983, J BIOL CHEM, V258, P7481; NARDELLI D, 1987, BIOCHEMISTRY-US, V26, P6397, DOI 10.1021/bi00394a014; NIKAIDO T, 1981, NATURE, V292, P845, DOI 10.1038/292845a0; NIMPF J, 1989, P NATL ACAD SCI USA, V86, P906, DOI 10.1073/pnas.86.3.906; NIMPF J, 1988, J LIPID RES, V29, P657; NIMPF J, 1989, J BIOL CHEM, V264, P1393; NIMPF J, 1991, J NUTR, V121, P1471, DOI 10.1093/jn/121.9.1471; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OHLSSON K, 1971, ACTA PHYSIOL SCAND, V81, P269, DOI 10.1111/j.1748-1716.1971.tb04900.x; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; RAJAVASHISTH TB, 1987, J BIOL CHEM, V262, P7058; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RETZEK H, 1992, DNA CELL BIOL, V11, P661, DOI 10.1089/dna.1992.11.661; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SCHNEIDER WJ, 1980, J BIOL CHEM, V255, P1442; SCHNEIDER WJ, 1983, J CELL BIOL, V97, P1635, DOI 10.1083/jcb.97.5.1635; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOUTAR AK, 1989, NATURE, V341, P106, DOI 10.1038/341106a0; STENFLO J, 1988, J BIOL CHEM, V263, P21; STEYRER E, 1990, J BIOL CHEM, V265, P19575; STIFANI S, 1988, BIOCHEM J, V250, P467, DOI 10.1042/bj2500467; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STIFANI S, 1990, P NATL ACAD SCI USA, V87, P1955, DOI 10.1073/pnas.87.5.1955; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; SUDHOF TC, 1985, SCIENCE, V228, P893, DOI 10.1126/science.3873704; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VONDIJK MCM, 1991, BIOCHEM J, V279, P863; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YOCHEM J, 1993, P NATL ACAD SCI USA, V90, P4572, DOI 10.1073/pnas.90.10.4572; ZIERE GJ, 1992, J BIOL CHEM, V267, P11229	79	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					212	219						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506255				2022-12-27	WOS:A1994MR21900040
J	PAN, CX; FUKUNAGA, R; YONEHARA, S; NAGATA, S				PAN, CX; FUKUNAGA, R; YONEHARA, S; NAGATA, S			UNIDIRECTIONAL CROSS-PHOSPHORYLATION BETWEEN THE GRANULOCYTE-COLONY-STIMULATING FACTOR AND INTERLEUKIN-3 RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; IL-6 SIGNAL TRANSDUCER; TYROSINE PHOSPHORYLATION; CELL-LINE; INTERMOLECULAR ASSOCIATION; ERYTHROPOIETIN RECEPTOR; EXPRESSION CLONING; BETA-SUBUNIT; GM-CSF; PROTEIN	The mouse interleukin-3 (IL-3)-dependent hemopoietic precursor cell line 32DCl3 responds to granulocyte colony-stimulating factor (G-CSF) for proliferation and differentiation. We established a subline (32D-FH) of the 32DCl3 cells which has lost the ability to respond to G-CSF. When murine G-CSF receptor cDNA was introduced into the 32D-FH cell line, the transformants responded to G-CSF as well as to IL-3 for proliferation. Adding G-CSF to the transformants rapidly induced tyrosine phosphorylation not only of the G-CSF receptor but also of both subtypes of the IL-3 receptor beta-chain (AIC2A and AIC2B molecules). On the other hand, stimulation of the transformants with IL-3 induced tyrosine phosphorylation of the AIC2A and AIC2B but not of the G-CSF receptor. These results indicate that the tyrosine kinase activated through the G-CSF receptor interacts with the IL-3 receptor beta-chains but not vice versa. This unidirectional cross-phosphorylation between the G-CSF and IL-3 receptors may play a role in granulopoiesis induced by G-CSF.	OSAKA BIOSCI INST, 6-2-4 FURUEDAI, SUITA, OSAKA 565, JAPAN; JT INC, PHARMACEUT BASIC RES LABS, KANAZAWA KU, YOKOHAMA 236, JAPAN				Fukunaga, Rikiro/CAG-2891-2022; Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; CLEVELAND JL, 1989, MOL CELL BIOL, V264, P11699; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DURONIO V, 1992, J BIOL CHEM, V267, P21856; FRACKELTON AR, 1983, MOL CELL BIOL, V3, P1343, DOI 10.1128/MCB.3.8.1343; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; LI W, 1991, J BIOL CHEM, V266, P6808; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; METCALF D, 1992, TRENDS BIOCHEM SCI, V17, P286, DOI 10.1016/0968-0004(92)90436-D; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUI ALF, 1992, P NATL ACAD SCI USA, V89, P10812, DOI 10.1073/pnas.89.22.10812; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURATA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1102, DOI 10.1016/S0006-291X(05)80899-X; NAGATA S, 1993, GROWTH FACTORS, V8, P99, DOI 10.3109/08977199309046930; NAGATA S, 1990, HDB EXPT PHARM, V95, P699; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHREURS J, 1991, INT IMMUNOL, V3, P1231, DOI 10.1093/intimm/3.12.1231; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TAKAKI S, 1991, EMBO J, V10, P2833, DOI 10.1002/j.1460-2075.1991.tb07832.x; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	52	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25818	25823						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503988				2022-12-27	WOS:A1993MK10000079
J	FERRERAS, M; GAVILANES, JG; LOPEZOTIN, C; GARCIASEGURA, JM				FERRERAS, M; GAVILANES, JG; LOPEZOTIN, C; GARCIASEGURA, JM			THIOL-DISULFIDE EXCHANGE OF RIBONUCLEASE INHIBITOR BOUND TO RIBONUCLEASE-A - EVIDENCE OF ACTIVE INHIBITOR-BOUND RIBONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT-BINDING INHIBITION; LEUCINE-RICH REPEATS; HUMAN-PLACENTA; CIRCULAR-DICHROISM; RNASE INHIBITOR; PROTEIN; PURIFICATION; ANGIOGENIN; RESIDUES; SYSTEM	Ribonuclease Inhibitor (RI) has been purified from pig testis. It contains 30 half-cystines whose oxidation affects its ability to bind and inhibit ribonuclease (RNase), By N-terminal sequence analyses testis RI showed to be identical to that from porcine liver, for which a characteristic all-or-none type of SH-oxidation by 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) has been reported (Fominaya, J. M., and Hofsteenge, J. (1992) J. Biol. Chem. 257, 24655-24660), Under comparable reaction conditions, testis RI bound to RNase A did not exhibit this particular type of oxidation; instead, bound RI got intermediate oxidation degrees (up to 14 thiols oxidized per RI moiety) without dissociating from RNase. Moreover, RNase bound to partially oxidized RI was able to express some (15%) of its potential activity (active complex). Only when DTNB treatments accounted for complex dissociation (>14 thiols oxidized per RI moiety) the released RI molecules exhibited the all-or-none oxidation behavior. By both kinetic and circular dichroism analyses, conformational changes have been evidenced for the transition from the inactive to the active form of RI-RNase complex. Relaxation of RI-RNase binding without major alterations in RI structure is proposed as responsible for complex activation. The results are discussed in terms of a model for the reversible regulation of RNase activity mediated by the redox status of RI.	UNIV COMPLUTENSE MADRID, FAC QUIM, DEPT BIOQUIM & BIOL MOLEC, E-28040 MADRID, SPAIN; UNIV OVIEDO, DEPT BIOL FUNC, E-33006 OVIEDO, SPAIN	Complutense University of Madrid; University of Oviedo			López-Otín, Carlos/AAB-2106-2020; GARCIA-SEGURA, JUAN MANUEL/H-8215-2015; Gavilanes, Jose G./K-5307-2014	López-Otín, Carlos/0000-0001-6964-1904; GARCIA-SEGURA, JUAN MANUEL/0000-0003-2616-8154; Gavilanes, Jose G./0000-0002-6852-341X				BLACKBURN P, 1982, J BIOL CHEM, V257, P316; BLACKBURN P, 1980, J BIOL CHEM, V255, P959; BLACKBURN P, 1977, J BIOL CHEM, V252, P5904; BLACKBURN P, 1979, J BIOL CHEM, V254, P2484; Blackburn P, 1982, ENZYMES, VXV, P317; BURTON LE, 1982, INT J PEPT PROT RES, V19, P372; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P2413; DEUTSCHER MP, 1993, J BIOL CHEM, V268, P13011; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FERRERAS M, 1993, ANAL BIOCHEM, V213, P206, DOI 10.1006/abio.1993.1410; FOMINAYA JM, 1988, BIOCHEM J, V253, P517, DOI 10.1042/bj2530517; FOMINAYA JM, 1992, J BIOL CHEM, V267, P24655; FOMINAYA JM, 1988, BIOCHIM BIOPHYS ACTA, V954, P216, DOI 10.1016/0167-4838(88)90074-X; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GLAZER AN, 1975, CHEM MODIFICATION PR, P113; GREIF RL, 1977, METABOLISM, V26, P851, DOI 10.1016/0026-0495(77)90003-8; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P8537, DOI 10.1021/bi00423a006; HOFSTEENGE J, 1991, J BIOL CHEM, V266, P24198; JANATOVA J, 1968, J BIOL CHEM, V243, P3612; JOHNSON WC, 1992, METHOD ENZYMOL, V210, P426; KISS Z, 1979, FEBS LETT, V108, P185, DOI 10.1016/0014-5793(79)81206-5; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRAFT N, 1970, AUST J BIOL SCI, V23, P175, DOI 10.1071/BI9700175; KRAFT N, 1970, BIOCHIM BIOPHYS ACTA, V217, P164, DOI 10.1016/0005-2787(70)90133-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE FS, 1988, BIOCHEMISTRY-US, V27, P8545, DOI 10.1021/bi00423a007; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; LEE FS, 1993, PROG NUCLEIC ACID RE, V44, P1, DOI 10.1016/S0079-6603(08)60215-9; LIU DK, 1975, BIOCHEM J, V148, P67, DOI 10.1042/bj1480067; Merril C.R., 1990, METHOD ENZYMOL, V182, P477; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; PIROTTE M, 1952, B SOC CHIM BELG, V61, P167; RICHARDS FM, 1971, ENZYMES, V4, P647; ROTH JS, 1967, METHOD CANCER RES, V3, P167; SAJDELSULKOWSKA EM, 1984, SCIENCE, V225, P947, DOI 10.1126/science.6206567; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; SUZUKI Y, 1970, J NEUROCHEM, V17, P1521, DOI 10.1111/j.1471-4159.1970.tb00520.x; VICENTINI AM, 1990, BIOCHEMISTRY-US, V29, P8827, DOI 10.1021/bi00489a046; WALTERS DW, 1986, J BIOL CHEM, V261, P5372; WALTERS DW, 1986, J BIOL CHEM, V261, P3135; WEAST RC, 1981, CRC HDB CHEM PHYSICS; YANG JT, 1986, METHOD ENZYMOL, V130, P208	46	18	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28570	28578		10.1074/jbc.270.48.28570	http://dx.doi.org/10.1074/jbc.270.48.28570			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499372	hybrid			2022-12-27	WOS:A1995TH05600016
J	KARKI, S; HOLZBAUR, ELF				KARKI, S; HOLZBAUR, ELF			AFFINITY-CHROMATOGRAPHY DEMONSTRATES A DIRECT BINDING BETWEEN CYTOPLASMIC DYNEIN AND THE DYNACTIN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; VESICLE MOTILITY; MICROTUBULES; POLYPEPTIDE; PROTEIN; ACTIN; LOCALIZATION; COMPONENT; TRANSPORT; HOMOLOGY	We used affinity chromatography to probe for a direct binding interaction between cytoplasmic dynein and dynactin. Purified cytoplasmic dynein was found to bind to an affinity column of p150(Glued), the largest polypeptide in the dynactin complex. To test the specificity of the interaction, we loaded rat brain cytosol onto the p150(Glued) affinity column and observed that cytoplasmic dynein from cytosol was specifically retained on the column. Preincubation of the p150(Glued) affinity matrix with excess exogenous dynein intermediate chain resulted in a significant reduction of dynein binding, suggesting that p150(Glued) may be interacting with dynein via this polypeptide. Therefore we constructed an affinity column of recombinant dynein intermediate chain and observed that dynactin was retained from rat brain cytosol. These results demonstrate that the native dynein and dynactin complexes are capable of direct in. vitro interaction mediated by a direct binding of the dynein intermediate chain to the p150(Glued) component of the dynactin complex. We have mapped the site of this interaction to the amino-terminal region of p150(Glued) which is predicted to form an Lu helical coiled-coil. Regulation of the dynein-dynactin interaction may prove to be key in the control mechanism for cytoplasmic dynein-mediated vesicular transport.	UNIV PENN, SCH VET MED, DEPT ANIM BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, CELL BIOL GRAD GRP, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048661] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48661] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ SFH, 1993, J CELL SCI, V106, P955; CLARK SW, 1992, NATURE, V359, P246, DOI 10.1038/359246a0; CLARK SW, 1994, J CELL BIOL, V127, P129, DOI 10.1083/jcb.127.1.129; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; FATH KR, 1994, J CELL BIOL, V126, P661, DOI 10.1083/jcb.126.3.661; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; HARTE PJ, 1982, GENETICS, V101, P477; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; HOLZBAUR ELF, 1989, BIOCHEMISTRY-US, V28, P7010, DOI 10.1021/bi00443a034; KING SM, 1990, J BIOL CHEM, V265, P19807; KUMAR J, 1995, SCIENCE, V267, P1834, DOI 10.1126/science.7892610; LACEY ML, 1992, J BIOL CHEM, V267, P4793; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER JP, 1992, NATURE, V359, P244, DOI 10.1038/359244a0; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; LIN SXH, 1993, J CELL SCI, V105, P579; MCGRAIL M, 1995, J CELL BIOL, V131, P411, DOI 10.1083/jcb.131.2.411; MUHUA L, 1994, CELL, V78, P669, DOI 10.1016/0092-8674(94)90531-2; PASCHAL BM, 1993, J BIOL CHEM, V268, P15318; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PASCHAL BM, 1992, J CELL BIOL, V118, P1133, DOI 10.1083/jcb.118.5.1133; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139; RICKARD JE, 1991, J BIOL CHEM, V266, P17597; SCHAFER DA, 1994, J CELL BIOL, V126, P402; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; SWAROOP A, 1987, P NATL ACAD SCI USA, V84, P6501, DOI 10.1073/pnas.84.18.6501; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; [No title captured]	36	280	285	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28806	28811		10.1074/jbc.270.48.28806	http://dx.doi.org/10.1074/jbc.270.48.28806			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499404	hybrid			2022-12-27	WOS:A1995TH05600048
J	YEDNOCK, TA; CANNON, C; VANDEVERT, C; GOLDBACH, EG; SHAW, G; ELLIS, DR; LIAW, C; FRITZ, LC; TANNER, LI				YEDNOCK, TA; CANNON, C; VANDEVERT, C; GOLDBACH, EG; SHAW, G; ELLIS, DR; LIAW, C; FRITZ, LC; TANNER, LI			ALPHA(4)BETA(1) INTEGRIN-DEPENDENT CELL-ADHESION IS REGULATED BY A LOW-AFFINITY RECEPTOR POOL THAT IS CONFORMATIONALLY RESPONSIVE TO LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; MONOCLONAL-ANTIBODY; GPIIB-IIIA; PLASMA FIBRONECTIN; ENDOTHELIAL-CELLS; ACTIVATION; VCAM-1; VLA-4; RECOGNITION; SPECIFICITY	alpha(4) beta(1) integrin (VLA-4) appears to be unique among the leukocyte integrins in that it can initiate the adhesion of circulating lymphocytes without cellular activation, It is not known how lymphocytes or other cell types maintain constitutive levels of alpha(4) beta(1) integrin activity. The current report describes a monoclonal antibody, 15/7, that recognizes a high affinity or ligand-occupied conformation of beta(1) integrin. Studies with 15/7 revealed that alpha(4) beta(1) integrin-dependent adhesion of leukocytic cell lines is mediated by a population of low affinity receptors that is conformationally responsive to ligand; the 15/7 epitope could be induced by nanomolar concentrations of soluble VCAM-1 or by micromolar concentrations of a peptide derived from the type III connecting segment domain of fibronectin (as ligands for alpha(4) beta(1) integrin). The same receptors were also responsive to adhesion activating reagents, such as Mn2+, activating anti-beta(1) integrin antibodies, and phorbol myristate acetate, which induced the 15/7 epitope directly and/or decreased the concentration of ligand required for epitope induction. In addition to the responsive receptor pool, cells expressed a second population of alpha(4) beta(1) integrin that was conformationally restrained, failing to respond to ligand or to any of the activating reagents. The relative size of the responsive and inactive receptor pools, as well as the affinity of the responsive receptors, represented a stable phenotype of different cell types and played important roles in defining the cells' adhesive capacity and ligand specificity. Similar receptor populations were measured on lymphocyte subsets in whole blood, These studies provide insight into how cells maintain different constitutive levels of alpha(4) beta(1) integrin activity, and how the activity of beta(1) integrin can be modulated by activators of cell adhesion.	ATHENA NEUROSCI INC, San Francisco, CA 94080 USA; GENET INST INC, CAMBRIDGE, MA 02140 USA									ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BEAMES B, 1991, BIOTECHNIQUES, V11, P378; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CYBULSKY MI, 1991, AM J PATHOL, V138, P815; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GAILIT J, 1988, J BIOL CHEM, V263, P12927; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HESSION C, 1991, J BIOL CHEM, V266, P6682; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JAKUBOWSKI A, 1995, J IMMUNOL, V155, P938; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KENT SJ, 1995, J NEUROIMMUNOL, V58, P1, DOI 10.1016/0165-5728(94)00165-K; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; LUSCINSKAS FW, 1995, J EXP MED, V181, P1179, DOI 10.1084/jem.181.3.1179; MAKAREM R, 1994, J BIOL CHEM, V269, P4005; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MOULD AP, 1990, J BIOL CHEM, V265, P4020; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; OVERLY CC, 1991, BIOCHEM BIOPH RES CO, V181, P513, DOI 10.1016/0006-291X(91)91218-2; PARKER CM, 1993, J BIOL CHEM, V268, P7028; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PLOW EF, 1981, J BIOL CHEM, V256, P9477; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SRIRAMARAO P, 1994, J IMMUNOL, V153, P4238; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; WAYNER EA, 1992, J CELL BIOL, V116, P489, DOI 10.1083/jcb.116.2.489; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321	49	144	155	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28740	28750		10.1074/jbc.270.48.28740	http://dx.doi.org/10.1074/jbc.270.48.28740			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499396	hybrid			2022-12-27	WOS:A1995TH05600040
J	NISHIKAWA, Y; CARR, BI; WANG, M; KAR, S; FINN, F; DOWD, P; ZHENG, ZB; KERNS, J; NAGANATHAN, S				NISHIKAWA, Y; CARR, BI; WANG, M; KAR, S; FINN, F; DOWD, P; ZHENG, ZB; KERNS, J; NAGANATHAN, S			GROWTH-INHIBITION OF HEPATOMA-CELLS INDUCED BY VITAMIN-K AND ITS ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXY PROTHROMBIN; C-MYC PROTEIN; HEPATOCELLULAR-CARCINOMA; ABNORMAL PROTHROMBIN; MENADIONE 2-METHYL-1,4-NAPHTHOQUINONE; ISOLATED HEPATOCYTES; OXIDATIVE STRESS; CYTO-TOXICITY; DEPENDENT CARBOXYLASE; TUMOR-CELLS	Congeners of vitamin K are known to inhibit cell growth, although the precise mechanisms of growth inhibition are not well understood. To investigate the mechanisms involved, we synthesized several vitamin K analogs and examined their growth inhibitory activities for a human hepatoma cell line (Hep3B). The analogs included 2-methyl-1,4-naphthoquinone and trimethylbenzoquinone, with and without aliphatic side chains at position 3. The side chains were all-carbon, thioethers, or O-ethers. Growth inhibition was potent in the compounds with short chains. The presence of a sulfur (thioether) or oxygen atom (O-ether) at the site of attachment of the side chain to the ring potentiated the activity. Apoptotic cell death was induced by the potent growth inhibitory compounds at low concentrations (20-60 mu M), whereas necrotic cell death followed treatment with the same compounds at high concentrations. Expression of c-myc, which is thought to be associated with apoptosis, was increased by most of the compounds tested. Both reduced glutathione and cysteine almost completely abrogated the growth inhibitory effects of the thioether analogs as well as of vitamin K-3. The effect of glutathione was less prominent for the all-carbon and O-ether analogs, and cysteine had no effect on these analogs. Catalase and deferoxamine mesylate had no significant effect on the thioether analogs, although they showed partial antagonistic effects on the growth inhibition of vitamin K-3 and the all-carbon and O-ether analogs. Other non-thiol antioxidants tested had no effect on any of the analogs. Our results indicated that vitamin K-related quinoid compounds cause growth inhibition and both apoptotic and necrotic cell death and that the effects may be mediated by interaction at position 3 of their quinoid nuclei with cellular thiols.	UNIV PITTSBURGH, PITTSBURGH TRANSPLANT INST, DEPT SURG, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, PROT RES LAB, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, DEPT CHEM, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Kar, Siddhartha/0000-0001-9293-9274; Carr, Brian/0000-0002-6111-5077	NCI NIH HHS [CA 57371] Funding Source: Medline; NHLBI NIH HHS [HL 50667] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA057371] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050667] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKEDO Y, 1992, BIOCHEM BIOPH RES CO, V187, P814, DOI 10.1016/0006-291X(92)91269-V; AKMAN SA, 1985, CANCER RES, V45, P5257; AKMAN SA, 1988, P AN M AM SOC CLIN, V7, P290; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; BROWN PC, 1991, ARCH BIOCHEM BIOPHYS, V285, P187, DOI 10.1016/0003-9861(91)90348-M; BUITENHUIS HC, 1990, BIOCHIM BIOPHYS ACTA, V1034, P170, DOI 10.1016/0304-4165(90)90072-5; CARR BI, 1994, HEPATOLOGY, V20, P727; CHLEBOWSKI RT, 1985, CANCER TREAT REP, V69, P527; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; DOROSHOW JH, 1986, P NATL ACAD SCI USA, V83, P4514, DOI 10.1073/pnas.83.12.4514; DOWD P, 1994, NAT PROD REP, V11, P251, DOI 10.1039/np9941100251; DYPBUKT JM, 1994, J BIOL CHEM, V269, P30553; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FUJIYAMA S, 1988, CANCER, V61, P1621, DOI 10.1002/1097-0142(19880415)61:8<1621::AID-CNCR2820610820>3.0.CO;2-C; FURUKAWA M, 1992, CANCER-AM CANCER SOC, V69, P31, DOI 10.1002/1097-0142(19920101)69:1<31::AID-CNCR2820690108>3.0.CO;2-6; GANT TW, 1988, CHEM-BIOL INTERACT, V65, P157, DOI 10.1016/0009-2797(88)90052-X; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLD J, 1986, CANCER TREAT REP, V70, P1433; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUISSE MG, 1994, CANCER, V74, P1533, DOI 10.1002/1097-0142(19940901)74:5<1533::AID-CNCR2820740507>3.0.CO;2-V; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JUAN CC, 1993, BIOCHEM BIOPH RES CO, V190, P907, DOI 10.1006/bbrc.1993.1135; KERNS J, 1995, BIOORG CHEM, V23, P101, DOI 10.1006/bioo.1995.1008; LEE RH, 1992, BIOCHEM BIOPH RES CO, V184, P765, DOI 10.1016/0006-291X(92)90656-6; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; LIEBMAN HA, 1984, NEW ENGL J MED, V310, P1427, DOI 10.1056/NEJM198405313102204; LIU BL, 1991, RECL TRAV CHIM PAY B, V110, P99; MACK DO, 1979, J BIOL CHEM, V254, P2656; MASAKI N, 1989, ARCH BIOCHEM BIOPHYS, V269, P390, DOI 10.1016/0003-9861(89)90122-7; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MCCONKEY DJ, 1988, TOXICOL LETT, V42, P123, DOI 10.1016/0378-4274(88)90069-0; NAKAO A, 1991, HEPATO-GASTROENTEROL, V38, P450; NGO EO, 1991, BIOCHEM PHARMACOL, V42, P1961, DOI 10.1016/0006-2952(91)90596-W; NISHIBAYASHI H, 1967, J BIOCHEM, V62, P215, DOI 10.1093/oxfordjournals.jbchem.a128651; NOTO V, 1989, CANCER, V63, P901, DOI 10.1002/1097-0142(19890301)63:5<901::AID-CNCR2820630518>3.0.CO;2-G; NUTTER LM, 1992, J BIOL CHEM, V267, P2474; OHTA H, 1995, CANCER RES, V55, P691; ONO M, 1990, AM J GASTROENTEROL, V85, P1149; PRASAD KN, 1981, LIFE SCI, V29, P1387, DOI 10.1016/0024-3205(81)90683-4; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P5243, DOI 10.1093/nar/20.19.5243; ROSS D, 1985, CHEM-BIOL INTERACT, V55, P177, DOI 10.1016/S0009-2797(85)80126-5; ROSS D, 1986, ARCH BIOCHEM BIOPHYS, V248, P460, DOI 10.1016/0003-9861(86)90499-6; ROSSI L, 1986, ARCH BIOCHEM BIOPHYS, V251, P25, DOI 10.1016/0003-9861(86)90047-0; SAKON M, 1991, AM J GASTROENTEROL, V86, P339; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STONE RL, 1994, J BIOL CHEM, V269, P31323; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; SUTTIE JW, 1991, HDB VITAMINS, P145; TAGGART WV, 1969, BIOCHEMISTRY-US, V8, P1141, DOI 10.1021/bi00831a047; TALCOTT RE, 1984, BIOCHEM PHARMACOL, V33, P2663, DOI 10.1016/0006-2952(84)90642-7; TAPER HS, 1987, INT J CANCER, V40, P575, DOI 10.1002/ijc.2910400424; THOR H, 1982, J BIOL CHEM, V257, P2419; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; WEITZ IC, 1993, HEPATOLOGY, V18, P990, DOI 10.1002/hep.1840180434; WILSON I, 1987, CHEM-BIOL INTERACT, V61, P229, DOI 10.1016/0009-2797(87)90003-2; WU FYH, 1993, LIFE SCI, V52, P1797, DOI 10.1016/0024-3205(93)90469-J; WU FYH, 1993, ONCOGENE, V8, P2237	59	151	185	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28304	28310						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499329				2022-12-27	WOS:A1995TG21000054
J	TU, GC; CAO, QN; ISRAEL, Y				TU, GC; CAO, QN; ISRAEL, Y			INHIBITION OF GENE-EXPRESSION BY TRIPLE-HELIX FORMATION IN HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE PROMOTER; T7 RNA-POLYMERASE; ANTISENSE OLIGONUCLEOTIDES; STEREOCONTROLLED SYNTHESIS; ALDEHYDE DEHYDROGENASES; FORMING OLIGONUCLEOTIDE; MOLECULAR ABNORMALITY; BINDING; TRANSCRIPTION; DNA	The aim of this study was to selectively inhibit human mitochondrial aldehyde dehydrogenase (ALDH(2)) gene expression by triple helix assembly. Eight 21-mer oligodeoxyribonucleotides were designed to bind to two purine-rich sequences in the 5'-flanking region of the human ALDH(2) gene. Gel mobility shift assays showed that tripler formation is sequence-specific for the target duplex and the third strand oligonucleotide, In the presence of Mg2+, but absence of K+, tripler-forming oligonucleotides bind to their target sites with apparent dissociation constants (K-d) in the 10(-7) to 10(-9) M range. Potassium cation virtually suppressed the tripler formation of G-C-rich duplex DNA with natural oligonucleotides, but did not prevent tripler formation with phosphorothioate-modified oligonucleotides. Phosphoro-thioate-modified oligonucleotides were delivered into human hepatoma Hep G2 cells by cationic liposomes. The reduction in ALDH(2) mRNA levels in the cells was determined by the competitive reverse transcription-polymerase chain reaction. One of the phosphorothioate-modified oligonucleotides designed to form an antiparallel tripler with a target in the 5'-flanking region of human ALDH(2) gene (-105 to -125 from the translation initiation codon ATG) reduced by 80-90% the ALDH(2) mRNA levels without affecting albumin mRNA levels. Data suggest that triple-helix formation may provide a means to selectively inhibit hepatic ALDH(2) gene expression for therapeutic use.			TU, GC (corresponding author), THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT PATHOL ANAT & CELL BIOL, 1020 LOCUST ST, RM 275, PHILADELPHIA, PA 19107 USA.			Israel, Yedy/0000-0003-3468-7966				ADACHI J, 1989, ALCOHOL CLIN EXP RES, V13, P601, DOI 10.1111/j.1530-0277.1989.tb00389.x; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BLUME SW, 1992, NUCLEIC ACIDS RES, V20, P1777; CHENG AJ, 1993, NUCLEIC ACIDS RES, V21, P5630, DOI 10.1093/nar/21.24.5630; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; DURLAND RH, 1994, NUCLEIC ACIDS RES, V22, P3233, DOI 10.1093/nar/22.15.3233; FRESHNEY RI, 1994, CULTURE ANIMAL CELLS, P275; GALLANT DM, 1987, ALCOHOLISM GUIDE DIA, P170; GAO X, 1993, NUCLEIC ACIDS RES, V21, P2867, DOI 10.1093/nar/21.12.2867; GEE JE, 1995, BIOCHEMISTRY-US, V34, P2042, DOI 10.1021/bi00006a026; GEE JE, 1992, J BIOL CHEM, V267, P11163; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; Gilman A., 1985, PHARM BASIS THERAPEU, Vseventh; GOEDDE HW, 1992, HUM GENET, V88, P344; GOEDDE HW, 1983, PHARMACOL BIOCHEM BE, V18, P161, DOI 10.1016/0091-3057(83)90165-X; GREENFIELD NJ, 1977, BIOCHIM BIOPHYS ACTA, V483, P35, DOI 10.1016/0005-2744(77)90005-5; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; HACIA JG, 1994, BIOCHEMISTRY-US, V33, P5367, DOI 10.1021/bi00184a002; HARADA S, 1982, LANCET, V2, P827, DOI 10.1016/s0140-6736(82)92722-2; HEMPEL J, 1989, ENZYMOLOGY MOL BIOL, V2, P3; Hsu LC, 1988, GENOMICS, V2, P57, DOI 10.1016/0888-7543(88)90109-7; ING NH, 1993, NUCLEIC ACIDS RES, V21, P2789, DOI 10.1093/nar/21.12.2789; LAPLANCHE LA, 1986, NUCLEIC ACIDS RES, V14, P9081, DOI 10.1093/nar/14.22.9081; LAPPALAINEN K, 1994, BBA-BIOMEMBRANES, V1196, P201, DOI 10.1016/0005-2736(94)00224-X; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P7587, DOI 10.1021/bi00148a021; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MAYFIELD C, 1994, J BIOL CHEM, V269, P18232; MCSHAN WM, 1992, J BIOL CHEM, V267, P5712; MILLIGAN JF, 1993, NUCLEIC ACIDS RES, V21, P327, DOI 10.1093/nar/21.2.327; MINGHETTI PP, 1986, J BIOL CHEM, V261, P6747; OLIVAS WM, 1995, NUCLEIC ACIDS RES, V23, P1936, DOI 10.1093/nar/23.11.1936; OLIVAS WM, 1995, BIOCHEMISTRY-US, V34, P278, DOI 10.1021/bi00001a034; ORSON FM, 1991, NUCLEIC ACIDS RES, V19, P3435, DOI 10.1093/nar/19.12.3435; PILCH DS, 1991, BIOCHEMISTRY-US, V30, P6083, DOI 10.1021/bi00239a001; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; QING NC, 1988, ALCOHOL CLIN EXP RES, V12, P720, DOI 10.1111/j.1530-0277.1988.tb00271.x; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; STEC WJ, 1991, NUCLEIC ACIDS RES, V19, P5883, DOI 10.1093/nar/19.21.5883; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; SUSKA A, 1993, PURE APPL CHEM, V65, P707, DOI 10.1351/pac199365040707; SVANAS GW, 1985, ARCH BIOCHEM BIOPHYS, V236, P36, DOI 10.1016/0003-9861(85)90603-4; THOMASSON HR, 1991, AM J HUM GENET, V48, P677; TIPTON KF, 1985, ENZYMOLOGY CARBONYL, V2, P3; TU GC, 1993, EUR J CLIN CHEM CLIN, V31, P591; TU GC, 1995, BEHAV GENET, V25, P59, DOI 10.1007/BF02197242; WICKSTROM E, 1986, J BIOCHEM BIOPH METH, V13, P97, DOI 10.1016/0165-022X(86)90021-7; WILK A, 1995, NUCLEIC ACIDS RES, V23, P530, DOI 10.1093/nar/23.3.530; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Yaswen P, 1993, Antisense Res Dev, V3, P67; YOSHIDA A, 1985, ALCOHOL, V2, P103, DOI 10.1016/0741-8329(85)90024-2; YOSHIDA A, 1984, P NATL ACAD SCI-BIOL, V81, P258, DOI 10.1073/pnas.81.1.258	54	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28402	28407						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499344				2022-12-27	WOS:A1995TG21000069
J	ZIMMANN, P; PUPPE, W; ALTENDORF, K				ZIMMANN, P; PUPPE, W; ALTENDORF, K			MEMBRANE TOPOLOGY ANALYSIS OF THE SENSOR KINASE KDPD OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE-PHOSPHATASE FUSIONS; DRIVEN POTASSIUM-TRANSPORT; PROTEIN TOPOLOGY; CYTOPLASMIC MEMBRANE; SIGNAL TRANSDUCTION; OPERON EXPRESSION; GENETIC-ANALYSIS; KDPABC OPERON; ATPASE; SEQUENCE	The expression of the kdpFABC operon, coding for the K+-translocating Kdp-ATPase, is under the control of the two regulatory proteins KdpD and KdpE, which belong to the group of sensor kinase/response regulator systems. The topology of the KdpD protein in the cytoplasmic membrane was investigated using LacZ and PhoA fusions at different sites within the polypeptide chain and by treating spheroplasts in the presence or absence of Triton X-100 with the protease kallikrein. The results revealed that KdpD has four membrane-spanning segments in the middle of the polypeptide chain, whereas N and C terminus are both cytoplasmic.	UNIV OSNABRUCK, FACHBEREICH BIOL CHEM, D-49069 OSNABRUCK, GERMANY	University Osnabruck								ALTENDORF K, 1994, RES MICROBIOL, V145, P374, DOI 10.1016/0923-2508(94)90084-1; ALTENDORF K, 1992, ANN NY ACAD SCI, V671, P228, DOI 10.1111/j.1749-6632.1992.tb43799.x; ANDERSSON H, 1993, J BIOL CHEM, V268, P21389; ASHA H, 1993, J BACTERIOL, V175, P4528, DOI 10.1128/JB.175.14.4528-4537.1993; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAKKER EP, 1993, ALKALI CATION TRANSP, P00205; BOSSEMEYER D, 1989, J BACTERIOL, V171, P2219, DOI 10.1128/jb.171.4.2219-2221.1989; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; COMEAU DE, 1985, J BACTERIOL, V164, P578, DOI 10.1128/JB.164.2.578-584.1985; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; DOSCH DC, 1991, J BACTERIOL, V173, P687, DOI 10.1128/jb.173.2.687-696.1991; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; EPSTEIN W, 1978, J BIOL CHEM, V253, P6666; EPSTEIN W, 1986, FEMS MICROBIOL LETT, V39, P73; EPSTEIN W, 1992, ACTA PHYSIOL SCAND, V146, P193; Epstein W, 1970, J BACTERIOL, V101, P836, DOI 10.1128/JB.101.3.836-843.1970; GUTTERSON NI, 1983, P NATL ACAD SCI-BIOL, V80, P4894, DOI 10.1073/pnas.80.16.4894; HAARDT M, 1993, THESIS U KONSTANZ; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; KOLLMANN R, 1993, BIOCHIM BIOPHYS ACTA, V1143, P62, DOI 10.1016/0005-2728(93)90216-3; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAIMINS LA, 1978, P NATL ACAD SCI USA, V75, P3216, DOI 10.1073/pnas.75.7.3216; LAIMINS LA, 1981, P NATL ACAD SCI-BIOL, V78, P464, DOI 10.1073/pnas.78.1.464; LEE C, 1989, J BACTERIOL, V171, P4609, DOI 10.1128/jb.171.9.4609-4616.1989; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MAKINO K, 1986, J MOL BIOL, V192, P549, DOI 10.1016/0022-2836(86)90275-5; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MCGOVERN K, 1991, EMBO J, V10, P2773, DOI 10.1002/j.1460-2075.1991.tb07826.x; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; NAKASHIMA H, 1992, FEBS LETT, V303, P141, DOI 10.1016/0014-5793(92)80506-C; NAKASHIMA K, 1993, MOL MICROBIOL, V7, P109, DOI 10.1111/j.1365-2958.1993.tb01102.x; NAKASHIMA K, 1992, MOL MICROBIOL, V6, P1777, DOI 10.1111/j.1365-2958.1992.tb01350.x; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; POLAREK JW, 1992, J BACTERIOL, V174, P2145, DOI 10.1128/JB.174.7.2145-2151.1992; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEBERS A, 1988, EUR J BIOCHEM, V178, P131, DOI 10.1111/j.1432-1033.1988.tb14438.x; TRAXLER B, 1993, J MEMBRANE BIOL, V132, P1; VOELKNER P, 1993, EUR J BIOCHEM, V217, P1019, DOI 10.1111/j.1432-1033.1993.tb18333.x; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WALDERHAUG MO, 1992, J BACTERIOL, V174, P2152, DOI 10.1128/JB.174.7.2152-2159.1992; WHITLEY P, 1994, EMBO J, V13, P4653, DOI 10.1002/j.1460-2075.1994.tb06788.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	50	55	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28282	28288						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499326				2022-12-27	WOS:A1995TG21000051
J	GURLEY, LR; VALDEZ, JG; BUCHANAN, JS				GURLEY, LR; VALDEZ, JG; BUCHANAN, JS			CHARACTERIZATION OF THE MITOTIC SPECIFIC PHOSPHORYLATION SITE OF HISTONE-H1 - ABSENCE OF A CONSENSUS SEQUENCE FOR THE P34(CDC2)/CYCLIN-B-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSINE-RICH HISTONE; AMINO-ACID-SEQUENCE; CELL-CYCLE; CHROMOSOME CONDENSATION; MESSENGER-RNA; H-1 HISTONE; CHROMATIN; DERIVATIZATION; VARIANT; REGIONS	P-32-Labeled histone H1 was isolated from synchronized Chinese hamster (line CHO) cells, subjected to tryptic digestion, and fractionated into 15 phosphopeptides by high performance liquid chromatography. These phosphopeptides were grouped into five classes having different cell cycle phosphorylation kinetics: 1) peptides reaching a maximum phosphorylation rate in S and then declining in G(2) and M, 2) peptides reaching a maximum phosphorylation rate in G(2) and then remaining constant or declining in M, 3) peptides with increasing phosphorylation throughout S and G(2) and reaching a maximum in M, 4) one peptide that was phosphorylated only in M, and 5) peptides that had low levels of phosphorylation that remained constant throughout the cell cycle, Amino acid analysis and sequencing demonstrated that the mitotic specific H1 phosphopeptide was the 16-amino acid, N-terminal, tryptic peptide Ac-SETAPAAPAAAPPAEK of the H1-1 class, This peptide, which is phosphorylated on both the Ser and Thr, does not contain the consensus sequence (S/T)PXZ (where X is any amino acid and Z is a basic amino acid), This sequence is thought to be required by the p34(cdc2)/cyclin B kinase that has maximum phosphorylating activity in mitosis, These data indicate that this kinase either does not have an obligatory requirement for the consensus sequence in vivo as generally believed or that it is not the enzyme responsible for the mitotic specific H1 phosphorylation.			GURLEY, LR (corresponding author), LOS ALAMOS NATL LAB,DIV LIFE SCI,MAILSTOP M-880,LOS ALAMOS,NM 87545, USA.							BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BRADBURY EM, 1973, EUR J BIOCHEM, V33, P131, DOI 10.1111/j.1432-1033.1973.tb02664.x; Cohen S., 1989, PICOTAG METHOD MANUA, P25; COHEN SA, 1984, AM LAB, V16, P48; COLE KD, 1990, GENE, V89, P265, DOI 10.1016/0378-1119(90)90015-J; CRISSMAN HA, 1991, P NATL ACAD SCI USA, V88, P7580, DOI 10.1073/pnas.88.17.7580; Drapeau G R, 1977, Methods Enzymol, V47, P189; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Gurley L., 1990, HPLC BIOL MACROMOLEC, P529; GURLEY LR, 1991, J PROTEIN CHEM, V10, P75, DOI 10.1007/BF01024658; GURLEY LR, 1983, ANAL BIOCHEM, V129, P132, DOI 10.1016/0003-2697(83)90061-1; GURLEY LR, 1974, J CELL BIOL, V60, P356, DOI 10.1083/jcb.60.2.356; GURLEY LR, 1975, J BIOL CHEM, V250, P3936; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; GURLEY LR, 1973, BIOCHEMISTRY-US, V12, P237, DOI 10.1021/bi00726a010; GURLEY LR, 1980, J TOXICOL ENV HEALTH, V6, P87, DOI 10.1080/15287398009529833; GURLEY LR, 1978, CELL CYCLE REGULATIO, P37; HARTMAN PG, 1977, EUR J BIOCHEM, V77, P45, DOI 10.1111/j.1432-1033.1977.tb11639.x; HOHMANN P, 1976, J BIOL CHEM, V251, P3685; JERZMANOWSKI A, 1992, J BIOL CHEM, V267, P8514; JONES GMT, 1974, J BIOL CHEM, V249, P2548; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LIAO LW, 1981, J BIOL CHEM, V256, P3024; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; OHE Y, 1986, J BIOCHEM-TOKYO, V100, P359, DOI 10.1093/oxfordjournals.jbchem.a121722; OHE Y, 1989, J BIOCHEM-TOKYO, V106, P844, DOI 10.1093/oxfordjournals.jbchem.a122941; ORD MG, 1968, BIOCHEM J, V107, P403, DOI 10.1042/bj1070403; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARSEGHIAN MH, 1994, PROTEIN SCI, V3, P575; PHILLIPS DM, 1963, BIOCHEM J, V87, P258, DOI 10.1042/bj0870258; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RALL SC, 1971, J BIOL CHEM, V246, P7175; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; TOBEY RA, 1990, P NATL ACAD SCI USA, V87, P5104, DOI 10.1073/pnas.87.13.5104; VANHOLDE KE, 1989, CHROMATIN, P88; YANG YS, 1987, J BIOL CHEM, V262, P17118	37	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27653	27660		10.1074/jbc.270.46.27653	http://dx.doi.org/10.1074/jbc.270.46.27653			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499230	hybrid			2022-12-27	WOS:A1995TE73600041
J	TERADA, K; KAZIRO, Y; SATOH, T				TERADA, K; KAZIRO, Y; SATOH, T			RAS IS NOT REQUIRED FOR THE INTERLEUKIN 3-INDUCED PROLIFERATION OF A MOUSE PRO-B CELL-LINE, BAF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE-2; RECEPTOR TYROSINE KINASES; HA-RAS; PROTEIN-KINASE; BETA-SUBUNIT; MAP KINASE; ACTIVATION; GROWTH; PHOSPHORYLATION; TRANSDUCTION	It has been demonstrated that Res is involved in interleukin 3 (IL-3)-stimulated signal transduction in various hematopoietic cultured cells (Satoh, T., Nakafuku, M., Miyajima, A., and Kaziro, Y. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 3314-3318; Duronio, V., Welham, M. J., Abraham, S., Dryden, P., and Schrader, J. W. (1992) Proc. Natl. Acad. Sci. U.S. A. 89, 1587-1591). However, it has not been fully understood which of IL-3-promoted cellular responses, i.e. proliferation, survival, and differentiation, requires Ras function. We employed a system of inducible expression of the dominant-negative (S17N) or dominant-active (G12V) mutant of Ras in BaF3 mouse pro-B cell line to analyze the role of Ras in IL-3-stimulated signal transduction. Induction of the dominant-negative Ras(S17N) effectively inhibited the IL-3-induced activation of c-Raf-1 and mitogen activated protein kinase (MAPK). Furthermore, the activation of fos gene promoter following IL-3 stimulation was almost completely abolished when Ras(Sl7N) was induced. Under these conditions, Ras(S17N) exhibited no inhibitory effect on IL-3-dependent proliferation assessed by the increase of cell numbers and a mitochondrial enzyme activity. The results indicate that Ras-dependent pathways, including the Raf/MAPK/Fos pathway, are dispensable for IL-3 induced growth stimulation. When BaF3 cells were treated with a tyrosine kinase inhibitor, herbimycin A, IL-3 dependent proliferation of the cells was impaired, suggesting that tyrosine kinase-mediated pathways are critical for growth promotion. On the other hand, apoptotic cell death caused by deprivation of IL-3 was prevented by the induction of the activated mutant Ras(G12V), although the rate of cell number increase was markedly reduced. Thus, it is likely that Ras-independent pathways play important roles to facilitate the proliferation although they may not be essential for IL-3-stimulated antiapoptotic signal transduction.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN	Tokyo Institute of Technology			Satoh, Takaya/K-2628-2014; Terada, Koji/G-3049-2012					ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENT P, 1995, MOL CELL BIOL, V15, P4125; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GOTOH Y, 1994, ONCOGENE, V9, P1891; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P2222; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OKUDA K, 1994, J BIOL CHEM, V269, P24602; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REIF K, 1994, J BIOL CHEM, V269, P14081; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SATO N, 1994, CURR OPIN CELL BIOL, V6, P174, DOI 10.1016/0955-0674(94)90133-3; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1988, BIOCHIM BIOPHYS ACTA, V949, P97, DOI 10.1016/0167-4781(88)90059-0; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SATOH T, 1992, J BIOL CHEM, V267, P25423; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TANAKA T, 1985, P NATL ACAD SCI USA, V82, P3400, DOI 10.1073/pnas.82.10.3400; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	59	63	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27880	27886		10.1074/jbc.270.46.27880	http://dx.doi.org/10.1074/jbc.270.46.27880			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499262	hybrid			2022-12-27	WOS:A1995TE73600073
J	BOWDITCH, RD; HARIHARAN, M; TOMINNA, EF; SMITH, JW; YAMADA, KM; GETZOFF, ED; GINSBERG, MH				BOWDITCH, RD; HARIHARAN, M; TOMINNA, EF; SMITH, JW; YAMADA, KM; GETZOFF, ED; GINSBERG, MH			IDENTIFICATION OF A NOVEL INTEGRIN BINDING-SITE IN FIBRONECTIN - DIFFERENTIAL UTILIZATION BY BETA-3 INTEGRINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIB-IIIA COMPLEX; IMMUNOGLOBULIN-LIKE DOMAINS; CELL-ADHESION; DIRECTED MUTAGENESIS; VITRONECTIN RECEPTOR; SECONDARY STRUCTURE; SYNTHETIC PEPTIDES; PLASMA FIBRONECTIN; RIBBON MODELS; HUMAN CD4	Fibronectin (Fn) binding to the integrins alpha IIb beta 3 and alpha v beta 3 involves the Arg-Gly-Asp sequence. The identification of other regions of Fn that interact with alpha IIb beta 3 suggests a potential mechanism for differential ligand recognition by integrins. We report here the identification of an 11-residue peptide sequence from the 9th type III repeat of Fn (3Fn9), which inhibits ligand binding to alpha IIb beta 3 by interacting directly with this receptor. Mutational analysis demonstrated that this same region was involved in the formation of epitopes for two anti-Fn mAbs that inhibit Fn binding to alpha IIb beta 3, thus emphasizing the role of this site in the macromolecule. Molecular modeling of the 3Fn9-10 modules suggested that Fn residues Asp(1373)-Th-1383 are at least 25 Angstrom distant from the Arg-Gly-Asp site and therefore does not directly interact with it. The 3Fn9 site was differentially recognized by the beta 3 integrin family. The Asp(1373)-Thr(1383) peptide failed to inhibit ligand binding to alpha v beta 3, a recombinant Fn Ala(1235)-Ser(1436) fragment was not recognized by alpha v beta 3, and addition of the 3Fn9 module to the amino terminus of the 3Fn10 did not affect the potency of inhibiton of Fn binding to alpha v beta 3. Thus, a novel integrin recognition site in the 3Fn9 module of Fn that is differentially recognized by the beta 3 integrins has been localized within the residues Asp(1373)-Thr(1383).	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; NIDR, DEV BIOL LAB, BETHESDA, MD 20892 USA	Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	BOWDITCH, RD (corresponding author), SCRIPPS RES INST, DEPT VASC BIOL, COMM VASC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Yamada, Kenneth/0000-0003-1512-6805	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411, P01HL031950, R01HL028235] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28235, HL31950, HL16411] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; AOTA S, 1991, J BIOL CHEM, V266, P15938; BARON M, 1992, BIOCHEMISTRY-US, V31, P2068, DOI 10.1021/bi00122a025; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BUSK M, 1992, J BIOL CHEM, V267, P5790; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; DALE GL, 1991, BLOOD, V77, P1096; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ENGVALL E, 1972, J IMMUNOL, V109, P129; FORSYTH J, 1992, METHOD ENZYMOL, V215, P311; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; GARDNER JM, 1985, CELL, V42, P439, DOI 10.1016/0092-8674(85)90101-1; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1983, J CLIN INVEST, V71, P619, DOI 10.1172/JCI110808; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; JONES FS, 1988, P NATL ACAD SCI USA, V85, P2186, DOI 10.1073/pnas.85.7.2186; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIMIZUKA F, 1991, J BIOL CHEM, V266, P3045; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1987, J BIOL CHEM, V262, P947; LAM SCT, 1989, J BIOL CHEM, V264, P3742; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MEINKE A, 1993, J BACTERIOL, V175, P1910, DOI 10.1128/JB.175.7.1910-1918.1993; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; ODERMATT E, 1989, FIBRONECTIN, P1; PARISE LV, 1986, J BIOL CHEM, V261, P14011; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PLOW EF, 1981, J BIOL CHEM, V256, P9477; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; ROSS L, 1992, J BIOL CHEM, V267, P8537; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SMITH JW, 1988, J BIOL CHEM, V263, P18726; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; VAUGHAN KT, 1993, J BIOL CHEM, V268, P3670; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WATANABE T, 1990, J BIOL CHEM, V265, P15659; WOODS VL, 1986, J BIOL CHEM, V261, P5242; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	60	186	188	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10856	10863						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511609				2022-12-27	WOS:A1994NF01700098
J	CHEDID, M; RUBIN, JS; CSAKY, KG; AARONSON, SA				CHEDID, M; RUBIN, JS; CSAKY, KG; AARONSON, SA			REGULATION OF KERATINOCYTE GROWTH-FACTOR GENE-EXPRESSION BY INTERLEUKIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; MORPHOGENESIS; KGF; DIFFERENTIATION; INDUCTION; INVITRO; FAMILY	Keratinocyte growth factor (KGF) is a stromally derived member of the fibroblast growth factor family (FGF7) with potent mitogenic activity on a variety of epithelial cells. To identify molecules that regulate the expression of this paracrine mediator of epithelial proliferation, we investigated the effects of various cytokines and growth factors on KGF production by fibroblasts. The proinflammatory cytokine interleukin 1 (IL1) strongly induced the expression of KGF RNA in fibroblasts from multiple sources. Platelet-derived growth factor BB, IL6, and transforming growth factor a caused a moderate elevation, while tumor necrosis factor a and basic FGF did not alter the level of KGF RNA expression. The induction by IL1 of KGF transcript levels was time and dose dependent and specifically blocked by anti-IL1 antibodies. Nuclear run on experiments indicated that IL1 stimulated KGF gene transcription. Western blot analysis and keratinocyte proliferation assays demonstrated a corresponding increase in mitogenically active KGF protein in conditioned medium obtained from IL1-treated fibroblasts. The stimulation of KGF expression by IL1 and other cytokines such as IL6, transforming growth factor alpha, and platelet-derived growth factor may provide a mechanism for KGF induction during inflammation that would support its proposed role as mediator of reepithelialization and wound healing.			CHEDID, M (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,BETHESDA,MD 20892, USA.							ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; CHUNG LWK, 1993, SEMIN CANCER BIOL, V4, P183; Cullen K J, 1992, Cancer Treat Res, V61, P413; CUNHA GR, 1991, DEVELOPMENT, V111, P145; Donjacour A A, 1991, Cancer Treat Res, V53, P335; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GAY CG, 1991, P NATL ACAD SCI USA, V88, P296, DOI 10.1073/pnas.88.1.296; HIRAI Y, 1992, CELL, V69, P471, DOI 10.1016/0092-8674(92)90448-L; KELLEY MJ, 1992, P NATL ACAD SCI USA, V89, P9287, DOI 10.1073/pnas.89.19.9287; KUPPER TS, 1990, J INVEST DERMATOL, V94, pS146, DOI 10.1111/1523-1747.ep12876130; LI BY, 1992, CANCER RES, V52, P2248; MARCHESE C, 1990, J CELL PHYSIOL, V144, P326, DOI 10.1002/jcp.1041440219; MERCOLA M, 1988, DEVELOPMENT, V102, P451; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; PANOS RJ, 1993, J CLIN INVEST, V92, P969, DOI 10.1172/JCI116673; Partanen A M, 1990, Curr Top Dev Biol, V24, P31, DOI 10.1016/S0070-2153(08)60083-6; PARTRIDGE M, 1991, J INVEST DERMATOL, V96, P771, DOI 10.1111/1523-1747.ep12471723; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SAKAKURA T, 1976, SCIENCE, V194, P1439, DOI 10.1126/science.827022; SARIOLA H, 1988, CELL, V54, P235, DOI 10.1016/0092-8674(88)90556-9; SAWHNEY N, 1992, CANCER, V70, P2115, DOI 10.1002/1097-0142(19921015)70:8<2115::AID-CNCR2820700818>3.0.CO;2-K; SMOLA H, 1993, J CELL BIOL, V122, P417, DOI 10.1083/jcb.122.2.417; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; TAMURA M, 1993, J BIOL CHEM, V268, P8140; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123	36	185	189	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10753	10757						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511604				2022-12-27	WOS:A1994NF01700084
J	LUBINUS, M; MEIER, KE; SMITH, EA; GAUSE, KC; LEROY, EC; TROJANOWSKA, M				LUBINUS, M; MEIER, KE; SMITH, EA; GAUSE, KC; LEROY, EC; TROJANOWSKA, M			INDEPENDENT EFFECTS OF PLATELET-DERIVED GROWTH-FACTOR ISOFORMS ON MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION AND MITOGENESIS IN HUMAN DERMAL FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA RECEPTORS; MAP KINASE; SIGNAL TRANSDUCTION; TGF-BETA; PDGF-AA; CELLS; PATHWAYS; PHOSPHORYLATION; PROGRESS; INVITRO	Mitogen-activated protein kinase (MAPK) is activated in many cell types in response to growth factors during the G0-G1 transition in the cell cycle. We investigated the effects of platelet-derived growth factor (PDGF) AA and PDGF BB on activation of MAPK in human dermal fibroblasts, and asked whether its activation correlates with proliferative responses of human fibroblasts to PDGF AA and PDGF BB. Treatment with either PDGF isoform for 20 min resulted in equal phosphorylation of MAPK as visualized by gel shifts in Western blotting with anti-MAPK polyclonal antibody. This finding was confirmed by measurements of MAPK activity in response to increasing doses (2-20 ng/ml) of PDGF AA and PDGF BB in in vitro assays with myelin basic protein as a substrate. PDGF AA was slightly less potent than PDGF BB, but both growth factors induced similar maximal activations. Kinetics of activation were also similar for both isoforms, with maximal induction of MAPK at 10-20 min after growth factor addition followed by a gradual decline to control levels at 1 h. Activation of MAPK by both PDGF isoforms was also confirmed by measuring myelin basis protein phosphorylation in MAPK immunoprecipitates. Thus both PDGF AA and PDGF BB are potent activators of MAPK in human dermal fibroblasts. In contrast, PDGF BB elicited a strong mitogenic response, while PDGF AA had no significant effect on DNA synthesis in human dermal fibroblasts. These data indicate that acute activation of MAPK is not sufficient to stimulate cells to progress through cell cycle. PDGF AA may have other biologic functions or may play a co-stimulatory role in proliferation of human dermal fibroblasts.	MED UNIV S CAROLINA,DEPT MED,DIV RHEUMATOL & IMMUNOL,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT PHARMACOL,CHARLESTON,SC 29425	Medical University of South Carolina; Medical University of South Carolina				Trojanowska, Maria/0000-0001-9550-7178				ADAMS PD, 1992, J BIOL CHEM, V267, P13135; AHN NG, 1990, J BIOL CHEM, V265, P11495; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DVONCH VM, 1992, SURGERY, V112, P18; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; GROTENDORST GR, 1991, J CELL PHYSIOL, V149, P235, DOI 10.1002/jcp.1041490209; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; ISHIKAWA O, 1990, J CELL PHYSIOL, V145, P181, DOI 10.1002/jcp.1041450124; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LUBINUS M, 1992, FASEB J, V6, pA1635; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MEIER KE, 1990, J BIOL CHEM, V265, P4365; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SACHINIDIS A, 1990, J BIOL CHEM, V265, P10238; SACHINIDIS A, 1993, FEBS LETT, V319, P221, DOI 10.1016/0014-5793(93)80550-E; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SIMM A, 1992, EXP CELL RES, V201, P192, DOI 10.1016/0014-4827(92)90363-D; SOMA Y, 1989, J CELL PHYSIOL, V140, P246, DOI 10.1002/jcp.1041400209; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; YAMAKAGE A, 1992, J EXP MED, V175, P1227, DOI 10.1084/jem.175.5.1227	33	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9822	9825						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511594				2022-12-27	WOS:A1994NE05300067
J	MARI, B; IMBERT, V; BELHACENE, N; FAR, DF; PEYRON, JF; POUYSSEGUR, J; VANOBBERGHENSCHILLING, E; ROSSI, B; AUBERGER, P				MARI, B; IMBERT, V; BELHACENE, N; FAR, DF; PEYRON, JF; POUYSSEGUR, J; VANOBBERGHENSCHILLING, E; ROSSI, B; AUBERGER, P			THROMBIN AND THROMBIN RECEPTOR AGONIST PEPTIDE INDUCE EARLY EVENTS OF T-CELL ACTIVATION AND SYNERGIZE WITH TCR CROSS-LINKING FOR CD69 EXPRESSION AND INTERLEUKIN-2 PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ANTIGEN RECEPTOR; PERTUSSIS TOXIN; PHOSPHOINOSITIDE HYDROLYSIS; PROTEOLYTIC MECHANISM; PLATELET ACTIVATION; SIGNALING PATHWAYS; STIMULATION; FIBROBLASTS; CLONING	Thrombin stimulation of the T leukemic cell line Jurkat induced a transient increase in [Ca2+](i). Proteolytic activity of the enzyme was required for this effect since diisopropyl fluorophosphate-thrombin failed to increase [Ca2+](i). Furthermore, hirudin and anti-thrombin III inhibited the thrombin-induced [Ca2+](i) rise in Jurkat T cells. A synthetic thrombin receptor agonist peptide (TRP) of 7 residues (SFLLRNP) was found to be as effective as thrombin for [Ca2+](i) mobilization, and both agonists induced Ca2+ release exclusively from internal stores. Thrombin stimulated tyrosine phosphorylation of several proteins of molecular mass 40, 42, 70, 120, and 130 kDa. There was a good correlation between thrombin-induced tyrosine phosphorylation of the latter three proteins and Ca2+ mobilization. Thrombin and TRP also caused translocation of protein kinase C from the cytosol to the plasma membrane. As a likely consequence of these events, thrombin activated the nuclear factor NF-kB. Several cell lines of hematopoietic origin including the leukemic T cell line HPB.ALL and the erythroleukemic cell line K562 were responsive to thrombin, whereas others such as THP1, a myelomonocytic cell line, and BL2, a Burkitt lymphoma were refractory to thrombin or TRP stimulation. The magnitude of the thrombin response in the different cell types paralleled the expression of the thrombin receptor mRNA. We found that activation of Jurkat T cells by a combination of phytohemagglutinin and phorbol 12-myristate 13-acetate led to a dramatic inhibition of thrombin receptor mRNA expression and to a concomitant loss of the thrombin response. Finally, we demonstrate that thrombin and TRP enhanced CD69 expression and interleukin 2 production induced by T cell receptor cross-linking in both Jurkat T cells and peripheral blood lymphocytes. These findings highlight the role of thrombin as a potential regulator of T lymphocyte activation.	FAC MED NICE, INSERM, U364, F-06107 NICE 02, FRANCE; CNRS, INSERM, CTR BIOCHIM, F-06034 NICE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur			Jean-Francois, Peyron/AAA-9496-2022; Imbert, Véronique/I-6093-2016; Mari, Bernard/Q-5832-2019; AUBERGER, Patrick/G-1491-2013; Van Obberghen-Schilling, Ellen/O-1581-2016; Mari, Bernard P/GVS-3100-2022; Peyron, Jean-Francois/M-5682-2016; Mari, Bernard P/D-7445-2015; Van Obberghen-Schilling, Ellen/Q-4372-2019; Mari, Bernard P/F-8960-2013	Jean-Francois, Peyron/0000-0001-6113-916X; Imbert, Véronique/0000-0003-2103-6718; Mari, Bernard/0000-0002-0422-9182; AUBERGER, Patrick/0000-0002-2481-8275; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Mari, Bernard P/0000-0002-0422-9182; Peyron, Jean-Francois/0000-0001-6113-916X; Mari, Bernard P/0000-0002-0422-9182; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Mari, Bernard P/0000-0002-0422-9182				AUBERGER P, 1989, J IMMUNOL, V142, P1253; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; BERNDT MC, 1986, ANN NY ACAD SCI, V485, P374, DOI 10.1111/j.1749-6632.1986.tb34598.x; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHEN LB, 1976, EXP CELL RES, V101, P41, DOI 10.1016/0014-4827(76)90409-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIS L, 1985, J IMMUNOL, V135, P2946; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FERRUA B, 1987, J IMMUNOL METHODS, V97, P215, DOI 10.1016/0022-1759(87)90462-5; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARNETT M, 1992, IMMUNOL TODAY, V13, P482, DOI 10.1016/0167-5699(92)90022-Y; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P17078; HUNG DT, 1992, J BIOL CHEM, V267, P20831; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; IMBODEN JB, 1985, J IMMUNOL, V134, P663; KENNEDY ICS, 1992, J BIOL CHEM, V267, P4924; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KROLL MH, 1989, BLOOD, V74, P1181; MARI B, 1992, EMBO J, V11, P3875, DOI 10.1002/j.1460-2075.1992.tb05480.x; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MODESTO J, 1991, CELL SIGNAL, V3, P25, DOI 10.1016/0898-6568(91)90004-E; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANTI JF, 1989, BIOCHEM J, V258, P141, DOI 10.1042/bj2580141; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TORDAI A, 1993, J IMMUNOL, V150, P4876; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; TROYER D, 1992, J BIOL CHEM, V267, P20126; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0	44	90	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8517	8523						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510689				2022-12-27	WOS:A1994NB40900103
J	TSAY, YF; SHANKWEILER, G; LAKE, J; WOOLFORD, JL				TSAY, YF; SHANKWEILER, G; LAKE, J; WOOLFORD, JL			LOCALIZATION OF SACCHAROMYCES-CEREVISIAE RIBOSOMAL-PROTEIN L16 ON THE SURFACE OF 60-S RIBOSOMAL-SUBUNITS BY IMMUNOELECTRON MICROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; RAT-LIVER RIBOSOMES; 5S RNA; CROSS-LINKING; BACILLUS-STEAROTHERMOPHILUS; ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE GELS; STRUCTURAL PROTEINS; ELECTRON-MICROSCOPY; BINDING PROTEINS	Antibodies raised against a trpE-L16 fusion protein expressed in Escherichia coli were used to examine immunological relatedness between Saccharomyces cerevisiae ribosomal protein L16 and ribosomal proteins from eubacteria, halobacteria, methanogens, eocytes, and other eukaryotes. Homologues of L16 also were identified by searches of sequence data bases. Among the bacterial proteins that are immunologically related and similar in sequence to L16 are ribosomal proteins that bind 5 S rRNA. L16 protein fused near its carboxyl terminus to E. coli beta-galactosidase could assemble into functional yeast 60 S ribosomal subunits. The RPL16AlacZ gene fusion partially complemented the slow growth or lethality of mutants containing null alleles of one or both RPL16 genes, respectively. L16-beta-galactosidase fusion protein cosedimented with ribosomes and polyribosomes, and remained associated with high salt-washed ribosomes. Monoclonal antibodies against beta-galactosidase were used to map the location of L16-beta P-galactosidase on the surface of the 60 S subunit by immunoelectron microscopy. L16 was localized near the top surface of the central protuberance, where the 60 S subunit potentially contacts the 40 S subunit. This is similar to the location of the bacterial homologues of L16 in 50 S ribosomal subunits.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT BIOL, LOS ANGELES, CA 90024 USA; CARNEGIE MELLON UNIV, DEPT BIOL SCI, PITTSBURGH, PA 15213 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Carnegie Mellon University			Tsay, Yi-Fang/ABB-3662-2021	Tsay, Yi-Fang/0000-0003-4271-0687; Woolford, John/0000-0002-7553-7043	NCI NIH HHS [CA-01000] Funding Source: Medline; NIGMS NIH HHS [GM-24034, GM-28301] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024034, R01GM028301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1989, GENETICS, V121, P675; AUER J, 1989, J MOL BIOL, V209, P21, DOI 10.1016/0022-2836(89)90167-8; AURON PE, 1981, J BIOL CHEM, V256, P105; BAIM SB, 1985, MOL CELL BIOL, V5, P1839, DOI 10.1128/MCB.5.8.1839; BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P1881, DOI 10.1073/pnas.68.8.1881; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CERETTI DP, 1983, NUCLEIC ACIDS RES, V11, P2599; CHAN YL, 1992, BIOCHEM BIOPH RES CO, V185, P356, DOI 10.1016/S0006-291X(05)80993-3; CHENSCHMEISSER U, 1977, FEBS LETT, V74, P287, DOI 10.1016/0014-5793(77)80866-1; DESHMUKH M, 1993, MOL CELL BIOL, V13, P2835, DOI 10.1128/MCB.13.5.2835; DOHME F, 1976, P NATL ACAD SCI USA, V73, P2221, DOI 10.1073/pnas.73.7.2221; GRITZ L, 1985, MOL CELL BIOL, V5, P3436, DOI 10.1128/MCB.5.12.3436; GROSS B, 1983, EMBO J, V2, P255, DOI 10.1002/j.1460-2075.1983.tb01414.x; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HATAKEYAMA T, 1990, BIOCHIM BIOPHYS ACTA, V1039, P343, DOI 10.1016/0167-4838(90)90269-L; HENDERSON E, 1983, J BACTERIOL, V15, P900; HORNE JR, 1972, MOL GEN GENET, V119, P337, DOI 10.1007/BF00272091; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; KAHAN L, 1981, J MOL BIOL, V145, P193, DOI 10.1016/0022-2836(81)90340-5; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lake J A, 1979, Methods Enzymol, V61, P250; LAKE JA, 1984, P NATL ACAD SCI-BIOL, V81, P3786, DOI 10.1073/pnas.81.12.3786; LAKE JA, 1976, J MOL BIOL, V105, P131, DOI 10.1016/0022-2836(76)90200-X; LEE JC, 1984, J BIOL CHEM, V259, P9971; LEE JC, 1990, YEASTS, P489; LEE JC, 1986, J BIOL CHEM, V258, P854; LEER RJ, 1984, FEBS LETT, V175, P371, DOI 10.1016/0014-5793(84)80771-1; LUTSCH G, 1990, EUR J CELL BIOL, V51, P140; LUTSCH G, 1979, MOL GEN GENET, V176, P281, DOI 10.1007/BF00273223; Miller J.H., 1972, EXPT MOL GENETICS; MOORE PB, 1986, STRUCTURE FUNCTION G, P87; MORELAND RB, 1985, P NATL ACAD SCI USA, V82, P6561, DOI 10.1073/pnas.82.19.6561; MORITZ M, 1991, MOL CELL BIOL, V11, P5681, DOI 10.1128/MCB.11.11.5681; MORITZ M, 1990, J CELL BIOL, V111, P2261, DOI 10.1083/jcb.111.6.2261; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NAZAR RN, 1979, EUR J BIOCHEM, V102, P573, DOI 10.1111/j.1432-1033.1979.tb04274.x; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OAKES MI, 1990, RIBOSOME, P180; OLSON HM, 1988, J BIOL CHEM, V263, P4801; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAUE HA, 1991, METHOD ENZYMOL, V194, P453; ROSENDAHL G, 1991, GENE, V98, P161, DOI 10.1016/0378-1119(91)90169-C; ROTENBERG MO, 1988, GENE DEV, V2, P160, DOI 10.1101/gad.2.2.160; ROTENBERG MO, 1986, MOL CELL BIOL, V6, P674, DOI 10.1128/MCB.6.2.674; SCHEINMAN A, 1992, BIOCHIMIE, V74, P307, DOI 10.1016/0300-9084(92)90108-Q; Sherman F., 1986, METHODS YEAST GENETI; SINGLETON CK, 1989, NUCLEIC ACIDS RES, V17, P9679, DOI 10.1093/nar/17.23.9679; SMITH N, 1978, EUR J BIOCHEM, V89, P501, DOI 10.1111/j.1432-1033.1978.tb12554.x; SPIERER P, 1978, BIOCHEMISTRY-US, V17, P2474, DOI 10.1021/bi00606a002; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STEITZ JA, 1988, J CELL BIOL, V106, P545, DOI 10.1083/jcb.106.3.545; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; TEEM JL, 1984, NUCLEIC ACIDS RES, V12, P8295, DOI 10.1093/nar/12.22.8295; TERAO K, 1980, BIOCHIM BIOPHYS ACTA, V621, P72, DOI 10.1016/0005-2795(80)90063-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Traut R. R., 1980, RIBOSOMES STRUCTURE, P89; TSAY YF, 1988, GENE DEV, V2, P664, DOI 10.1101/gad.2.6.664; TSAY YF, 1990, THESIS CARNEGIEMELLO; Warner J R, 1978, Methods Cell Biol, V20, P45, DOI 10.1016/S0091-679X(08)62008-7; WOOL IG, 1990, RIBOSOME, P203; WOOLFORD JL, 1979, CELL, V18, P1247, DOI 10.1016/0092-8674(79)90236-8; WOOLFORD JL, 1991, ADV GENET, V29, P63, DOI 10.1016/S0065-2660(08)60107-8; Woolford Jr JL, 1991, MOL CELLULAR BIOL YE, P587; WORMINGTON WM, 1989, MOL CELL BIOL, V9, P5281, DOI 10.1128/MCB.9.12.5281; XIANG RH, 1989, J BIOL CHEM, V264, P10542; YEH YC, 1986, J BIOL CHEM, V261, P14148	71	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7579	7586						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510288				2022-12-27	WOS:A1994NA03200086
J	MISSIAEN, L; DESMEDT, H; PARY, JB; OIKE, M; CASTEELS, R				MISSIAEN, L; DESMEDT, H; PARY, JB; OIKE, M; CASTEELS, R			KINETICS OF EMPTY STORE-ACTIVATED CA2+ INFLUX IN HELA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; SMOOTH-MUSCLE CELLS; CAPACITATIVE CALCIUM ENTRY; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; CA-2+ PUMP; THAPSIGARGIN; RAT; OSCILLATIONS	The intracellular Ca2+ indicator Indo-1 was used to monitor changes in cytosolic [Ca2+] ([Ca2+](i)) in single HeLa cells upon readmission of external Ca2+ after a short incubation in Ca2+-free solution. HeLa cells were responsive to histamine but not to caffeine, and their histamine-sensitive store was totally depleted by a 60-min exposure to 2 mu M thapsigargin. The resting [Ca2+](i) in thapsigargin-treated cells was higher than in control cells and low amplitude [Ca2+](i) oscillations were observed in about 20% of the cells. Readmission of external Ca2+ after a brief withdrawal of extracellular Ca2+ resulted in a transient [Ca2+](i) rise, which then decayed to the same elevated [Ca2+](i) measured before the Ca2+ withdrawal period. The [Ca2+](i) rise was associated with an increased rate of Mn2+ entry, measured as the rate of quenching of intracellular Fura-2. The same procedure did not affect the [Ca2+](i) in control cells not pretreated with thapsigargin. The amplitude of this [Ca2+](i) transient in thapsigargin pretreated cells depended on the duration of prior incubation in Ca2+-free medium, The [Ca2+](i) rise induced by elevating the extracellular [Ca2+] from 1.5 to 10 mM was more pronounced if the [Ca2+](i) during the initial incubation in 1.5 mM Ca2+ was first lowered by depolarizing the cells. We conclude that an empty store stimulates a Ca2+ entry pathway consisting of two components: a continuously elevated basal leak and a second component that is transient due to the high [Ca2+](i)-induced inhibition of the Ca2+ entry pathway. This inhibition and the subsequent recovery from it as the [Ca2+](i) is brought to resting levels could cause the oscillatory Ca2+ entry that we recorded in a fraction of the thapsigargin-treated cells.			MISSIAEN, L (corresponding author), KATHOLIEKE UNIV LEUVEN, FYSIOL LAB, CAMPUS GASTHUISBERG, HERESTR 49, B-3000 LOUVAIN, BELGIUM.			Parys, Jan/0000-0002-3591-4967				ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BECKER PL, 1989, SCIENCE, V244, P211, DOI 10.1126/science.2704996; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; CASTEELS R, 1981, J PHYSIOL-LONDON, V317, P263, DOI 10.1113/jphysiol.1981.sp013824; CHOQUETTE D, 1984, BIOCHEM BIOPH RES CO, V125, P908, DOI 10.1016/0006-291X(84)91369-X; CORCIA A, 1988, BIOCHEMISTRY-US, V27, P7499, DOI 10.1021/bi00419a048; DESMEDT H, 1991, J BIOL CHEM, V266, P7092; DESMEDT H, 1991, BIOCHEM J, V273, P219, DOI 10.1042/bj2730219; DIARRA A, 1992, PFLUG ARCH EUR J PHY, V422, P40, DOI 10.1007/BF00381511; DUDDY SK, 1989, J BIOL CHEM, V264, P20863; FOSKETT JK, 1991, J BIOL CHEM, V266, P14535; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; GILL DL, 1986, NATURE, V320, P461, DOI 10.1038/320461a0; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; HALLAM TJ, 1985, FEBS LETT, V186, P175, DOI 10.1016/0014-5793(85)80703-1; HEMMERICH S, 1988, BIOCHEMISTRY-US, V27, P7488, DOI 10.1021/bi00419a047; HEMMERICH S, 1991, BIOCHEMISTRY-US, V30, P1523, DOI 10.1021/bi00220a012; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; INO M, 1989, J GEN PHYSIOL, V94, P363, DOI 10.1085/jgp.94.2.363; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KHAN AA, 1992, P NATL ACAD SCI USA, V257, P815; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LAW GJ, 1990, BIOCHEM J, V267, P359, DOI 10.1042/bj2670359; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; MERTZ LM, 1992, J MEMBRANE BIOL, V126, P183; MISSIAEN L, 1993, PFLUG ARCH EUR J PHY, V423, P480, DOI 10.1007/BF00374944; MISSIAEN L, 1989, BIOCHEM J, V263, P687, DOI 10.1042/bj2630687; MISSIAEN L, 1990, J PHYSIOL-LONDON, V427, P171, DOI 10.1113/jphysiol.1990.sp018166; PANDOL SJ, 1990, J BIOL CHEM, V265, P12846; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; ROBINSON IM, 1991, J NEUROCHEM, V56, P1587, DOI 10.1111/j.1471-4159.1991.tb02055.x; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SHUTTLEWORTH TJ, 1992, CELL CALCIUM, V13, P541, DOI 10.1016/0143-4160(92)90034-P; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; SWANDULLA D, 1990, POTASSIUM CHANNELS S, P167; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TILLY BC, 1990, BIOCHEM J, V266, P235, DOI 10.1042/bj2660235; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; VROLIX M, 1988, BIOCHEM J, V255, P855, DOI 10.1042/bj2550855; ZHANG BX, 1992, J BIOL CHEM, V267, P15419	59	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5817	5823						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509791				2022-12-27	WOS:A1994MY84000054
J	DUNN, KW; PARK, J; SEMRAD, CE; GELMAN, DL; SHEVELL, T; MCGRAW, TE				DUNN, KW; PARK, J; SEMRAD, CE; GELMAN, DL; SHEVELL, T; MCGRAW, TE			REGULATION OF ENDOCYTIC TRAFFICKING AND ACIDIFICATION ARE INDEPENDENT OF THE CYSTIC-FIBROSIS TRANSMEMBRANE REGULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; WHEAT-GERM-AGGLUTININ; RECEPTOR-MEDIATED ENDOCYTOSIS; TRANSFERRIN RECEPTOR; CHLORIDE CONDUCTANCE; RAPID ENDOCYTOSIS; EPITHELIAL-CELLS; BINDING-SITES; K562 CELLS; PH	Cystic fibrosis is associated with mutations of the cystic fibrosis transmembrane regulator (CFTR), a cAMP-regulated plasma membrane Cl- channel. Mutations in the CFTR have been reported to not only impair Cl- transport at the plasma membrane but also inhibit organelle acidification and disrupt cAMP-regulated plasma membrane recycling. Comparisons of cultured pancreatic adenocarcinoma cells expressing the Delta 508 mutant CFTR (CFPAC-1 cells) with genetically matched CFPAC-1 cells transfected with the wild-type CFTR demonstrate that expression of wild-type CFTR restores cAMP-mediated plasma membrane Cl- transport, but has no effect on pH regulation of endosomes labeled with either transferrin or wheat germ agglutinin, Endosome pH was, in all cases, similar in the two cell lines and unaffected by treatment with the cAMP agonist forskolin. Forskolin treatment had no effect on transferrin internalization, but increased recycling by 30-40% in both cell Lines. The kinetics of wheat germ agglutinin recycling were negligibly affected by forskolin in either cell line. These results demonstrate that endocytic acidification and cAMP-mediated endocytic protein redistribution are similar in genetically matched CFPAC-1 cells which differ only in the expression of mutant or wildtype CFTR.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University; Columbia University								ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ALAWQATI Q, 1992, J EXP BIOL, V172, P245; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BARASCH J, 1988, J CELL BIOL, V107, P2137, DOI 10.1083/jcb.107.6.2137; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BHAVANANDAN VP, 1979, J BIOL CHEM, V254, P4000; Boat T.J., 1989, METABOLIC BASIS INHE, P2649; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRADBURY NA, 1992, AM J PHYSIOL, V262, pC752, DOI 10.1152/ajpcell.1992.262.3.C752; CAIN CC, 1988, J CELL BIOL, V106, P269, DOI 10.1083/jcb.106.2.269; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FUCHS R, 1989, J BIOL CHEM, V264, P2212; JOHNSON L, 1993, IN PRESS J CELL PHYS; JOHNSON VG, 1991, INTRACELLULAR TRAFFI, P183; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; MAXFIELD FR, 1990, OPTICAL MICROSCOPY FOR BIOLOGY, P357; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MURPHY RF, 1984, J CELL BIOL, V98, P1757, DOI 10.1083/jcb.98.5.1757; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; RAUB TJ, 1990, J CELL PHYSIOL, V144, P52, DOI 10.1002/jcp.1041440108; RAUB TJ, 1990, J CELL PHYSIOL, V143, P1, DOI 10.1002/jcp.1041430102; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBBINS AR, 1984, J CELL BIOL, V99, P1296, DOI 10.1083/jcb.99.4.1296; ROBBINS AR, 1983, J CELL BIOL, V96, P1064, DOI 10.1083/jcb.96.4.1064; ROEDERER M, 1987, J CELL PHYSIOL, V131, P200, DOI 10.1002/jcp.1041310209; ROFF CF, 1986, J CELL BIOL, V103, P2283, DOI 10.1083/jcb.103.6.2283; ROSE MC, 1988, HORM METAB RES, V20, P601, DOI 10.1055/s-2007-1010896; SANDVIG K, 1990, J BIOL CHEM, V265, P6382; SIPE DM, 1987, P NATL ACAD SCI USA, V84, P7119, DOI 10.1073/pnas.84.20.7119; STEIN BS, 1986, J BIOL CHEM, V261, P319; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2723, DOI 10.1083/jcb.105.6.2723; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2713, DOI 10.1083/jcb.105.6.2713; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; ZEN K, 1992, J CELL BIOL, V119, P99, DOI 10.1083/jcb.119.1.99	44	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5336	5345						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508934				2022-12-27	WOS:A1994MX57100096
J	NICOLAS, JP; LAMBEAU, G; LAZDUNSKI, M				NICOLAS, JP; LAMBEAU, G; LAZDUNSKI, M			IDENTIFICATION OF THE BINDING DOMAIN FOR SECRETORY PHOSPHOLIPASES A(2) ON THEIR M-TYPE 180-KDA MEMBRANE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE MANNOSE RECEPTOR; HIGH-AFFINITY BINDING; CARBOHYDRATE-RECOGNITION DOMAINS; PANCREATIC-TYPE PHOSPHOLIPASE-A2; AMINO-ACID-SEQUENCE; TOXIC PHOSPHOLIPASES-A2; SKELETAL-MUSCLE; BLOOD-PLASMA; EXPRESSION; VENOM	The rabbit muscle (M)-type receptor for secretory phospholipases A(2) (sPLA(2)s) has a large extracellular domain of 1394 amino acids, composed of an N-terminal cysteine-rich domain, a fibronectin-like type II domain, and eight carbohydrate recognition domains (CRDs). It is thought to mediate some of the physiological effects of mammalian sPLA(2)s, including vascular smooth muscle contraction and cell proliferation, and is able to internalize sPLA(2)s. Here, we show by site directed mutagenesis that OS1, a snake venom sPLA(2), binds to the receptor via its CRDs and that deletion of CRD 5 completely abolishes the binding of sPLA(2)s. Moreover, a receptor lacking all CRDs but CRD 5 was still able to bind OS1 although with a lower affinity. Deletion of CRDs 4 and 6, surrounding the CRD 5, slightly reduced the affinity for OS1, thus suggesting that these CRDs are also involved in the binding of OS1. The M-type sPLA(2) receptor and the macrophage mannose receptor are homologous and are predicted to share the same tertiary structure. p-Aminophenyl-alpha-D-mannopyranoside bovine serum albumin, a known ligand of the macrophage mannose receptor, binds to the M-type sPLA(2) receptor essentially via CRDs 3-6.	CNRS, INST PHARMACOL MOLEC & CELLULAIRE, F-06560 VALBONNE, FRANCE	Centre National de la Recherche Scientifique (CNRS)			Lambeau, Gerard/GRJ-5624-2022	Lambeau, Gerard/0000-0002-9239-518X				ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; ANCIAN P, 1995, IN PRESS BIOCHEMISTR; [Anonymous], 1994, PROGRAM MANUAL WISCO; ARITA H, 1991, J BIOL CHEM, V266, P19139; BOMALASKI JS, 1991, J IMMUNOL, V146, P3904; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P118, DOI 10.1016/0005-2744(68)90249-0; DENIS EA, 1994, J BIOL CHEM, V269, P13057; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; FISHER AB, 1994, BBA-LIPID LIPID MET, V1211, P256, DOI 10.1016/0005-2760(94)90148-1; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; Hawgood B., 1991, HDB NATURAL TOXINS R, P3; HIGASHINO K, 1994, EUR J BIOCHEM, V225, P375, DOI 10.1111/j.1432-1033.1994.00375.x; INOUE S, 1991, J BIOL CHEM, V266, P1001; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1993, ADV SEC MESS PHOSPH, V28, P81; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KRUSKAL BA, 1992, J EXP MED, V176, P1673, DOI 10.1084/jem.176.6.1673; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; LAMBEAU G, 1989, J BIOL CHEM, V264, P11503; LAMBEAU G, 1991, FEBS LETT, V293, P29, DOI 10.1016/0014-5793(91)81145-X; LAMBEAU G, 1995, J BIOL CHEM, V270, P5534, DOI 10.1074/jbc.270.10.5534; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LAMBEAU G, 1991, NEUROCHEM RES, V16, P651, DOI 10.1007/BF00965551; LANGLAIS J, 1992, BIOCHEM BIOPH RES CO, V182, P208, DOI 10.1016/S0006-291X(05)80132-9; LENNARTZ MR, 1987, BIOCHEM J, V245, P705, DOI 10.1042/bj2450705; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; MULLIN NP, 1994, J BIOL CHEM, V269, P28405; NAKAJIMA M, 1992, FEBS LETT, V309, P261, DOI 10.1016/0014-5793(92)80785-F; OHKURA N, 1993, J BIOCHEM-TOKYO, V113, P413, DOI 10.1093/oxfordjournals.jbchem.a124060; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; SOMMERS CD, 1992, EUR J PHARMACOL, V216, P87, DOI 10.1016/0014-2999(92)90213-N; STRONG PN, 1987, CELLULAR MOL BASIS C, P534; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; TOJO H, 1988, J BIOL CHEM, V263, P5724; VADAS P, 1989, AM J PATHOL, V134, P807; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; WAITE M, 1987, HDB LIPID RES, P111; YING Z, 1993, EUR J BIOCHEM, V215, P91, DOI 10.1111/j.1432-1033.1993.tb18010.x	50	63	67	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28869	28873		10.1074/jbc.270.48.28869	http://dx.doi.org/10.1074/jbc.270.48.28869			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499413	hybrid			2022-12-27	WOS:A1995TH05600057
J	GETHER, U; LIN, SS; KOBILKA, BK				GETHER, U; LIN, SS; KOBILKA, BK			FLUORESCENT LABELING OF PURIFIED BETA(2) ADRENERGIC-RECEPTOR - EVIDENCE FOR LIGAND-SPECIFIC CONFORMATIONAL-CHANGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; INTRINSIC ACTIVITY; ANTAGONISTS; COMPLEX; SYSTEM	The purpose of the present study was to develop an approach to directly monitor structural changes in a G protein coupled receptor in response to drug binding, Purified human beta(2) adrenergic receptor was covalently labeled with the cysteine-reactive, fluorescent probe N,N '-dimethyl-N-(iodoacetyl)-N '-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine (IANBD), IANBD is characterized by a fluorescence which is highly sensitive to the polarity of its environment, We found that the full agonist, isoproterenol, elicited a stereoselective and dose-dependent decrease in fluorescence from IANBD-labeled beta(2) receptor. The change in fluorescence could be plotted against the concentration of isoproterenol as a simple hyperbolic binding isotherm demonstrating interaction with a single binding site in the receptor, The ability of several adrenergic antagonists to reverse the response confirmed that this binding site is identical to the well described binding site in the beta(2) receptor, Comparison of the response to isoproterenol with a series of adrenergic agonists, having different biological efficacies, revealed a linear correlation between biological efficacy and the change in fluorescence, This suggests that the agonist-mediated decrease in fluorescence from IANBD-labeled beta(2) receptor is due to the same conformational change as involved in receptor activation and G protein coupling, In contrast to agonists, negative antagonists induced a small but significant increase in base line fluorescence. Despite the small amplitude of this response, it supports the notion that antagonists by themselves may alter receptor structure, In conclusion, our data provide the first direct evidence for ligand-specific conformational changes occurring in a G protein coupled receptor, Furthermore, the data demonstrate the potential of fluorescence spectroscopy as a tool for further delineating the molecular mechanisms of drug action at G protein-coupled receptors.	STANFORD UNIV, SCH MED, BECKMAN CTR B157, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DIV CARDIOVASC MED, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University				Gether, Ulrik/0000-0002-0020-3807; Kobilka, Brian/0000-0001-5958-3990	NINDS NIH HHS [R01 NS28471] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028471] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADHAM N, 1993, MOL PHARMACOL, V43, P427; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BARKER EL, 1994, J BIOL CHEM, V269, P11687; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; CERIONE RA, 1994, METHOD ENZYMOL, V237, P409; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; CHIDIAC P, 1995, TRENDS PHARMACOL SCI, V16, P83, DOI 10.1016/S0165-6147(00)88986-5; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; DUNN SMJ, 1993, BIOCHEMISTRY-US, V32, P8608, DOI 10.1021/bi00084a031; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1995, BIOCHEM SOC T, V23, P96, DOI 10.1042/bst0230096; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HEIN L, 1995, NEUROPHARMACOLOGY, V34, P357, DOI 10.1016/0028-3908(95)00018-2; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; JASPER JR, 1992, BIOCHEM PHARMACOL, V43, P119, DOI 10.1016/0006-2952(92)90268-N; KENAKIN T, 1994, TRENDS PHARMACOL SCI, V15, P408, DOI 10.1016/0165-6147(94)90086-8; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; KOBILKA BK, 1995, IN PRESS ANAL BIOCH; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKOWICZ J, 1983, PRINCIPLES FLUORESCE, P131; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; PHILLIPS WJ, 1991, J BIOL CHEM, V266, P11017; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SURYANARAYANA S, 1991, METHODS, V3, P193	33	258	266	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28268	28275						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499324				2022-12-27	WOS:A1995TG21000049
J	AARONSON, RM; GRAVEN, KK; TUCCI, M; MCDONALD, RJ; FARBER, HW				AARONSON, RM; GRAVEN, KK; TUCCI, M; MCDONALD, RJ; FARBER, HW			NONNEURONAL ENOLASE IS AN ENDOTHELIAL HYPOXIC STRESS PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; GLYCOLYTIC ENZYME ENOLASE; SEROTONIN UPTAKE; BINDING-PROTEIN; MESSENGER-RNAS; CELLS; GAMMA; LOCALIZATION; EXPRESSION; CENTROSOME	The hypoxia-associated proteins (HAPs) are five cell associated stress proteins (M(r) 34, 36, 39, 47, and 57) upregulated in cultured vascular endothelial cells (EC) exposed to hypoxia, While hypoxic exposure of other cell types induces heat shock and glucose-regulated proteins, EC preferentially up-regulate HAPs. In order to identify the 47 kDa HAP, protein from hypoxic bovine EC lysates was isolated, digested with trypsin, and sequenced. Significant identity was found with enolase, a glycolytic enzyme. Western analyses confirmed that non-neuronal enolase (NNE) is up-regulated in hypoxic EC. Western analysis of subcellular fractions localized NNE primarily to the cytoplasm and confirmed that it was up-regulated 2.3-fold by hypoxia. Interestingly, NNE also appeared in the nuclear fraction of EC but was unchanged by hypoxia. Northern analyses revealed that NNE mRNA hypoxic up-regulation began at 1-2 h, peaked at 18 h, persisted for 48 h, and returned to base line after return to 21% O-2 for 24 h, Hypoxia maximally up-regulated NNE mRNA levels 3.4-fold, While hypoxic up-regulation of NNE may have a protective effect by augmenting anaerobic metabolism, we speculate that enolase may contribute to EC hypoxia tolerance through one or more of its nonglycolytic functions.	BOSTON UNIV,SCH MED,CTR PULM,BOSTON,MA 02118	Boston University				Farber, Harrison/0000-0002-0297-7902	NHLBI NIH HHS [HL-03125, HL-45537] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045537] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALGIERY AG, BIOCHIM BIOPHYS ACTA, V1159, P134; ANG D, 1991, J BIOL CHEM, V266, P24233; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BRADY ST, 1981, CELL, V23, P515, DOI 10.1016/0092-8674(81)90147-1; CAMPISI J, 1984, CELL, V37, P241; DWYER BE, 1989, EXP NEUROL, V104, P28, DOI 10.1016/0014-4886(89)90005-8; FARBER HW, 1991, CIRC RES, V68, P1446, DOI 10.1161/01.RES.68.5.1446; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GERBITZ KD, 1986, J CLIN CHEM CLIN BIO, V24, P1009; GRAVEN KK, 1994, J BIOL CHEM, V269, P24446; GRAVEN KK, 1993, J CELL PHYSIOL, V157, P544, DOI 10.1002/jcp.1041570314; HAIMOTO H, 1985, LAB INVEST, V52, P257; HATTORI T, 1994, BIOCHEM BIOPH RES CO, V202, P25, DOI 10.1006/bbrc.1994.1888; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; IIDA H, 1985, NATURE, V315, P688, DOI 10.1038/315688a0; ISAWE K, 1986, J CLIN ENDOCR METAB, V63, P94; JOHNSTONE SA, 1992, EXP CELL RES, V202, P458, DOI 10.1016/0014-4827(92)90099-T; KATAGIRI T, 1993, MOL BRAIN RES, V19, P1, DOI 10.1016/0169-328X(93)90142-C; KELLER A, 1994, J NEUROSCI RES, V38, P493, DOI 10.1002/jnr.490380503; KNOWLTON AA, 1991, J CLIN INVEST, V87, P139, DOI 10.1172/JCI114963; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LEE SL, 1986, AM J PHYSIOL, V250, pC766, DOI 10.1152/ajpcell.1986.250.5.C766; LEE SL, 1987, CIRC RES, V60, P653, DOI 10.1161/01.RES.60.5.653; LOIKE JD, 1992, AM J PHYSIOL, V263, pC326, DOI 10.1152/ajpcell.1992.263.2.C326; MARANGOS PJ, 1980, BRAIN RES, V190, P185, DOI 10.1016/0006-8993(80)91168-3; MATHUR RL, 1992, EXP EYE RES, V54, P253, DOI 10.1016/S0014-4835(05)80215-5; MERTENS S, 1990, AM J PHYSIOL, V258, pH689, DOI 10.1152/ajpheart.1990.258.3.H689; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; PESHAVARIA M, 1990, BIOCHEM SOC T, V18, P254, DOI 10.1042/bst0180254; RATTNER JB, 1991, J IMMUNOL, V146, P2341; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; REDLITZ A, 1995, EUR J BIOCHEM, V227, P404; SCHMECHEL DE, 1985, LAB INVEST, V52, P239; SUBJECK JR, 1986, AM J PHYSIOL, V250, pC1, DOI 10.1152/ajpcell.1986.250.1.C1; TANAKA M, 1985, BIOCHEM BIOPH RES CO, V133, P868, DOI 10.1016/0006-291X(85)91215-X; TRETYAKOV AV, 1995, J CLIN INVEST, V95, P738, DOI 10.1172/JCI117721; TRETYAKOV AV, 1993, AM J PHYSIOL, V265, pC770, DOI 10.1152/ajpcell.1993.265.3.C770; VINORES SA, 1986, HISTOPATHOLOGY, V10, P891; WALSH JL, 1989, BIOCHIM BIOPHYS ACTA, V999, P64, DOI 10.1016/0167-4838(89)90031-9; WALSH JL, 1988, BIOCHIM BIOPHYS ACTA, V952, P83, DOI 10.1016/0167-4838(88)90104-5; ZIMMERMAN LH, 1991, J CLIN INVEST, V87, P908, DOI 10.1172/JCI115097	42	122	129	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27752	27757		10.1074/jbc.270.46.27752	http://dx.doi.org/10.1074/jbc.270.46.27752			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499243				2022-12-27	WOS:A1995TE73600054
J	DIEGEL, ML; RANKIN, BM; BOLEN, JB; DUBOIS, PM; KIENER, PA				DIEGEL, ML; RANKIN, BM; BOLEN, JB; DUBOIS, PM; KIENER, PA			CROSS-LINKING OF FC-GAMMA RECEPTOR TO SURFACE-IMMUNOGLOBULIN ON B-CELLS PROVIDES AN INHIBITORY SIGNAL THAT CLOSES THE PLASMA-MEMBRANE CALCIUM-CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INDEPENDENT LIGAND OCCUPANCY; LYMPHOCYTES-B; TYROSINE PHOSPHORYLATION; ANTIGEN RECEPTORS; T-CELLS; PROLIFERATION SIGNALS; HUMAN-PLATELETS; DNA-SYNTHESIS; ACTIVATION	Stimulation of B lymphocytes by the cross-linking of surface Ig (sIg) with an F(ab'), antibody fragment leads to the rapid activation of several tyrosine kinases. This gives rise to the activation of phospholipase C gamma (PLCgamma) and the generation of inositol phosphates. These, in turn, lead to a prolonged elevation of intracellular Ca2+ ([Ca2+]i) consisting of a rapid release of Ca2+ from intracellular stores and a sustained influx of extracellular Ca2+. In contrast, co-cross-linking sIg to Fcgamma receptor (FcgammaRII) with intact anti-sIg induces a much more transient increase in [Ca2+]i. Stimulation of the murine B cell lymphoma, A20, with F(ab')2 anti-sIgG leads to the production of high levels of IL-2, while co-cross-linking of sIgG with FcgammaRII blocks this response. In studies reported here, we show that co-cross-linking of FcgammaRII with sIg prevents the influx of extracellular Ca2+ without significantly affecting the tyrosine phosphorylation of substrates including PLCygamma1, PLCgamma2, and Syk or the mobilization of Ca2+ from intracellular stores. In cells that had been previously activated with F(ab')2 anti-IgG, co-cross-linking of slg to FcgammaRII rapidly abrogated the influx of extracellular Ca2+ by closing the plasma membrane Ca2+ channel. Additionally, even 2-3 h after stimulation of the cells with F(ab')2 fragment, addition of intact anti-IgG to the cells, or removal of extracellular Ca2+, markedly inhibited (>90%) IL-2 production. These results indicate that co-cross-linking slg with FcgammaRII both prevented the opening of and actively closed the Ca2+ channel, and, through this mechanism, FcgammaRII was able to control production of IL-2. Overall, since influx of extracellular Ca2+ has been found to be necessary for the proliferation and differentiation of B cells, FcgammaRII may play a critical role in controlling these responses by regulating the opening of the Ca2+ channel.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195	Bristol-Myers Squibb; Bristol-Myers Squibb; University of Washington; University of Washington Seattle								BAIXERAS E, 1993, IMMUNOL REV, V132, P5, DOI 10.1111/j.1600-065X.1993.tb00836.x; BERRY N, 1990, EUR J BIOCHEM, V189, P205, DOI 10.1111/j.1432-1033.1990.tb15478.x; BIJSTERBOSCH MK, 1985, J EXP MED, V162, P1825, DOI 10.1084/jem.162.6.1825; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBELL MA, 1990, EMBO J, V9, P2125; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; CLEVERS HC, 1985, J IMMUNOL, V135, P3827; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOLD MR, 1992, J IMMUNOL, V148, P2012; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAGIWARA S, 1967, J GEN PHYSIOL, V50, P583, DOI 10.1085/jgp.50.3.583; HALLAM TJ, 1985, FEBS LETT, V186, P175, DOI 10.1016/0014-5793(85)80703-1; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HAVERSTICK DM, 1993, MOL BIOL CELL, V4, P173, DOI 10.1091/mbc.4.2.173; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HUNZIKER W, 1990, NATURE, V345, P628, DOI 10.1038/345628a0; HUTCHCROFT J, 1991, J BIOL CHEM, V266, P17846; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KLAUS GGB, 1986, EUR J IMMUNOL, V16, P92, DOI 10.1002/eji.1830160118; KLAUS GGB, 1984, IMMUNOLOGY, V53, P693; KOLSCH E, 1980, IMMUNOL REV, V49, P62; LANE PJL, 1991, J IMMUNOL, V146, P715; LANE PJL, 1991, J IMMUNOL, V147, P4103; LAZARUS AH, 1990, J IMMUNOL, V144, P4147; LAZARUS AH, 1991, J IMMUNOL, V147, P1739; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; PHILLIPS NE, 1983, J IMMUNOL, V130, P602; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RANKIN BM, 1993, J IMMUNOL, V150, P605; RIGLEY KP, 1989, EUR J IMMUNOL, V19, P481, DOI 10.1002/eji.1830190311; RINK TJ, 1990, FEBS LETT, V268, P381, DOI 10.1016/0014-5793(90)81290-5; SAGE SO, 1987, J BIOL CHEM, V262, P16364; SIDMAN CL, 1976, J EXP MED, V144, P882, DOI 10.1084/jem.144.4.882; SMREKA AV, 1991, SCIENCE, V251, P804; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; UHER F, 1986, MOL IMMUNOL, V23, P1177, DOI 10.1016/0161-5890(86)90149-5; UHER F, 1986, J IMMUNOL, V137, P3124; UHER F, 1985, CELL IMMUNOL, V95, P369; WILSON HA, 1987, J IMMUNOL, V138, P1712; WILSON HA, 1987, J EXP MED, V166, P601, DOI 10.1084/jem.166.2.601	50	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11409	11416						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512564				2022-12-27	WOS:A1994NF96600065
J	WHALEY, AE; MEKA, CSR; HARBISON, LA; HUNT, JS; IMAKAWA, K				WHALEY, AE; MEKA, CSR; HARBISON, LA; HUNT, JS; IMAKAWA, K			IDENTIFICATION AND CELLULAR-LOCALIZATION OF UNIQUE INTERFERON MESSENGER-RNA FROM HUMAN PLACENTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVINE TROPHOBLAST PROTEIN-1; GENE-EXPRESSION; MESSENGER-RNA; PREGNANCY; SHEEP; EMBRYO; DNA; RECOGNITION; HORMONES; HOMOLOGY	Although constitutive expression of trophoblast or pregnancy-associated interferon (IFN) has long been recognized, their cDNA sequences have been determined for only ruminant ungulates. Here we show a human trophoblast IFN (htIFN) cDNA whose nucleotide sequence is very similar (85% identity) to that of ovine and bovine trophoblast IFNs, IFN tau s. Like ruminant IFN tau s, htIFN cDNAs contain an open reading frame of 195 codons including a signal sequence of 23 amino acids, resulting in a mature polypeptide of 172 amino acids. The deduced amino acid sequence of htIFN shares 73, 62, and 56% identities with ovine IFN tau, human IFN alpha II, and human IFN alpha I, respectively. However, the expression of htIFN is not limited to a specific period of pregnancy because transcripts of htIFN genes are detected in human lymphocytes, cells obtained by amniocentesis (amniocytes), first trimester, and term placentas. Human trophoblast IFN mRNA is localized mainly in extravillous trophoblast cells of placental villi, particularly in the migrating cytotrophoblast cells, which eventually replace maternal endothelial cells in spiral arteries of the decidua. Both sense and antisense mRNAs for human IFN alpha II are localized in the outer layer of villous structures. Coexistence of these mRNAs at the placental villi throughout pregnancy suggests that, in addition to a role in placental cell growth and differentiation, IFNs may play a role protecting the fetus in viral environments.	UNIV KANSAS,SCH MED,INST RES WOMEN & GENDER,DEPT OBSTET & GYNECOL,WICHITA,KS 67214; UNIV KANSAS,MED CTR,DEPT ANAT & CELL BIOL,KANSAS CITY,KS 66160	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center								BARLOW DP, 1984, DIFFERENTIATION, V27, P229, DOI 10.1111/j.1432-0436.1984.tb01433.x; BARTOL FF, 1985, BIOL REPROD, V32, P681, DOI 10.1095/biolreprod32.3.681; BAZER FW, 1991, AM J REPROD IMMUNOL, V26, P19, DOI 10.1111/j.1600-0897.1991.tb00696.x; BOURINBAIAR AS, 1992, FEBS LETT, V302, P206, DOI 10.1016/0014-5793(92)80441-I; BRANCA AA, 1986, J INTERFERON RES, V6, P305, DOI 10.1089/jir.1986.6.305; BULMER JN, 1990, AM J REPROD IMMUNOL, V22, P109, DOI 10.1111/j.1600-0897.1990.tb00652.x; CAPON DJ, 1985, MOL CELL BIOL, V5, P768, DOI 10.1128/MCB.5.4.768; CHARD T, 1989, J DEV PHYSIOL, V11, P271; CHARPIGNY G, 1988, FEBS LETT, V228, P12, DOI 10.1016/0014-5793(88)80574-X; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHEN HL, 1993, BIOL REPROD, V48, P707, DOI 10.1095/biolreprod48.4.707; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUCGOIRAN P, 1989, J BIOL CHEM, V264, P16507; FARIN CE, 1989, MOL ENDOCRINOL, V3, P1099, DOI 10.1210/mend-3-7-1099; FARIN CE, 1990, BIOL REPROD, V43, P210, DOI 10.1095/biolreprod43.2.210; FOWLER AK, 1980, NATURE, V286, P266, DOI 10.1038/286266a0; GODKIN JD, 1982, J REPROD FERTIL, V65, P141, DOI 10.1530/jrf.0.0650141; GREENE JJ, 1986, EXP CELL RES, V167, P400, DOI 10.1016/0014-4827(86)90180-1; HOWATSON AG, 1988, J ENDOCRINOL, V119, P531, DOI 10.1677/joe.0.1190531; IMAKAWA K, 1993, ENDOCRINOLOGY, V132, P1869, DOI 10.1210/en.132.4.1869; IMAKAWA K, 1987, NATURE, V330, P377, DOI 10.1038/330377a0; IMAKAWA K, 1989, MOL ENDOCRINOL, V3, P127, DOI 10.1210/mend-3-1-127; KELLY AC, 1991, DNA CELL BIOL, V10, P411, DOI 10.1089/dna.1991.10.411; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LAWRENCE JB, 1985, NUCLEIC ACIDS RES, V13, P1777; LEAMAN DW, 1992, J INTERFERON RES, V12, P1, DOI 10.1089/jir.1992.12.1; NEPHEW KP, 1993, BIOL REPROD, V48, P768, DOI 10.1095/biolreprod48.4.768; PONTZER CH, 1988, BIOCHEM BIOPH RES CO, V152, P801, DOI 10.1016/S0006-291X(88)80109-8; REDDY KJ, 1988, ANAL BIOCHEM, V168, P324, DOI 10.1016/0003-2697(88)90325-9; ROBERTS RM, 1989, J INTERFERON RES, V9, P175, DOI 10.1089/jir.1989.9.175; ROBERTS RM, 1992, ENDOCR REV, V13, P432, DOI 10.1210/er.13.3.432; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART HJ, 1987, J ENDOCRINOL, V115, pR13, DOI 10.1677/joe.0.115R013	35	53	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10864	10868						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511610				2022-12-27	WOS:A1994NF01700099
J	WILLIAMS, SE; INOUE, I; TRAN, H; FRY, GL; PLADET, MW; IVERIUS, PH; LALOUEL, JM; CHAPPELL, DA; STRICKLAND, DK				WILLIAMS, SE; INOUE, I; TRAN, H; FRY, GL; PLADET, MW; IVERIUS, PH; LALOUEL, JM; CHAPPELL, DA; STRICKLAND, DK			THE CARBOXYL-TERMINAL DOMAIN OF LIPOPROTEIN-LIPASE BINDS TO THE LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN/ALPHA(2)-MACROGLOBULIN RECEPTOR (LRP) AND MEDIATES BINDING OF NORMAL VERY-LOW-DENSITY LIPOPROTEINS TO LRP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; ACTIVATOR INHIBITOR TYPE-1; PLASMINOGEN-ACTIVATOR; MOLECULAR-WEIGHT; APOLIPOPROTEIN-E; BOVINE-MILK; COMPLEXES; CHYLOMICRONS; INTERNALIZES; MECHANISM	Lipoprotein lipase (LPL) binds with high affinity to the low density lipoprotein receptor-related protein/alpha(2)- macroglobulin receptor (LRP) and promotes binding, uptake, and degradation of normal triglyceride-rich lipoproteins in a process mediated by LRP (Chappell, D. A., Fry, G. L., Naknitx, M. A, Muhonen, L. E., Pladet, M. W., Iverius, P-H., and Strickland, D. K. (1993) J. Biol. Chem. 268, 14168-14175). To localize the portion of LPL that is responsible for interacting with LRP, fragments of LPL were expressed in bacteria. A fragment of human LPL containing the COOH-terminal domain (residues 313-448, designated LPLC) which lacks the catalytic site was able to bind to LRP. Purified LRP bound specifically to microtiter wells coated with LPL or LPLC with KD values of 2.8 and 5 nM, respectively. The effects of several mutations of LPLC were tested. Mutation of Lys(407) to Ala reduced the affinity of LPLC for LRP by approximately 10-fold. Like native LPL, LPLC prevented the binding of activated alpha(2)-macroglobulin and the 39-kDa receptor-associated protein to LRP and inhibited the internalization and degradation of activated alpha(2)-macroglobulin and receptor-associated protein in cultured fibroblasts. LPLC also bound to I-125-labeled human normal triglyceride-rich lipoproteins and promoted their binding to purified LRP and to cultured cells. Mutation of Trp(393) and Trp(394) to Ala completely abolished the ability of LPLC to bind to lipoproteins, but had little effect on its interaction with LRP These data indicate that the COOH-terminal domain of LPL may function both in binding lipoproteins and mediating their interaction with LRP.	AMER RED CROSS,BIOCHEM LAB,ROCKVILLE,MD 20855; UNIV IOWA,COLL MED,DEPT MED,IOWA CITY,IA 52242; UNIV UTAH,HLTH SCI CTR,VET AFFAIRS MED CTR,SALT LAKE CITY,UT 84148; UNIV UTAH,HLTH SCI CTR,DEPT INTERNAL MED,SALT LAKE CITY,UT 84148; UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84148; UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84148	American Red Cross; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049264, R01HL030200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49264, HL30200] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; ATTRI AK, 1983, ANAL BIOCHEM, V133, P142, DOI 10.1016/0003-2697(83)90235-X; AUWERX J, 1992, CRIT REV CL LAB SCI, V29, P243, DOI 10.3109/10408369209114602; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; FELTS JM, 1975, BIOCHEM BIOPH RES CO, V66, P1467, DOI 10.1016/0006-291X(75)90524-0; HALL PK, 1978, BIOCHEM J, V173, P27, DOI 10.1042/bj1730027; HATA A, 1993, J BIOL CHEM, V268, P8447; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; JONES JM, 1972, BIOCHEM J, V127, P187, DOI 10.1042/bj1270187; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LIU MS, 1992, BIOCHIM BIOPHYS ACTA, V1128, P113, DOI 10.1016/0005-2760(92)90264-V; LOOKENE A, 1993, EUR J BIOCHEM, V213, P185, DOI 10.1111/j.1432-1033.1993.tb17747.x; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NILSSONEHLE P, 1980, ANNU REV BIOCHEM, V49, P667, DOI 10.1146/annurev.bi.49.070180.003315; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WONG H, 1991, P NATL ACAD SCI USA, V88, P11290, DOI 10.1073/pnas.88.24.11290	38	110	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8653	8658						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510694				2022-12-27	WOS:A1994NB41100008
J	BERTI, L; MOSTHAF, L; KRODER, G; KELLERER, M; TIPPMER, S; MUSHACK, J; SEFFER, E; SEEDORF, K; HARING, H				BERTI, L; MOSTHAF, L; KRODER, G; KELLERER, M; TIPPMER, S; MUSHACK, J; SEFFER, E; SEEDORF, K; HARING, H			GLUCOSE-INDUCED TRANSLOCATION OF PROTEIN-KINASE-C ISOFORMS IN RAT-1 FIBROBLASTS IS PARALLELED BY INHIBITION OF THE INSULIN-RECEPTOR TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-CELLS; PHORBOL ESTERS; PHOSPHORYLATION; RESISTANCE; ADIPOCYTES; SUBUNIT; ACTIVATION; INVITRO; NIDDM; PATHOGENESIS	Rat-1 fibroblasts stably overexpressing high levels,of human insulin receptor were used as a model system to study the effects of hyperglycemia on insulin receptor tyrosine kinase (IRK) activity and protein kinase C (PKC) translocation in parallel in the intact cell. Glucose (10-25 mm) induced a significant reduction of IRK activity (tyrosine phosphorylation of IR-beta-subunit and IR-substrate-1) within 10 min. This effect was paralleled by a rapid translocation of several PKC isoforms (cPKC alpha, nPKC delta, nPKC epsilon, nPKC zeta) to the plasma membrane within 1 min. Kinetics of IRK inhibition and PKC translocation are consistent with the idea that the glucose effect on IRK is mediated by PKC activation. This hypothesis is supported by further observations. Addition of the protein kinase C inhibitor H-7 can prevent the effect of glucose on IRK. Inhibition of IRK is also observed after stimulation of the cells with the phorbol ester 12-0-tetradecanoylphorbol-13-acetate, which can substitute for a physiological activator of PKC. Glucose (25 mm) increases the P-32 incorporation in serine residues of the beta-subunit of IRK. We conclude that high levels of glucose induce inhibition of IRK in vivo. There is indirect evidence that this effect is mediated by a glucose-induced PKC translocation/activation and serine phosphorylation of the insulin receptor.	INST DIABET FORSCH MUNCHEN,KOLNER PL 1,D-80804 MUNICH,GERMANY; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society								BALLOTI R, 1990, COLLOQ INSE, V210, P29; BECKNIELSEN H, 1992, DIABETES CARE, V15, P418, DOI 10.2337/diacare.15.3.418; BORNER C, 1992, J BIOL CHEM, V267, P12892; CALLE R, 1992, J BIOL CHEM, V267, P18723; COOPER DR, 1990, BIOCHIM BIOPHYS ACTA, V1054, P95, DOI 10.1016/0167-4889(90)90210-5; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DRAZNIN B, 1988, BIOCHEM BIOPH RES CO, V156, P570, DOI 10.1016/S0006-291X(88)80880-5; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; ERMEL B, 1989, DIABETOLOGIA S1, V32, P485; GARVEY WT, 1992, DIABETES CARE, V15, P396, DOI 10.2337/diacare.15.3.396; HARING H, 1986, J BIOL CHEM, V261, P3869; HARING H, 1986, BIOCHEM J, V234, P59; HARING HU, 1981, AM J PHYSIOL, V240, pE556, DOI 10.1152/ajpendo.1981.240.5.E556; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; HARING HU, 1991, DIABETOLOGIA, V34, P848, DOI 10.1007/BF00400192; HARING HU, 1987, P NATL ACAD SCI USA, V84, P113, DOI 10.1073/pnas.84.1.113; HOFFMAN JM, 1991, ENDOCRINOLOGY, V128, P2937, DOI 10.1210/endo-128-6-2937; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KELLERER M, 1992, BIOCHEMISTRY-US, V31, P4588, DOI 10.1021/bi00134a008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MULLER HK, 1991, DIABETES, V40, P1440, DOI 10.2337/diabetes.40.11.1440; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OBERMAIER B, 1987, DIABETOLOGIA, V30, P93; OLEFSKY JM, 1985, AM J MED, V79, P12, DOI 10.1016/S0002-9343(85)80003-6; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; SWEET LJ, 1987, J BIOL CHEM, V262, P16730; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAVARE JM, 1991, BIOCHEM J, V274, P173, DOI 10.1042/bj2740173; VANOBBERGHEN E, 1983, P NATL ACAD SCI-BIOL, V80, P945; VUORINENMARKKOLA H, 1992, DIABETES, V41, P571, DOI 10.2337/diabetes.41.5.571; WHITE MF, 1985, J BIOL CHEM, V260, P9470; WHITE MF, 1985, NATURE, V163, P76	34	116	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3381	3386						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508912				2022-12-27	WOS:A1994MV63100040
J	WARSHAWSKY, I; BU, G; SCHWARTZ, AL				WARSHAWSKY, I; BU, G; SCHWARTZ, AL			BINDING ANALYSIS OF AMINO-TERMINAL AND CARBOXYL-TERMINAL REGIONS OF THE 39-KDA PROTEIN TO THE LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR TYPE-1; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; APOLIPOPROTEIN-E; HIGH-AFFINITY; COMPLEXES; IDENTIFICATION; LIGANDS; LIVER	A 39-kDa protein binds to the low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor (LRP/alpha2MR) and inhibits the binding of ligands to this. receptor. We recently reported that inhibition of tissue-type plasminogen activator binding to LRP/alpha2MR is mediated by both amino-terminal and carboxyl-terminal regions of the 39-kDa protein, whereas inhibition Of alpha2-macroglobulin-proteinase binding is mediated only by amino-terminal regions. In this report we show that amino-terminal and carboxyl-terminal regions of the 39-kDa protein bind specifically and with high affinity to LRP/alpha2MR on rat hepatoma MH1C1 cells. Following binding, these amino-terminal and carboxyl-terminal regions of the 39-kDa protein are each rapidly endocytosed and degraded with kinetics identical to the full-length 39-kDa protein. Competition binding experiments with these constructs demonstrate that amino-terminal and carboxyl-terminal regions of the 39-kDa protein compete with one another for binding to LRP/alpha2MR. A model is proposed in which amino-terminal and carboxyl-terminal regions of the 39-kDa protein bind to different sites on LRP/alpha2MR in order to inhibit ligand binding.	WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT MOLEC BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL017646, T32HL007275, P50HL017646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL17646, T32HL07275] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1993, J BIOL CHEM, V268, P13002; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; IODONATO SP, 1993, IN PRESS BIOCH J; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEGEL IH, 1975, ENZYME KINETICS, P125; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	24	34	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3325	3330						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508911				2022-12-27	WOS:A1994MV63100033
J	ZHANG, MJ; VOGEL, HJ				ZHANG, MJ; VOGEL, HJ			CHARACTERIZATION OF THE CALMODULIN-BINDING DOMAIN OF RAT CEREBELLAR NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; PEPTIDE COMPLEX; ALPHA-HELICES; BETA-TURNS; PROTEIN; IDENTIFICATION; RECOGNITION; PURIFICATION; EXPRESSION; SEQUENCE	Nitric oxide (NO) has recently been identified as an intercellular messenger which is involved in the regulation of neurotransmission, vasorelaxation, and cytotoxicity. In cerebellum and endothelium this compound is synthesized by ''constitutive'' nitric oxide synthases (NOS); these are Ca2+-calmodulin (CaM)-dependent enzymes. A potential CaM-binding domain for the CaM-dependent NOS has previously been identified in the gene sequence. In this work, a synthetic 23 residue peptide encompassing the putative CaM-binding domain of rat cerebellar NOS was studied. The constitutive NOS peptide binds to CaM in a calcium-dependent manner with 1:1 stoichiometry as determined by polyacrylamide gel electrophoresis of the peptide-CaM complex in 4 M urea. Circular dichroism studies showed that the peptide binds to CaM in an alpha-helical conformation. Binding of the constitutive NOS peptide inhibits the stimulatory effect of CaM on cyclic nucleotide phosphodiesterase. From competition experiments between the peptide and phosphodiesterase we have determined a K(d) of 2.2 nM for the peptide-CaM complex. Two-dimensional NMR and circular dichroism studies were used to determine the structure of the peptide in aqueous solution. In addition, the effect of increasing amounts of trifluoroethanol on the peptide structure was investigated. It was found that the peptide can adopt an alpha-helical structure which bears close resemblance to the structure of the CaM-bound form of the CaM-binding domains of myosin light chain kinases.	UNIV CALGARY, DEPT BIOL SCI, CALGARY T2N 1N4, ALBERTA, CANADA	University of Calgary				Zhang, Mingjie/0000-0001-9404-0190				BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; COX JA, 1985, J BIOL CHEM, V260, P2527; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; GIEDROC DP, 1983, BIOCHEMISTRY-US, V22, P5584, DOI 10.1021/bi00293a020; HANSEN RS, 1986, J BIOL CHEM, V261, P4636; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P1371, DOI 10.1016/S0006-291X(89)80155-X; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MANNING MC, 1988, BIOPHYS CHEM, V31, P77, DOI 10.1016/0301-4622(88)80011-5; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MUNIER H, 1993, J BIOL CHEM, V268, P1695; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; SCHMIDT HHH, 1989, BIOCHEM BIOPH RES CO, V165, P813; SESSA WC, 1992, J BIOL CHEM, V267, P15274; Sharma R K, 1979, Adv Cyclic Nucleotide Res, V10, P187; SHMIDT HHHW, 1992, CELL CALCIUM, V13, P427, DOI 10.1016/0143-4160(92)90055-W; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; Wuthrich K., 1986, NMR PROTEINS NUCL AC; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; ZHAN Q, 1991, J BIOL CHEM, V266, P21810; ZHANG M, 1993, IN PRESS PEPTIDES CH; ZHANG MJ, 1993, J BIOL CHEM, V268, P22420; ZHANG MJ, 1993, PROTEIN SCI, V2, P1931, DOI 10.1002/pro.5560021114	36	103	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					981	985						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507114				2022-12-27	WOS:A1994MR22000034
J	CALERO, M; ESCRIBANO, J; GRUBB, A; MENDEZ, E				CALERO, M; ESCRIBANO, J; GRUBB, A; MENDEZ, E			LOCATION OF A NOVEL TYPE OF INTERPOLYPEPTIDE CHAIN LINKAGE IN THE HUMAN PROTEIN HC-IGA COMPLEX (HC-IGA) AND IDENTIFICATION OF A HETEROGENEOUS CHROMOPHORE ASSOCIATED WITH THE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; FORMING GLYCOPROTEIN; INTERNAL THIOLESTER; BINDING PROTEIN; CHARGE; ALPHA-1-MICROGLOBULIN; BOND; POLYPEPTIDE; COMPONENT; PLASMA	Protein HC (human complex-forming glycoprotein, heterogeneous in charge) is a member of the lipocalin superfamily of hydrophobic ligand-binding proteins. The quantitatively dominating blood plasma form of protein HC is a protein HC-IgA complex (HC-IgA), which is the fourth most abundant immunoglobulin species in plasma. A photodiode array detection system on-line with a high performance liquid chromatograph has allowed the identification of low amounts of a heterogeneous fluorescent chromophore covalently bound to HC-IgA, and displaying significant absorption in the visible region in resemblance to the free protein HC chromophore. Several structurally related chromophore-containing linked peptides, carrying 80% of the light absorption at 330 nm of HC-IgA, were isolated from a pepsin-produced protein HC-alpha1-nonapeptide. Sequence analysis of these linked peptides demonstrated that the bond between protein HC and IgA represents a novel type of reduction-resistant linkage between polypeptide chains and involves the cysteine residue 34 of protein HC and the penultimate cysteine residue of the carboxyl-terminal part of one of the IgA heavy chains, as well as the heterogeneous fluorescent chromophore. The light absorption and fluorescent spectra of the chromophore-linked peptides were similar to those of native free protein HC.	UNIV LUND HOSP, DEPT CLIN CHEM, S-22185 LUND, SWEDEN; CTR ESPECIAL RAMON & CAJAL, SERV ENDOCRINOL, MADRID 34, SPAIN	Lund University; Skane University Hospital			Calero, Miguel/H-5691-2015; Escribano, Julio/D-9742-2015	Calero, Miguel/0000-0001-5366-3324; Escribano, Julio/0000-0002-8919-8134; Grubb, Anders/0000-0002-0125-3662				AKERSTROM B, 1990, TRENDS BIOCHEM SCI, V15, P240, DOI 10.1016/0968-0004(90)90037-C; BABIKERMOHAMED H, 1990, SCAND J IMMUNOL, V32, P37, DOI 10.1111/j.1365-3083.1990.tb02889.x; BERNIER I, 1980, EXPERIENTIA, V36, P1419, DOI 10.1007/BF01960136; BIZZOZERO OA, 1990, J NEUROCHEM, V55, P1986, DOI 10.1111/j.1471-4159.1990.tb05786.x; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIEHANOVER A, 1980, P NATL ACAD SCI USA, V77, P1365; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; EKSTROM B, 1977, J BIOL CHEM, V252, P8048; ENGHILD JJ, 1993, J BIOL CHEM, V268, P8711; ESCRIBANO J, 1991, J BIOL CHEM, V266, P15758; FALKENBERG C, 1990, J BIOL CHEM, V265, P16150; FERNANDEZLUNA JL, 1988, FEBS LETT, V236, P471, DOI 10.1016/0014-5793(88)80079-6; FERNANDEZLUNA JL, 1988, J CLIN PATHOL, V41, P1176, DOI 10.1136/jcp.41.11.1176; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; GAVILANES JG, 1984, BIOCHEMISTRY-US, V23, P1234, DOI 10.1021/bi00301a033; GEBHARD W, 1990, FEBS LETT, V269, P32, DOI 10.1016/0014-5793(90)81112-2; GRUBB A, 1986, J BIOL CHEM, V261, P14313; GRUBB A, 1992, CLIN NEPHROL, V38, pS20; GRUBB AO, 1983, J BIOL CHEM, V258, P4698; HAEFLIGER JA, 1987, BIOCHEM BIOPH RES CO, V149, P750, DOI 10.1016/0006-291X(87)90431-1; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; IMAI H, 1992, CLIN NEPHROL, V37, P169; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; ITOH Y, 1990, J CLIN LAB ANAL, V4, P376, DOI 10.1002/jcla.1860040511; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERCH K, 1982, J BIOL CHEM, V257, P6414; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; MENDEZ E, 1986, P NATL ACAD SCI USA, V83, P1472, DOI 10.1073/pnas.83.5.1472; MENDEZ E, 1973, BIOCHEM BIOPH RES CO, V55, P1291, DOI 10.1016/S0006-291X(73)80034-8; MENDEZ E, 1982, ARCH BIOCHEM BIOPHYS, V213, P240, DOI 10.1016/0003-9861(82)90458-1; MESTECKY J, 1974, P NATL ACAD SCI USA, V71, P544, DOI 10.1073/pnas.71.2.544; MOORE S, 1963, J BIOL CHEM, V238, P235; OTIN CL, 1984, ARCH BIOCHEM BIOPHYS, V228, P544, DOI 10.1016/0003-9861(84)90021-3; PERVAIZ S, 1985, SCIENCE, V228, P335, DOI 10.1126/science.2580349; PEVSNER J, 1988, SCIENCE, V241, P336, DOI 10.1126/science.3388043; SJOBERG M, 1991, EUR J BIOCHEM, V197, P61, DOI 10.1111/j.1432-1033.1991.tb15882.x; SOTTRUPJENSEN L, 1982, BIOCHEM BIOPH RES CO, V107, P93, DOI 10.1016/0006-291X(82)91674-6; TACK BF, 1980, P NATL ACAD SCI-BIOL, V77, P5764, DOI 10.1073/pnas.77.10.5764; TEJLER L, 1976, BIOCHIM BIOPHYS ACTA, V439, P82, DOI 10.1016/0005-2795(76)90164-1; TRUEDSSON L, 1988, SCAND J IMMUNOL, V27, P201, DOI 10.1111/j.1365-3083.1988.tb02340.x; Vincent C, 1987, Adv Exp Med Biol, V216B, P1231; ZAGALSKY PF, 1991, BIOCHEM J, V274, P79, DOI 10.1042/bj2740079	44	22	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					384	389						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506257				2022-12-27	WOS:A1994MR21900065
J	TIEN, XY; BRASITUS, TA; KAETZEL, MA; DEDMAN, JR; NELSON, DJ				TIEN, XY; BRASITUS, TA; KAETZEL, MA; DEDMAN, JR; NELSON, DJ			ACTIVATION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR BY CGMP IN THE HUMAN COLONIC-CANCER CELL-LINE, CACO-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTESTINAL GUANYLATE-CYCLASE; PROTEIN-KINASE; CHLORIDE CONDUCTANCE; ENDOGENOUS ACTIVATOR; CAMP; CHANNEL; CFTR; PHOSPHORYLATION; ENTEROTOXIN; EXPRESSION	Intestinal chloride (Cl-) secretion can be induced by the heat-stable enterotoxin (STa) from Escherichia coli via generation of cGMP. We investigated the regulatory pathway responsible for cGMP-mediated Cl- secretion in the human colonic carcinoma cell line Caco-2 using whole-cell voltage clamp techniques. Cyclic GMP or cAMP induced a 5-fold increase in Cl- conductance (g(Cl)) in the presence of intracellular ATP and 3-isobutyl-1-methylxanthine. Current activation by cGMP persisted in the presence of the type I cGMP-dependent protein kinase (PKG) inhibitor, KT5823, but was inhibited by the specific peptide inhibitor of the cAMP-dependent protein kinase A (PKA), PKI5-24. The stimulatory effects of cGMP and cAMP on g(Cl) were not additive. The cystic fibrosis transmembrane conductance regulator (CFTR) is a Cl- channel that is regulated by intracellular ATP and by cAMP-dependent phosphorylation. In order to determine whether CFTR was involved in the cGMP-dependent increase in g(Cl), we tested the effect of intracellularly injected anti-CFTR505-511 antibodies previously shown to inhibit CFTR function. Antibodies introduced into individual cells via the patch pipette completely inhibited cGMP-dependent current activation. Cyclic GMP also failed to activate g(Cl) in cystic fibrosis cells. Taken together, these studies demonstrate that activation of the CFTR via PKA-dependent phosphorylation accounts for the cGMP-mediated increase in Cl- secretion in Caco-2 cells.	UNIV CHICAGO,DEPT NEUROL,MC 2030,5841 S MARYLAND AVE,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CINCINNATI,COLL MED,DEPT PHYSIOL & BIOPHYS,CINCINNATI,OH 45267	University of Chicago; University of Chicago; University System of Ohio; University of Cincinnati					NCI NIH HHS [CA36745] Funding Source: Medline; NIDDK NIH HHS [DK39573, P30DK42086] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA036745, R01CA036745] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039573, P30DK042086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1992, AM J PHYSIOL, V262, pC251, DOI 10.1152/ajpcell.1992.262.1.C251; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; CHAN HC, 1992, AM J PHYSIOL, V262, pC1273, DOI 10.1152/ajpcell.1992.262.5.C1273; CHAN HC, 1992, J BIOL CHEM, V267, P8411; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; FESENKO EE, 1986, BIOCHIM BIOPHYS ACTA, V856, P661, DOI 10.1016/0005-2736(86)90162-8; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; FORTE LR, 1993, J CLIN INVEST, V91, P2423, DOI 10.1172/JCI116476; GARBERS DL, 1992, CELL, V71, P1; HUOTT PA, 1988, J CLIN INVEST, V82, P514, DOI 10.1172/JCI113626; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; MATESIC D, 1987, NATURE, V326, P600, DOI 10.1038/326600a0; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; PINTO M, 1983, BIOL CELL, V47, P323; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; SCHULZ S, 1989, FASEB J, V3, P2026, DOI 10.1096/fasebj.3.9.2568301; SHABB JB, 1991, J BIOL CHEM, V266, P24320; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TIEN XY, 1993, AM J PHYSIOL, V256, pG143; VAANDRAGER AB, 1992, GASTROENTEROLOGY, V102, P1161; WIEGAND RC, 1992, BIOCHEM BIOPH RES CO, V185, P812, DOI 10.1016/0006-291X(92)91699-Q; WONG SKF, 1992, J CLIN INVEST, V90, P299, DOI 10.1172/JCI115862	30	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					51	54						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506258				2022-12-27	WOS:A1994MR21900014
J	KANG, JJ; YOKOI, TJ; HOLLAND, MJ				KANG, JJ; YOKOI, TJ; HOLLAND, MJ			BINDING-SITES FOR ABUNDANT NUCLEAR FACTORS MODULATE RNA-POLYMERASE I-DEPENDENT ENHANCER FUNCTION IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III TRANSCRIPTION FACTOR; YEAST RIBOSOMAL DNA; SPACER REGION; 3'-END FORMATION; GENE-EXPRESSION; RDNA ENHANCER; PROTEIN; SEQUENCES; PROMOTER; ACTIVATION	The 190-base pair (bp) rDNA enhancer within the intergenic spacer sequences of Saccharomyces cerevisiae rRNA cistrons activates synthesis of the S-35-rRNA precursor about 20-fold in vivo (Mestel., R., Yip, M., Holland, J. P., Wang, E., Kang, J., and Holland, M. J. (1989) Mol. Cell. Biol. 9, 1243-1254). We now report identification and analysis of transcriptional activities mediated by three cis-acting sites within a 90-bp portion of the rDNA enhancer designated the modulator region. In vivo, these sequences mediated termination of transcription by RNA polymerase I and potentiated the activity of the rDNA enhancer element. Two trans acting factors, REB1 and REB2, bind independently to sites within the modulator region (Morrow, B. E., Johnson, S. P., and Warner, J. R. (1989) J. Biol. Chem. 264, 9061-9068). We show that REB2 is identical to the ABF1 protein, Site directed mutagenesis of REB1 and ABF1 binding sites demonstrated uncoupling of RNA polymerase I-dependent termination from transcriptional activation in vivo, We conclude that REB1 and ABF1 are required for RNA polymerase I-dependent termination and enhancer function, respectively. Since REB1 and ABF1 proteins also regulate expression of class II genes and other nuclear functions, our results suggest further similarities between RNA polymerase I and II regulatory mechanisms, Two rDNA enhancers flanking a rDNA minigene stimulated RNA polymerase I transcription in a ''multiplicative'' fashion, Deletion mapping analysis showed that similar cis-acting sequences were required for enhancer function when positioned upstream or down stream from a rDNA minigene.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030307] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07377, GM30307] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SM, 1986, CELL, V47, P839, DOI 10.1016/0092-8674(86)90795-6; BRINDLE PK, 1990, MOL CELL BIOL, V10, P4872, DOI 10.1128/MCB.10.9.4872; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; CARMEN AA, 1994, J BIOL CHEM, V269, P9790; CASSIDY BG, 1987, MOL CELL BIOL, V7, P2388, DOI 10.1128/MCB.7.7.2388; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWINTER RFJ, 1986, CELL, V44, P313, DOI 10.1016/0092-8674(86)90765-8; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; ELION EA, 1986, MOL CELL BIOL, V6, P2089, DOI 10.1128/MCB.6.6.2089; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GRIMALDI G, 1990, MOL CELL BIOL, V10, P4667, DOI 10.1128/MCB.10.9.4667; GRUMMT I, 1985, CELL, V43, P801, DOI 10.1016/0092-8674(85)90253-3; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HIGGUCHI R, 1990, PCR PROTOCOLS, P177; HOLLAND JP, 1990, MOL CELL BIOL, V10, P4863, DOI 10.1128/MCB.10.9.4863; HOLLAND MJ, 1987, MOL CELL BIOL, V7, P813, DOI 10.1128/MCB.7.2.813; JOHNSON SP, 1989, MOL CELL BIOL, V9, P4986, DOI 10.1128/MCB.9.11.4986; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KEMPERSVEENSTRA AE, 1986, EMBO J, V5, P2703, DOI 10.1002/j.1460-2075.1986.tb04554.x; KUHN A, 1990, NATURE, V344, P559, DOI 10.1038/344559a0; KUHN A, 1987, EMBO J, V6, P3487, DOI 10.1002/j.1460-2075.1987.tb02673.x; KULKENS T, 1989, CURR GENET, V16, P351, DOI 10.1007/BF00340714; KULKENS T, 1992, EMBO J, V11, P4665, DOI 10.1002/j.1460-2075.1992.tb05568.x; KUNKEL GR, 1991, BIOCHIM BIOPHYS ACTA, V1088, P1, DOI 10.1016/0167-4781(91)90146-D; LABHART P, 1987, CELL, V50, P51, DOI 10.1016/0092-8674(87)90661-1; LANG WH, 1994, CELL, V79, P527, DOI 10.1016/0092-8674(94)90261-5; LANG WH, 1993, MOL CELL BIOL, V13, P649, DOI 10.1128/MCB.13.1.649; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LORCH Y, 1990, P NATL ACAD SCI USA, V87, P8202, DOI 10.1073/pnas.87.21.8202; MAGER WH, 1990, BIOCHIM BIOPHYS ACTA, V1050, P351, DOI 10.1016/0167-4781(90)90193-6; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MARCZYNSKI GT, 1985, NUCLEIC ACIDS RES, V13, P8487, DOI 10.1093/nar/13.23.8487; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MCSTAY B, 1990, MOL CELL BIOL, V10, P2793, DOI 10.1128/MCB.10.6.2793; MESTEL R, 1989, MOL CELL BIOL, V9, P1243, DOI 10.1128/MCB.9.3.1243; MITCHELSON K, 1987, NUCLEIC ACIDS RES, V15, P9577, DOI 10.1093/nar/15.22.9577; MORROW BE, 1989, J BIOL CHEM, V264, P9061; MORROW BE, 1990, J BIOL CHEM, V265, P20778; MORROW BE, 1993, MOL CELL BIOL, V13, P1283, DOI 10.1128/MCB.13.2.1283; PAPE LK, 1989, MOL CELL BIOL, V9, P5093, DOI 10.1128/MCB.9.11.5093; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1992, J BIOL CHEM, V267, P679; Reeder RH, 1989, CURR OPIN CELL BIOL, V1, P466, DOI 10.1016/0955-0674(89)90007-0; RHODE PR, 1989, GENE DEV, V3, P1926, DOI 10.1101/gad.3.12a.1926; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SOLLNERWEBB B, 1991, TRENDS BIOCHEM SCI, V16, P58, DOI 10.1016/0968-0004(91)90025-Q; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; SWANSON ME, 1983, J BIOL CHEM, V258, P3242; SWANSON ME, 1985, J BIOL CHEM, V260, P9905; TOWER J, 1989, MOL CELL BIOL, V9, P1513, DOI 10.1128/MCB.9.4.1513; VANDERSANDE CAFM, 1989, NUCLEIC ACIDS RES, V17, P9127, DOI 10.1093/nar/17.22.9127; VERDIER JM, 1990, YEAST, V6, P271, DOI 10.1002/yea.320060402; WANG HM, 1990, MOL CELL BIOL, V10, P1743, DOI 10.1128/MCB.10.4.1743; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; YIP MT, 1989, J BIOL CHEM, V264, P4045	62	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28723	28732		10.1074/jbc.270.48.28723	http://dx.doi.org/10.1074/jbc.270.48.28723			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499394	hybrid			2022-12-27	WOS:A1995TH05600038
J	NEISH, AS; KHACHIGIAN, LM; PARK, A; BAICHWAL, VR; COLLINS, T				NEISH, AS; KHACHIGIAN, LM; PARK, A; BAICHWAL, VR; COLLINS, T			SP1 IS A COMPONENT OF THE CYTOKINE-INDUCIBLE ENHANCER IN THE PROMOTER OF VASCULAR CELL-ADHESION MOLECULE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MONONUCLEAR LEUKOCYTE ADHESION; INTEGRIN VLA-4; EXPRESSION; VCAM-1; ACTIVATION; BINDING; PROTEIN; GENE; FIBRONECTIN	Transcription of the vascular cell adhesion molecule-1 (VCAM-1) gene in endothelial cells is induced by the inflammatory cytokines interleukin-1 beta, tumor necrosis factor-alpha, and lipopolysaccharide. Previous studies demonstrated that the cytokine-response region in the VCAM1 promoter contains binding sites for the transcription factors nuclear factor-kappa B (NF-kappa B) and interferon regulatory factor-1. Using a saturation mutagenesis approach, we report that the cytokine inducible enhancer consists of these previously characterized elements and a novel region located 3' of the NF-kappa B sites. Electrophoretic mobility shift assays and DNase I footprint studies with endothelial nuclear extracts and recombinant protein revealed that the transcriptional activator Sp1 interacts with this novel element in a specific manner. Transient transfection assays using vascular endothelial cells revealed that site-directed mutations in the Sp1 binding element decreased tumor necrosis factor-alpha-induced activity of the VCAM1 promoter. The cytokine-induced enhancer of the VCAM1 gene requires constitutively bound Sp1 and induced heterodimeric NF-kappa B for maximal promoter activity.	BRIGHAM & WOMENS HOSP, DEPT PATHOL, DIV VASC RES, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; TULARIK INC, San Francisco, CA 94080 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Neish, Andrew/B-3895-2009; Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035716, R37HL035716] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45462, HL03011-01, HL 35716] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CAO XM, 1993, J BIOL CHEM, V268, P16949; CARLOS TM, 1994, BLOOD, V84, P2068; CARLOS TM, 1990, BLOOD, V76, P965; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; CYBULSKY MI, 1991, P NATL ACAD SCI USA, V88, P7859, DOI 10.1073/pnas.88.17.7859; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; FRIES JWU, 1993, AM J PATHOL, V143, P725; GIMBRONE MA, 1976, PROGR HEMOSTASIS THR, P1; GURTNER GC, 1995, GENE DEV, V9, P1, DOI 10.1101/gad.9.1.1; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KOOPMAN G, 1991, J EXP MED, V173, P1297, DOI 10.1084/jem.173.6.1297; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; MINOWA T, 1994, J BIOL CHEM, V269, P11656; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; RICE GE, 1991, AM J PATHOL, V138, P385; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; Sambrook J, 1989, MOL CLONING LABORATO; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5	37	111	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28903	28909		10.1074/jbc.270.48.28903	http://dx.doi.org/10.1074/jbc.270.48.28903			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499419	hybrid			2022-12-27	WOS:A1995TH05600063
J	LABOISSIERE, MCA; STURLEY, SL; RAINES, RT				LABOISSIERE, MCA; STURLEY, SL; RAINES, RT			THE ESSENTIAL FUNCTION OF PROTEIN-DISULFIDE ISOMERASE IS TO UNSCRAMBLE NONNATIVE DISULFIDE BONDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ENDOPLASMIC-RETICULUM; SECRETORY PROTEINS; ESCHERICHIA-COLI; PEPTIDE BINDING; ER PROTEINS; YEAST; THIOREDOXIN; GENE; MUTAGENESIS; POLYPEPTIDE	Protein-disulfide isomerase (PDI) is an abundant protein of the endoplasmic reticulum that catalyzes dithiol oxidation and disulfide bond reduction and isomerization using the active site CGHC. Haploid pdi1 Delta Saccharomyces cerevisiae are inviable, but can be complemented with either a wild-type rat PDI gene or a mutant gene coding for CGHS PDI (shufflease). In contrast, pdi1 Delta yeast cannot be complemented with a gene coding for SGHC PDI. In vitro, shufflease is an efficient catalyst for the isomerization of existing disulfide bonds but not for dithiol oxidation or disulfide bond reduction. SGHC PDT catalyzes none of these processes. These results indicate that in vivo protein folding pathways contain intermediates with non-native disulfide bonds, and that the essential role of PDI is to unscramble these intermediates.	UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison			Raines, Ronald T./A-5009-2013	Raines, Ronald T./0000-0001-7164-1719				Ausubel FM, 1988, MOL REPROD DEV; BOSTIAN KA, 1983, CELL, V32, P169, DOI 10.1016/0092-8674(83)90507-X; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P3576, DOI 10.1021/bi00011a012; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FARQUHAR R, 1991, GENE, V108, P81, DOI 10.1016/0378-1119(91)90490-3; FREEDMAN RB, 1988, BIOCHEM SOC T, V16, P96, DOI 10.1042/bst0160096; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FUCHS S, 1967, J BIOL CHEM, V242, P398; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GIVOL D, 1964, J BIOL CHEM, V239, P3114; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; HILLSON DA, 1980, BIOCHEM J, V191, P373, DOI 10.1042/bj1910373; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KOIVU J, 1987, J BIOL CHEM, V262, P6447; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURUP CKR, 1966, BIOCHIM BIOPHYS ACTA, V113, P255, DOI 10.1016/S0926-6593(66)80066-8; LABOISSIERE MCA, 1995, PROTEIN EXPRES PURIF, V6, P700, DOI 10.1006/prep.1995.1092; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LU XJ, 1992, BIOCHEMISTRY-US, V31, P4205, DOI 10.1021/bi00132a008; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; PUIG A, 1994, J BIOL CHEM, V269, P7764; PUIG A, 1994, J BIOL CHEM, V269, P19128; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; SCHERENS B, 1991, YEAST, V7, P185, DOI 10.1002/yea.320070212; SEGEL LA, 1980, MATH MODELS MOL CELL, P502; SHERMAN F, 1991, P3; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; TACHIKAWA H, 1991, J BIOCHEM, V110, P306, DOI 10.1093/oxfordjournals.jbchem.a123576; VUORI K, 1992, J BIOL CHEM, V267, P7211; WANG CC, 1993, FASEB J, V7, P1515, DOI 10.1096/fasebj.7.15.7903263; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; Wittrup K. Dane, 1995, Current Opinion in Biotechnology, V6, P203, DOI 10.1016/0958-1669(95)80033-6	50	174	185	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28006	28009						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499282				2022-12-27	WOS:A1995TG21000007
J	NOMURA, M; YAMAGISHI, SI; HARADA, SI; HAYASHI, Y; YAMASHIMA, T; YAMASHITA, J; YAMAMOTO, H				NOMURA, M; YAMAGISHI, SI; HARADA, SI; HAYASHI, Y; YAMASHIMA, T; YAMASHITA, J; YAMAMOTO, H			POSSIBLE PARTICIPATION OF AUTOCRINE AND PARACRINE VASCULAR ENDOTHELIAL GROWTH-FACTORS IN HYPOXIA-INDUCED PROLIFERATION OF ENDOTHELIAL-CELLS AND PERICYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; MESSENGER-RNA EXPRESSION; RECEPTOR TYROSINE KINASE; GENE-EXPRESSION; SIGNAL TRANSDUCTION; PERMEABILITY FACTOR; FACTOR FAMILY; TGF-BETA; ANGIOGENESIS; PURIFICATION	Hypoxia is the principal factor that causes angiogenesis. These experiments were conducted to explore how it induces the proliferation of vascular cells, a key step in angiogenesis, Human umbilical vein endothelial cells and bovine retinal pericytes were grown in controlled atmosphere culture chambers containing various concentrations of oxygen, The numbers of both endothelial cells and pericytes increased significantly under hypoxic conditions; the O-2 concentrations that achieved maximal growth promotion were 10% for endothelial cells and 2.5% for pericytes. Quantitative reverse transcription polymerase chain reaction analysis revealed that mRNAs coding for the secretory forms of vascular endothelial growth factor (VEGF), a mitogen specific to endothelial cells, were present in both endothelial cells and pericytes and that their levels increased significantly in the two cell types as the atmospheric O-2 concentration decreased, The two genes for VEGF receptors, kinase insert domain-containing receptor (kdr) and fms-like tyrosine kinase 1 (flt1), mere found to be constitutively expressed in endothelial cells, and their relative mRNA levels were ranked in that order. On the other hand, only flt1 mRNA was detected in pericytes under hypoxic conditions, Furthermore, most antisense oligodeoxyribonucleotides complementary to VEGF mRNAs efficiently inhibited DNA synthesis in endothelial cells cultured under hypoxic conditions. These results indicate that autocrine and paracrine VEGFs may take part in the hypoxia-induced proliferation of endothelial cells.	KANAZAWA UNIV, SCH MED, DEPT BIOCHEM, KANAZAWA, ISHIKAWA 920, JAPAN; KANAZAWA UNIV, SCH MED, DEPT NEUROSURG, KANAZAWA, ISHIKAWA 920, JAPAN	Kanazawa University; Kanazawa University								AIELLO LP, 1994, DIABETES, V43, pA148; Ausubel FM, 1994, CURRENT PROTOCOLS MO; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BRIGHTON CT, 1992, CLIN ORTHOP RELAT R, P287; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; DASH P, 1987, P NATL ACAD SCI USA, V84, P7896, DOI 10.1073/pnas.84.22.7896; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Ferrara N, 1991, Growth Factors, V5, P141, DOI 10.3109/08977199109000278; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FUNA K, 1990, CANCER RES, V50, P748; GALLAND F, 1993, ONCOGENE, V8, P1233; GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; HAEUPTLE MT, 1986, NUCLEIC ACIDS RES, V14, P1427, DOI 10.1093/nar/14.3.1427; HATAKEYAMA H, 1994, BIOCHEM MOL BIOL INT, V34, P127; HATAKEYAMA H, 1994, J BIOL CHEM, V269, P24316; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; IIJIMA K, 1993, KIDNEY INT, V44, P959, DOI 10.1038/ki.1993.337; IIZUKA M, 1994, BIOCHEM BIOPH RES CO, V205, P1474, DOI 10.1006/bbrc.1994.2831; KAN M, 1985, IN VITRO CELL DEV B, V21, P181; KAN M, 1988, J BIOL CHEM, V263, P11306; Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; LADOUX A, 1993, BIOCHEM BIOPH RES CO, V194, P799, DOI 10.1006/bbrc.1993.1892; LADOUX A, 1993, BIOCHEM BIOPH RES CO, V195, P1005, DOI 10.1006/bbrc.1993.2144; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1989, GROWTH FACTORS, V2, P9, DOI 10.3109/08977198909069077; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; MORII K, 1993, BIOCHEM BIOPH RES CO, V194, P749, DOI 10.1006/bbrc.1993.1885; NINOMIYA I, 1992, BRIT J CANCER, V66, P84, DOI 10.1038/bjc.1992.221; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PHILLIPS HJ, 1993, TISSUE CULTURE, P406; PHILLIPS HS, 1993, INT J ONCOL, V2, P913; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1990, CANCER RES, V50, P1774; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; THOMAS LL, 1992, ANN NY ACAD SCI, V660, P328, DOI 10.1111/j.1749-6632.1992.tb21103.x; TISCHER E, 1991, J BIOL CHEM, V266, P11947; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; YAMAGISHI S, 1993, BIOCHEM BIOPH RES CO, V191, P840, DOI 10.1006/bbrc.1993.1293; YAMAGISHI S, 1993, BIOCHEM BIOPH RES CO, V190, P418, DOI 10.1006/bbrc.1993.1064	65	287	308	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28316	28324						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499331				2022-12-27	WOS:A1995TG21000056
J	SANO, T; PANDORI, MW; CHEN, XM; SMITH, CL; CANTOR, CR				SANO, T; PANDORI, MW; CHEN, XM; SMITH, CL; CANTOR, CR			RECOMBINANT CORE STREPTAVIDINS - A MINIMUM-SIZED CORE STREPTAVIDIN HAS ENHANCED STRUCTURAL STABILITY AND HIGHER ACCESSIBILITY TO BIOTINYLATED MACROMOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; CLONED GENES; EXPRESSION; PROTEINS; BINDING; AVIDIN; UREA; TECHNOLOGY	Two recombinant core streptavidins were designed and characterized to understand the role of the terminal sequences, present in naturally truncated core streptavidins, in the properties of streptavidin, One recombinant core streptavidin, Stv-25, has an amino acid sequence very similar to natural core streptavidins. The other recombinant molecule, Stv-13, has further truncation of the terminal residues and consists essentially of only the beta-barrel structure characteristic of streptavidin, These recombinant core streptavidins are tetrameric and bind four biotins/molecule, as does natural streptavidin, The solubility characteristics of Stv-13, determined by varying the concentration of ammonium sulfate or ethanol, were almost the same as those of Stv-25 and natural core streptavidin, However, Stv-13 showed an enhanced structural stability compared with Stv-25 and natural core streptavidin, For example, Stv-13 retained greater than 80% of its biotin binding ability after incubation in 6 M guanidine hydrochloride at pH 1.5, under which conditions, Stv-25 and natural core streptavidin retained only about 20% of their biotin binding ability, In addition, Stv-13 showed higher accessibility to biotinylated DNA than natural core streptavidin, Apparently, the terminal regions, present on the surface of natural core streptavidin, spatially hinder biotinylated macromolecules from approaching the biotin binding sites.	BOSTON UNIV, CTR ADV BIOTECHNOL, BOSTON, MA 02215 USA; BOSTON UNIV, DEPT BIOMED ENGN, BOSTON, MA 02215 USA; BOSTON UNIV, DEPT PHARMACOL, BOSTON, MA 02215 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	Boston University; Boston University; Boston University; University of California System; University of California Berkeley				Smith, Cassandra/0000-0002-0346-8907	NATIONAL CANCER INSTITUTE [R35CA039782] Funding Source: NIH RePORTER; NCI NIH HHS [CA39782] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGARANA CE, 1986, NUCLEIC ACIDS RES, V14, P1871, DOI 10.1093/nar/14.4.1871; BAYER EA, 1986, J BIOCHEM BIOPH METH, V13, P103, DOI 10.1016/0165-022X(86)90022-9; BAYER EA, 1989, BIOCHEM J, V259, P369, DOI 10.1042/bj2590369; BLANKENBURG R, 1989, BIOCHEMISTRY-US, V28, P8214, DOI 10.1021/bi00446a037; CHAIET L, 1964, ARCH BIOCHEM BIOPHYS, V106, P1, DOI 10.1016/0003-9861(64)90150-X; CHAIET L, 1963, ANTIMICROB AGENTS CH, V3, P28; CHILKOTI A, 1995, P NATL ACAD SCI USA, V92, P1754, DOI 10.1073/pnas.92.5.1754; CREIGHTON TE, 1979, J MOL BIOL, V129, P235, DOI 10.1016/0022-2836(79)90279-1; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; HELM CA, 1991, P NATL ACAD SCI USA, V88, P8169, DOI 10.1073/pnas.88.18.8169; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; HOFMANN K, 1980, P NATL ACAD SCI-BIOL, V77, P4666, DOI 10.1073/pnas.77.8.4666; KURIYAN J, 1991, P NATL ACAD SCI USA, V88, P2773, DOI 10.1073/pnas.88.7.2773; KURZBAN GP, 1991, J BIOL CHEM, V266, P14470; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECKBAND DE, 1994, BIOCHEMISTRY-US, V33, P4611, DOI 10.1021/bi00181a023; MIYAMOTO S, 1993, PROTEINS, V16, P226, DOI 10.1002/prot.340160303; MOY VT, 1994, SCIENCE, V266, P257, DOI 10.1126/science.7939660; PAHLER A, 1987, J BIOL CHEM, V262, P13933; Sambrook J, 1989, MOL CLONING LABORATO; SANO T, 1991, BIOCHEM BIOPH RES CO, V176, P571, DOI 10.1016/S0006-291X(05)80222-0; SANO T, 1990, J BIOL CHEM, V265, P3369; SANO T, 1990, P NATL ACAD SCI USA, V87, P142, DOI 10.1073/pnas.87.1.142; SANO T, 1992, P NATL ACAD SCI USA, V89, P1534, DOI 10.1073/pnas.89.5.1534; SANO T, 1995, P NATL ACAD SCI USA, V92, P3180, DOI 10.1073/pnas.92.8.3180; SANO T, 1993, BIO-TECHNOL, V11, P201, DOI 10.1038/nbt0293-201; SANO T, 1992, SCIENCE, V258, P120, DOI 10.1126/science.1439758; Sano T., 1994, ADV BIOMAGNETIC SEPA, P21; SANO T, 1991, BIOTECHNOLOGY, V9, P1387; SAYERS JR, 1992, BIOTECHNIQUES, V13, P592; SCHMIDT TGM, 1994, J CHROMATOGR A, V676, P337, DOI 10.1016/0021-9673(94)80434-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOMPSON LD, 1993, GENE, V136, P243, DOI 10.1016/0378-1119(93)90472-F; VAJDA S, 1994, BIOCHEMISTRY-US, V33, P13977, DOI 10.1021/bi00251a004; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; WEI R. D., 1970, Methods in Enzymology, V18A, P424, DOI 10.1016/0076-6879(71)18343-7; WILCHEK M, 1990, METHOD ENZYMOL, V184, P5; WILCHEK M, 1990, METHOD ENZYMOL, V184, P14	41	98	106	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28204	28209						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499314				2022-12-27	WOS:A1995TG21000039
J	SMITH, MD; PETRAK, M; BOUCHER, PD; BARTON, KN; CARTER, L; REDDY, G; BLACHLYDYSON, E; FORTE, M; PRICE, J; VERNER, K; MCCAULEY, RB				SMITH, MD; PETRAK, M; BOUCHER, PD; BARTON, KN; CARTER, L; REDDY, G; BLACHLYDYSON, E; FORTE, M; PRICE, J; VERNER, K; MCCAULEY, RB			LYSINE RESIDUES AT POSITION-234 AND POSITION-236 IN YEAST PORIN ARE INVOLVED IN ITS ASSEMBLY INTO THE MITOCHONDRIAL OUTER-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ANION CHANNEL; PROTEIN-SYNTHESIS; CLONING; INVITRO; IMPORT; CDNA; EXPRESSION	Various point mutations of lysyl residues in yeast mitochondrial porin (283 residues) were tested for their ability to assemble in vitro into the outer membranes of intact yeast mitochondria, Assembly was evaluated by protection from proteinases, The extent of assembly of two of the mutants, K234E and K236E porins, was much less than for wild-type in either post-translational or co-translational assembly assays, Lysine to glutamate mutants at other positions and K234R porin assembled as well as wild-type, but K234Q porin was poorly in inserted, When both Lys-234 and Lys-236 were mutated, K234R/K236R porin was inserted better than K234Q/K236Q porin, which was inserted better than K234E/K236E; however, none of these mutants assembled as well as wild-type porin, It was concluded that optimal assembly of yeast porin depended on the presence of positively charged residues at both positions 234 and 236 and a lysine at one of these positions. After undergoing the assembly reaction, mutants that were vulnerable to proteinase K (i,e, K234E, K234Q, and K236E porins) seemed to be incompletely digested and were, to varying degrees, resistant to extraction by Na2CO3 (pH 11.5). These experiments suggested that these mutants were incompletely inserted into the outer membrane, Both Lys-234 and Lys-236 are included in an internal pentapeptide, VKAKV, that is conserved in porins from protists, plants, and animals, and it is possible that, at least, the lysines in this tract are one of the signals for the membrane assembly of these proteins.	WAYNE STATE UNIV, SCH MED, DEPT PHARMACOL, DETROIT, MI 48201 USA; OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA; PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT CELLULAR & MOLEC PHYSIOL, HERSHEY, PA 17033 USA	Wayne State University; Oregon Health & Science University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NATIONAL INSTITUTE OF MENTAL HEALTH [R24MH047181] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35759] Funding Source: Medline; NIMH NIH HHS [MH 47181] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; BUREAU MH, 1992, J BIOL CHEM, V267, P8679; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; FISHER K, 1994, J BIOL CHEM, V269, P25754; FUJIKI M, 1991, J BIOL CHEM, V266, P6841; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; GASSER SM, 1983, J BIOL CHEM, V258, P3427; HA HJ, 1993, J BIOL CHEM, V268, P12143; HAMAJIMA S, 1988, J BIOCHEM-TOKYO, V104, P362, DOI 10.1093/oxfordjournals.jbchem.a122474; HEINS L, 1994, J BIOL CHEM, V269, P26402; HWAUNG S, 1989, P NATL ACAD SCI USA, V86, P8432; KAYSER H, 1989, BIOL CHEM H-S, V370, P1265; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; MANNELLA CA, 1992, TRENDS BIOCHEM SCI, V17, P315, DOI 10.1016/0968-0004(92)90444-E; MIHARA K, 1985, EMBO J, V4, P769, DOI 10.1002/j.1460-2075.1985.tb03695.x; MIHARA K, 1982, P NATL ACAD SCI-BIOL, V79, P7102, DOI 10.1073/pnas.79.23.7102; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; PENG SZ, 1992, J BIOENERG BIOMEMBR, V24, P27, DOI 10.1007/BF00769527; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; SHORE GC, 1981, J BIOL CHEM, V256, P8761; SMITH M, 1994, J BIOL CHEM, V269, P28460; TROLL H, 1992, J BIOL CHEM, V267, P21072; ZHUANG Z, 1989, J BIOL CHEM, V264, P14594; ZHUANG ZP, 1992, J BIOL CHEM, V267, P591	28	26	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28331	28336						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499333				2022-12-27	WOS:A1995TG21000058
J	XIE, JX; DRUMM, ML; MA, JJ; DAVIS, PB				XIE, JX; DRUMM, ML; MA, JJ; DAVIS, PB			INTRACELLULAR LOOP BETWEEN TRANSMEMBRANE SEGMENTS-IV AND SEGMENTS-V OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IS INVOLVED IN REGULATION OF CHLORIDE CHANNEL CONDUCTANCE STATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CL CHANNEL; R-DOMAIN; CFTR; DELTA-F508; MUTATION; PHOSPHORYLATION; INACTIVATION; MECHANISMS; CELLS; DNA	The cystic fibrosis transmembrane conductance regulator (CFTR) contains two membrane-spanning domains; each consists of six transmembrane segments joined by three extracellular and two intracellular loops of different length, To examine the role of intracellular loops in CFTR channel function, we studied a deletion mutant of CFTR (Delta 19 CFTR) in which 19 amino acids were removed from the intracellular loop joining transmembrane segments IV and V. This mutant protein was expressed in a human embryonic kidney cell line (293 HEK), Fully mature glycosylated CFTR (similar to 170 kDa) was immunoprecipitated from cells transfected with wildtype CFTR cDNA, while cells transfected with the mutant gene expressed only a core-glycosylated form (similar to 140 kDa), The chloride efflux rate (measured by 6-methoxyl- N-(3-sulfopropyl) quinolinium SPQ fluorescence) from cells expressing wild-type CFTR increased 600% in response to forskolin, In contrast, Delta 19 CFTR-expressing cells had no significant response to forskolin, Western blotting performed on subcellular membrane fractions showed that Delta 19 CFTR was located in the same fractions as Delta F508 CFTR, a processing mutant of CFTR, These results suggest that Delta 19 CFTR is located in the intracellular membranes, without reaching the cell surface, Upon reconstitution into lipid bilayer membranes, Delta 19 CFTR formed a functional Cl- channel with gating properties nearly identical to those of the wild-type CFTR channel, However, Delta 19 CFTR channels exhibited frequent transitions to a 6-picosiemens subconductance state, whereas wild-type CFTR channels rarely exist in this subconductance state. These data suggest that the intracellular loop is involved in stabilizing the full conductance state of the CFTR Cl- channel.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT PEDIAT, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University					NHLBI NIH HHS [R01HL/DK49003] Funding Source: Medline; NIDDK NIH HHS [P30 DK27651] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHAO AC, 1989, BIOPHYS J, V56, P1071, DOI 10.1016/S0006-3495(89)82755-9; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DELANEY SJ, 1993, NAT GENET, V4, P426, DOI 10.1038/ng0893-426; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GADSBY DC, 1994, TRENDS BIOCHEM SCI, V19, P513, DOI 10.1016/0968-0004(94)90141-4; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HOROWITZ B, 1993, AM J PHYSIOL, V264, pH2214, DOI 10.1152/ajpheart.1993.264.6.H2214; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; MA JJ, 1994, BIOPHYS J, V67, P626, DOI 10.1016/S0006-3495(94)80522-3; NAGEL G, 1992, NATURE, V360, P81, DOI 10.1038/360081a0; OVERHOLT JL, 1995, AM J PHYSIOL-CELL PH, V268, pC636; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R	29	58	61	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28084	28091						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499295				2022-12-27	WOS:A1995TG21000020
J	RADDATZ, R; PARINI, A; LANIER, SM				RADDATZ, R; PARINI, A; LANIER, SM			IMIDAZOLINE/GUANIDINIUM BINDING DOMAINS ON MONOAMINE OXIDASES - RELATIONSHIP TO SUBTYPES OF IMIDAZOLINE-BINDING PROTEINS AND TISSUE-SPECIFIC INTERACTION OF IMIDAZOLINE LIGANDS WITH MONOAMINE-OXIDASE-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-3 IDAZOXAN BINDING; CLONIDINE-DISPLACING SUBSTANCE; GUANIDINIUM-RECEPTIVE SITES; MONOCLONAL-ANTIBODY; HUMAN-PLACENTA; HUMAN-PLATELET; HUMAN-BRAIN; RAT-BRAIN; PURIFICATION; KIDNEY	Pharmacologically active compounds with an imidazoline and/or guanidinium moiety are recognized with high affinity by a family of membrane-bound proteins collectively known as imidazoline binding sites or imidazoline/guanidinium receptive sites, Two such receptive sites may correspond to imidazoline binding domains identified on the A and B isoforms of monoamine oxidase (MAO), but the detection of monoamine oxidase isoforms in multiple tissues contrasts with the restricted expression of imidazoline-binding proteins. To address these issues, we determined the relationship between monoamine oxidase isoforms and subtypes of imidazoline-binding proteins in human tissues known to express one or both isoforms of MAO. 2-(3-Azido-4-[I-125]iodophenoxy)methylimidazoline ([I-125]A-ZIPI), a photoaffinity adduct that selectively labels imidazoline-binding proteins, photolabeled an M(r) = similar to 59,000 peptide in liver and an M(r) = similar to 63,000 peptide in placenta, consistent with the M(r) of the MAO isoforms identified by immunoblots in these tissues, The photolabeled species in liver was immunoprecipitated with MAO-B selective antibodies, whereas the photolabeled species in placenta was immunoprecipitated by MAO-A selective antibodies consistent with the isoform of MAO predominantly expressed in these tissues, The imidazoline/guanidinium ligands interact with the enzyme at a site distinct from the substrate recognition domain, and the immunoprecipitated peptides in liver and placenta display distinct ligand recognition properties consistent with those reported for subtypes of imidazoline binding sites. However, the imidazoline binding domain was not detected in platelet membrane preparations containing amounts of MAO-E equivalent to those in the photolabeled liver membranes indicating that recognition of this domain is tissue-restricted. Restricted access to the imidazoline binding domain on platelet MAO-B was not altered by membrane washing with 500 mM KCl or by solubilization and partial purification of the enzyme suggesting that there are distinct subpopulations of MAO. Identification of a binding domain on MAO that recognizes this class of pharmacologically active compounds suggests a novel mechanism for regulation of substrate oxidation/selectivity or that the enzyme may subserve an as yet undefined function.	MED UNIV S CAROLINA,DEPT CELL & MOLEC PHARMACOL & EXPTL THERAPEUT,CHARLESTON,SC 29425; INST LOUIS BUGNARD,INSERM,U388,F-31054 TOULOUSE,FRANCE	Medical University of South Carolina; Institut National de la Sante et de la Recherche Medicale (Inserm)				Lanier, Stephen/0000-0002-2740-7607; Parini, Angelo/0000-0002-9848-8838	NHLBI NIH HHS [5-T32-HL07260-18] Funding Source: Medline; NINDS NIH HHS [R01-NS24821] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATLAS D, 1994, SCIENCE, V266, P462, DOI 10.1126/science.7939689; ATLAS D, 1984, EUR J BIOCHEM, V144, P287, DOI 10.1111/j.1432-1033.1984.tb08462.x; ATLAS D, 1992, AM J HYPERTENS, V5, pS83, DOI 10.1093/ajh/5.4.83S; BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BALSA MD, 1991, J PHARM PHARMACOL, V43, P95, DOI 10.1111/j.2042-7158.1991.tb06639.x; BERRY MD, 1994, PROG NEUROBIOL, V42, P375, DOI 10.1016/0301-0082(94)90081-7; CARPENE C, 1995, J PHARMACOL EXP THER, V272, P681; CHEN K, 1993, J NEUROCHEM, V61, P187, DOI 10.1111/j.1471-4159.1993.tb03554.x; COUPRY I, 1990, J PHARMACOL EXP THER, V252, P293; DENNEY RM, 1982, MOL PHARMACOL, V22, P500; DENNEY RM, 1983, MOL PHARMACOL, V24, P60; DIAMANT S, 1992, BRIT J PHARMACOL, V106, P101, DOI 10.1111/j.1476-5381.1992.tb14300.x; FERNANDEZNOVOA L, 1991, BIOCHEM PHARMACOL, V42, P2351, DOI 10.1016/0006-2952(91)90240-6; GLOVER V, 1988, J NEUROCHEM, V51, P656, DOI 10.1111/j.1471-4159.1988.tb01089.x; IVKOVIC B, 1994, MOL PHARMACOL, V46, P15; KOCHERSPERGER LM, 1985, J NEUROSCI, V5, P2874; LACHAUDPETTITI V, 1991, EUR J PHARM-MOLEC PH, V206, P23, DOI 10.1016/0922-4106(91)90142-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGIN D, 1990, MOL PHARMACOL, V37, P876; LANIER SM, 1993, J BIOL CHEM, V268, P16047; LAZO O, 1991, MOL CELL BIOCHEM, V100, P159; LI G, 1994, SCIENCE, V263, P966, DOI 10.1126/science.7906055; LIMON I, 1992, J BIOL CHEM, V267, P21645; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARUYAMA W, 1993, J NEURAL TRANSM-GEN, V94, P91, DOI 10.1007/BF01245003; MICHEL MC, 1989, TRENDS PHARMACOL SCI, V10, P342, DOI 10.1016/0165-6147(89)90002-3; NAOI M, 1994, NEUROCHEM INT, V25, P475, DOI 10.1016/0197-0186(94)90024-8; OLMOS G, 1993, BRIT J PHARMACOL, V108, P597, DOI 10.1111/j.1476-5381.1993.tb12848.x; PILETZ JE, 1993, J PHARMACOL EXP THER, V267, P1493; PILETZ JE, 1995, J PHARMACOL EXP THER, V272, P581; REIS DJ, 1995, ANN NY ACAD SCI, V763; RENOUARD A, 1993, BRIT J PHARMACOL, V109, P625, DOI 10.1111/j.1476-5381.1993.tb13618.x; RILEY LA, 1989, MOL PHARMACOL, V36, P54; SASTRE M, 1993, J NEUROCHEM, V61, P881, DOI 10.1111/j.1471-4159.1993.tb03599.x; TESSON F, 1995, J BIOL CHEM, V270, P9856, DOI 10.1074/jbc.270.17.9856; TESSON F, 1991, J BIOL CHEM, V266, P155; WANG H, 1992, MOL PHARMACOL, V42, P792	37	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27961	27968		10.1074/jbc.270.46.27961	http://dx.doi.org/10.1074/jbc.270.46.27961			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499273	hybrid			2022-12-27	WOS:A1995TE73600084
J	CANTIELLO, HF; PRAT, AG; REISIN, IL; ERCOLE, LB; ABRAHAM, EH; AMARA, JF; GREGORY, RJ; AUSIELLO, DA				CANTIELLO, HF; PRAT, AG; REISIN, IL; ERCOLE, LB; ABRAHAM, EH; AMARA, JF; GREGORY, RJ; AUSIELLO, DA			EXTERNAL ATP AND ITS ANALOGS ACTIVATE THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR BY A CYCLIC AMP-INDEPENDENT MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIRWAY EPITHELIAL-CELLS; EXTRACELLULAR ATP; CHANNELS; BINDING; PROTEINS; CL	The cystic fibrosis transmembrane conductance regulator (CFTR) is a Cl- channel activated by protein kinase A and regulated by ATP in a complex manner. We have applied patch-clamp techniques to C127i mouse mammary carcinoma cells transfected with human CFTR to assess the role of external ATP in the modulation of CFTR function. Extracellular ATP was sufficient to activate non-rectifying, Cl-selective whole-cell currents in CFTR-transfected, but not mock-transfected cells. The ATP-mediated activation of CFTR was independent of protein kinase A since channel activation by ATP was preserved in cells that were (a) depleted of intracellular ATP, (b) incubated with the cAMP antagonist R(p)-cAMPS, or (c) exposed to the protein kinase A inhibitor, 5-24 amide. In each of these conditions, 8-Br-cAMP was no longer capable of activating CFTR. The possibility that the extracellular ATP activation of Cl- currents in CFTR-expressing C127i cells was mediated by a P2-type purinergic receptor was supported by studies in which the effect of external ATP on the Cl- currents was mimicked by the ATP analogs, ATP-gammaS and beta,gamma-methylene ATP, but not the uridine nucleotide, UTP. Single-channel analysis of ATP-activated Cl- currents under both cell-attached and excised, inside-out patch-clamp configurations indicated that this channel is only present in CFTR-transfected cells and indistinguishable from CFTR. External ATP also activated ATP currents in CFTR-transfected cells, a novel function of CFTR. These findings are consistent with the presence of a purinergic receptor signal transduction mechanism in C127i cells whose activation by external ATP is linked to the activation of CFTR in a cAMP-independent manner. The. data provide additional support for the use of ATP and its analogs as alternative therapies in cystic fibrosis.	MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; GENZYME CORP,FRAMINGHAM,MA 01701	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Sanofi-Aventis; Genzyme Corporation								ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; BOUCHER RC, 1988, J PHYSIOL-LONDON, V405, P77, DOI 10.1113/jphysiol.1988.sp017322; CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CANTIELLO HF, 1993, J BIOL CHEM, V268, P4596; CHENG HC, 1986, J BIOL CHEM, V261, P989; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; DUBYAK GR, 1990, BIOL ACTIONS EXTRACE, V603; EGAN M, 1992, NATURE, V358, P531; FALKE LC, 1989, J GEN PHYSIOL, V94, pA34; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; LEVITAN ES, 1990, NATURE, V348, P545, DOI 10.1038/348545a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; Reisin I. L., 1992, Journal of General Physiology, V100, p33A; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RUGGIERI MR, 1990, ANN NY ACAD SCI, V603, P458; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; VANHAASTERT PJM, 1984, J BIOL CHEM, V259, P20; YANKASKAS JR, 1985, AM REV RESPIR DIS, V132, P1281	23	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11224	11232						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512560				2022-12-27	WOS:A1994NF96600040
J	ALLANDER, SV; LARSSON, C; EHRENBORG, E; SUWANICHKUL, A; WEBER, G; MORRIS, SL; BAJALICA, S; KIEFER, MC; LUTHMAN, H; POWELL, DR				ALLANDER, SV; LARSSON, C; EHRENBORG, E; SUWANICHKUL, A; WEBER, G; MORRIS, SL; BAJALICA, S; KIEFER, MC; LUTHMAN, H; POWELL, DR			CHARACTERIZATION OF THE CHROMOSOMAL GENE AND PROMOTER FOR HUMAN INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; MAMMALIAN-CELLS; IGF-II; IDENTIFICATION; LOCALIZATION; REGION; ACID; IGFBP-5; VECTORS; SERUM	To better understand the regulation of insulin-like growth factor binding protein-5 (IGFBP-5) expression, we cloned the IGFBP-5 gene from human genomic libraries and identified a region in the 5' flanking sequence which functions as a promoter. The human IGFBP-5 gene is divided into four exons which, primarily due to a first intron of similar to 25 kilobases, span similar to 33 kilobases of DNA. Southern analysis identified a single copy of the IGFBP-5 gene in the haploid human genome, and several independent mapping strategies found this gene tightly linked with, and in opposite transcriptional orientation to, the IGFBP-2 gene at chromosomal region 2q33-34. Primer extension studies identified the IGFBP-5 mRNA cap site 772 base pairs (bp) 5' to the first nucleotide of the translation start codon. Analysis of the 5'-flanking sequence identified a potential TATA element beginning 33 bp 5' to the mRNA cap site. When a DNA fragment containing this cap site and 461 bp of upstream sequence was placed 5' to the chloramphenicol acetyltransferase reporter gene and transfected into MDA-MB-468 human breast cancer cells, it directed chloramphenicol acetyltransferase expression in an orientation specific manner, suggesting that this region contains elements essential for IGFBP-5 promoter activity.	KAROLINSKA INST, DEPT CLIN GENET, S-17176 STOCKHOLM, SWEDEN; BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA; CHIRON CORP, EMERYVILLE, CA 94608 USA	Karolinska Institutet; Baylor College of Medicine; Novartis			Weber, Günther/F-3410-2016	Ehrenborg, Ewa/0000-0003-1993-2468	NIDDK NIH HHS [R01 DK-38773] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038773] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; ANDRESS DL, 1991, BIOCHEM BIOPH RES CO, V176, P213, DOI 10.1016/0006-291X(91)90911-P; BACKELJAUW PF, 1993, ENDOCRINOLOGY, V132, P1677, DOI 10.1210/en.132.4.1677; BAJALICA S, 1992, HUM GENET, V89, P234; BAUTISTA CM, 1991, BIOCHEM BIOPH RES CO, V176, P756, DOI 10.1016/S0006-291X(05)80249-9; BERGERHEIM U, 1989, CANCER RES, V49, P1390; BERGERSL, 1987, METHDOS ENZYMOL, V152, P604; BINKERT C, 1992, MOL ENDOCRINOL, V6, P826, DOI 10.1210/me.6.5.826; BODMER WF, 1990, CYTOGENET CELL GENET, V55, P1; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CANNIZZARO LA, 1987, AM J HUM GENET, V41, P1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONOVER CA, 1993, ENDOCRINOLOGY, V132, P2525, DOI 10.1210/en.132.6.2525; CONOVER CA, 1993, J CLIN ENDOCR METAB, V76, P1153, DOI 10.1210/jc.76.5.1153; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; CUBBAGE ML, 1989, MOL ENDOCRINOL, V3, P846, DOI 10.1210/mend-3-5-846; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EHRENBORG E, 1992, GENOMICS, V12, P497, DOI 10.1016/0888-7543(92)90440-4; EHRENBORG E, 1991, BIOCHEM BIOPH RES CO, V176, P1250, DOI 10.1016/0006-291X(91)90420-C; ERICKSON GF, 1992, ENDOCRINOLOGY, V130, P1867, DOI 10.1210/en.130.4.1867; EVANS GA, 1989, GENE, V79, P9, DOI 10.1016/0378-1119(89)90088-7; FIGUEROA JA, 1993, J CELL BIOCHEM, V52, P196, DOI 10.1002/jcb.240520211; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JANSON M, 1991, P NATL ACAD SCI USA, V88, P10609, DOI 10.1073/pnas.88.23.10609; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; KUO JL, 1993, GENOMICS, V16, P173, DOI 10.1006/geno.1993.1155; LEE PDK, 1993, P SOC EXP BIOL MED, V204, P4; LEE YL, 1988, MOL ENDOCRINOL, V2, P404, DOI 10.1210/mend-2-5-404; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PENDLETON JW, 1993, P NATL ACAD SCI USA, V90, P6300, DOI 10.1073/pnas.90.13.6300; POWELL D, 1993, GROWTH REGULAT, V3, P11; POWELL DR, 1991, J BIOL CHEM, V266, P18868; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SHEIKH MS, 1992, BIOCHEM BIOPH RES CO, V183, P1003, DOI 10.1016/S0006-291X(05)80290-6; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SUWANICHKUL A, 1990, J BIOL CHEM, V265, P21185; SUWANICHKUL A, 1993, J BIOL CHEM, V268, P9730; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; UPTON Z, 1993, GROWTH REGULAT, V3, P29; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160; ZHU X, 1993, BIOCHEM BIOPH RES CO, V190, P1045, DOI 10.1006/bbrc.1993.1154; ENDOCRINOLOGY, V130, P1736	50	54	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10891	10898						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511611				2022-12-27	WOS:A1994NF01700103
J	MATSUGUCHI, T; SALGIA, R; HALLEK, M; EDER, M; DRUKER, B; ERNST, TJ; GRIFFIN, JD				MATSUGUCHI, T; SALGIA, R; HALLEK, M; EDER, M; DRUKER, B; ERNST, TJ; GRIFFIN, JD			SHC PHOSPHORYLATION IN MYELOID CELLS IS REGULATED BY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR, INTERLEUKIN-3, AND STEEL FACTOR AND IS CONSTITUTIVELY INCREASED BY P210(BCR/ABL)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; RECEPTOR GENE FAMILY; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; PHILADELPHIA-CHROMOSOME; EXPRESSION CLONING; GM-CSF; PROTEINS; ACTIVATION	Granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor induce proliferation of hematopoietic cells through binding to specific, high affinity, cell surface receptors. However, little is known about post-receptor signal transduction pathways. Here we report that an SH2 domain containing protein previously implicated in the activation of p21(ras), Shc, is transiently tyrosine phosphorylated in myeloid cells after stimulation with granulocyte macrophage colony-stimulating factor, interleukin-3, or steel factor. Also, Shc was found to be constitutively tyrosine phosphorylated in myeloid cell Lines made factor independent by expression of p210(BCR/ABL). A Shc-associated 140-kDa protein was identified, which was phosphorylated on tyrosine residues transiently after cytokine stimulation and constitutively after expression of p210(BCR/ABL). These findings suggest that She could play an important role in a signal transduction pathway, which leads to the proliferation of myeloid cells.	DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; DANA FARBER CANC INST,DIV MOLEC & CELLULAR BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School			Hallek, Michael/Y-3191-2019	Hallek, Michael/0000-0002-7425-4455; Druker, Brian/0000-0001-8331-8206	NCI NIH HHS [CA 34183, CA 36167] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036167, P01CA034183, R37CA036167] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BERNSTEIN A, 1991, SEMIN HEMATOL, V28, P138; BROXMEYER HE, 1988, CRC CR REV ONCOL-HEM, V8, P173, DOI 10.1016/S1040-8428(88)80016-7; CANNISTRA SA, 1990, P NATL ACAD SCI USA, V87, P93, DOI 10.1073/pnas.87.1.93; CANNISTRA SA, 1988, SEMIN HEMATOL, V25, P173; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COLLINS MKL, 1988, J CELL PHYSIOL, V137, P293, DOI 10.1002/jcp.1041370212; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DRUCKER B, 1992, BLOOD, V79, P2215; DRUKER B, 1992, BLOOD, V79, P2215; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GASSON JC, 1990, PROG CLIN BIOL RES, V352, P375; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HALLEK M, 1992, J CELL PHYSIOL, V153, P176, DOI 10.1002/jcp.1041530122; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KANAKURA Y, 1991, BLOOD, V77, P243; KANAKURA Y, 1990, BLOOD, V76, P706; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KUWAKI T, 1989, BIOCHEM BIOPH RES CO, V161, P16, DOI 10.1016/0006-291X(89)91553-2; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCOLL SR, 1991, BLOOD, V78, P1842; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; METCALF D, 1992, BLOOD, V79, P2861; METCALF D, 1986, BLOOD, V67, P257; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; PARK LS, 1990, PROG CLIN BIOL RES, V352, P189; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	46	166	168	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5016	5021						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508932				2022-12-27	WOS:A1994MX57100051
J	HEINRICH, JN; BRAVO, R				HEINRICH, JN; BRAVO, R			N51 COMPETES I-125 INTERLEUKIN (IL)-8 BINDING TO IL-8R-BETA BUT NOT IL-8R-ALPHA - STRUCTURE-FUNCTION ANALYSIS USING N51/IL-8 CHIMERIC MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN INTERLEUKIN-8 RECEPTOR	We have demonstrated that the mouse chemokine N51, also known as KC, can compete for I-125-human interleukin-8 (IL-8) binding to NIH 3T3 cells expressing the human IL-8 receptor beta (NIH-IL-8R beta) but not the IL-8 receptor alpha (NIH-IL-8R alpha). In addition, we used the chimeras between N51 and IL-8 described previously (Heinrich, J. N., O'Rourke, E. C., Chen, L., Gray, H., Dorfman, K. S., and Brave, R. (1994) Mol. Cell. Biol. 14, 2849-2861; Heinrich, J. N., and Bravo, R. (1995) J. Biol. Chem. 270, 4987-4989) to evaluate possible contributions of equivalent domains from each chemokine to binding and specificity. Specifically, the amino acid sequences between cysteines 2 and 3 or between cysteines 3 and 4 or the alpha-helical C-terminal end (domains I, II, and III, respectively) of one of the chemokines was exchanged with the corresponding sequence of the other and vice versa. Chimeras of IL-8 containing either domain II or III of N51 behaved similarly, but not identically, to IL-8 in competing I-125-IL-8 binding with both NIH-IL-8R alpha cells and NIH-IL-8R beta cells. The IL-8 chimera containing domain I of N51 did not compete. On the other hand, N51 competes I-125-IL-8 binding with NIH-IL-8R beta but not NIH-IL-8R alpha cells, The N51 chimera containing domain I of IL-8 was an agonist with NIH-IL-8R alpha cells and was an even more potent agonist with NIH-IL-8R beta cells, On the latter cells it was more potent than either IL-8 or N51, The N51 chimera containing domain II of IL-8, compared with N51, was a partial agonist with NIH-IL-8R alpha cells but was equivalent to N51 with NIH-IL-8R beta cells. However, N51 chimera containing domain III of IL-8 was a partial agonist with both cells, The results are consistent with the observations we originally made with human neutrophils and the NIH mouse IL-8R beta cells, i.e. domain I confers binding specificity for IL-8 and domains II and III of IL-8 and N51 may be interchangeable but they are not equivalent. Although we originally hypothesize that domains II and III confer binding specificity to N51, these results emphasize the role of domain III.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb								BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLARKLEWIS L, 1995, J LEUKOCYTE BIOL, V57, P703; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; HEINRICH JN, 1994, MOL CELL BIOL, V14, P2849, DOI 10.1128/MCB.14.5.2849; HEINRICH JN, 1995, J BIOL CHEM, V270, P4987, DOI 10.1074/jbc.270.10.4987; HERBERT CA, 1991, J BIOL CHEM, V266, P18989; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEE J, 1992, J BIOL CHEM, V267, P16283; MOSER B, 1991, J BIOL CHEM, V266, P10666; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SCHRAUFSTATTER IU, 1995, J BIOL CHEM, V270, P10428, DOI 10.1074/jbc.270.18.10428; SCHRAUFSTATTER IU, 1993, J IMMUNOL, V151, P6418; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355	20	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28014	28017						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499284				2022-12-27	WOS:A1995TG21000009
J	YU, LA; VASSILIEV, IR; JUNG, YS; BRYANT, DA; GOLBECK, JH				YU, LA; VASSILIEV, IR; JUNG, YS; BRYANT, DA; GOLBECK, JH			MODIFIED LIGANDS TO F-A AND F-B IN PHOTOSYSTEM-I .2. CHARACTERIZATION OF A MIXED-LIGAND [4FE-4S] CLUSTER IN THE C51D MUTANT OF PSAC UPON REBINDING TO P700-F-X CORES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; PROTEINS; RECONSTITUTION; RESOLUTION; POTENTIALS; BINDING; 3FE-4S; P-700	A Photosystem I (PS I) complex reconstituted with PsaC-C51D (aspartate in lieu of cysteine in position 51) shows light-induced EPR signals with g values, line widths, and photoreduction behavior characteristic of F-B. Contrary to an earlier report, a [3Fe-4S] cluster was not located in the reconstituted PS I complex, Instead, a second set of resonances with g values of 2.044, 1.942, and 1.853 becomes EPR-visible when the C51D-PS I complex is measured at 4.2 K, This fast relaxing center, termed F-A' is likely to represent a [4Fe-4S] cluster in the mixed ligand (3Cys . 1Asp) site, Redox studies show that the E(m) of F-A' and F-B are -630 mV and -575 mV, respectively. Room temperature optical studies support the presence of two functioning electron accepters subsequent to F-X, and NADP(+) photoreduction rates mediated by ferredoxin and flavodoxin are nearly equivalent to the wild type, In addition to [3Fe-4S] clusters and S = 1/2 ground state [4Fe-4S] clusters, the free PsaC-C51D protein shows resonances near g = 5.5, which may represent a population of high spin (S = 3/2) [4Fe-4S] clusters in the mixed ligand F-A' site, Similar to the C14D-PS I mutant complex, it is proposed that the P700-F-X core selectively rebinds those free PsaC-C51D proteins that contain two [4Fe-4S] clusters. These studies show that primary photochemistry and electron transfer rates in PS I are relatively unaffected by the presence of a highly reducing, mixed ligand cluster in the F-A' site.	UNIV NEBRASKA, DEPT BIOCHEM, LINCOLN, NE 68583 USA; UNIV NEBRASKA, CTR BIOL CHEM, LINCOLN, NE 68583 USA; PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, CTR BIOMOLEC STRUCT & FUNCT, UNIVERSITY PK, PA 16802 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park								BELFORD RL, 1979, 21ST EPR S ROCK MOUN; BOTTIN H, 1987, BIOCHIM BIOPHYS ACTA, V894, P39, DOI 10.1016/0005-2728(87)90210-6; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; GOLBECK JH, 1992, ANNU REV PLANT PHYS, V43, P293, DOI 10.1146/annurev.pp.43.060192.001453; GOLBECK JH, 1994, MOL BIOL CYANOBACTER, P179; HAGEN WR, 1992, ADV INORG CHEM, V38, P165, DOI 10.1016/S0898-8838(08)60064-1; KE B, 1973, P NATL ACAD SCI USA, V70, P2941, DOI 10.1073/pnas.70.10.2941; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; LOCKAU W, 1993, PHYSIOL PLANTARUM, V88, P372, DOI 10.1034/j.1399-3054.1993.880223.x; MEHARI T, 1991, BIOCHIM BIOPHYS ACTA, V1056, P139, DOI 10.1016/S0005-2728(05)80280-4; MEHARI T, 1995, J BIOL CHEM, V270, P28108; PARRETT KG, 1989, BIOCHIM BIOPHYS ACTA, V973, P324, DOI 10.1016/S0005-2728(89)80439-6; PARRETT KG, 1990, BIOCHIM BIOPHYS ACTA, V1015, P341, DOI 10.1016/0005-2728(90)90039-7; SAUER K, 1978, BIOCHIM BIOPHYS ACTA, V503, P120, DOI 10.1016/0005-2728(78)90166-4; THOMSON AJ, 1992, J INORG BIOCHEM, V47, P197, DOI 10.1016/0162-0134(92)84065-U; THOMSON AJ, 1991, FEBS LETT, V285, P230, DOI 10.1016/0014-5793(91)80807-F; YU J, IN PRESS PLANT MOL B; YU L, 1993, BIOCHEMISTRY-US, V32, P8251, DOI 10.1021/bi00083a028; YU L, 1995, BIOCHEMISTRY-US, V34, P7861, DOI 10.1021/bi00024a010; ZHAO JD, 1992, BIOCHEMISTRY-US, V31, P5093, DOI 10.1021/bi00137a001; ZHAO JD, 1990, FEBS LETT, V276, P175, DOI 10.1016/0014-5793(90)80536-R	22	36	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28118	28125						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499300				2022-12-27	WOS:A1995TG21000025
J	TOMINAGA, M; TOMINAGA, T; MIWA, A; OKADA, Y				TOMINAGA, M; TOMINAGA, T; MIWA, A; OKADA, Y			VOLUME-SENSITIVE CHLORIDE CHANNEL ACTIVITY DOES NOT DEPEND ON ENDOGENOUS P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; MONOCLONAL-ANTIBODIES; EPITHELIAL-CELLS; VINBLASTINE SECRETION; CONDUCTANCE; VERAPAMIL; CURRENTS; VINCRISTINE; MECHANISMS; EXPRESSION	To determine whether endogenous P-glycoprotein, the MDR1 gene product that functions as a drug transport pump, is a volume-sensitive Cl- channel molecule or a protein kinase C-mediated regulator of the Cl- channel, whole-cell patch clamp and molecular biological experiments were carried out in a human small intestinal epithelial cell line, Endogenous expression of P-glycoprotein was confirmed by Northern blot analysis, reverse transcription-polymerase chain reaction, Western blot analysis, and immunostaining, The P-glycoprotein expression was abolished by the antisense (but not sense) oligonucleotide for the MDR1 gene, whereas the magnitude of the Cl- current activated by osmotic swelling was not distinguishable between both antisense- and sense-treated cells, The volume-sensitive Cl- currents were not specifically affected by the anti-P-glycoprotein monoclonal antibodies, MRK16, C219, and UIC2, An inhibitor of P-glycoprotein-mediated pump activity, verapamil, was found to never affect the Cl- current, A substrate for the P-glycoprotein-mediated drug pump, vincristine or daunomycin, did not prevent swelling-induced activation of the Cl- current, Furthermore, the Cl- current was not affected by an activator of protein kinase C (12-O-tetradecanoylphorbol-13-acetate or 1-oleoyl-2-acetyl-sn-glycerol). Thus, it is concluded that the endogenous P-glycoprotein molecule is not itself a volume-sensitive Cl- channel nor a protein kinase C-mediated regulator of the channel in the human epithelial cells.			TOMINAGA, M (corresponding author), NATL INST PHYSIOL SCI,DEPT CELLULAR & MOLEC PHYSIOL,OKAZAKI,AICHI 444,JAPAN.							ACKERMAN MJ, 1994, J GEN PHYSIOL, V103, P153, DOI 10.1085/jgp.103.2.153; ALTENBERG GA, 1994, J BIOL CHEM, V269, P7145; BOTCHKIN LM, 1993, AM J PHYSIOL, V265, pC1037, DOI 10.1152/ajpcell.1993.265.4.C1037; CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679; DIAZ M, 1993, PFLUG ARCH EUR J PHY, V422, P347, DOI 10.1007/BF00374290; DONG YJ, 1994, CANCER RES, V54, P5029; DOROSHENKO P, 1992, J PHYSIOL-LONDON, V449, P197, DOI 10.1113/jphysiol.1992.sp019082; EHRING GR, 1994, J GEN PHYSIOL, V104, P1129, DOI 10.1085/jgp.104.6.1129; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HAN ES, 1994, J GEN PHYSIOL, V104, pA43; HARDY SP, 1995, EMBO J, V14, P68, DOI 10.1002/j.1460-2075.1995.tb06976.x; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HUNTER J, 1993, J BIOL CHEM, V268, P14991; INUI T, 1994, AM J PHYSIOL, V266, pL113, DOI 10.1152/ajplung.1994.266.2.L113; ITOH A, 1994, PFLUG ARCH EUR J PHY, V428, P468, DOI 10.1007/BF00374567; JACKSON PS, 1993, AM J PHYSIOL, V265, pC1489, DOI 10.1152/ajpcell.1993.265.6.C1489; JENTSCH TJ, 1994, CURR OPIN CELL BIOL, V6, P600, DOI 10.1016/0955-0674(94)90082-5; JIRSCH JD, 1994, AM J PHYSIOL, V267, pC688, DOI 10.1152/ajpcell.1994.267.3.C688; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KUBO M, 1992, J PHYSIOL-LONDON, V456, P351, DOI 10.1113/jphysiol.1992.sp019340; LEWIS RS, 1993, J GEN PHYSIOL, V101, P801, DOI 10.1085/jgp.101.6.801; LUCKIE DB, 1994, AM J PHYSIOL, V267, pC650, DOI 10.1152/ajpcell.1994.267.2.C650; MA LD, 1991, J BIOL CHEM, V266, P5593; MACLEOD RJ, 1991, AM J PHYSIOL, V260, pG26, DOI 10.1152/ajpgi.1991.260.1.G26; MCEWAN GTA, 1992, FEBS LETT, V304, P233, DOI 10.1016/0014-5793(92)80626-R; MEEHETNER EB, 1992, P NATL ACAD SCI USA, V89, P5824; MINTENIG GM, 1992, RECEPTOR CHANNEL, V1, P305; NILIUS B, 1994, J GEN PHYSIOL, V103, P787, DOI 10.1085/jgp.103.5.787; OKADA Y, 1989, NEWS PHYSIOL SCI, V4, P238; OKADA Y, 1979, MEMBRANE BIOCHEM, V2, P339, DOI 10.3109/09687687909063871; OKADA Y, 1994, JPN J PHYSIOL, V44, pS31; OKADA Y, 1994, JPN J PHYSIOL, V44, P403, DOI 10.2170/jjphysiol.44.403; RASOLA A, 1994, J BIOL CHEM, V269, P1432; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RIVOLTINI L, 1990, INT J CANCER, V46, P727, DOI 10.1002/ijc.2910460429; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; SOLC CK, 1991, AM J PHYSIOL, V261, pC658, DOI 10.1152/ajpcell.1991.261.4.C658; STODDARD JS, 1993, AM J PHYSIOL, V265, pC156, DOI 10.1152/ajpcell.1993.265.1.C156; SUGAWARA I, 1992, JPN J CANCER RES, V83, P795, DOI 10.1111/j.1349-7006.1992.tb01982.x; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TOMINAGA M, 1995, CIRC RES, V77, P417, DOI 10.1161/01.RES.77.2.417; TREZISE AEO, 1992, EMBO J, V11, P4291, DOI 10.1002/j.1460-2075.1992.tb05528.x; TSURUO T, 1981, CANCER RES, V41, P1967; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANDENBERG JI, 1994, J GEN PHYSIOL, V104, P997, DOI 10.1085/jgp.104.6.997; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	53	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27887	27893		10.1074/jbc.270.46.27887	http://dx.doi.org/10.1074/jbc.270.46.27887			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499263	hybrid			2022-12-27	WOS:A1995TE73600074
J	SPRENGER, H; LLOYD, AR; LAUTENS, LL; BONNER, TI; KELVIN, DJ				SPRENGER, H; LLOYD, AR; LAUTENS, LL; BONNER, TI; KELVIN, DJ			STRUCTURE, GENOMIC ORGANIZATION, AND EXPRESSION OF THE HUMAN INTERLEUKIN-8 RECEPTOR-B GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; BETA-2-ADRENERGIC RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; PROMOTER REGION; BINDING-PROTEIN; TATA-BOX; SEQUENCE; TRANSCRIPTION; FAMILY	Two distinct receptors for the chemoattractant interleukin-8 (designated IL-8RA and -B) have been cloned recently. The receptors are expressed almost exclusively on neutrophils and myelomonocytic cell lines. In an attempt to understand the tissue-specific expression and to identify transcriptional regulatory elements we have cloned, sequenced, and characterized the human IL-8RB gene. The gene consists of 3 exons, interrupted by two introns of 3 and 5.4 kilobases (kb). A 1065-base pair open reading frame is encoded entirely in the third exon. A 1.4-kb 3'-untranslated region contains clustered AU-rich elements, similar to those described for genes regulated by altering mRNA stability. The start site of transcription was mapped by a modified rapid amplification of cDNA ends technique and revealed an unexpectedly long 5'-untranslated region of 423 base pairs. A TATA box equivalent was found in the 5'-flanking region 20 nucleotides upstream of the start of the first exon. The promoter was separated from the ATG-initiation codon by 8.75 kb. Comparison of the IL-8RB promoter with the promoter region of the receptor for another chemoattractant ligand, the bacterial peptide f-Met-Leu-Phe, revealed 3 novel but conserved motifs occupying similar positions. The immediate 5'-flanking region was GC-rich with 3 SP-1-like and 2 AP-2 sites identified in close proximity to the transcription start site. This essential promoter region was found to be responsible for constitutive expression, inducible by granulocyte colony-stimulating factor and controlled by silencer elements located further upstream between positions -779 and -118.	NCI, FREDERICK CANC RES & DEV CTR, DIV CANC TREATMENT, BIOL RESPONSE MODIFIERS PROGRAM, FREDERICK, MD 21702 USA; NIMH, CELL BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			Lloyd, Andrew/AFJ-8960-2022; Lloyd, Andrew/E-7334-2017; Lloyd, Andrew/AAF-6071-2022	Lloyd, Andrew/0000-0001-6277-8887; Lloyd, Andrew/0000-0001-6277-8887				AHUJA SK, 1992, NAT GENET, V2, P31, DOI 10.1038/ng0992-31; ALLEN JM, 1988, EMBO J, V7, P133, DOI 10.1002/j.1460-2075.1988.tb02792.x; AUSUBEL FM, 1991, CUURRENT PROTOCOLS M; BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; BOURGEADE MF, 1992, NUCLEIC ACIDS RES, V20, P2997, DOI 10.1093/nar/20.12.2997; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Favaloro J, 1980, Methods Enzymol, V65, P718; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; INNIS JW, 1991, J BIOL CHEM, V266, P21765; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LLOYD A, 1993, CYTOGENET CELL GENET, V63, P238, DOI 10.1159/000133541; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; PEREZ HD, 1992, BIOCHEMISTRY-US, V31, P11595, DOI 10.1021/bi00161a044; RENKAWITZ R, 1984, CELL, V37, P503, DOI 10.1016/0092-8674(84)90380-5; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHRODER JM, 1988, J IMMUNOL, V140, P3534; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; VONDERAHE D, 1985, NATURE, V313, P706, DOI 10.1038/313706a0; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	44	54	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11065	11072						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512557				2022-12-27	WOS:A1994NF96600018
J	SAITO, S; LEVERY, SB; SALYAN, MEK; GOLDBERG, RI; HAKOMORI, S				SAITO, S; LEVERY, SB; SALYAN, MEK; GOLDBERG, RI; HAKOMORI, S			COMMON TETRASACCHARIDE EPITOPE NEUAC-ALPHA-2-]3GAL-BETA-1-],3(NEUAC-ALPHA-2-]6)GALNAC, PRESENTED BY DIFFERENT CARRIER GLYCOSYLCERAMIDES OR O-LINKED PEPTIDES, IS RECOGNIZED BY DIFFERENT ANTIBODIES AND LIGANDS HAVING DISTINCT SPECIFICITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY REGULATED ANTIGEN; UROPATHOGENIC ESCHERICHIA-COLI; IONIZATION MASS-SPECTROMETRY; METHYLATED ALDITOL ACETATES; HUMAN TERATOCARCINOMA CELLS; MONOCLONAL-ANTIBODY; GLOBO-SERIES; CONFORMATIONAL-ANALYSIS; STRUCTURAL-ANALYSIS; EPITHELIAL-CELLS	A novel globe-series disialoganglioside, disialosyl galactosyl globoside (Structure 1 below), defined by new monoclonal antibody (mAb) RM2, was isolated and characterized as having terminal structure identical to that of ganglio-series ganglioside GD1 alpha (Structure 2) and a common mucin-type epitope (Structure 3) widely distributed in glycoproteins such as glycophorin A. While these three structures share a common nonreducing tetrasaccharide terminus, mAb RM2 showed strong specific reactivity only with Structure 1, not with Structures 2 or 3. Another mAb, QSH2, reacted strongly with Structure 3 but did not cross-react with Structures I or 2. Conformational molecular models based on minimum energy hard sphere exoanomeric calculations suggest that Structure 1 presents a unique surface topology distinct from that of Structures 2 or 3. Our findings suggest the novel concept that reactivity of a common carbohydrate epitope with different antibodies or Ligands is highly dependent on the type of carrier glycosylceramide or carrier O-Iinked peptide. [GRAPHICS]	BIOMEMBRANE INST, SEATTLE, WA 98119 USA; UNIV WASHINGTON, DEPT PATHOBIOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle				Saito, Seiichi/0000-0001-8734-4591	NCI NIH HHS [CA42505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BJORNDAL H, 1970, CARBOHYD RES, V15, P339, DOI 10.1016/S0008-6215(00)80450-4; BJORNDAL HAKAN, 1967, CAR BOHYD RES, V5, P433, DOI 10.1016/S0008-6215(00)81115-5; BLOMBERG J, 1982, BIOCHIM BIOPHYS ACTA, V711, P466, DOI 10.1016/0005-2760(82)90061-3; BOCK K, 1985, J BIOL CHEM, V260, P8545; BREMER EG, 1984, J BIOL CHEM, V259, P4773; CHIEN JL, 1983, J BIOL CHEM, V258, P727; CLAUSEN H, 1984, BIOCHEM BIOPH RES CO, V124, P523, DOI 10.1016/0006-291X(84)91585-7; DABROWSKI J, 1980, BIOCHEMISTRY-US, V19, P5652, DOI 10.1021/bi00565a030; DABROWSKI J, 1989, J AM CHEM SOC, V111, P1510, DOI 10.1021/ja00186a063; DASGUPTA S, 1991, J LIPID RES, V32, P499; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUJII I, 1985, J CHEM SOC CHEM COMM, P405, DOI 10.1039/c39850000405; GILLECECASTRO BL, 1990, METHOD ENZYMOL, V193, P689, DOI 10.1016/0076-6879(90)93445-Q; HAKOMORI SI, 1971, J BIOL CHEM, V246, P2271; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HAKOMORI SI, 1983, SPHINGOLIPID BIOCH, P1; HANISCH FG, 1993, CANCER RES, V53, P4367; ISOBE R, 1987, TRAC-TREND ANAL CHEM, V6, P78, DOI 10.1016/0165-9936(87)87037-1; Jansson P-E., 1976, CHEM COMMUN U STOCKH, V8, P1; KANNAGI R, 1983, J BIOL CHEM, V258, P8934; KANNAGI R, 1983, EMBO J, V2, P2355, DOI 10.1002/j.1460-2075.1983.tb01746.x; KANNAGI R, 1984, J BIOL CHEM, V259, P8444; KANNAGI R, 1982, J BIOL CHEM, V257, P4865; KANNAGI R, 1983, CANCER RES, V43, P4997; KARLSSON KA, 1992, APMIS, V100, P71; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KLENK E, 1951, H-S Z PHYSIOL CHEM, V288, P220; KUNDY SJ, 1983, J BIOL CHEM, V147, P13857; LAINE RA, 1981, ANAL BIOCHEM, V116, P383, DOI 10.1016/0003-2697(81)90376-6; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; LI YT, 1974, METHODOLOGIE STRUCTU, P339; MAGNANI JL, 1980, ANAL BIOCHEM, V109, P399, DOI 10.1016/0003-2697(80)90667-3; MARCUS DM, 1981, SEMIN HEMATOL, V18, P63; MCNEIL M, 1977, CARBOHYD RES, V56, P239, DOI 10.1016/S0008-6215(00)83346-7; MURAYAMA K, 1986, CANCER RES, V46, P1395; NUDELMAN E, 1986, J BIOL CHEM, V261, P1247; NYHOLM PG, 1990, CHEM PHYS LIPIDS, V52, P1, DOI 10.1016/0009-3084(90)90002-9; PAULSEN H, 1984, LIEBIGS ANN CHEM, P951; POPPE L, 1990, J AM CHEM SOC, V112, P7762, DOI 10.1021/ja00177a042; POULTER L, 1990, METHOD ENZYMOL, V193, P661, DOI 10.1016/0076-6879(90)93444-P; SCARSDALE JN, 1988, J COMPUT CHEM, V9, P133, DOI 10.1002/jcc.540090206; SCARSDALE JN, 1986, J AM CHEM SOC, V108, P6778, DOI 10.1021/ja00281a053; SCARSDALE JN, 1990, ACS SYM SER, V430, P240; SCHWONZEN M, 1992, BRIT J CANCER, V65, P559, DOI 10.1038/bjc.1992.114; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; SIDDIQUI B, 1971, J BIOL CHEM, V246, P5766; STAPLETON A, 1992, J CLIN INVEST, V90, P965, DOI 10.1172/JCI115973; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P21, DOI 10.1515/bchm2.1973.354.1.21; STROMBERG N, 1991, P NATL ACAD SCI USA, V88, P9340, DOI 10.1073/pnas.88.20.9340; TAI T, 1975, J BIOCHEM-TOKYO, V78, P679, DOI 10.1093/oxfordjournals.jbchem.a130955; TAKI T, 1986, J BIOL CHEM, V261, P3075; THOMAS DB, 1969, J BIOL CHEM, V244, P5943; YAMAKAWA T, 1963, J BIOCHEM, V53, P28, DOI 10.1093/oxfordjournals.jbchem.a127654; YAMAKAWA T, 1965, JPN J EXP MED, V35, P201; YAMAKAWA T, 1951, J BIOCHEM-TOKYO, V38, P199, DOI 10.1093/oxfordjournals.jbchem.a126242	58	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5644	5652						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509790				2022-12-27	WOS:A1994MY84000028
J	MADSHUS, IH; WIEDLOCHA, A; SANDVIG, K				MADSHUS, IH; WIEDLOCHA, A; SANDVIG, K			INTERMEDIATES IN TRANSLOCATION OF DIPHTHERIA-TOXIN ACROSS THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW PH; B-FRAGMENT; VERO CELLS; ENTRY; PROTEIN; EXPRESSION; SEQUENCES; CHANNELS; RECEPTOR	Active diphtheria toxin consists of two parts, fragments A and B. Fragment A has enzymatic activity and inhibits protein synthesis. Fragment B binds to cellular receptors, and upon exposure to low pH it inserts into the membrane and facilitates translocation of the A fragment into the cytosol, concomitantly with formation of cation-selective channels. Reduction of the interfragment disulfide bridge is required for release of fragment A and intoxication. In cells treated with N-ethylmaleimide (NEM), which inhibits reduction of the disulfide bridge, fragment A was translocated to the cytosol but not released from fragment B. In the presence of NEM a peptide larger than fragment A was protected against extracellularly added Pronase. This peptide (M(r) similar to 24,000) was released to the supernatant fraction of saponin-treated cells. This indicates that fragment A, which is 21 kDa, is covalently attached via a disulfide bond to an N-terminal (M(r) similar to 3,000) piece of fragment B. The 24-kDa fragment disappeared upon reduction, and the 21-kDa fragment A appeared instead. NEM did not prevent channel activity by fragment B in the context of full-length toxin, demonstrating that channel formation occurs in spite of inhibited reduction of the disulfide bond. Thus, channel formation is not dependent on release of fragment A from the toxin-receptor complex.			MADSHUS, IH (corresponding author), NORWEGIAN RADIUM HOSP,INST CANC RES,N-0310 OSLO,NORWAY.							CABIAUX V, 1993, INFECT IMMUN, V61, P2200, DOI 10.1128/IAI.61.5.2200-2202.1993; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; FALNES PO, 1992, J BIOL CHEM, V267, P12284; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GILLILAND DG, 1981, J BIOL CHEM, V256, P2731; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; MINDELL JA, 1992, BIOPHYS J, V62, P41, DOI 10.1016/S0006-3495(92)81772-1; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; MOSKAUG JO, 1987, J BIOL CHEM, V262, P10339; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; OKEEFE DO, 1992, 92, V89, P6202; OLSNES S, 1990, MICROB PATHOGENESIS, V8, P163, DOI 10.1016/0882-4010(90)90043-P; OLSNES S, 1980, J BIOL CHEM, V255, P284; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; SANDVIG K, 1986, J BIOL CHEM, V261, P1639; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SANDVIG K, 1988, J CELL BIOCHEM, V36, P73, DOI 10.1002/jcb.240360108; SJOSTROM M, 1987, EMBO J, V6, P823, DOI 10.1002/j.1460-2075.1987.tb04825.x; STENMARK H, 1992, BIOCHEM J, V281, P619, DOI 10.1042/bj2810619; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	27	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4648	4652						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508447				2022-12-27	WOS:A1994MW98900110
J	MIROCHNITCHENKO, O; INOUYE, S; INOUYE, M				MIROCHNITCHENKO, O; INOUYE, S; INOUYE, M			PRODUCTION OF SINGLE-STRANDED-DNA IN MAMMALIAN-CELLS BY MEANS OF A BACTERIAL RETRON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							REVERSE-TRANSCRIPTASE; ESCHERICHIA-COLI; MSDNA; EXPRESSION	msDNA-Ec67, a peculiar multicopy single-stranded DNA of a specific sequence was produced in NIH3T3 mouse cells. Retron-Ec67, a retroelement from Escherichia coli, was introduced under the T7 polymerase promoter and the non-translated 5'-region of the encephalomyocarditis virus. The construct was then transfected into the NIH3T3 cells constitutively producing T7 RNA polymerase. Forty-eight hours after transfection, msDNA-Ec67 was detected in the cells by means of Southern blot hybridization and reverse transcriptase extension assay. The potential use of bacterial retrons as a vector for single-stranded DNA production in mammalian cells is discussed.	ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,675 HOES LA,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center			Inouye, Sharon/R-7216-2019					CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENG H, 1991, GENE, V109, P193, DOI 10.1016/0378-1119(91)90609-F; DERAGON JM, 1990, EMBO J, V9, P3363, DOI 10.1002/j.1460-2075.1990.tb07537.x; GHOSH M, 1991, PROG NUCLEIC ACID RE, P79; INOUYE M, 1991, ANNU REV MICROBIOL, V45, P163; INOUYE M, 1991, J BACTERIOL, V174, P2419; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAMPSON BC, 1989, SCIENCE, V243, P1033, DOI 10.1126/science.2466332; LAMPSON BC, 1990, J BIOL CHEM, V265, P8490; LEDOAN T, 1989, B CANCER, V76, P849; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MILLER PS, 1988, ANNU REP MED CHEM, V23, P295; MIYATA S, 1992, P NATL ACAD SCI USA, V89, P5735, DOI 10.1073/pnas.89.13.5735; NISHIKURA K, 1991, EMBO J, V10, P3523, DOI 10.1002/j.1460-2075.1991.tb04916.x; PARKS GD, 1986, J VIROL, V60, P376, DOI 10.1128/JVI.60.2.376-384.1986; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; SHIMAMOTO T, 1993, J BIOL CHEM, V268, P2684	17	23	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2380	2383						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7507924				2022-12-27	WOS:A1994MV43200009
J	YUEN, CT; BEZOUSKA, K; OBRIEN, J; STOLL, M; LEMOINE, R; LUBINEAU, A; KISO, M; HASEGAWA, A; BOCKOVICH, NJ; NICOLAOU, KC; FEIZI, T				YUEN, CT; BEZOUSKA, K; OBRIEN, J; STOLL, M; LEMOINE, R; LUBINEAU, A; KISO, M; HASEGAWA, A; BOCKOVICH, NJ; NICOLAOU, KC; FEIZI, T			SULFATED BLOOD-GROUP LEWIS(A) - A SUPERIOR OLIGOSACCHARIDE LIGAND FOR HUMAN E-SELECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOLECULE E-SELECTIN; STEREOCONTROLLED SYNTHESIS; LINKED OLIGOSACCHARIDES; CARBOHYDRATE; ADHESION; GLYCOLIPIDS; BINDING; GLYCOPROTEINS; ANTIGENS; RECEPTOR	In earlier studies of oligosaccharide probes (neoglycolipids) generated from an ovarian cystadenoma glycoprotein, one of the components that strongly supported binding of the endothelial adhesion molecule, E-selectin, was identified as an equimolar mixture of tetrasaccharides of blood group Le(a) and Le(x) type sulfated at position 3 of the outer galactose (C.-T. Yuen, A. M. Lawson, W. Chai, M. Larkin, M. S. Stoll, A. C. Stuart, F. X. Sullivan, T. J. Ahern, and T. Feizi (1992) Biochemistry 31, 9126-9131). In the present studies, the individual sulfated Le(a) and sulfated Le(x) oligosaccharides synthesized chemically have been investigated, first, for their ability to support E-selectin binding when converted into neoglycolipids, and second, for their ability to inhibit E-selectin binding to immobilized lipid-linked sialyl-Le(a), sialyl-Le(x), or sulfated Le(a) pentasaccharides; their activities have been compared with those of the sialyl-Le(a) and sialyl-Le(x) analogues. From these studies, the sulfated Le(a) tetra- and pentasaccharides emerge as the most potent E-selectin ligands so far. In particular, the inhibitory activity of the sulfated Le(a) pentasaccharide is substantially greater than that of the sialyl-Le(x) trisaccharide, which is currently the most widely used inhibitor of E-selectin binding: 45-,35-, or 15-fold greater depending on whether adhesion is to sialyl-Le(a), sulfated Le(a) or sialyl-Le(x) pentasaccharides, respectively. These findings have an important bearing on design of new generations of inhibitors of E-selectin binding as anti-inflammatory compounds.	MRC, CLIN RES CTR, GLYCOCONJUGATES SECT, WATFORD RD, HARROW HA1 3UJ, MIDDX, ENGLAND; UNIV PARIS 11, CHIM ORGAN MULTIFONCT LAB, F-91405 ORSAY, FRANCE; GIFU UNIV, DEPT BIOORGAN CHEM, GIFU 50111, JAPAN; Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA	Medical Research Council Clinical Trials Unit; UDICE-French Research Universities; Universite Paris Saclay; Gifu University; Scripps Research Institute								BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; CHILDS RA, 1992, J BIOL CHEM, V267, P9972; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; EDGINGTON SM, 1992, BIO-TECHNOL, V10, P383; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FEIZI T, 1994, METHOD ENZYMOL, V230, P484; Feizi Ten, 1993, Current Opinion in Structural Biology, V3, P701, DOI 10.1016/0959-440X(93)90053-N; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; HAKOMORI S, 1985, CANCER RES, V45, P2405; HARLAN JM, 1992, ADHESION ITS ROLE IN; HASEGAWA A, 1992, J CARBOHYD CHEM, V11, P645, DOI 10.1080/07328309208016154; HASEGAWA A, 1992, CARBOHYD RES, V230, pC1, DOI 10.1016/S0008-6215(00)90524-X; HASEGAWA A, 1994, IN PRESS ACS S SERIE; KABAT EA, 1982, AM J CLIN PATHOL, V78, P281, DOI 10.1093/ajcp/78.3.281; LARKIN M, 1992, J BIOL CHEM, V267, P13661; LUBINEAU A, 1993, J CHEM SOC CHEM COMM, P1419, DOI 10.1039/c39930001419; MULLIGAN MS, 1993, J EXP MED, V178, P623, DOI 10.1084/jem.178.2.623; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; NICOLAOU KC, 1993, J AM CHEM SOC, V115, P8843, DOI 10.1021/ja00072a049; SCHNAAR RL, 1989, METHOD ENZYMOL, V179, P542; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; TANG PW, 1985, BIOCHEM BIOPH RES CO, V132, P474, DOI 10.1016/0006-291X(85)91158-1; Watkins W M, 1980, Adv Hum Genet, V10, P1; Watkins W.M., 1980, ADV HUM GENET, V10, P379; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003	27	156	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1595	1598						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507478				2022-12-27	WOS:A1994MR98800008
J	SICILIANO, RA; MORRIS, HR; BENNETT, HPJ; DELL, A				SICILIANO, RA; MORRIS, HR; BENNETT, HPJ; DELL, A			O-GLYCOSYLATION MIMICS N-GLYCOSYLATION IN THE 16-KDA FRAGMENT OF BOVINE PROOPIOMELANOCORTIN - THE MAJOR O-GLYCAN ATTACHED TO THR-45 CARRIES SO4-4GALNAC-BETA-1-4GLCNAC-BETA-1-, WHICH IS THE ARCHETYPAL NONREDUCING EPITOPE IN THE N-GLYCANS OF PITUITARY GLYCOHORMONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; ENDORPHIN-DERIVED PEPTIDES; AMINO-TERMINAL FRAGMENT; ION MASS-SPECTROMETRY; GROUP CAD SPECIFICITY; VICIA-VILLOSA LECTIN; GAMMA-MSH; ACETYLGALACTOSAMINE-TRANSFERASE; ADRENOCORTICOTROPIN-ENDORPHIN; CARBOHYDRATE STRUCTURE	The NH2-terminal domain of pro-opiomelanocortin, designated as the 16-kDa fragment, is highly conserved throughout the vertebrate family and is likely therefore to have an important functional role. Bovine 16-kDa fragment is a 77-residue glycopeptide, which has been found to be glycosylated at threonine 45 and asparagine 65. Available evidence suggests that glycoforms lacking glycans at the O-linked site are processed in the intermediate pituitary at -Arg49-Lys50- to give the residue 1-49 amino-terminal peptide and a carboxyl-terminal glycopeptide referred to as Lys1gamma3-melanotropin. Glycoforms carrying O-glycans remain unprocessed in the intermediate pituitary. Thus O-glycosylation is likely to play an important role in controlling the fate of the NH2-terminal portion of proopiomelanocortin, thereby affecting the biological events that are influenced by peptides and glycopeptides derived from this domain. In a recent study (Siciliano, R. A., Morris, H. R., McDowell, R. A., Azadi, P., Rogers, M. E., Bennett, H. P. J., and Dell, A. (1993) Glycobiology 3, 225-239), we sequenced the N-glycans attached to Asn-65 of bovine 16-kDa fragment and demonstrated that the acidic components contain, in addition to neutral antennae, a single SO4-4GalNAcbeta1-4GlcNAcbeta1- antenna, which is characteristic of the pituitary glycohormone N-glycans (Baenziger, J. U., and Green, E. D. (1988) Biochim. Biophys. Acta 947, 287-306). We now report the structural characterization of the O-linked oligosaccharides found in bovine 16-kDa fragment. The major component, which constitutes about 80% of the O-glycan population, is a novel sulfated tetrasaccharide, which carries the same sulfated epitope as the N-glycans. This is the first time that the SO4-4GalNAcbeta1-4GlcNAcbeta1-moiety has been observed in O-glycans, and it raises the interesting possibility that the beta-N-acetylgalactosaminyltransferase responsible for the addition of N-acetylgalactosamine to the pituitary glycohormones (Smith, P. L., and Baenziger, J. U. (1988) Science, 242, 930-933) might be capable of glycosylating both N- and O-linked acceptors.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AZ,ENGLAND; ROYAL VICTORIA HOSP,MONTREAL H3A 1A1,QUEBEC,CANADA	Imperial College London; McGill University; Royal Victoria Hospital			Siciliano, Rosa Anna/G-9822-2013	SICILIANO, ROSAANNA/0000-0002-1042-3424	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; ALDUJAILI EAS, 1981, NATURE, V291, P156, DOI 10.1038/291156a0; ANDREWS PC, 1984, J BIOL CHEM, V259, P3267; ANGYAL SJ, 1970, AUST J CHEM, V23, P1209, DOI 10.1071/CH9701209; AZARYAN AV, 1993, J BIOL CHEM, V268, P11968; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BENNETT HPJ, 1986, PEPTIDES, V7, P615, DOI 10.1016/0196-9781(86)90036-7; BENNETT HPJ, 1986, INT J PEPT PROT RES, V27, P306; BENNETT HPJ, 1986, J CHROMATOGR, V359, P383, DOI 10.1016/0021-9673(86)80092-9; BENNETT HPJ, 1984, BIOCHEM BIOPH RES CO, V125, P229, DOI 10.1016/S0006-291X(84)80358-7; BERGWERFF AA, 1992, FEBS LETT, V314, P389, DOI 10.1016/0014-5793(92)81512-K; BERGWERFF AA, 1992, INT J PEPT PROT RES, V314, P389; BIRCH NP, 1991, FEBS LETT, V290, P191, DOI 10.1016/0014-5793(91)81257-9; BLANCHARD D, 1983, J BIOL CHEM, V258, P7691; BLANCHARD D, 1985, BIOCHEM J, V232, P813, DOI 10.1042/bj2320813; BLANCHARD D, 1985, J BIOL CHEM, V260, P7813; BROWNE CA, 1981, BIOCHEM BIOPH RES CO, V100, P336, DOI 10.1016/S0006-291X(81)80101-5; CALLAHAN MF, 1984, CLIN EXP HYPERTENS A, V6, P1727, DOI 10.3109/10641968409046067; CAPON C, 1989, EUR J BIOCHEM, V182, P139, DOI 10.1111/j.1432-1033.1989.tb14810.x; CHAN A L, 1991, Glycobiology, V1, P173, DOI 10.1093/glycob/1.2.173; CODDEVILLE B, 1992, CARBOHYD RES, V236, P145, DOI 10.1016/0008-6215(92)85013-P; CONZELMANN A, 1984, J BIOL CHEM, V259, P2536; CONZELMANN A, 1984, J BIOL CHEM, V259, P2528; DELL A, 1990, METHOD ENZYMOL, V193, P647, DOI 10.1016/0076-6879(90)93443-O; DELL A, 1991, CARBOHYD RES, V209, P33, DOI 10.1016/0008-6215(91)80143-B; DELL A, 1993, CURR OPIN STRUC BIOL, V3, P687, DOI 10.1016/0959-440X(93)90051-L; DEWILDT DJ, 1993, EUR J PHARMACOL, V233, P157, DOI 10.1016/0014-2999(93)90362-L; Eipper B A, 1980, Endocr Rev, V1, P1; EIPPER BA, 1978, J SUPRAMOL STR CELL, V8, P247, DOI 10.1002/jss.400080304; EMESON RB, 1986, J NEUROSCI, V6, P837; ESTIVARIZ FE, 1989, J BIOL CHEM, V264, P17796; ESTIVARIZ FE, 1982, NATURE, V297, P419, DOI 10.1038/297419a0; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GORR SU, 1991, J BIOL CHEM, V266, P5780; GRUBER KA, 1989, AM J PHYSIOL, V257, pR681, DOI 10.1152/ajpregu.1989.257.4.R681; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HIRANO T, 1993, EUR J BIOCHEM, V214, P763, DOI 10.1111/j.1432-1033.1993.tb17978.x; IWASAKI M, 1984, BIOCHEMISTRY-US, V23, P305, DOI 10.1021/bi00297a020; JAMES S, 1985, J CHROMATOGR, V326, P329, DOI 10.1016/S0021-9673(01)87458-6; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KAWAUCHI H, 1983, ARCH BIOCHEM BIOPHYS, V227, P343, DOI 10.1016/0003-9861(83)90462-9; KESSLER MJ, 1979, J BIOL CHEM, V254, P7909; KEUTMANN HT, 1981, BIOCHEMISTRY-US, V20, P4148, DOI 10.1021/bi00517a031; KHOO K-H, 1990, Glycobiology, V1, P83, DOI 10.1093/glycob/1.1.83; KHOO KH, 1993, CARBOHYD RES, V244, P205, DOI 10.1016/0008-6215(83)85002-2; KLEIN MC, 1985, LIFE SCI, V36, P769, DOI 10.1016/0024-3205(85)90197-3; LAI PH, 1986, J BIOL CHEM, V261, P3116; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LOWRY PJ, 1983, NATURE, V306, P70, DOI 10.1038/306070a0; LU CL, 1983, LIFE SCI, V33, P2599, DOI 10.1016/0024-3205(83)90343-0; MAINS RE, 1976, J BIOL CHEM, V251, P4115; MAWHINNEY TP, 1992, CARBOHYD RES, V223, P187, DOI 10.1016/0008-6215(92)80016-T; NASIRUDDIN, 1990, CARBOHYD RES, V205, P444, DOI 10.1016/0008-6215(90)80166-Z; NOEL G, 1991, MOL ENDOCRINOL, V5, P404, DOI 10.1210/mend-5-3-404; PARSONS TF, 1984, J BIOL CHEM, V259, P2662; PATZELT C, 1986, EMBO J, V5, P2103, DOI 10.1002/j.1460-2075.1986.tb04472.x; PEDERSEN RC, 1980, SCIENCE, V208, P1044, DOI 10.1126/science.6246578; PEDERSEN RC, 1980, P NATL ACAD SCI-BIOL, V77, P2239, DOI 10.1073/pnas.77.4.2239; PFEIFFER G, 1992, EUR J BIOCHEM, V205, P961, DOI 10.1111/j.1432-1033.1992.tb16863.x; ROSA P, 1985, J CELL BIOL, V101, P1977; SASAKI H, 1987, J BIOL CHEM, V262, P12059; SCAMMELL JG, 1993, TRENDS ENDOCRIN MET, V4, P14, DOI 10.1016/1043-2760(93)90058-M; SEGER MA, 1986, J STEROID BIOCHEM, V25, P703, DOI 10.1016/0022-4731(86)90298-0; SEIDAH NG, 1981, J BIOL CHEM, V256, P7977; SHIMAMURA M, 1983, BIOCHEMISTRY-US, V22, P959, DOI 10.1021/bi00273a039; SHIMOMURA K, 1988, MOL ENDOCRINOL, V2, P845, DOI 10.1210/mend-2-9-845; SICILIANO RA, 1993, GLYCOBIOLOGY, V3, P225, DOI 10.1093/glycob/3.3.225; SKELTON TP, 1992, J BIOL CHEM, V267, P12998; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1992, J BIOL CHEM, V267, P19140; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SUN XY, 1992, AM J PHYSIOL, V262, pR77, DOI 10.1152/ajpregu.1992.262.1.R77; TANAKA N, 1992, J BIOCHEM-TOKYO, V112, P68, DOI 10.1093/oxfordjournals.jbchem.a123867; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003; ZHOU A, 1993, J BIOL CHEM, V268, P1763	76	41	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					910	920						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507111				2022-12-27	WOS:A1994MR22000024
J	LOPEZBARAHONA, M; MINANO, M; MIRA, E; IGLESIAS, T; STUNNENBERG, HG; RODRIGUEZPENA, A; BERNAL, J; MUNOZ, A				LOPEZBARAHONA, M; MINANO, M; MIRA, E; IGLESIAS, T; STUNNENBERG, HG; RODRIGUEZPENA, A; BERNAL, J; MUNOZ, A			RETINOIC ACID POSTTRANSCRIPTIONALLY UP-REGULATES PROTEOLIPID PROTEIN GENE-EXPRESSION IN C6 GLIOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; MYELIN-DEFICIENT RAT; MESSENGER-RNAS; RESPONSE ELEMENT; TRANSCRIPTIONAL REGULATION; DEVELOPMENTAL EXPRESSION; BASIC-PROTEIN; BETA-GENE; PLP GENE; BRAIN	The proteolipid protein (PLP) gene codes for the major central nervous system myelin protein. We have studied the effects of different agents on the expression of the PLP gene in C6 glioma cells. Retinoic acid (RA), but not dexamethasone, estradiol, insulin, growth hormone, or vitamin D3, had a drastic effect, increasing 10-20-fold the level of PLP mRNA. Concomitantly, RA also induced the appearance of the corresponding immunoreactive protein. The increase in PLP RNA level showed a slow kinetics and was blocked by cycloheximide, suggesting a posttranscriptional regulation by RA. Nuclear run-on assays confirmed that the rate of PLP gene transcription was unchanged by RA. In contrast, we found that retinoic acid augmented PLP mRNA stability, causing a substantial increase in its half-life. RA action was independent of cell density, serum, or PDGF but was partially inhibited by bFGF. On the other hand, thyroid hormone caused a moderate increase in PLP mRNA levels in C6 cells but only when the low numbers of thyroid receptors in these cells were increased by retrovirally mediated expression of an exogenous c-erbA/TRalpha-1 gene. Our results indicate that RA specifically up-regulates PLP expression in glioma C6 cells at a posttranscriptional level by increasing PLP RNA half-life.	CSIC,INST INVEST BIOMED,ARTURO DUPERIER 4,E-28029 MADRID,SPAIN; ANTIBIOT FARMA SA,DEPT INVEST,E-28026 MADRID,SPAIN; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); European Molecular Biology Laboratory (EMBL)			Stunnenberg, Hendrik G./D-6875-2012; Bernal, Juan/J-6086-2014; Munoz, Alberto/O-6393-2014; MIRA, EMILIA/K-2456-2014	Stunnenberg, Hendrik G./0000-0002-0066-1576; Bernal, Juan/0000-0002-5867-4951; Munoz, Alberto/0000-0003-3890-4251; MIRA, EMILIA/0000-0002-4226-1829; Rodriguez-Pena, Angeles/0000-0002-2515-4626; Iglesias, Teresa/0000-0002-4326-9005				[Anonymous], MYELIN; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; BAHOUTH SW, 1991, J BIOL CHEM, V266, P15863; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; BOISON D, 1989, EMBO J, V8, P3295, DOI 10.1002/j.1460-2075.1989.tb08490.x; BRENT G A, 1989, New Biologist, V1, P329; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; BROCKES JP, 1989, NEURON, V2, P850; CAMPAGNONI AT, 1988, MOL NEUROBIOL, V2, P41, DOI 10.1007/BF02935632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLIFFORD JL, 1990, MOL ENDOCRINOL, V4, P1546, DOI 10.1210/mend-4-10-1546; DAVIDSON NO, 1988, J BIOL CHEM, V263, P13482; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DUBOISDALCQ M, 1987, EMBO J, V6, P2587, DOI 10.1002/j.1460-2075.1987.tb02549.x; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; FAHIM S, 1986, J NEUROSCI RES, V16, P303, DOI 10.1002/jnr.490160125; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GARDINIER MV, 1986, MOL CELL BIOL, V6, P3755, DOI 10.1128/MCB.6.11.3755; GELLERSEN B, 1992, ENDOCRINOLOGY, V131, P1017, DOI 10.1210/en.131.3.1017; GENCIC S, 1989, AM J HUM GENET, V45, P435; GLASS CK, 1991, DNA CELL BIOL, V10, P623, DOI 10.1089/dna.1991.10.623; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; HUDSON LD, 1989, P NATL ACAD SCI USA, V86, P8128, DOI 10.1073/pnas.86.20.8128; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KUMAR S, 1984, J NEUROCHEM, V43, P1455, DOI 10.1111/j.1471-4159.1984.tb05408.x; KUMAR S, 1989, P NATL ACAD SCI USA, V86, P6807, DOI 10.1073/pnas.86.17.6807; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LEHMANN JM, 1992, MOL CELL BIOL, V12, P2976, DOI 10.1128/MCB.12.7.2976; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LOTAN R, 1991, CANCER BIOL, V2, P197; MACKLIN WB, 1991, J NEUROCHEM, V56, P163, DOI 10.1111/j.1471-4159.1991.tb02576.x; MARTIN CA, 1990, P NATL ACAD SCI USA, V87, P4804, DOI 10.1073/pnas.87.12.4804; MCMORRIS FA, 1977, P NATL ACAD SCI USA, V74, P4501, DOI 10.1073/pnas.74.10.4501; MILNER RJ, 1985, CELL, V42, P931, DOI 10.1016/0092-8674(85)90289-2; MUNOZ A, 1991, MOL ENDOCRINOL, V5, P273, DOI 10.1210/mend-5-2-273; MUNOZ A, 1990, MOL ENDOCRINOL, V4, P312, DOI 10.1210/mend-4-2-312; NAVE KA, 1991, J NEUROSCI, V11, P3060; RENTOUMIS A, 1990, MOL ENDOCRINOL, V4, P1522, DOI 10.1210/mend-4-10-1522; Sambrook J, 1989, MOL CLONING LABORATO; SHAMBAUGH GE, 1969, J BIOL CHEM, V244, P5295; SHANKER G, 1985, NEUROCHEM RES, V10, P617, DOI 10.1007/BF00964401; SHERMAN MI, 1986, RETINOIDS CELL DIFFE; SHIOTA C, 1991, J NEUROCHEM, V56, P818, DOI 10.1111/j.1471-4159.1991.tb01997.x; SIMONS R, 1990, J NEUROCHEM, V54, P1079, DOI 10.1111/j.1471-4159.1990.tb02360.x; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TSUNEISHI S, 1991, DEV BRAIN RES, V61, P117, DOI 10.1016/0165-3806(91)90121-X; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; VIVANCO RM, 1991, EMBO J, V10, P3829; YAMAMURA T, 1991, J NEUROCHEM, V57, P1671, DOI 10.1111/j.1471-4159.1991.tb06367.x	59	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25617	25623						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503983				2022-12-27	WOS:A1993MK10000050
J	QUAITERANDALL, E; TRENT, JD; JOSEPHS, R; JOACHIMIAK, A				QUAITERANDALL, E; TRENT, JD; JOSEPHS, R; JOACHIMIAK, A			CONFORMATIONAL CYCLE OF THE ARCHAEOSOME, A TCP1-LIKE CHAPERONIN FROM SULFOLOBUS-SHIBATAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE; CENTRAL CAVITY; HEAT-SHOCK; GROEL; ARCHAEBACTERIUM; PROTEINS	The major heat shock proteins in the archaeon Sulfolobus shibatae are similar to the cytosolic eukaryotic chaperonin and form an 18-subunit bitoroidal complex. Two sequence-related subunits constitute a functional complex, named the archaeosome. The archaeosome exists in two distinct conformational states that are part of chaperonin functional cycle. The closed archaeosome complex binds ATP and forms an open complex. Upon ATP hydrolysis, the open complex dissociates into subunits, Free subunits reassemble into a two-ring structure. The equilibrium between the complexes and free subunits is affected by ATP and temperature. Denatured proteins associate with both conformational states as well as with free subunits that form an intermediate complex. These unexpected observations suggest a new mechanism of archaeosome-mediated thermotolerance and protein folding.	ARGONNE NATL LAB,ARGONNE,IL 60439; UNIV CHICAGO,CHICAGO,IL 60637	United States Department of Energy (DOE); Argonne National Laboratory; University of Chicago								AZEM A, 1994, NATURE, V265, P653; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRENNAN TV, 1993, PROTEIN SCI, V2, P331; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GAO Y, 1994, J CELL BIOL, V125, P989, DOI 10.1083/jcb.125.5.989; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GIOMETTI CS, 1994, J CHROMATOGR, V698, P341; GUAGLIARDI A, 1994, PROTEIN SCI, V3, P1436, DOI 10.1002/pro.5560030910; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HYNES G, 1995, FEBS LETT, V358, P129, DOI 10.1016/0014-5793(94)01408-S; ISHII N, 1995, FEBS LETT, V362, P121, DOI 10.1016/0014-5793(95)00222-U; JOACHIMIAK A, 1995, FASEB J, V9, P52; KAGAWA HK, 1995, J MOL BIOL, V253, P712, DOI 10.1006/jmbi.1995.0585; KNAPP S, 1994, J MOL BIOL, V242, P397; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LISSIN NM, 1995, FEBS LETT, V361, P55, DOI 10.1016/0014-5793(95)00151-X; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PHIPPS BM, 1991, EMBO J, V10, P1711, DOI 10.1002/j.1460-2075.1991.tb07695.x; PHIPPS BM, 1993, NATURE, V361, P474; ROBB FT, 1992, BIOCHIM BIOPHYS ACTA, V1120, P267, DOI 10.1016/0167-4838(92)90247-B; ROBINSON CV, 1994, NATURE, V372, P646, DOI 10.1038/372646a0; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; THOMAS PD, 1993, PROTEIN SCI, V2, P2050, DOI 10.1002/pro.5560021206; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZAHN R, 1993, J MOL BIOL, V229, P579, DOI 10.1006/jmbi.1993.1062	35	45	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28818	28823		10.1074/jbc.270.48.28818	http://dx.doi.org/10.1074/jbc.270.48.28818			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499406	hybrid			2022-12-27	WOS:A1995TH05600050
J	QUATTROCHI, LC; MILLS, AS; BARWICK, JL; YOCKEY, CB; GUZELIAN, PS				QUATTROCHI, LC; MILLS, AS; BARWICK, JL; YOCKEY, CB; GUZELIAN, PS			A NOVEL CIS-ACTING ELEMENT IN A LIVER CYTOCHROME-P450 3A GENE CONFERS SYNERGISTIC INDUCTION BY GLUCOCORTICOIDS PLUS ANTIGLUCOCORTICOIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT-RAT HEPATOCYTES; RESPONSE ELEMENTS; PREGNENOLONE 16-ALPHA-CARBONITRILE; HEPATIC CYTOCHROME-P-450; PROGESTERONE INDUCTION; MESSENGER-RNAS; RETINOIC ACID; TRANSCRIPTION; HORMONE; DNA	The induction by dexamethasone of rat liver CYP3A1 differs from classical glucocorticoid gene regulation in part because both glucocorticoids and antiglucocorticoids such as pregnenolone 16 alpha-carbonitrile (PCN) induce CYP3A1 through transcriptional gene activation. In the present study, we transiently expressed in primary cultures of rat hepatocytes plasmids consisting of CYP3A1 5'-flanking sequences fused to a chloramphenicol acetyltransferase reporter plasmid. Deletional analysis identified a 78-base pair (bp) element located approximately 135 bp upstream of the transcriptional start site that was inducible by treatment of the cultures with dexamethasone or PCN and was induced synergistically by dexamethasone plus PCN. Nuclear extract from control rat liver protected two regions within the 78-bp sequence against digestion with DNase I. The same two regions were protected when nuclear extracts from dexamethasone-treated animals were used. Analysis of both of the ''footprints'' (FP1 and FP2) failed to reveal a classical sequence for the glucocorticoid-responsive element. A 33-bp element that includes FP1 sequences inserted into the chloramphenicol acetyltransferase reporter plasmid and transiently expressed in rat hepatocytes conferred a profile of dexamethasone and PCN induction similar to that of the 78-bp element. However, an Escherichia coli expressed glucocorticoid receptor protein failed to protect sequences within FP1 in DNase I footprinting experiments and failed to change its mobility in gel shift assays. Moreover, as judged by the gel shift assay, the specific protein binding to this fragment was the same whether nuclear extracts from the liver of untreated or dexamethasone treated rats were used. We conclude that the activation of CYP3A1 gene transcription by glucocorticoids may involve proteins already bound to the controlling element in the CYP3A1 gene through a mechanism in which GR in the presence of hormone does not bind directly to CYP3A1 DNA.	UNIV COLORADO, HLTH SCI CTR,DEPT MED,HEPATOBILIARY RES CTR, MED TOXICOL SECT, DENVER, CO 80262 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PATHOL, RICHMOND, VA 23298 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Virginia Commonwealth University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004238] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34914] Funding Source: Medline; NIEHS NIH HHS [ES04238, ES05744] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BURGER HJ, 1990, ARCH BIOCHEM BIOPHYS, V281, P204, DOI 10.1016/0003-9861(90)90433-Y; BURGER HJ, 1992, P NATL ACAD SCI USA, V89, P2145, DOI 10.1073/pnas.89.6.2145; CARR KD, 1990, P NATL ACAD SCI USA, V87, P9300, DOI 10.1073/pnas.87.23.9300; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHAN GCK, 1991, J BIOL CHEM, V266, P22634; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; ELSHOURBAGY NA, 1980, J BIOL CHEM, V255, P1279; FISHER RC, 1991, MOL CELL BIOL, V11, P1614, DOI 10.1128/MCB.11.3.1614; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GONZALEZ FJ, 1985, J BIOL CHEM, V260, P7435; GRAHAM JM, 1990, ANAL BIOCHEM, V187, P318, DOI 10.1016/0003-2697(90)90463-J; GUERTIN M, 1983, BIOCHEMISTRY-US, V22, P4296, DOI 10.1021/bi00287a021; HEUMAN DM, 1982, MOL PHARMACOL, V21, P753; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOMORI M, 1994, J BIOCHEM-TOKYO, V116, P114, DOI 10.1093/oxfordjournals.jbchem.a124482; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; LI D, 1991, METHOD ENZYMOL, V206, P335; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P224; Maxam A M, 1980, Methods Enzymol, V65, P499; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; MITCHELL J, 1994, MOL ENDOCRINOL, V8, P585, DOI 10.1210/me.8.5.585; MIYATA M, 1995, ARCH BIOCHEM BIOPHYS, V318, P71, DOI 10.1006/abbi.1995.1206; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; PEREIRA TM, 1995, EUR J BIOCHEM, V229, P171, DOI 10.1111/j.1432-1033.1995.0171l.x; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; SCHUETZ EG, 1984, J BIOL CHEM, V259, P1999; SCHUETZ EG, 1984, J BIOL CHEM, V259, P2007; SCHUETZ EG, 1988, J CELL PHYSIOL, V134, P309, DOI 10.1002/jcp.1041340302; SIMMONS DL, 1987, J BIOL CHEM, V262, P326; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; TELHADA MB, 1992, ARCH BIOCHEM BIOPHYS, V298, P715, DOI 10.1016/0003-9861(92)90471-8; TEURICH S, 1995, CHEM SENSES, V20, P251, DOI 10.1093/chemse/20.2.251; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WATKINS PB, 1990, SEMIN LIVER DIS, V10, P235, DOI 10.1055/s-2008-1040480; WATKINS PB, 1985, P NATL ACAD SCI USA, V82, P6310, DOI 10.1073/pnas.82.18.6310; WEN P, 1994, MOL CELL BIOL, V14, P6616, DOI 10.1128/MCB.14.10.6616; WRIGHTON SA, 1985, MOL PHARMACOL, V28, P312	42	74	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28917	28923		10.1074/jbc.270.48.28917	http://dx.doi.org/10.1074/jbc.270.48.28917			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499421	hybrid			2022-12-27	WOS:A1995TH05600065
J	WALSH, JP; SUEN, R; GLOMSET, JA				WALSH, JP; SUEN, R; GLOMSET, JA			ARACHIDONOYL-DIACYLGLYCEROL KINASE - SPECIFIC IN-VITRO INHIBITION BY POLYPHOSPHOINOSITIDES SUGGESTS A MECHANISM FOR REGULATION OF PHOSPHATIDYLINOSITOL BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ESCHERICHIA-COLI; PHOSPHATIDIC-ACID; HUMAN-PLATELETS; RAT-BRAIN; SN-1,2-DIACYLGLYCEROL KINASE; CULTURED FIBROBLASTS; RECEPTOR ACTIVATION; PHOSPHOLIPASE-C; 2ND MESSENGERS	We previously described the purification of a membrane-bound diacylglycerol kinase highly selective for sn-1-acyl-2-arachidonoyl diacylglycerols (Walsh, J. P., Suen, R., Lemaitre, R. N., and Glomset, J. A. (1994) J. Biol. Chem. 269, 21155-21164), This enzyme appears to be responsible for the rapid clearance of the arachidonate rich pool of diacylglycerols generated during stimulus-induced phosphoinositide turnover, We have now shown phosphatidylinositol 4,5-bisphosphate to be a potent and specific inhibitor of arachidonoyl-diacylglycerol kinase, Kinetic analyses indicated a K-i for phosphatidylinositol 4,5-bisphosphate of 0.04 mol %. Phosphatidic acid also was an inhibitor with a K-i of 0.7 mol %, Other phospholipids had only small effects at these concentrations, A series of multiply phosphorylated lipid analogs also inhibited the enzyme, indicating that the head group phosphomonoesters are the primary determinants of the polyphosphoinositide effect. However, these compounds were not as potent as phosphatidylinositol 4,5-bisphosphate, indicating some specificity for the polyphosphoinositide additional to its total charge, Five other diacylglycerol kinases were activated to varying degrees by phosphatidylinositol 4,5-bisphosphate and phosphatidic acid, suggesting that inhibition by acidic lipids may be specific for the arachidonoyl-DAG kinase isoform. Given the presumed role of arachidonoyl-diacylglycerol kinase in the phosphoinositide cycle, this inhibition may represent a mechanism for polyphosphoinositides to regulate their own synthesis.	UNIV WASHINGTON, HOWARD HUGHES MED INST, RES LABS, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, RES LABS, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, HOWARD HUGHES MED INST, RES LABS, REG PRIMATE RES CTR, SEATTLE, WA 98195 USA; INDIANA UNIV, DEPT MED, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00166] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALSADEN A, 1977, J PHARM PHARMACOL, V29, pP23, DOI 10.1111/j.2042-7158.1977.tb11491.x; AUGERT G, 1989, J BIOL CHEM, V264, P2574; BISHOP WR, 1986, J BIOL CHEM, V261, P6993; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; CHEN Q, 1993, J NEUROCHEM, V60, P1212, DOI 10.1111/j.1471-4159.1993.tb03279.x; CLINT JH, 1975, J CHEM SOC FARAD T 1, V71, P1327, DOI 10.1039/f19757101327; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DIXON M, 1979, ENZYMES, P79; FUKAMI K, 1989, J BIOL CHEM, V264, P14985; GOLDFARB J, 1969, J COLLOID INTERF SCI, V31, P454, DOI 10.1016/0021-9797(69)90046-0; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; HELMS JB, 1991, J BIOL CHEM, V266, P21368; Holub B J, 1978, Adv Lipid Res, V16, P1; HUANG CF, 1990, J BIOL CHEM, V265, P17468; ISHITOYA J, 1987, BIOCHEM BIOPH RES CO, V144, P1025, DOI 10.1016/S0006-291X(87)80066-9; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; JONES GA, 1993, J BIOL CHEM, V268, P20845; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1983, J BIOL CHEM, V258, P1767; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KANOH H, 1993, CELL SIGNAL, V5, P495, DOI 10.1016/0898-6568(93)90045-N; KANOH H, 1978, EUR J BIOCHEM, V85, P225, DOI 10.1111/j.1432-1033.1978.tb12230.x; KANOH H, 1989, BIOCHEM J, V258, P455, DOI 10.1042/bj2580455; KATO M, 1990, J BIOL CHEM, V265, P794; KENNERLY DA, 1987, J BIOL CHEM, V262, P16305; KERWIN JL, 1994, J LIPID RES, V35, P1102; LEE C, 1991, J BIOL CHEM, V266, P22837; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; LEMAITRE RN, 1990, BIOCHEM J, V266, P291, DOI 10.1042/bj2660291; LIN CH, 1986, LIPIDS, V21, P206, DOI 10.1007/BF02534823; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; MARONEY AC, 1989, J BIOL CHEM, V264, P2537; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MONACO ME, 1992, ENDOCR REV, V13, P707, DOI 10.1210/er.13.4.707; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NGUYEN CM, 1986, J COLLOID INTERF SCI, V112, P438, DOI 10.1016/0021-9797(86)90112-8; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OSBORNELEE IW, 1985, J COLLOID INTERF SCI, V108, P60, DOI 10.1016/0021-9797(85)90236-X; PESSIN MS, 1989, J BIOL CHEM, V264, P8729; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RENARD DC, 1982, BIOCHEM J, V281, P775; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; Ribeiro A. A., 1987, NONIONIC SURFACTANTS, P971; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SCHAAP D, 1993, BIOCHEM J, V289, P875, DOI 10.1042/bj2890875; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SERDAREVICH B, 1966, CAN J BIOCHEM CELL B, V44, P743, DOI 10.1139/o66-092; SHEARS SB, 1991, PHARMACOL THERAPEUT, V49, P79, DOI 10.1016/0163-7258(91)90023-F; SHOJI N, 1978, J AM OIL CHEM SOC, V55, P297, DOI 10.1007/BF02676947; SINGH SS, 1993, BIOCHEM BIOPH RES CO, V195, P104, DOI 10.1006/bbrc.1993.2016; SOLING HD, 1989, J BIOL CHEM, V264, P10643; STATHOPOULOS VM, 1990, BIOCHEM J, V272, P569, DOI 10.1042/bj2720569; TERUI T, 1994, J BIOL CHEM, V269, P28130; TOKER A, 1994, J BIOL CHEM, V269, P32358; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WALSH JP, 1990, J BIOL CHEM, V265, P4374; WALSH JP, 1994, J BIOL CHEM, V269, P21155; WALSH JP, 1992, METHOD ENZYMOL, V209, P153; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; YADA Y, 1990, J BIOL CHEM, V265, P19237; YAMADA K, 1988, BIOCHEM J, V255, P601; [No title captured]	72	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28647	28653		10.1074/jbc.270.48.28647	http://dx.doi.org/10.1074/jbc.270.48.28647			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499383	hybrid			2022-12-27	WOS:A1995TH05600027
J	PESCHEK, GA; ALGE, D; FROMWALD, S; MAYER, B				PESCHEK, GA; ALGE, D; FROMWALD, S; MAYER, B			TRANSIENT ACCUMULATION OF HEME-O (CYTOCHROME-O) IN THE CYTOPLASMIC MEMBRANE OF SEMI-ANAEROBIC ANACYSTIS-NIDULANS - EVIDENCE FOR OXYGENASE-CATALYZED HEME-O/HEME-A TRANSFORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANES; C-OXIDASE; ELECTRON-TRANSPORT; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; PLASMA-MEMBRANE; PURIFIED PLASMA; CYANOBACTERIUM; CHLOROPHYLL; BIOSYNTHESIS	Incubation of obligately photoautotrophic and aerobic cyanobacterium Anacystis nidulans (Synechococcus sp, PCC 6301) in the light in the presence of the photo system II inhibitor 3-(3,4-dichlorophenyl)-1,1-dimethylurea and equilibrated with approximately 1% (v/v) O-2 in N-2 (10 mu M O-2 in solution) led to a decrease of the heme A content of isolated cytoplasmic membranes and to the appearance of heme O. The latter was not seen in membranes from fully aerated cells (>210 mu M dissolved O-2). Non-covalently bound hemes extracted from the membranes were identified by reversed phase high performance liquid chromatography. Heme A and O contents of the membranes changed in a reversible fashion solely depending on the ambient oxygen regime. Both hemes A and O combine with the same apoprotein as suggested by immunoblotting, CO/reduced-minus-reduced optical difference spectra, photoaction spectra of CO-inhibited O-2 uptake by the membranes, and pyridine hemochrome spectra pointed to either heme belonging to a functional form of the terminal oxidase, The NADH:O-2 oxidoreductase reaction catalyzed by membranes from both high O-2 and low O-2 cells was strictly dependent on the addition of catalytic amounts of cytochrome c, fully inhibited by 1.2 mu M KGN, and insensitive to 5 mu M 2-n-heptyl-4-hydroxyquinoline-N-oxide. O-2 uptake by the membranes was effectively catalyzed by N,N,N',N'-tetramethyl-p-phenylenediamine but not 2-methylnaphthoquinol or plastoquinol-1 as artificial substrates, Therefore we conclude that the cyanobacterial respiratory oxidase, irrespective of the type of heme in its O-2-reducing center, is a cytochrome c rather than a quinol oxidase.			PESCHEK, GA (corresponding author), UNIV VIENNA, INST PHYS CHEM, BIOPHYS CHEM GRP, WAHRINGERSTR 42, A-1090 VIENNA, AUSTRIA.							ALGE D, 1993, BIOCHEM MOL BIOL INT, V29, P511; ALGE D, 1994, GENE, V138, P127, DOI 10.1016/0378-1119(94)90794-3; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BARGHOOR.ES, 1966, SCIENCE, V152, P758, DOI 10.1126/science.152.3723.758; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODA E, 1979, J THEOR BIOL, V81, P201, DOI 10.1016/0022-5193(79)90160-7; BRODA E, 1975, EVOLUTION BIOENERGET; Bryant D.A., 1994, MOL BIOL CYANOBACTER; Fay P, 1987, CYANOBACTERIA; HANSSON M, 1993, FEMS MICROBIOL LETT, V107, P121; HINTERSTOISSER B, 1993, J PLANT PHYSIOL, V142, P407, DOI 10.1016/S0176-1617(11)81245-9; JONES DP, 1981, BIOCHEM PHARMACOL, V30, P1019, DOI 10.1016/0006-2952(81)90436-6; KRAUSHAAR H, 1990, FEBS LETT, V273, P227, DOI 10.1016/0014-5793(90)81091-2; Lemberg R., 1973, CYTOCHROMES; LUBBEN M, 1994, J BIOL CHEM, V269, P21473; MacKinney G, 1941, J BIOL CHEM, V140, P315; MATSUSHITA K, 1992, J BIOL CHEM, V267, P24748; MOLITOR V, 1986, FEBS LETT, V204, P251, DOI 10.1016/0014-5793(86)80822-5; MOLITOR V, 1986, FEBS LETT, V195, P145, DOI 10.1016/0014-5793(86)80149-1; MOLITOR V, 1990, ARCH MICROBIOL, V154, P112, DOI 10.1007/BF00423319; Morris J.G., 1975, ADV MICROB PHYSIOL, P169; NICHOLLS P, 1992, BIOCHIM BIOPHYS ACTA, V1098, P184, DOI 10.1016/S0005-2728(05)80335-4; NITSCHMANN WH, 1986, J BACTERIOL, V168, P1205, DOI 10.1128/jb.168.3.1205-1211.1986; NITSCHMANN WH, 1985, ANAL BIOCHEM, V147, P186, DOI 10.1016/0003-2697(85)90026-0; OMATA T, 1984, BIOCHIM BIOPHYS ACTA, V766, P395, DOI 10.1016/0005-2728(84)90255-X; OMATA T, 1985, BIOCHIM BIOPHYS ACTA, V810, P354, DOI 10.1016/0005-2728(85)90221-X; PESCHEK GA, 1988, METHOD ENZYMOL, V167, P437; PESCHEK GA, 1989, HIGHLIGHTS OF MODERN BIOCHEMISTRY, VOLS 1-2, P893; PESCHEK GA, 1989, J BIOL CHEM, V264, P11827; PESCHEK GA, 1989, BIOCHEMISTRY-US, V28, P3057, DOI 10.1021/bi00433a048; PESCHEK GA, 1981, BIOCHIM BIOPHYS ACTA, V635, P470, DOI 10.1016/0005-2728(81)90106-7; PESCHEK GA, 1994, BBA-BIOENERGETICS, V1187, P369, DOI 10.1016/0005-2728(94)90011-6; PESCHEK GA, 1994, FEMS MICROBIOL LETT, V124, P431, DOI 10.1111/j.1574-6968.1994.tb07320.x; PESCHEK GA, 1992, EBEC SHORT REPORTS, V7, P48; PORRA RJ, 1993, FEBS LETT, V323, P31, DOI 10.1016/0014-5793(93)81442-3; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; PUUSTINEN A, 1992, BIOCHEMISTRY-US, V31, P10363, DOI 10.1021/bi00157a026; SONE N, 1991, FEBS LETT, V288, P154, DOI 10.1016/0014-5793(91)81024-3; SVENSSON B, 1993, MOL MICROBIOL, V10, P193, DOI 10.1111/j.1365-2958.1993.tb00915.x; WASTYN M, 1988, BIOCHIM BIOPHYS ACTA, V935, P217, DOI 10.1016/0005-2728(88)90218-6	41	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27937	27941		10.1074/jbc.270.46.27937	http://dx.doi.org/10.1074/jbc.270.46.27937			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499269	hybrid			2022-12-27	WOS:A1995TE73600080
J	RICHARDON, RM; ALI, H; TOMHAVE, ED; HARIBABU, B; SNYDERMAN, R				RICHARDON, RM; ALI, H; TOMHAVE, ED; HARIBABU, B; SNYDERMAN, R			CROSS-DESENSITIZATION OF CHEMOATTRACTANT RECEPTORS OCCURS AT MULTIPLE LEVELS - EVIDENCE FOR A ROLE FOR INHIBITION OF PHOSPHOLIPASE-C ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED SIGNAL-TRANSDUCTION; POLYMORPHONUCLEAR LEUKOCYTES; DEPENDENT PHOSPHORYLATION; INOSITOL TRISPHOSPHATE; CELLS; FORMYLPEPTIDE; NEUTROPHILS; HYDROLYSIS; PEPTIDE; CALCIUM	To define the molecular mechanisms of cross-regulation among chemoattractant receptors, we stably coexpressed, in a rat basophilic leukemia (RBL-2H3) cell line, epitope tagged receptors for the chemoattractants formylmethionylleucylphenylalanine (fMLP), a peptide of the fifth component of the complement system (C5a), and interleukin-8 (IL-8), All the expressed receptors underwent homologous phosphorylation and desensitization upon agonist stimulation, When co-expressed, epitope-tagged C5a receptor (ET-C5aR) and epitope-tagged IL-8 receptor (ET-IL-8RA) were cross-phosphorylated by activation of the other. Activation of epitope-tagged fMLP receptor (ET-FR) also cross-phosphorylated ET-C5aR and ET-IL 8RA, but ET-FR was totally resistant to cross-phosphorylation. Similarly, C5a and IL-8 stimulation of [S-35]guanosine 5'-3-O-(thio) triphosphate (GTP gamma S) binding and Ca2+ mobilization were cross-desensitized by each other and by fMLP. Stimulation of [S-35]GTP gamma S binding by fMLP was also not cross-desensitized by C5a or IL-8, however, Ca2+ mobilization was, suggesting a site of inhibition distal to G protein activation, Consistent with this desensitization of Ca2+ mobilization, inositol 1,4,5-trisphosphate release in RBL-2H3 cells expressing both ET-C5aR and ET-FR revealed that fMLP and C5a cross-desensitized each other's ability to stimulate phosphoinositide hydrolysis, Taken together, these results indicate that receptor cross-phosphorylation correlates directly with desensitization at the level of G protein activation, The ET-FR was resistant to this process. Of note, cross desensitization of ET-FR at the level of phosphoinositide hydrolysis and Ca2+ mobilization was demonstrated in the absence of receptor phosphorylation, This suggests a new form of chemoattractant cross-regulation at a site distal to receptor/G; protein coupling, involving the activity of phospholipase C.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710	Duke University; Duke University			Bodduluri, Haribabu/A-2584-2010	Bodduluri, Haribabu/0000-0002-8261-3294	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE003738] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-03738] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALI H, 1994, J BIOL CHEM, V269, P24557; ALI H, 1993, J BIOL CHEM, V268, P24247; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; DOBOS GJ, 1992, J IMMUNOL, V149, P609; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LIGGETT SB, 1994, REGULATION CELLULAR, P71; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PARISH CA, 1995, BIOCHEMISTRY-US, V34, P7722, DOI 10.1021/bi00023a019; PIKE MC, 1986, BLOOD, V67, P909; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; SNYDERMAN R, 1992, INFLAMMATION BASIC P, P421; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; TARDIF M, 1993, J IMMUNOL, V150, P3534; TOMHAVE E, 1994, J IMMUNOL, V154, P3267; WILDE MW, 1989, J BIOL CHEM, V264, P190; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840	21	94	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27829	27833		10.1074/jbc.270.46.27829	http://dx.doi.org/10.1074/jbc.270.46.27829			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499254	hybrid			2022-12-27	WOS:A1995TE73600065
J	LINCHAO, S; WONG, TT; MCDOWALL, KJ; COHEN, SN				LINCHAO, S; WONG, TT; MCDOWALL, KJ; COHEN, SN			EFFECTS OF NUCLEOTIDE-SEQUENCE ON THE SPECIFICITY OF RNE-DEPENDENT AND RNASE E-MEDIATED CLEAVAGES OF RNA I-ENCODED BY THE PBR322 PLASMID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-AMS; MESSENGER-RNA; RIBONUCLEASE-E; RIBOSOMAL-PROTEIN; STABILITY AMS; BACTERIOPHAGE-T4 GENE-32; ENDONUCLEOLYTIC CLEAVAGE; STRUCTURAL-ANALYSIS; CELL-DIVISION; INVITRO	RNase E, an endoribonuclease encoded by the Escherichia coli ams/rne/hmp1 locus, cleaves RNA I, an antisense regulator of the replication of ColE1 type plasmids, in a single-stranded region near its 5' end. The rne-3071 mutation prolongs the RNA I half-life in cells cultured at an elevated temperature and imparts temperature sensitivity on RNase E isolated from the mutant strain. Here we report the effects of specific sequence changes introduced by site-directed mutagenesis on the location of ribonucleolytic cleavage near the 5' end of pBR322 RNA I in rne-3071 and congenic rne(+) E. coli and on cleavage of RNA I by RNase E in vitro. Primer extension analyses showed that the occurrence and position of cleavages in vivo and in vitro are altered highly specifically by sequence changes but that the site of cleavage bears no simple relationship to a particular nucleotide order. Our results do not support either the notion that cleavage by RNase E is determined by a consensus sequence or the contrary view that RNase E is a virtually nonspecific single-stranded endonuclease with a preference for cutting 5' to an AU dinucleotide.	NATL YANG MING MED COLL, INST BIOCHEM, TAIPEI 11221, TAIWAN; STANFORD UNIV, SCH MED, DEPT GENET, STANFORD, CA 94305 USA	National Yang Ming Chiao Tung University; Stanford University	LINCHAO, S (corresponding author), ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN.		Lin-Chao, Sue/AAZ-8246-2021; McDowall, Kenneth/GYA-5735-2022; Lin-Chao, Sue/AGI-2030-2022; Wong, Ten-Tsao/J-7524-2017	Lin-Chao, Sue/0000-0002-8415-9304; Lin-Chao, Sue/0000-0002-8415-9304; Wong, Ten-Tsao/0000-0001-5573-9767; McDowall, Kenneth/0000-0003-2528-2190	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027241] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27241] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; CARPOUSIS AJ, 1989, MOL GEN GENET, V219, P39, DOI 10.1007/BF00261155; CASAREGOLA S, 1992, J MOL BIOL, V228, P30, DOI 10.1016/0022-2836(92)90489-7; CESARENI G, 1991, TRENDS GENET, V7, P230, DOI 10.1016/0168-9525(91)90370-6; CHAMBERLIN M, 1983, METHOD ENZYMOL, V101, P540; CLAVERIEMARTIN F, 1991, J BIOL CHEM, V266, P2843; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; FAUBLADIER M, 1990, J MOL BIOL, V212, P461, DOI 10.1016/0022-2836(90)90325-G; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; GUREVITZ M, 1983, P NATL ACAD SCI-BIOL, V80, P4450, DOI 10.1073/pnas.80.14.4450; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; KOKOSKA RJ, 1990, BIOCHIMIE, V72, P803, DOI 10.1016/0300-9084(90)90189-N; Lin-Chao S, 1992, MOL MICROBIOL, V6, P3385, DOI 10.1111/j.1365-2958.1992.tb02206.x; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LOAYZA D, 1991, MOL MICROBIOL, V5, P715, DOI 10.1111/j.1365-2958.1991.tb00742.x; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; MACKIE GA, 1992, J BIOL CHEM, V267, P1054; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; Maniatis T., 1982, MOL CLONING; MCDOWALL KJ, 1993, J BACTERIOL, V175, P4245, DOI 10.1128/JB.175.13.4245-4249.1993; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; MEACOCK PA, 1980, CELL, V20, P529, DOI 10.1016/0092-8674(80)90639-X; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MELEFORS O, 1993, CONTROL MESSENGER RN, P53; MORITA M, 1979, EUR J BIOCHEM, V97, P435, DOI 10.1111/j.1432-1033.1979.tb13131.x; MUDD EA, 1988, EMBO J, V7, P3601, DOI 10.1002/j.1460-2075.1988.tb03238.x; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; NILSSON G, 1988, EMBO J, V7, P2269, DOI 10.1002/j.1460-2075.1988.tb03067.x; NILSSON P, 1991, MOL MICROBIOL, V5, P1791, DOI 10.1111/j.1365-2958.1991.tb01928.x; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PRAGAI B, 1982, J MOL BIOL, V154, P465, DOI 10.1016/S0022-2836(82)80007-7; REGNIER P, 1991, J MOL BIOL, V217, P283, DOI 10.1016/0022-2836(91)90542-E; ROTH JR, 1970, METHODS ENZYMOL    A, V17, P3; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; SRIVASTAVA RK, 1990, BIOCHIMIE, V72, P791, DOI 10.1016/0300-9084(90)90188-M; SUBBARAO MN, 1989, MOL GEN GENET, V217, P499, DOI 10.1007/BF02464923; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P851, DOI 10.1111/j.1365-2958.1991.tb00758.x; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; TUCKER WT, 1984, CELL, V38, P191, DOI 10.1016/0092-8674(84)90540-3; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756; YARCHUK O, 1992, J MOL BIOL, V226, P581, DOI 10.1016/0022-2836(92)90617-S; YOST HJ, 1990, TRENDS GENET, V6, P223, DOI 10.1016/0168-9525(90)90183-7	48	101	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10797	10803						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511607				2022-12-27	WOS:A1994NF01700091
J	SONCIN, F; SHAPIRO, R; FETT, JW				SONCIN, F; SHAPIRO, R; FETT, JW			A CELL-SURFACE PROTEOGLYCAN MEDIATES HUMAN ADENOCARCINOMA HT-29 CELL-ADHESION TO HUMAN ANGIOGENIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL RIBONUCLEASE INHIBITOR; MAMMARY EPITHELIAL-CELLS; HEPARAN-SULFATE PROTEOGLYCANS; AMINO-ACID SEQUENCE; CANCER METASTASIS; ENDOTHELIAL-CELLS; TUMOR-CELLS; BINDING; PROTEIN; PURIFICATION	Human angiogenin is an excellent substrate for the adhesion of HT-29 human colon adenocarcinoma cells. These cells adhere more quickly to human angiogenin than to fibronectin, laminin, collagen I, and collagen IV. Anti-angiogenin antibodies and the angiogenesis inhibitors platelet factor-4 and placental ribonuclease inhibitor prevent adhesion of HT-29 cells to angiogenin. Calcium and magnesium ions are not required for adhesion and Arg Gly-Asp-Ser has no effect, indicating that the interaction is integrin-independent. Instead, adhesion seems to involve a heparan/chondroitin sulfate proteoglycan. Treatment of the cells with heparinase or heparitinase decreases HT-29 cell adhesion onto angiogenin but not onto collagen I. Moreover, cell adhesion is decreased by the presence of heparin or chondroitin sulfates and by preincubation of the cells with inhibitors of proteoglycan synthesis or secretion. In addition, angiogenin binds tightly to heparin-Sepharose, requiring 0.78 M NaCl for elution. Angiogenin-affinity chromatography of a S-35-, H-3-labeled HT-29 cell fraction enriched in cell-surface proteoglycans yields a single, heparinase-sensitive component of apparent molecular mass >200 kDa, as detected by autoradiography after SDS-polyacrylamide gel electrophoresis. These results suggest that angiogenin could be an effective substrate for tumor cell adhesion during metastasis and may provide a basis for the design of inhibitors of this process.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BIOCHEM & BIOPHYS SCI & MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673				BADET J, 1989, P NATL ACAD SCI USA, V86, P8427, DOI 10.1073/pnas.86.21.8427; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BICKNELL R, 1989, P NATL ACAD SCI USA, V86, P1573, DOI 10.1073/pnas.86.5.1573; BRENNAN MJ, 1983, CANCER RES, V43, P4302; CRISCUOLO GR, 1988, J NEUROSURG, V69, P254, DOI 10.3171/jns.1988.69.2.0254; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; HALLAHAN TW, 1991, P NATL ACAD SCI USA, V88, P2222, DOI 10.1073/pnas.88.6.2222; HANDIN RI, 1976, J BIOL CHEM, V251, P4273; HEATH WF, 1989, P NATL ACAD SCI USA, V86, P2718, DOI 10.1073/pnas.86.8.2718; HU GF, 1993, P NATL ACAD SCI USA, V90, P1217, DOI 10.1073/pnas.90.4.1217; HUANG SS, 1982, J BIOL CHEM, V257, P1546; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KODA JE, 1985, J BIOL CHEM, V260, P8157; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE FS, 1988, BIOCHEMISTRY-US, V27, P8545, DOI 10.1021/bi00423a007; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; Linker A., 1972, METHODS ENZYMOL, P902; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1986, CANCER RES, V46, P1; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; LOESER RF, 1992, J BIOL CHEM, V267, P9459; MAES P, 1988, FEBS LETT, V241, P41, DOI 10.1016/0014-5793(88)81027-5; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; NICOLSON GL, 1975, NATURE, V255, P230, DOI 10.1038/255230a0; PATTHY L, 1987, J MOL BIOL, V198, P567, DOI 10.1016/0022-2836(87)90200-2; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; RAPRAEGER AC, 1983, J BIOL CHEM, V258, P3632; RYBAK SM, 1987, BIOCHEM BIOPH RES CO, V146, P1240, DOI 10.1016/0006-291X(87)90781-9; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SCHWARTZ NB, 1977, J BIOL CHEM, V252, P6316; SHAPIRO R, 1989, BIOCHEMISTRY-US, V28, P7401, DOI 10.1021/bi00444a038; SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P3527, DOI 10.1021/bi00360a008; SHAPIRO R, 1987, BIOCHEMISTRY-US, V26, P5141, DOI 10.1021/bi00390a037; SHAPIRO R, 1987, P NATL ACAD SCI USA, V84, P2238, DOI 10.1073/pnas.84.8.2238; SHAPIRO R, 1988, ANAL BIOCHEM, V175, P450, DOI 10.1016/0003-2697(88)90569-6; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SONCIN F, 1992, P NATL ACAD SCI USA, V89, P2232, DOI 10.1073/pnas.89.6.2232; STRYDOM DJ, 1985, BIOCHEMISTRY-US, V24, P5486, DOI 10.1021/bi00341a031; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0; TERRANOVA VP, 1982, CANCER RES, V42, P2265; TWINING SS, 1984, ANAL BIOCHEM, V143, P30, DOI 10.1016/0003-2697(84)90553-0; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YAMAGISHITA M, 1987, METHOD ENZYMOL, V138, P279	50	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8999	9005						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510698				2022-12-27	WOS:A1994NB41100058
J	RILEY, GR; CORELL, RA; STUART, K				RILEY, GR; CORELL, RA; STUART, K			MULTIPLE GUIDE RNAS FOR IDENTICAL EDITING OF TRYPANOSOMA-BRUCEI APOCYTOCHROME-B MESSENGER-RNA HAVE AN UNUSUAL MINICIRCLE LOCATION AND ARE DEVELOPMENTALLY-REGULATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETOPLASTID MITOCHONDRIA; LEISHMANIA-TARENTOLAE; AFRICAN TRYPANOSOME; NUCLEOTIDE-SEQUENCE; NADH DEHYDROGENASE; MESSENGER-RNA; DNA; TRANSCRIPTS; AMPLIFICATION; ENCODE	We identified four different guide RNAs (gRNAs) that specify identical editing of Typanosoma brucei apocytochrome b (CYb) mRNA, which indicates gRNA redundancy in T. brucei. All four gRNAs appear functional since they occur in chimeras, some of which contain an interesting gRNA 3' ''extension.'' The gRNAs are encoded in different minicircles, rather than maxicircles as in other species. However, these gRNA genes are not between 18-base pair repeats as are the other minicircle gRNA genes in T. brucei. The three minicircles cloned contain the same gRNA genes, one of which is substantially diverged, all in the same order, indicating that they are related. CYb gRNA is less abundant in procyclic than bloodstream forms. Procyclic forms contain abundant edited CYb mRNA unlike bloodstream forms thus suggesting that CYb mRNA editing may be regulated at the level of gRNA utilization.	SEATTLE BIOMED RES INST,SEATTLE,WA 98109	Center for Infectious Disease Research					NIGMS NIH HHS [1 F32 GM14126-01A1, GM42188] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014126] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BHAT GJ, 1991, NUCLEIC ACIDS RES, V19, P398, DOI 10.1093/nar/19.2.398; BIENEN EJ, 1991, MOL BIOCHEM PARASIT, V45, P185, DOI 10.1016/0166-6851(91)90085-K; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKSON AB, 1989, J BIOL CHEM, V264, P17770; CORELL RA, 1993, NUCLEIC ACIDS RES, V21, P4313, DOI 10.1093/nar/21.18.4313; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; FEAGIN JE, 1990, J BIOL CHEM, V265, P19373; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; FEAGIN JE, 1988, MOL CELL BIOL, V8, P1259, DOI 10.1128/MCB.8.3.1259; FEAGIN JE, 1987, M COLD SPRINGS HARBO, P113; Fourney R.M., 1988, FOCUS, V10, P5; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; JASMER DP, 1986, MOL BIOCHEM PARASIT, V18, P257, DOI 10.1016/0166-6851(86)90084-8; JASMER DP, 1986, MOL BIOCHEM PARASIT, V18, P321, DOI 10.1016/0166-6851(86)90089-7; KOSLOWSKY DJ, 1991, CELL, V67, P537, DOI 10.1016/0092-8674(91)90528-7; KOSLOWSKY DJ, 1992, MOL CELL BIOL, V12, P2043, DOI 10.1128/MCB.12.5.2043; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; Maniatis T., 1982, MOL CLONING; MARINI JC, 1980, J BIOL CHEM, V255, P4976; MYLER PJ, 1993, NUCLEIC ACIDS RES, V21, P687, DOI 10.1093/nar/21.3.687; POLLARD VW, 1991, MOL CELL BIOL, V11, P1668, DOI 10.1128/MCB.11.3.1668; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; READ LK, 1992, NUCLEIC ACIDS RES, V20, P2341, DOI 10.1093/nar/20.9.2341; READ LK, 1992, J BIOL CHEM, V267, P1123; ROHRER SP, 1987, CELL, V49, P625, DOI 10.1016/0092-8674(87)90538-1; SIMPSON L, 1987, J BIOL CHEM, V262, P6182; SOLLNERWEBB B, 1992, NATURE, V356, P743, DOI 10.1038/356743a0; SOUZA AE, 1992, MOL CELL BIOL, V12, P2100, DOI 10.1128/MCB.12.5.2100; SPENCER E, 1978, P NATL ACAD SCI USA, V75, P4793, DOI 10.1073/pnas.75.10.4793; STUART K, 1983, J CELL BIOCHEM, V23, P13, DOI 10.1002/jcb.240230103; STUART K, 1984, J PARASITOL, V70, P747, DOI 10.2307/3281757; STUART K, 1979, PLASMID, V2, P520, DOI 10.1016/0147-619X(79)90051-9; STUART K, 1991, ANNU REV MICROBIOL, V45, P327, DOI 10.1146/annurev.mi.45.100191.001551; STURM NR, 1992, CELL, V70, P469, DOI 10.1016/0092-8674(92)90171-8; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x	46	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6101	6108						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509798				2022-12-27	WOS:A1994MY84000094
J	KALAB, P; VISCONTI, P; LECLERC, P; KOPF, GS				KALAB, P; VISCONTI, P; LECLERC, P; KOPF, GS			P95, THE MAJOR PHOSPHOTYROSINE-CONTAINING PROTEIN IN MOUSE SPERMATOZOA, IS A HEXOKINASE WITH UNIQUE PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RAT-BRAIN HEXOKINASE; BINDING REGULATORY PROTEIN; INDUCED ACROSOME REACTION; OUTER MITOCHONDRIAL-MEMBRANE; SODIUM DODECYL-SULFATE; ZONA-PELLUCIDA; PERTUSSIS TOXIN; CLONED CDNA; MAMMALIAN SPERM	Mouse sperm contain a major phosphotyrosine-containing protein of M(r) 95,000 (nonreducing conditions) which has been implicated as a sperm membrane receptor for the egg zona pellucida glycoprotein, ZP3 (Leyton, L., and Saling, P. (1989) Cell 57, 1123-1130; Leyton, L., LeGuen, P., Bunch, D., and Saling, P. (1992) Proc. Natl. Acad. Sci. U. S. A. 89,11692-11695). This protein was purified and subjected to limited tryptic digestion and subsequent amino acid analysis. Three sequenced peptides revealed 100% amino acid identity to a mouse hepatoma hexokinase (Arora, K. K., Fanciulli, M., and Pederson, P. L. (1990) J. Biol. Chem. 265, 6481-6488). The purified protein, which migrated at M(r) 116,000 under reducing conditions (p95/116), reacted with an antiserum to the purified rat brain hexokinase, type 1, and comigrated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with the purified rat brain enzyme under both nonreducing and reducing conditions. Unlike p95/116, the rat brain enzyme was not a phosphotyrosine-containing protein. The p95/116 protein could be immunoprecipitated with the hexokinase antiserum or an O-phosphotyrosine antibody. Limited tryptic digestion of the purified p95/116 and the rat brain enzyme generated subsets of identical peptides which reacted with the hexokinase antiserum. However, p95/116 also contained phosphotyrosine-containing peptides that were not present in the rat brain hexokinase. When different mouse tissues were probed with the hexokinase antiserum all tissues, with the exception of liver, contained immunoreactive protein. In contrast, only sperm and testis possessed a phosphotyrosine-containing form of hexokinase. These data suggest that the germ cell component of the testis possesses a unique tyrosine-phosphorylated form of hexokinase.	UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,DIV REPROD BIOL,RM 313,JOHN MORGAN BLDG,PHILADELPHIA,PA 19104	University of Pennsylvania			Kalab, Petr/B-2478-2009	Leclerc, Pierre/0000-0003-2053-3958	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD022732] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD028514, P01HD006274] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 22732, HD 28514, HD 06274] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS V, 1991, BIOCHEM BIOPH RES CO, V177, P1101, DOI 10.1016/0006-291X(91)90652-N; ADAMS V, 1991, BIOCHEM MED METAB B, V45, P271, DOI 10.1016/0885-4505(91)90032-G; ANDREONE TL, 1989, J BIOL CHEM, V264, P363; ARORA KK, 1990, J BIOL CHEM, V265, P6481; ARORA KK, 1993, ARCH BIOCHEM BIOPHYS, V304, P515, DOI 10.1006/abbi.1993.1384; Bessman S P, 1980, Curr Top Cell Regul, V16, P55; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BLEIL JD, 1983, DEV BIOL, V95, P317, DOI 10.1016/0012-1606(83)90032-5; BUNCH DO, 1991, BIOL REPROD, V44, P672, DOI 10.1095/biolreprod44.4.672; CLARSON KE, 1989, J BIOL CHEM, V264, P5348; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORONEL CE, 1987, BIOL REPROD, V37, P1097, DOI 10.1095/biolreprod37.5.1097; EKMAN P, 1988, ARCH BIOCHEM BIOPHYS, V261, P275, DOI 10.1016/0003-9861(88)90342-6; ENDO Y, 1987, DEV BIOL, V119, P210, DOI 10.1016/0012-1606(87)90222-3; ENDO Y, 1988, DEV BIOL, V129, P12, DOI 10.1016/0012-1606(88)90157-1; FELGNER PL, 1977, ARCH BIOCHEM BIOPHYS, V182, P282, DOI 10.1016/0003-9861(77)90309-5; FELGNER PL, 1979, J BIOL CHEM, V254, P4946; FERNANDEZ R, 1988, J GEN MICROBIOL, V134, P2493; FLORMAN HM, 1989, DEV BIOL, V135, P133, DOI 10.1016/0012-1606(89)90164-4; GELB BD, 1992, P NATL ACAD SCI USA, V89, P202, DOI 10.1073/pnas.89.1.202; GRIFFIN LD, 1991, GENOMICS, V11, P1014, DOI 10.1016/0888-7543(91)90027-C; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASHIMOTO E, 1982, J BIOL CHEM, V257, P727; HERRERO P, 1989, J GEN MICROBIOL, V135, P1209; HOPPE PC, 1976, BIOL REPROD, V15, P39, DOI 10.1095/biolreprod15.1.39; HUANG CL, 1989, J BIOL CHEM, V264, P4391; IMAMURA K, 1988, J BIOL CHEM, V263, P14093; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KATZEN HM, 1965, P NATL ACAD SCI USA, V54, P1218, DOI 10.1073/pnas.54.4.1218; KLIGMAN I, 1991, DEV BIOL, V145, P344, DOI 10.1016/0012-1606(91)90133-N; KOPF GS, 1986, J BIOL CHEM, V261, P7327; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MA, 1989, GAMETE RES, V24, P303, DOI 10.1002/mrd.1120240307; LEE MA, 1985, BIOL REPROD, V33, P235, DOI 10.1095/biolreprod33.1.235; LEE MA, 1992, MOL REPROD DEV, V31, P78, DOI 10.1002/mrd.1080310114; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LEYTON L, 1992, P NATL ACAD SCI USA, V89, P11692, DOI 10.1073/pnas.89.24.11692; LEYTON L, 1993, J REPROD DEV S, V39, P57; LIANG M, 1991, J BIOL CHEM, V266, P13342; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; MORI C, 1993, BIOL REPROD, V49, P191, DOI 10.1095/biolreprod49.2.191; NISHI S, 1988, BIOCHEM BIOPH RES CO, V157, P937, DOI 10.1016/S0006-291X(88)80964-1; NOLAND T D, 1988, Biology of Reproduction, V38, P94; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAL N, 1988, BIOCHEM BIOPH RES CO, V154, P450, DOI 10.1016/0006-291X(88)90707-3; PARRISH JJ, 1989, BIOL REPROD, V41, P683, DOI 10.1095/biolreprod41.4.683; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; POLAKIS PG, 1984, ARCH BIOCHEM BIOPHYS, V234, P341, DOI 10.1016/0003-9861(84)90279-0; POLAKIS PG, 1985, ARCH BIOCHEM BIOPHYS, V236, P328, DOI 10.1016/0003-9861(85)90633-2; SALINOVICH O, 1986, ANAL BIOCHEM, V156, P341, DOI 10.1016/0003-2697(86)90263-0; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; SCHWAB DA, 1991, ARCH BIOCHEM BIOPHYS, V285, P365, DOI 10.1016/0003-9861(91)90373-Q; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; THELEN AP, 1991, ARCH BIOCHEM BIOPHYS, V286, P645, DOI 10.1016/0003-9861(91)90094-Y; Towbin H, 1979, P NATL ACAD SCI USA, V76, P4359; WARD CR, 1992, J BIOL CHEM, V267, P14061; WARD CR, 1993, DEV BIOL, V158, P9, DOI 10.1006/dbio.1993.1165; WASSARMAN PM, 1990, DEVELOPMENT, V108, P1; WILDE MW, 1992, MOL REPROD DEV, V31, P297, DOI 10.1002/mrd.1080310411; WILSON JE, 1978, TRENDS BIOCHEM SCI, V3, P124, DOI 10.1016/S0968-0004(78)80029-2; YANG LJ, 1991, J BIOL CHEM, V266, P22451; YANG LJ, 1993, J BIOL CHEM, V268, P3739; ZOLLER MJ, 1981, J BIOL CHEM, V256, P1837; 1989, PROBLOTT IMMOBILIZAT	67	162	164	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3810	3817						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508920				2022-12-27	WOS:A1994MV63100099
J	FOGUEL, D; WEBER, G				FOGUEL, D; WEBER, G			PRESSURE-INDUCED DISSOCIATION AND DENATURATION OF ALLOPHYCOCYANIN AT SUBZERO TEMPERATURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL DRIFT; REVERSIBLE DISSOCIATION; HYDROSTATIC-PRESSURE; QUATERNARY STRUCTURE; STABILITY; PROTEINS; ASSOCIATION; PHYCOCYANIN; EQUILIBRIUM; DILUTION	The thermodynamics of assembly of the allophycocyanin hexamer was examined employing hydrostatic pressures in the range of 1 bar to 2.4 kbar and temperatures of 20 to -12 degrees C, the latter made possible by the decrease of the freezing point of water under pressure. The existence of two processes, dissociation of the hexamer into dimers, (alpha beta)(3) --> 3 (alpha beta), and dissociation of the alpha beta dimers into monomers, (alpha beta)(3) --> alpha + beta have been recognized previously by changes in the absorbance and fluorescence of the tetrapyrrolic chromophores owing to added ligands. The same changes are observed in the absence of ligands at pressures of under 2.4 kbar and temperatures down to -12 degrees C. On decompression from 2.4 kbar at 0 degrees C, appreciable hysteresis and a persistent loss of 50% in the absorbance at 653 nm is observed, It results from the conformational drift of the isolated subunits and is reduced to 10% when the highest pressure is limited to 1.6 kbar, The thermodynamic parameters of the reaction alpha + beta --> alpha beta can be determined from pressure effects on perchlorate solutions of allophycocyanin, which consist of dimers alone, Their previous knowledge permits estimation, under suitable hypotheses, of the thermodynamic parameters of the reaction 3(alpha beta) --> (alpha beta(3) from the overall pressure effects on the hexamers. Both association reactions have positive enthalpy changes, and the whole hexamer assembly is made possible by the excess entropy.	UNIV ILLINOIS,SCH CHEM SCI,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign				Foguel, Debora/0000-0001-7312-7115	NIGMS NIH HHS [GM11223] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECK WF, 1992, J PHYS CHEM-US, V96, P4658, DOI 10.1021/j100190a094; CANAANI OD, 1980, BIOCHEMISTRY-US, V19, P2950, DOI 10.1021/bi00554a021; CHEN CH, 1978, BIOPHYS CHEM, V8, P203, DOI 10.1016/0301-4622(78)87002-1; CHEN CH, 1977, BIOPHYS CHEM, V7, P81, DOI 10.1016/0301-4622(77)87018-X; COOPER A, 1988, J MOL LIQ, V39, P196; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CSATORDAY K, 1984, BIOCHEMISTRY-US, V23, P6466, DOI 10.1021/bi00321a029; ERIJMAN L, 1993, BIOCHEMISTRY-US, V32, P5187, DOI 10.1021/bi00070a030; EROKHINA L G, 1974, Molekulyarnaya Biologiya (Moscow), V8, P651; EVERETT DH, 1955, T FARADAY SOC, V51, P167; FOGUEL D, 1992, BIOPHYS J, V63, P1613, DOI 10.1016/S0006-3495(92)81756-3; GRIKO YV, 1988, J MOL BIOL, V202, P127, DOI 10.1016/0022-2836(88)90525-6; GURTIN ME, 1968, ARCH RATION MECH AN, V28, P40, DOI 10.1007/BF00281562; HOLZWARTH AR, 1990, BIOPHYS J, V57, P132; HUANG C, 1987, BIOCHEMISTRY-US, V26, P243, DOI 10.1021/bi00375a033; KING L, 1986, BIOCHEMISTRY-US, V25, P3632, DOI 10.1021/bi00360a023; LAUFFER MA, 1975, ENTROPYDRIVEN PROCES; MACCOLL R, 1983, ARCH BIOCHEM BIOPHYS, V223, P24, DOI 10.1016/0003-9861(83)90567-2; MACCOLL R, 1981, ARCH BIOCHEM BIOPHYS, V208, P42, DOI 10.1016/0003-9861(81)90121-1; MACCOLL R, 1980, BIOCHEMISTRY-US, V19, P2817, DOI 10.1021/bi00553a043; MACCOLL R, 1971, ARCH BIOCHEM BIOPHYS, V146, P477, DOI 10.1016/0003-9861(71)90151-2; NEUMAN RC, 1973, J PHYS CHEM-US, V77, P2687, DOI 10.1021/j100640a025; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; PALADINI AA, 1981, REV SCI INSTRUM, V52, P419, DOI 10.1063/1.1136596; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612; RUAN K, 1989, BIOCHEMISTRY-US, V28, P2144, DOI 10.1021/bi00431a028; RUAN KC, 1993, BIOCHEMISTRY-US, V32, P6295, DOI 10.1021/bi00075a025; SCHEER H, 1977, Z NATURFORSCH C, V32, P513; SILVA JL, 1986, BIOCHEMISTRY-US, V25, P5780, DOI 10.1021/bi00367a065; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; TRUESDELL C, 1985, ELEMENTS CONTINUUM M, P199; WEBER G, 1995, J PHYS CHEM-US, V99, P1052, DOI 10.1021/j100003a031; WEBER G, 1986, BIOCHEMISTRY-US, V25, P3626, DOI 10.1021/bi00360a022; WEBER G, 1993, J PHYS CHEM-US, V97, P7108, DOI 10.1021/j100129a031; XU GJ, 1980, P NATL ACAD SCI USA, V79, P5268; ZILINSKAS BA, 1978, PHOTOCHEM PHOTOBIOL, V27, P587, DOI 10.1111/j.1751-1097.1978.tb07650.x	38	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28759	28766		10.1074/jbc.270.48.28759	http://dx.doi.org/10.1074/jbc.270.48.28759			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499398	hybrid			2022-12-27	WOS:A1995TH05600042
J	TARDIF, M; HUANG, S; REDMOND, T; SAFER, D; PRING, M; ZIGMOND, SH				TARDIF, M; HUANG, S; REDMOND, T; SAFER, D; PRING, M; ZIGMOND, SH			ACTIN POLYMERIZATION INDUCED BY GTP-GAMMA-S IN PERMEABILIZED NEUTROPHILS IS INDUCED AND MAINTAINED BY FREE BARBED ENDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHONUCLEAR LEUKOCYTES; F-ACTIN; CYTOCHALASIN-B; PROFILIN; CELLS; NUCLEATION; THYMOSIN-BETA-4; STIMULATION; FILAMENTS; PLATELETS	To address the mechanisms through which agonists stimulate actin polymerization, we examined the roles of monomer sequestering proteins and free barbed ends on actin polymerization induced by guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) in neutrophils permeabilized with streptolysin O. Addition of profilin (without GTP gamma S) caused a net decrease in F-actin. Thus, merely making profilin available in the cell was not sufficient to induce actin polymerization. On the other hand, addition of profilin hardly affected the polymerization induced by GTP gamma S, while thymosin beta(4) or DNase I decreased this polymerization. These data suggested that GTP gamma S induced polymerization by increasing the availability of barbed ends, In the presence of cytochalasin B, profilin did inhibit polymerization induced by GTP gamma S, demonstrating that GTP gamma S did not inhibit profilin's monomer sequestering ability. The F-actin induced by GTP gamma S was not limited by a time dependent loss of G-actin or G-proteins from permeabilized cells since, following stimulation with suboptimal concentrations of GTP gamma S, addition of more GTP gamma S induced further polymerization. Barbed ends remained free after F-actin reached plateau since (a) cytochalasin B caused depolymerization of induced F-actin and (b) profilin did not depolymerize induced F-actin unless the cells were first treated with cytochalasin to cap barbed ends. The data indicate that GTP gamma S maintains an increased level of F-actin by keeping at least a few barbed ends available for polymerization.	UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT CELL & DEV BIOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			Tardif, Marianne/AAA-5357-2019	Tardif, Marianne/0000-0003-4438-8281	NIAID NIH HHS [AI 19883] Funding Source: Medline; NIAMS NIH HHS [AR40840] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019883, R37AI019883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040840] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENGTSSON T, 1990, P NATL ACAD SCI USA, V87, P2921, DOI 10.1073/pnas.87.8.2921; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; BUSS F, 1992, CELL MOTIL CYTOSKEL, V22, P51, DOI 10.1002/cm.970220106; CANO ML, 1991, J CELL BIOL, V115, P677, DOI 10.1083/jcb.115.3.677; CANO ML, 1992, CELL MOTIL CYTOSKEL, V21, P147, DOI 10.1002/cm.970210208; CANO ML, 1992, J CELL BIOL, V116, P1123, DOI 10.1083/jcb.116.5.1123; Carlier Marie-France, 1994, Seminars in Cell Biology, V5, P183, DOI 10.1006/scel.1994.1023; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CARSON M, 1986, J CELL BIOL, V103, P2707, DOI 10.1083/jcb.103.6.2707; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; CONDEELIS J, 1988, CELL MOTIL CYTOSKEL, V10, P77, DOI 10.1002/cm.970100113; DOWNEY GP, 1989, BIOCHEM BIOPH RES CO, V164, P700, DOI 10.1016/0006-291X(89)91516-7; FECHHEIMER M, 1993, J CELL BIOL, V123, P1, DOI 10.1083/jcb.123.1.1; GIULIANO KA, 1994, J CELL BIOL, V124, P971, DOI 10.1083/jcb.124.6.971; HALL AL, 1989, J CELL BIOL, V109, P2207, DOI 10.1083/jcb.109.5.2207; HANDEL SE, 1990, J CELL SCI, V97, P325; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HOWARD TH, 1985, CELL MOTIL CYTOSKEL, V5, P545, DOI 10.1002/cm.970050609; JANMEY PA, 1991, METHOD ENZYMOL, V196, P92; KAISER DA, 1989, CELL MOTIL CYTOSKEL, V14, P251, DOI 10.1002/cm.970140211; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; Machesky Laura M., 1993, Trends in Cell Biology, V3, P381, DOI 10.1016/0962-8924(93)90087-H; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; NACHMIAS VT, 1993, EUR J CELL BIOL, V61, P314; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; POLLARD TD, 1986, J CELL BIOCHEM, V31, P87, DOI 10.1002/jcb.240310202; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; REDMOND T, 1994, J BIOL CHEM, V269, P21657; ROSENBLATT J, 1995, MOL BIOL CELL, V6, P227, DOI 10.1091/mbc.6.2.227; SAFER D, 1990, P NATL ACAD SCI USA, V87, P2536, DOI 10.1073/pnas.87.7.2536; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; SANDERS MC, 1990, J CELL BIOL, V110, P359, DOI 10.1083/jcb.110.2.359; SOHN RH, 1994, BIOESSAYS, V16, P465, DOI 10.1002/bies.950160705; SOUTHWICK FS, 1986, J BIOL CHEM, V261, P14191; SULLIVAN SJ, 1980, J CELL BIOL, V85, P703, DOI 10.1083/jcb.85.3.703; THERRIEN S, 1989, J CELL BIOL, V109, P1125, DOI 10.1083/jcb.109.3.1125; TILNEY LG, 1983, J CELL BIOL, V97, P113; WEBER A, 1992, BIOCHEMISTRY-US, V31, P6179, DOI 10.1021/bi00142a002; WHITE JR, 1983, J BIOL CHEM, V258, P4041; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YOUNG CL, 1990, BIOCHEMISTRY-US, V29, P2232, DOI 10.1021/bi00461a005	44	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28075	28083						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499294				2022-12-27	WOS:A1995TG21000019
J	KHACHIGIAN, LM; WILLIAMS, AJ; COLLINS, T				KHACHIGIAN, LM; WILLIAMS, AJ; COLLINS, T			INTERPLAY OF SP1 AND EGR-1 IN THE PROXIMAL PLATELET-DERIVED GROWTH-FACTOR-A-CHAIN PROMOTER IN CULTURED VASCULAR ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILMS-TUMOR LOCUS; GENE; REGION; TRANSCRIPTION; SEQUENCE; PRODUCT; BINDING; CDNA; WT1; LOCALIZATION	The platelet-derived growth factor (PDGF) A-chain has been implicated in the initiation and progression of vascular occlusive lesions. The elements in the human PDGF-A promoter that mediate increased expression of the gene in vascular endothelial cells have not been identified. A potent inducer of PDGF-A expression in endothelial cells is phorbol 12-myristate 13-acetate (PMA). 5'-Deletion and transfection analysis revealed that a G+C-rich region in the proximal PDGF-A promoter is required for PMA-inducible gene expression. This region bears overlapping consensus recognition se quences for Sp1 and Egr-1. PMA induces Egr-1 mRNA expression within 1 h, whereas PDGF-A transcript levels increase after 2-4 h. Constitutive levels of Sp1 are not altered over 24 h. A specific nucleoprotein complex is formed when an oligonucleotide bearing the G+C-rich element is incubated with nuclear extracts from PMA-treated cells. The temporal appearance of this complex is consistent with the transient increase in Egr-1 transcripts. Antibodies to Egr-1 completely supershift the PMA-induced complex. Interestingly, increased nuclear levels of Egr-1 attenuate the ability of Sp1 to interact with the oligonucleotide, implicating competition between Egr-1 and Sp1 for the G+C-rich element. Binding studies with recombinant proteins demonstrate that Egr-1 can displace Sp1 from this region. Insertion of the G+C-rich element into a hybrid promoter-reporter construct confers PMA inducibility on the construct. Mutations that abolish Egr-1 binding also abrogate expression induced by PMA or overexpressed Egr-1. These findings demonstrate that PMA-induced Egr-1 displaces Sp1 from the G+C-rich element and activates expression driven by the PDGF-A proximal promoter in endothelial cells. The Sp1/Egr-1 displacement mechanism may be an important regulatory circuit in the control of inducible gene expression in vascular endothelial cells.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV VASC RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035716, R37HL035716] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 35716, HL 45462] Funding Source: Medline; PHS HHS [P01 36028] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BHANDARI B, 1995, J BIOL CHEM, V270, P5541, DOI 10.1074/jbc.270.10.5541; BONTHRON D, 1992, GENOMICS, V13, P257, DOI 10.1016/0888-7543(92)90240-S; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; CAO XM, 1993, J BIOL CHEM, V268, P16949; COLLINS T, 1987, NATURE, V328, P621, DOI 10.1038/328621a0; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ESPOSITO F, 1994, BIOCHEM J, V301, P649, DOI 10.1042/bj3010649; FAZIO MJ, 1991, J INVEST DERMATOL, V97, P281, DOI 10.1111/1523-1747.ep12480380; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; JOHN S, 1995, MOL CELL BIOL, V15, P1786; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAETZEL DM, 1994, BIOCHEM J, V301, P321, DOI 10.1042/bj3010321; KANAZASHI S, 1994, MOL IMMUNOL, V31, P21; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KHACHIGIAN LM, 1993, PLATELETS, V4, P304, DOI 10.3109/09537109309013233; KIM SJ, 1989, J BIOL CHEM, V264, P402; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; LARSEN FG, 1994, J INVEST DERMATOL, V102, P730, DOI 10.1111/1523-1747.ep12375840; LIN XH, 1992, J BIOL CHEM, V267, P25614; MACKMAN N, 1989, BIOCHEMISTRY-US, V28, P1755, DOI 10.1021/bi00430a050; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MINOWA T, 1994, J BIOL CHEM, V269, P11656; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Raines E.W., 1990, PEPTIDE GROWTH FACTO, DOI [10.1007/978-3-642-49295-2_5, DOI 10.1007/978-3-642-49295-2_5]; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; ROSS R, 1993, NATURE, V363, P801; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ A, 1991, GENE, V98, P295, DOI 10.1016/0378-1119(91)90189-I; SHNGU T, 1994, J BIOL CHEM, V269, P32551; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; TAKIMOTO Y, 1995, BBA-GENE STRUCT EXPR, V1260, P176, DOI 10.1016/0167-4781(94)00197-B; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TONG BD, 1987, NATURE, V328, P619, DOI 10.1038/328619a0; WANG ZY, 1992, J BIOL CHEM, V267, P17022; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WILLIAMS T, 1989, GENE DEV, V3, P1507	48	270	275	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27679	27686		10.1074/jbc.270.46.27679	http://dx.doi.org/10.1074/jbc.270.46.27679			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499234	hybrid			2022-12-27	WOS:A1995TE73600045
J	KIM, MH; PETERSON, DO				KIM, MH; PETERSON, DO			OCT-1 PROTEIN PROMOTES FUNCTIONAL TRANSCRIPTION COMPLEX ASSEMBLY ON THE MOUSE MAMMARY-TUMOR VIRUS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; RNA POLYMERASE-II; NEGATIVE REGULATORY ELEMENT; HORMONE-RESPONSIVE PROMOTER; GLUCOCORTICOID RECEPTOR; ACTIVATION DOMAINS; DNA-SEQUENCES; POU DOMAIN; INITIATION; BINDING	The ubiquitous transcription factor Oct-1 stimulates basal transcription from the mouse mammary tumor virus (MMTV) promoter by binding to octamer-related sequences present in the proviral long terminal repeat. The mechanism of transcriptional activation by Oct-1 was investigated using in vitro transcription assays with a HeLa cell nuclear extract depleted of endogenous Oct-1. Oct-1-mediated transcriptional activation could be reconstituted by addition of bacterially expressed recombinant Oct-1 protein. The stimulatory effect of Oct-1 was observed only when the protein was present during formation of transcription preinitiation complexes and not when added to fully assembled complexes. Furthermore, assembled MMTV preinitiation complexes were resistant to inhibition by a competitor oligonucleotide containing MMTV octamer-related elements that could eliminate Oct-1-mediated stimulation when present during the assembly process. The time course of transcription complex assembly revealed that Oct-1 increases the number of templates an which functional transcription complexes form. Finally, experiments designed to exploit the sensitivity of discrete steps in transcription complex assembly to the anionic detergent Sarkosyl demonstrated that Oct-1 must be present during formation of an early intermediate in the assembly process.	TEXAS A&M UNIV, DEPT BIOCHEM & BIOPHYS, COLLEGE STN, TX 77843 USA	Texas A&M University System; Texas A&M University College Station					NATIONAL CANCER INSTITUTE [R01CA032695] Funding Source: NIH RePORTER; NCI NIH HHS [CA32695] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANNWEILER A, 1993, J BIOL CHEM, V268, P2525; ARNOSTI DN, 1993, EMBO J, V12, P157, DOI 10.1002/j.1460-2075.1993.tb05641.x; ASO T, 1994, J BIOL CHEM, V269, P26575; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BUETTI E, 1994, MOL CELL BIOL, V14, P1191, DOI 10.1128/MCB.14.2.1191; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GEISSE S, 1982, EMBO J, V1, P1613, DOI 10.1002/j.1460-2075.1982.tb01363.x; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HSU CLL, 1988, J VIROL, V62, P4644, DOI 10.1128/JVI.62.12.4644-4652.1988; HUANG M, 1993, NUCLEIC ACIDS RES, V21, P5235, DOI 10.1093/nar/21.22.5235; HYNES N, 1983, P NATL ACAD SCI-BIOL, V80, P3637, DOI 10.1073/pnas.80.12.3637; KIM MH, 1995, J VIROL, V69, P4717, DOI 10.1128/JVI.69.8.4717-4726.1995; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LANGER SJ, 1988, MOL CELL BIOL, V8, P3872, DOI 10.1128/MCB.8.9.3872; LEE F, 1984, NUCLEIC ACIDS RES, V12, P4191, DOI 10.1093/nar/12.10.4191; LEE JW, 1991, J BIOL CHEM, V266, P24101; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MAJORS J, 1983, P NATL ACAD SCI-BIOL, V80, P5866, DOI 10.1073/pnas.80.19.5866; MINK S, 1990, NUCLEIC ACIDS RES, V18, P2017, DOI 10.1093/nar/18.8.2017; MORLEY KL, 1987, NUCLEIC ACIDS RES, V15, P6973, DOI 10.1093/nar/15.17.6973; OCONNOR M, 1995, VIROLOGY, V207, P77, DOI 10.1006/viro.1995.1053; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PIERCE J, 1993, J VIROL, V67, P415, DOI 10.1128/JVI.67.1.415-424.1993; REINBERG D, 1987, J BIOL CHEM, V262, P3310; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TOOHEY MG, 1990, J VIROL, V64, P4477, DOI 10.1128/JVI.64.9.4477-4488.1990; VERRIJZER CP, 1992, MOL CELL BIOL, V12, P542, DOI 10.1128/MCB.12.2.542; VONDERAHE D, 1985, NATURE, V313, P706, DOI 10.1038/313706a0; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x; ZWILLING S, 1994, NUCLEIC ACIDS RES, V22, P1655, DOI 10.1093/nar/22.9.1655	44	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27823	27828		10.1074/jbc.270.46.27823	http://dx.doi.org/10.1074/jbc.270.46.27823			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499253	hybrid			2022-12-27	WOS:A1995TE73600064
J	KUMAR, S; MINNICH, MD; YOUNG, PR				KUMAR, S; MINNICH, MD; YOUNG, PR			ST2/T1 PROTEIN FUNCTIONALLY BINDS TO 2 SECRETED PROTEINS FROM BALB/C 3T3 AND HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS BUT DOES NOT BIND INTERLEUKIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-1 RECEPTOR; IMMUNOGLOBULIN SUPERFAMILY; SOLUBLE RECEPTOR; GENE; EXPRESSION; PRODUCT; IDENTIFICATION; MECHANISM; ONCOGENE; VACCINIA	The ST2/T1 receptor, a homologue of the interleukin 1 receptor (IL-1R), was expressed in COS and Drosophila S2 cells as a human IgG-Fc fusion protein, While a type I IL-1RFc fusion protein bound human IL-1 in vitro, the ST2Fc fusion protein did not, Furthermore, IL-1 stimulated a synthetic interleukin-g promoter reporter gene that was cotransfected into Jurkat cells with a full-length IL-IR type I (IL-1RI) or a chimeric receptor composed of the IL-1RI extracellular domain and ST2 intracellular domain, In contrast, IL-1 did not stimulate the interleukin-8 promoter when cotransfected with a full-length ST2 or an ST2 extracellular/IL-1R intracellular domain fusion protein. Both IL-IRI and the IL-1R/ST2R chimeric receptor also activated a receptor-associated kinase and CSBP/p38 MAP kinase. Using ST2Fc receptor, we have identified, through receptor precipitation, receptor-dot blot and surface plasmon resonance, a putative ligand of ST2 secreted from Balb/c 3T3 and human umbilical vein endothelial cells. The putative ligand was also able to stimulate CSBP/p38 RAP kinase through the ST2 receptor, These results suggest that the ST2 is not an IL-1 receptor but rather has its own cognate ligand.	SMITHKLINE BEECHAM PHARMACEUT,RES & DEV,DEPT MOLEC IMMUNOL,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,RES & DEV,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline								ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; ANGELICHIO ML, 1991, NUCLEIC ACIDS RES, V19, P5037, DOI 10.1093/nar/19.18.5037; ASUBEL MF, 1987, CURRENT PROTOCOLS MO; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BERGERS G, 1994, EMBO J, V13, P1176, DOI 10.1002/j.1460-2075.1994.tb06367.x; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; EASTGATE JA, 1990, FEBS LETT, V260, P213, DOI 10.1016/0014-5793(90)80106-S; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GUIDA S, 1992, GENE, V111, P239, DOI 10.1016/0378-1119(92)90693-J; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARRIS KW, 1992, J BIOL CHEM, V267, P15205; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HEIDARAN MA, 1995, FASEB J, V9, P140, DOI 10.1096/fasebj.9.1.7821753; JOHANSON K, 1995, J BIOL CHEM, V270, P9459, DOI 10.1074/jbc.270.16.9459; JOHANSSON B, 1991, ANAL BIOCHEM, V198, P268; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; KUNO K, 1993, J BIOL CHEM, V268, P13510; LARSEN CG, 1989, BIOCHEM BIOPH RES CO, V160, P1403, DOI 10.1016/S0006-291X(89)80160-3; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MARTIN M, 1994, EUR J IMMUNOL, V24, P1566, DOI 10.1002/eji.1830240717; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; REIKERSTORFER A, 1995, J BIOL CHEM, V270, P17645, DOI 10.1074/jbc.270.30.17645; ROBLER U, 1995, DEV BIOL, V168, P86; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; SYMONS JA, 1991, J EXP MED, V174, P1251, DOI 10.1084/jem.174.5.1251; SYMONS JA, 1990, FEBS LETT, V272, P133, DOI 10.1016/0014-5793(90)80466-V; TAKAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1178, P194, DOI 10.1016/0167-4889(93)90009-E; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; TOMINAGA S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P1, DOI 10.1016/0167-4781(91)90029-L; WERENSKIOLD AK, 1992, EUR J BIOCHEM, V204, P1041, DOI 10.1111/j.1432-1033.1992.tb16726.x; WERENSKIOLD AK, 1995, CELL GROWTH DIFFER, V6, P171; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U	43	64	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27905	27913		10.1074/jbc.270.46.27905	http://dx.doi.org/10.1074/jbc.270.46.27905			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499265	hybrid			2022-12-27	WOS:A1995TE73600076
J	MAHADEVAN, D; YU, JC; SALDANHA, JW; THANKI, N; MCPHIE, P; UREN, A; LAROCHELLE, WJ; HEIDARAN, MA				MAHADEVAN, D; YU, JC; SALDANHA, JW; THANKI, N; MCPHIE, P; UREN, A; LAROCHELLE, WJ; HEIDARAN, MA			STRUCTURAL ROLE OF EXTRACELLULAR DOMAIN-1 OF ALPHA-PLATELET-DERIVED GROWTH-FACTOR (PDGF) RECEPTOR FOR PDGF-AA AND PDGF-BB BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-RECEPTOR; CRYSTAL-STRUCTURE; LIGAND-BINDING; DIMERIZATION; IDENTIFICATION; ACTIVATION; DEFINE; OCCURS; DIMER; AB	The purpose of this study was to bacterially express, purify, and refold combinations of the extracellular immunoglobulin (Ig)-like domains (2-3, 1-3, and 1-5) of the human alpha-platelet-derived growth factor receptor (alphaPDGFR) to characterize molecular interactions with its ligand, platelet-derived growth factor (PDGF). The far UV circular dichromism spectroscopy of the alpha-PDGFR extracellular domains (ECDs) revealed a predominantly beta-sheet protein, with a structure consistent with folded Ig-like domains. The addition of PDGF-BB to these ECD types changed the conformation of all three types with a decrease in mean residue ellipticity in the following rank order: 1-5=1-3 greater than 2-3. In striking contrast, addition of PDGF-AA to these ECD types markedly changed the conformation of ECD 2-3, by an increased mean residue ellipticity but no changes were observed for ECDs 1-3 and 1-5. PDGF-AA bound to the immobilized ECD types 2-3, 1-3, and 1-5 at concentrations of 20, 11, and 7.5nM, respectively. In contrast, PDGF-BB bound the ECD types 2-3, 1-3, and 1-5 at concentrations of 3,3, and 2.2 nM, respectively. Scatchard analysis of binding studies using labeled ECDs indicated that PDGF-BB bound ECD 1-3 and ECD 2-3 with K-D values of 74 and 72 nM, respectively. While, PDGF-AA bound ECD 1-3 and ECD 2-3 with K-D values of 33 and 87 nM, respectively. Therefore, our results indicated that the loss of ECD 1 impaired the binding affinity of alphaPDGFR ECD 1-3 toward PDGF-AA without having a similar effect on PDGF-BB binding. Together all of our data suggest that ECD 1 is differentially required for proper orientation of PDGF-AA but not PDGF-BB binding determinant within ECDs 2 and 3	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; NIDDK,BIOCHEM PHARMACOL LAB,BETHESDA,MD 20892; MRC,CTR COLLABORAT,LONDON,ENGLAND	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUAN DSR, 1991, J BIOL CHEM, V266, P413; Eriksson A, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008867; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1992, J BIOL CHEM, V267, P2884; HEIDARAN MA, 1995, FASEB J, V9, P140, DOI 10.1096/fasebj.9.1.7821753; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HERREN B, 1993, J BIOL CHEM, V268, P15088; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; JENSEN RA, 1992, BIOCHEMISTRY-US, V31, P10887, DOI 10.1021/bi00159a032; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; LAROCHELLE WJ, 1992, J BIOL CHEM, V267, P17074; LAROCHELLE WJ, 1993, CELL GROWTH DIFFER, V4, P547; MAHADEVAN D, 1994, BIOCHEMISTRY-US, V33, P746, DOI 10.1021/bi00169a016; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MIDDAUGH CR, 1992, BIOCHEMISTRY-US, V31, P9016, DOI 10.1021/bi00152a044; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PRASAD K, 1986, BIOCHEMISTRY-US, V25, P5214, DOI 10.1021/bi00366a035; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; TIMM DE, 1992, PROTEIN SCI, V1, P236; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU JC, 1994, J BIOL CHEM, V269, P10668	32	21	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27595	27600		10.1074/jbc.270.46.27595	http://dx.doi.org/10.1074/jbc.270.46.27595			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499222	hybrid			2022-12-27	WOS:A1995TE73600033
J	SCHWEMMLE, M; STAEHELI, P				SCHWEMMLE, M; STAEHELI, P			THE INTERFERON-INDUCED 67-KDA GUANYLATE-BINDING PROTEIN (HGBP1) IS A GTPASE THAT CONVERTS GTP TO GMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MX1 PROTEIN; CELLULAR PROTEINS; DOMAIN; MOTIF; P21; MECHANISM; MEMBRANE; VIRUS; GDP	hGBP1 is an interferon-induced 67-kDa protein of human cells that readily binds to agarose-immobilized GTP, GDP, and GMP but not to other nucleotides. We cloned hGBP1 cDNA into a histidine-tagging vector, produced recombinant hGBP1 with 6 extra histidine residues at its N terminus in Escherichia coli, and purified this protein to near homogeneity from bacterial lysates. Purified hGBP1 hydrolyzed radiolabeled GTP but failed to hydrolyze ATP, UTP, or CTP at significant rates. Unexpectedly, the principal product of the GTP hydrolysis reaction was GMP rather than GDP. Although significant amounts of GDP were produced when the reaction was performed at 15-degrees-C, GDP could not serve as substrate or as inhibitor of hGBP1. hGBP1 lacked guanylate cyclase and guanylyltransferase activity. Degradation of GTP to GMP most likely occurred via two consecutive cleavages of single phosphate groups, because pyrophosphate was not a reaction product, and because hGBP1 failed to hydrolyze GTPgammaS. In vitro modification assays with radiolabeled mevalonic acid and farnesyl pyrophosphate showed that the CaaX motif at the C terminus of hGBP1 functions as an isoprenylation signal. Thus, hGBP1 is a GTPase with novel biochemical properties that may be membrane-associated in eukaryotic cells.	UNIV FREIBURG,INST MIKROBIOL & HYG,VIROL ABT,HERMANN HERDER STR 11,D-79008 FREIBURG,GERMANY	University of Freiburg								BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHENG YSE, 1991, MOL CELL BIOL, V11, P4717, DOI 10.1128/MCB.11.9.4717; CHENG YSE, 1983, J BIOL CHEM, V258, P7746; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HORISBERGER MA, 1992, J VIROL, V66, P4705, DOI 10.1128/JVI.66.8.4705-4709.1992; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; NAKAYAMA M, 1991, J BIOL CHEM, V266, P21404; NAKAYAMA M, 1992, VIRUS RES, V22, P227, DOI 10.1016/0168-1702(92)90054-D; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PITOSSI F, 1993, J VIROL, V67, P6726, DOI 10.1128/JVI.67.11.6726-6732.1993; PROCHAZKA M, 1985, VIROLOGY, V145, P273, DOI 10.1016/0042-6822(85)90160-6; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; STAEHELI P, 1984, VIROLOGY, V137, P135, DOI 10.1016/0042-6822(84)90016-3; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; Staeheli Peter, 1993, Trends in Cell Biology, V3, P268, DOI 10.1016/0962-8924(93)90055-6; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; ZWEIG G, 1971, PAPER CHROMATOGRAPHY, V2	30	125	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11299	11305						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512561				2022-12-27	WOS:A1994NF96600051
J	DHAR, A; SHUKLA, SD				DHAR, A; SHUKLA, SD			ELECTROTRANSJECTION OF PP60(V-SRC) MONOCLONAL-ANTIBODY INHIBITS ACTIVATION OF PHOSPHOLIPASE-C IN PLATELETS - A NEW MECHANISM FOR PLATELET-ACTIVATING-FACTOR RESPONSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; EXPRESS HIGH-LEVELS; PROTEIN-PHOSPHORYLATION; SIGNAL TRANSDUCTION; PP60C-SRC; CELLS; THROMBIN; STIMULATION; ONCOGENES; P60C-SRC	Antibodies to pp60(v-src)and phosphotyrosine were introduced into rabbit platelets using an electropermeabilization technique. The presence of these antibodies inside platelets was detected by flow cytometry. Platelet-activating factor (PAF)-stimulated phospholipase C activity (inositol phosphate production) and aggregation were dramatically inhibited in platelets transjected with either of these antibodies. Incubation of these antibodies with intact cells (i.e. nonpermeabilized) or electrotransjection of several nonspecific antibodies/agents (e.g. goat anti-mouse IgG, mouse serum, human platelet glycoprotein Tb monoclonal antibody, and fetal calf serum) into platelets had no effect on the PAF responses. trpE (another isotype matched control antibody of pp60(v-src) and pp56(lck) polyclonal antibody (another src-related kinase not present in platelets) also had no effect on PAF-induced aggregation and inositol phosphate production in permeabilized platelets. This indicates that the effect of internalized pp60(v-src) antibody is direct and specific in platelets. Stimulation of platelets by PAF increased the association and phosphorylation of both pp60(c-src) (60 kDa) and phospholipase C gamma 1 (145 kDa). This study provides the first evidence in platelets for a direct and specific involvement of pp60(c-src) in PAF-mediated phospholipase C activation and aggregation response.	UNIV MISSOURI,SCH MED,DEPT PHARMACOL,COLUMBIA,MO 65212	University of Missouri System; University of Missouri Columbia					NIDDK NIH HHS [R01 DK35170, DK07182] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035170] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAKRABARTI R, 1989, J BIOL CHEM, V264, P15494; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DHAR A, 1990, MOL PHARMACOL, V37, P519; DHAR A, 1993, BRIT J HAEMATOL, V84, P1, DOI 10.1111/j.1365-2141.1993.tb03018.x; DHAR A, 1991, J BIOL CHEM, V266, P1877; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; JAMIESON GA, 1988, PLATELET MEMBRANE RE; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; MICHELSON AD, 1991, BLOOD, V77, P770; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; THURSTON AW, 1992, BIOCHEM BIOPH RES CO, V185, P1062, DOI 10.1016/0006-291X(92)91734-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUY FPD, 1983, NATURE, V305, P435; TUZYNSKI GP, 1987, PLATELET RESPONSES M, V2, P187; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WILSON AK, 1991, AM J PHYSIOL, V260, pC355, DOI 10.1152/ajpcell.1991.260.2.C355; ZHU CY, 1993, LIFE SCI, V53, P175, DOI 10.1016/0024-3205(93)90665-P	33	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9123	9127						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510703				2022-12-27	WOS:A1994NB41100076
J	ZHANG, HL; DIGATE, RJ				ZHANG, HL; DIGATE, RJ			THE CARBOXYL-TERMINAL RESIDUES OF ESCHERICHIA-COLI DNA TOPOISOMERASE-III ARE INVOLVED IN SUBSTRATE-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOTYPIC SELECTION; PROTEIN-OMEGA; CLEAVAGE; ENZYME; SEQUENCE; COMPLEX; GYRASE	The nucleic acid-binding domain of Escherichia coli DNA topoisomerase III (Topo III) has been identified using a selection procedure designed to isolate inactive Topo III polypeptides. Deletion of this binding domain, contained in the carboxyl terminus of Topo III, results in a drastic reduction in the ability of the enzyme to bind to single-stranded DNA and RNA substrates. Successive truncation of the enzyme within this region results in the gradual loss of nucleic acid binding activity and in a gradual change in the mechanism of Topo III catalyzed relaxation of negatively supercoiled DNA. The reduction of nucleic acid binding activity of the truncated polypeptides does not result in a loss of cleavage site specificity for the enzyme, suggesting that other amino acids are involved in the positioning of the nucleic acid within the nicking/closing site of the topoisomerase.	UNIV MARYLAND,SCH PHARM,DEPT BIOMED CHEM,BALTIMORE,MD 21201; UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR MED BIOTECHNOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	ZHANG, HL (corresponding author), UNIV MARYLAND,MOLEC & CELL BIOL PROGRAM,BALTIMORE,MD 21201, USA.				NCRR NIH HHS [RR05770-14] Funding Source: Medline; NIGMS NIH HHS [GM48445] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048445, R29GM048445] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; DEAN F, 1984, THESIS U CHICAGO; DEPEW RE, 1978, J BIOL CHEM, V253, P511; DIGATE RJ, 1992, J BIOL CHEM, V267, P20532; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HIASA H, 1994, J BIOL CHEM, V269, P2093; KATO JI, 1990, CELL, V63, P3967; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MORHAM SG, 1990, GENE DEV, V4, P515, DOI 10.1101/gad.4.4.515; PASTORCIC M, 1982, THESIS U CHICAGO; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SRIVENUGOPAL KS, 1984, BIOCHEMISTRY-US, V23, P1899, DOI 10.1021/bi00304a002; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; TSEDINH YC, 1986, J MOL BIOL, V191, P321, DOI 10.1016/0022-2836(86)90129-4; TSEDINH YC, 1991, J BIOL CHEM, V266, P14317; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; Wang JC, 1990, DNA TOPOLOGY ITS BIO	30	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9052	9059						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510701				2022-12-27	WOS:A1994NB41100066
J	GRONOWSKI, AM; ROTWEIN, P				GRONOWSKI, AM; ROTWEIN, P			RAPID CHANGES IN NUCLEAR-PROTEIN TYROSINE PHOSPHORYLATION AFTER GROWTH-HORMONE TREATMENT IN-VIVO - IDENTIFICATION OF PHOSPHORYLATED MITOGEN-ACTIVATED PROTEIN-KINASE AND STAT91	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; MAP KINASE; FACTOR-I; C-FOS; GENE; INDUCTION; RAT; STIMULATION; FAMILY; MEMBER	Growth hormone (GH) plays a central role in regulating growth and intermediary metabolism in vertebrates, although the mechanisms by which GH initiates these actions are largely unknown. The GH receptor, a member of the cytokine receptor superfamily, does not demonstrate homology with any known tyrosine kinases. However, addition of GH to cells in vitro has been shown to stimulate tyrosine phosphorylation of various intracellular proteins including mitogen-activated protein kinases (MAP kinases) and the newly described Janus kinase, JAK2. Subsequent steps in GH-mediated signal transduction have not been delineated. In the present study, we have examined early events in GH action in vivo. Hypophysectomized juvenile male rats were treated with GH for 15, 30, or 60 min. Rat liver whole cell and nuclear extracts were prepared and analyzed via SDS-polyacrylamide gel electrophoresis and Western blotting techniques. GH rapidly stimulated the tyrosine phosphorylation of at least 8 nuclear proteins of 205, 91, 83, 80, 65, 53, 44, and 42 kDa, and caused the dephosphorylation of a single similar to 149-kDa protein. Using specific antibodies, we have identified three of these nuclear phosphoproteins as 42- and 44-kDa MAP kinases, and as STAT91, a 91-kDa component of the interferon-stimulated gene factor-3 protein complex. One consequence of the activation of STAT91 in the nucleus is the appearance of GH-stimulated DNA binding activity, as assessed by gel-mobility shift assay using an oligonucleotide containing a c-sis-inducible element from the c-fos prometer. These results show that nuclear protein tyrosine phosphorylation is a prominent early event in GH action in vivo and demonstrate a link between GH stimulated signal transduction and target gene expression.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007120, R01DK037449] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07120, 5-RO1-DK37449] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; FOLLI F, 1992, J BIOL CHEM, V267, P22171; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; HARPUR AG, 1992, ONCOGENE, V7, P1347; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LAMY F, 1993, J BIOL CHEM, V268, P8398; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MONTMINY M, 1993, SCIENCE, V261, P1694, DOI 10.1126/science.8397444; PAQUEREAU L, 1992, EUR J BIOCHEM, V209, P1053, DOI 10.1111/j.1432-1033.1992.tb17381.x; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHAUI K, 1993, SCIENCE, V261, P1744; SHAUI K, 1992, SCIENCE, V258, P1808; SILVA CM, 1993, ENDOCRINOLOGY, V133, P2307, DOI 10.1210/en.133.5.2307; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLOOTWEG MC, 1991, J MOL ENDOCRINOL, V6, P179, DOI 10.1677/jme.0.0060179; STREHLOW I, 1993, J BIOL CHEM, V268, P16590; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; YOON JB, 1990, J BIOL CHEM, V265, P19947	31	136	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7874	7878						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510676				2022-12-27	WOS:A1994NB40900010
J	IWATA, T; LEE, S; OISHI, O; AOYAGI, H; OHNO, M; ANZAI, K; KIRINO, Y; SUGIHARA, G				IWATA, T; LEE, S; OISHI, O; AOYAGI, H; OHNO, M; ANZAI, K; KIRINO, Y; SUGIHARA, G			DESIGN AND SYNTHESIS OF AMPHIPATHIC 3(10)-HELICAL PEPTIDES AND THEIR INTERACTIONS WITH PHOSPHOLIPID-BILAYERS AND ION-CHANNEL FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID BILAYERS; ANTIMICROBIAL ACTIVITY; CIRCULAR-DICHROISM; MODEL PEPTIDES; BASIC PEPTIDES; S4 SEGMENT; MEMBRANES; PROTEINS; HELIX; OLIGOPEPTIDES	It has been reported that a peptide corresponding to the S-4 segment in sodium channel protein is able to form voltage-dependent cation-selective ion channels (Tosteson, M. T., Auld, D. S., and Tosteson, D. C. (1989) Proc. Natl. Acad. Sci. U.S. A. 86, 707-710). However biological and other physical properties remain unexamined. In the present study, three peptides, H-(Ala-Arg-Leu)(8)-OH (ARL(8)), H-(Val-Arg-Leu)(8)-OH (VRL(8)), and H-(Leu-Arg-Leu)(8)-OH (LRL(8)) which were designed on the basis of the S-4 Segment and expected to form 3(10)-helix, were synthesized and examined with regard to conformational change by the interaction with membranes, membrane perturbation ability, ion channel formation, and antimicrobial activity. According to CD spectre, these peptides were found to form a 3(10)-helical structure in the presence of dipalmitoyl-DL-alpha-phosphatidylcholine/ dipalmitoyl-DL-alpha-phosphatidylglycerol (3:1) liposomes. The experiment of the peptide-induced leakage of carboxyfluorescein from Liposomes showed that all the peptides had a strong ability to perturb membranes. The peptides were able to form cation-selective ion channels in planar asolectin lipid bilayers. The conductances of the ion channels were small (similar to 2 picosiemens for VRL(8) and LRL(8) and similar to 23 picosiemens for ARL(8)), suggesting that the peptides produce narrow pores or wider pores with certain permeable barriers that are a portion of the whole channels. The differences in their conductances depend possibly on the sizes of the side chains of Ala, Val, and Leu residues. However, non of the peptides showed antimicrobial activity (minimum inhibitory concentrations, >50 mu g/ml). Here, we present the first evidence that the peptides can form 3(10)-helical structures with long chain lengths in a lipid bilayer environment.	FUKUOKA UNIV,FAC SCI,DEPT CHEM,JONAN KU,FUKUOKA 81401,JAPAN; KYUSHU UNIV,FAC SCI,DEPT CHEM,HIGASHI KU,FUKUOKA 812,JAPAN; KYUSHU UNIV,FAC PHARMACEUT SCI,HIGASHI KU,FUKUOKA 812,JAPAN	Fukuoka University; Kyushu University; Kyushu University			Anzai, Kazunori/C-8577-2009					AGAWA Y, 1991, J BIOL CHEM, V266, P20218; ANZAI K, 1991, BIOCHIM BIOPHYS ACTA, V1064, P256, DOI 10.1016/0005-2736(91)90310-5; ARNOTT S, 1966, J MOL BIOL, V21, P371, DOI 10.1016/0022-2836(66)90105-7; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; DUCLOHIER H, 1989, BIOPHYS J, V56, P1017, DOI 10.1016/S0006-3495(89)82746-8; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; KAISER ET, 1987, ANNU REV BIOPHYS BIO, V16, P561; KARLE IL, 1991, P NATL ACAD SCI USA, V88, P5307, DOI 10.1073/pnas.88.12.5307; KENNEDY DF, 1991, BIOCHEMISTRY-US, V30, P6541, DOI 10.1021/bi00240a026; KONIG W, 1970, CHEM BER-RECL, V103, P788, DOI 10.1002/cber.19701030319; LEE S, 1986, BIOCHIM BIOPHYS ACTA, V862, P211, DOI 10.1016/0005-2736(86)90485-2; MULVEY D, 1989, FEBS LETT, V257, P113, DOI 10.1016/0014-5793(89)81799-5; OIKI S, 1988, P NATL ACAD SCI USA, V85, P2393, DOI 10.1073/pnas.85.7.2393; ONO S, 1990, BIOCHIM BIOPHYS ACTA, V1022, P237, DOI 10.1016/0005-2736(90)90119-9; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V401, P317, DOI 10.1016/0005-2736(75)90233-3; PARK NG, 1992, BIOCHEMISTRY-US, V31, P12241, DOI 10.1021/bi00163a038; PAULING L, 1951, P NATL ACAD SCI USA, V37, P205, DOI 10.1073/pnas.37.4.205; RAPAPORT D, 1992, BIOCHEMISTRY-US, V31, P8868, DOI 10.1021/bi00152a025; SAKAKIBARA S, 1967, B CHEM SOC JPN, V40, P2164, DOI 10.1246/bcsj.40.2164; SUDHA TS, 1983, INT J PEPT PROT RES, V22, P464; SUENAGA M, 1989, BIOCHIM BIOPHYS ACTA, V981, P143, DOI 10.1016/0005-2736(89)90092-8; TONIOLO C, 1983, BIOPOLYMERS, V22, P1335, DOI 10.1002/bip.360220507; TOSTESON MT, 1989, P NATL ACAD SCI USA, V86, P707, DOI 10.1073/pnas.86.2.707; TOSTESON MT, 1981, BIOPHYS J, V36, P109, DOI 10.1016/S0006-3495(81)84719-4; WEINSTEIN JN, 1977, SCIENCE, V195, P489, DOI 10.1126/science.835007	29	54	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4928	4933						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508930				2022-12-27	WOS:A1994MX57100038
J	FILARDO, EJ; CHERESH, DA				FILARDO, EJ; CHERESH, DA			A BETA-TURN IN THE CYTOPLASMIC TAIL OF THE INTEGRIN ALPHA-V SUBUNIT INFLUENCES CONFORMATION AND LIGAND-BINDING OF ALPHA-V-BETA-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN-IIB; ASP-DIRECTED RECEPTOR; CELL-ADHESION; FIBRONECTIN RECEPTOR; VITRONECTIN RECEPTOR; GPIIB-IIIA; ELECTRON-MICROSCOPY; DOMAIN; FIBRINOGEN; SITE	Integrins undergo conformational alterations in response to extracellular or intracellular stimuli, suggesting that structural elements within their exo- and cytoplasmic domains cooperate during transmembrane signaling. In this report, we identify a beta turn in the cytoplasmic tail of the alpha v subunit that impacts the ligand binding and conformation of the alpha v beta 3 heterodimer. Cells expressing a mutant alpha v beta 3 heterodimer composed of a truncated alpha v subunit, alpha v1000, lacking 18 carboxyl-terminal amino acids exhibits wild-type receptor structure and function. However, a truncation mutant, alpha v995, lacking five additional residues (PPQEE), which define a beta turn, is deficient in vitronectin and fibrinogen adhesion. This alteration in adhesive function is associated with two detectable structural changes in the alpha v beta 3 heterodimer. First, the alpha v995 membrane-spanning light chain exhibits retarded electrophoretic mobility on SDS-polyacrylamide gels. Second, the alpha v995 beta 3 receptor shows an altered chymotryptic profile as measured by the loss of a 39-kDa proteolytic fragment from its ectodomain. These findings demonstrate that the ligand binding and structural properties of the intact alpha v beta 3 heterodimer can be influenced by a beta turn within the cytoplasmic tail of its alpha v subunit. The presence of homologous beta turns within other alpha subunit cytoplasmic tails suggests that this structural motif may play a role in regulating integrin-mediated bidirectional transmembrane signals.	SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				Filardo, Edward/0000-0002-3930-324X	NATIONAL CANCER INSTITUTE [R01CA050286, R37CA050286, R01CA045726] Funding Source: NIH RePORTER; NCI NIH HHS [CA50286, CA45726] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BOSSY B, 1991, EMBO J, V10, P2375, DOI 10.1002/j.1460-2075.1991.tb07776.x; BURGESS WH, 1980, BIOCHIM BIOPHYS ACTA, V623, P257, DOI 10.1016/0005-2795(80)90254-8; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COBURN J, 1993, P NATL ACAD SCI USA, V90, P7059, DOI 10.1073/pnas.90.15.7059; DAVIS LS, 1990, J IMMUNOL, V145, P785; DEDHAR S, 1987, J CELL BIOL, V105, P1175, DOI 10.1083/jcb.105.3.1175; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; FELDINGHABERMANN B, 1992, J BIOL CHEM, V267, P5070; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MERCURIO AM, 1988, J CELL BIOL, V107, P1873, DOI 10.1083/jcb.107.5.1873; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PEPINSKY RB, 1983, J VIROL, V45, P648, DOI 10.1128/JVI.45.2.648-658.1983; PONCZ M, 1987, J BIOL CHEM, V262, P8476; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; RELMAN D, 1990, CELL, V61, P1375, DOI 10.1016/0092-8674(90)90701-F; ROSE GD, 1978, NATURE, V272, P586, DOI 10.1038/272586a0; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STUPACK DG, 1992, EXP CELL RES, V203, P443, DOI 10.1016/0014-4827(92)90019-5; SUZUKI S, 1986, P NATL ACAD SCI USA, V83, P8614, DOI 10.1073/pnas.83.22.8614; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; YAMADA KM, 1990, CANCER RES, V50, P4485; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	55	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4641	4647						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508446				2022-12-27	WOS:A1994MW98900109
J	SAKAMOTO, K; EZASHI, T; MIWA, K; OKUDAASHITAKA, E; HOUTANI, T; SUGIMOTO, T; ITO, S; HAYAISHI, O				SAKAMOTO, K; EZASHI, T; MIWA, K; OKUDAASHITAKA, E; HOUTANI, T; SUGIMOTO, T; ITO, S; HAYAISHI, O			MOLECULAR-CLONING AND EXPRESSION OF A CDNA OF THE BOVINE PROSTAGLANDIN-F(2-ALPHA) RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOXANE-A2 RECEPTOR; CORPORA-LUTEA; PROSTAGLANDIN-F2-ALPHA; CELLS; POLYPHOSPHOINOSITIDES; HYDROLYSIS; ASTROCYTES; PROTEIN	Capitalizing on the significant sequence homology comprising the transmembrane motif regions of known prostanoid receptor family, we targeted the cloning of a cDNA clone for prostaglandin (PG) F2alpha receptor from a bovine corpus luteum cDNA library. By using several pairs of degenerated primers created from a common motif of transmembrane domains, polymerase chain reaction gave a clone SN463 carrying the homologous sequence, which covered transmembrane motif IV-VI of the thromboxane (TX) A2 receptor. This polymerase chain reaction product was used as a DNA probe for the following cross-hybridization, and a clone BC2211 carrying a 2.2-kilobase pair DNA insert was isolated. This clone encodes a protein of 362 amino acid residues (M(r) = 40,983) with seven potential transmembrane domains and represented significant overall sequence homology to human TXA2 receptor protein (34% in amino acid). Injection of the mRNA synthesized in vitro from the cloned cDNA into a Xenopus oocyte elicited electrophysiological response to PGF2alpha. Ligand binding displacement in membranes of mammalian COS-7 cells transfected with the cDNA indicated the rank order of affinity of the receptor to PGs: PGF2alpha > PGD2 > PGE2 > STA2, a TXA2 agonist. PGF2alpha activated inositol phosphate formation in COS-7 cells transfected with receptor cDNA. Northern blot analysis and in situ hybridization indicated that the PGF2alpha receptor mRNA is highly expressed and accumulated in corpus luteum. This is the first report on a successful cloning of functional receptor cDNA for PGF2alpha.	OSAKA BIOSCI INST, DEPT CELL BIOL, SUITA 565, JAPAN; KANSAI MED UNIV, DEPT ANAT, MORIGUCHI, OSAKA 570, JAPAN	Kansai Medical University								ANGGARD E, 1963, ACTA PHYSIOL SCAND, V59, P170; ANGGARD E, 1963, ACTA PHYSIOL SCAND, V58, P1, DOI 10.1111/j.1748-1716.1963.tb02622.x; BALAPURE AK, 1989, BIOCHEM PHARMACOL, V38, P2375, DOI 10.1016/0006-2952(89)90478-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAVIS JS, 1987, P NATL ACAD SCI USA, V84, P3728, DOI 10.1073/pnas.84.11.3728; DORFLINGER LJ, 1983, MOL CELL ENDOCRINOL, V33, P225, DOI 10.1016/0303-7207(83)90169-7; FUKAMI K, 1989, J BIOL CHEM, V264, P14985; HAKEDA Y, 1987, ENDOCRINOLOGY, V121, P1966, DOI 10.1210/endo-121-6-1966; HESKETH TR, 1985, NATURE, V313, P481, DOI 10.1038/313481a0; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HONDA A, 1993, J BIOL CHEM, V268, P7759; HORTON EW, 1976, PHYSIOL REV, V56, P595, DOI 10.1152/physrev.1976.56.4.595; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; ITO S, 1992, GLIA, V6, P67, DOI 10.1002/glia.440060109; ITO S, 1990, ADV PROSTAGLANDIN TH, V21, P371; JIMENEZDEASUA L, 1975, P NATL ACAD SCI USA, V72, P2724; KITANAKA J, 1991, BIOCHEM BIOPH RES CO, V178, P946, DOI 10.1016/0006-291X(91)90983-E; KYLDEN U, 1980, EUR J BIOCHEM, V109, P489, DOI 10.1111/j.1432-1033.1980.tb04820.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWRENCE RA, 1992, BRIT J PHARMACOL, V105, P271, DOI 10.1111/j.1476-5381.1992.tb14245.x; MINAMI T, 1992, PAIN, V50, P223, DOI 10.1016/0304-3959(92)90166-9; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOENNER M, 1987, BIOCHEM BIOPH RES CO, V146, P32, DOI 10.1016/0006-291X(87)90686-3; MONCADA S, 1985, GOODMAN GILMANS PHAR, P660; NAMBA T, 1992, BIOCHEM BIOPH RES CO, V184, P1197, DOI 10.1016/S0006-291X(05)80009-9; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NEGISHI M, 1987, J BIOL CHEM, V262, P12077; OKUDAASHITAKA E, 1993, BIOCHIM BIOPHYS ACTA, V1176, P148, DOI 10.1016/0167-4889(93)90190-Z; PERKINS ES, 1975, ADV OPHTHALMOL, V29, P2; POWELL WS, 1976, EUR J BIOCHEM, V61, P605, DOI 10.1111/j.1432-1033.1976.tb10056.x; POWELL WS, 1975, EUR J BIOCHEM, V56, P73, DOI 10.1111/j.1432-1033.1975.tb02208.x; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; WATABE A, 1993, J BIOL CHEM, V268, P20175; YAMASHITA M, 1991, P NATL ACAD SCI USA, V88, P11515, DOI 10.1073/pnas.88.24.11515; YOKOHAMA H, 1988, J BIOL CHEM, V263, P1119	37	124	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3881	3886						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508922				2022-12-27	WOS:A1994MV63100109
J	BRASS, LF; PIZARRO, S; AHUJA, M; BELMONTE, E; BLANCHARD, N; STADEL, JM; HOXIE, JA				BRASS, LF; PIZARRO, S; AHUJA, M; BELMONTE, E; BLANCHARD, N; STADEL, JM; HOXIE, JA			CHANGES IN THE STRUCTURE AND FUNCTION OF THE HUMAN THROMBIN RECEPTOR DURING RECEPTOR ACTIVATION, INTERNALIZATION, AND RECYCLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PLATELET ACTIVATION; PHOSPHOINOSITIDE HYDROLYSIS; HOMOLOGOUS DESENSITIZATION; PROTEOLYTIC MECHANISM; ENDOTHELIAL-CELLS; AGONIST PEPTIDES; ALPHA-THROMBIN; MOBILIZATION; BINDS; SITE	According to current models, human thrombin receptors are activated when thrombin cleaves the receptor's N terminus, exposing the tethered ligand domain, SFLLRN. In the megakaryoblastic CHRF-288 cell line, thrombin receptor activation is followed by the rapid internalization of >90% of the receptors. In the present studies, antibodies directed at the site of cleavage by thrombin were used to examine changes in receptor structure during activation, internalization, and recovery. As would be expected, the initial rate of receptor cleavage was directly related to the thrombin concentration. However, even after prolonged incubation, receptor cleavage was incomplete until the thrombin concentration exceeded the receptor concentration. Only cleaved receptors were internalized in response to thrombin and only catalytically active thrombin and active variants of SFLLRN-containing peptides caused receptor internalization. Over a 3-h period following receptor activation by thrombin, there was a gradual recovery of approximately one-quarter of the receptors on the cell surface. These receptors were detectable with antibodies directed at retained portions of the receptor N terminus, but not with antibodies directed at the proposed site of cleavage, confirming that they are recycled, rather than new, receptors. At 4-degrees-C two-thirds of the receptors cleaved by thrombin were retained on the cell surface. Like recycled receptors these ''cold-cleaved'' receptors failed to self-activate when warmed to 37-degrees-C, but could be activated by SFLLRN. Unlike recycled receptors, however, the cold-cleaved receptors were also internalized and appeared to be activated by a second addition of thrombin. These results 1) provide strong evidence at the protein level that thrombin cleaves its receptors at the predicted site, 2) show that receptor activation is necessary for internalization, 3) suggest that each thrombin molecule may not activate large numbers of receptors, 4) demonstrate that a substantial fraction of internalized thrombin receptors can be recycled, and 5) suggest that the failure of recycled receptors to be reactivated by thrombin may involve a change in the receptor that does not occur at 4-degrees-C. Finally, the inability of cold-cleaved receptors to self activate in the absence of thrombin, suggests that in addition to cleaving the receptor, thrombin may also play an important role in guiding the tethered ligand domain to regions on the remainder of the receptor that mediate activation.	UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104; SMITHKLINE BEECHAM PHARMACEUT,DEPT CARDIOVASC PHARMACOL,KING OF PRUSSIA,PA 19406	University of Pennsylvania; GlaxoSmithKline	BRASS, LF (corresponding author), UNIV PENN,DEPT MED,DIV HEMATOL ONCOL,SILVERSTEIN 7,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.			Pizarro, Shelly/0000-0002-3193-7037	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL049987] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL49987, P01 HL40387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; BRASS LF, 1991, J BIOL CHEM, V266, P958; BRASS LF, 1992, J BIOL CHEM, V267, P6044; BRASS LF, 1992, J BIOL CHEM, V267, P13795; BRASS LF, 1985, J BIOL CHEM, V260, P5172; CHAO BH, 1992, BIOCHEMISTRY-US, V31, P6175, DOI 10.1021/bi00142a001; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; DORN GW, 1992, AM J PHYSIOL, V263, pC864, DOI 10.1152/ajpcell.1992.263.4.C864; FUGMAN DA, 1990, BLOOD, V75, P1252; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HARMON JT, 1986, J BIOL CHEM, V261, P5928; HOLLENBERG MD, 1992, MOL PHARMACOL, V42, P186; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUANG EM, 1987, BIOCHEM J, V242, P11, DOI 10.1042/bj2420011; HUANG RS, 1991, J BIOL CHEM, V266, P18435; HUI KY, 1992, BIOCHEM BIOPH RES CO, V184, P790, DOI 10.1016/0006-291X(92)90659-9; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; ISHII K, 1993, J BIOL CHEM, V268, P9780; JAFFE EA, 1987, J BIOL CHEM, V262, P8557; JONES LG, 1989, MOL PHARMACOL, V36, P142; JOSEPH S, 1993, BIOCHEM J, V290, P571, DOI 10.1042/bj2900571; LEONG L, 1992, BIOCHEMISTRY-US, V31, P2567, DOI 10.1021/bi00124a017; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; PARIS S, 1988, J BIOL CHEM, V263, P11250; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SABO T, 1992, BIOCHEM BIOPH RES CO, V188, P604, DOI 10.1016/0006-291X(92)91099-C; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; TIRUPPATHI C, 1992, AM J PHYSIOL, V263, pL595, DOI 10.1152/ajplung.1992.263.5.L595; TROYER D, 1992, J BIOL CHEM, V267, P20126; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975	37	143	147	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2943	2952						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7507931				2022-12-27	WOS:A1994MV43200085
J	CRATER, DL; DOUGHERTY, BA; VANDERIJN, I				CRATER, DL; DOUGHERTY, BA; VANDERIJN, I			MOLECULAR CHARACTERIZATION OF HASC FROM AN OPERON REQUIRED FOR HYALURONIC-ACID SYNTHESIS IN GROUP-A STREPTOCOCCI - DEMONSTRATION OF UDP-GLUCOSE PYROPHOSPHORYLASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; ACETOBACTER-XYLINUM; ESCHERICHIA-COLI; RHEUMATIC-FEVER; POTATO-TUBER; GENE; EXPRESSION; SEQUENCE; PHOSPHOGLUCOMUTASE; BIOSYNTHESIS	Hyaluronic acid is a high molecular weight glycosaminoglycan composed of repeating subunits of glucuronic acid and N-acetylglucosamine. It is synthesized by the group A streptococcal membrane-associated enzyme hyaluronate synthase. In previous reports, the locus required for expression of hyaluronic acid, the has operon, was identified and found to consist of two genes, hasA and hasB encoding hyaluronate synthase and UDP-glucose dehydrogenase, respectively. Since a transcription terminator was not found at the end of hasB, it was the aim of this study to identify the remaining gene(s) in the has operon. By utilizing the Tn1000 method of DNA sequencing and inverse polymerase chain reaction, hasC, the third gene in the has operon was shown to be 915 base pairs in length (304 amino acids) and located 192 base pairs downstream of hasB. Sequence similarities to other genes suggested that hasC encodes UDP-glucose pyrophosphorylase. Overexpression of hasC using isopropyl-1-thio-beta-D-galactopyranoside induction of the T7 promoter in the pET translation system allowed for the production of bacterial extracts from Escherichia coli that possessed increased UDP-glucose pyrophosphorylase activity as compared to nondetectable levels in extracts with vector alone, In addition, expression of HasC resulted in a protein of approximately 36 kDa as shown by SDS-polyacrylamide gel electrophoresis. These data as well as complementation analysis of hasC in an E. coli galU mutant confirmed that hasC encodes UDP-glucose pyrophosphorylase. Finally, since sequence analysis identified a potential rho-independent transcription terminator at the 3-prime terminus of the gene, hasC is the third and probably the final gene in the has operon.	WAKE FOREST UNIV,MED CTR,WINSTON SALEM,NC 27157	Wake Forest University					NCI NIH HHS [CA12107] Funding Source: Medline; NIAID NIH HHS [AI37320, T32-AI-07401] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037320, T32AI007401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BREDE G, 1991, J BACTERIOL, V173, P7042, DOI 10.1128/jb.173.21.7042-7045.1991; CRATER DL, 1995, J BIOL CHEM, V270, P18452, DOI 10.1074/jbc.270.31.18452; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DILLARD JP, 1995, J EXP MED, V181, P973, DOI 10.1084/jem.181.3.973; DOUGHERTY BA, 1994, J BIOL CHEM, V269, P169; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; DOUGHERTY BA, 1992, J EXP MED, V175, P1291, DOI 10.1084/jem.175.5.1291; FJAERVIK E, 1991, FEMS MICROBIOL LETT, V77, P325, DOI 10.1111/j.1574-6968.1991.tb04370.x; GLUCKSMANN MA, 1993, J BACTERIOL, V175, P7045, DOI 10.1128/jb.175.21.7045-7055.1993; HOSSAIN SA, 1994, J BIOCHEM-TOKYO, V115, P965, DOI 10.1093/oxfordjournals.jbchem.a124446; JOHNSON DR, 1992, J INFECT DIS, V166, P374, DOI 10.1093/infdis/166.2.374; JOSHI JG, 1982, METHOD ENZYMOL, V89, P599; KATSUBE T, 1991, BIOCHEMISTRY-US, V30, P8546, DOI 10.1021/bi00099a008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCEFIELD RC, 1962, J IMMUNOL, V89, P307; LUDWIG W, 1985, J GEN MICROBIOL, V131, P543; MARKOVITZ A, 1959, J BIOL CHEM, V234, P2343; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NAKANO K, 1989, J BIOCHEM-TOKYO, V106, P528, DOI 10.1093/oxfordjournals.jbchem.a122886; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; REMES B, 1980, J BACTERIOL, V143, P1054, DOI 10.1128/JB.143.2.1054-1056.1980; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980; VARON D, 1993, J BACTERIOL, V175, P3964; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; WEISSBORN AC, 1994, J BACTERIOL, V176, P2611, DOI 10.1128/JB.176.9.2611-2618.1994; WESSELS MR, 1994, P NATL ACAD SCI USA, V91, P12238, DOI 10.1073/pnas.91.25.12238; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317; WESSELS MR, 1994, INFECT IMMUN, V62, P433, DOI 10.1128/IAI.62.2.433-441.1994	34	45	50	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28676	28680		10.1074/jbc.270.48.28676	http://dx.doi.org/10.1074/jbc.270.48.28676			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499387	hybrid			2022-12-27	WOS:A1995TH05600031
J	ENGLAND, SK; UEBELE, VN; KODALI, J; BENNETT, PB; TAMKUN, MM				ENGLAND, SK; UEBELE, VN; KODALI, J; BENNETT, PB; TAMKUN, MM			A NOVEL K+ CHANNEL BETA-SUBUNIT (HKV-BETA-1.3) IS PRODUCED VIA ALTERNATIVE MESSENGER-RNA SPLICINGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSIENT OUTWARD CURRENT; GUINEA-PIG ATRIAL; POTASSIUM CHANNELS; DELAYED RECTIFIER; VENTRICULAR MYOCYTES; SKELETAL-MUSCLE; RAT-BRAIN; XENOPUS-OOCYTES; MOLECULAR-BASIS; 2 COMPONENTS	Voltage-gated K+ channels can form multimeric complexes with accessory beta-subunits. We report here a novel K+ channel beta-subunit cloned from human heart, hKv beta 1.3, that has 74-83% overall identity with previously cloned beta-subunits. Comparison of hKv beta 1.3 with the previously cloned hKv beta 3 and rKv beta 1 proteins indicates that the carboxyl terminal 328 amino acids are identical, while unique variable length amino termini exist. Analysis of human beta-subunit cDNA and genomic nucleotide sequences confirm that these three beta-subunits are alternatively spliced from a common beta-subunit gene. Co-expression of hKv beta 1.3 in Xenopus oocytes with the delayed rectifier hKv1.5 indicated that hKv beta 1.3 has unique functional effects. This novel beta-subunit induced a time dependent inactivation during membrane voltage steps to positive potentials, induced a 13-mV hyperpolarizing shift in the activation curve, and slowed deactivation (tau = 13 +/- 0.5 ms versus 35 +/- 1.7 ms at -40 mV). Most notably, hKv beta 1.3 converted the Kv1.5 outwardly rectifying current voltage relationship to one showing strong inward rectification. These data suggest that Kv channel current diversity may arise from association with alternatively spliced Kv beta-subunits. A simplified nomenclature for the K+ channel beta-subunit subfamilies is suggested.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049330, P01HL046681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007628] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 49330, HL 46681] Funding Source: Medline; NIGMS NIH HHS [GM 07628] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALSER JR, 1990, J GEN PHYSIOL, V96, P835, DOI 10.1085/jgp.96.4.835; BENNDORF K, 1987, PFLUEGERS ARCH, V413, P127; BENNETT PB, 1993, FEBS LETT, V326, P21, DOI 10.1016/0014-5793(93)81752-L; BOYLE WA, 1991, AM J PHYSIOL, V260, pH1236, DOI 10.1152/ajpheart.1991.260.4.H1236; CASTELLINO RC, 1995, AM J PHYSIOL-HEART C, V38, pH385; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; CHOUINARD SW, 1995, P NATL ACAD SCI USA, V92, P6763, DOI 10.1073/pnas.92.15.6763; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; ENGLAND SK, 1995, P NATL ACAD SCI USA, V92, P6309, DOI 10.1073/pnas.92.14.6309; ESCANDE D, 1985, AM J PHYSIOL, V252, pH142; HEIDBUCHEL H, 1990, CIRC RES, V66, P1277, DOI 10.1161/01.RES.66.5.1277; Heinemann Stefan H., 1995, Biophysical Journal, V68, pA361; Hille B., 1992, IONIC CHANNELS EXCIT; HUME JR, 1985, J PHYSIOL-LONDON, V368, P525, DOI 10.1113/jphysiol.1985.sp015874; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; MAKITA N, 1994, J BIOL CHEM, V269, P7571; MCCORMACK K, 1995, FEBS LETT, V370, P32, DOI 10.1016/0014-5793(95)00785-8; MCHUGHSUTKOWSKI E, 1990, J BIOL CHEM, V265, P12393; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; MESSNER DJ, 1986, J BIOL CHEM, V261, P4882; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PO S, 1992, CIRC RES, V71, P732, DOI 10.1161/01.RES.71.3.732; PO S, 1993, CIRC RES, V72, P1326, DOI 10.1161/01.RES.72.6.1326; POWERS PA, 1992, J BIOL CHEM, V267, P22967; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P641, DOI 10.1113/jphysiol.1984.sp015088; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SANGUINETTI MC, 1991, AM J PHYSIOL, V260, pH393, DOI 10.1152/ajpheart.1991.260.2.H393; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; SNYDERS DJ, 1993, J GEN PHYSIOL, V101, P513, DOI 10.1085/jgp.101.4.513; TAMKUN MM, 1991, FASEB J, V5, P331, DOI 10.1096/fasebj.5.3.2001794; TRIMMER JS, 1991, P NATL ACAD SCI USA, V88, P10764, DOI 10.1073/pnas.88.23.10764; TSENG GN, 1989, CIRC RES, V64, P633, DOI 10.1161/01.RES.64.4.633; WHITE MM, 1991, MOL PHARMACOL, V39, P604; YUE DT, 1988, PFLUG ARCH EUR J PHY, V413, P127, DOI 10.1007/BF00582522	43	107	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28531	28534		10.1074/jbc.270.48.28531	http://dx.doi.org/10.1074/jbc.270.48.28531			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499366	hybrid			2022-12-27	WOS:A1995TH05600010
J	SOUZA, GM; HIRAI, J; MEHTA, DP; FREEZE, HH				SOUZA, GM; HIRAI, J; MEHTA, DP; FREEZE, HH			IDENTIFICATION OF 2 NOVEL DICTYOSTELIUM-DISCOIDEUM CYSTEINE PROTEINASES THAT CARRY N-ACETYLGLUCOSAMINE-1-P MODIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR SLIME-MOLDS; AMINO-ACID SEQUENCE; SPORE COAT PROTEINS; LIVER CATHEPSIN-B; MOLECULAR-CLONING; PRESPORE; EXPRESSION; CELLS; CDNA; PROTEOGLYCAN	Dictyostelium discoideum makes multiple developmentally regulated lysosomal cysteine proteinases. One of these, a lysosomal enzyme called proteinase I, contains a cluster of GlcNAc-alpha-1-P-Ser residues. We call this phosphoglycosylation. To study its function, a cDNA library from vegetative cells was screened, and two novel cysteine proteinase clones were characterized (cprD and cprE). Each of them has highly conserved regions expected for cysteine proteinases, but unlike any other, each has a serine-rich domain containing three distinct motifs, poly-S, SGSQ, and SGSG, cprD and cprE cDNAs were overexpressed in Dictyostelium and the active enzymes identified, cprD codes for a protein of approximately 36 kDa (CP4), which is recognized by monoclonal antibodies against GlcNAc-1-P and fucose, cprE corresponds to a 29-kDa protein, which is recognized by antibodies against GlcNAc-1-P. mRNA for both enzymes is present in the vegetative phase and increases during growth on bacteria but decreases throughout development. When the formation of the fruiting body is complete the mRNA for both messages is detected again but in very low levels. Having cloned cDNAs for proteins that carry GlcNAc-1-P should allow us to probe the function of the carbohydrate in these putative lysosomal enzymes.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute			Souza, Glaucia/E-6780-2012	Souza, Glaucia/0000-0001-6903-9913; Freeze, Hudson/0000-0001-6316-0501	PHS HHS [32485] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AVRAHAM S, 1989, P NATL ACAD SCI USA, V86, P3763, DOI 10.1073/pnas.86.10.3763; BAKER EN, 1980, J MOL BIOL, V141, P441, DOI 10.1016/0022-2836(80)90255-7; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; BURDINE V, 1995, MOL BIOL CELL, V6, P311, DOI 10.1091/mbc.6.3.311; CARNE A, 1979, BIOCHEM J, V173, P73; DASILVA AM, 1990, DEV BIOL, V140, P139, DOI 10.1016/0012-1606(90)90061-M; DEVINE KM, 1982, P NATL ACAD SCI-BIOL, V79, P7361, DOI 10.1073/pnas.79.23.7361; DEVINE KM, 1983, DEV BIOL, V99, P437, DOI 10.1016/0012-1606(83)90293-2; EARLY AE, 1988, DEVELOPMENT, V103, P519; FONG D, 1978, J BACTERIOL, V134, P521, DOI 10.1128/JB.134.2.521-527.1978; FONG D, 1979, P NATL ACAD SCI USA, V76, P6481, DOI 10.1073/pnas.76.12.6481; FOSNAUGH KL, 1989, NUCLEIC ACIDS RES, V17, P9489, DOI 10.1093/nar/17.22.9489; FOSNAUGH KL, 1989, MOL CELL BIOL, V9, P5215, DOI 10.1128/MCB.9.11.5215; FREEZE HH, 1980, J BIOL CHEM, V255, P1081; FREEZE HH, 1995, BIOCHEM BIOPH RES CO, V208, P384, DOI 10.1006/bbrc.1995.1349; FREEZE HH, 1991, CELL SURFACE CARBOHY, P285; FUCHS R, 1988, BIOL CHEM H-S, V369, P469, DOI 10.1515/bchm3.1988.369.1.469; GOMER RH, 1986, J CELL BIOL, V103, P1999, DOI 10.1083/jcb.103.5.1999; GUSTAFSON GL, 1980, J BIOL CHEM, V255, P7208; GUSTAFSON GL, 1979, BIOCHEM BIOPH RES CO, V86, P667, DOI 10.1016/0006-291X(79)91765-0; GUSTAFSON GL, 1979, J BIOL CHEM, V254, P2471; HARLOW E, 1988, ANTIBODIES LABORATOR, P490; ILG T, 1994, J BIOL CHEM, V269, P24073; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; JULIANI MH, 1990, J BIOL CHEM, V265, P9077; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOOMIS WF, 1995, GENETICS, V141, P147; LOOMIS WF, 1982, DEV DICTYOSTELIUM DI; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MEHTA DP, 1995, ARCH BIOCHEM BIOPHYS, V321, P191, DOI 10.1006/abbi.1995.1385; MERELLO S, 1995, J BIOL CHEM, V270, P7281, DOI 10.1074/jbc.270.13.7281; MITCHEL REJ, 1970, J BIOL CHEM, V245, P3485; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; NELLEN W, 1987, METHOD CELL BIOL, V28, P87; NORTH MJ, 1988, BIOCHEM J, V254, P269, DOI 10.1042/bj2540269; NORTH MJ, 1991, DEV GENET, V12, P154, DOI 10.1002/dvg.1020120124; NORTH MJ, 1988, BIOCHEM J, V254, P261, DOI 10.1042/bj2540261; PEARS CJ, 1985, NUCLEIC ACIDS RES, V13, P8853, DOI 10.1093/nar/13.24.8853; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PRESSE F, 1986, MOL GEN GENET, V203, P324, DOI 10.1007/BF00333975; RITONJA A, 1985, FEBS LETT, V181, P169, DOI 10.1016/0014-5793(85)81136-4; Sambrook J, 1989, MOL CLONING LABORATO; SIEGEL LI, 1986, ANAL BIOCHEM, V159, P82, DOI 10.1016/0003-2697(86)90310-6; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; WEST C, UNPUB; WEST CM, 1986, MOL CELL BIOCHEM, V72, P121; WIEDERANDERS B, 1992, J BIOL CHEM, V267, P13708; WIESE M, 1995, EMBO J, V14, P1067, DOI 10.1002/j.1460-2075.1995.tb07089.x; WILLIAMS JG, 1985, EMBO J, V4, P999, DOI 10.1002/j.1460-2075.1985.tb03730.x	50	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28938	28945		10.1074/jbc.270.48.28938	http://dx.doi.org/10.1074/jbc.270.48.28938			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499424	hybrid			2022-12-27	WOS:A1995TH05600068
J	BOUVET, P; MATSUMOTO, K; WOLFFE, AP				BOUVET, P; MATSUMOTO, K; WOLFFE, AP			SEQUENCE-SPECIFIC RNA RECOGNITION BY THE XENOPUS Y-BOX PROTEINS - AN ESSENTIAL ROLE FOR THE COLD SHOCK DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OOCYTE-SPECIFIC PROTEINS; MESSENGER-RNA; ESCHERICHIA-COLI; DNA-BINDING; CONSENSUS SEQUENCE; BACILLUS-SUBTILIS; TRANSCRIPTION; RIBONUCLEOPROTEIN; IDENTIFICATION; TRANSLATION	The Xenopus Y-box protein FRGY2 has a role in the translational silencing of masked maternal mRNA. Here, we determine that FRGY2 will recognize specific RNA sequences. The evolutionarily conserved nucleic acid-binding cold shock domain is required for sequence-specific interactions with RNA. However, RNA binding by FRGY2 is facilitated by N- and C-terminal regions flanking the cold shock domain. The hydrophilic C-terminal tail domain of FRGY2 interacts with RNA independent of the cold shock domain but does not determine sequence specificity. Thus, both sequence-specific and nonspecific RNA recognition domains are contained within the FRGY2 protein.	NICHHD, MOLEC EMBRYOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			, Bouvet/AAC-8779-2020; Matsumoto, Ken/F-9083-2013	Matsumoto, Ken/0000-0002-7864-3394; Bouvet, Philippe/0000-0003-4524-2233				BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; DARNBROUGH CH, 1981, EUR J BIOCHEM, V113, P415, DOI 10.1111/j.1432-1033.1981.tb05081.x; DESCHAMPS S, 1992, J BIOL CHEM, V267, P13799; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; JONES PG, 1992, J BACTERIOL, V174, P5798, DOI 10.1128/jb.174.18.5798-5802.1992; KASHANCHI F, 1994, J VIROL, V68, P561, DOI 10.1128/JVI.68.1.561-565.1994; KERR D, 1994, J VIROL, V68, P7637, DOI 10.1128/JVI.68.11.7637-7643.1994; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; LADOMERY M, 1994, NUCLEIC ACIDS RES, V22, P5582, DOI 10.1093/nar/22.25.5582; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; LATEANA A, 1991, P NATL ACAD SCI USA, V88, P10907, DOI 10.1073/pnas.88.23.10907; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MARELLO K, 1992, NUCLEIC ACIDS RES, V20, P5593, DOI 10.1093/nar/20.21.5593; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; MURRAY MT, 1994, BIOCHEMISTRY-US, V33, P13910, DOI 10.1021/bi00250a046; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; Tafuri Sherrie R., 1993, Trends in Cell Biology, V3, P94, DOI 10.1016/0962-8924(93)90080-K; TAFURI SR, 1993, J BIOL CHEM, V268, P12213; TAFURI SR, 1993, J BIOL CHEM, V268, P24255; TAFURI SR, 1992, NEW BIOL, V4, P349; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; WISTOW G, 1990, NATURE, V344, P823, DOI 10.1038/344823c0; WOLFFE A, 1992, CHROMATIN STRUCTURE; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1	39	129	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28297	28303						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499328				2022-12-27	WOS:A1995TG21000053
J	CHAI, XY; ZHAI, Y; POPESCU, G; NAPOLI, JL				CHAI, XY; ZHAI, Y; POPESCU, G; NAPOLI, JL			CLONING OF A CDNA FOR A 2ND RETINOL DEHYDROGENASE TYPE-II - EXPRESSION OF ITS MESSENGER-RNA RELATIVE TO TYPE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING PROPERTIES; CORTICOSTEROID 11-BETA-DEHYDROGENASE; ACID HOMEOSTASIS; ESCHERICHIA-COLI; RAT-TISSUES; VITAMIN-A; CRABP-I; PROTEINS; BIOSYNTHESIS; CRBP	A retinol dehydrogenase, RoDH(I), which recognizes hole-cellular retinol-binding protein (CRBP) as substrate, has been cloned, expressed, and identified as a short-chain dehydrogenase/reductase (Chai, X., Boerman, M. H. E. M., Zhai, Y., and Napoli, J. L. (1995) J. Biol. Chem. 270, 3900-3904). This work reports the cloning and expression of a cDNA encoding a RoDH isozyme, RoDH(II). The predicted amino acid sequence verifies RoDH(II) as a short-chain dehydrogenase/reductase, 82% identical with RoDH(I), RoDH(II) recognized the physiological form of retinol as substrate, CRBP, with a K-m of 2 mM. Similar to microsomal RoDH and RoDH(I), RoDH(II) had higher activity with NADP rather than NAD, was stimulated by ethanol and phosphatidyl choline, was not inhibited by the medium chain alcohol dehydrogenase inhibitor 4-methylpyrazole, but was inhibited by phenylarsine oxide and the short-chain dehydrogenase/reductase inhibitor carbenoxolone. Northern blot analysis detected RoDH(I) and RoDH(II) mRNA only in rat liver, but RNase protection assays revealed RoDH(I) and RoDH(II) mRNA in kidney, lung, testis, and brain. These data indicate that short-chain dehydrogenases/reductase isozymes expressed tissue-distinctively catalyze the first step of retinoic acid biogenesis from the physiologically most abundant substrate, CRBP.	SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT BIOCHEM, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			popescu, gabriela k/AAB-6155-2022	popescu, gabriela k/0000-0003-4658-2002	NIDDK NIH HHS [DK36870] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036870] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; BERLETH ES, 1992, J BIOL CHEM, V267, P16403; BOERMAN MHEM, 1995, BIOCHEMISTRY-US, V34, P7027, DOI 10.1021/bi00021a014; BOERMAN MHEM, 1995, ARCH BIOCHEM BIOPHYS, V321, P434, DOI 10.1006/abbi.1995.1415; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHURCHILL P, 1992, BIOCHEMISTRY-US, V31, P3793, DOI 10.1021/bi00130a009; CHYTIL F, 1987, ANNU REV NUTR, V7, P321, DOI 10.1146/annurev.nu.07.070187.001541; CHYTIL F, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P61; CLARKE SD, 1989, FASEB J, V3, P2480, DOI 10.1096/fasebj.3.13.2680704; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; EDWARDS CRW, 1993, J STEROID BIOCHEM, V45, P1, DOI 10.1016/0960-0760(93)90114-C; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FESUS L, 1991, EUR J CELL BIOL, V56, P170; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GUSTAFSON AL, 1993, DEVELOPMENT, V117, P451; HARRISON EH, 1987, J LIPID RES, V28, P973; HOFFMAN RD, 1992, J BIOL CHEM, V267, P14005; JAUHIAINEN M, 1988, J BIOL CHEM, V263, P6525; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; LI E, 1991, J BIOL CHEM, V266, P3622; LOHNES D, 1992, J CELL SCI S, V16, P69; Lotan R, 1988, Prog Clin Biol Res, V259, P261; MARKS AR, 1992, J BIOL CHEM, V267, P15459; MONDER C, 1989, ENDOCRINOLOGY, V125, P1046, DOI 10.1210/endo-125-2-1046; NAPOLI JL, 1986, METHOD ENZYMOL, V123, P112, DOI 10.1016/S0076-6879(86)23015-3; NAPOLI JL, 1987, ARCH BIOCHEM BIOPHYS, V255, P95, DOI 10.1016/0003-9861(87)90298-0; NAPOLI JL, 1993, J NUTR, V123, P362, DOI 10.1093/jn/123.suppl_2.362; NAPOLI JL, 1991, BIOMED PHARMACOTHER, V45, P131, DOI 10.1016/0753-3322(91)90101-X; NAPOLI JL, 1992, BIOCHIM BIOPHYS ACTA, V1120, P183, DOI 10.1016/0167-4838(92)90267-H; NAPOLI JL, 1990, METHOD ENZYMOL, V189, P470; NAPOLI JL, 1994, BASIC SCI CLIN ASPEC, pCH6; ONG DE, 1982, J BIOL CHEM, V257, P13385; ONG DE, 1994, NUTR REV, V52, P24, DOI 10.1111/j.1753-4887.1994.tb01383.x; PAWLOWSKI JE, 1994, J BIOL CHEM, V269, P13502; PETKOVICH M, 1992, ANNU REV NUTR, V12, P443, DOI 10.1146/annurev.nu.12.070192.002303; POSCH KC, 1992, J BIOL CHEM, V267, P19676; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; RUBERTE E, 1992, DEVELOPMENT, V115, P973; SEMBA RD, 1994, CLIN INFECT DIS, V19, P489, DOI 10.1093/clinids/19.3.489; SIEGENTHALER G, 1990, BIOCHEM J, V268, P371, DOI 10.1042/bj2680371; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979	45	85	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28408	28412						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499345	hybrid			2022-12-27	WOS:A1995TG21000070
J	LLOYD, AR; BIRAGYN, A; JOHNSTON, JA; TAUB, DD; XU, LL; MICHIEL, D; SPRENGER, H; OPPENHEIM, JJ; KELVIN, DJ				LLOYD, AR; BIRAGYN, A; JOHNSTON, JA; TAUB, DD; XU, LL; MICHIEL, D; SPRENGER, H; OPPENHEIM, JJ; KELVIN, DJ			GRANULOCYTE-COLONY-STIMULATING FACTOR AND LIPOPOLYSACCHARIDE REGULATE THE EXPRESSION OF INTERLEUKIN-8 RECEPTORS ON POLYMORPHONUCLEAR LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PROPERTIES; TUMOR-NECROSIS-FACTOR; FUNCTIONAL EXPRESSION; CHEMOTACTIC FACTOR; CYTOKINE FAMILY; HIGH-AFFINITY; SEQUENCE; SECRETE; CLONING; ALPHA	Interleukin 8 (IL-8) is a potent chemoattractant and activating factor for human polymorphonuclear leukocytes (PMN) and hence plays a critical role in the pathogenesis of acute inflammation, Two unique but homologous receptors for IL-8 have been cloned (IL-8RA and -B), each of which binds the IL-8 ligand with high affinity, PMN stimulated by cytokines or lipopolysaccharide (LPS) exhibit changes in IL-8R mRNA and I-125-IL-8 binding, Granulocyte-colony stimulating factor (G-CSF) treatment of PMN enhances, and LPS inhibits, IL-8R mRNA expression, Similarly, I-125-IL-8 ligand binding to PMN is increased by G-CSF and decreased by LPS treatment, The stimulatory effect of G-CSF on IL-8R expression is transcriptional as it is inhibited by actinomycin D and is evident in nuclear run-on analyses. In contrast, LPS down-regulates IL-8R by both transcriptional and post-transcriptional mechanisms. The alterations in IL-8R expression are associated with similar changes in the IL-8-induced chemotactic responses of PMN. In conclusion, the two types of IL-8 receptor differ in their cellular distribution and are regulated in response to cytokines and LPS, Regulation of IL-8R expression by endogenous and exogenous immunomodulators may be important in the in vivo control of PMN effector functions in inflammation.	NCI, MOLEC IMMUNOREGULAT LAB, BIOL RESPONSE MODIFIERS PROGRAM, FREDERICK, MD 21702 USA; NCI, PROGRAM RESOURCES INC DYNCORP, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA; UNIV WESTERN ONTARIO, JOHN P ROBARTS RES INST, AUTOIMMUN GRP, LONDON, ON N6G 2V4, CANADA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Western University (University of Western Ontario)			Lloyd, Andrew/E-7334-2017	Lloyd, Andrew/0000-0001-6277-8887				AHUJA SK, 1992, NAT GENET, V2, P31, DOI 10.1038/ng0992-31; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COLLINS S, 1991, ANNU REV PHYSIOL, V53, P497, DOI 10.1146/annurev.physiol.53.1.497; COLOTTA F, 1992, BLOOD, V80, P2012; DUBRAVEC DB, 1990, P NATL ACAD SCI USA, V87, P6758, DOI 10.1073/pnas.87.17.6758; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; LEE J, 1992, J BIOL CHEM, V267, P16283; LLOYD A, 1993, CYTOGENET CELL GENET, V63, P238, DOI 10.1159/000133541; LLOYD AR, 1992, IMMUNOL TODAY, V13, P169, DOI 10.1016/0167-5699(92)90121-M; LORD PCW, 1991, J CLIN INVEST, V87, P1312, DOI 10.1172/JCI115134; Maniatis T, 1989, MOL CLONING; MARUCHA PT, 1991, J IMMUNOL, V147, P2603; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; MOSER B, 1993, BIOCHEM J, V294, P285, DOI 10.1042/bj2940285; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SAMANTA AK, 1989, J EXP MED, V169, P1185, DOI 10.1084/jem.169.3.1185; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHRODER JM, 1990, J EXP MED, V171, P1091, DOI 10.1084/jem.171.4.1091; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPRENGER H, 1994, J IMMUNOL, V153, P2524; SPRENGER H, 1994, J BIOL CHEM, V269, P11065; TAUB DD, 1993, CYTOKINE, V5, P175, DOI 10.1016/1043-4666(93)90001-L; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; XU L, 1994, J LEUKOCYTE BIOL, V57, P335; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233	30	103	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28188	28192						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499311				2022-12-27	WOS:A1995TG21000036
J	MORI, Y; FOLCO, E; KOREN, G				MORI, Y; FOLCO, E; KOREN, G			GH3 CELL-SPECIFIC EXPRESSION OF KV1.5 GENE - REGULATION BY A SILENCER CONTAINING A DINUCLEOTIDE REPETITIVE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED POTASSIUM CHANNEL; K+ CHANNEL; RAT SKELETAL; DNA; CLONING; TRANSCRIPTION; SEQUENCES; BRAIN; HELIX	A silencer element (Kv1.5 repressor element; KRE) was characterized by deletion analyses in the promoter of Kv1.5, a voltage-gated potassium channel, The silencer element selectively decreases expression of Kv1.5- and thymidine kinase-chloramphenicol acetyltransferase reporter gene constructs in cell lines that do not express Kv1.5 polypeptide. It contains a dinucleotide repetitive element (poly(GT)(19)(GA)(1)(CA)(15)(GA)(16)), and self associates spontaneously in vitro to form complexes with slow electrophoretic mobility, Deletion of the repetitive element abolished self-association in vitro and the silencing activity in transient transfection experiments in vivo, Electromobility gel shift assays of KRE with GH3 cells nuclear extracts detected the formation of a unique DNA-protein complex, which was not detectable in Chinese hamster ovary and COS-7 cells. This complex does not react with an antibody against nonhistone high mobility group 1 protein, which binds KRE in gel retardation assays, These observations establish that a dinucleotide tandem repeat sequence, capable of self-association, forms part of a cell-specific silencer element in a mammalian gene.	BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046005, F32HL146005] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 46005] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BROWN AM, 1993, ANNU REV BIOPH BIOM, V22, P173, DOI 10.1146/annurev.bb.22.060193.001133; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GAILLARD C, 1994, SCIENCE, V264, P433, DOI 10.1126/science.8153633; GE H, 1994, J BIOL CHEM, V269, P17136; HAMADA H, 1982, NATURE, V298, P396, DOI 10.1038/298396a0; HANIFORD DB, 1983, NATURE, V302, P632, DOI 10.1038/302632a0; HERRERA VLM, 1990, J BIOL CHEM, V265, P9555; Hille B., 1992, IONIC CHANNELS EXCIT; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KOREN G, 1990, NEURON, V4, P39, DOI 10.1016/0896-6273(90)90442-I; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LANGE AJ, 1992, J BIOL CHEM, V267, P15673; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; MATSUBARA H, 1991, J BIOL CHEM, V266, P13324; MORI Y, 1993, J BIOL CHEM, V268, P26482; MURPHY KE, 1986, NUCLEIC ACIDS RES, V14, P7325, DOI 10.1093/nar/14.18.7325; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; STRONG M, 1993, MOL BIOL EVOL, V10, P221; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; TAKIMOTO K, 1993, NEURON, V11, P359, DOI 10.1016/0896-6273(93)90191-S; THERRIEN M, 1993, MOL CELL BIOL, V13, P2342, DOI 10.1128/MCB.13.4.2342; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WEBER JL, 1989, AM J HUM GENET, V44, P388	29	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27788	27796		10.1074/jbc.270.46.27788	http://dx.doi.org/10.1074/jbc.270.46.27788			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499248	hybrid			2022-12-27	WOS:A1995TE73600059
J	MUKHOPADHYAY, K; LEFEBVRE, V; ZHOU, G; GAROFALO, S; KIMURA, JH; DECROMBRUGGHE, B				MUKHOPADHYAY, K; LEFEBVRE, V; ZHOU, G; GAROFALO, S; KIMURA, JH; DECROMBRUGGHE, B			USE OF A NEW RAT CHONDROSARCOMA CELL-LINE TO DELINEATE A 119-BASE PAIR CHONDROCYTE-SPECIFIC ENHANCER ELEMENT AND TO DEFINE ACTIVE PROMOTER SEGMENTS IN THE MOUSE PRO-ALPHA-1(II) COLLAGEN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; TRANSGENIC MICE; MAMMALIAN-CELLS; 1ST INTRON; II GENE; CARTILAGE; IDENTIFICATION; FIBRILS; IX; TRANSFORMATION	We show that a new rat chondrosarcoma (RCS) cell line established in long-term culture from the Swarm tumor displayed a stable differentiated chondrocyte-like phenotype, Indeed, these cells produced the collagen types II, IX, and XI and alcian blue-stainable cartilage-specific proteoglycans, but no type I or type III collagen, To functionally characterize their chondrocytic nature, the cells were stably transfected with a type II collagen/beta geo chimeric gene which confers essentially perfect chondrocyte-specific expression in transgenic mice, RCS cells expressed both beta-galactosidase and G418 resistance, in comparison with similarly transfected 10T1/2 and NIH/3T3 fibroblasts which did not, These cells were then used to perform a systematic deletion analysis of the first intron of the mouse type II collagen gene (Col2a1) using transient expression experiments to determine which segments stimulated expression of a luciferase reporter gene in RCS cells but not in 10T1/2 fibroblasts, Cloning of two tandem copies of a 156-base pair (bp) intron 1 fragment (+2188 to +2343) in a construction containing a 314-bp Col2a1 promoter caused an almost 200-fold increase in promoter activity in RCS cells but no increase in 10T1/2 cells, DNase I footprint analysis over this 156-bp fragment revealed two adjacent protected regions, FP1 and FP2, located in the 3'-half of this segment, but no differences were seen with nuclear extracts of RCS cells and 10T1/2 fibroblasts, Deletion of FP2 to leave a 119-bp segment decreased enhancer activity by severalfold, but RCS cell specificity was maintained, Further deletions indicated that sequences both in the 5' part of the 119-bp fragment and in FP1 were needed simultaneously for RCS cell-specific enhancer activity, A series of deletions in the promoter region of the mouse Col2a1 gene progressively reduced activity when these promoters were tested by themselves in transient expression experiments, However, these promoter deletions were all activated to a similar level in RCS cells by a 231-bp intron 1 fragment that included the 156-bp enhancer, The RCS cell-specific activity persisted even if the Col2a1 promoter was replaced by a minimal adenovirus major late promoter, This 231-bp intron 1 fragment also had strong enhancing activity in transiently transfected mouse primary chondrocytes, Our experiments establish the usefulness of RCS cells as an experimental system for studies of the control of chondrocyte-specific genes, provide an extensive delineation of segments in the Col2a1 first intron involved in chondrocyte-specific activity, and show that promoter sequences are dispensable for chondrocyte specificity.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA; HENRY FORD HOSP, CTR BONE & JOINT, BIOCHEM SECT, DETROIT, MI 48202 USA	University of Texas System; UTMD Anderson Cancer Center; Henry Ford Health System; Henry Ford Hospital				GAROFALO, SILVIO/0000-0001-7460-3179	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040335, R01AR042909] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline; NIAMS NIH HHS [AR 40335, AR 42909] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRUCKNER P, 1988, J BIOL CHEM, V263, P16911; CHEAH KSE, 1991, DEVELOPMENT, V111, P945; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI HU, 1971, P NATL ACAD SCI USA, V68, P877, DOI 10.1073/pnas.68.5.877; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GAROFALO S, 1991, P NATL ACAD SCI USA, V88, P9648, DOI 10.1073/pnas.88.21.9648; GIONTI E, 1983, J BIOL CHEM, V258, P7190; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; GRIGORIADIS AE, 1989, ENDOCRINOLOGY, V125, P2103, DOI 10.1210/endo-125-4-2103; HALL B, 1991, CARTILAGE MOL ASPECT, P1; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; HORTON WE, 1988, EXP CELL RES, V178, P457, DOI 10.1016/0014-4827(88)90414-4; LEE B, 1989, SCIENCE, V244, P978, DOI 10.1126/science.2543071; LEFEBVRE V, 1995, J CELL BIOL, V128, P239, DOI 10.1083/jcb.128.1.239; LEFEBVRE V, 1994, MATRIX BIOL, V14, P329, DOI 10.1016/0945-053X(94)90199-6; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MALLEINGERIN F, 1993, P NATL ACAD SCI USA, V90, P3289, DOI 10.1073/pnas.90.8.3289; Maxam A M, 1980, Methods Enzymol, V65, P499; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; METSARANTA M, 1991, J BIOL CHEM, V266, P16862; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SHEENAN DC, 1987, THEORY PRACTICE HIST; VIKKULA M, 1994, ANN MED, V26, P107; VIKKULA M, 1992, BIOCHEM J, V285, P287, DOI 10.1042/bj2850287; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WANG LQ, 1991, J BIOL CHEM, V266, P19878; WANG ZQ, 1993, J BONE MINER RES, V8, P839; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YASUI N, 1986, J BIOL CHEM, V261, P7997	33	127	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27711	27719		10.1074/jbc.270.46.27711	http://dx.doi.org/10.1074/jbc.270.46.27711			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499238				2022-12-27	WOS:A1995TE73600049
J	GRIBKOFF, VK; CHAMPIGNY, G; BARBRY, P; DWORETZKY, SI; MEANWELL, NA; LAZDUNSKI, M				GRIBKOFF, VK; CHAMPIGNY, G; BARBRY, P; DWORETZKY, SI; MEANWELL, NA; LAZDUNSKI, M			THE SUBSTITUTED BENZIMIDAZOLONE NS004 IS AN OPENER OF THE CYSTIC-FIBROSIS CHLORIDE CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL-CELLS; GENE; IDENTIFICATION; EXPRESSION; CFTR; DELTA-F508; CL	Cystic fibrosis is a major inherited disorder involving abnormalities of fluid and electrolyte transport in a number of different organs. Epithelial cells of cystic fibrosis patients have a decreased capacity to secrete chloride in response to cAMP-mobilizing agents because of the mutation of a single gene. The gene product, the cystic fibrosis transmembrane conductance regulator or CFTR, is a chloride channel. The most frequent mutation is a deletion of phenylalanine in position 508 (DELTAF08-CFTR) that reduces both the expression of the CFTR protein at the cell surface, and the activity of the Cl- channel. This work presents the properties of NS004, a substituted benzimidazolone, which is the first activator of normal and mutant CFTR-associated chloride channels to be described. NS004 activated CFTR and DELTAF508-CFTR Cl- channels expressed in Xenopus oocytes, and increased I-125 efflux (via the Cl- channel) from Vero cells expressing CFTR and DELTAF508-CFTR. Application of NS004 to the external side of outside-out patches excised from these CFTR- and DELTAF508-CFTR-expressing cells induced a marked and reversible increase in channel activity.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DIV CHEM,WALLINGFORD,CT 06492; CNRS,INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE	Bristol-Myers Squibb; Centre National de la Recherche Scientifique (CNRS)	GRIBKOFF, VK (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT CNS BIOPHYS & MOLEC BIOL 405,5 RES PKWY,WALLINGFORD,CT 06492, USA.		Barbry, Pascal/O-5021-2016	Barbry, Pascal/0000-0001-9632-6483; Meanwell, Nicholas/0000-0002-8857-1515				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BECQ F, 1993, FEBS LETT, V327, P337, DOI 10.1016/0014-5793(93)81016-S; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BOUCHER RC, 1992, DRUGS, V43, P431, DOI 10.2165/00003495-199243040-00001; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIGGINS CF, 1992, BRIT MED BULL, V48, P754, DOI 10.1093/oxfordjournals.bmb.a072576; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; OLESEN SP, 1992, Patent No. 477819; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R	27	97	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					10983	10986						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512555				2022-12-27	WOS:A1994NF96600005
J	WOHRL, BM; HOWARD, KJ; JACQUES, PS; LEGRICE, SFJ				WOHRL, BM; HOWARD, KJ; JACQUES, PS; LEGRICE, SFJ			ALTERNATIVE MODES OF POLYMERIZATION DISTINGUISH THE SUBUNITS OF EQUINE INFECTIOUS-ANEMIA VIRUS REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL CHELATE ADSORBENT; RNASE-H ACTIVITY; ESCHERICHIA-COLI; DNA-SYNTHESIS; AIDS VIRUS; PURIFICATION; TYPE-1; HETERODIMER; EXPRESSION; MUTAGENESIS	A comparative study of recombinant 51- and 66-kDa subunits comprising equine infectious anemia virus reverse transcriptase (EIAV RT) is reported. Both polypeptides sedimented as stable homodimers (molecular mass, 102 and 132 kDa, respectively) when analyzed by rate sedimentation through glycerol gradients. Consistent with their dimer composition, each preparation displayed considerable levels of both RNA and DNA-dependent DNA polymerase activity on different homopolymeric template/primer combinations. However, a detailed analysis of the polymerization products indicated qualitative differences. Whereas p66 EIAV RT proceeded essentially unimpaired along both RNA and DNA templates, p51-catalyzed DNA synthesis was interrupted close to or in the immediate vicinity of the primer. A series of ''programed'' 2-step polymerization reactions suggests that p51 EIAV RT enters an abortive mode of polymerization. Duplication of this observation with p51 human immunodeficiency virus-1 RT, together with recent observations from murine RT, suggests that lack of a ribonuclease H domain and loss of contact with the nascent product from the polymerase active center have profound consequences on the mode of polymerization.	CASE WESTERN RESERVE UNIV,SCH MED,DIV INFECT DIS,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046623] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 46623] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; DEVICO A, 1991, VIROLOGY, V185, P387, DOI 10.1016/0042-6822(91)90786-B; ELDER JH, 1993, J VIROL, V67, P1869, DOI 10.1128/JVI.67.4.1869-1876.1993; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; HUBER HE, 1990, J BIOL CHEM, V265, P10565; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRAUS G, 1990, EUR J BIOCHEM, V192, P207, DOI 10.1111/j.1432-1033.1990.tb19216.x; LARDER B, 1987, EMBO J, V6, P3133, DOI 10.1002/j.1460-2075.1987.tb02623.x; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LEGRICE SFJ, 1991, J VIROL, V65, P7004, DOI 10.1128/JVI.65.12.7004-7007.1991; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; MOELLING K, 1974, VIROLOGY, V62, P46, DOI 10.1016/0042-6822(74)90302-X; MULLER B, 1991, J BIOL CHEM, V266, P14709; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RESTLE T, 1992, FEBS LETT, V300, P97, DOI 10.1016/0014-5793(92)80172-D; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SCHIFF RD, 1978, J VIROL, V28, P279, DOI 10.1128/JVI.28.1.279-291.1978; STEPHENS RM, 1986, SCIENCE, V231, P589, DOI 10.1126/science.3003905; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504	30	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8541	8548						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510690				2022-12-27	WOS:A1994NB40900107
J	KRAMER, KK; DUFFY, JY; KLEMANN, SW; BIXBY, JA; LOW, BG; POPE, WF; ROBERTS, RM				KRAMER, KK; DUFFY, JY; KLEMANN, SW; BIXBY, JA; LOW, BG; POPE, WF; ROBERTS, RM			SELECTIVE CLONING OF CDNA FOR SECRETORY PROTEINS OF EARLY EMBRYOS - IDENTIFICATION OF A TRANSIENTLY EXPRESSED KUNITZ DOMAIN PROTEIN FROM PREIMPLANTATION SHEEP TROPHOBLAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; MOLECULAR-WEIGHT PROTEIN; AMINO-ACID-SEQUENCE; ANTIGENIC DETERMINANTS; INTERFERON; RNA; TROPHECTODERM; PURIFICATION; PREGNANCY; PRECURSOR	The preimplantation ovine conceptus transiently secretes several proteins, including a type I interferon (IFN-tau), that are likely involved in establishment of pregnancy. A method has been developed to identify proteins produced simultaneously with IFN-tau. An antiserum against total ovine conceptus secretory proteins, from which IFN-tau and proteins common to maternal uterine tract secretions had first been removed, was used to immunoscreen cDNA libraries created from mRNA of days 13 and 15 ovine conceptuses. This approach has allowed several unique cDNA to be identified, including one particularly abundant transcript for a novel member of the Kunitz family of serine protease inhibitors. This cDNA encodes a 265-amino acid protein with a 20-amino acid signal sequence. A 64-amino acid Kunitz domain occupies the carboxyl terminus. It is preceded by two similar repeats of 84 residues that bear no obvious similarity to any sequences present in the protein data banks. The protein present in conceptus secretions (M(r) of similar to 14,000) represents only the carboxyl terminus of the molecule. The mRNA for this putative proteinase inhibitor was confined to trophectoderm and was highly expressed for only a few days (similar to 13-18) of development. A similar transcript was detected during the days 17-21 period in cattle embryos. Despite their high expression, no proteinase-inhibitory activity can so far be ascribed to either the ovine or bovine proteins. The P-1 residue, an asparagine, is not represented in any other known Kunitz inhibitors.	UNIV MISSOURI, DEPT ANIM SCI, COLUMBIA, MO 65211 USA; UNIV MISSOURI, DEPT BIOCHEM, COLUMBIA, MO 65211 USA; OHIO STATE UNIV, DEPT ANIM SCI, COLUMBUS, OH 43210 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; Ohio State University					NICHD NIH HHS [HD21980] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021980] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; [Anonymous], 1982, REPROD MAMMALS; BAZER FW, 1987, REPRODUCTION FARM AN, P210; BOSHIER DP, 1969, J REPROD FERTIL, V19, P51, DOI 10.1530/jrf.0.0190051; BRENNAN GL, 1983, BIOTECHNIQUES, V1, P78; BRUCK C, 1982, J IMMUNOL METHODS, V53, P313, DOI 10.1016/0022-1759(82)90178-8; CECHOVA D, 1971, COLLECT CZECH CHEM C, V36, P3342; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER H, 1988, CURRENT PROTOCOLS MO; CREIGHTON TE, 1987, J MOL BIOL, V194, P11, DOI 10.1016/0022-2836(87)90711-X; CREIGHTON TE, 1987, COLD SPRING HARB SYM, V52, P511, DOI 10.1101/SQB.1987.052.01.058; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; FARIN CE, 1989, MOL ENDOCRINOL, V3, P1099, DOI 10.1210/mend-3-7-1099; FULLER SA, 1988, CURRENT PROTOCOLS MO; GODKIN JD, 1982, J REPROD FERTIL, V65, P141, DOI 10.1530/jrf.0.0650141; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAMMARBACK JA, 1990, J BIOL CHEM, V265, P12763; HANDYSIDE AH, 1991, REPROD BIOL, P273; HANSEN TR, 1988, J BIOL CHEM, V263, P12801; HOOG C, 1991, NUCLEIC ACIDS RES, V19, P6123, DOI 10.1093/nar/19.22.6123; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HYNES TR, 1990, BIOCHEMISTRY-US, V29, P10018, DOI 10.1021/bi00495a002; IMAKAWA K, 1987, NATURE, V330, P377, DOI 10.1038/330377a0; IMAKAWA K, 1989, MOL ENDOCRINOL, V3, P127, DOI 10.1210/mend-3-1-127; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; KAZEMI M, 1990, BIOL REPROD, V43, P80, DOI 10.1095/biolreprod43.1.80; KINGSTON IB, 1986, BIOCHEM J, V233, P443, DOI 10.1042/bj2330443; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; MCDONALD NQ, 1993, TRENDS BIOCHEM SCI, V18, P208, DOI 10.1016/0968-0004(93)90190-X; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; RASP G, 1987, BIOL CHEM H-S, V368, P727, DOI 10.1515/bchm3.1987.368.1.727; REDDY KJ, 1988, ANAL BIOCHEM, V168, P324, DOI 10.1016/0003-2697(88)90325-9; ROBERTS RM, 1992, ENDOCR REV, V13, P432, DOI 10.1210/er.13.3.432; SINHA S, 1991, J BIOL CHEM, V266, P21011; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; STRYDOM DJ, 1973, NATURE-NEW BIOL, V243, P88; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VETR H, 1988, FEBS LETT, V245, P137; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WACHTER E, 1980, FEBS LETT, V119, P58, DOI 10.1016/0014-5793(80)80997-5; WILMUT I, 1981, J REPROD FERTIL, V61, P179, DOI 10.1530/jrf.0.0610179; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6	44	18	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7255	7261						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510284				2022-12-27	WOS:A1994NA03200036
J	COMINELLI, F; BORTOLAMI, M; PIZARRO, TT; MONSACCHI, L; FERRETTI, M; BREWER, MT; EISENBERG, SP; NG, RK				COMINELLI, F; BORTOLAMI, M; PIZARRO, TT; MONSACCHI, L; FERRETTI, M; BREWER, MT; EISENBERG, SP; NG, RK			RABBIT INTERLEUKIN-1 RECEPTOR ANTAGONIST - CLONING, EXPRESSION, FUNCTIONAL-CHARACTERIZATION, AND REGULATION DURING INTESTINAL INFLAMMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-1 RECEPTOR; HUMAN-MONOCYTES; RECOMBINANT INTERLEUKIN-1; IL-1-BETA PRODUCTION; CELLS; GENE; DNA; PURIFICATION; INHIBITOR; PROTEIN	Genomic and cDNA clones for rabbit interleukin-l re antagonist (IL-1ra) were isolated based on homology with the human, mouse, and rat IL-1ra gene. A partial genomic clone, obtained by screening a rabbit genomic library, contained coding sequences for the carboxyl-terminal 108 amino acids of rabbit IL-1ra. Two classes of cDNA for rabbit IL-1ra were obtained using RNA from inflamed rabbit colon tissue. One class of cDNA coded for a secreted form of IL-1ra, whereas the other coded for a putative intracellular form of rabbit IL-1ra. The latter form is similar to that isolated from human epithelial cells. A partially synthetic rabbit IL-1ra gene was constructed and expressed in Escherichia coli. The recombinant rabbit IL-1ra was purified to ho mogeneity by ion exchange chromatography. Its affinity was similar to that of human IL-1ra for the human and mouse type I IL-1 receptor. From the cDNA clone and the purified recombinant protein, specific probes were developed for measuring levels of rabbit IL-1ra mRNA and protein in normal and inflamed rabbit tissues. Unlike IL-1 alpha and IL-1 beta, IL-1ra mRNA and protein were present at detectable levels in normal rabbit colon. During the development of an experimental formalin-immune complex colitis, rabbit IL-1 alpha showed a dramatic increase in tissue levels, consistent with previous results; IL-1ra also increased 3-4-fold. Treatment of colitis rabbits with corticosteroids significantly suppressed neutrophil infiltration, IL-1 alpha levels, but not IL-1ra levels. In contrast, corticosteroid treatment suppressed IL-1ra but not IL-1 alpha mRNA steady-state levels. Our observations demonstrate that IL-1 and IL-1ra synthesis is differentially regulated in healthy and inflamed intestinal tissue.	UNIV SO CALIF, SCH MED, DEPT MED, LOS ANGELES, CA 90033 USA; SYNERGEN INC, BOULDER, CO 80301 USA	University of Southern California					NIDDK NIH HHS [DK45740, DK42191] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042191, R37DK042191, R01DK045740, R01DK042191] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AREND WP, 1991, J IMMUNOL, V147, P1530; AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; AREND WP, 1990, J CLIN INVEST, V85, P1694, DOI 10.1172/JCI114622; AREND WP, 1985, J IMMUNOL, V134, P3868; AREND WP, 1990, ARTHRITIS RHEUM-US, V33, P305, DOI 10.1002/art.1780330302; BHATTACHERJEE P, 1987, CURR EYE RES, V6, P929, DOI 10.3109/02713688709034861; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK BD, 1991, J APPL PHYSIOL, V71, P2412, DOI 10.1152/jappl.1991.71.6.2412; CLINTON SK, 1991, AM J PATHOL, V138, P1005; COMINELLI F, 1990, J CLIN INVEST, V86, P972, DOI 10.1172/JCI114799; COMINELLI F, 1990, J CLIN INVEST, V85, P582, DOI 10.1172/JCI114476; COMINELLI F, 1992, GASTROENTEROLOGY, V103, P65, DOI 10.1016/0016-5085(92)91096-M; COMINELLI F, 1992, GASTROENTEROLOGY, V102, pA608; DINARELLO CA, 1986, J CLIN INVEST, V77, P1734, DOI 10.1172/JCI112495; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; DRIPPS DJ, 1991, J BIOL CHEM, V266, P20311; EISENBERG SP, 1991, P NATL ACAD SCI USA, V88, P5232, DOI 10.1073/pnas.88.12.5232; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENTON MJ, 1987, J IMMUNOL, V138, P3972; FISCHER E, 1992, BLOOD, V79, P2196; GILLIS S, 1979, J IMMUNOL, V123, P1624; GOTO F, 1992, IMMUNOLOGY, V77, P235; GRANOWITZ EV, 1991, LANCET, V338, P1423, DOI 10.1016/0140-6736(91)92725-H; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUSS HJ, 1992, LANCET, V340, P968; HAMMERBERG C, 1992, J CLIN INVEST, V90, P571, DOI 10.1172/JCI115896; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HASKILL S, 1991, P NATL ACAD SCI USA, V88, P3681, DOI 10.1073/pnas.88.9.3681; HAZUDA DJ, 1990, J BIOL CHEM, V265, P6318; HENDERSON B, 1988, CLIN EXP IMMUNOL, V74, P371; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; KERN JA, 1988, J CLIN INVEST, V81, P237, DOI 10.1172/JCI113301; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; LEW W, 1988, J IMMUNOL, V140, P1895; Maniatis T, 1989, MOL CLONING; MATSUKAWA A, 1992, BIOMED RES-TOKYO, V13, P269, DOI 10.2220/biomedres.13.269; MAYBUTT HN, 1990, ENDOCRINOLOGY, V127, P476; MILLER LC, 1993, LANCET, V341, P146, DOI 10.1016/0140-6736(93)90006-3; MORIMOTO A, 1989, AM J PHYSIOL, V256, pR35, DOI 10.1152/ajpregu.1989.256.1.R35; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; OPP MR, 1991, AM J PHYSIOL, V260, pR453, DOI 10.1152/ajpregu.1991.260.2.R453; POUTSIAKA DD, 1991, BLOOD, V78, P1275; RAMBALDI A, 1991, BLOOD, V78, P3248; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS AA, 1993, ARCH SURG-CHICAGO, V128, P138; SAUKKONEN K, 1990, J EXP MED, V171, P439, DOI 10.1084/jem.171.2.439; SECKINGER P, 1987, J IMMUNOL, V139, P1546; SHUCK ME, 1991, EUR J IMMUNOL, V21, P2775, DOI 10.1002/eji.1830211119; SNYDER DS, 1982, J IMMUNOL, V129, P1803; STOCKMAN BJ, 1992, BIOCHEMISTRY-US, V31, P5237, DOI 10.1021/bi00138a001; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635	58	40	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6962	6971						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509813				2022-12-27	WOS:A1994MZ50300107
J	SERVE, H; HSU, YC; BESMER, P				SERVE, H; HSU, YC; BESMER, P			TYROSINE RESIDUE-719 OF THE C-KIT RECEPTOR IS ESSENTIAL FOR FINDING OF THE P85 SUBUNIT OF PHOSPHATIDYLINOSITOL (PI) 3-KINASE AND FOR C-KIT-ASSOCIATED PI 3-KINASE ACTIVITY IN COS-1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC SIGNALING PROTEINS; GTPASE-ACTIVATING PROTEIN; GROWTH-FACTOR RECEPTORS; KINASE INSERT DOMAIN; W-MUTANT MICE; PDGF RECEPTOR; SH2 DOMAINS; SI-LOCUS; V-KIT; LIGAND	The receptor tyrosine kinase c-kit is thought to mediate its diverse effects on different cell lineages by association and activation of distinct second messenger systems. One of the immediate events after binding of the kit ligand to the receptor is its association with the 85-kDa subunit (p85) of the phosphatidylinositol (PI) 2-kinase and the activation of the enzyme. In the present study, we examined the association and activation of PI 3-kinase with mutant forms of the c-kit receptor transiently expressed in COS-1 cells. To define the binding site of p85 we substituted the putative tyrosine phosphorylation sites in the kinase insert region of the c-Kit receptor by phenylalanine (YF702, YF719, YF728, and YF745, respectively). The results indicate that, upon stimulation of cells with kit ligand, 1) the wild-type c-kit protein was readily autophosphorylated and autophosphorylation was not diminished significantly with any of the mutant proteins; 2) p85 and PI 3-kinase activity associated with wild-type c-Kit protein as well as with the mutant proteins YF702, YF728, and YF745. Ligand-induced association of p85 and PIS-kinase activity were abolished with the YF719 c-Kit protein, and this was not due to different levels of expression of p85 or c-kit; and 3) c-kit receptor-bound p85 was not phosphorylated on tyrosine residues. These results indicate that tyrosine 719 within the (719)YMDM motif in the kinase insert plays an important role in binding of p85 and that its phosphorylation is a prerequisite for binding of p85 and the subsequent activation of PI 3-kinase.	SLOAN KETTERING INST,MOLEC BIOL PROGRAM,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University					NCI NIH HHS [R37 CA 32926] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA032926] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUANG EJ, 1993, DEV BIOL, V157, P100, DOI 10.1006/dbio.1993.1115; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; MANOVA K, 1992, J NEUROSCI, V12, P4663; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RAY P, 1991, GENE DEV, V5, P2265, DOI 10.1101/gad.5.12a.2265; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Silver W. K., 1979, COAT COLORS MICE MOD, P243; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YEE NS, 1993, J BIOL CHEM, V268, P14189; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	58	127	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6026	6030						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509796				2022-12-27	WOS:A1994MY84000083
J	MELEN, K; RONNI, T; LOTTA, T; JULKUNEN, I				MELEN, K; RONNI, T; LOTTA, T; JULKUNEN, I			ENZYMATIC CHARACTERIZATION OF INTERFERON-INDUCED ANTIVIRAL GTPASES MURINE MX1 AND HUMAN MXA PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA SYNTHESIS; INFLUENZA-VIRUS; CELLULAR PROTEINS; BINDING PROTEINS; LEUCINE ZIPPER; DYNAMIN; RESISTANCE; GTP; EXPRESSION; INHIBITION	Interferons induce a number of different proteins which mediate the antiproliferative, antiviral, and immunomodulatory functions of interferons. Interferon-induced Mx proteins, which confer resistance to influenza, vesicular stomatitis, and measles viruses, contain consensus GTPase sequence elements. Insect cell produced purified murine Mx1 and human MxA proteins were found to hydrolyze GTP with K(m) = 65 muM (V(max), 7.1 min-1) and 62 muM (V(max), 3.1 min-1), respectively. The GTPase activity of Mx1 and MxA proteins was strictly dependent on Mg2+ ions. Murine Mx1 protein was inactivated at 10-degrees-C lower temperatures than MxA protein. As analyzed, by filter binding assay, Mx1 protein (at 1 muM) showed a relatively high affinity for GDP (K(d) = 1.0 x 10(-7) m) and approximately 340-fold lower affinity for guanosine 5'-3-0-(thio)triphosphate (GTPgammaS) (K(d) = 3.4 x 10(-5) m). The K(d) values for MxA protein were 2.0 x 10(-7) m for GDP and 5.9 x 10(-6) m for GTPgammaS, showing approximately a 30-fold affinity difference. ATP, UTP, or CTP did not inhibit the Mx protein-dependent GTPase activity, suggesting that Mx1 and MxA proteins are highly specific for guanosine nucleotides. In conclusion recombinant nuclear murine Mx1 and cytoplasmic human MxA proteins show clear differences in their enzymatic activities and nucleotide binding characteristics. How these differences influence their cellular functions and antiviral potential is presently not known.	NATL PUBL HLTH INST,MOLEC BIOL PROGRAM,MANNERHEIMINTE 166,SF-00300 HELSINKI,FINLAND; ORION FARMOS PHARMACEUT,ORION RES CTR,SF-02100 ESPOO,FINLAND	Finland National Institute for Health & Welfare								AEBI M, 1989, MOL CELL BIOL, V9, P5062, DOI 10.1128/MCB.9.11.5062; ARNHEITER H, 1990, CELL, V62, P51, DOI 10.1016/0092-8674(90)90239-B; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HORISBERGER MA, 1991, VIROLOGY, V180, P185, DOI 10.1016/0042-6822(91)90022-4; HORISBERGER MA, 1992, J VIROL, V66, P4705, DOI 10.1128/JVI.66.8.4705-4709.1992; HORISBERGER MA, 1990, J VIROL, V64, P1171, DOI 10.1128/JVI.64.3.1171-1181.1990; JOHN J, 1988, J BIOL CHEM, V263, P12792; KRUG RM, 1985, J VIROL, V56, P201, DOI 10.1128/JVI.56.1.201-206.1985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MELEN K, 1992, J BIOL CHEM, V267, P25898; NAKAYAMA M, 1991, J BIOL CHEM, V266, P21404; NAKAYAMA M, 1992, VIRUS RES, V22, P227, DOI 10.1016/0168-1702(92)90054-D; NEAL SE, 1988, J BIOL CHEM, V263, P19718; NOTEBORN M, 1987, J INTERFERON RES, V7, P657, DOI 10.1089/jir.1987.7.657; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; PAVLOVIC J, 1992, J VIROL, V66, P2564, DOI 10.1128/JVI.66.4.2564-2569.1992; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; RONNI T, 1993, J IMMUNOL, V150, P1715; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SCHNORR JJ, 1993, J VIROL, V67, P4760, DOI 10.1128/JVI.67.8.4760-4768.1993; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; STAEHELI P, 1991, J VIROL, V65, P4498, DOI 10.1128/JVI.65.8.4498-4501.1991; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; STRIDH S, 1983, ARCH VIROL, V77, P223, DOI 10.1007/BF01309269; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555, P11; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WEITZ G, 1989, J INTERFERON RES, V9, P679, DOI 10.1089/jir.1989.9.679	37	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2009	2015						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507489				2022-12-27	WOS:A1994MR98800071
J	FOO, NC; FUNKHOUSER, JM; CARTER, DA; MURPHY, D				FOO, NC; FUNKHOUSER, JM; CARTER, DA; MURPHY, D			A TESTIS-SPECIFIC PROMOTER IN THE RAT VASOPRESSIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTICULAR ANDROGEN BIOSYNTHESIS; MESSENGER-RNA; ARGININE-VASOPRESSIN; PROTO-ONCOGENE; LEYDIG-CELLS; VITAMIN-A; TRANSCRIPTION INITIATION; DIFFERENTIAL EXPRESSION; DIRECT INHIBITION; BINDING-PROTEIN	In the rat testis, the vasopressin gene is transcribed into precursor RNAs that are processed into a number of mature transcripts. One of these transcripts has a structure identical to that of the hypothalamic RNA that encodes the vasopressin prepropeptide, but is present at such low levels that it can only be detected by the polymerase chain reaction. Other vasopressin-like RNAs are derived from differential splicing events that join transcribed sequences between 3 and 9 kilobases upstream of the hypothalamic transcription start site to exons corresponding to II and III of the hypothalamic-type RNA. Here we describe the sequence of a testis-specific promoter and the exon structure of its transcription unit. We show that an in vitro synthesized RNA corresponding to the longer testicular vasopressin gene-derived transcript is not able to act as a template for protein synthesis in two different cell-free lysates. As attempts to localize the vasopressin-gene derived RNAs to particular cell types in the testis by in situ hybridization have consistently failed, we have used indirect methods. Three different procedures were used to effect germ cell depletion in adult male rats. Acute heat treatment of the testis, chronic ingestion of hydroxyurea, and chronic vitamin A deficiency all reduced the level of the aberrant testicular vasopressin-gene derived RNAs, indicating that their expression is closely associated with the integrity of germ cells and ongoing spermatogenesis.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,NEUROPEPTIDE LAB,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Carter, David/A-4479-2010; Murphy, David/C-3967-2012	Carter, David/0000-0002-8419-3975; Murphy, David/0000-0003-2946-0353				ADASHI EY, 1981, NATURE, V293, P650, DOI 10.1038/293650a0; ADASHI EY, 1981, ENDOCRINOLOGY, V109, P1793, DOI 10.1210/endo-109-5-1793; ADASHI EY, 1981, J BIOL CHEM, V257, P1301; AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; AHLUWALIA B, 1971, J NUTR, V100, P715; ANG HL, 1991, ENDOCRINOLOGY, V128, P2110, DOI 10.1210/endo-128-4-2110; APPLING DR, 1981, ENDOCRINOLOGY, V108, P2120, DOI 10.1210/endo-108-6-2120; BROWNSTEIN MJ, 1980, SCIENCE, V207, P373, DOI 10.1126/science.6153132; COLLINS P, 1969, PROC R SOC SER B-BIO, V172, P17, DOI 10.1098/rspb.1969.0009; COMB M, 1982, NATURE, V295, P663, DOI 10.1038/295663a0; ERICKSON RP, 1990, TRENDS GENET, V6, P264, DOI 10.1016/0168-9525(90)90209-O; FOO NC, 1991, ENDOCRINOLOGY, V128, P2118, DOI 10.1210/endo-128-4-2118; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GARRETT JE, 1989, MOL CELL BIOL, V9, P4381, DOI 10.1128/MCB.9.10.4381; HAKE LE, 1993, J BIOL CHEM, V268, P4788; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; HUANG HFS, 1979, BIOL REPROD, V21, P891, DOI 10.1095/biolreprod21.4.891; HUANG HFS, 1983, ENDOCRINOLOGY, V112, P1163, DOI 10.1210/endo-112-4-1163; HUGGENVIK JI, 1987, ENDOCRINOLOGY, V120, P332, DOI 10.1210/endo-120-1-332; IVELL R, 1992, MOL CELL ENDOCRINOL, V89, P59, DOI 10.1016/0303-7207(92)90211-N; IVELL R, 1986, EMBO J, V5, P971, DOI 10.1002/j.1460-2075.1986.tb04311.x; IVELL R, 1992, INT J ANDROL, V15, P85, DOI 10.1111/j.1365-2605.1992.tb01117.x; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; JEANNOTTE L, 1987, MOL ENDOCRINOL, V1, P749, DOI 10.1210/mend-1-10-749; KASSON BG, 1986, ENDOCRINOLOGY, V118, P23, DOI 10.1210/endo-118-1-23; KASSON BG, 1986, ENDOCR REV, V7, P156, DOI 10.1210/edrv-7-2-156; KASSON BG, 1985, J BIOL CHEM, V260, P5302; KATZ A, 1988, J BIOL CHEM, V263, P7604; KEIME S, 1990, EUR J BIOCHEM, V190, P200; KILPATRICK DL, 1990, MOL CELL BIOL, V10, P3717, DOI 10.1128/MCB.10.7.3717; KILPATRICK DL, 1987, P NATL ACAD SCI USA, V84, P5695, DOI 10.1073/pnas.84.16.5695; LACAZEMASMONTEIL T, 1987, P NATL ACAD SCI USA, V84, P7261, DOI 10.1073/pnas.84.20.7261; LEFEBVRE DL, 1991, MOL ENDOCRINOL, V5, P645, DOI 10.1210/mend-5-5-645; MECKLENBURG RS, 1975, ENDOCRINOLOGY, V96, P564, DOI 10.1210/endo-96-3-564; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; MORALES CR, 1989, MOL ENDOCRINOL, V3, P725, DOI 10.1210/mend-3-4-725; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PAULES RS, 1988, ONCOGENE, V3, P59; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; REEVES WB, 1992, WILLIAMS TXB ENDOCRI, P311; RENAUD LP, 1991, PROG NEUROBIOL, V36, P131, DOI 10.1016/0301-0082(91)90020-2; RICH KA, 1977, ENDOCRINOLOGY, V101, P959, DOI 10.1210/endo-101-3-959; RICHTER D, 1988, AM J PHYSIOL, V255, pF207, DOI 10.1152/ajprenal.1988.255.2.F207; Sambrook J, 1989, MOL CLONING LABORATO; SHARPE RM, 1987, J ENDOCRINOL, V113, P89, DOI 10.1677/joe.0.1130089; STALLARD BJ, 1990, MOL ENDOCRINOL, V4, P393, DOI 10.1210/mend-4-3-393; STALLARD BJ, 1991, MOL CELL BIOL, V11, P1448, DOI 10.1128/MCB.11.3.1448; STRUHL K, 1990, CURENT PROTOCOLS MOL, V2; TAHRIJOUTEI A, 1988, J REPROD FERTIL, V82, P247, DOI 10.1530/jrf.0.0820247; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; TREIZENBERG SJ, 1990, CURRENT PROTOCOLS MO, V1; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WIDMARK A, 1991, INT J ANDROL, V14, P58, DOI 10.1111/j.1365-2605.1991.tb01063.x; WILLIAMS TDM, 1985, ENDOCRINOLOGY, V116, P738, DOI 10.1210/endo-116-2-738; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4; WOLGEMUTH DJ, 1987, P NATL ACAD SCI USA, V84, P5813, DOI 10.1073/pnas.84.16.5813; YOUNG WS, 1992, J NEUROENDOCRINOL, V4, P527, DOI 10.1111/j.1365-2826.1992.tb00201.x; ZAKERI ZF, 1988, DEV BIOL, V125, P417, DOI 10.1016/0012-1606(88)90222-9	58	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					659	667						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506260				2022-12-27	WOS:A1994MR21900104
J	ODA, Y; KUO, MD; HUANG, SS; HUANG, JS				ODA, Y; KUO, MD; HUANG, SS; HUANG, JS			THE MAJOR ACIDIC FIBROBLAST GROWTH-FACTOR (AFGF)-STIMULATED PHOSPHOPROTEIN FROM BOVINE LIVER PLASMA-MEMBRANES HAS AFGF-STIMULATED KINASE, AUTOADENYLYLATION, AND ALKALINE NUCLEOTIDE PHOSPHODIESTERASE ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC ENDOTHELIAL-CELLS; GLYCOPROTEIN PC-1; HUMAN-PLATELETS; THREONINE; PEPTIDE; IDENTIFICATION; ADENYLYLATION; PURIFICATION; SEQUENCE; ANTIGEN	The major acidic fibroblast growth factor (aFGF)-stimulated phosphoprotein (MAFP) purified from bovine liver exhibits kinase, autoadenylylation, and alkaline nucleotide phosphodiesterase activities depending upon reaction conditions. In the presence of divalent ions, MAFP showed intrinsic and aFGF-stimulated kinase activities (autophosphorylation) using either [gamma-P-32]ATP or [gamma-P-32]GTP as a substrate. The autophosphorylation activity of MAFP was stimulated at low concentrations of Ca2+, Mg2+, or Mn2+ (0.2-2 muM). Depletion of the divalent ions by EDTA abolished the autophosphorylation activity but enhanced the autoadenylylation activity of MAFP. [Alpha-P-32]ATP as well as [alpha-P-32]NAD could serve as substrates for autoadenylylation activity of MAFP. aFGF appeared to enhance the autoadenylylation activity of MAFP with an optimal concentration (0.6-1.2 nM). P1,P3-di(adenosine-5')-triphosphate (AP3A) was found to be a potent inhibitor for the autophosphorylation and autoadenylylation activities of MAFP. Analyses by automated Edman degradation of the adenylylated and phosphorylated peptides derived from autoadenylylated and autophosphorylated MAFP revealed that both autoadenylylation and autophosphorylation occurred at residue Thr204. The kinase and autoadenylylation activities of MAFP had an optimal pH of 6.9-7.4. However, at pH 8.9, MAFP showed intrinsic and aFGF-stimulated phosphodiesterase activities. aFGF appeared to stimulate the phosphodiesterase activity of MAFP without altering the K(m) (approximately 0.2 mM) of its substrate.	ST LOUIS UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, 1402 S GRAND BLVD, ST LOUIS, MO 63104 USA	Saint Louis University					NCI NIH HHS [CA 38808] Funding Source: Medline; NHLBI NIH HHS [HL 41782] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041782] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADLEY MK, 1984, P NATL ACAD SCI-BIOL, V81, P6574, DOI 10.1073/pnas.81.21.6574; BUCKLEY MF, 1990, J BIOL CHEM, V265, P17506; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CODINI M, 1992, BIOCHEM INT, V28, P989; CULP JS, 1985, J BIOL CHEM, V260, P8320; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EVANS WH, 1973, BIOCHEM J, V135, P819, DOI 10.1042/bj1350819; FLODGAARD H, 1982, BIOCHEM J, V208, P737, DOI 10.1042/bj2080737; HARTMANN M, 1992, BIOCHIM BIOPHYS ACTA, V1136, P189, DOI 10.1016/0167-4889(92)90256-B; HUANG JS, 1986, J BIOL CHEM, V261, P1600; HUANG JS, 1982, J BIOL CHEM, V257, P8130; HUANG SS, 1986, J BIOL CHEM, V261, P9568; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; JOSE ES, 1990, J BIOL CHEM, V265, P20653; KUO MD, 1990, J BIOL CHEM, V265, P16455; LUTHJE J, 1983, BIOCHEM BIOPH RES CO, V115, P253, DOI 10.1016/0006-291X(83)90997-X; MARSHAK DR, 1991, METHOD ENZYMOL, V200, P134; MARUYAMA E, 1993, BIOCHEM MOL BIOL INT, V29, P579; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; ODA Y, 1991, J BIOL CHEM, V266, P16791; PIROTTON S, 1992, BIOCHEM J, V285, P585, DOI 10.1042/bj2850585; RAZZELL WE, 1963, METHOD ENZYMOL, V6, P236, DOI 10.1016/0076-6879(63)06169-3; REBBE NF, 1991, P NATL ACAD SCI USA, V88, P5192, DOI 10.1073/pnas.88.12.5192; SKUBITZ KM, 1991, BIOCHEM BIOPH RES CO, V174, P49, DOI 10.1016/0006-291X(91)90483-N; TAKAHASHI T, 1970, J EXP MED, V131, P1325, DOI 10.1084/jem.131.6.1325; VANDRIEL IR, 1987, J BIOL CHEM, V262, P4882; WANG YH, 1988, ANAL BIOCHEM, V174, P537, DOI 10.1016/0003-2697(88)90053-X	28	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27318	27326						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7505270				2022-12-27	WOS:A1993MM26200070
J	SCHMIDT, J; BUBUNENKO, M; SUBRAMANIAN, AR				SCHMIDT, J; BUBUNENKO, M; SUBRAMANIAN, AR			A NOVEL OPERON ORGANIZATION INVOLVING THE GENES FOR CHORISMATE SYNTHASE (AROMATIC BIOSYNTHESIS PATHWAY) AND RIBOSOMAL GTPASE CENTER PROTEINS (L11, L1, L10, L12-RPLKAJL) IN CYANOBACTERIUM SYNECHOCYSTIS PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORYDALIS-SEMPERVIRENS PERS; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; EQUIVALENT; PURIFICATION; CLUSTER; CHLOROPLASTS; PRECURSOR	Many of the ribosomal protein (RP) genes in both bacterial and chloroplast genomes occur, for reasons not yet understood, in operons that include nonribosomal genes. Here we report such an operon organization in a cyanobacterium (Synechocystis PCC6803) involving the genes for four RPs that are important in the GTPase function of the ribosome and the aroC gene encoding chorismate synthase, a key enzyme in the shikimate pathway for biosynthesis of aromatic amino acids and cell wall components. The Synechocystis aroC encodes a 362-amino-acid residue protein which is 52, 60, and 68% identical to two eubacterial (both 52%), yeast, and a higher plant (Corydalis) chorismate synthase, respectively. The gene was overexpressed in Escherichia coli, and the gene product was shown to cross-react with antibodies to Corydalis chorismate synthase; it also complemented an aroC-lacking E. coli strain. The Synechocystis rpl1 and rpl11 genes encode polypeptides of 237 and 141 amino acid residues, respectively, also with high sequence identities to the corresponding RP sequences from other eubacteria and higher plant chloroplasts. The gene order is shown to be: rpl11-86bp spacer-rpl1-460bp spacer-rpl10-87-bp spacer-rpl12-206bp spacer-aroC. Southern and Northern blot analyses of Synechocystis DNA and RNA, respectively, revealed a single cluster of these genes per genome which is transcribed from a common promoter to an unusually long, approximately 9500-nucleotide transcript. Several constructs of the cyanobacterial aroC and rpl12 genes were made and expressed in E. coli to examine the mechanisms for their very differential expression from a polycistronic mRNA (e.g. four copies L12/ribosome; chorismate synthase, a non-abundant protein). These results present the first biochemical/molecular genetic evidence of shikimate pathway in the cyanobacterial group.	MAX PLANCK INST MOLEC GENET,IHNESTR 73,D-14195 BERLIN,GERMANY	Max Planck Society								ALLEN MM, 1968, J GEN MICROBIOL, V51, P199, DOI 10.1099/00221287-51-2-199; ANDERSSON SGE, 1990, MICROBIOL REV, V54, P198, DOI 10.1128/MMBR.54.2.198-210.1990; ARNDT E, 1990, NUCLEIC ACIDS RES, V18, P1285, DOI 10.1093/nar/18.5.1285; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BAIER G, 1990, NUCLEIC ACIDS RES, V18, P719, DOI 10.1093/nar/18.4.719; BARTSCH M, 1982, P NATL ACAD SCI-BIOL, V79, P6871, DOI 10.1073/pnas.79.22.6871; BAUGHMAN G, 1984, P NATL ACAD SCI-BIOL, V81, P5389, DOI 10.1073/pnas.81.17.5389; BRAUER D, 1978, FEBS LETT, V96, P317, DOI 10.1016/0014-5793(78)80426-8; CHARLES IG, 1990, J GEN MICROBIOL, V136, P353, DOI 10.1099/00221287-136-2-353; CHRISTENSEN T, 1984, EMBO J, V3, P1609, DOI 10.1002/j.1460-2075.1984.tb02018.x; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; DAVIS BD, 1992, ANNU REV MICROBIOL, V46, P1; DELLACIOPPA G, 1986, P NATL ACAD SCI USA, V83, P6873, DOI 10.1073/pnas.83.18.6873; DOGNIN MJ, 1980, EUR J BIOCHEM, V84, P342; DOUGLAS SE, 1984, NUCLEIC ACIDS RES, V12, P3373, DOI 10.1093/nar/12.7.3373; DOWNING WL, 1987, J MOL BIOL, V194, P609, DOI 10.1016/0022-2836(87)90238-5; GOLDEN SS, 1987, METHOD ENZYMOL, V153, P215; HARDY SJS, 1975, MOL GEN GENET, V140, P253, DOI 10.1007/BF00334270; HASAN N, 1978, J BIOL CHEM, V251, P4993; HEIN J, 1989, MOL BIOL EVOL, V6, P649; JONES DGL, 1991, MOL MICROBIOL, V5, P2143, DOI 10.1111/j.1365-2958.1991.tb02144.x; KIMURA M, 1985, EUR J BIOCHEM, V150, P491, DOI 10.1111/j.1432-1033.1985.tb09049.x; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P627, DOI 10.1146/annurev.bi.57.070188.003211; KROGER M, 1991, NUCLEIC ACIDS RES, V19, P2023, DOI 10.1093/nar/19.suppl.2023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI D, 1992, J BIOL CHEM, V267, P22787; LISSER S, 1993, NUCLEIC ACIDS RES, V21, P1507, DOI 10.1093/nar/21.7.1507; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MOUSDALE DM, 1986, FEBS LETT, V205, P328, DOI 10.1016/0014-5793(86)80922-X; PITTARD AJ, 1987, ESCHERICHIA COLI SAL, P368; PUCCIARELLI MG, 1990, NUCLEIC ACIDS RES, V18, P4409, DOI 10.1093/nar/18.15.4409; Sambrook J, 1989, MOL CLONING LABORATO; SANDER G, 1983, J BIOL CHEM, V258, P98; SCHALLER A, 1991, J BIOL CHEM, V266, P21434; SCHALLER A, 1990, ARCH BIOCHEM BIOPHYS, V282, P437, DOI 10.1016/0003-9861(90)90141-K; SCHMIDT J, 1993, NUCLEIC ACIDS RES, V21, P2519, DOI 10.1093/nar/21.10.2519; SHIMMIN LC, 1989, EMBO J, V8, P1225, DOI 10.1002/j.1460-2075.1989.tb03496.x; SIBOLD C, 1990, BIOCHIM BIOPHYS ACTA, V1050, P61, DOI 10.1016/0167-4781(90)90142-O; SMOOKER PM, 1991, BIOCHIMIE, V73, P845, DOI 10.1016/0300-9084(91)90064-8; SOR F, 1987, MOL GEN GENET, V180, P52; STARK M, 1979, J MOL BIOL, V134, P767, DOI 10.1016/0022-2836(79)90485-6; SUBRAMANIAN AR, 1980, EUR J BIOCHEM, V112, P425, DOI 10.1111/j.1432-1033.1980.tb07222.x; SUBRAMANIAN AR, 1975, J MOL BIOL, V95, P1, DOI 10.1016/0022-2836(75)90330-7; SUBRAMANIAN AR, 1993, TRENDS BIOCHEM SCI, V18, P177, DOI 10.1016/0968-0004(93)90110-9; SUBRAMANIAN AR, 1991, TRANSLATIONAL APPARA, P95; WADA KN, 1992, NUCLEIC ACIDS RES, V20, P2111, DOI 10.1093/nar/20.suppl.2111; WHITE PJ, 1988, BIOCHEM J, V251, P313, DOI 10.1042/bj2510313; WILSON EO, 1989, BIODIVERSITY, P3; WITTMANNLIEBOLD B, 1990, RIBOSOME, P598; XIE WQ, 1991, ARCH BIOCHEM BIOPHYS, V284, P22, DOI 10.1016/0003-9861(91)90256-I	51	19	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27447	27457						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	7505271				2022-12-27	WOS:A1993MM26200086
J	HILBICH, C; MONNING, U; GRUND, C; MASTERS, CL; BEYREUTHER, K				HILBICH, C; MONNING, U; GRUND, C; MASTERS, CL; BEYREUTHER, K			AMYLOID-LIKE PROPERTIES OF PEPTIDES FLANKING THE EPITOPE OF AMYLOID PRECURSOR PROTEIN-SPECIFIC MONOCLONAL ANTIBODY-22C11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; CONGO RED; BETA-A4 PEPTIDES; CONFORMATION; IDENTIFICATION; BINDING	Alzheimer's disease is one of the prevalent forms of human dementia. Its pathology is distinguished by proteinaceous deposits (''amyloid'') in the brain. They contain a peptide (betaA4) that is proteolytically derived from a larger transmembrane protein. To follow the different metabolic pathways of this Amyloid Precursor Protein (APP) may thus lead to the elucidation of the molecular basis of Alzheimer's disease. Specific antibodies are necessary tools for this task. Using synthetic peptides, we have characterized the epitope of the APP-specific monoclonal antibody 22C11; it is localized between residues 66 and 81 of APP. Some of the peptides flanking this site exhibited properties generally associated with amyloid, i.e. low solubility, filament formation, and birefringence after Congo Red staining. Exploiting differences in the peptides' aggregational properties, we present evidence that the two dyes Eosin and Direct Red 254, in conjunction with classical amyloid staining by Congo Red, can be used to characterize aggregating, amyloid-like peptides in vitro.	GERMAN CANC RES CTR,DEPT CELL BIOL,D-69120 HEIDELBERG,GERMANY; UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA	Helmholtz Association; German Cancer Research Center (DKFZ); University of Melbourne	HILBICH, C (corresponding author), UNIV HEIDELBERG,CTR MOLEC BIOL,NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.							BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; CAPUTO CB, 1992, ARCH BIOCHEM BIOPHYS, V292, P199, DOI 10.1016/0003-9861(92)90068-8; CASTANO EM, 1988, LAB INVEST, V58, P122; COOPER JH, 1974, LAB INVEST, V31, P232; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1972, J HISTOCHEM CYTOCHEM, V20, P821, DOI 10.1177/20.10.821; HARDY J, 1992, NAT GENET, V1, P233, DOI 10.1038/ng0792-233; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HILBICH C, 1991, EUR J BIOCHEM, V201, P61, DOI 10.1111/j.1432-1033.1991.tb16256.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; KOSIK KS, 1992, SCIENCE, V256, P780, DOI 10.1126/science.1589757; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENARD J, 1967, J AM CHEM SOC, V89, P181, DOI 10.1021/ja00977a057; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; ROSEN DR, 1989, P NATL ACAD SCI USA, V86, P2478, DOI 10.1073/pnas.86.7.2478; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNELL WG, 1992, J MOL BIOL, V227, P1205, DOI 10.1016/0022-2836(92)90532-O; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	24	132	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26571	26577						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	7504673				2022-12-27	WOS:A1993MK42500081
J	DIVITA, G; BAILLON, JG; RITTINGER, K; CHERMANN, JC; GOODY, RS				DIVITA, G; BAILLON, JG; RITTINGER, K; CHERMANN, JC; GOODY, RS			INTERFACE PEPTIDES AS STRUCTURE-BASED HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPESVIRUS RIBONUCLEOTIDE REDUCTASE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; SUBUNIT BINDING; HIV-1; DIMERIZATION; HETERODIMER; RESISTANCE; EXPRESSION	Reverse transcriptases from both human immunodeficiency viruses type 1 and 2 are obligatory dimers. A tryptophan-rich repeat motif that is highly conserved between these proteins, as well as in the reverse transcriptase from simian immunodeficiency virus, has been postulated to be involved in hydrophobic subunit interactions. A synthetic 19-mer peptide covering part of this tryptophan repeat motif was recently shown to inhibit human immunodeficiency viruses type 1 reverse transcriptase subunit dimerization (Divita, G., Restle, T., Goody, R. S., Chermann, J.-C., and Baillon, J. G. (1994) J. Biol. Chem. 269, 13080-13083). In the present study, we show that the same peptide can also inhibit human immunodeficiency virus type 2 reverse transcriptase subunit dimerization, suggesting that the same inhibitors might be used as agents against both viruses as well as against variants of human immunodeficiency virus type 1 that differ from the variant against which they were developed. Under appropriate experimental conditions, e.g. at acidic pH, this peptide is also able to induce the dissociation of the enzyme from human immunodeficiency virus type 1.	MAX PLANCK INST MOLEK PHYSIOL, D-44139 DORTMUND, GERMANY; MAX PLANCK INST MED RES, BIOPHYS ABT, D-69120 HEIDELBERG, GERMANY; INSERM, U322, F-13273 MARSEILLE 09, FRANCE	Max Planck Society; Max Planck Society; Institut National de la Sante et de la Recherche Medicale (Inserm)			DIVITA, GILLES/AAV-9214-2021; Rittinger, Katrin/D-2586-2014; Rittinger, Katrin/N-3344-2019; Goody, Roger S/J-8845-2014	Rittinger, Katrin/0000-0002-7698-4435; Rittinger, Katrin/0000-0002-7698-4435; Goody, Roger S/0000-0002-0772-0444				BAILLON JG, 1991, NEW BIOL, V3, P1015; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDRA A, 1986, FEBS LETT, V200, P327, DOI 10.1016/0014-5793(86)81162-0; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; DEVICO AL, 1989, AIDS RES HUM RETROV, V5, P51, DOI 10.1089/aid.1989.5.51; DIVITA G, 1993, FEBS LETT, V324, P153, DOI 10.1016/0014-5793(93)81383-B; DIVITA G, 1994, J BIOL CHEM, V269, P13080; DIVITA G, 1995, J MOL BIOL, V245, P508, DOI 10.1006/jmbi.1994.0042; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; HOWARD KJ, 1991, J BIOL CHEM, V266, P23003; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LIUZZI M, 1994, NATURE, V372, P695, DOI 10.1038/372695a0; MULLER B, 1989, J BIOL CHEM, V264, P13975; MULLER B, 1991, J BIOL CHEM, V266, P14709; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RESTLE T, 1992, FEBS LETT, V300, P97, DOI 10.1016/0014-5793(92)80172-D; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WANG J, 1994, P NATL ACAD SCI USA, V91, P7242, DOI 10.1073/pnas.91.15.7242; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591	30	29	30	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28642	28646		10.1074/jbc.270.48.28642	http://dx.doi.org/10.1074/jbc.270.48.28642			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499382	hybrid			2022-12-27	WOS:A1995TH05600026
J	ICHIMURA, T; UCHIYAMA, J; KUNIHIRO, O; ITO, M; HORIGOME, T; OMATA, S; SHINKAI, F; KAJI, H; ISOBE, T				ICHIMURA, T; UCHIYAMA, J; KUNIHIRO, O; ITO, M; HORIGOME, T; OMATA, S; SHINKAI, F; KAJI, H; ISOBE, T			IDENTIFICATION OF THE SITE OF INTERACTION OF THE 14-3-3-PROTEIN WITH PHOSPHORYLATED TRYPTOPHAN-HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							KINASE-DEPENDENT ACTIVATOR; TYROSINE	The 14-3-3 protein family plays a role in a wide variety of cell signaling processes including monoamine synthesis, exocytosis, and cell cycle regulation, but the structural requirements for the activity of this protein family are not known, We have previously shown that the 14-3-3 protein binds with and activates phosphorylated tryptophan hydroxylase (TPH, the rate-limiting enzyme in the biosynthesis of neurotransmitter serotonin) and proposed that this activity might be mediated through the COOH-terminal acidic region of the 14-3-3 molecules. In this report we demonstrate, using a series of truncation mutants of the 14-3-3 eta isoform expressed in Escherichia coli, that the COOH-terminal region, especially restricted in amino acids 171-213, binds indeed with the phosphorylated TPH. This restricted region, which we termed 14-3-3 box I, is one of the structural regions whose sequence is highly conserved beyond species, allowing that the plant 14-3-3 isoform (GF14) could also activate rat brain TPH. The 14-3-3 box I is the first functional region whose activity has directly been defined in the 14-3-3 sequence and may represent a common structural element whereby 14-3-3 interacts with other target proteins such as Raf-1 kinase, The result is consistent with the recently published crystal structure of this protein family, which suggests the importance of the negatively charged groove like structure in the ligand binding.	TOKYO METROPOLITAN UNIV, FAC SCI, DEPT CHEM, HACHIOJI 19203, TOKYO, JAPAN	Tokyo Metropolitan University	ICHIMURA, T (corresponding author), NIIGATA UNIV, FAC SCI, DEPT BIOCHEM, 2-IGARASHI, NIIGATA 95021, JAPAN.		Shinkai-ouchi, Fumiko/E-3207-2010; Isobe, Toshiaki/Q-9279-2017; Kaji, Hiroyuki/L-7122-2018	Shinkai-ouchi, Fumiko/0000-0002-0095-941X; Kaji, Hiroyuki/0000-0002-0910-9999				AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ISOBE T, 1992, FEBS LETT, V308, P121, DOI 10.1016/0014-5793(92)81257-M; ISOBE T, 1991, J MOL BIOL, V217, P125, DOI 10.1016/0022-2836(91)90616-E; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LU GH, 1994, PLANT MOL BIOL, V25, P659, DOI 10.1007/BF00029604; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Moore BE, 1967, PHYSL BIOCH ASPECTS, P343; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Sambrook J, 1989, MOL CLONING LABORATO; TANJI M, 1994, J NEUROCHEM, V63, P1908; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; YAMAUCHI T, 1981, J BIOL CHEM, V256, P5404	17	76	77	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28515	28518		10.1074/jbc.270.48.28515	http://dx.doi.org/10.1074/jbc.270.48.28515			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499362	hybrid			2022-12-27	WOS:A1995TH05600006
J	PITTMAN, N; SHUE, GL; LELEIKO, NS; WALSH, MJ				PITTMAN, N; SHUE, GL; LELEIKO, NS; WALSH, MJ			TRANSCRIPTION OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR REQUIRES A CCAAT-LIKE ELEMENT FOR BOTH BASAL AND CAMP-MEDIATED REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ENHANCER BINDING-PROTEIN; EPITHELIAL-CELLS; GENE-EXPRESSION; DOWN-REGULATION; LEUCINE ZIPPER; RESPONSE ELEMENT; PROMOTER REGION; C/EBP ISOFORMS; PHORBOL ESTER	The cystic fibrosis transmembrane conductance regulator (CFTR) gene in man is controlled by a tightly regulated and weak promoter. The architecture of the CFTR promoter suggests regulatory characteristics that are consistent with the absence of a TATA-like sequence, including the ability to initiate RNA transcription at numerous positions. Detailed investigation of the most proximal region of the human CFTR gene promoter through deletion and mutational analysis reveals that expression is contingent on the conservation of the inverted CCAAT sequence. Basal expression of CFTR transcription and cAMP-mediated transcriptional regulation require the presence of an imperfect and inverted CCAAT element recognized as 5'-AATTGGAAGCAAAT-3', located between 132 and 119 nucleotides upstream of the translational start site. RNA isolated from a transfected pancreatic cell line carrying integrated wild-type and mutant CFTR-directed transgenes was used to map the 5' termini of the transgenic transcripts. Analysis of the transcript termini by ribonuclease protection analysis reflects the direct association of the conserved inverted CCAAT sequence in promoting transcript initiation. Because of the requirement for the inverted CCAAT sequence for promoting transcription of CFTR, the involvement of CCAAT-binding factors is suspected in the regulation of CFTR gene transcription. To test this, we used electrophoretic mobility shift assays to demonstrate that the majority of the binding to the inverted CCAAT element, between -135 and -116, was easily competed for by binding to cognate nucleotide sequences for CCAAT-enhancer binding protein (C/EBP). An antibody specific for the C/EBP-related protein, C/EBP delta, detected C/EBP delta as part of a nuclear protein complex bound to the inverted CCAAT sequence of the CFTR gene. Also, the detection of specific activating transcription factor/cyclic-AMP response element binding protein antigens by antibody supershift analysis of nuclear complexes suggest that species of this family of transcription factors could be involved in the formation of complexes with C/EBP delta within the CFTR gene inverted CCAAT-like element. These studies raise the possibility of interactions between individual members of the C/EBP and activating transcription factor/cyclic-AMP response element binding protein families potentially contribute to the tight transcriptional control rendered by the CFTR gene promoter.	CUNY MT SINAI SCH MED,DEPT PEDIAT,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			LeLeiko, Neal/GRJ-6855-2022	leleiko, neal/0000-0001-7699-1400				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARGON J, 1992, MOL CELL BIOL, V12, P1872, DOI 10.1128/MCB.12.4.1872; BARGON J, 1992, J BIOL CHEM, V267, P16056; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; BREUER W, 1993, J BIOL CHEM, V268, P13935; BREUER W, 1992, J BIOL CHEM, V267, P10465; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHENKIANG S, 1993, CURR OPIN IMMUNOL, V5, P124, DOI 10.1016/0952-7915(93)90091-6; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHOU JL, 1991, J BIOL CHEM, V266, P24471; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; DIEHL AM, 1994, HEPATOLOGY, V19, P447; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P7863; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAGAWA N, 1990, J BIOL CHEM, V265, P11299; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KINANE TB, 1992, J BIOL CHEM, V268, P24669; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KOH J, 1993, J BIOL CHEM, V268, P15912; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1989, SCIENCE, V243, P681; LEVINE A, 1992, P NATL ACAD SCI USA, V89, P10119, DOI 10.1073/pnas.89.21.10119; LUND J, 1990, J BIOL CHEM, V265, P3304; MCKNIGHT S, 1987, CELL, V46, P795; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MONTMINY MR, 1986, P NATL ACAD SCI USA, V86, P56; MURO AF, 1992, J BIOL CHEM, V267, P12767; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PARK EA, 1992, J BIOL CHEM, V268, P613; PARK K, 1993, J BIOL CHEM, V268, P17811; PITTMAN N, 1994, PEDIATR RES, V35, pA904; QUITON PM, 1990, FASEB J, V4, P2709; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SIERRA F, 1990, LABORATORY GUIDE IN, P30; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SOOD R, 1992, EMBO J, V11, P2487, DOI 10.1002/j.1460-2075.1992.tb05313.x; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VELLEJO M, 1994, TRANSCRIPTION MECHAN, P353; VINSON CR, 1988, SCIENCE, V246, P911; WALSH MJ, 1992, J BIOL CHEM, V267, P7026; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140	60	61	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28848	28857		10.1074/jbc.270.48.28848	http://dx.doi.org/10.1074/jbc.270.48.28848			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499410	hybrid			2022-12-27	WOS:A1995TH05600054
J	SHAW, P; KNEZ, J; CAPONE, JP				SHAW, P; KNEZ, J; CAPONE, JP			AMINO-ACID SUBSTITUTIONS IN THE HERPES-SIMPLEX VIRUS TRANSACTIVATOR VP16 UNCOUPLE DIRECT PROTEIN-PROTEIN INTERACTION AND DNA-BINDING FROM COMPLEX ASSEMBLY AND TRANSACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-ACTIVATOR; HOMEO DOMAIN; TRANSCRIPTION COMPLEX; MUTATIONAL ANALYSIS; REGULATORY PROTEIN; CELLULAR PROTEINS; POSITIVE CONTROL; GENE-EXPRESSION; FACTOR VMW65; OCT-1	The herpes simplex virus transactivator VP16 directs the assembly of a multicomponent protein-DNA complex that requires the participation of two cellular factors, the POU homeodomain protein Oct-1, which binds independently to response elements, and VCAF-1 (VP16 complex assembly factor; also called HCF, C1), a factor that binds directly to VP16. A number of distinct properties of VP16 have been implicated in the assembly of the VP16-induced complex (VIC). These include its independent association with VCAF-1 and, under appropriate conditions, its ability to bind to DNA or to DNA-bound Oct-1 in the absence of VCAF-1, In order to probe the requirements of these individual interactions in the functional asembly of VIC, we mutated selected charged amino acids in two subdomains of VP16 previously shown to be important in protein-DNA complex formation, Purified VP16 proteins were analyzed for their ability to direct protein-DNA complex formation and to interact directly with VCAF-1. Several classes of mutants that were differentially compromised in VCAF-1 interaction, direct DNA binding, and/or association with DNA-bound Oct-1 were obtained. Interestingly, all of the derivatives were still capable of generating the VIC complex in vitro and activating transcription in vivo, Our findings indicate that the cooperative assembly of functional VP16-containing complexes can occur by pathways that do not necessarily require the prior interaction of VP16 with VCAF-1 or the ability of VP16 to bind directly to DNA or associate with DNA-bound Oct-1.	MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA	McMaster University								ACE CI, 1988, J GEN VIROL, V69, P2595, DOI 10.1099/0022-1317-69-10-2595; APRHYS CMJ, 1989, J VIROL, V63, P2798, DOI 10.1128/JVI.63.6.2798-2812.1989; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLEARY MA, 1995, MOL CELL BIOL, V15, P2090; CLEARY MA, 1993, GENE DEV, V7, P72, DOI 10.1101/gad.7.1.72; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; DOUVILLE P, 1995, VIROLOGY, V207, P107, DOI 10.1006/viro.1995.1056; EASTMAN A, 1987, BIOTECHNIQUES, V5, P730; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GREAVES R, 1989, J VIROL, V63, P1642; GREAVES RF, 1990, J VIROL, V64, P2716, DOI 10.1128/JVI.64.6.2716-2724.1990; HAYES S, 1993, J VIROL, V67, P852, DOI 10.1128/JVI.67.2.852-862.1993; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; KATAN M, 1990, NUCLEIC ACIDS RES, V18, P6871, DOI 10.1093/nar/18.23.6871; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KRISTIE TM, 1995, J BIOL CHEM, V270, P4387, DOI 10.1074/jbc.270.9.4387; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MCKNIGHT JLC, 1987, P NATL ACAD SCI USA, V84, P7061, DOI 10.1073/pnas.84.20.7061; OHARE P, 1993, SEMIN VIROL, V4, P145, DOI 10.1006/smvy.1993.1010; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; POPOVA B, 1995, VIROLOGY, V209, P19, DOI 10.1006/viro.1995.1227; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; ROIZMAN B, 1991, HERPESVIRUS TRANSCRI, P17; SMIBERT CA, 1994, J VIROL, V68, P2239; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WALKER S, 1994, CELL, V79, P841, DOI 10.1016/0092-8674(94)90073-6; WERSTUCK G, 1989, J VIROL, V63, P5509, DOI 10.1128/JVI.63.12.5509-5513.1989; WERSTUCK G, 1989, GENE, V75, P213, DOI 10.1016/0378-1119(89)90267-9; WERSTUCK G, 1993, THESIS MCMASTER U ON; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; WU TJ, 1994, MOL CELL BIOL, V14, P3484, DOI 10.1128/MCB.14.5.3484; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974	43	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					29030	29037		10.1074/jbc.270.48.29030	http://dx.doi.org/10.1074/jbc.270.48.29030			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499437	hybrid			2022-12-27	WOS:A1995TH05600081
J	GARWICZ, D; LINDMARK, A; GULLBERG, U				GARWICZ, D; LINDMARK, A; GULLBERG, U			HUMAN CATHEPSIN-G LACKING FUNCTIONAL GLYCOSYLATION SITE IS PROTEOLYTICALLY PROCESSED AND TARGETED FOR STORAGE IN GRANULES AFTER TRANSFECTION TO THE RAT BASOPHILIC/MAST CELL-LINE RBL OR THE MURINE MYELOID CELL-LINE 32D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL ELASTASE; DIPEPTIDYL PEPTIDASE-I; SERINE PROTEASE; MAST-CELL; MEMBRANE ASSOCIATION; LYSOSOMAL-ENZYMES; PROGENITOR-CELL; PROCATHEPSIN-L; HEPG2 CELLS; ACTIVATION	The neutral protease cathepsin G belongs to a family of hematopoietic serine proteases stored in the azurophil granules of the neutrophil granulocyte. To investigate the function of asparagine-linked carbohydrates in neutrophil serine proteases, we constructed a mutant cDNA, coding for human cathepsin G deficient of a functional glycosylation site, for use in a transgenic cellular model. Wild type and mutant cDNA were stably expressed in the rat basophilic/mast cell line RBL and in the murine myeloblast-like cell line 32D. Biosynthetic labeling, followed by immunoprecipitation, SDS-polyacrylamide gel electrophoresis, and fluorography, showed that carbohydrate-deficient cathepsin G was synthesized as a 29-kDa preform in both cell lines. The preform was proteolytically processed into a stable form with an apparent molecular mass of 27.5 kDa, indicating removal of the carboxyl-terminal prodomain. The mutant cathepsin G was enzymatically activated as determined by acquisition of affinity to aprotinin, a serine protease inhibitor. As for wild type cathepsin G, small amounts of the unprocessed form of the mutated enzyme were released from the cells, while the major part was transferred to a granular compartment as demonstrated by subcellular fractionation. Thus, neither processing leading to enzymatic activation nor granular sorting was obviously affected by the lack of oligosaccharides on the mutant cathepsin G. Our results therefore indicate that glycosylation is not essential for these processes. In addition to the previously utilized cell line RBL, we propose the 32D cell line as a suitable cellular model for transgenic expression of human neutrophil serine proteases.	LUND UNIV, DEPT MED, DIV HEMATOL, LUND, SWEDEN	Lund University								BAINTON DF, 1992, INFLAMMATION BASIC P, P303; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; BRETZ R, 1977, EUR J BIOCHEM, V77, P181, DOI 10.1111/j.1432-1033.1977.tb11656.x; BROWN GR, 1993, J IMMUNOL, V150, P4733; BURGE V, 1991, BIOCHEM J, V275, P797, DOI 10.1042/bj2750797; CAMPANELLI D, 1990, J EXP MED, V172, P1709, DOI 10.1084/jem.172.6.1709; CAPUTO A, 1993, J BIOL CHEM, V268, P17672; CAUGHEY GH, 1994, AM J RESP CRIT CARE, V150, pS138, DOI 10.1164/ajrccm/150.6_Pt_2.S138; ELBEIN AD, 1991, TRENDS BIOTECHNOL, V9, P346, DOI 10.1016/0167-7799(91)90117-Z; ELSBACH P, 1992, INFLAMMATION BASIC P; FLODGAARD H, 1991, EUR J BIOCHEM, V197, P535, DOI 10.1111/j.1432-1033.1991.tb15942.x; GABAY JE, 1993, CURR OPIN IMMUNOL, V5, P97, DOI 10.1016/0952-7915(93)90087-9; GRACE ME, 1990, BIOCHEM BIOPH RES CO, V168, P771, DOI 10.1016/0006-291X(90)92388-G; GRASSEL S, 1992, BIOCHEM BIOPH RES CO, V182, P276, DOI 10.1016/S0006-291X(05)80141-X; GULLBERG U, 1995, J BIOL CHEM, V270, P12912, DOI 10.1074/jbc.270.21.12912; GULLBERG U, 1994, J BIOL CHEM, V269, P25219; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUDIG D, 1993, CURR OPIN IMMUNOL, V5, P90, DOI 10.1016/0952-7915(93)90086-8; HULTBERG B, 1976, BIOCHEM J, V155, P599, DOI 10.1042/bj1550599; KIDO H, 1986, J IMMUNOL, V136, P1061; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREIDER BL, 1990, MOL CELL BIOL, V10, P4846, DOI 10.1128/MCB.10.9.4846; LEHRER RI, 1990, BLOOD, V76, P2169; LINDMARK A, 1990, BLOOD, V76, P2374; LIU L, 1995, BLOOD, V85, P1095, DOI 10.1182/blood.V85.4.1095.bloodjournal8541095; LUDWIG T, 1995, TRENDS CELL BIOL, V5, P202, DOI 10.1016/S0962-8924(00)89000-5; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MCINTYRE GF, 1994, J BIOL CHEM, V269, P567; MCINTYRE GF, 1993, P NATL ACAD SCI USA, V90, P10588, DOI 10.1073/pnas.90.22.10588; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; POHL J, 1990, FEBS LETT, V272, P200, DOI 10.1016/0014-5793(90)80484-Z; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; SALVESEN G, 1987, BIOCHEMISTRY-US, V26, P2289, DOI 10.1021/bi00382a032; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; SALVESEN G, 1991, BIOMED BIOCHIM ACTA, V50, P665; SHIVER JW, 1991, CELL, V64, P1175, DOI 10.1016/0092-8674(91)90272-Z; URATA H, 1993, J BIOL CHEM, V268, P24318; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VERNET T, 1990, J BIOL CHEM, V265, P16661; von Figura K, 1991, Curr Opin Cell Biol, V3, P642, DOI 10.1016/0955-0674(91)90035-W; WATOREK W, 1993, BIOL CHEM H-S, V374, P385, DOI 10.1515/bchm3.1993.374.1-6.385	48	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28413	28418						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499346				2022-12-27	WOS:A1995TG21000071
J	LEE, Y; MELEKHOVETS, YF; NAZAR, RN				LEE, Y; MELEKHOVETS, YF; NAZAR, RN			TERMINATION AS A FACTOR IN QUALITY-CONTROL DURING RIBOSOME BIOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MESSENGER-RNA STABILITY; SACCHAROMYCES-CEREVISIAE; 5S RNA; TRANSCRIPTION TERMINATION; YEAST; DROSOPHILA; PRECURSOR; MATURATION	In eukaryotes, nascent rDNA and 5 S rRNA gene transcripts undergo 3'-end processing after termination. Mutations in which terminator sequences in these ribosomal RNA genes are deleted completely result in highly unstable transcripts, which are not properly processed and integrated into stable ribosome structure. Mutations that retard RNA processing by extending the 3' external transcribed spacer or by introducing additional secondary structure in the spacers have a similar effect on stable transcript integration. The results indicate that proper termination coupled with efficient rRNA processing acts as a ''quality control'' process, which helps to ensure that only normal rRNA precursors are effectively processed and assembled into active ribosomes.			LEE, Y (corresponding author), UNIV GUELPH, DEPT MOLEC BIOL & GENET, GUELPH, ON N1G 2W1, CANADA.							ABOUELELA S, 1995, BBA-GENE STRUCT EXPR, V1262, P164, DOI 10.1016/0167-4781(95)00074-Q; ABOUELELA S, 1994, NUCLEIC ACIDS RES, V22, P668; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; FRENDEWEY D, 1985, J BIOL CHEM, V260, P449; GOOD L, 1992, NUCLEIC ACIDS RES, V20, P4934, DOI 10.1093/nar/20.18.4934; HAMADA H, 1979, CELL, V17, P163, DOI 10.1016/0092-8674(79)90304-0; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; JACQ B, 1977, J MOL BIOL, V117, P785, DOI 10.1016/0022-2836(77)90069-9; JOHNSON SP, 1989, MOL CELL BIOL, V9, P4986, DOI 10.1128/MCB.9.11.4986; KUHN A, 1988, EMBO J, V7, P1497, DOI 10.1002/j.1460-2075.1988.tb02968.x; LABHART P, 1990, GENE DEV, V4, P269, DOI 10.1101/gad.4.2.269; LEE Y, 1995, NUCLEIC ACIDS RES, V23, P634, DOI 10.1093/nar/23.4.634; LOSSON R, 1983, CELL, V32, P371, DOI 10.1016/0092-8674(83)90456-7; MELEKHOVETS YF, 1994, J MOL BIOL, V239, P170, DOI 10.1006/jmbi.1994.1361; MORROW BE, 1993, MOL CELL BIOL, V13, P1283, DOI 10.1128/MCB.13.2.1283; NAZAR RN, 1982, CELL NUCLEUS, V11, P1; PIPER PW, 1983, EMBO J, V2, P353, DOI 10.1002/j.1460-2075.1983.tb01430.x; RICHARDSON JP, 1993, CRIT REV BIOCHEM MOL, V28, P1, DOI 10.3109/10409239309082571; RUBIN GM, 1975, CELL, V6, P207, DOI 10.1016/0092-8674(75)90011-2; VANDERSANDE CAFM, 1989, NUCLEIC ACIDS RES, V17, P9127, DOI 10.1093/nar/17.22.9127; VANRYK DI, 1990, J BIOL CHEM, V265, P8377; XING YY, 1989, GENE DEV, V3, P1008, DOI 10.1101/gad.3.7.1008	24	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28003	28005						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499281				2022-12-27	WOS:A1995TG21000006
J	BELUNIS, CJ; CLEMENTZ, T; CARTY, SM; RAETZ, CRH				BELUNIS, CJ; CLEMENTZ, T; CARTY, SM; RAETZ, CRH			INHIBITION OF LIPOPOLYSACCHARIDE BIOSYNTHESIS AND CELL-GROWTH FOLLOWING INACTIVATION OF THE KDTA GENE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DEOXY-D-MANNO-OCTULOSONIC ACID TRANSFERASE; NUCLEAR MAGNETIC-RESONANCE; LIPID-A PRECURSORS; SALMONELLA-TYPHIMURIUM; CTP-CMP-3-DEOXY-D-MANNO-OCTULOSONATE CYTIDYLYLTRANSFERASE; 3-DEOXY-D-MANNOOCTULOSONATE-8-PHOSPHATE SYNTHETASE; BACTERIAL-ENDOTOXINS; DEFICIENT MUTANT; CLONING; C-13	The enzyme 3 deoxy-D-manno-octulosonic acid (Kdo) transferase is encoded by the kdtA gene in Escherichia coli, The enzyme is a single polypeptide that catalyzes the transfer of two Kdo residues to a tetraacyldisaccharide-1,4'-bisphosphate precursor of lipid A, designated lipid IVA (Belunis, C. J., and Raetz, C. R. H. (1992) J. Biol. Chem. 267, 9988-9997), To determine if Kdo transfer to lipid IVA is required for growth, we constructed a strain of E. coli with a chromosomal kdtA::kan insertion mutation, In mutants carrying the kdtA::kan allele on the chromosome, cell growth and Kdo transferase activity were dependent upon a copy of the intact kdtA gene on a plasmid, When the kdtA-bearing plasmid was itself temperature sensitive for replication, the growth of these strains was inhibited after several hours at 44 degrees C, and Kdo transferase activity in extracts became undetectable, Concomitantly, the cells accumulated massive amounts of lipid IVA, precursor of (Kdo)(2)-lipid IVA. The kdtA::kan mutation could also be complemented by hybrid plasmids bearing the gseA gene of Chlamydia trachomatis, gseA specifies a distinct Kdo transferase that adds three Kdo moieties to lipid IVA. Lipopolysaccharide from E. coli kdtA::kan constructs complemented by gseA reacts strongly with antibodies directed against the genus-specific epitope of Chlamydia, whereas lipopolysaccharide from parental E. coli K-12 does not. Our studies prove that Kdo attachment during lipid A biosynthesis is essential for cell growth and accounts for the conditional lethality associated with mutations in Kdo biosynthesis.	MERCK RES LABS,DEPT BIOCHEM,RAHWAY,NJ 07065; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Merck & Company; Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-51310] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON L, 1983, ACS S SERIES, V231; Ausubel FM, 1988, MOL REPROD DEV; BELUNIS CJ, 1992, J BIOL CHEM, V267, P18702; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BHATTACHARJEE AK, 1978, BIOCHEMISTRY-US, V17, P645, DOI 10.1021/bi00597a013; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; CROWELL DN, 1986, J BACTERIOL, V168, P152, DOI 10.1128/jb.168.1.152-159.1986; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GHALAMBOR MA, 1966, J BIOL CHEM, V241, P3216; GOLDMAN R, 1987, NATURE, V329, P162, DOI 10.1038/329162a0; GOLDMAN RC, 1988, J BIOL CHEM, V263, P5217; GOLDMAN RC, 1988, J BACTERIOL, V170, P2185, DOI 10.1128/jb.170.5.2185-2191.1988; GOLDMAN RC, 1986, J BIOL CHEM, V261, P5831; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; KOHLBRENNER WE, 1985, J BIOL CHEM, V260, P4695; Maniatis T., 1982, MOL CLONING; Miller J.H., 1972, EXPT MOL GENETICS; MORRISON DC, 1992, BACTERIAL ENDOTOXIC, V1; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RICK PD, 1977, J BIOL CHEM, V252, P4904; RICK PD, 1977, J BIOL CHEM, V252, P4895; RICK PD, 1987, ESCHERICHIA COLI SAL, V1, P648; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; SCHMIDT MA, 1983, EUR J BIOCHEM, V131, P509, DOI 10.1111/j.1432-1033.1983.tb07291.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; Unger F. M., 1981, ADV CARBOHYD CHEM BI, V38, P324; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	35	73	83	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27646	27652		10.1074/jbc.270.46.27646	http://dx.doi.org/10.1074/jbc.270.46.27646			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499229				2022-12-27	WOS:A1995TE73600040
J	PARRIES, G; CHEN, K; MISONO, KS; COHEN, S				PARRIES, G; CHEN, K; MISONO, KS; COHEN, S			THE HUMAN URINARY EPIDERMAL GROWTH-FACTOR (EGF) PRECURSOR - ISOLATION OF A BIOLOGICALLY-ACTIVE 160-KILODALTON HEPARIN-BINDING PRO-EGF WITH A TRUNCATED CARBOXYL-TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY MEMBRANES; HUMAN FLUIDS; SEQUENCE; PROTEINS; CDNA; UROGASTRONE; IDENTIFICATION; EXPRESSION; RECEPTORS; CELLS	In this report, we describe the isolation from human urine of a predominant 160-kDa epidermal growth factor (EGF)-immunoreactive glycoprotein that exhibits affinity for heparin, The purification procedure involved concentration and dialysis of 20-30-liter batches of fresh urine on a high capacity ultrafiltration apparatus followed by chromatography on DEAE-Sephacel, heparin-agarose, and Sephacryl S-300, A nearly homogeneous preparation of 160-kDa protein was obtained with a yield of approximately 1 mg of 160-kDa protein from 25 liters of urine. The amino-terminal sequence of the purified 160-kDa protein, H2N-SAPQHXSXPEGTXA-, matched residues 21-34 of the predicted sequence of human prepro-EGF and established that the 160 kDa protein (pro-EGF) is a product of the prepro-EGF gene, Characterization of the carboxyl terminus of the purified protein by digestion with carboxypeptidase B and by immunoblotting with antisera against synthetic carboxyl-terminal and juxtatransmembrane peptides of prepro-EGF indicated that the carboxyl terminus has been truncated at an arginine residue that corresponds, most likely, to the carboxyl-terminal arginine of the EGF moiety. The intact 160-kDa pro-EGF is biologically active as evidenced by its specific binding to the EGF receptor and activation of the EGF receptor tyrosine kinase in A-431 cell membranes. Purified pro-EGF competitively inhibited the binding of I-125-EGF to human fibroblasts, and it stimulated the proliferation of these cells in culture, When immobilized onto culture dishes, the heparin-binding pro-EGF appeared to function both as an adhesion molecule and as a growth factor for serum-free mouse embryo cells.	VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; CLEVELAND CLIN FDN, RES INST, DEPT MOLEC CARDIOL, CLEVELAND, OH 44195 USA	Vanderbilt University; Cleveland Clinic Foundation					NICHD NIH HHS [HD-00700] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AVIEZER D, 1994, P NATL ACAD SCI USA, V91, P12173, DOI 10.1073/pnas.91.25.12173; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BREYER JA, 1990, J BIOL CHEM, V265, P16564; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CARPENTER G, 1990, PEPTIDE GROWTH FACTO, P69; CARREA G, 1973, BIOCHIM BIOPHYS ACTA, V295, P274, DOI 10.1016/0005-2795(73)90094-9; COHEN S, 1982, J BIOL CHEM, V257, P1523; COHEN S, 1962, J BIOL CHEM, V237, P1555; COHEN S, 1975, P NATL ACAD SCI USA, V72, P1317, DOI 10.1073/pnas.72.4.1317; FISHER DA, 1990, ENDOCR REV, V11, P418, DOI 10.1210/edrv-11-3-418; FISHER DA, 1989, ANNU REV PHYSIOL, V51, P67, DOI 10.1146/annurev.physiol.51.1.67; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GREGORY H, 1988, REGUL PEPTIDES, V22, P217, DOI 10.1016/0167-0115(88)90034-1; GREGORY H, 1975, NATURE, V257, P325, DOI 10.1038/257325a0; HIRATA Y, 1979, J CLIN ENDOCR METAB, V48, P673, DOI 10.1210/jcem-48-4-673; JORGENSEN PE, 1991, BIOCHIM BIOPHYS ACTA, V1074, P284, DOI 10.1016/0304-4165(91)90165-D; JORGENSEN PE, 1994, GROWTH FACTORS, V11, P113, DOI 10.3109/08977199409001053; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKSHMANAN J, 1992, AM J PHYSIOL, V263, pE142, DOI 10.1152/ajpendo.1992.263.1.E142; LAKSHMANAN J, 1990, BIOCHEM BIOPH RES CO, V173, P902, DOI 10.1016/S0006-291X(05)80871-X; LOO DT, 1987, SCIENCE, V236, P200, DOI 10.1126/science.3494308; MARGOLIUS HS, 1984, ANNU REV PHYSIOL, V46, P309; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOOS M, 1988, J BIOL CHEM, V263, P6005; MOUNT CD, 1987, ARCH BIOCHEM BIOPHYS, V255, P1, DOI 10.1016/0003-9861(87)90287-6; MROCZKOWSKI B, 1989, MOL CELL BIOL, V9, P2771, DOI 10.1128/MCB.9.7.2771; MROCZKOWSKI B, 1993, ENDOCRINOLOGY, V132, P417, DOI 10.1210/en.132.1.417; MROCZKOWSKI B, 1988, P NATL ACAD SCI USA, V85, P126, DOI 10.1073/pnas.85.1.126; MUCHMORE AV, 1985, SCIENCE, V229, P479, DOI 10.1126/science.2409603; ONO M, 1994, J BIOL CHEM, V269, P31315; POULSEN SS, 1986, HISTOCHEMISTRY, V85, P389, DOI 10.1007/BF00982668; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; TAYLOR JM, 1970, P NATL ACAD SCI USA, V67, P164, DOI 10.1073/pnas.67.1.164; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	42	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27954	27960		10.1074/jbc.270.46.27954	http://dx.doi.org/10.1074/jbc.270.46.27954			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499272	hybrid			2022-12-27	WOS:A1995TE73600083
J	UCKUN, FM; KUROSAKI, T; JIN, J; JUN, X; MORGAN, A; TAKATA, M; BOLEN, J; LUBEN, R				UCKUN, FM; KUROSAKI, T; JIN, J; JUN, X; MORGAN, A; TAKATA, M; BOLEN, J; LUBEN, R			EXPOSURE OF B-LINEAGE LYMPHOID-CELLS TO LOW-ENERGY ELECTROMAGNETIC-FIELDS STIMULATES LYN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRICAL WIRING CONFIGURATIONS; ACUTE LYMPHOBLASTIC-LEUKEMIA; RADIATION-INDUCED ACTIVATION; PROTEIN-TYROSINE KINASE; MAGNETIC-FIELDS; SIGNAL-TRANSDUCTION; CHILDHOOD LEUKEMIA; CANCER PROMOTION; PHOSPHORYLATION; WORKERS	Here, we present evidence that exposure of B-lineage lymphoid cells to low energy electromagnetic fields (EMF) stimulates the protein tyrosine kinases Lyn and Syk, results in tyrosine phosphorylation of multiple electrophoretically distinct substrates, and leads to downstream activation of protein kinase C (PKC), EMF exposure enhances protein tyrosine phosphorylation in Syk deficient but not in Lyn-deficient B-lineage lymph old cells and stimulates Lyn kinase activity in wild-type as well as Syk-deficient B-lineage lymphoid cells, These results indicate that activation of Lyn kinase is sufficient and mandatory for EMF-induced tyrosine phosphorylation in B-lineage lymphoid cells, The PKC activity increases later than the Lyn activity and pretreatment with the PTK inhibitors genistein or herbimycin A abrogates the EMF-induced PKC signal, Thus, stimulation of Lyn is a proximal and mandatory step in EMF-induced activation of PKC in B-lineage lymphoid cells, Our observations prompt the hypothesis that a delicate growth regulatory balance might be altered in B-lineage lymphoid cells by EMF-induced activation of Lyn.	UNIV MINNESOTA,CTR HLTH SCI,DEPT THERAPEUT RADIOL RADIAT ONCOL,MOLEC BIOCHEM LAB,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,CTR HLTH SCI,DEPT PEDIAT & PHARMACOL,MOLEC BIOCHEM LAB,BIOTHERAPY PROGRAM,MINNEAPOLIS,MN 55455; LEDERLE LABS,DEPT CARDIOVASC MOLEC BIOL,PEARL RIVER,NY 10965; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,SIGNAL TRANSDUCT LAB,PRINCETON,NJ 08543; UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 95251	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Bristol-Myers Squibb; University of California System; University of California Riverside			Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Uckun, Fatih M./0000-0001-9334-183X	NIEHS NIH HHS [R01-ES-07175] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007175] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAIR RK, 1991, PHYS REV A, V43, P1039, DOI 10.1103/PhysRevA.43.1039; ADEY WR, 1988, NEUROCHEM RES, V13, P671, DOI 10.1007/BF00973286; ADEY WR, 1986, BIOELECTROCH BIOENER, V15, P447, DOI 10.1016/0302-4598(86)85033-4; ANDERSON LE, 1991, HEALTH PHYS, V61, P41, DOI 10.1097/00004032-199107000-00004; BASTUJIGARIN S, 1990, EUR J CANCER, V26, P1119, DOI 10.1016/0277-5379(90)90266-V; BELL J, 1990, BRIT J CANCER, V62, P331, DOI 10.1038/bjc.1990.289; Bennett M.V.L, 1979, MEMBRANE TRANSDUCTIO, P91; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BROWN HD, 1988, CANCER BIOCHEM BIOPH, V9, P295; CAIN CD, 1987, J BONE MINER RES, V2, P437; CHAE HP, 1993, CANCER RES, V53, P447; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; CHAMPLIN R, 1989, BLOOD, V73, P2051; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EASTERLY CE, 1981, AM J EPIDEMIOL, V114, P169, DOI 10.1093/oxfordjournals.aje.a113179; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; FARRAR YJK, 1991, BIOCHEM BIOPH RES CO, V180, P694, DOI 10.1016/S0006-291X(05)81121-0; FEYCHTING M, 1992, IMM692 SWED NAT I OC; FULTON JP, 1980, AM J EPIDEMIOL, V111, P292, DOI 10.1093/oxfordjournals.aje.a112899; GREAVES MF, 1986, SCIENCE, V234, P697, DOI 10.1126/science.3535067; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; Kalmijn A.J., 1984, P525; KIRSCHVINK JL, 1992, BIOELECTROMAGNETICS, V13, P401, DOI 10.1002/bem.2250130507; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LIBOFF AR, 1985, J BIOL PHYS, V12, P99; LIBURDY RP, 1992, FEBS LETT, V301, P53, DOI 10.1016/0014-5793(92)80209-Y; LONDON SJ, 1991, AM J EPIDEMIOL, V134, P923, DOI 10.1093/oxfordjournals.aje.a116176; LUBEN RA, 1991, HEALTH PHYS, V61, P15, DOI 10.1097/00004032-199107000-00002; LUBEN RA, 1982, J ELECTROCHEM SOC, V128, P298; LUBEN RA, 1993, DEP ENERGY ANN REV R; MCDOWALL ME, 1983, LANCET, V1, P246; MERRITT R, 1983, REV SCI INSTRUM, V54, P879, DOI 10.1063/1.1137480; MILHAM S, 1988, AM J EPIDEMIOL, V127, P50, DOI 10.1093/oxfordjournals.aje.a114790; POOL R, 1990, SCIENCE, V249, P1378, DOI 10.1126/science.2402634; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; SAVITZ DA, 1989, EPIDEMIOL REV, V11, P59, DOI 10.1093/oxfordjournals.epirev.a036045; SAVITZ DA, 1988, AM J EPIDEMIOL, V131, P763; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SHEIKH K, 1986, ARCH ENVIRON HEALTH, V41, P56, DOI 10.1080/00039896.1986.9935766; SIDORENKO SP, 1992, P NATL ACAD SCI USA, V92, P359; SMITH OM, 1991, BIOELECTROMAGNETICS, V12, P197, DOI 10.1002/bem.2250120307; STUCHLY MA, 1991, BIOELECTROMAGNETICS, V12, P261, DOI 10.1002/bem.2250120502; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TOMENIUS L, 1986, BIOELECTROMAGNETICS, V7, P191, DOI 10.1002/bem.2250070209; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; UCKUN FM, 1992, BLOOD, V79, P3116; UCKUN FM, 1990, BLOOD, V76, P1908; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; WADDICK KG, 1993, RADIAT RES, V136, P313, DOI 10.2307/3578542; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; WRIGHT WE, 1982, LANCET, V2, P1160; 1991, EPA600690005A DOC	56	101	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27666	27670		10.1074/jbc.270.46.27666	http://dx.doi.org/10.1074/jbc.270.46.27666			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499232				2022-12-27	WOS:A1995TE73600043
J	WANG, ZY; BRZESKA, H; BAINES, IC; KORN, ED				WANG, ZY; BRZESKA, H; BAINES, IC; KORN, ED			PROPERTIES OF ACANTHAMOEBA MYOSIN-I HEAVY-CHAIN KINASE BOUND TO PHOSPHOLIPID-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING-SITES; COFACTOR PROTEIN; PLASMA-MEMBRANES; LOCALIZATION; CASTELLANII; AUTOPHOSPHORYLATION; PHOSPHORYLATION; ACTIVATION; PURIFICATION; SPECIFICITY	The actin activated Mg2+-ATPase and in vitro motility activities of the three Acanthamoeba myosin I isozymes depend upon phosphorylation of their single heavy chains by myosin I heavy chain kinase, Previously, the kinase had been shown to be activated by autophosphorylation, which is enhanced by acidic phospholipids, or simply by binding to purified plasma membranes in the absence of significant autophosphorylation, Tn this paper, we show that the rate of phosphorylation of myosin I by unphosphorylated kinase is similar to 20-fold faster when both the myosin I and the kinase are bound to acidic phospholipid vesicles than when both are soluble, This activation is not due to an increase in the local concentrations of vesicle-bound kinase and myosin I, Thus, acidic phospholipids, like membranes, can activate myosin I heavy chain kinase in the absence of significant autophosphorylation, i.e. membrane proteins are not required, Kinetic studies show that both binding of kinase to phospholipid vesicles and autophosphorylation of kinase in the absence of phospholipid increase the V-max relative to soluble, unphosphorylated kinase with either an increase in the apparent K-m (when myosin I is the substrate) or no significant change in K-m (when a synthetic peptide is the substrate), Kinetic data showed that autophosphorylation of phospholipid bound kinase is both intermolecular and intervesicular, and that phosphorylation of phospholipid-bound myosin I by phospholipid-bound kinase is also intervesicular even when the kinase and myosin are bound to the same vesicles. The relevance of these results to the activation of myosin I heavy chain kinase and phosphorylation of myosin I isozymes in situ are discussed.	NHLBI, CELL BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BAINES IC, 1995, J CELL BIOL, V130, P591, DOI 10.1083/jcb.130.3.591; BAINES IC, 1990, J CELL BIOL, V111, P1895, DOI 10.1083/jcb.111.5.1895; BAINES IC, 1992, J CELL BIOL, V119, P1193, DOI 10.1083/jcb.119.5.1193; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRZESKA B, 1993, MOL BIOL CELL S, V4, pA158; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1990, J BIOL CHEM, V265, P16138; BRZESKA H, 1992, J BIOL CHEM, V267, P23870; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; BRZESKA H, 1992, J BIOL CHEM, V267, P4949; BRZESKA H, 1988, J BIOL CHEM, V263, P427; BRZESKA H, 1989, J BIOL CHEM, V264, P10234; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; DOBERSTEIN SK, 1993, NATURE, V365, P841, DOI 10.1038/365841a0; Hammer J A, 1991, Trends Cell Biol, V1, P50, DOI 10.1016/0962-8924(91)90089-R; HAMMER JA, 1994, J MUSCLE RES CELL M, V15, P1, DOI 10.1007/BF00123827; HAMMER JA, 1983, J BIOL CHEM, V258, P168; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; JUNG G, 1989, GENE, V82, P269, DOI 10.1016/0378-1119(89)90052-8; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; Korn ED, 1990, CURR OPIN CELL BIOL, V2, P57, DOI 10.1016/S0955-0674(05)80031-6; KULESZALIPKA D, 1993, J BIOL CHEM, V268, P17995; KULESZALIPKA D, 1991, J CELL BIOL, V115, P109, DOI 10.1083/jcb.115.1.109; LYNCH TJ, 1987, J BIOL CHEM, V262, P13842; LYNCH TJ, 1986, J BIOL CHEM, V262, P17156; LYNCH TJ, 1991, METHOD ENZYMOL, V196, P12; MARUTA H, 1977, J BIOL CHEM, V252, P8329; MIYATA H, 1989, J CELL BIOL, V109, P1519, DOI 10.1083/jcb.109.4.1519; POLLARD TD, 1973, J BIOL CHEM, V248, P4691; TODHUNTER JA, 1977, BIOCHIM BIOPHYS ACTA, V485, P87, DOI 10.1016/0005-2744(77)90195-4; ZHI G, 1994, J BIOL CHEM, V269, P24723	33	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27969	27976		10.1074/jbc.270.46.27969	http://dx.doi.org/10.1074/jbc.270.46.27969			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499274	hybrid			2022-12-27	WOS:A1995TE73600085
J	ZHANG, DE; HETHERINGTON, CJ; TAN, SC; DZIENNIS, SE; GONZALEZ, DA; CHEN, HM; TENEN, DG				ZHANG, DE; HETHERINGTON, CJ; TAN, SC; DZIENNIS, SE; GONZALEZ, DA; CHEN, HM; TENEN, DG			SP1 IS A CRITICAL FACTOR FOR THE MONOCYTIC SPECIFIC EXPRESSION OF HUMAN CD14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUCIFERASE REPORTER GENE; TRANSCRIPTION FACTOR-SP1; DNA-BINDING; DIFFERENTIATION ANTIGEN; PROTEIN-BINDING; PROMOTER; UPSTREAM; DOMAINS; CELLS; SITE	CD14 is a membrane glycoprotein expressed specifically on monocytes and macrophages, and its expression is markedly increased during the process of monocyte differentiation. In order to study CD14 gene regulation, the human CD14 gene was cloned from a partial EcoRI digested chromosome 5 library. A 5.5-kilobase genomic clone contained the full-length CD14 coding sequence and 4.2 kilobases of 5'-upstream sequence. One major and one minor transcription start site were identified 101 and 130 base pairs (bp) upstream, respectively, from the protein translation start ATG. A DNA fragment containing 128 bp of upstream sequence had strong, monocyte-specific promoter activity in the CD14 positive monocytic cell line Mono Mac 6 as compared to the non-monocytic cell lines HeLa and REX. Four regions in this DNA fragment interact with nuclear proteins isolated from monocytic cells. The Sp1 transcription factor bound to three different regions in the CD14 promoter. Mutation of the major Sp1 binding site (-110 bp) decreased tissue-specific promoter activity, and these results, together with transactivation experiments, demonstrate that Sp1 plays a critical role in the tissue-specific expression of CD14 in monocytic cells. CD14 Sp1 site oligonucleotides bound preferentially to a 105-kDa Spl species, which is present in higher relative levels in monocytic than non-monocytic cells, suggesting that modification of Sp1, such as phosphorylation, may explain how the Sp1 site mediates monocytic specific promoter activity.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	ZHANG, DE (corresponding author), BETH ISRAEL HOSP,DEPT MED,DIV HEMATOL ONCOL,RE 217,330 BROOKLINE AVE,BOSTON,MA 02215, USA.			Tenen, Daniel/0000-0002-6423-3888	NATIONAL CANCER INSTITUTE [R01CA041456] Funding Source: NIH RePORTER; NCI NIH HHS [CA41456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSABEL FM, 1989, CURRENT PROTOCOLS MO; BALL ED, 1982, P NATL ACAD SCI-BIOL, V79, P5374, DOI 10.1073/pnas.79.17.5374; BORELLINI F, 1991, J BIOL CHEM, V266, P15850; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DARROW AL, 1990, MOL CELL BIOL, V10, P5883, DOI 10.1128/MCB.10.11.5883; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GHOSH D, 1992, NUCLEIC ACIDS RES, V20, P2091, DOI 10.1093/nar/20.suppl.2091; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GRIFFIN JD, 1981, J CLIN INVEST, V68, P932, DOI 10.1172/JCI110348; GUMUCIO DL, 1991, BLOOD, V78, P1853; HAZIOT A, 1988, J IMMUNOL, V141, P547; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JANE SM, 1993, MOL CELL BIOL, V13, P3272, DOI 10.1128/MCB.13.6.3272; KATAI H, 1991, MOL CELL BIOL, V11, P73; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUENER RP, 1990, EUR J IMMUNOL, V20, P2375, DOI 10.1002/eji.1830201103; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; MATSUURA K, 1992, J BIOL CHEM, V267, P21787; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OBERG F, 1993, J IMMUNOL, V150, P3487; PAHL HL, 1992, BLOOD, V79, P865; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SIMMONS DL, 1989, BLOOD, V73, P284; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SMALE ST, 1989, CELL, V57, P1036; SPANOPOULOU E, 1991, MOL CELL BIOL, V11, P2216, DOI 10.1128/MCB.11.4.2216; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YU CY, 1991, J BIOL CHEM, V266, P8907; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZHANG DE, 1990, J BIOL CHEM, V265, P3382; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZIEGLERHEITBROCK HWL, 1989, EUR J CELL BIOL, V49, P1; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	55	174	179	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11425	11434						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512565				2022-12-27	WOS:A1994NF96600067
J	KOLB, JP; PAULEUGENE, N; DAMAIS, C; YAMAOKA, K; DRAPIER, JC; DUGAS, B				KOLB, JP; PAULEUGENE, N; DAMAIS, C; YAMAOKA, K; DRAPIER, JC; DUGAS, B			INTERLEUKIN-4 STIMULATES CGMP PRODUCTION BY IFN-GAMMA-ACTIVATED HUMAN MONOCYTES - INVOLVEMENT OF THE NITRIC-OXIDE SYNTHASE PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONONUCLEAR PHAGOCYTES; TUMOR-NECROSIS-FACTOR; INTERFERON-GAMMA; L-ARGININE; MURINE MACROPHAGES; SUPEROXIDE PRODUCTION; SIGNAL-TRANSDUCTION; EFFECTOR MECHANISM; NITROGEN-OXIDES; IL-4	Resting human blood monocytes from some donors were found to produce a small amount of 3'-5' guanine cyclic monophosphate (CGMP) in response to interleukin 4 (IL-4). A much higher response was observed when monocytes were preincubated with interferon (IFN-gamma), which alone was ineffective. Preincubation of monocytes with IL-4 led, in contrast, to their subsequent incapacity to generate cGMP in response to IL-4. The accumulation of cGMP induced by IL-4 in IFN-gamma preincubated monocytes was dose-dependent and peaked about 15 min after its addition. It was inhibited in the presence of N(G)-mono-methyl-L-arginine (L-NMMA), an inhibitor of the nitric oxide synthase pathway. This suppressive effect Of L-NMMA was reverted by an excess Of L- but not of D-arginine. Accumulation of cGMP was significantly reduced by addition of soluble guanylyl cyclase inhibitors, such as LY83853 and methylene blue, but was not impaired in the presence of EGTA, suggesting that the pathway involved is calcium independent. In addition, IL-4 induced an increased secretion of nitrite by monocytes, that was potentiated by IFN-gamma and inhibited by L-NMMA. Taken together, these results suggest that the sequential exposure of monocytes to IFN-gamma and IL-4 elicits the release of NO from L-arginine, which in turn is capable to stimulate soluble guanylyl cyclase.	CHU PITIE SALPETRIERE, INSERM, U313, F-75634 PARIS 13, FRANCE; INSERM, F-34100 MONTPELLIER, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	KOLB, JP (corresponding author), INST CURIE, INSERM, U365, 26 RUE ULM, F-75231 PARIS 05, FRANCE.							ABRAMSON SL, 1990, J IMMUNOL, V144, P625; BECKER S, 1990, CELL IMMUNOL, V129, P351, DOI 10.1016/0008-8749(90)90211-9; BELENKY SN, 1993, J LEUKOCYTE BIOL, V53, P498, DOI 10.1002/jlb.53.5.498; BOGDAN C, 1991, EUR J IMMUNOL, V21, P327, DOI 10.1002/eji.1830210213; CAMERON ML, 1990, AM REV RESPIR DIS, V142, P1313, DOI 10.1164/ajrccm/142.6_Pt_1.1313; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DENIS M, 1991, J LEUKOCYTE BIOL, V49, P380, DOI 10.1002/jlb.49.4.380; DRANSFIELD I, 1988, IMMUNOLOGY, V63, P491; DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018; FIGDOR CG, 1992, IL 4 STRUCTURE FUNCT, P187; FINNEY M, 1990, EUR J IMMUNOL, V20, P151, DOI 10.1002/eji.1830200122; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GREEN SJ, 1991, J LEUKOCYTE BIOL, V50, P93, DOI 10.1002/jlb.50.1.93; HAMILTON TA, 1987, IMMUNOL TODAY, V8, P151, DOI 10.1016/0167-5699(87)90145-9; HIBBS JB, 1992, J CLIN INVEST, V89, P867, DOI 10.1172/JCI115666; HIBBS JB, 1990, INT CONGR SER, V897, P189; HUNT NCA, 1992, J HEPATOL, V14, P146, DOI 10.1016/0168-8278(92)90150-N; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IGNARRO LJ, 1990, PHARMACOL TOXICOL, V67, P1, DOI 10.1111/j.1600-0773.1990.tb00772.x; KARLSEN AE, 1993, ENDOTHELIUM S, V1, pS26; LEE CE, 1993, CELL IMMUNOL, V146, P171, DOI 10.1006/cimm.1993.1015; LEHN M, 1989, J IMMUNOL, V143, P3020; LIEW FY, 1991, EUR J IMMUNOL, V21, P2489, DOI 10.1002/eji.1830211027; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MAIER R, 1993, ENDOTHELIUM S, V1, pS48; MARTIN JHJ, 1993, J IMMUNOL, V150, P3478; MAUTINO G, 1994, IN PRESS J LEUKOCYTE; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUNOZFERNANDEZ MA, 1992, IMMUNOL LETT, V33, P35, DOI 10.1016/0165-2478(92)90090-B; MURRAY HW, 1992, J INFECT DIS, V165, P513, DOI 10.1093/infdis/165.3.513; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NUSSLER AK, 1992, J EXP MED, V176, P261, DOI 10.1084/jem.176.1.261; OCHOA JB, 1992, J NATL CANCER I, V84, P864, DOI 10.1093/jnci/84.11.864; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; PAULEUGENE N, 1992, J IMMUNOL, V149, P3066; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; SALVEMINI D, 1989, P NATL ACAD SCI USA, V86, P6328, DOI 10.1073/pnas.86.16.6328; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHNEEMANN M, 1993, J INFECT DIS, V167, P1358, DOI 10.1093/infdis/167.6.1358; SCHWARTZ D, 1963, METHODES STATISTIQUE, P151; SIEBERT PD, 1992, CLONTECHNIQUES, V7, P1; STUEHR DJ, 1987, J IMMUNOL, V139, P518; STUEHR DJ, 1992, ADV ENZYMOL, V65, P287; TEVELDE AA, 1988, J IMMUNOL, V140, P1548	45	105	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9811	9816						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511593				2022-12-27	WOS:A1994NE05300065
J	FISONE, G; CHENG, SXJ; NAIRN, AC; CZERNIK, AJ; HEMMINGS, HC; HOOG, JO; BERTORELLO, AM; KAISER, R; BERGMAN, T; JORNVALL, H; APERIA, A; GREENGARD, P				FISONE, G; CHENG, SXJ; NAIRN, AC; CZERNIK, AJ; HEMMINGS, HC; HOOG, JO; BERTORELLO, AM; KAISER, R; BERGMAN, T; JORNVALL, H; APERIA, A; GREENGARD, P			IDENTIFICATION OF THE PHOSPHORYLATION SITE FOR CAMP-DEPENDENT PROTEIN-KINASE ON NA+,K+-ATPASE AND EFFECTS OF SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+-ATPASE ACTIVITY; POLYACRYLAMIDE GELS; CYCLIC-AMP; CAUSES INHIBITION; XENOPUS OOCYTES; TUBULE CELLS; RAT-BRAIN; (NA++K+)-ATPASE; STIMULATION; BINDING	Phosphorylation of purified Na+,K+-ATPase by cAMP-dependent protein kinase (protein kinase A) decreases the activity of this enzyme. We have now shown, using several experimental approaches, that a highly conserved seryl residue on the catalytic (alpha) subunit of Na+,K+-ATPase, corresponding to Ser(943) of the rat alpha 1 isoform, is the phosphorylation site for protein kinase A. cDNAs corresponding to wild-type Na+,K+-ATPase and Na+,K+-ATPase in which Ser(943) was mutated to Ala were transfected into COS cells. Treatment of the transfected cells with forskolin plus 3-isobutyl-1-methylxanthine resulted in a decrease in the activity of the wild-type enzyme but not in that of the mutated enzyme. The results suggest that, in intact cells, the activity of the Na+,K+-ATPase is regulated in part by signal transduction pathways that use protein kinase A-dependent phosphorylation of the Na+,K+-ATPase alpha subunit.	ROCKEFELLER UNIV, MOLEC & CELLULAR NEUROSCI LAB, NEW YORK, NY 10021 USA; KAROLINSKA INST, ST GORANS CHILDRENS HOSP, DEPT PEDIAT, S-11281 STOCKHOLM, SWEDEN; CORNELL UNIV, MED CTR, COLL MED, DEPT ANESTHESIOL, NEW YORK, NY 10021 USA; KAROLINSKA INST, DEPT CHEM 1, S-17177 STOCKHOLM, SWEDEN	Rockefeller University; Karolinska Institutet; Cornell University; Karolinska Institutet				Nairn, Angus/0000-0002-7075-0195; Fisone, Gilberto/0000-0002-0719-8000	NIMH NIH HHS [MH-40899] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; APERIA A, 1987, AM J PHYSIOL, V252, pF39, DOI 10.1152/ajprenal.1987.252.1.F39; BEACH RE, 1987, AM J PHYSIOL, V252, pF215, DOI 10.1152/ajprenal.1987.252.2.F215; BERGMAN T, 1987, EUR J BIOCHEM, V169, P9, DOI 10.1111/j.1432-1033.1987.tb13573.x; BERTORELLO AM, 1990, NATURE, V347, P386, DOI 10.1038/347386a0; BERTORELLO AM, 1992, J CELL SCI, V101, P343; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIBALIN AV, 1992, J BIOL CHEM, V267, P22378; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CZERNIK AJ, 1991, METHOD ENZYMOL, V201, P264; FRYCKSTEDT J, 1992, ACTA PHYSIOL SCAND, V144, P185, DOI 10.1111/j.1748-1716.1992.tb09284.x; HERMENEGILDO C, 1992, J NEUROCHEM, V58, P1246, DOI 10.1111/j.1471-4159.1992.tb11335.x; HORIUCHI A, 1993, MOL PHARMACOL, V43, P281; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBARRA F, 1993, P NATL ACAD SCI USA, V90, P21, DOI 10.1073/pnas.90.1.21; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGHAM RB, 1982, BIOCHIM BIOPHYS ACTA, V688, P475, DOI 10.1016/0005-2736(82)90359-5; LOWNDES JM, 1990, BIOCHIM BIOPHYS ACTA, V1052, P143, DOI 10.1016/0167-4889(90)90069-P; LYNCH CJ, 1986, J BIOL CHEM, V261, P4551; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NELLES LP, 1976, ANAL BIOCHEM, V73, P522, DOI 10.1016/0003-2697(76)90202-5; PESSIN MS, 1993, IN PRESS 1992 P WENN; SATOH T, 1992, J CLIN INVEST, V89, P1496, DOI 10.1172/JCI115740; SHAHEDI M, 1992, PFLUG ARCH EUR J PHY, V420, P269, DOI 10.1007/BF00374458; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SHYIAN AW, 1990, P NATL ACAD SCI USA, V87, P1178; SKOU JC, 1979, BIOCHIM BIOPHYS ACTA, V567, P436, DOI 10.1016/0005-2744(79)90129-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VASILETS LA, 1992, J MEMBRANE BIOL, V125, P119; YEH LA, 1983, J BIOL CHEM, V258, P6567	35	140	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9368	9373						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510709				2022-12-27	WOS:A1994NB41100108
J	NATHANSON, MH; FALLON, MB; PADFIELD, PJ; MARANTO, AR				NATHANSON, MH; FALLON, MB; PADFIELD, PJ; MARANTO, AR			LOCALIZATION OF THE TYPE-3 INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR IN THE CA2+ WAVE TRIGGER ZONE OF PANCREATIC ACINAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSMEMBRANE CONDUCTANCE REGULATOR; ADRENAL CHROMAFFIN CELLS; AGONIST-INDUCED CHANGES; CYTOSOLIC CALCIUM; SECRETION; PROTEINS; RELEASE; FURA-2; CA-2+	Agonist-induced cytosolic Ca2+ (Ca-i(2+)) signals begin as apical-to-basal Ca-i(2+) waves in pancreatic acinar cells and in other polarized epithelia. However, the basis of this polarized Ca-i(2+) signaling pattern is unknown. Here we use immunocytochemistry to demonstrate that the type 3 inositol trisphosphate receptor is localized to the extreme apex of pancreatic acinar cells, the region which corresponds to the trigger zone from which Ca-i(2+) signals originate in this cell type (Kasai, H., Li, Y.X., and Miyashita, Y. (1993) Cell 74, 669-677). We also show that inositol trisphosphate-mediated Ca2+ release induces amylase release from permeabilized pancreatic acini. Since Ca-i(2+) signals begin by inositol trisphosphate mediated Ca-i(2+) release, these findings suggest that localization of the type 3 inositol trisphosphate receptor to the trigger zone is responsible for the generation of apical-to-basal Ca-i(2+) waves, and that this organization may be important for regulating apical exocytosis in pancreatic acinar cells.	ST LOUIS UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63104; TUFTS UNIV,ST ELIZABETHS MED CTR,SCH MED,DEPT MED,BOSTON,MA 02135; TUFTS UNIV,ST ELIZABETHS MED CTR,SCH MED,DEPT BIOMED RES,BOSTON,MA 02135	Saint Louis University; St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University	NATHANSON, MH (corresponding author), YALE UNIV,SCH MED,CTR LIVER,LIVER STUDY UNIT,1080 LMP,333 CEDAR ST,NEW HAVEN,CT 06510, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034989, K11DK002030, R29DK044475] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK34989, DK02030, DK44475] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRAND SH, 1991, J BIOL CHEM, V266, P1899; CHEEK TR, 1989, J CELL BIOL, V109, P1219, DOI 10.1083/jcb.109.3.1219; FITZ JG, 1993, J CLIN INVEST, V91, P319, DOI 10.1172/JCI116188; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KITAGAWA M, 1990, AM J PHYSIOL, V259, pG157, DOI 10.1152/ajpgi.1990.259.2.G157; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; MARUYAMA Y, 1988, J PHYSIOL-LONDON, V406, P299, DOI 10.1113/jphysiol.1988.sp017381; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; NATHANSON MH, 1993, HEPATOLOGY, V18, pA134; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PADFIELD PJ, 1991, BIOCHEM BIOPH RES CO, V174, P536, DOI 10.1016/0006-291X(91)91450-Q; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; SALUJA AK, 1992, J BIOL CHEM, V267, P11202; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SUDHOF TC, 1991, EMBO J, V10, P199; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0	27	188	188	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4693	4696						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508924				2022-12-27	WOS:A1994MX57100001
J	KNAUS, HG; GARCIACALVO, M; KACZOROWSKI, GJ; GARCIA, ML				KNAUS, HG; GARCIACALVO, M; KACZOROWSKI, GJ; GARCIA, ML			SUBUNIT COMPOSITION OF THE HIGH-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNEL FROM SMOOTH-MUSCLE, A REPRESENTATIVE OF THE MSLO AND SLOWPOKE FAMILY OF POTASSIUM CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SKELETAL-MUSCLE; PROTEIN; BINDING; BRAIN; CHARYBDOTOXIN; DROSOPHILA; SEQUENCE; RECEPTOR	High conductance Ca2+-activated K+ (maxi-K) channels from bovine tracheal and aortic smooth muscle membranes have been purified employing monoiodotyrosine charybdotoxin binding as a marker for the channel and conventional chromatographic techniques. This K+ channel is composed of two subunits, alpha and beta, of 62 and 31 kDa, respectively. After sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the electroeluted tracheal smooth muscle alpha-subunit was subjected to tryptic cleavage and a number of fragments were isolated by microbore C-18 high performance liquid chromatography. Several of these peptides were microsequenced using Edman degradation techniques. Amino acid sequence information obtained from these fragments reveals the existence of very high sequence homology with the recently cloned mSlo maxi-K channel (Butler, A., Tsunoda, S., McCobb, D. P., Wei, A., and Salkoff, L. (1993) Science 261, 221-224). A specific antipeptide antibody directed against the amino acid sequence of one of the fragments of the alpha-subunit is capable of specifically immunoprecipitating not only the denatured I-125-Bolton-Hunter-labeled alpha-subunit, but also, under nondenaturing conditions, the complex of alpha and beta subunits, demonstrating specific noncovalent association of both subunits. Thus, our results indicate that the alpha-subunit of the purified tracheal smooth muscle maxi-K channel is a member of the mSlo family of K+ channels and forms a noncovalent complex with a beta-subunit. It is concluded that the extensive biochemical information acquired to date on smooth muscle charybdotoxin receptors is pertinent to the structure of native maxi-K channels.	MERCK RES LABS, DEPT MEMBRANE BIOCHEM & BIOPHYS, RAHWAY, NJ 07065 USA; UNIV INNSBRUCK, DEPT BIOCHEM PHARMACOL, A-6020 INNSBRUCK, AUSTRIA	Merck & Company; University of Innsbruck								ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GARCIACALVO M, 1991, BIOCHEMISTRY-US, V30, P11157, DOI 10.1021/bi00110a020; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; SCOTT VES, 1990, J BIOL CHEM, V265, P20094; SEAGAR MJ, 1986, BIOCHEMISTRY-US, V25, P4051, DOI 10.1021/bi00362a010; SMITH JA, 1993, CURRENT PROTOCOLS MO; STOSCHECK CM, 1987, ANAL BIOCHEM, V160, P301, DOI 10.1016/0003-2697(87)90051-0; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; VAZQUEZ J, 1989, J BIOL CHEM, V264, P20902	19	189	192	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3921	3924						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508434				2022-12-27	WOS:A1994MW98900005
J	PALMER, LR; MERRILL, AR				PALMER, LR; MERRILL, AR			MAPPING THE MEMBRANE TOPOLOGY OF THE CLOSED STATE OF THE COLICIN E1 CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-VESICLES; PENETRATION DEPTH; TERMINAL PEPTIDE; LIGHT-SCATTERING; FORMING PEPTIDE; PARALLAX METHOD; ION CHANNEL; FLUORESCENCE; INSERTION; PROTEINS	The membrane-associated closed channel state of the colicin E1 thermolytic peptide was studied by the Parallax Method of depth-dependent fluorescence quenching. A number of single Trp-containing peptides of colicin E1 were prepared to facilitate the use of Trp as a probe for the topography of the channel peptide in the membrane-bound state. The bound form of the channel peptide was studied by binding channel peptide to 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine/1-pal-mitoy1-2-oleoyl-sn-glycero-3-phosphatidylglycerol large unilamellar vesicles (60:40, mol/mol, similar to 0.1 mu m diameter vesicles prepared by an extrusion technique) at low pH (pH 3.5). Depth-dependent fluorescence quenching studies using two nitroxide-labeled phospho-lipids (1-palmitoyl-2-(5-doxylstearoyl)-sn-glycero-3-phosphatidylcholine and 1-palmitoyl-2-(12-doxylstearoyl)-sn-glycero-3-phosphatidyl were conducted to determine the membrane location of each Trp residue for the vesicle-bound peptide. The three naturally occurring Trp residues in the colicin channel peptide, Trp-424, Trp-460, and Trp-495, were found to reside at membrane depths (from the C-2 carbon of the fatty acyl chain) of 7.4, 3.1, and 8.4 Angstrom, respectively. Three Trp residues (Trp-355, Trp-460, and Trp-507) in the channel peptide were classified as shallow (0-5.0 Angstrom from C-2 carbon). The remaining 9 Trp residues were classified as moderately buried (5.1-10.0 Angstrom). None of the dozen tryptophyls were classified as deeply buried in the membrane bilayer (10.1-15.0 Angstrom). A model for the colicin E1 channel based on these measurements along with previous data obtained from proteolysis, chemical labeling, ESR quenching, and mutagenesis experiments is proposed. This model for the closed state of the channel has as its central feature the presence of only two trans-membrane segments. The membrane-associated portion of the channel includes the hydrophobic membrane anchor domain, Ala-474 to Ile-508. Furthermore, the fluorescence quenching data are consistent with the NH2-terminal helices (helices 1-7) lying on the surface of the membrane with the helical axis being oriented parallel to the membrane plane.	UNIV GUELPH, GUELPH WATERLOO CTR GRAD WORK CHEM, DEPT CHEM & BIOCHEM, GUELPH N1G 2W1, ON, CANADA	University of Guelph; University of Waterloo; Guelph-Waterloo Centre for Graduate Work in Chemistry & Biochemistry			Merrill, Rod/M-8313-2014					ABRAMS CK, 1991, J GEN PHYSIOL, V98, P77, DOI 10.1085/jgp.98.1.77; ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5322, DOI 10.1021/bi00138a011; ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5313; AMES BN, 1960, J BIOL CHEM, V235, P769; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BRUNDEN KR, 1984, J BIOL CHEM, V259, P7682; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; CHATTOPADHYAY A, 1991, BIOCHEMISTRY-US, V30, P7159, DOI 10.1021/bi00243a017; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CHUNG LA, 1992, BIOCHEMISTRY-US, V31, P6608, DOI 10.1021/bi00143a035; CLAGUE MJ, 1991, BIOCHEMISTRY-US, V30, P5491, DOI 10.1021/bi00236a023; CLEVELAND MB, 1983, P NATL ACAD SCI USA, V80, P8706; CRAMER WA, 1990, MOL MICROBIOL, V4, P519, DOI 10.1111/j.1365-2958.1990.tb00619.x; EAST JM, 1982, BIOCHEMISTRY-US, V21, P4144, DOI 10.1021/bi00260a035; GOULD JM, 1977, J BIOL CHEM, V252, P5491; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; JACOBS RE, 1989, BIOCHEMISTRY-US, V28, P3421, DOI 10.1021/bi00434a042; JIANG JX, 1991, BIOCHEMISTRY-US, V30, P3857, DOI 10.1021/bi00230a008; LAKEY JH, 1993, J MOL BIOL, V230, P1055, DOI 10.1006/jmbi.1993.1218; LAKEY JH, 1991, J MOL BIOL, V218, P639, DOI 10.1016/0022-2836(91)90707-D; MERRILL AR, 1993, BIOCHEMISTRY-US, V32, P6974, DOI 10.1021/bi00078a023; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P8529, DOI 10.1021/bi00489a004; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; PETERSON AA, 1987, J MEMBRANE BIOL, V99, P197, DOI 10.1007/BF01995700; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; RATH P, 1991, BIOPHYS J, V59, P516, DOI 10.1016/S0006-3495(91)82268-8; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; SCHEIN SJ, 1978, NATURE, V276, P159, DOI 10.1038/276159a0; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; SHIVER JW, 1989, METHOD ENZYMOL, V172, P439; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; STRAWBRIDGE KB, 1992, CAN J PHYS, V70, P401, DOI 10.1139/p92-069; XU S, 1988, P NATL ACAD SCI USA, V85, P7531, DOI 10.1073/pnas.85.20.7531; ZHANG YL, 1992, PROTEIN SCI, V1, P1666, DOI 10.1002/pro.5560011215	35	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4187	4193						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508440				2022-12-27	WOS:A1994MW98900046
J	SHIMADA, M; HOSAKA, H; TAKAKU, H; SMITH, JS; ROTH, MJ; INOUYE, S; INOUYE, M				SHIMADA, M; HOSAKA, H; TAKAKU, H; SMITH, JS; ROTH, MJ; INOUYE, S; INOUYE, M			SPECIFICITY OF PRIMING REACTION OF HIV-1 REVERSE-TRANSCRIPTASE, 2'-OH OR 3'-OH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note								It has not been unambiguously demonstrated whether the priming reaction of human immunodeficiency virus, type 1 (HIV-1) cDNA synthesis initiates with either the 2'-OH or 3'-OH group of the 3'-terminal adenosine residue of tRNA(Lys-3). In this report, we synthesized tRNA(Lys-3) Of which the 3'-terminal adenosine residue lacks either a 2'-OH or 3'-OH. These tRNA molecules were used for the HIV-1 cDNA-priming reaction in a cell-free system consisting of a 141-base RNA template and purified HIV-1 reverse transcriptase. It was found that under the conditions used, the tRNA containing the 2'-deoxyadenosine was able to initiate the cDNA synthesis, while the tRNA with the 3'-deoxyadenosine was not. The results show that retroviral reverse transcriptase specifically primes cDNA synthesis from the 3'-OH group. This is in contrast to bacterial reverse transcriptase, which initiates cDNA synthesis from the 2'-OH group of an internal guanosine residue of a template RNA.	CHIBA INST TECHNOL,DEPT IND CHEM,NARASHINO,CHIBA 275,JAPAN	Chiba Institute of Technology	SHIMADA, M (corresponding author), ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854, USA.		Roth, Monica/AAN-8742-2020; Inouye, Sharon/R-7216-2019					ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; BENN S, 1985, SCIENCE, V230, P949, DOI 10.1126/science.2997922; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; COBRINIK D, 1988, J VIROL, V62, P3622, DOI 10.1128/JVI.62.10.3622-3630.1988; INOUYE M, 1991, ANNU REV MICROBIOL, V45, P163; RICHTERCOOK NJ, 1992, J BIOL CHEM, V267, P15952; SAKATSUME O, 1991, TETRAHEDRON, V47, P8717, DOI 10.1016/S0040-4020(01)96193-9; WEISS R, 1985, RNA TUMOR VIRUS, P76	9	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3925	3927						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508435				2022-12-27	WOS:A1994MW98900006
J	KLATT, P; SCHMIDT, K; BRUNNER, F; MAYER, B				KLATT, P; SCHMIDT, K; BRUNNER, F; MAYER, B			INHIBITORS OF BRAIN NITRIC-OXIDE SYNTHASE - BINDING-KINETICS, METABOLISM, AND ENZYME INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC ENDOTHELIAL-CELLS; METHYL-L-ARGININE; RELAXING FACTOR; PORCINE CEREBELLUM; NG-NITROARGININE; GUANYLYL CYCLASE; PURIFICATION; MACROPHAGE; IDENTIFICATION; BIOSYNTHESIS	Nitric oxide (NO) is synthesized from L-arginine by different NO synthase isozymes, which are inhibited by the substrate analogs N(G)-methyl- and N(G)-nitro-L-arginine. We studied binding of H-3-labeled N(G)-nitro-L-arginine to purified brain NO synthase and compared the data with results obtained in enzyme kinetic experiments. Binding data revealed a single binding site for N(G)-nitro-L-[H-3]arginine (K(I) = 0.17 muM). Binding was competitively antagonized by L-arginine (K(I) = 2.9 mum). The half-time of dissociation was remarkably slow (9.4 min) and closely correlated with the time necessary for surmounting NO synthase inhibition by dilution. Although an apparently less potent inhibitor, N(G)-methyl-L-arginine exhibited the same affinity for brain NO synthase as the nitro derivative (K(I) = 0.17 muM), and in initial rate experiments, almost equal K(I) values were obtained for N(G)-methyl-L-arginine (0.61 muM) and N(G)-nitro-L-arginine (0.53 muM). However, after prolonged incubation periods, N(G)-nitro-L-arginine induced a rapid inactivation of the enzyme, whereas the methyl derivative turned out to be a substrate of NO synthase, which was slowly converted into stoichiometric amounts of NO and L-citrulline.	GRAZ UNIV,INST PHARMACOL & TOXIKOL,UNIV PL 2,A-8010 GRAZ,AUSTRIA	University of Graz			Mayer, Bernd/B-9391-2008	Mayer, Bernd/0000-0002-2921-3494				ARCHER SL, 1992, BIOCHEM BIOPH RES CO, V188, P590, DOI 10.1016/0006-291X(92)91097-A; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNNER F, 1991, BRIT J PHARMACOL, V102, P373, DOI 10.1111/j.1476-5381.1991.tb12181.x; DWYER MA, 1991, BIOCHEM BIOPH RES CO, V176, P1136, DOI 10.1016/0006-291X(91)90403-T; FELDMAN PL, 1993, J MED CHEM, V36, P491, DOI 10.1021/jm00056a009; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; Hammes G.G., 1970, ENZYMES, V2, P67; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; KAWATA S, 1983, BIOCHEM PHARMACOL, V32, P3723; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KLATT P, 1992, J BIOL CHEM, V267, P11374; KNOWLES RG, 1990, BIOCHEM J, V269, P207, DOI 10.1042/bj2690207; KWON NS, 1990, J BIOL CHEM, V265, P13442; LEONE AM, 1991, J BIOL CHEM, V266, P23790; MAELICKE A, 1977, J BIOL CHEM, V252, P4811; MAYER B, 1991, J CARDIOVASC PHARM, V17, pS46, DOI 10.1097/00005344-199117003-00009; MAYER B, 1992, J NEUROCHEM, V59, P2024; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MAYER B, 1993, SEMIN NEUROSCI, V5, P197, DOI 10.1016/S1044-5765(05)80053-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURPHY ME, 1991, J BIOL CHEM, V266, P19378; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; OLKEN NM, 1991, BIOCHEM BIOPH RES CO, V177, P828, DOI 10.1016/0006-291X(91)91864-9; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; POU S, 1992, J BIOL CHEM, V267, P24173; PUFAHL RA, 1992, BIOCHEMISTRY-US, V31, P6822, DOI 10.1021/bi00144a024; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TSENG CM, 1993, J APPL PHYSIOL, V74, P549, DOI 10.1152/jappl.1993.74.2.549; WALLACE GC, 1991, J MED CHEM, V34, P1746, DOI 10.1021/jm00109a032; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WINN MJ, 1993, J PHARMACOL EXP THER, V264, P265; WOLFF DJ, 1992, BIOCHEM J, V285, P201, DOI 10.1042/bj2850201; ZHANG J, 1993, BRAIN RES, V606, P56, DOI 10.1016/0006-8993(93)91569-E	51	158	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1674	1680						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507482				2022-12-27	WOS:A1994MR98800023
J	CARTER, NS; BERGER, BJ; FAIRLAMB, AH				CARTER, NS; BERGER, BJ; FAIRLAMB, AH			UPTAKE OF DIAMIDINE DRUGS BY THE P2 NUCLEOSIDE TRANSPORTER IN MELARSEN-SENSITIVE AND -RESISTANT TRYPANOSOMA-BRUCEI-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FINE-STRUCTURE; RHODESIENSE; PENTAMIDINE; METABOLISM; EVANSI	The African trypanosome, Trypanosoma brucei brucei, possesses at least two nucleoside transporter systems designated P1 and P2, the latter being implicated in the selective uptake of melaminophenyl arsenical drugs, Since arsenical-resistant trypanosomes show cross-resistance in vivo to aromatic diamidines, we have investigated whether these drugs are also substrates for the P2 nucleoside transporter, In melarsen-sensitive T. b. brucei, the diamidines, including the commonly used trypanocides, pentamidine and berenil, were found to abrogate lysis induced by the P2 transport of melarsen oxide in vitro, Measurement of [ring-H-3]pentamidine transport in melarsen-sensitive T. b. brucei, demonstrated that uptake is carrier-mediated, with a K-m of 0.84 mu M and a V-max of 9.35 pmol s(-1) (10(8) cells)(-1). Pentamidine transport appears to be P2-mediated in these cells, as pentamidine strongly inhibited uptake of [2',5',8-H-3]adenosine by the P2 transporter, with a K-i of 0.56 mu M, Furthermore, [ring-H-3]pentamidine transport was blocked by a number of P2 transporter substrates and inhibitors, as well as by other diamidine drugs, Analysis of the uptake of pentamidine and other diamidines in melarsen-resistant trypanosomes in vitro and in vivo, which also show differential levels of resistance to these compounds in vivo, indicated that P2 transport was altered in these cells and that accumulation of these drugs was markedly reduced.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT MED PARASITOL, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine			, Brad/ABC-8284-2020; Fairlamb, Alan/A-5272-2009	Fairlamb, Alan/0000-0001-5134-0329	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APTED FIC, 1980, PHARMACOL THERAPEUT, V11, P391, DOI 10.1016/0163-7258(80)90035-2; ARONOW B, 1985, J BIOL CHEM, V260, P6226; BACCHI CJ, 1993, BIOCHEM PHARMACOL, V46, P471, DOI 10.1016/0006-2952(93)90524-Z; BERGER BJ, 1991, J PHARMACOL EXP THER, V256, P883; BERGER BJ, 1995, MOL BIOCHEM PARASIT, V69, P289, DOI 10.1016/0166-6851(94)00215-9; BERGER BJ, 1993, ACTA TROP, V54, P215, DOI 10.1016/0001-706X(93)90094-R; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; DAMPER D, 1976, BIOCHEM PHARMACOL, V25, P271, DOI 10.1016/0006-2952(76)90213-6; Dixon M., 1979, ENZYMES, Vthird; FAIRLAMB AH, 1992, MOL BIOCHEM PARASIT, V53, P213, DOI 10.1016/0166-6851(92)90023-D; FROMMEL TO, 1987, MOL BIOCHEM PARASIT, V26, P183, DOI 10.1016/0166-6851(87)90142-3; Fulton J. D., 1944, ANN TROP MED AND PARASITOL, V38, P78; HOEIJMAKERS JHJ, 1980, GENE, V8, P391, DOI 10.1016/0378-1119(80)90043-8; KAZYUMBA GL, 1988, B SOC PATHOL EXOT, V81, P591; KUZOE FAS, 1993, ACTA TROP, V54, P153, DOI 10.1016/0001-706X(93)90089-T; LANHAM SM, 1968, NATURE, V218, P1273, DOI 10.1038/2181273a0; LAUNOY L, 1960, Ann Pharm Fr, V18, P273; LAUNOY L, 1960, Ann Pharm Fr, V18, P424; MACADAM RF, 1972, T ROY SOC TROP MED H, V66, P897, DOI 10.1016/0035-9203(72)90125-3; OPPERDOES FR, 1984, J CELL BIOL, V98, P1178, DOI 10.1083/jcb.98.4.1178; OSMAN AS, 1992, ACTA TROP, V50, P249, DOI 10.1016/0001-706X(92)90081-8; PEREGRINE AS, 1993, ACTA TROP, V54, P185, DOI 10.1016/0001-706X(93)90092-P; POSPICHAL H, 1994, ACTA TROP, V58, P187, DOI 10.1016/0001-706X(94)90013-2; REID JC, 1951, CANCER RES, V11, P188; RIFKIN MR, 1985, MOL BIOCHEM PARASIT, V15, P245, DOI 10.1016/0166-6851(85)90088-X; ROLLO IM, 1951, NATURE, V167, P147, DOI 10.1038/167147a0; SCHOENBACH EB, 1948, MEDICINE, V27, P327, DOI 10.1097/00005792-194809000-00003; WILLIAMSON J, 1979, PHARMACOL THERAPEUT, V7, P445, DOI 10.1016/0163-7258(79)90040-8; Williamson J., 1970, P125; WILLIAMSON J, 1962, AFRICAN TRYPANOSOMIA, V12, P274; ZHANG ZQ, 1993, EXP PARASITOL, V77, P387, DOI 10.1006/expr.1993.1098; 1993, 11TH UNDP WORLD BANK	32	172	172	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28153	28157						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499305	Green Published, hybrid			2022-12-27	WOS:A1995TG21000030
J	JANSSEN, OE; CHEN, BK; BUTTNER, C; REFETOFF, S; SCRIBA, PC				JANSSEN, OE; CHEN, BK; BUTTNER, C; REFETOFF, S; SCRIBA, PC			MOLECULAR AND STRUCTURAL CHARACTERIZATION OF THE HEAT-RESISTANT THYROXINE-BINDING GLOBULIN CHICAGO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 NUCLEOTIDE SUBSTITUTIONS; PARTIAL TBG DEFICIENCY; PROTEIN STABILITY; ALPHA-HELIX; T4 LYSOZYME; VARIANT; SECRETION; SEQUENCE; ALPHA-1-ANTITRYPSIN; FAMILY	Thyroxine-binding globulin (TBG) is the main transport protein for thyroxine (T-4) in blood, It shares considerable sequence homology with alpha(1)-antitrypsin (AT) and other members of the serine proteinase inhibitor (serpin) superfamily of proteins. The crystallographic structure of AT has been determined and was found to represent the archetype of the serpins, This model has been used for structure-function correlations of TBG. Sequence analysis of the heat-resistant variant TBG-Chicago (TBG-CH) revealed a substitution of the normal tyrosine 309 with phenylalanine. For further analysis, vectors containing the coding regions of normal TBG (TBG-N) and TBG-CH were constructed, transcribed in vitro, and expressed in Xenopus oocytes, Both TBGs were secreted into the culture medium and could not be distinguished by gel electrophoresis. Scatchard analysis of T-4 binding to TBG-N and -CH revealed no significant differences in binding affinity. The rate of heat denaturation of TBGs was determined by measurement of residual T-4 binding capacity after incubation at 60 degrees C for various periods of time, The half-life values of denaturation of TBG-N and -CH were 7 and 132 min, respectively, The tyrosine 309 to phenylalanine substitution of TBG-CH involves a highly conserved phenylalanine residue of the serpins. The respective phenylalanine 312 of AT ties the alpha-helix hI1 to the molecule, thus stabilizing the tertiary structure. A substitution with tyrosine would disrupt this interaction, Accordingly, stabilization of the TBG molecule by replacement of tyrosine with phenylalanine in position 309 causes the increased heat stability of TBG-CH.	UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PEDIAT, CHICAGO, IL 60637 USA; UNIV CHICAGO, JOSEPH P KENNEDY JR MENTAL RETARDAT RES CTR, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	JANSSEN, OE (corresponding author), UNIV MUNICH, KLINIKUM INNENSTADT,DEPT MED,LAB 278, MOLEC THYROID STUDY UNIT, ZIEMSSENSTR 1, D-80336 MUNICH, GERMANY.		Refetoff, Samuel/ABB-1263-2021	Refetoff, Samuel/0000-0003-0164-8231	NIDDK NIH HHS [DK 15070] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK015070, R01DK015070] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; BARTALENA L, 1990, ENDOCR REV, V11, P47, DOI 10.1210/edrv-11-1-47; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BERTENSHAW R, 1991, AM J HUM GENET, V48, P741; BERTENSHAW R, 1992, BIOCHIM BIOPHYS ACTA, V1139, P307, DOI 10.1016/0925-4439(92)90105-V; BETZ SF, 1993, PROTEIN SCI, V2, P1551, DOI 10.1002/pro.5560021002; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DAOPIN S, 1990, PROTEINS, V7, P198, DOI 10.1002/prot.340070208; DOAN DNP, 1992, FEBS LETT, V309, P265, DOI 10.1016/0014-5793(92)80786-G; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FLINK IL, 1986, P NATL ACAD SCI USA, V83, P7708, DOI 10.1073/pnas.83.20.7708; FOREMAN RC, 1987, BIOSCIENCE REP, V7, P307, DOI 10.1007/BF01121452; GOODENOUGH PW, 1991, BIOCHEM SOC T, V19, P655, DOI 10.1042/bst0190655; HAYASHI Y, 1993, MOL ENDOCRINOL, V7, P1049, DOI 10.1210/me.7.8.1049; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JAENICKE R, 1991, EUR J BIOCHEM, V202, P715, DOI 10.1111/j.1432-1033.1991.tb16426.x; JANSSEN OE, 1991, HUM GENET, V87, P119, DOI 10.1007/BF00204164; JANSSEN OE, 1992, J BIOL CHEM, V267, P13998; JANSSEN OE, 1992, TRENDS ENDOCRIN MET, V3, P49, DOI 10.1016/1043-2760(92)90043-Z; KAMBE F, 1992, MOL ENDOCRINOL, V6, P443, DOI 10.1210/me.6.3.443; KAMBE F, 1988, MOL ENDOCRINOL, V2, P181, DOI 10.1210/mend-2-2-181; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; Kristjansson M M, 1991, Adv Food Nutr Res, V35, P237, DOI 10.1016/S1043-4526(08)60066-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; LOBERMANN H, 1984, J MOL BIOL, V177, P531; MALLER JL, 1983, METHOD ENZYMOL, V99, P219; MARSHALL JS, 1978, ARCH BIOCHEM BIOPHYS, V156, P456; MATSUMURA M, 1986, NATURE, V323, P356, DOI 10.1038/323356a0; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; MIURA Y, 1994, J CLIN ENDOCR METAB, V78, P283, DOI 10.1210/jc.78.2.283; MIURA Y, 1993, ENDOCR J, V40, P127, DOI 10.1507/endocrj.40.127; MORI Y, 1990, J CLIN ENDOCR METAB, V70, P804, DOI 10.1210/jcem-70-3-804; MORI Y, 1989, MOL ENDOCRINOL, V3, P575, DOI 10.1210/mend-3-3-575; MURATA Y, 1985, J ENDOCRINOL INVEST, V8, P225, DOI 10.1007/BF03348482; MURPHY KP, 1992, J MOL BIOL, V227, P293, DOI 10.1016/0022-2836(92)90699-K; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; PANTOLIANO MW, 1989, BIOCHEMISTRY-US, V28, P7205, DOI 10.1021/bi00444a012; REFETOFF S, 1970, ENDOCRINOLOGY, V86, P793, DOI 10.1210/endo-86-4-793; REFETOFF S, 1994, ENDOCRINE REV MONOGR, V3, P162; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWARZ H, 1987, BIOCHEMISTRY-US, V26, P3544, DOI 10.1021/bi00386a044; SERRANO L, 1992, J MOL BIOL, V227, P544, DOI 10.1016/0022-2836(92)90906-Z; SERRANO L, 1993, J MOL BIOL, V233, P305, DOI 10.1006/jmbi.1993.1508; SHORTLE D, 1989, J BIOL CHEM, V264, P5315; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; STEARMAN RS, 1988, BIOCHEMISTRY-US, V27, P7571, DOI 10.1021/bi00419a059; TAKAMATSU J, 1986, J CLIN ENDOCR METAB, V63, P1140, DOI 10.1210/jcem-63-5-1140; TRENT JM, 1987, AM J HUM GENET, V41, P428; VERBANAC KM, 1986, J BIOL CHEM, V261, P9979; WALTZ MR, 1990, J ENDOCRINOL INVEST, V13, P343, DOI 10.1007/BF03349576; WRBA A, 1990, BIOCHEMISTRY-US, V29, P7584, DOI 10.1021/bi00485a007; ZHANG XJ, 1991, BIOCHEMISTRY-US, V30, P2012, DOI 10.1021/bi00222a001; ZINN AB, 1978, J BIOL CHEM, V253, P6768; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962; [No title captured]	64	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28234	28238						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499319				2022-12-27	WOS:A1995TG21000044
J	LEWIS, BA; ORKIN, SH				LEWIS, BA; ORKIN, SH			A FUNCTIONAL INITIATOR ELEMENT IN THE HUMAN BETA-GLOBIN PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TATA-LESS PROMOTER; TRANSCRIPTION INITIATION; ACCURATE TRANSCRIPTION; TFIID COMPLEX; BOX; THALASSEMIA; MUTATION; BINDING; DNA	Core promoters are defined by the presence of either a TATA box at approximately 30 base pairs upstream of the transcriptional start site (+1) and/or an initiator element centered around the +1 site. The prevalence, function, and significance of the various combinations of core promoter elements are as yet unclear, We describe here the identification and characterization of an initiator element in the TATA-containing human beta-globin promoter, Mutagenesis of the beta-globin initiator element at positions +2/+3 and +4/+5 abrogates transcription in a heterologous construct, Interestingly, we have found a beta-globin initiator binding activity in nuclear extracts whose presence or absence correlates with function of the beta-globin initiator. Accordingly, this binding activity may be part of the machinery required for beta-globin initiator-dependent transcription, Our analysis further describes a previously uncharacterized beta-thalassemia mutation at the +1 site as a mutation that decreases beta-globin initiator activity, Finally, consistent with other initiator elements, the beta-globin initiator requires a TFIID-containing fraction for in vitro activity, Thus, the human beta-globin promoter contains an initiator element whose function, as revealed by a beta-thalassemia mutation, is of physiological relevance.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	LEWIS, BA (corresponding author), HARVARD UNIV, CHILDRENS HOSP,SCH MED,DIV HEMATOL ONCOL,ENDERS, RM 750, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.			Lewis, Brian/0000-0002-8321-0665				ANTONARAKIS SE, 1984, P NATL ACAD SCI-BIOL, V81, P1154, DOI 10.1073/pnas.81.4.1154; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CAI SP, 1989, AM J HUM GENET, V45, P112; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; COLGAN J, 1995, P NATL ACAD SCI USA, V92, P1955, DOI 10.1073/pnas.92.6.1955; COWIE A, 1988, MOL CELL BIOL, V8, P3122, DOI 10.1128/MCB.8.8.3122; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HAM J, 1994, EMBO J, V13, P147, DOI 10.1002/j.1460-2075.1994.tb06244.x; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; ORKIN SH, 1984, ANNU REV GENET, V18, P131; ORKIN SH, 1983, NUCLEIC ACIDS RES, V11, P4727, DOI 10.1093/nar/11.14.4727; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TAKIHARA Y, 1986, BLOOD, V67, P547; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WEAVER RF, 1979, NUCLEIC ACIDS RES, V7, P1175, DOI 10.1093/nar/7.5.1175; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WONG C, 1987, NATURE, V330, P384, DOI 10.1038/330384a0; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	40	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28139	28144						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499303				2022-12-27	WOS:A1995TG21000028
J	YIM, HS; KANG, SO; HAH, YC; CHOCK, PB; YIM, MB				YIM, HS; KANG, SO; HAH, YC; CHOCK, PB; YIM, MB			FREE-RADICALS GENERATED DURING THE GLYCATION REACTION OF AMINO-ACIDS BY METHYLGLYOXAL - A MODEL STUDY OF PROTEIN-CROSS-LINKED FREE-RADICALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-ENZYMATIC GLYCOSYLATION; DIABETES-MELLITUS; AUTOXIDATIVE GLYCOSYLATION; PHYSIOLOGICAL CONDITIONS; GLUCOSE AUTOXIDATION; HUMAN COLLAGEN; END-PRODUCTS; COMPLICATIONS; MECHANISM; N-EPSILON-(CARBOXYMETHYL)LYSINE	The formation of alpha-dicarbonyl compounds seems to be an important step for cross-linking proteins in the glycation or Maillard reaction, To elucidate the mechanism for the cross linking reaction, we studied the reaction between a three-carbon alpha-dicarbonyl compound, methylglyoxal, and amino acids, Our results showed that this reaction generated yellow fluorescent products as formed in some glycated proteins, In addition, three types of free radical species were also produced, and their structures were determined by EPR spectroscopy, These free radicals are 1) the cross-linked radical cation, 2) the methylglyoxal radical anion as the counterion, and 3) the superoxide radical anion produced only in the presence of oxygen. The generation of the cross-linked radical cations and the methylglyoxal radical anions does not require metal ions or oxygens, These results indicate that dicarbonyl compounds cross-link free amino groups of protein by forming Schiff bases, which donate electrons directly to dicarbonyl compounds to form the cross-linked radical cations and the methylglyoxal radical anions, Oxygen can accept an electron from the radical anion to generate a superoxide radical anion, which can initiate damaging chain reactions, Time course studies suggest that the cross linked radical cation is a precursor of yellow fluorescent glycation end products.	NHLBI, BIOCHEM LAB, BETHESDA, MD 20892 USA; SEOUL NATL UNIV, COLL NAT SCI, DEPT MICROBIOL, SEOUL 151742, SOUTH KOREA; SEOUL NATL UNIV, MOLEC MICROBIOL RES CTR, SEOUL 151742, SOUTH KOREA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Seoul National University (SNU); Seoul National University (SNU)								AHMED MU, 1986, J BIOL CHEM, V261, P4889; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; BUCALA R, 1991, J CLIN INVEST, V87, P432, DOI 10.1172/JCI115014; DUNN JA, 1989, BIOCHEMISTRY-US, V28, P9464, DOI 10.1021/bi00450a033; DUNN JA, 1990, BIOCHEMISTRY-US, V29, P10964, DOI 10.1021/bi00501a014; DYER DG, 1991, J BIOL CHEM, V266, P11654; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; GASCOYNE PRC, 1980, INT J QUANTUM CHEM S, V8, P265; GASCOYNE PRC, 1983, INT J QUANTUM CHEM Q, V10, P123; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; HAYASHI T, 1977, J AGR FOOD CHEM, V25, P1282, DOI 10.1021/jf60214a047; HAYASHI T, 1985, AGR BIOL CHEM TOKYO, V49, P3131, DOI 10.1080/00021369.1985.10867244; HICKS M, 1988, BIOCHEM BIOPH RES CO, V151, P649, DOI 10.1016/S0006-291X(88)80330-9; HODGE JE, 1953, J AGR FOOD CHEM, V1, P928, DOI 10.1021/jf60015a004; HUNT JV, 1990, DIABETES, V39, P1420, DOI 10.2337/diabetes.39.11.1420; HUNT JV, 1988, BIOCHEM J, V256, P205, DOI 10.1042/bj2560205; JIANG ZY, 1990, FEBS LETT, V268, P89; KATO H, 1987, AGR BIOL CHEM TOKYO, V51, P2009, DOI 10.1080/00021369.1987.10868313; KATO H, 1987, AGR BIOL CHEM TOKYO, V51, P683, DOI 10.1080/00021369.1987.10868106; LIANG JN, 1986, DIABETOLOGIA, V29, P225, DOI 10.1007/BF00454880; MCLAUGHLIN JA, 1980, P NATL ACAD SCI-BIOL, V77, P949, DOI 10.1073/pnas.77.2.949; MIYATA S, 1992, J CLIN INVEST, V89, P1102, DOI 10.1172/JCI115690; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; MULLARKEY CJ, 1990, BIOCHEM BIOPH RES CO, V173, P932, DOI 10.1016/S0006-291X(05)80875-7; NAMIKI M, 1975, J AGR FOOD CHEM, V23, P487, DOI 10.1021/jf60199a024; NAMIKI M, 1983, ACS SYM SER, V215, P21; REYNOLDS T. M., 1963, ADVAN FOOD RES, V12, P1; Reynolds T M, 1965, Adv Food Res, V14, P167; SAKURAI T, 1988, FEBS LETT, V236, P406, DOI 10.1016/0014-5793(88)80066-8; SELL DR, 1989, J BIOL CHEM, V264, P21597; SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449; SIMPSON JA, 1992, BIOCHEM J, V282, P621, DOI 10.1042/bj2820621; STEENKEN S, 1975, PHOTOCHEM PHOTOBIOL, V21, P21, DOI 10.1111/j.1751-1097.1975.tb06624.x; THORNALLEY P, 1984, BIOCHIM BIOPHYS ACTA, V797, P276, DOI 10.1016/0304-4165(84)90131-4; VLASSARA H, 1983, DIABETES, V32, P670, DOI 10.2337/diabetes.32.7.670; VLASSARA H, 1981, P NATL ACAD SCI-BIOL, V78, P5190, DOI 10.1073/pnas.78.8.5190; WOLFF SP, 1987, BIOELECTROCH BIOENER, V18, P283, DOI 10.1016/0302-4598(87)85030-4; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243	43	235	246	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28228	28233						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499318				2022-12-27	WOS:A1995TG21000043
J	DRUKER, BJ; NEUMANN, M; OKUDA, K; FRANZA, BR; GRIFFIN, JD				DRUKER, BJ; NEUMANN, M; OKUDA, K; FRANZA, BR; GRIFFIN, JD			REL IS RAPIDLY TYROSINE-PHOSPHORYLATED FOLLOWING GRANULOCYTE-COLONY-STIMULATING FACTOR TREATMENT OF HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DNA-BINDING SUBUNIT; VIRUS STRAIN-T; C-REL; SIGNAL TRANSDUCTION; FACTOR RECEPTOR; PROTO-ONCOGENE; PROTEINS; DORSAL; DROSOPHILA	Stimulation of neutrophils with granulocyte-colony stimulating factor (G-CSF) results in an enhanced respiratory burst, prolonged survival, and increased tumor cell killing. The effects of G-CSF are mediated by binding to specific, high affinity receptors. G-CSF receptors lack intrinsic tyrosine kinase activity, but activation of the receptor results in the rapid induction of tyrosine kinase activity. Antiphosphotyrosine immunoblots of whole cell lysates prepared from neutrophils show that the G-CSF rapidly induces prominent tyrosine phos phosphorylation of a protein of a relative molecular mass of 80 kDa. Using monospecific antibodies, the 80-kDa tyrosine-phosphorylated protein has been shown to be p80(c-rel), a proto-oncogene belonging to a family of transcriptional regulators which include NF-kB. The induction of tyrosine phosphorylation of p80(c-rel) was unique to G-CSF in that granulocyte-macrophage colony stimulating factor which also stimulates neutrophils and induces tyrosine phosphorylation does not result in tyro sine phosphorylation of p80(c-rel). The consequences of p80(c-rel) tyrosine phosphorylation are not yet known; however, tyrosine-phosphorylated p80(c-rel) is capable of binding to DNA, and G-CSF stimulation results in an increase in the amount of p80(c-rel) which binds to DNA, These results demonstrate that one of the first biochemical events which occurs in neutrophils following G-CSF stimulation, activation of a tyrosine kinase, leads directly to the tyrosine phosphorylation of p80(c-rel). Thus, the tyrosine kinase activated by G-CSF appears to directly transduce a signal to a protein which functions as a transcriptional regulator.	DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115; DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; COLD SPRING HARBOR LAB,FREEMAN LAB CANC CELL BIOL,COLD SPRING HARBOR,NY 11724	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Cold Spring Harbor Laboratory				Druker, Brian/0000-0001-8331-8206	NATIONAL CANCER INSTITUTE [P01CA034183, R37CA036167, R01CA036167, K08CA001422] Funding Source: NIH RePORTER; NCI NIH HHS [CA34183, CA01422, CA36167] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63; BAUERLE PA, 1988, SCIENCE, V242, P540; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMETRI GD, 1991, BLOOD, V78, P2791; DRUKER B, 1992, BLOOD, V79, P2215; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HALLEK M, 1992, J CELL PHYSIOL, V153, P176, DOI 10.1002/jcp.1041530122; IP YT, 1991, CELL, V64, P439; KANAKURA Y, 1990, BLOOD, V76, P706; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; NAGATA S, 1991, Progress in Growth Factor Research, V3, P131, DOI 10.1016/S0955-2235(05)80004-3; NEUMANN M, 1992, ONCOGENE, V7, P2095; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OKUDA K, 1992, BLOOD, V79, P2880; RICE NR, 1988, ONCOGENE HDB, P495; ROBINSON FR, 1974, AVIAN DIS, V18, P278, DOI 10.2307/1589142; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; YUO A, 1993, BIOCHIM BIOPHYS ACTA, V1156, P197, DOI 10.1016/0304-4165(93)90136-V	29	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5387	5390						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508937				2022-12-27	WOS:A1994MX57100103
J	HU, L; GUDAS, LJ				HU, L; GUDAS, LJ			ACTIVATION OF KERATIN-19 GENE-EXPRESSION BY A 3' ENHANCER CONTAINING AN AP1 SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; RETINOIC ACID RECEPTOR; TRANSCRIPTION FACTOR AP-1; F9 TERATOCARCINOMA CELLS; MAMMARY EPITHELIAL-CELLS; C-JUN; TERMINAL DIFFERENTIATION; VITAMIN-A; EPIDERMAL-KERATINOCYTES; REGULATORY ELEMENTS	We previously reported that the human keratin 19 (K19) gene was expressed in nonkeratinizing oral epithelial subtypes, and that the steady state K19 mRNA levels in different normal epithelial subtypes correlated with the levels of the retinoic acid receptor (RAR) beta-mRNA (Hu, L., Crowe, D. L., Rheinwald, J. G., Chambon, P., and Gudas, L. J. (1991) Cancer Res. 51, 3972-3981). To elucidate the mechanisms by which the K19 gene is differentially expressed in various epithelial subtypes, we isolated phage containing human K19 genomic DNA from a human placental library. Through transient transfection assays with various K19/CAT constructs that contain different portions of K19 genomic DNA, an enhancer sequence has been identified in the K19 3'-flanking region. In normal human epithelial cell strains, the activity of this enhancer correlates with K19 mRNA abundance. This enhancer activates both the K19 and TK basal promoters in HeLa cells. A high level of K19/CAT fusion mRNA was detected when this K19 3' enhancer sequence was present at the 3' end of the fusion gene whereas no K19/CAT fusion transcript was detected if this 3' K19 enhancer sequence was absent, suggesting that the 3' K19 enhancer is crucial for the positive regulation of K19 expression. Deletion analysis has permitted the localization of the enhancer to a 19-base pair sequence which contains an AP1 binding site (AGTCATCT). Point mutations within this AP1 site completely abolished K19 enhancer activity in HeLa cells. Co-transfections of a c-jun expression vector with K19/CAT reporter constructs demonstrated that c-jun was able to activate the K19 promoter via the 3' K19 enhancer. Collectively, these data indicate that a cis-acting AP1 element and its associated trans-acting effector proteins regulate expression of lineage-specific genes in epithelial cells.	CORNELL UNIV,MED CTR,COLL MED,DEPT PHARMACOL,NEW YORK,NY 10021	Cornell University					NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010389] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01DE10389] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANESKIEVICH BJ, 1992, MOL CELL BIOL, V12, P4862, DOI 10.1128/MCB.12.11.4862; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; BADER BL, 1986, EMBO J, V5, P1865, DOI 10.1002/j.1460-2075.1986.tb04438.x; BADER BL, 1988, EUR J CELL BIOL, V47, P300; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLESSING M, 1989, EMBO J, V8, P117, DOI 10.1002/j.1460-2075.1989.tb03355.x; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CLAUSEN H, 1986, J ORAL PATHOL MED, V15, P36, DOI 10.1111/j.1600-0714.1986.tb00561.x; CREMISI C, 1987, NUCLEIC ACIDS RES, V15, P6105, DOI 10.1093/nar/15.15.6105; CROWE DL, 1991, DIFFERENTIATION, V48, P199, DOI 10.1111/j.1432-0436.1991.tb00258.x; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P1585, DOI 10.1093/nar/19.7.1585; DORAN TI, 1980, CELL, V22, P17, DOI 10.1016/0092-8674(80)90150-6; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; ECKERT RL, 1988, P NATL ACAD SCI USA, V85, P1114, DOI 10.1073/pnas.85.4.1114; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; ECKERT RL, 1984, P NATL ACAD SCI-BIOL, V81, P4321, DOI 10.1073/pnas.81.14.4321; EDWARDS SA, 1988, DEV BIOL, V129, P91, DOI 10.1016/0012-1606(88)90164-9; ERMICH T, 1988, BIOMED BIOCHIM ACTA, V47, P737; FISHER C, 1991, DEVELOPMENT, V111, P253; FUCHS E, 1981, CELL, V25, P617, DOI 10.1016/0092-8674(81)90169-0; GARCIA J, 1987, NUCLEIC ACIDS RES, V15, P8367, DOI 10.1093/nar/15.20.8367; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; HU L, 1991, CANCER RES, V51, P3972; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; JIANG CK, 1990, NUCLEIC ACIDS RES, V18, P247, DOI 10.1093/nar/18.2.247; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENSTRA JA, 1983, EUR J BIOCHEM, V130, P419, DOI 10.1111/j.1432-1033.1983.tb07168.x; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LINDBERG K, 1990, DIFFERENTIATION, V45, P230, DOI 10.1111/j.1432-0436.1990.tb00477.x; LINDBERG K, 1989, AM J PATHOL, V134, P89; LOCKETT TJ, 1987, EXP CELL RES, V173, P370, DOI 10.1016/0014-4827(87)90277-1; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUSSIER M, 1989, GENE, V85, P435, DOI 10.1016/0378-1119(89)90437-X; LUSSIER M, 1990, GENE, V95, P203, DOI 10.1016/0378-1119(90)90363-V; Maniatis T., 1982, MOL CLONING; MASON I, 1985, DIFFERENTIATION, V30, P76, DOI 10.1111/j.1432-0436.1985.tb00516.x; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MORGAN PR, 1987, EPITHELIA, V1, P31; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OGUIN WM, 1987, CURR TOP DEV BIOL, V22, P97; OHTSUKI M, 1992, J INVEST DERMATOL, V99, P206, DOI 10.1111/1523-1747.ep12650436; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; OSHIMA RG, 1988, GENE DEV, V2, P505, DOI 10.1101/gad.2.5.505; PAN LY, 1992, NUCLEIC ACIDS RES, V20, P3105, DOI 10.1093/nar/20.12.3105; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; REIBEL J, 1989, DIFFERENTIATION, V41, P237, DOI 10.1111/j.1432-0436.1989.tb00752.x; ROSENTHAL DS, 1991, CELL GROWTH DIFFER, V2, P107; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SAVENTCHO ES, 1988, AM J HUM GENET, V43, P630; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; STASIAK PC, 1987, NUCLEIC ACIDS RES, V15, P10058, DOI 10.1093/nar/15.23.10058; STELLMACH V, 1991, P NATL ACAD SCI USA, V88, P4582, DOI 10.1073/pnas.88.11.4582; STELLMACH V M, 1989, New Biologist, V1, P305; TAKAHASHI N, 1991, BIOCHEM BIOPH RES CO, V180, P393, DOI 10.1016/S0006-291X(05)81306-3; TAKEMOTO Y, 1991, NUCLEIC ACIDS RES, V19, P2761, DOI 10.1093/nar/19.10.2761; TOMIC M, 1990, CELL REGUL, V1, P965, DOI 10.1091/mbc.1.12.965; TRASK DK, 1990, P NATL ACAD SCI USA, V87, P2319, DOI 10.1073/pnas.87.6.2319; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; WU YJ, 1981, CELL, V25, P627, DOI 10.1016/0092-8674(81)90170-7; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670; YANG-YEN H-F, 1990, New Biologist, V2, P351	84	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					183	191						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506253				2022-12-27	WOS:A1994MR21900036
J	CHEN, QL; OLASHAW, N; WU, J				CHEN, QL; OLASHAW, N; WU, J			PARTICIPATION OF REACTIVE OXYGEN SPECIES IN THE LYSOPHOSPHATIDIC ACID-STIMULATED MITOGEN-ACTIVATED PROTEIN-KINASE KINASE ACTIVATION PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IDENTIFICATION; GENE; STRESS; EGF	Recent evidence suggests that reactive oxygen species (ROS) may function as second messengers in intracellular signal transduction pathways. We explored the possibility that ROS were involved in lysophosphatidic acid (LPA)-induced mitogen-activated protein (MAP) kinase signaling pathway in HeLa cells. Antioxidant N-acetylcysteine inhibited the LPA stimulated MAP kinase kinase activity. Direct exposure of HeLa cells to hydrogen peroxide resulted in a concentration- and time-dependent activation of MAP kinase kinase. Inhibition of catalase with aminotriazole enhanced the effect of LPA on induction of MAP kinase kinase. Further, LPA stimulated ROS production in HeLa cells. These findings suggest that ROS participate in the LPA-elicited MAP kinase signaling pathway.	UNIV S FLORIDA,H LEE MOFFITT CANC CTR & RES INST,MOLEC ONCOL PROGRAM,TAMPA,FL 33612; UNIV S FLORIDA,H LEE MOFFITT CANC CTR & RES INST,CELL BIOL PROGRAM,TAMPA,FL 33612; UNIV S FLORIDA,DEPT MED MICROBIOL & IMMUNOL,TAMPA,FL 33612; UNIV S FLORIDA,DEPT ANAT,TAMPA,FL 33612	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida			Wu, Jie/R-2404-2019	Wu, Jie/0000-0002-2864-1606				BASUMODAK S, 1993, CANCER RES, V53, P4505; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BUTTKE TM, 1994, IMMUNOL TODAY, V7, P7; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DEFORGE LE, 1993, J BIOL CHEM, V268, P25568; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DURIEUX ME, 1993, TRENDS PHARMACOL SCI, V14, P249, DOI 10.1016/0165-6147(93)90021-B; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; GOTZ ME, 1994, PHARMACOL THERAPEUT, V63, P37, DOI 10.1016/0163-7258(94)90055-8; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HARWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; RIZZO MT, 1994, EXP HEMATOL, V22, P87; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; RUBINEK T, 1993, BIOCHIM BIOPHYS ACTA, V1176, P51, DOI 10.1016/0167-4889(93)90176-P; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SPIEGEL S, 1993, ADV LIPID RES, V25, P105; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	33	172	174	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28499	28502		10.1074/jbc.270.48.28499	http://dx.doi.org/10.1074/jbc.270.48.28499			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499358	hybrid			2022-12-27	WOS:A1995TH05600002
J	EARP, HS; HUCKLE, WR; DAWSON, TL; LI, X; GRAVES, LM; DY, R				EARP, HS; HUCKLE, WR; DAWSON, TL; LI, X; GRAVES, LM; DY, R			ANGIOTENSIN-II ACTIVATES AT LEAST 2 TYROSINE KINASES IN RAT-LIVER EPITHELIAL-CELLS - SEPARATION OF THE MAJOR CALCIUM-REGULATED TYROSINE KINASE FROM P125(FAK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; SMOOTH-MUSCLE CELLS; EPIDERMAL GROWTH-FACTOR; BOMBESIN STIMULATION; SIGNAL TRANSDUCTION; MAP KINASE; PROTEIN; PHOSPHORYLATION; IDENTIFICATION; VASOPRESSIN	In rat liver epithelial cell lines (WB or GN4), angiotensin II (Ang II) stimulates cytosolic tyrosine kinase activity, in part, through a calcium-dependent mechanism. In other cell types, selected hormones that activate G(i)- or G(q)-coupled receptors stimulate the soluble tyrosine kinase, p125(FAK). Immunoprecipitation of p125(FAK) from Ang II-activated GN4 cells demonstrated a doubling of p125(FAK) kinase activity. However, an additional Ang II-activated tyrosine kinase (or kinases) representing the majority of the total activity was detected when the remaining cell lysate, immunodepleted of p125(FAK), was reimmunoprecipitated with an anti phosphotyrosine antibody. Cytochalasin D pretreatment blocks G-protein receptor-dependent tyrosine phosphorylation in Swiss 3T3 cells. While cytochalasin D decreased the Tyr(P) content of 65-75-kDa substrates in Ang II-treated GN4 cells, it did not diminish tyrosine phosphorylation of 115-130-kDa substrates, again suggesting activation of at least two tyrosine kinase pathways in GN4 cells. To search for additional Ang II-activated enzymes, we used molecular techniques to identify 20 tyrosine kinase sequences in these cell lines. None was the major cytosolic enzyme activated by Ang II. Specifically, JAK2, which had been shown by others to be stimulated by Ang II in smooth muscle cells, was not activated by Ang II in GN4 cells. Finally, we purified Tyr(P)-containing tyrosine kinases from Ang II-treated cells, using anti-Tyr(P) and ATP affinity resins; 80% of the tyrosine kinase activity migrated as a single 115-120-kDa tyrosine-phosphorylated protein immunologically distinct from p125(FAK). In summary, Ang II activates at least two separate tyrosine kinases in rat liver epithelial cells; p125(FAK) and a presumably novel, cytosolic 115-120-kDa protein referred to as the calcium-dependent tyrosine kinase.	UNIV N CAROLINA, DEPT MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; MERCK & CO INC, W POINT, PA 19486 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Merck & Company	EARP, HS (corresponding author), UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA.		Graves, Lee/AAG-5470-2021	Huckle, William/0000-0001-7838-329X; Dawson, Thomas/0000-0003-3878-1722	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031683] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31683] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BUTCHER RD, 1993, BIOCHEM BIOPH RES CO, V196, P1280, DOI 10.1006/bbrc.1993.2391; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; FLORDELLIS CS, 1995, J BIOL CHEM, V270, P3491, DOI 10.1074/jbc.270.8.3491; FORCE T, 1991, J BIOL CHEM, V266, P6650; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUTKIND JS, 1992, BIOCHEM BIOPH RES CO, V188, P155; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HARPUR AG, 1992, ONCOGENE, V7, P1347; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; Huckle William R., 1994, Progress in Growth Factor Research, V5, P177, DOI 10.1016/0955-2235(94)90004-3; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; ISHIDA Y, 1992, FEBS LETT, V310, P41, DOI 10.1016/0014-5793(92)81142-9; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KOHNO M, 1986, BIOCHEM J, V238, P451, DOI 10.1042/bj2380451; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LAI C, 1994, ONCOGENE, V9, P2567; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LEEBLUNDBERG LMF, 1993, J BIOL CHEM, V268, P8151; LETWIN K, 1988, ONCOGENE, V3, P621; LUTZ MP, 1993, J BIOL CHEM, V268, P11119; MARI B, 1994, J BIOL CHEM, V269, P8517; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MCCUNE BK, 1989, J BIOL CHEM, V264, P15501; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; POLTE TR, 1994, J CELL BIOCHEM, V55, P106, DOI 10.1002/jcb.240550113; SADOSHIMA J, 1995, CIRC RES, V76, P1; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	53	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28440	28447						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499350				2022-12-27	WOS:A1995TG21000075
J	FANKHAUSER, H; ZURLINDEN, A; SCHWEINGRUBER, AM; EDENHARTER, E; SCHWEINGRUBER, ME				FANKHAUSER, H; ZURLINDEN, A; SCHWEINGRUBER, AM; EDENHARTER, E; SCHWEINGRUBER, ME			SCHIZOSACCHAROMYCES-POMBE THIAMINE PYROPHOSPHOKINASE IS ENCODED BY GENE TNR3 AND IS A REGULATOR OF THIAMINE METABOLISM, PHOSPHATE-METABOLISM, MATING, AND GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-PHOSPHATASE; FISSION YEAST; STRUCTURAL GENE; BIOSYNTHESIS; CLONING; MUTANTS	The Schizosaccharomyces pombe gene tnr3 has been genetically defined as a negative regulator of genes involved in thiamine metabolism (Schweingruber, A. M., Fankhauser, H., Dlugonski, J., Steinmann-Loss, C., and Schweingruber, M. E. (1992) Genetics 130, 445-449). We have isolated and sequenced the gene and show that it codes for a putative protein of 569 amino acids which exhibits, in its carboxyl-terminal half, good homology to Saccharomyces cerevisiae thiamine pyrophosphokinase (TPK). tnr3 mutants have reduced levels of intracellular thiamine diphosphate, show impaired TPK activity, which is enhanced by introducing the tnr3 wild type gene on a plasmid, and can be complemented by the S. cerevisiae TPK-encoding gene TH180. These data strongly suggest that tnr3 encodes S. pombe TPK. We present evidence that TPK also acts as a negative regulator for gene pho1, which is derepressed when cells are starved for phosphate and show that in contrast to wild type cells, tnr3 mutants mate constitutively in response to thiamine, indicating that TPK is also involved in regulation of mating. Disruption of the tnr3 gene is lethal, and a tnr3 mutant expressing only residual TPK activity grows slowly and shows aberrant morphology.	UNIV BERN, INST GEN MICROBIOL, CH-3012 BERN, SWITZERLAND	University of Bern								Alfa C., 1993, EXPT FISSION YEAST; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHERNIKEVICH I P, 1988, Biokhimiya, V53, P1728; EGI Y, 1992, BIOCHIM BIOPHYS ACTA, V1160, P171, DOI 10.1016/0167-4838(92)90004-W; ELLIOTT S, 1986, J BIOL CHEM, V261, P2936; FANKHAUSER H, 1994, GENE, V147, P141, DOI 10.1016/0378-1119(94)90054-X; Friedrich W., 1987, HDB VITAMINE, P240; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; Gutz H., 1974, HDB GENETICS, V1, P395; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; LEDER IG, 1975, METABOLIC PATHWAYS, V7, P57; MANETTI AGO, 1994, YEAST, V10, P1075, DOI 10.1002/yea.320100809; MAUNDRELL K, 1985, GENE, V39, P223, DOI 10.1016/0378-1119(85)90316-6; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NOSAKA K, 1993, J BIOL CHEM, V268, P17440; Sambrook J, 1989, MOL CLONING LABORATO; SANEMORI H, 1980, J BIOCHEM, V88, P223; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEINGRUBER AM, 1991, CURR GENET, V19, P249, DOI 10.1007/BF00355050; SCHWEINGRUBER AM, 1986, EUR J BIOCHEM, V158, P133, DOI 10.1111/j.1432-1033.1986.tb09730.x; SCHWEINGRUBER AM, 1992, GENETICS, V130, P445; SCHWEINGRUBER ME, 1990, CURR GENET, V17, P191, DOI 10.1007/BF00312609; SCHWEINGRUBER ME, 1986, J BIOL CHEM, V261, P5877; SCHWEINGRUBER ME, 1982, CURR GENET, V5, P109, DOI 10.1007/BF00365701; VOSKOBOYEV AI, 1982, ANN NY ACAD SCI, V378, P161, DOI 10.1111/j.1749-6632.1982.tb31195.x; YANG JW, 1990, CURR GENET, V18, P269, DOI 10.1007/BF00318392; ZURLINDEN A, 1994, J BACTERIOL, V176, P6631, DOI 10.1128/JB.176.21.6631-6635.1994; ZURLINDEN A, 1992, GENE, V117, P141, DOI 10.1016/0378-1119(92)90503-H; 1994, PACKAGE PROGRAM MANU	32	35	37	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28457	28462						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499352				2022-12-27	WOS:A1995TG21000077
J	LOPEZ, MM; KOSKKOSICKA, D				LOPEZ, MM; KOSKKOSICKA, D			HOW DO VOLATILE ANESTHETICS INHIBIT CA2+-ATPASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM ADENOSINE-TRIPHOSPHATASE; COOPERATIVE CALCIUM-BINDING; VARIABLE-FREQUENCY PHASE; ERYTHROCYTE CA-2+-ATPASE; FLUORESCENCE SPECTROSCOPY; MODULATION DATA; ACTIVATION; CALMODULIN; PROTEIN; OLIGOMERIZATION	Volatile anesthetics at concentrations that are used in clinical practice to induce anesthesia selectively inhibit activity of the plasma membrane Ca2+-transport ATPase (Kosk-Kosicka, D., and Roszczynska, G. (1993) Anesthesiology 79, 774-780), We have investigated the mechanism of the inhibitory action of several anesthetics on the purified erythrocyte Ca2+-ATPase by employing fluorescence spectroscopy measurements that report changes in the environment of intrinsic tryptophans and of an extrinsic probe attached in the active site of the enzyme, We have shown that the observed inhibition of the Ca2+-dependent activation of the enzyme correlates well with the elimination of the Ca2+-induced conformational change that is important for the proper function of the enzyme, Analysis of the anesthetics effects on the total tryptophan fluorescence indicates a significant effect on enzyme conformation. Similar changes have been observed in the sarcoplasmic reticulum Ca2+-ATPase, We propose that volatile anesthetics inhibit Ca2+-ATPase by interacting with nonpolar sites in protein interior, in analogy to the binding demonstrated for myoglobin, hemoglobin, and adenylate kinase (Schoenborn, B. P., and Featherstone, R. M. (1967) Adv. Pharmacol. 5, 1-17; Tilton, R. F., Kuntz, I. D., and Petsko, G. A, (1984) Biochemistry 23, 2849-2857), Such binding is expected to modify conformational substate(s) of the enzyme and perturb its function, We view this process as an example of a general phenomena of interaction of small molecules with internal sites in proteins.	JOHNS HOPKINS UNIV, SCH MED, DEPT ANESTHESIOL CRIT CARE MED, BALTIMORE, MD 21287 USA	Johns Hopkins University					NIGMS NIH HHS [GM 447130] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AREVALO JH, 1994, J MOL BIOL, V241, P663, DOI 10.1006/jmbi.1994.1543; BROWN FF, 1976, PROC R SOC SER B-BIO, V193, P387, DOI 10.1098/rspb.1976.0053; COLLINS KD, 1985, Q REV BIOPHYS, V18, P323, DOI 10.1017/S0033583500005369; COOPER A, 1976, P NATL ACAD SCI USA, V73, P2740, DOI 10.1073/pnas.73.8.2740; DUPONT Y, 1976, BIOCHEM BIOPH RES CO, V71, P544, DOI 10.1016/0006-291X(76)90821-4; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EGAN W, 1977, ANNU REV BIOPHYS BIO, V6, P383, DOI 10.1146/annurev.bb.06.060177.002123; EGER EI, 1978, ANESTHETIC UPTAKE AC, P1; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; ENGLANDER SW, 1972, ANNU REV BIOCHEM, V41, P903, DOI 10.1146/annurev.bi.41.070172.004351; ERIKSSON AE, 1992, NATURE, V355, P371, DOI 10.1038/355371a0; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FRANKS JJ, 1995, ANESTHESIOLOGY, V82, P108, DOI 10.1097/00000542-199501000-00015; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; GRATTON E, 1984, BIOPHYS J, V46, P479, DOI 10.1016/S0006-3495(84)84044-8; GRYCZYNSKI I, 1988, BIOCHIM BIOPHYS ACTA, V954, P244, DOI 10.1016/0167-4838(88)90079-9; GRYCZYNSKI I, 1989, BIOCHEMISTRY-US, V28, P3490, DOI 10.1021/bi00434a051; HIBBARD LS, 1978, BIOCHEMISTRY-US, V17, P5460, DOI 10.1021/bi00618a021; HUBBARD SJ, 1994, PROTEIN ENG, V7, P613, DOI 10.1093/protein/7.5.613; INESI G, 1980, J BIOL CHEM, V255, P3025; JAIN A, 1994, J MED CHEM, V37, P2100, DOI 10.1021/jm00039a023; KARON BS, 1994, BIOCHEMISTRY-US, V33, P13928, DOI 10.1021/bi00250a048; KOBLIN DD, 1990, ANESTHESIA, V1, P51; Kosk-Kosicka D, 1994, Adv Pharmacol, V31, P313, DOI 10.1016/S1054-3589(08)60624-9; KOSKKOSICKA D, 1988, J BIOL CHEM, V263, P18184; KOSKKOSICKA D, 1993, ANESTHESIOLOGY, V79, P774, DOI 10.1097/00000542-199310000-00020; KOSKKOSICKA D, 1989, J BIOL CHEM, V264, P19495; KOSKKOSICKA D, 1990, BIOCHEMISTRY-US, V29, P3772, DOI 10.1021/bi00467a025; KOSKKOSICKA D, 1983, BIOCHEMISTRY-US, V22, P2559, DOI 10.1021/bi00279a037; KOSKKOSICKA D, 1990, BIOCHEMISTRY-US, V29, P1875, DOI 10.1021/bi00459a030; KOSKKOSICKA D, 1985, FEBS LETT, V189, P67, DOI 10.1016/0014-5793(85)80843-7; KOSKKOSICKA D, 1992, ANN NY ACAD SCI, V671, P424, DOI 10.1111/j.1749-6632.1992.tb43818.x; KOSKKOSICKA D, 1995, PROG ANESTH MECH, V3, P279; KOSKKOSICKA D, 1995, PROG ANESTHETIC MECH, V3, P140; KOSKOSICKA D, 1986, J BIOL CHEM, V261, P3333; LAKOWICZ JR, 1973, BIOCHEMISTRY-US, V12, P4161, DOI 10.1021/bi00745a020; LAKOWICZ JR, 1986, J BIOL CHEM, V261, P2240; LAKOWICZ JR, 1984, BIOPHYS J, V46, P463, DOI 10.1016/S0006-3495(84)84043-6; LAKOWICZ JR, 1991, TOPICS FLUORESCENCE, V2, P53; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; LIM WA, 1994, P NATL ACAD SCI USA, V91, P423, DOI 10.1073/pnas.91.1.423; MAKHATADZE GI, 1995, ADV PROTEIN CHEM, V47, P389; MILLER KW, 1985, INT REV NEUROBIOL, V27, P1, DOI 10.1016/S0074-7742(08)60555-3; NUNES AC, 1973, MOL PHARMACOL, V9, P835; OTTING G, 1991, SCIENCE, V254, P974, DOI 10.1126/science.1948083; PESCE AJ, 1971, FLUORESCENCE SPECTRO, P37; SACHSENHEIMER W, 1977, FEBS LETT, V79, P310, DOI 10.1016/0014-5793(77)80809-0; Schoenborn B P, 1967, Adv Pharmacol, V5, P1, DOI 10.1016/S1054-3589(08)60652-3; SCHOENBORN BP, 1969, J MOL BIOL, V45, P297, DOI 10.1016/0022-2836(69)90106-5; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; SCHOENBORN BP, 1965, NATURE, V208, P760, DOI 10.1038/208760a0; SCHOENBORN BP, 1976, P NATL ACAD SCI USA, V73, P4195, DOI 10.1073/pnas.73.11.4195; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; SELLERS DR, 1973, PHOTOCHEM PHOTOBIOL, V18, P393, DOI 10.1111/j.1751-1097.1973.tb06439.x; Settle W, 1973, GUIDE MOL PHARM TO 2, P477; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; TILTON RF, 1982, BIOCHEMISTRY-US, V21, P6850, DOI 10.1021/bi00269a035; TILTON RF, 1986, J MOL BIOL, V192, P443, DOI 10.1016/0022-2836(86)90374-8; WANG CK, 1992, BIOCHEMISTRY-US, V31, P4289, DOI 10.1021/bi00132a020; WILLIAMS MA, 1994, PROTEIN SCI, V3, P1224, DOI 10.1002/pro.5560030808	60	32	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28239	28245						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499320				2022-12-27	WOS:A1995TG21000045
J	NAKAMURA, C; BURGESS, JG; SODE, K; MATSUNAGA, T				NAKAMURA, C; BURGESS, JG; SODE, K; MATSUNAGA, T			AN IRON-REGULATED GENE, MAGA, ENCODING AN IRON TRANSPORT PROTEIN OF MAGNETOSPIRILLUM SP STRAIN AMB-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; MAGNETIC BACTERIUM; AQUASPIRILLUM-MAGNETOTACTICUM; SIDEROPHORE PRODUCTION; ENTEROCOCCUS-HIRAE; FUR GENE; CLONING; SEQUENCE; MUTAGENESIS; INHIBITORS	Magnetospirillum sp. AMB-1 is a freshwater magnetic bacterium which synthesizes intracellular particles of magnetite (Fe3O4). A genomic DNA fragment required for synthesis of magnetic particles was previously isolated from a nonmagnetic transposon Tn5 mutant, We have determined the complete nucleotide sequence of this fragment. The 2975-base pair region contains two putative open reading frames. One open reading frame, designated magA, encodes a polypeptide which is ho homologous to the cation efflux proteins, the Escherichia coli potassium ion-translocating protein, KefC, and the putative Na+/H+-antiporter, NapA, from Enterococcus hirae. Northern hybridization demonstrated that the magA mRNA transcript is 1.3 kilobases in size, corresponding to the size of the magA gene, A functional promoter was located upstream from the magA gene, and the transcription in AMB-I was regulated by environmental iron concentration, Vesicles isolated from E. coli in which the MagA protein was expressed exhibited iron accumulation ability. We consider that the MagA protein is an iron transport involved in the synthesis of magnetic particles in AMB-1.	TOKYO UNIV AGR & TECHNOL, DEPT BIOTECHNOL, KOGANEI 184, TOKYO, JAPAN	Tokyo University of Agriculture & Technology			Matsunaga, Tadashi/A-6293-2015; Sode, Koji/F-6914-2013; Sode, Koji/P-6461-2019; Nakamura, Chikashi/G-9732-2013	Matsunaga, Tadashi/0000-0002-6216-3687; Sode, Koji/0000-0002-9833-2091; Sode, Koji/0000-0002-9833-2091; Nakamura, Chikashi/0000-0002-8012-2192				ACTIS LA, 1986, J BACTERIOL, V167, P57, DOI 10.1128/jb.167.1.57-65.1986; ADAMS CW, 1989, J BACTERIOL, V171, P473, DOI 10.1128/jb.171.1.473-482.1989; AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BAGG A, 1987, MICROBIOL REV, V51, P509, DOI 10.1128/MMBR.51.4.509-518.1987; BLAKEMORE RP, 1979, J BACTERIOL, V140, P720, DOI 10.1128/JB.140.2.720-729.1979; BURGESS JG, 1993, J BACTERIOL, V175, P6689, DOI 10.1128/jb.175.20.6689-6694.1993; DEWEGER LA, 1988, J BACTERIOL, V170, P4693, DOI 10.1128/JB.170.10.4693-4698.1988; GORBY YA, 1988, J BACTERIOL, V170, P834, DOI 10.1128/jb.170.2.834-841.1988; GUERIN WF, 1992, APPL ENVIRON MICROB, V58, P1102, DOI 10.1128/AEM.58.4.1102-1109.1992; ITAYA M, 1990, P NATL ACAD SCI USA, V87, P8587, DOI 10.1073/pnas.87.21.8587; KAWAGUCHI R, 1992, NUCLEIC ACIDS RES, V20, P1140, DOI 10.1093/nar/20.5.1140; KIRSCHVINK JL, 1985, J COMP PHYSIOL A, V157, P375, DOI 10.1007/BF00618127; LITWIN CM, 1992, J BACTERIOL, V174, P1897, DOI 10.1128/jb.174.6.1897-1903.1992; LOWENSTAM HA, 1962, GEOL SOC AM BULL, V73, P435, DOI 10.1130/0016-7606(1962)73[435:MIDCIR]2.0.CO;2; MAHASNEH IA, 1991, MICROBIOS, V65, P97; MANN S, 1990, ADV MICROB PHYSIOL, V31, P125; MATSUNAGA T, 1990, IEEE T MAGN, V26, P1557, DOI 10.1109/20.104444; MATSUNAGA T, 1993, APPL MICROBIOL BIOT, V39, P368; MATSUNAGA T, 1992, J BACTERIOL, V174, P2748, DOI 10.1128/JB.174.9.2748-2753.1992; MATSUNAGA T, 1991, APPL MICROBIOL BIOT, V35, P651; MUNRO AW, 1991, MOL MICROBIOL, V5, P607, DOI 10.1111/j.1365-2958.1991.tb00731.x; NAKAMURA C, 1993, APPL BIOCHEM BIOTECH, V39, P169, DOI 10.1007/BF02918987; NAKAMURA K, 1989, ACS SYM SER, V402, P106; PAOLETTI LC, 1986, J BACTERIOL, V167, P73, DOI 10.1128/jb.167.1.73-76.1986; PRINCE RW, 1993, J BACTERIOL, V175, P2589, DOI 10.1128/JB.175.9.2589-2598.1993; REIZER J, 1992, FEMS MICROBIOL LETT, V94, P161; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEIFER KH, 1991, SYST APPL MICROBIOL, V14, P379, DOI 10.1016/S0723-2020(11)80313-9; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; STAGGS TM, 1991, J BACTERIOL, V173, P417, DOI 10.1128/jb.173.2.417-425.1991; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016; TOMASIEWICZ HG, 1987, J BACTERIOL, V169, P5735, DOI 10.1128/jb.169.12.5735-5744.1987; VISCA P, 1991, FEMS MICROBIOL LETT, V79, P225, DOI [10.1111/j.1574-6968.1991.tb04533.x, 10.1016/0378-1097(91)90090-W]; WALKER MM, 1984, SCIENCE, V224, P751, DOI 10.1126/science.224.4650.751; WASER M, 1992, J BIOL CHEM, V267, P5396	37	137	160	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28392	28396						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499342				2022-12-27	WOS:A1995TG21000067
J	RESING, KA; THULIN, C; WHITING, K; ALALAWI, N; MOSTAD, S				RESING, KA; THULIN, C; WHITING, K; ALALAWI, N; MOSTAD, S			CHARACTERIZATION OF PROFILAGGRIN ENDOPROTEINASE-1 - A REGULATED CYTOPLASMIC ENDOPROTEINASE OF EPIDERMIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT-ASSOCIATED PROTEIN; FILAGGRIN; GENE; IDENTIFICATION; SEQUENCE; SITES; ORGANIZATION; CONVERSION; CDNA; RAT	Profilaggrin, an insoluble precursor of the intermediate filament-associated protein filaggrin, contains multiple internal repeats (PIRs), At terminal differentiation of epidermis, proteolytic processing within a ''linker'' region of each PIR releases soluble filaggrin in a two-stage process, The first stage endoproteinase (PEP1, profilaggrin endoproteinase 1) cleaves mouse profilaggrin at a subset of the linkers, yielding processing intermediates consisting of several filaggrin repeats, An epidermal endoproteinase that cleaves the requisite linker subset has been purified 4,966-fold from mouse epidermal extracts, SDS-polyacrylamide gel electrophoresis demonstrated a band of molecular mass of 29.5 kDa that correlated with the activity, Labeling with [H-3]diisopropylfluorophosphate identified PEP1 as a serine protease; inhibitor studies suggest that it is similar to chymotrypsin, as expected from previous in vivo studies, The purified PEP1 cleaved a peptide derived from profilaggrin (P1) at three residues within and adjacent to a multiple tyrosine sequence, consistent with the in vivo processing sites, No exopeptidase activity was detected, PEP1 is only active toward insoluble profilaggrin, resulting in partial solubilization, consistent with a role in dispersal of profilaggrin during terminal differentiation, In contrast to the specific cleavage of mouse profilaggrin, PEP1 cleaved all linker regions of rat profilaggrin, Studies with phosphorylated P1 suggest that PEP1 specificity may be partly regulated by profilaggrin phosphorylation.	UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV CALIF SAN DIEGO, DEPT BIOCHEM, LA JOLLA, CA 92037 USA	University of Colorado System; University of Colorado Boulder; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of California System; University of California San Diego					NCRR NIH HHS [RR05543] Funding Source: Medline; NIAMS NIH HHS [AR39730] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039730] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRAKCH N, 1993, BIOCHEMISTRY-US, V32, P4925, DOI 10.1021/bi00069a029; Dale Beverly A., 1993, P79; GAN SQ, 1990, BIOCHEMISTRY-US, V29, P9432, DOI 10.1021/bi00492a018; HAYDOCK PV, 1990, DNA CELL BIOL, V9, P251, DOI 10.1089/dna.1990.9.251; KAM E, 1993, J CELL SCI, V106, P219; MARKOVA NG, 1993, MOL CELL BIOL, V13, P613, DOI 10.1128/MCB.13.1.613; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCKINLEYGRANT LJ, 1989, P NATL ACAD SCI USA, V86, P4848, DOI 10.1073/pnas.86.13.4848; PRESLAND RB, 1992, J BIOL CHEM, V267, P23772; RESING KA, 1985, BIOCHEMISTRY-US, V24, P4167, DOI 10.1021/bi00336a053; RESING KA, 1995, BIOCHEMISTRY-US, V34, P9477, DOI 10.1021/bi00029a024; RESING KA, 1989, J BIOL CHEM, V264, P1837; RESING KA, 1993, BIOCHEMISTRY-US, V32, P10036, DOI 10.1021/bi00089a020; RESING KA, 1993, J BIOL CHEM, V268, P25139; RESING KA, 1984, J CELL BIOL, V99, P1372, DOI 10.1083/jcb.99.4.1372; ROTHNAGEL JA, 1987, J BIOL CHEM, V262, P15643; ROTHNAGEL JA, 1990, J BIOL CHEM, V265, P1862; STEINERT PM, 1993, J INVEST DERMATOL, V100, P729, DOI 10.1111/1523-1747.ep12475665	18	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28193	28198						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499312				2022-12-27	WOS:A1995TG21000037
J	MCDONOUGH, PM; STELLA, SL; GLEMBOTSKI, CC				MCDONOUGH, PM; STELLA, SL; GLEMBOTSKI, CC			INVOLVEMENT OF CYTOPLASMIC CALCIUM AND PROTEIN-KINASES IN THE REGULATION OF ATRIAL-NATRIURETIC-FACTOR SECRETION BY CONTRACTION RATE AND ENDOTHELIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK HEART-CELLS; VENTRICULAR MYOCYTES; CARDIAC MYOCYTES; PEPTIDE SECRETION; HUMAN FIBROBLASTS; PHOSPHOLIPASE-C; PHORBOL ESTERS; GROWTH-FACTORS; ANP SECRETION; CA-2+	To characterize the effects of the cellular events associated with contraction on atrial natriuretic factor (ANF) secretion, primary neonatal rat atrial myocytes were electrically paced to contract while being monitored for ANF release, cytoplasmic calcium, phosphoinositide hydrolysis, and protein kinase C activation. Similar measurements were also carried out in the presence of endothelin-1 (ET) for comparison of contraction-related and hormone-stimulated ANF secretion. Pacing (6-8 Hz) immediately increased ANF secretion by 3-5-fold and the time-averaged cytoplasmic calcium concentration (as monitored with indo-1 fluorescence) varied with pace frequency in a similar manner, suggesting that cytoplasmic calcium may play a key role in pace-induced ANF secretion. Furthermore, nifedipine and ryanodine, which inhibited the contractile calcium transients, inhibited pace-induced ANF release, whereas Bay K 8644 increased both the calcium transients and ANF secretion. Pace-induced ANF release was also completely inhibited by KN-62, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMK) but was not inhibited by chelerythrine, a protein kinase C-selective inhibitor. Pace-induced ANF release averaged 40% of that elicited by ET which is known to require both PKC and CaMK for maximal effects on ANF secretion. The effects of pacing and ET on ANF secretion were approximately additive. In contrast to pacing, ET strongly stimulated phosphoinositide hydrolysis, activated PKC, and did not increase cytoplasmic calcium. Thus, regulation of ANF secretion by contraction rate depends primarily on the contractile calcium transients and CaMK and is independent of PKC.	SAN DIEGO STATE UNIV,INST MOLEC BIOL,SAN DIEGO,CA 92182	California State University System; San Diego State University	MCDONOUGH, PM (corresponding author), SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182, USA.			Stella Jr., Salvatore/0000-0003-1971-2537	NHLBI NIH HHS [HL46345] Funding Source: Medline; NINDS NIH HHS [NS-25037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADOLPH EF, 1967, AM J PHYSIOL, V212, P595, DOI 10.1152/ajplegacy.1967.212.3.595; BALS S, 1990, CELL CALCIUM, V11, P385, DOI 10.1016/0143-4160(90)90050-5; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BEST L, 1986, BIOCHEM J, V238, P773, DOI 10.1042/bj2380773; BILDER GE, 1989, CIRC RES, V64, P799, DOI 10.1161/01.RES.64.4.799; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BREVET A, 1976, SCIENCE, V193, P1152, DOI 10.1126/science.959833; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CFHRISTENSEN G, 1989, AM J PHYSIOL, V256, pR1245; CHO KW, 1991, AM J PHYSIOL, V260, pR39, DOI 10.1152/ajpregu.1991.260.1.R39; CHRISTENSEN G, 1988, ACTA PHYSIOL SCAND, V134, P263, DOI 10.1111/j.1748-1716.1988.tb08487.x; DIETZ JR, 1987, AM J PHYSIOL, V252, pR498, DOI 10.1152/ajpregu.1987.252.3.R498; DOUBELL AF, 1991, HYPERTENSION, V18, P648, DOI 10.1161/01.HYP.18.5.648; DOUBELL AF, 1989, LIFE SCI, V45, P2193, DOI 10.1016/0024-3205(89)90059-3; ETSCHEID BG, 1991, CELL REGUL, V2, P229, DOI 10.1091/mbc.2.3.229; FABIATO A, 1985, FED PROC, V44, P2970; FISHER SK, 1989, MOL PHARMACOL, V35, P195; FURUKAWA T, 1992, CIRC RES, V71, P1242, DOI 10.1161/01.RES.71.5.1242; GALRON R, 1989, BIOCHEM BIOPH RES CO, V163, P936, DOI 10.1016/0006-291X(89)92312-7; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANSFORD RG, 1987, J PHYSIOL-LONDON, V390, P453, DOI 10.1113/jphysiol.1987.sp016711; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HOVEMADSEN L, 1992, BIOPHYS J, V63, P89, DOI 10.1016/S0006-3495(92)81597-7; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; IRONS CE, 1992, J BIOL CHEM, V267, P5211; JOHNSON CL, 1990, AM J PHYSIOL, V258, pC533, DOI 10.1152/ajpcell.1990.258.3.C533; JONES LG, 1988, CIRC RES, V62, P299, DOI 10.1161/01.RES.62.2.299; KIM D, 1991, CIRC RES, V69, P250, DOI 10.1161/01.RES.69.1.250; KNIGHT DE, 1989, TRENDS NEUROSCI, V12, P451, DOI 10.1016/0166-2236(89)90095-7; KOJIMA S, 1993, AM J PHYSIOL, V264, pH183, DOI 10.1152/ajpheart.1993.264.1.H183; LAUER MR, 1992, J PHYSIOL-LONDON, V448, P729, DOI 10.1113/jphysiol.1992.sp019067; LEE HC, 1989, PFLUG ARCH EUR J PHY, V413, P225, DOI 10.1007/BF00583534; MALATINO LS, 1990, AM HEART J, V119, P97, DOI 10.1016/S0002-8703(05)80088-2; MARBAN E, 1985, CIRC RES, V56, P133, DOI 10.1161/01.RES.56.1.133; MATSUBARA H, 1988, AM J PHYSIOL, V255, pH405, DOI 10.1152/ajpheart.1988.255.3.H405; MCDONOUGH PM, 1988, MOL PHARMACOL, V33, P310; PEETERS GA, 1987, AM J PHYSIOL, V253, pH1400, DOI 10.1152/ajpheart.1987.253.6.H1400; PETERSON MW, 1992, AM J PHYSIOL, V263, pC1216, DOI 10.1152/ajpcell.1992.263.6.C1216; POPOLI M, 1993, FEBS LETT, V317, P85, DOI 10.1016/0014-5793(93)81496-M; QIU ZH, 1992, EUR J PHARMACOL, V214, P293; RANKIN AJ, 1986, LIFE SCI, V38, P1951, DOI 10.1016/0024-3205(86)90224-9; RENARD D, 1990, J MOL CELL CARDIOL, V22, P13, DOI 10.1016/0022-2828(90)90968-8; RIDDERVOLD F, 1991, AM J PHYSIOL, V260, pH1953, DOI 10.1152/ajpheart.1991.260.6.H1953; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SCHIEBINGER RJ, 1990, ENDOCRINOLOGY, V127, P119, DOI 10.1210/endo-127-1-119; SCHIEBINGER RJ, 1992, ENDOCRINOLOGY, V130, P1017, DOI 10.1210/en.130.2.1017; SCHIEBINGER RJ, 1986, AM J PHYSIOL, V251, P1095; SCHRAMM M, 1983, NATURE, V303, P535, DOI 10.1038/303535a0; SEI CA, 1990, J BIOL CHEM, V265, P7166; SHIELDS PP, 1988, J BIOL CHEM, V263, P12619; SHIELDS PP, 1989, J BIOL CHEM, V264, P9322; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SPURGEON HA, 1990, AM J PHYSIOL, V258, pH574, DOI 10.1152/ajpheart.1990.258.2.H574; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; VIGNE P, 1990, J BIOL CHEM, V265, P6782; WIER WG, 1985, FED PROC, V44, P2989	59	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9466	9472						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511588				2022-12-27	WOS:A1994NE05300014
J	WEISZ, A; OGUCHI, S; CICATIELLO, L; ESUMI, H				WEISZ, A; OGUCHI, S; CICATIELLO, L; ESUMI, H			DUAL MECHANISM FOR THE CONTROL OF INDUCIBLE-TYPE NO SYNTHASE GENE-EXPRESSION IN MACROPHAGES DURING ACTIVATION BY INTERFERON-GAMMA AND BACTERIAL LIPOPOLYSACCHARIDE - TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; MOLECULAR-CLONING; PROPIONIBACTERIUM-ACNES; DEPENDENT FORMATION; CELL-LINE; LIVER; RATS; IDENTIFICATION; PURIFICATION; CALMODULIN	Production of nitric oxide (NO) by macrophages is enhanced upon activation by bacterial endotoxins and cytokines mainly via an increase of the intracellular content of the inducible isoform of nitric oxide synthase (i-NOS). We have studied in detail the effect of several modulators of macrophage activity on steady state levels of i-NOS mRNA in the mouse macrophage-like cell line RAW 264.7. Bacterial lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma) were found to be effective inducers of i-NOS mRNA, in accordance with their known ability to stimulate both i-NOS activity and NO production in macrophages from different sources, while TNF-alpha, IL-1, or IL-6 was ineffective in this regard. Accumulation of i-NOS mRNA in response to either LPS or IFN-gamma stimulation was accompanied by increased i-NOS gene transcription, as detected both by using a nuclear ''run-on'' transcription assay and by transient transfection of the cloned gene promoter in RAW 264.7 cells. Co-stimulation of the cells with both inducers resulted in higher steady state levels of i-NOS mRNA in the absence, however, of a corresponding potentiation of the rate of gene transcription. This was due primarily to a considerable effect of LPS on i-NOS mRNA stability, with prolongation of its half-life from 1-1.5 h, in the presence of LFN-gamma alone, to 4-6 h in the presence of both LPS and IFN-gamma.	NATL CANC CTR,RES INST,DIV BIOCHEM,CHUO KU,TOKYO 104,JAPAN	National Cancer Center - Japan			Weisz, Alessandro/A-1317-2014	Weisz, Alessandro/0000-0003-0455-2083				ADACHI H, 1993, EUR J BIOCHEM, V217, P37, DOI 10.1111/j.1432-1033.1993.tb18215.x; ADAMS DO, 1992, MACROPHAGE, P75; AMBER IJ, 1988, J LEUKOCYTE BIOL, V44, P58, DOI 10.1002/jlb.44.1.58; AMBROSINO C, 1993, IN PRESS MOL ENDOCRI; Auger M. J., 1992, MACROPHAGE, P1; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BRENDT DS, 1990, P NATL ACAD SCI USA, V87, P682; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; CUNHA FQ, 1993, J IMMUNOL, V150, P1908; DING AH, 1988, J IMMUNOL, V141, P2407; EIZIRIK DL, 1993, FEBS LETT, V317, P62, DOI 10.1016/0014-5793(93)81492-I; FARBER JM, 1992, MOL CELL BIOL, V12, P1535, DOI 10.1128/MCB.12.4.1535; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GOUREAU O, 1993, P NATL ACAD SCI USA, V90, P4276, DOI 10.1073/pnas.90.9.4276; HAMILTON TA, 1987, IMMUNOL TODAY, V8, P151, DOI 10.1016/0167-5699(87)90145-9; HECK DE, 1992, J BIOL CHEM, V267, P21277; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; IIDA S, 1992, J BIOL CHEM, V267, P25385; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; KNOWLES RG, 1990, BIOCHEM BIOPH RES CO, V172, P1042, DOI 10.1016/0006-291X(90)91551-3; KOIDE M, 1993, FEBS LETT, V318, P213, DOI 10.1016/0014-5793(93)80514-U; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MIWA M, 1989, BIOCHEM BIOPH RES CO, V159, P373, DOI 10.1016/0006-291X(89)90001-6; MOLLACE V, 1993, BIOCHEM BIOPH RES CO, V191, P327, DOI 10.1006/bbrc.1993.1221; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; OGUCHI S, 1992, FEBS LETT, V308, P22, DOI 10.1016/0014-5793(92)81041-J; OHSHIMA H, 1991, CARCINOGENESIS, V12, P1217, DOI 10.1093/carcin/12.7.1217; OHSHIMA H, 1992, BIOCHEM BIOPH RES CO, V187, P1291, DOI 10.1016/0006-291X(92)90443-O; RUCO LP, 1978, J IMMUNOL, V121, P2035; SEN GC, 1992, J BIOL CHEM, V267, P5017; SESSA WC, 1992, J BIOL CHEM, V267, P15274; STUEHR DJ, 1987, CANCER RES, V47, P5590; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WEISZ A, 1990, MOL ENDOCRINOL, V4, P1041, DOI 10.1210/mend-4-7-1041; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; WOOD ER, 1993, BIOCHEM BIOPH RES CO, V191, P767, DOI 10.1006/bbrc.1993.1283; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; YUI Y, 1991, J BIOL CHEM, V266, P12544	54	158	161	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8324	8333						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510685				2022-12-27	WOS:A1994NB40900075
J	AGAZIE, YM; LEE, JS; BURKHOLDER, GD				AGAZIE, YM; LEE, JS; BURKHOLDER, GD			CHARACTERIZATION OF A NEW MONOCLONAL-ANTIBODY TO TRIPLER DNA AND IMMUNOFLUORESCENT STAINING OF MAMMALIAN CHROMOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRAL PH; SEQUENCE; HETEROCHROMATIN; LOCALIZATION; INVIVO; BINDS	A monoclonal antibody, Jel 466, was prepared from mice immunized with poly[d((TmC)-C-5)].poly[d(GA)]. The binding of Jel 466 to nucleic acids was characterized by solid phase radioimmunoassays and competition experiments. There was no binding to single-stranded DNAs or to duplexes which could not form triplexes. In addition, the antibody preferred the tripler form of poly[d(TC)].poly[d(GA)]; it bound weakly to the triplex derived from poly[d(G)].poly[d(C)], but there was no interaction with poly[d(T)].poly[d(A)].poly[d(T)]. This pattern of specificity is very different from that of Jel 318, a triplex-specific antibody that will bind to poly[d(T)].poly[d(A)].poly[d(T)]. The amino acid sequence of Jel 466 also showed very little homology with Jel 318, although both contain many positively charged amino acids. The immunofluorescent staining of mouse and human chromosomes with Jel 466 was studied. In all cases, there was a marked reciprocal relationship between the pattern of Jel 466 on the one hand and that of Hoechst 33258 and Jel 318 on the other. Jel 466 was negative for C-band and G-band but positive for R-band, whereas the opposite was found for Hoechst and Jel 318. Since C and G-bands are AT-rich and R-bands are GC rich, these staining patterns match the sequence preferences of the two antibodies, Thus the base composition of tripler-forming DNA differs from domain to domain.	UNIV SASKATCHEWAN, DEPT BIOCHEM, SASKATOON S7N 0W0, SK, CANADA; UNIV SASKATCHEWAN, DEPT ANAT, SASKATOON S7N 0W0, SK, CANADA	University of Saskatchewan; University of Saskatchewan								ARRIGHI FE, 1971, CYTOGENETICS, V10, P81, DOI 10.1159/000130130; BARRY MM, 1994, J BIOL CHEM, V269, P3623; BIRNBOIM HC, 1979, EUR J BIOCHEM, V98, P301, DOI 10.1111/j.1432-1033.1979.tb13189.x; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P14, DOI 10.1002/jcb.240520104; BRAUN RP, 1986, NUCLEIC ACIDS RES, V14, P5049, DOI 10.1093/nar/14.12.5049; BURKHOLDER GD, 1988, CHROMOSOMA, V97, P185, DOI 10.1007/BF00292959; BURKHOLDER GD, 1991, CHROMOSOMA, V101, P11, DOI 10.1007/BF00360681; CHENG YK, 1992, PROG BIOPHYS MOL BIO, V58, P225, DOI 10.1016/0079-6107(92)90007-S; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DERVAN PB, 1992, NATURE, V359, P87, DOI 10.1038/359087a0; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; HAMPEL KJ, 1991, BIOCHEMISTRY-US, V30, P4455, DOI 10.1021/bi00232a012; HAMPEL KJ, 1993, BIOCHEM CELL BIOL, V71, P190, DOI 10.1139/o93-030; HAMPEL KJ, 1993, BIOCHEMISTRY-US, V32, P1072, DOI 10.1021/bi00055a012; HILWIG I, 1972, EXP CELL RES, V75, P122, DOI 10.1016/0014-4827(72)90527-7; HOFFMANLIEBERMANN B, 1986, MOL CELL BIOL, V6, P3632, DOI 10.1128/MCB.6.11.3632; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; LATIMER LJP, 1989, NUCLEIC ACIDS RES, V17, P1549, DOI 10.1093/nar/17.4.1549; LEE JS, 1984, NUCLEIC ACIDS RES, V12, P6603, DOI 10.1093/nar/12.16.6603; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; LYAMICHEV VI, 1986, J BIOMOL STRUCT DYN, V3, P667, DOI 10.1080/07391102.1986.10508454; MAHER LJ, 1992, BIOESSAYS, V14, P807, DOI 10.1002/bies.950141204; MANOR H, 1988, J MOL EVOL, V27, P96, DOI 10.1007/BF02138367; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; PARDUE ML, 1970, SCIENCE, V168, P1356, DOI 10.1126/science.168.3937.1356; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; RADIC MZ, 1991, J IMMUNOL, V146, P176; SARKAR PS, 1992, NUCLEIC ACIDS RES, V20, P5713, DOI 10.1093/nar/20.21.5713; ULRICH MJ, 1992, J BIOL CHEM, V267, P18649; WEIR DM, 1986, HDB EXPT IMMUNOLOGY, V1; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791	32	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					7019	7023						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509814				2022-12-27	WOS:A1994MZ50300115
J	CHOQUET, D; KU, G; CASSARD, S; MALISSEN, B; KORN, H; FRIDMAN, WH; BONNEROT, C				CHOQUET, D; KU, G; CASSARD, S; MALISSEN, B; KORN, H; FRIDMAN, WH; BONNEROT, C			DIFFERENT PATTERNS OF CALCIUM SIGNALING TRIGGERED THROUGH 2 COMPONENTS OF THE B-LYMPHOCYTE ANTIGEN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA-2+; PLASMA-MEMBRANE; CELLS; PHOSPHORYLATION; IMMUNOGLOBULIN; OSCILLATIONS; COMPLEX; STORES; IG; TRANSDUCTION	The engagement of the B cell antigen receptor is the first step of antigenic stimulation of B lymphocytes. This step is followed by a series of biochemical events, including the activation of protein-tyrosine kinases, phosphoinositide turnover, and multiple patterns of calcium mobilization, which lead to the regulation of gene transcription and cellular responses. The B cell antigen receptor complex is composed of membrane immunoglobulins (as antigen recognition subunits) and associated chains (Ig-alpha and Ig-beta) that couple the receptor to cytoplasmic protein kinases. To investigate independently the relative signaling capacity of Ig-alpha and Ig-beta, chimeric proteins containing their cytoplasmic domains were expressed in a B cell line. We found that Ig-alpha and Ig-beta activate two distinct intracellular signaling pathways. The engagement of Ig-alpha chimeras induces a complete release of calcium from intracellular stores, followed by transmembrane calcium influx and late cell activation signals, detected by lymphokine secretion. In contrast, Ig-beta chimeras do not induce lymphokine secretion or calcium influx, but induce short oscillatory release of calcium, dependent on the activity of the Ca-ATPase pump of the endoplasmic reticulum. These results provide a structural basis for the diversity of B cell responses.	INST CURIE, INSERM, U255, F-75005 PARIS, FRANCE; INST PASTEUR, INSERM, U261, F-75015 PARIS, FRANCE; CNRS MARSEILLE LUMINY, INSERM, CTR IMMUNOL, F-13288 MARSEILLE 9, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			Malissen, Bernard/AAK-4659-2020; Choquet, Daniel/K-7893-2018; Choquet, Daniel/GOJ-8825-2022; Choquet, Daniel/E-4203-2013	Choquet, Daniel/0000-0003-4726-9763; Choquet, Daniel/0000-0003-4726-9763; fridman, wolf herman/0000-0002-1332-0973				BONNEROT C, 1992, EMBO J, V11, P2747, DOI 10.1002/j.1460-2075.1992.tb05340.x; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; CAMBIER JC, 1992, FASEB J, V6, P3207, DOI 10.1096/fasebj.6.13.1397843; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CARAFOLI E, 1991, ANNU REV PHYSIOL, V53, P531, DOI 10.1146/annurev.physiol.53.1.531; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CUSHLEY W, 1993, BIOCHEM J, V292, P313, DOI 10.1042/bj2920313; DENNIS GJ, 1987, J IMMUNOL, V138, P4307; DONNADIEU E, 1992, J BIOL CHEM, V267, P25864; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; FISHER CL, 1991, J IMMUNOL, V146, P1743; FRIEDRICH RJ, 1993, J IMMUNOL, V150, P2814; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HESS SD, 1993, J IMMUNOL, V150, P2620; HIDERO Y, 1993, J EXP MED, V177, P1613; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; ISHIHARA K, 1993, J IMMUNOL, V150, P2253; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEWIS RS, 1989, CELL REGUL, V1, P199; MASON MJ, 1991, J BIOL CHEM, V266, P10872; PIKE BL, 1987, IMMUNOL REV, V99, P119, DOI 10.1111/j.1600-065X.1987.tb01175.x; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Rink TJ, 1990, CURR OPIN CELL BIOL, V2, P198, DOI 10.1016/0955-0674(90)90007-2; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; TADA M, 1988, METHOD ENZYMOL, V157, P107; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WILSON HA, 1987, J EXP MED, V166, P601, DOI 10.1084/jem.166.2.601; XU A, 1993, J BIOL CHEM, V268, P8394	43	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6491	6497						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509805				2022-12-27	WOS:A1994MZ50300037
J	SANDOVAL, IV; ARREDONDO, JJ; ALCALDE, J; NORIEGA, AG; VANDEKERCKHOVE, J; JIMENEZ, MA; RICO, M				SANDOVAL, IV; ARREDONDO, JJ; ALCALDE, J; NORIEGA, AG; VANDEKERCKHOVE, J; JIMENEZ, MA; RICO, M			THE RESIDUES LEU(ILE)(475)-ILE(LEU,VAL,ALA)(476), CONTAINED IN THE EXTENDED CARBOXYL CYTOPLASMIC TAIL, ARE CRITICAL FOR TARGETING OF THE RESIDENT LYSOSOMAL MEMBRANE-PROTEIN LIMP-II TO LYSOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; TRANS-GOLGI-APPARATUS; HAMSTER OVARY CELLS; CASEIN KINASE-II; RAT-LIVER; INTERNALIZATION SIGNAL; ACID-PHOSPHATASE; RECOGNITION MARKER; SYNTHETIC PEPTIDES; INVARIANT CHAIN	LIMP II, a type II lysosomal integral membrane protein, and the CD36/LIMP II construct are targeted to lysosomes by means of a signal expressed in the tyrosine-lacking carboxyl cytoplasmic tail of LIMP II (Vega, M. A., Rodriguez, F., Segui, B., Cales, C., Alcalde, J., and Sandoval, I. V. (1991) J. Biol. Chem. 266, 16269-16272; Vega, M. A., Segui-Real, B., Garcia, J. A., Cales, C., Rodriguez, F., Vandekerckhove, J., and Sandoval, I. V. (1991) J. Biol. Chem. 266, 16818-16824). Substitution of Leu(475) with Ile resulted in a decreased efficiency of targeting. Mutant forms produced by substituting Leu(475) by hydrophobic residues with either large (Val) or small (Ala, Gly) side chains, or by a charged residue (Asp), showed inhibited targeting. In contrast, the contiguous Ile(476) residue could be replaced by either Leu, without loss in the efficiency of targeting, or by Val or Ala, with some impediment. Substitution of Ile(476) by either Gly or Asp inhibited completely the targeting. The addition of the sequence Ser-Trp-Asp to the carboxyl end of the construct did not interfere with targeting. Data from H-1 NMR analysis of the icosapeptide corresponding to the carboxyl cytoplasmic tail of LIMP II indicated the predominance of structures with extended random coil conformations, suggesting that the targeting signal is contained in a domain with an extended configuration.	STATE UNIV GHENT,PHYSIOL CHEM LAB,B-9000 GHENT,BELGIUM; CSIC,INST ESTRUCTURA MAT,E-28006 MADRID,SPAIN; UNIV NACL AUTONOMA MEXICO,INST INVEST BIOMED,UNIDAD GENET NUTR,MEXICO CITY 04530,DF,MEXICO	Ghent University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Estructura de la Materia (IEM); Universidad Nacional Autonoma de Mexico	SANDOVAL, IV (corresponding author), UNIV AUTONOMA MADRID,CSIC,FAC CIENCIAS,CTR BIOL MOLEC SEVERO OCHOA,CANTOBLANCO,E-28049 MADRID,SPAIN.		Jimenez, M. Angeles/C-7193-2008; Arredondo, Juan/L-2404-2013	Jimenez, M. Angeles/0000-0001-6835-5850; Arredondo, Juan/0000-0002-6784-0990				ALCALDE J, 1992, J CELL BIOL, V116, P69, DOI 10.1083/jcb.116.1.69; ANE WP, 1976, J CHEM PHYS, V64, P222; ARMSTRONG J, 1991, J CELL SCI, V98, P567; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BARRIOCANAL JG, 1986, J BIOL CHEM, V261, P6755; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1986, J MAGN RESON, V70, P327, DOI 10.1016/0022-2364(86)90018-1; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRAULKE T, 1987, EUR J CELL BIOL, V43, P316; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; CAMPBELL CH, 1983, J BIOL CHEM, V258, P3347; CARLSSON SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P630, DOI 10.1016/0003-9861(92)90619-8; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; de Duve D, 1963, CIBA F S LYSOSOMES, P1; DENG YP, 1991, J CELL SCI, V99, P571; DEUTSCHER SL, 1983, P NATL ACAD SCI-BIOL, V80, P3938, DOI 10.1073/pnas.80.13.3938; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FEDDE KN, 1985, BIOCHEM BIOPH RES CO, V133, P614, DOI 10.1016/0006-291X(85)90949-0; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GEUZE HJ, 1987, J CELL BIOL, V104, P1715, DOI 10.1083/jcb.104.6.1715; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HOFLACK B, 1985, P NATL ACAD SCI USA, V82, P4428, DOI 10.1073/pnas.82.13.4428; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; HUGHES EN, 1982, J BIOL CHEM, V257, P3970; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JADOT M, 1992, J BIOL CHEM, V267, P11069; JIMENEZ MA, 1986, J MOL STRUCT, V143, P435, DOI 10.1016/0022-2860(86)85294-2; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KAPLAN A, 1977, P NATL ACAD SCI USA, V74, P2026, DOI 10.1073/pnas.74.5.2026; KIEFFER N, 1989, BIOCHEM J, V262, P835, DOI 10.1042/bj2620835; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LEMANSKY P, 1987, J CELL BIOL, V104, P1743, DOI 10.1083/jcb.104.6.1743; LERHMAN MA, 1985, CELL, V41, P735; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MALISSEN B, 1982, EUR J IMMUNOL, V12, P734; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARION D, 1985, FEBS LETT, V192, P99, DOI 10.1016/0014-5793(85)80051-X; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; MEGGIO F, 1984, J BIOL CHEM, V259, P4576; MERESSE S, 1990, J BIOL CHEM, V265, P18833; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MINNIFIELD N, 1986, EUR J CELL BIOL, V42, P92; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; NIETO A, 1990, BIOCHEM J, V267, P317, DOI 10.1042/bj2670317; NOVIKOFF AB, 1963, CIBA F S LYSOSOMES, P36; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; POHLMANN R, 1982, J BIOL CHEM, V257, P5323; SAHAGIAN GG, 1983, J BIOL CHEM, V258, P7121; SCHMID S, 1989, J CELL BIOL, V108, P1291, DOI 10.1083/jcb.108.4.1291; STRAUS W, 1963, CIBA F S LYSOSOMES, P151; VEGA MA, 1991, J BIOL CHEM, V266, P16818; VEGA MA, 1991, J BIOL CHEM, V266, P16269; VLADUTIU GD, 1983, BIOCHIM BIOPHYS ACTA, V760, P363, DOI 10.1016/0304-4165(83)90374-4; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	78	122	125	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6622	6631						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509809				2022-12-27	WOS:A1994MZ50300057
J	BASTIAN, NR; YIM, CY; HIBBS, JB; SAMLOWSKI, WE				BASTIAN, NR; YIM, CY; HIBBS, JB; SAMLOWSKI, WE			INDUCTION OF IRON-DERIVED EPR SIGNALS IN MURINE CANCERS BY NITRIC-OXIDE - EVIDENCE FOR MULTIPLE INTRACELLULAR TARGETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; TOXIC ACTIVATED MACROPHAGES; L-ARGININE; EFFECTOR MECHANISM; CYTO-TOXICITY; TUMOR-CELLS; NEOPLASTIC-CELLS; INHIBITION; COMPLEXES; SPECTROSCOPY	The cell-mediated immune response to syngeneic tumors activates the cytokine inducible nitric oxide synthase. We observed that syngeneic murine tumors exhibited EPR signals related to iron-nitrosyl complex formation. Three different EPR active iron-nitrosyl species were observed, an Fe(RS)(2)(N0)(2) signal and two differentiable heme-nitrosyl complexes, Hemoglobin assays showed that the heme-nitrosyl signals were not derived from contaminating hemoglobin. Signal amplitudes were attenuated in mice treated with N-omega-monomethyl-L-arginine (MLA), an inhibitor of nitric oxide synthase. Tumors grown in vivo contained EPR signals while those grown in culture without continuing cytokine stimulation lost the signals after a few days. Cultured cells that were treated with cytokines, or that were cocultivated with cytokine-activated macro phages, regained EPR active complexes. These results show that the cell-mediated immune response to syngeneic tumors involves the induction of nitric oxide synthase. While nitric oxide synthesis is induced in both tumor infiltrating macrophages and in the tumor cells themselves, only tumor cells contributed to formation of heme-nitrosyl complexes. This result indicates the presence of a novel intracellular target for NO within tumor cells.	UNIV UTAH,SCH MED,DEPT INTERNAL MED,SALT LAKE CITY,UT 84132; UNIV UTAH,SCH MED,VET ADM MED CTR,CANC IMMUNOTHERAPY PROGRAM,SALT LAKE CITY,UT 84132; VET ADM MED CTR,SALT LAKE CITY,UT 84148	Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BASTIAN, NR (corresponding author), UNIV UTAH,SCH MED,DEPT INTERNAL MED,DIV INFECT DIS,SALT LAKE CITY,UT 84132, USA.			Samlowski, Wolfram/0000-0002-0713-914X	NCI NIH HHS [U01-CA58248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA058248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMBER IJ, 1988, J LEUKOCYTE BIOL, V43, P187, DOI 10.1002/jlb.43.2.187; BAKER JE, 1988, P NATL ACAD SCI USA, V85, P2786, DOI 10.1073/pnas.85.8.2786; BRENNAN MJ, 1966, P SOC EXP BIOL MED, V123, P715; BUTLER AR, 1985, POLYHEDRON, V4, P797, DOI 10.1016/S0277-5387(00)87029-1; CHIANG RW, 1972, BIOCHIM BIOPHYS ACTA, V257, P452, DOI 10.1016/0005-2795(72)90298-X; COMMONER B, 1970, CANCER RES, V30, P2091; CURRAN RD, 1991, FASEB J, V5, P2085, DOI 10.1096/fasebj.5.7.1707021; Davidsohn I, 1974, CLIN DIAGNOSIS LABOR, P100; DING AH, 1988, J IMMUNOL, V141, P2407; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018; EMANUEL NM, 1969, NATURE, V222, P165, DOI 10.1038/222165a0; FOLEY GE, 1960, CANCER RES, V20, P930; GILLESPIE GY, 1980, J RETICULOENDOTH SOC, V27, P535; GRANGER DL, 1990, J CLIN INVEST, V85, P264, DOI 10.1172/JCI114422; GRANGER DL, 1982, J CELL BIOL, V95, P527, DOI 10.1083/jcb.95.2.527; GRANGER DL, 1980, J CLIN INVEST, V65, P357, DOI 10.1172/JCI109679; HIBBS JB, 1984, BIOCHEM BIOPH RES CO, V123, P716, DOI 10.1016/0006-291X(84)90288-2; HIBBS JB, 1987, J IMMUNOL, V138, P550; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIBBS JB, 1989, BIOCHEM BIOPH RES CO, V158, P624; HIBBS JB, 1990, NITRIC OXIDE L ARGIN, P189; HILLE R, 1979, J BIOL CHEM, V254, P2110; KELLER R, 1973, J EXP MED, V138, P625, DOI 10.1084/jem.138.3.625; KON H, 1969, BIOCHEMISTRY-US, V8, P4757, DOI 10.1021/bi00840a016; KON H, 1968, J BIOL CHEM, V243, P4350; KRAHENBUHL JL, 1976, IMMUNOLOGY, V31, P837; KRIPKE ML, 1977, CANCER RES, V37, P1395; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MARUYAMA T, 1971, CANCER RES, V31, P179; MILLS CD, 1991, J IMMUNOL, V146, P2719; MISHELL BB, 1980, SELECTED METHODS CEL, P3; MORSE RH, 1980, J BIOL CHEM, V255, P7876; PELLAT C, 1990, BIOCHEM BIOPH RES CO, V166, P119, DOI 10.1016/0006-291X(90)91919-J; SCHOLLER DM, 1979, J BIOL CHEM, V254, P4072; SHU S, 1985, CANCER RES, V45, P1657; VANIN A F, 1967, Biofizika, V12, P829; VANIN AF, 1991, FEBS LETT, V289, P1, DOI 10.1016/0014-5793(91)80894-9; WARTHON M, 1988, J IMMUNOL, V141, P1311	43	76	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5127	5131						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508933				2022-12-27	WOS:A1994MX57100068
J	SLATER, SJ; KELLY, MB; TADDEO, FJ; HO, CJ; RUBIN, E; STUBBS, CD				SLATER, SJ; KELLY, MB; TADDEO, FJ; HO, CJ; RUBIN, E; STUBBS, CD			THE MODULATION OF PROTEIN-KINASE-C ACTIVITY BY MEMBRANE LIPID BILAYER STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC PHASE-BEHAVIOR; PHOSPHOLIPID-BILAYERS; CYTOPLASMIC PROTEINS; UNILAMELLAR VESICLES; ACTIVATION; MONOLAYERS; DIACYLGLYCEROL; PHOSPHATIDYLETHANOLAMINE; ASSOCIATION; CHOLESTEROL	The hypothesis that protein kinase C (PKC) activity is sensitive to phospholipid head group interactions was tested using lipid bilayers of defined composition with PKC purified from rat brain. The head group interactions were modulated by varying phosphatidylcholine cis-unsaturation, vesicle curvature, and by the addition of phosphatidylethanolamine and cholesterol. With unilamellar vesicles (including 20 mol % brain phosphatidylserine), increased phosphatidylcholine unsaturation potentiated basal and phorbol ester stimulated PKC activity. By contrast, in the presence of phosphatidylethanolamine, the activity decreased with increasing phosphatidylcholine unsaturation. Weakening phospholipid head group interactions spaces the head group region and increases interstitial water, and this effect was assessed from its effect on the fluorescence intensity of the phospholipid-labeled fluorophore 1-palmitoyl-2-N(4- nitrobenzo-2-oxa-1,3-diazole)aminohexanoylphosphatidylcholine (C-6-NBD-PC). When the PKC activities with vesicles of varying phosphatidylcholine unsaturation, with and without phosphatidylethanolamine, were plotted as a function of the fluorescence intensity of C6NBD-PC-labeIed vesicles, a biphasic profile was obtained, which had an optimum value of intensity, relating to head group spacing, that corresponded to a maximal enzyme activity. A similar biphasic curve was also found when PKC activities were plotted as a function of published bilayer intrinsic curvature x-ray diffraction data, a parameter closely related to head group spacing. By contrast, no simple relationship was evident between PKC activity and 1,6-diphenyl-1,3,5-hexatriene anisotropy, taken as a measure of Lipid order or fluidity. Therefore, increasing the level of phosphatidylcholine unsaturation, phosphatidylethanolamine, or cholesterol either potentiates or attenuates PKC activity, dependent on whether the initial condition is above or below its optimum.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA008022, R01AA008022, P50AA007186] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA08022, AA07186, AA07215] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BAZZI MD, 1992, BIOCHEMISTRY-US, V31, P1125, DOI 10.1021/bi00119a022; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P6776, DOI 10.1021/bi00418a020; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BELL RM, 1991, J BIOL CHEM, V266, P4661; BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; BOLEN EJ, 1992, BIOCHEMISTRY-US, V31, P5945, DOI 10.1021/bi00140a034; BONI LT, 1985, J BIOL CHEM, V260, P819; BOSCA L, 1993, BIOCHEM J, V290, P827, DOI 10.1042/bj2900827; BRUMFELD V, 1990, ARCH BIOCHEM BIOPHYS, V277, P318, DOI 10.1016/0003-9861(90)90586-N; CHATTOPADHYAY A, 1988, BIOCHIM BIOPHYS ACTA, V938, P24, DOI 10.1016/0005-2736(88)90118-6; CONROY DM, 1986, BIOCHIM BIOPHYS ACTA, V861, P457, DOI 10.1016/0005-2736(86)90454-2; COX KJ, 1992, BIOCHEMISTRY-US, V31, P1112, DOI 10.1021/bi00119a020; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V513, P31, DOI 10.1016/0005-2736(78)90109-8; CUNNINGHAM BA, 1989, BIOCHEMISTRY-US, V28, P32, DOI 10.1021/bi00427a006; DAS S, 1986, BIOCHEMISTRY-US, V25, P2882, DOI 10.1021/bi00358a022; DAS S, 1984, BIOCHEM BIOPH RES CO, V124, P491, DOI 10.1016/0006-291X(84)91580-8; DEKRUYFF B, 1973, BIOCHIM BIOPHYS ACTA, V307, P1, DOI 10.1016/0005-2736(73)90020-5; DEMEL RA, 1972, BIOCHIM BIOPHYS ACTA, V266, P26, DOI 10.1016/0005-2736(72)90116-2; EPAND RM, 1989, BIOSCIENCE REP, V9, P315, DOI 10.1007/BF01114684; EPAND RM, 1992, BIOCHEMISTRY-US, V31, P1550, DOI 10.1021/bi00120a036; EPAND RM, 1985, BIOCHEMISTRY-US, V24, P7092, DOI 10.1021/bi00346a011; EPAND RM, 1988, BIOCHIM BIOPHYS ACTA, V944, P144, DOI 10.1016/0005-2736(88)90427-0; FINDLAY EJ, 1978, BIOCHEMISTRY-US, V17, P2400, DOI 10.1021/bi00605a023; GHOSH R, 1988, BIOCHEMISTRY-US, V27, P7750, DOI 10.1021/bi00420a025; GRUNER SM, 1985, P NATL ACAD SCI USA, V82, P3665, DOI 10.1073/pnas.82.11.3665; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUI SW, 1989, P NATL ACAD SCI USA, V86, P5825, DOI 10.1073/pnas.86.15.5825; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; KAIBUCHI K, 1981, J BIOL CHEM, V256, P7146; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KELLER SL, 1993, BIOPHYS J, V65, P23, DOI 10.1016/S0006-3495(93)81040-3; KIRK GL, 1984, BIOCHEMISTRY-US, V23, P1093, DOI 10.1021/bi00301a009; Kitano T, 1986, Methods Enzymol, V124, P349; LIS LJ, 1982, BIOPHYS J, V37, P667; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; SENISTERRA G, 1993, ARCH BIOCHEM BIOPHYS, V300, P378, DOI 10.1006/abbi.1993.1051; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; SLATER SJ, 1993, BIOCHEMISTRY-US, V32, P3714, DOI 10.1021/bi00065a025; SLATER SJ, 1993, NATURE, V364, P82, DOI 10.1038/364082a0; SNOEK GT, 1986, BIOCHIM BIOPHYS ACTA, V860, P336, DOI 10.1016/0005-2736(86)90530-4; SNOEK GT, 1988, BIOCHEM J, V255, P629; SOUVIGNET C, 1991, J BIOL CHEM, V266, P40; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STUBBS CD, 1981, BIOCHEMISTRY-US, V20, P4257, DOI 10.1021/bi00518a004; VANDIJCK PWM, 1976, BIOCHIM BIOPHYS ACTA, V455, P576, DOI 10.1016/0005-2736(76)90326-6; VERGER R, 1973, CHEM PHYS LIPIDS, V10, P127, DOI 10.1016/0009-3084(73)90009-1; ZIDOVETZKI R, 1992, BIOCHIM BIOPHYS ACTA, V1134, P261, DOI 10.1016/0167-4889(92)90185-E	54	160	161	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4866	4871						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508929				2022-12-27	WOS:A1994MX57100028
J	ELEMER, GS; EDGINGTON, TS				ELEMER, GS; EDGINGTON, TS			MICROFILAMENT REORGANIZATION IS ASSOCIATED WITH FUNCTIONAL ACTIVATION OF ALPHA(M)BETA(2) ON MONOCYTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULES; FACTOR-X; MONOCLONAL-ANTIBODIES; DEOXYRIBONUCLEASE-I; MEMBRANE SKELETON; HUMAN-NEUTROPHILS; ACTIN-FILAMENTS; ANTIGEN FAMILY; CYTOCHALASIN-B; BETA-SUBUNIT	Selected agonists convert the leukocyte integrin alpha(M)beta(2) on monocytes from a low to a high affinity, state competent to bind factor X and fibrinogen. Conformational, changes of alpha(M)beta2 are hypothesized to account for this functional transition. Here we report that cytochalasins known to interfere with actin filaments induce the alpha(M)beta2 functional transition. Upon exposure to cytochalasin B, isolated human blood monocytes and cells of the monocytic cell line THP-1 bound I-125-factor X (X) or I-125-fibrinogen (Fg) in a Ca2+-dependent, saturable manner. Monoclonal antibodies (mAbs) to the alpha(M) subunit and the common beta2 subunit of leukocyte integrins inhibited X and Fg binding, whereas mAbs to the a chains of the other leukocyte integrins had no effect. Anti-alpha(M) mAb immunoprecipitated I-125-X that had been chemically cross-linked to its cognate receptor. Specific binding was not associated with an increased surface density of beta2 integrins consistent with conformational remodeling of the receptor. Simultaneous analysis of actin forms in viable monocytes indicated a dynamic redistribution of cellular actin. The transient increase in G actin concurrent with an agonist action such as cytochalasin or ADP was reversed by an increase in F actin coincident with X/Ca2+ binding. A potential role of actin redistribution in alpha(M)beta2 functional transition is supported by the finding that cells in which cellular actin is restricted to G rather than F form bound X and initiated a rapid coagulant response. We propose that a transient disassembly of actin filaments may relieve constraints on alpha(M)beta2 via the cytoplasmic domains, permitting the conformational dynamics required for recognition of ligands.	Scripps Res Inst, DEPT IMMUNOL,VASC CELL MOLEC BIOL PROGRAM,IMM-17, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER; NHLBI NIH HHS [P0 HL-16411] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALI IU, 1977, BIOCHIM BIOPHYS ACTA, V471, P16, DOI 10.1016/0005-2736(77)90388-1; ALTIERI DC, 1988, J IMMUNOL, V141, P2656; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ALTIERI DC, 1989, J BIOL CHEM, V264, P2969; ALTIERI DC, 1988, P NATL ACAD SCI USA, V85, P7462, DOI 10.1073/pnas.85.20.7462; ARNAOUT MA, 1990, BLOOD, V75, P1037; ARNAOUT MA, 1988, J CELL PHYSIOL, V137, P305, DOI 10.1002/jcp.1041370214; BURN P, 1988, P NATL ACAD SCI USA, V85, P497, DOI 10.1073/pnas.85.2.497; CAO LG, 1992, J CELL BIOL, V117, P1023, DOI 10.1083/jcb.117.5.1023; CARTER SB, 1967, NATURE, V213, P261, DOI 10.1038/213261a0; CASELLA JF, 1981, NATURE, V293, P302, DOI 10.1038/293302a0; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; ESCANDEGERAUD ML, 1988, BIOCHIM BIOPHYS ACTA, V939, P247, DOI 10.1016/0005-2736(88)90068-5; FAIR DS, 1979, J CLIN INVEST, V64, P884, DOI 10.1172/JCI109554; FAULSTICH H, 1988, J MUSCLE RES CELL M, V9, P370, DOI 10.1007/BF01774064; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1988, BIOESSAYS, V8, P14, DOI 10.1002/bies.950080105; GOLDMAN RD, 1973, P NATL ACAD SCI USA, V70, P750, DOI 10.1073/pnas.70.3.750; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; GROVE DS, 1992, EXP CELL RES, V202, P303, DOI 10.1016/0014-4827(92)90079-N; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HITCHCOCK SE, 1980, J BIOL CHEM, V255, P5668; HO MK, 1983, J BIOL CHEM, V258, P2766; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KEIZER GD, 1985, EUR J IMMUNOL, V15, P1142, DOI 10.1002/eji.1830151114; KURKINEN M, 1978, EXP CELL RES, V111, P127, DOI 10.1016/0014-4827(78)90243-4; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; MAEKAWA S, 1989, J BIOL CHEM, V264, P7458; MANNHERZ HG, 1980, EUR J BIOCHEM, V104, P367, DOI 10.1111/j.1432-1033.1980.tb04437.x; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; Pollard TD, 1990, CURR OPIN CELL BIOL, V2, P33, DOI 10.1016/S0955-0674(05)80028-6; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SANGER JM, 1990, P NATL ACAD SCI USA, V87, P5474, DOI 10.1073/pnas.87.14.5474; SCHWARTING R, 1985, BLOOD, V65, P974; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TELLAM R, 1982, BIOCHEMISTRY-US, V21, P3207, DOI 10.1021/bi00256a027; THERRIEN S, 1989, J CELL BIOL, V109, P1125, DOI 10.1083/jcb.109.3.1125; TRACY PB, 1985, J BIOL CHEM, V260, P2119; WALLIS WJ, 1986, BLOOD, V67, P1007; WEHLAND J, 1981, EUR J CELL BIOL, V24, P176; WESSELLS NK, 1971, SCIENCE, V171, P135, DOI 10.1126/science.171.3967.135; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699	47	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3159	3166						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508910				2022-12-27	WOS:A1994MV63100010
J	MARSHALL, J; FANG, S; OSTEDGAARD, LS; ORIORDAN, CR; FERRARA, D; AMARA, JF; HOPPE, H; SCHEULE, RK; WELSH, MJ; SMITH, AE; CHENG, SH				MARSHALL, J; FANG, S; OSTEDGAARD, LS; ORIORDAN, CR; FERRARA, D; AMARA, JF; HOPPE, H; SCHEULE, RK; WELSH, MJ; SMITH, AE; CHENG, SH			STOICHIOMETRY OF RECOMBINANT CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR IN EPITHELIAL-CELLS AND ITS FUNCTIONAL RECONSTITUTION INTO CELLS IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GENE-TRANSFER; CFTR CHLORIDE CHANNEL; MOUSE CELLS; R-DOMAIN; EXPRESSION; KINASE; IDENTIFICATION; TRANSPORT; MUTATIONS; DNA	We have generated several clones of Chinese hamster ovary, mouse epitheloid C127, and pig kidney epithelial LLCPK1 cells producing high levels of functional recombinant human cystic fibrosis transmembrane conductance regulator (CFTR). Processing of CFTR to the mature and fully glycosylated form in these cells is inefficient with only approximately 40% of all newly synthesized CFTR being converted to the mature form. Furthermore, expression of the most frequent mutant allele of the cystic fibrosis (CF) gene, the DELTAF508 mutant in these epithelial cells, indicated that it is biosynthetically arrested at the endoplasmic reticulum and fails to traffic to the plasma membrane. Using a combination of CFTR mutants and monoclonal antibodies, all the detectable recombinant CFTR in these cells was determined at least under the conditions used, to be present as a monomer. To demonstrate the feasibility of protein replacement therapy, we were able to effect the physical transfer of functional recombinant CFTR produced in Chinese hamster ovary cells to the plasma membranes of Ha3b fibroblasts, a cell line devoid of cAMP-stimulated chloride channels. Transfer of CFTR was mediated by the hemagglutinin viral fusion protein of influenza virus present on the Ha3b cells. Efficiency of transfer was up to 25% of the target cells, and CFTR chloride channel activity was detectable for up to 12 h post-fusion. Therefore, with the development of an appropriate formulation of fusogenic proteoliposome or virosome containing reconstituted purified CFTR, it should be feasible to introduce functional CFTR into CF-affected cells.	GENZYME CORP,MT RD,FRAMINGHAM,MA 01701; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Sanofi-Aventis; Genzyme Corporation; Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa			Cheng, Seng H/AAC-6564-2022	Welsh, Michael/0000-0002-1646-6206; Ostedgaard, Lynda/0000-0001-7717-3442; Marshall, John/0000-0003-1361-2869				ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDREWS GK, 1987, NUCLEIC ACIDS RES, V15, P5461, DOI 10.1093/nar/15.13.5461; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; Cheng Seng H., 1993, P175; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DEYDALEMANS W, 1991, NATURE, V354, P524; DITULLIO P, 1992, BIO-TECHNOL, V10, P74, DOI 10.1038/nbt0192-74; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; ELLENS H, 1990, BIOCHEMISTRY-US, V29, P9697, DOI 10.1021/bi00493a027; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; FIDDES J C, 1981, Journal of Molecular and Applied Genetics, V1, P3; GOULDFOGERITE S, 1993, LIPOSOME TECHNOLOGY, V3, P261; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GUNZBURG JD, 1989, P NATL ACAD SCI USA, V86, P4007; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; OSTEDGAARD LS, 1992, J BIOL CHEM, V267, P26142; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; REDDY VB, 1987, DNA-J MOLEC CELL BIO, V6, P461, DOI 10.1089/dna.1987.6.461; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, HUM GENE THER, V4, P461, DOI 10.1089/hum.1993.4.4-461; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RICH DP, 1993, IN PRESS RECEPTOR SC; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; SAMBROOK J, 1985, EMBO J, V4, P91, DOI 10.1002/j.1460-2075.1985.tb02322.x; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; SMITH AE, 1992, ANNU REP MED CHEM, V27, P235; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; TILLY BC, 1992, J BIOL CHEM, V267, P9470; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WANG HY, 1989, J BIOL CHEM, V264, P14424; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YOSHIMURA K, 1992, NUCLEIC ACIDS RES, V20, P3233, DOI 10.1093/nar/20.12.3233; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	62	104	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2987	2995						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7507932				2022-12-27	WOS:A1994MV43200090
J	MULLERHUSMANN, G; GLOOR, S; SCHACHNER, M				MULLERHUSMANN, G; GLOOR, S; SCHACHNER, M			FUNCTIONAL-CHARACTERIZATION OF BETA-ISOFORMS OF MURINE NA,K-ATPASE - THE ADHESION MOLECULE ON GLIA (AMOG/BETA-2), BUT NOT BETA-1, PROMOTES NEURITE OUTGROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; 2ND MESSENGER SYSTEMS; (NA+ + K+)-ATPASE; N-CAM; MOUSE CEREBELLUM; CELL-MIGRATION; SODIUM-PUMP; SUBUNIT; EXPRESSION; PROTEIN	We have previously provided evidence for a dual function of the adhesion molecule on glia (AMOG/beta2), the beta2 subunit of the murine Na,K-ATPase, both as neural recognition molecule mediating neuron-glia interactions and as functional beta subunit of the sodium pump. To analyze the functional role of AMOG/beta2 in neurite outgrowth, AMOG/beta2-expressing L-cells were generated by transfection and used as substrates for neurite outgrowth of cerebellar and hippocampal neurons. AMOG/beta2-transfected L-cells led to an increase in neurite length after 6 h, which was specifically inhibited by antibodies to AMOG/beta2 and a neuronal membrane fraction. Moreover, the extracellular domain of AMOG/beta2 generated as a soluble recombinant protein in Chinese hamster ovary cells partially inhibited the increase in neurite outgrowth on AMOG/beta2-transfected L-cells. L-cells transfected with the mouse beta1 subunit had no effect on neurite extension. Our observations show for the first time differences in functional properties for different beta isoforms of the Na,K-ATPase and suggest that AMOG/beta2 but not beta1 is able to interact with an unknown neuronal receptor leading to increased neurite outgrowth, most likely via signal transduction.			MULLERHUSMANN, G (corresponding author), SWISS FED INST TECHNOL,DEPT NEUROBIOL,CH-8093 ZURICH,SWITZERLAND.							ALTMAN J, 1982, EXP BRAIN RES S, V6, P8; ANTONICEK H, 1987, J CELL BIOL, V104, P1587, DOI 10.1083/jcb.104.6.1587; ANTONICEK H, 1988, J NEUROSCI, V8, P2961; APPEL F, 1993, IN PRESS J NEUROSCI; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BIXBY JL, 1990, J CELL BIOL, V111, P2725, DOI 10.1083/jcb.111.6.2725; BIXBY JL, 1989, NEURON, V3, P287, DOI 10.1016/0896-6273(89)90253-5; BIXBY JL, 1987, P NATL ACAD SCI USA, V84, P2555, DOI 10.1073/pnas.84.8.2555; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; CLAUSS G, 1977, GRUNDLAGEN STATISTIK, P224; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; Doherty P, 1989, CURR OPIN CELL BIOL, V1, P1102, DOI 10.1016/S0955-0674(89)80057-2; FAHRIG T, 1990, EUR J NEUROSCI, V2, P153, DOI 10.1111/j.1460-9568.1990.tb00407.x; FISCHER G, 1982, NEUROSCI LETT, V28, P325, DOI 10.1016/0304-3940(82)90079-9; FREGIEN N, 1986, GENE, V48, P1, DOI 10.1016/0378-1119(86)90346-X; FUJITA S, 1967, J CELL BIOL, V32, P277, DOI 10.1083/jcb.32.2.277; GLOOR S, 1989, NUCLEIC ACIDS RES, V17, P10117; GLOOR S, 1992, GENE, V120, P307, DOI 10.1016/0378-1119(92)90111-2; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORVEL GP, 1984, CELL TISSUE RES, V238, P253; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; KEILHAUER G, 1985, NATURE, V316, P728, DOI 10.1038/316728a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LANDER AD, 1985, P NATL ACAD SCI USA, V82, P2183, DOI 10.1073/pnas.82.7.2183; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; LOCHTER A, 1991, J CELL BIOL, V113, P1159, DOI 10.1083/jcb.113.5.1159; MANTHORPE M, 1983, J CELL BIOL, V97, P1882, DOI 10.1083/jcb.97.6.1882; MARTINI R, 1986, J CELL BIOL, V103, P2439, DOI 10.1083/jcb.103.6.2439; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MARXER A, 1989, J CELL BIOL, V109, P1057, DOI 10.1083/jcb.109.3.1057; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MCGRAIL KM, 1991, J NEUROSCI, V11, P381, DOI 10.1523/jneurosci.11-02-00381.1991; PAGLIUSI S, 1989, J NEUROSCI RES, V22, P113, DOI 10.1002/jnr.490220202; POLLERBERG GE, 1986, NATURE, V324, P462, DOI 10.1038/324462a0; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; ROGERS SL, 1985, J NEUROSCI, V5, P369; Sambrook J, 1989, MOL CLONING LABORATO; SCHMALZING G, 1991, BIOCHEM J, V279, P329, DOI 10.1042/bj2790329; SCHMALZING G, 1992, J BIOL CHEM, V267, P20212; SCHNITZER J, 1981, J NEUROIMMUNOL, V1, P429, DOI 10.1016/0165-5728(81)90022-9; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SWEADNER KJ, 1985, J BIOL CHEM, V260, P9016; SWEADNER KJ, 1985, J BIOL CHEM, V260, P1508; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAMKUN MM, 1986, J BIOL CHEM, V261, P1009; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TULSIANI DRP, 1982, J BIOL CHEM, V257, P7936; VONBOHLEN F, 1992, EUR J NEUROSCI, V4, P896; WATTS AG, 1991, P NATL ACAD SCI USA, V88, P7425, DOI 10.1073/pnas.88.16.7425	57	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26260	26267						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	7504672				2022-12-27	WOS:A1993MK42500040
J	EVANS, GA; GOLDSMITH, MA; JOHNSTON, JA; XU, WD; WEILER, SR; ERWIN, R; HOWARD, OMZ; ABRAHAM, RT; OSHEA, JJ; GREENE, WC; FARRAR, WL				EVANS, GA; GOLDSMITH, MA; JOHNSTON, JA; XU, WD; WEILER, SR; ERWIN, R; HOWARD, OMZ; ABRAHAM, RT; OSHEA, JJ; GREENE, WC; FARRAR, WL			ANALYSIS OF INTERLEUKIN-2 DEPENDENT SIGNAL-TRANSDUCTION THROUGH THE SHC/GRB2 ADAPTER PATHWAY - INTERLEUKIN-2-DEPENDENT MITOGENESIS DOES NOT REQUIRE SHC PHOSPHORYLATION OR RECEPTOR ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; IL-2 RECEPTOR; CELL LINE; PROTEIN; ACTIVATION; GROWTH; RAF-1; GRB2; DOMAIN	The interleukin (IL)-2 receptor system has previously been shown to signal through the association and tyrosine phosphorylation of Shc. This study demonstrates that the IL-2 receptor beta (IL-2R beta) chain is the critical receptor component required to mediate this effect. The use of IL-2R beta chain deletion mutants transfected into a Ba/F3 murine cell model describes a requirement for the IL-2R beta ''acid-rich'' domain between amino acids 315 and 384 for Shc tyrosine phosphorylation and receptor association. COS cell co-transfection studies of IL-BR beta chain constructs containing point mutations of tyrosine to phenylalanine along with the tyrosine kinase Jak-1 and a hemagglutinin-tagged Shc revealed that the motif surrounding phosphorylated tyrosine 338 within the acid-rich domain of the IL-2R beta is a binding site for Shc. Deletion of this domain has previously been shown to abrogate the ability of IL-2 to activate Ras but does not affect IL-2-dependent mitogenesis in the presence of serum. Proliferation assays of Ba/F3 cells containing IL-2R beta chain deletion mutants in serum-free medium with or without insulin shows that deletion of the acid-rich domain does not affect IL-2-driven mitogenesis regardless of the culture conditions. This study thus defines the critical domain within the IL-2R beta chain required to mediate Shc binding and Shc tyrosine phosphorylation and further shows that Shc binding and phosphorylation are not required for IL-2-dependent mitogenesis. Neither serum nor insulin is required to supplement the loss of induction of the Shc adapter or Ras pathways, which therefore suggests a novel mechanism for mitogenic signal transduction mediated by this hematopoietin receptor.	SCI APPLICAT INT CORP, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, MOLEC IMMUNOREGULAT LAB, CYTOKINE MECH SECT, FREDERICK, MD 21702 USA; UNIV CALIF SAN FRANCISCO, SCH MED, GLADSTONE INST VIROL & IMMUNOL, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT MED, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT IMMUNOL & MICROBIOL, SAN FRANCISCO, CA 94141 USA; NIAMSD, ARTHRITIS & RHEUMATISM BRANCH, LYMPHOCYTE CELL BIOL SECT, BETHESDA, MD 20892 USA; MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55905 USA	Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Mayo Clinic			Howard, O M Zack/B-6117-2012	Howard, O M Zack/0000-0002-0505-7052				[Anonymous], 1994, PROGRAM MANUAL WISCO; BENJAMIN CW, 1994, J BIOL CHEM, V269, P30911; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V82, P2296; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; EVANS GA, 1994, J BIOL CHEM, V269, P23407; EVANS GA, 1992, BIOCHEM J, V282, P759, DOI 10.1042/bj2820759; GAULTON GN, 1994, CHEM IMMUNOL, V59, P91; GOLDSMITH MA, 1995, J BIOL CHEM, V270, P21729, DOI 10.1074/jbc.270.37.21729; GOLDSMITH MA, 1995, IN PRESS J VIROL; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HOWARD OMZ, 1995, BIOCHEM J, V306, P217, DOI 10.1042/bj3060217; IHLE JN, 1982, J IMMUNOL, V129, P1377; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; LEONARD WJ, 1994, ADV EXP MED BIOL, V365, P225; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MILLS GB, 1985, J BIOL CHEM, V260, P2500; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUI H, 1992, J BIOL CHEM, V267, P24076; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SAKAMAKI K, 1994, FEBS LETT, V353, P133, DOI 10.1016/0014-5793(94)01024-2; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SATOH T, 1992, J BIOL CHEM, V267, P25423; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WLODZIMIERZ M, 1992, J BIOL CHEM, V267, P15281; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHU XY, 1994, J BIOL CHEM, V269, P5518	50	68	68	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28858	28863		10.1074/jbc.270.48.28858	http://dx.doi.org/10.1074/jbc.270.48.28858			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499411	hybrid			2022-12-27	WOS:A1995TH05600055
J	LESAGE, F; GUILLEMARE, E; FINK, M; DUPRAT, F; HEURTEAUX, C; FOSSET, M; ROMEY, G; BARHANIN, J; LAZDUNSKI, M				LESAGE, F; GUILLEMARE, E; FINK, M; DUPRAT, F; HEURTEAUX, C; FOSSET, M; ROMEY, G; BARHANIN, J; LAZDUNSKI, M			MOLECULAR-PROPERTIES OF NEURONAL G-PROTEIN-ACTIVATED INWARDLY RECTIFYING K+ CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANOMALOUS RECTIFICATION; EXPRESSION CLONING; POTASSIUM CHANNEL; BINDING PROTEIN; CARDIAC-CELLS; STARFISH EGG; ION CHANNELS; BRAIN; SOMATOSTATIN; MUSCLE	Four cDNA-encoding G-activated inwardly rectifying K+ channels have been cloned recently (Kubo, Y., Reuveny, E., Slesinger, P. A., Jan, Y. N., and Jan, L. Y. (1993) Nature 364, 802-806; Lesage, F., Duprat, F., Fink, M., Guillemare, E., Coppola, T., Lazdunski, M., and Hugnot, J. P. (1994) FEES Lett. 353, 37-42; Krapivinsky, G., Gor don, E. A., Wickman, K., Velimirovic, B., Krapivinsky, L., and Clapham, D. E. (1995) Nature 374, 135-141). We report the cloning of a mouse GIRK2 splice variant, noted mGIRK2A. Both channel proteins are functionally expressed in Xenopus oocytes upon injection of their cRNA, alone or in combination with the GIRK1 cRNA. Three GIRK channels, mGIRK1-3, are shown to be present in the brain. Colocalization in the same neurons of mGIRK1 and mGIRK2 supports the hypothesis that native channels are made by an heteromeric subunit assembly. GIRK3 channels have not been expressed successfully, even in the presence of the other types of subunits. However, GIRK3 chimeras with the amino and carboxyl-terminal of GIRK2 are functionally expressed in the presence of GIRK1. The expressed mGIRK2 and mGIRK1, -2 currents are blocked by Ba2+ and Cs+ ions. They are not regulated by protein kinase A and protein kinase C. Channel activity runs down in inside-out excised patches, and ATP is required to prevent this rundown. Since the nonhydrolyzable ATP analog AMP-PCP is also active and since addition of kinases A and C as well as alkaline phosphatase does not modify the ATP effect, it is concluded that ATP hydrolysis is not required. An ATP binding process appears to be essential for maintaining a functional state of the neuronal inward rectifier K+ channel. A Na+ binding site on the cytoplasmic face of the membrane acts in synergy with the ATP binding site to stabilize channel activity.	CNRS,INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS)			Duprat, Fabrice/D-1221-2013; HEURTEAUX, Catherine/M-4947-2016; Lesage, Florian/D-5097-2011; Lesage, Florian/P-9780-2019	Duprat, Fabrice/0000-0001-8774-1220; HEURTEAUX, Catherine/0000-0002-9741-9777; Lesage, Florian/0000-0002-4406-7106; Lesage, Florian/0000-0002-4406-7106				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; AMOROSO S, 1990, SCIENCE, V247, P852, DOI 10.1126/science.2305257; ASHFORD MLJ, 1988, PFLUG ARCH EUR J PHY, V412, P297, DOI 10.1007/BF00582512; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BERNARDI H, 1988, P NATL ACAD SCI USA, V85, P9816, DOI 10.1073/pnas.85.24.9816; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; DEWEILLE JR, 1989, P NATL ACAD SCI USA, V86, P2971; DRYER SE, 1994, TRENDS NEUROSCI, V17, P155, DOI 10.1016/0166-2236(94)90093-0; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; FAKLER B, 1994, NEURON, V13, P1413, DOI 10.1016/0896-6273(94)90426-X; FAKLER B, 1994, FEBS LETT, V356, P199, DOI 10.1016/0014-5793(94)01258-X; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; GUILLEMARE E, 1992, BIOCHEMISTRY-US, V31, P12463, DOI 10.1021/bi00164a024; HAGIWARA S, 1979, J PHYSIOL-LONDON, V292, P251, DOI 10.1113/jphysiol.1979.sp012849; HAGIWARA S, 1974, J MEMBRANE BIOL, V18, P61, DOI 10.1007/BF01870103; HARTZELL HC, 1981, NATURE, V291, P539, DOI 10.1038/291539a0; HEURTEAUX C, 1993, MOL BRAIN RES, V18, P17, DOI 10.1016/0169-328X(93)90169-P; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INOUE M, 1988, J PHYSIOL-LONDON, V407, P177, DOI 10.1113/jphysiol.1988.sp017409; KAMEYAMA M, 1984, NATURE, V309, P354, DOI 10.1038/309354a0; KARSCHIN C, 1994, FEBS LETT, V348, P139, DOI 10.1016/0014-5793(94)00590-7; KATZ B, 1949, ARCH SCI PHYSIOL, V3, P285; KOBAYASHI T, 1995, BIOCHEM BIOPH RES CO, V208, P1166, DOI 10.1006/bbrc.1995.1456; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1994, TRENDS CARDIOVAS MED, V4, P64, DOI 10.1016/1050-1738(94)90011-6; LESAGE F, 1992, FEBS LETT, V310, P162, DOI 10.1016/0014-5793(92)81320-L; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; LUK HN, 1990, PFLUG ARCH EUR J PHY, V416, P766, DOI 10.1007/BF00370627; MA GH, 1995, MOL PHARMACOL, V47, P1035; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; MIYAKE M, 1989, P NATL ACAD SCI USA, V86, P3419, DOI 10.1073/pnas.86.9.3419; NORTH RA, 1989, BRIT J PHARMACOL, V98, P13, DOI 10.1111/j.1476-5381.1989.tb16855.x; QUAST U, 1993, TRENDS PHARMACOL SCI, V14, P332, DOI 10.1016/0165-6147(93)90006-6; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; VANDONGEN AMJ, 1988, SCIENCE, V242, P1433, DOI 10.1126/science.3144040; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0	46	228	234	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28660	28667		10.1074/jbc.270.48.28660	http://dx.doi.org/10.1074/jbc.270.48.28660			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499385	hybrid			2022-12-27	WOS:A1995TH05600029
J	BAGRODIA, S; DERIJARD, B; DAVIS, RJ; CERIONE, RA				BAGRODIA, S; DERIJARD, B; DAVIS, RJ; CERIONE, RA			CDC42 AND PAK-MEDIATED SIGNALING LEADS TO JUN KINASE AND P38 MITOGEN-ACTIVATED PROTEIN-KINASE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSDUCTION	The PAK family of protein kinases has been suggested as a potential target of the Cdc42 and Rac GTPases based on studies in vitro. We show that PAK-3 is activated by Cdc42 in vivo. Both, activated (GTPase-defective) Cdc42 and a constitutively active PAK-3 mutant stimulated the activity of Jun kinase 1 (JNK1) in transfected cells. Activated Cdc42 also stimulated the activity of the related p38 mitogen-activated protein kinase but was a less effective activator of ERK2. The effect of Cdc42 on JNK activity was similar to that of the potent inflammatory cytokine interleukin-1 (IL-1). The observation that a dominant-negative Cdc42 mutant inhibited IL-1 activation of JNK1 indicates a role for Cdc42 in IL-1 signaling. These results suggest that Cdc42 and PAK may mediate the effects of cytokines on transcriptional regulation.	CORNELL UNIV, DEPT PHARMACOL, ITHACA, NY 14853 USA; UNIV MASSACHUSETTS, SCH MED, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA	Cornell University; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NATIONAL CANCER INSTITUTE [R01CA065861, R01CA058396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER; NCI NIH HHS [CA65861, CA58396] Funding Source: Medline; NIGMS NIH HHS [GM47458] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHENEVERT J, 1994, MOL BIOL CELL, V5, P1169, DOI 10.1091/mbc.5.11.1169; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; HART MJ, 1994, J BIOL CHEM, V269, P62; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; YAN MH, 1994, NATURE, V372, P798; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	36	587	598	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					27995	27998						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499279				2022-12-27	WOS:A1995TG21000004
J	ICHINOHE, T; TAKAYAMA, H; EZUMI, Y; YANAGI, S; YAMAMURA, H; OKUMA, M				ICHINOHE, T; TAKAYAMA, H; EZUMI, Y; YANAGI, S; YAMAMURA, H; OKUMA, M			CYCLIC AMP-INSENSITIVE ACTIVATION OF C-SRC AND SYK PROTEIN-TYROSINE KINASES THROUGH PLATELET MEMBRANE GLYCOPROTEIN-VI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN; THROMBIN; PHOSPHORYLATION; ADHESION; MOBILIZATION; AGGREGATION; ASSOCIATION; RECEPTOR; PATIENT; SUBSTRATE	Platelet glycoprotein (GP) VI is a so-far uncharacterized 62-kDa membrane protein, whose deficiency results in selective impairment in collagen-induced platelet aggregation, Our group previously reported a human polyclonal antibody (anti-p62 IgG) that induces activation of normal, but not of GPVI-deficient, platelets in an Fc-independent manner. The F(ab')(2) fragments of this antibody (F(ab')(2)-anti-p62) stimulated tyrosine phosphorylation of numerous proteins, which was not prevented even in the presence of cAMP-increasing agents such as prostacyclin. Pretreatment of platelets with the protein-tyrosine kinase (PTK) inhibitor tyrphostin A47 completely abolished F(ab')(2)-anti-p62-induced platelet aggregation in parallel with dose-dependent inhibition of protein-tyrosine phosphorylation, indicating an essential requirement of PTK activity for generating GPVI-mediated signaling. We found that two cytosolic PTKs, c-Src and Syk, became rapidly activated in response to F(ab')(2)-anti-p62 in a way insensitive to elevation of cAMP, In contrast, in the presence of prostacyclin, F(ab')(2)-anti-p62 did not stimulate tyrosine phosphorylation of the focal adhesion kinase, cAMP-insensitive activation of c-Src and Syk was also observed in collagen-but not thrombin-stimulated platelets, Moreover, either F(ab')(2)-anti-p62 or collagen stimulated cAMP-insensitive tyrosine phosphorylation of phospholipase C-gamma 2. These results indicate that the receptor-mediated activation of several PTKs in platelets is regulated through a cAMP-sensitive or -insensitive mechanism depending on the nature of each stimulus, and also suggest that GPVI engagement is coupled to cAMP-insensitive activation of c-Src and Syk accompanied by tyrosine phosphorylation of numerous substrates including phospholipase C-gamma 2 in a manner similar to collagen stimulation.	KYOTO UNIV, FAC MED, DEPT INTERNAL MED, DIV 1, SAKYO KU, KYOTO 606, JAPAN; KOBE UNIV, SCH MED, DEPT BIOCHEM, KOBE 650, JAPAN	Kyoto University; Kobe University								ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; CLARK EA, 1994, J BIOL CHEM, V269, P21940; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; CLARK EA, 1994, J BIOL CHEM, V269, P28859; CLEMETSON KJ, 1995, THROMB HAEMOSTASIS, V74, P111; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; DEREYS S, 1994, BLOOD, V84, P547; DUNLOP LC, 1994, THROMBOSIS HEMORRHAG, P615; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HORVATH AR, 1992, EMBO J, V11, P851; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; ICHINOHE T, 1984, BLOOD, V84, pA533; KARNIGUIAN A, 1990, BIOCHEM J, V268, P325, DOI 10.1042/bj2680325; KO FN, 1990, BIOCHIM BIOPHYS ACTA, V1052, P360, DOI 10.1016/0167-4889(90)90144-3; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KROLL MH, 1989, BLOOD, V74, P1181; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LIEBENHOFF U, 1993, BIOCHEM J, V295, P41, DOI 10.1042/bj2950041; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; OHTA S, 1992, BIOCHEM BIOPH RES CO, V185, P1128, DOI 10.1016/0006-291X(92)91743-A; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; OZAKI Y, 1995, J BIOL CHEM, V270, P15119, DOI 10.1074/jbc.270.25.15119; PHILLIPS DR, 1977, BIOCHEM BIOPH RES CO, V75, P940, DOI 10.1016/0006-291X(77)91473-5; PHILLIPS DR, 1979, THROMB HAEMOSTASIS, V42, P1638; PUMIGLIA KM, 1990, BIOCHEM BIOPH RES CO, V171, P738, DOI 10.1016/0006-291X(90)91208-A; RYO R, 1992, AM J HEMATOL, V39, P25, DOI 10.1002/ajh.2830390107; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SMITH JB, 1990, ANAL BIOCHEM, V187, P173, DOI 10.1016/0003-2697(90)90437-E; SMITH JB, 1993, BIOCHEM BIOPH RES CO, V191, P695, DOI 10.1006/bbrc.1993.1273; SMITH JB, 1992, BIOCHEM J, V283, P889, DOI 10.1042/bj2830889; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; SUGIYAMA T, 1987, BLOOD, V69, P1712; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TAKAYAMA H, 1991, BIOCHEM BIOPH RES CO, V174, P922, DOI 10.1016/0006-291X(91)91506-8; TAKAYAMA H, 1993, BIOCHEM BIOPH RES CO, V194, P472, DOI 10.1006/bbrc.1993.1843; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TOHYAMA Y, 1994, J BIOL CHEM, V269, P32796; WATSON SP, 1985, BIOCHEM J, V226, P831, DOI 10.1042/bj2260831; WONG S, 1992, ONCOGENE, V7, P2407	46	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28029	28036						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499287				2022-12-27	WOS:A1995TG21000012
J	NELSON, WC; HOWARD, MT; SHERMAN, JA; MATSON, SW				NELSON, WC; HOWARD, MT; SHERMAN, JA; MATSON, SW			THE TRAY GENE-PRODUCT AND INTEGRATION HOST FACTOR STIMULATE ESCHERICHIA-COLI DNA HELICASE I-CATALYZED NICKING AT THE F-PLASMID ORIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNWINDING ENZYME; SEX FACTOR; PROTEIN; ORIGIN; BINDING; PURIFICATION; SYSTEM	F plasmid conjugative transfer is initiated by the introduction of a site- and strand-specific nick within the plasmid origin of transfer (oriT), Genetic studies have shown nick formation to be dependent on both the traI and traY genes, However, highly purified TraIp, the traI gene product, nicks oriT in a site- and strand-specific manner in the absence of the traY gene product (TraYp) in vitro (Matson, S. W., and Morton, B. S. (1991) J. Biol, Chem. 266, 16232-16237). Analysis of the oriT region has revealed binding sites for TraYp and the host protein integration host factor (IHF). To explore possible interactions occurring at oriT, highly purified TraIp, TraYp, and IHF were incubated with a supercoiled oriT-containing DNA substrate, A marked enhancement of the nicking reaction catalyzed by TraIp was observed in a reaction that required both TraYp and IHF, In addition, TraIp was able to nick a linear oriT-containing double-stranded DNA substrate when IHF and TraYp were present in the reaction; such a substrate is not nicked by TraIp alone, Individual protein concentration requirements for the supercoiled and linear nicking reactions were similar, and the reactions occurred at equal velocity, suggesting that they are biochemically identical, Concentrations of TraYp and IHF that yield half-maximal activity in the nicking assays compare well with the reported K-D values for the IHF and TraYp binding sites in oriT, These data, coupled with data presented in the accompanying report, suggest that TraYp and IHF bind independent of one another, forming a nucleo-protein complex with oriT that can be recognized and nicked by TraIp.	UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULUM GENET & MOLEC BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Nelson, William C/E-9263-2016	Nelson, William C/0000-0002-1873-3929	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033476] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 33476] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P441, DOI 10.1111/j.1432-1033.1976.tb10359.x; ABDELMONEM M, 1977, J MOL BIOL, V110, P667, DOI 10.1016/S0022-2836(77)80083-1; ABDELMONEM M, 1983, P NATL ACAD SCI-BIOL, V80, P4659, DOI 10.1073/pnas.80.15.4659; ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P431, DOI 10.1111/j.1432-1033.1976.tb10358.x; BENZ I, 1990, EUR J BIOCHEM, V189, P267, DOI 10.1111/j.1432-1033.1990.tb15486.x; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CLEWELL DB, 1993, BACTERIAL CONJUGATIO, P23; DILAURENZIO L, 1992, MOL MICROBIOL, V6, P2951; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; EVERETT R, 1980, J MOL BIOL, V136, P129, DOI 10.1016/0022-2836(80)90309-5; EVERETT R, 1982, EMBO J, V1, P747, DOI 10.1002/j.1460-2075.1982.tb01241.x; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; FU YHF, 1991, J BACTERIOL, V173, P1012, DOI 10.1128/jb.173.3.1012-1020.1991; GAMAS P, 1987, MOL GEN GENET, V207, P302, DOI 10.1007/BF00331593; GAO Q, 1994, MOL MICROBIOL, V11, P449, DOI 10.1111/j.1365-2958.1994.tb00326.x; INAMOTO S, 1994, J BIOCHEM-TOKYO, V116, P838, DOI 10.1093/oxfordjournals.jbchem.a124604; IPPENIHLER KA, 1986, ANNU REV GENET, V20, P593, DOI 10.1146/annurev.ge.20.120186.003113; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHUE EE, 1990, J BACTERIOL, V172, P1385, DOI 10.1128/jb.172.3.1385-1391.1990; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; LUO Y, 1994, MOL MICROBIOL, V11, P459, DOI 10.1111/j.1365-2958.1994.tb00327.x; MATSON SW, 1991, J BIOL CHEM, V266, P16232; MATSON SW, 1993, J BACTERIOL, V175, P2599, DOI 10.1128/JB.175.9.2599-2606.1993; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; NELSON WC, 1993, J BACTERIOL, V175, P2221, DOI 10.1128/JB.175.8.2221-2228.1993; REYGERS U, 1991, EMBO J, V10, P2689, DOI 10.1002/j.1460-2075.1991.tb07812.x; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SHERMAN JA, 1994, J BIOL CHEM, V269, P26620; TRAXLER BA, 1988, J MOL BIOL, V204, P205, DOI 10.1016/0022-2836(88)90609-2; TSAI MM, 1990, J BACTERIOL, V172, P4603, DOI 10.1128/jb.172.8.4603-4609.1990; WILLETTS N, 1980, ANNU REV GENET, V14, P41, DOI 10.1146/annurev.ge.14.120180.000353	32	81	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28374	28380						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499339				2022-12-27	WOS:A1995TG21000064
J	ADEBAYO, AO; ENYEDI, A; VERMA, AK; FILOTEO, AG; PENNISTON, JT				ADEBAYO, AO; ENYEDI, A; VERMA, AK; FILOTEO, AG; PENNISTON, JT			2 RESIDUES THAT MAY LIGATE CA2+ IN TRANSMEMBRANE DOMAIN 6 OF THE PLASMA-MEMBRANE CA2+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SECRETORY PATHWAY; SARCOPLASMIC-RETICULUM; MOLECULAR-CLONING; CALCIUM-PUMP; FUNCTIONAL CONSEQUENCES; ERYTHROCYTE-MEMBRANE; ATPASE; CA-2+-ATPASE; SEQUENCE; MUTATIONS	In order to identify Ca2+ ligands in the putative transmembrane domain 6 of the plasma membrane Ca2+ pump, amino acids Asn(879), Met(882), Asp(883), and Ser(887) were singly altered, Asn(879), Met(882), and Asp(883) were chosen because the corresponding amino acids have been proposed as Ca2+ ligands in the sarcoplasmic reticulum Ca2+ pump (Clarke, D, M,, Loo, T, W,, and MacLennan, D, H, (1990) J, Biol, Chem, 265, 6262-6267). For the alterations, a fully active truncated version of the pump was used, because the interaction of Ca2+ with the pump could be studied without interference from calmodulin binding, The mutants at Asn and Asp did not carry out ATP-supported Ca2+ uptake and formed no acylphosphate from [gamma-P-32]ATP, suggesting that, like the corresponding amino acids in the sarcoplasmic reticulum Ca2+ pump, these two are Ca2+ ligands, However, all the mutants at the position of Met(882) showed some activity, Indeed, the Met(882) --> Ile mutant was fully active at a saturating Ca2+ concentration and only the K-1/2, for Ca2+ activation was shifted slightly upward, Converting the Met to Thr (which is the corresponding residue in the sarcoplasmic reticulum Ca2+ pump) reduced the activity to 20% of the wild type, further emphasizing the differences between the two Ca2+ pumps, The mutant Ser(887) --> Ala was expressed in greater amounts than, and had a specific activity about 50% higher than, the wild type, indicating that this serine also could not be a Ca2+ ligand and could not replace the missing Thr at position Met(882).	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic			Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28835] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1986, P NATL ACAD SCI USA, V86, P1234; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CHIESI M, 1984, BIOCHEMISTRY-US, V23, P2595, DOI 10.1021/bi00307a009; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; HAO LN, 1994, J BIOL CHEM, V269, P14268; HARPER JF, 1989, P NATL ACAD SCI USA, V86, P1234, DOI 10.1073/pnas.86.4.1234; HUANG LQ, 1993, P NATL ACAD SCI USA, V90, P10066, DOI 10.1073/pnas.90.21.10066; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; KYTE J, 1995, STRUCTURE PROTEIN CH, P248; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NIGGLI V, 1981, J BIOL CHEM, V256, P395; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; VERMA AK, 1994, J BIOL CHEM, V269, P1687	24	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27812	27816		10.1074/jbc.270.46.27812	http://dx.doi.org/10.1074/jbc.270.46.27812			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499251	hybrid			2022-12-27	WOS:A1995TE73600062
J	KUNO, K; ISHIKAWA, Y; ERNST, MK; OGATA, M; RICE, NR; MUKAIDA, N; MATSUSHIMA, K				KUNO, K; ISHIKAWA, Y; ERNST, MK; OGATA, M; RICE, NR; MUKAIDA, N; MATSUSHIMA, K			IDENTIFICATION OF AN I-KAPPA-B-ALPHA-ASSOCIATED PROTEIN-KINASE IN A HUMAN MONOCYTIC CELL-LINE AND DETERMINATION OF ITS PHOSPHORYLATION SITES ON I-KAPPA-B-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR; ACTIVATION; PRECURSOR; P105; MACROPHAGES; INVITRO; P50	Nuclear factor kappa B (NF-kappa B) is stored in the cytoplasm as an inactive form through interaction with I kappa B, Stimulation of cells leads to a rapid phosphorylation of I kappa B alpha, which is presumed to be important for the subsequent degradation, We have recently reported the establishment of a lipopolysaccharide (LPS)-dependent cell free activation system of NF-kappa B in association with the induction of I kappa B alpha phosphorylation, In this study, we have identified a kinase in cell extracts from the LPS stimulated human monocytic cell line, THP-1, that specifically binds and phosphorylates I kappa B alpha. LPS stimulation transiently enhanced the I kappa B alpha-bound kinase activity in THP-1 cells, Mutational analyses of I kappa B alpha and competition experiments with the synthetic peptides identified major phosphorylation sites by the bound kinase as Ser and Thr residues in the C-terminal acidic domain of I kappa B alpha, Moreover, we show that the peptide, corresponding to the C-terminal acidic domain of I kappa B alpha, blocked the LPS induced NF-kappa B activation as well as inducible phosphorylation of endogenous I kappa B alpha in a cell-free system using THP-1 cells. These results suggested that the bound kinase is involved in the signaling pathway of LPS by inducing the phosphorylation of the C terminal region of I kappa B alpha and subsequent dissociation of the NF-kappa B . I kappa B alpha complex.	KANAZAWA UNIV,CANC RES INST,DEPT PHARMACOL,KANAZAWA,ISHIKAWA 920,JAPAN; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MOLEC VIROL & CARCINOGENESIS LAB,FREDERICK,MD 21702	Kanazawa University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			KUNO, Kouji/D-8439-2015; Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1994, MOL CELL BIOL, V13, P3301; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; COOPER JA, 1982, METHOD ENZYMOL, V99, P387; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; ERNST MK, 1995, MOL CELL BIOL, V15, P872; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; GENG Y, 1993, J IMMUNOL, V151, P6692; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOHMANN HP, 1991, MOL CELL BIOL, V11, P2315, DOI 10.1128/MCB.11.4.2315; ISHIKAWA Y, 1995, J BIOL CHEM, V270, P4158, DOI 10.1074/jbc.270.8.4158; KERR JD, 1991, GENE DEV, V5, P1464; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Leonardo MJ, 1998, CELL, V58, P227; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MUKAIDA N, 1991, J BIOL CHEM, V265, P21128; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; NAUMANN M, 1994, EMBO J, V13, P4595; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955	41	13	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27914	27919		10.1074/jbc.270.46.27914	http://dx.doi.org/10.1074/jbc.270.46.27914			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499266	hybrid			2022-12-27	WOS:A1995TE73600077
J	MCDOWALL, KJ; LINCHAO, S; COHEN, SN				MCDOWALL, KJ; LINCHAO, S; COHEN, SN			A+U CONTENT RATHER THAN A PARTICULAR NUCLEOTIDE ORDER DETERMINES THE SPECIFICITY OF RNASE E-CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; RIBONUCLEASE-E; RIBOSOMAL-RNA; PLASMID DNA; ENDONUCLEOLYTIC CLEAVAGE; STRUCTURAL-ANALYSIS; GROWTH-RATE; REPLICATION; GENE	Ribonuclease E has a central role in Escherichia coli mRNA decay and is dependent on a functional product of the me (also called ams or hmp1) gene. We investigated the requirements for RNase E cleavage by introducing random mutations into the decanucleotide region at the 5' end of pACYC184 RNA I and studying the effects of these mutations on the position of rne-dependent cleavage in vivo and RNase E-mediated cutting in vitro. We find that the precise point of RNase E cleavage can be altered specifically and reproducibly by sequence changes in the region cleaved and, therefore, is not determined by a distance measured in nucleotides from any other sequence or region of secondary structure in RNA I. Although cleavage by RNase E occurs within sequences rich in A and/or U nucleotides and is affected by the extent of continuity of A and U nucleotides in the regions cleaved, there is no simple relationship between the order of nucleotides and the phosphodiester bond cleaved. Thus, our results are not consistent with either the notion that RNase E cleavages are determined by a simple consensus sequence or the contrary view that RNase E has few primary structural constraints other than a preference for cleaving 5' to an AU dinucleotide.	STANFORD UNIV, MED CTR, SCH MED, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT MED, STANFORD, CA 94305 USA; ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN	Stanford University; Stanford University; Academia Sinica - Taiwan			Lin-Chao, Sue/AAZ-8246-2021; Lin-Chao, Sue/AGI-2030-2022; McDowall, Kenneth/GYA-5735-2022	Lin-Chao, Sue/0000-0002-8415-9304; Lin-Chao, Sue/0000-0002-8415-9304; McDowall, Kenneth/0000-0003-2528-2190	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027241] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27241] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APIRION D, 1978, J BIOL CHEM, V253, P1738; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BIEK DP, 1989, J BACTERIOL, V171, P2066, DOI 10.1128/jb.171.4.2066-2074.1989; BOLIVAR F, 1977, P NATL ACAD SCI USA, V74, P5265, DOI 10.1073/pnas.74.12.5265; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; BRUN YV, 1990, J MOL BIOL, V214, P845, DOI 10.1016/0022-2836(90)90340-R; CESARENI G, 1991, TRENDS GENET, V7, P230, DOI 10.1016/0168-9525(91)90370-6; CHAMBERLIN M, 1983, METHOD ENZYMOL, V101, P540; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHAUHAN AK, 1991, MOL GEN GENET, V228, P49, DOI 10.1007/BF00282446; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; DAVISON J, 1984, GENE, V28, P1, DOI 10.1016/0378-1119(84)90082-9; DOOLEY TP, 1985, J MOL BIOL, V186, P87, DOI 10.1016/0022-2836(85)90259-1; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; EHRETSMANN CP, 1992, FASEB J, V6, P3186, DOI 10.1096/fasebj.6.13.1397840; GEGENHEIMER P, 1977, J BIOL CHEM, V252, P3064; GEORGELLIS D, 1992, J BACTERIOL, V174, P5382, DOI 10.1128/JB.174.16.5382-5390.1992; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; JAURIN B, 1982, EMBO J, V1, P875, DOI 10.1002/j.1460-2075.1982.tb01263.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUWANO M, 1977, MOL GEN GENET, V154, P279, DOI 10.1007/BF00571283; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; MACKIE GA, 1992, J BIOL CHEM, V267, P1054; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MCDOWALL KJ, 1993, J BACTERIOL, V175, P4245, DOI 10.1128/JB.175.13.4245-4249.1993; MELEFORS O, 1992, CONTROL MRNA STABILI, P53; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; MESSING J, 1983, METHOD ENZYMOL, V101, P20; NER SS, 1989, BIORAD MOL BIOL REP, V7, P1; NILSSON G, 1984, NATURE, V312, P75, DOI 10.1038/312075a0; NORDSTROM K, 1977, PLASMID, V1, P117, DOI 10.1016/0147-619X(77)90013-0; POLISKY B, 1988, CELL, V55, P929, DOI 10.1016/0092-8674(88)90235-8; REGNIER P, 1991, J MOL BIOL, V217, P283, DOI 10.1016/0022-2836(91)90542-E; RESNEKOV O, 1990, P NATL ACAD SCI USA, V87, P8355, DOI 10.1073/pnas.87.21.8355; ROTH JR, 1970, METHODS ENZYMOL    A, V17, P3; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT JR, 1984, MICROBIOL REV, V48, P1; SELZER G, 1983, CELL, V32, P119, DOI 10.1016/0092-8674(83)90502-0; SOM T, 1982, MOL GEN GENET, V187, P375, DOI 10.1007/BF00332615; TAMM J, 1983, NUCLEIC ACIDS RES, V11, P6381, DOI 10.1093/nar/11.18.6381; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P851, DOI 10.1111/j.1365-2958.1991.tb00758.x; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; TOMIZAWA J, 1977, P NATL ACAD SCI USA, V74, P1865, DOI 10.1073/pnas.74.5.1865; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133; ZVEREV VV, 1985, PLASMID, V14, P192, DOI 10.1016/0147-619X(85)90002-2	51	208	208	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10790	10796						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511606				2022-12-27	WOS:A1994NF01700090
J	LOEB, DM; STEPHENS, RM; COPELAND, T; KAPLAN, DR; GREENE, LA				LOEB, DM; STEPHENS, RM; COPELAND, T; KAPLAN, DR; GREENE, LA			A TRK NERVE GROWTH-FACTOR (NGF) RECEPTOR POINT MUTATION AFFECTING INTERACTION WITH PHOSPHOLIPASE C-GAMMA-1 ABOLISHES NGF-PROMOTED PERIPHERIN INDUCTION BUT NOT NEURITE OUTGROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES TYROSINE PHOSPHORYLATION; INTERMEDIATE FILAMENT PROTEIN; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; PROTOONCOGENE PRODUCT; KINASE-ACTIVITY; HIGH-AFFINITY; MONOCLONAL-ANTIBODIES; SIGNALING COMPLEX; C-GAMMA	We analyzed the function of Trk nerve growth factor (NGF) receptors containing a point mutation (Tyr --> Phe) in a major autophosphorylation site (Tyr-785). Tyr-785 is required for phospholipase C-gamma 1 to interact with Trk and to become tyrosine-phosphorylated in response to NGF. The altered receptors were transfected into a mutant subline of PC12 rat pheochromocytoma cells (designated PC12nnr5) that, unlike wild-type PC12 cells, lack expression of endogenous Trk and responsiveness to NGF. PC12nnr5 cells permanently transfected with Trk Y785F exhibit NGF-dependent autophosphorylation and normal NGF binding and internalization. Moreover, Trk Y785F mediates NGF-stimulated neurite outgrowth as well as a variety of additional responses including induction of immediate-early and late genes. However, in contrast to cells expressing wild-type Trk, cells expressing Trk Y785F lack NGF-promoted elevation of peripherin intermediate filament mRNA and protein. These observations indicate that phospholipase C-gamma 1 activation or other signaling pathways dependent on Tyr-785 autophosphorylation are selectively required for regulation of peripherin expression by NGF, but not for many other functional NGF responses. This supports the presence of multiple and separable signaling pathways in the NGF mechanism of action.	COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA; NCI, FREDERICK CANC RES CTR, ADV BIOSCI LABS, BASIC RES PROGRAM, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES CTR,ADV BIOSCI LABS, BASIC RES PROGRAM,PROT STRUCT GRP, FREDERICK, MD 21702 USA	Columbia University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALETTA JM, 1990, FID RES FDN, V3, P203; ALETTA JM, 1988, J NEUROCHEM, V51, P1317, DOI 10.1111/j.1471-4159.1988.tb03104.x; ALETTA JM, 1988, J CELL BIOL, V106, P1573, DOI 10.1083/jcb.106.5.1573; ALTIN JG, 1990, J NEUROCHEM, V54, P1666, DOI 10.1111/j.1471-4159.1990.tb01220.x; BATISTATOU A, 1992, MOL BIOL CELL, V3, P363, DOI 10.1091/mbc.3.3.363; BERND P, 1984, J BIOL CHEM, V259, P5509; BLOOM GS, 1985, P NATL ACAD SCI USA, V82, P5404, DOI 10.1073/pnas.82.16.5404; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUCK CR, 1988, DEV BRAIN RES, V44, P259, DOI 10.1016/0165-3806(88)90224-6; BURSTEIN DE, 1982, DEV BIOL, V94, P477, DOI 10.1016/0012-1606(82)90364-5; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; EAGER KB, 1991, ONCOGENE, V6, P819; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GREEN SH, 1986, J BIOL CHEM, V261, P5316; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1981, J BIOL CHEM, V256, P6363; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GREENE LA, 1991, CULTURING NERVE CELL, P207; HARI J, 1987, J BIOL CHEM, V262, P15341; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KUJUBU DA, 1987, ONCOGENE, V1, P257; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEONARD DGB, 1988, J CELL BIOL, V106, P181, DOI 10.1083/jcb.106.1.181; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LEVI A, 1991, ANNU REV PHARMACOL, V31, P205; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LOEB DM, 1993, J NEUROSCI, V13, P2919; MACHIDA CM, 1991, J CELL BIOL, V114, P1037, DOI 10.1083/jcb.114.5.1037; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P215, DOI 10.1159/000112348; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; SUH PG, 1988, J BIOL CHEM, V263, P14497; Summers MD, 1987, MANUAL METHODS BACUL; THOMPSON MA, 1992, MOL CELL BIOL, V117, P1085; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROY CM, 1992, J CELL BIOL, V117, P1085, DOI 10.1083/jcb.117.5.1085; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650	71	121	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8901	8910						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510697				2022-12-27	WOS:A1994NB41100044
J	MELILLO, G; COX, GW; BIRAGYN, A; SHEFFLER, LA; VARESIO, L				MELILLO, G; COX, GW; BIRAGYN, A; SHEFFLER, LA; VARESIO, L			REGULATION OF NITRIC-OXIDE SYNTHASE MESSENGER-RNA EXPRESSION BY INTERFERON-GAMMA AND PICOLINIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MURINE PERITONEAL-MACROPHAGES; HUMAN-CELLS INVITRO; IFN-GAMMA; L-ARGININE; EFFECTOR MECHANISM; HUMAN-MONOCYTES; FACTOR-ALPHA; INDOLEAMINE 2,3-DIOXYGENASE; TRYPTOPHAN DEGRADATION	Picolinic acid, a catabolite of L-tryptophan, is a potent co-stimulatory agent for the induction of tumoricidal activity and the production of L-arginine-dependent reactive nitrogen intermediates (RNI) in murine macrophages. We studied whether picolinic acid could affect nitric-oxide synthase (NOS) expression at the gene level in the macrophage cell line ANA-1. NOS mRNA was neither constitutively expressed nor induced by treatment with picolinic acid alone. However, low levels of NOS mRNA were induced by interferon (IFN)-gamma alone. In contrast, a major increase of NOS mRNA expression was observed after treatment with IFN-gamma plus picolinic acid. The synergism was already detectable after 5-6 h and increased up to 20 h of treatment. The ability of picolinic acid to augment IFN-gamma-dependent NOS mRNA expression was associated with a parallel increase in transcription, as demonstrated by nuclear run-on experiments. Protein synthesis was required for the induction of NOS mRNA because addition of cycloheximide dramatically reduced IFN-gamma plus picolinic acid-induced NOS mRNA expression. Finally, interleukin-4 significantly decreased IFN-gamma plus picolinic acid-induced NOS mRNA expression and NOS transcription. These data provide evidence of a molecular event connecting arginine and tryptophan metabolic pathways in the generation of RNI, and they indicate that picolinic acid can induce transcriptional activation of gene expression.	NCI, FREDERICK CANC RES & DEV CTR, DIV CANC TREATMENT, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	MELILLO, G (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, DIV CANC TREATMENT, BRMP, EXPTL IMMUNOL LAB, FREDERICK, MD 21702 USA.		varesio, luigi/J-8261-2016	varesio, luigi/0000-0001-5659-2218				AUSUBAL FM, 1989, CURRENT PROTOCOLS MO; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BLASI E, 1988, J IMMUNOL, V141, P2153; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BROWN RR, 1989, CANCER RES, V49, P4941; BYRNE GI, 1986, J INTERFERON RES, V6, P389, DOI 10.1089/jir.1986.6.389; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COX GW, 1992, J IMMUNOL, V149, P3290; COX GW, 1991, J IMMUNOL, V147, P3809; DENIS M, 1991, J LEUKOCYTE BIOL, V49, P380, DOI 10.1002/jlb.49.4.380; DING A, 1990, J IMMUNOL, V145, P940; DING AH, 1988, J IMMUNOL, V141, P2407; DOKTER WHA, 1993, BLOOD, V81, P337; DONNELLY RP, 1991, J IMMUNOL, V146, P3431; DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018; ESSNER R, 1989, J IMMUNOL, V142, P3857; EVANS GW, 1980, PEDIATR RES, V14, P867; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAUTAM S, 1992, J IMMUNOL, V148, P1725; HART PH, 1989, P NATL ACAD SCI USA, V86, P3803, DOI 10.1073/pnas.86.10.3803; HEYES MP, 1992, FASEB J, V6, P2977, DOI 10.1096/fasebj.6.11.1322853; HIBBS JB, 1992, J CLIN INVEST, V89, P867, DOI 10.1172/JCI115666; HIBBS JB, 1987, J IMMUNOL, V138, P550; HIBBS JB, 1990, INT CONGR SER, V897, P189; HIGUCHI M, 1990, J IMMUNOL, V144, P1425; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; LAHN M, 1989, J IMMUNOL, V143, P3020; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LARNER AC, 1993, J IMMUNOL, V150, P1944; LEUTHAUSER SWC, 1982, J NATL CANCER I, V68, P123; LIEW FY, 1991, EUR J IMMUNOL, V21, P2489, DOI 10.1002/eji.1830211027; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MAZA LM, 1988, CANCER RES, V48, P346; MELILLO G, 1993, J IMMUNOL, V150, P4031; MURRAY HW, 1989, INFECT IMMUN, V57, P845, DOI 10.1128/IAI.57.3.845-849.1989; NARUMI S, 1990, J BIOL CHEM, V265, P7036; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OSIPOVICH OA, 1993, J IMMUNOL, V150, P4958; OZAKI Y, 1988, P NATL ACAD SCI USA, V85, P1242, DOI 10.1073/pnas.85.4.1242; REBELLO T, 1982, AM J CLIN NUTR, V35, P1; RUFFMANN R, 1984, J IMMUNOPHARMACOL, V6, P291, DOI 10.3109/08923978409028605; RUFFMANN R, 1987, DRUG EXP CLIN RES, V13, P607; SESSA WC, 1992, J BIOL CHEM, V267, P15274; STUEHR DJ, 1987, J IMMUNOL, V139, P518; TEVELDE AA, 1990, BLOOD, V76, P1392; VARESIO L, 1990, J IMMUNOL, V145, P4265; VARESIO L, 1992, CURR TOP MICROBIOL, V181, P208; WERNER ER, 1987, BIOL CHEM H-S, V368, P1407, DOI 10.1515/bchm3.1987.368.2.1407; WERNERFELMAYER G, 1989, BIOCHIM BIOPHYS ACTA, V1012, P140, DOI 10.1016/0167-4889(89)90087-6; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YOSHIDA R, 1978, P NATL ACAD SCI USA, V75, P3998, DOI 10.1073/pnas.75.8.3998	53	116	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8128	8133						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510678				2022-12-27	WOS:A1994NB40900047
J	HASEGAWA, H; MA, TH; SKACH, W; MATTHAY, MA; VERKMAN, AS				HASEGAWA, H; MA, TH; SKACH, W; MATTHAY, MA; VERKMAN, AS			MOLECULAR-CLONING OF A MERCURIAL-INSENSITIVE WATER CHANNEL EXPRESSED IN SELECTED WATER-TRANSPORTING TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL CHIP28 PROTEIN; RECONSTITUTION; BRAIN	Two mercurial-inhibitable water-transporting proteins have been identified: CHIP28, an erythrocyte water channel also expressed in kidney tubules and selected extrarenal epithelia, and WCH-CD, a kidney collecting duct water channel. In searching for a protein responsible for the high transcellular water permeability in lung alveolus, we cloned a 32-kDa water channel (mercurial-insensitive water channel (MIWC)) from a rat lung cDNA library with several novel features. Water permeability was strongly increased,in Xenopus oocytes expressing MIWC in a-mercurial-insensitive manner, in contrast to known water channels. By in situ hybridization, MIWC showed an unique distribution in cells that do not express CHIP28, including kidney papillary vasa recta, cells lining ther subarachnoid space and ventricles in brain, the inner nuclear layer in retina, and the conjunctival epithelium. An alternatively spliced form of MIWC with a 165-base pair deletion in the coding sequence was also identified; relative expression of the spliced mRNA was tissue-specific. The MIWC water channel may participate in the urinary concentrating mechanism, the absorption of cerebrospinal fluid, and other physiological processes.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco				Ma, Tonghui/0000-0001-9338-1030	NHLBI NIH HHS [HL42368] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500; DEEN PMT, 1992, BIOCHEM BIOPH RES CO, V188, P1267, DOI 10.1016/0006-291X(92)91368-Z; FOLKESSON HG, 1994, IN PRESS P NATL ACAD; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HASEGAWA H, 1992, SCIENCE, V258, P1477, DOI 10.1126/science.1279809; HASEGAWA H, 1993, AM J PHYSIOL, V264, pC237, DOI 10.1152/ajpcell.1993.264.1.C237; HASEGAWA H, 1994, IN PRESS AM J PHYSL; MA TH, 1994, AM J PHYSIOL, V266, pC189, DOI 10.1152/ajpcell.1994.266.1.C189; MOON C, 1993, J BIOL CHEM, V268, P15772; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; PALLONE TL, 1991, J CLIN INVEST, V87, P12, DOI 10.1172/JCI114960; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; RAO Y, 1990, NATURE, V345, P163, DOI 10.1038/345163a0; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; Verkman AS, 1993, WATER CHANNELS; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359	21	451	487	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5497	5500						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509789				2022-12-27	WOS:A1994MY84000005
J	KUME, T; TSUNEIZUMI, K; WATANABE, T; THOMAS, ML; OISHI, M				KUME, T; TSUNEIZUMI, K; WATANABE, T; THOMAS, ML; OISHI, M			INDUCTION OF SPECIFIC PROTEIN-TYROSINE-PHOSPHATASE TRANSCRIPTS DURING DIFFERENTIATION OF MOUSE ERYTHROLEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ERYTHROID-DIFFERENTIATION; MEL CELLS; INVITRO DIFFERENTIATION; DIMETHYL SULFOXIDE; FRIEND-CELLS; KINASES; CLONING; IDENTIFICATION; INHIBITORS; EXPRESSION	We reported previously that most of the phosphotyrosine-containing cellular proteins were quickly dephosphorylated at the very early stage of erythroid differentiation of mouse erythroleukemia (MEL) cells. These and other experimental results implicated a specific protein tyrosine phosphatase(s) (PTPase(s)) involved in the commitment of the erythroid differentiation. We have investigated the pattern of transcripts of PTPases during MEL cell differentiation and found that while the transcripts of most PTPases were unchanged or undetected in the cells, transcripts for two PTPases (PTP beta 2 and RIP) exhibited distinct patterns of induction at a very early stage of differentiation. Some of the mutant cells defective in differentiation did not show the induction of these PTPase transcripts. We discuss the possible role played by the PTPases in the commitment of MEL cell differentiation.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	KUME, T (corresponding author), UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN.							FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; KAKIZUKA A, 1992, GENE DEV, V6, P578, DOI 10.1101/gad.6.4.578; KANEKO T, 1984, CANCER RES, V44, P1756; KONDO K, 1989, J CELL BIOL, V109, P285, DOI 10.1083/jcb.109.1.285; LEDER A, 1975, CELL, V5, P319, DOI 10.1016/0092-8674(75)90107-5; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; NUDEL U, 1977, CELL, V12, P463, DOI 10.1016/0092-8674(77)90122-2; OISHI M, 1990, MECHANISM DIFFERENTI, V2, P129; REUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862, DOI 10.1073/pnas.73.3.862; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI H, 1987, JPN J CANCER RES, V78, P776; SODHU K, 1990, P NATL ACAD SCI USA, V87, P5139; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; SWARUP G, 1991, FEBS LETT, V280, P65, DOI 10.1016/0014-5793(91)80205-H; TAKAHASHI E, 1975, GANN, V66, P577; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; THOMAS ML, 1993, PROG IMMUNOL, V8, P213; WATANABE T, 1991, CANCER RES, V51, P764; WATANABE T, 1992, EXP CELL RES, V199, P269, DOI 10.1016/0014-4827(92)90434-A; WATANABE T, 1992, J BIOL CHEM, V267, P17116; WATANABE T, 1989, EXP CELL RES, V183, P335, DOI 10.1016/0014-4827(89)90394-7; WATANABE T, 1987, P NATL ACAD SCI USA, V84, P6481, DOI 10.1073/pnas.84.18.6481; WATANABE T, 1992, CELL GROWTH DIFFER, V3, P865; YOSHIDA M, 1987, CANCER RES, V47, P3688	28	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4709	4712						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508927				2022-12-27	WOS:A1994MX57100005
J	XIE, QW; KASHIWABARA, Y; NATHAN, C				XIE, QW; KASHIWABARA, Y; NATHAN, C			ROLE OF TRANSCRIPTION FACTOR NF-KAPPA-B/REL IN INDUCTION OF NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOUSE MACROPHAGES; INHIBITORS; CELLS	The promoter of the murine gene encoding inducible nitric oxide synthase (iNOS) contains an NF-kappa B site beginning 55 base pairs upstream of the TATA box, designated NF-kappa Bd. Reporter constructs containing truncated promoter regions, when transfected into macrophages, revealed that NF-kappa Bd is necessary to confer inducibility by bacterial lipopolysaccharide (LPS). Oligonucleotide probes containing NF-kappa Bd plus the downstream 9 or 47 base pairs bound proteins that rapidly appeared in the nuclei of LPS-treated macrophages. The nuclear proteins bound to both probes in an NF-kappa Bd-dependent manner, but binding was resistant to cycloheximide only for the shorter probe. The proteins binding both probes reacted with antibodies against p50 and c-rel but not RelB; those binding the shorter probe also reacted with anti-RelA (p65). Pyrrolidine dithiocarbamate, which acts as a specific inhibitor of NF-kappa B, blocked both the activation of the NF-kappa Bd-binding proteins and the production of NO in LPS-treated macrophages. Thus, activation of NF-kappa Bd/Rel is critical in the induction of iNOS by LPS. However, additional, newly synthesized proteins contribute to the NF-kappa Bd-dependent transcription factor complex on the iNOS promoter in LPS treated mouse macrophages.			XIE, QW (corresponding author), CORNELL UNIV,COLL MED,DEPT MED,BEATRICE & SAMUEL A SEAVER LAB,BOX 57,1300 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034543, R21AI034543] Funding Source: NIH RePORTER; NIAID NIH HHS [AI/CA 34543] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COLLART MA, 1990, MOL CELL BIOL, V10, P2598; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; DING AH, 1988, J IMMUNOL, V141, P2407; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GRILLI M, 1993, INT REV CYTOL, V143, P1; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; KARUPIAH G, 1993, SCIENCE, V261, P445; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KLEEMANN R, 1993, FEBS LETT, V328, P9, DOI 10.1016/0014-5793(93)80954-S; LANDER HM, 1993, J IMMUNOL, V150, P1509; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; MCCARTNEYFRANCIS N, 1993, J EXP MED, V178, P749, DOI 10.1084/jem.178.2.749; MULSCH A, 1993, FEBS LETT, V321, P215, DOI 10.1016/0014-5793(93)80111-7; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SHERMAN MP, 1993, BIOCHEM BIOPH RES CO, V191, P1301, DOI 10.1006/bbrc.1993.1359; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; THAMOS D, 1992, CELL, V71, P777; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; XIE QW, 1993, T ASSOC AM PHYSICIAN, V106, P1; ZHENG S, 1993, J BIOL CHEM, V268, P17233	27	2039	2092	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4705	4708						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508926				2022-12-27	WOS:A1994MX57100004
J	ZHOU, QG; HAKOMORI, S; KITAMURA, K; IGARASHI, Y				ZHOU, QG; HAKOMORI, S; KITAMURA, K; IGARASHI, Y			G(M3) DIRECTLY INHIBITS TYROSINE PHOSPHORYLATION AND DE-N-ACETYL-G(M3) DIRECTLY ENHANCES SERINE PHOSPHORYLATION OF EPIDERMAL GROWTH-FACTOR RECEPTOR, INDEPENDENTLY OF RECEPTOR-RECEPTOR INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GANGLIOSIDE-MEDIATED MODULATION; CELL-GROWTH; KINASE-ACTIVITY; PROTEIN-KINASE; SIGNAL TRANSDUCTION; PARTIAL-PURIFICATION; CARCINOMA-CELLS; GM3; DIMERIZATION; FIBROBLASTS	G(M3) ganglioside (II3NeuAcLacCer) inhibits epidermal growth factor (EGF)-dependent receptor autophosphorylation and cell growth (Bremer, E. G., Schlessinger, J., and Hakomori, S. (1986) J. Biol. Chem. 261,2434-2440), whereas de-N-acetyl-G(M3) (deNAcG(M3); II3NeuNH2LacCer) promotes these processes (Hanai, N., Dohi, T., Nores, G. A., and Hakomori, S. (1988) J. Biol. Chem. 263, 6296-6301). Receptor-receptor interaction has been proposed as an essential initial mechanism for EGF-dependent activation of EGF receptor kinase (EGF-RK) (Schlessinger, J. (1988) Trends Biochem. Sci. 13,443-447). We studied the effects of G(M3) and deNAcG(M3) on EGF-RK function and EGF-R dimerization, and observed that (i) EGF-dependent in vitro and in vivo (in situ) phosphorylation of A431 cells at both monomeric and dimeric forms of EGF-R was inhibited in a dose-dependent manner by G(M3), but unaffected by GM1. (ii) Quantities of both forms of EGF-R remained constant regardless of addition of various quantities of G(M3) or G(M1), as revealed by blotting with antibodies directed to the C-terminal region of EGF-R, or by cell surface I-125-labeling followed by immunoprecipitation. (iii) DeNaCG(M3) in the absence as well as in the presence of a minimal quantity of detergent significantly enhanced EGF-R phosphorylation, particularly Ser phosphorylation. (iv) DeNAcG(M3) was detected in a large variety of actively growing tumor cells. Findings i and ii above indicate that G(M3) directly inhibits EGF-dependent Tyr phosphorylation but does not affect receptor-receptor interaction. Findings iii and iv suggest that deNAcG(M3) strongly promotes serine phosphorylation (in addition to Tyr phosphorylation) of EGF-R and may function as a second messenger in the process of cell growth stimulation.	UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NCI NIH HHS [CA42505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CHAN KFJ, 1988, J BIOL CHEM, V263, P568; CHAN KFJ, 1987, J BIOL CHEM, V262, P5248; COCHET C, 1988, J BIOL CHEM, V263, P3290; COCHET C, 1984, J BIOL CHEM, V259, P2553; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DOHI T, 1988, CANCER RES, V48, P5680; DOWNWARD J, 1985, GENE EXPRESSION NORM, P237; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; GOLDKORN T, 1991, J BIOL CHEM, V266, P10692; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HAKOMORI SI, 1983, SPHINGOLIPID BIOCH, P1; HANAI N, 1988, J BIOL CHEM, V263, P10915; HANAI N, 1988, J BIOL CHEM, V263, P6296; IWASHITA S, 1984, J BIOL CHEM, V259, P2559; KLENK E, 1960, Z VERDAUUNGS STOFFWE, V20, P180; KREUTTER D, 1987, J BIOL CHEM, V262, P1633; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; NORES GA, 1988, CARBOHYD RES, V179, P393, DOI 10.1016/0008-6215(88)84135-1; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SONG WX, 1991, J BIOL CHEM, V266, P10174; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJI S, 1983, J BIOCHEM-TOKYO, V94, P303, DOI 10.1093/oxfordjournals.jbchem.a134344; TSUJI S, 1988, J BIOCHEM-TOKYO, V104, P493; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; USUKI S, 1988, J BIOL CHEM, V263, P10595; USUKI S, 1988, J BIOL CHEM, V263, P6847; WARREN L, 1959, J BIOL CHEM, V234, P1971; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YATES AJ, 1993, EXP CELL RES, V204, P38, DOI 10.1006/excr.1993.1006	36	114	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1959	1965						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507488				2022-12-27	WOS:A1994MR98800064
J	CLARK, BR; DESHPANDE, SV; SHARMA, SD; NAG, B				CLARK, BR; DESHPANDE, SV; SHARMA, SD; NAG, B			ANTIGEN-SPECIFIC DELETION OF CLONED T-CELLS USING PEPTIDE-TOXIN CONJUGATE COMPLEXED WITH PURIFIED CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; MYELIN BASIC-PROTEIN; MYCOPHENOLIC-ACID; AUTOIMMUNE ENCEPHALOMYELITIS; ACETYLCHOLINE-RECEPTOR; IMMUNE INTERVENTION; RECOGNITION; MOLECULES; LYMPHOCYTES; ADRIAMYCIN	In a previous report, we showed that cloned T cells incubated with soluble, cognate major histocompatibility complex (MHC) II-peptide complex internalized the peptide moiety of the complex. Here, we report antigen-specific deletion of cloned T cells by treatment with soluble, cognate MHC II-(peptide-toxin) complexes. Toxin (doxorubicin or mycophenolic acid) was attached to synthetic AcMBP(1-14)Ala4 peptide, an analog of the natural acetylated NH2-terminal segment, AcMBP(1-14), of rat myelin basic protein (MBP). IA(k)-restricted, AcMBP(1-14)-specific AJ1.2 and 4R3.9 cloned murine T cells were killed by IA(k)-(AcMBP(1-14)Ala4-toxin). No killing resulted from incubating A.J1.2 and 4R3.9 cells with irrelevant MHC II-(peptide-toxin) or treating IE(k)-restricted, pigeon cytochrome c-specific A.E7 cloned murine T cells with IA(k)-(AcMBP(1-14)Ala4-toxin). T cell receptor-mediated T cell uptake of the peptide-toxin moiety of relevant complex was blocked by anti-T cell receptor-alpha/beta antibody and by excess toxin-free complex. LD50 determinations revealed that cognate MHC II-(peptide-toxin) killed T cells much more effectively than did peptide-toxin conjugate alone. Finally, T cell uptake of peptide-toxin and intracellular release of toxin occurred after incubation with relevant MHC II-(peptide-toxin) containing radiolabeled toxin. These findings, which provide the first evidence that cloned T cells can be deleted with soluble, cognate MHC II-(peptide-toxin) complexes, may have significant clinical relevance for antigen-specific therapy of autoimmune or other T cell-mediated diseases.	ANERGEN INC,301 PENOBSCOT DR,REDWOOD CITY,CA 94063									ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ALLEN PM, 1987, IMMUNOL REV, V98, P171, DOI 10.1111/j.1600-065X.1987.tb00524.x; ALLISON AC, 1991, TRANSPL P, V23, P10; Arcamone F, 1972, INT S ADRIAMYCIN SPR, P9, DOI [10.1007/978-3-642-95227-2_2, DOI 10.1007/978-3-642-95227-2_2]; BLATTLER WA, 1985, BIOCHEMISTRY-US, V24, P1517, DOI 10.1021/bi00327a034; BLUM RH, 1974, ANN INTERN MED, V80, P249, DOI 10.7326/0003-4819-80-2-249; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; BUUS S, 1987, IMMUNOL REV, V98, P115, DOI 10.1111/j.1600-065X.1987.tb00522.x; CALENDI E, 1965, BIOCHIM BIOPHYS ACTA, V103, P25, DOI 10.1016/0005-2787(65)90539-3; DAVIS CB, 1989, J IMMUNOL, V143, P2083; DIMARCO A, 1975, CANCER CHEMOTH REP 3, V6, P91; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EUGUI EM, 1991, SCAND J IMMUNOL, V33, P175, DOI 10.1111/j.1365-3083.1991.tb03747.x; HAUGHTON G, 1986, IMMUNOL REV, V93, P35, DOI 10.1111/j.1600-065X.1986.tb01501.x; HECHT TT, 1983, J IMMUNOL, V131, P1049; KILLEN JA, 1984, J IMMUNOL, V133, P2549; KIM KJ, 1979, J IMMUNOL, V122, P549; MORRIS RE, 1990, TRANSPLANT P, V22, P1659; NAG B, 1993, J BIOL CHEM, V268, P14360; NAG B, 1991, J IMMUNOL METHODS, V142, P105, DOI 10.1016/0022-1759(91)90297-S; NAG B, 1992, J IMMUNOL, V148, P369; OKSENBERG JR, 1990, CURR OPIN IMMUNOL, V2, P619, DOI 10.1016/0952-7915(90)90021-8; OLSBERG CA, 1985, J IMMUNOL, V135, P3062; PURI J, 1980, EUR J IMMUNOL, V10, P273, DOI 10.1002/eji.1830100410; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SHEN WC, 1981, BIOCHEM BIOPH RES CO, V102, P1048, DOI 10.1016/0006-291X(81)91644-2; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; TRITTON TR, 1982, SCIENCE, V217, P248, DOI 10.1126/science.7089561; URBATSCH IL, 1993, EUR J IMMUNOL, V23, P776, DOI 10.1002/eji.1830230332; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; WRAITH DC, 1989, CELL, V57, P709, DOI 10.1016/0092-8674(89)90786-1; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	34	9	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					94	99						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506264				2022-12-27	WOS:A1994MR21900022
J	OH, Y; MULLER, HL; PHAM, H; ROSENFELD, RG				OH, Y; MULLER, HL; PHAM, H; ROSENFELD, RG			DEMONSTRATION OF RECEPTORS FOR INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-3 ON HS578T HUMAN BREAST-CANCER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IGF-I; MOLECULAR-CLONING; FIBROBLASTS; IDENTIFICATION; MECHANISMS; SEQUENCE; SERUM	Hs578T human breast cancer cells are from an estrogen receptor-negative breast cell line derived from a highly aggressive mammary tumor. Our previous insulin-like growth factor binding protein-3 (IGFBP-3) binding studies (Oh, Y., Muller, H. L., Lamson, G., and Rosenfeld, R. G. (1993) J. Biol. Chem. 268, 14964-14971) have demonstrated specific binding of IGFBP-3 on the Hs578T cell surface and a significant inhibitory effect of IGFBP-3, itself, on monolayer growth. In this study, we have demonstrated cell surface association proteins that are specific for IGFBP-3 by showing: 1) detection of 20-, 26-, and 50-kDa proteins by affinity cross-linking with I-125-IGFBP-3E. coli and immunoprecipitation of cell monolayers and cell lysates with anti-IGFBP-3 antibodies; 2) dose-dependent competition of I-125-IGFBP-3E. coli by unlabeled IGFBP-3E. coli; 3) inhibition of IGFBP-3 binding to these cell surface proteins by EDTA and by coincubation with native insulin-like growth factor II (IGF-II), but not by coincubation with [Gln6,Ala7,Tyr18, Leu19,Leu27]IGF-II, an IGF-II analog with decreased affinity for IGFBP-3; and 4) partial purification of 20- and 26-kDa species by IGFBP-3-anti-IGFBP-3 antibody immunoaffinity membranes. Characteristics of these specific IGFBP-3 cell surface association proteins are identical to those observed in our previous monolayer binding assay and monolayer growth assay experiments. The specificity of binding and the inhibitory effect of IGFBP-3 binding on Hs578T cell growth suggest that these cell surface proteins are IGFFBP-3-specific receptors or receptor subunits mediating the direct inhibitory effect of IGFBP-3 on monolayer growth of Hs578T cells.			OH, Y (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PEDIAT,DIV PEDIAT ENDOCRINOL,RM S306,STANFORD,CA 94305, USA.		müller, Hermann l/AAC-1637-2020	Muller, Hermann L./0000-0003-4929-9966	NCI NIH HHS [CA58110] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058110] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BEUKERS MW, 1991, ENDOCRINOLOGY, V128, P1201, DOI 10.1210/endo-128-2-1201; BINKERT C, 1989, EMBO J, V8, P2497, DOI 10.1002/j.1460-2075.1989.tb08386.x; BINOUX M, 1988, J CLIN ENDOCR METAB, V67, P509, DOI 10.1210/jcem-67-3-509; BRINKMAN A, 1988, EMBO J, V7, P2417, DOI 10.1002/j.1460-2075.1988.tb03087.x; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; CONOVER CA, 1990, ENDOCRINOLOGY, V126, P3139, DOI 10.1210/endo-126-6-3139; De Leon DD, 1992, GROWTH FACTORS, V6, P327, DOI 10.3109/08977199209021544; DELBE J, 1991, BIOCHEM BIOPH RES CO, V179, P495, DOI 10.1016/0006-291X(91)91398-V; FURLANETTO RW, 1984, CANCER RES, V44, P2122; GARGOSKY SE, 1992, ENDOCRINOLOGY, V131, P3041; HUFF KK, 1988, MOL ENDOCRINOL, V2, P200, DOI 10.1210/mend-2-3-200; LATOUR D, 1990, MOL ENDOCRINOL, V4, P1806, DOI 10.1210/mend-4-12-1806; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; OH Y, 1992, ENDOCRINOLOGY, V131, P3123, DOI 10.1210/en.131.6.3123; OH Y, 1993, GROWTH REGULAT, V3, P84; OH YM, 1993, J BIOL CHEM, V268, P14964; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7270; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; SMITH EP, 1992, ENDOCRINOLOGY, V131, P2733, DOI 10.1210/en.131.6.2733; Spratt SK, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037503; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1176, DOI 10.1210/mend-2-12-1176	23	291	293	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26045	26048						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	7504671				2022-12-27	WOS:A1993MK42500004
J	YANO, H; NAKANISHI, S; KIMURA, K; HANAI, N; SAITOH, Y; FUKUI, Y; NONOMURA, Y; MATSUDA, Y				YANO, H; NAKANISHI, S; KIMURA, K; HANAI, N; SAITOH, Y; FUKUI, Y; NONOMURA, Y; MATSUDA, Y			INHIBITION OF HISTAMINE-SECRETION BY WORTMANNIN THROUGH THE BLOCKADE OF PHOSPHATIDYLINOSITOL 3-KINASE IN RBL-2H3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; MYOSIN LIGHT CHAIN; PROTEIN-KINASE-C; RECEPTOR TYROSINE KINASES; PHOSPHOLIPASE C-GAMMA-1; SIGNAL TRANSDUCTION; GROWTH-FACTOR; 2H3 CELLS; MEDIATED HISTAMINE; HUMAN NEUTROPHIL	The surface engagement of high affinity immunoglobulin E receptor (FcepsilonRI) of rat basophilic leukemia 2H3 (RBL-2H3) cells induced histamine secretion and leukotriene release following activation of the tyrosine kinase Lyn together with phosphatidylinositol 3-kinase (PI3-kinase). Wortmannin inhibited the activity of partially purified PI3-kinase from calf thymus, as well as the PI3-kinase activity in anti-PI3-kinase p85 immunoprecipitates from RBL-2H3 cells, at a concentration as low as 1.0 nM and with IC50 values of 3.0 nM, but did not inhibit P14-kinase activity. The inhibition of PI3-kinase by wortmannin was irreversible. Wortmannin inhibited both FcepsilonRI-mediated histamine secretion and leukotriene release up to 80% with IC50 values of 2.0 and 3.0 nM, respectively. Wortmannin inhibited PI3-kinase activity in intact cells up to 80% with an IC50 value of 2.0 nM, which is almost equal to those for PI3-kinase in vitro and for histamine secretion and leukotriene release. With anti-wortmannin antibody, we have shown that wortmannin binds to the 110-kDa protein, but not to P13-kinase 85-kDa regulatory subunit both in vitro and in whole cells. Furthermore, there was a positive correlation between the potencies of wortmannin derivatives as inhibitors of P13-kinase and as inhibitors of histamine secretion. Wortmannin had no effect on the activation of the tyrosine kinase Lyn. These results suggest that P13-kinase is involved in the signal transduction pathway responsible for histamine secretion following stimulation of FcepsilonRI and that wortmannin blocks these responses through direct interaction with the catalytic subunit of this enzyme.	KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,3-6-6 ASAHIMACHI,MACHIDA,TOKYO 194,JAPAN; UNIV TOKYO,FAC AGR,DEPT AGR CHEM,BIOCHEM LAB,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT PHARMACOL 1,BUNKYOU KU,TOKYO 113,JAPAN	Kyowa Kirin Ltd; University of Tokyo; University of Tokyo			Fukui, Yasuhisa/E-8806-2010; Kimura, Koutarou D./T-9645-2019	Kimura, Koutarou D./0000-0002-3359-1578				ABBAS HK, 1988, APPL ENVIRON MICROB, V54, P1268, DOI 10.1128/AEM.54.5.1268-1274.1988; ATKINSON TP, 1992, J IMMUNOL, V148, P2194; AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; BEAVEN MA, 1984, J BIOL CHEM, V259, P7137; BONSER RW, 1991, BRIT J PHARMACOL, V103, P1237, DOI 10.1111/j.1476-5381.1991.tb12330.x; BRAIN PW, 1957, T BR MYCOL SOC, V40, P365; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CREWS FT, 1980, BIOCHEM BIOPH RES CO, V93, P42, DOI 10.1016/S0006-291X(80)80243-9; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; DEWALD B, 1988, J BIOL CHEM, V263, P16179; EISEMAN E, 1992, NATURE, V355, P78; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FUKUI Y, 1991, ONCOGENE, V6, P407; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GOLD MR, 1992, J IMMUNOL, V148, P2012; GUNTHER R, 1989, IMMUNOPHARM IMMUNOT, V11, P559, DOI 10.3109/08923978909005385; HAEFLIGER W, 1975, HELV CHIM ACTA, V58, P1620, DOI 10.1002/hlca.19750580616; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P17078; HATTORI Y, 1987, IMMUNOLOGY, V60, P573; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOLGATE ST, 1988, IMMUNOLOGY MED SERIE, P129; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KITANI S, 1992, BIOCHEM BIOPH RES CO, V183, P48, DOI 10.1016/0006-291X(92)91607-R; KNOL EF, 1991, EUR J IMMUNOL, V21, P881, DOI 10.1002/eji.1830210404; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MACMILLAN J, 1972, J CHEM SOC PERK T 1, P2898, DOI 10.1039/p19720002898; MAEYAMA K, 1986, J BIOL CHEM, V261, P2583; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MORITZ A, 1992, METHOD ENZYMOL, V209, P202; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; OHARAIMAIZUMI M, 1992, BIOCHEM BIOPH RES CO, V185, P1016, DOI 10.1016/0006-291X(92)91728-9; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OKADA T, 1992, SEIKAGAKU, V64, P1040; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; OZAWA K, 1993, J BIOL CHEM, V268, P2280; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PARK DJ, 1991, J BIOL CHEM, V266, P24237; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHMITTVERHULST AM, 1978, J EXP MED, V147, P352, DOI 10.1084/jem.147.2.352; SCHNEIDER H, 1992, INT IMMUNOL, V4, P447, DOI 10.1093/intimm/4.4.447; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SEVERINSSON L, 1990, MOL CELL BIOL, V10, P801, DOI 10.1128/MCB.10.2.801; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SIEGEL PD, 1990, ANAL BIOCHEM, V188, P416, DOI 10.1016/0003-2697(90)90629-N; SIEGHART W, 1978, NATURE, V275, P329, DOI 10.1038/275329a0; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TESHIMA R, 1989, MOL IMMUNOL, V26, P641; THOMPSON NT, 1991, TRENDS PHARMACOL SCI, V12, P404, DOI 10.1016/0165-6147(91)90617-2; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WARNER JA, 1987, J IMMUNOL, V139, P161; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WIESINGE.D, 1974, EXPERIENTIA, V30, P135, DOI 10.1007/BF01927691; YAMADA K, 1992, J IMMUNOL, V149, P1031; YAMAKAWA A, 1988, J BIOL CHEM, V263, P17555; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YATOMI Y, 1992, BIOCHEM J, V285, P745, DOI 10.1042/bj2850745; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	77	739	773	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25846	25856						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503989				2022-12-27	WOS:A1993MK10000082
J	HURD, C; KHATTREE, N; ALBAN, P; NAG, K; JHANWAR, SC; DINDA, S; MOUDGIL, VK				HURD, C; KHATTREE, N; ALBAN, P; NAG, K; JHANWAR, SC; DINDA, S; MOUDGIL, VK			HORMONAL-REGULATION OF THE P53 TUMOR-SUPPRESSOR PROTEIN IN T47D HUMAN BREAST-CARCINOMA CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DNA-BINDING; PROGESTERONE RECEPTORS; CANCER-CELLS; PHOSPHORYLATION	Under normal culturing conditions, the T47D human breast cancer cell line expresses progesterone receptor constitutively and is responsive to estrogen. Because the tumor suppressor protein p53 plays a central role in determining genetic stability and cell proliferation, we have examined the effects of 17 beta-estradiol, the synthetic progestin R5020, and the antiprogestin RU486 on the levels of this protein in T47D cells. Western blot analysis of cellular extracts, performed with a monoclonal antibody capable of quantitatively supershifting a specific p53-p53 response element complex in a gel mobility shift assay, detected a single immunoreactive band representing p53. When cells were grown for 4-5 days in culture medium containing charcoal-treated fetal calf serum, p53 levels declined to 10% of the level seen in the control (no charcoal treatment) group. Supplementation of culture medium containing charcoal-treated calf serum with 0.1-1 nM 17 beta-estradiol restored p53 to its normal levels. A 4-day treatment of cells with R5020 or RU486 lowered the p53 levels in cells grown in normal culturing conditions to 15 and 30% of control levels, respectively. R5020 and RU486 treatments also caused down regulation and/or hyperphosphorylation of the progesterone receptor, which correlated with the down regulation of p53. These observations indicate that in T47D cells, p53 is up-regulated by estradiol while R5020 down-regulates this protein. Since estradiol is known to promote cell proliferation, the induction of p53 observed in this study leads us to propose that estradiol stimulates p53 to regulate proliferation of T47D cells in culture.	OAKLAND UNIV,DEPT BIOL SCI,ROCHESTER,MI 48309; OAKLAND UNIV,INST BIOCHEM & BIOTECHNOL,ROCHESTER,MI 48309; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021	Oakland University; Oakland University; Memorial Sloan Kettering Cancer Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020893] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-20893] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; BANERJEE PP, 1995, P ANN M ENDOCRINE SO; BARTEK J, 1991, ONCOGENE, V6, P1699; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELASHRYSTOWERS D, 1988, CANCER RES, V48, P6662; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; GRONEMEYER H, 1992, J STEROID BIOCHEM, V41, P217, DOI 10.1016/0960-0760(92)90347-L; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HORWITZ KB, 1986, J STEROID BIOCHEM, V25, P911, DOI 10.1016/0022-4731(86)90323-7; HORWITZ KB, 1994, J STEROID BIOCHEM, V49, P295, DOI 10.1016/0960-0760(94)90271-2; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IWASAKI K, 1994, MAY P AM SOC BIOCH M; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KODALI S, 1994, BIOCHEM BIOPH RES CO, V202, P1413, DOI 10.1006/bbrc.1994.2088; MCGUIRE WL, 1978, SEMIN ONCOL, V5, P428; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REIHSAUS E, 1990, ONCOGENE, V5, P137; SCHUCHARD M, 1993, ENDOCR REV, V14, P659, DOI 10.1210/er.14.6.659; TAKIMOTO GS, 1992, P NATL ACAD SCI USA, V89, P3050, DOI 10.1073/pnas.89.7.3050; WEI LL, 1988, MOL ENDOCRINOL, V2, P62, DOI 10.1210/mend-2-1-62; ZAVA DT, 1978, ENDOCRINOLOGY, V103, P624, DOI 10.1210/endo-103-2-624	28	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28507	28510		10.1074/jbc.270.48.28507	http://dx.doi.org/10.1074/jbc.270.48.28507			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499360	hybrid			2022-12-27	WOS:A1995TH05600004
J	MORI, S; SATOH, T; KOIDE, H; NAKAFUKU, M; VILLAFRANCA, E; KAZIRO, Y				MORI, S; SATOH, T; KOIDE, H; NAKAFUKU, M; VILLAFRANCA, E; KAZIRO, Y			INHIBITION OF RAS/RAF INTERACTION BY ANTI-ONCOGENIC MUTANTS OF NEUROFIBROMIN, THE NEUROFIBROMATOSIS TYPE-1 (NF1) GENE-PRODUCT, IN CELL-FREE SYSTEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GAP-RELATED DOMAIN; SACCHAROMYCES-CEREVISIAE; RAS GTPASE; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; KINASE KINASE; CDNA CLONING; HA-RAS; EXPRESSION; ENCODES	The neurofibromatosis type 1 (NF1) gene encodes a protein, neurofibromin, containing GTPase-activating protein-related domain (GRD) that stimulates intrinsic GTPase activity of Ras protein, By screening a randomly mutagenized NF1-GRD library in Saccharomyces cerevisiae, we isolated two NF1-GRD mutants (NF201 and NF204) with single amino acid substitutions, which suppress the heat shock sensitive phenotype of the RAS2(G19V) mutant. The NF1-GRD mutants also suppress the oncogenic Res-induced transformation of NIH 3T3 mouse fibroblasts (Nakafuku, M., Nagamine, M., Ohtoshi, A., Tanaka, K., Toh-e, A., and Kaziro, Y. (1993) Proc. Natl. Acad, Sci. U. S. A. 90, 6706-6710), In this paper, we investigated the molecular mechanism of inhibition of the transforming Ras-specific function by the NF1-GRD mutants in mammalian cells. In human embryonic kidney (HEK) 293 cells, the mutant NF1-GRDs attenuated the stimulation of mitogen-activated protein kinase by Ras(G12V), but not by platelet-derived growth factor. In cell-free systems, purified recombinant NF1-GRD mutants showed ale inhibitory effect on the association of Ras . guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) with Raf at several times lower concentrations than the wild type. Furthermore, it was revealed that the binding affinity of the mutant NF1-GRDs toward Ras . GTP gamma S is approximately 5-10 times higher than the wild type. These results suggest that the mutant NF1-GRDs tightly bind to an oncogenic Res in its GTP-bound active conformation and block the interaction between Ras and its effector, Raf.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN; INST ADV SCI & TECHNOL,NARA 63001,JAPAN; AGOURON PHARMACEUT INC,SAN DIEGO,CA 92121	Tokyo Institute of Technology; Pfizer			Koide, Hiroshi/E-9000-2011; Satoh, Takaya/K-2628-2014; Nakafuku, Masato/J-3068-2013	Nakafuku, Masato/0000-0001-7783-9005; Mori, Sadao/0000-0003-4723-726X; Koide, Hiroshi/0000-0001-5916-3179				ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; FRIDMAN M, 1994, J BIOL CHEM, V269, P30105; GOTOH Y, 1994, ONCOGENE, V9, P1891; GUTMANN DH, 1992, ANN NEUROL, V31, P555, DOI 10.1002/ana.410310515; GUTMANN DH, 1993, ONCOGENE, V8, P761; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; LI Y, 1992, CELL, V69, P215; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MIURA K, 1986, JPN J CANCER RES, V77, P45; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKAFUKU M, 1993, P NATL ACAD SCI USA, V90, P6706, DOI 10.1073/pnas.90.14.6706; NISHI T, 1991, ONCOGENE, V6, P1555; NURKEKAMAL MSA, 1993, J BIOL CHEM, V268, P22331; POULLET P, 1994, MOL CELL BIOL, V14, P815, DOI 10.1128/MCB.14.1.815; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P27; SATOH T, 1988, BIOCHIM BIOPHYS ACTA, V949, P97, DOI 10.1016/0167-4781(88)90059-0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; White R, 1991, Curr Opin Neurobiol, V1, P462, DOI 10.1016/0959-4388(91)90070-N; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	48	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28834	28838		10.1074/jbc.270.48.28834	http://dx.doi.org/10.1074/jbc.270.48.28834			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499408	hybrid			2022-12-27	WOS:A1995TH05600052
J	PATRIE, KM; KUDLA, AJ; OLWIN, BB; CHIU, IM				PATRIE, KM; KUDLA, AJ; OLWIN, BB; CHIU, IM			CONSERVATION OF LIGAND SPECIFICITY BETWEEN THE MAMMALIAN AND AMPHIBIAN FIBROBLAST GROWTH-FACTOR RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR FGF RECEPTOR; SIGNAL-TRANSDUCTION; DEVELOPMENTAL EXPRESSION; TERMINAL DIFFERENTIATION; BINDING SPECIFICITY; LIMB REGENERATION; MESSENGER-RNA; GENE; FAMILY; MOUSE	We have previously cloned and sequenced a newt keratinocyte growth factor receptor (KGFR) cDNA which exhibited a unique spatial and temporal expression pattern in the regenerating newt limb. In this report, we further characterize the biochemical and functional properties of this newt KGFR. A stable Chinese hamster ovary transfectant overexpressing the newt KGFR was capable of binding both I-125-fibroblast growth factor-1 (FGF-1) and I-125-FGF-7 but not I-125-FGF-2, indistinguishable from the human KGFR. Scatchard analysis and cross-linking studies further support the conclusion that FGF-1 and FGF-7 are the ligands for the newt KGFR. In addition to their ability to bind to FGFs, both the human and the newt KGFR are also capable of repressing differentiation in mouse MM14 myoblasts. MM14 cells express FGFR1 and are repressed from differentiation by FGF-1, FGF-2, and FGF-4 but not FGF-7. Co-transfection of MM14 cells with either a human or newt KGFR expression construct conferred a response to FGF-7 as determined by a human alpha-cardiac actin/ luciferase reporter construct. The response to FGF-7 was similar to the endogenous FGF response as FGF-7 prevented MM14 myoblasts from undergoing terminal differentiation. Thus, both the human and the newt KGFRs transduce signals similar to those transduced via the endogenous mouse FGFR1. Together these data indicate that this newly isolated newt KGFR is a functional receptor as it binds two FGF family members with high affinity and mediates signaling in skeletal muscle myoblasts. Because the binding pattern of the newt KGFR is similar to the pattern observed for its mammalian counterpart, it emphasizes the strict conservation that this ligand/receptor system has undergone through evolution.	OHIO STATE UNIV, DAVIS MED RES CTR, MOLEC CELLULAR & DEV BIOL PROGRAM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DAVIS MED RES CTR, DEPT INTERNAL MED, COLUMBUS, OH 43210 USA; PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA; WALTHER CANC INST, INDIANAPOLIS, IN 46208 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Walther Cancer Institute			Chiu, Ing-Ming/B-1534-2008; Olwin, Bradley B/A-1333-2014		NATIONAL CANCER INSTITUTE [R01CA045611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047506] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA45611] Funding Source: Medline; NIAMS NIH HHS [R01AR39467] Funding Source: Medline; NIDDK NIH HHS [R01DK47506] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOILLY B, 1991, DEV BIOL, V145, P302, DOI 10.1016/0012-1606(91)90128-P; CASTILLA M, 1992, MG DEVEL B, V23, P116; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIU IM, 1989, TROPHIC FACTORS NERV, P57; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; CLEMENTS DA, 1993, ONCOGENE, V8, P1311; CRUMLEY G, 1991, ONCOGENE, V6, P2255; DELL KR, 1992, J BIOL CHEM, V267, P21225; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; Gospodarowicz D, 1980, Ann N Y Acad Sci, V339, P151, DOI 10.1111/j.1749-6632.1980.tb15976.x; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LINKHART TA, 1980, J SUPRAMOL STR CELL, V14, P483, DOI 10.1002/jss.400140407; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; NISWANDER L, 1992, DEVELOPMENT, V114, P755; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; ONDA H, 1991, DEV BIOL, V148, P219, DOI 10.1016/0012-1606(91)90331-V; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; PETERS KG, 1992, DEVELOPMENT, V114, P233; POULIN ML, 1994, BBA-MOL CELL RES, V1220, P209, DOI 10.1016/0167-4889(94)90137-6; POULIN ML, 1993, DEVELOPMENT, V119, P353; POULIN ML, 1995, DEV DYNAM, V202, P378, DOI 10.1002/aja.1002020407; RAPRAEGER AC, 1994, METHOD ENZYMOL, V245, P219; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; Sambrook J, 1989, MOL CLONING LABORATO; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; Singer M., 1961, GROWTH LIVING SYSTEM, P277; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANNAHILL D, 1992, DEVELOPMENT, V115, P695; TASSAVA RA, 1986, J EXP ZOOL, V239, P229, DOI 10.1002/jez.1402390210; TEMPLETON TJ, 1992, DEV BIOL, V154, P169, DOI 10.1016/0012-1606(92)90057-N; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WHIMAN M, 1989, ANN REV CELL BIOL, V5, P93	56	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					29018	29024		10.1074/jbc.270.48.29018	http://dx.doi.org/10.1074/jbc.270.48.29018			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499435	hybrid			2022-12-27	WOS:A1995TH05600079
J	WEISKIRCHEN, R; PINO, JD; MACALMA, T; BISTER, K; BECKERLE, MC				WEISKIRCHEN, R; PINO, JD; MACALMA, T; BISTER, K; BECKERLE, MC			THE CYSTEINE-RICH PROTEIN FAMILY OF HIGHLY RELATED LIM-DOMAIN PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER MOTIF; C-MYC; TRANSGENIC MICE; GROWTH-FACTOR; INSULIN GENE; SEQUENCE; FIBROBLASTS; LEUKEMIA; CLONING; MEMBER	Here we describe a family of closely related LIM do main proteins in avian cells, The LlM motif defines a zinc binding domain that is found in a variety of transcriptional regulators, proto-oncogene products, and proteins associated with sites of cell substratum con tact, One type of LIM-domain protein, called the cysteine-rich protein (CRP), is characterized by the presence of two LIM domains linked to short glycine-rich repeats and a potential nuclear localization signal, We have identified and characterized two evolutionarily conserved members of the CRP family, CRP1 and CRP2, in chicken and quail, Expression of the genes encoding both CRP1 and CRP2 is differentially regulated in normal versus transformed cells, raising the possibility that members of the CRP family may function in control of cell growth and differentiation.	UNIV INNSBRUCK, INST BIOCHEM, A-6020 INNSBRUCK, AUSTRIA; UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA	University of Innsbruck; Utah System of Higher Education; University of Utah			Bister, Klaus/AFA-9400-2022; Weiskirchen, Ralf/O-1734-2018	Weiskirchen, Ralf/0000-0003-3888-0931; Bister, Klaus/0000-0001-6545-5653	NCI NIH HHS [CA 42014] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; ARCHER VEV, 1994, P NATL ACAD SCI USA, V91, P316, DOI 10.1073/pnas.91.1.316; BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FISCH P, 1992, ONCOGENE, V7, P2389; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARTL M, 1995, VIROLOGY, V207, P321, DOI 10.1006/viro.1995.1086; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; JANSEN HW, 1983, J VIROL, V48, P61, DOI 10.1128/JVI.48.1.61-73.1983; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; MIZUNO K, 1994, ONCOGENE, V9, P1605; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; OKANO I, 1993, FEBS LETT, V333, P51, DOI 10.1016/0014-5793(93)80373-3; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SCHUURMAN R, 1991, BIOTECHNIQUES, V10, P185; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WANG XK, 1992, GENOMICS, V14, P391, DOI 10.1016/S0888-7543(05)80231-9; WANG XK, 1992, J BIOL CHEM, V267, P9176; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEISKIRCHEN R, 1993, GENE, V128, P269, DOI 10.1016/0378-1119(93)90573-L; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; WU RY, 1994, J BIOL CHEM, V269, P25085	49	101	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28946	28954		10.1074/jbc.270.48.28946	http://dx.doi.org/10.1074/jbc.270.48.28946			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499425	hybrid			2022-12-27	WOS:A1995TH05600069
J	ANTONI, FA; BARNARD, RJO; SHIPSTON, MJ; SMITH, SM; SIMPSON, J; PATERSON, JM				ANTONI, FA; BARNARD, RJO; SHIPSTON, MJ; SMITH, SM; SIMPSON, J; PATERSON, JM			CALCINEURIN FEEDBACK INHIBITION OF AGONIST-EVOKED CAMP FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN PHOSPHATASE; ADENYLYL-CYCLASE; CYCLOSPORINE-A; ADRENOCORTICOTROPIN RELEASE; CALCIUM CHANNELS; TUMOR-CELLS; CORTICOTROPIN; EXPRESSION; SECRETION; CLONING	The effects of immunosuppressant blockers of calcineurin (protein phosphatase 2B) on cAMP formation and hormone release were investigated in mouse pituitary tumor (AtT20) cells, Immunosuppressants enhanced corticotropin-releasing factor- and isoproterenol-evoked cAMP production in proportion with their potency to block calcineurin. Further analysis of cAMP production revealed that intracellular Ca2+ derived through voltage-regulated calcium channels reduces cAMP formation induced by corticotropin releasing-factor or beta(2)-adrenergic stimulation and that this effect of Ca2+ is inhibited by blockers of calcineurin. AtT20 cells were found to express at least three species of adenylyl cyclase mRNA-encoding types 1 and 6 as well as a novel isotype, which appeared to be the predominant species. In two cell lines expressing very low or undetectable levels of the novel cyclase mRNA (NCB20 and HEK293 cells respectively), corticotropin-releasing factor-induced cAMP formation was not altered upon blockage of calcineurin activity, These data identify calcineurin as a Ca2+ sensor that mediates the negative feedback effect of intracellular Ca2+ on receptor-stimulated cAMP production. Furthermore, the effect of calcineurin on cAMP synthesis appears to be associated with the expression of a novel adenylyl cyclase isotype, which is highly abundant in AtT20 cells.			ANTONI, FA (corresponding author), UNIV EDINBURGH, DEPT PHARMACOL, MRC, BRAIN METAB UNIT, EDINBURGH EH8 9JZ, MIDLOTHIAN, SCOTLAND.		Shipston, Mike/C-7309-2013; Antoni, Ferenc/AAI-7351-2020	Shipston, Mike/0000-0001-7544-582X; 				ANTONI FA, 1986, ENDOCR REV, V7, P351, DOI 10.1210/edrv-7-4-351; ANTONI FA, 1993, BIOCHEM BIOPH RES CO, V194, P226, DOI 10.1006/bbrc.1993.1808; ANTONI FA, 1992, J ENDOCRINOL, V133, pR13; ANTONI FA, 1994, J PHYSL, V475, P137; ARBUCKLE JB, 1993, J PHYSL, V473, P267; ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P117, DOI 10.1016/0166-2236(89)90168-9; BAUKAL AJ, 1994, J BIOL CHEM, V269, P24546; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BOYAJIAN CL, 1990, CELL CALCIUM, V11, P299, DOI 10.1016/0143-4160(90)90007-H; BROOKER G, 1979, ADV CYCLIC NUCLEOTID, V10, P2; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DEBERNARDI MA, 1993, BIOCHEM J, V293, P325, DOI 10.1042/bj2930325; DUFAU ML, 1973, ENDOCRINOLOGY, V92, P6, DOI 10.1210/endo-92-1-6; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; FLIRI H, 1993, ANTIBIOTICS ANTIVIRA, P229; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GUILD S, 1991, BRIT J PHARMACOL, V109, P117; HEISLER S, 1983, BIOCHEM BIOPH RES CO, V111, P112, DOI 10.1016/S0006-291X(83)80124-7; HELLEVUO K, 1993, BIOCHEM BIOPH RES CO, V192, P311, DOI 10.1006/bbrc.1993.1415; HOUSLAY MD, 1994, GTPASES BIOL, V108, P147; IYENGAR R, 1993, ADV SEC MESS PHOSPH, V28, P27; Klee C.B., 1988, CALMODULIN, P225; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOCH B, 1994, CELL SIGNAL, V6, P467, DOI 10.1016/0898-6568(94)90094-9; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LAI Y, 1993, J NEUROCHEM, V61, P1333, DOI 10.1111/j.1471-4159.1993.tb13626.x; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; LUINI A, 1985, P NATL ACAD SCI USA, V82, P8034, DOI 10.1073/pnas.82.23.8034; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NICHOLS RA, 1994, J BIOL CHEM, V269, P23817; PATERSON JM, 1995, IN PRESS BIOCH BIOPH; PREMONT RT, 1994, METHOD ENZYMOL, V238, P116; PYNE NJ, 1992, BIOCHEM BIOPH RES CO, V186, P1081, DOI 10.1016/0006-291X(92)90857-H; REISINE T, 1987, MOL PHARMACOL, V32, P488; SAEKI T, 1993, J BIOL CHEM, V268, P6077; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SHIPSTON MJ, 1994, ANN NY ACAD SCI, V746, P453; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SIEKIERKA JJ, 1989, J IMMUNOL, V143, P1580; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SLATER RS, 1981, J BIOL CHEM, V256, P9830; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; STRASSHEIM D, 1994, J BIOL CHEM, V269, P14307; TALLANT EA, 1984, ARCH BIOCHEM BIOPHYS, V232, P269, DOI 10.1016/0003-9861(84)90543-5; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; WOODS MD, 1992, ENDOCRINOLOGY, V131, P2873, DOI 10.1210/en.131.6.2873; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YU HJ, 1993, MOL PHARMACOL, V44, P689	52	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28055	28061						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499291				2022-12-27	WOS:A1995TG21000016
J	DIAMANT, S; AZEM, A; WEISS, C; GOLOUBINOFF, P				DIAMANT, S; AZEM, A; WEISS, C; GOLOUBINOFF, P			INCREASED EFFICIENCY OF GROE-ASSISTED PROTEIN-FOLDING BY MANGANESE IONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; HEAT-SHOCK; CHAPERONIN; HYDROLYSIS; ATP	This study addresses the role of ATP-bound and free Mg2+ and Mn2+ ions in the activation and modulation of chaperonin-assisted refolding of urea-denatured malate dehydrogenase. As compared with Mg2+, Mn2+ ions caused a significant increase in the rate of GroE-assisted malate dehydrogenase refolding and, concomitantly, a decrease in the rate of ATP hydrolysis. Moreover, Mn2+ increases the affinity of GroES for GroEL, even in the presence of saturating amounts of Mg2+ Chemical cross-linking showed that lower concentrations of Mn-ATP as compared with Mg-ATP are needed to form both asymmetric GroEL(14)GroES(7) and symmetric GroEL(14)(GroES(7))(2) particles. The manganese-dependent increase in the rate of protein folding concurred with a specific increase in the amount of symmetric GroEL(14)-(GroES(7))(2) particles detected in a chaperonin solution. Thus, Mn2+ is a cofactor that can markedly increase the efficiency of the chaperonin reaction in vitro, Mn2+ ions can serve as an important tool for analyzing the molecular mechanism and the structure of chaperonins.	HEBREW UNIV JERUSALEM, ALEXANDER SILBERMAN INST LIFE SCI, DEPT BOT, IL-91904 JERUSALEM, ISRAEL	Hebrew University of Jerusalem				Goloubinoff, Pierre/0000-0002-4802-0807				AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; AZEM A, 1995, IN PRESS P NATL ACAD; BAIS R, 1975, ANAL BIOCHEM, V63, P271, DOI 10.1016/0003-2697(75)90215-8; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; DIAMANT S, 1995, BIOCHEMISTRY-US, V34, P273, DOI 10.1021/bi00001a033; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GOLOUBINOFF P, 1991, ACS SYM SER, V470, P110; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TODD MJ, 1995, J BIOL CHEM, V270, P5388, DOI 10.1074/jbc.270.10.5388; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363	25	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28387	28391						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499341				2022-12-27	WOS:A1995TG21000066
J	KAMPFENKEL, K; KUSHNIR, S; BABIYCHUK, E; INZE, D; VANMONTAGU, M				KAMPFENKEL, K; KUSHNIR, S; BABIYCHUK, E; INZE, D; VANMONTAGU, M			MOLECULAR CHARACTERIZATION OF A PUTATIVE ARABIDOPSIS-THALIANA COPPER TRANSPORTER AND ITS YEAST HOMOLOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; IRON UPTAKE; FUNCTIONAL EXPRESSION; FERRIC REDUCTASE; ESCHERICHIA-COLI; RESISTANCE; PROTEIN; CLONING; COMPLEMENTATION; SEQUENCE	At the molecular level, little is known about the transport of copper across plant membranes. We have isolated an Arabidopsis thaliana cDNA by complementation of a mutant (ctr1-3) of Saccharomyces cerevisiae defective in high affinity copper uptake. This cDNA codes for a highly hydrophobic protein (COPT1) of 169 amino acid residues and with three putative transmembrane domains. Most noteworthy, the first 44 residues display significant homology to the methionine- and histidine-rich copper binding domain of three bacterial copper binding proteins, among these a copper transporting ATPase. Mutant yeast cells expressing COPT1 exhibit nearly wild type behavior with regard to growth on a nonfermentable carbon source and resistance to copper and iron starvation. Expression of COPT1 is also associated with an increased sensitivity to copper toxicity. Additionally, COPT1 shows significant homology to an open reading frame of 189 amino acid residues on yeast chromosome VIII. This gene (CTR2) may encode an additional yeast metal transporter able to mediate the uptake of copper. A mutation in CTR2 displays a higher level of resistance to toxic copper concentrations. Overexpression of CTR2 provides increased resistance to copper starvation and is also associated with an increased sensitivity to copper toxicity. The amino acid sequence of CTR2, like Arabidopsis COPT1, contains three potential transmembrane domains. Taken together, the data suggest that a plant metal transporter, which is most likely involved in the transport of copper, has been identified.	STATE UNIV GHENT, INRA LAB, B-9000 GHENT, BELGIUM	Ghent University	KAMPFENKEL, K (corresponding author), STATE UNIV GHENT, GENET LAB, KL LEDEGANCKSTRAAT 35, B-9000 GHENT, BELGIUM.		Inzé, Dirk/AAW-6381-2021; kushnir, sergei/GPK-2171-2022; Babiychuk, Eduard/AAV-7223-2021	Inzé, Dirk/0000-0002-3217-8407; Kushnir, Sergei/0000-0002-1818-5803				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; AUSUBEL FM, 1993, CURRENT PROTOCOLS MO, V2; BAYLIS HA, 1993, MOL BIOCHEM PARASIT, V61, P171, DOI 10.1016/0166-6851(93)90063-4; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BOWEN JE, 1969, PLANT PHYSIOL, V44, P255, DOI 10.1104/pp.44.2.255; BROWN NL, 1985, TRENDS BIOCHEM SCI, V10, P400, DOI 10.1016/0968-0004(85)90069-6; CHA JS, 1991, P NATL ACAD SCI USA, V88, P8915, DOI 10.1073/pnas.88.20.8915; CHANEY RL, 1972, PLANT PHYSIOL, V50, P208, DOI 10.1104/pp.50.2.208; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; EIDE D, 1992, J BIOL CHEM, V267, P20774; FROMMER WB, 1993, P NATL ACAD SCI USA, V90, P5944, DOI 10.1073/pnas.90.13.5944; Graham R. D., 1981, Copper in soils and plants., P141; GUERINOT ML, 1994, PLANT PHYSIOL, V104, P815, DOI 10.1104/pp.104.3.815; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; HSU LC, 1993, P NATL ACAD SCI USA, V90, P7441, DOI 10.1073/pnas.90.16.7441; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; KAMPFENKEL K, 1995, PLANT PHYSIOL, V107, P725, DOI 10.1104/pp.107.3.725; KOCHIAN L V, 1991, P229; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LESUISSE E, 1987, J GEN MICROBIOL, V133, P3229; MELLANO MA, 1988, J BACTERIOL, V170, P2879, DOI 10.1128/jb.170.6.2879-2883.1988; MEYEROWITZ EM, 1994, ARABIDOPSIS, P21; MINET M, 1992, PLANT J, V2, P417; MURPHY A, 1995, PLANT PHYSIOL, V108, P29, DOI 10.1104/pp.108.1.29; NINNEMANN O, 1994, EMBO J, V13, P3464, DOI 10.1002/j.1460-2075.1994.tb06652.x; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; RIESMEIER JW, 1992, EMBO J, V11, P4705, DOI 10.1002/j.1460-2075.1992.tb05575.x; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Sambrook J, 1989, MOL CLONING LABORATO; Sandmann G., 1983, Inorganic plant nutrition, P563; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SHERMAN F, 1989, LABORATORY COURSE MA; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SMITH RL, 1993, J BIOL CHEM, V268, P14071; SOLIOZ M, 1995, J BIOL CHEM, V270, P9217, DOI 10.1074/jbc.270.16.9217; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; VELTRUP W, 1976, PHYSIOL PLANTARUM, V36, P217, DOI 10.1111/j.1399-3054.1976.tb04415.x; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; [No title captured]	51	212	232	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28479	28486						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499355	Green Published, hybrid			2022-12-27	WOS:A1995TG21000080
J	LIEVENEMA, H; LABRUYERE, WT; VANROON, MA; DEBOER, PAJ; MOORMAN, AFM; BERNS, AJM; LAMERS, WH				LIEVENEMA, H; LABRUYERE, WT; VANROON, MA; DEBOER, PAJ; MOORMAN, AFM; BERNS, AJM; LAMERS, WH			THE SPATIOTEMPORAL CONTROL OF THE EXPRESSION OF GLUTAMINE-SYNTHETASE IN THE LIVER IS MEDIATED BY ITS 5'-ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT-RAT LIVER; HETEROGENEOUS DISTRIBUTION; ENZYMIC ZONATION; GENE-EXPRESSION; MOUSE-LIVER; HEPATOCYTES; AMMONIA; RNA; ARCHITECTURE; EXTRACTION	In previous studies of the glutamine synthetase gene, the promoter and two enhancer elements, one in the upstream region and one within the first intron, were identified, To analyze the role of the far-upstream enhancer element in the regulation of the expression of the glutamine synthetase gene, two classes of transgenic mice were generated, In GSK mice, the basal promoter directs the expression of the chloramphenicol acetyltransferase reporter gene, In GSL mice reporter gene expression is driven, in addition, by the upstream regulatory region, including the far-upstream enhancer, Whereas chloramphenicol acetyltransferase expression was barely detectable in GSK mice, high levels were detected in GSL mice, By comparing chloramphenicol acetyltransferase expression with that of endogenous glutamine synthetase in GSL mice, three groups of organs were distinguished in which the effects of the upstream regulatory region on the expression of glutamine synthetase were quantitatively different, The chloramphenicol acetyltransferase mRNA in the GSL mice was shown to be localized in the pericentral hepatocytes of the liver, The developmental changes in chloramphenicol acetyltransferase enzyme activity in the liver were similar to those in endogenous glutamine synthetase, These results show that the upstream region is a major determinant for three characteristics of glutamine synthetase expression: its organ specificity, its pericentral expression pattern in the liver, and its developmental appearance in the liver.	UNIV AMSTERDAM, ACAD MED CTR, DEPT ANAT & EMBRYOL, 1105 AZ AMSTERDAM, NETHERLANDS; NETHERLANDS CANC INST, DEPT MOLEC GENET, 1066 CX AMSTERDAM, NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; Netherlands Cancer Institute			Lamers, Wouter H./D-2965-2012					Ausubel FM, 1994, CURRENT PROTOCOLS MO; BENNETT AL, 1987, J CELL BIOL, V105, P1073, DOI 10.1083/jcb.105.3.1073; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEGROOT CJ, 1987, BIOCHIM BIOPHYS ACTA, V908, P231, DOI 10.1016/0167-4781(87)90103-5; FAHRNER J, 1993, EUR J BIOCHEM, V213, P1067, DOI 10.1111/j.1432-1033.1993.tb17854.x; GEBHARDT R, 1983, EMBO J, V2, P567, DOI 10.1002/j.1460-2075.1983.tb01464.x; GEBHARDT R, 1994, HEPATOLOGY, V20, P684, DOI 10.1016/0270-9139(94)90105-8; GEBHARDT R, 1986, DIFFERENTIATION, V33, P45, DOI 10.1111/j.1432-0436.1986.tb00409.x; HAUSSINGER D, 1992, ENZYME, V46, P72; HOGAN B, 1986, MANIPULATION MOUSE E; Janzen JWG, 1987, J HISTOCHEM CYTOCHEM, V35, P49, DOI 10.1177/35.1.2878950; JANZEN JWG, 1984, J HISTOCHEM CYTOCHEM, V32, P557, DOI 10.1177/32.6.6373912; JUNGERMANN K, 1989, PHYSIOL REV, V69, P708, DOI 10.1152/physrev.1989.69.3.708; KUO CF, 1988, MOL CELL BIOL, V8, P4966, DOI 10.1128/MCB.8.11.4966; KUO CF, 1989, J MOL BIOL, V208, P45, DOI 10.1016/0022-2836(89)90086-7; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAMERS WH, 1987, DIFFERENTIATION, V35, P228, DOI 10.1111/j.1432-0436.1987.tb00173.x; LAMERS WH, 1988, ANAT EMBRYOL, V178, P175, DOI 10.1007/BF02463651; LEVINTOW L, 1954, J NATL CANCER I, V15, P347; LOUIE M, 1978, J BIOL CHEM, V253, P6119; MOORMAN AFM, 1988, J HISTOCHEM CYTOCHEM, V36, P751, DOI 10.1177/36.7.2898495; MOORMAN AFM, 1993, HISTOCHEM J, V25, P251, DOI 10.1007/BF00159117; MOORMAN AFM, 1991, FEBS LETT, V288, P133, DOI 10.1016/0014-5793(91)81019-5; MOORMAN AFM, 1994, FEBS LETT, V356, P76, DOI 10.1016/0014-5793(94)01230-X; Sambrook J, 1989, MOL CLONING LABORATO; SCHRODE W, 1990, EUR J CELL BIOL, V53, P35; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SIKES ML, 1994, HUM GENE THER, V5, P837, DOI 10.1089/hum.1994.5.7-837; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; VANDENHOFF MJB, 1993, NUCLEIC ACIDS RES, V21, P4987, DOI 10.1093/nar/21.21.4987; VANDENHOFF MJB, 1995, EUR J BIOCHEM, V228, P351; VANDEZANDE L, 1990, GENE, V87, P225, DOI 10.1016/0378-1119(90)90306-C; WAGENAAR GTM, 1993, HEPATOLOGY, V18, P1144; WAGENAAR GTM, 1993, J HEPATOL, V17, P397, DOI 10.1016/S0168-8278(05)80224-7	35	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28251	28256						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499322				2022-12-27	WOS:A1995TG21000047
J	MCFARLAND, EDC; THOMAS, ML				MCFARLAND, EDC; THOMAS, ML			CD45 PROTEIN-TYROSINE-PHOSPHATASE ASSOCIATES WITH THE WW DOMAIN-CONTAINING PROTEIN, CD45AP, THROUGH THE TRANSMEMBRANE REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; EXPRESSION; PHOSPHORYLATION; ANTIGEN; KINASES	CD45 is a transmembrane protein-tyrosine phosphatase required for antigen receptor signaling in lymphocytes. CD45 activates the Src family protein-tyrosine kinases, p56(lck) and p59(fyn), by dephosphorylating a negative regulatory tyrosine in the carboxyl terminus, Immunoprecipitation of CD45 precipitates p56(lck) and CD45AP, Although the function of CD45AP is unknown, it has been proposed to be an adapter between p56(lck) and CD45, To assess the ability of CD45AP to function as an adapter, we determined the regions required for the interaction with CD45 by expressing chimeric proteins in HeLa cells, CD45AP has a region similar to a potential protein-protein interaction domain, the WW domain, Surprisingly, this domain was not necessary for the association with CD45, Rather, a 40-amino acid sequence encompassing the putative transmembrane domain of CD45AP was sufficient to mediate binding to CD45, Similarly, a 39-amino acid sequence encompassing the CD45 transmembrane region was sufficient to direct the interaction with CD45AP, Expression of p56(lck) with CD45AP resulted in an interaction that could only be detected by in vitro kinase reaction, suggesting that the association of p56(lck) and CD45AP is weak, These data support a model in which CD45AP links CD45 with other proteins but not necessarily p56(lck).	WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, CTR IMMUNOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026363, T32AI007163] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 26363, AI 07163] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDRE B, 1994, BIOCHEM BIOPH RES CO, V205, P1201, DOI 10.1006/bbrc.1994.2793; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; FRA A, 1995, J BIOL CHEM, V269, P30745; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GERVAIS FG, 1995, MOL CELL BIOL, V15, P2393; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SHIMIZU Y, 1994, FEBS LETT, V35, P30; SUDOL M, 1994, ONCOGENE, V9, P2145; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TAKEDA A, 1994, J BIOL CHEM, V269, P2357; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0	27	51	51	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28103	28107						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499298				2022-12-27	WOS:A1995TG21000023
J	TEBOUL, L; GAILLARD, D; STACCINI, L; INADERA, H; AMRI, EZ; GRIMALDI, PA				TEBOUL, L; GAILLARD, D; STACCINI, L; INADERA, H; AMRI, EZ; GRIMALDI, PA			THIAZOLIDINEDIONES AND FATTY-ACIDS CONVERT MYOGENIC CELLS INTO ADIPOSE-LIKE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; AP2 GENE-EXPRESSION; CLONAL LINE; DIFFERENTIATION; INSULIN; GROWTH; MUSCLE; MOUSE; 3T3-CELLS; INDUCTION	Fatty acids and thiazolidinediones act as potent activators of the adipose differentiation program in established preadipose cell lines, In this report, the effects of these agents on the differentiation pathway of myoblasts have been investigated, Exposure of C2C12N myoblasts (a subclone of the C2C12 cell line) to thiazolidinediones or fatty acids prevents the expression of myogenin, cy-actin, and creatine kinase, thus abolishing the formation of multinucleated myotubes, These treatments lead in parallel to the expression of a typical adipose differentiation program including acquisition of adipocyte morphology and activation of adipose-related genes, A similar transition toward the adipose differentiation pathway also occurs in mouse muscle satellite cells maintained in primary culture, Thiazolidinediones exert their adipogenic effects only in non-terminally differentiated myoblasts; myotubes are insensitive to the compounds, Continuous exposure to inducers after growth arrest is not required to maintain the adipose phenotype, but proliferation of adipose-like C2C12N cells leads to a complete reversion toward undifferentiated cells able to undergo either myogenic or adipogenic differentiation depending on the composition of culture medium, These results indicate that adipogenic inducers, such as thiazolidinediones or fatty acids, specifically convert the differentiation pathway of myoblasts into that of adipoblasts.	UNIV NICE, FAC SCI, CTR BIOCHIM, CNRS, UMR 134, F-06108 NICE 2, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Teboul, Lydia/P-2428-2019	Teboul, Lydia/0000-0002-2789-8637; amri, Ez-Zoubir/0000-0001-8426-5396				AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; AMRI EZ, 1994, J LIPID RES, V35, P930; AMRI EZ, 1991, J LIPID RES, V32, P1457; AMRI EZ, 1991, J LIPID RES, V32, P1449; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; AMRI EZ, 1986, BIOCHEM J, V238, P115, DOI 10.1042/bj2380115; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; CAWTHORNE MA, 1993, DIABETES, V42, pA204; CHANG AY, 1983, DIABETES, V32, P839, DOI 10.2337/diabetes.32.9.839; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARMON M, 1981, EXP CELL RES, V132, P313, DOI 10.1016/0014-4827(81)90107-5; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; DOGLIO A, 1986, BIOCHEM J, V238, P123, DOI 10.1042/bj2380123; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GRIGORIADIIS AE, 1990, J CELL BIOL, V106, P2139; GRIMALDI PA, 1992, P NATL ACAD SCI USA, V89, P10930, DOI 10.1073/pnas.89.22.10930; HIRAGUN A, 1988, J CELL PHYSIOL, V134, P124, DOI 10.1002/jcp.1041340115; IBRAHIMI A, 1994, MOL PHARMACOL, V46, P1070; IKEDA H, 1990, ARZNEIMITTEL-FORSCH, V40-1, P156; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; LIN CH, 1969, LIFE SCI PT 1 PHYSI, V8, P21, DOI 10.1016/0024-3205(69)90112-X; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORGANHUGHES JA, 1986, MYOLOGY, V2, P1709; MUNSON R, 1982, J CELL BIOL, V92, P350, DOI 10.1083/jcb.92.2.350; NEGREL R, 1978, P NATL ACAD SCI USA, V75, P6054, DOI 10.1073/pnas.75.12.6054; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; REINILA A, 1984, DIABETOLOGIA, V27, P397, DOI 10.1007/BF00304857; ROSEN DM, 1988, J CELL PHYSIOL, V134, P337, DOI 10.1002/jcp.1041340304; STOCKDALE FE, 1992, DEV BIOL, V154, P284, DOI 10.1016/0012-1606(92)90068-R; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yaffe D, 1973, TISSUE CULTURE METHO, P106; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681	41	188	198	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28183	28187						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499310	hybrid			2022-12-27	WOS:A1995TG21000035
J	BRIATA, P; VANDEWERKEN, B; AIROLDI, I; ILENGO, C; DIBLAS, E; BONCINELLI, E; CORTE, G				BRIATA, P; VANDEWERKEN, B; AIROLDI, I; ILENGO, C; DIBLAS, E; BONCINELLI, E; CORTE, G			TRANSCRIPTIONAL REPRESSION BY THE HUMAN HOMEOBOX PROTEIN EVX1 IN TRANSFECTED MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EVEN-SKIPPED PROTEIN; PANCREATIC-ISLET CELLS; TATA-BINDING PROTEIN; DNA-BINDING; SYNERGISTIC ACTIVATION; HOMEODOMAIN PROTEINS; DROSOPHILA EMBRYOS; GENE-TRANSCRIPTION; TRANSGENIC MICE; GLUCAGON GENE	The human homeobox protein EVX1 (EVX1) is thought to play an important role during embryogenesis. In this study, the effect of EVX1 on gene transcription has been investigated in transfected mammalian cells. EVX1 expression represses transcription of a reporter gene directed by either cell-specific or viral promoter/enhancer sequences in a variety of mammalian cell lines and in a concentration-dependent manner. Transcriptional repression is independent of the presence of DNA-binding sites for EVX1 in all the promoters we tested. Furthermore, repression by EVX1 is evident also using a TATA-less minimal promoter in the reporter construct. A carboxyl-terminal proline/alanine-rich region of EVX1 seems to be responsible for the transcriptional repression activity, as suggested by transfection of EVX1 mutants. We speculate that the repressor function of EVX1 contributes to its proposed role in embryogenesis.	DIBIT HS RAFFAELE,I-20132 MILAN,ITALY; UNIV GENOA,SCH MED,INST BIOCHEM,I-16132 GENOA,ITALY	University of Genoa	BRIATA, P (corresponding author), ADV BIOTECHNOL CTR,IMMUNOBIOL LAB,IST,VIALE R BENZI 10,I-16132 GENOA,ITALY.		airoldi, irma/I-6169-2017; Briata, Paola/AAC-6039-2020	airoldi, irma/0000-0002-4352-8396; Briata, Paola/0000-0003-3470-0454				ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; ANANTHAN J, 1993, MOL CELL BIOL, V13, P1599, DOI 10.1128/MCB.13.3.1599; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CORSETTI MT, 1992, NUCLEIC ACIDS RES, V20, P4465, DOI 10.1093/nar/20.17.4465; CORTE G, 1981, EUR J IMMUNOL, V11, P162, DOI 10.1002/eji.1830110220; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DESPOSITO M, 1991, GENOMICS, V10, P43, DOI 10.1016/0888-7543(91)90482-T; DRUCKER DJ, 1987, J BIOL CHEM, V262, P15659; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FAIELLA A, 1992, NUCLEIC ACIDS RES, V23, P6541; FEHMANN HC, 1982, ENDOCRINOLOGY, V130, P159; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; GEFTER ML, 1977, SOMAT CELL GENET, V3, P231, DOI 10.1007/BF01551818; GEHRING WJ, 1993, GENE, V135, P215, DOI 10.1016/0378-1119(93)90068-E; GHERZI R, 1995, FEBS LETT, V369, P335, DOI 10.1016/0014-5793(95)00778-8; GHERZI R, 1994, EXP CELL RES, V213, P20, DOI 10.1006/excr.1994.1168; GHERZI R, 1995, EXP CELL RES, V218, P460, DOI 10.1006/excr.1995.1179; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; INOSTROZA JA, 1992, CELL, V70, P477; Jackle H, 1993, CURR OPIN CELL BIOL, V5, P505, DOI 10.1016/0955-0674(93)90017-K; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; JOHNSON FB, 1992, GENE DEV, V6, P2177, DOI 10.1101/gad.6.11.2177; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2086, DOI 10.1073/pnas.89.6.2086; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; KUZIORA MA, 1989, CELL, V59, P563, DOI 10.1016/0092-8674(89)90039-1; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; MACDONALD PM, 1986, CELL, V47, P721, DOI 10.1016/0092-8674(86)90515-5; MAVILIO F, 1986, NATURE, V324, P664, DOI 10.1038/324664a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; MONUKI ES, 1993, MECH DEVELOP, V42, P15, DOI 10.1016/0925-4773(93)90095-F; ODENWALD WF, 1989, GENE DEV, V3, P158, DOI 10.1101/gad.3.2.158; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SPYROPOULOS DD, 1994, GENE DEV, V8, P1949, DOI 10.1101/gad.8.16.1949; STERN S, NATUR, V345, P783; Summers MD, 1987, TEXAS AGR EXPT STATI; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; TENHARMSEL A, 1993, MOL CELL BIOL, V13, P2742, DOI 10.1128/MCB.13.5.2742; VERSHON AK, 1995, GENE DEV, V9, P182, DOI 10.1101/gad.9.2.182; WALDBIESER GC, 1991, ENDOCRINOLOGY, V128, P3228, DOI 10.1210/endo-128-6-3228; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; ZAPPAVIGNA V, 1991, EMBO J, V10, P4177, DOI 10.1002/j.1460-2075.1991.tb04996.x; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732	67	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27695	27701		10.1074/jbc.270.46.27695	http://dx.doi.org/10.1074/jbc.270.46.27695			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499236	hybrid			2022-12-27	WOS:A1995TE73600047
J	HO, GY; CHEN, TLL; CHISHOLM, RL				HO, GY; CHEN, TLL; CHISHOLM, RL			BOTH THE AMINO AND CARBOXYL TERMINI OF DICTYOSTELIUM MYOSIN ESSENTIAL LIGHT-CHAIN ARE REQUIRED FOR BINDING TO MYOSIN HEAVY-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE MYOSIN; CENTRAL HELIX; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODIES; SECONDARY STRUCTURE; PEPTIDE COMPLEX; TROPONIN-C; CALMODULIN; DISCOIDEUM; EVOLUTION	Dictyostelium myosin deficient in the essential light chain (ELC) does not function normally either in vivo or in vitro (Pollent, R. S., Chen, T. L., Trivinos-Lagos, L., and Chisholm, R. L. (1992) Cell 69, 951-962). Since normal myosin function requires association of ELC, we investigated the domains of ELC that are necessary for binding to the myosin heavy chain (MHC), Deleting the NH2-terminal 11 or 28 amino acid residues (Delta N11 or Delta N28) or the COOH terminal 15 amino acid residues (Delta C15) abolished binding of the ELC to the MHC when the mutants were expressed in wild-type (WT) cells, In contrast, the ELC carrying deletion or insertion of four amino acid residues (D4 or I4) in the central linker segment bound the MHC in WT cells, although less efficient competition with WT ELC suggested that the affinity for the MHC is reduced, When these mutants were ex pressed in ELC-minus (mlcE(-)) cells, where the binding to the heavy chain is not dependent on efficient competition with the endogenous ELC, Delta N28 and Delta N11 bound to the MHC at 15% of WT levels and Delta C15 did not bind to a significant degree, 14 and D4, however, bound with normal stoichiometry. These data indicate that residues at both termini of the ELC are required for association with the MHC, while the central linker domain appears to be less critical for binding, When the mutants were analyzed for their ability to complement the cytokinesis defect displayed by mlcE(-) cells, a correlation to the level of ELC carried by the MHC was observed, indicating that a stoichiometric ELC MHC association is necessary for normal myosin function in vivo.	NORTHWESTERN UNIV, SCH MED, DEPT CELL & MOLEC BIOL, CHICAGO, IL 60611 USA	Northwestern University			Chisholm, Rex L/B-3418-2009	Chisholm, Rex L/0000-0002-5638-3990	NIGMS NIH HHS [GM-39264] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039264] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BECHET JJ, 1989, BIOCHIM BIOPHYS ACTA, V996, P199, DOI 10.1016/0167-4838(89)90248-3; CHEN PX, 1994, J CELL BIOL, V127, P1933, DOI 10.1083/jcb.127.6.1933; CHISHOLM RL, 1988, J MOL BIOL, V86, P209; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIFFARD RG, 1983, J MUSCLE RES CELL M, V4, P115, DOI 10.1007/BF00711962; HAILSTONES DL, 1990, MOL CELL BIOL, V10, P1095, DOI 10.1128/MCB.10.3.1095; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOWARD PK, 1988, NUCLEIC ACIDS RES, V16, P2613, DOI 10.1093/nar/16.6.2613; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KATCH T, 1989, J CELL BIOL, V109, P1549; KING SM, 1986, METHOD ENZYMOL, V134, P291; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; OSTROW BD, 1994, J CELL BIOL, V127, P1945, DOI 10.1083/jcb.127.6.1945; PAABO S, 1990, J BIOL CHEM, V265, P4718; PERIASAMY M, 1989, NUCLEIC ACIDS RES, V17, P7723, DOI 10.1093/nar/17.19.7723; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLENZ RS, 1992, CELL, V69, P951, DOI 10.1016/0092-8674(92)90614-I; POLLENZ RS, 1991, CELL MOTIL CYTOSKEL, V20, P83, DOI 10.1002/cm.970200202; PUTKEY JA, 1988, J BIOL CHEM, V263, P11242; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SOLDATI T, 1991, CELL, V66, P277, DOI 10.1016/0092-8674(91)90618-9; Stryer L., 1988, BIOCHEMISTRY-US, P15; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; UENO H, 1985, J BIOCHEM-TOKYO, V97, P1785, DOI 10.1093/oxfordjournals.jbchem.a135237; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WINKELMANN DA, 1986, J MOL BIOL, V188, P595, DOI 10.1016/S0022-2836(86)80009-2; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	40	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27977	27981		10.1074/jbc.270.46.27977	http://dx.doi.org/10.1074/jbc.270.46.27977			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499275	hybrid			2022-12-27	WOS:A1995TE73600086
J	ROYAL, I; PARK, M				ROYAL, I; PARK, M			HEPATOCYTE GROWTH FACTOR-INDUCED SCATTER OF MADIN-DARBY CANINE KIDNEY-CELLS REQUIRES PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-DEPENDENT PROCESSES; EPITHELIAL-CELLS; FACTOR-RECEPTOR; MET PROTOONCOGENE; TYROSINE KINASE; SIGNAL TRANSDUCTION; PROTEIN-KINASE; POLYMORPHONUCLEAR NEUTROPHILS; DESMOPLAKIN ORGANIZATION; EXTRACELLULAR CALCIUM	Hepatocyte growth factor/scatter factor (HGF/SF) is a multifunctional cytokine that induces mitogenesis, motility, invasion, and morphogenesis of several epithelial and endothelial cell lines in culture. The receptor for HGF/SF has been identified as the Met tyrosine kinase. To investigate the signaling pathways that are involved in these events, we have generated chimeric receptors containing the extracellular domain of the colony stimulating factor-1 (CSF-1) receptor fused to the transmembrane and intracellular domains of the Met receptor (MET). Madin-Darby canine kidney (MDCK) epithelial cells expressing the CSF-MET chimera dissociate and scatter in response to CSF-1. However, cells expressing a mutant CSF-MET receptor containing a phenylalanine substitution for tyrosine 1356 were unable to scatter or form branching tubules following stimulation with CSF-1. Tyrosine 1356 is essential for the recruitment of multiple substrates including the p85 subunit of PI3-kinase, phospholipase C gamma, and Grb2. In this study, we have investigated the role of PI3-kinase and a downstream target of PI3-kinase, pp70(S6K), in the induction of MDCK cell scatter in response to HGF/SF. Our results demonstrate that following stimulation with HGF/SF, activation of PI3-kinase but not pp70(S6K) is essential for MDCK cell scatter.	ROYAL VICTORIA HOSP, ONCOL MOLEC LAB, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, DEPT MED, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, DEPT ONCOL, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3A 1A1, CANADA	McGill University; Royal Victoria Hospital; McGill University; McGill University; McGill University				Royal, Isabelle/0000-0002-7548-1182				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BIZXXON D, 1995, J  IOL HDM, V270, P5225; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CITI S, 1992, J CELL BIOL, V117, P169, DOI 10.1083/jcb.117.1.169; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DOWRICK PG, 1991, EXP SUPPL, V59, P89; FALETTO DL, 1993, HEPATOCYTE GROWTH FA, P108; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FIXMAN ED, 1995, ONCOGENE, V10, P237; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; GHERARDI E, 1991, EUR J CANCER, V27, P403, DOI 10.1016/0277-5379(91)90370-S; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1989, ONCOGENE, V4, P1983; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HALABAN R, 1992, ONCOGENE, V7, P2195; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LIU C, 1992, ONCOGENE, V7, P181; LONGATI P, 1994, ONCOGENE, V9, P49; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MATSUMOTO K, 1993, HEPATOCYTE GROWTH FA, P226; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NOBES CD, 1995, J CELL SCI, V108, P225; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; OKANO Y, 1993, BIOCHEM BIOPH RES CO, V190, P842, DOI 10.1006/bbrc.1993.1125; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PASDAR M, 1989, J CELL BIOL, V109, P163, DOI 10.1083/jcb.109.1.163; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; PASDAR M, 1988, J CELL BIOL, V106, P687, DOI 10.1083/jcb.106.3.687; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1995, ONCOGENE, V10, P1631; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1990, J CELL SCI, V96, P639; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SHORE EM, 1991, J BIOL CHEM, V266, P19672; SILICIANO JD, 1988, J CELL BIOL, V107, P2389, DOI 10.1083/jcb.107.6.2389; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; STEVENSON BR, 1988, MOL CELL BIOCHEM, V83, P129; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKEICHI M, 1991, SCIENCE, V251, P14551; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359; ZHU H, 1994, J BIOL CHEM, V269, P29943	82	233	242	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27780	27787		10.1074/jbc.270.46.27780	http://dx.doi.org/10.1074/jbc.270.46.27780			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499247	hybrid			2022-12-27	WOS:A1995TE73600058
J	SCHIEMANN, WP; NATHANSON, NM				SCHIEMANN, WP; NATHANSON, NM			INVOLVEMENT OF PROTEIN-KINASE-C DURING ACTIVATION OF THE MITOGEN-ACTIVATED PROTEIN-KINASE CASCADE BY LEUKEMIA INHIBITORY FACTOR - EVIDENCE FOR PARTICIPATION OF MULTIPLE SIGNALING PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; RIBOSOMAL PROTEIN-S6; MAP KINASE; GP130; TRANSDUCER; CELLS; PHOSPHORYLATION; EXPRESSION; LIF; RAS	We show here that treatment of 3T3-L1 cells with leukemia inhibitory factor (LIF) stimulates the activation of mitogen-activated protein kinase kinase (MAPKK), mitogen-activated protein kinase (MAPK), and S6 protein kinase (S6K) activities both in a time- and dose-dependent manner. A single peak of MAPKK activity, four peaks of activity against the S6 synthetic peptide, RRLSSLRA (S6 peptide), and three distinct peaks toward myelin basic protein (MBP) were observed after Mono Q chromatography of LIF-stimulated cell extracts. Two of the MBP kinase activities correlated with the stimulation of extracellular signal-regulated kinases 1 and 2. Interestingly, down-regulation of protein kinase C (PKC) by chronic treatment of 3T3-L1 cells with phorbol ester was found to attenuate, but not block, the LIF-mediated stimulation of MAPKK, MAPK, and S6K activities in 3T3-L1 cells. Treatment of 3T3-L1 cells with epidermal growth factor increased MAPKK, MAPK, and S6K activities to a similar extent as LIF, but this activation was not attenuated by down-regulation of PKC. Our results suggest that the full activation of the MAPK cascade by LIF may require inputs from multiple signaling pathways, one of which is dependent upon the presence of functional PKC.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM07750] Funding Source: Medline; NINDS NIH HHS [NS26920] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026920] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHN NG, 1990, J BIOL CHEM, V265, P11487; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BLENIS J, 1986, P NATL ACAD SCI USA, V83, P1733, DOI 10.1073/pnas.83.6.1733; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1991, J CELL BIOCHEM, V46, P21, DOI 10.1002/jcb.240460105; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P73; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; KALBERG C, 1993, J NEUROCHEM, V60, P145, DOI 10.1111/j.1471-4159.1993.tb05832.x; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEVIN DE, 1993, J NIH RES, V5, P49; LIU JW, 1992, J BIOL CHEM, V267, P16763; METCALF D, 1991, INT J CELL CLONING, V9, P95, DOI 10.1002/stem.5530090201; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORI M, 1989, BIOCHEM BIOPH RES CO, V160, P1085, DOI 10.1016/S0006-291X(89)80114-7; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NORTHWOOD IC, 1990, P NATL ACAD SCI USA, V87, P6107, DOI 10.1073/pnas.87.16.6107; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; QURESHI SA, 1991, ONCOGENE, V6, P995; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WEIEL JE, 1990, BIOL MED SIGNAL TRAN; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YANG YC, 1992, BIOFACTORS, V4, P15	48	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6376	6382						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509801				2022-12-27	WOS:A1994MZ50300021
J	MARTINPADURA, I; BAZZONI, G; ZANETTI, A; BERNASCONI, S; ELICES, MJ; MANTOVANI, A; DEJANA, E				MARTINPADURA, I; BAZZONI, G; ZANETTI, A; BERNASCONI, S; ELICES, MJ; MANTOVANI, A; DEJANA, E			NOVEL MECHANISM OF COLON-CARCINOMA CELL - ADHESION TO THE ENDOTHELIUM TRIGGERED BY BETA(1) INTEGRIN CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MONOCLONAL-ANTIBODY; HUMAN-MELANOMA; BETA-1 INTEGRINS; LAMININ RECEPTOR; NUDE-MICE; T-CELLS; GLYCOPROTEIN; MEMBRANE; EXPRESSION	We have found a monoclonal antibody, called BV7, that rapidly stimulated by 6-10-folds HT-29 colon carcinoma cell adhesion to resting human umbilical vein endothelial cells. This effect was directed to tumor cells and not to endothelial cells and was cell-specific. BV7 was also active on the HCCP-2998 but did not change adhesion to endothelial cells of other tumor cells (MG63 osteosarcoma, A375 melanoma, MHCC-1410 and Love colon carcinoma) even if, by flow cytometry, this monoclonal antibody could bind to them. Additionally, BV7 effect was substratum-specific, since it did not increase but rather blocked HT-29 adhesion to matrix proteins. Immunoprecipitation analysis and binding to specific transfectants revealed that BV7 recognizes beta(1)-subunit of integrin receptors and antibody blocking experiments showed that alpha(2) beta(1) antibodies were able to counteract BV7 effect on HT-29 adhesion to endothelial cells. In contrast, antibodies directed to other integrins or endothelial adhesive receptors (E- and P-selectin, VCAM-1, ICAM-1, ICAM-2) were ineffective. Induction of HT-29 adhesion to endothelial cells by BV7 was Fc- and protein synthesis-independent but required metabolically active cells. The presence of physiological concentrations of divalent cations and of cytoskeletal integrity was not needed, Comparative studies with eight different prototypic beta(1) antibodies showed that five of them induced HT-29 adhesion to endothelial cells in a way unrelated to their ability to interfere with HT-29 adhesion to matrix proteins. Cross-blocking binding assays demonstrated that all the five antibodies recognized a topographically related epitope. Taken together these results provide evidence that beta(1) antibodies may trigger a novel pathway of HT-29 colon carcinoma adhesion to endothelial cells with different features in respect to other described mechanisms of tumor cell interaction with the endothelium.	CENG, DBMS, INSERM, U217, HEMATOL LAB, GRENOBLE, FRANCE; CYTEL CORP, SAN DIEGO, CA 92121 USA	Institut National de la Sante et de la Recherche Medicale (Inserm)	MARTINPADURA, I (corresponding author), IST RIC FARMACOL MARIO NEGRI, VASC BIOL LAB, VIA ERITREA 62, I-20157 MILAN, ITALY.		Mantovani, Alberto/HCI-7449-2022; adriana, zanetti/ABA-1189-2020	Mantovani, Alberto/0000-0001-5578-236X; adriana, zanetti/0000-0002-5825-9707; DEJANA, ELISABETTA/0000-0002-0007-0426				ALBELDA SM, 1993, LAB INVEST, V68, P4; ALTIERI DC, 1988, J IMMUNOL, V141, P2656; AMIOT M, 1986, SCAND J IMMUNOL, V23, P109, DOI 10.1111/j.1365-3083.1986.tb01948.x; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; ARROYO AG, 1993, J BIOL CHEM, V268, P9863; BALZAC F, 1993, J CELL BIOL, V121, P171, DOI 10.1083/jcb.121.1.171; BARBIERI B, 1981, P SOC EXP BIOL MED, V168, P204; BAZZONI G, 1993, J SURG ONCOL, P24; BELLONI PN, 1990, CANCER METAST REV, V8, P353, DOI 10.1007/BF00052608; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; CAIXIA S, 1991, CELL IMMUNOL, V138, P216, DOI 10.1016/0008-8749(91)90146-3; CAMPANERO MR, 1992, EUR J IMMUNOL, V22, P3111, DOI 10.1002/eji.1830221213; CAMPANERO MR, 1990, J CELL BIOL, V110, P2157, DOI 10.1083/jcb.110.6.2157; CARLOS TM, 1990, BLOOD, V76, P965; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; CONFORTI G, 1989, BLOOD, V73, P1576; CONFORTI G, 1992, BLOOD, V80, P437; de la Hera A, 1989, Int Immunol, V1, P598, DOI 10.1093/intimm/1.6.598; DEFILIPPI P, 1992, J BIOL CHEM, V267, P18303; DEFILIPPI P, 1991, J CELL BIOL, V114, P855, DOI 10.1083/jcb.114.4.855; DEJANA E, 1988, J CLIN INVEST, V82, P1466, DOI 10.1172/JCI113753; DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELBATTARI A, 1986, J CELL SCI, V80, P269; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Galfre G, 1981, Methods Enzymol, V73, P3; GIAVAZZI R, 1990, CANCER RES, V50, P4771; GIAVAZZI R, 1986, CANCER RES, V46, P1928; GROUX H, 1989, NATURE, V339, P152, DOI 10.1038/339152a0; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HOOGENRAAD NJ, 1986, METHOD ENZYMOL, V121, P375; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; LAURI D, 1991, JNCI-J NATL CANCER I, V83, P1321, DOI 10.1093/jnci/83.18.1321; LAURI D, 1991, LAB INVEST, V65, P525; LAURI D, 1991, VASCULAR ENDOTHELIUM, P111; MARCHISIO PC, 1991, J CELL BIOL, V112, P761, DOI 10.1083/jcb.112.4.761; MARTINPADURA I, 1991, CANCER RES, V51, P2239; METZELAAR MJ, 1991, VIRCHOWS ARCH B, V61, P269; MORTAMO P, 1991, J IMMUNOL, V16, P2530; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; NICOLSON GL, 1988, CANCER METAST REV, V7, P143, DOI 10.1007/BF00046483; PARHAM P, 1983, J IMMUNOL, V131, P2895; PARHAM P, 1985, HDB EXPT IMMUNOLOGY, V14, P1; PELLEGRINI R, 1992, TUMORI, V78, P1; PHILLIPS DR, 1988, BLOOD, V71, P831; PIGOTT R, 1991, J IMMUNOL, V147, P130; PULIDO R, 1991, J BIOL CHEM, V266, P10241; RICE GE, 1988, AM J PATHOL, V133, P204; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SANCHEZMATEOS P, 1993, J IMMUNOL, V151, P3817; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SONNENBERG A, 1987, J BIOL CHEM, V262, P10376; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; TIMPL R, 1979, J BIOL CHEM, V254, P9933; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; WELLICOME SM, 1990, J IMMUNOL, V144, P2558; ZHU DZ, 1992, J CLIN INVEST, V89, P1718, DOI 10.1172/JCI115773; ZYLSTRA S, 1986, CANCER RES, V46, P6446	80	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6124	6132						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509799				2022-12-27	WOS:A1994MY84000097
J	HORDIJK, PL; VERLAAN, I; JALINK, K; VANCORVEN, EJ; MOOLENAAR, WH				HORDIJK, PL; VERLAAN, I; JALINK, K; VANCORVEN, EJ; MOOLENAAR, WH			CAMP ABROGATES THE P21(RAS)-MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY IN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; CELL-PROLIFERATION; DNA-SYNTHESIS; RAS; ACTIVATION; P21RAS; PHOSPHORYLATION; TRANSFORMATION; INVOLVEMENT; STIMULATION	The mechanism by which cAMP inhibits growth factor-induced DNA synthesis in fibroblasts is not understood. Here we show that in Rat-1 fibroblasts, cAMP-raising agents inhibit p21ras-mediated mitogen-activated protein (MAP) kinase activation induced by either epidermal growth factor or lysophosphatidic acid. Under the same conditions, however, epidermal growth factor- or lysophosphatidic acid-induced protein tyrosine phosphorylation, Ca2+ mobilization, and activation of Na+/H+ exchange are not attenuated. In ras-transformed Rat-1 cells, 8-bromo-cAMP rapidly deactivates constitutively active MAP kinase without reducing p21ras.GTP levels; long term 8-bromo-cAMP treatment of these cells leads to growth arrest and reversion of the transformed phenotype. These results show that elevation of intracellular cAMP levels abrogates the p21ras MAP kinase pathway at a step downstream of p21ras activation. This finding provides a molecular basis for the growth-inhibitory action of cAMP in normal and transformed fibroblasts.			HORDIJK, PL (corresponding author), NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.			Hordijk, Peter/0000-0002-3348-078X; Jalink, Kees/0000-0001-7019-3440				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BLOMHOFF HK, 1987, J CELL PHYSIOL, V131, P426, DOI 10.1002/jcp.1041310315; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P76; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HELDIN NE, 1989, J CELL PHYSIOL, V138, P17, DOI 10.1002/jcp.1041380104; HOLLENBERG MD, 1973, P NATL ACAD SCI USA, V70, P2964, DOI 10.1073/pnas.70.10.2964; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HUGHES DA, 1993, NATURE, V364, P349, DOI 10.1038/364349a0; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; JALINK K, 1990, J BIOL CHEM, V265, P12232; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; NILSSON J, 1984, ATHEROSCLEROSIS, V53, P77, DOI 10.1016/0021-9150(84)90107-2; PASTAN I, 1978, NATURE, V274, P645, DOI 10.1038/274645a0; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; POLAKIS P, 1992, J BIOL CHEM, V267, P10780; PUCK TT, 1981, J CELL PHYSIOL, V107, P399, DOI 10.1002/jcp.1041070312; QUINONES MA, 1991, J BIOL CHEM, V266, P14055; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SIESS W, 1990, BIOCHEM BIOPH RES CO, V170, P944, DOI 10.1016/0006-291X(90)92182-Y; TAGLIAFERRI P, 1988, J BIOL CHEM, V263, P409; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TIGYI G, 1992, J BIOL CHEM, V267, P21360; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	44	162	164	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3534	3538						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508916				2022-12-27	WOS:A1994MV63100063
J	SEIFFERT, D; CIAMBRONE, G; WAGNER, NV; BINDER, BR; LOSKUTOFF, DJ				SEIFFERT, D; CIAMBRONE, G; WAGNER, NV; BINDER, BR; LOSKUTOFF, DJ			THE SOMATOMEDIN-B DOMAIN OF VITRONECTIN - STRUCTURAL REQUIREMENTS FOR THE BINDING AND STABILIZATION OF ACTIVE TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; EXTRACELLULAR-MATRIX; PROTEIN; HEPARIN; PLASMA; SITES; PAI-1; PURIFICATION; SPECIFICITY; ADHESION	We recently localized the high affinity binding site for activated type plasminogen activator inhibitor (PAI-1) to the somatomedin B domain (i.e. amino acid (aa) 1-51) of vitronectin (Vn). In this study to further define this site, N-terminal Vn fragments of various lengths were expressed in Escherichia coli and tested for PAI-1 binding activity. Vn polypeptides containing aa 1-52 and 1-40 retained PAI-1 binding activity and stabilized PAI-1 to a similar extent as intact Vn, but polypeptides containing aa 1-30 did not bind to PAI-1 nor stabilize its activity. The effects of monoclonal antibodies (mAbs) to Vn on PAI-1 binding was also determined. One mAb bound to Vn and blocked its ability to bind to PAI-1. It also dissociated pre-existing PAI-1.Vn complexes, and prevented the incorporation of PAI-1 into extracellular matrix of HT 1080 cells. This mAb bound to the recombinant peptide containing aa 1-40, but not to the peptide consisting of aa 1-30. A second randomly chosen mAb with similar affinity for Vn was inactive in these assays and bound to the region between aa 52 and 239. These results indicate that the high affinity binding site for active PAI-1 in Vn is between aa 1 and 40, and that this domain may also stabilize active PAI-1.	Scripps Res Inst, DEPT VASC BIOL CVB-3, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; UNIV VIENNA, DEPT MED PHYSIOL, CLIN EXPTL PHYSIOL LAB, A-1010 VIENNA, AUSTRIA	Scripps Research Institute; University of Vienna					NHLBI NIH HHS [HL31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES DW, 1985, J BIOL CHEM, V260, P9117; CIAMBRONE GJ, 1990, J CELL BIOL, V111, P2183, DOI 10.1083/jcb.111.5.2183; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; FRYKLUND L, 1974, BIOCHEM BIOPH RES CO, V61, P950, DOI 10.1016/0006-291X(74)90247-2; FRYKLUND L, 1978, FEBS LETT, V87, P55, DOI 10.1016/0014-5793(78)80132-X; HARLOW E, 1988, ANTIBODIES LABORATOR; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HEKMAN CM, 1988, BIOCHEMISTRY-US, V27, P2911, DOI 10.1021/bi00408a037; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HELDIN CH, 1981, SCIENCE, V213, P1122, DOI 10.1126/science.6973821; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOOISTRA T, 1986, BIOCHEM J, V239, P497, DOI 10.1042/bj2390497; KOST C, 1992, J BIOL CHEM, V267, P12098; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; LOSKUTOFF DJ, 1991, FIBRINOLYSIS, V5, P197, DOI 10.1016/0268-9499(91)90001-K; MIMURO J, 1987, BLOOD, V70, P721; MIMURO J, 1989, J BIOL CHEM, V264, P936; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHLEEF RR, 1985, J LAB CLIN MED, V106, P408; SEIFFERT D, 1990, J CELL BIOL, V111, P1283, DOI 10.1083/jcb.111.3.1283; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1991, BIOCHIM BIOPHYS ACTA, V1078, P23, DOI 10.1016/0167-4838(91)90087-G; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; WAJCHENBERG BL, 1980, HORM METAB RES, V12, P516, DOI 10.1055/s-2007-999189; WIMAN B, 1988, THROMB HAEMOSTASIS, V59, P392; WIRTH S, 1983, ACTA ENDOCRINOL-COP, V102, P16, DOI 10.1530/acta.0.1020016; YALOW RS, 1975, J CLIN INVEST, V55, P127, DOI 10.1172/JCI107903; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	42	124	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2659	2666						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7507927				2022-12-27	WOS:A1994MV43200048
J	SEELIG, GF; PROSISE, WW; TAREMI, SS				SEELIG, GF; PROSISE, WW; TAREMI, SS			SYNTHETIC MIMICS OF JUXTAPOSED AMINO-TERMINAL AND CARBOXYL-TERMINAL PEPTIDE DOMAINS OF HUMAN GAMMA-INTERFERON BLOCK LIGAND-BINDING TO HUMAN GAMMA-INTERFERON RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; BIOLOGICAL-ACTIVITY; ANTIPEPTIDE ANTIBODIES; ANTIGENIC STRUCTURE; IMMUNE INTERFERON; NATIVE PROTEIN; C-TERMINUS; IFN-GAMMA; MACROPHAGE; MYOGLOBIN	The epitopes of two neutralizing antibodies (47N3-6 and 47N30A35) raised against rhuIFN-gamma each mapped both to amino-terminal regions (22-29 and 12-19, respectively) and to a carboxyl-terminal region 131-139, suggesting the juxtaposition of these two domains in the native protein. Three novel peptides were designed to mimic a conformation of rhuIFN-gamma that places the two regions in close proximity (discontinuous peptides 1 (15-21-GGG-132-138), 2 (15-29...111-118...130-138), and 3 (15-21-CGPGC-130-138)), by bridging the amino- and carboxyl-terminal regions of gamma interferon. Each discontinuous peptide inhibits biological or receptor binding activities with an IC50 of 15-50 muM and produces a neutralizing antibody when used as an immunogen. Neutralizing rabbit polyclonal antibody (P616) raised against discontinuous peptide 1 was used as immunogen to generate an anti-idiotypic response. This anti-idiotypic antibody inhibits receptor binding and recognizes soluble gamma interferon receptor on direct enzyme-linked immunosorbent assay. The anti-idiotypic response suggests that juxtaposed regions at the amino and carboxyl termini serve as the receptor-ligand binding site of human gamma interferon.			SEELIG, GF (corresponding author), SCHERING PLOUGH CORP,RES INST,KENILWORTH,NJ 07033, USA.							ARAKAWA T, 1986, J BIOL CHEM, V261, P8534; BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; BILLIAU A, 1988, IMMUNOL TODAY, V9, P37, DOI 10.1016/0167-5699(88)91256-X; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTON LE, 1985, BIOL INTERFERON SYST, P403; CARUSO A, 1992, J INTERFERON RES, V12, P49, DOI 10.1089/jir.1992.12.49; CZARNIECKI CW, 1985, TNO ISIR M INTERFERO; DELAMAZA LM, 1987, INFECT IMMUN, V55, P2727, DOI 10.1128/IAI.55.11.2727-2733.1987; DEPLA E, 1991, MOL IMMUNOL, V28, P743, DOI 10.1016/0161-5890(91)90117-3; DOBELI H, 1988, J BIOTECHNOL, V7, P199, DOI 10.1016/0168-1656(88)90052-1; DOROW DS, 1985, MOL IMMUNOL, V22, P1255, DOI 10.1016/0161-5890(85)90044-6; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; EPSTEIN LB, 1984, INTERFERONS IMMUNE S, P185; EPSTEIN LB, 1977, INTERFERONS THEIR AC, P91; GEORGIADES JA, 1984, INTERFERONS THEIR AP, V71, P305; GETZOFF ED, 1987, SCIENCE, V235, P1191, DOI 10.1126/science.3823879; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GIBSON UEM, 1989, J IMMUNOL METHODS, V125, P105, DOI 10.1016/0022-1759(89)90083-5; GRAY PW, 1983, P S BIOL BASIS NEW D, P35; ICHIMORI Y, 1987, HYBRIDOMA, V6, P173, DOI 10.1089/hyb.1987.6.173; ICHIMORI Y, 1985, J IMMUNOL METHODS, V80, P55, DOI 10.1016/0022-1759(85)90164-4; JOHNSON HM, 1982, J IMMUNOL, V129, P2357; LANDO G, 1982, J IMMUNOL, V129, P212; LEINIKKI PO, 1987, J IMMUNOL, V139, P3360; LEIST T, 1985, MOL IMMUNOL, V22, P929, DOI 10.1016/0161-5890(85)90079-3; LORD SC, 1989, MOL IMMUNOL, V26, P637, DOI 10.1016/0161-5890(89)90045-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDELL D, 1991, PROTEIN ENG, V4, P335, DOI 10.1093/protein/4.3.335; LUNN CA, 1992, J BIOL CHEM, V267, P17920; LYDON NB, 1985, BIOCHEMISTRY-US, V24, P4131, DOI 10.1021/bi00336a048; MAGAZINE HI, 1991, BIOCHEMISTRY-US, V30, P5784, DOI 10.1021/bi00237a022; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NAGABHUSAN TL, 1989, Patent No. 4751078; NAGABHUSHAN TL, 1985, INTERFERON ALPHA 2 P, P1; NICOLETTI F, 1990, LANCET, V336, P319, DOI 10.1016/0140-6736(90)91860-D; OZMEN L, 1988, LYMPHOKINE RES, V7, P328; PACE JL, 1983, P NATL ACAD SCI-BIOL, V80, P3782, DOI 10.1073/pnas.80.12.3782; RAYMOND CA, 1986, JAMA-J AM MED ASSOC, V256, P685, DOI 10.1001/jama.256.6.685; ROSE K, 1983, BIOCHEM J, V215, P273, DOI 10.1042/bj2150273; SAKAGUCHI M, 1988, FEBS LETT, V230, P201, DOI 10.1016/0014-5793(88)80671-9; SEELIG GF, 1988, BIOCHEMISTRY-US, V27, P1981, DOI 10.1021/bi00406a026; SEELIG GF, 1992, J CELL BIOCHEM, V16, P101; SEELIG GF, 1989, J INTERFERON RES, V4, P184; SIMS JM, 1985, BIOL INTERFERON SYST, P411; SONNENFELD G, 1980, LYMPHOKINE REPORTS, V1, P113; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; TROTTA PP, 1986, INTERFERONS CELL GRO, P497; WETZEL R, 1990, PROTEIN ENG, V3, P611, DOI 10.1093/protein/3.7.611; WONG GHW, 1983, J IMMUNOL, V131, P788	50	6	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					358	363						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506256				2022-12-27	WOS:A1994MR21900060
J	KRAPIVINSKY, G; KRAPIVINSKY, L; VELIMIROVIC, B; WICKMAN, K; NAVARRO, B; CLAPHAM, DE				KRAPIVINSKY, G; KRAPIVINSKY, L; VELIMIROVIC, B; WICKMAN, K; NAVARRO, B; CLAPHAM, DE			THE CARDIAC INWARD RECTIFIER K+ CHANNEL SUBUNIT, CIR, DOES NOT COMPRISE THE ATP-SENSITIVE K+ CHANNEL, I-KATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; GAMMA-SUBUNIT; ACTIVATION; MECHANISM; MYOCYTES; MEMBRANE; HEART	Cardiac I-KACh is comprised of two inwardly rectifying K+ channel subunits, CIR and GIRK1 (Krapivinsky, G., Gordon, E. G., Wickman, K., Velimirovic, B., Krapivinsky, L., and Clapham, D. E. (1995) Nature 374, 135-141). A cardiac protein virtually identical to CIR, termed rcKATP-1 (Ashford, M. L. J., Bond, C. T., Blair, T. A., and Adelman, J. P. (1994) Nature 370, 456-459), was reported to form an ATP-sensitive inwardly rectifying K+ channel, I-KATP. We attempted to determine whether CIR alone or together with an unknown protein(s) participated in the formation of cardiac I-KATP. Expression of CIR in insect, oocyte, and mammalian cell systems did not increase the appearance of ATP-sensitive currents, but rather gave rise to unique strongly inwardly rectifying, G protein-regulated K+ currents. CIR protein is found exclusively in atria, in contrast to the predominance of I-KATP functional activity in ventricle. Also, CIR was completely depleted from heart membrane after immunodepletion of GLRK1. We conclude that CIR/rcK-ATP-1 is not a subunit of cardiac I-KATP and that GIRK1 is the only channel protein coassociating with CIR in heart.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic			Clapham, David/R-5974-2019	Wickman, Kevin/0000-0002-5179-9540; Clapham, David/0000-0002-4459-9428	PHS HHS [54873] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; ITO H, 1991, J GEN PHYSIOL, V98, P517, DOI 10.1085/jgp.98.3.517; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KURACHI Y, 1992, PROG NEUROBIOL, V39, P229, DOI 10.1016/0301-0082(92)90017-9; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; NESBITT SA, 1992, ANAL BIOCHEM, V206, P267, DOI 10.1016/0003-2697(92)90365-E; NICHOLS CG, 1990, J PHYSIOL-LONDON, V423, P91, DOI 10.1113/jphysiol.1990.sp018013; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P3183; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; TERZIC A, 1995, AM J PHYSIOL-CELL PH, V269, pC525, DOI 10.1152/ajpcell.1995.269.3.C525; VANWAGONER DR, 1993, CIRC RES, V72, P973, DOI 10.1161/01.RES.72.5.973; WICKMAN K, 1995, IN PRESS PHYSL REV, V75; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	20	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28777	28779		10.1074/jbc.270.48.28777	http://dx.doi.org/10.1074/jbc.270.48.28777			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499400	hybrid			2022-12-27	WOS:A1995TH05600044
J	TAYLOR, V; WELCHER, AA; SUTER, U				TAYLOR, V; WELCHER, AA; SUTER, U			EPITHELIAL MEMBRANE PROTEIN-1, PERIPHERAL MYELIN PROTEIN-22, AND LENS MEMBRANE-PROTEIN-20 DEFINE A NOVEL GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOOTH DISEASE TYPE-1A; ARREST-SPECIFIC GENE; TREMBLER-J MOUSE; POINT MUTATION; GROWTH ARREST; PMP22 GENE; NERVOUS-SYSTEM; SCHWANN-CELLS; BOVINE LENS; EXPRESSION	Peripheral myelin protein 22 (PMP22) is expressed in many tissues but mainly by Schwann cells as a component of compact myelin of the peripheral nervous system (PNS). Mutations affecting PMP22 are associated with hereditary motor and sensory neuropathies. Although these phenotypes are restricted to the PNS, PMP22 is thought to play a dual role in myelin formation and in cell proliferation. We describe the cloning and characterization of epithelial membrane protein-1 (EMP-1), a putative four-transmembrane protein of 160 amino acids with 40% amino acid identity to PMP22. EMP-1 and PMP22 are co-expressed in most tissues but with differences in relative expression levels. EMP-1 is most prominently found in the gastrointestinal tract, skin, lung, and brain but not in liver. In the corpus gastricum, EMP-1 protein can be detected in epithelial cells of the gastric pit and isthmus of the gastric gland in a pattern consistent with plasma membrane association, EMP-1 and PMP22 mRNA levels are inversely regulated in the degenerating rat sciatic nerve after injury and by growth arrest in NIH 3T3 fibroblasts. The discovery of EMP-1 as the second member of a novel gene family led to the identification of the lens-specific membrane protein 20 (MP20) as a third but distant relative. The proteins of this family are likely to serve similar functions possibly related to cell proliferation and differentiation in a variety of cell types.	ETH HONGGERBERG,INST CELL BIOL,DEPT CELL BIOL,CH-8093 ZURICH,SWITZERLAND; AMGEN INC,THOUSAND OAKS,CA 91320	Swiss Federal Institutes of Technology Domain; ETH Zurich; Amgen			Suter, Ueli/A-1624-2010					ADLKOFER K, 1995, IN PRESS NAT GENET; BAECHNER D, 1995, IN PRESS J NEUROSCI; BANSAL R, 1987, J NEUROCHEM, V49, P1902, DOI 10.1111/j.1471-4159.1987.tb02453.x; BOSSE F, 1994, J NEUROSCI RES, V37, P529, DOI 10.1002/jnr.490370412; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; CHANCE PF, 1994, HUM MOL GENET, V3, P223, DOI 10.1093/hmg/3.2.223; CHANCE PF, 1993, CELL, V72, P143, DOI 10.1016/0092-8674(93)90058-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELEON M, 1991, J NEUROSCI RES, V29, P437; FALK MM, 1994, J CELL BIOL, V127, P343, DOI 10.1083/jcb.127.2.343; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GALVAN A, 1989, J BIOL CHEM, V264, P19974; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GUTEKUNST KA, 1990, CURR EYE RES, V9, P955, DOI 10.3109/02713689009069931; JARVIS LJ, 1993, INVEST OPHTH VIS SCI, V34, P613; KITAMURA K, 1981, 6TH P INT S GLYC, P273; KUHN G, 1993, GLIA, V8, P256, DOI 10.1002/glia.440080406; KUMAR NM, 1993, EXP EYE RES, V56, P35, DOI 10.1006/exer.1993.1006; LEMKE G, 1988, DEVELOPMENT, V102, P499; LOUIS CF, 1989, J BIOL CHEM, V264, P19967; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MATSUNAMI N, 1992, NAT GENET, V1, P176, DOI 10.1038/ng0692-176; MULDERS JWM, 1988, CURR EYE RES, V7, P207, DOI 10.3109/02713688808995750; PAREEK S, 1993, J BIOL CHEM, V268, P10372; PARMANTIER E, 1995, EUR J NEUROSCI, V7, P1080, DOI 10.1111/j.1460-9568.1995.tb01095.x; PATEL PI, 1992, NAT GENET, V1, P159, DOI 10.1038/ng0692-159; ROA BB, 1993, NAT GENET, V5, P189, DOI 10.1038/ng1093-189; ROA BB, 1993, NEW ENGL J MED, V329, P96, DOI 10.1056/NEJM199307083290205; ROA BB, 1993, NAT GENET, V5, P269, DOI 10.1038/ng1193-269; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SNIPES GJ, 1992, J CELL BIOL, V117, P225, DOI 10.1083/jcb.117.1.225; SPREYER P, 1991, EMBO J, V10, P3661, DOI 10.1002/j.1460-2075.1991.tb04933.x; SUTER U, 1994, HUM MUTAT, V3, P95, DOI 10.1002/humu.1380030203; SUTER U, 1993, TRENDS NEUROSCI, V16, P50, DOI 10.1016/0166-2236(93)90015-E; SUTER U, 1992, P NATL ACAD SCI USA, V89, P4382, DOI 10.1073/pnas.89.10.4382; SUTER U, 1995, ANNU REV NEUROSCI, V18, P45, DOI 10.1146/annurev.ne.18.030195.000401; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; SUTER U, 1995, J NEUROSCI RES, V40, P145, DOI 10.1002/jnr.490400202; SUTER U, 1994, J BIOL CHEM, V269, P1; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; TENBROEK E, 1992, J CELL SCI, V103, P245; TIMMERMAN V, 1992, J NEUROL SCI, V109, P41, DOI 10.1016/0022-510X(92)90091-X; VALENTIJN LJ, 1992, NAT GENET, V2, P288, DOI 10.1038/ng1292-288; VALENTIJN LJ, 1992, NAT GENET, V1, P166, DOI 10.1038/ng0692-166; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P7195, DOI 10.1073/pnas.88.16.7195; WISTOW G, 1993, TRENDS BIOCHEM SCI, V18, P301, DOI 10.1016/0968-0004(93)90041-K; ZOIDL G, 1995, EMBO J, V14, P1122, DOI 10.1002/j.1460-2075.1995.tb07095.x	48	133	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28824	28833		10.1074/jbc.270.48.28824	http://dx.doi.org/10.1074/jbc.270.48.28824			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499407	hybrid			2022-12-27	WOS:A1995TH05600051
J	THOMAS, D; PATTERSON, SD; BRADSHAW, RA				THOMAS, D; PATTERSON, SD; BRADSHAW, RA			SRC HOMOLOGOUS AND COLLAGEN (SHC) PROTEIN BINDS TO F-ACTIN AND TRANSLOCATES TO THE CYTOSKELETON UPON NERVE GROWTH-FACTOR STIMULATION IN PG12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 CELLS; RAPID REORGANIZATION; SIGNAL TRANSDUCTION; MEMBRANE SKELETON; TYROSINE KINASES; FACTOR RECEPTOR; V-SRC; IDENTIFICATION; CALCIUM; PHOSPHORYLATION	Immunoprecipitates of metabolically labeled PC12 cells consistently contained a 43-kDa protein that was associated with Shc, a signal-transducing protein with a single SH2 domain. Following affinity chromatography with immobilized recombinant glutathione S-transferase (GST)-Shc fusion protein, the 43-kDa protein was identified as actin by mass spectrometry and immunoblotting. Cosedimentation experiments using purified actin and GST Shc showed that Shc binds directly to F-actin, confirming Shc actin interaction in vivo. Various GST-truncated Shc fusion proteins were prepared and used in actin cosedimentation assays. Constructs containing the SH2 and collagen homology domains were not precipitated, and those containing the aminoterminal domain were. Thus, Shc-actin interactions do not occur in the region of tyrosine phosphorylation and leave the SH2 domain free to bind to other tyrosine-phosphorylated molecules. Although the major pool of Shc in unstimulated PC12 cells is soluble, two other pools are associated with the cytoskeleton and the submembranous cytoskeleton. Upon nerve growth factor stimulation, approximately 50% of the soluble Shc translocates to both cytoskeleton environments within 2 min, decreasing thereafter. When cells were pretreated with cytochalasin D, a drug that disrupts actin filaments, Shc translocation to the cytoskeleton was abolished. However, in the submembranous fraction, the Shc level was elevated in resting cells following cytochalasin D treatment. The kinetics of translocation, compared to mitogen-activated protein kinase activation, and the nature of the Shc-actin interaction suggest that the cytoskeletal association of Shc, induced by growth factors, may be related to membrane ruffling and actin fiber reorganization.	AMGEN INC, THOUSAND OAKS, CA 91320 USA	Amgen	THOMAS, D (corresponding author), UNIV CALIF IRVINE, COLL MED, DEPT BIOL CHEM, IRVINE, CA 92717 USA.		Patterson, Scott/A-7404-2009; Bradshaw, Ralph A/K-1515-2013		NATIONAL INSTITUTE ON AGING [R01AG009735] Funding Source: NIH RePORTER; NIA NIH HHS [AG09735] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BASU T, 1994, ONCOGENE, V9, P3483; BENJAMIN CW, 1994, J BIOL CHEM, V269, P30911; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CHANG CP, 1991, J BIOL CHEM, V266, P23467; CONTRERAS ML, 1987, J NEUROCHEM, V48, P1466, DOI 10.1111/j.1471-4159.1987.tb05687.x; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DILIBERTO PA, 1992, J BIOL CHEM, V267, P11888; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; FOX GM, 1988, J BIOL CHEM, V263, P18452; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; GUINEBAULT C, 1994, CELL MOL BIOL, V40, P687; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HABIB T, 1994, J BIOL CHEM, V269, P25243; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; HENKE RC, 1991, NEUROCHEM RES, V16, P675, DOI 10.1007/BF00965554; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KIM UH, 1991, J BIOL CHEM, V266, P1359; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; KUMAR G, 1995, BIOCHEM J, V307, P215, DOI 10.1042/bj3070215; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; OKAMURA H, 1994, ONCOGENE, V9, P2293; OWENLYNCH PJ, 1995, J BIOL CHEM, V270, P5956, DOI 10.1074/jbc.270.11.5956; PATTERSON SD, 1994, ANAL BIOCHEM, V221, P1, DOI 10.1006/abio.1994.1371; PATTERSON SD, 1994, ANAL CHEM, V66, P3727, DOI 10.1021/ac00093a030; PATTERSON SD, 1995, ELECTROPHORESIS, V16, P1104, DOI 10.1002/elps.11501601187; PAVES H, 1990, EXP CELL RES, V186, P218, DOI 10.1016/0014-4827(90)90299-P; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIDLEY AJ, 1994, J CELL SCI, P127; RIJKEN PJ, 1991, J CELL SCI, V100, P491; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SAXTON TM, 1994, J IMMUNOL, V153, P623; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPENGLER B, 1992, RAPID COMMUN MASS SP, V6, P105, DOI 10.1002/rcm.1290060207; SZEBERENYI J, 1992, ONCOGENE, V7, P2105; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TOHYAMA Y, 1994, J BIOL CHEM, V269, P32796; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHANG WZ, 1994, PROTEIN SCI, V3, P677	79	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28924	28931		10.1074/jbc.270.48.28924	http://dx.doi.org/10.1074/jbc.270.48.28924			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499422	hybrid			2022-12-27	WOS:A1995TH05600066
J	WANG, D; SUL, HS				WANG, D; SUL, HS			UPSTREAM STIMULATORY FACTORS BIND TO INSULIN-RESPONSE SEQUENCE OF THE FATTY-ACID SYNTHASE PROMOTER - USF1 IS REGULATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; HELIX-LOOP-HELIX; MAJOR LATE PROMOTER; GROWTH-HORMONE GENE; RNA POLYMERASE-II; DEHYDROGENASE GENE; MULTIPLE FORMS; RAT-LIVER; ELEMENT; EXPRESSION	Fatty acid synthase (FAS) plays a central role in de novo lipogenesis in mammals, The concentration or activity of FAS in liver and adipose tissue changes dramatically when animals are subjected to nutritional and hormonal manipulations. We previously reported that due to changes in transcription, FAS synthesis declines and increases in an insulin-dependent manner during fasting and refeeding, respectively, and that insulin administration of streptozotocin-diabetic mice stimulates FAS transcription. We previously mapped the FAS insulin response sequence (IRS) to the proximal promoter region from position -71 to position -50, which contains an E-box DNA binding motif, Here, using competition gel shift assays and specific upstream stimulatory factor (USF) antibodies, we identified USF1 and USF2 as major components of complexes that bind to the FAS IRS, W-cross-linking experiments further supported that USFs bind the FAS IRS, We also found that the amount of the 43-kDa USF1 was dramatically increased in liver of refed rats, In contrast, the amount of USF2 remained the same in liver of fasted or refed rats, Moreover, a 17-kDa protein in both fasted and refed rat liver was recognized by anti-USF1 antibodies, and this 17-kDa USF1 related protein was expressed in a manner opposite to that of the 43-kDa USF1, i.e. high in liver of fasted rats and decreased in liver of refed rats. These data suggest that the regulation of USF expression mayplay an important role in the regulation of FAS transcription.	UNIV CALIF BERKELEY, DEPT NUTR SCI, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			Han, Zaiqi/AAI-2233-2019		NIDDK NIH HHS [DK-36264] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036264] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BUNGERT J, 1992, J MOL BIOL, V223, P885, DOI 10.1016/0022-2836(92)90250-N; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHANG LS, 1989, J VIROL, V63, P3479, DOI 10.1128/JVI.63.8.3479-3488.1989; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GREAVES RF, 1991, J VIROL, V65, P6705, DOI 10.1128/JVI.65.12.6705-6713.1991; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; JUMP DB, 1985, ENDOCRINOLOGY, V117, P2259, DOI 10.1210/endo-117-6-2259; KAULEN H, 1991, MOL CELL BIOL, V11, P412, DOI 10.1128/MCB.11.1.412; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; KOZLOWSKI MT, 1991, DEV BIOL, V148, P625, DOI 10.1016/0012-1606(91)90280-G; LAKSHMAN.MR, 1972, P NATL ACAD SCI USA, V69, P3516, DOI 10.1073/pnas.69.12.3516; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; LEMAIGRE FP, 1989, EUR J BIOCHEM, V181, P555, DOI 10.1111/j.1432-1033.1989.tb14760.x; LIAW C, 1983, BIOCHEMISTRY-US, V22, P213, DOI 10.1021/bi00270a031; MILLIPORE, 1990, PROTEIN BLOTTING PRO; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MOUSTAID N, 1993, BIOCHEM J, V292, P767, DOI 10.1042/bj2920767; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; OSBORN L, 1988, J BIOL CHEM, V263, P16519; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; PERITZ LN, 1988, J BIOL CHEM, V263, P5005; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; POTTER JJ, 1991, J BIOL CHEM, V266, P15457; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; SATO M, 1990, EUR J BIOCHEM, V188, P231, DOI 10.1111/j.1432-1033.1990.tb15394.x; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCOTTO KW, 1989, GENE DEV, V3, P651, DOI 10.1101/gad.3.5.651; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; ZWARTKRUIS F, 1991, MECH DEVELOP, V33, P179, DOI 10.1016/0925-4773(91)90026-3	48	105	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28716	28722		10.1074/jbc.270.48.28716	http://dx.doi.org/10.1074/jbc.270.48.28716			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499393	hybrid			2022-12-27	WOS:A1995TH05600037
J	AMATRUDA, TT; DRAGASGRAONIC, S; HOLMES, R; PEREZ, HD				AMATRUDA, TT; DRAGASGRAONIC, S; HOLMES, R; PEREZ, HD			SIGNAL-TRANSDUCTION BY THE FORMYL PEPTIDE RECEPTOR - STUDIES USING CHIMERIC RECEPTORS AND SITE-DIRECTED MUTAGENESIS DEFINE A NOVEL DOMAIN FOR INTERACTION WITH G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHOLIPASE-C; PERTUSSIS TOXIN; LIGAND-BINDING; AMINO-ACID; ACTIVATION; FORMYLPEPTIDE; NEUTROPHILS; CELLS	The binding of small peptide ligands to high affinity chemoattractant receptors on the surface of neutrophils and monocytes leads to activation of heterotrimeric G-proteins, stimulation of phosphatidylinositol-phospho lipase C (PI-PLC), and subsequently to the inflammatory response, It was recently shown (Amatruda, T. T., Gerard, N. P., Gerard, C., and Simon, M. I. (1993) J. Biol. Chem, 268, 10139-10144) that the receptor for the chemoattractant peptide C5a specifically interacts with G alpha(16), a G-protein alpha subunit of the G(q) class, to trigger ligand-dependent stimulation of PI-PLC in transfected cells. In order to further characterize this chemoattractant peptide signal transduction pathway, we transfected cDNAs encoding the formylmethionylleucylphenylalanine receptor (fMLPR) into COS cells and measured the production of inositol phosphates. Ligand-dependent activation of PI-PLC was seen in COS cells transfected with the fMLPR and G alpha(16) and stimulated with fMLP but not in cells transfected with receptor alone or with receptor plus G alpha(q). Chimeric receptors in which the N-terminal extracellular domain, the second intracellular domain, or the intracellular C-terminal tail of the fMLP receptor was replaced with C5a receptor domains (Perez, H. D., Holmes, R., Vilander, L. R., Adams, R. R., Manzana, W., Jolley, D., and Andrews, W. H. (1993) J. Biol. Chem. 268, 2292-2295) were capable of ligand-dependent activation of PI-PLC when co-transfected with G alpha(16). A chimeric receptor exchanging the first intracellular domain of the fMLPR was constitutively activated, stimulating PI-PLC in the absence of ligand, Constitutive activation of PI-PLC, to a level 233% of that seen in cells transfected with wild-type fMLP receptors, was dependent on G alpha(16). Site-directed mutagenesis of the first intracellular domain of the fMLPR (amino acids 54-62) reveals this to be a domain necessary for ligand-dependent activation of G alpha(16). These results suggest that different receptors which mediate similar biochemical responses may utilize distinct mechanisms to activate G-proteins, Differences among the signaling pathways triggered by chemoattractant factor receptors suggest an opportunity for pharmacologic modifications of the inflammatory response.	BERLEX BIOSCI, DEPT IMMUNOL, RICHMOND, CA 94804 USA		AMATRUDA, TT (corresponding author), UNIV MINNESOTA, DEPT MED, DIV MED ONCOL, UMHC BOX 286, MINNEAPOLIS, MN 55455 USA.							AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BOMMAKANTI RK, 1993, J LEUKOCYTE BIOL, V54, P572, DOI 10.1002/jlb.54.6.572; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; BUHL AM, 1993, FEBS LETT, V323, P123; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KRAUSE KH, 1985, J CLIN INVEST, V76, P1348, DOI 10.1172/JCI112109; MORO O, 1993, J BIOL CHEM, V268, P22273; OMANN GM, 1987, J IMMUNOL, V138, P2626; PEREZ HD, 1994, J BIOL CHEM, V269, P22485; PEREZ HD, 1993, J BIOL CHEM, V268, P2292; POLAKIS PG, 1988, J BIOL CHEM, V263, P4969; QUEHENBERGER O, 1993, J BIOL CHEM, V268, P18167; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SMITH CD, 1986, SCIENCE, V232, P97, DOI 10.1126/science.3006254; SNYDERMAN R, 1990, ADP RIBOSYLATING TOX, P295; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; WU DQ, 1992, J BIOL CHEM, V267, P1811	21	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28010	28013						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499283				2022-12-27	WOS:A1995TG21000008
J	HANSEN, SH; OLSSON, A; CASANOVA, JE				HANSEN, SH; OLSSON, A; CASANOVA, JE			WORTMANNIN, AN INHIBITOR OF PHOSPHOINOSITIDE 3-KINASE, INHIBITS TRANSCYTOSIS IN POLARIZED EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MDCK CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; BREFELDIN-A; RECEPTOR; COMPLEX; ENDOCYTOSIS; TRANSPORT; SECRETION; SURFACE	Wortmannin, an inhibitor of phosphoinositide 3-kinase, inhibits both basolateral to apical and apical to basolateral transcytosis of ricin in Fisher rat thyroid (FRT) cells by 50% at 100 nM in a continuous transcytosis assay. In MDCK cells, a similar effect of wortmannin on basolateral to apical transcytosis of ricin was found, whereas apical to basolateral transcytosis was inhibited to a lesser degree. Transcytosis of dimeric IgA in MDCK cells expressing the polymeric immunoglobulin receptor was also reduced to 50% of controls, suggesting that wortmannin inhibits membrane translocation rather than sorting of specific proteins in the transcytotic pathway. This effect of wortmannin is selective, however, in that endocytosis at the basolateral domain and recycling at both the basolateral and apical membrane domains are unaffected, and apical endocytosis and apical secretion are only moderately reduced. We have shown previously that cAMP stimulates a late stage in basolateral to apical transcytosis in MDCK cells through activation of protein kinase A (Hansen, S. H., and Casanova, J. E. (1994) J. Cell Biol. 126, 677-687). Elevation of cellular cAMP still induced a 100% increase in transcytosis in wortmannin-treated cells, but transcytosis was no longer increased when compared to cells which received no drugs. In contrast, in experiments using a 17 degrees C block to accumulate ricin internalized from the basolateral surface in the apical compartment of MDCK cells, wortmannin had little effect on the stimulation of transcytosis by activators of protein kinase A observed under these conditions. The data thus suggest the existence of a wortmannin sensitive step in the transcytotic pathway, positioned after endocytosis but prior to translocation into the protein kinase A-sensitive apical compartment, implying a role for phosphoinositide 3-kinase in an intermediate step in transcytosis in polarized epithelial cells.			HANSEN, SH (corresponding author), MASSACHUSETTS GEN HOSP E, DEPT PEDIAT, 149 13TH ST, BOSTON, MA 02129 USA.			Hansen, Steen/0000-0002-9408-4676	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033506] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32291] Funding Source: Medline; NIDDK NIH HHS [DK33506] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APODACA G, 1994, J BIOL CHEM, V269, P19005; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BRANTZAEG P, 1977, CLIN EXP IMMUNOL, V30, P77; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; EKER P, 1994, J BIOL CHEM, V269, P18607; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; HUNZIKER W, 1994, J BIOL CHEM, V269, P29003; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LAM K, 1994, J BIOL CHEM, V269, P20648; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MATLIN KS, 1983, CELL, V233; MATTER K, 1990, EMBO J, V9, P3163, DOI 10.1002/j.1460-2075.1990.tb07514.x; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; POWIS G, 1994, CANCER RES, V54, P2419; PRYDZ K, 1992, J CELL BIOL, V119, P259, DOI 10.1083/jcb.119.2.259; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHIMIZU H, 1969, J NEUROCHEM, V16, P1609, DOI 10.1111/j.1471-4159.1969.tb10360.x; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STACK JH, 1994, J BIOL CHEM, V269, P31552; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VANDEURS B, 1990, EUR J CELL BIOL, V51, P96; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YANO H, 1993, J BIOL CHEM, V268, P25846; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031	58	101	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28425	28432						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499348				2022-12-27	WOS:A1995TG21000073
J	ROSING, J; HOEKEMA, L; NICOLAES, GAF; CHRISTELLA, M; THOMASSEN, LGD; HEMKER, HC; VARADI, K; SCHWARZ, HP; TANS, G				ROSING, J; HOEKEMA, L; NICOLAES, GAF; CHRISTELLA, M; THOMASSEN, LGD; HEMKER, HC; VARADI, K; SCHWARZ, HP; TANS, G			EFFECTS OF PROTEIN-S AND FACTOR XA ON PEPTIDE-BOND CLEAVAGES DURING INACTIVATION OF FACTOR VA AND FACTOR VA(R506Q) BY ACTIVATED PROTEIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POOR ANTICOAGULANT RESPONSE; BLOOD-COAGULATION; THROMBOTIC DISEASE; HUMAN-PLASMA; BOVINE; PROTHROMBIN; DEFICIENCY; PHOSPHOLIPIDS; THROMBOPHILIA; INHIBITION	Inactivation of membrane-bound factor Va by activated protein C (APC) proceeds via a biphasic reaction that consists of a rapid and a slow phase, which are associated with cleavages at Arg(506),and Arg(306) Of the heavy chain of factor Va, respectively, We have investigated the effects of protein S and factor Xa on APC-catalyzed factor Va inactivation, Protein S accelerates factor Va inactivation by selectively promoting the slow cleavage at Arg(306) (20-fold), Factor Xa protects factor Va from inactivation by APC by selectively blocking cleavage at Arg(506). Inactivation of factor Va(R506Q), which was isolated from the plasma of a homozygous APC resistant patient and which lacks the Arg(506) cleavage site, was also stimulated by protein S but was not affected by factor Xa, This confirms that the target sites of protein S and factor Xa involve Arg(306) and Arg(506), respectively, Factor Xa completely blocked APC-catalyzed cleavage at Arg(506) in, normal factor Va (1 nM) With a half-maximal effect (K-1/2Xa) at 1.9 nM factor Xa. Expression of cofactor activity of factor Va in prothrombin activation required much lower factor Xa concentrations (K-1/2Xa = 0.08 nM). When the ability of factor Xa to protect factor Va from inactivation by APC was determined at low factor Va concentrations during prothrombin activation much lower amounts of factor Xa were required (K-1/2Xa = 0.03 nM). This indicates 1) that factor Va is optimally protected from inactivation by APC by incorporation into the prothrombinase complex during ongoing prothrombin activation, and 2) that the formation of a catalytically active prothrombinase complex and protection of factor Va from inactivation by APC likely involves the same interaction of factor Xa with factor Va, In accordance with the proposed mechanisms of action of protein S and factor Xa, we observed that the large differences between the rates of APC-catalyzed inactivation of normal factor Va and factor Va(R506Q) Were almost annihilated in the presence of factor Xa and protein S, This observation may explain why, in the absence of other risk factors, APC resistance only results in a weak prothrombotic condition,	IMMUNO AG WIEN,A-1220 VIENNA,AUSTRIA		ROSING, J (corresponding author), UNIV LIMBURG,CARDIOVASC RES INST MAASTRICHT,DEPT BIOCHEM,POB 616,6200 MD MAASTRICHT,NETHERLANDS.		Nicolaes, Gerry A.F./A-8421-2016	Nicolaes, Gerry A.F./0000-0002-2482-0412; Thomassen, Stella/0000-0002-9686-6364; Hemker, Coen/0000-0003-1669-2358				BAKKER HM, 1992, EUR J BIOCHEM, V208, P171, DOI 10.1111/j.1432-1033.1992.tb17171.x; BAUER KA, 1995, NEW ENGL J MED, V332, P1383; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; COMP PC, 1979, BLOOD, V54, P1272; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DISCIPIO RG, 1979, BIOCHEMISTRY-US, V18, P899, DOI 10.1021/bi00572a026; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FAIONI EM, 1993, THROMB HAEMOSTASIS, V70, P1067; FERSHT A, 1985, ENZYME STRUCTURE MEC, P128; FULCHER CA, 1984, BLOOD, V63, P486; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; GRIFFIN JH, 1993, BLOOD, V82, P1989; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; GRUBER A, 1989, BLOOD, V73, P639; HEEB MJ, 1994, P NATL ACAD SCI USA, V91, P2728, DOI 10.1073/pnas.91.7.2728; HOPMEIER P, 1995, NEW ENGL J MED, V332, P1381; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KALAFATIS M, 1995, J BIOL CHEM, V270, P4054; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; PLETCHER CH, 1982, J BIOL CHEM, V257, P5342; ROSING J, 1993, J BIOL CHEM, V268, P21130; ROSING J, 1980, J BIOL CHEM, V255, P274; SALA N, 1984, BLOOD, V63, P671; SCHIFFMAN S, 1969, BIOCHEMISTRY-US, V8, P1397, DOI 10.1021/bi00832a014; SCHWARZ HP, 1984, BLOOD, V64, P1297; SIMIONI P, 1995, NEW ENGL J MED, V332, P1382; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RL, 1973, J BIOL CHEM, V248, P2418; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; TANS G, 1991, BLOOD, V77, P2641; TANS G, 1991, J BIOL CHEM, V266, P21864; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; ZOLLER B, 1994, LANCET, V343, P1536, DOI 10.1016/S0140-6736(94)92940-8	48	205	209	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27852	27858		10.1074/jbc.270.46.27852	http://dx.doi.org/10.1074/jbc.270.46.27852			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499257				2022-12-27	WOS:A1995TE73600068
J	YODERHILL, J; GOLUBIC, M; STACEY, DW				YODERHILL, J; GOLUBIC, M; STACEY, DW			A CONSERVED REGION OF C-HA-RAS IS REQUIRED FOR EFFICIENT GTPASE STIMULATION BY GTPASE-ACTIVATING PROTEIN BUT NOT NEUROFIBROMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; CATALYTIC DOMAIN; BINDING DOMAIN; GAP; P21; INTERACTS; MUTANTS	The effector binding domain and the switch II region of c-Ha-Ras are necessary for p120(GAP)-stimulated GTP hydrolysis. We report a third region of c-Ha-Ras located within the alpha3 helix (amino acids 101-103) which is also required for efficient p120(GAP), but not neurofibromin-mediated hydrolysis. This highly conserved region of the Ras protein was investigated using an insertion-deletion mutant (Ras-100LIR104) originally characterized by Willumsen et al. (Willumsen, B.M., Adari, H., Zhang, K., Papageorge, A.G., Stone, J.C., McCormick, F., and Lowy, D.R. (1989) in The Guanine Nucleotide Binding Proteins; Common Structural and Functional Properties (Bosch, L., Kraal, B., and Parmeggiane, A., eds) pp. 165-178, Plenum Press, New York). The 100LIR substitution did not alter the intrinsic hydrolytic rate of the protein. The p120(GAP)-stimulated hydrolysis of Ras-100LIR104, however, was decreased by 2-3-fold compared to wild type Ras. This decrease in p120(GAP)-stimulated hydrolysis was not due to its inability to physically associate with Ras-100LIR104-GTP (as determined by competitive binding assays). Surprisingly, neurofibromin-stimulated GTP hydrolysis was unaltered by the mutation. Finally, no differences were observed in the ability of either the p120(GAP) catalytic domain or the neurofibromin GRD to accelerate Ras-100LIR104 GTPase activity, indicating that the amino-terminal noncatalytic GAP region is critical for p120(GAP)-stimulated GTP hydrolysis. This is the first report of a Ras mutation which differentiates between p120(GAP) and neurofibromin activity.	CLEVELAND CLIN FDN, RES INST, DEPT MOLEC BIOL, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation					NCI NIH HHS [CA53496] Funding Source: Medline; NIGMS NIH HHS [GM 52271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; GOLUBIC M, 1992, ONCOGENE, V7, P2151; HETTICH L, 1994, CANCER RES, V54, P5438; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARUTA H, 1991, J BIOL CHEM, V266, P11661; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PARK S, 1992, J BIOL CHEM, V267, P11612; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; WILLUMSEN BM, 1989, NATO ADV SCI I A-LIF, V165, P165; WOOD DR, 1994, J BIOL CHEM, V269, P5322; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380; ZHANG K, 1991, SCIENCE, V254, P1630, DOI 10.1126/science.1749934	22	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27615	27621		10.1074/jbc.270.46.27615	http://dx.doi.org/10.1074/jbc.270.46.27615			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499225	hybrid			2022-12-27	WOS:A1995TE73600036
J	QIAN, YW; LEE, EYHP				QIAN, YW; LEE, EYHP			DUAL RETINOBLASTOMA-BINDING PROTEINS WITH PROPERTIES RELATED TO A NEGATIVE REGULATOR OF RAS IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLADDER-CARCINOMA CELLS; SACCHAROMYCES-CEREVISIAE; GENE-PRODUCT; RB GENE; TUMOR SUPPRESSOR; EXPRESSION; CYCLE; TUMORIGENICITY; IDENTIFICATION; TRANSCRIPTION	The retinoblastoma protein (Rb) interacts with multiple cellular proteins that mediate its cellular function. We have identified nine polypeptides that bind to the T-binding domains of Rb using an Rb affinity resin. RbAp48 and RbAp46 are quantitatively the major Rb-associated proteins purified by this approach. RbAp48 was characterized previously and was found to be related to MSI1, a negative regulator of has in the yeast Saccharomyces cerevisiae. Here we report the cloning and characterization of RbAp46. RbAp46 shares 89.4% amino acid identity with RbAp48. The internal WD repeats, which are found in a growing number of eukaryotic proteins, are conserved between RbAp46 and RbAp48. Like RbAp48, RbAp46 forms a complex with Rb both in vitro and in vivo and suppresses the heat-shock sensitivity of the yeast RAS2(val-19) strains. We have also isolated the murine cDNA homologs of RbAp48 and RbAp46. Although both mRNA can be detected in all mouse tissues, their mRNA levels vary dramatically between different tissues. No significant differences were observed in the expression patterns of these genes in most tissues except thymus, testis, and ovary/uterus, in which 2-fold differences were observed. Interestingly, the mouse and human RbAp48 amino acid sequences are completely identical, and the mouse and human RbAp46 differ only by one conserved amino acid substitution. These results suggest that RbAp48 and RbAp46 may have shared as well as unique functions in the regulation of cell proliferation and differentiation.	UNIV TEXAS,HLTH SCI CTR,CTR MOLEC MED,INST BIOTECHNOL,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Health San Antonio					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R43HD030625] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA049649, R37CA049649, R29CA049649] Funding Source: NIH RePORTER; NCI NIH HHS [CA49649] Funding Source: Medline; NICHD NIH HHS [HD30625] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEIER DR, 1982, NATURE, V300, P724, DOI 10.1038/300724a0; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOOKSTEIN R, 1991, Critical Reviews in Oncogenesis, V2, P211; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN PL, 1992, CELL GROWTH DIFFER, V3, P119; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; ENGELBERG D, 1994, MOL CELL BIOL, V14, P4929, DOI 10.1128/MCB.14.7.4929; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1993, NAT GENET, V5, P3, DOI 10.1038/ng0993-3; NEVINS JR, 1992, SCIENCE, V258, P424; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; RUGGIERI R, 1989, P NATL ACAD SCI USA, V86, P8778, DOI 10.1073/pnas.86.22.8778; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307	46	126	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25507	25513		10.1074/jbc.270.43.25507	http://dx.doi.org/10.1074/jbc.270.43.25507			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7503932	hybrid			2022-12-27	WOS:A1995TB46600036
J	MUDGAPALLI, A; ROY, SK; HOLMES, EH; VIJAY, IK				MUDGAPALLI, A; ROY, SK; HOLMES, EH; VIJAY, IK			PHOTOIDENTIFICATION OF MANNOSYLTRANSFERASES OF DOLICHOL CYCLE IN THE MAMMARY-GLAND - PURIFICATION AND CHARACTERIZATION OF GDP-MAN MAN-BETA-1-]4GLCNAC-BETA-1-]4GLCNAC-P-P-DOLICHOL MANNOSYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; ASPARAGINE-LINKED OLIGOSACCHARIDE; 35-KDA MEMBRANE-PROTEIN; UDP-N-ACETYLGLUCOSAMINE; CULTURED SOYBEAN CELLS; MOLECULAR-CLONING; MURINE BETA-1,4-GALACTOSYLTRANSFERASE; TRANSCRIPTIONAL REGULATION; GLYCOSYLATION PATHWAY; TRANSMEMBRANE DOMAIN	Glc3Man9GlcNAc2-P-P-Dol serves as the major precursor for the biosynthesis of asparagine-linked glycoproteins in eukaryotes. The first 5 of the 9 mannosyl residues during the assembly of the oligosaccharide moiety within the dolichol cycle in the endoplasmic reticulum are incorporated directly by the action of GDP-Man-requiring mannosyltransferases while the remaining last 4 mannosyl residues are transferred by Man-P-Dol-requiring enzymes. In an earlier study (Shailubhai, K., Illeperuma, C., Tayal, M., and Vijay, I. K. (1990) J. Biol. Chem. 265,14105-14108), we identified the enzyme UDPGlc:Dol-P glucosyltransferase by photolabeling rat mammary microsomes with 5-N3-[beta-P-32]UDP-Glc. Applying a similar strategy, GDP-hexanolamine-I-125-azidosalicylic acid, an analog of GDP-Man, was found to photolabel two polypeptides of 37 and 69 kDa among the microsomal proteins of the rat mammary gland. A differential ammonium sulfate saturation (60-80%) of the detergent-solubilized microsomal proteins enriched the 69-kDa polypeptide. Photolabeling of this polypeptide was specifically inhibited by guanine-containing nucleotides and nucleotide-sugars and was associated with a GDP-Man-requiring mannosyltransferase. The mannosyltransferase was purified nearly 16,000-fold and shown to contain the 69-kDa polypeptide. The purified enzyme catalyzes the transfer of [C-14]Man from GDP-[C-14]Man to Manbeta1 --> 4GlcNAcbeta1 --> 4GlcNAc-P-P-Dol in alpha1,3-linkage to give [C-14]Manalpha1 --> 3Manbeta1 --> 4GlcNAcbeta1 --> 4GlcNAc-P-P-Dol as the product. Antibodies raised against the 69-kDa polypeptide removed the enzymatic activity from the detergent extract of the rat mammary microsomes and reacted specifically with a polypeptide band of the same size on immunoblots. The purified enzyme showed a pH optima of 7.4-7.8, K(m) approximately 4 muM for GDP-Man, approximately 2-fold activation by phosphatidylcholine, and a strong inhibition by sulfhydryl-selective reagents, N-ethylmaleimide and p-chloromercuribenzoate. The availability of the highly purified enzyme and a monospecific antibody should allow its molecular cloning for investigating the regulation of the machinery for protein N-glycosylation upon hormonally modulated growth and differentiation of the mammary gland during its ontogeny.	UNIV MARYLAND, DEPT ANIM SCI, COLL PK, MD 20742 USA; PACIFIC NW RES FDN, SEATTLE, WA 98122 USA	University System of Maryland; University of Maryland College Park					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019682] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19682] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBRIGHT CF, 1990, J BIOL CHEM, V265, P7042; ALBRIGHT CF, 1989, P NATL ACAD SCI USA, V86, P7366, DOI 10.1073/pnas.86.19.7366; AMES BN, 1960, J BIOL CHEM, V235, P769; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; CHATTERJEE S, 1992, J BIOL CHEM, V267, P7148; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; CZICHI U, 1977, J BIOL CHEM, V252, P7901; D'SOUZA-SCHOREY C, 1993, J BIOL CHEM, V268, P4720; DRAKE R, 1990, BIOSCIENCE REP, V10, P61, DOI 10.1007/BF01116852; DRAKE RR, 1991, PLANT PHYSIOL, V97, P396, DOI 10.1104/pp.97.1.396; ESTON BW, 1991, J BIOL CHEM, V267, P4152; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GOLD P, 1983, J BIOL CHEM, V258, P2967; HASELBECK A, 1989, EUR J BIOCHEM, V181, P663, DOI 10.1111/j.1432-1033.1989.tb14774.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; HOLLIS GF, 1989, BIOCHEM BIOPH RES CO, V162, P1069, DOI 10.1016/0006-291X(89)90782-1; HOLMES EH, 1990, J BIOL CHEM, V265, P13150; HORI H, 1985, PLANT PHYSIOL, V77, P840, DOI 10.1104/pp.77.4.840; JENSEN JW, 1981, J BIOL CHEM, V256, P2899; JENSEN JW, 1985, EUR J BIOCHEM, V153, P41, DOI 10.1111/j.1432-1033.1985.tb09264.x; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1991, J BIOL CHEM, V266, P6991; KAUSHAL GP, 1986, PLANT PHYSIOL, V82, P748, DOI 10.1104/pp.82.3.748; KAUSHAL GP, 1985, J BIOL CHEM, V260, P6303; KAUSHAL GP, 1986, PLANT PHYSIOL, V81, P1086, DOI 10.1104/pp.81.4.1086; KAUSHAL GP, 1986, ARCH BIOCHEM BIOPHYS, V250, P38, DOI 10.1016/0003-9861(86)90699-5; KAUSHAL GP, 1987, BIOCHEMISTRY-US, V26, P7953, DOI 10.1021/bi00398a061; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; KUMAR R, 1991, J BIOL CHEM, V266, P21777; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; Lowe J B, 1991, Semin Cell Biol, V2, P289; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MATERN H, 1990, EUR J BIOCHEM, V190, P99, DOI 10.1111/j.1432-1033.1990.tb15551.x; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PALAMARCZYK G, 1990, P NATL ACAD SCI USA, V87, P2666, DOI 10.1073/pnas.87.7.2666; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PRAKASH C, 1984, EUR J BIOCHEM, V139, P87, DOI 10.1111/j.1432-1033.1984.tb07980.x; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROBBINS PW, 1991, BIOCHEM SOC T, V19, P642, DOI 10.1042/bst0190642; ROYCHOUDHURY S, 1989, J BIOL CHEM, V264, P9380; RUNGE KW, 1984, J BIOL CHEM, V259, P412; RUNGE KW, 1986, J BIOL CHEM, V261, P5582; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SARNESTO A, 1992, J BIOL CHEM, V267, P2737; SARNESTO A, 1992, J BIOL CHEM, V267, P2745; SCHUTZBACH JS, 1980, J BIOL CHEM, V255, P4170; SHAILUBHAI K, 1990, J BIOL CHEM, V265, P14105; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; SHARMA CB, 1990, BIOCHEMISTRY-US, V29, P8901, DOI 10.1021/bi00490a004; SHARMA CB, 1982, EUR J BIOCHEM, V126, P319; SHIELDS D, 1978, J BIOL CHEM, V253, P3753; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; SILBERSTEIN S, 1992, J BIOL CHEM, V267, P23658; SVENSSON EC, 1992, J BIOL CHEM, V267, P3466; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; TAI T, 1977, BIOCHEM BIOPH RES CO, V78, P434, DOI 10.1016/0006-291X(77)91273-6; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TRIMBLE RB, 1979, J BIOL CHEM, V254, P9708; VIJAY IK, 1980, J BIOL CHEM, V255, P1221; VIJAY IK, 1980, J BIOL CHEM, V255, P1210; VIJAY IK, 1977, J SUPRAMOL STR CELL, V7, P251, DOI 10.1002/jss.400070209; VIJAY IK, 1984, ADV CHITIN CHITOSAN, P347; WANG XC, 1990, J BIOL CHEM, V265, P17849; WEN DX, 1992, J BIOL CHEM, V267, P21011; WEN DX, 1992, J BIOL CHEM, V267, P2512; WESTPHAL H, 1989, FASEB J, V3, P117, DOI 10.1096/fasebj.3.2.2492478; YADAV SP, 1991, J BIOL CHEM, V266, P698	76	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11327	11336						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512562				2022-12-27	WOS:A1994NF96600055
J	DING, YG; BRUNDEN, KR				DING, YG; BRUNDEN, KR			THE CYTOPLASMIC DOMAIN OF MYELIN GLYCOPROTEIN P-0 INTERACTS WITH NEGATIVELY CHARGED PHOSPHOLIPID-BILAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL-NERVE MYELIN; PERFORMANCE LIQUID-CHROMATOGRAPHY; PROTEIN-INDUCED AGGREGATION; SHIVERER MUTANT MICE; BASIC-PROTEIN; UNMYELINATED NERVES; SCHWANN-CELLS; PO-PROTEIN; PHOSPHORYLATION; GENE	The intracellular COOH-terminal domain of the glycoprotein, P-0, has been proposed to be involved in the formation of the major dense line of peripheral myelin. We have addressed this hypothesis by generating and subsequently isolating a peptide fragment that contains 65 of the 69 residues of the cytoplasmic region of rat P-0. This peptide, termed P-0(intra), bound to artificial phospholipid vesicles and caused their rapid aggregation. The peptide-induced aggregation of membrane bilayers appeared to result from ionic interactions, since P-0(intra)-vesicle association was decreased by 1) reducing the phosphatidylserine content of the membranes, 2) increasing the NaCl concentration of the surrounding buffer, or 3) elevating the divalent cation concentration within the buffers. Cationic disc gel electrophoresis of P-0(intra), revealed at least four charge isoforms of the peptide. Treatment of sciatic nerve slices with phorbol ester prior to isolation of P-0(intra), increased the amount of the more negatively charged species, suggesting that at least some of the charge heterogeneity of the peptide can be attributed to differing phosphorylation states. The ability of P-0(intra), to bind to phospholipid bilayers implies that the cytoplasmic domain of P-0 may be responsible for the formation and maintenance of the myelin major dense line.	GLIATECH INC, DISCOVERY RES GRP, CLEVELAND, OH 44122 USA; UNIV MISSISSIPPI, MED CTR, DEPT BIOCHEM, JACKSON, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center			Brunden, Kurt/D-1994-2009		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS027587] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-27587] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGRAWAL HC, 1990, NEUROCHEM RES, V15, P993, DOI 10.1007/BF00965745; AGUAYO AJ, 1976, J NEUROCYTOL, V5, P565, DOI 10.1007/BF01175570; AGUAYO AJ, 1976, BRAIN RES, V104, P1, DOI 10.1016/0006-8993(76)90643-0; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BIZZOZERO OA, 1989, ANAL BIOCHEM, V180, P59, DOI 10.1016/0003-2697(89)90087-0; BRAY GM, 1981, ANNU REV NEUROSCI, V4, P127, DOI 10.1146/annurev.ne.04.030181.001015; BRUNDEN KR, 1987, ANAL BIOCHEM, V164, P474, DOI 10.1016/0003-2697(87)90521-5; BRUNDEN KR, 1987, J NEUROCHEM, V49, P1863, DOI 10.1111/j.1471-4159.1987.tb02448.x; CHEIFETZ S, 1985, BIOCHEMISTRY-US, V24, P5170, DOI 10.1021/bi00340a032; CHEIFETZ S, 1985, BIOCHEMISTRY-US, V24, P1909, DOI 10.1021/bi00329a016; DAVIDSON VL, 1984, J BIOL CHEM, V259, P594; DEAN WL, 1984, MEMBRANE BIOCHEM, V5, P181, DOI 10.3109/09687688409150277; DURSO D, 1990, NEURON, V4, P449, DOI 10.1016/0896-6273(90)90057-M; DYCK PJ, 1970, MAYO CLIN PROC, V45, P286; FILBIN MT, 1990, NATURE, V344, P871, DOI 10.1038/344871a0; GREENFIELD S, 1973, J NEUROCHEM, V20, P1207, DOI 10.1111/j.1471-4159.1973.tb00089.x; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; HAYASAKA K, 1993, NAT GENET, V5, P31, DOI 10.1038/ng0993-31; HAYASAKA K, 1993, BIOCHEM BIOPH RES CO, V194, P1317, DOI 10.1006/bbrc.1993.1968; KITAMURA K, 1976, BIOCHIM BIOPHYS ACTA, V455, P806, DOI 10.1016/0005-2736(76)90050-X; KULKENS T, 1993, NAT GENET, V5, P35, DOI 10.1038/ng0993-35; LEBLANC AC, 1990, J NEUROSCI RES, V26, P317, DOI 10.1002/jnr.490260308; LEBLANC AC, 1987, MOL BRAIN RES, V2, P57, DOI 10.1016/0169-328X(87)90021-0; LEMKE G, 1985, CELL, V40, P501, DOI 10.1016/0092-8674(85)90198-9; MAHONEY WC, 1981, BIOCHEMISTRY-US, V20, P443, DOI 10.1021/bi00505a033; MATTHIEU JM, 1975, BIOCHIM BIOPHYS ACTA, V392, P167, DOI 10.1016/0304-4165(75)90177-4; MEZEI C, 1981, J NEUROCHEM, V37, P550; PAULSON JR, 1992, ANAL BIOCHEM, V203, P227, DOI 10.1016/0003-2697(92)90307-S; POPKO B, 1988, NEURON, V1, P221, DOI 10.1016/0896-6273(88)90142-0; ROACH A, 1985, CELL, V42, P149, DOI 10.1016/S0092-8674(85)80110-0; ROACH A, 1983, CELL, V34, P799, DOI 10.1016/0092-8674(83)90536-6; ROOMI MW, 1978, BIOCHIM BIOPHYS ACTA, V536, P112, DOI 10.1016/0005-2795(78)90057-0; SALZER JL, 1989, DEV NEUROSCI-BASEL, V11, P377, DOI 10.1159/000111914; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SINGH H, 1976, BIOCHIM BIOPHYS ACTA, V448, P325, DOI 10.1016/0005-2736(76)90246-7; SUZUKI M, 1990, J NEUROCHEM, V55, P1966, DOI 10.1111/j.1471-4159.1990.tb05783.x; TRAPP BD, 1988, J NEUROSCI, V8, P3515; WEINBERG HJ, 1976, BRAIN RES, V113, P363, DOI 10.1016/0006-8993(76)90947-1; WEINBERG HJ, 1975, J NEUROCYTOL, V4, P395, DOI 10.1007/BF01261372; WIGGINS RC, 1980, J NEUROCHEM, V34, P627, DOI 10.1111/j.1471-4159.1980.tb11190.x; WOOD DD, 1989, J BIOL CHEM, V264, P5121; YOUNG PR, 1982, J AM CHEM SOC, V104, P7287, DOI 10.1021/ja00389a062	42	71	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10764	10770						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511605				2022-12-27	WOS:A1994NF01700086
J	CONOVER, CA; DELEON, DD				CONOVER, CA; DELEON, DD			ACID-ACTIVATED INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-3 PROTEOLYSIS IN NORMAL AND TRANSFORMED-CELLS - ROLE OF CATHEPSIN-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; PROTEASE; PREGNANCY; SECRETION; INDUCTION; COMPLEX; SURGERY	Insulin like growth factor-binding protein-3 (IGFBP-3) is an important member of a family of proteins which binds IGF peptides and modulates their biological actions. In this study, we describe an acid-activated IGFBP-3 protease in media derived from a variety of human cell lines. Radiolabeled IGFBP-3 remained intact during incubation (pH 5.5-8) in media conditioned by normal and transformed human fibroblasts, MG-63 osteoblastic cells, and breast cancer cell lines MCF-7 and Hs578T. However, acidification of the conditioned medium samples (pH < 5.5) resulted in I-125-IGFBP-3 hydrolysis and the appearance of specific radiolabeled fragments. No proteolysis of I-125-IGFBP-3 occurred during incubation in unconditioned medium at neutral or acid pH. Estrogen treatment of estrogen receptor-positive MCF-7 cells enhanced acid-activatable IGFBP-3 proteolysis in the cell conditioned medium but had no effect on proteolytic activity in estrogen receptor negative Hs578T cells. The cell-derived IGFBP-3 protease was identified as the aspartic proteinase cathepsin D, based on acidic pH optimum, inhibition by pepstatin, distinctive proteolytic fragment pattern, and immunoreactivity with cathepsin D antisera. Furthermore, immunodepletion of cathepsin D effectively attenuated acid-activated IGFBP-3 proteolysis. These data suggest a role for cathepsin D in the regulation of cellular IGF action by virtue of its potential to alter the structure/function of IGFBP-3.	MAYO CLIN & MAYO FDN,ENDOCRINE RES UNIT,ROCHESTER,MN 55905; NCI,BETHESDA,MD 20892	Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				De Leon, Daisy D./0000-0002-2693-0957	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043258, R01DK043258] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43258] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALE LK, 1992, ENDOCRINOLOGY, V131, P608, DOI 10.1210/en.131.2.608; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; CAMPBELL PG, 1992, ENDOCRINOLOGY, V130, P1401, DOI 10.1210/en.130.3.1401; Carrel A, 1926, J EXP MED, V44, P503, DOI 10.1084/jem.44.4.503; CLEMMONS DR, 1990, TRENDS ENDOCRIN MET, V1, P412, DOI 10.1016/1043-2760(90)90102-9; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; CONOVER CA, 1993, J CLIN INVEST, V91, P1129, DOI 10.1172/JCI116272; DAVENPORT ML, 1992, J CLIN ENDOCR METAB, V75, P590, DOI 10.1210/jc.75.2.590; DAVIES SC, 1991, J ENDOCRINOL, V130, P469, DOI 10.1677/joe.0.1300469; DAVIES SC, 1991, CLIN ENDOCRINOL, V34, P501, DOI 10.1111/j.1365-2265.1991.tb00331.x; DELEON DD, 1989, MOL ENDOCRINOL, V3, P567, DOI 10.1210/mend-3-3-567; FIGUEROA JA, 1992, BREAST CANCER RES TR, V22, P81, DOI 10.1007/BF01833336; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GIUDICE LC, 1990, J CLIN ENDOCR METAB, V71, P806, DOI 10.1210/jcem-71-4-806; HASSAGER C, 1992, J CLIN ENDOCR METAB, V75, P228, DOI 10.1210/jc.75.1.228; HOSSENLOPP P, 1990, J CLIN ENDOCR METAB, V71, P797, DOI 10.1210/jcem-71-4-797; HUANG JS, 1979, J BIOL CHEM, V254, P1405; HUGHES SCC, 1992, J ENDOCRINOL, V135, P135, DOI 10.1677/joe.0.1350135; LAMSON G, 1991, J CLIN ENDOCR METAB, V72, P1391, DOI 10.1210/jcem-72-6-1391; LU L, 1993, 75TH ANN M END SOC L, P421; MATHIEU M, 1991, MOL ENDOCRINOL, V5, P815, DOI 10.1210/mend-5-6-815; MONTCOURRIER P, 1990, CANCER RES, V50, P6045; NISSLEYP, 1992, INSULIN LIKE GROWTH, P111; ROCHEFORT H, 1990, CANCER METAST REV, V9, P321, DOI 10.1007/BF00049522; ROSENFEELD RG, 1990, RECENT PROG HORM RES, V4, P99; SAHAGIAN GG, 1981, THESIS U MICHIGAN; SHIMASAKI S, 1989, BIOCHEM BIOPH RES CO, V165, P907, DOI 10.1016/S0006-291X(89)80052-X; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; VANBEEK WP, 1973, CANCER RES, V33, P2913; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1175	31	99	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7076	7080						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510281				2022-12-27	WOS:A1994NA03200008
J	TAYLOR, PB; CULP, JS; DEBOUCK, C; JOHNSON, RK; PATIL, AD; WOOLF, DJ; BROOKS, I; HERTZBERG, RP				TAYLOR, PB; CULP, JS; DEBOUCK, C; JOHNSON, RK; PATIL, AD; WOOLF, DJ; BROOKS, I; HERTZBERG, RP			KINETIC AND MUTATIONAL ANALYSIS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE INHIBITION BY INOPHYLLUMS, A NOVEL CLASS OF NONNUCLEOSIDE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; ANTI-HIV AGENTS; NONNUCLEOSIDE INHIBITORS; SELECTIVE-INHIBITION; TIBO DERIVATIVES; BINDING-SITE; RESISTANCE; INVITRO; REPLICATION; AZT	Inophyllums are novel non-nucleoside inhibitors of human immunodeficiency virus (HIV) type 1 reverse transcriptase identified through an enzyme screening program and isolated from the plant Calophyllum inophyllum. The kinetics of reverse transcriptase inhibition by inophyllum B were characterized using recombinant purified enzyme, a heteropolymeric RNA template, and a scintillation proximity assay. Preincubation of inhibitor with the enzyme-template-primer complex for 11 min was required for maximal inhibition of reverse transcriptase to occur, suggesting that inophyllum B had a slow on-rate and that template-primer must bind to reverse transcriptase prior to inhibitor binding. Inhibition of reverse transcriptase by inophyllums was shown to be reversible. When thymidine triphosphate was the variable substrate, inophyllum B inhibited reverse transcriptase noncompetitively with a K-i of 42 nM. Enzyme inhibition with respect to template-primer was uncompetitive with a K-i of 26 nM. Reverse transcriptase enzymes containing point mutations in which tyrosine 181 was changed to either cysteine or isoleucine exhibited marginal resistance to inophyllums but were resistant to (+)-(5S) 4,5,6,7-tetrahydro-9-chloro-5-methyl-6-(3-methyl-2-butenyl)- imidazo[4,5,1-j,k][1,4]benzodiazepin-2-(1H)-thione (TIBO RS2913). A mutant enzyme in which tyrosine 188 was changed to leucine was cross-resistant to both inophyllum B and TIBO RS2913, as was HIV type 2 reverse transcriptase. These studies suggest that inophyllum B and TIBO R82913 bind to distinct but overlapping sites. Inhibition of avian myeloblastosis virus reverse transcriptase and Moloney murine leukemia virus reverse transcriptase by inophyllum B was detectible, suggesting that these inhibitors may be more promiscuous than other previously described non-nucleoside inhibitors. Inophyllums were active against HIV type 1 in cell culture with IC50 values of approximately 1.5 mu M. These studies imply that the inophyllums have a novel mechanism of interaction with reverse transcriptase and as such could conceivably play a role in combination therapy.	SMITHKLINE BEECHAM PHARMACEUT, DEPT BIOMOLEC DISCOVERY, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT PROT BIOCHEM, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT MOLEC GENET, KING OF PRUSSIA, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI024845] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039526] Funding Source: NIH RePORTER; NIAID NIH HHS [NCDDG-AI24845-07] Funding Source: Medline; NIGMS NIH HHS [GM-39526] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTHAUS IW, 1993, J BIOL CHEM, V268, P6119; BABA M, 1991, P NATL ACAD SCI USA, V88, P2356, DOI 10.1073/pnas.88.6.2356; BALZARINI J, 1992, P NATL ACAD SCI USA, V89, P4392, DOI 10.1073/pnas.89.10.4392; BALZARINI J, 1993, VIROLOGY, V192, P246, DOI 10.1006/viro.1993.1027; BOSWORTH N, 1989, NATURE, V341, P167, DOI 10.1038/341167a0; BOYER PL, 1993, J VIROL, V67, P2412, DOI 10.1128/JVI.67.4.2412-2420.1993; BUTLER KM, 1991, NEW ENGL J MED, V324, P137, DOI 10.1056/NEJM199101173240301; CHIMIRRI A, 1991, FARMACO, V46, P925; CHIMIRRI A, 1991, FARMACO, V46, P817; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; COHEN KA, 1991, J BIOL CHEM, V266, P14670; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DEBYSER Z, 1992, MOL PHARMACOL, V41, P203; DEVREESE K, 1992, VIROLOGY, V188, P900, DOI 10.1016/0042-6822(92)90550-9; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FRANK KB, 1991, J BIOL CHEM, V266, P14232; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; GREENE PJ, 1978, NUCLEIC ACIDS RES, V5, P2373, DOI 10.1093/nar/5.7.2373; KASHMAN Y, 1992, J MED CHEM, V35, P2735, DOI 10.1021/jm00093a004; Kawazu K., 1972, B I CHEM RES KYOTO U, V50, P160; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOPP EB, 1991, NUCLEIC ACIDS RES, V19, P3035, DOI 10.1093/nar/19.11.3035; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MELLORS JW, 1992, MOL PHARMACOL, V41, P446; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; PARKER WB, 1991, J BIOL CHEM, V266, P1754; PATIL AD, 1993, IN PRESS J MED CHEM; PAUWELS R, 1993, P NATL ACAD SCI USA, V90, P1711, DOI 10.1073/pnas.90.5.1711; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; REARDON JE, 1990, J BIOL CHEM, V265, P20302; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806; SARDANA VV, 1992, J BIOL CHEM, V267, P17526; Segel I.H., 1975, ENZYME KINETICS; SHIH CK, 1991, P NATL ACAD SCI USA, V88, P9878, DOI 10.1073/pnas.88.21.9878; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TAN GT, 1991, J BIOL CHEM, V266, P23529; Ternansky R. J., 1993, Antiviral Research, V20, P68; VASUDEVACHARI MB, 1992, VIROLOGY, V190, P269, DOI 10.1016/0042-6822(92)91213-E; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003	46	51	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6325	6331						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509800				2022-12-27	WOS:A1994MZ50300014
J	RUI, H; KIRKEN, RA; FARRAR, WL				RUI, H; KIRKEN, RA; FARRAR, WL			ACTIVATION OF RECEPTOR-ASSOCIATED TYROSINE KINASE JAK2 BY PROLACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH SIGNAL TRANSDUCTION; PROTEIN-KINASE; CYTOKINE RECEPTORS; CYTOPLASMIC REGION; BETA-SUBUNIT; FAMILY; HORMONE; DOMAIN; FORM; PHOSPHORYLATION	JAK family tyrosine kinases have recently been implicated in intracellular signal transduction by transmembrane cytokine receptors of the interferon (IFN) and hematopoietin receptor families. Using the prolactin (PRL) dependent rat pre-T cell line Nb2, a PRL receptor-associated, candidate tyrosine kinase of 120-130 kDa was recently characterized (1). In the present work this protein is identified as JAK2, based upon reciprocal anti-JAK2 and anti-phosphotyrosine immunoprecipitation and immunoblotting. JAK2 underwent rapid and transient tyrosine phosphorylation in response to receptor activation, reaching peak levels within 5 min of exposure to 100 nm PRL at 37 degrees C. In vitro tyrosine kinase assays using either [gamma-P-32]ATP and autoradiography or unlabeled ATP combined with anti-phosphotyrosine immunoblotting, demonstrated that the activity of JAK2 was stimulated by PRL. Phosphoamino acid analysis of JAK2 after in vitro tyrosine kinase assay revealed that the majority of phosphate was incorporated into tyrosine residues. Furthermore, JAK2 was associated with PRL receptors to a comparable extent before and after PRL binding, as demonstrated by anti-receptor immunoprecipitation and subsequent anti-JAK2 immunoblotting. We propose that binding of ligand to the PRL receptor activates preassociated JAK2, and that this enzyme generates the initial signal in the intracellular communication cascade.			RUI, H (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, DIV CANC TREATMENT, FREDERICK, MD 21702 USA.				FOGARTY INTERNATIONAL CENTER [F05TW004300] Funding Source: NIH RePORTER; FIC NIH HHS [5FO5 TWO4300-02] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ALI S, 1991, J BIOL CHEM, V266, P20110; ALI S, 1992, MOL ENDOCRINOL, V6, P1242, DOI 10.1210/me.6.8.1242; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BERNARDS A, 1991, ONCOGENE, V6, P1185; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; COLOSI P, 1993, J BIOL CHEM, V268, P12617; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; HARADA N, 1992, J BIOL CHEM, V267, P22752; HARPUR AG, 1992, ONCOGENE, V7, P1347; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HOWARD OMZ, 1992, ONCOGENE, V7, P895; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LESUEUR L, 1991, P NATL ACAD SCI USA, V88, P824, DOI 10.1073/pnas.88.3.824; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NICOLL CS, 1980, FED PROC, V39, P2563; OKAMURA H, 1989, ENDOCRINOLOGY, V124, P2499, DOI 10.1210/endo-124-5-2499; PRITCHARD MA, 1992, MAMM GENOME, V3, P36, DOI 10.1007/BF00355839; RILLEMA JA, 1992, ENDOCRINOLOGY, V131, P973, DOI 10.1210/en.131.2.973; RUI H, 1992, J BIOL CHEM, V267, P24076; RUSSELL DH, 1989, TRENDS PHARMACOL SCI, V10, P40, DOI 10.1016/0165-6147(89)90106-5; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	47	317	320	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5364	5368						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508935				2022-12-27	WOS:A1994MX57100099
J	MAKAREM, R; NEWHAM, P; ASKARI, JA; GREEN, LJ; CLEMENTS, J; EDWARDS, M; HUMPHRIES, MJ; MOULD, AP				MAKAREM, R; NEWHAM, P; ASKARI, JA; GREEN, LJ; CLEMENTS, J; EDWARDS, M; HUMPHRIES, MJ; MOULD, AP			COMPETITIVE-BINDING OF VASCULAR CELL-ADHESION MOLECULE-1 AND THE HEPII/IIICS DOMAIN OF FIBRONECTIN TO THE INTEGRIN ALPHA-4-BETA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III CONNECTING SEGMENT; HUMAN-PLASMA FIBRONECTIN; LYMPHOCYTE ADHESION; ENDOTHELIAL-CELLS; MELANOMA ADHESION; GERMINAL-CENTERS; COUNTER-RECEPTOR; SPLICED DOMAIN; LATE ANTIGEN-4; T-CELLS	The integrin receptor alpha 4 beta 1 binds to two different ligands, the extracellular matrix glycoprotein fibronectin and the endothelial cell surface protein vascular cell adhesion molecule-1 (VCAM-1). Using probes derived from each ligand and a variety of cell adhesion and ligand-receptor binding assays, we have investigated the relationship between the mechanisms of fibronectin and VCAM-1 interaction with alpha 4 beta 1. CS1 peptide, which represents the dominant active site from the HepII/IIICS recognition domain in fibronectin, was found to inhibit VCAM-1-dependent adhesion in three different assays: MOLT-4 T lymphoblastic leukaemia cell attachment to immobilized recombinant soluble VCAM-1 (rsVCAM-1), MOLT-4 cell attachment to monolayers of VCAM-1-transfected COS-1 cells, and A375-SM melanoma cell spreading on immobilized rsVCAM-1. Half-maximal inhibition required CS1 concentrations of 1.7-3.0 mg/ml, some 3-7-fold higher than that needed to autoinhibit adhesion to CS1-IgG conjugate. Using a more sensitive solid phase receptor-ligand binding assay, CS1 was found to be a potent inhibitor of the binding of rsVCAM-1 to alpha 4 beta 1 (half maximal inhibition at 13 mu g/ml). In agreement with cell-based assays, severalfold lower concentrations of CS1 were required to inhibit binding of recombinant HepII/IIICS region of fibronectin (half-maximal inhibition at 3 mu g/ml). VCAM-1-alpha 4 beta 1 binding was blocked not only by CS1 peptide but also by the recombinant HepII/IIICS region of fibronectin. Kinetic analysis of CS1 inhibition of VCAM-1 binding revealed that it was directly competitive in nature, indicating that VCAM-1 and fibronectin recognize either identical or spatially overlapping binding sites on alpha 4 beta 1. The implications of these results for the future design of VCAM-1 antagonists are discussed.	UNIV MANCHESTER,SCH BIOL SCI,DEPT BIOCHEM & MOLEC BIOL,MANCHESTER M13 9PT,ENGLAND; BRITISH BIOTECHNOL LTD,OXFORD OX4 5LY,ENGLAND	University of Manchester				Humphries, Martin/0000-0002-4331-6967	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGER A, 1990, INT IMMUNOL, V2, P921, DOI 10.1093/intimm/2.10.921; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; CARLOS TM, 1990, BLOOD, V76, P965; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CLARK EA, 1992, J IMMUNOL, V148, P3327; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; CYBULSKY MI, 1991, AM J PATHOL, V138, P815; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DUFOUR S, 1988, EMBO J, V7, P2661, DOI 10.1002/j.1460-2075.1988.tb03119.x; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; FREEDMAN AS, 1992, BLOOD, V79, P206; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HESSION C, 1991, J BIOL CHEM, V266, P6682; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HUMPHRIES MJ, 1988, J CELL BIOL, V106, P1289, DOI 10.1083/jcb.106.4.1289; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KOZLOWSKI JM, 1984, J NATL CANCER I, V72, P913; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFON A, 1991, J CLIN INVEST, V88, P546, DOI 10.1172/JCI115338; LAM SCT, 1987, J BIOL CHEM, V262, P947; MAHLER HR, 1966, BIOL CHEM, P250; MASINOVSKY B, 1990, J IMMUNOL, V145, P2886; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MOULD AP, 1991, J BIOL CHEM, V266, P3579; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PLOW EF, 1985, BLOOD, V66, P724; POLTE T, 1990, NUCLEIC ACIDS RES, V18, P5901, DOI 10.1093/nar/18.19.5901; POLTE T, 1991, DNA CELL BIOL, V10, P349, DOI 10.1089/dna.1991.10.349; PULIDO R, 1991, J BIOL CHEM, V266, P10241; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; SAMBROOK T, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SIMMONS PJ, 1992, BLOOD, V80, P388; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; TEIXIDO J, 1992, J CLIN INVEST, V90, P358, DOI 10.1172/JCI115870; THORNHILL MH, 1991, J IMMUNOL, V146, P592; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WALMSLEY AR, 1985, COMPUT METH PROG BIO, V21, P113, DOI 10.1016/0169-2607(85)90070-7; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; ZARDI L, 1985, EUR J BIOCHEM, V146, P571, DOI 10.1111/j.1432-1033.1985.tb08690.x	55	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4005	4011						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508437				2022-12-27	WOS:A1994MW98900019
J	PALMER, FBS; THEOLIS, R; COOK, HW; BYERS, DM				PALMER, FBS; THEOLIS, R; COOK, HW; BYERS, DM			PURIFICATION OF 2 IMMUNOLOGICALLY RELATED PHOSPHATIDYLINOSITOL-(4,5)-BISPHOSPHATE PHOSPHATASES FROM BOVINE BRAIN CYTOSOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT-BRAIN; INOSITOL POLYPHOSPHATE-5-PHOSPHATASE; HUMAN-ERYTHROCYTES; 4,5-BISPHOSPHATE; MEMBRANE; POLYPHOSPHOINOSITIDES; 5-PHOSPHATASE; 4-PHOSPHATE; PHOSPHOMONOESTERASE	Two phosphatidylinositol-(4,5)-bisphosphate (PtdIns(4,5)P2) phosphatase activities were isolated from a 45% saturated (NH4)2SO4 fraction of the soluble cytosol (100,000 x g supernatant) of bovine cerebral 'hemispheres by ion-exchange chromatography on Q-Sepharose (Q-1 and Q-2). Each was further purified on heparin-Sepharose, butyl-agarose, and/or Cibacron blue F3GA to yield products of similar specific activity (70-100 mumol/min/mg protein, 1000-2000-fold purification). Salt was required to stabilize activity and dithiothreitol was required to preserve maximum activity and to prevent or reverse aggregation that resisted disruption by mercaptoethanol and/or SDS. Monoclonal antibodies were prepared that recognized several components in the partially purified preparations. Immunoabsorption of activity by monoclonal antibodies that had been chemically cross-linked to protein A-Sepharose followed by SDS-polyacrylamide gel electrophoresis of absorbed proteins was used to identify the active components as a 155-kDa protein in Q-1 and a 115-kDa protein in Q-2. Two antibodies recognized different epitopes in the 155-kDa phosphatase. A third antibody recognized a common epitope in both phosphatases indicating that the two enzymes are related. Both phosphatases were Me2+-dependent, exhibited similar kinetic properties, and hydrolyzed PtdIns(4,5)P2 but not PtdIns(4)P, phosphatidic acid, or several other phosphate monoesters. They hydrolyzed inositol (1,4,5)-trisphosphate at 30% of the rate with PtdIns(4,5)P2 and this activity co-purified with PtdIns(4,5)P2 phosphatase activity. High molecular weight PtdIns(4,5)P2 phosphatases may be precursors of lower molecular weight soluble Type II inositol polyphosphate-5-phosphatases shown to account for the PtdIns(4,5)P2 phosphatase activity in platelets (Matzaris, M., Jackson, S. P., Laxminarayan, M., Speed, C. J., and Mitchell, C. A. (1994) J. Biol. Chem. 269,3397-3402). The three antibodies did not inhibit activity but recognized both native and denatured (Western blots) phosphatases and should be useful tools to study the distribution, structure, and regulation of the two forms of PtdIns(4,5)P2 phosphatase.	DALHOUSIE UNIV, DEPT BIOCHEM, HALIFAX B3H 4H7, NS, CANADA; DALHOUSIE UNIV, DEPT PEDIAT, HALIFAX B3H 4H7, NS, CANADA	Dalhousie University; Dalhousie University	PALMER, FBS (corresponding author), DALHOUSIE UNIV, ATLANTIC RES CTR, CLIN RES CTR, RM C-202, 5894 UNIV AVE, HALIFAX B3H 4H7, NS, CANADA.							BECK KA, 1991, J BIOL CHEM, V266, P4442; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BORDIN L, 1992, BIOCHEM BIOPH RES CO, V187, P853, DOI 10.1016/0006-291X(92)91275-U; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; BUTLER JE, 1992, J IMMUNOL METHODS, V150, P77, DOI 10.1016/0022-1759(92)90066-3; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHAUHAN A, 1991, ARCH BIOCHEM BIOPHYS, V287, P283, DOI 10.1016/0003-9861(91)90480-7; DIVECHA N, 1992, BIOCHEM J, V288, P637, DOI 10.1042/bj2880637; DOBOS GJ, 1992, J IMMUNOL, V149, P609; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; ERNEUX C, 1989, EUR J BIOCHEM, V181, P317, DOI 10.1111/j.1432-1033.1989.tb14726.x; FOWLER CJ, 1990, BIOCHEM J, V271, P735, DOI 10.1042/bj2710735; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GARFIN DE, 1990, METHOD ENZYMOL, V182, P459; GLANVILLE NT, 1989, BIOCHIM BIOPHYS ACTA, V1004, P169, DOI 10.1016/0005-2760(89)90265-8; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HARLOW E, 1988, ANTIBODIES LABORATOR; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HUANG FL, 1991, J BIOL CHEM, V266, P8727; IMES SS, 1987, ANAL BIOCHEM, V161, P316, DOI 10.1016/0003-2697(87)90457-X; INOKUCHI S, 1990, J BIOL CHEM, V265, P5983; KING CE, 1989, BIOCHEM J, V259, P893, DOI 10.1042/bj2590893; KINOUCHI H, 1990, MOL CHEM NEUROPATHOL, V12, P215, DOI 10.1007/BF03159946; KNOWLES AF, 1985, BIOCHEM BIOPH RES CO, V129, P220, DOI 10.1016/0006-291X(85)91425-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1990, FEBS LETT, V262, P231, DOI 10.1016/0014-5793(90)80197-Q; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; MACK SE, 1988, BIOCHEM CELL BIOL, V66, P199, DOI 10.1139/o88-027; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; MEMON AR, 1989, BIOCHEM BIOPH RES CO, V162, P1295, DOI 10.1016/0006-291X(89)90814-0; MISSIAEN L, 1989, BIOCHEM J, V261, P1055, DOI 10.1042/bj2611055; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NIJJAR MS, 1977, BIOCHIM BIOPHYS ACTA, V480, P390, DOI 10.1016/0005-2744(77)90032-8; ORDOVAS JM, 1987, J LIPID RES, V28, P371; PALMER FBS, 1990, BIOCHEM CELL BIOL, V68, P800; PALMER FBS, 1985, ANAL BIOCHEM, V150, P345, DOI 10.1016/0003-2697(85)90521-4; PALMER FBS, 1987, BIOCHEM CELL BIOL, V65, P890, DOI 10.1139/o87-115; PALMER FBSC, 1977, PREP BIOCHEM, V7, P457, DOI 10.1080/00327487708065513; PALMER FBSC, 1981, CAN J BIOCHEM CELL B, V59, P469, DOI 10.1139/o81-065; PIKE LJ, 1992, ENDOCR REV, V13, P692, DOI 10.1210/er.13.4.692; ROACH PD, 1981, BIOCHIM BIOPHYS ACTA, V661, P323, DOI 10.1016/0005-2744(81)90021-8; ROSS TS, 1991, J BIOL CHEM, V266, P20283; SAHYOUN NE, 1989, J BIOL CHEM, V264, P1062; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SEYFRED MA, 1984, J BIOL CHEM, V259, P3204; SMITH CD, 1984, ARCH BIOCHEM BIOPHYS, V235, P529, DOI 10.1016/0003-9861(84)90226-1; SMITH CD, 1988, BIOCHEM J, V256, P125, DOI 10.1042/bj2560125; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SORENSEN K, 1986, J IMMUNOL METHODS, V95, P291, DOI 10.1016/0022-1759(86)90419-9; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TAKIMOTO K, 1989, J BIOCHEM-TOKYO, V106, P684, DOI 10.1093/oxfordjournals.jbchem.a122917; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERJANS B, 1992, EUR J BIOCHEM, V204, P1083, DOI 10.1111/j.1432-1033.1992.tb16732.x	55	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3403	3410						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508913				2022-12-27	WOS:A1994MV63100043
J	HOOPS, TC; IVANOV, I; CUI, Z; COLOMERGOULD, V; RINDLER, MJ				HOOPS, TC; IVANOV, I; CUI, Z; COLOMERGOULD, V; RINDLER, MJ			INCORPORATION OF THE PANCREATIC MEMBRANE-PROTEIN GP-2 INTO SECRETORY GRANULES IN EXOCRINE BUT NOT ENDOCRINE-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMIDATING MONOOXYGENASE; PITUITARY-TUMOR-CELLS; CELLULAR SECRETION; MESSENGER-RNA; GENE-TRANSFER; RAT PANCREAS; PHOSPHATIDYLINOSITOL; GLYCOPROTEIN; BIOSYNTHESIS; EXPRESSION	The pancreatic zymogen granule membrane protein GP-2 was introduced into cells of exocrine or endocrine origin by transfection of its cDNA in order to investigate the mechanisms by which proteins are specifically incorporated into the membranes of secretory granules. Permanent transformants expressing GP-2 were isolated from exocrine pancreatic-derived AR42J cells as well as AtT20 cells of anterior pituitary origin and insulinoma-derived Rin5F cells. In AR42J cells, GP-2 was localized by immunofluorescence and immunoelectron microscopy to the endogenous zymogen-like granules as well as to the plasma membrane. In experiments supporting the localization data, incubation of the AR42J transformants with the secretagogue cholecystokinin (CCK8) resulted in enhanced release of a shed form of GP-2 into the medium in parallel with amylase, suggesting that the two proteins were secreted from the same compartment. By contrast, when expressed in AtT20 cells, the protein was found by immunofluorescence microscopy on the plasma membrane as well as in intracellular vesicles that differed in size and location from the endogenous secretory vesicles. By electron microscopy, large (approximately 5 mum) multivesicular structures were observed. Single- and double-label immunoelectron microscopy demonstrated that these large organelles labeled with anti-GP-2 antibodies, whereas the smaller adrenocorticotropic hormone (ACTH)-containing secretory vesicles did not. In permanent transformants of Rin5F cells, GP-2 was also excluded from the insulin-containing granules and found in multivesicular bodies similar to those in the AtT20 cells and containing the endosomal/lysosomal marker endolyn-78. Despite the apparent accumulation of GP-2 in lysosome-like structures, it turned over slowly and did not undergo rapid endocytosis from the cell surface. We conclude that GP-2 is targeted to secretory granule membranes by cell type-specific mechanisms that likely involve its interaction with other membrane or content proteins expressed only in the exocrine cells.	NYU MED CTR,DEPT CELL BIOL,550 1ST AVE,NEW YORK,NY 10016; NYU MED CTR,DEPT ENVIRONM MED,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104	New York University; New York University; New York University; University of Pennsylvania					NIA NIH HHS [AG01461] Funding Source: Medline; NIDDK NIH HHS [DK44238] Funding Source: Medline; NIEHS NIH HHS [ES00136] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K12ES000136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG001461] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARVAN P, 1987, J CELL BIOL, V104, P243, DOI 10.1083/jcb.104.2.243; BRAAS KM, 1989, MOL ENDOCRINOL, V3, P1387, DOI 10.1210/mend-3-9-1387; BRETSCHER MS, 1988, EMBO J, V7, P4087, DOI 10.1002/j.1460-2075.1988.tb03302.x; BURGESS TL, 1985, J CELL BIOL, V101, P639, DOI 10.1083/jcb.101.2.639; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; CROZE E, 1989, J CELL BIOL, V108, P1597, DOI 10.1083/jcb.108.5.1597; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; DITTIE A, 1992, EUR J CELL BIOL, V58, P243; FISHER JM, 1988, CELL, V54, P813, DOI 10.1016/S0092-8674(88)91131-2; FUKUOKA SI, 1992, P NATL ACAD SCI USA, V89, P1189, DOI 10.1073/pnas.89.4.1189; GRIMES M, 1992, J CELL BIOL, V117, P539, DOI 10.1083/jcb.117.3.539; GUMBINER B, 1982, CELL, V28, P51, DOI 10.1016/0092-8674(82)90374-9; HASHIMOTO S, 1987, J CELL BIOL, V105, P1579, DOI 10.1083/jcb.105.4.1579; HAVINGA JR, 1985, EUR J CELL BIOL, V39, P70; HAVINGA JR, 1983, EUR J BIOCHEM, V133, P449, DOI 10.1111/j.1432-1033.1983.tb07484.x; HE HT, 1987, J CELL BIOL, V105, P2489, DOI 10.1083/jcb.105.6.2489; HOOPS TC, 1991, J BIOL CHEM, V266, P4257; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KAETZEL DM, 1990, J BIOL CHEM, V265, P15932; KODUKULA K, 1992, P NATL ACAD SCI USA, V89, P1350, DOI 10.1073/pnas.89.4.1350; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; LAMOUROUX A, 1987, EMBO J, V6, P3931, DOI 10.1002/j.1460-2075.1987.tb02734.x; LEBEL D, 1988, BIOCHEM BIOPH RES CO, V154, P818, DOI 10.1016/0006-291X(88)90213-6; LEBEL D, 1989, BIOCHEM CELL BIOL, V67, P281, DOI 10.1139/o89-042; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LEMANSKY P, 1990, J CELL BIOL, V110, P1525, DOI 10.1083/jcb.110.5.1525; LOGSDON CD, 1985, J CELL BIOL, V100, P1200, DOI 10.1083/jcb.100.4.1200; MAINS RE, 1976, J BIOL CHEM, V251, P4115; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MONACO ME, 1988, BIOCHEM BIOPH RES CO, V151, P717, DOI 10.1016/S0006-291X(88)80339-5; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; NODA T, 1992, J CELL BIOL, V119, P85, DOI 10.1083/jcb.119.1.85; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; ORNITZ DM, 1985, NATURE, V313, P600, DOI 10.1038/313600a0; PERIN MS, 1988, EMBO J, V7, P2697, DOI 10.1002/j.1460-2075.1988.tb03123.x; RINDLER M J, 1992, Current Opinion in Cell Biology, V4, P616, DOI 10.1016/0955-0674(92)90080-V; RINDLER MJ, 1990, J BIOL CHEM, V265, P20784; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; RINDLER MJ, 1990, EUR J CELL BIOL, V53, P154; RIVAS RJ, 1989, J CELL BIOL, V109, P51, DOI 10.1083/jcb.109.1.51; RONZIO RA, 1978, BIOCHIM BIOPHYS ACTA, V508, P65, DOI 10.1016/0005-2736(78)90189-X; ROSEN CL, 1992, J CELL BIOL, V117, P617, DOI 10.1083/jcb.117.3.617; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; SWAROVSKY B, 1988, EUR J CELL BIOL, V47, P101; TOOZE J, 1989, J CELL BIOL, V109, P35, DOI 10.1083/jcb.109.1.35; TOUTANT JP, 1990, EUR J BIOCHEM, V187, P31, DOI 10.1111/j.1432-1033.1990.tb15274.x; VOORBERG J, 1993, EMBO J, V12, P749, DOI 10.1002/j.1460-2075.1993.tb05709.x; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I	53	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25694	25705						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503984				2022-12-27	WOS:A1993MK10000061
J	BONNARDEL, JA; DAVIS, RA				BONNARDEL, JA; DAVIS, RA			IN HEPG2 CELLS, TRANSLOCATION, NOT DEGRADATION, DETERMINES THE FATE OF THE DE-NOVO SYNTHESIZED APOLIPOPROTEIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-TRANSFER PROTEIN; LOW-DENSITY LIPOPROTEINS; ENDOPLASMIC-RETICULUM; DISULFIDE ISOMERASE; OLEIC-ACID; G2 CELLS; SECRETION; HEP-G2; LIVER; LINE	Previous studies show that translocation and degradation of apolipoprotein B (apoB), two processes occurring on or within the endoplasmic reticulum, determine how much de novo synthesized apoB is secreted. We determined which of these processes regulates the intracellular fate of apoB by examining whether degradation determines how much apoB is translocated or if translocation determines how much apoB is degraded. HepG2 cells, treated with the cysteine active site protease inhibitor ALLN, previously shown to block the degradation of translocation-arrested apoB in Chinese hamster ovary cells (Du, E., Kurth, J., Wang, S.-L., Humiston, P., and Davis, R. A. (1994) J. Biol. Chem. 269, 24169-24176), showed a 10-fold increase in the accumulation of de novo synthesized [S-35] methionine-labeled apoB. The majority (80%) of the apoB accumulated in response to ALLN was in the microsomal fraction, In contrast, ALLN did not effect apoB secretion, Since ALLN did not effect the intracellular accumulation of [S-35]methionine-labeled albumin and other proteins (trichloroacetic acid precipitable [S-35]methionine-labeled proteins), its effect on apoB was specific. Pulse-chase studies showed that ALLN dramatically reduced the first-order rate of removal of [S-35]methionine-labeled apoB from the cell but did not effect its rate of secretion. The finding that ALLN caused the intracellular accumulation of incompletely translated chains of apoB suggests that at least some of the degradation occurs at the ribosomal level. Moreover, 85% of the apoB that accumulated in isolated microsomes in response to ALLN was accessible to exogenous trypsin, indicating this pool of apoB was incompletely translocated. The combined data suggest that translocation, not degradation, determines the intracellular fate of de novo synthesized apoB.	SAN DIEGO STATE UNIV,DEPT BIOL,MAMMALIAN CELL & MOLEC BIOL LAB,SAN DIEGO,CA 92182	California State University System; San Diego State University					NHLBI NIH HHS [HL51643] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BJORNSSON OG, 1994, EUR J CLIN INVEST, V24, P137, DOI 10.1111/j.1365-2362.1994.tb00979.x; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; Davis R.A., 1991, BIOCH LIPIDS LIPOPRO, P403; DAVIS RA, 1982, J BIOL CHEM, V257, P908; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DU EZ, 1994, J BIOL CHEM, V269, P24169; ERICKSON SK, 1986, J LIPID RES, V27, P875; GILMORE R, 1993, CELL, V75, P589, DOI 10.1016/0092-8674(93)90476-7; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; HARTMANN E, 1994, NATURE, V37, P654; HAVEL RJ, 1992, SEMINARS LIVER DISEA, P356; JUNGNICKEL B, 1994, FEBS LETT, V346, P73, DOI 10.1016/0014-5793(94)00367-X; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LIN MCM, 1994, J BIOL CHEM, V269, P29138; PATSCH W, 1983, J CLIN INVEST, V72, P371, DOI 10.1172/JCI110977; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SALAM WH, 1988, BIOCHEM J, V251, P809, DOI 10.1042/bj2510809; SPARKS JD, 1994, BBA-LIPID LIPID MET, V1215, P9, DOI 10.1016/0005-2760(94)90088-4; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; THRIFT RN, 1986, J LIPID RES, V27, P236; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; VANCE JE, 1990, ANNU REV NUTR, V10, P337, DOI 10.1146/annurev.nu.10.070190.002005; WANG HX, 1994, J BIOL CHEM, V269, P18514; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006; WETTERAU JR, 1908, J BIOL CHEM, V259, P10863; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; YAO Z, 1901, J BIOL CHEM, V266, P3300; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	40	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28892	28896		10.1074/jbc.270.48.28892	http://dx.doi.org/10.1074/jbc.270.48.28892			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499417	hybrid			2022-12-27	WOS:A1995TH05600061
J	GADDYKURTEN, D; VALE, WW				GADDYKURTEN, D; VALE, WW			ACTIVIN INCREASES PHOSPHORYLATION AND DECREASES STABILITY OF THE TRANSCRIPTION FACTOR PIT-1 IN MTTW15 SOMATOTROPE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE SERINE KINASE; GLOBIN GENE-EXPRESSION; BETA FAMILY MEMBER; GROWTH-HORMONE; TGF-BETA; II RECEPTOR; PROTEIN; CLONING; BINDING; IDENTIFICATION	Activin is a polypeptide growth factor which exerts endocrine, paracrine, and autocrine effects in a variety of tissues. In the pituitary somatotrope, activin represses proliferation and growth hormone (GH) biosynthesis and secretion. We previously demonstrated that decreases in GH biosynthesis in MtTW15 somatotrope cells are due at least in part to decreased binding of the tissue specific transcription factor, Pit-1, to the GH promoter, resulting in decreased transcription of the GH gene. The objective of the current study was to determine the extent to which activin-mediated decreases in GH transcription were the result of decreased Pit-1 activity and/or decreased Pit-1 protein content in MtTW15 cells. Activin caused rapid increases in Pit-1 phosphorylation, which were temporally correlated with de creases in GH DNA binding. Pit-1 phosphorylation preceded marked decreases in steady-state levels of Pit-1 protein. The rate of Pit-1 synthesis was only moderately decreased by activin, with a time course similar to that observed for decreases in GH biosynthesis. However, Pit-1 stability was markedly decreased after more than 4 h of activin treatment. These data demonstrate that activin decreases GH expression in MtTW15 cells through multilevel regulation of Pit-1, which may represent a more general mechanism whereby activin and other transforming growth factor beta family members modulate gene expression through regulation of transcription factor activity as well as content.	SALK INST BIOL STUDIES, CLAYTON FDN LABS PEPTIDE BIOL, LA JOLLA, CA 92037 USA	Salk Institute					NICHD NIH HHS [HD 13527] Funding Source: Medline; NIDDK NIH HHS [DK 26741] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD013527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK026741] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BILEZIKJIAN LM, 1990, ENDOCRINOLOGY, V126, P2369, DOI 10.1210/endo-126-5-2369; BILLESTRUP N, 1990, MOL ENDOCRINOL, V4, P356, DOI 10.1210/mend-4-2-356; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; DEPAOLO LV, 1991, P SOC EXP BIOL MED, V198, P500; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FISCHBERG DJ, 1994, MOL ENDOCRINOL, V8, P1566, DOI 10.1210/me.8.11.1566; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FRIGON NL, 1992, BLOOD, V79, P765; GUTIERREZHARTMANN A, 1994, MOL ENDOCRINOL, V8, P1447, DOI 10.1210/me.8.11.1447; HOWARD PW, 1994, J BIOL CHEM, V269, P28662; ICHIJO H, 1993, BIOCHEM BIOPH RES CO, V194, P1508, DOI 10.1006/bbrc.1993.1995; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JUDD AM, 1984, BRAIN RES, V308, P137, DOI 10.1016/0006-8993(84)90924-7; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KARIN M, 1990, TRENDS GENET, V6, P92, DOI 10.1016/0168-9525(90)90100-K; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KONZAK KE, 1992, MOL ENDOCRINOL, V6, P241, DOI 10.1210/me.6.2.241; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; MATHEWS LS, 1993, J BIOL CHEM, V268, P19013; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MEISENHELDER J, 1991, METHOD ENZYMOL, V197, P288; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; NAKAMURA T, 1992, J BIOL CHEM, V267, P18924; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; OKIMURA Y, 1994, MOL ENDOCRINOL, V8, P1559, DOI 10.1210/me.8.11.1559; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; ROBERTS V, 1989, ENDOCRINOLOGY, V124, P552, DOI 10.1210/endo-124-1-552; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SAWCHENKO PE, 1988, NATURE, V334, P615, DOI 10.1038/334615a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAO LE, 1992, BLOOD, V79, P773; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; STEINFELDER HJ, 1992, P NATL ACAD SCI USA, V89, P5942, DOI 10.1073/pnas.89.13.5942; STRUTHERS RS, 1992, P NATL ACAD SCI USA, V89, P11451, DOI 10.1073/pnas.89.23.11451; SU JGJ, 1994, ENDOCRINE, V2, P715; THEILL LE, 1992, EMBO J, V11, P2261, DOI 10.1002/j.1460-2075.1992.tb05285.x; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; TSUCHIDA K, 1995, IN PRESS ENDOCRINOLO, V136; VALE W, 1983, METHOD ENZYMOL, V103, P565; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; VOSS JW, 1991, J BIOL CHEM, V266, P12832; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	61	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28733	28739		10.1074/jbc.270.48.28733	http://dx.doi.org/10.1074/jbc.270.48.28733			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499395	hybrid			2022-12-27	WOS:A1995TH05600039
J	JIMENEZRUIZ, A; ZHANG, QY; SHEN, CKJ				JIMENEZRUIZ, A; ZHANG, QY; SHEN, CKJ			IN-VIVO BINDING OF TRIMETHYLPSORALEN DETECTS DNA STRUCTURAL ALTERATIONS ASSOCIATED WITH TRANSCRIBING REGIONS IN THE HUMAN BETA-GLOBIN CLUSTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONTROL REGION; CHROMATIN STRUCTURE; GENE-EXPRESSION; LOCUS; CELLS; TRANSCRIPTION; HEMOGLOBIN; ACTIVATION; DROSOPHILA; DELETION	In order to increase our knowledge about the mechanisms that regulate expression of human beta-like globin genes, we have used a novel technique to analyze the chromatin structure in living cells. This approach allowed us to detect specific DNA regions in vivo where nucleosome folding or unconstrained DNA supercoiling in erythroid cells differs from that in non-erythroid cells, In this method, we use 4,5',8-trimethylpsoralen (TMP) as a probe capable of detecting altered chromatin conformations, Our results show that TMP binds to DNA with a higher affinity over the regions in the locus that are actively expressed, including both the promoter and the transcribed region. This higher affinity detected when comparing erythroid cells with non-erythroid cells does not extend to other regions inside the beta-globin cluster, Our data suggest that the observed effect is likely due to nucleosome displacement. Alternatively, it could result from localized DNA supercoiling, but not from widespread torsional stress across the entire beta-like globin locus as hypothesized previously,	UNIV CALIF DAVIS, MOL & CELLULAR BIOL SECT, DAVIS, CA 95616 USA; ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN	University of California System; University of California Davis; Academia Sinica - Taiwan			Jimenez-Ruiz, Antonio/K-2991-2014	Jimenez-Ruiz, Antonio/0000-0001-8238-3081	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029800] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK29800] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRESNICK EH, 1994, P NATL ACAD SCI USA, V91, P1314, DOI 10.1073/pnas.91.4.1314; CECH T, 1977, CELL, V11, P631, DOI 10.1016/0092-8674(77)90080-0; CHARNAY P, 1983, SCIENCE, V220, P1281, DOI 10.1126/science.6574602; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; COOK DN, 1989, J BACTERIOL, V171, P4836, DOI 10.1128/jb.171.9.4836-4843.1989; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; ELDER JT, 1990, MOL CELL BIOL, V10, P1382, DOI 10.1128/MCB.10.4.1382; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; GROUDINE M, 1983, P NATL ACAD SCI-BIOL, V80, P7551, DOI 10.1073/pnas.80.24.7551; GROUDINE M, 1983, DEV ASPECTS CHROMATI, P159; HYDE JE, 1978, BIOCHEMISTRY-US, V17, P1251, DOI 10.1021/bi00600a019; JUPE ER, 1993, EMBO J, V12, P1067, DOI 10.1002/j.1460-2075.1993.tb05748.x; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LJUNGMAN M, 1992, P NATL ACAD SCI USA, V89, P6055, DOI 10.1073/pnas.89.13.6055; Sambrook J, 1989, MOL CLONING LABORATO; SOGO JM, 1984, J MOL BIOL, V178, P897, DOI 10.1016/0022-2836(84)90318-8; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; YOAKUM GH, 1978, BIOCHIM BIOPHYS ACTA, V521, P529, DOI 10.1016/0005-2787(78)90295-2; ZHANG QY, 1993, MOL CELL BIOL, V13, P2298, DOI 10.1128/MCB.13.4.2298	24	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28978	28981		10.1074/jbc.270.48.28978	http://dx.doi.org/10.1074/jbc.270.48.28978			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499429	hybrid			2022-12-27	WOS:A1995TH05600073
J	NADEL, Y; WEISMANSHOMER, P; FRY, M				NADEL, Y; WEISMANSHOMER, P; FRY, M			THE FRAGILE-X SYNDROME SINGLE-STRAND D(CGG)(N) NUCLEOTIDE REPEATS READILY FOLD BACK TO FORM UNIMOLECULAR HAIRPIN STRUCTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIETHYL PYROCARBONATE; TELOMERIC SEQUENCES; CGG REPEAT; FMR1 GENE; DNA; INSTABILITY; METHYLATION; SITES; EXPRESSION; GUANINE	Expansion of a d(CGG)(n) run within the 5'-untranslated region of the X-linked human gene FMR1 blocks FMR1 transcription, delays its replication, and precipitates the fragile X syndrome, We showed previously that d(CGG)(n) tracts aggregate into interstrand tetrahelical complexes (Fry, M,, and Loeb, L, A, (1994) Proc. Natl. Acad. Sci, U. S. A. 91, 4950-4954), Here we show that these sequences also form under physiological conditions in in vitro unimolecular hairpin structures, Folding is demonstrated by temperature-dependent mobility of d(CGG)(n) oligomers in a nondenaturing polyacrylamide gel, by UV-hyperchromicity of thermally denaturing oligomers, and by UV cross-linking of compact forms of d(CGG)(n) runs interspersed by thymidine clusters, That the compact d(CGG)(n) structures are unimolecular is suggested by their zero-order kinetics of formation, Diethyl pyrocarbonate modification reveals a single, 4-5 residue-long central or epicentral unpaired loop in folded d(CGG)(n) oligomers. The position of this loop remains unchanged by insertion of thymidine clusters into 15- or 33-mer d(CGG) tracts as indicated by KMnO4 probing of unpaired thymidines. The presence of a single loop in folded d(CGG)(n) oligomers and the accessibility of every guanine to dimethyl sulfate modification suggest that they are hairpin and not tetraplex structures, Modeling indicates that different d(CGG)(n) hairpins are stabilized by guanine-guanine Hoogsteen hydrogen bonds or by Hoogsteen and Watson-Crick bonds. If formed in vivo, d(CGG)(n) hairpins could entail slippage and trinucleotide expansion during replication and could obstruct FMR1 gene transcription and replication.	TECHNION ISRAEL INST TECHNOL,BRUCE RAPPAPORT FAC MED,BIOCHEM UNIT,IL-31096 HAIFA,ISRAEL	Technion Israel Institute of Technology; Rappaport Faculty of Medicine								BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061; BALAGURUMOORTHY P, 1994, J BIOL CHEM, V269, P21858; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BURTON K, 1966, BIOCHEM J, V98, P70, DOI 10.1042/bj0980070; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; CHOI H, 1994, BIOCHIM BIOPHYS ACTA, V1217, P341; CHRISTIANSEN J, 1994, NUCLEIC ACIDS RES, V22, P5709, DOI 10.1093/nar/22.25.5709; FENG Y, 1995, SCIENCE, V268, P731, DOI 10.1126/science.7732383; FRIEDMANN T, 1978, NUCLEIC ACIDS RES, V5, P615, DOI 10.1093/nar/5.2.615; FRY M, 1992, P NATL ACAD SCI USA, V89, P763, DOI 10.1073/pnas.89.2.763; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; FURLONG JC, 1986, NUCLEIC ACIDS RES, V14, P3995, DOI 10.1093/nar/14.10.3995; GACY AM, 1995, CELL, V81, P533; GUO Q, 1993, BIOCHEMISTRY-US, V32, P3596, DOI 10.1021/bi00065a010; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HERR W, 1985, P NATL ACAD SCI USA, V82, P8009, DOI 10.1073/pnas.82.23.8009; HUERTAS D, 1993, EMBO J, V12, P4029, DOI 10.1002/j.1460-2075.1993.tb06081.x; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; LEE BL, 1992, NUCL ACIDS S SERIES, V29, P183; LUO S, 1993, SOMAT CELL MOLEC GEN, V9, P393; MURCHIE AIH, 1994, EMBO J, V13, P993, DOI 10.1002/j.1460-2075.1994.tb06344.x; NAKAHORI Y, 1991, NUCLEIC ACIDS RES, V19, P4355, DOI 10.1093/nar/19.16.4355; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARDS RI, 1993, HUM MOL GENET, V2, P1429, DOI 10.1093/hmg/2.9.1429; RICHARDS RI, 1992, TRENDS GENET, V8, P249, DOI 10.1016/0168-9525(92)90124-M; Sambrook J, 1989, MOL CLONING LABORATO; SCARIA PV, 1992, P NATL ACAD SCI USA, V89, P10336, DOI 10.1073/pnas.89.21.10336; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; Sen D, 1991, CURR OPIN STRUC BIOL, V1, P435, DOI 10.1016/0959-440X(91)90044-T; SMITH SS, 1994, J MOL BIOL, V243, P143, DOI 10.1006/jmbi.1994.1640; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SUTHERLAND GR, 1977, SCIENCE, V197, P265, DOI 10.1126/science.877551; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V369, P624; WEBB T, 1989, FRAGILE X SYNDROME, P50; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WILLIAMSON JR, 1992, CURR OPIN STRUC BIOL, V3, P357; WOODFORD KJ, 1994, J BIOL CHEM, V269, P27029; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0	46	95	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28970	28977		10.1074/jbc.270.48.28970	http://dx.doi.org/10.1074/jbc.270.48.28970			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499428	hybrid			2022-12-27	WOS:A1995TH05600072
J	PALSRYLAARSDAM, R; XU, YR; WITTENDERBY, P; BENOVIC, JL; HOSEY, MM				PALSRYLAARSDAM, R; XU, YR; WITTENDERBY, P; BENOVIC, JL; HOSEY, MM			DESENSITIZATION AND INTERNALIZATION OF THE M2 MUSCARINIC ACETYLCHOLINE-RECEPTOR ARE DIRECTED BY INDEPENDENT MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED PHOSPHORYLATION; CHOLINERGIC RECEPTORS; CHICK HEART; ADENYLYL CYCLASE; PROTEIN-KINASE; DIFFERENTIAL REGULATION; EXPRESSION; IDENTIFICATION; CLONING; CELLS	The phenomenon of acute desensitization of G-protein-coupled receptors has been associated with several events, including receptor phosphorylation, loss of high affinity agonist binding, receptor:G-protein uncoupling, and receptor internalization. However, the biochemical events underlying these processes are not fully understood, and their contributions to the loss of signaling remain correlative, In addition, the nature of the kinases and the receptor domains which are involved in modulation of activity have only begun to be investigated, In order to directly measure the role of G-protein-coupled receptor kinases (GRKs) in the desensitization of the m2 muscarinic acetylcholine receptor (m2 mAChR), a dominant-negative allele of GRK2 was used to inhibit receptor phosphorylation by endogenous GRK activity in a human embryonic kidney cell line. The dominant-negative GRK2K(220R) reduced agonist dependent phosphorylation of the m2 mAChR by similar to 50% and prevented acute desensitization of the receptor as measured by the ability of the m2 mAChR to attenuate adenylyl cyclase activity, In contrast, the agonist-induced internalization of the m2 mAChR was unaffected by the GRK2(K220R) construct. Further evidence linking receptor phosphorylation to acute receptor desensitization was obtained when two deletions of the third intracellular loop were made which created m2 mAChRs that did not become phosphorylated in an agonist dependent manner and did not desensitize. However, the mutant mAChRs retained the ability to internalize. These data provide the first direct evidence that GRK-mediated receptor phosphorylation is necessary for m2 mAChR desensitization; the likely sites of in vivo phosphorylation are in the central portion of the third intracellular loop (amino acids 282-323). These results also indicate that internalization of the m2 receptor is not a key event in desensitization and is mediated by mechanisms distinct from GRK phosphorylation of the receptor.	NORTHWESTERN UNIV, SCH MED, DEPT MOLEC PHARMACOL & BIOL CHEM, CHICAGO, IL 60611 USA; THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA	Northwestern University; Jefferson University				Witt-Enderby, Paula/0000-0002-1844-4457	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL050201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 50201] Funding Source: Medline; NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM 44944] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1989, TRENDS NEUROSCI, V12, P148, DOI 10.1016/0166-2236(89)90054-4; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P244; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; HABECKER BA, 1992, P NATL ACAD SCI USA, V89, P5035, DOI 10.1073/pnas.89.11.5035; HARGRAVE PA, 1994, REGULATION CELLULAR, P25; HOSEY MM, 1994, REGULATION SIGNAL TR, P113; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; ISHII K, 1994, J BIOL CHEM, V269, P1125; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KAMEYAMA K, 1994, EUR J BIOCHEM, V226, P267, DOI 10.1111/j.1432-1033.1994.tb20050.x; KONG GH, 1994, J BIOL CHEM, V269, P13084; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; KWATRA MM, 1989, MOL PHARMACOL, V35, P553; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LEUTJE CW, 1987, BIOCHEMISTRY-US, V26, P6892; LEVEY AI, 1991, J NEUROSCI, V11, P3218; LEVEY AI, 1995, J COMP NEUROL, V351, P339, DOI 10.1002/cne.903510303; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LIGGETT SB, 1994, REGULATION CELLULAR, P71; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MORO O, 1993, J BIOL CHEM, V268, P6862; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PETERSON GL, 1995, J BIOL CHEM, V270, P17808, DOI 10.1074/jbc.270.30.17808; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SCHERER NM, 1990, BIOCHEMISTRY-US, V29, P8475, DOI 10.1021/bi00488a039; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VANKOPPEN CJ, 1994, EUR J BIOCHEM, V222, P525; VOGEL WK, 1995, J BIOL CHEM, V270, P15485, DOI 10.1074/jbc.270.26.15485; WEI HB, 1994, EUR J PHARM-MOLEC PH, V268, P381, DOI 10.1016/0922-4106(94)90063-9; WELLER M, 1975, P NATL ACAD SCI USA, V72, P381, DOI 10.1073/pnas.72.1.381; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YU SS, 1993, J BIOL CHEM, V268, P337	64	132	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					29004	29011		10.1074/jbc.270.48.29004	http://dx.doi.org/10.1074/jbc.270.48.29004			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499433	hybrid			2022-12-27	WOS:A1995TH05600077
J	GILLESPIEBROWN, J; FULLER, SJ; BOGOYEVITCH, MA; COWLEY, S; SUGDEN, PH				GILLESPIEBROWN, J; FULLER, SJ; BOGOYEVITCH, MA; COWLEY, S; SUGDEN, PH			THE MITOGEN-ACTIVATED PROTEIN-KINASE KINASE MEK1 STIMULATES A PATTERN OF GENE-EXPRESSION TYPICAL OF THE HYPERTROPHIC PHENOTYPE IN RAT VENTRICULAR CARDIOMYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT CHAIN-2; SIGNAL TRANSDUCTION PATHWAYS; PHORBOL ESTER STIMULATION; ATRIAL-NATRIURETIC-FACTOR; MUSCLE-SPECIFIC GENES; CARDIAC MYOCYTES; ADRENERGIC-STIMULATION; MYOCARDIAL-CELLS; PHOSPHOINOSITIDE HYDROLYSIS; TRANSCRIPTIONAL ACTIVATION	Adult mammalian ventricular cardiomyocytes are terminally differentiated cells that enlarge adaptively by hypertrophy. In this situation, genes normally expressed in the fetal ventricular cardiomyocyte (e.g. atrial natriuretic factor (ANF), beta-myosin heavy chain (beta-MHC), and skeletal muscle (SkM) alpha-actin) are re-expressed, and there is transient expression of immediate early genes (e.g. c-fos), Using appropriate reporter plasmids, we studied the effects of transfection of the constitutively active or dominant negative mitogen-activated protein kinase kinase MEK1 on ANF, beta-MHC, and SkM alpha-actin promoter activities in cultured ventricular cardiomyocytes, ANF expression was stimulated (maximally 75-fold) by the hypertrophic agonist phenylephrine in a dose-dependent manner (EC(50), 10 mu M), and this stimulation was inhibited by dominant negative MEK1, Cotransfection of dominant negative MEK1 with a dominant negative mitogen-activated protein kinase (extracellular signal-regulated protein kinase (ERK2)) increased this inhibition. Transfection with constitutively active MEK1 constructs doubled ANF promoter activity, The additional cotransfection of wild-type ERK2 stimulated ANF promoter activity by about 5-fold. Expression of beta-MHC and SkM alpha-actin was also stimulated. Promoter activity regulated by activator protein-1 or c-fos serum response element consensus sequences was also increased, We conclude that the MEK1/ERK2 cascade may play a role in regulating gene expression during hypertrophy.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT CARDIAC MED, LONDON SW3 6LY, ENGLAND; UNIV LONDON, INST CANC RES, CHESTER BEATTY LABS, CELL & MOLEC BIOL SECT, LONDON SW3 6JB, ENGLAND	Imperial College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK				Brown, Judith/0000-0003-4092-9685; Bogoyevitch, Marie/0000-0001-9745-3716; Cowley, Sally/0000-0003-0297-6675	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; ADACHI S, 1994, J MOL CELL CARDIOL, V26, P789, DOI 10.1006/jmcc.1994.1096; AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALLO SN, 1992, AM J PHYSIOL, V263, pC319, DOI 10.1152/ajpcell.1992.263.2.C319; ALLO SN, 1991, J BIOL CHEM, V266, P22003; BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; BOGOYEVITCH MA, 1995, BIOCHEM J, V309, P437, DOI 10.1042/bj3090437; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRAND T, 1993, J BIOL CHEM, V268, P11500; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CLERK A, 1994, J BIOL CHEM, V269, P32848; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DECOCK JBJ, 1994, FEBS LETT, V356, P275, DOI 10.1016/0014-5793(94)01283-0; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; GARDNER DG, 1991, AM J PHYSIOL, V261, pE177, DOI 10.1152/ajpendo.1991.261.2.E177; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; ITO H, 1993, CIRCULATION, V87, P1715, DOI 10.1161/01.CIR.87.5.1715; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IWAKI K, 1990, J BIOL CHEM, V265, P13809; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KAKU T, 1991, AM J PHYSIOL, V260, pC635, DOI 10.1152/ajpcell.1991.260.3.C635; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LAZOU A, 1994, AM J PHYSIOL, V267, pH970, DOI 10.1152/ajpheart.1994.267.3.H970; LEE HR, 1988, J BIOL CHEM, V263, P7352; LEEVERS SJ, 1993, THESIS U LONDON; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; NEYSES L, 1991, BIOCHEM BIOPH RES CO, V181, P22, DOI 10.1016/S0006-291X(05)81376-2; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OTANI H, 1988, CIRC RES, V62, P8, DOI 10.1161/01.RES.62.1.8; PARKER TG, 1992, J BIOL CHEM, V267, P3343; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SADOSHIMA J, 1995, CIRC RES, V76, P1; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; STEINBERG SF, 1989, J PHARMACOL EXP THER, V250, P1141; SUGDEN PH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P327, DOI 10.1016/0167-4889(93)90225-E; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUZUKI T, 1990, FEBS LETT, V268, P149, DOI 10.1016/0014-5793(90)80995-U; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VIGNE P, 1989, FEBS LETT, V249, P143, DOI 10.1016/0014-5793(89)80611-8; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	78	142	144	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28092	28096						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499296				2022-12-27	WOS:A1995TG21000021
J	HUMPHREYS, DP; WEIR, N; MOUNTAIN, A; LUND, PA				HUMPHREYS, DP; WEIR, N; MOUNTAIN, A; LUND, PA			HUMAN PROTEIN DISULFIDE-ISOMERASE FUNCTIONALLY COMPLEMENTS A DSBA MUTATION AND ENHANCES THE YIELD OF PECTATE-LYASE-C IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOND FORMATION INVIVO; ENDOPLASMIC-RETICULUM; ALKALINE-PHOSPHATASE; IN-VIVO; GENE; IDENTIFICATION; MEMBRANE; RESIDENT; VECTORS; LUMEN	Human PDI was expressed to the Escherichia coli periplasm, by using a plasmid encoded ompA-PDI fusion under the control of the trp promoter, Periplasmic extracts were shown to contain active PDI using the scrambled ribonuclease assay, PDI activity was also demonstrated by complementation of two phenotypes associated with a dsbA mutation, Alkaline phosphatase activity, which is reduced in dsbA cells, was restored to wild type levels by PDI, PelC, a pectate lyase from Erwinia carotovora, was shown to be DsbA dependent in E. coli. PDI was able to restore its activity to that seen in wild type cells. Increased expression of PDI was found to increase the yield of active PelC above that seen in wild type cells, PDI also enhanced the yield of PelC in DsbA(-) cells but only in the presence of exogenous oxidized glutathione, PDI is thus able to functionally substitute for DsbA in the folding of disulfide-bonded proteins in the bacterial periplasm and to enhance the yield of highly expressed protein when the ability of the E. coli periplasm to fold protein may be saturated, However, our results suggest that the activities of DsbA and PDI in vivo may be different.	UNIV BIRMINGHAM, SCH BIOL SCI, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; CELLTECH LTD, SLOUGH SL1 4EN, BERKS, ENGLAND	University of Birmingham; Celltech Group Ltd			lund, peter a/N-9785-2018	Lund, Peter/0000-0002-6381-8526				BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; DARBY NJ, 1994, BIOCHEMISTRY-US, V33, P7937, DOI 10.1021/bi00191a022; EMTAGE JS, 1983, P NATL ACAD SCI-BIOL, V80, P3671, DOI 10.1073/pnas.80.12.3671; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; HALLEWELL RA, 1980, GENE, V9, P27, DOI 10.1016/0378-1119(80)90165-1; HINTON JCD, 1989, MOL MICROBIOL, V3, P1785, DOI 10.1111/j.1365-2958.1989.tb00164.x; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JACOBDUBUISSON F, 1994, P NATL ACAD SCI USA, V91, P11552, DOI 10.1073/pnas.91.24.11552; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; JOLY JC, 1994, BIOCHEMISTRY-US, V33, P4231, DOI 10.1021/bi00180a017; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; LILIE H, 1994, J BIOL CHEM, V269, P14290; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OSTERMEIER M, 1994, J BIOL CHEM, V269, P21072; OTSU M, 1994, J BIOL CHEM, V269, P6874; RAO NN, 1990, MOL MICROBIOL, V4, P1083, DOI 10.1111/j.1365-2958.1990.tb00682.x; ROTH RA, 1987, BIOCHEMISTRY-US, V26, P4179, DOI 10.1021/bi00388a001; Sambrook J, 1989, MOL CLONING LABORATO; SECKLER R, 1992, FASEB J, V6, P2545, DOI 10.1096/fasebj.6.8.1592207; SHEVCHIK VE, 1994, EMBO J, V13, P2007, DOI 10.1002/j.1460-2075.1994.tb06470.x; STARR MP, 1977, J CLIN MICROBIOL, V6, P379; TANG B, 1994, BIOCHEM J, V301, P17, DOI 10.1042/bj3010017; TASANEN K, 1988, J BIOL CHEM, V263, P16218; TORRIANI AM, 1990, BIOESSAYS, V12, P371, DOI 10.1002/bies.950120804; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALKER KW, 1994, J BIOL CHEM, V269, P28487; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WUNDERLICH M, 1993, J BIOL CHEM, V268, P24547; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025	44	48	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28210	28215						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499315				2022-12-27	WOS:A1995TG21000040
J	IZUMIYA, H; YAMAMOTO, M				IZUMIYA, H; YAMAMOTO, M			CLONING AND FUNCTIONAL-ANALYSIS OF THE NDK1 GENE ENCODING NUCLEOSIDE-DIPHOSPHATE KINASE IN SCHIZOSACCHAROMYCES-POMBE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISSION YEAST; TUMOR-METASTASIS; DROSOPHILA DEVELOPMENT; TRANSCRIPTION FACTOR; ALPHA-SUBUNIT; DNA; DICTYOSTELIUM; DISRUPTION; PROTEINS; MEIOSIS	We cloned the ndk1 gene encoding a subunit of nucleoside-diphosphate kinase (NDK) from Schizosaccharomyces pombe, by using polymerase chain reaction. The deduced ndk1 gene product has 151 amino acid residues and is similar to 60% identical with both Saccharomyces cerevisiae and mammalian NDKs. The gene product exhibited NDK activity and cross-reacted with antibodies raised against rat NDK. Disruption of ndk1 greatly reduced the cellular NDK activity but caused no obvious phenotype in cell growth and sexual development of the organism. However, a mutated allele of ndk1 could inhibit sexual development in a dominant-negative manner. This allele carried a point mutation in cysteine 116, which locates next to the putative active center histidine 117, and the mutant gene product showed no NDK activity. Gene expression inducible in response to mating pheromone signaling was decreased in cells carrying the dominant-negative allele, Cases have been reported in higher eukaryotes in which NDK appears to play a more sophisticated role than a simple catalyst in cell physiology, and the results of this study suggest that S. pombe NDK may also perform such a role in regulation of sexual development in the fission yeast.	UNIV TOKYO,SCH SCI,DEPT BIOPHYS & BIOCHEM,TOKYO 113,JAPAN	University of Tokyo								AONO T, 1994, YEAST, V10, P757, DOI 10.1002/yea.320100607; BEACH D, 1985, CURR GENET, V10, P297, DOI 10.1007/BF00365626; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOMINAAR AA, 1993, EMBO J, V12, P2275, DOI 10.1002/j.1460-2075.1993.tb05881.x; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; DEAOLF C, 1988, DEV BIOL, V129, P169; EGEL R, 1973, MOL GEN GENET, V121, P277, DOI 10.1007/BF00267055; EGEL R, 1974, EXP CELL RES, V88, P127, DOI 10.1016/0014-4827(74)90626-0; FUKUCHI T, 1993, GENE, V129, P141; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; Gutz H., 1974, HDB GENETICS, V1, P395; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUGHES DA, 1993, SIGNAL TRANSDUCTION, P123; IMAI Y, 1992, MOL CELL BIOL, V12, P1827, DOI 10.1128/MCB.12.4.1827; Ingraham J L, 1978, Methods Enzymol, V51, P371; ISSHIKI T, 1992, GENE DEV, V6, P2455, DOI 10.1101/gad.6.12b.2455; KAVANAUGHBLACK A, 1994, P NATL ACAD SCI USA, V91, P5883, DOI 10.1073/pnas.91.13.5883; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KIMURA N, 1988, J BIOL CHEM, V263, P4647; KIMURA N, 1990, BIOCHEM BIOPH RES CO, V168, P99, DOI 10.1016/0006-291X(90)91680-Q; KIMURA N, 1990, J BIOL CHEM, V265, P15744; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASCU I, 1992, J BIOL CHEM, V267, P12775; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; NICKERSON JA, 1984, J BIOL CHEM, V259, P1297; NIELSEN O, 1992, EMBO J, V11, P1391, DOI 10.1002/j.1460-2075.1992.tb05184.x; OBARA T, 1991, P NATL ACAD SCI USA, V88, P5877, DOI 10.1073/pnas.88.13.5877; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAEKI T, 1974, J BIOCHEM-TOKYO, V76, P631, DOI 10.1093/oxfordjournals.jbchem.a130607; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI; SHIMADA N, 1993, J BIOL CHEM, V268, P2583; Southern E, 1979, Methods Enzymol, V68, P152; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; WANG LM, 1993, CANCER RES, V53, P717; WATANABE Y, 1994, CELL, V78, P487, DOI 10.1016/0092-8674(94)90426-X; WATANABE Y, 1988, EMBO J, V7, P761, DOI 10.1002/j.1460-2075.1988.tb02873.x	56	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27859	27864		10.1074/jbc.270.46.27859	http://dx.doi.org/10.1074/jbc.270.46.27859			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499258	hybrid			2022-12-27	WOS:A1995TE73600069
J	FALLON, RJ; DANAHER, M; SAYLORS, RL; SAXENA, A				FALLON, RJ; DANAHER, M; SAYLORS, RL; SAXENA, A			DEFECTIVE ASIALOGLYCOPROTEIN RECEPTOR ENDOCYTOSIS MEDIATED BY TYROSINE KINASE INHIBITORS - REQUIREMENT FOR A TYROSINE IN THE RECEPTOR INTERNALIZATION SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; EPIDERMAL GROWTH-FACTOR; COATED PIT FORMATION; HEPATOMA-CELL LINE; PROTEIN-KINASE; PHORBOL ESTERS; EGF RECEPTOR; STAUROSPORINE; PHOSPHORYLATION; AUTOPHOSPHORYLATION	Regulated endocytosis by growth factor receptors requires intact receptor-associated tyrosine kinase activity. To determine whether a similar requirement exists for the asialoglycoprotein (ASGP) receptor which lacks intrinsic tyrosine kinase activity and participates in constitutive endocytosis, we examined the effect of three tyrosine kinase inhibitors, tyrphostin, genistein, and staurosporine, on receptor-mediated endocytosis in the human hepatoma line HepG2. These compounds inhibited early receptor internalization from the plasma membrane to internal protease-resistant sites in a concentration-dependent manner. This effect correlated with their inhibition of tyrosine phosphorylation of the ASGP receptor in vitro. Receptor trafficking subsequent to receptor internalization was unaffected. Endocytosis of another constitutively internalized protein, the transferrin receptor, was also inhibited by these compounds. In contrast, pinocytosis of the fluid-phase marker Lucifer yellow was not inhibited. The tyrosine kinase inhibitors also decreased the endocytic rate of transfected ASGP receptor H1 subunit in SK-Hep-1 cells. Therefore an intact ASGP receptor heterooligomeric complex is not required for this effect. Mutation of the single cytoplasmic tyrosine at position 5 of the HI subunit to phenylalanine produced an ASGP receptor which was endocytosed regardless of treatment with the tyrosine kinase inhibitors. We conclude that tyrosine kinase activity modulates the rate of receptor endocytosis at a point early in the internalization process.	WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)	FALLON, RJ (corresponding author), WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,1 CHILDRENS PL,BOX 8116,ST LOUIS,MO 63110, USA.				NIDDK NIH HHS [DK42081] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042081] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BERG T, 1980, BIOCHEM PHARMACOL, V29, P917, DOI 10.1016/0006-2952(80)90222-1; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; BRAITERMAN LT, 1989, J BIOL CHEM, V264, P1682; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; CLARKE BL, 1985, J BIOL CHEM, V260, P128; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; FALLON RJ, 1987, MOL PHARMACOL, V32, P348; FALLON RJ, 1992, EXP CELL RES, V203, P420, DOI 10.1016/0014-4827(92)90016-2; FALLON RJ, 1990, J BIOL CHEM, V265, P3401; FALLON RJ, 1988, J BIOL CHEM, V263, P13159; FALLON RJ, 1990, BIOCHEM BIOPH RES CO, V170, P1191, DOI 10.1016/0006-291X(90)90519-S; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; GEFFEN I, 1991, P NATL ACAD SCI USA, V88, P8425, DOI 10.1073/pnas.88.19.8425; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GEFFEN I, 1989, EMBO J, V8, P2855, DOI 10.1002/j.1460-2075.1989.tb08433.x; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HARI J, 1987, J BIOL CHEM, V262, P15341; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; NAKANO H, 1987, J ANTIBIOT, V40, P706, DOI 10.7164/antibiotics.40.706; OKA JA, 1989, J BIOL CHEM, V264, P12016; OSHEROV N, 1993, J BIOL CHEM, V268, P11134; OZAKI K, 1993, J BIOCHEM-TOKYO, V113, P271, DOI 10.1093/oxfordjournals.jbchem.a124038; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PURE E, 1992, P NATL ACAD SCI USA, V89, P114, DOI 10.1073/pnas.89.1.114; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SCHWARTZ AL, 1982, J BIOL CHEM, V257, P4230; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; SIMMONS CF, 1984, MOL PHARMACOL, V26, P509; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; SPIESS M, 1985, J BIOL CHEM, V260, P1979; SWANSON JA, 1985, J CELL BIOL, V100, P851, DOI 10.1083/jcb.100.3.851; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; WESSELS HP, 1989, J BIOL CHEM, V264, P17; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILEY HS, 1991, J BIOL CHEM, V263, P13159; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	48	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11011	11017						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512556				2022-12-27	WOS:A1994NF96600010
J	SAENKO, EL; SHIMA, M; RAJALAKSHMI, KJ; SCANDELLA, D				SAENKO, EL; SHIMA, M; RAJALAKSHMI, KJ; SCANDELLA, D			A ROLE FOR THE C2 DOMAIN OF FACTOR-VIII IN BINDING TO VON-WILLEBRAND-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND FACTOR; COAGULATION FACTOR-VIII; ACTIVATED PROTEIN-C; LIGHT CHAIN; MONOCLONAL-ANTIBODIES; INHIBITOR ANTIBODIES; LOCALIZATION; PEPTIDES; SITE	We examined the possibility that the C2 domain, amino acid residues 2173-2332, of factor VIII (fVIII) contains a binding site for von Willebrand factor (vWf) to clarify previous data showing that some monoclonal and human inhibitor antibodies with epitopes in C2 prevent fVIII-vWf binding. We constructed a fusion protein, glutathione S-transferase-C2, which binds to immobilized vWf in a dose-dependent saturable fashion, suggesting that the fVIII C2 domain contains a binding site for vWf. This site was further localized by testing the effect of a synthetic peptide on fVIII-vWf binding. Peptide 23032332, consisting of a previously identified phosphatidylserine binding site, prevented fVIII binding to vWf, suggesting that the sites for fVIII binding to vWf or phosphatidylserine have some overlap. The effect of anti-C2 domain antibodies further supported these observations. The inhibition of fVIII binding to vWf by monoclonal antibody NMC-VIII/5 IgG or F(ab)'2 (epitope within residues 2170-2327) and by inhibitor antibody MU IgG or Fab' (epitope within residues 2248-2312) was demonstrated by a fluid-phase binding assay and enzyme-linked immunosorbent assay. Two monoclonal antibodies with epitopes within amino acid residues 2170-2218 or 2248-2285, which do not overlap the phosphatidylserine binding site, did not have any inhibitory effect. Our data suggest that the previously described antagonistic binding of vWf and phospholipid to fVIII is due to the involvement of some C2 domain amino acids in both processes.			SAENKO, EL (corresponding author), AMER RED CROSS,HOLLAND LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855, USA.				NHLBI NIH HHS [P50-HL44336, R01-HL36094] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL044336] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BLOOM JW, 1987, THROMB RES, V48, P439, DOI 10.1016/0049-3848(87)90401-4; CHOPEK MW, 1986, BIOCHEMISTRY-US, V25, P3146, DOI 10.1021/bi00359a012; DENT JA, 1991, J CLIN INVEST, V88, P774, DOI 10.1172/JCI115376; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1988, J BIOL CHEM, V263, P5230; GRIFFIN BD, 1986, THROMB HAEMOSTASIS, V55, P40; HAMER RJ, 1987, EUR J BIOCHEM, V166, P37, DOI 10.1111/j.1432-1033.1987.tb13480.x; HAY JM, 1992, BIOTECHNIQUES, V13, P856; HOYER LW, 1982, METHOD ENZYMOL, V84, P51; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; LAJMANOVICH A, 1981, BIOCHIM BIOPHYS ACTA, V678, P132, DOI 10.1016/0304-4165(81)90056-8; LAZARCHICK J, 1978, J CLIN INVEST, V62, P1048, DOI 10.1172/JCI109209; LEYTE A, 1989, BIOCHEM J, V257, P679, DOI 10.1042/bj2570679; LEYTE A, 1991, J BIOL CHEM, V266, P740; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; SCANDELLA D, 1989, BLOOD, V74, P1618; SCANDELLA D, 1992, THROMB HAEMOSTASIS, V67, P665; SCANDELLA D, 1988, P NATL ACAD SCI USA, V85, P6152, DOI 10.1073/pnas.85.16.6152; SHIMA M, 1991, INT J HEMATOL, V54, P515; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; UEHLINGER J, 1991, TRANSFUSION, V31, P265, DOI 10.1046/j.1537-2995.1991.31391165179.x; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WALKER FJ, 1990, J BIOL CHEM, V265, P1484	28	157	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11601	11605						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512568				2022-12-27	WOS:A1994NF96600093
J	BELANGER, L; ROY, S; ALLARD, D				BELANGER, L; ROY, S; ALLARD, D			NEW ALBUMIN GENE 3' ADJACENT TO THE ALPHA(1)-FETOPROTEIN LOCUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT ALPHA-FETOPROTEIN; ALPHA-1-FETOPROTEIN GENE; BINDING-PROTEIN; SERUM-ALBUMIN; 5'-FLANKING REGION; PROMOTER; ENHANCER; REPRESSION; EXPRESSION; SEQUENCES	The albumin multigene family encodes proteins synthesized in the liver and secreted in the serum to fulfill ligand-carrier functions. The albumin (ALB), alpha(1)-fetoprotein (AFP), and vitamin D-binding protein genes are syntenic, the ALB and AFP genes are organized in tandem, and the AFP gene is selectively expressed in the fetal liver. We how report the existence of a fourth member of the albumin gene family, located 10 kilobases downstream from the AFP locus. The new gene, named alpha-albumin (alpha ALB), is selectively expressed in the liver at late stages of development. The alpha ALB mRNA sequence encodes a predicted secreted protein with the typical triple domain disulfide cross-linked structure. Comparisons of coding and promoter sequences suggest that alpha ALB could be a phylogenetic intermediate between the ALB and AFP genes. The developmental switch between alpha ALB gene activation and AFP gene repression suggests new regulatory interplays at the albumin locus and adult stage-specific ligand binding functions carried out by the alpha ALB gene product.			BELANGER, L (corresponding author), UNIV LAVAL,HOTEL DIEU QUEBEC,CTR RECH CANCEROL,QUEBEC CITY G1R 2J6,PQ,CANADA.							ATTARDI B, 1976, NATURE, V263, P685, DOI 10.1038/263685a0; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAYARD B, 1983, EUR J BIOCHEM, V137, P319, DOI 10.1111/j.1432-1033.1983.tb07831.x; BELANGER L, 1975, NATURE, V256, P657, DOI 10.1038/256657a0; BELANGER L, 1983, ADV ENZYME REGUL, V23, P73; BERNIER D, 1993, MOL CELL BIOL, V13, P1619, DOI 10.1128/MCB.13.3.1619; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BOMAN H, 1976, CLIN GENET, V9, P513; BROWN JR, 1976, FED PROC, V35, P2141; CHEVRETTE M, 1987, NUCLEIC ACIDS RES, V15, P1338, DOI 10.1093/nar/15.3.1338; GITLIN D, 1971, NEW ENGL J MED, V285, P1436; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; HAEFLIGER DN, 1989, J MOL EVOL, V29, P344, DOI 10.1007/BF02103621; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; JAGODZINSKI LL, 1981, P NATL ACAD SCI-BIOL, V78, P3521, DOI 10.1073/pnas.78.6.3521; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAGASE S, 1979, SCIENCE, V205, P590, DOI 10.1126/science.451621; NAHON JL, 1987, P NATL ACAD SCI USA, V84, P2135, DOI 10.1073/pnas.84.8.2135; NUNEZ E, 1971, CR ACAD SCI D NAT, V273, P831; PARMELEE DC, 1978, J BIOL CHEM, V253, P2114; PETERSON KR, 1993, MOL CELL BIOL, V13, P4836, DOI 10.1128/MCB.13.8.4836; RAY K, 1991, J BIOL CHEM, V266, P6221; SARGENT TD, 1981, MOL CELL BIOL, V1, P871, DOI 10.1128/MCB.1.10.871; TAMAOKI T, 1984, RECOMBINANT DNA CELL, P145; THOMASSIN H, 1992, NUCLEIC ACIDS RES, V20, P3091, DOI 10.1093/nar/20.12.3091; Tilghman S M, 1985, Oxf Surv Eukaryot Genes, V2, P160; TRONCHE F, 1990, MOL BIOL MED, V7, P173; TURCOTTE B, 1985, NUCLEIC ACIDS RES, V13, P2387, DOI 10.1093/nar/13.7.2387; TURCOTTE B, 1986, NUCLEIC ACIDS RES, V14, P9827, DOI 10.1093/nar/14.24.9827; WITKE WF, 1993, GENOMICS, V16, P751, DOI 10.1006/geno.1993.1258	31	60	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5481	5484						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509788				2022-12-27	WOS:A1994MY84000001
J	MOHRAZ, M; ARYSTARKHOVA, E; SWEADNER, KJ				MOHRAZ, M; ARYSTARKHOVA, E; SWEADNER, KJ			IMMUNOELECTRON MICROSCOPY OF EPITOPES ON NA,K-ATPASE CATALYTIC SUBUNIT - IMPLICATIONS FOR THE TRANSMEMBRANE ORGANIZATION OF THE C-TERMINAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; SARCOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODY; OUABAIN BINDING; OUTER MEDULLA; ION-TRANSPORT; NA+,K+-ATPASE; IDENTIFICATION; TOPOLOGY; VESICLES	The transmembrane folding of the alpha subunit of Na,K-ATPase was studied by using immunoelectron microscopy to determine whether monoclonal antibodies with defined epitopes bind to the extracellular or cytoplasmic surface. In double labeling experiments, an antibody and a reference marker were bound to purified membrane-associated Na,K-ATPase and were visualized by employing colloidal gold particles of two different sizes. Wheat germ agglutinin and a previously characterized monoclonal antibody were used as control markers for the exoplasmic and cytoplasmic surfaces, respectively. Three antibodies, VG4, VG2, and IIC9, unambiguously bound to the extracellular surface. Previously IIC9 had been assigned to the cytoplasmic surface because, in immunofluorescence studies, it stained intact cells only when they were detergent-permeabilized. To investigate the basis for this contradiction, a third assay for sidedness was used: competition binding in solution to right-side-out renal medullary vesicles. IIC9 was found to bind to the extracellular surface of sealed vesicles, but only in certain experimental conditions. It was concluded that IIC9 has an epitope that is not always accessible and that in this instance, studies of binding to intact and detergent-treated cells had given misleading results. An extracellular disposition for all three antibodies is not compatible with existing folding models, and new models are presented.	MASSACHUSETTS GEN HOSP,WELLMAN 4,FRUIT ST,BOSTON,MA 02114; NYU,DEPT CELL BIOL,NEW YORK,NY 10016; MM SHEMYAKIN INST BIOORGAN CHEM,117871 MOSCOW,RUSSIA; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; New York University; Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035399] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36271] Funding Source: Medline; NIGMS NIH HHS [GM35399] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BALL WJ, 1986, BIOCHEMISTRY-US, V25, P7155, DOI 10.1021/bi00370a058; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; DELEMOSCHIARANDINI C, 1987, J CELL BIOL, V104, P209, DOI 10.1083/jcb.104.2.209; DEWEER P, 1988, ANNU REV PHYSIOL, V50, P225, DOI 10.1146/annurev.physiol.50.1.225; DZHANDZHUGAZYAN KN, 1985, BIOCHIM BIOPHYS ACTA, V817, P165, DOI 10.1016/0005-2736(85)90079-3; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; FORBUSH B, 1982, J BIOL CHEM, V257, P2678; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN PL, 1992, MOL ASPECTS TRANSPOR, P1; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KNAUF PA, 1974, J GEN PHYSIOL, V63, P305, DOI 10.1085/jgp.63.3.305; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; MODYANOV N, 1992, ACTA PHYSIOL SCAND, V146, P49; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; OMORI K, 1983, J BIOCHEM-TOKYO, V94, P1857, DOI 10.1093/oxfordjournals.jbchem.a134539; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; SWEADNER KJ, 1975, J BIOL CHEM, V250, P4022; SWEADNER KJ, 1992, ANN NY ACAD SCI, V671, P217, DOI 10.1111/j.1749-6632.1992.tb43798.x; SWEADNER KJ, 1985, J BIOL CHEM, V260, P1508; XU KY, 1989, BIOCHEMISTRY-US, V28, P5764, DOI 10.1021/bi00440a010	24	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2929	2936						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7507930				2022-12-27	WOS:A1994MV43200083
J	VILLALBA, M; MARTINEZSERRANO, A; GOMEZPUERTAS, P; BLANCO, P; BORNER, C; VILLA, A; CASADO, M; GIMENEZ, C; PEREIRA, R; BOGONEZ, E; POZZAN, T; SATRUSTEGUI, J				VILLALBA, M; MARTINEZSERRANO, A; GOMEZPUERTAS, P; BLANCO, P; BORNER, C; VILLA, A; CASADO, M; GIMENEZ, C; PEREIRA, R; BOGONEZ, E; POZZAN, T; SATRUSTEGUI, J			THE ROLE OF PYRUVATE IN NEURONAL CALCIUM HOMEOSTASIS - EFFECTS ON INTRACELLULAR CALCIUM POOLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM NEURONS; ENDOPLASMIC-RETICULUM; SYMPATHETIC NEURONS; CYTOSOLIC CALCIUM; GROWTH-FACTOR; CELLS; CA-2+; CA2+; MEMBRANE; SYNAPTOSOMES	It has long been known that pyruvate is essential for survival of prenatal neurons in culture. To understand the role of exogenous pyruvate in neuronal calcium homeostasis, we have investigated the effects of pyruvate (plus malate) addition to dissociated adult rat hippocampal and cerebral cortex cells and cultured CNS neurons having an unrestricted glucose supply. We found that pyruvate (plus malate) increased the respiration rate while ATP levels were unchanged. At the same time, cytosolic free calcium concentrations, [Ca2+]i, decreased while total CA-45(2+) and CA-40(2+) accumulation increased. The extra Ca2+ accumulated by the cells is attributable to an increase in the size of the intracellular calcium pools. Two such pools were identified on the basis of their sensitivity to specific drugs. The first pool was mobilized by thapsigargin plus tert-butyl hydroquinone and caffeine while the second pool was discharged by the mitochondrial uncoupler carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) (plus oligomycin). The two pools represented about 15-20% and 15-30%, respectively, of the rapidly exchangeable Ca-45(2+) pools in cerebral cortex cells. In cultured hippocampal neurons, the collapse of the mitochondrial membrane potential (as induced by uncouplers (FCCP) or respiratory chain inhibitors (antimycin) caused a large increase in [Ca2+]i which varied in size and shape among cells and was reduced by external Ca2+ chelation. The latter condition also resulted in a partial discharge of FCCP-releasable Ca-45(2+). The effects of FCCP did not result simply from ATP depletion since incubation in glucose-free medium and sequential additions of 2 mM deoxyglucose and 10 muM oligomycin, conditions that led to a dramatic reduction in cellular ATP levels, did not abolish the FCCP-induced [Ca2+]i rise. Taken together, the results indicate that mitochondria harbor a significant proportion of cellular Ca2+. The sensitivity of the mitochondrial pool size to pyruvate (plus malate) questions previous hypotheses concerning a kinetic limitation for Ca2+ accumulation in mitochondria in resting neurons.	CSIC,CTR BIOL MOLEC SEVERO OCHOA,DEPT BIOL MOLEC,E-28049 MADRID,SPAIN; UNIV AUTONOMA MADRID,E-28049 MADRID,SPAIN; UNIV PADUA,CNR,CTR BIOMEMBRANES,INST GEN PATHOL,I-35100 PADUA,ITALY	Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Consiglio Nazionale delle Ricerche (CNR); University of Padua			Satrustegui, Jorgina/R-6732-2019; Gimenez, Cecilio/K-8027-2014; Gomez-Puertas, Paulino/G-8821-2014; Martínez-Serrano, Alberto/J-8146-2014; villalba, martin/N-7123-2017	Gimenez, Cecilio/0000-0001-6726-8405; Gomez-Puertas, Paulino/0000-0003-3131-729X; Villa Diaz, Ana/0000-0001-5419-3387; Blanco Morales, Pablo/0000-0003-1933-6818; Martinez Serrano, Alberto/0000-0003-3927-6699; Casado, Mariano/0000-0001-8049-8096; villalba, martin/0000-0002-4385-4888				AKERMAN KEO, 1981, BIOCHIM BIOPHYS ACTA, V645, P41, DOI 10.1016/0005-2736(81)90509-5; BRECHT M, 1992, BIOCHEM J, V283, P399, DOI 10.1042/bj2830399; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; CHACON E, 1992, BIOCHEM J, V281, P871, DOI 10.1042/bj2810871; CHEESEMAN AJ, 1988, J NEUROCHEM, V50, P1559, DOI 10.1111/j.1471-4159.1988.tb03044.x; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; CHOI DW, 1987, J NEUROSCI, V7, P369; COLLINS F, 1991, J NEUROSCI, V11, P2582; CORKEY BE, 1988, J BIOL CHEM, V263, P4247; DUCHEN MR, 1992, BIOCHEM J, V283, P41, DOI 10.1042/bj2830041; DUCHEN MR, 1992, J PHYSIOL-LONDON, V450, P33, DOI 10.1113/jphysiol.1992.sp019115; FACCI L, 1985, J NEUROCHEM, V45, P926, DOI 10.1111/j.1471-4159.1985.tb04082.x; FACCI L, 1986, BIOCHEM J, V234, P605, DOI 10.1042/bj2340605; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; GLENNON MC, 1992, J BIOL CHEM, V267, P25568; GOMEZA J, 1991, BIOCHEM J, V275, P435, DOI 10.1042/bj2750435; GOMEZPUERTAS P, 1991, J NEUROCHEM, V56, P2039, DOI 10.1111/j.1471-4159.1991.tb03464.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HERTZ L, 1989, BRAIN RES REV, V14, P335, DOI 10.1016/0165-0173(89)90017-9; HERZENBERG LA, 1960, EXP CELL RES, V21, P430, DOI 10.1016/0014-4827(60)90275-5; HOLLIDAY J, 1991, NEURON, V7, P787, DOI 10.1016/0896-6273(91)90281-4; JENSEN JR, 1991, BRAIN RES, V551, P311, DOI 10.1016/0006-8993(91)90947-T; KAUFMAN EE, 1992, J NEUROCHEM, V58, P258, DOI 10.1111/j.1471-4159.1992.tb09304.x; KAUPPINEN RA, 1986, EUR J BIOCHEM, V158, P159, DOI 10.1111/j.1432-1033.1986.tb09733.x; KOIKE T, 1991, P NATL ACAD SCI USA, V88, P3892, DOI 10.1073/pnas.88.9.3892; LAW GJ, 1990, BIOCHEM J, V267, P359, DOI 10.1042/bj2670359; Lemasters J.J., 1978, BIOLUMINESCENCE CHEM, P36, DOI [10.1016/0076-6879(78)57006-7, DOI 10.1016/0076-6879(78)57006-7]; MARRION NV, 1992, J PHYSIOL-LONDON, V445, P515, DOI 10.1113/jphysiol.1992.sp018937; MARTINEZSERRANO A, 1992, J BIOL CHEM, V267, P4672; MARTINEZSERRANO A, 1992, MOL BIOL CELL, V3, P235, DOI 10.1091/mbc.3.2.235; MATTSON MP, 1989, J NEUROSCI, V9, P3728; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; MILLER RJ, 1992, TRENDS NEUROSCI, V15, P317, DOI 10.1016/0166-2236(92)90045-A; MILLS LR, 1990, NEURON, V2, P149; MINTA A, 1989, J BIOL CHEM, V264, P8171; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; NOBES CD, 1990, J BIOL CHEM, V265, P12910; NOBES CD, 1990, J BIOL CHEM, V265, P12903; PIKE SE, 1991, P NATL ACAD SCI USA, V88, P11081, DOI 10.1073/pnas.88.24.11081; PRENTKI M, 1984, J BIOL CHEM, V259, P118; REBER BFX, 1991, J PHYSIOL-LONDON, V435, P145, DOI 10.1113/jphysiol.1991.sp018502; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; SCHARFMAN HE, 1989, SCIENCE, V246, P257, DOI 10.1126/science.2508225; SELAK I, 1985, J NEUROSCI, V5, P23; SHANK RP, 1984, J NEUROCHEM, V42, P1153, DOI 10.1111/j.1471-4159.1984.tb12724.x; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VILLALBA M, 1992, BRAIN RES, V570, P347, DOI 10.1016/0006-8993(92)90600-E; VITORICA J, 1986, BRAIN RES, V378, P36, DOI 10.1016/0006-8993(86)90284-2; VITORICA J, 1984, J NEUROCHEM, V42, P531; WILLOUGHBY J, 1986, BIOCHEM J, V235, P2105; WINGROVE DE, 1984, J BIOL CHEM, V259, P9390	53	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2468	2476						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7507925				2022-12-27	WOS:A1994MV43200022
J	ATTANASIO, R; STUNZ, GW; KENNEDY, RC				ATTANASIO, R; STUNZ, GW; KENNEDY, RC			FOLDING PATTERNS OF IMMUNOGLOBULIN MOLECULES IDENTIFIED BY UREA GRADIENT ELECTROPHORESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LIGHT CHAIN; CONSTANT FRAGMENT; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODIES; TRYPTOPHAN SYNTHASE; FAB FRAGMENT; FV FRAGMENT; PROTEINS; EXPRESSION	The reversible denaturant-induced unfolding of immunoglobulin molecules has been analyzed by transverse urea gradient gel electrophoresis and the effects that urea-induced unfolding exerts on the functional properties associated with their variable region, i.e. antigen binding and idiotypic expression, have been determined by Western blot analysis. Results obtained from these experiments indicate that urea-induced unfolding of the immunoglobulin molecule is a highly cooperative reversible process that occurs through a two-state transition with no accumulation of intermediates. The unfolding transition has its midpoint at about 6.5 m urea and appears to be slow on the time scale of electrophoresis. Folding intermediates in rapid equilibrium with the unfolded state as well as molecular forms with different electrophoretic mobility can be detected during refolding reactions. Results from Western blot analysis confirm the highly cooperative reversible urea-induced unfolding of immunoglobulin molecules and demonstrate that the unfolding transition leads to disappearance of both antigen binding and idiotypic expression, whereas the ability to interact with antibodies directed to continuous epitopes of the variable region is preserved. After progressive removal of the denaturing agent, the variable region refolds into structures that regain the functional properties of the native conformation.	SW FDN BIOMED RES,CTR AIDS RES,SAN ANTONIO,TX 78228	Texas Biomedical Research Institute	ATTANASIO, R (corresponding author), SW FDN BIOMED RES,DEPT VIROL & IMMUNOL,SAN ANTONIO,TX 78228, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI026462] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 26462] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; ATTANASIO R, 1993, MOL IMMUNOL, V30, P9, DOI 10.1016/0161-5890(93)90421-7; ATTANASIO R, 1991, J BIOL CHEM, V266, P14611; ATTANASIO R, 1990, MOL IMMUNOL, V27, P513, DOI 10.1016/0161-5890(90)90070-G; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BLOND S, 1987, P NATL ACAD SCI USA, V84, P1147, DOI 10.1073/pnas.84.5.1147; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOSS MA, 1984, NUCLEIC ACIDS RES, V12, P3791, DOI 10.1093/nar/12.9.3791; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P6922, DOI 10.1021/bi00242a016; CABILLY S, 1984, P NATL ACAD SCI-BIOL, V81, P3273, DOI 10.1073/pnas.81.11.3273; Creighton T E, 1986, Methods Enzymol, V131, P156; CREIGHTON TE, 1980, J MOL BIOL, V137, P61, DOI 10.1016/0022-2836(80)90157-6; DAVIES DR, 1983, ANNU REV IMMUNOL, V1, P87, DOI 10.1146/annurev.iy.01.040183.000511; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; GOLDENBERG DP, 1984, ANAL BIOCHEM, V138, P1, DOI 10.1016/0003-2697(84)90761-9; GOTO Y, 1988, BIOCHEMISTRY-US, V27, P1670, DOI 10.1021/bi00405a043; GOTO Y, 1987, BIOCHEMISTRY-US, V26, P1879, DOI 10.1021/bi00381a014; GOTO Y, 1982, J MOL BIOL, V156, P891, DOI 10.1016/0022-2836(82)90146-2; HORWITZ AH, 1988, P NATL ACAD SCI USA, V85, P8678, DOI 10.1073/pnas.85.22.8678; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KAWATA Y, 1991, BIOCHEMISTRY-US, V30, P4367, DOI 10.1021/bi00232a001; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KUROKAWA T, 1983, NUCLEIC ACIDS RES, V11, P3077, DOI 10.1093/nar/11.10.3077; MAKHATADZE GI, 1992, J MOL BIOL, V226, P491, DOI 10.1016/0022-2836(92)90963-K; MARQUART M, 1982, IMMUNOL TODAY, V3, P160, DOI 10.1016/0167-5699(82)90107-4; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MURPHY KP, 1992, J MOL BIOL, V227, P293, DOI 10.1016/0022-2836(92)90699-K; MURRYBRELIER A, 1988, BIOCHEMISTRY-US, V27, P7633, DOI 10.1021/bi00420a010; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; PARHAM P, 1982, J IMMUNOL METHODS, V53, P133, DOI 10.1016/0022-1759(82)90137-5; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; RIECHMANN L, 1988, J MOL BIOL, V203, P825, DOI 10.1016/0022-2836(88)90214-8; ROWE ES, 1976, BIOCHEMISTRY-US, V15, P905, DOI 10.1021/bi00649a028; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; TSUNENAGA M, 1987, BIOCHEMISTRY-US, V26, P6044, DOI 10.1021/bi00393a015	36	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1834	1838						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507486				2022-12-27	WOS:A1994MR98800045
J	BERNINSONE, P; MIRET, JJ; HIRSCHBERG, CB				BERNINSONE, P; MIRET, JJ; HIRSCHBERG, CB			THE GOLGI GUANOSINE DIPHOSPHATASE IS REQUIRED FOR TRANSPORT OF GDP-MANNOSE INTO THE LUMEN OF SACCHAROMYCES-CEREVISIAE GOLGI VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; SECRETORY VESICLES; NUCLEOSIDE-DIPHOSPHATASE; RAT-LIVER; YEAST; GLYCOSYLATION; MEMBRANE; BIOSYNTHESIS; APPARATUS; PROTEIN	The Saccharomyces cerevisiae Golgi lumenal guanosine diphosphatase is hypothesized to generate GMP which in turn allows entry of GDP-mannose into the lumen to serve as substrate for mannosylation of proteins and lipids. We have recently shown in studies in vivo that this GDPase is required for protein and sphingolipid mannosylation in the Golgi lumen of S. cerevisiae. We have now isolated Golgi-vesicles from wild type and gda1 null mutants (GDPase defective) and have found that the initial rate of GDP-mannose entry into mutant vesicles was 5-fold lower than into those of wild type. Because the concentration of GDP within vesicles is insufficient to inhibit Golgi lumenal mannosyltransferases and the null mutant vesicles are impaired in synthesis of Golgi mannoproteins, the above results demonstrate that the reduced availability of GDP-mannose in the null mutants is the cause for altered Golgi mannosylation of macromolecules.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester				Hirschberg, Carlos/0000-0003-2299-7721	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030365, R01GM030365] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; BRAELL WA, 1988, ANAL BIOCHEM, V170, P328, DOI 10.1016/0003-2697(88)90638-0; BRANDAN E, 1982, BIOCHEMISTRY-US, V21, P4640, DOI 10.1021/bi00262a019; CAPASSO JM, 1984, P NATL ACAD SCI-BIOL, V81, P7051, DOI 10.1073/pnas.81.22.7051; CUNNINGHAM KW, 1989, YEAST, V5, P25, DOI 10.1002/yea.320050105; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; KHATRA BS, 1974, EUR J BIOCHEM, V44, P537, DOI 10.1111/j.1432-1033.1974.tb03513.x; KUBOTA S, 1977, J BIOCHEM-TOKYO, V81, P197, DOI 10.1093/oxfordjournals.jbchem.a131436; KUHN NJ, 1977, BIOCHEM J, V168, P423, DOI 10.1042/bj1680423; NAKAJIMA T, 1975, P NATL ACAD SCI USA, V72, P3912, DOI 10.1073/pnas.72.10.3912; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PEREZ M, 1987, METHOD ENZYMOL, V138, P709; PEREZ M, 1986, J BIOL CHEM, V261, P6822; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; SHERMAN F, 1986, METHODS YEAST GENETI, P20; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; WICE BM, 1985, J BIOL CHEM, V260, P139	20	63	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					207	211						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506254				2022-12-27	WOS:A1994MR21900039
J	HONORE, B; RASMUSSEN, HH; VORUM, H; DEJGAARD, K; LIU, XD; GROMOV, P; MADSEN, P; GESSER, B; TOMMERUP, N; CELIS, JE				HONORE, B; RASMUSSEN, HH; VORUM, H; DEJGAARD, K; LIU, XD; GROMOV, P; MADSEN, P; GESSER, B; TOMMERUP, N; CELIS, JE			HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN-H, RIBONUCLEOPROTEIN-H', AND RIBONUCLEOPROTEIN-F ARE MEMBERS OF A UBIQUITOUSLY EXPRESSED SUBFAMILY OF RELATED BUT DISTINCT PROTEINS ENCODED BY GENES MAPPING TO DIFFERENT CHROMOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; HUMAN KERATINOCYTES; RNA RECOGNITION; SEQUENCE; BINDING; CELLS; PARTICLES; IDENTIFICATION; TRANSFORMATION; TRANSLATION	Molecular cDNA cloning, two-dimensional gel immunoblotting, and amino acid microsequencing identified three sequence-unique and distinct proteins that constitute a subfamily of ubiquitously expressed heterogeneous nuclear ribonucleoproteins corresponding to hnRNPs H, H', and F. These proteins share epitopes and sequence identity with two other proteins, isoelectric focusing sample spot numbers 2222 (37.6 kDa; pI 6.5) and 2326 (39.5 kDa; pI 6.6), indicating that the subfamily may contain additional members. The identity between hnRNPs H and H' is 96%, between H and F 78%, and between H' and F 75%, respectively. The three proteins contain three repeats, which we denote quasi-RRMs (qRRMs) since they have a remote similarity to the RNA recognition motif (RRM). The three qRRMs of hnRNP H, with a few additional NH2-terminal amino acids, were constructed by polymerase chain reaction amplification and used for ribohomopolymer binding studies, Each qRRM repeat bound poly(rG), while only the NH2-terminal qRRM bound poly(rC) and poly(rU). None of the repeats bound detectable amounts of poly(rA). The expression levels of hnRNPs H and F were differentially regulated in pairs of normal and transformed fibro blasts and keratinocytes, In normal human keratinocytes, the expression level of H was unaffected by treatment with several substances tested including two second messengers and seven cytokines, Likewise the expression level of F was independent of these substances, although it was strikingly down-regulated by long term treatment with 4 beta-phorbol 12-myristate 13-acetate, indicating that the protein kinase C signaling pathway regulates its expression. No effect of 4 beta-phorbol 12-myristate 13-acetate was observed on the expression of hnRNP H. The genes coding for hnRNPs H, H', and F were chromosome-mapped to 5q35.3 (HNRPH1), 6q25.3-q26, and/or Xq22 (HNRPH2) and 10q11.21-q11.22 (HNRPF), respectively.	AARHUS UNIV, DANISH CTR HUMAN GENOME RES, DK-8000 AARHUS C, DENMARK; JOHN F KENNEDY INST, DK-2600 GLOSTRUP, DENMARK	Aarhus University	HONORE, B (corresponding author), AARHUS UNIV, DEPT BIOCHEM MED, OLE WORMS ALLE, BLDG 170, DK-8000 AARHUS C, DENMARK.		Honoré, Bent/ABF-3650-2021; Tommerup, Niels/T-8776-2017	Madsen, Peder Sondergaard/0000-0002-8845-4802; Tommerup, Niels/0000-0003-2304-0112; Honore, Bent/0000-0002-3459-7429				BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BIAMONTI G, 1994, FEBS LETT, V340, P1, DOI 10.1016/0014-5793(94)80162-2; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BRAVO R, 1982, J MOL BIOL, V154, P121, DOI 10.1016/0022-2836(82)90421-1; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CELIS JE, 1990, ELECTROPHORESIS, V11, P989, DOI 10.1002/elps.1150111202; CELIS JE, 1986, FEBS LETT, V194, P101, DOI 10.1016/0014-5793(86)80059-X; CELIS JE, 1994, ELECTROPHORESIS, V15, P1349, DOI 10.1002/elps.11501501208; CELIS JE, 1994, ELECTROPHORESIS, V15, P309, DOI 10.1002/elps.1150150153; CELIS JE, 1994, CELL BIOL LABORATORY, V3, P222; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; DEJGAARD K, 1994, J MOL BIOL, V236, P33, DOI 10.1006/jmbi.1994.1116; DEJGAARD K, 1994, CELL BIOL LABORATORY, P339; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; DUZGUNES N, 1993, METHOD ENZYMOL, V221, P303, DOI 10.1016/0076-6879(93)21025-4; FRANCKE U, 1994, CYTOGENET CELL GENET, V65, P206, DOI 10.1159/000133633; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORLACH M, 1994, J BIOL CHEM, V269, P23074; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HONORE B, 1993, EUR J BIOCHEM, V218, P421, DOI 10.1111/j.1432-1033.1993.tb18392.x; HONORE B, 1992, J BIOL CHEM, V267, P8485; HONORE B, 1993, J BIOCHEM BIOPH METH, V27, P39, DOI 10.1016/0165-022X(93)90066-W; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; JACOBS KA, 1988, NUCLEIC ACIDS RES, V16, P4637, DOI 10.1093/nar/16.10.4637; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MADSEN P, 1992, J INVEST DERMATOL, V99, P299, DOI 10.1111/1523-1747.ep12616641; MATUNIS MJ, 1994, NUCLEIC ACIDS RES, V22, P1059, DOI 10.1093/nar/22.6.1059; MCDONALD H, 1992, GENOMICS, V13, P344, DOI 10.1016/0888-7543(92)90251-M; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; QIAN ZW, 1994, NUCLEIC ACIDS RES, V22, P2334, DOI 10.1093/nar/22.12.2334; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; RASMUSSEN HH, 1992, ELECTROPHORESIS, V13, P960, DOI 10.1002/elps.11501301199; Sambrook J, 1989, MOL CLONING LABORATO; SHAMOO Y, 1994, BIOCHEMISTRY-US, V33, P8272, DOI 10.1021/bi00193a014; SILLEKENS PTG, 1987, EMBO J, V6, P3841, DOI 10.1002/j.1460-2075.1987.tb02721.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; TUNON P, 1984, J BIOCHEM BIOPH METH, V9, P171, DOI 10.1016/0165-022X(84)90008-3; VANDEKERCKHOVE J, 1994, CELL BIOL LAB HDB, P359; VORECHOVSKY I, 1994, GENOMICS, V21, P517, DOI 10.1006/geno.1994.1310	48	97	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28780	28789						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499401				2022-12-27	WOS:A1995TH05600045
J	MINER, JH; LEWIS, RM; SANES, JR				MINER, JH; LEWIS, RM; SANES, JR			MOLECULAR-CLONING OF A NOVEL LAMININ CHAIN, ALPHA-5, AND WIDESPREAD EXPRESSION IN ADULT-MOUSE TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN S-LAMININ; A-CHAIN; NEUROMUSCULAR-JUNCTION; BASEMENT-MEMBRANES; SYNAPTIC CLEFT; B2 CHAIN; CELLS; SEQUENCE; GLYCOPROTEIN; DROSOPHILA	We have identified a fifth member of the alpha subfamily of vertebrate laminin chains. Sequence analysis revealed a close relationship of alpha 5 to the only known Drosophila alpha chain, suggesting that the ancestral alpha gene was more similar to alpha 5 than to alpha 1-4. Analysis of RNA expression showed that alpha 5 is widely expressed in adult tissues, with highest levels in lung, heart, and kidney. Our results suggest that alpha 5 may be a major laminin chain of adult basal laminae.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)								ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BROWN JC, 1994, J CELL SCI, V107, P329; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CHUNG AE, 1979, CELL, V16, P277, DOI 10.1016/0092-8674(79)90005-9; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURHAM PL, 1995, DEV DYNAM, V203, P408, DOI 10.1002/aja.1002030404; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; EKBLOM M, 1990, CELL, V60, P337, DOI 10.1016/0092-8674(90)90748-4; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; GRANT DS, 1992, J CELL PHYSIOL, V153, P614, DOI 10.1002/jcp.1041530324; GREEN TL, 1992, J BIOL CHEM, V267, P2014; HENCHCLIFFE C, 1993, DEVELOPMENT, V118, P325; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; JAAKKOLA S, 1993, J NEUROCYTOL, V22, P215, DOI 10.1007/BF01246360; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; KOIVUNEN E, 1994, METHOD ENZYMOL, V245, P346; KROLL TG, 1994, J BIOL CHEM, V269, P9270; KUSCHEGULLBERG M, 1992, EMBO J, V11, P4519, DOI 10.1002/j.1460-2075.1992.tb05553.x; LINDBLOM A, 1994, EUR J BIOCHEM, V219, P383, DOI 10.1111/j.1432-1033.1994.tb19950.x; MACKRELL AJ, 1993, FASEB J, V7, P375, DOI 10.1096/fasebj.7.2.8440414; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; PORTER BE, 1995, NEURON, V14, P549, DOI 10.1016/0896-6273(95)90311-9; RICHARDS AJ, 1994, GENOMICS, V22, P237, DOI 10.1006/geno.1994.1372; RYAN MC, 1994, J BIOL CHEM, V269, P22779; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SOLBERG S, 1992, Journal of Investigative Dermatology, V98, P864; SOROKIN L, 1994, EUR J BIOCHEM, V223, P603, DOI 10.1111/j.1432-1033.1994.tb19031.x; SOROKIN LM, 1992, EXP CELL RES, V201, P137, DOI 10.1016/0014-4827(92)90357-E; SUGIYAMA S, 1995, EUR J BIOCHEM, V228, P120, DOI 10.1111/j.1432-1033.1995.0120o.x; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; TIMPL R, 1979, J BIOL CHEM, V254, P9933; VAILLY J, 1994, EUR J BIOCHEM, V219, P209, DOI 10.1111/j.1432-1033.1994.tb19932.x; VIRTANEN I, 1995, J HISTOCHEM CYTOCHEM, V43, P621, DOI 10.1177/43.6.7769233; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; WEWER UM, 1994, METHOD ENZYMOL, V245, P85	44	227	232	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28523	28526		10.1074/jbc.270.48.28523	http://dx.doi.org/10.1074/jbc.270.48.28523			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499364	hybrid			2022-12-27	WOS:A1995TH05600008
J	YAO, M; KOW, YW				YAO, M; KOW, YW			INTERACTION OF DEOXYINOSINE 3'-ENDONUCLEASE FROM ESCHERICHIA-COLI WITH DNA CONTAINING DEOXYINOSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISMATCH REPAIR; HYPOXANTHINE; GLYCOSYLASE; COMPLEXES; EXCISION; RESIDUES; RELEASE; SITE; ION	By using a band mobility shift assay, deoxyinosine 3'-endonuclease, an Escherichia coli enzyme which recognizes deoxyinosine, AP site, urea residue, and base mismatches in DNA, was shown to bind tightly to deoxyinosine containing oligonucleotide duplexes, Two distinct protein-DNA complexes were observed, the faster migrating complex (complex I, K-d = 4 X 10(-9) M) contained one molecule of deoxyinosine 3'-endonuclease, while the slower migrating complex (complex II, K-d = 4 x 10(-7) M) contained two molecules of the protein bound to every molecule of duplex DNA, The endonucleolytic activity of deoxyinosine 3'-endonuclease paralleled the formation of the complex I, Interestingly, deoxyinosine 3'-endonuclease exhibited similar affinities for both the substrate and the nicked duplex product and thus remained bound to the DNA after the cleavage reaction, The formation of a stable complex required the presence of a duplex structure 5' to the deoxyinosine residue, DNase I footprinting revealed that deoxyinosine 3'-endonuclease protected 4-5 nucleotides 5' to the deoxyinosine, and when complex II was formed, at least 13 nucleotides 3' to deoxyinosine were protected. Based on these results, a model is proposed for the interaction of deoxyinosine 3'-endonuclease with DNA containing deoxyinosine.	UNIV VERMONT,MARKEY CTR MOLEC GENET,DEPT MICROBIOL & MOLEC GENET,BURLINGTON,VT 05405	University of Vermont								AU KG, 1992, J BIOL CHEM, V267, P12142; CASTAING B, 1992, NUCLEIC ACIDS RES, V20, P389, DOI 10.1093/nar/20.3.389; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; HAROSH I, 1988, J BIOL CHEM, V263, P3328; HILLPERKINS M, 1986, MUTAT RES, V162, P153, DOI 10.1016/0027-5107(86)90081-3; KARRAN P, 1980, BIOCHEMISTRY-US, V19, P6005, DOI 10.1021/bi00567a010; KARRAN P, 1978, J BIOL CHEM, V253, P5877; KLAND MJ, 1957, J AM CHEM SOC, V79, P6187, DOI 10.1021/ja01580a022; KUWABARA M, 1986, BIOCHEMISTRY-US, V25, P7401, DOI 10.1021/bi00371a023; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MYRNES B, 1982, NUCLEIC ACIDS RES, V10, P3693, DOI 10.1093/nar/10.12.3693; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; ORCHARD K, 1993, NUCLEIC ACIDS RES, V21, P3335, DOI 10.1093/nar/21.14.3335; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; PONNAMPERUMA C, 1961, SCIENCE, V134, P113, DOI 10.1126/science.134.3472.113; Roberts R, 1993, NUCLEASES, P35; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; YAO M, 1994, J BIOL CHEM, V269, P31390; YAO M, 1994, J BIOL CHEM, V269, P16260	23	43	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28609	28616		10.1074/jbc.270.48.28609	http://dx.doi.org/10.1074/jbc.270.48.28609			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499377	hybrid			2022-12-27	WOS:A1995TH05600021
J	FENG, JQ; CHEN, D; COONEY, AJ; TSAI, MJ; HARRIS, MA; TSAI, SY; FENG, M; MUNDY, GR; HARRIS, SE				FENG, JQ; CHEN, D; COONEY, AJ; TSAI, MJ; HARRIS, MA; TSAI, SY; FENG, M; MUNDY, GR; HARRIS, SE			THE MOUSE BONE MORPHOGENETIC PROTEIN-4 GENE - ANALYSIS OF PROMOTER UTILIZATION IN FETAL-RAT CALVARIAL OSTEOBLASTS AND REGULATION BY COUP-TFI ORPHAN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID; INDUCTION; ELECTROPORATION; IDENTIFICATION; ORGANIZATION; ELEMENTS; PATHWAYS; FAMILY; BMP-4; CELL	Bone morphogenetic protein-4 (BMP-4) is one of a member of related polypeptides that are important in bone formation and other developmental processes, We isolated the BMP-4 gene from a mouse genomic library and characterized the exon-intron structure and one of the candidate promoters. Two alternative 5'-noncoding exons, 1A and 1B, were identified by reverse transcription polymerase chain reaction assays, Quantitative competitive polymerase chain reaction using Exon 1A, Exon 1B, and Exon 3 primers indicate the 1A-containing transcript is the primary BMP-4 mRNA expressed in bone cell cultures. Primer extension analysis supports that 1A is the major promoter utilized in bone cell cultures as well as in 9.5-day mouse embryos, 1A promoter activity indicate selective DNA regions functional in bone cells. We found potential regulatory response regions in the IA 5'-flanking region of the BMP-4 gene for the chicken ovalbumin upstream-transcription factor I (COUP TFI). Specific binding to the COUP-TFI response regions in the BMP-4 1A promoter was demonstrated, By co transfection of a COUP-TFI expression plasmid with the BMP-4 1A promoter in fetal rat calvarial osteoblasts, we demonstrated that COUP-TFI inhibits the BMP-4 promoter activity, This suggests that COUP-TFI could act as a silencer for BMP-4 transcription in vivo.	UNIV TEXAS, HLTH SCI CTR, DEPT MED ENDOCRINOL & METAB, SAN ANTONIO, TX 78284 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	University of Texas System; University of Texas Health San Antonio; Baylor College of Medicine					NCI NIH HHS [CA-40035] Funding Source: Medline; NIAMS NIH HHS [AR-39529] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039529] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLESSING M, 1993, GENE DEV, V7, P204, DOI 10.1101/gad.7.2.204; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CHEN D, 1993, BIOCHIM BIOPHYS ACTA, V1174, P289, DOI 10.1016/0167-4781(93)90200-W; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; FENG JQ, 1995, BBA-GENE STRUCT EXPR, V1263, P163, DOI 10.1016/0167-4781(95)00106-Q; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; GORMAN C, 1988, DNA CLONING PRACTICA, V2, P157; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HARRIS SE, 1994, J BONE MINER RES, V9, P855; HARRIS SE, 1994, J BONE MINER RES, V9, P389; JONES CM, 1991, DEVELOPMENT, V111, P531; JONES CM, 1992, DEVELOPMENT, V115, P639; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KURIHARA T, 1993, BIOCHEM BIOPH RES CO, V192, P1049, DOI 10.1006/bbrc.1993.1523; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEHMANN JM, 1991, NUCLEIC ACIDS RES, V19, P573, DOI 10.1093/nar/19.3.573; LU XP, 1994, MOL ENDOCRINOL, V8, P1774, DOI 10.1210/me.8.12.1774; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; NISHIMATSU SI, 1993, GROWTH FACTORS, V8, P173, DOI 10.3109/08977199309011020; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; POTTER H, 1988, ANAL BIOCHEM, V174, P361, DOI 10.1016/0003-2697(88)90035-8; ROUET P, 1992, BIOTECHNIQUES, V13, P700; Sambrook J, 1989, MOL CLONING LABORATO; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SHIMIZU K, 1994, CLIN ORTHOP RELAT R, P274; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; SUZUKI A, 1993, BIOCHEM J, V291, P413, DOI 10.1042/bj2910413; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212	37	90	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28364	28373						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499338	hybrid			2022-12-27	WOS:A1995TG21000063
J	SPIRO, C; BAZETTJONES, DP; WU, XL; MCMURRAY, CT				SPIRO, C; BAZETTJONES, DP; WU, XL; MCMURRAY, CT			DNA-STRUCTURE DETERMINES PROTEIN-BINDING AND TRANSCRIPTIONAL EFFICIENCY OF THE PROENKEPHALIN CAMP-RESPONSIVE ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGATION-MEDIATED PCR; CYCLIC AMP; GENE; ELEMENT; PHOSPHORYLATION; POLYMERASE; INTERACTS; CELLS; SITES	Two precisely arranged proenkephalin cAMP response elements (CREs) behave as a single protein binding site, The experiments described support a model in which a secondary structural change creates a new binding site, which is made up of sequences from both of the CREs. The CRE-binding protein (CREB) binds CRE-1, but binding there is entirely dependent on the presence of CRE-2. Electron spectroscopic images show that a CREB dimer occupies twice as much DNA in the proenkephalin gene as in the prodynorphin gene, The enhancer region is sensitive to P-1 nuclease in a CREB concentration-dependent manner, and sensitivity is strand-specific, indicating protein-stabilized structural change. DNase I analysis shows that in the native proenkephalin gene, CREB binds both CRE-1 and CRE-2. In vivo, both CREs are occupied in the transcriptionally active proenkephalin gene, while neither is in the silent gene, Whereas CREB can bind CRE-2, mutation or elimination of either proenkephalin CRE alters response to second messengers and transcription factors. Thus, binding to CRE-2 alone is not sufficient. Specific and efficient transcription of the proenkephalin gene requires the presence of both CREs, precisely arranged to allow them to form a single protein binding site.	MAYO FDN & GRAD SCH,DEPT PHARMACOL,ROCHESTER,MN 55905; MAYO FDN & GRAD SCH,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; UNIV CALGARY,DEPT MED BIOCHEM,CALGARY,AB T2N 4N1,CANADA; UNIV CALGARY,DEPT ANAT,CALGARY,AB T2N 4N1,CANADA	Mayo Clinic; Mayo Clinic; University of Calgary; University of Calgary								BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; BAZETTJONES DP, 1989, MOL CELL BIOL, V9, P336, DOI 10.1128/MCB.9.1.336; BAZETTJONES DP, 1992, ELECTRON MICROSC REV, V5, P37, DOI 10.1016/0892-0354(92)90004-A; BORSOOK D, 1994, MOL ENDOCRINOL, V8, P240, DOI 10.1210/me.8.2.240; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINSHICOK J, 1994, MOL CELL BIOL, V14, P2837, DOI 10.1128/MCB.14.5.2837; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; COMB M, 1983, DNA-J MOLEC CELL BIO, V2, P213, DOI 10.1089/dna.1983.2.213; DOUGLASS J, 1994, MOL ENDOCRINOL, V8, P333, DOI 10.1210/me.8.3.333; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GACY AM, 1994, BIOCHEMISTRY-US, V33, P11951, DOI 10.1021/bi00205a034; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORNSTRA IK, 1993, ANAL BIOCHEM, V213, P179, DOI 10.1006/abio.1993.1407; JOSHI J, 1991, MOL ENDOCRINOL, V5, P1069, DOI 10.1210/mend-5-8-1069; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; KONRADI C, 1994, J NEUROSCI, V14, P5623; KONRADI C, 1993, P NATL ACAD SCI USA, V90, P7005, DOI 10.1073/pnas.90.15.7005; LAFORGE KS, 1995, MOL CELL BIOL, V15, P2080; MATTES WB, 1986, BIOCHIM BIOPHYS ACTA, V868, P71, DOI 10.1016/0167-4781(86)90088-6; Maxam A M, 1980, Methods Enzymol, V65, P499; MCMURRAY CT, 1991, P NATL ACAD SCI USA, V88, P666, DOI 10.1073/pnas.88.2.666; MCMURRAY CT, 1994, BIOCHEMISTRY-US, V33, P11960, DOI 10.1021/bi00205a035; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUELLER PR, 1992, CURRENT PROTOCOLS MO; NGUYEN TV, 1990, J NEUROSCI, V10, P2825; OLSON GA, 1994, PEPTIDES, V15, P1513, DOI 10.1016/0196-9781(94)90131-7; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; POON D, 1993, J BIOL CHEM, V268, P5005; ROSEN H, 1984, J BIOL CHEM, V259, P4309; SEARS LE, 1992, BIOTECHNIQUES, V13, P626; SHEEN JY, 1988, BIOTECHNIQUES, V6, P942; SPIRO C, 1993, P NATL ACAD SCI USA, V90, P4606, DOI 10.1073/pnas.90.10.4606; TAN Y, 1994, MOL CELL BIOL, V14, P7546, DOI 10.1128/MCB.14.11.7546; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TUGORES A, 1994, J BIOL CHEM, V269, P30789; WOHLRAB F, 1992, METHOD ENZYMOL, V212, P294; ZHU YS, 1994, DNA CELL BIOL, V13, P25, DOI 10.1089/dna.1994.13.25	43	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27702	27710		10.1074/jbc.270.46.27702	http://dx.doi.org/10.1074/jbc.270.46.27702			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499237	hybrid			2022-12-27	WOS:A1995TE73600048
J	KOVALA, T; LORIMER, IAJ; BRICKENDEN, AM; BALL, EH; SANWAL, BD				KOVALA, T; LORIMER, IAJ; BRICKENDEN, AM; BALL, EH; SANWAL, BD			PROTEIN-KINASE-A REGULATION OF CAMP-PHOSPHODIESTERASE EXPRESSION IN RAT SKELETAL MYOBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; DROSOPHILA DUNCE+ GENE; MOLECULAR-CLONING; ADENYLYL CYCLASE; HORMONAL-REGULATION; CELL; DIFFERENTIATION; MYOGENESIS; SUBUNIT; BETA	We have been studying cAMP signaling in L6 myoblasts because of its potential role in regulating the differentiation of these cells into multinucleate myotubes. Previous studies have shown that treatment of L6 myoblasts with cAMP analogs causes an increase in cAMP phosphodiesterase activity. To assess the role of protein kinase A in this cAMP-mediated increase in cAMP phosphodiesterase activity, L6 myoblasts were transfected with a plasmid containing the cDNA for a mutant regulatory subunit of protein kinase A, which functions as a dominant negative inhibitor of this enzyme. The cDNA was under control of the metallothionein promoter in the construct. Induction of the mutant regulatory subunit with Zn2+ decreased cAMP-dependent protein kinase activity by 90%. Zn2+ treatment was also able to completely block the cAMP-mediated increase in phosphodiesterase activity, showing that this effect is mediated by protein kinase A. The activity of the cAMP-induced phosphodiesterase was inhibited by low concentrations of RO 20-1724, showing that it was a member of the type IV low K-m cAMP phosphodiesterase family of enzymes. We used the polymerase chain reaction and consensus primers designed to amplify phosphodiesterase sequences to show that L6 myoblasts also contain mRNA for a type IV low K-m cAMP phosphodiesterase designated PDES3.1. The levels of this mRNA were increased greatly by treatment with dibutyryl cAMP or forskolin in L6 myoblasts and also in differentiated L6 myotubes. Run off transcription assays showed that this increase in PDE mRNA was regulated, at least in part, by an increase in the rate of transcription of the PDES gene. The induction of PDES message by cAMP was blocked when the L6 transfectants were treated with Zn2+ to induce protein kinase A inhibition. Therefore, some of the cAMP-mediated increase in phosphodiesterase activity seen in L6 myoblasts is due to a protein kinase A-mediated increase in PDE3 mRNA. This pathway may serve as a feedback mechanism to modulate the inhibitory effects of cAMP on myogenesis.			KOVALA, T (corresponding author), UNIV WESTERN ONTARIO, DEPT BIOCHEM, LONDON N6A 5C1, ON, CANADA.			Ball, Eric/0000-0003-2542-9156				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BALL EH, 1980, J BIOL CHEM, V255, P2962; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BOURNE HR, 1973, SCIENCE, V181, P952, DOI 10.1126/science.181.4103.952; CASPERSON GF, 1987, ANNU REV PHARMACOL, V27, P371; CATES GA, 1984, J BIOL CHEM, V259, P2646; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLLINS S, 1992, TRENDS BIOCHEM SCI, V17, P37, DOI 10.1016/0968-0004(92)90425-9; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; DAVIS RL, 1991, TRENDS GENET, V7, P224, DOI 10.1016/0168-9525(91)90369-2; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSS RE, 1990, J BIOL CHEM, V265, P8152; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HU JS, 1988, J BIOL CHEM, V263, P19670; JIN SLC, 1992, J BIOL CHEM, V267, P18929; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; LORIMER IAJ, 1987, J BIOL CHEM, V262, P17200; LORIMER IAJ, 1989, BIOCHEM J, V264, P305, DOI 10.1042/bj2640305; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; MEDFORD RM, 1983, J BIOL CHEM, V258, P1063; NARINDRASORASAK S, 1982, J BIOL CHEM, V257, P4618; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; REPASKE DR, 1992, J BIOL CHEM, V267, P18683; ROGERS JE, 1985, J BIOL CHEM, V260, P8002; Rosen K., 1990, FOCUS, V12, P23; SALMINEN A, 1991, J CELL BIOL, V115, P905, DOI 10.1083/jcb.115.4.905; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; SWINNEN JV, 1991, J BIOL CHEM, V266, P18370; SWINNEN JV, 1991, J BIOL CHEM, V266, P14383; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; WAHRMANN JP, 1973, NATURE-NEW BIOL, V245, P112, DOI 10.1038/newbio245112a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WINTER B, 1993, J BIOL CHEM, V268, P9869; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; [No title captured]	48	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8680	8685						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510696				2022-12-27	WOS:A1994NB41100012
J	LACRAZ, S; DAYER, JM; NICOD, L; WELGUS, HG				LACRAZ, S; DAYER, JM; NICOD, L; WELGUS, HG			1,25-DIHYDROXYVITAMIN D-3 DISSOCIATES PRODUCTION OF INTERSTITIAL COLLAGENASE AND 92-KDA GELATINASE IN HUMAN MONONUCLEAR PHAGOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALVEOLAR MACROPHAGES; HUMAN SYNOVIAL-CELLS; HUMAN-MONOCYTES; IV COLLAGENASE; VITAMIN-D; METALLOPROTEINASE PRODUCTION; MYCOBACTERIUM-TUBERCULOSIS; STIMULATES COLLAGENASE; INTERFERON-GAMMA; GENE-EXPRESSION	To study the effect of mononuclear cell differentiation on metalloproteinase production, the human monocytic cell lines U937 and THP-1 were exposed to two well known differentiating agents, the phorbol esters (phorbol myristate acetate (PMA)) and 1,25-dihydroxyvitamin D-3 (1,25-(OH)(2)D-3). With U937 cells, PMA-induced differentiation increased the production of both interstitial collagenase and 92-kDa gelatinase, whereas exposure to 1,25-(OH)(2)D-3 induced full interstitial collagenase expression in the absence of any detectable 92-kDa gelatinase production, In fact, when U937 cells were differentiated with PMA and then exposed to vitamin D-3, the hormone actually suppressed phorbol-induced 92-kDa gelatinase biosynthesis. With THP-1 cells, PMA also induced the production of 92-kDa gelatinase fully, but unlike U937 cells, the combination of PMA and 1,25-(OH)(2)D-3 was required for substantial interstitial collagenase biosynthesis. As with U937 cells, the addition of 1,25-(OH)(2)D-3 to PMA differentiated THP-1 cells caused a dose-dependent inhibition of 92-kDa gelatinase production. Northern hybridizations demonstrated that both phorbol esters and vitamin D-3 act on monocytic cell lines at a pretranslational level. To determine whether metalloproteinase biosynthesis in normal differentiated mononuclear phagocytes was also modified by 1,25-(OH)(2)D-3, human blood monocytes and alveolar macrophages were exposed to this hormone. In both cell types, basal and Staphylococcal-stimulated 92-kDa gelatinase production was markedly inhibited by 1,25-(OH)(2)D-3. In contrast, interstitial collagenase production was completely unaffected by the hormone. In summary, the two major metalloproteinases produced by monocytic cells are regulated via distinct molecular pathways by the action of PMA and 1,25-(OH)(2)D-3. Furthermore, vitamin D-3 completely dissociates the production of 92-kDa gelatinase and interstitial collagenase in human mononuclear phagocytes.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV DERMATOL,ST LOUIS,MO 63110; UNIV HOSP GENEVA,DEPT MED,DIV IMMUNOL & ALLERGY,GENEVA,SWITZERLAND; UNIV HOSP GENEVA,DEPT MED,DIV PULM,GENEVA,SWITZERLAND	Barnes-Jewish Hospital; Washington University (WUSTL); University of Geneva; University of Geneva			Nicod, Laurent/ABD-3360-2020	Nicod, Laurent P/0000-0002-0905-916X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087, R01AR035805] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29594] Funding Source: Medline; NIAMS NIH HHS [AR32087, AR35805] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE E, 1984, P NATL ACAD SCI-BIOL, V81, P7112, DOI 10.1073/pnas.81.22.7112; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BERGMANN U, 1989, J CLIN CHEM CLIN BIO, V27, P351; BHALLA AK, 1986, CELL IMMUNOL, V98, P311, DOI 10.1016/0008-8749(86)90291-1; BHALLA AK, 1991, IMMUNOLOGY, V72, P61; BLIFELD C, 1991, TRANSPLANTATION, V51, P498, DOI 10.1097/00007890-199102000-00043; CAMPBELL EJ, 1991, J IMMUNOL, V146, P1286; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN MS, 1986, J IMMUNOL, V136, P1049; CONCA W, 1991, J BIOL CHEM, V266, P1625; COOPER TW, 1983, COLLAGEN REL RES, V3, P205; CORCORAN ML, 1992, J BIOL CHEM, V267, P515; CURY JD, 1988, J IMMUNOL, V141, P4306; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; DENIS M, 1991, CLIN EXP IMMUNOL, V84, P200, DOI 10.1111/j.1365-2249.1991.tb08149.x; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GALVEDEROCHEMONTEIX B, 1990, AM J RESP CELL MOL, V3, P355, DOI 10.1165/ajrcmb/3.4.355; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; KELSEY SM, 1992, LEUKEMIA RES, V16, P427, DOI 10.1016/0145-2126(92)90167-6; LACRAZ S, 1992, J CLIN INVEST, V90, P382, DOI 10.1172/JCI115872; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MUNKER R, 1986, J CLIN INVEST, V78, P424, DOI 10.1172/JCI112593; PROVENDINI DM, 1984, SCIENCE, V221, P1181; RASTOGI N, 1990, ZBL BAKT-INT J MED M, V273, P344; ROUXLOMBARD P, 1986, CELL IMMUNOL, V97, P286, DOI 10.1016/0008-8749(86)90399-0; SATO H, 1993, ONCOGENE, V8, P395; SENIOR RM, 1982, J CLIN INVEST, V69, P384, DOI 10.1172/JCI110462; SHAPIRO SD, 1990, J CLIN INVEST, V86, P1204, DOI 10.1172/JCI114826; SHAPIRO SD, 1991, J IMMUNOL, V146, P2724; SHAPIRO SD, 1993, J BIOL CHEM, V268, P8170; SUDA T, 1992, J CELL BIOCHEM, V49, P53, DOI 10.1002/jcb.240490110; UCLA C, 1990, J CLIN INVEST, V85, P1181; VEY E, 1992, J IMMUNOL, V149, P2040; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WELGUS HG, 1986, J CLIN INVEST, V77, P1675, DOI 10.1172/JCI112485; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	42	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6485	6490						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509804				2022-12-27	WOS:A1994MZ50300036
J	STRAUSS, BL; PITTMAN, R; PIXLEY, MR; NILSON, J; BOIME, I				STRAUSS, BL; PITTMAN, R; PIXLEY, MR; NILSON, J; BOIME, I			EXPRESSION OF THE BETA-SUBUNIT OF CHORIONIC-GONADOTROPIN IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL LACTOGEN-I; MESSENGER-RNA; LUTEINIZING-HORMONE; GENE-CLUSTER; RESPONSE ELEMENT; HUMAN PITUITARY; RAT PLACENTA; CELLS; SECRETION; DIFFERENTIATION	Transcriptional activation of the chorionic gonadotropin (CG) genes is linked to trophoblast differentiation. In a multistep process, cytotrophoblasts expressing only the alpha subunit differentiate into intermediates that coexpress the CG beta subunit. To study the regulation of expression of the CG beta genes in vivo, we constructed mice carrying a 36-kilobase cosmid insert containing the six CG beta genes. In the placenta of all three constructed lines, expression occurred at approximately 1% of the levels in first trimester human placenta. The amount of CG beta mRNA in mouse placenta was a function of gestational age; however, in contrast to the human placenta where CG beta peaks early in pregnancy, CG beta transcripts were only detectable in the mouse placenta fate in gestation, i.e. from day 14 onward. Human CG beta was expressed also in cerebral cortex, pituitary, and at minute levels in adrenal. Pituitary CG beta expression was significantly lower than in placenta. Unexpectedly, transcripts were observed in cerebral cortex at levels comparable with the placenta. Most of the CG beta transcripts in mouse placenta are derived from CG beta genes 5, 3, and 8, in a ratio similar to that found in human placenta. In contrast, only CG beta genes 1 and 2 were transcribed in transgenic mouse brain; open reading frames from the CG beta 1 and beta 2 transcripts differ substantially from the CG beta protein. The data show that although the mouse lacks a CG beta-like gene, the human CG beta genes are transcribed in a regulated fashion in mouse placenta. Moreover, the stage-specific induction of the transgene suggests that mouse placental cells may express CG beta in an intermediate cell comparable with that seen in human placenta. Taken together these data suggest that transgenic mice can be used as a model for elucidating the mechanisms involved in regulated expression of the CG beta gene cluster in vivo. Additionally, a different subset of CG beta genes (CG beta 1 and beta 2) is active in the mouse brain.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT OBSTET & GYNECOL,ST LOUIS,MO 63110; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106	Washington University (WUSTL); Washington University (WUSTL); Case Western Reserve University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028559] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-28559] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANESE C, 1991, MOL ENDOCRINOL, V5, P693, DOI 10.1210/mend-5-5-693; ASHITAKA Y, 1980, CHORIONIC GONADOTROP, P147; BO M, 1992, J BIOL CHEM, V267, P3179; Boime I., 1978, Structure and function of the gonadotropins., P235; BOIME I, 1982, BIOL REPROD, V26, P73, DOI 10.1095/biolreprod26.1.73; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; BOORSTEIN WR, 1982, NATURE, V300, P419, DOI 10.1038/300419a0; BRAUNSTEIN GD, 1980, CHORIONIC GONADOTROP, P383; CHATTERJEE VKK, 1991, MOL ENDOCRINOL, V5, P100, DOI 10.1210/mend-5-1-100; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU JY, 1992, NATURE, V268, P543; DARNELL RB, 1985, MOL CELL BIOL, V5, P3157, DOI 10.1128/MCB.5.11.3157; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; EMANUELE NV, 1983, NEUROENDOCRINOLOGY, V36, P254, DOI 10.1159/000123464; EMANUELE NV, 1992, MOL ENDOCRINOL, V6, P35, DOI 10.1210/me.6.1.35; ENDERS AC, 1965, OBSTET GYNECOL, V25, P378; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; FARIA TN, 1990, DEV BIOL, V141, P279, DOI 10.1016/0012-1606(90)90384-U; FARIA TN, 1991, BIOL REPROD, V44, P327, DOI 10.1095/biolreprod44.2.327; FENSTERMAKER RA, 1989, MOL ENDOCRINOL, V3, P1070, DOI 10.1210/mend-3-7-1070; FENSTERMAKER RA, 1990, MOL ENDOCRINOL, V4, P1480, DOI 10.1210/mend-4-10-1480; FIDDES JC, 1984, RECENT PROG HORM RES, V40, P43; GRAHAM MY, 1987, NUCLEIC ACIDS RES, V15, P4437, DOI 10.1093/nar/15.11.4437; HOCHBERG A, 1991, J BIOL CHEM, V266, P8517; HOGAN B, 1986, MANIPULATING MOUSE E; HOSHINA M, 1983, J CELL BIOL, V97, P1200, DOI 10.1083/jcb.97.4.1200; HOSHINA M, 1985, PLACENTA, V6, P163, DOI 10.1016/S0143-4004(85)80066-7; HOSTETTER G, 1987, NEUROENDOCRINOLOGY, V46, P185, DOI 10.1159/000124818; ILGREN EB, 1983, PLACENTA, V4, P307, DOI 10.1016/S0143-4004(83)80010-1; JAMESON JL, 1990, GLYCOPROTEIN HORMONE, P269; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; MCGREGOR WG, 1980, SCIENCE, V220, P306; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; ODELL WD, 1990, J CLIN ENDOCR METAB, V71, P1318, DOI 10.1210/jcem-71-5-1318; OTANI T, 1988, J BIOL CHEM, V263, P7322; OTANI T, 1986, ENDOCRINOLOGY, V119, P1195; PIERCE GB, 1963, AM J PATHOL, V43, P153; POLICASTRO P, 1983, J BIOL CHEM, V258, P1492; POLICASTRO PF, 1986, J BIOL CHEM, V261, P5907; RAMSEY EM, 1982, PLACENTA; ROTHMAN PA, 1992, MOL REPROD DEV, V33, P1, DOI 10.1002/mrd.1080330102; RUDDON RW, 1980, J BIOL CHEM, V255, P1000; SHERMAN GB, 1992, MOL ENDOCRINOL, V6, P951, DOI 10.1210/me.6.6.951; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; SOARES MJ, 1985, DEV BIOL, V107, P520, DOI 10.1016/0012-1606(85)90332-X; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; VANSTRIEN A, 1989, NUCLEIC ACIDS RES, V17, P5406, DOI 10.1093/nar/17.13.5406; WATER P, 1984, CELL, V38, P5; WURZEL JM, 1983, ENDOCRINOLOGY, V113, P1854, DOI 10.1210/endo-113-5-1854; WYNN RM, 1972, AM J OBSTET GYNECOL, V114, P339, DOI 10.1016/0002-9378(72)90612-6	53	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4968	4973						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508931				2022-12-27	WOS:A1994MX57100044
J	TANG, CL; WILKENS, S; CAPALDI, RA				TANG, CL; WILKENS, S; CAPALDI, RA			STRUCTURE OF THE GAMMA-SUBUNIT OF ESCHERICHIA-COLI F1 ATPASE PROBED IN TRYPSIN DIGESTION AND BIOTIN-AVIDIN BINDING-STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; ADENOSINE-TRIPHOSPHATASE; EPSILON-SUBUNIT; F1 ATPASE; H+-ATPASE; SECONDARY-STRUCTURE; CROSS-LINKING; F1-ATPASE; SYNTHASE; PROTEINS	The arrangement and functional role of the gamma subunit of the Escherichia coli F(1)ATPase (ECF(1)) has been probed by protease digestion and avidin-biotin labeling experiments using wild-type enzyme and four mutants, gamma S8C, gamma T106C, gamma S179C, and gamma V286C, respectively. Trypsin was found to cleave the gamma subunit at four sites, Arg(70), Lys(199), Lys(201), and Lys(212). Cleavage at these four sites did not greatly reduce the high ATPase activity of the enzyme that is obtained when the epsilon subunit is removed by the protease treatment. However, prolonged trypsin cleavage led to loss of inhibition by epsilon subunit added back to the trypsin-treated enzyme. Endoproteinase-Lys-C cleaves the gamma subunit of ECF(1) at three of the four sites, i.e. Lys(199), Lys(201), and Lys(212), but not at Arg(70). The enzyme was activated by treatment with this protease because of degradation and release of the epsilon subunit, but added pure epsilon subunit still caused inhibition of ATPase activity. Therefore, cleavage at Arg(70) by trypsin is responsible for the loss of response to the epsilon subunit inhibition. Biotin was reacted with Cys residues at positions 8, 106, 179, and 286 in different gamma subunit mutants and the accessibility of the biotin to avidin monitored in the intact ECF(1) from the different mutants. Avidin was able to react with biotin when incorporated at position 106, not at 8, 179, or 286. The four trypsin cleavage sites, Arg(70), Lys(199), Lys(201), and Lys(212), as well as Thr(106) are in regions of the gamma subunit predicted to be mainly beta-sheet and beta-turn structures.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA	University of Oregon					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 24526] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1993, EMBO J, V12, P1775, DOI 10.1002/j.1460-2075.1993.tb05825.x; AGGELER R, 1993, J BIOL CHEM, V268, P14576; AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; AGGELER R, 1993, J BIOL CHEM, V268, P20831; AGGELER R, 1992, J BIOL CHEM, V267, P21355; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; BRAGG PD, 1980, EUR J BIOCHEM, V106, P495, DOI 10.1111/j.1432-1033.1980.tb04596.x; BRAGG PD, 1987, BIOCHIM BIOPHYS ACTA, V894, P127, DOI 10.1016/0005-2728(87)90182-4; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; DUNN SD, 1982, J BIOL CHEM, V257, P7354; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1977, BIOCHEM BIOPH RES CO, V79, P1231, DOI 10.1016/0006-291X(77)91138-X; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GAVILANESRUIZ M, 1988, BIOCHEMISTRY-US, V27, P603, DOI 10.1021/bi00402a016; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; GROMETELHANAN Z, 1992, BIOCHIM BIOPHYS ACTA, V1102, P379, DOI 10.1016/0167-4838(92)90525-I; HARATA M, 1990, BIOCHIM BIOPHYS ACTA, V1056, P279; ISHII N, 1993, J BIOCHEM-TOKYO, V113, P245, DOI 10.1093/oxfordjournals.jbchem.a124034; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; KAIBARA C, 1993, FEBS LETT, V321, P46, DOI 10.1016/0014-5793(93)80618-5; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MIWA K, 1989, P NATL ACAD SCI USA, V86, P6484, DOI 10.1073/pnas.86.17.6484; NAKAMOTO RK, 1993, J BIOL CHEM, V268, P867; NELSON N, 1972, J BIOL CHEM, V247, P7657; NOUMI T, 1987, FEBS LETT, V213, P381, DOI 10.1016/0014-5793(87)81526-0; OHTA S, 1990, BIOCHEM BIOPH RES CO, V171, P1258, DOI 10.1016/0006-291X(90)90821-4; PATEL AM, 1990, MOL MICROBIOL, V4, P1941, DOI 10.1111/j.1365-2958.1990.tb02043.x; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RICHTER ML, 1984, J BIOL CHEM, V259, P7371; SCHUMANN J, 1985, J BIOL CHEM, V260, P1817; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SHIN K, 1992, J BIOL CHEM, V267, P20835; SMITH JB, 1977, BIOCHEMISTRY-US, V16, P306, DOI 10.1021/bi00621a023; SOTEROPOULOS P, 1992, J BIOL CHEM, V267, P10348; TUTTASDORSCHUG R, 1989, BIOCHEMISTRY-US, V28, P5107, DOI 10.1021/bi00438a030; WILKENS S, 1992, ARCH BIOCHEM BIOPHYS, V299, P105, DOI 10.1016/0003-9861(92)90250-Z; WISE JG, 1981, J BIOL CHEM, V256, P383; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480	43	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4467	4472						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508444				2022-12-27	WOS:A1994MW98900087
J	WANG, MH; YOSHIMURA, T; SKEEL, A; LEONARD, EJ				WANG, MH; YOSHIMURA, T; SKEEL, A; LEONARD, EJ			PROTEOLYTIC CONVERSION OF SINGLE-CHAIN PRECURSOR MACROPHAGE-STIMULATING PROTEIN TO A BIOLOGICALLY-ACTIVE HETERODIMER BY CONTACT ENZYMES OF THE COAGULATION CASCADE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; AMINO-ACID-SEQUENCE; SCATTER FACTOR; HUMAN-PLASMA; ACTIVATION; PLASMINOGEN; PROTHROMBIN; UROKINASE; CLEAVAGE; HOMOLOGY	Human serum macrophage stimulating protein (MSP) is a disulfide-linked heterodimer that induces motile and phagocytic activity of mouse resident peritoneal macrophages. It is a member of the family of kringle proteins, which typically exist in extracellular fluid as single chain precursors that are activated by proteolytic cleavage. In this work, we expressed [S-35]cysteine-labeled recombinant pro-MSP in MSP cDNA-transfected Chinese hamster ovary cells and studied proteolytic processing of pro-MSP and the requirement of cleavage for biological activity. In media containing heat-inactivated fetal bovine serum, the protein was secreted as single chain pro-MSP, which was cleaved over a period of hours to the mature heterodimer. Cleavage was prevented by serine protease inhibitors such as leupeptin or aprotinin; it did not occur if cells were cultured in serum-free medium. Nanomolar concentrations of coagulation proteases kallikrein, factor XIIa or factor XIa cleaved pro-MSP to MSP within 30 min. Pro-MSP had no biological activity. After cleavage by kallikrein, biological activity was quantitatively comparable to that of natural MSP isolated from human plasma. These results support our hypothesis that MSP circulates as the biologically inactive precursor and can be activated by enzymes of the intrinsic coagulation cascade.			WANG, MH (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,IMMUNOBIOL LAB,IMMUNOPATHOL SECT,BLDG 506,RM 12-71,FREDERICK,MD 21702, USA.							COLVIN RB, 1973, J EXP MED, V138, P686, DOI 10.1084/jem.138.3.686; FRANCIS CW, 1990, HEMATOLOGY, P1313; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GREGORY SA, 1985, J CLIN INVEST, V76, P2440, DOI 10.1172/JCI112260; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; KAPLAN AP, 1987, BLOOD, V70, P1; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LEONARD EJ, 1978, EXP CELL RES, V114, P117, DOI 10.1016/0014-4827(78)90043-5; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIZUNO K, 1992, BIOCHEM BIOPH RES CO, V189, P1631, DOI 10.1016/0006-291X(92)90264-L; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; PARK CH, 1986, BIOCHEMISTRY-US, V25, P3977, DOI 10.1021/bi00362a001; SCOTT CF, 1986, J CLIN INVEST, V77, P631, DOI 10.1172/JCI112346; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SOTTRUPJENSEN L, 1975, P NATL ACAD SCI USA, V72, P2577, DOI 10.1073/pnas.72.7.2577; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; WANG MH, 1993, J LEUKOCYTE BIOL, V54, P289, DOI 10.1002/jlb.54.4.289; WUN TC, 1982, J BIOL CHEM, V257, P7262; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	22	83	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3436	3440						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508914				2022-12-27	WOS:A1994MV63100048
J	LI, WQ; MISCHAK, H; YU, JC; WANG, LM; MUSHINSKI, JF; HEIDARAN, MA; PIERCE, JH				LI, WQ; MISCHAK, H; YU, JC; WANG, LM; MUSHINSKI, JF; HEIDARAN, MA; PIERCE, JH			TYROSINE PHOSPHORYLATION OF PROTEIN-KINASE C-DELTA IN RESPONSE TO ITS ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSFORM FIBROBLASTS; SIGNAL TRANSDUCTION; MAP KINASES; RECEPTOR; CELLS; STIMULATION; PATHWAYS; ALPHA; CDNA; IL-3	Retroviral vectors containing five different protein kinase C (PKC) isoenzymes (alpha, delta, epsilon, eta, xeta) were expressed in 32D hematopoietic cells and NIH-3T3 fibroblasts. In an effort to investigate signaling events regulated by PKC activation, we analyzed whether tyrosine phosphorylation of cellular proteins would occur after 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment of the various transfectants. While no detectable tyrosine-specific phosphorylation was observed after treatment of the majority of the transfectants, pronounced TPA-dependent tyrosine phosphorylation of an 82-kDa protein was detected in the 32D/PKC-delta and NIH-3T3/PKC-delta lines. Interestingly, the 82-kDa substrate proved to be PKC-delta itself. Tyrosine phosphorylation of purified PKC-delta by src family or receptor tyrosine kinases in vitro enhanced PKC-delta activity, suggesting that tyrosine phosphorylation of PKC-delta may positively affect its function.	NCI,MOLEC GENET SECT,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; NCI,MOLEC GENET SECT,GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Mischak, Harald/E-8685-2011	Mischak, Harald/0000-0003-0323-0306				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BEELER JF, 1994, IN PRESS MOL CELL BI; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; EINSPAHR KJ, 1990, J IMMUNOL, V145, P1490; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG K-P, 1990, Biofactors, V2, P171; JENSEN RA, 1992, BIOCHEMISTRY-US, V31, P10887, DOI 10.1021/bi00159a032; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NEL AE, 1990, J IMMUNOL, V145, P971; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032	26	178	180	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2349	2352						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7507923				2022-12-27	WOS:A1994MV43200001
J	CHATTERJEE, S				CHATTERJEE, S			NEUTRAL SPHINGOMYELINASE ACTION STIMULATES SIGNAL-TRANSDUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA IN THE SYNTHESIS OF CHOLESTERYL ESTERS IN HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED FIBROBLASTS; GENTAMICIN	We have investigated biochemical mechanisms of tumor necrosis factor (TNF)-alpha signaling in cultured human skin fibroblasts. We found that TNF-alpha signaling may involve activation of a cell membrane neutral sphingomyelinase (N-SMase) in that within 2.5-5 min of treatment of cells with TNF-alpha there was a 2-fold increase in the activity of N-SMase compared to control. This reaction led to the hydrolysis of sphingomyelin as evidenced by a decrease in sphingomyelin mass and in the radioactivity associated with [C-14]choline-labeled sphingomyelin. This was accompanied by a 4-fold increase in the formation of cholesteryl [C-14]oleate within 2.5 min of incubation with TNF-alpha. This reaction also stimulated the mobilization of cell surface-associated [H-3]cholesterol and its utilization in the synthesis of [H-3]cholesteryl esters via acyl coenzyme-A cholesterol acyltransferase (ACAT). Gas chromatographic analysis revealed that the cellular level of cholesteryl esters increased about 2.5-3-fold following treatment with TNF-alpha compared to control. Cholesteryl ester synthesis was compromised upon incubation of cells with antibody against N-SMase and remained unaltered with TNF-beta and fibroblast growth factor. Furthermore, TNF-alpha-mediated stimulation of cholesteryl ester synthesis was compromised by incubation of cells with an inhibitor of ACAT. These findings suggest a possible biological role of N-SMase in the signal transduction of TNF-alpha in the synthesis of cholesteryl esters in human fibroblasts.			CHATTERJEE, S (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21287, USA.				NIDDK NIH HHS [R01-DK-31722] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031722] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; CHATTERJEE S, 1993, J BIOL CHEM, V268, P3401; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; CHATTERJEE S, 1989, J BIOL CHEM, V264, P12554; CHATTERJEE S, 1988, J BIOCHEM TOXICOL, V3, P47, DOI 10.1002/jbt.2570030106; CHATTERJEE S, 1991, FASEB J, V5, P6364; CHATTERJEE S, 1987, BIOCH TOXICOL, V19, P181; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; GHOSH P, 1987, J BIOL CHEM, V262, P12550; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; IKEKAWA N, 1971, JPN J EXP MED, V41, P163; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACGEE J, 1973, J LAB CLIN MED, V82, P656; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; SHUTZE S, 1992, CELL, V71, P765; SLOTTE JP, 1990, BIOCHIM BIOPHYS ACTA, V1025, P152; SLOTTE JP, 1987, BIOCHIM BIOPHYS ACTA, V917, P231, DOI 10.1016/0005-2760(87)90127-5; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SPENCE MW, 1989, METABOLIC BASIS INHE, P1655; YOUNGKIM M, 1991, J BIOL CHEM, V266, P484	20	84	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					879	882						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507110				2022-12-27	WOS:A1994MR22000020
J	CONG, JY; THOMPSON, VF; GOLL, DE				CONG, JY; THOMPSON, VF; GOLL, DE			EFFECT OF MONOCLONAL-ANTIBODIES SPECIFIC FOR THE 28-KDA SUBUNIT ON CATALYTIC PROPERTIES OF THE CALPAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; KINASE-C; CA-2+-DEPENDENT PROTEINASES; DROSOPHILA-MELANOGASTER; PROCOAGULANT ACTIVITY; HUMAN-NEUTROPHILS; MU-CALPAIN; CALCIUM; MEMBRANE; AUTOLYSIS	Nine monoclonal antibodies (mAbs) specific for the 28-kDa subunit common to mu- and m-calpains have been assayed for their effects on mu- and m-calpains. All nine react with the COOH-terminal part (domain VI) of the 28-kDa subunit, and all nine affect the Ca2+ concentration required for autolysis of m-calpain, but have little effect on the Ca2+ concentration required for autolysis of mu-calpain. None of the nine affect the specific proteolytic activity of mu- or m-calpain. Two of the mAbs, 5B9 and 5B3, were selected for further study. mAb 5B9 decreased the Ca2+ concentration required for autolysis to one-fifth of that required in its absence; sequencing of chymotryptic fragments showed that the epitope for mAb 5B9 is between amino acid residues 92 and 104 of the 28-kDa subunit. mAb 5B3 increased the Ca2+ concentration required for autolysis; the epitope for mAb 5B3 is located between amino acid residues 148 and 178 of the 28-kDa subunit, which is the region that contains the first EF-hand Ca2+-binding sequence in this subunit. Although it increases the Ca2+ concentration required for autolysis, mAb 5B3 has no effect on the Ca2+ concentration required for proteolytic activity of m-calpain, and unautolyzed m-calpain is not a proenzyme. That all nine mAbs react with domain VI and not with the NH2-terminal domain V of the 28-kDa subunit suggests that domain VI (and not domain V) is involved in autolysis, contrary to the view that phosphatidylinositol lowers the Ca2+ concentration required for autolysis by binding to domain V.	UNIV ARIZONA,MUSCLE BIOL GRP,TUCSON,AZ 85721	University of Arizona					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020984] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-20984] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANAGLI J, 1993, BIOCHEM J, V289, P93, DOI 10.1042/bj2890093; ANDRESEN K, 1991, J BIOL CHEM, V266, P15085; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONG JY, 1989, J BIOL CHEM, V264, P10096; COOLICAN SA, 1984, J BIOL CHEM, V259, P1627; CORPS AN, 1989, CELL REGUL, V1, P75, DOI 10.1091/mbc.1.1.75; EDMUNDS T, 1991, BIOCHIM BIOPHYS ACTA, V1077, P197, DOI 10.1016/0167-4838(91)90059-9; ELCE JS, 1989, BIOCHEM J, V261, P1039, DOI 10.1042/bj2611039; FOX JEB, 1990, BLOOD, V76, P2510; FOX JEB, 1991, J BIOL CHEM, V266, P13289; GOLL D E, 1986, Ciencia Biologica Molecular and Cellular Biology, V11, P75; GOLL DE, 1964, J FOOD SCI, V29, P608, DOI 10.1111/j.1365-2621.1964.tb00418.x; GOLL DE, 1992, BIOESSAYS, V14, P549, DOI 10.1002/bies.950140810; HAYASHI M, 1992, BIOCHEM BIOPH RES CO, V182, P939, DOI 10.1016/0006-291X(92)91822-8; IMAJOH S, 1986, J BIOCHEM-TOKYO, V99, P1281, DOI 10.1093/oxfordjournals.jbchem.a135593; ISHII H, 1992, BIOCHIM BIOPHYS ACTA, V1175, P37, DOI 10.1016/0167-4889(92)90007-X; JI SQ, 1992, J ANIM SCI S1, V70, P208; KASAI Y, 1986, J BIOCHEM-TOKYO, V100, P183, DOI 10.1093/oxfordjournals.jbchem.a121691; KIKUCHI T, 1984, ARCH BIOCHEM BIOPHYS, V234, P639, DOI 10.1016/0003-9861(84)90314-X; KUBOKI M, 1987, BIOCHIM BIOPHYS ACTA, V929, P164, DOI 10.1016/0167-4889(87)90172-8; KUBOKI M, 1992, BIOCHEM BIOPH RES CO, V185, P1122, DOI 10.1016/0006-291X(92)91742-9; KUNIMATSU M, 1990, BIOCHEM BIOPH RES CO, V169, P1242, DOI 10.1016/0006-291X(90)92030-4; KUNIMATSU M, 1989, BIOCHEM BIOPH RES CO, V164, P875, DOI 10.1016/0006-291X(89)91540-4; KUREBAYASHI N, 1993, BIOPHYS J, V64, P1934, DOI 10.1016/S0006-3495(93)81564-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P49; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; MELLGREN RL, 1988, BIOCHIM BIOPHYS ACTA, V954, P154, DOI 10.1016/0167-4838(88)90066-0; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MINAMI Y, 1988, J BIOCHEM-TOKYO, V104, P927, DOI 10.1093/oxfordjournals.jbchem.a122585; NISHIMURA T, 1991, J BIOL CHEM, V266, P11842; PINTER M, 1988, BIOCHEM J, V253, P467, DOI 10.1042/bj2530467; PINTER M, 1992, BIOCHEMISTRY-US, V31, P8201, DOI 10.1021/bi00150a012; PONTREMOLI S, 1988, J BIOL CHEM, V263, P1915; PONTREMOLI S, 1985, BIOCHEM BIOPH RES CO, V129, P389, DOI 10.1016/0006-291X(85)90163-9; SAIDO TC, 1991, BIOMED BIOCHIM ACTA, V50, P485; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; Suzuki K., 1990, INTRACELLULAR CALCIU, P25; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TWINING SS, 1984, ANAL BIOCHEM, V143, P30, DOI 10.1016/0003-2697(84)90553-0; VERHALLEN PFJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P206, DOI 10.1016/0005-2736(87)90170-2; WOLFE FH, 1989, LIFE SCI, V45, P2093, DOI 10.1016/0024-3205(89)90074-X; WOLFE FH, 1989, BIOCHIM BIOPHYS ACTA, V998, P236, DOI 10.1016/0167-4838(89)90280-X; ZIMMERMAN UJP, 1991, BIOCHIM BIOPHYS ACTA, V1078, P192, DOI 10.1016/0167-4838(91)99009-H	46	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25740	25747						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503986				2022-12-27	WOS:A1993MK10000068
J	SCHURMANN, A; BRAUERS, A; MASSMANN, S; BECKER, W; JOOST, HG				SCHURMANN, A; BRAUERS, A; MASSMANN, S; BECKER, W; JOOST, HG			CLONING OF A NOVEL FAMILY OF MAMMALIAN GTP-BINDING PROTEINS (RAGA, RAGB(S), RAGB(1)) WITH REMOTE SIMILARITY TO THE RAS-RELATED GTPASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; ADDITIONAL MEMBERS; ARF FAMILY; CELL-LINE; GENES; MEMBRANE; YEAST; SITE; IDENTIFICATION	cDNA clones of two novel Ras-related GTP-binding proteins (RagA and RagB) were isolated from rat and human cDNA libraries, Their deduced amino acid sequences comprise four of the six known conserved GTP-binding motifs (PM1, -2, -3, G1), the remaining two (G2, G3) being strikingly different from those of the Ras family, and an unusually large C-terminal domain (100 amino acids) presumably unrelated to GTP binding. RagA and RagB differ by seven conservative amino acid substitutions (98% identity), and by 33 additional residues at the N terminus of RagB, In addition, two isoforms of RagB (RagB(s) and RagB(l)) were found that differed only by an insertion of 28 codons between the GTP-binding motifs PM2 and PM3, apparently generated by alternative mRNA splicing, Polymerase chain reaction amplification with specific primers indicated that both long and short form of RagB transcripts were present in adrenal gland, thymus, spleen, and kidney, whereas in brain, only the long form RagB(1) was detected, A long splicing variant of RagA was not detected, Recombinant glutathione S-transferase (GST) fusion proteins of RagA and RagB(s) bound large amounts of radiolabeled GTP gamma S in a specific and saturable manner, In contrast, GTP gamma S binding of GST-RagB(l) hardly exceeded that of recombinant GST, GTP gamma S bound to recombinant RagA, and RagB(s) was rapidly exchangeable for GTP, whereas no intrinsic GTPase activity was detected. A multiple sequence alignment indicated that RagA and RagB cannot be assigned to any of the known subfamilies of Ras related GTPases but exhibit a 52% identity with a yeast protein (Gtr1) presumably involved in phosphate transport and/or cell growth. It is suggested that RagA and RagB are the mammalian homologues of Gtr1 and that they represent a novel subfamily of Ras-homologous GTP binding proteins.	RHEIN WESTFAL TH AACHEN, FAK MED, INST PHARMAKOL & TOXIKOL, D-52057 AACHEN, GERMANY	RWTH Aachen University			Becker, Walter/B-8889-2008; Joost, Hans-Georg/J-4462-2013	Becker, Walter/0000-0002-0347-4768; Joost, Hans-Georg/0000-0002-5860-606X; Schurmann, Annette/0000-0002-4113-4377				AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CAVENAGH MM, 1994, J BIOL CHEM, V269, P18937; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; DHAR R, 1984, NUCLEIC ACIDS RES, V12, P3611, DOI 10.1093/nar/12.8.3611; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MASANORI BY, 1992, MOL CELL BIOL, V12, P2958, DOI 10.1128/MCB.12.7.2958; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RUTA M, 1986, MOL CELL BIOL, V6, P1706, DOI 10.1128/MCB.6.5.1706; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; SERVENTI IM, 1993, J BIOL CHEM, V268, P4863; TAN TJ, 1991, FEBS LETT, V291, P322, DOI 10.1016/0014-5793(91)81312-V; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WICHMANN H, 1989, NUCLEIC ACIDS RES, V17, P6737, DOI 10.1093/nar/17.16.6737; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	35	96	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28982	28988		10.1074/jbc.270.48.28982	http://dx.doi.org/10.1074/jbc.270.48.28982			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499430	hybrid			2022-12-27	WOS:A1995TH05600074
J	SHORT, MK; JEFFREY, PD; KWONG, RF; MARGOLIES, MN				SHORT, MK; JEFFREY, PD; KWONG, RF; MARGOLIES, MN			CONTRIBUTION OF ANTIBODY HEAVY-CHAIN CDR1 TO DIGOXIN BINDING ANALYZED BY RANDOM MUTAGENESIS OF PHAGE-DISPLAYED FAB-26-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESHAPING HUMAN-ANTIBODIES; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; ANTIDIGOXIN ANTIBODIES; HYPERVARIABLE REGIONS; FV FRAGMENT; AFFINITY; SPECIFICITY; MUTATIONS; RECOGNITION	We constructed a bacteriophage-displayed library containing randomized mutations at H chain residues 30-35 of the anti-digoxin antibody 26-10 Fab to investigate sequence constraints necessary for high affinity binding in an antibody of known crystal structure. Phage were selected by panning against digoxin and three C-16-substituted analogues. All antigen-positive mutants selected using other analogues also bound digoxin. Among 73 antigen-positive clones, 26 different nucleotide sequences were found. The majority of Fabs had high affinity for digoxin (K-alpha 3.4 x 10(9) M(-1)) despite wide sequence diversity, Two mutants displayed affinities 2- and 4-fold higher than the parental antibody. Analysis of the statistical distribution of sequences showed that highest affinity binding occurred with a restricted set of amino acid substitutions at positions H33-35. All clones save two retained the parental Asn-H35, which contacts hapten and hydrogen bonds to other binding site residues in the parental structure, Positions H30-32 display remarkable diversity, with 10-14 different substitutions for each residue, consistent with high affinity binding. Thus complementarity can be retained and even improved despite diversity in the conformation of the N-terminal portion of the H-CDR1 loop.	MASSACHUSETTS GEN HOSP, DEPT SURG, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA; MEM SLOAN KETTERING CANC CTR, DEPT CELLULAR BIOCHEM & BIOPHYS, NEW YORK, NY 10021 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Memorial Sloan Kettering Cancer Center				Jeffrey, Philip/0000-0002-4351-5341	NHLBI NIH HHS [R01 HL47415] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047415] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARBAS CF, 1991, METHODS COMPANION ME, V2, P119; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BURTON DR, 1994, ADV IMMUNOL, V57, P191, DOI 10.1016/S0065-2776(08)60674-4; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; DAVIES DR, 1993, ACCOUNTS CHEM RES, V26, P421, DOI 10.1021/ar00032a005; FOLZ RJ, 1988, J BIOL CHEM, V263, P2070; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; JACKSON JR, 1995, J IMMUNOL, V154, P3310; JEFFREY PD, 1993, P NATL ACAD SCI USA, V90, P10310, DOI 10.1073/pnas.90.21.10310; Kabat EA, 1991, SEQUENCES PROTEINS I; MARSHAKROTHSTEIN A, 1980, P NATL ACAD SCI-BIOL, V77, P1120, DOI 10.1073/pnas.77.2.1120; MATTHEWS DJ, 1994, PROTEIN SCI, V3, P1197, DOI 10.1002/pro.5560030805; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; MUDGETTHUNTER M, 1982, J IMMUNOL, V129, P1165; NEAR RI, 1991, J IMMUNOL, V146, P627; NOTHWEHR SF, 1989, J BIOL CHEM, V264, P3979; OLSEN DB, 1993, METHOD ENZYMOL, V217, P189; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; PANKA DJ, 1988, P NATL ACAD SCI USA, V85, P3080, DOI 10.1073/pnas.85.9.3080; PING J, 1993, J BIOL CHEM, V268, P23000; PLUCKTHUN A, 1989, METHOD ENZYMOL, V178, P497; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; RIECHMANN L, 1993, BIOCHEMISTRY-US, V32, P8848, DOI 10.1021/bi00085a016; ROSE DR, 1983, J MOL BIOL, V165, P203, DOI 10.1016/S0022-2836(83)80252-6; SAMBROOK J, 1990, MOL CLONING LABORATO; SCHILDBACH JF, 1994, PROTEIN SCI, V3, P737; SCHILDBACH JF, 1993, PROTEIN SCI, V2, P206; SCHILDBACH JF, 1993, J BIOL CHEM, V268, P21739; SCHILDBACH JF, 1991, J BIOL CHEM, V266, P4640; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; SMITH TW, 1970, BIOCHEMISTRY-US, V9, P331, DOI 10.1021/bi00804a020; THOMAS RE, 1992, MOL STRUCTURE BIOL A, P399; VERHOEYEN M, 1988, SCIENCE, V239, P1534, DOI 10.1126/science.2451287; WILSON IA, 1991, METHOD ENZYMOL, V203, P153; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211; ZURAWSKI VR, 1978, J IMMUNOL, V121, P122	41	33	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28541	28550		10.1074/jbc.270.48.28541	http://dx.doi.org/10.1074/jbc.270.48.28541			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499368	hybrid			2022-12-27	WOS:A1995TH05600012
J	BOLAND, K; MANIAS, K; PERLMUTTER, DH				BOLAND, K; MANIAS, K; PERLMUTTER, DH			SPECIFICITY IN RECOGNITION OF AMYLOID-BETA PEPTIDE BY THE SERPIN-ENZYME COMPLEX RECEPTOR IN HEPATOMA-CELLS AND NEURONAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PRECURSOR; SEC RECEPTOR; NEUROTOXICITY; ENDOCYTOSIS; DERIVATIVES; LINE	The serpin-enzyme complex (SEC) receptor was originally identified using a synthetic peptide (peptide 105Y) based on the sequence of a candidate receptor-binding domain of alpha 1-antitrypsin (1-AT) and was subsequently shown to be a receptor on the surface of hepatocytes, monocytes, and neutrophils for recognition of alpha 1-AT-elastase and several other serpin-enzyme complexes (Perlmutter, D. H., Glover, G. I., Rivetna, M., Schasteen, C. S., and Fallen, R. J. (1990) Proc. Natl. Acad. Sci. U.S.A. 87, 3753-3757). Studies of the minimal requirements for binding to SEC receptor (SEC-R) showed that a pentapeptide FVFLM within the carboxyl-terminal tail of alpha 1-AT was sufficient for binding to SEC-R and interacted with SEC-R in a sequence-specific manner (Joslin, G., Krause, J. E., Hershey, A. D,, Adams, S. P., Fallen, R. J., and Perlmutter, D. H. (1991) J. Biol. Chem. 266, 21897-21902). Sequence motifs bearing homology with this pentapeptide domain were found in the amyloid-beta peptide, and amyloid-beta peptide 1-42 was shown to compete for binding to SEC-R on hepatoma cells (Joslin, G., Fallen, R. J., Bullock, J., Adams, S. P., and Perlmutter, D. H. (1991) J. Biol. Chem. 266, 11281-11288). In this study we examined the sequence specificity by which amyloid-beta peptide competes for binding to SEC-R and examined the possibility that SEC-R is expressed in cells of neuronal origin. The results show that amyloid-beta-(25-35) and amyloid-beta-(31-35) compete for binding to SEC-R as effectively as amyloid-beta-(1-39), amyloid-beta-(1-40), and amyloid-beta-(1-42). Amyloid-beta-(1-16) does not compete for binding to SEC-R. There is cross-competition for binding to the same site by I-125-peptide 105Y and amyloid-beta-(25-35) as well as by I-125-Y amyloid-beta-(25-35) and peptide 105Y. By deletions and substitutions within amyloid-beta-(25-35) and generation of chimeric amyloid-beta-alpha 1-AT peptides, amyloid-beta-(31-35) is shown to be critical for binding to the SEC receptor. However, the upstream region, amyloid-beta-(25-30), also contributes to recognition by SEC-R. The SEC-R is present on the surface of a neuronal cell line PC12 as well as that of murine cortical neurons in primary culture, and the specificity of neuronal SEC-R for amyloid-beta peptide is identical to that on hepatoma cells. Finally, SEC-R mediates internalization and degradation of amyloid beta-peptide in PC12 cells. These results provide evidence that SEC-R plays a role in metabolism of amyloid-beta peptide in the nervous system.	WASHINGTON UNIV, ST LOUIS CHILDRENS HOSP, SCH MED, DEPT PEDIAT, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, ST LOUIS CHILDRENS HOSP, SCH MED, DEPT CELL BIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, ST LOUIS CHILDRENS HOSP, SCH MED, DEPT PHYSIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, ST LOUIS CHILDRENS HOSP, SCH MED, DIV GASTROENTEROL & NUTR, ST LOUIS, MO 63110 USA	St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)					NHLBI NIH HHS [HL-37784] Funding Source: Medline; NIA NIH HHS [AG11577] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011577] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BEHL C, 1984, CELL, V77, P813; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHOI DW, 1987, J NEUROSCI, V7, P357; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FORLONI G, 1993, NEUROREPORT, V4, P523, DOI 10.1097/00001756-199305000-00015; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1994, J BIOL CHEM, V269, P17741; JOSLIN G, 1993, J BIOL CHEM, V268, P1886; JOSLIN G, 1991, J BIOL CHEM, V266, P21897; JOSLIN G, 1992, J CLIN INVEST, V90, P1150, DOI 10.1172/JCI115934; JOSLIN G, 1991, J BIOL CHEM, V266, P11281; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; KOSIK KS, 1994, J CELL BIOL, V127, P1501, DOI 10.1083/jcb.127.6.1501; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; OWENSBY DA, 1988, J BIOL CHEM, V263, P10587; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PERLMUTTER DH, 1994, PEDIATR RES, V36, P271, DOI 10.1203/00006450-199409000-00001; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PRICE DL, 1993, P NATL ACAD SCI USA, V90, P6381, DOI 10.1073/pnas.90.14.6381; SCHWARTZ AL, 1982, J BIOL CHEM, V257, P4230; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YANKNER BA, 1991, NEW ENGL J MED, V325, P1849	31	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28022	28028						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499286				2022-12-27	WOS:A1995TG21000011
J	CHOI, SG; HARDMAN, JK				CHOI, SG; HARDMAN, JK			UNFOLDING PROPERTIES OF TRYPTOPHAN-CONTAINING ALPHA-SUBUNITS OF THE ESCHERICHIA-COLI TRYPTOPHAN SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE; STABILITIES	The urea-induced unfolding of the Escherichia coli tryptophan synthase alpha-subunit is examined via fluorescence measurements with tryptophan-containing alpha-subunit mutants, constructed by in vitro mutagenesis, Early unfolding studies with urea and guanidine suggested that the wild type protein unfolded in a two-step process with a stable intermediate composed of a native alpha-1 folding unit (residues 1-188) and a completely unfolded alpha-2 folding unit (residues 189-268), Recently, more detailed spectroscopic and calorimetric data from the Matthews and Yutani groups indicate that such a structure for the intermediates seems unlikely, Previously, we described the introduction of Trp residues as unfolding reporter groups separately into each of the folding domains and showed that these proteins are wild type enzymatically and in their stability to urea, The unfolding behavior of these alpha-subunits, monitored by fluorescence intensity changes at the discrete emission lambda(max) for each, in both equilibrium and kinetic experiments, suggest that: (a) both folding units commence unfolding simultaneously (near 2 M urea); (b) the larger alpha-1 unit unfolds in a multistep process, initially yielding a partially unfolded intermediate form which subsequently appears to unfold progressively to completion; and (c) the smaller alpha-2 unit unfolds in a single step event, These results are also clearly incompatible with the early proposals on the structure of the intermediate, It is suggested here that the intermediate is heterogeneous, consisting of a stable, partially unfolded form of alpha-1 attached to either a completely folded or completely unfolded form of alpha-2, These results are consistent with and provide an added dimension to the recent description of the proposed structure of the intermediate.	UNIV ALABAMA, DEPT BIOL SCI, CELL & DEV BIOL SECT, TUSCALOOSA, AL 35487 USA	University of Alabama System; University of Alabama Tuscaloosa								BEASTY AM, 1985, BIOCHEMISTRY-US, V24, P3547, DOI 10.1021/bi00335a024; CHEN XW, 1994, BIOCHEMISTRY-US, V33, P6356, DOI 10.1021/bi00186a040; CHOI SG, 1995, J BIOL CHEM, V270, P17712, DOI 10.1074/jbc.270.30.17712; CRISANTI MM, 1981, BIOCHEMISTRY-US, V20, P2700, DOI 10.1021/bi00512a052; FABR GK, 1990, TRENDS BIOCHEM SCI, V15, P228; HYDE CC, 1988, J BIOL CHEM, V263, P17857; LIM WK, 1992, ARCH BIOCHEM BIOPHYS, V292, P34, DOI 10.1016/0003-9861(92)90047-Z; MATTHEWS CR, 1981, BIOCHEMISTRY-US, V20, P784, DOI 10.1021/bi00507a021; MILES EW, 1982, BIOCHEMISTRY-US, V21, P2586, DOI 10.1021/bi00540a002; OGASAHARA K, 1994, J MOL BIOL, V236, P1227, DOI 10.1016/0022-2836(94)90023-X; OGASAHARA K, 1993, J MOL BIOL, V234, P1197, DOI 10.1006/jmbi.1993.1670; Pace C N, 1986, Methods Enzymol, V131, P266; SAABRINCON G, 1993, BIOCHEMISTRY-US, V32, P13981, DOI 10.1021/bi00213a031; SARKER KD, 1995, PROTEINS, V21, P130, DOI 10.1002/prot.340210207; TSUJI T, 1993, BIOCHEMISTRY-US, V32, P5566, DOI 10.1021/bi00072a011	15	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28177	28182						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499309				2022-12-27	WOS:A1995TG21000034
J	HWANG, A; MAITY, A; MCKENNA, WG; MUSCHEL, RJ				HWANG, A; MAITY, A; MCKENNA, WG; MUSCHEL, RJ			CELL CYCLE-DEPENDENT REGULATION OF THE CYCLIN B1 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; GENE-PRODUCT; PROTEIN; BINDING; PHASE; G2; PHOSPHORYLATION; INITIATION; EXPRESSION	Cyclin B1 mRNA expression varies through the cell cycle with its peak in G(2)/M. In cycling mammalian cells, its lowest level is in G(1) with a steady increase in S until a level 50-fold greater than that in G(1) is reached. In order to characterize the transcriptional component to this variation in expression, we cloned the upstream region 872 base pairs upstream from the start site of the cyclin B1 gene and have demonstrated that it confers cell cycle-dependent regulation onto two reporter genes, both chloramphenicol acetyltransferase and luciferase. Its activity was 25-fold greater in G(2)/M than in G(1) in HeLa cells with intermediate activity in S. This cyclical activity could be seen with sequences encompassing only 90 base pairs upstream from the start site. Protein binding to this region was demonstrated using electrophoretic mobility shift assays, and the binding profiles appeared to vary depending upon the phase of the cycle in which the extracts are made. Thus, transcriptional control plays an important role in determining cyclin B1 mRNA levels, and cell cycle-dependent activity is regulated through interactions with the region 90 bases upstream from the start site.	UNIV PENN, DEPT LAB MED & PATHOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT RADIAT ONCOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania				Maity, Amit/0000-0001-7151-2845	NIGMS NIH HHS [GM 43759] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; HALL FL, 1993, ONCOGENE, V8, P1377; HATAKEYAMA M, 1994, COLD SPRING HARB SYM, V59, P1; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; KATO J, 1993, GENE DEV, V7, P331; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MAHER M, 1995, MOL CELL BIOL, V15, P3129; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MARKIEWICZ DA, 1994, INT J RADIAT ONCOL, V28, P135, DOI 10.1016/0360-3016(94)90151-1; MEAD DA, 1991, BIO-TECHNOL, V9, P657, DOI 10.1038/nbt0791-657; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOSCA PJ, 1992, MOL CELL BIOL, V12, P4375, DOI 10.1128/MCB.12.10.4375; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SALA A, 1994, CANCER RES, V54, P1402; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503	36	107	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28419	28424						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499347				2022-12-27	WOS:A1995TG21000072
J	Van Eynde, A; WERA, S; BEULLENS, M; TORREKENS, S; VANLEUVEN, F; STALMANS, W; BOLLEN, M				Van Eynde, A; WERA, S; BEULLENS, M; TORREKENS, S; VANLEUVEN, F; STALMANS, W; BOLLEN, M			MOLECULAR-CLONING OF NIPP-1, A NUCLEAR INHIBITOR OF PROTEIN PHOSPHATASE-1, REVEALS HOMOLOGY WITH POLYPEPTIDES INVOLVED IN RNA PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION	NIPP-1 was originally isolated as a potent and specific nuclear inhibitory polypeptide (16-18 kDa) of protein phosphatase-1. We report here the cDNA cloning of NIPP-1 from bovine thymus and show that the native polypeptide consists of 351 residues and has a calculated mass of 38.5 kDa. The bacterially expressed central third of NIPP-1 completely inhibited the type-1 catalytic subunit, but displayed a reduced inhibitory potency after phosphorylation by protein kinase A and casein kinase 2, Translation of NIPP-1 mRNA in reticulocyte lysates resulted in the accumulation of both intact NIPP-1 and a smaller polypeptide generated by alternative initiation at the codon corresponding to Met(143), A data base search showed that the COOH terminus of NIPP-1 is nearly identical to the human ard-1 protein (13 kDa), which has been implicated in RNA processing (Wang, M., and Cohen, S. N. (1994) Proc. Natl. Acad. Sci, U. S. A. 91, 10591-10595), Comparison of the cDNAs encoding ard-1 and NIPP-1 suggests that their mRNAs are generated by alternative splicing of the same pre-mRNA. Western blotting with antibodies against the COOH terminus of NIPP-1, however, showed a single polypeptide of 47 kDa, which was enriched in the nucleus. Northern analysis revealed a single transcript of 2.2 kilobases in bovine thymus and of 2.4 kilobases in various human tissues.	KATHOLIEKE UNIV LEUVEN, AFDELING BIOCHEM, B-3000 LOUVAIN, BELGIUM; KATHOLIEKE UNIV LEUVEN, FAC GENEESKUNDE,CTR HUMAN GENET, B-3000 LOUVAIN, BELGIUM	KU Leuven; KU Leuven								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEULLENS M, 1993, J BIOL CHEM, V268, P13172; BEULLENS M, 1992, J BIOL CHEM, V267, P16538; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; CAYLA X, 1994, J BIOL CHEM, V269, P15668; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; GETTEMANS J, 1992, EMBO J, V11, P3185, DOI 10.1002/j.1460-2075.1992.tb05395.x; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; KENNEDY TE, 1988, P NATL ACAD SCI USA, V85, P7008, DOI 10.1073/pnas.85.18.7008; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STONE EM, 1993, CURR BIOL, V3, P13, DOI 10.1016/0960-9822(93)90140-J; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; URIARTE M, 1993, BIOCHEM J, V293, P93, DOI 10.1042/bj2930093; VAN EYNDE A, 1994, BIOCHEM J, V297, P447, DOI 10.1042/bj2970447; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; WANG M, 1994, P NATL ACAD SCI USA, V91, P10591, DOI 10.1073/pnas.91.22.10591; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611	24	95	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28068	28074						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499293	hybrid			2022-12-27	WOS:A1995TG21000018
J	SHERIFF, S; DU, H; GRABOWSKI, GA				SHERIFF, S; DU, H; GRABOWSKI, GA			CHARACTERIZATION OF LYSOSOMAL ACID LIPASE BY SITE-DIRECTED MUTAGENESIS AND HETEROLOGOUS EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER STORAGE-DISEASE; INSECT CELLS; POSITIONAL SPECIFICITY; CHOLESTERYL ESTERASE; PANCREATIC LIPASE; BETA-GLUCOSIDASE; GAUCHER DISEASE; CLONING; CDNA; PURIFICATION	Lysosomal acid lipase (LAL) is essential for the hydrolysis of cholesterol esters and triglycerides that are delivered to the lysosomes via the low density lipoprotein receptor system, The deficiency of LAL is associated with cholesteryl ester storage disease (CESD) and Wolman's disease (WD), We cloned the human LAL cDNA and expressed the active enzyme in the baculovirus system, Two molecular forms (M(r) similar to 41,000 and similar to 46,000) with different glycosylation were found intracellularly, and similar to 24% of the M(r) similar to 46,000 form was secreted into the medium, Tunicamycin treatment produced only an inactive M(r) similar to 41,000 form, This result implicates glycosylation occupancy in the proper folding for active-site function, Catalytic activity was greater toward cis- than trans-unsaturated fatty acid esters of 4-methylumbelliferone and toward esters with 7-carbon length acyl chains, LAL cleaved cholesterol esters and mono-, tri-, and diglycerides. Heparin had a biphasic effect on enzymatic activity with initial activation followed by inhibition, Inhibition of LAL activity by tetrahydrolipstatin and diethyl p-nitrophenyl phosphate suggested the presence of active serines in binding/catalytic domain(s) of the protein, Site-directed mutagenesis at two putative active centers, GXSXG, showed that Ser(153) was important to catalytic activity, whereas Ser(99) was not and neither was the catalytic nucleophile, Three reported mutations (L179P, L336P, and Delta AG302 deletion) from CESD patients were created and expressed in the Sf9 cell system, None cleaved cholesterol esters, and L179P and L336P cleaved only triolein at similar to 4% of wild-type levels, These results suggest that mechanisms, in addition to LAL defects, may operate in the selective accumulation of cholesterol esters or triglycerides in CESD and WD patients.	CHILDRENS HOSP,MED CTR,RES FDN,DIV HUMAN GENET,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati					NIDDK NIH HHS [DK 36729] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036729] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMEIS D, 1994, EUR J BIOCHEM, V219, P905, DOI 10.1111/j.1432-1033.1994.tb18572.x; AMEIS D, 1995, J LIPID RES, V36, P241; ANDERSON RA, 1991, J BIOL CHEM, V266, P22479; ANDERSON RA, 1993, GENOMICS, V15, P245, DOI 10.1006/geno.1993.1052; ANDERSON RA, 1994, P NATL ACAD SCI USA, V91, P2718, DOI 10.1073/pnas.91.7.2718; ASLANIDIS C, 1994, GENOMICS, V20, P329, DOI 10.1006/geno.1994.1180; ASSMANN G, 1973, J BIOL CHEM, V248, P7184; ASSMANN G, 1995, METABOLIC MOL BASES, P2563; BERGFUSSMAN A, 1993, J BIOL CHEM, V268, P14861; BROWN MS, 1976, J BIOL CHEM, V251, P3277; BURKE JA, 1972, SCIENCE, V30, P309; CORTNER JA, 1976, PEDIATR RES, V10, P932; FABBRO D, 1987, AM J HUM GENET, V40, P15; GOLDSTEIN JL, 1975, J BIOL CHEM, V250, P8487; GRACE ME, 1990, J BIOL CHEM, V265, P6827; HADVARY P, 1991, J BIOL CHEM, V266, P2021; HERNELL O, 1976, PEDIATR RES, V16, P882; IMANAKA T, 1982, FEBS LETT, V137, P115, DOI 10.1016/0014-5793(82)80327-X; IMANAKA T, 1985, J BIOCHEM-TOKYO, V98, P927, DOI 10.1093/oxfordjournals.jbchem.a135372; IMANAKA T, 1984, J BIOCHEM, V96, P1089, DOI 10.1093/oxfordjournals.jbchem.a134926; JARVIS DL, 1989, MOL CELL BIOL, V9, P214, DOI 10.1128/MCB.9.1.214; KLIMA H, 1993, J CLIN INVEST, V92, P2713, DOI 10.1172/JCI116888; KOMAROMY MC, 1987, P NATL ACAD SCI USA, V84, P1526, DOI 10.1073/pnas.84.6.1526; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOWE ME, 1989, J BIOL CHEM, V264, P20042; MATTSON F. H., 1955, JOUR BIOL CHEM, V214, P115; MOREAU H, 1991, BIOCHEMISTRY-US, V30, P1037, DOI 10.1021/bi00218a022; NEUFELD EF, 1977, J SUPRAMOL STR CELL, V6, P95, DOI 10.1002/jss.400060108; NILSSONE.P, 1973, J BIOL CHEM, V248, P6734; Patrick A D, 1969, Nature, V222, P1067, DOI 10.1038/2221067a0; SAMBROOK J, 1988, MOL CLONING LABORATO; SANCHEZMARTINEZ D, 1991, VIROLOGY, V182, P229, DOI 10.1016/0042-6822(91)90666-Y; SANDO GN, 1985, J BIOL CHEM, V260, P5186; SANDO GN, 1982, J LIPID RES, V23, P114; SEEDORF U, 1993, CIRCULATION, V88, P2268; SHIMADA Y, 1989, J BIOCHEM-TOKYO, V106, P383, DOI 10.1093/oxfordjournals.jbchem.a122862; SLOAN HR, 1972, J CLIN INVEST, V51, P1923, DOI 10.1172/JCI106997; TAKANO T, 1974, J BIOL CHEM, V249, P6732; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; TORNQVIST H, 1976, J BIOL CHEM, V251, P813; WARNER TG, 1981, J BIOL CHEM, V256, P2952	42	91	100	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27766	27772		10.1074/jbc.270.46.27766	http://dx.doi.org/10.1074/jbc.270.46.27766			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499245	hybrid			2022-12-27	WOS:A1995TE73600056
J	ADACHI, K; KONITZER, P; SURREY, S				ADACHI, K; KONITZER, P; SURREY, S			ROLE OF GAMMA-87 GLN IN THE INHIBITION OF HEMOGLOBIN-S POLYMERIZATION BY HEMOGLOBIN-F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL DISEASE; NUCLEATION-CONTROLLED AGGREGATION; DEOXYHEMOGLOBIN-S; CRYSTAL-STRUCTURE; FETAL HEMOGLOBIN; GELATION; PARTICIPATION; RESOLUTION	Previous studies suggested that gamma87 Gln in hemoglobin (Hb) F is an important site for promoting inhibition of Hb S (alpha2beta2(6 Glu --> Val) polymerization by Hb F. We engineered and isolated the double mutant (Hb alpha2beta2(6 Glu --> Val,87 Thr --> Gln) using a yeast expression system and characterized polymerization properties of this modified tetramer in an effort to clarify the role of Gln at position 87 in inhibiting Hb S polymerization. Electrophoretic mobility and absorption spectra of this double mutant were the same as that of Hb S, while oxygen affinity was higher, and effects of organic phosphates on oxygen affinity were reduced. The deoxy form of the double mutant showed a characteristic delay time prior to polymerization in vitro. The critical concentration for polymerization of the double mutant was about 1.5 times higher than Hb S, and delay and polymerization times were much longer than Hb S at the same hemoglobin concentrations. The logarithmic plot of delay time versus hemoglobin concentration for the double mutant showed a straight line that was intermediate between lines for AS and FS mixtures. These results and those of kinetics of polymerization of Hb S/double mutant mixtures indicate that substitution of Gln for Thr at beta87 in Hb S prolongs delay time and inhibits polymerization, although the double mutant forms polymers like Hb S.			ADACHI, K (corresponding author), UNIV PENN, CHILDRENS HOSP, SCH MED, DIV HEMATOL, 34TH ST & CIVIC CTR BLVD, PHILADELPHIA, PA 19104 USA.				NHLBI NIH HHS [P60 HL38632, HL32908] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038632, R01HL032908] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1980, J MOL BIOL, V144, P467, DOI 10.1016/0022-2836(80)90332-0; ADACHI K, 1990, BLOOD, V75, P2070; ADACHI K, 1993, J BIOL CHEM, V268, P21650; ADACHI K, 1980, J BIOL CHEM, V255, P3092; ADACHI K, 1979, J BIOL CHEM, V254, P7765; ADACHI K, 1980, J BIOL CHEM, V255, P7595; ADACHI K, 1978, J BIOL CHEM, V253, P382; ADACHI K, 1992, PROTEIN ENG, V5, P807, DOI 10.1093/protein/5.8.807; BENESCH RE, 1980, P NATL ACAD SCI-BIOL, V77, P5130, DOI 10.1073/pnas.77.9.5130; BIHOREAU MT, 1992, PROTEIN SCI, V1, P145; BOOKCHIN RM, 1975, NATURE, V256, P667, DOI 10.1038/256667a0; BOOKCHIN RM, 1970, BIOCHIM BIOPHYS ACTA, V221, P373, DOI 10.1016/0005-2795(70)90279-5; BOOKCHIN RM, 1967, J BIOL CHEM, V242, P248; BUNN HF, 1974, BIOCHEMISTRY-US, V13, P988, DOI 10.1021/bi00702a024; BUNN HF, 1982, P NATL ACAD SCI-BIOL, V79, P7527, DOI 10.1073/pnas.79.23.7527; BUNN HF, 1970, J CLIN INVEST, V49, P1088, DOI 10.1172/JCI106324; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P452; DELLANO JJM, 1993, P NATL ACAD SCI USA, V90, P918, DOI 10.1073/pnas.90.3.918; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; FERRONE FA, 1980, BIOPHYS J, V32, P361, DOI 10.1016/S0006-3495(80)84962-9; GOLDBERG MA, 1977, J BIOL CHEM, V252, P3414; JONES DH, 1992, BIOTECHNIQUES, V12, P528; KUTLAR F, 1991, HUM GENET, V86, P591; LANGDOWN JV, 1989, BRIT J HAEMATOL, V71, P443; MONPLAISIR N, 1986, P NATL ACAD SCI USA, V83, P9363, DOI 10.1073/pnas.83.24.9363; NAGEL RL, 1979, P NATL ACAD SCI USA, V76, P670, DOI 10.1073/pnas.76.2.670; NIBU K, 1985, BIOCHIM BIOPHYS ACTA, V829, P97, DOI 10.1016/0167-4838(85)90072-X; NOGUCHI CT, 1988, NEW ENGL J MED, V318, P96, DOI 10.1056/NEJM198801143180207; PADLAN EA, 1985, J BIOL CHEM, V260, P8272; PERUTZ MF, 1968, NATURE, V219, P131, DOI 10.1038/219131a0; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; SUNSHINE HR, 1979, J MOL BIOL, V133, P435, DOI 10.1016/0022-2836(79)90402-9; TRIFILLIS P, 1991, BLOOD, V78, P3298; WATERMAN MR, 1979, J MOL BIOL, V129, P337, DOI 10.1016/0022-2836(79)90287-0; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; WITKOWSKA HE, 1991, NEW ENGL J MED, V325, P1150, DOI 10.1056/NEJM199110173251607; [No title captured]	37	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9562	9567						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511590				2022-12-27	WOS:A1994NE05300028
J	STUTTS, MJ; GABRIEL, SE; PRICE, EM; SARKADI, B; OLSEN, JC; BOUCHER, RC				STUTTS, MJ; GABRIEL, SE; PRICE, EM; SARKADI, B; OLSEN, JC; BOUCHER, RC			PYRIDINE-NUCLEOTIDE REDOX POTENTIAL MODULATES CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CL- CONDUCTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RESISTANCE P-GLYCOPROTEIN; CFTR CHLORIDE CHANNEL; MULTIDRUG-RESISTANCE; ANION SELECTIVITY; APICAL MEMBRANE; CELL-LINE; CAMP; TRANSPORT; GENE	Cl- conductance of the apical membrane of airway epithelial cells has properties of a passive diffusion mechanism but is decreased by inhibition of oxidative metabolism. Recent reports that cAMP-dependent Cl- conductance also requires ATP at the intracellular domains of the cystic fibrosis transmembrane conductance regulator (CFTR) suggest that ATP concentration could mediate metabolic regulation of Cl- conductance. However, metabolic inhibitors affect processes other than ATP free energy levels, including notably the metabolic pathways that set the redox potential of pyridine nucleotides within the cell. We have investigated the possibility that CFTR-mediated Cl- conductance is affected by the ratio of oxidized to reduced intracellular pyridine nucleotides. CFTR was expressed in airway and heterologous cells and studied under whole cell. voltage clamp conditions, which permitted the intracellular NAD(P)(+)/ NAD(P)H ratio to be varied independently of ATP concentration. In three cell types expressing CFTR, whole cell dialysis with reduced pyridine nucleotides inhibited activation of Cl- currents by forskolin and 8-(4-chlorophenylthio)-cAMP (CPT-cAMP), whereas dialysis with oxidized pyridines increased both basal and stimulated CFTR-mediated Cl- conductance. In cell-attached membrane patches, the open probability of 5-6-picosiemens Cl- channels that had been activated by forskolin and CPT-cAMP was further and reversibly increased by permeant oxidants. Neither swelling-induced whole cell K+ currents in CFTR-expressing cells nor swelling-induced whole cell Cl- currents in multidrug resistance protein-expressing cells were affected by NADPH. Pyridine nucleotide redox potential had little effect on phosphorylation of histone by protein kinase A. We conclude that CFTR Cl- conductance function can be modulated by pyridine nucleotide redox potential. This effect points to the existence of a mechanism or mechanisms by which cytosolic nucleotides other than ATP can affect plasma membrane Cl- conductance and may help explain how a passive ion conductance is linked to cellular energy metabolism.	UNIV N CAROLINA, DEPT PHARMACOL, LINEBERGER CANC CTR, CYST FIBROSIS RES CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	STUTTS, MJ (corresponding author), UNIV N CAROLINA, DEPT MED, LINEBERGER CANC CTR, CYST FIBROSIS RES CTR, CB 7020, CHAPEL HILL, NC 27599 USA.		Sarkadi, Balazs/I-5024-2013					ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BELL CL, 1992, AM J PHYSIOL, V262, pC555, DOI 10.1152/ajpcell.1992.262.3.C555; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COHN JA, 1992, P NATL ACAD SCI USA, V89, P2340, DOI 10.1073/pnas.89.6.2340; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DEJONGE HR, 1989, BIOCHEM SOC T, V17, P816, DOI 10.1042/bst0170816; DIAMOND G, 1991, J BIOL CHEM, V266, P22761; FLOCKHART DA, 1984, EUR J BIOCHEM, V140, P289, DOI 10.1111/j.1432-1033.1984.tb08100.x; FORSYTH GW, 1989, J MEMBRANE BIOL, V107, P137, DOI 10.1007/BF01871719; FUHRMANN GF, 1985, BIOCHIM BIOPHYS ACTA, V820, P223, DOI 10.1016/0005-2736(85)90116-6; GABRIEL SE, 1992, AM J PHYSIOL, V263, pC708, DOI 10.1152/ajpcell.1992.263.3.C708; GAETANI GF, 1989, BLOOD, V73, P334; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GLOCK GE, 1955, BIOCHEM J, V61, P388, DOI 10.1042/bj0610388; GRAY MA, 1990, AM J PHYSIOL, V259, pC752, DOI 10.1152/ajpcell.1990.259.5.C752; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAWS C, 1992, AM J PHYSIOL, V263, pL692, DOI 10.1152/ajplung.1992.263.6.L692; HEDESKOV CJ, 1987, BIOCHEM J, V241, P161, DOI 10.1042/bj2410161; HIGGINS CF, 1985, EMBO J, V4, P1033, DOI 10.1002/j.1460-2075.1985.tb03735.x; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KREBS HA, 1967, ADV ENZYME REGUL, V5, P405; LARSEN EH, 1992, PEDIATR PULM S, V8, P267; MARSHALL J, 1991, J BIOL CHEM, V266, P22749; OLSEN JC, 1992, HUM GENE THER, V3, P253, DOI 10.1089/hum.1992.3.3-253; PARKER JC, 1969, J CLIN INVEST, V48, P117, DOI 10.1172/JCI105960; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RAN S, 1992, J BIOL CHEM, V267, P3618; ROMMENS JM, 1991, P NATL ACAD SCI USA, V88, P7500, DOI 10.1073/pnas.88.17.7500; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SCHINDLER H, 1984, P NATL ACAD SCI-BIOL, V81, P6222, DOI 10.1073/pnas.81.19.6222; SHOTT S, 1990, STATISTICS HLTH PROF, P342; STUTTS MJ, 1988, J APPL PHYSIOL, V64, P253, DOI 10.1152/jappl.1988.64.1.253; STUTTS MJ, 1993, J BIOL CHEM, V268, P20653; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TABCHARANI JA, 1992, BIOPHYS J, V62, P1, DOI 10.1016/S0006-3495(92)81759-9; TATA F, 1991, GENOMICS, V10, P301, DOI 10.1016/0888-7543(91)90312-3; TIETZE F, 1970, ARCH BIOCHEM BIOPHYS, V138, P177, DOI 10.1016/0003-9861(70)90297-3; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; YANKASKAS JR, 1993, AM J PHYSIOL, V264, pC1219, DOI 10.1152/ajpcell.1993.264.5.C1219	45	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8667	8674						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510695				2022-12-27	WOS:A1994NB41100010
J	BAHK, YY; LEE, YH; LEE, TG; SEO, JK; RYU, SH; SUH, PG				BAHK, YY; LEE, YH; LEE, TG; SEO, JK; RYU, SH; SUH, PG			2 FORMS OF PHOSPHOLIPASE C-BETA-1 GENERATED BY ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; BOVINE BRAIN; TYROSINE PHOSPHORYLATION; COMPLETE CDNA; C ISOZYMES; ACTIVATION; PURIFICATION; KINASE; LYMPHOCYTES; C-GAMMA-1	Phospholipase C-beta 1 (PLC-beta 1) exists as two immunologically indistinguishable polypeptides of 150 and 140 kDa and is encoded in rat brain by two distinct transcripts of 5.4 and 7.2 kilobases (kb). cDNA corresponding to the entire 5.4-kb transcript as reported previously reveals an open reading frame that is capable of coding a 1216-amino acid polypeptide (Suh, P. G., Ryu, S. H., Moon, K. H., Suh, H. W., and Rhee, S. G. (1988) Cell 54, 161-169). We have now isolated cDNAs corresponding to the entire 7.2-kb transcript from a rat brain cDNA library. The 7.2-kb transcript differs from the previously reported 5.4-kb transcript by possessing both an additional 118 nucleotides located near the end of the coding sequence and a 1738-nucleotide extension of the 3'-flanking region. The presence of the 118-nucleotide insert in the cumulative 7.2-kb sequence gives rise to an open reading frame that is capable of coding a 1173-amino acid polypeptide (PLC-beta 1b), the carboxyl terminal sequence of which differs from that of the 1216-amino acid polypeptide (PLC-beta 1a) derived from the 5.4-kb transcript. Antibodies were raised against synthetic peptides corresponding to the carboxyl-terminal portions of PLC- beta 1a and PLC-beta 1b. Immunoblot analysis with these isozyme specific antibodies revealed that both PLC-beta 1a and PLC-beta 1b are expressed in rat brain and C(6)Bu-1 glioma cells and that PLC-beta 1a and PLC-beta 1b correspond to the previously identified 150- and 140-kDa PLC-beta 1 enzymes, respectively. Analysis of PLC-beta 1 genomic DNA indicates that PLC-beta 1a and PLC-beta 1b are derived from a single gene by alternative RNA splicing.	POHANG UNIV SCI & TECHNOL, DEPT LIFE SCI, POHANG 790600, SOUTH KOREA	Pohang University of Science & Technology (POSTECH)			Seo, Jeong Kon/H-4770-2016; Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048				BANNO Y, 1990, BIOCHEM BIOPH RES CO, V167, P396, DOI 10.1016/0006-291X(90)92035-X; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BRADFORD PG, 1986, BIOCHEM J, V239, P97, DOI 10.1042/bj2390097; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERREIRA PA, 1993, P NATL ACAD SCI USA, V90, P6042, DOI 10.1073/pnas.90.13.6042; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; HARLOW E, 1988, ANTIBODIES LABORATOR; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; JHON DY, 1993, J BIOL CHEM, V268, P6654; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KATAN M, 1987, EUR J BIOCHEM, V168, P413, DOI 10.1111/j.1432-1033.1987.tb13435.x; KIM MJ, 1993, BIOCHEM BIOPH RES CO, V194, P706, DOI 10.1006/bbrc.1993.1879; KRIZ R, 1990, CIBA F SYMP, V150, P112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MIN DS, 1993, J BIOL CHEM, V268, P12207; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHTA S, 1988, FEBS LETT, V242, P31, DOI 10.1016/0014-5793(88)80979-7; PARK D, 1992, J BIOL CHEM, V267, P16048; PARK DG, 1993, J BIOL CHEM, V268, P3710; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; RYU SH, 1986, BIOCHEM BIOPH RES CO, V141, P137, DOI 10.1016/S0006-291X(86)80345-X; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, J BIOL CHEM, V263, P14497; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WU DQ, 1993, J BIOL CHEM, V268, P3704; WU DQ, 1992, J BIOL CHEM, V267, P25798	47	93	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8240	8245						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510682				2022-12-27	WOS:A1994NB40900063
J	HAN, JH; MATHISON, JC; ULEVITCH, RJ; TOBIAS, PS				HAN, JH; MATHISON, JC; ULEVITCH, RJ; TOBIAS, PS			LIPOPOLYSACCHARIDE (LPS) BINDING-PROTEIN, TRUNCATED AT ILE-197, BINDS LPS BUT DOES NOT TRANSFER LPS TO CD14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ACUTE PHASE REACTANT; PARTICIPATION	Lipopolysaccharide (LPS) binding protein (LBP), a 58-60 kDa glycoprotein, binds to the lipid A region of LPS. The resulting LPS.LBP complex is recognized by both the membrane-bound (mCD14) and soluble forms of CD14 (sCD14), thereby enhancing the ability of LPS to activate myeloid, endothelial, and epithelial cells. To begin to characterize the structure-function relationships within LBP, we have created and expressed a truncated form of human LBP (herein called NH-LBP) comprising amino acid residues 1-197 of the parent molecule. Experiments were done to characterize the ability of NH-LBP to bind LPS and to promote LPS binding to CD14. We found that NH-LBP efficiently binds LPS but does not transfer the LPS to either mCD14 or sCD14. Additionally, NH-LBP inhibited LPS binding to LBP, inhibited the LBP-promoted binding of LPS to CD14, and inhibited the LBP-dependent activation of rabbit peritoneal exudate macrophages. The apparent dissociation constant for LPS NH-LBP complexes is less than 1 x 10(-8) M which compares well with the dissociation constant for LPS.LBP complexes of approximately 1 x 10(-9) M. We conclude from these studies that the LPS binding site of LBP resides in the amino terminal half of LBP and that the CD14 interaction site resides in the carboxyl-terminal half of LBP. These data suggest that appropriately modified fragments of LBP might provide novel reagents with high LPS binding affinity that could be useful in inhibiting LPS-dependent cellular activation in vivo.			HAN, JH (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.		Han, J/G-4671-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015136, R01AI032021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15136, AI32021] Funding Source: Medline; NIGMS NIH HHS [GM37696] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; HEUMANN D, 1992, J IMMUNOL, V148, P3505; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; MATHISON JC, 1988, J CLIN INVEST, V81, P1925, DOI 10.1172/JCI113540; OOI CE, 1991, J EXP MED, V174, P649, DOI 10.1084/jem.174.3.649; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; Sambrook J., 1989, MOL CLONING; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SKELLY RR, 1979, INFECT IMMUN, V23, P287, DOI 10.1128/IAI.23.2.287-293.1979; SUMMERS MD, 1988, MANUAL METHODS BACUL; SWENSON TL, 1988, J BIOL CHEM, V263, P5150; TOBIAS PS, 1993, J IMMUNOL, V150, P3011; TOBIAS PS, 1992, AM J RESP CELL MOL, V7, P239, DOI 10.1165/ajrcmb/7.3.239; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; ULEVITCH RJ, 1993, IN PRESS CURR OPIN I; WOLLENWEBER HW, 1985, J BIOL CHEM, V260, P5068; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	20	59	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8172	8175						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510680				2022-12-27	WOS:A1994NB40900054
J	LI, H; KUO, A; KOCHAN, J; STRICKLAND, D; KARIKO, K; BARNATHAN, ES; CINES, DB				LI, H; KUO, A; KOCHAN, J; STRICKLAND, D; KARIKO, K; BARNATHAN, ES; CINES, DB			ENDOCYTOSIS OF UROKINASE-PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 COMPLEXES BOUND TO A CHIMERIC TRANSMEMBRANE UROKINASE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; GLYCOSYL-PHOSPHATIDYLINOSITOL; CELLULAR RECEPTOR; IL-2 RECEPTOR; DEGRADATION; CELLS; CHAIN; INTERNALIZATION; LOCALIZATION; EXPRESSION	The urokinase receptor (uPAR) is linked to plasma membranes through a glycosylphosphatidylinositol (GPI) anchor. It has been posited that the GPI anchor facilitates clearance of uPAR-bound complexes between two chain urokinase (tcuPA) and plasminogen activator inhibitor type 1 (PAI-1) by the alpha(2)-macroglobulin receptor (alpha(2)MR) which permits re-expression of unoccupied uPA receptors on the cell surface. To test this hypothesis we compared internalization and degradation of I-125-labeled tcuPA.PAI-1 by COS cells expressing either transfected wild-type, GPI-linked uPAR (uPAR/GPI), or a chimeric receptor composed of the extracellular domains of uPAR linked to the transmembrane and cytosolic domains of the alpha chain (p55 subunit) of the interleukin-2 receptor (uPAR/IL-2R(alpha)). The kinetics of binding, internalization and degradation of tcuPA.PAI-1 by COS cells expressing each form of uPAR were virtually identical. However, internalization of complexes by uPAR/IL-2R(alpha) was more susceptible to inhibition by recombinant soluble 39-kDa alpha(2)MR-associated protein (RAP) which competes for binding of tcuPA.PAI-1 complexes to alpha(2)MR (p < 0.001), and the internalization was accompanied by a greater reduction in the number of surface uPAR/IL-2R(alpha), than uPAR/GPI (p < 0.05). These studies indicate that the rate of internalization of tcuPA. PAI-1 is governed primarily by the extracellular domains of uPAR, whereas the GPI anchor may facilitate internalization of complexes and re-expression of uPAR when binding sites on (alpha(2)MR are limiting.	HOSP UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104; HOSP UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104; HOFFMANN LA ROCHE INC,DEPT BRONCHOPULM RES,NUTLEY,NJ 07110; AMER RED CROSS,DEPT BIOCHEM,ROCKVILLE,MD 20855	University of Pennsylvania; University of Pennsylvania; Roche Holding; American Red Cross					NHLBI NIH HHS [HL47839, HL 40387, F32HL08621] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047839, F32HL008621, P01HL040387] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNATHAN ES, 1990, BLOOD, V76, P1795; BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; DUPREZ V, 1992, J BIOL CHEM, V267, P18639; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FUNG MR, 1988, J EXP MED, V168, P1928; GROBMYER SR, 1993, J BIOL CHEM, V268, P13291; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; MOLLER LB, 1992, EUR J BIOCHEM, V208, P493, DOI 10.1111/j.1432-1033.1992.tb17213.x; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OLSON D, 1992, J BIOL CHEM, V267, P9129; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PLESNER T, 1992, BLOOD S, V80, pA98; PLOUG M, 1991, J BIOL CHEM, V266, P1926; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; POLLANEN J, 1990, P NATL ACAD SCI USA, V87, P2230, DOI 10.1073/pnas.87.6.2230; SHULDINER AR, 1991, ANAL BIOCHEM, V194, P9, DOI 10.1016/0003-2697(91)90144-I; SINGH N, 1991, MOL CELL BIOL, V11, P2362, DOI 10.1128/MCB.11.5.2362; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TODD RF, 1988, J IMMUNOL, V140, P1095; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035	30	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8153	8158						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510679				2022-12-27	WOS:A1994NB40900051
J	SORRIBAS, V; MARKOVICH, D; HAYES, G; STANGE, G; FORGO, J; BIBER, J; MURER, H				SORRIBAS, V; MARKOVICH, D; HAYES, G; STANGE, G; FORGO, J; BIBER, J; MURER, H			CLONING OF A NA/P-I COTRANSPORTER FROM OPOSSUM KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITS PHOSPHATE-TRANSPORT; XENOPUS-LAEVIS OOCYTES; FUNCTIONAL ASYMMETRY; CELLULAR MECHANISMS; INORGANIC-PHOSPHATE; PARATHYROID-HORMONE; OK CELLS; EXPRESSION; REABSORPTION; ADAPTATION	Opossum kidney (OK) cells have been extensively used to study cellular mechanisms of renal proximal tubular Na/P-i cotransport. We have cloned a cDNA (NaPi-4) most likely encoding an apical Na/P-i cotransporter from OK cells. The cloning strategy was based on homology to the recently cloned human renal (NaPi-3) Na/P-i cotransporter (Magagnin, S., Werner, A, Markovich, D., Sorribas, V., Stange, G., Biber, J., and Murer, H. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 5979-5983). Kinetic characterization (Pi interaction, sodium interaction, and pH dependence) of NaPi-4-induced Na/P-i uptake showed high similarity to apical Pi transport in OK cell monolayers. The NaPi-4 cDNA is 2548 base pairs long and encodes a protein of 70.5 kDa, containing at least 8 predicted transmembrane domains. Northern blot analysis with OK cell mRNA shows a NaPi-4-related signal (2.5 kilobases) in cells grown on impermeant and permeant supports. Hybrid depletion with NaPi-4 antisense oligonucleotides abolished the mRNA-induced Na/P-i cotransport in oocytes. Similarly, NaPi-4 antisense oligonucleotides inhibited (up to 70%) Na/P-i cotransport in OK cell. monolayers. We presume that NaPi-4 is closely related to the OK cell apical Na/P-i cotransporter.	UNIV ZURICH,INST PHYSIOL,CH-8057 ZURICH,SWITZERLAND	University of Zurich			Markovich, Daniel/F-7884-2012	Sorribas, Victor/0000-0003-3457-323X				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BIBER J, 1993, PFLUG ARCH EUR J PHY, V424, P210, DOI 10.1007/BF00384344; BIBER J, 1990, METHOD ENZYMOL, V191, P494; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNETTE MG, 1984, PFLUG ARCH EUR J PHY, V400, P356, DOI 10.1007/BF00587532; CAVERZASIO J, 1992, ENDOCRINOLOGY, V130, P373, DOI 10.1210/en.130.1.373; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CROOKE ST, 1993, FASEB J, V7, P533, DOI 10.1096/fasebj.7.6.7682523; CUSTER M, 1993, PFLUG ARCH EUR J PHY, V424, P203, DOI 10.1007/BF00384343; FRIEDLANDER G, 1992, J CLIN INVEST, V90, P848, DOI 10.1172/JCI115960; GMAJ P, 1986, PHYSIOL REV, V66, P36, DOI 10.1152/physrev.1986.66.1.36; GSTRAUNTHALER GJA, 1988, RENAL PHYSIOL BIOCH, V11, P1; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOGHMANADHAM M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P67, DOI 10.1016/0005-2736(92)90163-G; LOGHMANADHAM M, 1992, AM J PHYSIOL, V263, pF301, DOI 10.1152/ajprenal.1992.263.2.F301; MAGAGNIN S, 1992, J BIOL CHEM, V267, P15384; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MALMSTROM K, 1986, AM J PHYSIOL, V251, pC23, DOI 10.1152/ajpcell.1986.251.1.C23; MARKOVICH D, 1994, IN PRESS J BIOL CHEM, V269; MURER H, 1991, AM J PHYSIOL, V260, pC885, DOI 10.1152/ajpcell.1991.260.5.C885; MURER H, 1992, J AM SOC NEPHROL, V2, P1649; MURER H, 1992, KIDNEY PHYSL PATHOPH, P2481; QUAMME G, 1989, AM J PHYSIOL, V257, pF967, DOI 10.1152/ajprenal.1989.257.6.F967; QUAMME GA, 1984, AM J PHYSIOL, V246, pF323, DOI 10.1152/ajprenal.1984.246.3.F323; RESHKIN SJ, 1990, PFLUG ARCH EUR J PHY, V416, P624, DOI 10.1007/BF00370606; RESHKIN SJ, 1990, PFLUG ARCH EUR J PHY, V416, P554, DOI 10.1007/BF00382689; RESHKIN SJ, 1991, PFLUG ARCH EUR J PHY, V419, P256, DOI 10.1007/BF00371104; SORRIBAS V, 1993, BIOCHIM BIOPHYS ACTA, V1178, P141, DOI 10.1016/0167-4889(93)90004-9; ULLRICH KJ, 1978, PFLUG ARCH EUR J PHY, V377, P33, DOI 10.1007/BF00584371; WERNER A, 1990, J BIOL CHEM, V265, P12331; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; YAGEI A, 1992, PFLUGERS ARCH, V422, P211; 1991, GCG PROGRAM MANUAL	35	112	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6615	6621						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509808				2022-12-27	WOS:A1994MZ50300056
J	MEYER, DJ; CAMPBELL, GS; COCHRAN, BH; ARGETSINGER, LS; LARNER, AC; FINBLOOM, DS; CARTERSU, C; SCHWARTZ, J				MEYER, DJ; CAMPBELL, GS; COCHRAN, BH; ARGETSINGER, LS; LARNER, AC; FINBLOOM, DS; CARTERSU, C; SCHWARTZ, J			GROWTH-HORMONE INDUCES A DNA-BINDING FACTOR-RELATED TO THE INTERFERON-STIMULATED 91-KDA TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-TYROSINE KINASES; SERUM RESPONSE ELEMENT; C-FOS; ALPHA; GENE; PHOSPHORYLATION; REGION; ACTIVATION; INDUCTION; SECRETION	Signaling mechanisms leading to regulation of gene transcription by growth hormone (GH) and other molecules that signal via the cytokine receptor family have been elusive. Based upon recent findings that GH and interferons activate JAK family tyrosine kinases, we have identified a novel signaling pathway leading from the GH receptor to the nucleus. We report that in 3T3-F442A fibroblasts, GH stimulates tyrosyl phosphorylation of a protein recognized by antibody to p91, a component of DNA-binding complexes that are activated by tyrosyl phosphorylation in response to interferons alpha and gamma. In addition, a GH-inducible DNA binding factor (GHIF) is identified that binds to the c-sis-inducible element of the c-fos promoter. GHIF contains a protein antigenically related to p91 and is tyrosyl-phosphorylated. These findings indicate that in signaling between their receptors and the nucleus, GH and interferons utilize related or identical components, including JAK family tyrosine kinases and proteins in the p91 family. When combined with recent findings that many members of the cytokine receptor family activate JAK kinases, including some cytokines that activate p91-related proteins, these findings suggest that signaling pathways involving JAB kinases and p91 family members may be broadly distributed.	UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111; CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892	University of Michigan System; University of Michigan; Tufts University; US Food & Drug Administration (FDA)					NCI NIH HHS [P01-CA42063] Funding Source: Medline; NIDDK NIH HHS [DK34171, R01 DK034171] Funding Source: Medline; NIGMS NIH HHS [GM07315, T32 GM007315] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034171, R37DK034171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; DAVID M, 1993, J BIOL CHEM, V268, P6593; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; EDEN S, 1979, ENDOCRINOLOGY, V105, P555, DOI 10.1210/endo-105-2-555; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GUAN K, 1990, SCIENCE, V257, P813; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HANNIGAN GE, 1992, J INTERFERON RES, V12, P355, DOI 10.1089/jir.1992.12.355; HARPUR AG, 1992, ONCOGENE, V7, P1347; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MEYER DJ, 1993, P NATL ACAD SCI USA, V90, P6721, DOI 10.1073/pnas.90.14.6721; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; NIXON T, 1984, ENDOCRINOLOGY, V114, P527, DOI 10.1210/endo-114-2-527; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHINDLER C, 1992, ENDOCRINOLOGY, V89, P7836; SHNAI K, 1993, SCIENCE, V268, P7427; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1994, IN PRESS SCIENCE; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	41	172	174	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4701	4704						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508925				2022-12-27	WOS:A1994MX57100003
J	LI, SH; BURNS, DK; RUMBERGER, JM; PRESKY, DH; WILKINSON, VL; ANOSTARIO, M; WOLITZKY, BA; NORTON, CR; FAMILLETTI, PC; KIM, KJ; GOLDSTEIN, AL; COX, DC; HUANG, KS				LI, SH; BURNS, DK; RUMBERGER, JM; PRESKY, DH; WILKINSON, VL; ANOSTARIO, M; WOLITZKY, BA; NORTON, CR; FAMILLETTI, PC; KIM, KJ; GOLDSTEIN, AL; COX, DC; HUANG, KS			CONSENSUS REPEAT DOMAINS OF E-SELECTIN ENHANCE LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULE-1; CARBOHYDRATE-RECOGNITION DOMAINS; NODE HOMING RECEPTOR; NEUTROPHIL ADHERENCE; CELL-ADHESION; VASCULAR ENDOTHELIUM; SIALYL-LEX; PROTEINS; EXPRESSION; GMP-140	To study the structural characteristics of E-selectin necessary for mediating cell adhesion, we examined the role of the consensus repeat (CR) domains in E-selectin function. Soluble constructs containing different numbers of CR domains were stably expressed in Chinese hamster ovary cells, purified to homogeneity, and characterized. The minimum functional unit of soluble E-selectin consisted of the lectin (Lee) and epidermal growth factor (EGF) domains alone (Lec-EGF) as indicated by its ability to mediate in vitro HL-60 cell adhesion. However, E-selectin containing all six CR domains (Lec-EGF-CR6) at its COOH terminus was the most potent in blocking neutrophil or HL-60 cell adhesion to either immobilized E-selectin or cytokine-stimulated human umbilical vein endothelial cells. This increased potency of Lec-EGF-CR6 in blocking cell adhesion was not due to CR-mediated oligomerization of the protein. Lec-EGF-CR6 was most likely monomeric in solution, as judged by gel filtration fast protein liquid chromatography, membrane ultrafiltration, and chemical cross-linking analysis. Therefore, although the lectin and EGF do mains are necessary and sufficient for mediating cell adhesion, the additional six CR domains, present in native E-selectin, contribute to the enhanced binding of E-selectin to its ligand.	HOFFMANN LA ROCHE INC,DEPT INFLAMMAT AUTOIMMUNE DIS,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,DEPT MOLEC SCI,NUTLEY,NJ 07110	Roche Holding; Roche Holding								ARNAOUT MA, 1988, J CELL PHYSIOL, V137, P305, DOI 10.1002/jcp.1041370214; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CAMERINI D, 1989, NATURE, V342, P78, DOI 10.1038/342078a0; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; GIMBRONE M A JR, 1978, TCA (Tissue Culture Association) Manual, V4, P813, DOI 10.1007/BF00918403; HARLAN JM, 1985, BLOOD, V66, P167; HENSLEY P, 1993, BIOPHYS J, V64, pA375; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUTILA MA, 1992, J EXP MED, V175, P1565, DOI 10.1084/jem.175.6.1565; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LUSCINSKAS FW, 1989, J IMMUNOL, V142, P2257; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NEWMAN W, 1993, J IMMUNOL, V150, P644; NORTON C R, 1990, Journal of Cell Biology, V111, p158A; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; PIGOTT R, 1991, J IMMUNOL, V147, P130; POBER JS, 1986, J IMMUNOL, V136, P1680; POHLMAN TH, 1986, J IMMUNOL, V136, P4548; SCALLON BJ, 1992, BIO-TECHNOL, V10, P550, DOI 10.1038/nbt0592-550; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1991, J CELL BIOL, V115, P235, DOI 10.1083/jcb.115.1.235; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	40	57	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4431	4437						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508442				2022-12-27	WOS:A1994MW98900083
J	ISEL, C; MARQUET, R; KEITH, G; EHRESMANN, C; EHRESMANN, B				ISEL, C; MARQUET, R; KEITH, G; EHRESMANN, C; EHRESMANN, B			MODIFIED NUCLEOTIDES OF TRANSFER RNA(3)(LYS) MODULATE PRIMER TEMPLATE LOOP-LOOP INTERACTION IN THE INITIATION COMPLEX OF HIV-1 REVERSE TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS; DEPENDENT DNA POLYMERASE; ROUS-SARCOMA VIRUS; TRANSFER-RNA; SEQUENCE; VIRIONS; PROTEIN; ACID	In all retroviruses, reverse transcription is primed by a tRNA whose 3' end 18 nucleotides are complementary to the so called viral primer binding site. Previous work showed that reverse transcription of HIV-1 RNA is initiated by tRNA3Lys. Using a variety of chemical and enzymatic structural probes, we investigated the interactions between HIV-1 RNA and its natural primer tRNA3Lys. In addition to the predictable contacts between the viral primer binding site and the 3' end of tRNA3Lys, a specific interaction takes place between an A-rich loop located upstream of the primer binding site region and the anticodon loop of tRNA3Lys. This AAAA/Umcm5s2UUU loop-loop interaction is not observed when the natural primer is replaced by an in vitro synthesized tRNA3Lys transcript. Furthermore, dethiolation of the modified nucleotide mcm5s2U at position 34 of tRNA3Lys strongly destabilizes this interaction. Sequence and structure comparisons indicate that the primer/template loop-loop interaction is conserved in all HIV-1 isolates, and possibly also in HIV-2 and SIV.	INST BIOL MOLEC & CELLULAIRE,CNRC,UNITE RECH 9002,15 RUE R DESCARTES,F-670084 STRASBOURG,FRANCE				Isel, Catherine/B-9406-2015; Isel, Catherine/AAH-2174-2020	Isel, Catherine/0000-0001-7258-869X; Isel, Catherine/0000-0002-8014-7525; Marquet, Roland/0000-0002-4209-3976				AIYAR A, 1992, J VIROL, V66, P2464, DOI 10.1128/JVI.66.4.2464-2472.1992; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; BERKHOUT B, 1993, NUCLEIC ACIDS RES, V21, P1171, DOI 10.1093/nar/21.5.1171; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; HARADA F, 1979, J BIOL CHEM, V254, P979; HARADA F, 1975, J BIOL CHEM, V250, P3487; HOUSSIER C, 1988, J BIOMOL STRUCT DYN, V5, P1259, DOI 10.1080/07391102.1988.10506468; JIANG M, 1993, J VIROL, V67, P3246, DOI 10.1128/JVI.67.6.3246-3253.1993; KEITH G, 1983, BIOCHIMIE, V65, P661; KLEIMAN L, 1991, BIOCHEM BIOPH RES CO, V174, P1272, DOI 10.1016/0006-291X(91)91559-U; KOHLSTAEDT LA, 1992, P NATL ACAD SCI USA, V89, P9652, DOI 10.1073/pnas.89.20.9652; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RHIM H, 1991, J VIROL, V65, P4555, DOI 10.1128/JVI.65.9.4555-4564.1991; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; VLASSOV VV, 1981, EUR J BIOCHEM, V119, P51, DOI 10.1111/j.1432-1033.1981.tb05575.x	18	188	188	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25269	25272						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503978				2022-12-27	WOS:A1993MK10000003
J	BALOW, JP; WEISSMAN, JD; KEARSE, KP				BALOW, JP; WEISSMAN, JD; KEARSE, KP			UNIQUE EXPRESSION OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I PROTEINS IN THE ABSENCE OF GLUCOSE TRIMMING AND CALNEXIN ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL; INHIBITORS; MOLECULES; DEFICIENT; ANTIGENS; ER	Recent evidence indicates that efficient expression of major histocompatibility complex (MHC) complexes requires their interaction with the resident endoplasmic reticulum (ER) chaperone calnexin, which for certain proteins functions as a lectin specific for monoglucosylated glycans, In the current report, we studied the expression of MHC class I proteins in BW wild type thymoma cells (BW WT) and glucosidase II-deficient BW PHAR2.7 cells, Consistent with a requirement for glucose (Glc) trimming for interaction of class I proteins with calnexin, we found that nascent H-2K(k) proteins associated with calnexin in untreated BW WT cells, but not in BW WT cells treated with the glucosidase inhibitor castanospermine (cas), or in untreated glucosidase II-deficient BW PHAR2.7 cells, Suprisingly, we found that H-2K(k) expression occurred with similar efficiency in EW PHAR2.7 cells as in BW WT cells and that formation of nascent H-2K(k) complexes was perturbed by cas treatment in BW WT cells but not in BW PHAR2.7 cells, Finally, it was noted that expression of the molecular chaperone Rip was markedly increased in BW PHAR2.7 cells relative to EW WT cells, which is suggested to play a role in regulating the expression of H-2K(k) complexes in BW PHAR2.7 cells, The current study demonstrates that Glc trimming is required for efficient interaction of nascent H-2K(k) proteins with calnexin; that expression of MHC class I proteins can, under certain conditions, proceed effectively in the absence of Glc trimming and calnexin association; and that Bip expression is markedly increased under conditions where diglucosylated glycans persist on nascent glycoproteins within the ER, These data are consistent with the hypothesis that alternative oligomerization pathways exist for class I proteins within the quality control system of the ER that have differential requirements for removal of Glc residues from nascent glycan chains.	NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; HYMAN R, 1974, J NATL CANCER I, V52, P429, DOI 10.1093/jnci/52.2.429; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LOO TW, 1994, J BIOL CHEM, V269, P28683; MOORE SEH, 1992, J BIOL CHEM, V267, P8443; MOORE SEH, 1994, J BIOL CHEM, V268, P3809; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; MORI K, 1993, CELL, V74, P743; NOBNER E, 1995, J EXP MED, V181, P327; OZATO K, 1980, J IMMUNOL, V124, P533; PEYRIERAS N, 1983, EMBO J, V2, P823, DOI 10.1002/j.1460-2075.1983.tb01509.x; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RAJAGOPALAN S, 1994, J EXP MED, V180, P407, DOI 10.1084/jem.180.1.407; REITMAN ML, 1982, J BIOL CHEM, V257, P357; SCOTT JE, 1995, J IMMUNOL, V155, P143; SONG ES, 1994, J BIOL CHEM, V269, P7024; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5	29	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					29025	29029		10.1074/jbc.270.48.29025	http://dx.doi.org/10.1074/jbc.270.48.29025			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499436	hybrid			2022-12-27	WOS:A1995TH05600080
J	GOROVITS, BM; HOROWITZ, PM				GOROVITS, BM; HOROWITZ, PM			THE CHAPERONIN GROEL IS DESTABILIZED BY BINDING OF ADP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN; ATP; HYDROLYSIS	The urea induced dissociation and subsequent conformational transitions of the nucleotide-bound form of GroEL were studied by light scattering, 4,4'-bis(1-anilino-8-naphthalenesulfonic acid) binding, and intrinsic tyrosine fluorescence. Magnesium ion alone (10 mM) stabilizes GroEL and leads to coordination of the structural transitions monitored by the different parameters. The midpoint of the light-scattering transition that monitored dissociation of the 14-mer with bound magnesium was raised to similar to 3 M, which is considerably higher than the ligand-free form of the protein, which exhibits a transition with a midpoint at similar to 2 M urea. Binding of ADP results in destabilization of the GroEL oligomeric structure, and complete dissociation of the 14-mer in the presence of 5 mM ADP occurs at about 2 M urea with the midpoint of the transition at similar to 1 M urea. The same destabilization by ADP and stabilization by Mg2+ were seen when the conformation was followed by the intrinsic fluorescence. Complexation with the nonhydrolyzable ATP analog, 5'-adenylimidodiphosphate gave an apparent stability of the quaternary structure that was between that observed with Mg2+ and that with ADP. The ADP-bound form of the protein demonstrated increased hydrophobic exposure at lower urea concentrations than the uncomplexed GroEL. In addition, the GroEL-ADP complex is more accessible for proteolytic digestion by chymotrypsin than the uncomplexed protein, consistent with a more open, flexible form of the protein. The implication of the conformational changes to the mechanism of the GroEL function is discussed.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NIEHS NIH HHS [ESO5729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRANDSCH R, 1992, J BIOL CHEM, V267, P20844; DIAMANT S, 1995, BIOCHEMISTRY-US, V34, P273, DOI 10.1021/bi00001a033; FISHER MT, 1994, J BIOL CHEM, V269, P13629; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GIBBONS DL, 1995, J BIOL CHEM, V270, P7335, DOI 10.1074/jbc.270.13.7335; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOROVITS B, 1995, J BIOL CHEM, V270, P2061, DOI 10.1074/jbc.270.5.2061; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; HARTL FU, 1994, TRENDS BIOCHEM SCI, V217, P20; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11599; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LISSIN NM, 1995, FEBS LETT, V361, P55, DOI 10.1016/0014-5793(95)00151-X; LORIMER GH, 1993, PHILOS T R SOC B, V339, P297, DOI 10.1098/rstb.1993.0028; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1995, BBA-PROTEIN STRUCT M, V1247, P209, DOI 10.1016/0167-4838(94)00231-5; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; MIZOBATA T, 1994, BBA-PROTEIN STRUCT M, V1209, P83, DOI 10.1016/0167-4838(94)90140-6; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PRICE NC, 1993, BIOCHIM BIOPHYS ACTA, V1161, P52, DOI 10.1016/0167-4838(93)90195-W; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SEALE JW, 1995, BIOCHEMISTRY-US, V34, P7443, DOI 10.1021/bi00022a018; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TODD MJ, 1995, J BIOL CHEM, V270, P5388, DOI 10.1074/jbc.270.10.5388; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WEAST RC, 1982, CRC HDB CHEM MOL BIO; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	37	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28551	28556		10.1074/jbc.270.48.28551	http://dx.doi.org/10.1074/jbc.270.48.28551			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499369	hybrid			2022-12-27	WOS:A1995TH05600013
J	MARVIN, KW; FUJIMOTO, W; JETTEN, AM				MARVIN, KW; FUJIMOTO, W; JETTEN, AM			IDENTIFICATION AND CHARACTERIZATION OF A NOVEL SQUAMOUS CELL-ASSOCIATED GENE-RELATED TO PMP22	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACHEAL EPITHELIAL-CELLS; HUMAN EPIDERMAL KERATINOCYTE; RETINOIC ACID; GROWTH ARREST; L2/HNK-1 CARBOHYDRATE; MYELIN PROTEIN; DIFFERENTIATION; ADHESION; EXPRESSION; TRANSGLUTAMINASE	In this study, we identify and characterize a novel gene, CL-20, that encodes a 17.8-kDa protein with sequence and structural similarity to the growth arrest specific gene gas3/peripheral myelin protein gene PMP22. The CL-20 protein exhibits a 43% identity with PMP22. The positions of the four lipophilic domains and the N-glycosylation site of PMP22 are conserved in CL-20, suggesting that it also is an integral membrane glycoprotein. The CL-20 gene is located on human chromosome 12 rather than 17 and encodes a 2.8-kilobase mRNA instead of 1.7-kilobase mRNA. These observations indicate that the CL-20 gene is related to but distinct from PMP22. In contrast to PMP22, CL-20 mRNA and protein are induced during squamous differentiation of rabbit tracheal epithelial cells in vitro, and Northern blot analysis and in situ hybridization demonstrated that CL-20 mRNA is most abundant in squamous epithelia. These results indicate that the high expression of CL-20 is closely correlated with squamous differentiation. The differences in tissue-specific expression and regulation between CL-20 and PMP22 suggest different roles for these two proteins. Retinoids, which inhibit squamous differentiation, repress the induction of CL-20. The retinoic acid receptor selective retinoid SRI-6751-84 is the most effective in suppressing CL-20, suggesting that the activation of the retinoic acid receptor signaling pathway is important in this suppression.			MARVIN, KW (corresponding author), NIEHS,PULM PATHOBIOL LAB,CELL BIOL SECT,POB 12233,RES TRIANGLE PK,NC 27709, USA.		Jetten, Anton/C-3736-2019	Jetten, Anton/0000-0003-0954-4445				BREEZE RG, 1977, AM REV RESPIR DIS, V116, P705, DOI 10.1164/arrd.1977.116.4.705; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; DELEON M, 1991, J NEUROSCI RES, V29, P437; DELEON M, 1994, J NEUROSCI RES, V38, P167, DOI 10.1002/jnr.490380207; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V2, P387; DUGAICZYK AD, 1983, BIOCHEMISTRY-US, V2, P1605; ECKERT RL, 1989, ENVIRON HEALTH PERSP, V80, P109, DOI 10.2307/3430736; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; FIELD MC, 1992, J NEUROCHEM, V58, P993, DOI 10.1111/j.1471-4159.1992.tb09353.x; FILBIN MT, 1991, NEURON, V7, P845, DOI 10.1016/0896-6273(91)90286-9; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; FUJIMOTO W, 1993, J INVEST DERMATOL, V101, P268, DOI 10.1111/1523-1747.ep12365200; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GRIFFITH LS, 1992, J NEUROSCI RES, V33, P639, DOI 10.1002/jnr.490330417; HAMMER JA, 1993, J NEUROSCI RES, V35, P546, DOI 10.1002/jnr.490350511; HARRIS CC, 1973, J NATL CANCER I, V48, P743; HOLBROOK KA, 1983, J INVEST DERMATOL, V81, P125; ILYAS AA, 1986, BRAIN RES, V385, P1, DOI 10.1016/0006-8993(86)91540-4; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; JETTEN AM, 1991, AM J PHYSIOL, V260, pL361, DOI 10.1152/ajplung.1991.260.6.L361; JETTEN AM, 1987, LAB INVEST, V56, P654; JETTEN AM, 1992, CELL GROWTH DIFFER, V3, P549; JETTEN AM, 1986, J BIOL CHEM, V261, P5097; KEILHAUER G, 1985, NATURE, V316, P728, DOI 10.1038/316728a0; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; Martinotti Alessia, 1992, Human Molecular Genetics, V1, P331, DOI 10.1093/hmg/1.5.331; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; MATSUNAMI N, 1992, NAT GENET, V1, P176, DOI 10.1038/ng0692-176; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; PHELPS WC, 1987, J VIROL, V6, P1630; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; QUARLES RH, 1989, NEUROBIOLOGY GLYCOCO, P243; RAO BB, 1993, NAT GENET, V5, P269; REARICK JI, 1987, J BIOL CHEM, V262, P13069; RIOPELLE RJ, 1986, BRAIN RES, V367, P20, DOI 10.1016/0006-8993(86)91573-8; RUSSNAK R, 1990, GENE DEV, V4, P764, DOI 10.1101/gad.4.5.764; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; SAUNDERS NA, 1993, BIOCHEM BIOPH RES CO, V197, P46, DOI 10.1006/bbrc.1993.2439; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SNIPES GJ, 1992, J CELL BIOL, V117, P225, DOI 10.1083/jcb.117.1.225; STELLMACH V M, 1989, New Biologist, V1, P305; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; SUTER U, 1992, NAT NEW GENET, V1, P159; VALENTIJN LJ, 1992, NAT GENET, V1, P166, DOI 10.1038/ng0692-166; VOLLBERG TM, 1992, MOL ENDOCRINOL, V6, P667, DOI 10.1210/mend.6.5.1318502; VOLLBERG TM, 1991, EXP CELL RES, V193, P93, DOI 10.1016/0014-4827(91)90542-3; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P7195, DOI 10.1073/pnas.88.16.7195; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WONG YC, 1971, LAB INVEST, V24, P55	56	50	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28910	28916		10.1074/jbc.270.48.28910	http://dx.doi.org/10.1074/jbc.270.48.28910			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499420	hybrid			2022-12-27	WOS:A1995TH05600064
J	TORRIGLIA, A; CHAUDUN, E; CHANYFOURNIER, F; JEANNY, JC; COURTOIS, Y; COUNIS, MF				TORRIGLIA, A; CHAUDUN, E; CHANYFOURNIER, F; JEANNY, JC; COURTOIS, Y; COUNIS, MF			INVOLVEMENT OF DNASE-II IN NUCLEAR DEGENERATION DURING LENS CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEASE-II; POLYACRYLAMIDE-GEL; APOPTOSIS; DEGRADATION; PROTEINS; DEATH; IDENTIFICATION; PURIFICATION; THYMOCYTES; ACTIVATION	The characterization of DNase II and DNase I activity was undertaken to discriminate their different roles in physiological nuclear degradation during lens fiber cell differentiation. The activity of both nucleases determined in a new assay allows to discriminate DNase II from DNase I in the same extract, In fibers, both types of nuclease activities are found and appear higher than in epithelial cells. Specific polyclonal antibodies directed against these two nucleases reveal by Western blot analysis the presence of various DNase isoforms, DNase II like-nuclease, present in fibers, is represented by three major bands (60, 23, and 18 kDa), which are not detected, at least for two of them (60 and 23 kDa), in epithelial cells, DNase I like nuclease pattern in fiber cells shows a single 32-kDa band, while several bands can be detected in epithelial cells, Immunocytochemistry studies show both nucleases present in lens cell sections, DNase II is, as usual, in cytoplasm of epithelial cells, but it appears strikingly concentrated in the nuclei of fibers, DNase I is always concentrated in nuclei of epithelial and fiber cells, DNA degradation observed in agarose gels shows that DNase II-activating medium cleaves the DNA from fiber cells more efficiently than DNase I-activating buffer, In addition, DNase II antibody is able to prevent this degradation, These results suggest a specific involvement of DNase II in nuclear degradation during lens cell differentiation.	ASSOC CLAUDE BERNARD,INSERM,XR118,F-75016 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Torriglia, Alicia/Q-3509-2019; Torriglia, Alicia/L-6957-2017	Torriglia, Alicia/0000-0003-1181-6710; 				APPLEBY DW, 1977, P NATL ACAD SCI USA, V74, P5579, DOI 10.1073/pnas.74.12.5579; Arruti C, 1995, Cell Death Differ, V2, P47; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; Bernardi G., 1971, HYDROLYSIS, P271; BLOEMENDAL H, 1977, SCIENCE, V197, P127, DOI 10.1126/science.877544; CHAUDUN E, 1994, J CELL PHYSIOL, V158, P354, DOI 10.1002/jcp.1041580218; COUNIS MF, 1989, CELL DIFFER DEV, V27, P137, DOI 10.1016/0922-3371(89)90743-0; COUNIS MF, 1989, INT J BIOCHEM, V21, P235, DOI 10.1016/0020-711X(89)90181-X; COUNIS MF, 1977, DEV BIOL, V57, P47, DOI 10.1016/0012-1606(77)90353-0; Eastman A, 1994, Cell Death Differ, V1, P7; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; Hughes F M Jr, 1994, Cell Death Differ, V1, P11; KIM HS, 1982, ANAL BIOCHEM, V119, P96, DOI 10.1016/0003-2697(82)90671-6; LACKS SA, 1981, J BIOL CHEM, V256, P2644; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESCA P, 1968, NATURE, V220, P76, DOI 10.1038/220076a0; LIAO TH, 1989, BIOCHIM BIOPHYS ACTA, V1007, P15, DOI 10.1016/0167-4781(89)90124-3; LOCKSHIN RA, 1990, J GERONTOL, V45, P135; MANNHERZ HG, 1992, J BIOL CHEM, V267, P11661; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MODAK S. P., 1976, BIOL EPITHELIAL LENS, V60, P105; MONTAGUE JW, 1994, J BIOL CHEM, V269, P18877; MOORE S, 1981, ENZYMES A, V14, P281; MUEL AS, 1986, J CELL PHYSIOL, V127, P167, DOI 10.1002/jcp.1041270120; Peitsch M C, 1994, Cell Death Differ, V1, P1; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; PRICE PA, 1969, J BIOL CHEM, V244, P917; RAMOTAR D, 1987, J BIOL CHEM, V262, P425; ROCHE J, 1992, EXP EYE RES, V55, P183, DOI 10.1016/0014-4835(92)90107-4; ROSENTHAL AL, 1977, ANAL BIOCHEM, V80, P76, DOI 10.1016/0003-2697(77)90627-3; SANWAL M, 1986, EXP CELL RES, V167, P429, DOI 10.1016/0014-4827(86)90183-7; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SLOR H, 1973, BIOCHEM BIOPH RES CO, V52, P556, DOI 10.1016/0006-291X(73)90748-1; SLOR H, 1971, BIOCHEM J, V123, P993, DOI 10.1042/bj1230993; SWANSON AA, 1966, EXP EYE RES, V5, P145, DOI 10.1016/S0014-4835(66)80030-1; TORRIGLIA A, 1994, NEUROSCIENCE, V60, P969, DOI 10.1016/0306-4522(94)90276-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLIAMS G T, 1992, Trends in Cell Biology, V2, P263, DOI 10.1016/0962-8924(92)90198-V; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YASUDA T, 1992, BIOCHIM BIOPHYS ACTA, V1119, P185, DOI 10.1016/0167-4838(92)90390-Y; ZOTIKOV L, 1970, J ULTRA MOL STRUCT R, V30, P642, DOI 10.1016/S0022-5320(70)90057-2	43	98	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28579	28585		10.1074/jbc.270.48.28579	http://dx.doi.org/10.1074/jbc.270.48.28579			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499373	hybrid			2022-12-27	WOS:A1995TH05600017
J	DUGGAN, LJ; HILL, TM; WU, S; GARRISON, K; ZHANG, XL; GOTTLIEB, PA				DUGGAN, LJ; HILL, TM; WU, S; GARRISON, K; ZHANG, XL; GOTTLIEB, PA			USING MODIFIED NUCLEOTIDES TO MAP THE DNA DETERMINANTS OF THE TUS-TERB COMPLEX, THE PROTEIN-DNA INTERACTION ASSOCIATED WITH TERMINATION OF REPLICATION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE ANALOG SUBSTITUTIONS; FUNCTIONAL-GROUP CHANGES; LAC REPRESSOR; RESTRICTION ENDONUCLEASE; RECOGNITION SITE; ECO-RI; OPERATOR; SEQUENCE; CLEAVAGE; BINDING	A series of modified nucleotides was used to map the hydrogen-bonding and hydrophobic sites of the TerB DNA required for Tus interaction. Each of four consensus guanine residues in the TerB-binding site was replaced by 7-deazaguanine, 2-aminopurine, or inosine nucleobase analogues, and each thymine by a uracil analogue, The observable equilibrium dissociation constant for the Tus protein-TerB DNA complex was measured at pH 7.5, 25 degrees C, and 150 mM potassium glutamate using a competition binding method. Substitutions made at position 10 with a 7-deazaguanine, 2-aminopurine, or inosine analogue had a large effect on the stability of the complex, approximately +3 kcal/mol in each case. Substitutions made at positions 13 and 17 had a varied response, For uracil substitutions, potential hydrophobic sites were identified at six positions in the TerB DNA. The energetic penalty for the removal of a single methyl group ranged between +1 and +2 kcal/mol. Rate dissociation measurements agree with these results. Overall, major and minor groove determinants are required for binding, An unusual result was that the conserved nucleotide at position 6 did not significantly affect in vitro binding of the complex.	UNIV DELAWARE, DEPT CHEM & BIOCHEM, NEWARK, DE 19716 USA; DREXEL UNIV, DEPT BIOSCI & BIOTECHNOL, PHILADELPHIA, PA 19104 USA	University of Delaware; Drexel University			Gottlieb, Philip/C-3113-2019	Gottlieb, Philip/0000-0003-3764-9885				BRENNAN CA, 1986, J BIOL CHEM, V261, P7270; COSKUNARI FF, 1994, J BIOL CHEM, V269, P4027; DUBENDORFF JW, 1987, J BIOL CHEM, V262, P892; GOEDDEL DV, 1978, P NATL ACAD SCI USA, V75, P3578, DOI 10.1073/pnas.75.8.3578; GOTTLIEB PA, 1992, J BIOL CHEM, V267, P7434; HIASA H, 1992, J BIOL CHEM, V267, P11379; HILL TM, 1989, P NATL ACAD SCI USA, V86, P1593, DOI 10.1073/pnas.86.5.1593; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; HILL TM, 1992, ANNU REV MICROBIOL, V46, P603, DOI 10.1146/annurev.micro.46.1.603; JENJACOBSON L, 1991, NUCLEIC ACIDS MOL BI, V5, P141; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; MAZZARELLI J, 1989, BIOCHEMISTRY-US, V28, P4616, DOI 10.1021/bi00437a016; MAZZARELLI JM, 1992, BIOCHEMISTRY-US, V31, P5925, DOI 10.1021/bi00140a032; MCLAUGHLIN LW, 1988, NUCLEIC ACIDS RES, V16, P5631, DOI 10.1093/nar/16.12.5631; MCLAUGHLIN LW, 1987, BIOCHEMISTRY-US, V26, P7238, DOI 10.1021/bi00397a007; NATARAJAN S, 1993, CELL, V72, P113, DOI 10.1016/0092-8674(93)90055-U; NEDVED ML, 1994, NUCLEIC ACIDS RES, V22, P5024, DOI 10.1093/nar/22.23.5024; NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9902, DOI 10.1021/bi00494a021; SEELA F, 1983, LIEBIGS ANN CHEM, P876; SEELA F, 1986, CHEM SCRIPTA, V26, P173; SEELA F, 1983, NUCLEOS NUCLEOT, P181; SISTA PR, 1991, GENE DEV, V5, P74, DOI 10.1101/gad.5.1.74; SKOKOTAS A, 1994, J BIOL CHEM, V269, P20446; SOWERS LC, 1986, P NATL ACAD SCI USA, V83, P5434, DOI 10.1073/pnas.83.15.5434; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; ZHANG XL, 1993, BIOCHEMISTRY-US, V32, P11374, DOI 10.1021/bi00093a014; ZHANG XL, 1995, NUCLEIC ACIDS RES, V23, P1502, DOI 10.1093/nar/23.9.1502	31	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28049	28054						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499290				2022-12-27	WOS:A1995TG21000015
J	FROELICHAMMON, SJ; BURDEN, DA; PATCHAN, MW; ELSEA, SH; THOMPSON, RB; OSHEROFF, N				FROELICHAMMON, SJ; BURDEN, DA; PATCHAN, MW; ELSEA, SH; THOMPSON, RB; OSHEROFF, N			INCREASED DRUG AFFINITY AS THE MECHANISTIC BASIS FOR DRUG HYPERSENSITIVITY OF A MUTANT TYPE-II TOPOISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							STRAND BREAK REPAIR; OVARY CELL-LINE; DNA TOPOISOMERASE; ANTINEOPLASTIC DRUGS; POINT MUTATION; YEAST; RESISTANCE; AMSACRINE; ETOPOSIDE; CLEAVAGE	Altered sensitivity of topoisomerase II to anticancer drugs profoundly affects the response of eukaryotic cells to these agents. Therefore, several approaches were employed to elucidate the mechanism of drug hypersensitivity of the mutant yeast type II topoisomerase, top2H1012Y. This mutant, which is similar to 5-fold hypersensitive to ellipticine, formed DNA cleavage complexes more rapidly than the wild-type yeast enzyme in the presence of the drug. Conversely, no change in the rate of DNA religation was observed. There was, however, a correlation between increased cleavage rates and enhanced drug binding affinity. The apparent dissociation constant for ellipticine in the mutant topoisomerase II . drug . DNA ternary complex was similar to 5-fold lower than in the wild-type ternary complex. Furthermore, the apparent K-D value for the mutant binary (topoisomerase II . drug) complex was similar to 2-fold lower than the corresponding wild-type complex, indicating that drug hypersensitivity is intrinsic to the enzyme. These findings strongly suggest that the enhanced ellipticine binding affinity for topoisomerase II is the mechanistic basis for drug hypersensitivity of top2H1012Y.	VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; UNIV MARYLAND, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21201 USA	Vanderbilt University; Vanderbilt University; University System of Maryland; University of Maryland Baltimore				Elsea, Sarah/0000-0002-1400-8519; Patchan, Marcia/0000-0002-0485-0403	NCI NIH HHS [5 T32 CA 09582] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTON PA, 1993, BRIT J HAEMATOL, V85, P241, DOI 10.1111/j.1365-2141.1993.tb03162.x; ANDERSON RD, 1994, MUTAT RES-FUND MOL M, V309, P109, DOI 10.1016/0027-5107(94)90048-5; Beck W T, 1994, Adv Pharmacol, V29B, P145; BECK WT, 1994, CANCER CHEMOTH PHARM, V34, pS14, DOI 10.1007/BF00684858; BECK WT, 1993, ADV ENZYME REGUL, V33, P113; CALDECOTT K, 1990, CANCER RES, V50, P5778; CHAN VTW, 1993, J BIOL CHEM, V268, P2160; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CORBETT AH, 1992, J BIOL CHEM, V267, P683; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; D'Arpa P, 1994, Adv Pharmacol, V29B, P127; DANKS MK, 1988, BIOCHEMISTRY-US, V27, P8861, DOI 10.1021/bi00424a026; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; ELSEA SH, 1992, J BIOL CHEM, V267, P13150; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P14998, DOI 10.1074/jbc.270.25.14998; FROELICHAMMON SJ, 1994, J BIOL CHEM, V269, P7719; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; HARRISON DJ, 1995, J PATHOL, V175, P7, DOI 10.1002/path.1711750103; HSIUNG YC, 1995, J BIOL CHEM, V270, P20359, DOI 10.1074/jbc.270.35.20359; JANNATIPOUR M, 1993, J BIOL CHEM, V268, P18586; JEGGO PA, 1989, CANCER RES, V49, P7057; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LIU L, 1994, DNA TOPOISOMERASES T; LIU YX, 1994, CANCER RES, V54, P2943; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; NITISS JL, 1994, CANCER CHEMOTH PHARM, V34, pS6, DOI 10.1007/BF00684857; NITISS JL, 1993, CANCER RES, V53, P89; NITISS JL, 1992, CANCER RES, V52, P4467; NITISS JL, 1994, MOL PHARMACOL, V46, P773; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; POMMIER Y, 1993, CANCER CHEMOTH PHARM, V32, P103, DOI 10.1007/BF00685611; POMMIER Y, 1994, CANCER INVEST, V12, P530, DOI 10.3109/07357909409021413; POTMESIL M, 1990, DNA TOPOLOGY ITS BIO, P391; Potmesil M., 1991, DNA TOPOISOMERASES C; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; Sambrook J, 1989, MOL CLONING LABORATO; SANDER M, 1983, J BIOL CHEM, V258, P8421; SINHA BK, 1995, DRUGS, V49, P11, DOI 10.2165/00003495-199549010-00002; SULLIVAN DM, 1989, BIOCHEMISTRY-US, V28, P5680, DOI 10.1021/bi00439a051; SULLIVAN DM, 1987, CANCER RES, V47, P3973; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TARTOF KD, 1987, FOCUS, V9, P2; THOMPSON RB, 1988, ANAL CHEM, V60, P670, DOI 10.1021/ac00158a014; WASSERMAN RA, 1994, J BIOL CHEM, V269, P20943; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WILLMOTT CJR, 1993, ANTIMICROB AGENTS CH, V37, P126, DOI 10.1128/AAC.37.1.126; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; ZWELLING LA, 1989, J BIOL CHEM, V264, P16411	48	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28018	28021						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499285				2022-12-27	WOS:A1995TG21000010
J	MATSUO, N; OGAWA, S; IMAI, Y; TAKAGI, T; TOHYAMA, M; STERN, D; WANAKA, A				MATSUO, N; OGAWA, S; IMAI, Y; TAKAGI, T; TOHYAMA, M; STERN, D; WANAKA, A			CLONING OF A NOVEL RNA-BINDING POLYPEPTIDE (RA301) INDUCED BY HYPOXIA/REOXYGENATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; RAT-BRAIN; PROTEINS; LOCALIZATION; EXPRESSION; INDUCTION; DNA	Astrocytes have a critical role in the neuronal response to ischemia, as their production of neurotrophic mediators can favorably impact on the extreme sensitivity of nervous tissue to oxygen deprivation, Using a differential display method, a novel putative RNA binding protein, RA301, was cloned from reoxygenated astrocytes, Analysis of the deduced amino acid sequence showed two ribonucleoprotein domains and serine/arginine-rich domains, suggestive of their function as RNA splicing factor, Northern analysis displayed striking induction only in cultured astrocytes within 15 min of reoxygenation and reached a maximum by 60 min after hypoxia/reoxygenation. Immunoblotting demonstrated expression of an immunoreactive polypeptide of the expected molecular mass, 36 kDa, in lysates of hypoxia/reoxygenated astrocytes. Induction of RA301 mRNA was mediated, in large part, by endogenously generated reactive oxygen species, as shown by diphenyl iodonium, an inhibitor of neutrophil-type nicotinamide adenine dinucleotide phosphate oxidase which blocks oxygen-free radical formation by astrocytes. Similarly, increased expression of RA301 in supporting a neurotrophic function of astrocytes was suggested by inhibition of interleukin-6 elaboration, a neuroprotective cytokine, in the presence of antisense oligonucleotide for RA301, These studies provide a first step in characterizing a novel putative RNA binding protein, whose expression is induced by oxygen-free radicals generated during hypoxia/reoxygenation, and which may have an important role in redirection of biosynthetic events observed in the ischemic tissues.	OSAKA UNIV, SCH MED, DEPT ANAT & NEUROSCI, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT MED 1, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT MOLEC NEUROBIOL TANABE, SUITA, OSAKA 565, JAPAN; COLUMBIA UNIV COLL PHYS & SURG, DEPT PHYSIOL & CELLULAR BIOPHYS, NEW YORK, NY 10033 USA	Osaka University; Osaka University; Osaka University; Columbia University			Wanaka, Akio/AAC-9754-2019; Wanaka, Akio/ABE-4671-2020; Wanaka, Akio/GPW-8926-2022	Wanaka, Akio/0000-0001-9951-9862; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050629, R01HL042507] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42507, HL50629] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GOODCHILD J, 1989, OLIGODEOXYNUCLEOTIDE, P53; HORI O, 1994, J NEUROCHEM, V62, P1489; HORNIG H, 1989, EUR J BIOCHEM, V182, P45, DOI 10.1111/j.1432-1033.1989.tb14798.x; HUGOWISSEMANN D, 1991, HEPATOLOGY, V13, P3297; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; KOGA S, 1992, J CLIN INVEST, V90, P1007, DOI 10.1172/JCI115913; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LOIKE JD, 1992, AM J PHYSIOL, V263, pC326, DOI 10.1152/ajpcell.1992.263.2.C326; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; MAGISTRETTI PJ, 1983, REGUL PEPTIDES, V6, P71, DOI 10.1016/0167-0115(83)90136-2; MATTOX W, 1990, GENE DEV, V4, P789, DOI 10.1101/gad.4.5.789; MAYER M, 1994, OXIDATIVE STRESS CEL, P217; MAYER M, 1993, EMBO J, V12, P2005; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; PETITO CK, 1990, J CEREBR BLOOD F MET, V10, P850, DOI 10.1038/jcbfm.1990.141; SAILER A, 1992, NUCLEIC ACIDS RES, V20, P2374, DOI 10.1093/nar/20.9.2374; SCIANDRA JJ, 1984, P NATL ACAD SCI-BIOL, V81, P4843, DOI 10.1073/pnas.81.15.4843; SHRECK R, 1991, EMBO J, V10, P2247; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; WILSON RE, 1989, INT J RADIAT ONCOL, V6, P9561; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769	28	62	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28216	28222						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499316	hybrid			2022-12-27	WOS:A1995TG21000041
J	MEHARI, T; QIAO, FY; SCOTT, MP; NELLIS, DF; ZHAO, JD; BRYANT, DA; GOLBECK, JH				MEHARI, T; QIAO, FY; SCOTT, MP; NELLIS, DF; ZHAO, JD; BRYANT, DA; GOLBECK, JH			MODIFIED LIGANDS TO F-A AND F-B IN PHOTOSYSTEM-I .1. STRUCTURAL CONSTRAINTS FOR THE FORMATION OF IRON-SULFUR CLUSTERS IN FREE AND REBOUND PSAC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; AZOTOBACTER-VINELANDII; 4FE-4S CLUSTER; PYROCOCCUS-FURIOSUS; 3FE-4S CLUSTER; FERREDOXIN; PROTEIN; RESOLUTION; CONVERSION	Cysteines 14, 21, 34, 51, or 58 in PsaC of photosystem I (PS I) were replaced with aspartic acid (C21D and C58D), serine (C14S, C34S, and C51S), and alanine (C14A, C34A, and C51A). When free in solution, the C34S and C34A holoproteins contained two S = 1/2 ground state [4Fe-4S] clusters; all other mutant proteins contained [3Fe-4S] clusters and [4Fe-4S] clusters; in addition, there was evidence in C14S, C51S, C14A, and C51A for high spin (S = 3/2) [4Fe-4S] clusters, presumably in the modified site. These findings are consistent with the assignment of C14, C21, C51, and C58, but not C34, as ligands to F-A and F-B. The [4Fe-4S] clusters in the unmodified sites in C14S, C51S, C14A, and C51A remained highly electronegative, with E(m) values ranging from -495 to -575 mV. The [3Fe-4S] clusters in the modified sites were driven 400 to 450 mV more oxidizing than the native [4Fe-4S] clusters, with E(m) values ranging from -98 mV to -171 mV. A C14D/C51D double mutant contains [3Fe-4S] and S = 1/2 [4Fe-4S] clusters, showing that the 3Cys . 1Asp motif is also able to accommodate a low spin cubane. When C34S, C34A, C14S, C51S, C14A, and C51A were rebound to P700-F-X cores, electron transfer to F-A/F-B was regained, but functional reconstitution has not yet been achieved for C21D, C58D, or C14D/C51D. These data imply that PsaC requires two iron-sulfur clusters to refold, one of which must be a cubane. Since two [4Fe-4S] clusters are found in all reconstituted PS I complexes, the presence of two cubanes in free PsaC may be a necessary precondition for binding to P700-F-X cores.	UNIV NEBRASKA, DEPT CHEM, LINCOLN, NE 68588 USA; UNIV ADDIS ABABA, DEPT CHEM, ADDIS ABABA, ETHIOPIA; UNIV NEBRASKA, CTR BIOL CHEM, LINCOLN, NE 68588 USA; UNIV NEBRASKA, DEPT BIOCHEM, LINCOLN, NE 68588 USA; PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, CTR BIOMOLEC STRUCT & FUNCT, UNIVERSITY PK, PA 16802 USA	University of Nebraska System; University of Nebraska Lincoln; Addis Ababa University; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park								ADMAN ET, 1973, J BIOL CHEM, V248, P3987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG H, 1994, BIOCHEMISTRY-US, V33, P3155, DOI 10.1021/bi00177a003; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; DUNN PPJ, 1988, PLANT MOL BIOL, V11, P311, DOI 10.1007/BF00027388; FUJINAGA J, 1993, BIOCHEM BIOPH RES CO, V194, P104, DOI 10.1006/bbrc.1993.1791; HAGEN WR, 1992, ADV INORG CHEM, V38, P165, DOI 10.1016/S0898-8838(08)60064-1; HANLEY JA, 1992, BIOCHIM BIOPHYS ACTA, V1099, P152, DOI 10.1016/0304-4173(92)90021-6; HOLDEN HM, 1994, J BIOENERG BIOMEMBR, V26, P67, DOI 10.1007/BF00763220; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; KE B, 1973, P NATL ACAD SCI USA, V70, P2941, DOI 10.1073/pnas.70.10.2941; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; LINDAHL PA, 1985, J BIOL CHEM, V260, P1160; MANODORI A, 1992, BIOCHEMISTRY-US, V31, P2703, DOI 10.1021/bi00125a010; MATHEWS R, 1974, J BIOL CHEM, V249, P4326; OHOKA H, 1988, J BIOCHEM-TOKYO, V103, P962, DOI 10.1093/oxfordjournals.jbchem.a122394; PARK JB, 1991, J BIOL CHEM, V266, P19351; PARRETT KG, 1990, BIOCHIM BIOPHYS ACTA, V1015, P341, DOI 10.1016/0005-2728(90)90039-7; ROTHERY RA, 1993, BIOCHEMISTRY-US, V32, P5855, DOI 10.1021/bi00073a019; ROTHERY RA, 1991, BIOCHEMISTRY-US, V30, P8296, DOI 10.1021/bi00098a003; SALMON RT, 1980, J ELECTROANAL CHEM, V112, P253, DOI 10.1016/S0022-0728(80)80407-4; Sambrook J, 1989, MOL CLONING LABORATO; SMART LB, 1993, P NATL ACAD SCI USA, V90, P1132, DOI 10.1073/pnas.90.3.1132; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TELSER J, 1995, J AM CHEM SOC, V117, P5133, DOI 10.1021/ja00123a016; THOMSON AJ, 1992, J INORG BIOCHEM, V47, P197, DOI 10.1016/0162-0134(92)84065-U; WARREN PV, 1993, BIOCHEMISTRY-US, V32, P4411, DOI 10.1021/bi00067a034; YANO T, 1994, FEBS LETT, V354, P160, DOI 10.1016/0014-5793(94)01107-9; YU L, 1993, BIOCHEMISTRY-US, V32, P8251, DOI 10.1021/bi00083a028; YU L, 1995, BIOCHEMISTRY-US, V34, P7861, DOI 10.1021/bi00024a010; YU LA, 1995, J BIOL CHEM, V270, P28118; ZHAO J, 1993, MOL MICROBIOL, V9, P183, DOI 10.1111/j.1365-2958.1993.tb01680.x; ZHAO JD, 1992, BIOCHEMISTRY-US, V31, P5093, DOI 10.1021/bi00137a001	36	42	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28108	28117						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499299				2022-12-27	WOS:A1995TG21000024
J	SINGH, K; BALLIGAND, JL; FISCHER, TA; SMITH, TW; KELLY, RA				SINGH, K; BALLIGAND, JL; FISCHER, TA; SMITH, TW; KELLY, RA			GLUCOCORTICOIDS INCREASE OSTEOPONTIN EXPRESSION IN CARDIAC MYOCYTES AND MICROVASCULAR ENDOTHELIAL-CELLS - ROLE IN REGULATION OF INDUCIBLE NITRIC-OXIDE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH-FACTOR; RAT-KIDNEY CELLS; PHYSIOLOGICAL-PROPERTIES; NONPHOSPHORYLATED FORMS; MESSENGER-RNA; INDUCTION; BONE; GENE; GLYCOPROTEIN; PROMOTER	In heart muscle, the cytokine-inducible isoform of nitric oxide synthase (NOS2) is expressed in both cardiac myocytes and microvascular endothelial cells (CMEC). mRNA levels for both NOS2 and for osteopontin, a multifunctional extracellular matrix phosphoprotein containing an RGD integrin binding domain, are increased in cardiac muscle following intraperitoneal injection of adult rats with lipopolysaccharide. In vitro, interleukin- 1-beta and interferon-gamma increased osteopontin mRNA levels in CMEC as well as NOS2 expression in both CMEC and cardiac myocytes. However, osteopontin mRNA levels in heart muscle in vivo, and in cardiac myocytes and CMEC in vitro, also are increased 10-30-fold by the synthetic glucocorticoid dexamethasone, an agent that suppresses cytokine induction of NOS2 in both cell types. The hexapeptide GRGDSP, which interrupts binding of RGD-containing proteins to cell surface integrins, increased NOS2 mRNA, while a synthetic osteopontin peptide analogue decreased NOS2 mRNA and protein levels in both cytokine-pretreated cardiac myocytes and CMEC cultures. Also, transfection with a full-length antisense-osteopontin cDNA in cytokine-pretreated CMEC decreased endogenous osteopontin mRNA and increased NOS2 mRNA levels. These results suggest that osteopontin could regulate the location and extent of NOS2 induction in the heart. Increased expression of osteopontin also may be one mechanism by which glucocorticoids suppress NOS2 activity in cardiac myocytes and microvascular endothelial cells.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Balligand, Jean-Luc J/D-7543-2012	BALLIGAND, Jean-Luc/0000-0002-0522-4156	NHLBI NIH HHS [R37-HL36141, IP50-HL52320] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036141, P50HL052320] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLIGAND JL, 1995, AM J PHYSIOL-HEART C, V268, pH1293, DOI 10.1152/ajpheart.1995.268.3.H1293; BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461; BALLIGAND JL, 1994, J BIOL CHEM, V269, P27580; BENINATI S, 1993, J BIOCHEM-TOKYO, V114, P702; BERGER HJ, 1994, AM J PHYSIOL, V266, pH41; BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169; BUTTER WT, 1989, CONNECT TISSUE RES, V23, P123; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; ELLINGSEN O, 1993, AM J PHYSIOL, V265, pH747, DOI 10.1152/ajpheart.1993.265.2.H747; FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715; GADEAU AP, 1993, ARTERIOSCLER THROMB, V13, P120, DOI 10.1161/01.ATV.13.1.120; GIACHELLI C, 1991, BIOCHEM BIOPH RES CO, V177, P867, DOI 10.1016/0006-291X(91)91870-I; GIACHELLI CM, 1995, TRENDS CARDIOVAS MED, V5, P88, DOI 10.1016/1050-1738(95)00005-T; HWANG S, 1994, J BIOL CHEM, V269, P711; JIN CH, 1990, MOL CELL ENDOCRINOL, V74, P221; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; MURRY CE, 1994, AM J PATHOL, V145, P1450; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NEMIR M, 1989, J BIOL CHEM, V264, P18202; NISHIDA M, 1993, AM J PHYSIOL, V264, pH639, DOI 10.1152/ajpheart.1993.264.2.H639; NODA M, 1988, J BIOL CHEM, V263, P13916; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; PERRELLA MA, 1994, J BIOL CHEM, V269, P27045; PINSKY DJ, 1995, J CLIN INVEST, V95, P677, DOI 10.1172/JCI117713; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SINGH K, 1990, J BIOL CHEM, V265, P18696; SINGH K, 1992, J BIOL CHEM, V267, P23847; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; UNGUREANULONGROIS D, 1995, CIRC RES, V77, P486, DOI 10.1161/01.RES.77.3.486; UNGUREANULONGROIS D, 1995, J MOL CELL CARDIOL, V27, P155, DOI 10.1016/S0022-2828(08)80015-6; UNGUREANULONGROIS D, 1995, CIRC RES, V77, P494, DOI 10.1161/01.RES.77.3.494; WILLIAMS EB, 1995, CIRCULATION, V92, P705, DOI 10.1161/01.CIR.92.4.705; YANG XC, 1994, J CLIN INVEST, V94, P714, DOI 10.1172/JCI117390; YOON K, 1987, BIOCHEM BIOPH RES CO, V148, P1129, DOI 10.1016/S0006-291X(87)80250-4; ZHANG Q, 1992, EUR J BIOCHEM, V207, P649, DOI 10.1111/j.1432-1033.1992.tb17092.x	45	118	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28471	28478						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499354				2022-12-27	WOS:A1995TG21000079
J	SURREY, T; JAHNIG, F				SURREY, T; JAHNIG, F			KINETICS OF FOLDING AND MEMBRANE INSERTION OF A BETA-BARREL MEMBRANE-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RECONSTITUTION; RENATURATION; INTERMEDIATE; OMPA	We have studied the kinetics of folding and membrane insertion of the outer membrane protein OmpA of Escherichia coli. In the native structure, its membrane-inserted domain forms a beta-barrel. The protein was unfolded in solubilized form in water/urea, and refolding was induced by dilution of urea and simultaneous addition of lipid vesicles, Three transitions along the folding pathway could be distinguished. Their characteristic times lie below a second, in the range of minutes, and in the range of an hour. The fast process corresponds to the transition from the unfolded state in water/urea to a misfolded state in water, the moderately slow process to a transition from the misfolded state to a partially folded state in the membrane, and the slow process to the transition from the partially folded to the native state. The partially folded state in the membrane is interpreted as the analogue of the molten globule state of soluble proteins.	MAX PLANCK INST BIOL, MEMBRANBIOCHEM ABT, D-72076 TUBINGEN, GERMANY	Max Planck Society			Surrey, Thomas/AAC-4608-2021	Surrey, Thomas/0000-0001-9082-1870				BOOTH PJ, 1995, NAT STRUCT BIOL, V2, P139, DOI 10.1038/nsb0295-139; CHRISTENSEN H, 1991, EUR BIOPHYS J, V19, P221, DOI 10.1007/BF00183530; DORNMAIR K, 1990, J BIOL CHEM, V265, P18907; EISELE JL, 1990, J BIOL CHEM, V265, P10217; Engelman DM, 1984, PROTEIN FOLDING PROB, P87; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FREUDL R, 1986, J BIOL CHEM, V261, P1355; Garel Jean-Renaud, 1992, P405; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; HUANG KS, 1981, J BIOL CHEM, V256, P3802; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; Schmid Franz X., 1992, P197; SCHWARZ G, 1987, BIOPHYS J, V52, P685, DOI 10.1016/S0006-3495(87)83263-0; SCHWEIZER M, 1978, EUR J BIOCHEM, V82, P211, DOI 10.1111/j.1432-1033.1978.tb12013.x; SCOTTO AW, 1985, BIOCHEMISTRY-US, V24, P4066, DOI 10.1021/bi00336a040; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SURREY T, 1992, P NATL ACAD SCI USA, V89, P7457, DOI 10.1073/pnas.89.16.7457; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VOGEL H, 1986, J MOL BIOL, V190, P191, DOI 10.1016/0022-2836(86)90292-5; WEI J, 1995, BIOCHEMISTRY-US, V34, P6408, DOI 10.1021/bi00019a021	20	102	103	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28199	28203						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499313				2022-12-27	WOS:A1995TG21000038
J	XIE, WL; HERSCHMAN, HR				XIE, WL; HERSCHMAN, HR			V-SRC INDUCES PROSTAGLANDIN SYNTHASE-2 GENE-EXPRESSION BY ACTIVATION OF THE C-JUN N-TERMINAL KINASE AND THE C-JUN TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE SYNTHASE; SIGNAL-TRANSDUCTION; MESSENGER-RNA; SARCOMA VIRUS; PROTEIN; PHOSPHORYLATION; TYROSINE; FOS; CYCLOOXYGENASE; RECONSTITUTION	A consensus cyclic AMP response element (CRE) in the murine prostaglandin synthase-2 (PGS2) promoter is essential for pgs2 gene expression induced by pp60(v-src) the v-src oncogene product. In this study, we investigate (i) the transcription factors active at the PGS2 ''CRE site'' in response to v-src activation and (ii) the signal transduction pathways by which pp60(v-src) activates these transcription factors. Transient transfection assays with pgs2 promoter/luciferase reporter chimeric genes suggest that c-Jun mediates v-src-induced pgs2 gene expression. Antibody supershift experiments demonstrate that c-Jun can participate in a complex with the pgs2 promoter CRE site. Moreover, in vitro immunocomplex assays demonstrate that pp60(v-src) expression strongly activates c-Jun N-terminal kinase (JNK1) enzyme activity, Serines 63 and 73, the sites of c-Jun phosphorylation by JNK, are essential for v-src-induced, pgs2 promoter mediated luciferase expression. Cotransfection studies with plasmids expressing wild-type JNK, dominant-negative JNK, and dominant-negative MEKK-1 confirm that activation of the Ras/MEKK-1/JNK/c-Jun pathway is required for v-src-induced pgs2 gene expression. Overexpression of either wild type ERK-1 or ERK-2 proteins also potentiate v-src-mediated luciferase expression driven by the pgs2 promoter, and expression of dominant-negative mutants of ERK-1, ERK-2, or Raf-1 attenuate this response. Thus, in response to v-src expression, a Ras/MEKK-1/JNK signal transduction pathway activating c-Jun and a Ras/Raf-1/ERK pathway converge to mediate pgs2 gene expression via the CRE site in the pgs2 promoter.	UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,DEPT PHARMACOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,STRUCT BIOL & MOLEC MED LAB,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024797] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24797] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; BARKER K, 1989, J VIROL, V63, P2929, DOI 10.1128/JVI.63.7.2929-2935.1989; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; CAHILL MA, 1994, FEBS LETT, V344, P105, DOI 10.1016/0014-5793(94)00320-3; COLLETT MS, 1980, NATURE, V285, P167, DOI 10.1038/285167a0; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LOW KG, 1994, MOL CELL BIOL, V14, P4959; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEL AE, 1994, J IMMUNOL, V152, P4347; PEDRAZAALVA G, 1994, J BIOL CHEM, V269, P6978; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P443; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531	45	289	300	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27622	27628		10.1074/jbc.270.46.27622	http://dx.doi.org/10.1074/jbc.270.46.27622			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499226	hybrid			2022-12-27	WOS:A1995TE73600037
J	YANG, Y; FRUH, K; AHN, K; PETERSON, PA				YANG, Y; FRUH, K; AHN, K; PETERSON, PA			IN-VIVO ASSEMBLY OF THE PROTEASOMAL COMPLEXES, IMPLICATIONS FOR ANTIGEN-PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; LINKED LMP GENE; MULTICATALYTIC PROTEINASE; HUMAN MHC; SUBUNITS; EXPRESSION; PHOSPHORYLATION; INTERFERON; REGION	The multicatalytic and multisubunit proteasomal complexes have been implicated in the processing of antigens to peptides presented by class I major histocompatibility complex molecules, Two structural complexes of this proteinase, 20 S and 26 S proteasomes, have been isolated from cells. Ey analyzing in vivo assembly of the proteasomal complexes we show that the 20 S proteasomal complexes are irreversibly assembled via 15 S assembly intermediates containing unprocessed beta-type subunits, The 20 S proteasomes further associate reversibly with proteasome activators PA28 or pre-existing ATPase complexes to form 26 S proteasomal complexes, Our findings that not all of the 20 S proteasomal complexes are assembled into 26 S proteasomal complexes within cells and that all of PA28 and ATPase complexes are associated with 20 S proteasomes strongly suggest that all proteasomal complexes coexist within cells, We further demonstrate that 26 S proteasomal complexes are predominantly present in the cytoplasm and a significant portion of the 20 S proteasomal complexes is associated with the endoplasmic reticulum membrane, Taken together, our findings suggest that depending upon their associated regulatory components, 26 S and 20 S-PA28 proteasomal complexes serve different housekeeping functions within the cells, while they degrade antigens in a cooperative manner in antigen processing.			YANG, Y (corresponding author), SCRIPPS RES INST, RW JOHNSON PHARMACEUT RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.			Frueh, Klaus/0000-0001-8014-3877				AKI M, 1994, J BIOCHEM, V115, P257, DOI 10.1093/oxfordjournals.jbchem.a124327; AKIYAMA KY, 1994, SCIENCE, V265, P1231, DOI 10.1126/science.8066462; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; DEMARTINO GN, 1993, ENZYME PROTEIN, V47, P314, DOI 10.1159/000468689; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; ETLINGER JD, 1993, ENZYME PROTEIN, V47, P325, DOI 10.1159/000468690; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; FRUH K, 1994, EMBO J, V13, P3236, DOI 10.1002/j.1460-2075.1994.tb06625.x; FRUH K, 1992, J BIOL CHEM, V267, P22131; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; JACKSON MR, 1993, ANNU REV CELL BIOL, V9, P207, DOI 10.1146/annurev.cb.09.110193.001231; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUDEMANN R, 1993, J BIOL CHEM, V268, P17413; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MOMBURG F, 1994, CURR OPIN IMMUNOL, V6, P32, DOI 10.1016/0952-7915(94)90030-2; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MOTT JD, 1994, J BIOL CHEM, V269, P31466; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PATEL SD, 1994, P NATL ACAD SCI USA, V91, P296, DOI 10.1073/pnas.91.1.296; PETERS JM, 1994, J BIOL CHEM, V269, P7709; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; REALINI C, 1994, J BIOL CHEM, V269, P20727; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; TANAHASHI N, 1993, ENZYME PROTEIN, V47, P241, DOI 10.1159/000468683; TANAKA K, 1992, NEW BIOL, V4, P173; TANAKA K, 1990, BIOCHEMISTRY-US, V29, P3777, DOI 10.1021/bi00467a026; TECTOR M, 1994, J BIOL CHEM, V269, P25816; USTRELL V, 1995, P NATL ACAD SCI USA, V92, P584, DOI 10.1073/pnas.92.2.584; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; WOONGKYUNG S, 1994, SCIENCE, V264, P1322; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; YANG Y, 1992, J BIOL CHEM, V267, P11669; ZWICKL P, 1992, FEBS LETT, V312, P157, DOI 10.1016/0014-5793(92)80925-7; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	46	174	176	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27687	27694		10.1074/jbc.270.46.27687	http://dx.doi.org/10.1074/jbc.270.46.27687			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499235	hybrid			2022-12-27	WOS:A1995TE73600046
J	KANE, SA; NATRAJAN, A; HECHT, SM				KANE, SA; NATRAJAN, A; HECHT, SM			ON THE ROLE OF THE BITHIAZOLE MOIETY IN SEQUENCE-SELECTIVE DNA CLEAVAGE BY FE-CENTER-DOT-BLEOMYCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID; NUCLEOTIDE-SEQUENCE; BINDING; DEGRADATION; RECOGNITION; FLUORESCENCE; INHIBITION; CHEMISTRY; MOLECULES; CONTACTS	A recent study of Fe(II) bleomycin-mediated DNA strand scission suggested that the metal binding domain of the drug is also the primary determinant of the observed sequence selectivity of strand scission (Carter, B. J., Murty, V. S., Reddy, K. S., Wang, S.-N., and Hecht, S. M. (1990) J. Biol. Chem. 265, 4193-4196). Although it is well established that the bithiazole moiety + C-terminal substituent of bleomycin are required for DNA binding, the role of the bithiazole in sequence-selective DNA recognition remains unclear. To determine whether the bithiazole moiety exhibits an intrinsic DNA binding selectivity, three synthetic EDTA-conjugated bithiazole derivatives were used to mediate DNA cleavage in the presence of Fe2+ and dithiothreitol. Incubation of these Fe(II) EDTA-bithiazoles in the presence of a 5'-P-32 end-labeled DNA duplex resulted in strand scission at every position to essentially the same extent. The relative cleavage efficiencies among the bithiazoles were a strong function of their ionic state. These findings imply that the bithiazoles can bind to many sites on the DNA; they support a model of bleomycin-DNA interaction in which the bithiazole moiety + C-terminal substituent are required only for DNA binding, whereas the metal binding domain is responsible for metal ion coordination and oxygen activation as well as being the primary determinant of sequence selective DNA cleavage.	UNIV VIRGINIA, DEPT CHEM, CHARLOTTESVILLE, VA 22901 USA; UNIV VIRGINIA, DEPT BIOL, CHARLOTTESVILLE, VA 22901 USA	University of Virginia; University of Virginia					NATIONAL CANCER INSTITUTE [R35CA053913] Funding Source: NIH RePORTER; NCI NIH HHS [CA53913] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGELICI RJ, 1968, J AM CHEM SOC, V90, P2499, DOI 10.1021/ja01012a010; ANGELICI RJ, 1967, J AM CHEM SOC, V89, P4605, DOI 10.1021/ja00994a007; BERRY DE, 1985, BIOCHEMISTRY-US, V24, P3207, DOI 10.1021/bi00334a020; BEYER VL, 1965, Z ANORG CHEM, V339, P8; CARTER BJ, 1990, J BIOL CHEM, V265, P4193; CARTER BJ, 1990, P NATL ACAD SCI USA, V87, P9373, DOI 10.1073/pnas.87.23.9373; CARTER BJ, 1991, TETRAHEDRON, V47, P2463, DOI 10.1016/S0040-4020(01)81781-6; CASTRO B, 1975, TETRAHEDRON LETT, P1219; CHIEN M, 1977, BIOCHEMISTRY-US, V16, P3641, DOI 10.1021/bi00635a021; DABROWIAK JC, 1980, J INORG BIOCHEM, V13, P317, DOI 10.1016/S0162-0134(00)80252-4; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P3608, DOI 10.1073/pnas.75.8.3608; DERVAN PB, 1986, SCIENCE, V232, P464, DOI 10.1126/science.2421408; FISHER LM, 1985, BIOCHEMISTRY-US, V24, P3199, DOI 10.1021/bi00334a019; GRIFFIN JH, 1987, J AM CHEM SOC, V109, P6840, DOI 10.1021/ja00256a043; HAY RW, 1974, J CHEM SOC DALTON, P2542, DOI 10.1039/dt9740002542; HECHT SM, 1986, ACCOUNTS CHEM RES, V19, P383, DOI 10.1021/ar00132a002; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HERTZBERG RP, 1988, BIOCHEMISTRY-US, V27, P3164, DOI 10.1021/bi00409a007; HOLMES CE, 1993, BIOCHEMISTRY-US, V32, P4293, DOI 10.1021/bi00067a019; HUANG CH, 1980, BIOCHEMISTRY-US, V19, P1761, DOI 10.1021/bi00550a006; KANE SA, 1993, THESIS U VIRGINIA; KILKUSKIE RE, 1985, J AM CHEM SOC, V107, P260, DOI 10.1021/ja00287a052; KROSS J, 1982, BIOCHEMISTRY-US, V21, P3711, DOI 10.1021/bi00258a029; KUWAHARA J, 1988, P NATL ACAD SCI USA, V85, P2459, DOI 10.1073/pnas.85.8.2459; LEACH BE, 1968, J AM CHEM SOC, V90, P2504, DOI 10.1021/ja01012a011; LEVIN MD, 1980, J AM CHEM SOC, V102, P1452, DOI 10.1021/ja00524a055; LEVY MJ, 1988, BIOCHEMISTRY-US, V27, P2647, DOI 10.1021/bi00408a002; MCGOWAN DA, 1977, J AM CHEM SOC, V99, P8078, DOI 10.1021/ja00466a066; POVIRK LF, 1979, BIOCHEMISTRY-US, V18, P96, DOI 10.1021/bi00568a015; SAKAI TT, 1983, BIOCHIM BIOPHYS ACTA, V758, P176, DOI 10.1016/0304-4165(83)90299-4; Sambrook J, 1989, MOL CLONING LABORATO; SCHULTZ PG, 1983, J AM CHEM SOC, V105, P7748, DOI 10.1021/ja00364a049; SHIPLEY JB, 1988, CHEM RES TOXICOL, V1, P25, DOI 10.1021/tx00001a004; SHIPLEY JB, 1986, THESIS U VIRGINIA; Slick B. I., 1985, BLEOMYCIN CHEMOTHERA; SLUKA JP, 1987, SCIENCE, V238, P1129, DOI 10.1126/science.3120311; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; SUGIURA Y, 1982, J BIOL CHEM, V257, P544; SUGIYAMA H, 1985, J AM CHEM SOC, V107, P7765, DOI 10.1021/ja00311a092; SUGIYAMA H, 1986, J AM CHEM SOC, V108, P352; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TAKESHITA M, 1978, P NATL ACAD SCI USA, V75, P5983, DOI 10.1073/pnas.75.12.5983; Tanaka W., 1977, J ANTIBIOT, V30, pS; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; TULLIUS TD, 1985, SCIENCE, V230, P679, DOI 10.1126/science.2996145; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; WU JC, 1983, J BIOL CHEM, V258, P4694; YOUNGQUIST RS, 1985, P NATL ACAD SCI USA, V82, P2565, DOI 10.1073/pnas.82.9.2565; ZEE-CHENG K Y, 1970, Journal of Heterocyclic Chemistry, V7, P1439	49	65	66	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10899	10904						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511612				2022-12-27	WOS:A1994NF01700104
J	ANEL, A; RICHIERI, GV; KLEINFELD, AM				ANEL, A; RICHIERI, GV; KLEINFELD, AM			A TYROSINE PHOSPHORYLATION REQUIREMENT FOR CYTOTOXIC T-LYMPHOCYTE DEGRANULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL ANTIGEN RECEPTOR; FREE FATTY-ACIDS; MEDIATED LYSIS; ACTIVATION; EXOCYTOSIS; DIACYLGLYCEROL; STIMULATION; PHOSPHATASE; GRANULES	Phorbol myristate acetate (PMA) plus ionomycin induces the tyrosine phosphorylation of several cytotoxic T lymphocyte (CTL) substrates, including one with an apparent molecular weight of 100,000 (pp100) in cloned murine CTL. cis-Unsaturated fatty acids and low concentrations of phenylarsine oxide specifically inhibit the tyrosine phosphorylation of pp100. Genistein also inhibits tyrosine phosphorylation of pp100, but not with the same specificity as cis-fatty acids or low concentrations of phenylarsine oxide. Degranulation triggered by PMA plus ionomycin is inhibited by cis-fatty acids, low concentrations of phenylarsine oxide, and genistein, under the same conditions that these agents inhibit tyrosine phosphorylation of pp100. Depleting CTL of protein kinase C (PKC) activity by prolonged exposure to PMA eliminates the increase in tyrosine phosphorylation when challenged by PMA plus ionomycin, but not when these PKC-depleted CTL are activated by cognate target cells, immobilized anti-T cell receptor (TCR) antibodies, or concanavalin A. Tyrosine phosphorylation of pp100 triggered by TCR engagement in PKC-depleted cells is inhibited by cis-fatty acids and phenylarsine oxide, indicating that the inhibitory mechanism of the tyrosine phosphorylation of pp100 is independent of PKC. Furthermore, because all three tyrosine phosphorylation inhibitors are unlikely to inhibit PKC, these results suggest that, in addition to PKC activation and a rise in intracellular Ca2+, CTL degranulation requires the tyrosine phosphorylation of a CTL substrate(s), in addition to phospholipase C, and the present results are consistent with pp100 as that substrate. Taken together with previous studies, these results suggest that tyrosine phosphorylation of pp100 may play a central role in CTL function.	MED BIOL INST,DIV MEMBRANE BIOL,11077 N TORREY PINES RD,LA JOLLA,CA 92037				Anel, Alberto/Z-3068-2019					ANEL A, 1993, BIOCHEMISTRY-US, V32, P530, DOI 10.1021/bi00053a018; ANEL A, 1993, J BIOL CHEM, V268, P17578; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; BOYER C, 1991, EUR J IMMUNOL, V21, P1623, DOI 10.1002/eji.1830210707; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CASNELLIE JE, 1986, J BIOL CHEM, V261, P4921; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; FLETCHER MC, 1993, J BIOL CHEM, V268, P23697; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAVERSTICK DM, 1991, J IMMUNOL, V146, P3306; HENGEL H, 1991, J IMMUNOL, V147, P1115; HENKART PA, 1984, J EXP MED, V160, P75, DOI 10.1084/jem.160.1.75; HSI ED, 1989, J BIOL CHEM, V264, P10836; JUNE CH, 1990, J IMMUNOL, V144, P1591; KALDJIAN E, 1988, FASEB J, V2, P2801, DOI 10.1096/fasebj.2.12.3261700; KANAKURA Y, 1991, J BIOL CHEM, V266, P490; KHAN WA, 1992, J BIOL CHEM, V267, P3605; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KLEINFELD AM, 1993, CYTOTOXIC CELLS GENE, P321; KOLBER MA, 1989, J IMMUNOL, V143, P1461; KRAHENBUHL O, 1991, IMMUNOL TODAY, V12, P399, DOI 10.1016/0167-5699(91)90139-K; LANCKI DW, 1989, J IMMUNOL, V142, P416; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARTH JD, 1989, J IMMUNOL, V142, P2430; MESCHER MF, 1992, J IMMUNOL, V149, P2402; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OROURKE AM, 1992, NATURE, V358, P253, DOI 10.1038/358253a0; OSTERGAARD HL, 1989, J IMMUNOL, V143, P2120; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; PODACK ER, 1985, P NATL ACAD SCI USA, V82, P8629, DOI 10.1073/pnas.82.24.8629; RATNER A, 1991, J IMMUNOL, V147, P55; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; RICHIERI GV, 1993, BIOCHEMISTRY-US, V32, P7574, DOI 10.1021/bi00080a032; RICHIERI GV, 1990, J IMMUNOL, V145, P1074; RICHIERI GV, 1989, J IMMUNOL, V143, P2302; RICHIERI GV, 1990, J IMMUNOL, V144, P671; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; SPECTOR AA, 1975, J LIPID RES, V16, P165; STAERZ UD, 1985, J IMMUNOL, V134, P3994; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; TAKAYAMA H, 1987, J EXP MED, V166, P725, DOI 10.1084/jem.166.3.725; YOSHIDA K, 1992, P NATL ACAD SCI USA, V89, P6443, DOI 10.1073/pnas.89.14.6443	48	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9506	9513						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511589				2022-12-27	WOS:A1994NE05300020
J	GRUBE, BJ; COCHRANE, CG; YE, RD; GREEN, CE; MCPHAIL, ME; ULEVITCH, RJ; TOBIAS, PS				GRUBE, BJ; COCHRANE, CG; YE, RD; GREEN, CE; MCPHAIL, ME; ULEVITCH, RJ; TOBIAS, PS			LIPOPOLYSACCHARIDE-BINDING PROTEIN EXPRESSION IN PRIMARY HUMAN HEPATOCYTES AND HEPG2 HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE PROTEINS; STIMULATING FACTORS; GENE-EXPRESSION; PLASMA-PROTEINS; TUMOR NECROSIS; LPS; INTERLEUKIN-1; PATHOGENESIS; INFLAMMATION; RECOGNITION	Lipopolysaccharide (LPS)-binding protein (LBP) is a normal plasma protein and an acute phase reactant important for host responses to Gram-negative bacteria and LPS. LBP forms high affinity complexes with LPS which bind to CD14, a monocyte surface protein, to initiate the release of inflammatory mediators. We found that human primary hepatocytes synthesize LBP and that the synthesis is up-regulated by interleukin (IL)-6. To examine this phenomenon in more detail, we evaluated the capacity of IL-6, IL-1, and tumor necrosis factor to induce LBP synthesis in HepG2 cells in the presence or absence of dexamethasone. IL-6 induced LBP synthesis. Dexamethasone, IL-1, and tumor necrosis factor had a synergistic effect when combined with IL-6, but demonstrated minimal effect independently. LBP biosynthesis was evaluated by immunoprecipitation of S-35-labeled LBP from HepG2 supernatants, measurement of steady-state LBP mRNA levels, and analysis of LBP-dependent LPS binding to CD14 positive cells. An S-35-labeled, 60-kDa protein was immunoprecipitated with anti-LBP antibody from IL-6-stimulated HepG2 cell supernatants. Northern blot analysis of cellular RNA revealed an increase in LBP mRNA in IL-6-stimulated cells. CD14 expressing cells bound fluoresceinated LPS in the presence of supernatants from HepG2 cells treated with IL-6. These data provide the first information about specific cytokine and dexamethasone regulation of LBP expression in HepG2 cells. LBP behaves like a Type 1 acute phase protein.	SRI INT, MENLO PK, CA 94025 USA	SRI International	GRUBE, BJ (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Ye, Richard/O-5223-2016; Ye, Richard/ABF-2413-2020	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL023584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-23584] Funding Source: Medline; NIAID NIH HHS [AI-15136] Funding Source: Medline; NIGMS NIH HHS [GM-37696] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen Katherine L., 1993, P262; BAUMANN H, 1987, J IMMUNOL, V139, P4122; BAUMANN H, 1989, J IMMUNOL, V143, P1163; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BAUMANN H, 1987, J BIOL CHEM, V262, P9756; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; DARLINGTON GJ, 1987, IN VITRO CELL DEV B, V23, P349; DINARELLO CA, 1984, NEW ENGL J MED, V311, P1413; DUNN JCY, 1989, FASEB J, V3, P174, DOI 10.1096/fasebj.3.2.2914628; EY PL, 1986, METHOD ENZYMOL, V121, P497; GALANOS C, 1985, EUR J BIOCHEM, V148, P1, DOI 10.1111/j.1432-1033.1985.tb08798.x; GELLER DA, 1993, ARCH SURG-CHICAGO, V128, P22; GREEN CE, 1983, ANAL BIOCHEM, V129, P269, DOI 10.1016/0003-2697(83)90550-X; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LETURCQ D, 1992, J CELL BIOCHEM, V16, P161; MACKIEWICZ A, 1991, J IMMUNOL, V146, P3032; MACKIEWICZ A, 1990, P NATL ACAD SCI USA, V87, P1491, DOI 10.1073/pnas.87.4.1491; MAGIELSKAZERO D, 1988, BIOCHEM INT, V17, P17; MAHER JJ, 1988, HEPATOLOGY, V8, P1162, DOI 10.1002/hep.1840080534; MATHISON JC, 1992, J IMMUNOL, V149, P200; MORRISON DC, 1978, AM J PATHOL, V93, P526; MUNRO H. N., 1966, METHOD BIOCHEM ANAL, V14, P113; PERLMUTTER DH, 1986, J CLIN INVEST, V78, P1349, DOI 10.1172/JCI112721; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; RAMADORI G, 1990, PATHOBIOLOGY, V58, P89, DOI 10.1159/000163569; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; SCHNEIDER WC, 1957, METHOD ENZYMOL, V3, P680, DOI 10.1016/S0076-6879(57)03442-4; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SEHGAL PB, 1990, MOL BIOL MED, V7, P117; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; Tobias PS, 1992, J CELL BIOCHEM, V16C, P151; Ulevitch R J, 1989, Prog Clin Biol Res, V299, P193; WRIGHT SD, 1989, J EXP MED, V170, P1231, DOI 10.1084/jem.170.4.1231; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	38	96	100	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8477	8482						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510687				2022-12-27	WOS:A1994NB40900096
J	BUTTON, D; ROTHMAN, A; BONGIORNO, C; KUPPERMAN, E; WOLNER, B; TAYLOR, P				BUTTON, D; ROTHMAN, A; BONGIORNO, C; KUPPERMAN, E; WOLNER, B; TAYLOR, P			AGONIST-SELECTIVE REGULATION OF POLYPHOSPHOINOSITIDE METABOLISM IN PULMONARY-ARTERY SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; EPIDERMAL GROWTH-FACTOR; MIDDLE T-ANTIGEN; SIGNAL TRANSDUCTION; TYROSINE KINASE; HUMAN PLATELETS; ANGIOTENSIN-II; ACINAR-CELLS; C-FOS; RECEPTOR	Using a rat pulmonary artery smooth muscle cell line (PAC1), detailed analysis of polyphosphoinositide (PPI) metabolism reveals receptor type-selective patterns in the formation of inositol phosphates and and 3-hydroxy-phosphorylated PPIs. Responses to several agonists that stimulate hypertrophy or proliferation were examined, and distinct categories of response profile were observed. Thrombin and angiotensin II stimulated the hydrolysis of phosphatidylinositol (PI) 4,5-bisphosphate and the formation of several cytosolic species of inositol phosphates without the activation of PI 3-hydroxykinase. The response to thrombin was distinctive because a very large production of inositol 1,4-bisphosphate was accompanied by hydrolysis of PI 4 phosphate. The response to platelet-derived growth factor (PDGF) was distinguished by the production of the PI 3-hydroxykinase product, PI 3,4,5-trisphosphate, and the appearance of PI 3-hydroxykinase activity in immunoprecipitates. PDGF treatment of PAC1 cultures did not produce accumulation of detectable amounts of inositol 1,4,5-trisphosphate, although a small sustained elevation in the level of inositol monophosphate and a gradual accumulation of inositol 1,3,4 trisphosphate were observed. Characterization of these distinctive responses permitted us to correlate agonist-regulated PPI metabolism with induction of immediate-early genes and stimulation of hypertrophy or proliferation of PAC1 cultures (Rothman, A., Wolner, B., Button, D., and Taylor, P. (1994) J. Biol. Chem. 269, 6399-6404). Thrombin-stimulated PPI turnover and the production of a high level of inositol bisphosphate may be early signals linked to the induction of fosB and PAC1 cell hypertrophy, whereas the activation of PI 5-hydroxykinase and the accumulation of PI 3,4,5-trisphosphate in response to PDGF appear to be associated with mitogenesis.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PEDIAT, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			Wolner, Branden/A-9615-2015	Wolner, Branden/0000-0003-0021-2073	NHLBI NIH HHS [HL 35018] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL035018] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BALLA T, 1988, J BIOL CHEM, V263, P4083; BATTY IH, 1989, BIOCHEM J, V260, P237, DOI 10.1042/bj2600237; BERK BC, 1989, J CLIN INVEST, V83, P822, DOI 10.1172/JCI113964; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BROWN DM, 1966, BIOCHIM BIOPHYS ACTA, V125, P413, DOI 10.1016/0005-2760(66)90029-4; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER AN, 1992, J BIOL CHEM, V267, P14563; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GEISTERFER AAT, 1989, HYPERTENSION, V14, P413, DOI 10.1161/01.HYP.14.4.413; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HUGHES AR, 1989, J BIOL CHEM, V264, P9400; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; MILLER ES, 1990, BIOCHEM BIOPH RES CO, V173, P289, DOI 10.1016/S0006-291X(05)81055-1; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; POYNER DR, 1993, BIOCHEM J, V290, P901, DOI 10.1042/bj2900901; POYNER DR, 1990, BIOCHEM J, V271, P605, DOI 10.1042/bj2710605; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; ROTHMAN A, 1994, J BIOL CHEM, V269, P6399; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SANCHEZBUENO A, 1993, BIOCHEM J, V291, P163, DOI 10.1042/bj2910163; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8	38	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6390	6398						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509802				2022-12-27	WOS:A1994MZ50300023
J	KOO, PH; QIU, WS				KOO, PH; QIU, WS			MONOAMINE-ACTIVATED ALPHA(2)-MACROGLOBULIN BINDS TRK RECEPTOR AND INHIBITS NERVE GROWTH FACTOR-STIMULATED TRK PHOSPHORYLATION AND SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PC12 PHEOCHROMOCYTOMA CELLS; PHOSPHOLIPASE-C-GAMMA; HUMAN NGF RECEPTOR; PROTEIN-KINASE; ALPHA-2-MACROGLOBULIN RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; ALPHA-MACROGLOBULIN; PROTOONCOGENE PRODUCT; MOLECULAR-CLONING	Monoamine-activated alpha(2)-macroglobulin (alpha(2)M) has been shown to inhibit beta-nerve growth factor (NGF)-promoted neurite outgrowth and the survival of embryonic sensory and forebrain neurons, whereas normal alpha(2)M has little or no such activity. The objective of this study is to elucidate the mechanism of inhibition by monoamine-activated alpha(2)M. Methylamine-activated alpha(2)M (MA-alpha(2)M) and serotonin-activated alpha(2)M (5HT-alpha(2)M) dose dependently inhibit NGF-promoted neurite outgrowth of the pheochromocytoma PC12 cell and its subline PC12(6- 24) which overexpresses human trk protooncogene product, but have no effect on their viability, and this inhibition can be blocked by high concentrations of NGF. The binding of MA-alpha(2)M to trk, which is a part of high-affinity NGF receptor, was studied with PC12(6-24) cells and NIH-3T3 fibroblasts expressing trk (trk-3T3). In each case MA-alpha(2)M readily forms stable complexes with trk in vivo, whereas normal alpha(2)M does not. Both 5HT-alpha(2)M and MA-alpha(2)M also dose dependently block NGF-promoted autophosphorylation of trk in vivo, whereas normal alpha(2)M and plasmin-reacted alpha(2)M are inactive or much less active. MA-alpha(2)M also blocks NGF-promoted incorporation of P-32 from [P-32]ATP into trk receptors in vitro, Neither MA-alpha(2)M, 5HT-alpha(2)M, nor normal alpha(2)M, however, blocks either platelet-derived growth factor-stimulated or epidermal growth factor-stimulated tyrosine phosphorylation of the respective receptors. Tyrosine phosphorylation of two of the intracellular substrates, phospholipase C-gamma 1 and extracellular signal-regulated kinase-2, in the NGF-promoted pathways is also dose dependently blocked by MA-alpha(2)M. However, by comparison MA-alpha(2)M is more effective in inhibiting the activation of phospholipase C-gamma 1 than trk. We conclude that monoamine-activated alpha(2)M may block neurite outgrowth and neuronal survival by its specific binding to NGF receptors, thus inhibiting the NGF-promoted activation of intracellular second messenger pathways.			KOO, PH (corresponding author), NE OHIO UNIV,COLL MED,DEPT MICROBIOL & IMMUNOL,POB 95,ROOTSTOWN,OH 44272, USA.				NINDS NIH HHS [NS30698] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIN JG, 1993, NEUROTROPHIC FACTORS, P129; Altin JG, 1991, GROWTH FACTORS, V4, P145, DOI 10.3109/08977199109000265; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BLENIS J, 1986, EMBO J, V5, P3441, DOI 10.1002/j.1460-2075.1986.tb04667.x; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CARTER AN, 1992, J BIOL CHEM, V267, P14563; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; GARTON MJ, 1991, J NEUROL SCI, V104, P74, DOI 10.1016/0022-510X(91)90218-V; GLIEMANN J, 1986, BIOCHIM BIOPHYS ACTA, V885, P49, DOI 10.1016/0167-4889(86)90037-6; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1980, ANNU REV NEUROSCI, V3, P353, DOI 10.1146/annurev.ne.03.030180.002033; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1990, J NEUROSCI, V10, P1479; HELDIN CH, 1983, J BIOL CHEM, V258, P54; HELGOUA S, 1991, CURR TOP MICROBIOL I, V165, P119; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HUDSON NW, 1982, BIOCHIM BIOPHYS ACTA, V704, P290, DOI 10.1016/0167-4838(82)90159-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAPLAN J, 1979, J BIOL CHEM, V254, P7323; KEMP BE, 1988, METHOD ENZYMOL, V159, P173; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNUSEL B, 1992, NEUROREPORT, V3, P885; KOIZUMI S, 1988, J NEUROSCI, V8, P715; KOO PH, 1992, J NEUROSCI RES, V31, P678, DOI 10.1002/jnr.490310412; KOO PH, 1989, J NEUROSCI RES, V22, P247, DOI 10.1002/jnr.490220304; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEVI-MONTALCINI RITA, 1966, HARVEY LECT, V60, P217; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LIEBL DJ, 1993, J NEUROSCI RES, V35, P170, DOI 10.1002/jnr.490350207; LIM RW, 1987, ONCOGENE, V1, P263; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LONGO FM, 1990, CELL REGUL, V1, P189, DOI 10.1091/mbc.1.2.189; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MUROYA K, 1992, BIOCHIM BIOPHYS ACTA, V1135, P353, DOI 10.1016/0167-4889(92)90243-5; MUTOH T, 1988, J BIOL CHEM, V263, P15853; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SOTTRUPJENSEN L, 1981, FEBS LETT, V128, P127, DOI 10.1016/0014-5793(81)81097-6; SOTTRUPJENSEN L, 1981, FEBS LETT, V128, P123, DOI 10.1016/0014-5793(81)81096-4; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; STRAIGHT DL, 1988, BIOCHEMISTRY-US, V27, P2885, DOI 10.1021/bi00408a033; STRAUSS S, 1992, LAB INVEST, V66, P223; SWENSON RP, 1979, P NATL ACAD SCI USA, V76, P4313, DOI 10.1073/pnas.76.9.4313; TSAO H, 1990, J BIOL CHEM, V265, P15471; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANLEUVEN F, 1979, J BIOL CHEM, V254, P5155; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; VOLONTE C, 1989, J CELL BIOL, V109, P2395, DOI 10.1083/jcb.109.5.2395; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WRANN MM, 1979, J BIOL CHEM, V254, P8083	70	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5369	5376						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508936				2022-12-27	WOS:A1994MX57100100
J	HASSE, A; SCHULZ, WA				HASSE, A; SCHULZ, WA			ENHANCEMENT OF REPORTER GENE DE-NOVO METHYLATION BY DNA FRAGMENTS FROM THE ALPHA-FETOPROTEIN CONTROL REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERATOCARCINOMA CELLS; CPG ISLANDS; METHYLTRANSFERASE; PATTERNS; PROMOTERS; INVITRO; CLONING	The 5'-upstream region of the rat a-fetoprotein (AFP) gene strongly increased de novo methylation of an adjacent chloramphenicol acetyltransferase (CAT) gene upon transfection into F9 mouse embryonal carcinoma cells. The same effect was exerted by a distal 775-base pair (bp) fragment and by 300- and 1-kb fragments preceding the transcriptional start site, but not by other parts of the control region. Further division of the larger, strongly active fragments resulted in a gradual decrease of methylation and clonal variation in the methylation patterns. The effect of the 775-bp fragment did not depend on its orientation. It was ablated by insertion of the mouse metallothionein I promoter between the AFP gene fragment and the CAT gene, but not by its insertion upstream of the AFP gene fragment. Two fragments from the AFP control region increasing methylation contained B1 and B2 small interspersed repetitive elements, respectively. B1 and B2 sequences of different origin also acted strongly to increase methylation. These findings support the idea that mammalian genes contain specific sequences involved in regulating their methylation. The effects of these sequences appear to be exerted in cis, to be dependent on proximity, but not on orientation, and to require an optimal size of 500-700 bp. Small retrotransposon sequences within such elements may be particularly effective in attracting de novo methylation.	HEINRICH HEINE UNIV, INST PHYS CHEM 1, POSTFACH 101007, D-40001 DUSSELDORF, GERMANY	Heinrich Heine University Dusseldorf			Schulz, Wolfgang A./A-6523-2008	Schulz, Wolfgang/0000-0002-2196-463X				ALTON NK, 1979, NATURE, V282, P864, DOI 10.1038/282864a0; BESTOR T, 1987, NUCLEIC ACIDS RES, V15, P3835, DOI 10.1093/nar/15.9.3835; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, GENET ANAL-BIOMOL E, V9, P48, DOI 10.1016/1050-3862(92)90030-9; BOLDEN AH, 1986, PROG NUCLEIC ACID RE, V33, P231, DOI 10.1016/S0079-6603(08)60025-2; CAROTTI D, 1986, BIOCHIM BIOPHYS ACTA, V866, P135, DOI 10.1016/0167-4781(86)90110-7; DOERFLER W, 1991, BIOL CHEM H-S, V372, P557; FRANK D, 1991, NATURE, V351, P239, DOI 10.1038/351239a0; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; HASSE A, 1992, BIOCHIM BIOPHYS ACTA, V1131, P16, DOI 10.1016/0167-4781(92)90092-E; Hasties ND, 1989, GENETIC VARIANTS STR, P559; JAHNER D, 1985, DNA METHYLATION BIOC, P189; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MEUNIERROTIVAL M, 1982, P NATL ACAD SCI-BIOL, V79, P355, DOI 10.1073/pnas.79.2.355; MONK M, 1987, DEVELOPMENT, V99, P371; MUGLIA L, 1986, P NATL ACAD SCI USA, V83, P7653, DOI 10.1073/pnas.83.20.7653; MUMMANENI P, 1993, J BIOL CHEM, V268, P552; NIWA O, 1985, MOL CELL BIOL, V5, P2325, DOI 10.1128/MCB.5.9.2325; OREND G, 1991, J VIROL, V65, P4301, DOI 10.1128/JVI.65.8.4301-4308.1991; Razin A., 1993, Experientia Supplementum (Basel), V64, P343; RAZIN A, 1984, P NATL ACAD SCI-BIOL, V81, P2275, DOI 10.1073/pnas.81.8.2275; SCHULZ WA, 1989, BIOCHIM BIOPHYS ACTA, V1013, P125, DOI 10.1016/0167-4889(89)90040-2; SHEMER R, 1991, P NATL ACAD SCI USA, V88, P11300, DOI 10.1073/pnas.88.24.11300; SHEMER R, 1991, J BIOL CHEM, V266, P23676; SMITH SS, 1991, J MOL BIOL, V217, P39, DOI 10.1016/0022-2836(91)90609-A; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; SZYF M, 1990, MOL CELL BIOL, V10, P4396, DOI 10.1128/MCB.10.8.4396; SZYF M, 1991, BIOCHEM CELL BIOL, V69, P764, DOI 10.1139/o91-117; TURKER MS, 1991, SOMAT CELL MOLEC GEN, V17, P151, DOI 10.1007/BF01232972; WEN P, 1991, DNA CELL BIOL, V10, P525, DOI 10.1089/dna.1991.10.525	31	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1821	1826						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507485				2022-12-27	WOS:A1994MR98800043
J	BHATHAL, HS; ZAMROD, Z; TOBARU, T; STUMPH, WE				BHATHAL, HS; ZAMROD, Z; TOBARU, T; STUMPH, WE			IDENTIFICATION OF PROXIMAL SEQUENCE ELEMENT NUCLEOTIDES CONTRIBUTING TO THE DIFFERENTIAL EXPRESSION OF VARIANT-U4 SMALL NUCLEAR-RNA GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; SPH MOTIFS; U6 GENES; ENHANCER; OCTAMER; REQUIREMENTS; PROMOTER; PROTEIN	The two U4 genes in the chicken genome code for distinct sequence variants of U4 small nuclear RNA that are differentially expressed during development. Whereas U4B RNA is constitutively expressed, U4X RNA is specifically down regulated relative to U4B in a tissue-specific manner during development, To investigate mechanisms controlling the differential expression of the U4B and U4X genes, chimeric U4 genes were constructed and their transcriptional activities assayed by injection into Xenopus oocytes or by transfection of CV-1 cells. The proximal regulatory region of the U4B gene and the enhancers of both the U4B and U4X genes functioned efficiently in each expression system, However, the proximal region of the U4X gene was inactive. To localize and identify the responsible nucleotides, reciprocal point mutations were introduced into the U4X and U4B proximal regulatory regions, The results indicate that the U4X gene contains a suboptimal proximal sequence element, and that this results primarily from the identities of the nucleotides at positions -61 and -57 relative to the transcription start site.	SAN DIEGO STATE UNIV,DEPT CHEM,SAN DIEGO,CA 92182; SAN DIEGO STATE UNIV,INST MOLEC BIOL,SAN DIEGO,CA 92182	California State University System; San Diego State University; California State University System; San Diego State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033512] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33512] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACH RA, 1991, NUCLEIC ACIDS RES, V19, P4209, DOI 10.1093/nar/19.15.4209; ARES M, 1987, GENE DEV, V1, P808, DOI 10.1101/gad.1.8.808; CACERES JF, 1992, NUCLEIC ACIDS RES, V20, P4247, DOI 10.1093/nar/20.16.4247; CHEUNG CH, 1993, NUCLEIC ACIDS RES, V21, P281, DOI 10.1093/nar/21.2.281; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; HOFFMAN ML, 1986, MOL CELL BIOL, V6, P3910, DOI 10.1128/MCB.6.11.3910; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; KORF GM, 1988, MOL CELL BIOL, V8, P5566, DOI 10.1128/MCB.8.12.5566; MCNAMARA KJ, 1990, J BIOL CHEM, V265, P9728; MCNAMARA KJ, 1989, NUCLEIC ACIDS RES, V17, P6748, DOI 10.1093/nar/17.16.6748; Miyake Jon H., 1992, Gene Expression, V2, P161; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; PARRY HD, 1989, TRENDS BIOCHEM SCI, V14, P15, DOI 10.1016/0968-0004(89)90083-2; REDDY R, 1991, PROGR MOL SUBCELLULA, P1; ROEBUCK KA, 1987, MOL CELL BIOL, V7, P4185, DOI 10.1128/MCB.7.12.4185; ROEBUCK KA, 1990, MOL CELL BIOL, V10, P341, DOI 10.1128/MCB.10.1.341; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; Stefanovic Branko, 1994, Gene Expression, V4, P1; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WANANDI I, 1993, J BIOL CHEM, V268, P6629; WELLER P, 1988, GENE DEV, V2, P1389, DOI 10.1101/gad.2.11.1389; YOON JB, 1995, MOL CELL BIOL, V15, P2019; ZAMROD Z, 1993, MOL CELL BIOL, V13, P5918, DOI 10.1128/MCB.13.9.5918; ZAMROD Z, 1990, NUCLEIC ACIDS RES, V18, P7323, DOI 10.1093/nar/18.24.7323	26	1	1	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27629	27633		10.1074/jbc.270.46.27629	http://dx.doi.org/10.1074/jbc.270.46.27629			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499227	hybrid			2022-12-27	WOS:A1995TE73600038
J	GERECKE, DR; WAGMAN, DW; CHAMPLIAUD, MF; BURGESON, RE				GERECKE, DR; WAGMAN, DW; CHAMPLIAUD, MF; BURGESON, RE			THE COMPLETE PRIMARY STRUCTURE FOR A NOVEL LAMININ CHAIN, THE LAMININ-B1K CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; A-CHAIN; CLEAVAGE SITES; CELL-ADHESION; HEART LAMININ; PROTEIN; IDENTIFICATION; DOMAINS; VARIANT; SIGNAL	We have isolated overlapping cDNA clones encoding the entire kalinin B1 chain. The predicted sequences are consistent with the models proposed for the structure of this chain as a truncated homologue of the B1 chain of laminin. The percent sequence homology with other laminin B1 chains is relatively low, suggesting that this chain is functionally different. The sequence of the VI domain of this chain is consistent with the possibility that it serves to bind specifically the kalinin A chain and subsequently covalently binds to it. In keeping with the accepted nomenclature for the laminin chains we name this novel polypeptide the laminin B1k chain.	MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BLDG 149,13TH ST,BOSTON,MA 02129; HARVARD UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02129; HARVARD UNIV,SCH MED,DEPT DERMATOL,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NIAMS NIH HHS [AR35689, AR07098] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035689, T32AR007098, R37AR035689] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ANDREWS DW, 1991, TECHNIQUES PROTEIN C, V2, P75; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER AR, 1981, EUR J BIOCHEM, V119, P189, DOI 10.1111/j.1432-1033.1981.tb05593.x; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ENGEL J, 1991, BIOCHEM SOC T, V19, P839, DOI 10.1042/bst0190839; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; ENGVALL E, 1993, KIDNEY INT, V43, P2, DOI 10.1038/ki.1993.2; FOIDART JM, 1980, LAB INVEST, V42, P336; Fourney R.M., 1988, FOCUS, V10, P5; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; HAAPARANTA T, 1991, MATRIX, V11, P151, DOI 10.1016/S0934-8832(11)80153-8; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; KLEINMAN HK, 1989, ARCH BIOCHEM BIOPHYS, V272, P39, DOI 10.1016/0003-9861(89)90192-6; LUNSTRUM GP, 1986, J BIOL CHEM, V261, P9042; MARINKOVICH MP, 1993, LAB INVEST, V69, P295; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; OREAR JJ, 1992, J BIOL CHEM, V267, P20555; PAULSSON M, 1991, J BIOL CHEM, V266, P17545; PAULSSON M, 1989, J BIOL CHEM, V264, P18726; PAULSSON M, 1985, EMBO J, V4, P309, DOI 10.1002/j.1460-2075.1985.tb03630.x; PETERS BP, 1985, J BIOL CHEM, V260, P4732; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TOKIDA Y, 1990, J BIOL CHEM, V265, P18123; TOMITA M, 1978, BIOCHEMISTRY-US, V17, P4756, DOI 10.1021/bi00615a025; VAILLY J, 1994, EUR J BIOCHEM, V219, P209, DOI 10.1111/j.1432-1033.1994.tb19932.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WILKE MS, 1991, J INVEST DERMATOL, V97, P141, DOI 10.1111/1523-1747.ep12479311; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636	39	124	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11073	11080						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512558				2022-12-27	WOS:A1994NF96600019
J	SCHWARTZ, MA; DENNINGHOFF, K				SCHWARTZ, MA; DENNINGHOFF, K			ALPHA(V)-INTEGRINS MEDIATE THE RISE IN INTRACELLULAR CALCIUM IN ENDOTHELIAL-CELLS ON FIBRONECTIN EVEN THOUGH THEY PLAY A MINOR ROLE IN ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; VONWILLEBRAND-FACTOR; RECEPTOR; INTEGRIN; VITRONECTIN; ATTACHMENT; IDENTIFICATION; SURFACE; SUBUNIT; INTEGRIN-ALPHA-V-BETA-5	We have investigated which integrins mediate the elevation of intracellular calcium ([Ca2+]i) triggered by spreading of endothelial cells on fibronectin (FN). Specific anti-integrin monoclonal antibodies immobilized on glass surfaces were used as agonists to trigger cell spreading. These experiments demonstrated that an antibody to alpha(v), could induce the rise in [Ca2+]i, whereas two antibodies to alpha5beta1 were inactive, despite their ability to induce cell spreading and elevation of intracellular pH. Antibodies in solution were then used as agonists to block association of specific integrins with FN. These experiments also showed that alpha(v) integrin(s) but not alpha5beta1 mediated the rise in [Ca2+]i in cells spreading on FN. Adhesion assays in the presence of function-blocking anti-integrin antibodies and affinity chromatography on FN columns of surface-labeled cell extracts were carried out to characterize the integrins that bind to FN. Both methods showed that alpha(v) integrin(s) and alpha5beta1 participate in FN binding, however, the contribution from alpha(v) integrin(s) was much less than that of alpha5beta1. These results demonstrate that two receptors for FN on the same cells can trigger distinct intracellular signaling pathways and, furthermore, that an integrin whose contribution to adhesion is barely detectable can have a major effect on cellular responses. The results also suggest that the specificity for activation of the calcium signaling pathway resides primarily in the integrin alpha subunit.			SCHWARTZ, MA (corresponding author), SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA.			schwartz, martin/0000-0002-2071-1243	NHLBI NIH HHS [P01 HL48728] Funding Source: Medline; NIGMS NIH HHS [R01 GM47214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBELDA SM, 1989, J CLIN INVEST, V83, P1992, DOI 10.1172/JCI114109; BUSK M, 1992, J BIOL CHEM, V267, P5790; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; PASQUALINI R, 1993, J CELL SCI, V105, P101; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SMITH JW, 1990, J BIOL CHEM, V265, P11008; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877	29	109	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11133	11137						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512559				2022-12-27	WOS:A1994NF96600027
J	NAMBA, T; OIDA, H; SUGIMOTO, Y; KAKIZUKA, A; NEGISHI, M; ICHIKAWA, A; NARUMIYA, S				NAMBA, T; OIDA, H; SUGIMOTO, Y; KAKIZUKA, A; NEGISHI, M; ICHIKAWA, A; NARUMIYA, S			CDNA CLONING OF A MOUSE PROSTACYCLIN RECEPTOR - MULTIPLE SIGNALING PATHWAYS AND EXPRESSION IN THYMIC MEDULLA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASTOCYTOMA P-815 CELLS; PROTEIN KINASE-C; THROMBOXANE-A2 RECEPTOR; ADENYLATE-CYCLASE; PROSTAGLANDIN-E; IDENTIFICATION; PEPTIDES; BINDING; REQUIREMENTS; INACTIVATION	A functional cDNA for a mouse prostacyclin receptor was isolated from a mouse cDNA library by reverse transcription polymerase chain reaction and hybridization screening. The cDNA encodes a polypeptide of 417 amino acid residues with putative seven transmembrane domains and an calculated molecular weight of 44,722. The amino acid sequence is 30-40% identical in the transmembrane domains to those of the mouse prostaglandin (PG) E receptor subtypes and thromboxane A2 receptor. [H-3]Iloprost, a specific prostacyclin receptor radioligand, specifically bound to the membrane of Chinese hamster ovary cells permanently expressing the cDNA with K(d) of 4.6 nM. This binding was displaced with unlabeled prostanoids in the order of cicaprost > iloprost, both prostacyclin agonists > PGE1 > carbacyclin >> PGD2 almost-equal-to STA2, a thromboxane A2 agonist - PGE2 > PGF2alpha. Iloprost in a concentration-dependent fashion increased cAMP level and generated inositol phosphates in these cells, indicating that the receptor couples to multiple signal transduction pathways. Northern blot analysis revealed that the mRNA is expressed most abundantly in thymus, followed by spleen, heart, and lung. In situ hybridization of thymus showed that it is expressed exclusively in medulla and not in cortex.	KYOTO UNIV, FAC MED, DEPT PHARMACOL, KYOTO 606, JAPAN; KYOTO UNIV, FAC MED, DEPT ANESTHESIA, KYOTO 606, JAPAN; KYOTO UNIV, FAC PHARMACEUT SCI, DEPT PHYSIOL CHEM, KYOTO 606, JAPAN	Kyoto University; Kyoto University; Kyoto University			Sugimoto, Yukihiko/AAV-6470-2021	Sugimoto, Yukihiko/0000-0001-6973-932X				ARMSTRONG RA, 1989, BRIT J PHARMACOL, V97, P657, DOI 10.1111/j.1476-5381.1989.tb12001.x; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; CHANG FH, 1989, J BIOL CHEM, V264, P5352; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coleman RA, 1990, COMPREHENSIVE MED CH, P643; CORSINI A, 1987, BRIT J PHARMACOL, V90, P255, DOI 10.1111/j.1476-5381.1987.tb16847.x; DONG YJ, 1982, BRIT J PHARMACOL, V76, P149, DOI 10.1111/j.1476-5381.1982.tb09200.x; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GLASS DB, 1986, J BIOL CHEM, V261, P2987; GOLDYNE ME, 1988, PROG ALLERGY, V44, P140; HALUSHKA PV, 1989, ANNU REV PHARMACOL, V29, P213; HASHIMOTO H, 1990, PROSTAGLANDINS, V40, P491, DOI 10.1016/0090-6980(90)90111-8; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HOMODELARCHE F, 1985, J IMMUNOL, V135, P506; HONDA A, 1993, J BIOL CHEM, V268, P7759; KAMAKURA T, 1987, AGR BIOL CHEM TOKYO, V51, P3165; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWRENCE RA, 1992, BRIT J PHARMACOL, V105, P271, DOI 10.1111/j.1476-5381.1992.tb14245.x; LEIGH PJ, 1984, J BIOL CHEM, V259, P2431; MACDERMOT J, 1981, EUR J PHARMACOL, V75, P127, DOI 10.1016/0014-2999(81)90071-6; MCCORMACK JE, 1991, J IMMUNOL, V146, P239; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MONCADA S, 1982, BRIT J PHARMACOL, V76, P3, DOI 10.1111/j.1476-5381.1982.tb09186.x; MONCADA S, 1985, PHARMACOL BASIS THER, P660; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; NAMBA T, 1992, BIOCHEM BIOPH RES CO, V184, P1197, DOI 10.1016/S0006-291X(05)80009-9; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NEGISHI M, 1990, J BIOL CHEM, V265, P6182; NEGISHI M, 1991, PROSTAGLANDINS, V42, P225, DOI 10.1016/0090-6980(91)90112-S; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; SCHWANER I, 1992, BIOCHEM J, V281, P301, DOI 10.1042/bj2810301; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; TOWN MH, 1982, PROSTAG OTH LIPID M, V24, P61, DOI 10.1016/0090-6980(82)90177-0; Tsai A L, 1989, Eicosanoids, V2, P131; TSAI AL, 1989, J BIOL CHEM, V264, P61; USHIKUBI F, 1993, J EXP MED, V178, P1825, DOI 10.1084/jem.178.5.1825; VASSAUX G, 1992, J BIOL CHEM, V267, P11092; WATABE A, 1993, J BIOL CHEM, V268, P20175; WATANABE T, 1991, BLOOD, V78, P2328; WHITTLE BJR, 1979, EUR J PHARMACOL, V53, P167, DOI 10.1016/0014-2999(79)90162-6; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	43	237	246	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9986	9992						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511597				2022-12-27	WOS:A1994NE05300089
J	BUDAY, L; EGAN, SE; VICIANA, PR; CANTRELL, DA; DOWNWARD, J				BUDAY, L; EGAN, SE; VICIANA, PR; CANTRELL, DA; DOWNWARD, J			A COMPLEX OF GRB2 ADAPTER PROTEIN, SOS EXCHANGE FACTOR, AND A 36-KDA MEMBRANE-BOUND TYROSINE PHOSPHOPROTEIN IS IMPLICATED IN RAS ACTIVATION IN T-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE C-GAMMA-1; PHOSPHORYLATION; P21RAS; VAV; STIMULATION; SHC	T lymphocytes contain both Grb2, an SH2 and SH3 domain containing adaptor protein, and Sos, a guanine nucleotide exchange factor for Ras. Immunoprecipitates of Sos from the lysates of T cells contain a 36-kDa protein which is phosphorylated on tyrosine residues in response to T cell receptor/CD3 cross-linking. In vitro studies using different bacterially synthesized GST-Sos fusion proteins confirm the formation of complexes con taining p36 and the proline-rich COOH-terminal domain of Sos. The use of mutant GST-Grb2 proteins in which both SH3 domains have been mutationally inactivated shows that Grb2 binds to tyrosine phosphorylated p36 via its SH2 domain. In Jurkat cells phosphorylated p36 is localized exclusively in the particulate fraction. In addition, another SH2 domain-containing protein, p52(She) is tyrosine phosphorylated upon TCR.CD3 crosslinking and associates with a 150-kDa phosphotyrosine containing protein. Taken together these data suggest that activation of Ras in T cells via the TCR.CD3 complex might be controlled, at least in part, by mechanisms similar to those found in fibroblasts, involving in this case formation of a complex of Grb2, Sos, and a membrane-bound tyrosine phosphoprotein of molecular mass 36-kDa.	IMPERIAL CANC RES FUND,SIGNAL TRANSDUCT LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,LYMPHOCYTE ACTIVAT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; Cancer Research UK				Downward, Julian/0000-0002-2331-4729				ADAMS JM, 1992, ONCOGENE, V7, P611; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; GRAVES JD, 1992, J IMMUNOL, V148, P2417; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HSI ED, 1989, J BIOL CHEM, V264, P10836; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MALISSEN B, 1993, CURR OPIN IMMUNOL, V5, P324, DOI 10.1016/0952-7915(93)90049-X; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PERI KG, 1993, ONCOGENE, V8, P2765; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SEFTON BM, 1973, J VIROL, V11, P730, DOI 10.1128/JVI.11.5.730-735.1973; SEFTON BM, 1991, ANNU REV CELL BIOL, V7, P257, DOI 10.1146/annurev.cellbio.7.1.257; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	30	224	227	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9019	9023						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510700				2022-12-27	WOS:A1994NB41100061
J	LUBIN, IM; HEALEY, JF; SCANDELLA, D; RUNGE, MS; LOLLAR, P				LUBIN, IM; HEALEY, JF; SCANDELLA, D; RUNGE, MS; LOLLAR, P			ELIMINATION OF A MAJOR INHIBITOR EPITOPE IN FACTOR-VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PORCINE FACTOR-VIII; LIGHT CHAIN; ANTIBODIES; THROMBIN; CONSTRUCTION; ACTIVATION; FRAGMENTS; CLONING	The A2 and C2 domains of human blood coagulation factor VIII (fVIII) contain the epitopes targeted by most inhibitory allo- and autoantibodies. Human inhibitors usually display limited or no reaction with porcine fVIII. We constructed an active, recombinant hybrid human/porcine fVIII molecule by replacing the putative human fVIII A2 domain epitope with the homologous porcine sequence. The hybrid retained full activity in the presence of antibodies with specificity restricted to the human A2 epitope. In contrast, the hybrid was neutralized by an anti-C2 antibody. These findings provide a basis for fine epitope mapping and for therapy of the inhibitor patient.	EMORY UNIV, DEPT MED, ATLANTA, GA 30322 USA; AMER RED CROSS, HOLLAND LAB, ROCKVILLE, MD 20855 USA	Emory University; American Red Cross					NHLBI NIH HHS [P50-HL44336, R01-HL46215, R01-HL36094] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL044336, R01HL046215] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BOWIE EJW, 1984, DISORDERS HEMOSTASIS, P43; BRETTLER DB, 1989, ARCH INTERN MED, V149, P1381, DOI 10.1001/archinte.149.6.1381; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; FULCHER CA, 1985, P NATL ACAD SCI USA, V82, P7728, DOI 10.1073/pnas.82.22.7728; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LEYTE A, 1991, J BIOL CHEM, V266, P740; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1994, IN PRESS J CLIN INVE; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; SCANDELLA D, 1992, THROMB HAEMOSTASIS, V67, P665; SCANDELLA D, 1993, BLOOD, V82, P1767; SCANDELLA D, 1988, P NATL ACAD SCI USA, V85, P6152, DOI 10.1073/pnas.85.16.6152; SELDEN RF, 1991, CURRENT PROTOCOLS MO; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WARE J, 1992, BLOOD COAGUL FIBRIN, V3, P703, DOI 10.1097/00001721-199212000-00002	23	43	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					8639	8641						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510693				2022-12-27	WOS:A1994NB41100005
J	CONDORELLI, G; BUENO, R; SMITH, RJ				CONDORELLI, G; BUENO, R; SMITH, RJ			2 ALTERNATIVELY SPLICED FORMS OF THE HUMAN INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR HAVE DISTINCT BIOLOGICAL-ACTIVITIES AND INTERNALIZATION KINETICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUXTAMEMBRANE REGION; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; PROTEIN; EXPRESSION; MUSCLE; IRS-1	Two alternatively spliced human insulin-like growth factor I (IGF I) receptor mRNA transcripts have been described that differ by three nucleotides (CAG) starting at position 2829. This results in an amino acid coding sequence change from Thr-Gly to Arg in the extracellular portion of the receptor beta subunit. To investigate the functional significance of this sequence difference, we obtained full-length cDNAs for the CAG+ and CAG- receptor forms, transfected CHO cells, and isolated multiple clones expressing approximately equal numbers of receptors (0.57-0.73 x 10(6) receptors/cell). The two receptors bound IGF I with similar affinity (K-d similar to 1.7 nM), but the CAG- form exhibited an approximately 2-fold increase in IGF I stimulation of receptor autophosphorylation, insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation, thymidine incorporation, and IRS-1-associated phosphatidylinositol 3-kinase activity. In contrast to its higher signaling activity, the rate of receptor mediated internalization of IGF I by the CAG-receptor was decreased by 50% in comparison with the CAG+ receptor. We conclude that proteins corresponding to the two alternatively spliced human IGF I receptor transcripts are biologically active, but have distinct signaling properties. These experiments further indicate a previously unrecognized role for the extramembranous portion of the beta subunit in receptor signaling and internalization.	JOSLIN DIABET CTR,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Condorelli, Gerolama/AAC-3472-2022	Condorelli, Gerolama/0000-0003-0177-8829	NIDDK NIH HHS [DK43038] Funding Source: Medline; NIGMS NIH HHS [GM07560] Funding Source: Medline; PHS HHS [36836] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043038] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOTT AM, 1992, J BIOL CHEM, V267, P10759; ALEXANDRIDES TK, 1989, J BIOL CHEM, V264, P12922; ALEXANDRIDES TK, 1993, REGUL PEPTIDES, V48, P279, DOI 10.1016/0167-0115(93)90357-E; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GIORGINO F, 1992, ENDOCRINOLOGY, V130, P1433, DOI 10.1210/en.130.3.1433; GONCALVES E, 1993, P NATL ACAD SCI USA, V90, P5762, DOI 10.1073/pnas.90.12.5762; JUI HY, 1993, EXP CLIN ENDOCRIN S2, V101, P55; KATO H, 1993, J BIOL CHEM, V268, P2655; KELLERER M, 1990, J BIOL CHEM, V265, P9340; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUND KA, 1990, J BIOL CHEM, V265, P15713; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; MOSTHAF L, 1993, P NATL ACAD SCI USA, V90, P2633, DOI 10.1073/pnas.90.7.2633; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YEE D, 1989, J BIOL CHEM, V264, P21439	30	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8510	8516						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510688				2022-12-27	WOS:A1994NB40900102
J	SIGEL, E; BAUR, R; MALHERBE, P				SIGEL, E; BAUR, R; MALHERBE, P			PROTEIN-KINASE-C TRANSIENTLY ACTIVATES HETEROMERIC N-METHYL-D-ASPARTATE RECEPTOR CHANNELS INDEPENDENT OF THE PHOSPHORYLATABLE C-TERMINAL SPLICE DOMAIN AND OF CONSENSUS PHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-A-RECEPTOR; NMDA-RECEPTOR; RAT-BRAIN; MOLECULAR DIVERSITY; XENOPUS OOCYTES; ALPHA-SUBUNIT; MODULATION; EXPRESSION; CLONING; POTENTIATION	We have expressed dual subunit combinations of isoforms of the N-methyl-D-aspartate receptor, NR1A-NR2A and NR1C-NR2A, in Xenopus oocytes. We show that both forms of the receptor are stereospecifically activated by low concentrations (10 nM) of the phorbol ester 4-beta-phorbol 12-myristate 13-acetate, known to activate protein kinase C (PKC). The activation is transient, and, after reaching a maximum in about 10 min, it decreases rapidly in spite of the continuous presence of phorbol ester. The addition of 2 mu M oleoylacetylglycerol had similar consequences. NR1C differs from NR1A by a deletion of 37 amino acids that include four consensus phosphorylation sites for PKC in the C-terminal region. The corresponding peptide has been shown to become phosphorylated upon activation of PKC in neurons (Tingley, W. G., Roche, K. W, Thompson, A. K., and Huganir, R. L. (1993) Nature 364, 70-73). However, the activity of NR1C-NR2A receptors was stimulated 7-fold, twice the potentiation observed for NR1A-NR2A. By site-specific mutagenesis of NR1C and NR2A, we removed additional consensus PKC phosphorylation sites located between TM3 and TM4. Coexpression of these mutant subunits showed a similar response to phorbol esters as wild type receptors. Our results indicate that neither the predicted consensus phosphorylation sites between transmembrane sequences TM3 and TM4 nor the phosphorylatable C-terminal splice domain is essential for the modulation of N-methyl-D aspartate receptors by PKC.	F HOFFMANN LA ROCHE & CO LTD, PRECLIN RES, CH-4002 BASEL, SWITZERLAND	Roche Holding	SIGEL, E (corresponding author), UNIV BERN, INST PHARMAKOL, FRIEDBUHLSTR 49, CH-3010 BERN, SWITZERLAND.		Sigel, Erwin/F-7736-2015					BENARI Y, 1992, TRENDS NEUROSCI, V15, P333, DOI 10.1016/0166-2236(92)90049-E; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; KELLENBERGER S, 1992, J BIOL CHEM, V267, P25660; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; MALHERBE P, 1990, FEBS LETT, V260, P261, DOI 10.1016/0014-5793(90)80118-3; MALHERBE P, 1990, J NEUROSCI, V10, P2330; MALHERBE P, 1990, MOL BRAIN RES, V8, P199, DOI 10.1016/0169-328X(90)90017-8; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SIGEL E, 1987, J PHYSIOL-LONDON, V386, P73, DOI 10.1113/jphysiol.1987.sp016523; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; URUSHIHARA H, 1992, J BIOL CHEM, V267, P11697; VASILETS LA, 1990, J MEMBRANE BIOL, V118, P131, DOI 10.1007/BF01868470; YAMAZAKI M, 1992, FEBS LETT, V300, P39, DOI 10.1016/0014-5793(92)80160-I	27	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8204	8208						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510681				2022-12-27	WOS:A1994NB40900058
J	GAERTNER, HF; OFFORD, RE; COTTON, R; TIMMS, D; CAMBLE, R; ROSE, K				GAERTNER, HF; OFFORD, RE; COTTON, R; TIMMS, D; CAMBLE, R; ROSE, K			CHEMOENZYMATIC BACKBONE ENGINEERING OF PROTEINS - SITE-SPECIFIC INCORPORATION OF SYNTHETIC PEPTIDES THAT MIMIC THE 64-74-DISULFIDE LOOP OF GRANULOCYTE-COLONY-STIMULATING FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; FRAGMENTS; SEMISYNTHESIS; CONDENSATION; ANALOGS	We present the concept of chemo-enzymic backbone engineering of proteins. Recombinant DNA techniques are used to produce appropriate proteins that are enzymically fragmented to give the starting materials. These fragments are modified specifically at their chain termini either enzymically (coupling of a hydrazide to the C terminus) or chemically (periodate oxidation of N-terminal serine to a glyoxylyl function). The modified fragments, which need no side protection whatever, are mixed together and religate themselves spontaneously under mild conditions. The hydrazone bond thus formed can be reduced if desired, which stabilizes the linkage and enhances the flexibility of the local conformation. In this way biologically or chemically derived structures can be incorporated into the protein, and the choice of the chemical ones is free of all of the constraints of the genetic code. We believe that this combined approach gives access to constructions that could not be derived by either recombinant or chemical methods alone. We illustrate the particularity of this concept by the engineered modifications of the 64-74 disulfide loop region of human granulocyte colony stimulating factor. Analogs constructed include one which, in spite of having nonpeptide link in its backbone, has full biological activity.	ZENECA PHARMACEUT, MACCLESFIELD SK10 4TG, CHESHIRE, ENGLAND		GAERTNER, HF (corresponding author), CTR MED UNIV GENEVA, DEPT BIOCHIM MED, 1 RUE MICHEL SERVET, CH-1211 GENEVA 4, SWITZERLAND.							Balaram P., 1992, CURR OPIN STRUC BIOL, V2, P845, DOI [10.1016/0959-440X(92)90110-S, DOI 10.1016/0959-440X(92)90110-S]; BRINKLEY M, 1992, BIOCONJUGATE CHEM, V3, P2, DOI 10.1021/bc00013a001; CAMBLE R, 1991, Patent No. 459630; CARA JF, 1990, J BIOL CHEM, V265, P17820; CORRADIN G, 1974, BIOCHEM BIOPH RES CO, V61, P1400, DOI 10.1016/S0006-291X(74)80439-0; DEFILIPPIS V, 1990, INT J PEPT PROT RES, V35, P219; FISCH I, 1992, BIOCONJUGATE CHEM, V3, P147, DOI 10.1021/bc00014a009; GAERTNER HF, 1992, BIOCONJUGATE CHEM, V3, P262, DOI 10.1021/bc00015a010; GAERTNER HF, 1992, PEPTIDES 1992, P239; GEOGHEGAN KF, 1992, BIOCONJUGATE CHEM, V3, P138, DOI 10.1021/bc00014a008; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5167, DOI 10.1073/pnas.90.11.5167; Means GE, 1990, BIOCONJUGATE CHEM, V1, P2, DOI 10.1021/bc00001a001; OFFORD RE, 1990, N HORIZ TH, P253; PROUDFOOT AEI, 1989, J BIOL CHEM, V264, P8764; RIZO J, 1992, ANNU REV BIOCHEM, V61, P387, DOI 10.1146/annurev.bi.61.070192.002131; ROSE K, 1988, BIOCHEM J, V249, P83, DOI 10.1042/bj2490083; SCHNOLZER M, 1992, SCIENCE, V256, P221, DOI 10.1126/science.1566069; VITA C, 1992, EUR J BIOCHEM, V204, P631, DOI 10.1111/j.1432-1033.1992.tb16676.x; WALLACE CJA, 1991, J BIOL CHEM, V266, P21355; WINGFIELD P, 1988, BIOCHEM J, V256, P213, DOI 10.1042/bj2560213	20	39	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7224	7230						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510283				2022-12-27	WOS:A1994NA03200031
J	BOURGET, I; DIBERARDINO, W; BREITTMAYER, JP; GRENIERBROSSETTE, N; PLANAPRADES, M; BONNEFOY, JY; COUSIN, JL				BOURGET, I; DIBERARDINO, W; BREITTMAYER, JP; GRENIERBROSSETTE, N; PLANAPRADES, M; BONNEFOY, JY; COUSIN, JL			CD20 MONOCLONAL-ANTIBODIES STIMULATE EXTRACELLULAR CLEAVAGE OF THE LOW-AFFINITY RECEPTOR FOR IGE (FC-EPSILON-RII/CD23) IN EPSTEIN-BARR-TRANSFORMED B-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON RECEPTOR; HUMAN LYMPHOCYTES-B; BINDING FACTORS; SOLUBLE CD23; CD40 LIGAND; T-CELL; ACTIVATION; EXPRESSION; SURFACE; ANTIGEN	This study demonstrates that monoclonal antibodies to the B cell-specific CD20 molecule down-regulate both constitutive and interleukin-4-induced CD23 expression on Epstein-Barr-transformed B cells. This effect of CD20 antibody B1 does not take place at the transcriptional level as shown by the lack of effect on the CD23 mRNA level. Incorporation of S-35-labeled amino acids into CD23 polypeptide chain is not affected either. In cycloheximide-treated cells, B1 increases the decline of CD23 from the cell surface. The disappearance of CD23 molecule correlates with an increase of soluble CD23 fragments detected in the culture medium. Taken collectively, these results indicate that CD20 mAb B1 stimulates the cleavage of the CD23 molecule at the sur face of B cells.	FAC MED PASTEUR, INSERM, U364, IMMUNOL CELLULAIRE & MOLEC LAB, F-06107 NICE, FRANCE; FAC MED PASTEUR, INSERM, U343, UNITE RECH INTERACT CELLULAIRES IMMUNOL & IMMUNOP, F-06107 NICE, FRANCE; GLAXO INST MOLEC BIOL, CH-1228 PLAN LES OUATES, SWITZERLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; GlaxoSmithKline				BOURGET, Isabelle/0000-0001-6369-8176				ARMITAGE RJ, 1992, EUR J IMMUNOL, V22, P2071, DOI 10.1002/eji.1830220817; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BONNEFOY JY, 1987, J IMMUNOL, V138, P2970; BONNEFOY JY, 1993, EUR J IMMUNOL, V23, P969; BOURGET I, 1993, EUR J IMMUNOL, V23, P768, DOI 10.1002/eji.1830230330; CAIRNS J, 1988, EUR J IMMUNOL, V18, P349, DOI 10.1002/eji.1830180305; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK EA, 1987, J IMMUNOL, V138, P720; CLARK EA, 1985, P NATL ACAD SCI USA, V82, P1766, DOI 10.1073/pnas.82.6.1766; CONRAD DH, 1987, J IMMUNOL, V139, P2290; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; DELESPESSE G, 1991, ADV IMMUNOL, V49, P149; DELESPESSE G, 1992, IMMUNOL REV, V125, P77, DOI 10.1111/j.1600-065X.1992.tb00626.x; EINFELD DA, 1988, EMBO J, V7, P711, DOI 10.1002/j.1460-2075.1988.tb02867.x; GOLAY JT, 1985, J IMMUNOL, V135, P3795; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; GRENIERBROSSETTE N, 1992, EUR J IMMUNOL, V22, P1573, DOI 10.1002/eji.1830220634; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; HUDAK SA, 1987, P NATL ACAD SCI USA, V84, P4606, DOI 10.1073/pnas.84.13.4606; KIKUTANI H, 1986, J EXP MED, V164, P1455, DOI 10.1084/jem.164.5.1455; KINTNER C, 1981, NATURE, V294, P458, DOI 10.1038/294458a0; LETELLIER M, 1988, J IMMUNOL, V141, P2374; LETELLIER M, 1990, J EXP MED, V172, P693, DOI 10.1084/jem.172.3.693; MELCHERS F, 1985, NATURE, V317, P264, DOI 10.1038/317264a0; NAKAJIMA T, 1987, J IMMUNOL, V139, P848; SARFATI M, 1986, IMMUNOLOGY, V59, P569; SARFATI M, 1992, IMMUNOLOGY, V76, P662; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; STAMENKOVIC I, 1988, J EXP MED, V167, P1975, DOI 10.1084/jem.167.6.1975; SUEMURA M, 1986, J IMMUNOL, V137, P1214; TEDDER TF, 1988, P NATL ACAD SCI USA, V85, P208, DOI 10.1073/pnas.85.1.208; TEDDER TF, 1986, EUR J IMMUNOL, V16, P881, DOI 10.1002/eji.1830160802; TEDDER TF, 1985, J IMMUNOL, V135, P973; TEDDER TF, 1989, LEUKOCYTE TYPING, V4, P48; THORLEYLAWSON DA, 1985, J EXP MED, V162, P45, DOI 10.1084/jem.162.1.45; THORLEYLAWSON DA, 1986, J IMMUNOL, V136, P1745; WILSON BS, 1985, BLOOD, V66, P824	38	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6927	6930						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509812				2022-12-27	WOS:A1994MZ50300102
J	ZIZI, M; FORTE, M; BLACHLYDYSON, E; COLOMBINI, M				ZIZI, M; FORTE, M; BLACHLYDYSON, E; COLOMBINI, M			NADH REGULATES THE GATING OF VDAC, THE MITOCHONDRIAL OUTER-MEMBRANE CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SYNTHETIC POLYANION; PORIN; PERMEABILITY; HEXOKINASE; CLONING; PROTEIN; CDNA	Aerobic energy metabolism in cells involves the transfer of reducing equivalents from organic molecules to oxygen. NADH is important as a carrier of these reducing equivalents and as a feedback regulator of glycolysis. We report that micromolar quantities of NADH double the voltage dependence of the mitochondrial channel, VDAC, a critical pathway for the flux of metabolites between the cytoplasm and the mitochondrial spaces. In the presence of NADH, the opening and closing of this channel is more sensitive to changes in membrane potential and thus presumably better able to respond to changes in metabolic conditions. This effect was observed both on a human and two fungal forms of VDAC, indicating a highly conserved regulatory mechanism. NAD+ and other nucleotides tested failed to mimic the action of NADH. This ability of NADH to facilitate VDAC closure could be one mechanism by which glycolysis can suppress oxidative phosphorylation (Crabtree effect).	OREGON HLTH SCI UNIV,VOLLUM INST ADV BIOMED RES,PORTLAND,OR 97201	Oregon Health & Science University	ZIZI, M (corresponding author), UNIV MARYLAND,DEPT ZOOL,CELL BIOL LAB,COLL PK,MD 20742, USA.		Colombini, Marco/A-1540-2014		NIGMS NIH HHS [GM 35759] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENZ R, 1988, FEBS LETT, V231, P75, DOI 10.1016/0014-5793(88)80706-3; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; BUREAU MH, 1992, J BIOL CHEM, V267, P8679; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; COLOMBINI M, 1987, BIOCHIM BIOPHYS ACTA, V905, P279, DOI 10.1016/0005-2736(87)90456-1; Crabtree HG, 1929, BIOCHEM J, V23, P536, DOI 10.1042/bj0230536; FIECK C, 1982, BIOCHIM BIOPHYS ACTA, V688, P429; GELLERICH FN, 1987, BIOCHIM BIOPHYS ACTA, V890, P117, DOI 10.1016/0005-2728(87)90012-0; HOGEBOOM GH, 1948, J BIOL CHEM, V165, P615; Holbrook JJ., 1975, ENZYMES, P191; KLEENE R, 1987, EMBO J, V6, P2623; LINDEN M, 1982, FEBS LETT, V141, P189, DOI 10.1016/0014-5793(82)80044-6; LIU MY, 1992, BIOCHIM BIOPHYS ACTA, V1098, P255, DOI 10.1016/S0005-2728(05)80344-5; MANNELLA CA, 1975, BIOCHIM BIOPHYS ACTA, V413, P226, DOI 10.1016/0005-2736(75)90106-6; MANNELLA CA, 1986, BIOPHYS J, V49, P272; MIHARA K, 1985, EMBO J, V4, P769, DOI 10.1002/j.1460-2075.1985.tb03695.x; NELSON BD, 1984, BIOCHEM J, V219, P159, DOI 10.1042/bj2190159; OSTLUND AK, 1983, BIOCHEM MED METAB B, V30, P231, DOI 10.1016/0006-2944(83)90089-3; PALADE GE, 1952, ANAT RECORD, V114, P427, DOI 10.1002/ar.1091140304; PARSONS DF, 1965, CAN J BOTANY, V43, P647, DOI 10.1139/b65-072; ROSE IA, 1966, COMPREHENSIVE BIOCH, V17, P93; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; TOOZE J, 1991, INTRO PROTEIN STRUCT, P141; TROLL H, 1992, J BIOL CHEM, V267, P21072; TYLER DD, 1992, MITOCHONDRION HLTH D, P403; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WUNDER UR, 1991, J MEMBRANE BIOL, V123, P83, DOI 10.1007/BF01993966; ZIMMERBERG J, 1986, NATURE, V323, P36, DOI 10.1038/323036a0	30	171	177	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1614	1616						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507479				2022-12-27	WOS:A1994MR98800013
J	SAWADA, R; TSUBOI, S; FUKUDA, M				SAWADA, R; TSUBOI, S; FUKUDA, M			DIFFERENTIAL E-SELECTIN-DEPENDENT ADHESION EFFICIENCY IN SUBLINES OF A HUMAN COLON-CANCER EXHIBITING DISTINCT METASTATIC POTENTIALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE-GLYCOPROTEINS; SIALYL-LEWIS-X; MYELOGENOUS LEUKEMIA-CELLS; MIDDLE-T-ONCOGENE; CARBOHYDRATE LIGAND; MOLECULE-1 ELAM-1; HOMING RECEPTOR; EXPRESSION; ANTIGEN; LEUKOSIALIN	Previously we have shown that high metastatic colonic carcinoma cells express relatively more lamp molecules and sialyl Lex structures on the cell surface than their corresponding low metastatic counterparts (Saitoh, O., Wang, W.-L., Lotan, R., and Fukuda, M. (1992) J. Biol. Chem. 267, 5700-5711). In the present study, we extended these findings by testing whether these high and low metastatic colonic carcinoma cells differ in their adhesion efficiency to E-selectin-expressing cells. First, it was found that the high metastatic cells, as compared to their low metastatic counterparts, bind more efficiently to activated human endothelial cells that express E-selectin. This was also true when the adhesion was tested for Chinese hamster ovary cells stably expressing E-selectin. In addition, it was found that the high metastatic cells also adhere more efficiently to mouse endothelioma cells after activation with interleukin-1beta. It was also shown that the adhesion can be inhibited by soluble lamp-1 or soluble leukosialin that contain sialyl Le(x) termini. The inhibition was not, however, observed when these soluble glycoproteins lack sialyl Le(x) structures. The results indicate that the efficiency of the E-selectin-mediated binding of colonic carcinoma cells to human and mouse endothelial cells correlates with the metastatic potential of the cells and suggest that this adhesive event may be one of the critical factors for the metastatic spread of tumor cells. Soluble forms of leukosialin or lamp-1 may be useful as therapeutic agents for the inhibition of E-selectin-mediated binding to tumor cells.	LA JOLLA CANC RES FDN,CANC RES CTR,GLYCOBIOL PROGRAM,10901 N TORREY PINES RD,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA048737, R01CA033895] Funding Source: NIH RePORTER; NCI NIH HHS [CA48737, R01 CA33895] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BALL ED, 1983, BLOOD, V61, P456; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1991, J BIOL CHEM, V266, P14869; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BUSSOLINO F, 1991, J IMMUNOL, V147, P2122; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CARLSSON SR, 1993, ARCH BIOCHEM BIOPHYS, V304, P65, DOI 10.1006/abbi.1993.1322; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA M, 1985, J BIOL CHEM, V260, P2957; FUKUDA M, 1984, BIOL GLYCOPROTEINS, P183; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; KAMEYAMA A, 1991, CARBOHYD RES, V209, pC1, DOI 10.1016/0008-6215(91)80171-I; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEE N, 1990, J BIOL CHEM, V265, P20476; LEY K, 1991, BLOOD, V77, P2553; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MORIKAWA K, 1988, CANCER RES, V48, P1943; MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446; MULLIGAN MS, 1993, J EXP MED, V178, P623, DOI 10.1084/jem.178.2.623; NAKAMORI S, 1993, CANCER RES, V53, P3632; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SAWADA R, 1993, J BIOL CHEM, V268, P12675; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; THURIN J, 1985, J BIOL CHEM, V260, P4556; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VIITALA J, 1988, P NATL ACAD SCI USA, V85, P3743, DOI 10.1073/pnas.85.11.3743; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WELLER A, 1992, J BIOL CHEM, V267, P15167; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WILLIAMS RL, 1988, CELL, V52, P121	55	217	238	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1425	1431						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507108				2022-12-27	WOS:A1994MR22000101
J	DENISON, SH; OREJAS, M; ARST, HN				DENISON, SH; OREJAS, M; ARST, HN			SIGNALING OF AMBIENT PH IN ASPERGILLUS INVOLVES A CYSTEINE PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTION FACTORS; NEUTRAL PROTEASE; NIDULANS; CALCIUM; CALPAIN; GENE; AUTOLYSIS; PROTEINS; CLONING; KINASE	In Aspergillus nidulans, the regulation of gene expression in response to changes in ambient pH is mediated by the PacC zinc finger transcriptional regulator, At alkaline ambient pH, PacC is proteolytically processed to a functional form serving as an activator of alkaline-expressed genes and a repressor of acid expressed genes. This activation of PacC occurs in response to a signal mediated by the products of the pal genes. Thus, the products of the palA, -B, -C, -F, -H, and -I genes constitute an alkaline ambient pH signal transduction pathway. How the pal signal transduction pathway senses ambient pH and transduces a signal to trigger PacC processing is a fascinating unresolved problem. We have cloned and sequenced the palB gene. The predicted palB gene product has similarity to the catalytic domain of the calpain family of calcium-activated cysteine proteases, We have shown, however, that the PalB protein does not catalyze the final step of proteolytic processing of PacC.	ROYAL POSTGRAD MED SCH,DEPT INFECT DIS & BACTERIOL,LONDON W12 0NN,ENGLAND; CSIC,CTR INVEST BIOL,E-28006 MADRID,SPAIN	Imperial College London; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			Orejas, Margarita/K-6821-2014	Orejas, Margarita/0000-0002-9974-8021				ARST HN, 1994, MOL GEN GENET, V245, P787, DOI 10.1007/BF00297286; BRODY H, 1991, NUCLEIC ACIDS RES, V19, P3105, DOI 10.1093/nar/19.11.3105; CADDICK MX, 1986, MOL GEN GENET, V203, P346, DOI 10.1007/BF00333978; CHUTTERBUCK AJ, 1993, GENETIC MAPS LOCUS M, V3; CLUTTERBUCK AJ, 1990, J GEN MICROBIOL, V136, P1731, DOI 10.1099/00221287-136-9-1731; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DELANEY SJ, 1991, P NATL ACAD SCI USA, V88, P7214, DOI 10.1073/pnas.88.16.7214; DORN G, 1965, GENET RES, V6, P13, DOI 10.1017/S0016672300003943; GOLL DE, 1992, BIOESSAYS, V14, P549, DOI 10.1002/bies.950140810; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; JOHNSTONE IL, 1985, EMBO J, V4, P1307, DOI 10.1002/j.1460-2075.1985.tb03777.x; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; OREJAS M, 1995, GENE DEV, V9, P1622, DOI 10.1101/gad.9.13.1622; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; ROSSI A, 1990, FEMS MICROBIOL LETT, V66, P51, DOI 10.1016/0378-1097(90)90257-Q; SIMON J, 1995, FEBS LETT, V368, P397; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; THEOPOLD U, 1995, MOL CELL BIOL, V15, P824; TILBURN J, 1995, EMBO J, V14, P779, DOI 10.1002/j.1460-2075.1995.tb07056.x; WATT F, 1993, NUCLEIC ACIDS RES, V21, P5092, DOI 10.1093/nar/21.22.5092; ZIMMERMAN UJP, 1982, BIOCHEMISTRY-US, V21, P3977, DOI 10.1021/bi00260a012; 1991, PROGRAM MANUAL GCG P	26	119	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28519	28522		10.1074/jbc.270.48.28519	http://dx.doi.org/10.1074/jbc.270.48.28519			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499363	hybrid			2022-12-27	WOS:A1995TH05600007
J	HAAS, M; MCBRAYER, D; LYTLE, C				HAAS, M; MCBRAYER, D; LYTLE, C			[CL-](I)-DEPENDENT PHOSPHORYLATION OF THE NA-K-CL COTRANSPORT PROTEIN OF DOG TRACHEAL EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHARK RECTAL GLAND; CANINE AIRWAY EPITHELIA; H-3 BUMETANIDE BINDING; SQUID GIANT-AXON; ION-TRANSPORT; RED-CELLS; MECHANISM; SECRETION; VOLUME; STIMULATION	Basolateral Na-K-Cl cotransport activity in primary cultures of dog tracheal epithelial cells is stimulated by beta-adrenergic agents, such as isoproterenol, and by apical UTP, which acts through an apical P-2-purinergic receptor, While at least part of the stimulatory effect of isoproterenol appears to involve direct activation of the cotransporter via cAMP-dependent protein kinase, cotransport stimulation by apical UTP is entirely secondary to apical Cl- efflux and a resultant decrease in intracellular [Cl-] ([Cl-](i)) and/or cell shrinkage (Haas, M., and McBrayer, D. G. (1994) Am. J. Physiol. 266, C1440-C1452), In the secretory epithelia of the shark rectal gland and avian salt gland, Na-K-Cl cotransport activation by both cAMP dependent and cAMP-independent secretagogues has been shown to be accompanied by phosphorylation of the cotransport protein itself (Lytle, C., and Forbush, B., III (1992) J. Biol. Chem. 267, 25438-25443; Torchia, J., Lytle, C,, Pen, D. J., Forbush, B., III, and Sen, A. K. (1992) J. Biol. Chem. 267, 25444-25450). In the present study, we immunoprecipitate the similar to 170 kDa Na-K-Cl cotransport protein of dog tracheal epithelial cells with a monoclonal antibody against the cotransporter of the intestinal cell line T84. Incubation of confluent primary cultures of tracheal cells with isoproterenol and apical UTP increases basolateral-to-apical Cl-36(-) flux 3.4- and 2.6-fold, respectively, and produces similar increases (3.2- and 2.8-fold, respectively) in P-32 incorporation into the similar to 170-kDa cotransport protein. Decreasing [Cl-](i) (without concomitant cell shrinkage) by incubating cultures with apical nystatin and reduced apical [Cl-] ([Cl-](alpha)) likewise increases both cotransport activity and cotransport protein phosphorylation. These effects become more pronounced with greater reductions in [Cl-](alpha); after 20 min of incubation with nystatin and 32 mM [Cl-](alpha), cotransport activity and P-32 incorporation into the cotransport protein are increased 2.8- and 2.7-fold, respectively, similar to increases seen with apical UTP. 2-3-fold increases in cotransporter activity and phosphorylation are also seen in nystatin-treated cells under hypertonic conditions (50 mM sucrose added apically and basolaterally). These findings suggest a close correlation between Na-K-Cl cotransport activity and phosphorylation of the similar to 170-kDa cotransport protein. The latter is phosphorylated in response to both reduced [Cl-](i) and cell shrinkage, either or both of which are likely to be involved in secondary cotransport activation in response to apical UTP.	UNIV CALIF RIVERSIDE, DIV BIOMED SCI, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside	HAAS, M (corresponding author), UNIV CHICAGO, DEPT PATHOL, MC 6101, 5841 S MARYLAND AVE, CHICAGO, IL 60637 USA.		Lytle, Christian/X-2836-2019	Lytle, Christian/0000-0001-5442-1546	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043967] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43967] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTAMIRANO AA, 1988, AM J PHYSIOL, V254, pC582, DOI 10.1152/ajpcell.1988.254.4.C582; BOUCHER RC, 1988, AM J PHYSIOL, V254, pC535, DOI 10.1152/ajpcell.1988.254.4.C535; BREITWIESER GE, 1990, AM J PHYSIOL, V258, pC749, DOI 10.1152/ajpcell.1990.258.4.C749; CASS A, 1973, NATURE-NEW BIOL, V244, P47, DOI 10.1038/newbio244047a0; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; FONG P, 1991, AM J PHYSIOL, V261, pL290, DOI 10.1152/ajplung.1991.261.4.L290; FORBUSH B, 1992, AM J PHYSIOL, V262, pC1000, DOI 10.1152/ajpcell.1992.262.4.C1000; FOSKETT JK, 1990, AM J PHYSIOL, V259, pC998; GREGER R, 1984, PFLUG ARCH EUR J PHY, V402, P376, DOI 10.1007/BF00583938; HAAS M, 1986, J BIOL CHEM, V261, P8434; HAAS M, 1994, AM J PHYSIOL, V266, pC1440, DOI 10.1152/ajpcell.1994.266.5.C1440; HAAS M, 1982, J GEN PHYSIOL, V80, P125, DOI 10.1085/jgp.80.1.125; HAAS M, 1993, AM J PHYSIOL, V264, pC189, DOI 10.1152/ajpcell.1993.264.1.C189; HAAS M, 1990, AM J PHYSIOL, V259, pC557, DOI 10.1152/ajpcell.1990.259.4.C557; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HAAS M, 1991, AM J PHYSIOL, V260, pC791, DOI 10.1152/ajpcell.1991.260.4.C791; HAAS M, 1987, AM J PHYSIOL, V253, pC243, DOI 10.1152/ajpcell.1987.253.2.C243; HAAS M, 1995, FASEB J, V9, P599; KLEIN JD, 1993, J MEMBRANE BIOL, V132, P243; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINSON C, 1990, BIOCHIM BIOPHYS ACTA, V1021, P1, DOI 10.1016/0005-2736(90)90375-X; LIEDTKE CM, 1992, AM J PHYSIOL, V262, pL621, DOI 10.1152/ajplung.1992.262.5.L621; LYTLE C, 1992, AM J PHYSIOL, V262, pC1009, DOI 10.1152/ajpcell.1992.262.4.C1009; LYTLE C, 1992, J BIOL CHEM, V267, P25438; LYTLE C, 1995, IN PRESS AM J PHYSL; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; NAKAHARI T, 1995, AM J PHYSIOL-RENAL, V268, pF64, DOI 10.1152/ajprenal.1995.268.1.F64; ONEILL WC, 1992, AM J PHYSIOL, V262, pC436, DOI 10.1152/ajpcell.1992.262.2.C436; PAULAIS M, 1992, J BIOL CHEM, V267, P21558; PEWITT EB, 1990, J BIOL CHEM, V265, P20747; ROBERTSON MA, 1994, AM J PHYSIOL, V267, pC146, DOI 10.1152/ajpcell.1994.267.1.C146; SHOROFSKY SR, 1984, J MEMBRANE BIOL, V81, P1, DOI 10.1007/BF01868804; SUN D, 1995, IN PRESS AM J PHYSL; TOHDA H, 1994, AM J PHYSIOL, V266, pC104, DOI 10.1152/ajpcell.1994.266.1.C104; TORCHIA J, 1992, J BIOL CHEM, V267, P25444; TORCHIA J, 1994, J BIOL CHEM, V269, P29778; TREHARNE KJ, 1994, AM J PHYSIOL-LUNG C, V267, pL592, DOI 10.1152/ajplung.1994.267.5.L592; VANSCOTT MR, 1988, AM J PHYSIOL, V255, pC237, DOI 10.1152/ajpcell.1988.255.2.C237; VIGNE P, 1994, J BIOL CHEM, V269, P19925; WELSH MJ, 1983, J CLIN INVEST, V71, P1392, DOI 10.1172/JCI110892	40	98	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28955	28961		10.1074/jbc.270.48.28955	http://dx.doi.org/10.1074/jbc.270.48.28955			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499426	hybrid			2022-12-27	WOS:A1995TH05600070
J	NODA, K; SAAD, Y; KARNIK, SS				NODA, K; SAAD, Y; KARNIK, SS			INTERACTION OF PHE(8) OF ANGIOTENSIN-II WITH LYS(199) AND HIS(256) OF AT(1) RECEPTOR IN AGONIST ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ANALOGS	The acidic pharmacophores of selective ligands bind to Lys(199) and His(256) of the AT(1) receptor (Noda, K., Saad, Y., Kinoshita, A., Boyle, T. P., Graham, R. M., Husain, A., and Karnik, S. (1995) J. Biol. Chem. 270, 2284-2289). In this report we examine how interactions between these residues and agonists activate inositol phosphate production in transiently transfected COS-1 cells, [Sar(1)] angiotensin (Ang II) II and [Sar(1)]Ang II-amide stimulated a 5-fold inositol phosphate response from wild-type AT(1) receptor. The peptide antagonist [Sar(1),Ile(8)]Ang II and the non-peptide agonist L-162,313 produced a partial but saturating response. Stimulation of wild-type receptor by [Sar(1)]Ang II-amide and the mutant K199Q and K199A receptors by [Sar(1)]Ang II demonstrates that AT(1) receptor activation is not critically dependent on the ion-pairing of the alpha-COOH group of Ang II with Lys(199). The mutation of His(256) produced diminished inositol phosphate response without commensurate change in binding affinity of ligands. The His(256) Side chain is critical for maximal activation of the AT(1) receptor, although isosteric Gln substitution is sufficient for preserving the affinity for Phe(8)-substituted analogues of [Sar(1)]Ang II. Therefore, AT(1) receptor activation requires interaction of Phe(8) side chain of Ang II with His(256), which is achieved by docking the alpha-COOH group of Phe(8) to Lys(199). Furthermore, non-peptide agonists interact with Lys(199) and His(256) in a similar fashion.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC CARDIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Karnik, Sadashiva/Y-2477-2019	Karnik, Sadashiva/0000-0003-0746-2753	NHLBI NIH HHS [HL33713, R01 HL057470] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL033713] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUMELAS A, 1985, P NATL ACAD SCI USA, V82, P1881, DOI 10.1073/pnas.82.7.1881; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BUMPUS FM, 1977, HYPERTENSION PHYSIOP, P183; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Creighton T. E., 1984, PROTEINS STRUCTURES, V2nd; FENG YH, 1995, J BIOL CHEM, V270, P12846, DOI 10.1074/jbc.270.21.12846; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; HSIEH KH, 1986, J MED CHEM, V29, P1968, DOI 10.1021/jm00160a028; HUSAIN A, 1986, J PHARMACOL EXP THER, V239, P71; JI H, 1994, J BIOL CHEM, V269, P16533; KIVLIGHN SD, 1995, IN PRESS AM J PHARM; MARIE J, 1994, J BIOL CHEM, V269, P20815; NIKIFOROVICH GV, 1994, BIOCHEMISTRY-US, V33, P3591, DOI 10.1021/bi00178a016; NODA K, 1995, J BIOL CHEM, V270, P2284, DOI 10.1074/jbc.270.5.2284; NODA K, 1994, J BIOL CHEM, V269, P6743; PERLMAN S, 1995, J BIOL CHEM, V270, P1493, DOI 10.1074/jbc.270.4.1493; SCHAMBYE HT, 1995, MOL PHARMACOL, V47, P425; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205	20	111	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28511	28514		10.1074/jbc.270.48.28511	http://dx.doi.org/10.1074/jbc.270.48.28511			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499361	hybrid			2022-12-27	WOS:A1995TH05600005
J	SEKLER, I; LO, RS; KOPITO, RR				SEKLER, I; LO, RS; KOPITO, RR			A CONSERVED GLUTAMATE IS RESPONSIBLE FOR ION SELECTIVITY AND PH-DEPENDENCE OF THE MAMMALIAN ANION-EXCHANGERS AE1 AND AE2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RED-BLOOD-CELLS; SULFATE-BINDING PROTEIN; BAND-3 PROTEIN; INTRACELLULAR PH; IMPERMEANT CARBODIIMIDE; CHEMICAL MODIFICATION; PHOSPHATE-TRANSPORT; ACTIVE-TRANSPORT; MEMBRANE	The erythrocyte anion exchanger AE1 (band 3) serves as an important model for the study of the mechanism of ion transport. Chemical modification of human erythrocyte AE1 has previously suggested that glutamic acid residue 681 lies within the transport pathway and can cross the permeability barrier. This glutamate is conserved in all anion exchangers sequenced to date. We examined the effect on divalent (sulfate) and monovalent (chloride and bicarbonate) anion transport of mutating the corresponding glutamates in mouse AE1 and the closely related anion exchanger, AE2. Substitution of this conserved glutamate with uncharged or basic amino acids had a negligible effect on the maximal rate of sulfate-sulfate exchange in AE-reconstituted proteoliposomes, but largely abolished the steep pH dependence of sulfate transport observed in wild-type AE1 and AE2. In contrast, exchange of monovalent anions was undetectable in cells expressing these mutants. Replacement of the conserved glutamate with aspartate abolished both monovalent and divalent anion transport. These data suggest that the conserved glutamate residue plays a dual role in determining anion selectivity and in proton coupling to sulfate transport. A model explaining the role of the conserved glutamate in promoting ion selectivity and pH regulation is discussed.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NIGMS NIH HHS [GM38543] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; BJERRUM PJ, 1989, J GEN PHYSIOL, V93, P813, DOI 10.1085/jgp.93.5.813; Brahm J, 1988, Soc Gen Physiol Ser, V43, P141; CABANTCHIK ZI, 1974, J MEMBRANE BIOL, V15, P207, DOI 10.1007/BF01870088; CRAIK JD, 1985, J BIOL CHEM, V260, P2404; CREIGHTON TE, 1992, PROTEIN FOLDING; GARCIA AM, 1989, J BIOL CHEM, V264, P19607; GASKO OD, 1976, ANAL BIOCHEM, V72, P57, DOI 10.1016/0003-2697(76)90506-6; Gunn RB, 1972, OXYGEN AFFINITY HEMO, P823; HE JJ, 1991, SCIENCE, V251, P1479, DOI 10.1126/science.1900953; JACOBSON BL, 1991, J BIOL CHEM, V266, P5220; JACOBSON BL, 1992, J MOL BIOL, V223, P27, DOI 10.1016/0022-2836(92)90712-S; JENNINGS ML, 1985, J BIOL CHEM, V260, P5472; JENNINGS ML, 1976, J MEMBRANE BIOL, V28, P187, DOI 10.1007/BF01869697; JENNINGS ML, 1987, J BIOL CHEM, V262, P1691; JENNINGS ML, 1988, J GEN PHYSIOL, V92, P161, DOI 10.1085/jgp.92.2.161; JENNINGS ML, 1992, J BIOL CHEM, V267, P13964; JENNINGS ML, 1989, ANN NY ACAD SCI, V274, P84; JULIEN T, 1988, J MEMBRANE BIOL, V102, P217, DOI 10.1007/BF01925715; KNAUF PA, 1986, PHYSL MEMBRANE DISOR, P191; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KRUPKA RM, 1989, J MEMBRANE BIOL, V109, P159, DOI 10.1007/BF01870855; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEE BS, 1991, J BIOL CHEM, V266, P11448; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOWE AG, 1982, BIOCHIM BIOPHYS ACTA, V694, P353, DOI 10.1016/0304-4157(82)90002-8; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MACARA IG, 1983, CELL MEMBRANES METHO, P41; MILANICK MA, 1984, AM J PHYSIOL, V247, pC247, DOI 10.1152/ajpcell.1984.247.3.C247; PARADISO AM, 1987, NATURE, V325, P447, DOI 10.1038/325447a0; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; RESTREPO D, 1991, AM J PHYSIOL, V260, pC535, DOI 10.1152/ajpcell.1991.260.3.C535; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHNELL KF, 1977, J MEMBRANE BIOL, V30, P319; SEKLER I, 1995, J BIOL CHEM, V270, P11251, DOI 10.1074/jbc.270.19.11251; THOMAS HA, 1989, AM J PHYSIOL, V257, pC537, DOI 10.1152/ajpcell.1989.257.3.C537; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VAUGHANJONES RD, 1982, PHILOS T ROY SOC B, V299, P537, DOI 10.1098/rstb.1982.0150; VAUGHANJONES RD, 1979, J PHYSIOL-LONDON, V295, P111, DOI 10.1113/jphysiol.1979.sp012957; WARD CL, 1994, J BIOL CHEM, V269, P25710; WIETH JO, 1982, PHILOS T ROY SOC B, V299, P383, DOI 10.1098/rstb.1982.0139; WOOD PG, 1992, J MEMBRANE BIOL, V127, P139	48	47	47	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28751	28758		10.1074/jbc.270.48.28751	http://dx.doi.org/10.1074/jbc.270.48.28751			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499397	hybrid			2022-12-27	WOS:A1995TH05600041
J	TSUBAKI, M; HORI, H; MOGI, T; ANRAKU, Y				TSUBAKI, M; HORI, H; MOGI, T; ANRAKU, Y			CYANIDE-BINDING SITE OF BD-TYPE UBIQUINOL OXIDASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D TERMINAL OXIDASE; CYTOCHROME-C-OXIDASE; AEROBIC RESPIRATORY-CHAIN; ELECTRON-PARAMAGNETIC-RESONANCE; D COMPLEX; RAMAN-SPECTROSCOPY; BINUCLEAR CENTER; LIGAND-BINDING; IDENTIFICATION; PURIFICATION	We extended our investigation on the structure of the redox centers of bd-type ubiquinol oxidase from Escherichia coli using cyanide as a monitoring probe. We found that addition of cyanide to the air-oxidized O-2-bound enzyme caused appearance of an infrared C-N stretching band at 2161 cm(-1) and concomitant disappearance of the 647 nm absorption band of the cytochrome d (Fe2+)-O-2 species. Addition of cyanide to the air oxidized CO-bound enzyme also resulted in disappearance of the 635 nm absorption band and the 1983.4 cm(-1) C-O infrared band of the cytochrome d (Fe2+)-CO species. The resulting species had a derivative shaped electron paramagnetic resonance signal at g = 3.15. Upon partial reduction with sodium dithionite, this species was converted partly to a transient heme d (Fe3+)-C=N species having an electron paramagnetic resonance signal at g(z) = 2.96 and a C-N infrared band at 2138 cm(-1). These observations suggest that the active site of the enzyme has a heme-heme binuclear metal center distinct from that of the heme-copper terminal oxidase and that the treatment of the air-oxidized enzyme with cyanide resulted in a cyanide-bridging species with ''heme d(Fe3(+))-C=N-heme b(595)(Fe3+)'' structure.	OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN; UNIV TOKYO,GRAD SCH SCI,DEPT BIOL SCI,BUNKYO KU,TOKYO 113,JAPAN	Osaka University; University of Tokyo	TSUBAKI, M (corresponding author), HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,KAMIGORI,HYOGO 67812,JAPAN.							ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; ARGADE PV, 1984, SCIENCE, V225, P329, DOI 10.1126/science.6330890; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; GREEN GN, 1988, J BIOL CHEM, V263, P13138; GREEN GN, 1984, J BIOL CHEM, V259, P7994; GREEN GN, 1984, GENE, V32, P99, DOI 10.1016/0378-1119(84)90037-4; HATA A, 1985, BIOCHIM BIOPHYS ACTA, V810, P62, DOI 10.1016/0005-2728(85)90206-3; HATATANAKA A, 1987, BIOCHIM BIOPHYS ACTA, V893, P289, DOI 10.1016/0005-2728(87)90050-8; HILL JJ, 1993, P NATL ACAD SCI USA, V90, P5863, DOI 10.1073/pnas.90.12.5863; HILL JJ, 1994, BIOPHYS J, V66, P367; INGLEDEW WJ, 1992, BIOCHEM J, V282, P255, DOI 10.1042/bj2820255; INGLEDEW WJ, 1993, EUR J BIOCHEM, V212, P657, DOI 10.1111/j.1432-1033.1993.tb17703.x; JIANG FS, 1993, J AM CHEM SOC, V115, P10293, DOI 10.1021/ja00075a052; JOHNSON MK, 1981, BIOCHEM J, V193, P699, DOI 10.1042/bj1930699; JUNEMANN S, 1995, J BIOL CHEM, V270, P16213, DOI 10.1074/jbc.270.27.16213; KAHLOW MA, 1991, BIOCHEMISTRY-US, V30, P11485, DOI 10.1021/bi00113a001; KAHLOW MA, 1993, J AM CHEM SOC, V115, P5845, DOI 10.1021/ja00066a071; KAUFFMAN HF, 1973, BIOCHIM BIOPHYS ACTA, V314, P276, DOI 10.1016/0005-2728(73)90112-6; KITA K, 1984, J BIOL CHEM, V259, P3375; KOLAND JG, 1984, BIOCHEMISTRY-US, V23, P1051, DOI 10.1021/bi00301a003; KONISHI K, 1986, J BIOCHEM, V99, P1227, DOI 10.1093/oxfordjournals.jbchem.a135586; KRASNOSELSKAYA I, 1993, FEBS LETT, V327, P279, DOI 10.1016/0014-5793(93)81004-J; LORENCE RM, 1986, BIOCHEMISTRY-US, V25, P2314, DOI 10.1021/bi00357a003; LORENCE RM, 1989, J BIOL CHEM, V264, P7135; MEINHARDT SW, 1989, BIOCHIM BIOPHYS ACTA, V975, P175, DOI 10.1016/S0005-2728(89)80216-6; MILLER MJ, 1983, J BIOL CHEM, V258, P9159; PENG QY, 1994, FEBS LETT, V356, P159, DOI 10.1016/0014-5793(94)01253-9; POOLE RK, 1983, J GEN MICROBIOL, V129, P1335; POOLE RK, 1983, BIOCHIM BIOPHYS ACTA, V726, P205, DOI 10.1016/0304-4173(83)90006-X; PUDEK MR, 1974, ARCH BIOCHEM BIOPHYS, V164, P682, DOI 10.1016/0003-9861(74)90081-2; ROTHERY RA, 1989, BIOCHEM J, V261, P437, DOI 10.1042/bj2610437; SCOTT MJ, 1994, J AM CHEM SOC, V116, P11357, DOI 10.1021/ja00104a015; SPINNER F, 1995, BIOCHEM J, V308, P641, DOI 10.1042/bj3080641; TIMKOVICH R, 1985, J AM CHEM SOC, V107, P6069, DOI 10.1021/ja00307a041; TSUBAKI M, 1982, BIOCHEMISTRY-US, V21, P1132, DOI 10.1021/bi00535a004; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; TSUBAKI M, 1992, BIOPHYS J, V63, P1564, DOI 10.1016/S0006-3495(92)81747-2; TSUBAKI M, 1993, FEBS LETT, V335, P13, DOI 10.1016/0014-5793(93)80430-3; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P164, DOI 10.1021/bi00052a022; UNO T, 1994, J BIOL CHEM, V269, P11912; UNO T, 1985, J BIOL CHEM, V260, P6755; YANG FD, 1986, J BIOL CHEM, V261, P4987; YOSHIKAWA S, 1985, J BIOL CHEM, V260, P3518; YOSHIKAWA S, 1982, J BIOL CHEM, V257, P412	44	66	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28565	28569		10.1074/jbc.270.48.28565	http://dx.doi.org/10.1074/jbc.270.48.28565			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499371	hybrid			2022-12-27	WOS:A1995TH05600015
J	CLINE, GW; SHULMAN, GI				CLINE, GW; SHULMAN, GI			MASS AND POSITIONAL ISOTOPOMER ANALYSIS OF GLUCOSE-METABOLISM IN PERIPORTAL AND PERICENTRAL HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; GLYCOGEN-SYNTHESIS; RAT-LIVER; QUANTITATIVE-ANALYSIS; REPLETION; PATHWAYS; INVIVO	To determine whether the source of carbon for the indirect pathway of hepatic glycogen synthesis differs between the periportal and pericentral zones, we studied seven 24-h-fasted conscious rats given a constant 2-h intraduodenal infusion of glucose, 40% labeled with [U-C-13]glucose (99% C-13 enriched), to raise and maintain plasma glucose concentration at similar to 10 mM. Glycogen, glutamate, aspartate, and alanine were selectively sampled from the periportal and pericentral zones of the liver by the dual-digitonin pulse technique and analyzed by C-13 NMR for positional isotopomer distribution and by gas chromatography-mass spectrometry for mass isotopomer distribution. Plasma glucose mass isotopomer distribution was determined from gas chromatography-mass spectrometry. The isotopomer distribution indicates that there was no significant difference between the zones with respect to 1) percent direct flux of glucose into the glycogen (periportal, 34 +/- 4; pericentral, 38 +/- 4), 2) extent of oxaloacetate/fumarate equilibration (periportal, 0.54 +/- .01;, pericentral, 0.53 +/- 0.01), 3) dilution of tracer in oxaloacetate (periportal, 0.64 +/- 0.07;, pericentral, 0.64 +/- 0.07), or 4) inflow of pyruvate versus tricarboxylic acid cycle flux (periportal, 0.70 +/- 0.20; pericentral, 0.68 +/- 0.16). Positional isotopomer populations, determined from the C-13-C-13 splitting in C3 and C4 of periportal and pericentral glycogen, were indistinguishable, indicating no significant differences in the source of the 3-carbon precursors for hepatic glycogen synthesis by the indirect pathway, In conclusion, glucose metabolism is the same in the periportal and pericentral zones with regard to 1) the relative flux of carbon via the direct/indirect pathways, 2) the source of the 3-carbon precursor used in the indirect pathway of glycogen synthesis, and 3) the flux of the 3-carbon precursors through the tricarboxylic acid cycle.			CLINE, GW (corresponding author), YALE UNIV, SCH MED, DEPT INTERNAL MED, FITKIN 1, POB 208020, NEW HAVEN, CT 06520 USA.		Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040936, P30DK045735] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK040936, DK 45735, DK 40936] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTELS H, 1987, FEBS LETT, V221, P277, DOI 10.1016/0014-5793(87)80940-7; BERGMAYER HU, 1979, METHOD ENZYMAT AN, P574; CLINE GW, 1991, J BIOL CHEM, V266, P4094; GEBHARDT R, 1983, EMBO J, V2, P567, DOI 10.1002/j.1460-2075.1983.tb01464.x; JUNGERMANN K, 1992, ENZYME, V46, P33, DOI 10.1159/000468777; JUNGERMANN K, 1976, Z PHYSL CHEM, V357, P359; KATZ J, 1989, J BIOL CHEM, V264, P12994; KATZ J, 1991, P NATL ACAD SCI USA, V88, P2103, DOI 10.1073/pnas.88.6.2103; KATZ J, 1991, AM J PHYSIOL, V261, pE332, DOI 10.1152/ajpendo.1991.261.3.E332; LANDAU BERNARD R., 1955, JOUR BIOL CHEM, V214, P525; LEIMER KR, 1977, J CHROMATOGR, V141, P121, DOI 10.1016/S0021-9673(00)99131-3; MARKS PA, 1956, J BIOL CHEM, V218, P327; MOORE MC, 1991, J CLIN INVEST, V88, P578, DOI 10.1172/JCI115342; QUISTORFF B, 1987, BIOCHEM J, V243, P87, DOI 10.1042/bj2430087; ROSENBLATT J, 1992, AM J PHYSIOL, V263, pE584, DOI 10.1152/ajpendo.1992.263.3.E584; ROSIERS CD, 1990, AM J PHYSIOL, V259, pE757, DOI 10.1152/ajpendo.1990.259.5.E757; SHULMAN GI, 1985, J CLIN INVEST, V76, P1229, DOI 10.1172/JCI112078; SHULMAN GI, 1987, J CLIN INVEST, V80, P387, DOI 10.1172/JCI113084; VORHABEN JE, 1973, BIOCHEM J, V135, P893, DOI 10.1042/bj1350893; WALS PA, 1988, J BIOL CHEM, V263, P4876	20	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28062	28067						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499292				2022-12-27	WOS:A1995TG21000017
J	ROCKENSTEIN, EM; MCCONLOGUE, L; TAN, H; POWER, M; MASLIAH, E; MUCKE, L				ROCKENSTEIN, EM; MCCONLOGUE, L; TAN, H; POWER, M; MASLIAH, E; MUCKE, L			LEVELS AND ALTERNATIVE SPLICING OF AMYLOID-BETA PROTEIN-PRECURSOR (APP) TRANSCRIPTS IN BRAINS OF APP TRANSGENIC MICE AND HUMANS WITH ALZHEIMERS-DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; DIFFERENTIAL EXPRESSION; INHIBITOR DOMAIN; CELL-LINE; GENE; CORTEX; NEURONS; RAT; LOCALIZATION; HIPPOCAMPUS	Abnormal expression of human amyloid precursor protein (hAPP) gene products may play a critical role in Alzheimer's disease (AD). Recently, a transgenic model was established in which platelet-derived growth factor (PDGF) promoter-driven neuronal expression of an alternatively spliced hAPP minigene resulted in prominent AD-type neuropathology (Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., Guido, T., Hagopian, S., Johnson-Wood, K., Khan, K., Lee, M., Leibowitz, P., Lieberburg, I., Little, S., Masliah, E., McConlogue, L., Montoya-Zavala, M., Mucke, L., Paganini, L., and Penniman, E. (1995) Nature 373, 523-527). Here we compared the levels and alternative splicing of APP transcripts in brain tissue of hAPP transgenic and nontransgenic mice and of humans with and without AD. PDGF-hAPP mice showed severalfold higher levels of total APP mRNA than did nontransgenic mice or humans, whereas their endogenous mouse APP mRNA levels were decreased. This resulted in a high ratio of mRNAs encoding mutated hAPP versus wild-type mouse APP. Modifications of hAPP introns 6, 7, and 8 in the PDGF-hAPP construct resulted in a prominent change in alternative splice site selection with transcripts encoding hAPP770 or hAPP751 being expressed at substantially higher levels than hAPP695 mRNA. Frontal cortex of humans with AD showed a subtle increase in the relative abundance of hAPP751 mRNA compared with normal controls. These data identify specific intron sequences that may contribute to the normal neuron-specific alternative splicing of APP pre-mRNA in vivo and support a causal role of hAPP gene products in the development of AD-type brain alterations.	Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; ATHENA NEUROSCI INC, San Francisco, CA 94080 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego; University of California System; University of California San Diego				Mucke, Lennart/0000-0001-6256-9559	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011385, R37AG011385] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00833] Funding Source: Medline; NIA NIH HHS [AG11385, AG05131] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JP, 1989, EMBO J, V8, P3627, DOI 10.1002/j.1460-2075.1989.tb08536.x; BEYREUTHER K, 1993, ANN NY ACAD SCI, V695, P91, DOI 10.1111/j.1749-6632.1993.tb23035.x; BORDONARO M, 1994, BIOTECHNIQUES, V16, P428; BURKE WJ, 1991, MOL BRAIN RES, V11, P37, DOI 10.1016/0169-328X(91)90018-S; BUXBAUM JD, 1993, BIOCHEM BIOPH RES CO, V197, P639, DOI 10.1006/bbrc.1993.2527; CLARK AW, 1989, ANN NEUROL, V25, P331, DOI 10.1002/ana.410250404; CLARK RF, 1993, ARCH NEUROL-CHICAGO, V50, P1164, DOI 10.1001/archneur.1993.00540110044004; DESAUVAGE F, 1992, EMBO J, V11, P3099, DOI 10.1002/j.1460-2075.1992.tb05382.x; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; DESTROOPER B, 1991, BIOCHIM BIOPHYS ACTA, V1129, P141, DOI 10.1016/0167-4781(91)90231-A; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; FILLIT H, 1995, LAB INVEST, V72, P249; FUKUCHI K, 1989, NUCLEIC ACIDS RES, V17, P5396, DOI 10.1093/nar/17.13.5396; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOEDERT M, 1987, EMBO J, V6, P3627, DOI 10.1002/j.1460-2075.1987.tb02694.x; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOODISON KL, 1993, J NEUROPATH EXP NEUR, V52, P192, DOI 10.1097/00005072-199305000-00002; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HIGGINS GA, 1988, P NATL ACAD SCI USA, V85, P1297, DOI 10.1073/pnas.85.4.1297; HIGGINS LS, 1994, ANN NEUROL, V35, P598, DOI 10.1002/ana.410350514; JACOBSEN JS, 1991, NEUROBIOL AGING, V12, P585, DOI 10.1016/0197-4580(91)90090-7; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; JOHNSON SA, 1989, NEUROBIOL AGING, V10, P267, DOI 10.1016/0197-4580(89)90061-4; JOHNSON SA, 1988, EXP NEUROL, V102, P264, DOI 10.1016/0014-4886(88)90104-5; JOHNSTONE EM, 1989, BIOCHEM BIOPH RES CO, V163, P1248, DOI 10.1016/0006-291X(89)91112-1; KANG J, 1990, BIOCHEM BIOPH RES CO, V166, P1192, DOI 10.1016/0006-291X(90)90992-V; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KONIG G, 1991, MOL BRAIN RES, V9, P259, DOI 10.1016/0169-328X(91)90010-U; KONIG G, 1990, FEBS LETT, V269, P305, DOI 10.1016/0014-5793(90)81181-M; Konig G, 1989, Prog Clin Biol Res, V317, P1027; KOO EH, 1990, NEURON, V4, P97, DOI 10.1016/0896-6273(90)90446-M; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LAMB BT, 1993, NAT GENET, V5, P22, DOI 10.1038/ng0993-22; LANNFELT L, 1994, BIOCHEM SOC T, V22, P176, DOI 10.1042/bst0220176; LANNFELT L, 1993, BEHAV BRAIN RES, V57, P207, DOI 10.1016/0166-4328(93)90137-F; LEVEUGLE B, 1994, MOL NEUROBIOL, V9, P25, DOI 10.1007/BF02816102; MASLIAH E, 1995, NEUROBIOL AGING, V16, P280, DOI 10.1016/0197-4580(95)00020-F; MASLIAH E, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P405; MASLIAH E, 1994, NEUROSCI LETT, V174, P67, DOI 10.1016/0304-3940(94)90121-X; MORRIS JC, 1988, ANN NEUROL, V24, P17, DOI 10.1002/ana.410240105; MUCKE L, 1991, NEW BIOL, V3, P465; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NEVE RL, 1990, NEURON, V5, P329, DOI 10.1016/0896-6273(90)90169-G; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; ODAKA A, 1995, BIOCHEM BIOPH RES CO, V206, P821, DOI 10.1006/bbrc.1995.1117; OYAMA F, 1994, J NEUROCHEM, V62, P1062; PALMERT MR, 1988, SCIENCE, V241, P1080, DOI 10.1126/science.2457949; PAUL G, 1992, FEBS LETT, V307, P329, DOI 10.1016/0014-5793(92)80706-M; PEARSON BE, 1993, P NATL ACAD SCI USA, V90, P10578, DOI 10.1073/pnas.90.22.10578; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRICE DL, 1994, ANNU REV MED, V45, P435; ROBINSON CA, 1994, NEUROBIOL AGING, V15, P681, DOI 10.1016/0197-4580(94)90049-3; SANDBRINK R, 1994, BBA-GENE STRUCT EXPR, V1219, P167, DOI 10.1016/0167-4781(94)90263-1; SANDBRINK R, 1994, J BIOL CHEM, V269, P1510; SANDBRINK R, 1993, ANN NY ACAD SCI, V695, P183, DOI 10.1111/j.1749-6632.1993.tb23049.x; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; Schmechel D E, 1988, Alzheimer Dis Assoc Disord, V2, P96, DOI 10.1097/00002093-198802020-00002; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SHERMAN CA, 1992, DEV BRAIN RES, V66, P63, DOI 10.1016/0165-3806(92)90141-I; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SMITH CJ, 1991, MOL BRAIN RES, V10, P351, DOI 10.1016/0169-328X(91)90095-F; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; SPILLANTINI MG, 1989, MOL BRAIN RES, V6, P143, DOI 10.1016/0169-328X(89)90048-X; STANLEY LC, 1994, J NEUROPATH EXP NEUR, V53, P231, DOI 10.1097/00005072-199405000-00003; STGEORGEHYSLOP P, 1994, SCIENCE, V263, P537, DOI 10.1126/science.8290965; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TANAKA S, 1989, BIOCHEM BIOPH RES CO, V165, P1406, DOI 10.1016/0006-291X(89)92760-5; TANAKA S, 1988, BIOCHEM BIOPH RES CO, V157, P472, DOI 10.1016/S0006-291X(88)80273-0; TANAKA S, 1992, MOL BRAIN RES, V15, P303, DOI 10.1016/0169-328X(92)90122-R; TANAKA S, 1993, NEUROSCI LETT, V163, P19, DOI 10.1016/0304-3940(93)90219-B; TANZI RE, 1993, MOL BRAIN RES, V18, P246, DOI 10.1016/0169-328X(93)90196-V; TERRY RD, 1981, ANN NEUROL, V10, P184, DOI 10.1002/ana.410100209; VANDERWAL EA, 1993, NEUROREPORT, V4, P69, DOI 10.1097/00001756-199301000-00018; WEISGRABER KH, 1994, CURR OPIN STRUC BIOL, V4, P507, DOI 10.1016/S0959-440X(94)90212-7; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; WHITSON JS, 1994, BIOCHEM BIOPH RES CO, V199, P163, DOI 10.1006/bbrc.1994.1209; WILLOUGHBY DA, 1992, EXP NEUROL, V118, P332, DOI 10.1016/0014-4886(92)90191-R; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; WYSSCORAY T, 1995, AM J PATHOL, V147, P53; YAMADA T, 1989, BIOCHEM BIOPH RES CO, V158, P906, DOI 10.1016/0006-291X(89)92808-8; YOSHIKAI S, 1991, GENE, V102, P291, DOI 10.1016/0378-1119(91)90093-Q	88	211	228	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28257	28267						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499323				2022-12-27	WOS:A1995TG21000048
J	WANG, XY; FUHRER, DK; MARSHALL, MS; YANG, YC				WANG, XY; FUHRER, DK; MARSHALL, MS; YANG, YC			INTERLEUKIN-11 INDUCES COMPLEX-FORMATION OF GRB2, FYN, AND JAK2 IN 3T3L1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RECEPTOR TYROSINE KINASES; GTPASE-ACTIVATING PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; SH3 DOMAIN; RAS; FAMILY	Previous studies suggested that interleukin-11 (IL-11) induces the activation of mitogen-activated protein kinase (MAPK) in mouse 3T3L1 cells. However, the mechanisms by which IL-11 activates MAPK remain elusive. Our present results show that IL-11 promotes the formation of the active GTP-bound form of Ras, suggesting that IL-11 actions may be transduced in part through the Ras/MAPK signaling pathway. By immunoblotting and immunoprecipitation, we further demonstrate the association of tyrosine phosphoproteins with Grb2, an adaptor protein serving as a key intermediate for Ras activation. These phosphotyrosine-containing proteins have been subsequently identified to be JAK2, Fyn, and Syp. JAK2 and Fyn are transiently associated with Grb2 upon stimulation with IL-11, suggesting that JAK2 and Fyn may be involved in transducing signals from the IL-11 receptor glycoprotein 130 to the Ras system through Grb2. Taken together, these results suggest that IL-11-induced interactions of JAK2, Fyn, and Grb2 may not only provide a novel mechanism for the activation of the Ras/MAPK system but also indicate cross-talk among diverse signaling pathways.	INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043105] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL48819] Funding Source: Medline; NIDDK NIH HHS [R01DK43105] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBER DL, 1994, MOL CELL BIOL, V14, P6506, DOI 10.1128/MCB.14.10.6506; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ELLIS C, 1991, ONCOGENE, V6, P895; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1994, J AM SOC NEPHROL, V5, P1288; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; WEBB GC, 1993, GENOMICS, V18, P14, DOI 10.1006/geno.1993.1421; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; YANG YC, 1993, STEM CELLS, V11, P474, DOI 10.1002/stem.5530110617; YIN TG, 1994, J BIOL CHEM, V269, P3731; YIN TG, 1993, J IMMUNOL, V151, P2555; YIN TG, 1994, EXP HEMATOL, V22, P467	31	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					27999	28002						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499280				2022-12-27	WOS:A1995TG21000005
J	NORGARDSUMNICHT, KE; ROUX, L; TOOMRE, DK; MANZI, A; FREEZE, HH; VARKI, A				NORGARDSUMNICHT, KE; ROUX, L; TOOMRE, DK; MANZI, A; FREEZE, HH; VARKI, A			UNUSUAL ANIONIC N-LINKED OLIGOSACCHARIDES FROM BOVINE LUNG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; PULSED AMPEROMETRIC DETECTION; SIALIC ACIDS; DICTYOSTELIUM-DISCOIDEUM; EXCHANGE CHROMATOGRAPHY; STRUCTURAL-ANALYSIS; HNK-1 CARBOHYDRATE; MAMMALIAN-CELLS; KERATAN SULFATE; SUGAR CHAINS	We previously described a diverse family of sulfated anionic N-linked oligosaccharides released by peptide: N-glycosidase F (PNGaseF) from calf pulmonary artery endothelial (CPAE) cells (Roux, L., Holoyda, S,, Sundblad, G,, Freeze, H.H., and Varki, A, (1988) J. Biol. Chem. 263, 8879-8889), Since a major fraction of the intact lung consists of endothelial cells, we reasoned that bovine lung might be a rich source of similar molecules, Total N-linked oligosaccharides from bovine lung acetone powder were released by PNGaseF, labeled by [H-3]NaBH4 reduction, and the anionic fractions were studied with a variety of techniques, The sugar chains with lesser negative charge (designated Class I) share several properties of conventional multiantennary complex-type chains, However, unlike the case with CPAE cells, sialic acids account only for a minority of the anionic properties and only a small proportion carry sulfate esters, A variety of different treatments indicate that most of the unexplained negative charge is due to multiple carboxylic acid groups, Resistance to beta glucuronidase and alpha-iduronidase suggests that these may be previously undescribed modifications of mammalian oligosaccharides. The most highly charged N-linked chains (designated Class II) are more similar in general structure to the corresponding ones from CPAE cells, although relatively more abundant, Their high charge is primarily due to chondroitin sulfate, heparin/heparan sulfate, or keratan sulfate glycosaminoglycan chains, Sequential digestion studies suggest that a significant proportion of these molecules have more than one type of glycosaminoglycan chain associated with them, Compositional analysis indicates the presence of xylose residues in Class II, but not Class I molecules, However, unlike the case with conventional glycosaminoglycans, these residues are not at the reducing terminus. Most previously reported structures of complex-type N-linked oligosaccharides are derived from the glycoproteins of blood cells, plasma, or the secretions of cultured mammalian cells, This library of N-linked oligosaccharides from an intact mammalian organ (lung) contains a high proportion of novel anionic sugar chains whose structures are different from conventional complex-type sialylated chains and only partially related to those from CPAE cells, Further exploration of the N-linked chains of intact mammalian tissues seems warranted.	UNIV CALIF SAN DIEGO, SCH MED, CTR CANC, GLYCOBIOL PROGRAM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA; LA JOLLA CANC RES FDN, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute				Freeze, Hudson/0000-0001-6316-0501	NATIONAL CANCER INSTITUTE [R01CA038701] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA38701] Funding Source: Medline; NHLBI NIH HHS [HL07107-19, P50 HL 23594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BADACHE A, 1992, DEV NEUROSCI-BASEL, V14, P342, DOI 10.1159/000111681; BAENZIGER JU, 1994, FASEB J, V8, P1019, DOI 10.1096/fasebj.8.13.7926366; BRENNER W, 1995, ANAL BIOCHEM, V225, P213, DOI 10.1006/abio.1995.1146; CUMMINGS RD, 1984, J BIOL CHEM, V259, P6253; EDGE ASB, 1984, J BIOL CHEM, V259, P4710; Evans MJ, 1989, LUNG CELL BIOL, P1; FREEZE HH, 1986, J BIOL CHEM, V261, P127; FREEZE HH, 1983, J BIOL CHEM, V258, P4874; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; GOWDA DC, 1989, BIOCHEMISTRY-US, V28, P4468, DOI 10.1021/bi00436a052; GREEN ED, 1988, J BIOL CHEM, V263, P25; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HARDY MR, 1989, METHOD ENZYMOL, V179, P76; HART GW, 1978, J BIOL CHEM, V253, P5795; HOFLACK B, 1982, EUR J BIOCHEM, V124, P527; KARLSSON NG, 1995, GLYCOCONJUGATE J, V12, P69, DOI 10.1007/BF00731871; KOBATA A, 1992, CELL SURFACE CARBOHY, P1; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRESSE H, 1981, J BIOL CHEM, V256, P2926; LEE YC, 1990, ANAL BIOCHEM, V189, P151, DOI 10.1016/0003-2697(90)90099-U; LOHMANDER LS, 1980, J BIOL CHEM, V255, P6084; MANZI A, 1995, J BIOL CHEM, V270, P9154, DOI 10.1074/jbc.270.16.9154; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MCMANUS MT, 1988, PLANTA, V175, P506, DOI 10.1007/BF00393072; MELLIS SJ, 1983, ANAL BIOCHEM, V134, P442, DOI 10.1016/0003-2697(83)90320-2; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; MIKOL DD, 1990, J CELL BIOL, V110, P471, DOI 10.1083/jcb.110.2.471; MOPPER K, 1973, ANAL BIOCHEM, V56, P440, DOI 10.1016/0003-2697(73)90210-8; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NILSSON B, 1983, J BIOL CHEM, V258, P6056; OKA S, 1992, J BIOL CHEM, V267, P22711; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; ROUX L, 1988, J BIOL CHEM, V263, P8879; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SILVESTRI LJ, 1982, ANAL BIOCHEM, V123, P303, DOI 10.1016/0003-2697(82)90450-X; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; SUNDBLAD G, 1988, J BIOL CHEM, V263, P8890; TAKAHASHI N, 1990, J BIOL CHEM, V265, P7793; TAKAHASHI N, 1986, BIOCHEMISTRY-US, V25, P388, DOI 10.1021/bi00350a018; TAKASAKI S, 1974, J BIOCHEM-TOKYO, V76, P783; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1980, J BIOL CHEM, V255, P847; WAFFENSCHMIDT S, 1987, ANAL BIOCHEM, V165, P337, DOI 10.1016/0003-2697(87)90278-8; WEIBEL ER, 1976, LUNG CELLS DISEASE, P3; WING DR, 1992, GLYCOCONJUGATE J, V9, P293, DOI 10.1007/BF00731089; YAMASHITA K, 1983, J BIOL CHEM, V258, P4144	51	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27634	27645		10.1074/jbc.270.46.27634	http://dx.doi.org/10.1074/jbc.270.46.27634			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499228	hybrid			2022-12-27	WOS:A1995TE73600039
J	RAO, GN; DELAFONTAINE, P; RUNGE, MS				RAO, GN; DELAFONTAINE, P; RUNGE, MS			THROMBIN STIMULATES PHOSPHORYLATION OF INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR, INSULIN-RECEPTOR SUBSTRATE-1, AND PHOSPHOLIPASE C-GAMMA-1 IN RAT AORTIC SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE-KINASE; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; MOLECULAR-CLONING; ACTIVATION; INVITRO; MITOGENESIS; MECHANISM; SEVENLESS	It has recently been reported that protein-tyrosine kinase activity is required for thrombin-induced growth in vascular smooth muscle cells (VSMC). In the present study, we have identified several phosphoproteins that are tyrosine-phosphorylated in response to thrombin in quiescent VSMC. These proteins are insulin-like growth factor-1 receptor beta-subunit (IGF-IR beta), insulin receptor substrate-1 (IRS-1), and phospholipase C-gamma 1 (PLC-gamma 1). Thrombin-stimulated phosphorylation of these proteins was rapid; it was maximal at 1 min and reduced thereafter. Thrombin also activated mitogen-activated protein kinases (MAPK) in quiescent VSMC in a biphasic manner with a rapid and larger peak at 10 min (6-fold) followed by a sustained smaller second peak at 2 h (2-fold). Inhibition of protein-tyrosine kinase activity by the use of two structurally different protein-tyrosine kinase inhibitors, genistein and herbimycin A, significantly blocked the thrombin-induced tyrosine phosphorylation of IGF-1R beta, IRS-1, and PLC-gamma 1 and decreased thrombin-stimulated DNA synthesis. In contrast, however, inhibition of protein-tyrosine kinase activity had no effect on thrombin activation of MAPK. Collectively, these findings suggest a role for tyrosine phosphorylation of IGF-IR beta, IRS-1, and PLC-gamma 1 in thrombin-induced mitogenic signaling events in VSMC. Furthermore, while protein tyrosine phosphorylation is essential for thrombin-induced DNA synthesis, it is not required for thrombin-stimulated MAPK activation. Since thrombin rapidly activated Src in VSMC, Src may be involved in the cross-talk between the G-protein-coupled receptor agonist and a tyrosine kinase receptor such as IGF-1R.	EMORY UNIV,SCH MED,DIV CARDIOL,ATLANTA,GA 30322	Emory University	RAO, GN (corresponding author), UNIV TEXAS,MED BRANCH,DIV CARDIOL,9138 MED RES BLDG,RT 1064,301 UNIV BLVD,GALVESTON,TX 77555, USA.			Delafontaine, Patrice/0000-0003-3744-3617				ADAMO M, 1992, BIOFACTORS, V3, P151; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BRASS LF, 1992, J BIOL CHEM, V267, P6044; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CHUANG LM, 1994, J BIOL CHEM, V268, P27645; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; FEINSTEIN MB, 1993, ADV EXP MED BIOL, V344, P129; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HOWE LR, 1993, J BIOL CHEM, V268, P20717; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P318; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIEBENHOFF U, 1993, BIOCHEM J, V295, P41, DOI 10.1042/bj2950041; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MELZIG M, 1986, BIOMED BIOCHIM ACTA, V45, P1199; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; RAO GN, 1994, J BIOL CHEM, V269, P32586; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAREMBOCK IJ, 1991, CIRCULATION, V84, P232, DOI 10.1161/01.CIR.84.1.232; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WHITE MF, 1989, J CELL BIOCHEM, V39, P429, DOI 10.1002/jcb.240390409; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975	49	132	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27871	27875		10.1074/jbc.270.46.27871	http://dx.doi.org/10.1074/jbc.270.46.27871			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499260	hybrid			2022-12-27	WOS:A1995TE73600071
J	SANCEAU, J; KAISHO, T; HIRANO, T; WIETZERBIN, J				SANCEAU, J; KAISHO, T; HIRANO, T; WIETZERBIN, J			TRIGGERING OF THE HUMAN INTERLEUKIN-6 GENE BY INTERFERON-GAMMA AND TUMOR-NECROSIS-FACTOR-ALPHA IN MONOCYTIC CELLS INVOLVES COOPERATION BETWEEN INTERFERON REGULATORY FACTOR-I, NF-KAPPA-B, AND SP1 TRANSCRIPTION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TYROSINE PHOSPHORYLATION; FACTOR-II; ACTIVATION; PROTEIN; EXPRESSION; BINDING; PROMOTER; ELEMENTS; IRF-1	We investigated the molecular basis of the synergistic induction by iterferon-gamma (IFN-gamma)/tumor necrosis factor-alpha (TNF-alpha) of human interleukin-6 (IL-6) gene in THP-1 monocytic cells, and compared it with the basis of this induction by lipopolysaccharide (LPS), Functional studies with IL-6 promoter demonstrated that three regions are the targets of the IFN-gamma and/or TNF-gamma action, whereas only one of these regions seemed to be implicated in LPS activation, The three regions concerned are: 1) a region between -73 and -36, which is the minimal element inducible by LPS or TNF-alpha; 2) an element located between -181 and -73, which appeared to regulate the response to IFN-gamma and TNF-alpha negatively; and 3) a distal element upstream of -224, which was inducible by IFN-gamma alone. LPS signaling was found to involve MF kappa B activation by the p50/p65 heterodimers. Synergis tic induction of the IL-6 gene by IFN-gamma and TNF-alpha, in monocytic cells, involved cooperation between the IRF-1 and NF kappa B p65 homodimers with concomitant removal of the negative effect of the retinoblastoma control element present in the IL-6 promoter. This removal occurred by activation of the constitutive Sp1 factor, whose increased binding activity and phosphorylation were mediated by IFN-gamma.	OSAKA UNIV, SCH MED, CTR BIOMED RES, DIV MOLEC ONCOL, SUITA, OSAKA 565, JAPAN	Osaka University	SANCEAU, J (corresponding author), INST CURIE, INSERM, U365, RECH SECT, 26 RUE ULM, F-75231 PARIS, FRANCE.		Kaisho, Tsuneyasu/B-4130-2012; Hirano, Toshio/C-8194-2009					BAGNARA GP, 1993, STEM CELLS, V11, P137; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOUTWOOD J, 1993, BLOOD, V82, P2611; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; DIEHL JA, 1995, J BIOL CHEM, V270, P2703, DOI 10.1074/jbc.270.6.2703; DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018; EMILIE D, 1994, BLOOD, V84, P2472; EMILIE D, 1992, BLOOD, V80, P498; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HIRANO T, 1992, CHEM IMMUNOL, V51, P153; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; INOUE K, 1994, BLOOD, V84, P2672, DOI 10.1182/blood.V84.8.2672.bloodjournal8482672; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; KERR IM, 1991, FEBS LETT, V285, P194, DOI 10.1016/0014-5793(91)80802-A; KIEHNTOPF M, 1995, J EXP MED, V181, P793, DOI 10.1084/jem.181.2.793; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; KRUYS V, 1994, BIOCHIMIE, V76, P862, DOI 10.1016/0300-9084(94)90188-0; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LIN RT, 1994, J BIOL CHEM, V269, P17542; LIU JM, 1994, BLOOD, V84, P3995, DOI 10.1182/blood.V84.12.3995.bloodjournal84123995; MCGINLEY MD, 1995, J BIOL CHEM, V270, P5213, DOI 10.1074/jbc.270.10.5213; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; MORI N, 1994, BLOOD, V84, P2904; MURATA Y, 1994, J BIOL CHEM, V269, P20674; NICHOLS J, 1992, BLOOD, V80, P2953; PARRINGTON J, 1993, EUR J BIOCHEM, V214, P617, DOI 10.1111/j.1432-1033.1993.tb17961.x; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PORGADOR A, 1992, CANCER RES, V52, P3679; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; REIMANN T, 1994, J IMMUNOL, V153, P5740; REVEL M, 1989, EXPERIENTIA, V45, P549, DOI 10.1007/BF01990505; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROSSELLI F, 1992, HUM GENET, V89, P42, DOI 10.1007/BF00207040; Sambrook J, 1989, MOL CLONING LABORATO; SANCEAU J, 1991, J IMMUNOL, V147, P2630; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCAMBIA G, 1995, BRIT J CANCER, V71, P354, DOI 10.1038/bjc.1995.71; SEHGAL PB, 1987, SCIENCE, V235, P731, DOI 10.1126/science.3492764; SEHGAL PB, 1990, MOL BIOL MED, V7, P117; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SUZUKI T, 1990, JPN J CANCER RES, V81, P979, DOI 10.1111/j.1349-7006.1990.tb03335.x; TANABE O, 1988, J IMMUNOL, V141, P3875; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; UDVADIA AJ, 1992, CELL GROWTH DIFFER, V3, P597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; UEDA A, 1994, J IMMUNOL, V153, P2052; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; WANLENG D, 1993, J IMMUNOL, V151, P322; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WIETZERBIN J, 1990, J LEUKOCYTE BIOL, V48, P149, DOI 10.1002/jlb.48.2.149; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x	81	187	191	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27920	27931		10.1074/jbc.270.46.27920	http://dx.doi.org/10.1074/jbc.270.46.27920			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499267	hybrid			2022-12-27	WOS:A1995TE73600078
J	YU, JC; MAHADEVAN, D; LAROCHELLE, WJ; PIERCE, JH; HEIDARAN, MA				YU, JC; MAHADEVAN, D; LAROCHELLE, WJ; PIERCE, JH; HEIDARAN, MA			STRUCTURAL COINCIDENCE OF ALPHA-PDGFR EPITOPES BINDING TO PLATELET-DERIVED GROWTH FACTOR-AA AND A POTENT NEUTRALIZING MONOCLONAL-ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTORS; SIGNAL TRANSDUCTION; CELLS; DIMERIZATION; LOCALIZATION; EXPRESSION; ACTIVATION; PATHWAYS; CLONING; PROTEIN	We have generated two groups of deletion mutants of the alpha PDGFR and one group of chimeras between alpha PDGFR and beta PDGFR to further investigate the structural requirements of the alpha PDGFR for binding to platelet-derived growth factor (PDGF)-AA and to a monoclonal antibody against alpha PDGFR (designated as mAb-alpha R1). The mAb-alpha R1 has recently been reported to block high affinity binding of PDGF-AA to alpha PDGFR The first group of mutants were carboxyl-terminal deletion mutants encoding the first two immunoglobulin (Ig)-like domains (alpha R1-216), the first four Ig-Like domains (alpha R1-415), or all five Ig-like domains (alpha R1-530) of the alpha PDGFR Since these mutants lacked transmembrane domains, their expression in NIH/3T3 cells resulted in secretion of the truncated alpha PDGFRs. Using conditioned medium from NIH/3T3 transfectants, we showed that mAb-alpha R1 was able to immunoprecipitate each of these secreted form of alpha PDGFRs, suggesting that the epitope recognized by mAb-alpha R1 is located within Ig-like domains 1 and 2 of the alpha PDGFR. Furthermore, PDGF-AA exhibited detectable binding to alpha R1-415 or alpha 1-530 but failed to interact with alpha R1-216, suggesting that the first two Ig-like domains of the alpha PDGFR are not sufficient for PDGF-AA binding. The second group of alpha PDGFR mutants were internal deletion mutants lacking Ig-like loop 1 (alpha R(Delta 49-100)), Ig-like loop 2 (alpha R(Delta 150-189)), Ig-like loop 3 (alpha R(Delta 235-290)), or part of Ig-like loops 4 and 5 (alpha R(Delta 375-450)). The internal deletion mutants were transfected into 32D cells which lack both alpha PDGFR and beta PDGFR PDGF-AA bound with high affinity to 32D cells expressing alpha R(Delta 375-450) but not to 32D cells expressing the other three internal deletion mutants, suggesting that the region required for PDGF-AA binding should be within the first three Ig-like domains of the alpha PDGFR. In addition, mAb-alpha R1 bound to 32D cells expressing alpha R(Delta 235-290) but failed to bind 32D cells transfected with alpha R(Delta 49-100) or alpha R(Delta 150-189). Since this antibody could immunoprecipitate alpha R(Delta 49-100), but not alpha R(Delta 150-189) in cell lysates of the 32D transfectants, these results suggest that Ig-like loop 1 is dispensible for mAb-alpha R1 recognition and deletion of Ig-like loop 1 of alpha PDGFR significantly inhibits cell surface expression. The two alpha/beta PDGFR chimeras generated were an alpha PDGFR containing the first Ig-like domain of beta PDGFR (beta(126)alpha(127)R) and a beta PDGFR possessing the first Ig-Like domain of alpha PDGFR (alpha(119)beta(119)R). PDGF-AA-bound to 32D cells expressing beta(126)alpha(127)R, but not to those expressing alpha(119)beta(119)R, suggesting that Ig-like domain 1 is not required for conferring PDGF-AA binding specificity. Taken together, we conclude that major high affinity sites for PDGF-AA binding are located within Ig-like domains 2 and 3 and that the epitope recognized by mAb-alpha R1 is located within Ig-like domain 2 of the alpha PDGFR.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DROZDOFF V, 1991, J BIOL CHEM, V266; FLEMING TP, 1992, ONCOGENE, V7, P1355; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HEIDARAN MA, 1992, J BIOL CHEM, V257, P2884; HELDIN CH, 1985, MOL CELL ENDOCRINOL, V39, P169, DOI 10.1016/0303-7207(85)90061-9; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; LAROCHELLE WJ, 1993, CELL GROWTH DIFFER, V4, P547; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MAYSIROFF M, 1993, BIOCHEMISTRY-US, V32, P11734; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; MUNSON PJ, 1984, COMPUTERS ENDOCRINOL, P117; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	32	23	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10668	10674						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511602				2022-12-27	WOS:A1994NF01700072
J	CAIRNS, J; QIN, SX; PHILP, R; TAN, YH; GUY, GR				CAIRNS, J; QIN, SX; PHILP, R; TAN, YH; GUY, GR			DEPHOSPHORYLATION OF THE SMALL HEAT-SHOCK PROTEIN HSP27 IN-VIVO BY PROTEIN PHOSPHATASE 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CHINESE-HAMSTER-CELLS; ENDOTHELIAL-CELLS; STRESS PROTEINS; ALPHA-CRYSTALLIN; MAPKAP KINASE-2; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION; INTERLEUKIN-1	The phosphorylation of the Hsp27 complex is rapidly altered in MRC-5 cells when they are exposed to mitogens, cytokines, stress, or serine/threonine protein phosphatase inhibitors. Here we performed experiments to identify which cellular protein phosphatase (PP1, PP2A, or PP2B) is responsible for the in vivo phosphorylation/dephosphorylation of Hsp27. In their purified forms, PP2A dephosphorylates Hsp27 more effectively than PP2B, whereas PP1 is weakly active. Measurements of enzyme activity of lysates derived from inhibitor-treated cells indicated that Hsp27 phosphatase activity is equally sensitive to okadaic acid (PPI/PP2A inhibitor) and cyclosporin (PP2B inhibitor) and that both okadaic acid and cyclosporin treatment inhibited Hsp27 phosphatase activity additively. Together the in vitro data suggest that both PP2A and PP2B can dephosphorylate Hsp27. However, the phosphorylation of Hsp27 in vivo is only affected when cells are treated with PP1 and PP2A inhibitors (okadaic acid, calyculin A) or cantharidin (PP2A inhibitor), but not the PP2B inhibitor, cyclosporin A, suggesting PP2A to be the main enzyme dephosphorylating Hsp27 in the cells. Purification and immuoblotting of Hsp27 phosphatase from MRC-5 cells also suggest it to be PP2A and not PP1 or PP2B. The ability of PP2A to dephosphorylate Hsp27 is shown to be regulated by the phosphorylation state of PP2A itself.	NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, SIGNAL TRANSDUCT LAB, SINGAPORE 0511, SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore								ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BITAR KN, 1991, BIOCHEM BIOPH RES CO, V181, P1192, DOI 10.1016/0006-291X(91)92065-R; CAO XM, 1992, J BIOL CHEM, V267, P12991; CHAMBARD JC, 1983, BIOCHEM BIOPH RES CO, V111, P1034, DOI 10.1016/0006-291X(83)91404-3; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CIOCCA DR, 1983, CANCER RES, V43, P1204; CRETE P, 1990, RADIAT RES, V121, P320, DOI 10.2307/3577783; DARBON JM, 1986, J BIOL CHEM, V261, P8002; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; DEMOLLE D, 1988, J BIOL CHEM, V263, P18459; DENAGEL DC, 1991, IMMUNOL RES, V10, P66, DOI 10.1007/BF02918168; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; FUQUA SAW, 1989, CANCER RES, V49, P4126; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GAESTEL M, 1992, J BIOL CHEM, V267, P21607; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUESDON F, 1991, J IMMUNOL, V147, P3402; GUO H, 1993, J BIOL CHEM, V268, P11193; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1992, J BIOL CHEM, V267, P1846; GUY GR, 1993, J BIOL CHEM, V268, P2141; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; HUOT J, 1991, CANCER RES, V51, P5245; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; KAUR P, 1989, FEBS LETT, V258, P269, DOI 10.1016/0014-5793(89)81671-0; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LI YM, 1992, P NATL ACAD SCI USA, V89, P11867, DOI 10.1073/pnas.89.24.11867; LINQUIST S, 1988, ANNU REV GENET, V22, P631; MENON SD, 1993, J BIOL CHEM, V268, P26805; MICHISHITA M, 1991, BIOCHEM BIOPH RES CO, V176, P979, DOI 10.1016/0006-291X(91)90378-K; MING Z, 1993, J BIOL CHEM, V268, P35; REGAZZI R, 1988, BIOCHEM BIOPH RES CO, V152, P62, DOI 10.1016/S0006-291X(88)80680-6; ROBAYE B, 1989, BIOCHEM BIOPH RES CO, V163, P301, DOI 10.1016/0006-291X(89)92135-9; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHIBANUMA M, 1991, CELL GROWTH DIFFER, V2, P583; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STRAHLER JR, 1991, BIOCHEM BIOPH RES CO, V175, P134, DOI 10.1016/S0006-291X(05)81211-2; TAN YH, 1993, SCIENCE, V262, P376, DOI 10.1126/science.7692598; TETU B, 1992, CANCER RES, V52, P2325; THOR A, 1991, J NATL CANCER I, V83, P170, DOI 10.1093/jnci/83.3.170; VITEK MP, 1984, J MOL BIOL, V178, P173, DOI 10.1016/0022-2836(84)90138-4; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; WELSH MJ, 1992, BIOCHEM BIOPH RES CO, V184, P217, DOI 10.1016/0006-291X(92)91181-O	50	87	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9176	9183						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510704				2022-12-27	WOS:A1994NB41100082
J	ANOUAR, Y; MACARTHUR, L; COHEN, J; IACANGELO, AL; EIDEN, LE				ANOUAR, Y; MACARTHUR, L; COHEN, J; IACANGELO, AL; EIDEN, LE			IDENTIFICATION OF A TPA-RESPONSIVE ELEMENT MEDIATING PREFERENTIAL TRANSACTIVATION OF THE GALANIN GENE PROMOTER IN CHROMAFFIN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; SIGNAL TRANSDUCTION PATHWAYS; NUCLEOTIDE-SEQUENCE ANALYSIS; PHORBOL ESTER TREATMENT; TRANSCRIPTION FACTORS; BINDING-PROTEINS; ADRENAL-MEDULLA; ANTERIOR-PITUITARY; ENHANCER ELEMENTS; INDUCIBLE GENES	The gene encoding the neuropeptide galanin is upregulated by second messenger signal transduction pathways in bovine chromaffin cells. To identify its transcriptional regulatory elements, 5'-flanking sequences of the galanin gene were transiently transfected into primary cultures of bovine chromaffin cells within reporter gene constructs. Multiple regions of the galanin 5' flank seem to be necessary for basal activity. The most promoter-proximal of these regions contains a sequence (TGACG) -66 to -62 nucleotides upstream from the transcriptional start site which mediates stimulation by 12-O-tetradecanoylphorbol- 13 acetate (TPA), as demonstrated by site-directed mutagenesis and cis-activation experiments. This cis-regulatory element mediates preferential TPA stimulation of transcription from the galanin promoter in chromaffin cells compared with bovine endothelial or HeLa cells, DNA-protein binding assays indicate that an oligonucleotide that includes the galanin TPA-responsive element (GTRE) binds specifically to proteins from nuclear extracts of chromaffin cells. TPA treatment persistently increases this binding activity in chromaffin but not in endothelial cells. Mutation of the galanin promoter within the -66 to -62 region renders it unresponsive to transcriptional stimulation by TPA, and a correspondingly mutated oligonucleotide fails to bind chromaffin cell nuclear proteins in a gel-shift assay. Chromaffin cell nuclear extracts also contain proteins that bind consensus TPA-responsive (TRE) and cyclic AMP-responsive (CRE) elements. GTRE, TRE, and CRE oligonucleotides all compete more efficiently for protein binding to their labeled congeners than for protein binding to either of the other labeled oligonucleotides, suggesting that the GTRE, TRE, and CRE oligo nucleotides each bind unique as well as common proteins, likely to be members of the Jun/Fos and cAMP-responsive element-binding protein/activating transcription factors (CREB/ATF) families of transcription factors, in chromaffin cells.			ANOUAR, Y (corresponding author), NIMH,CELL BIOL LAB,MOLEC NEUROSCI SECT,BLDG 36,RM 3A-17,BETHESDA,MD 20892, USA.		Anouar, Youssef/F-9683-2017	Eiden, Lee/0000-0001-7524-944X				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENBROOK DM, 1990, ONCOGENE, V5, P295; BURGOYNE RD, 1988, FEBS LETT, V238, P151, DOI 10.1016/0014-5793(88)80246-1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EIDEN LE, 1984, NATURE, V312, P661, DOI 10.1038/312661a0; EIDEN LE, 1983, LIFE SCI, V33, P687, DOI 10.1016/0024-3205(83)90772-5; EIDEN LE, 1987, CELL MOL NEUROBIOL, V7, P339, DOI 10.1007/BF00733787; EVANS HF, 1991, ENDOCRINOLOGY, V129, P1682, DOI 10.1210/endo-129-3-1682; FINK JS, 1991, J BIOL CHEM, V266, P3882; FISCHERCOLBRIE R, 1992, J NEUROCHEM, V59, P780, DOI 10.1111/j.1471-4159.1992.tb09440.x; FISONE G, 1987, P NATL ACAD SCI USA, V84, P7339, DOI 10.1073/pnas.84.20.7339; GABRIEL SM, 1990, NEUROENDOCRINOLOGY, V51, P168, DOI 10.1159/000125333; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; KAPLAN LM, 1988, P NATL ACAD SCI USA, V85, P1065, DOI 10.1073/pnas.85.4.1065; KAPLAN LM, 1988, P NATL ACAD SCI USA, V85, P7408, DOI 10.1073/pnas.85.19.7408; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MACARTHUR L, 1993, MOL PHARMACOL, V44, P545; MALHOTRA RK, 1989, J NEUROSCI, V9, P4150; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MIRALLES P, 1990, DIABETES, V39, P996, DOI 10.2337/diabetes.39.8.996; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OTTLECZ A, 1988, P NATL ACAD SCI USA, V85, P9861, DOI 10.1073/pnas.85.24.9861; PRUSS RM, 1988, J BIOL CHEM, V263, P13173; RAUSCH DM, 1988, MOL ENDOCRINOL, V2, P921, DOI 10.1210/mend-2-10-921; ROKAEUS A, 1990, ENDOCRINOLOGY, V127, P3096, DOI 10.1210/endo-127-6-3096; ROKAEUS A, 1986, P NATL ACAD SCI USA, V83, P6287, DOI 10.1073/pnas.83.17.6287; ROKAEUS A, 1988, FEBS LETT, V234, P400, DOI 10.1016/0014-5793(88)80125-X; ROSS ME, 1990, J NEUROSCI, V10, P520; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMITH SE, 1993, NUCLEIC ACIDS RES, V21, P1581, DOI 10.1093/nar/21.7.1581; TATEMOTO K, 1983, FEBS LETT, V164, P124, DOI 10.1016/0014-5793(83)80033-7; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; WAYMIRE JC, 1983, J NEUROSCI METH, V7, P329, DOI 10.1016/0165-0270(83)90026-2; WILSON SP, 1981, EXP CELL RES, V133, P159, DOI 10.1016/0014-4827(81)90366-9; WILSON SP, 1990, J BIOL CHEM, V265, P648; WOYCHIK RP, 1982, NUCLEIC ACIDS RES, V10, P7197, DOI 10.1093/nar/10.22.7197; WYNICK D, 1993, NATURE, V364, P529, DOI 10.1038/364529a0	53	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6823	6831						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509811				2022-12-27	WOS:A1994MZ50300089
J	CASCIERI, MA; MACLEOD, AM; UNDERWOOD, D; SHIAO, LL; BER, E; SADOWSKI, S; YU, H; MERCHANT, KJ; SWAIN, CJ; STRADER, CD; FONG, TM				CASCIERI, MA; MACLEOD, AM; UNDERWOOD, D; SHIAO, LL; BER, E; SADOWSKI, S; YU, H; MERCHANT, KJ; SWAIN, CJ; STRADER, CD; FONG, TM			CHARACTERIZATION OF THE INTERACTION OF N-ACYL-L-TRYPTOPHAN BENZYL ESTER NEUROKININ ANTAGONISTS WITH THE HUMAN NEUROKININ-1 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-P; BINDING; POTENT; PROTEINS; MODEL	We have recently shown that a series of N-acyl-L-tryptophan benzyl esters are potent substance P antagonists (Macleod, A. M., Merchant, K. J., Cascieri, M. A., Sadowski, S., Ber, E., Swain, C, J., and Baker, R. (1993) J. Med Chem, 14, 2044-2045). We now report the detailed characterization of the interaction of N-acetyl-L-tryptophan-3,5-bistrifluoromethyl benzyl ester (L-732,138) with the human neurokinin-1 (NK-1) receptor. L-732,138 inhibits the binding of I-125-substance P to the cloned human NK1 receptor expressed in Chinese hamster ovary cells with an IC50 of 2.3 +/- 0.7 nM. In contrast, it has 200-fold lower affinity for the cloned rat NK-1 receptor and has > 1000-fold lower affinity for the human NK-2 and NK-3 receptors. L-732,138 acts as a competitive antagonist of substance P, as shown by functional Schild analysis of the inhibition of substance P-induced inositol phosphate synthesis, by kinetic analysis of the dissociation rate, and by thermodynamic analysis of the equilibrium binding of I-125-substance P to the NK-1 receptor. L-732,138 also competitively inhibits the binding of the quinuclidine amine antagonist, [I-125]L-703,606, to the receptor. The compound has 230- and 10-fold reduced affinity for mutant NK-1 receptors in which histidine 265 or histidine 197, respectively, are replaced with alanine. We have previously shown that these residues play key roles in the binding of quinuclidine antagonists to the NK-1 receptor. These results suggest that the tryptophan and quinuclidine series of NK-1 antagonists bind to similar binding sites on the human NK-1 receptor.	MERCK & CO INC, RES LABS, DEPT MOLEC SYST, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, RES LABS, NEUROSCI RES CTR, HARLOW CM20 2PT, ESSEX, ENGLAND	Merck & Company; Merck & Company	CASCIERI, MA (corresponding author), MERCK & CO INC, RES LABS, DEPT MOLEC PHARMACOL & BIOCHEM, BLDG 80M-213, POB 2000, RAHWAY, NJ 07065 USA.							BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CASCIERI MA, 1992, MOL PHARMACOL, V42, P458; DE KONINCK Y, 1991, P NATL ACAD SCI USA, V88, P11344, DOI 10.1073/pnas.88.24.11344; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; EGLEZOS A, 1991, EUR J PHARMACOL, V209, P277, DOI 10.1016/0014-2999(91)90183-Q; FONG TM, 1992, MOL PHARMACOL, V41, P24; FONG TM, 1993, NATURE, V362, P350; FONG TM, 1994, IN PRESS J BIOL CHEM; GARRET C, 1991, P NATL ACAD SCI USA, V88, P10208, DOI 10.1073/pnas.88.22.10208; MACLEOD AM, 1993, J MED CHEM, V36, P2044, DOI 10.1021/jm00066a015; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAGAHISA A, 1992, EUR J PHARMACOL, V217, P191, DOI 10.1016/0014-2999(92)90847-W; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; SEWARD EM, 1993, BIOORG MED CHEM LETT, V3, P1361, DOI 10.1016/S0960-894X(00)80349-2; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; SWAIN CJ, 1993, BIOORG MED CHEM LETT, V3, P1703, DOI 10.1016/S0960-894X(00)80046-3; XU XJ, 1992, EUR J PHARMACOL, V216, P337, DOI 10.1016/0014-2999(92)90428-7	20	90	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6587	6591						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509807				2022-12-27	WOS:A1994MZ50300051
J	CHARTRAIN, NA; GELLER, DA; KOTY, PP; SITRIN, NF; NUSSLER, AK; HOFFMAN, EP; BILLIAR, TR; HUTCHINSON, NI; MUDGETT, JS				CHARTRAIN, NA; GELLER, DA; KOTY, PP; SITRIN, NF; NUSSLER, AK; HOFFMAN, EP; BILLIAR, TR; HUTCHINSON, NI; MUDGETT, JS			MOLECULAR-CLONING, STRUCTURE, AND CHROMOSOMAL LOCALIZATION OF THE HUMAN INDUCIBLE NITRIC-OXIDE SYNTHASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; RELAXING FACTOR; L-ARGININE; NITROGEN-OXIDES; MOUSE MACROPHAGES; KAPPA-B; CELLS; EXPRESSION; INDUCTION; ENZYME	Nitric oxide, a multifunctional effector molecule synthesized by nitric oxide synthase (NOS) from L-arginine, conveys signals for vasorelaxation, neurotransmission, and cytotoxicity. Three different NOS isoforms have been identified which fall into two distinct types, constitutive and inducible. The inducible NOS (iNOS) isoform is expressed in a variety of cell types and tissues in response to inflammatory agents and cytokines, The human iNOS (NOS2) gene was isolated on overlapping cosmid clones from a human genomic library using both the murine macrophage and the human hepatocyte iNOS cDNAs as probes, Ah isolated cosmids were part of a single genomic locus and no other genomic loci were identified or isolated. Analysis of this locus indicated that the human iNOS gene is similar to 37 kilobases in length and consists of 26 exons and 25 introns. Primer extension analysis of lipopolysaccharide and cytokine-stimulated human hepatocyte RNA mapped the transcriptional initiation site 30 base pairs downstream of a TATA sequence, and a 400-base pair 5'-flanking region was found to be structurally similar to the recently described murine iNOS promoter. Polymerase chain reaction analysis of a human/rodent genomic DNA somatic cell hybrid panel and fluorescent in situ hybridization indicated that the human iNOS gene is located on chromosome 17 at position 17cen-q11.2.	MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOLEC IMMUNOL,RAHWAY,NJ 07065; UNIV PITTSBURGH,DEPT SURG,PITTSBURGH,PA 15261; UNIV PITTSBURGH,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	Merck & Company; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Nussler, Andreas/H-3557-2019	Nussler, Andreas/0000-0002-6666-6791; Hoffman, Eric/0000-0001-6470-5139	NIGMS NIH HHS [GM44100] Funding Source: Medline; NINDS NIH HHS [NS29525] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044100, R37GM044100, R29GM044100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029525] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461; BILLIAR TR, 1990, BIOCHEM BIOPH RES CO, V168, P1034, DOI 10.1016/0006-291X(90)91133-D; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRENNER CA, 1989, BIOTECHNIQUES, V7, P1096; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P1731, DOI 10.1073/pnas.90.5.1731; CUNHA FQ, 1993, J IMMUNOL, V150, P1908; CURRAN RD, 1989, J EXP MED, V170, P1769, DOI 10.1084/jem.170.5.1769; EIZIRIK DL, 1993, FEBS LETT, V317, P62, DOI 10.1016/0014-5793(93)81492-I; EVANS GA, 1989, GENE, V79, P9, DOI 10.1016/0378-1119(89)90088-7; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GOUREAU O, 1993, P NATL ACAD SCI USA, V90, P4276, DOI 10.1073/pnas.90.9.4276; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HECK DE, 1992, J BIOL CHEM, V267, P21277; HIBBS JB, 1992, J CLIN INVEST, V89, P867, DOI 10.1172/JCI115666; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; IMAI T, 1992, BIOMED RES-TOKYO, V13, P371, DOI 10.2220/biomedres.13.371; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; KALING M, 1991, MOL CELL BIOL, V11, P93, DOI 10.1128/MCB.11.1.93; KISHIMOTO J, 1992, GENOMICS, V14, P802, DOI 10.1016/S0888-7543(05)80192-2; KOIDE M, 1993, FEBS LETT, V318, P213, DOI 10.1016/0014-5793(93)80514-U; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MICHEL T, 1992, J CARDIOVASC PHARM, V20, pS45, DOI 10.1097/00005344-199204002-00014; MUDGETT JS, 1990, GENOMICS, V8, P623, DOI 10.1016/0888-7543(90)90248-S; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NAKAYAMA DK, 1992, AM J RESP CELL MOL, V7, P471, DOI 10.1165/ajrcmb/7.5.471; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; NUSSLER AK, 1992, J EXP MED, V176, P261, DOI 10.1084/jem.176.1.261; OBERMAIER B, 1992, BIOTECHNIQUES, V13, P46; OCHOA JB, 1992, J NATL CANCER I, V84, P864, DOI 10.1093/jnci/84.11.864; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; Sambrook J, 1989, MOL CLONING LABORATO; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SESSA WC, 1993, HYPERTENSION, V21, P934, DOI 10.1161/01.HYP.21.6.934; SESSA WC, 1992, J BIOL CHEM, V267, P15274; STADLER J, 1991, J IMMUNOL, V147, P3915; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; Trask B, 1990, Methods Cell Biol, V33, P383; VERMA RS, 1989, HUMAN CHROMOSOMES MA, P6; WOOD ER, 1993, BIOCHEM BIOPH RES CO, V191, P767, DOI 10.1006/bbrc.1993.1283; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; YANG Z, 1990, P NATL ACAD SCI USA, V87, P9226, DOI 10.1073/pnas.87.23.9226	64	352	373	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6765	6772						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509810				2022-12-27	WOS:A1994MZ50300080
J	LI, ZW; DEUTSCHER, MP				LI, ZW; DEUTSCHER, MP			ROLE OF INDIVIDUAL EXORIBONUCLEASES IN PROCESSING AT THE 3' END OF ESCHERICHIA-COLI TRANSFER-RNA PRECURSORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; POLYNUCLEOTIDE PHOSPHORYLASE; RIBONUCLEASE; PURIFICATION; TURNOVER; INVITRO; PH; OVEREXPRESSION; VIABILITY; GENE	We have used an in vitro Escherichia coli tRNA processing system to investigate the specific role of individual exoribonucleases in the 3' maturation of tRNA precursors. The processing of pre-tRNA(Tyr)su(3)(+) and pre-tRNA(2)(Arg) was studied using extracts from cells lacking one or multiple exoribonucleases or using purified RNases. Earlier genetic studies had suggested that multiple exoribonucleases contributed to the maturation of tRNA precursors, and this was proven directly in the studies described here. Complete 3' processing required the combined action of multiple exoribonucleases, and each BNase showed distinct specificities for maturation of the different parts of the 3' precursor segment. RNase II and polynucleotide phosphorylase were most effective in shortening long 3' trailer sequences to intermediates with 2-4 extra 3' residues. Final trimming of the last few 3' nucleotides of these precursors was carried out most efficiently by RNases T and PH, but the two enzymes differed in their specificity for individual nucleotide positions. Depending on the tRNA precursor, the relative importance of the various RNases to the overall maturation process differed. We also showed that purified exoribonucleases can completely complement mutant extracts and that tRNA maturation can be totally reconstructed in vitro using purified enzymes. These studies provide the first detailed information about the specific role of individual exoribonucleases in tRNA processing, and bring us closer to defining a complete E. coli tRNA maturation pathway.	UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, FARMINGTON, CT 06030 USA	University of Connecticut					NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN S, 1987, MOL BIOL RNA NEW PER, P3; BIKOFF EK, 1975, J BIOL CHEM, V250, P6248; BIKOFF EK, 1975, J BIOL CHEM, V250, P6240; BOSL M, 1991, NUCLEIC ACIDS RES, V19, P5863, DOI 10.1093/nar/19.21.5863; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER S, 1965, J MOL BIOL, V13, P629, DOI 10.1016/S0022-2836(65)80131-0; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CUDNY H, 1988, J BIOL CHEM, V263, P1518; CUDNY H, 1986, J BIOL CHEM, V261, P6450; CUDNY H, 1980, P NATL ACAD SCI USA, V77, P834; DEUTSCHER MP, 1985, P NATL ACAD SCI USA, V82, P6427, DOI 10.1073/pnas.82.19.6427; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; DEUTSCHER MP, 1984, P NATL ACAD SCI-BIOL, V81, P4290, DOI 10.1073/pnas.81.14.4290; DEUTSCHER MP, 1985, J BIOL CHEM, V260, P7067; DEUTSCHER MP, 1988, P NATL ACAD SCI USA, V85, P4710, DOI 10.1073/pnas.85.13.4710; DEUTSCHER MP, 1994, TRANSFER RNA; DEUTSCHER MP, 1991, P NATL ACAD SCI USA, V88, P2277; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; KELLY KO, 1992, J BIOL CHEM, V267, P17153; KELLY KO, 1992, J BACTERIOL, V174, P6682, DOI 10.1128/JB.174.20.6682-6684.1992; KELLY KO, 1992, J BIOL CHEM, V267, P16015; MCCLAIN WH, 1977, ACCOUNTS CHEM RES, V10, P418, DOI 10.1021/ar50119a006; NOMURA T, 1988, EMBO J, V7, P3539, DOI 10.1002/j.1460-2075.1988.tb03230.x; REILLY RM, 1986, J BIOL CHEM, V261, P2928; REUVEN NB, 1993, FASEB J, V7, P143, DOI 10.1096/fasebj.7.1.8422961; REUVEN NB, 1993, P NATL ACAD SCI USA, V90, P4350, DOI 10.1073/pnas.90.10.4350; ROBERTSON HD, 1972, J BIOL CHEM, V247, P5243; SAKANO H, 1978, J MOL BIOL, V123, P287, DOI 10.1016/0022-2836(78)90082-7; SAKANO H, 1975, P NATL ACAD SCI USA, V72, P3369, DOI 10.1073/pnas.72.9.3369; SCHEDL P, 1976, CELL, V8, P581, DOI 10.1016/0092-8674(76)90226-9; SEKIYA T, 1979, J BIOL CHEM, V254, P5802; SHIMURA Y, 1978, EUR J BIOCHEM, V86, P267, DOI 10.1111/j.1432-1033.1978.tb12308.x; TUOHY TMF, 1993, IN PRESS J MOL BIOL; ZHANG J, 1988, J BIOL CHEM, V263, P17909; ZHU LQ, 1990, J BACTERIOL, V172, P3146, DOI 10.1128/jb.172.6.3146-3151.1990	36	75	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6064	6071						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509797				2022-12-27	WOS:A1994MY84000089
J	TRUITT, KE; MILLS, GB; TURCK, CW; IMBODEN, JB				TRUITT, KE; MILLS, GB; TURCK, CW; IMBODEN, JB			SH2-DEPENDENT ASSOCIATION OF PHOSPHATIDYLINOSITOL 3'-KINASE 85-KDA REGULATORY SUBUNIT WITH THE INTERLEUKIN-2 RECEPTOR-BETA CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; TYROSINE PHOSPHORYLATION; IL-2 RECEPTOR; SIGNAL TRANSDUCTION; PROTEIN-KINASE; LYMPHOCYTES-T; SH2 DOMAINS; GAMMA-CHAIN; EXPRESSION; ACTIVATION	Interleukin-2 (IL-2) signaling results in tyrosine phosphorylation of the 75-kDa IL-2 receptor (IL-2R) beta chain and the activation of phosphatidylinositol 3'-kinase (PI3-K). Herein, we demonstrate that the 85-kDa (p85) regulatory subunit of PI3-K physically associates with the tyrosine-phosphorylated IL-2R beta chain. A fusion protein containing both the amino- and the carboxyl-terminal src homology 2 domains of p85 precipitates an 80-kDa tyrosine-phosphorylated protein (pp80) from the lysates of IL-2-stimulated, but not unstimulated, human T lymphoblasts. Preclearing studies and immunoblot ting with an antiserum to the IL-2R beta chain demonstrates that pp80 represents a portion of the IL-2R beta chain pool. A tyrosine-phosphorylated oligopeptide corresponding to tyrosine 392 of the IL-2R beta chain partially inhibits binding of the IL-2R beta chain by p85 fusion protein, raising the possibility that this residue plays a role in the interaction of PI3-K with the receptor.	VET AFFAIRS MED CTR, ARTHRIT IMMUNOL SECT, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94121 USA; TORONTO GEN HOSP, TORONTO M5G 2C4, ON, CANADA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIAID NIH HHS [K11-AI01114, AI26644] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026644, K11AI001114] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265; ASAO H, 1992, FEBS LETT, V304, P141, DOI 10.1016/0014-5793(92)80605-G; ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BENEDICT SH, 1987, J IMMUNOL, V139, P1694; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Kanof M., 1991, CURRENT PROTOCOLS IM; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONO T, 1990, P NATL ACAD SCI USA, V87, P1806, DOI 10.1073/pnas.87.5.1806; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MERIDA I, 1993, J BIOL CHEM, V268, P6765; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RIGGS P, 1992, CURRENT PROTOCOLS S, V19; ROBB RJ, 1981, J EXP MED, V154, P1455, DOI 10.1084/jem.154.5.1455; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TSUDO M, 1989, P NATL ACAD SCI USA, V86, P1982, DOI 10.1073/pnas.86.6.1982; TSUDO M, 1989, J IMMUNOL, V143, P4039; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5937	5943						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509794				2022-12-27	WOS:A1994MY84000071
J	FOX, JEB; LIPFERT, L; CLARK, EA; REYNOLDS, CC; AUSTIN, CD; BRUGGE, JS				FOX, JEB; LIPFERT, L; CLARK, EA; REYNOLDS, CC; AUSTIN, CD; BRUGGE, JS			ON THE ROLE OF THE PLATELET MEMBRANE SKELETON IN MEDIATING SIGNAL-TRANSDUCTION - ASSOCIATION OF GP-IIB-IIIA, PP60(C-SRC), PP62(C-YES), AND THE P21(RAS) GTPASE-ACTIVATING PROTEIN WITH THE MEMBRANE SKELETON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; INSOLUBLE CELLULAR MATRIX; GLYCOPROTEIN-IIB; TYROSINE PHOSPHORYLATION; ACTIN-FILAMENTS; PHOSPHOLIPASE-C; CYTOSKELETAL STRUCTURES; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; FOCAL ADHESIONS	The platelet plasma membrane is lined with a membrane skeleton composed of short actin filaments, actin-binding protein, spectrin, vinculin, and other unidentified proteins. It is connected to the outside of the cell through association with the cytoplasmic domains of transmembrane receptors. In detergent-lysed platelets, cytoplasmic actin filaments are sedimented by centrifugation at 15,600 X g, but the sedimentation of membrane skeleton fragments requires higher g-forces (100,000 X g). In the present study, we show that the major platelet integrin, glycoprotein (GP) IIb-IIIa, sediments from detergent-lysed platelets at 100,000 x g together with fragments of the membrane skeleton that contain the cytoskeletal proteins spectrin, vinculin, and talin. In addition, this cell fraction contained the tyrosine kinases pp60c-src and pp62c-yes and the p21ras GTPase-activating protein (GAP). After thrombin-induced platelet aggregation mediated by fibrinogen binding to GP IIb-IIIa on adjacent platelets, we detected a redistribution of spectrin, talin, vinculin, pp60c-src, and pp62c-yes to the fraction that sediments at 15,600 X g. The redistribution of these proteins from the high-speed detergent-insoluble fraction to the low-speed fraction correlated with the extent of aggregation and was not detected in aggregation-defective thrombasthenic platelets (which lack the GP IIb-IIIa complex). In addition, many of the proteins phosphorylated on tyrosine in activated platelets were present in detergent-insoluble fractions. These results are consistent with the possibilities that 1) GP IIb-IIIa, pp60c-src, pp62c-yes, and GAP associate with a membrane skeleton fraction that contains spectrin, vinculin, and talin, 2) the association of GP IIb-IIIa with adhesive ligand in a platelet aggregate causes components of the membrane skeleton to undergo altered association with cytoplasmic actin filaments, and 3) many of the proteins phosphorylated on tyrosine residues in activated platelets are components of the cytoskeleton. The results imply that the membrane skeleton may play an important role in binding signaling molecules at sites of integrin-cytoskeleton interactions and in mediating signal transduction events in platelets. Further, GP IIb-IIIa-induced redistribution of components of the membrane skeleton and associated signaling molecules may represent an important step in regulating integrin-induced motile events in platelets.	GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; ARIAD PHARMACEUT INC,CAMBRIDGE,MA 02139; UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MICROBIOL,PHILADELPHIA,PA 19104	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Takeda Pharmaceutical Company Ltd; Takeda Oncology; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	FOX, JEB (corresponding author), CHILDRENS HOSP,OAKLAND RES INST,747 52ND ST,OAKLAND,CA 94609, USA.				NCI NIH HHS [CA47572] Funding Source: Medline; NHLBI NIH HHS [HL30657] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047572] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL030657, R01HL030657, R37HL030657] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASIJEE GM, 1990, EUR J BIOCHEM, V189, P131, DOI 10.1111/j.1432-1033.1990.tb15469.x; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BOYLES J, 1985, J CELL BIOL, V101, P1463, DOI 10.1083/jcb.101.4.1463; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1990, ONCOGENE, V5, P1033; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FOX JEB, 1982, J BIOL CHEM, V257, P4120; FOX JEB, 1984, J CELL BIOL, V98, P1985, DOI 10.1083/jcb.98.6.1985; FOX JEB, 1987, BLOOD, V69, P537; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FOX JEB, 1981, NATURE, V292, P650, DOI 10.1038/292650a0; FOX JEB, 1987, THROMB DIATH HAEMO, P175; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GARTNER TK, 1988, THROMB RES, V49, P43; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HAMAGUCHI M, 1989, ONCOGENE RES, V4, P29; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; KARLSSON R, 1984, J CELL PHYSIOL, V121, P96, DOI 10.1002/jcp.1041210113; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; PHILLIPS DR, 1972, BIOCHEMISTRY-US, V11, P4582, DOI 10.1021/bi00774a025; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1988, BLOOD, V71, P831; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RESH MD, 1990, ONCOGENE, V5, P1437; RITTENHOUSE SE, 1983, P NATL ACAD SCI-BIOL, V80, P5417, DOI 10.1073/pnas.80.17.5417; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1992, J BIOL CHEM, V267, P18424; TORI M, 1992, P NATL ACAD SCI USA, V89, P7796; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; WEISS HJ, 1991, THROMB HAEMOSTASIS, V65, P202; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WHITE JG, 1984, AM J PATHOL, V117, P207; WONG S, 1992, ONCOGENE, V7, P2407; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; ZHANG J, 1992, J BIOL CHEM, V267, P4686	72	238	240	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25973	25984						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503992				2022-12-27	WOS:A1993MK10000098
J	VERONESE, FD; REITZ, MS; GUPTA, G; ROBERTGUROFF, M; BOYERTHOMPSON, C; LOUIE, A; GALLO, RC; LUSSO, P				VERONESE, FD; REITZ, MS; GUPTA, G; ROBERTGUROFF, M; BOYERTHOMPSON, C; LOUIE, A; GALLO, RC; LUSSO, P			LOSS OF A NEUTRALIZING EPITOPE BY A SPONTANEOUS POINT MUTATION IN THE V3 LOOP OF HIV-1 ISOLATED FROM AN INFECTED LABORATORY WORKER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; TRANSMEMBRANE PROTEIN; MONOCLONAL-ANTIBODY; HTLV-III; TYPE-1; DETERMINANT; GENERATION; RESISTANT; PEPTIDES	The third hypervariable region, or V3 loop, represents the principal neutralizing domain of the gp120 envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1). Sequential viral isolates from a laboratory worker (LW) accidentally infected with HIV-1IIIB in 1985 were analyzed using type-specific neutralizing monoclonal antibodies directed to the V3 loop. A single amino acid substitution, Ala --> Thr at position 21 in the V3 loop of HIV-1LW isolated in 1987, was shown to determine the loss of the neutralizing epitope recognized by one of the monoclonal antibodies (M77). However, this antibody efficiently recognized linear V3 loop peptides containing either the Ala or Thr residue at position 21, indicating that a local change in conformation was responsible for the epitope loss in the native gp120. Molecular modeling studies, experimentally supported by different amino acid replacements at position 21, indicated that the Ala --> Thr substitution leads to a drastic change in the domain of the V3 loop, which contains the complementary surface for antibody binding. These results provide evidence for the first time that a conformation-dependent epitope within the V3 loop of HIV-1 is involved in the generation of neutralization escape mutants in vivo.	NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20892; LOS ALAMOS NATL LAB,THEORET BIOL & BIOPHYS GRP,LOS ALAMOS,NM 87545	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Energy (DOE); Los Alamos National Laboratory	VERONESE, FD (corresponding author), ADV BIOSCI LABS INC,DEPT CELL BIOL,KENSINGTON,MD 20895, USA.				NCI NIH HHS [N01-CP-73723, N01-CP-73722] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP073723, N01CP073722] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290; CHANDRASEKHAR K, 1991, BIOCHEMISTRY-US, V30, P9187, DOI 10.1021/bi00102a009; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DELEAGE G, 1989, PREDICTION PROTEIN S, P587; Fletcher R., 1984, PRACTICAL METHODS OP; GUPTA G, 1990, 5 C CENT GARD PAR, P99; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LORI F, 1992, J VIROL, V66, P5553, DOI 10.1128/JVI.66.9.5553-5560.1992; MATSUSHITA S, 1988, J VIROL, V62, P2107, DOI 10.1128/JVI.62.6.2107-2114.1988; MCKEATING JA, 1989, AIDS, V3, P777, DOI 10.1097/00002030-198912000-00001; NARA PL, 1990, J VIROL, V64, P3779, DOI 10.1128/JVI.64.8.3779-3791.1990; NARA PL, 1992, VACCINES 92 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P175; PAL R, 1992, INTERVIROLOGY, V86, P86; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; REITZ MS, 1988, CELL, V54, P57, DOI 10.1016/0092-8674(88)90179-1; ROBERTGUROFF M, 1992, J VIROL, V66, P3602, DOI 10.1128/JVI.66.6.3602-3608.1992; ROBERTGUROFF M, 1986, J IMMUNOL, V137, P3306; ROBERTSON R, 1990, THEOR CULT SOC, V7, P15; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SIPPL MJ, 1984, J PHYS CHEM-US, V88, P6231, DOI 10.1021/j150669a035; SKINNER MA, 1988, AIDS RES HUM RETROV, V4, P187, DOI 10.1089/aid.1988.4.187; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; WEISS SH, 1988, SCIENCE, V239, P68, DOI 10.1126/science.3336776; WILSON C, 1990, J VIROL, V64, P3240, DOI 10.1128/JVI.64.7.3240-3248.1990	28	52	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25894	25901						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503990				2022-12-27	WOS:A1993MK10000087
J	FELSCHOW, DM; MACDIARMID, J; BARDOS, T; WU, RH; WOSTER, PM; PORTER, CW				FELSCHOW, DM; MACDIARMID, J; BARDOS, T; WU, RH; WOSTER, PM; PORTER, CW			PHOTOAFFINITY-LABELING OF A CELL-SURFACE POLYAMINE BINDING-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; L1210 LEUKEMIA-CELLS; HAMSTER OVARY CELLS; BIOLOGICAL PROPERTIES; TRANSPORT PROTEIN; SPERMIDINE; DERIVATIVES; DEFICIENT; RECEPTORS; ANALOGS	Intracellular polyamine pools are partially maintained by an active transport apparatus that is specific for and regulated by polyamines. Although mammalian transport activity has been characterized by kinetic studies, the actual protein itself has yet to be identified, purified, or cloned. As one approach to this problem, we attempted photoaffinity labeling of plasma membrane proteins using two specifically designed and synthesized polyamine conjugates as photoprobes. The first is a spermidine conjugate bearing the photoreactive moiety 4-azidosalicylic acid at the N-4 position via an alkyl linkage, and the second is a norspermine conjugate with 4 azidosalicylic acid at the N-1 position via an acyl linkage, Labeling of murine L1210 lymphocytic leukemia cells was carried out at 4 degrees C to promote selective alkylation of cell surface proteins, Separation of plasma membrane proteins from cells cross-linked with the N-4-spermidine conjugate by SDS-polyacrylamide gel electrophoresis revealed two heavily labeled proteins at similar to 118 and similar to 50 kDa (designated p118 and p50, respectively). Band p118 was more well defined and much more intensely labeled. Analogous proteins were also observed in human U937 lymphoma cells, Specificity of labeling was strongly suggested by competition with polyamines and analogs during labeling and further indicated by the nearly identical labeling of the same protein by the N-1-norspermine photoprobe but not by the unconjugated photoreagent. Neuraminidase pretreatment of L1210 cells increased mobility of the p118, suggesting that it was glycosylated and, thus, of plasma membrane origin. In transport deficient L1210 cells, p118 and p50 were found to have a slightly higher molecular mass and were accompanied by a less distinct protein band (similar to 100 kDa), These findings indicate the presence of a poly amine binding protein at the surface of murine and human leukemia cells, which could be directly or indirectly related to the polyamine transport apparatus.	ROSWELL PK CANC INST,GRACE CANC DRUG CTR,BUFFALO,NY 14263; SUNY BUFFALO,DEPT MED CHEM,BUFFALO,NY 14214; WAYNE STATE UNIV,COLL PHARM & ALLIED HLTH PROFESS,DEPT PHARMACEUT SCI,DETROIT,MI 48202	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Wayne State University			Woster, Patrick M/A-5604-2010	Woster, Patrick M/0000-0002-9471-1916	NCI NIH HHS [R01 CA22153, CA63552, CA01072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063552, R01CA022153] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONY AC, 1992, BLOOD, V79, P2807; BERGERON RJ, 1984, SYNTHESIS-STUTTGART, P782; BERSE C, 1957, J ORG CHEM, V22, P805, DOI 10.1021/jo01358a024; BROWN PD, 1992, CELL BIOL, P77; BYERS TL, 1989, BIOCHEM J, V263, P745, DOI 10.1042/bj2630745; BYERS TL, 1990, J CELL PHYSIOL, V143, P460, DOI 10.1002/jcp.1041430309; DAVE C, 1973, FED PROC, V32, P736; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FELSCHOW DM, 1995, P AM ASSOC CANC RES, V36, P507; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; FINDLAY JBC, 1987, BIOL MEMBRANES PRACT, P197; FURUCHI T, 1991, J BIOL CHEM, V266, P20928; GAWELTHOMPSON K, 1988, J CELL PHYSIOL, V136, P237, DOI 10.1002/jcp.1041360205; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; JASYS VJ, 1992, J ORG CHEM, V57, P1814, DOI 10.1021/jo00032a039; JI TH, 1977, J BIOL CHEM, V252, P1566; KANKINUMA Y, 1988, EUR J BIOCHEM, V176, P409; KASHIWAGI K, 1990, J BIOL CHEM, V265, P20893; KASHIWAGI K, 1993, J BIOL CHEM, V268, P19358; KASHIWAGI K, 1991, J BIOL CHEM, V266, P20922; Keller O., 1985, ORG SYNTH, V63, P160, DOI 10.1002/0471264180.OS063.19; KHAN NA, 1991, CELL BIOL INT REP, V15, P9, DOI 10.1016/0309-1651(91)90078-W; KRAMER DL, 1993, J CELL PHYSIOL, V155, P399, DOI 10.1002/jcp.1041550222; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEROY D, 1995, J BIOL CHEM, V270, P17400, DOI 10.1074/jbc.270.29.17400; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; METTERS KM, 1993, J BIOL CHEM, V268, P6487; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MORGAN JE, 1989, BIOCHEMISTRY-US, V28, P5095, DOI 10.1021/bi00438a029; PERSSON L, 1988, CANCER RES, V48, P4807; PORTER CW, 1985, CANCER RES, V45, P2050; PORTER CW, 1982, CANCER RES, V42, P4072; PORTER CW, 1983, SCIENCE, V219, P1083, DOI 10.1126/science.6823570; PRICE EM, 1987, BIOCHEMISTRY-US, V198, P4757; ROEMMELE RC, 1988, J ORG CHEM, V53, P2367, DOI 10.1021/jo00245a049; RYLANDER PN, 1985, HYDROGENATION METHOD, P163; SAAB NH, 1993, J MED CHEM, V36, P2998, DOI 10.1021/jm00072a020; SEILER N, 1990, INT J BIOCHEM, V22, P11; SHANAHAN MF, 1985, J BIOL CHEM, V260, P897; SIDDIQUI F, 1994, NEUROCHEM RES, V19, P1421, DOI 10.1007/BF00972471; SPINELLA MJ, 1995, J BIOL CHEM, V270, P7842, DOI 10.1074/jbc.270.14.7842; STAROS JV, 1978, BIOCHEM BIOPH RES CO, V80, P568, DOI 10.1016/0006-291X(78)91606-6; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TAE HJ, 1982, ANAL BIOCHEM, V121, P286; THOM D, 1977, BIOCHEM J, V80, P649; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810	46	11	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28705	28711		10.1074/jbc.270.48.28705	http://dx.doi.org/10.1074/jbc.270.48.28705			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499391	hybrid			2022-12-27	WOS:A1995TH05600035
J	HE, YF; CHEN, H; QUON, MJ; REITMAN, M				HE, YF; CHEN, H; QUON, MJ; REITMAN, M			THE MOUSE OBESE GENE - GENOMIC ORGANIZATION, PROMOTER ACTIVITY, AND ACTIVATION BY CCAAT/ENHANCER-BINDING PROTEIN-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; DIFFERENTIATION; TRANSCRIPTION; DNA; TRANSFECTION; INSULIN; CELLS; C/EBP; RATS; SITE	The obese gene product, leptin, regulates adiposity. Mice homozygous for a nonfunctional obese gene become massively obese and develop diabetes mellitus due to overeating and increased metabolic efficiency. The cDNA sequence of obese was recently reported (Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., and Friedman, J. L. (1994) Nature 372, 425-432; Correction: (1995 Nature 374, 479). We have determined the genomic organization of the 5' end of the mouse obese gene. The coding sequence is in exons 2 and 3, A single TATA-containing promoter was found upstream of exon 1. A minority (probably similar to 5%) of the obese mRNA contained an extra, untranslated exon between exons 1 and 2. Transcription of the obese gene was detected only in adipose cells. A 762 base pair obese gene promoter driving a luciferase gene yielded abundant activity in transiently transfected rat adipose cells in primary culture. The obese promoter was inactive in erythroid K562 cells. Deletion of bases from -762 downstream to -161 did not affect promoter activity in transfected adipose cells. The -161 minimal promoter contained consensus Spl and CCAAT/enhancer-binding protein (C/EBP) motifs. Cotransfection with C/EBP alpha (a transcription factor important in adipose cell differentiation) caused 23-fold activation. These data suggest that the obese promoter is a natural target of C/EBP alpha.	NIDDK, DIABET BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Quon, Michael/B-1970-2008; Reitman, Marc/B-4448-2013	Reitman, Marc/0000-0002-0426-9475; QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915				ALEXANDERBRIDGES M, 1992, ADV ENZYME REGUL, V32, P149; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; [Anonymous], 1994, PROGRAM MANUAL WISCO; BLAKE WL, 1990, J NUTR, V120, P1727, DOI 10.1093/jn/120.12.1727; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CLARKE SD, 1992, FASEB J, V6, P3146, DOI 10.1096/fasebj.6.13.1397836; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; FAUST IM, 1977, SCIENCE, V197, P393, DOI 10.1126/science.877564; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HARRIS RBS, 1986, J NUTR, V116, P2536, DOI 10.1093/jn/116.12.2536; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HERVEY GR, 1959, J PHYSIOL-LONDON, V145, P336, DOI 10.1113/jphysiol.1959.sp006145; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; LIIMATTA M, 1994, MOL ENDOCRINOL, V8, P1147, DOI 10.1210/me.8.9.1147; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; Moore DD, 1995, GLOB MOB SURV; MOUTAID N, 1994, J BIOL CHEM, V269, P5629; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; RINK TJ, 1994, NATURE, V372, P406, DOI 10.1038/372406a0; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SPIEGELMAN BM, 1993, J BIOL CHEM, V268, P6823; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; ZHANG YY, 1995, NATURE, V374, P479, DOI 10.1038/374479a0	41	153	174	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28887	28891		10.1074/jbc.270.48.28887	http://dx.doi.org/10.1074/jbc.270.48.28887			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499416	hybrid			2022-12-27	WOS:A1995TH05600060
J	LEE, YJ; GALOFORO, SS; BERNS, CM; ERDOS, G; GUPTA, AK; WAYS, DK; CORRY, PM				LEE, YJ; GALOFORO, SS; BERNS, CM; ERDOS, G; GUPTA, AK; WAYS, DK; CORRY, PM			EFFECT OF IONIZING-RADIATION ON AP-1 BINDING-ACTIVITY AND BASIC FIBROBLAST GROWTH-FACTOR GENE-EXPRESSION IN DRUG-SENSITIVE HUMAN BREAST-CARCINOMA MCF-7 AND MULTIDRUG-RESISTANT MCF-7/ADR CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SERUM RESPONSE ELEMENT; DNA-BINDING; TRANSCRIPTION FACTOR; JUN ACTIVITY; HEAT-SHOCK; FACTOR-BETA-1 GENE; ACTIVATION DOMAIN; ENDOTHELIAL-CELLS; FACTOR P62TCF	We studied the effect of ionizing radiation on the activation of the AP-1 transcription factors and the regulation of basic fibroblast growth factor (bFGF) gene expression in drug-sensitive human breast carcinoma (MCF-7) cells and its drug-resistant variant (MCF-7/ADR) cells, Northern blot and gel mobility shift assays showed that 135 cGy of ionizing radiation induced c-jun. and c-fos gene expression, AP-1 binding activity, as well as bFGF gene expression in MCF-7/ADR cells, In MCF-7 cells, however, we observed little/no induction of bFGF gene expression and AP-1 binding activity after the stress. Nevertheless, MCF-7 cells transfected with plasmids containing c-jun gene contain high levels of bFGF protein. H-7 (60 mu g/ml), a potent protein kinase C (PKC) inhibitor, inhibited the stress-induced AP-1 binding activity and bFGF gene expression in MCF-7/ADR cells. Corroborating this observation, overexpression of PKC alpha induced bFGF gene expression in MCF-7 cells. Taken together, these results suggest that stress-induced bFGF gene expression is mediated through the activation of PKC and AP-1 transcription factors, Differences in the levels of PKC activity and AP-1 binding factors may be responsible for differential expression of bFGF among breast cancer cell lines. Although there are large differences in response to ionizing radiation between MCF-7 and MCF-7/ADR cell lines, we observed no significant differences in radiocytotoxicity between them.	E CAROLINA UNIV,SCH MED,DEPT MED,GREENVILLE,NC 27858	University of North Carolina; East Carolina University	LEE, YJ (corresponding author), WILLIAM BEAUMONT HOSP,DEPT RADIAT ONCOL,RES LABS,3601 W 13 MILE RD,ROYAL OAK,MI 48073, USA.				NCI NIH HHS [CA44550, CA48000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048000, R37CA044550, R01CA044550] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1985, CANCER CELL, V3, P315; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUKH A, 1990, J IMMUNOL, V144, P4835; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FUKS Z, 1994, CANCER RES, V54, P2582; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAIMOVITZFRIEDM.A, 1994, CANCER RES, V54, P2591; HAIMOVITZFRIEDM.A, 1991, CANCER RES, V51, P2552; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; HALLAHAN DE, 1991, CANCER RES, V51, P4565; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HOLLANDER MC, 1989, CANCER RES, V49, P1687; KIM SJ, 1989, J BIOL CHEM, V264, P19373; KIM SJ, 1989, J BIOL CHEM, V264, P402; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; LEE SA, 1992, CANCER RES, V52, P3750; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MERGIA A, 1986, BIOCHEM BIOPH RES CO, V138, P644, DOI 10.1016/S0006-291X(86)80545-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NORDHEIM A, 1994, FOS JUN FAMILIES TRA, P97; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; PLATE KH, 1993, CANCER RES, V53, P5822; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; SHING Y, 1985, J CELL BIOCHEM, V29, P275, DOI 10.1002/jcb.240290402; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SOUTTER AD, 1993, CANCER RES, V53, P5297; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; STEVENSON MA, 1994, CANCER RES, V54, P12; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TUSHINSKI RJ, 1977, P NATL ACAD SCI USA, V74, P2357, DOI 10.1073/pnas.74.6.2357; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WALKER JM, 1984, METHOD MOL BIOL, P57; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WINKLES JA, 1992, CANCER RES, V52, P1040; WITTE L, 1989, CANCER RES, V49, P5066; WOOTEN MW, 1991, EXP CELL RES, V193, P274, DOI 10.1016/0014-4827(91)90096-D; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	63	61	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28790	28796		10.1074/jbc.270.48.28790	http://dx.doi.org/10.1074/jbc.270.48.28790			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499402	hybrid			2022-12-27	WOS:A1995TH05600046
J	PARK, YW; KATZE, MG				PARK, YW; KATZE, MG			TRANSLATIONAL CONTROL BY INFLUENZA-VIRUS - IDENTIFICATION OF CIS-ACTING SEQUENCES AND TRANS-ACTING FACTORS WHICH MAY REGULATE SELECTIVE VIRAL MESSENGER-RNA TRANSLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; MESSENGER-RNA TRANSLATION; NS1 PROTEIN; CELLULAR PROTEIN; INFECTED-CELLS; POLIOVIRUS RNA; INITIATION; ADENOVIRUS; EXPRESSION; INHIBITION	We have shown that sequences contained within the viral mRNA 5'-untranslated region (UTR) played a critical role in directing selective influenza viral mRNA translation. We therefore attempted to identify transacting factors that may regulate viral mRNA translation through interactions with the 5'-UTR and at the same time map the precise sequences to which these factors bind. We can now demonstrate that multiple cellular proteins interact with influenza viral but not cellular 5'-UTRs using gel mobility shift and UV cross linking analyses. Gel supershift studies revealed that the La autoantigen was one of the cellular proteins that interacted with the viral 5'-UTR. Utilizing mutants of the viral mRNA 5' UTR, we have determined that sequences within the very 5'-conserved region and nucleotides immediately 3' are necessary but not always sufficient for binding certain cellular proteins. Northwestern analysis showed the binding of a distinct subset of cellular proteins to the viral 5'-UTR, but also demonstrated interactions of the viral nonstructural protein NS1. Gel shift analysis with purified recombinant NS1 confirmed the binding of the viral protein to a specific region of the viral 5'-UTRs. A model describing the possible role of these cellular and viral RNA-binding proteins in regulating influenza virus mRNA translation will be discussed.	UNIV WASHINGTON, SCH MED, DEPT MICROBIOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NCRR NIH HHS [RR 00166] Funding Source: Medline; NIAID NIH HHS [AI-22646] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022646] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALONSOCAPLEN FV, 1992, GENE DEV, V6, P255, DOI 10.1101/gad.6.2.255; Ausubel FA, 1990, CURRENT PROTOCOLS MO; CHAN EKL, 1987, J EXP MED, V166, P1627, DOI 10.1084/jem.166.6.1627; DELALUNA S, 1995, J VIROL, V69, P2427, DOI 10.1128/JVI.69.4.2427-2433.1995; DOLPH PJ, 1990, J VIROL, V64, P2669, DOI 10.1128/JVI.64.6.2669-2677.1990; ENAMI K, 1994, J VIROL, V68, P1432, DOI 10.1128/JVI.68.3.1432-1437.1994; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; FEIGENBLUM D, 1993, J VIROL, V67, P3027, DOI 10.1128/JVI.67.6.3027-3035.1993; Garfinkel Michele S., 1993, Gene Expression, V3, P109; GARFINKEL MS, 1993, J BIOL CHEM, V268, P22223; GARFINKEL MS, 1992, J BIOL CHEM, V267, P9383; GARFINKEL MS, 1994, SCI MED, V1, P64; HATADA E, 1992, J GEN VIROL, V73, P17, DOI 10.1099/0022-1317-73-1-17; HATADA E, 1992, J GEN VIROL, V73, P3325, DOI 10.1099/0022-1317-73-12-3325; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; JANG SK, 1990, ENZYME, V44, P292, DOI 10.1159/000468766; KATZE MG, 1993, SEMIN VIROL, V4, P259, DOI 10.1006/smvy.1993.1022; KATZE MG, 1984, MOL CELL BIOL, V4, P2198, DOI 10.1128/MCB.4.10.2198; KATZE MG, 1986, J VIROL, V60, P1027, DOI 10.1128/JVI.60.3.1027-1039.1986; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; KRUG RM, 1973, VIROLOGY, V56, P334, DOI 10.1016/0042-6822(73)90310-3; KRUG RM, 1989, EXPRESSION REPLICATI, V2, P89; LU Y, 1994, GENE DEV, V8, P1817, DOI 10.1101/gad.8.15.1817; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; ONEILL RE, 1994, INFECT AGENT DIS, V3, P77; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; POGUE GP, 1993, J VIROL, V67, P7106, DOI 10.1128/JVI.67.12.7106-7117.1993; QIU Y, 1994, J VIROL, V68, P2425, DOI 10.1128/JVI.68.4.2425-2432.1994; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RILEY D, 1993, J VIROL, V67, P3586, DOI 10.1128/JVI.67.6.3586-3595.1993; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; SONENBERG N, 1991, TRENDS GENET, V7, P105, DOI 10.1016/0168-9525(91)90440-2; SONENBERG N, 1990, ENZYME, V44, P278, DOI 10.1159/000468765; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; SONENBERG N, 1987, ADV VIRUS RES, V33, P175, DOI 10.1016/S0065-3527(08)60318-8; SVITKIN YV, 1994, J VIROL, V68, P1544, DOI 10.1128/JVI.68.3.1544-1550.1994; SVITKIN YV, 1994, J VIROL, V68, P7001, DOI 10.1128/JVI.68.11.7001-7007.1994; YAMANAKA K, 1991, ARCH VIROL, V120, P33, DOI 10.1007/BF01310947; YAMANAKA K, 1988, VIRUS GENES, V1, P19; YEN JH, 1995, VIROLOGY, V208, P723, DOI 10.1006/viro.1995.1204	41	97	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28433	28439						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499349				2022-12-27	WOS:A1995TG21000074
J	SMITH, CD; ZILFOU, JT				SMITH, CD; ZILFOU, JT			CIRCUMVENTION OF P-GLYCOPROTEIN-MEDIATED MULTIPLE-DRUG RESISTANCE BY PHOSPHORYLATION MODULATORS IS INDEPENDENT OF PROTEIN-KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST CANCER-CELLS; MULTIDRUG-RESISTANCE; SELECTIVE INHIBITOR; POTENT INHIBITOR; PHORBOL ESTERS; LEUKEMIA-CELLS; TUMOR-CELLS; HL60 CELLS; KB CELLS; STAUROSPORINE	Expression of P-glycoprotein by tumor cells confers resistance to multiple natural product drugs because of its ability to export these compounds, This transporter is a substrate for several protein kinases; however, the functional significance of its phosphorylation is not defined, We examined the effects of many activators and inhibitors of protein kinases on the activity of P-glycoprotein in drug-resistant human breast carcinoma cells (MCF-7/ADR), Several phorbol esters sensitized these cells to P-glycoprotein substrate drugs; however, there was no correlation with activation of protein kinase C. The 4 alpha- and 4 beta-isomers of phorbol 12-myristate 13-acetate were equally potent in sensitizing the cells to actinomycin D and daunomycin and in increasing the intracellular accumulation of [H-3]vinblastine. These effects of 4 beta-phorbol myristate acetate required much higher concentrations than were needed to increase P-glycoprotein phosphorylation and were not antagonized by staurosporine, Similar to verapamil, the phorbol esters did not sensitize MCF-7/ADR cells to cisplatin, nor parental MCF-7 cells to any of the anticancer drugs, Mezerein, K-252a, and H-89 sensitized MCF-7/ADR cells, increased intracellular accumulation of [H-3]vinblastine, and antagonized photolabeling of P-glycoprotein by [H-3]azidopine. Therefore, phosphorylation does not appear to play a significant role in regulating P-glycoprotein activity in MCF-7/ADR cells.			SMITH, CD (corresponding author), FOX CHASE CANC CTR, DEPT PHARMACOL, 7701 BURHOLME AVE, PHILADELPHIA, PA 19111 USA.							ABRAHAM I, 1990, EXP CELL RES, V189, P133, DOI 10.1016/0014-4827(90)90265-C; AFTAB DT, 1994, ONCOL RES, V6, P59; BATES SE, 1993, BIOCHEMISTRY-US, V32, P9156, DOI 10.1021/bi00086a022; BECK WT, 1992, BIOCHEM PHARMACOL, V43, P89, DOI 10.1016/0006-2952(92)90665-6; BECK WT, 1987, BIOCHEM PHARMACOL, V36, P2879, DOI 10.1016/0006-2952(87)90198-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSEN SA, 1977, BIOCHIM BIOPHYS ACTA, V467, P238, DOI 10.1016/0005-2736(77)90199-7; CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679; CHAMBERS TC, 1994, BIOCHEM J, V299, P309, DOI 10.1042/bj2990309; CHAMBERS TC, 1993, J BIOL CHEM, V268, P4592; CHAMBERS TC, 1990, BIOCHEM BIOPH RES CO, V169, P253, DOI 10.1016/0006-291X(90)91461-Z; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHORVATH B, 1994, INT J CANCER, V59, P852, DOI 10.1002/ijc.2910590624; CORREALE P, 1994, INT J ONCOL, V4, P423; DOLFINI E, 1993, ANTICANCER RES, V13, P1123; DONG ZY, 1991, MOL PHARMACOL, V39, P563; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FERGUSON PJ, 1987, CANCER RES, V47, P433; FINE RL, 1988, P NATL ACAD SCI USA, V85, P582, DOI 10.1073/pnas.85.2.582; FORD JM, 1990, PHARMACOL REV, V42, P155; FORD JM, 1989, MOL PHARMACOL, V35, P105; GANAPATHI R, 1984, EUR J CANCER CLIN ON, V20, P799, DOI 10.1016/0277-5379(84)90219-0; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GUPTA S, 1994, CANCER LETT, V76, P139, DOI 10.1016/0304-3835(94)90390-5; HAMADA H, 1987, CANCER RES, V47, P2860; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIM SH, 1993, CANCER LETT, V74, P37, DOI 10.1016/0304-3835(93)90041-7; LAREDO J, 1994, BLOOD, V84, P229; MA LD, 1991, J BIOL CHEM, V266, P5593; MELLADO W, 1987, BIOCHEMISTRY-US, V26, P6900, DOI 10.1021/bi00396a005; Meyers M B, 1989, Cancer Commun, V1, P233; MIYAMOTO KI, 1990, CANCER LETT, V51, P37, DOI 10.1016/0304-3835(90)90228-P; MOSCOW JA, 1988, J NATL CANCER I, V80, P14, DOI 10.1093/jnci/80.1.14; NYGREN P, 1990, BIOCHIM BIOPHYS ACTA, V1052, P392, DOI 10.1016/0167-4889(90)90148-7; OBRIAN CA, 1991, BIOCHEM PHARMACOL, V41, P797, DOI 10.1016/0006-2952(91)90083-H; ORR GA, 1993, J BIOL CHEM, V268, P25054; RICHERT ND, 1988, BIOCHEMISTRY-US, V27, P7607, DOI 10.1021/bi00420a006; SAMPSON KE, 1993, CANCER LETT, V68, P7, DOI 10.1016/0304-3835(93)90213-S; SATO W, 1990, BIOCHEM BIOPH RES CO, V173, P1252, DOI 10.1016/S0006-291X(05)80921-0; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SMITH CD, 1995, CANCER-AM CANCER SOC, V75, P2597, DOI 10.1002/1097-0142(19950515)75:10<2597::AID-CNCR2820751030>3.0.CO;2-R; SMITH CD, 1994, ONCOL RES, V6, P211; SMITH CD, 1995, MOL PHARMACOL, V47, P241; SPEICHER LA, 1994, J NATL CANCER I, V86, P688, DOI 10.1093/jnci/86.9.688; STAATS J, 1990, J BIOL CHEM, V265, P4084; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; YOKOZAKI H, 1993, INT J ONCOL, V3, P423	49	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28145	28152						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499304				2022-12-27	WOS:A1995TG21000029
J	TODISCO, A; TAKEUCHI, Y; SEVA, C; DICKINSON, CJ; YAMADA, T				TODISCO, A; TAKEUCHI, Y; SEVA, C; DICKINSON, CJ; YAMADA, T			GASTRIN AND GLYCINE-EXTENDED PROGASTRIN PROCESSING INTERMEDIATES INDUCE DIFFERENT PROGRAMS OF EARLY GENE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH; IDENTIFICATION; MECHANISM; DOMAIN	We recently reported that gastrin and glycine-extended progastrin processing intermediates (G-Gly) exert growth promoting effects on AR4-2J cells (derived from rat pancreas) via interaction with distinct receptors, In this study we sought to investigate the mechanisms by which gastrin and G-Gly stimulate cell proliferation, While gastrin increased [Ca2+](i) in AR4-2J cells, G-Gly had no effect. Similarly, G-Gly had no effect either on basal and 10(-7) M vasoactive intestinal polypeptide-stimulated cAMP generation, although gastrin is known to inhibit cAMP generation, Gastrin dose dependently stimulated AR4-2J cell mRNA content of both c-fos and c-jun, two genes known to function in regulating cell proliferation, but G-Gly had no effect, Gastrin also induced the expression of luciferase in AR4-2J cells transfected with a construct consisting of a luciferase reporter gene coupled to the serum response element of the c-fos gene promoter, In similar fashion, gastrin stimulated the activity of mitogen-activated protein kinase, an enzyme known to mediate the induction of the c-fos serum response element in response to growth factor stimulation. Although G-Gly had none of these effects of gastrin in AR4-2J cells, it stimulated activity of c-Jun amino-terminal kinase, an enzyme known to phosphorylate and transcriptionally activate c-Jun. These data support the notion that gastrin stimulates cell proliferation by inducing c-fos and c-jun gene expression, while G-Gly acts by post-translationally regulating early gene transcriptional activation, Our studies represent a novel model in which both the precursor and the product of a key processing reaction, peptide alpha-amidation, act cooperatively to stimulate cell proliferation via distinct receptors linked to different signal transduction pathways.	UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT PEDIAT, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA; INSERM, U151, F-31054 TOULOUSE, FRANCE	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Institut National de la Sante et de la Recherche Medicale (Inserm)				Catherine, SEVA/0000-0002-4265-7372	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034306, P30DK034933] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK34306, P30DK34933] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADBURY AF, 1982, NATURE, V298, P686, DOI 10.1038/298686a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTOPHE J, 1994, AM J PHYSIOL, V266, pG963, DOI 10.1152/ajpgi.1994.266.6.G963; DELVALLE J, 1989, GASTROENTEROLOGY, V97, P1159, DOI 10.1016/0016-5085(89)91685-5; Edkins JS, 1906, J PHYSIOL-LONDON, V34, P133; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HILSTED L, 1991, REGUL PEPTIDES, V36, P323, DOI 10.1016/0167-0115(91)90067-Q; JOHNSON LR, 1977, ANNU REV PHYSIOL, V39, P135, DOI 10.1146/annurev.ph.39.030177.001031; KAISE M, 1995, J BIOL CHEM, V270, P11155, DOI 10.1074/jbc.270.19.11155; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARX JL, 1987, SCIENCE, V237, P854, DOI 10.1126/science.3039659; MATSUMOTO M, 1987, AM J PHYSIOL, V252, pG315, DOI 10.1152/ajpgi.1987.252.3.G315; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; SADOSHIMA J, 1995, CIRC RES, V76, P1; SCEMAMA JL, 1988, FEBS LETT, V242, P61, DOI 10.1016/0014-5793(88)80985-2; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; SINGH P, 1986, CANCER RES, V46, P1612; SMITH MJ, 1992, BLOOD, V79, P2107; SOLOMON TE, 1987, GASTROENTEROLOGY, V92, P429, DOI 10.1016/0016-5085(87)90138-7; SUGANO K, 1985, J BIOL CHEM, V260, P1724; TANIGUCHI T, 1994, ONCOGENE, V9, P861; TODISCO A, 1994, AM J PHYSIOL, V267, pG245, DOI 10.1152/ajpgi.1994.267.2.G245; TODISCO A, 1995, AM J PHYSIOL, V268, pG160; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YOO OJ, 1982, P NATL ACAD SCI-BIOL, V79, P1049, DOI 10.1073/pnas.79.4.1049	33	84	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28337	28341						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499334				2022-12-27	WOS:A1995TG21000059
J	BARR, VA; SCOTT, LJ; HUBBARD, AL				BARR, VA; SCOTT, LJ; HUBBARD, AL			IMMUNOADSORPTION OF HEPATIC VESICLES CARRYING NEWLY SYNTHESIZED DIPEPTIDYL PEPTIDASE-IV AND POLYMERIC IGA RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE PLASMA-MEMBRANE; CARBOHYDRATE RECOGNITION SYSTEMS; TRANS-CELLULAR TRANSPORT; RAT-LIVER; MEDIATED ENDOCYTOSIS; SUBCELLULAR FRACTIONATION; IMMUNOELECTRON MICROSCOPY; TRANSCYTOTIC VESICLES; ENDOPLASMIC-RETICULUM; SECRETORY COMPONENT	Hepatocytes must transport newly synthesized apical membrane proteins from the basolateral to the apical plasma membrane, Our earlier morphological study showed that the apical proteins share a late (subapical) part of the transcytotic pathway with the well characterized polymeric immunoglobulin A receptor (Barr, V. A., and Hubbard, A. L. (1993) Gastroenterology 105, 554-571), Starting with crude microsomes from the livers of [S-35]methionine-labeled rats, we sequentially immuno-adsorbed first vesicles containing the endocytic asialoglycoprotein receptor and then (from the depleted supernatant) vesicles containing the polymeric IgA receptor, Biochemical characterization indicated that early basolateral and late endosomes were present in the first population but not in the second. Neither Golgi, apical plasma membrane (PM)-, nor basolateral PM-derived vesicles were significant contaminants of either population. Both vesicle populations contained S-35-labeled receptor and S-35-labeled-dipeptidyl peptidase TV, Importantly, the elevated relative specific activity of the dipeptidyl peptidase (% of S-35-labeled/% immunoblotted) in the second population indicated that these vesicles must transport newly synthesized dipeptidyl peptidase IV. A distinct kind of vesicle was immunoadsorbed from a ''carrier-vesicle fraction''; surprisingly, these vesicles contained little S-35-receptor and virtually no dipeptidyl peptidase IV. These results, together with previous kinetic data from in vivo experiments, are consistent with a computer-generated model predicting that newly synthesized dipeptidyl peptidase IV is delivered to basolateral endosomes, which also contain newly synthesized polymeric immunoglobulin A receptor. The two proteins are then transcytosed together to the subapical region.	JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, BALTIMORE, MD 21205 USA; NIH, DIABET BRANCH, BETHESDA, MD 20892 USA; UNIV MICHIGAN, SCH PUBL HLTH, ANN ARBOR, MI 48109 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; University of Michigan System; University of Michigan								ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; Barr V. A., 1994, Molecular Biology of the Cell, V5, p72A; BARR VA, 1993, GASTROENTEROLOGY, V105, P554, DOI 10.1016/0016-5085(93)90734-T; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BARTLES JR, 1985, J BIOL CHEM, V260, P2792; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BARTLES JR, 1990, METHOD ENZYMOL, V191, P825; BLEIL JD, 1982, EMBO J, V1, P351, DOI 10.1002/j.1460-2075.1982.tb01173.x; BRANCH WJ, 1987, BIOCHEM J, V244, P311, DOI 10.1042/bj2440311; BROWN WR, 1989, HEPATOLOGY, V9, P763, DOI 10.1002/hep.1840090518; CARIAPPA R, 1992, AM J PHYSIOL, V263, pE1021; Cariappa R., 1994, Molecular Biology of the Cell, V5, p72A; CASANOVA JE, 1992, ANN NY ACAD SCI, V664, P27, DOI 10.1111/j.1749-6632.1992.tb39746.x; CASCIOLAROSEN LA, 1992, J BIOL CHEM, V267, P11856; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COURTOY PJ, 1985, ENDOCYTOSIS, P163; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; GURD JW, 1974, ARCH BIOCHEM BIOPHYS, V164, P305, DOI 10.1016/0003-9861(74)90035-6; HANDLER JS, 1989, ANNU REV PHYSIOL, V51, P729, DOI 10.1146/annurev.ph.51.030189.003501; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; HONG WJ, 1987, P NATL ACAD SCI USA, V84, P7962, DOI 10.1073/pnas.84.22.7962; HOPPE CA, 1985, J CELL BIOL, V101, P2113, DOI 10.1083/jcb.101.6.2113; Hubbard AL, 1989, CURR OPIN CELL BIOL, V1, P675, DOI 10.1016/0955-0674(89)90033-1; HUBBARD AL, 1979, J CELL BIOL, V83, P65, DOI 10.1083/jcb.83.1.65; HUBBARD AL, 1979, J CELL BIOL, V83, P47, DOI 10.1083/jcb.83.1.47; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; HUBBARD AL, 1988, CELL FREE ANAL MEMBR, P115; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; Kraehenbuhl J P, 1992, Trends Cell Biol, V2, P170, DOI 10.1016/0962-8924(92)90036-M; KUHN LC, 1983, ANN NY ACAD SCI, V409, P751, DOI 10.1111/j.1749-6632.1983.tb26914.x; LARKIN JM, 1991, J CELL SCI, V98, P205; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOW SH, 1992, J CELL BIOL, V118, P51, DOI 10.1083/jcb.118.1.51; MAMADI Y, 1994, LIVER BIOL PATHOBIOL, P155; MAROUX S, 1983, BRUSH BORDER MEMBRAN, P34; MATLIN K S, 1992, Current Opinion in Cell Biology, V4, P623; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MAXFIELD FR, 1991, INTRACELLULAR TRAFFI; MISUMI Y, 1990, J BIOL CHEM, V265, P2178; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MUELLER SC, 1986, J CELL BIOL, V102, P932, DOI 10.1083/jcb.102.3.932; MULLOCK BM, 1978, BIOCHIM BIOPHYS ACTA, V543, P497, DOI 10.1016/0304-4165(78)90304-5; MULLOCK BM, 1980, FEBS LETT, V113, P201, DOI 10.1016/0014-5793(80)80591-6; MULLOCK BM, 1979, BIOCHIM BIOPHYS ACTA, V587, P381, DOI 10.1016/0304-4165(79)90442-2; MUSIL LS, 1988, J BIOL CHEM, V263, P15799; OGATA S, 1989, J BIOL CHEM, V264, P3596; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; RANK J, 1983, HEPATOLOGY, V3, P241; RENSTON RH, 1980, SCIENCE, V208, P1276, DOI 10.1126/science.7375938; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; ROMAN LM, 1983, J CELL BIOL, V96, P1548, DOI 10.1083/jcb.96.6.1548; SANDVIG K, 1991, CELL BIOL INT REP, V15, P3, DOI 10.1016/0309-1651(91)90077-V; SCHELL MJ, 1992, J CELL BIOL, V119, P1173, DOI 10.1083/jcb.119.5.1173; SCOTT LJ, 1992, J BIOL CHEM, V267, P6099; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SZTUL E, 1993, J BIOL CHEM, V268, P1876; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; SZTUL ES, 1985, J CELL BIOL, V100, P1255, DOI 10.1083/jcb.100.4.1255; SZTUL ES, 1983, J CELL BIOL, V97, P1582, DOI 10.1083/jcb.97.5.1582; TAKAHASHI I, 1982, J IMMUNOL, V128, P1181; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; VEGA MA, 1989, P NATL ACAD SCI USA, V86, P2688, DOI 10.1073/pnas.86.8.2688; WALL DA, 1985, J CELL BIOL, V101, P2104, DOI 10.1083/jcb.101.6.2104; WATTS C, 1992, J CELL SCI, V103, P1	74	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27834	27844		10.1074/jbc.270.46.27834	http://dx.doi.org/10.1074/jbc.270.46.27834			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499255	hybrid			2022-12-27	WOS:A1995TE73600066
J	KAVITA, U; MIZEL, SB				KAVITA, U; MIZEL, SB			DIFFERENTIAL SENSITIVITY OF INTERLEUKIN-1-ALPHA AND INTERLEUKIN-1-BETA PRECURSOR PROTEINS TO CLEAVAGE BY CALPAIN, A CALCIUM-DEPENDENT PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; ACTIVATED NEUTRAL PROTEASE; SECRETORY SIGNAL SEQUENCE; RETICULUM-GOLGI-COMPLEX; CRYSTAL-STRUCTURE; PATHWAY; CELLS; RESOLUTION; CLONING; RELEASE	In view of the observations that the calcium ionophores, A23187 and ionomycin, enhance the processing and secretion of interleukin-1 (IL-1 alpha) and IL-1 beta from macrophages, and IL-1 alpha processing is mediated by calpain, a calcium-dependent protease, we evaluated the possibility that calpain might also play a role in the processing of IL-1 beta, Whereas calpain-containing P388D1 macrophage lysates and purified calpain processed precursor IL-1 alpha to its mature 17-kDa form, precursor IL-1 beta was degraded by both sources of calpain, However, the activation of calpain in P388D1 cells that were transiently transfected with a cDNA expression vector encoding the precursor form of IL-1 beta did not result in the degradation of precursor IL-1 beta, but did result in the processing and secretion of IL-1 alpha, implying that precursor IL-1 beta is protected from calpain degradation in vivo. Furthermore, calpain did not enhance the processing of the IL-1 beta precursor by the IL-1 beta-converting enzyme, These results indicate that calpain is not involved in the processing of precursor IL-1 beta in vitro or in vivo, The IL-1 beta precursor may be protected from calpain degradation by a sequestering mechanism that involves a cytoplasmic factor(s) that reduces the sensitivity of IL-1 beta to attach by calpain or localizes IL-1 beta to a site that precludes any interaction with the protease. Although MDL 28,170, a calpain inhibitor, prevented the ionomycin-induced processing of precursor IL-1 alpha to the mature protein in P388D1 cells, it did not inhibit the ionomycin-induced secretion of the mature IL-1 alpha and -beta proteins expressed in these cells. These results indicate that a calcium-dependent factor other than calpain is involved in the secretion of the mature IL-1 proteins.	WAKE FOREST UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,WINSTON SALEM,NC 27157	Wake Forest University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025836, T32AI007401] Funding Source: NIH RePORTER; NIAID NIH HHS [AI25836, AI07401] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARIYOSHI H, 1993, BIOCHEM MOL BIOL INT, V30, P63; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; AYALA JM, 1994, J IMMUNOL, V153, P2592; BURSTEN SL, 1985, J CLIN INVEST, V82, P1479; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DINARELLO CA, 1994, EUR CYTOKINE NETW, V5, P517; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; GAGLIARDINO JJ, 1980, BIOCHEM J, V192, P919, DOI 10.1042/bj1920919; GIRI JG, 1985, J IMMUNOL, V134, P343; Gruenberg Jean, 1993, Trends in Cell Biology, V3, P224, DOI 10.1016/0962-8924(93)90116-I; HABAZETTL J, 1992, NATURE, V359, P855, DOI 10.1038/359855a0; KENIGSBERG RL, 1985, NEUROSCIENCE, V14, P335, DOI 10.1016/0306-4522(85)90183-6; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; LOMEDICO PT, 1984, NATURE, V312, P58; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; MILLER BE, 1995, J IMMUNOL, V154, P1331; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; MURACHI T, 1989, BIOCHEM SOC SYMP, V55, P29; OKAZAKI K, 1994, J BIOL CHEM, V269, P6149; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; RADDING W, 1994, J CELL PHYSIOL, V160, P17, DOI 10.1002/jcp.1041600104; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; SIDERS WM, 1993, J BIOL CHEM, V268, P22170; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SINGER II, 1988, J EXP MED, V167, P389, DOI 10.1084/jem.167.2.389; SUTTLES J, 1990, J IMMUNOL, V144, P175; SWEET RM, 1974, BIOCHEMISTRY-US, V13, P4212, DOI 10.1021/bi00717a024; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615; THORNBERRY NA, 1992, NATURE, V5356, P768; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	43	66	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27758	27765		10.1074/jbc.270.46.27758	http://dx.doi.org/10.1074/jbc.270.46.27758			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499244	hybrid			2022-12-27	WOS:A1995TE73600055
J	UNSON, CG; CYPESS, AM; KIM, HN; GOLDSMITH, PK; CARRUTHERS, CJL; MERRIFIELD, RB; SAKMAR, TP				UNSON, CG; CYPESS, AM; KIM, HN; GOLDSMITH, PK; CARRUTHERS, CJL; MERRIFIELD, RB; SAKMAR, TP			CHARACTERIZATION OF DELETION AND TRUNCATION MUTANTS OF THE RAT GLUCAGON RECEPTOR - 7 TRANSMEMBRANE SEGMENTS ARE NECESSARY FOR RECEPTOR TRANSPORT TO THE PLASMA-MEMBRANE AND GLUCAGON BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; BETA-ADRENERGIC-RECEPTOR; HORMONE-RELATED PEPTIDE; EXPRESSION CLONING; BOVINE RHODOPSIN; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; PARATHYROID-HORMONE; ACTIVATION; GENE	Glucagon receptor mutants were characterized with the aim of elucidating minimal structural requirements for proper biosynthesis, ligand binding, and adenylyl cyclase coupling. One N-terminal deletion mutant and five truncation mutants with progressively shorter C termini were expressed in transiently transfected monkey kidney (COS-1) cells. Each truncation mutant was designed so that the truncated C-terminal tail would remain on the cytoplasmic surface of the receptor. In order to characterize the cellular location of the expressed receptor mutants, a highly specific, high affinity antipeptide antibody was prepared against the extracellular, N-terminal tail of the receptor, Immunoblot analysis and immunofluorescence microscopy showed that the presence of all seven putative transmembrane segments, but not an intact N-terminal tail, was required for cell surface expression of the receptor, Membranes from cells expressing receptor mutants lacking a large portion of the N-terminal tail or any of the seven putative transmembrane segments failed to bind glucagon. Membranes from cells expressing the C-terminal tail truncation mutants, which retained all seven transmembrane segments, bound glucagon with affinities similar to that of the native receptor and activated cellular adenylyl cyclase in response to glucagon. These results indicate that all seven helices are necessary for the proper folding and processing of the glucagon receptor, Glycosylation is not required for the receptor to reach the cell surface, and it may not be required for ligand binding, However, the N-terminal extracellular portion of the receptor is required for ligand binding, Most of the distal C-terminal tail is not necessary for ligand binding, and the absence of the tail may increase slightly the receptor binding affinity for glucagon. The C-terminal tail is also not necessary for adenylyl cyclase coupling and therefore does not play a direct role in G protein (G(s)) activation by the glucagon receptor.	ROCKEFELLER UNIV,NEW YORK,NY 10021; HOWARD HUGHES MED INST,MOLEC BIOL & BIOCHEM LAB,NEW YORK,NY 10021; NIDDKD,MOLEC PATHOPHYSIOL BRANCH,BETHESDA,MD 20892	Rockefeller University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK024039] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK24039] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; ANUKANTH A, 1994, J BIOL CHEM, V269, P19738; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BERRIDGE MJ, 1985, NATURE, V312, P315; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; BUGGY JJ, 1995, J BIOL CHEM, V270, P7474, DOI 10.1074/jbc.270.13.7474; CARRUTHERS CJL, 1994, J BIOL CHEM, V269, P29321; CARRUTHERS CJL, 1995, METH NEUROSCI, V25, P322; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CHRISTOPHE J, 1995, BBA-REV BIOMEMBRANES, V1241, P45, DOI 10.1016/0304-4157(94)00015-6; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14397; IIDAKLEIN A, 1995, J BIOL CHEM, V270, P8458, DOI 10.1074/jbc.270.15.8458; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; IYENGAR R, 1988, J BIOL CHEM, V263, P15348; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUSUI T, 1994, BIOCHEMISTRY-US, V33, P12968, DOI 10.1021/bi00248a005; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LO KM, 1984, P NATL ACAD SCI-BIOL, V81, P2285, DOI 10.1073/pnas.81.8.2285; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; MAYO KE, 1992, MOL ENDOCRINOL, V6, P1734, DOI 10.1210/me.6.10.1734; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PARKER EM, 1991, J BIOL CHEM, V266, P9987; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P3261, DOI 10.1021/bi00010a016; ROBBINS PW, 1977, CELL, V12, P893, DOI 10.1016/0092-8674(77)90153-2; SAKMAR TP, 1988, NUCLEIC ACIDS RES, V16, P6361, DOI 10.1093/nar/16.14.6361; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SALESSE R, 1991, BIOCHIMIE, V73, P109, DOI 10.1016/0300-9084(91)90083-D; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRENGEL R, 1994, HDB RECEPTORS CHANNE, P153; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; UNSON CG, IN PRESS P NATL ACAD; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; WAKELAM MJO, 1986, NATURE, V323, P68, DOI 10.1038/323068a0; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431	54	93	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27720	27727		10.1074/jbc.270.46.27720	http://dx.doi.org/10.1074/jbc.270.46.27720			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499239	hybrid			2022-12-27	WOS:A1995TE73600050
J	MARTIN, JL; COVERLEY, JA; BAXTER, RC				MARTIN, JL; COVERLEY, JA; BAXTER, RC			REGULATION OF IMMUNOREACTIVE INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-6 IN NORMAL AND TRANSFORMED HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN FIBROBLASTS; FACTOR-II BINDING; ADULT HUMAN SERUM; IGF-I; MOLECULAR-CLONING; GRANULOSA-CELLS; MESSENGER-RNA; RETINOIC ACID; CEREBROSPINAL-FLUID; FACTOR-BETA	Insulin-like growth factor-binding proteins (IGFBPs) have been shown to both potentiate and inhibit IGF bioactivity in vitro; thus, changes to the type or amount of IGFBPs present in the cellular environment will ultimately affect insulin-like growth factor action. In this study, we have investigated the production of immunoreactive IGFBP-6 by normal human fibroblasts (NHF) and an SV-40-transformed human fibroblast line (AG2804). When analyzed by SDS-polyacrylamide gel electrophoresis and immunoblotting, IGFBP-6 appeared as a doublet of 32-34-kDa in conditioned medium of both cell lines, with the lower molecular mass band predominating in the NHF cell line. Measured by a specific radioimmunoassay, serum-free NHF, and AG2804 cultures secreted IGFBP-6 at 1.44 +/- 0.09 and 1.23 +/- 0.08 ng/10(4) cells (mean +/- S.E.), respectively. Despite a relatively weak IGFBP-6 signal by ligand blot compared with IGFBP-3, the two proteins were secreted in similar molar concentrations by NHF. Retinoic acid increased IGFBP-6 by 3-fold in NHF and AG2804-conditioned media, maximal at approximately 100 nM retinoic acid. In contrast, IGFBP-6 production was inhibited by transforming growth factor-beta1 and agents that increase intracellular cAMP concentrations, including dibutyryl cAMP, forskolin, isobutylmethylxanthine, and cholera toxin. This study indicates that IGFBP-6 has a pattern of regulation unique among the IGFBPs, supporting the concept of specific roles for each binding protein in regulating cell growth and metabolism.	ROYAL PRINCE ALFRED HOSP,DEPT ENDOCRINOL,CAMPERDOWN,NSW 2050,AUSTRALIA	University of Sydney	MARTIN, JL (corresponding author), UNIV SYDNEY,DEPT MED,SYDNEY,NSW 2006,AUSTRALIA.		Baxter, Robert C/F-3927-2012	Baxter, Robert C/0000-0001-5061-2142				ADASHI EY, 1993, ENDOCRINOLOGY, V132, P1463, DOI 10.1210/en.132.4.1463; ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; BACH LA, 1993, ENDOCRINOLOGY, V133, P990, DOI 10.1210/en.133.3.990; BACH LA, 1992, BIOCHEM BIOPH RES CO, V186, P301, DOI 10.1016/S0006-291X(05)80807-1; BACH LA, 1993, J BIOL CHEM, V268, P9246; BALE LK, 1992, ENDOCRINOLOGY, V131, P608, DOI 10.1210/en.131.2.608; BALLARD FJ, 1985, MECH AGEING DEV, V30, P11, DOI 10.1016/0047-6374(85)90055-7; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BAXTER RC, 1992, J ENDOCRINOL, V134, P133, DOI 10.1677/joe.0.1340133; BAXTER RC, 1987, J CLIN ENDOCR METAB, V65, P423, DOI 10.1210/jcem-65-3-423; BAXTER RC, 1986, CLIN ENDOCRINOL, V24, P267, DOI 10.1111/j.1365-2265.1986.tb03267.x; BELL SC, 1991, J CLIN ENDOCR METAB, V72, P1014, DOI 10.1210/jcem-72-5-1014; BINKERT C, 1989, EMBO J, V8, P2497, DOI 10.1002/j.1460-2075.1989.tb08386.x; BINOUX M, 1982, J CLIN ENDOCR METAB, V55, P600, DOI 10.1210/jcem-55-3-600; BLUM WF, 1989, ENDOCRINOLOGY, V125, P766, DOI 10.1210/endo-125-2-766; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CONOVER CA, 1987, J CELL PHYSIOL, V133, P560, DOI 10.1002/jcp.1041330318; CONOVER CA, 1991, J CLIN INVEST, V88, P1354, DOI 10.1172/JCI115441; CONOVER CA, 1989, J CLIN INVEST, V83, P852, DOI 10.1172/JCI113968; CORPS AN, 1991, ENDOCRINOLOGY, V128, P1057, DOI 10.1210/endo-128-2-1057; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; DROP SLS, 1992, GROWTH REGULAT, V2, P69; FONTANA JA, 1991, ENDOCRINOLOGY, V128, P1115, DOI 10.1210/endo-128-2-1115; FORBES B, 1990, J ENDOCRINOL, V126, P497, DOI 10.1677/joe.0.1260497; HORIE S, 1992, BIOCHEM J, V281, P149, DOI 10.1042/bj2810149; JUNGMANN RA, 1983, J BIOL CHEM, V258, P5312; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; KIEFER MC, 1992, J BIOL CHEM, V267, P12692; KOISTINEN R, 1990, CLIN ENDOCRINOL, V32, P635, DOI 10.1111/j.1365-2265.1990.tb00907.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATOUR D, 1990, MOL ENDOCRINOL, V4, P1806, DOI 10.1210/mend-4-12-1806; LEWITT MS, 1989, J CLIN ENDOCR METAB, V69, P246, DOI 10.1210/jcem-69-2-246; MAGOFFIN DA, 1989, ENDOCRINOLOGY, V125, P1951, DOI 10.1210/endo-125-4-1951; MARTIN CA, 1990, P NATL ACAD SCI USA, V87, P4804, DOI 10.1073/pnas.87.12.4804; MARTIN JL, 1990, J BIOL CHEM, V265, P4124; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1568, DOI 10.1210/en.131.3.1568; MARTIN JL, 1990, ENDOCRINOLOGY, V127, P781, DOI 10.1210/endo-127-2-781; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; MARTIN JL, 1991, ENDOCRINOLOGY, V128, P1425, DOI 10.1210/endo-128-3-1425; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MOHAN S, 1989, P NATL ACAD SCI USA, V86, P8338, DOI 10.1073/pnas.86.21.8338; MONDSCHEIN JS, 1990, ENDOCRINOLOGY, V127, P2298, DOI 10.1210/endo-127-5-2298; OCRANT I, 1992, ENDOCRINOLOGY, V131, P221, DOI 10.1210/en.131.1.221; POWELL DR, 1991, J BIOL CHEM, V266, P18868; RECHLER MM, 1992, GROWTH REGULAT, V2, P55; ROGHANI M, 1989, FEBS LETT, V255, P253, DOI 10.1016/0014-5793(89)81101-9; SCHMID C, 1992, FEBS LETT, V303, P205, DOI 10.1016/0014-5793(92)80520-Q; SHEIKH MS, 1992, BIOCHEM BIOPH RES CO, V183, P1003, DOI 10.1016/S0006-291X(05)80290-6; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; TORRING O, 1991, ENDOCRINOLOGY, V128, P1006; UI M, 1989, ENDOCRINOLOGY, V125, P912, DOI 10.1210/endo-125-2-912; VILLAFUERTE BC, 1992, DIABETES, V41, P835, DOI 10.2337/diabetes.41.7.835; YATEMAN ME, 1993, J ENDOCRINOL, V137, P151, DOI 10.1677/joe.0.1370151; ZAPF J, 1990, J BIOL CHEM, V265, P14892; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	56	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11470	11477						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512566				2022-12-27	WOS:A1994NF96600073
J	BAGRODIA, S; LAUDANO, AP; SHALLOWAY, D				BAGRODIA, S; LAUDANO, AP; SHALLOWAY, D			ACCESSIBILITY OF THE C-SRC SH2-DOMAIN FOR BINDING IS INCREASED DURING MITOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; HOMOLOGY REGION-2; SH3 DOMAINS; PP60C-SRC; ACTIVATION; TRANSFORMATION; PROTEINS; P60C-SRC; SITES	The Src homology 2 (SH2) region is a noncatalytic domain of Src-family tyrosine kinases and other proteins which participates in inter- and intramolecular interactions of tyrosine-phosphorylated proteins. A synthetic peptide modeled on the c-Src carboxyl terminus, which contains phosphotyrosine at position 527, binds recombinant SH2 and the SH2 domain of c-Src which lacks phosphotyrosine 527. Unphosphorylated peptide does not bind detectably. Thus, the phosphorylated peptide is a specific probe for investigating SH2 accessibility. Since Src and other tyrosine kinases may participate in regulating events in mitosis, we used the SH2-binding probe to test the prediction that decreased tyrosine 527 phosphorylation would lead to increased accessibility of the c-Src SH2-domain during mitosis. Probe binding to overexpressed chicken c-Src was enhanced at least 6-fold during mitosis, indicating that the c-Src SH2-domain is more accessible in this part of the cell cycle. This suggests that there may be mitosis-specific interactions of the c-Src SH2-domain with cellular proteins in vivo.	CORNELL UNIV, DEPT PATHOL, CANC BIOL LAB, ITHACA, NY 14853 USA; UNIV NEW HAMPSHIRE, DEPT BIOCHEM, DURHAM, NH 03825 USA	Cornell University; University System Of New Hampshire; University of New Hampshire	BAGRODIA, S (corresponding author), CORNELL UNIV, DEPT PATHOL, MOLEC & CELL BIOL LABS, BIOCHEM SECT, ITHACA, NY 14853 USA.				NCI NIH HHS [CA323178, CA56908-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R15CA056908] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHACKALAPARAMPI.I, 1994, IN PRESS ONCOGENE; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LIU XQ, 1993, ONCOGENE, V8, P1119; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SOUTHERN PJ, 1982, J MOL APPL GENET, V1, P326; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5	27	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10247	10251						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511598				2022-12-27	WOS:A1994NF01700015
J	KOBAYASHI, S; NISHIMURA, J; KANAIDE, H				KOBAYASHI, S; NISHIMURA, J; KANAIDE, H			CYTOSOLIC CA2+ TRANSIENTS ARE NOT REQUIRED FOR PLATELET-DERIVED GROWTH-FACTOR TO INDUCE CELL-CYCLE PROGRESSION OF VASCULAR SMOOTH-MUSCLE CELLS IN PRIMARY CULTURE - ACTIONS OF TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; PDGF RECEPTOR; INTRACELLULAR CALCIUM; PHOSPHORYLATION; ACTIVATION; MITOGENESIS; EXPRESSION; PROTEIN; TRANSFORMATION; STIMULATION	We investigated interrelations among changes in cytosolic Ca2+ concentrations ([Ca2+](i)), tyrosine phosphorylation, and the cell cycles of rat aorta smooth muscle cells in primary culture, as stimulated with platelet derived growth factor (PDGF). Changes in [Ca2+](i) were monitored using the microfluorometry of Fura-2. The phase of the cell cycle and the extent of tyrosine phosphorylation were examined by immunocytochemical analysis of monoclonal antibodies against cell cycle-specific nuclear antigens and against phosphotyrosine, respectively. Prior to the application of PDGF, the cell cycle was synchronized in the G(0) phase by serum deprivation for 24 h. In the presence of extracellular Ca2+, PDGF induced an initial transient (first component) and a subsequent lower steady-state (second component) elevation of [Ca2+](i). NiCl2 and the removal of extracellular Ca2+ inhibited the second, but not the first, component. The first component was inhibited by pretreatment with ryanodine. These results are compatible with the notion that the first and second components may be mediated mainly through the release of intracellular Ca2+ and the influx of extracelluIar Ca2+, respectively. After pretreatment with ryanodine and in the presence of NiCl2, PDGF also stimulated the entry of G(0) cells into G(1) phase, but there were no [Ca2+]i transients. Genistein, a tyrosine kinase blocker, inhibited tyrosine phosphorylation induced by PDGF and blocked the first, but not the second, component of [Ca2+](i) elevation induced by PDGF. However, genistein did not inhibit the release of intracellular Ca2+ induced by angiotensin II or by caffeine. Genistein prevented G(0) cells from entering the G(1) phase, as induced by PDGF, but this was not the case when serum was reapplied to the growth medium. Similar results were obtained with another tyrosine kinase blocker, tyrphostin. These data suggest that in vascular smooth muscle cells: 1) an increase in [Ca2+](i) is not required for competent (G(0) to G(1)) cell proliferation induced by PDGF; and 2) tyrosine kinase plays an important role the release of intracellular Ca2+ and in cell proliferation, as induced by PDGF.	KYUSHU UNIV,FAC MED,ANGIOCARDIOL RES INST,DIV MOLEC CARDIOL,FUKUOKA 812,JAPAN	Kyushu University								AKAIKE N, 1989, J PHYSIOL-LONDON, V416, P141, DOI 10.1113/jphysiol.1989.sp017754; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLOCK LH, 1989, P NATL ACAD SCI USA, V86, P2388, DOI 10.1073/pnas.86.7.2388; DILIBERTO PA, 1990, J CELL BIOCHEM, V44, P39, DOI 10.1002/jcb.240440104; EK B, 1982, NATURE, V295, P419, DOI 10.1038/295419a0; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HOSHI M, 1988, J BIOL CHEM, V263, P5396; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KANAIDE H, 1988, CIRC RES, V63, P16, DOI 10.1161/01.RES.63.1.16; KANAIDE H, 1990, ASIA PAC J PHARMACOL, V5, P177; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KOBAYASHI S, 1985, SCIENCE, V229, P553, DOI 10.1126/science.3927484; KOBAYASHI S, 1986, J BIOL CHEM, V261, P5709; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LANDBERG G, 1990, EXP CELL RES, V187, P111, DOI 10.1016/0014-4827(90)90124-S; LEWIS RS, 1988, SCIENCE, V239, P771, DOI 10.1126/science.2448877; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MEISENHELDER J, 1989, CELL, V57, P1108; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NISHIMURA J, 1992, BIOCHEM BIOPH RES CO, V188, P1198, DOI 10.1016/0006-291X(92)91358-W; OLAH Z, 1990, P AM ASSOC CANC RES, V31, pA76; QU Z, 1990, NEURON, V2, P367; QUINONES MA, 1991, J BIOL CHEM, V266, P14055; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TUCKER RW, 1989, J CELL BIOCHEM, V39, P139, DOI 10.1002/jcb.240390206; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YAMAMOTO H, 1983, BRIT J EXP PATHOL, V64, P156; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; YUKI H, 1971, GANN, V62, P199	34	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9011	9018						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510699				2022-12-27	WOS:A1994NB41100060
J	BRADBURY, NA; COHN, JA; VENGLARIK, CJ; BRIDGES, RJ				BRADBURY, NA; COHN, JA; VENGLARIK, CJ; BRIDGES, RJ			BIOCHEMICAL AND BIOPHYSICAL IDENTIFICATION OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CHLORIDE CHANNELS AS COMPONENTS OF ENDOCYTIC CLATHRIN-COATED VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; EPITHELIAL-CELL LINE; PLASMA-MEMBRANE; ELECTROLYTE TRANSPORT; CFTR; RECEPTOR; BINDING; PHOSPHORYLATION; GENE; INTERNALIZATION	Cystic fibrosis results from mutations in the gene encoding the CFTR Cl- channel. Although CFTR occurs as an integral component of the plasma membrane, recent studies implicate CFTR in endocytic recycling and suggest that the protein may also exist in intracellular vesicular compartments. To test this, we analyzed CFTR in clathrin-coated vesicles (CCV) purified from cells constitutively expressing CFTR at high levels. CFTR immunoreactivity was detected in CCV by immunoblot and was identified as CFTR based on labeling of immunoprecipitates with protein kinase A and by tryptic phosphopeptide mapping. Fusion of uncoated CCV with planar lipid bilayers resulted in the incorporation of kinase- and ATP-activated Cl- channel activity (7.8 pS at 20 degrees C; 11.9 pS at 37 degrees C), with a linear current-voltage relation under symmetrical conditions. Thus, functional CFTR occurs in CCV. Moreover, CFTR interacts with the plasma membrane specific adaptor complex during endocytosis through clathrin-coated pits. Therefore, the abundance of CFTR in the plasma membrane may be regulated by exocytic insertion and endocytic recycling, and these processes may provide an augmentation to protein kinase A activation as a mechanism for regulating CFTR Cl channels in the plasma membrane.	UNIV ALABAMA, GREGORY FLEMING CYSTIC FIBROSIS RES CTR, BIRMINGHAM, AL 35294 USA; DUKE UNIV, DEPT MED, DURHAM, NC 27710 USA; VET ADM MED CTR, DURHAM, NC 27710 USA	University of Alabama System; University of Alabama Birmingham; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BRADBURY, NA (corresponding author), UNIV ALABAMA, DEPT PHYSIOL & BIOPHYS, UAB STN, BIRMINGHAM, AL 35294 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040701, P50DK042017, R01DK045970, R01DK040701] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45970, DK42017, DK40701] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLE S, 1989, J BIOL CHEM, V264, P20089; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1992, AM J PHYSIOL, V262, pC251, DOI 10.1152/ajpcell.1992.262.1.C251; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRADBURY NA, 1992, BIOCHEM BIOPH RES CO, V184, P1173, DOI 10.1016/S0006-291X(05)80006-3; BRADBURY NA, 1992, AM J PHYSIOL, V262, pC752, DOI 10.1152/ajpcell.1992.262.3.C752; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIDGES RJ, 1989, AM J PHYSIOL, V256, pC902, DOI 10.1152/ajpcell.1989.256.4.C902; BUANES T, 1988, GASTROENTEROLOGY, V95, P417, DOI 10.1016/0016-5085(88)90499-4; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHANG D, 1988, COMPUT BIOL MED, V18, P351, DOI 10.1016/0010-4825(88)90022-4; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COHN JA, 1992, P NATL ACAD SCI USA, V89, P2340, DOI 10.1073/pnas.89.6.2340; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COURTOY PJ, 1991, ENDOCYTOSIS, P163; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; FIEDLER MA, 1992, AM J PHYSIOL, V262, pL779, DOI 10.1152/ajplung.1992.262.6.L779; FORGAC M, 1983, P NATL ACAD SCI-BIOL, V80, P1300, DOI 10.1073/pnas.80.5.1300; FULLER CM, 1994, IN PRESS AM J PHYSL; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; HAWS C, 1992, AM J PHYSIOL, V263, pL692, DOI 10.1152/ajplung.1992.263.6.L692; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEEN JH, 1989, BIOCHEM BIOPH RES CO, V158, P17, DOI 10.1016/S0006-291X(89)80170-6; KEMPSON SA, 1990, AM J PHYSIOL, V258, pF1336, DOI 10.1152/ajprenal.1990.258.5.F1336; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; MARINO CR, 1993, CLIN RES, V41, pA219; MULBERG AE, 1991, J BIOL CHEM, V266, P20590; PEARSE BMF, 1985, EMBO J, V4, P2457, DOI 10.1002/j.1460-2075.1985.tb03956.x; PEARSE BMF, 1982, P NATL ACAD SCI-BIOL, V79, P451, DOI 10.1073/pnas.79.2.451; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; PUCHELLE E, 1992, AM J RESP CELL MOL, V7, P485, DOI 10.1165/ajrcmb/7.5.485; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROMMENS JM, 1988, SCIENCE, V245, P1066; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SINGH AK, 1991, AM J PHYSIOL, V260, pC51; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; STETSON DL, 1983, AM J PHYSIOL, V245, pC113, DOI 10.1152/ajpcell.1983.245.1.C113; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	54	105	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8296	8302						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510684				2022-12-27	WOS:A1994NB40900070
J	DILDA, P; LELIEVRE, LG				DILDA, P; LELIEVRE, LG			FUNCTIONAL-CHARACTERIZATION OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) IN APICAL MEMBRANES PURIFIED FROM BOVINE TRACHEAL EPITHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CHLORIDE CHANNEL; RAT-HEART; R-DOMAIN; VESICLES; TRANSPORT; GENE; CAMP; RECONSTITUTION; INHIBITION	Inside-out apical membrane vesicles were isolated from bovine tracheal epithelium. They were enriched 13- and 18-fold in two apical membrane markers, alkaline phosphatase and gamma-glutamyltransferase, respectively, and presented a low level of contamination by basolateral and intracellular membranes. These apical membrane vesicles of homogeneous inside-out orientation were used to measure Cl-36- influx. The Cl-36- influx was found to be (i) voltage insensitive (ii) diphenylcarboxylic acid-insensitive, and (iii) from 55 to 100% activated by cAMP-dependent protein kinase according to initial rates and accumulation capacities. This rapid and ATP-dependent activation was associated with phosphorylation of a 170-180-kDa protein but was not observed with a nonhydrolyzable nucleotide like adenosine 5'-O-(3-thiotriphosphate). Immunodetection experiments showed that the mature form of bovine cystic fibrosis transmembrane conductance regulator (CFTR) was only present in the apical membranes. As compared with the previously described characteristics of CFTR, the Cl-36- uptakes detected here are the in vitro manifestation of the functional form of bovine CFTR located at the apical level in these tracheal epithelial cells. Inside-out apical membrane vesicles, with freely accessible cytoplasmic sides and functional CFTR, offer a new model system to study CFTR.	UNIV PARIS 07,PHARMACOL TRANSPORTS ION MEMBRANAIRES LAB,F-75251 PARIS 05,FRANCE	UDICE-French Research Universities; Universite Paris Cite								ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DECHECCHI MC, 1993, J BIOL CHEM, V268, P11321; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DIAMOND G, 1991, J BIOL CHEM, V266, P22761; DISTEFANO A, 1985, PFLUG ARCH EUR J PHY, V405, pS95, DOI 10.1007/BF00581787; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DUBINSKY WP, 1986, AM J PHYSIOL, V251, pC713, DOI 10.1152/ajpcell.1986.251.5.C713; EMMER E, 1989, J MEMBRANE BIOL, V108, P207, DOI 10.1007/BF01871735; FONG P, 1988, J MEMBRANE BIOL, V104, P233, DOI 10.1007/BF01872325; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; GARTY H, 1983, J BIOL CHEM, V258, P3094; GOLSTEIN P, 1992, AM J PHYSIOL, V263, pC590, DOI 10.1152/ajpcell.1992.263.3.C590; HANRAHAN JW, 1990, J MEMBRANE BIOL, V116, P65, DOI 10.1007/BF01871673; HWANG TC, 1993, 7TH ANN N AM CYST FI; JONES LR, 1977, J BIOL CHEM, V252, P3315; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEENOY MY, 1990, DIABETES RES CLIN EX, V14, P139; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY DW, 1987, J GEN PHYSIOL, V90, P779, DOI 10.1085/jgp.90.6.779; LANGRIDGESMITH JE, 1983, BIOCHIM BIOPHYS ACTA, V731, P318, DOI 10.1016/0005-2736(83)90024-X; LANGRIDGESMITH JE, 1984, BIOCHIM BIOPHYS ACTA, V777, P84, DOI 10.1016/0005-2736(84)90499-1; LELIEVRE LG, 1986, AM J PHYSIOL, V250, pH923, DOI 10.1152/ajpheart.1986.250.6.H923; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANSIER P, 1983, J BIOL CHEM, V258, P6628; ORLOWSKI M, 1963, BIOCHIM BIOPHYS ACTA, V73, P679; PLACCHI P, 1991, J MEMBRANE BIOL, V119, P25, DOI 10.1007/BF01868537; PUCHELLE E, 1992, AM J RESP CELL MOL, V7, P485, DOI 10.1165/ajrcmb/7.5.485; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; REEVES WB, 1989, J MEMBRANE BIOL, V109, P65, DOI 10.1007/BF01870791; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; SHEN BQ, 1991, AM J PHYSIOL, V261, pL102, DOI 10.1152/ajplung.1991.261.2.L102; THOMAS R, 1979, EUR J PHARMACOL, V53, P227, DOI 10.1016/0014-2999(79)90128-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WIDDICOMBE JH, 1985, P NATL ACAD SCI USA, V82, P6167, DOI 10.1073/pnas.82.18.6167	48	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7801	7806						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510290				2022-12-27	WOS:A1994NA03200117
J	JOHNSON, GD; HERSH, LB				JOHNSON, GD; HERSH, LB			EXPRESSION OF MEPRIN SUBUNIT PRECURSORS - MEMBRANE ANCHORING THROUGH THE BETA-SUBUNIT AND MECHANISM OF ZYMOGEN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY MICROVILLAR MEMBRANE; MOUSE KIDNEY; IMMUNOHISTOCHEMICAL LOCALIZATION; RAT-KIDNEY; PROTEINS; ENDOPEPTIDASE-2; CLONING; METALLOENDOPEPTIDASES; PURIFICATION; ASTACIN	The biosynthesis of the membrane-bound metalloendopeptidase meprin was studied after the introduction of cDNAs encoding the rat meprin alpha and beta subunits into human 293 cells. When expressed individually the meprin a subunit was found to be primarily secreted into the culture medium, while the beta subunit was determined to be an integral membrane protein, Coexpression of the alpha and beta subunits results in the localization of both subunits to the plasma membrane. In this case the alpha subunit is specifically released from the cell surface by dithiothreitol, indicating the a subunit is associated with the membrane via disulfide bond(s) to the beta subunit. Meprin expressed in 293 cells is similar to the rat kidney enzyme in that it forms disulfide-linked dimers and has a similar pattern of glycosylation. However, the expressed protein displayed no detectable peptidase activity against four meprin substrates. Processing of the a subunit was followed after the introduction of sequences coding for the human c-myc peptide epitope EQKLISEEDL into its cDNA in the region of its prosequence and at the COOH terminus. Detection of the resulting proteins using a monoclonal an tibody specific for the c-myc epitope indicates the a subunit is processed at its COOH terminus but retains the prosequence which is absent from the enzyme purified from rat kidney. Limited trypsin digestion of meprin precursors expressed in 293 cells results in both the activation of the enzyme and the removal of the prosequence. This result supports the hypothesis of Bode et al. (Bode W, Gomis-Ruth, F.X., Huber, R., Zwilling, R., and Stocker, W (1992) Nature 358, 164-167) that meprin and other astacin family proteases require removal of NH2-terminal prosequences at the junction of the astacin protease domain for zymogen activation. Trypsin-activated meprin was assayed with the protein substrate azocasein and three synthetic peptide substrates. The membrane-bound beta subunit was found to be more active than the secreted a subunit against azocasein but much less active toward the synthetic peptide substrates.	UNIV KENTUCKY,CHANDLER MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Kentucky					NIDA NIH HHS [DA02243] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002243] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARNES K, 1989, BIOCHEM J, V264, P335, DOI 10.1042/bj2640335; BEYNON RJ, 1981, BIOCHEM J, V199, P591, DOI 10.1042/bj1990591; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BUTLER PE, 1988, J BIOL CHEM, V263, P13419; BUTLER PE, 1987, BIOCHEM J, V241, P229, DOI 10.1042/bj2410229; CORBEIL D, 1992, FEBS LETT, V309, P203, DOI 10.1016/0014-5793(92)81095-4; CORBEIL D, 1993, FEBS LETT, V335, P361, DOI 10.1016/0014-5793(93)80420-Y; CRAIG SS, 1991, J HISTOCHEM CYTOCHEM, V39, P123, DOI 10.1177/39.1.1701182; DUMERMUTH E, 1993, FEBS LETT, V335, P367, DOI 10.1016/0014-5793(93)80421-P; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GORBEA CM, 1993, J BIOL CHEM, V268, P21035; GORBEA CM, 1991, ARCH BIOCHEM BIOPHYS, V290, P549, DOI 10.1016/0003-9861(91)90580-C; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUNBERG J, 1993, FEBS LETT, V335, P376, DOI 10.1016/0014-5793(93)80422-Q; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JOHNSON GD, 1992, J BIOL CHEM, V267, P13505; KENNY AJ, 1987, BIOCHEM J, V245, P515, DOI 10.1042/bj2450515; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPAGE T, 1992, DEVELOPMENT, V114, P147; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; SANGER F, 1977, P NATL ACAD SCI USA, V76, P4350; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STERCHI EE, 1988, ARCH BIOCHEM BIOPHYS, V265, P105, DOI 10.1016/0003-9861(88)90376-1; STOCKER W, 1993, EUR J BIOCHEM, V214, P215, DOI 10.1111/j.1432-1033.1993.tb17915.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	31	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7682	7688						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510289				2022-12-27	WOS:A1994NA03200101
J	YONEZAWA, K; ANDO, A; KABURAGI, Y; YAMAMOTOHONDA, R; KITAMURA, T; HARA, K; NAKAFUKU, M; OKABAYASHI, Y; KADOWAKI, T; KAZIRO, Y; KASUGA, M				YONEZAWA, K; ANDO, A; KABURAGI, Y; YAMAMOTOHONDA, R; KITAMURA, T; HARA, K; NAKAFUKU, M; OKABAYASHI, Y; KADOWAKI, T; KAZIRO, Y; KASUGA, M			SIGNAL-TRANSDUCTION PATHWAYS FROM INSULIN-RECEPTORS TO RAS - ANALYSIS BY MUTANT INSULIN-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; STIMULATES TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; INTACT-CELLS; SH3 DOMAINS; FACTOR-I; PROTEIN; ACTIVATION; SUBSTRATE	We have examined the involvement of insulin receptor (IR) substrate-1 (IRS-1) and/or Shc in the upstream of Res activation in insulin signaling using Chinese hamster ovary (CHO) cell lines overexpressing wild-type (CHO-IR cells) or mutant insulin receptors. In CHO-IR cells, insulin rapidly phosphorylated IRS-1 and Shc at tyrosine residues and stimulated the formation of the active GTP-bound Ras (Ras GTP). In contrast, a CHO cell line overexpressing the kinase-negative mutant insulin receptor substituting Arg(1018) for Lys(1018) was unable to tyrosine phosphorylate IRS-1 and Shc and failed to activate Ras in response to insulin. A CHO cell line overexpressing the mutant insulin receptor, substituting Ala(960) for Tyr(960) and which was known to exhibit impaired tyrosine phosphorylation of IRS-1 and biological effects evoked by insulin, showed severely impaired insulin-dependent tyrosine phosphorylation of She and moderately impaired activation of Ras. Another cell line overexpressing the mutant insulin receptor, lacking 82 amino acids of the C terminus of beta-subunit and which was recently reported to retain normal insulin depend ent tyrosine phosphorylation of IRS-1, showed slightly impaired Ras activation at 10(-7) M insulin with severely reduced tyrosine phosphorylation of Shc protein. Furthermore, insulin did not induce the association of tyrosine-phosphorylated IRS 1 and Shc in CHO-IR cells. These results suggest that Shc and IRS-1 lie in the separate signaling pathways and that the tyrosine phos phorylation of IRS-1 with or without some low level of Shc phosphorylation may be enough to stimulate the submaximal accumulation of Ras-GTP complex and may need synergistically the higher level of tyrosine phosphorylation of Shc to induce the full activation of Ras in insulin signaling.	KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE,HYOGO 650,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO,TOKYO 113,JAPAN; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304	Kobe University; University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Kitamura, Toshio/AAA-2071-2021; Nakafuku, Masato/J-3068-2013	Nakafuku, Masato/0000-0001-7783-9005				ANDO A, 1992, J BIOL CHEM, V267, P12788; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECKER AB, 1990, ANNU REV MED, V41, P99; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EAGAN SE, 1993, NATURE, V363, P45; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; IZUMI T, 1987, J BIOL CHEM, V262, P1282; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOSHIO O, 1989, FEBS LETT, V254, P22, DOI 10.1016/0014-5793(89)81001-4; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEWIS RE, 1990, J BIOL CHEM, V265, P947; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P481; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MCCLADE J, 1992, P NATL ACAD SCI USA, V89, P8869; MYERS MG, 1991, J BIOL CHEM, V266, P10616; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1992, J BIOL CHEM, V267, P24149; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TASHIROHASHIMOTO Y, 1989, J BIOL CHEM, V264, P6879; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOBE K, 1993, J BIOL CHEM, V268, P11167; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAMOTOHONDA R, 1993, J BIOL CHEM, V268, P16859; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	61	122	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4634	4640						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508445				2022-12-27	WOS:A1994MW98900108
J	HOKLAND, BM; SLOTTE, JP; BIERMAN, EL; ORAM, JF				HOKLAND, BM; SLOTTE, JP; BIERMAN, EL; ORAM, JF			CYCLIC-AMP STIMULATES EFFLUX OF INTRACELLULAR STEROL FROM CHOLESTEROL-LOADED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; PROTEIN-KINASE-C; PLASMA-MEMBRANE; HUMAN FIBROBLASTS; ENDOPLASMIC-RETICULUM; BINDING; POOLS; TRANSLOCATION; MACROPHAGES; METABOLISM	The interaction of high density lipoprotein with its putative receptor stimulates translocation and efflux of intracellular sterols by a process involving activation of protein kinase C. This study shows that activation of cAMP-dependent protein kinase also stimulates efflux of intracellular sterols. When intracellular sterol pools of cholesterol-loaded cultured human skin fibroblasts and bovine aortic endothelial cells were radiolabeled with the biosynthetic precursor [H-3]mevalonolactone, high density lipoprotein3 (HDL3)-mediated H-3-sterol efflux was enhanced by addition of the adenylylcyclase activator forskolin, the phosphodiesterase inhibitors theophylline and 3-isobutyl-1-methylxanthine, and the cAMP analogues N-benzoyl-cAMP (N6-cAMP) and 8-thiomethyl-cAMP. The effect of N-cAMP was abolished by an inhibitor of cAMP-dependent protein kinase (H8). The enhanced sterol efflux was independent of receptor binding of HDL3, as similar effects were observed in the presence of tetranitromethane-modified HDL3, which lacks receptor binding activity. N6-cAMP stimulated efflux of several subspecies of newly synthesized sterols, including cholesterol. Elevation of cAMP levels increased the proportion of radiosterols that were accessible to treatment of cells with the enzyme cholesterol oxidase, suggesting that activation of cAMP-dependent protein kinase stimulates translocation of sterols from intracellular compartments to the plasma membrane where they desorb from the cell surface. Thus, at least two distinct protein kinase signalling pathways modulate transport of intracellular sterols in cholesterol-loaded cells.	UNIV WASHINGTON,DEPT MED,DIV METAB ENDOCRINOL & NUTR RG-26,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL31194, HL18645] Funding Source: Medline; NIDDK NIH HHS [DK-02456] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031194, P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS JJ, 1986, METHOD ENZYMOL, V129, P691; AVIRAM M, 1989, J LIPID RES, V30, P65; BERNARD DW, 1991, J BIOL CHEM, V266, P710; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BRINTON EA, 1985, ARTERIOSCLEROSIS, V5, P329, DOI 10.1161/01.ATV.5.4.329; BRINTON EA, 1986, J BIOL CHEM, V261, P495; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRAENKELCONRAT H, 1957, METHOD ENZYMOL, V4, P247, DOI 10.1016/0076-6879(57)04059-8; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; LANGE Y, 1992, J LIPID RES, V33, P315; LANGE Y, 1985, J BIOL CHEM, V260, P5592; LANGE Y, 1991, J BIOL CHEM, V266, P21439; LANGE Y, 1991, J LIPID RES, V32, P329; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MENDEZ AJ, 1991, T ASSOC AM PHYSICIAN, V104, P48; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; Oram J F, 1986, Methods Enzymol, V129, P645; ORAM JF, 1983, J CLIN INVEST, V72, P1611, DOI 10.1172/JCI111120; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; PINKERTON FD, 1982, J BIOL CHEM, V257, P1929; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; THERET N, 1990, BIOCHEM BIOPH RES CO, V173, P1361, DOI 10.1016/S0006-291X(05)80938-6; URBANI L, 1990, J BIOL CHEM, V265, P1919	27	52	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25343	25349						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503979				2022-12-27	WOS:A1993MK10000013
J	MATHER, MW; YU, L; YU, CA				MATHER, MW; YU, L; YU, CA			THE INVOLVEMENT OF THREONINE-160 OF CYTOCHROME-B OF RHODOBACTER-SPHAEROIDES CYTOCHROME BC(1) COMPLEX IN QUINONE BINDING AND INTERACTION WITH SUBUNIT-IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; IRON-SULFUR PROTEIN; RHODOPSEUDOMONAS-SPHAEROIDES; C OXIDOREDUCTASE; PHOTOSYNTHETIC GROWTH; RESPIRATORY-CHAIN; ELECTRON-TRANSFER; Q0 SITE; UBIQUINONE; MUTANTS	The cytochrome b subunit (subunit I) of the ubiquinolcytochrome c reductase (bc(1) complex) is thought to participate in the formation of two quinone/quinol reaction centers, an oxidizing center (Q(o)) and a reducing center, in accordance with the quinone cycle mechanism, Threonine 160 is a highly conserved residue in a segment of subunit I that was shown to bind quinone and is placed near the putative Q(o) site in current models of the bc(1) complex, Rhodobacter sphaeroides cells expressing bc(1) complexes with Ser or Tyr substituted for Thr(160) grow photosynthetically at a reduced rate, and cells expressing the mutated complexes produce an ''elevated' level of the bc(1) complex. The Ser substitution also affects the interaction of subunit IV with subunit I. Replacement of Thr(160) by Ser results in about a 70% loss of the activity in the purified complex, whereas substitution by Tyr lowers the activity by more than 80%. Both replacements lower the apparent K-m for ubiquinol. Electron paramagnetic resonance (EPR) spectroscopy shows that in the Ser substituted complex, the environments of the Rieske iron sulfur cluster in subunit III and the high potential cytochrome b (b(562)) in subunit I have been modified, The spectra of the Ser(160) and Tyr(160) iron-sulfur clusters have become redox-insensitive, with a line shape resembling that of the native complex in the fully reduced state, The EPR signal of b(562) in the Ser(160) complex is shifted from g = 3.50 to g = 3.52, but otherwise the line shape is very similar to the spectrum of the native complex. Most of these results are consistent with current ideas regarding the structure and function of Q(o) in the bc(1) complex, except for the alteration of the b(562) EPR feature, because this heme is not thought to be located in proximity to Q(o). Immunoblotting analysis showed that the Ser or Tyr substituted complex contained significantly less than a stoichiometric amount of subunit IV. The enzymatic activity of mutated bc(1) complex was found to be activable by the addition of purified subunit IV. These results indicate that Thr(160) plays an important role in the structure and/or function of the bc(1) complex.			MATHER, MW (corresponding author), OKLAHOMA STATE UNIV,OKLAHOMA AGR EXPT STN,DEPT BIOCHEM & MOLEC BIOL,246B NOBLE RES CTR,STILLWATER,OK 74078, USA.			Mather, Michael/0000-0002-1062-0137	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS KM, 1990, BIOCHEMISTRY-US, V29, P2645, DOI 10.1021/bi00463a004; ATTAASAFOADJEI E, 1991, P NATL ACAD SCI USA, V88, P492, DOI 10.1073/pnas.88.2.492; BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; BOWYER JR, 1982, J BIOL CHEM, V257, P8321; BROSIUS J, 1989, DNA-J MOLEC CELL BIO, V8, P759, DOI 10.1089/dna.1989.8.759; CHEN YR, 1994, BIOCHEMISTRY-US, V33, P10207, DOI 10.1021/bi00199a050; CLAYTON RK, 1973, BIOCHIM BIOPHYS ACTA, V75, P312; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; COLSON AM, 1993, J BIOENERG BIOMEMBR, V25, P211, DOI 10.1007/BF00762583; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DEVRIES S, 1979, BIOCHIM BIOPHYS ACTA, V546, P316, DOI 10.1016/0005-2728(79)90049-5; DEVRIES S, 1982, BIOCHIM BIOPHYS ACTA, V681, P41, DOI 10.1016/0005-2728(82)90276-6; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; DU ZJ, 1993, METHOD ENZYMOL, V218, P104; Feher G., 1978, PHOTOSYNTHETIC BACTE, P349; GABELLINI N, 1982, EUR J BIOCHEM, V126, P105, DOI 10.1111/j.1432-1033.1982.tb06753.x; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; HACKER B, 1993, BIOCHEMISTRY-US, V32, P4403, DOI 10.1021/bi00067a033; HALEY PE, 1986, J BIOL CHEM, V261, P4593; HAUSKA G, 1988, J BIOENERG BIOMEMBR, V20, P2155; HE DY, 1994, J BIOL CHEM, V269, P2292; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KHOSRAVI M, 1990, PLASMID, V23, P138, DOI 10.1016/0147-619X(90)90032-8; Kroger A, 1978, Methods Enzymol, V53, P579; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK TA, 1993, J BIOENERG BIOMEMBR, V25, P221, DOI 10.1007/BF00762584; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUURA K, 1983, J BIOL CHEM, V258, P1571; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; MEINHARDT SW, 1987, J BIOL CHEM, V262, P8702; NANO FE, 1984, J BACTERIOL, V158, P1094, DOI 10.1128/JB.158.3.1094-1103.1984; ORMEJOHNSON NR, 1974, BIOCHEM BIOPH RES CO, V45, P871; PEMBERTON JM, 1981, J BACTERIOL, V147, P110, DOI 10.1128/JB.147.1.110-117.1981; PURVIS DJ, 1990, J BIOL CHEM, V265, P1208; QIAN L, 1991, BIOTECHNIQUES, V10, P736; Redfearn E. R., 1967, METHOD ENZYMOL, V10, P381, DOI [10.1016/0076-6879(67)10071-2, DOI 10.1016/0076-6879(67)10071-2]; ROBERTSON DE, 1990, BIOCHEMISTRY-US, V29, P11249, DOI 10.1021/bi00503a014; ROTT MA, 1993, J BACTERIOL, V175, P358, DOI 10.1128/JB.175.2.358-366.1993; SALERNO JC, 1984, J BIOL CHEM, V259, P2331; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEIDOW J, 1978, J BIOL CHEM, V253, P2392; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SISTROM WR, 1960, J GEN MICROBIOL, V22, P778, DOI 10.1099/00221287-22-3-778; TITUS DE, 1991, PROMEGA PROTOCOLS AP, P105; TRON T, 1991, EUR J BIOCHEM, V199, P753, DOI 10.1111/j.1432-1033.1991.tb16180.x; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; TWOBIN H, 1979, P NATL ACAD SCI USA, V76, P4350; VIEIRA J, 1983, GENE, V19, P254; WARD JM, 1982, PLASMID, V7, P239, DOI 10.1016/0147-619X(82)90005-1; YANG XH, 1986, J BIOL CHEM, V261, P2282; YU CA, 1993, J BIOENERG BIOMEMBR, V23, P259; YU L, 1984, J BIOL CHEM, V259, P5752; YU L, 1991, BIOCHEMISTRY-US, V30, P4934, DOI 10.1021/bi00234a014; YU L, 1986, BIOCHIM BIOPHYS ACTA, V852, P203, DOI 10.1016/0005-2728(86)90225-2; YUN CH, 1990, EUR J BIOCHEM, V194, P399, DOI 10.1111/j.1432-1033.1990.tb15633.x	58	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28668	28675		10.1074/jbc.270.48.28668	http://dx.doi.org/10.1074/jbc.270.48.28668			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499386	hybrid			2022-12-27	WOS:A1995TH05600030
J	PETROV, VV; SLAYMAN, CW				PETROV, VV; SLAYMAN, CW			SITE-DIRECTED MUTAGENESIS OF THE YEAST PMA1 H+-ATPASE - STRUCTURAL AND FUNCTIONAL-ROLE OF CYSTEINE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ATPASE; SARCOPLASMIC-RETICULUM; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SECRETORY VESICLES; NEUROSPORA-CRASSA; SENSORY RECEPTOR; CROSS-LINKING; CONSEQUENCES; CA-2+-ATPASE	The yeast plasma-membrane H+-ATPase contains nine cysteines, three in presumed transmembrane segments (Cys-148, Cys-312, and Cys-867) and the rest in hydrophilic regions thought to be exposed at the cytoplasmic surface (Cys-221, Cys-376, Cys-409, Cys-472, Cys-532, and Cys-569). To gather new functional and structural information, we have studied the yeast ATPase by cysteine mutagenesis. It proved possible to replace seven of the nine cysteines by alanine, one at a time, without any significant decrease in ATP hydrolysis or ATP-dependent proton pumping. In the remaining two cases (Cys-409 and Cys-472), there were small but reproducible effects; the results clearly indicated, however, that no single Cys is required for activity and that, if a disulfide bridge is formed in the yeast ATPase, it does not play an obligatory structural or functional role. Next, multiple mutants were constructed to ask how many Cys residues could be replaced simultaneously while leaving a fully functional enzyme. After substitution of all ''membrane'' Cys (Cys-148, Cys-312, and Cys-867) together with two non-conserved Cys located in hydrophilic regions (Cys-221 and Cys-569), there were no significant abnormalities in expression (87%) or activity (89% ATP hydrolysis/93% H+ pumping) of the mutant protein. Replacement of two additional cysteines (Cys-376 near the phosphorylation site and Cys-532, in or near the ATP-binding site) caused a drop in expression (to 54%), although the corrected hydrolytic and H+ pumping activities were still normal. When Cys-472 was also mutated, the corrected activity fell to 44% hydrolysis/47% pumping; finally, substitution of Cys-409 to give a ''cysteine-free'' ATPase led to a very poorly expressed and poorly active enzyme. Brief exposure of the ''one-cysteine'' and ''two-cysteine'' ATPases to trypsin revealed a normal pattern of degradation, but there was a slight impairment in the ability of vanadate to protect against proteolysis. Thus, although single Cys replacements are tolerated well by the yeast ATPase, multiple replacements are progressively more harmful, suggesting that they cause small but additive perturbations of protein folding.	YALE UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, NEW HAVEN, CT 06510 USA	Yale University	PETROV, VV (corresponding author), YALE UNIV, SCH MED, DEPT GENET, 333 CEDAR ST, NEW HAVEN, CT 06510 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015761, R01GM015761] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15761] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER KJ, 1994, BBA-BIOMEMBRANES, V1192, P53, DOI 10.1016/0005-2736(94)90142-2; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; CAREAGA CL, 1992, BIOPHYS J, V62, P209, DOI 10.1016/S0006-3495(92)81806-4; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CORBALANGARCIA S, 1993, EUR J BIOCHEM, V217, P737, DOI 10.1111/j.1432-1033.1993.tb18300.x; DAIHO T, 1994, J BIOL CHEM, V269, P11060; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P12644, DOI 10.1021/bi00210a012; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FAGAN MJ, 1994, J MOL EVOL, V38, P57; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; FENG Y, 1994, J BIOL CHEM, V269, P13224; FLITSCH SL, 1989, BIOCHEMISTRY-US, V28, P7800, DOI 10.1021/bi00445a041; FRILLINGOS S, 1994, BIOCHEMISTRY-US, V33, P8074, DOI 10.1021/bi00192a012; GEORGOUSSI Z, 1985, BIOCHEM BIOPH RES CO, V126, P1196, DOI 10.1016/0006-291X(85)90312-2; GREEN NM, 1992, ANN NY ACAD SCI, V671, P104, DOI 10.1111/j.1749-6632.1992.tb43788.x; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; INESI G, 1994, BIOPHYS CHEM, V50, P129, DOI 10.1016/0301-4622(94)85025-9; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LEE MH, 1994, J BACTERIOL, V176, P4825, DOI 10.1128/jb.176.16.4825-4837.1994; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MUTOH Y, 1992, SANGYO IKA DAIGAKU Z, V14, P253; NAKAMOTO RK, 1989, ANN NY ACAD SCI, V574, P165; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PARDO JP, 1988, J BIOL CHEM, V263, P18664; PERLIN DS, 1987, J BIOL CHEM, V262, P6788; PERLIN DS, 1992, ACTA PHYSIOL SCAND, V146, P183; PETROV VV, 1992, YEAST, V8, P589, DOI 10.1002/yea.320080803; PORTILLO F, 1989, EUR J BIOCHEM, V186, P501, DOI 10.1111/j.1432-1033.1989.tb15235.x; PRINZ C, 1992, YALE J BIOL MED, V65, P577; RAO R, 1993, J BIOL CHEM, V268, P6708; RAO R, 1989, ION TRANSPORT, P35; RAO R, 1995, IN PRESS MYCOTA, V4; RAO US, 1990, J BIOL CHEM, V265, P7227; SACHS G, 1992, J BIOENERG BIOMEMBR, V24, P301; Schekman R, 1982, MOL BIOL YEAST SACCH, VII, P361; SERRANO R, 1990, BIOCHIM BIOPHYS ACTA, V1018, P195, DOI 10.1016/0005-2728(90)90247-2; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; Serrano R, 1991, MOL CELLULAR BIOL YE, P523; SOLIOZ M, 1994, FEBS LETT, V346, P44, DOI 10.1016/0014-5793(94)00316-5; THORLEYLAWSON DA, 1977, BIOCHEM J, V167, P739, DOI 10.1042/bj1670739; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; ULASZEWSKI S, 1983, EUR J BIOCHEM, V130, P235, DOI 10.1111/j.1432-1033.1983.tb07141.x; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; WANG ZY, 1992, P NATL ACAD SCI USA, V89, P11814, DOI 10.1073/pnas.89.24.11814	52	40	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28535	28540		10.1074/jbc.270.48.28535	http://dx.doi.org/10.1074/jbc.270.48.28535			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499367	hybrid			2022-12-27	WOS:A1995TH05600011
J	TAIRA, E; NAGINO, T; TANIURA, H; TAKAHA, N; KIM, CH; KUO, CH; LI, BS; HIGUCHI, H; MIKI, N				TAIRA, E; NAGINO, T; TANIURA, H; TAKAHA, N; KIM, CH; KUO, CH; LI, BS; HIGUCHI, H; MIKI, N			EXPRESSION AND FUNCTIONAL-ANALYSIS OF A NOVEL ISOFORM OF GICERIN, AN IMMUNOGLOBULIN SUPERFAMILY CELL-ADHESION MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURITE OUTGROWTH FACTOR; MYELIN-ASSOCIATED GLYCOPROTEIN; GROWTH CONE GUIDANCE; NEURAL DEVELOPMENT; NERVOUS-SYSTEM; FASCICLIN-II; N-CAM; SURFACE; DROSOPHILA; PROTEINS	We have cloned a novel cDNA of gicerin, a cell adhesion molecule belonging to the immunoglobulin super-family. Both gicerin isoforms share the same extracellular domain, which has five immunoglobulin-like loop structures and a transmembrane domain as s-gicerin, but differ in the cytoplasmic tail domain. As the newly identified form has a larger cytoplasmic domain than the previously reported form, we refer to them as l-gicerin and s-gicerin, respectively, l-gicerin is transcribed from a distinct mRNA containing an inserted sequence not found in s-gicerin mRNA which caused a frameshift for the coding region for a cytoplasmic domain. Previous studies demonstrated that gicerin showed a doublet band of 82 and 90 kDa in chicken gizzard smooth muscle. We report that the 82-kDa protein corresponds to s-gicerin and the 90-kDa protein to l-gicerin. We also found that the two gicerin isoforms are expressed differentially in the developing nervous system, Functional analysis of these gicerin isoforms in stable transfectants revealed that they had differ in their homophilic adhesion properties, as well as in heterophilic cell adhesion assayed with neurite outgrowth factor. In addition, these isoforms have neurite-promoting activity by their homophilic adhesion, but differ in their ability to promote neurite outgrowth.			TAIRA, E (corresponding author), OSAKA UNIV, SCH MED, DEPT PHARMACOL 1, 2-2 YAMADAOKA, SUITA, OSAKA 565, JAPAN.			Kim, Cheol-Hee/0000-0002-3019-0699				ARQUINT M, 1987, P NATL ACAD SCI USA, V84, P600, DOI 10.1073/pnas.84.2.600; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; DOHERTY P, 1992, J NEUROCHEM, V58, P2338, DOI 10.1111/j.1471-4159.1992.tb10984.x; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DOHERTY P, 1989, J CELL BIOL, V109, P789, DOI 10.1083/jcb.109.2.789; DOHERTY P, 1991, NEURON, V6, P247, DOI 10.1016/0896-6273(91)90360-C; DOHERTY P, 1991, J CELL SCI, P13; DULAC C, 1992, NEURON, V8, P323, DOI 10.1016/0896-6273(92)90298-R; EDELMAN GM, 1986, ANNU REV PHYSIOL, V48, P417; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; GUMBINER BM, 1993, NEURON, V11, P551, DOI 10.1016/0896-6273(93)90068-3; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HASLER TH, 1993, EUR J BIOCHEM, V211, P329, DOI 10.1111/j.1432-1033.1993.tb19902.x; HAYASHI Y, 1985, J BIOL CHEM, V260, P4269; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; KANIA A, 1993, NEURON, V11, P673, DOI 10.1016/0896-6273(93)90078-6; KATO S, 1992, NEUROSCI LETT, V140, P78, DOI 10.1016/0304-3940(92)90686-2; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; Maniatis T., 1982, MOL CLONING; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; NISHI R, 1979, NATURE, V277, P232, DOI 10.1038/277232a0; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; RAMOS RGP, 1993, GENE DEV, V7, P2533, DOI 10.1101/gad.7.12b.2533; RATHJEN FG, 1987, J CELL BIOL, V104, P343, DOI 10.1083/jcb.104.2.343; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHACHNER M, 1991, NEURAL RECOGNITION M; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SONDEREGGER P, 1992, J CELL BIOL, V119, P1387, DOI 10.1083/jcb.119.6.1387; TAIRA E, 1994, NEURON, V12, P861, DOI 10.1016/0896-6273(94)90338-7; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; TANIURA H, 1991, J CELL BIOL, V112, P313, DOI 10.1083/jcb.112.2.313; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; URUSHIHARA H, 1979, DEV BIOL, V70, P206, DOI 10.1016/0012-1606(79)90017-4	47	40	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28681	28687		10.1074/jbc.270.48.28681	http://dx.doi.org/10.1074/jbc.270.48.28681			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499388	hybrid			2022-12-27	WOS:A1995TH05600032
J	SETHY, I; MOIR, RD; LIBRIZZI, M; WILLIS, IM				SETHY, I; MOIR, RD; LIBRIZZI, M; WILLIS, IM			IN-VITRO EVIDENCE FOR GROWTH-REGULATION OF TRANSFER-RNA GENE-TRANSCRIPTION IN YEAST - A ROLE FOR TRANSCRIPTION FACTOR (TF) IIIB70 AND TFIIIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-III; SACCHAROMYCES-CEREVISIAE; EXTRACTS; COMPLEXES; HOMOLOGY; FRACTION; ENCODES; PROTEIN	We report in vitro studies showing that tRNA gene transcription in yeast is down-regulated during the transition from logarithmic to stationary phase growth. Transcription in a postdiauxic (early stationary) phase extract of a wild-type strain decreased 3-fold relative to a log phase extract. This growth stage-related difference in transcription was amplified to 20-fold in extracts of a strain containing a mutation (pcf1-4) in the 131-kDa subunit of TFIIIC. The reduction in transcription activity in both wild-type and mutant postdiauxic phase extracts was correlated with a decrease in the amount of TFIIIB70, the limiting factor in these extracts. However, the 3.7 +/- 0.5-fold decrease in amount of TFIIIB70 in mutant extracts does not, by itself, account for the 20-fold decrease in transcription, Accordingly, transcription in the mutant postdiauxic phase extract could be reconstituted to a level equal to the mutant log phase extract by the addition of two components, TFIIIB70 and TFIIIC. Addition of TFIIIB70 increased transcription 10-fold, while a 2-fold effect of TFIIIC was seen at saturating levels of TFIIIB70. The data suggest that both TFIIIB70 and TFIIIC play a role in coordinating the level of polymerase III transcription with cell growth rate.	ALBERT EINSTEIN MED CTR, DEPT BIOCHEM, BRONX, NY 10461 USA	Yeshiva University				Willis, Ian/0000-0001-6599-2395	NIGMS NIH HHS [GM07128, GM07491, GM42728] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042728, T32GM007128] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTHOLOMEW B, 1994, J BIOL CHEM, V269, P18090; BRUN RP, 1994, MOL CELL BIOL, V14, P5010, DOI 10.1128/MCB.14.7.5010; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; DIECI G, 1993, J BIOL CHEM, V268, P11199; EDWARDS DR, 1985, MOL CELL BIOL, V5, P3715; EVANS CF, 1990, METHOD ENZYMOL, V181, P439; Geiduschek E.P., 1992, TRANSCRIPTIONAL REGU, P247; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; HARLOW E, 1988, ANTIBODIES LABORATOR; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HUIBREGTSE JM, 1989, MOL CELL BIOL, V9, P3244, DOI 10.1128/MCB.9.8.3244; JU QD, 1994, YEAST, V10, P151, DOI 10.1002/yea.320100203; KALB VF, 1977, ANAL BIOCHEM, V82, P362, DOI 10.1016/0003-2697(77)90173-7; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; Paule Marvin R., 1993, Gene Expression, V3, P1; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; SETHY I, 1995, GENE EXPRESSION, V5, P35; SOGIN SJ, 1980, J BACTERIOL, V144, P74, DOI 10.1128/JB.144.1.74-81.1980; Struhl K, 1993, CURR OPIN CELL BIOL, V5, P513, DOI 10.1016/0955-0674(93)90018-L; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOWER J, 1988, MOL CELL BIOL, V8, P1001, DOI 10.1128/MCB.8.2.1001; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; WHITE RJ, 1994, RNA POLYM 3 TRANSCRI; WILLIS I, 1992, NUCLEIC ACIDS RES, V20, P3725, DOI 10.1093/nar/20.14.3725; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x	32	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28463	28470						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499353				2022-12-27	WOS:A1995TG21000078
J	SHANKAR, S; KAVANAUGHBLACK, A; KAMATH, S; CHAKRABARTY, AM				SHANKAR, S; KAVANAUGHBLACK, A; KAMATH, S; CHAKRABARTY, AM			CHARACTERIZATION OF A PHOSPHOPROTEIN PHOSPHATASE FOR THE PHOSPHORYLATED FORM OF NUCLEOSIDE-DIPHOSPHATE KINASE FROM PSEUDOMONAS-AERUGINOSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; TUMOR-METASTASIS; DROSOPHILA DEVELOPMENT; C-MYC; GENE; BCL-2; SURVIVAL; NM23; PROTEINS; GTP	Nucleoside-diphosphate kinase (ATP:nucleoside-diphosphate phosphotransferase, EC 2.7.4.6; NDP kinase) is an important enzyme for the maintenance of the correct cellular levels of nucleoside triphosphates (NTPs) and their deoxy derivatives (dNTPs) and is involved in the regulation of cellular development, The enzyme is under the dual control of algR2 and algH in Pseudomonas aeruginosa. We report here the purification and characterization of a protein that dephosphorylates the phosphorylated intermediate form of the P. aeruginosa NDP kinase (Ndk), Dephosphorylation of Ndk phosphate leads to loss of its enzymatic activity, The 10.1-kDa polypeptide shows 77% homology at the N terminus with the Spo0E phosphatase, identified as a negative regulator of sporulation in Bacillus subtilis and 66% with the human Bax protein, identified as an effector of programmed cell death, The phosphatase termed Npp showed varied specificity toward phosphorylated Ndks from different sources including human erythrocyte Ndk phosphate. Its activity toward other histidine phosphates such as CheA or the alpha-subunit of succinyl-CoA synthetase or phosphoesters such as p-nitrophenyl phosphate was quite limited, Npp was stable at room temperature up to 2 h and required Mg2+ for activity, The presence of a phosphatase capable of dephosphorylating the phosphorylated form of P. aeruginosa Ndk represents an interesting and efficient mode of post-translational modification of an enzyme crucial to cellular development.	UNIV ILLINOIS, COLL MED, DEPT MICROBIOL IMMUNOL MC 790, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NIAID NIH HHS [AI 16790-16, AI 31546-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI016790, R01AI016790, R01AI031546] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMAULA N, 1995, J BACTERIOL, V177, P2524, DOI 10.1128/jb.177.9.2524-2529.1995; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BLACK AK, 1994, P NATL ACAD SCI USA, V91, P5883; BOMINAAR AA, 1994, FEBS LETT, V353, P5, DOI 10.1016/0014-5793(94)00997-X; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MUNOZDORADO J, 1993, J BACTERIOL, V175, P1176; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OHLSEN KL, 1994, P NATL ACAD SCI USA, V91, P1756, DOI 10.1073/pnas.91.5.1756; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PALL ML, 1988, J BIOL CHEM, V263, P11168; PALL ML, 1985, CURR TOP CELL REGUL, V25, P1; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PARKS RW, 1973, ENZYMES, P307; PEREGO M, 1987, MOL MICROBIOL, V1, P125, DOI 10.1111/j.1365-2958.1987.tb00536.x; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; RAY NB, 1992, CURR TOP CELL REGUL, V33, P343; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SCHLICTMAN D, 1995, J BACTERIOL, V177, P2469, DOI 10.1128/jb.177.9.2469-2474.1995; SCHLICTMAN D, 1995, MOL MICROBIOL, V16, P309, DOI 10.1111/j.1365-2958.1995.tb02303.x; SHANKAR S, 1995, IN PRESS MOL MICROBI; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199	28	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28246	28250						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499321				2022-12-27	WOS:A1995TG21000046
J	WELLS, NJ; FRY, AM; GUANO, F; NORBURY, C; HICKSON, ID				WELLS, NJ; FRY, AM; GUANO, F; NORBURY, C; HICKSON, ID			CELL-CYCLE PHASE-SPECIFIC PHOSPHORYLATION OF HUMAN TOPOISOMERASE II-ALPHA - EVIDENCE OF A ROLE FOR PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE; DEPENDENT PHOSPHORYLATION; ATP HYDROLYSIS; LEUKEMIA-CELLS; PHORBOL ESTER; FISSION YEAST; MITOSIS; ENZYME; DIFFERENTIATION; PURIFICATION	Type II topoisomerases are essential for faithful cell division in all organisms. In human cells, the alpha isozyme of topoisomerase II has been implicated in catalyzing mitotic chromosome segregation via its action as a DNA unlinking enzyme. Here, we have shown that the enzymatic activity of topoisomerase II alpha protein purified from HeLa cell nuclei was strongly enhanced following phosphorylation by protein kinase C. We have investigated the possibility that this kinase is involved in cell cycle phase-specific phosphorylation of topoisomerase II alpha in HeLa cells. Two-dimensional tryptic phosphopeptide tide mapping revealed that topoisomerase II alpha protein immunoprecipitated from metabolically labeled HeLa cells was differentially phosphorylated during the G(2)/M phases of the cell cycle. To identify sites of phosphorylation and the kinase(s) responsible for this modification, oligohistidine-tagged recombinant domains of topoisomerase II alpha protein were overexpressed in Escherichia coli and purified by affinity chromatography. Phosphorylation of a short fragment of the N-terminal ATPase domain of topoisomerase II alpha by protein kinase C in vitro generated two phosphopeptides that co-migrated with prominent G(2)/M phase-specific phosphopeptides from the HeLa cell-derived topoisomerase II alpha protein. Site-directed mutagenesis studies indicated that phosphorylation of serine 29 generated both of these phosphopeptides. Our results implicate protein kinase C in the cell cycle phase-dependent modulation of topoisomerase II alpha enzymatic activity in human cells.	JOHN RADCLIFFE HOSP, INST MOLEC MED, IMPERIAL CANC RES FUND LABS, OXFORD OX3 9DU, ENGLAND	Cancer Research UK; University of Oxford			Hickson, Ian/AAJ-7548-2020	Hickson, Ian/0000-0002-0583-566X				ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; AUSTIN CA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P283, DOI 10.1016/0167-4781(93)90215-Y; BURDEN DA, 1993, BIOCHEM J, V293, P297, DOI 10.1042/bj2930297; BURDEN DA, 1994, BIOCHEMISTRY-US, V33, P14651, DOI 10.1021/bi00253a001; CAMPBELL DG, 1986, J BIOL CHEM, V261, P489; CARDENAS ME, 1993, J CELL SCI, V104, P219; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARON PR, 1994, ADV PHARM DNA TOPOIS, P79; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; CLEMENS MJ, 1992, J CELL SCI, V103, P881; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; CORBETT AH, 1993, BIOCHEMISTRY-US, V32, P2090, DOI 10.1021/bi00059a029; DEVORE RF, 1992, CANCER RES, V52, P2156; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1987, J BIOL CHEM, V262, P16739; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; GANAPATHI R, 1993, BIOCHEM BIOPH RES CO, V192, P1274, DOI 10.1006/bbrc.1993.1554; GOSS VL, 1994, J BIOL CHEM, V269, P19074; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; KIMURA K, 1994, J BIOL CHEM, V269, P24523; KROLL DJ, 1991, J BIOL CHEM, V266, P7957; KUANG J, 1993, J CELL BIOL, V123, P859, DOI 10.1083/jcb.123.4.859; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN DE, 1990, CELL, V62, P13; MILLER KG, 1981, J BIOL CHEM, V256, P9334; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; ROSE D, 1993, MOL CELL BIOL, V13, P3445, DOI 10.1128/MCB.13.6.3445; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SAIJO M, 1990, BIOCHEMISTRY-US, V29, P583, DOI 10.1021/bi00454a036; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SMITH PJ, 1989, CANCER RES, V49, P1118; SPELL RM, 1994, MOL CELL BIOL, V14, P1465, DOI 10.1128/MCB.14.2.1465; STRAUSFELD U, 1989, PREP BIOCHEM, V19, P37, DOI 10.1080/10826068908544895; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; TAN KB, 1992, CANCER RES, V52, P231; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WELLS NJ, 1995, EUR J BIOCHEM, V231, P491, DOI 10.1111/j.1432-1033.1995.tb20723.x; WELLS NJ, 1994, J BIOL CHEM, V269, P29746; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714	60	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28357	28363						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499337				2022-12-27	WOS:A1995TG21000062
J	ZHAN, SL; SHAPIRO, D; ZHAN, SX; ZHANG, LJ; HIRSCHFELD, S; ELASSAL, J; HELMAN, LJ				ZHAN, SL; SHAPIRO, D; ZHAN, SX; ZHANG, LJ; HIRSCHFELD, S; ELASSAL, J; HELMAN, LJ			CONCORDANT LOSS OF IMPRINTING OF THE HUMAN-INSULIN-LIKE-GROWTH-FACTOR-II GENE PROMOTERS IN CANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							UNIPARENTAL PATERNAL DISOMY; WILMS-TUMOR; RELAXATION; H19	The human insulin-like growth factor II (IGFII) gene has been shown to be imprinted for the promoters P2, P3, and P4 but not for the promoter P1 in liver and chondrocytes. Loss of imprinting of the IGFII gene has been found in a variety of human tumors including rhabdomyosarcoma and lung cancer, In this report, we determined whether loss of imprinting in tumors displays a promoter-specific pattern. We examined allelic expression of all four IGFII promoters in rhabdomyosarcoma, lung cancer, and normal skeletal muscle. We demonstrate that the imprinting of all IGFII promoters is relaxed in rhabdomyosarcoma and lung cancer, These data suggest that loss of imprinting of IGFII gene promoters may be regulated coordinately by a common mechanism in these tumors, Unexpectedly, we also found that P1, in addition to P2, P3, and P4 is monoallelically expressed in three informative adult skeletal muscle tissues. This indicates that imprinting of the IGFII promoter P1 occurs in a tissue-specific manner.	NCI, PEDIAT BRANCH, BETHESDA, MD 20892 USA; ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38101 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); St Jude Children's Research Hospital			Hirschfeld, Steven/E-2987-2016	Hirschfeld, Steven/0000-0003-0627-7249	NCI NIH HHS [CA-23099, CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023099, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CHRISTOFORI T, 1995, NAT GENET, V10, P196; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; ELBADRY OM, 1991, J CLIN INVEST, V87, P648, DOI 10.1172/JCI115042; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; HALL JG, 1990, AM J HUM GENET, V46, P857; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HU JF, 1995, MOL ENDOCRINOL, V9, P628, DOI 10.1210/me.9.5.628; KONDO M, 1995, ONCOGENE, V10, P1193; LATHAM KE, 1994, GENE DEV, V8, P290, DOI 10.1101/gad.8.3.290; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; MALCOLM S, 1991, LANCET, V337, P694, DOI 10.1016/0140-6736(91)90278-W; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1994, DEVELOPMENT, V120, P361; PEDONE PV, 1994, J BIOL CHEM, V269, P23970; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; STEENMAN MJC, 1994, NAT GENET, V7, P432; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9; VU TH, 1995, J CLIN ENDOCR METAB, V80, P1670, DOI 10.1210/jc.80.5.1670; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344	31	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					27983	27986						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499276				2022-12-27	WOS:A1995TG21000001
J	LOHR, D; LOPEZ, J				LOHR, D; LOPEZ, J			GAL4/GAL80-DEPENDENT NUCLEOSOME DISRUPTION DEPOSITION ON THE UPSTREAM REGIONS OF THE YEAST GAL1-10 AND GAL80 GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; REGULATORY PROTEIN; DNA-BINDING; INVIVO; TRANSCRIPTION; ACTIVATION; ORGANIZATION; DISRUPTION; MECHANISM	Metabolic reactivation (incubating spheroplasts with galactose and casamino acids) causes disruption of nucleosomes from the upstream regions of the yeast GAL1, GAL10, and GAL80 genes, The disruption is specific. It depends on the transcription activator Gal4; it only occurs in galactose-reactivated chromatin from galactose-grown cells; it only affects upstream region, gene-proximal nucleosomes. Due to this specificity and because some of the same regions have shown induction-dependent changes by in vivo analyses, we suggest that the nucleosome-disrupted structure produced by reactivation is the authentic chromatin structure for these regions under conditions of galactose-induced GALI-10 and GAL80 expression. It is necessary to carry out a spheroplast reactivation treatment in order to observe this disrupted structure in nuclear chromatin because nucleosomes are redeposited onto these regions during the preliminary steps of nuclear isolation (cell harvest/ spheroplast preparation) probably in response to the nonphysiological conditions associated with these steps, However, during the same isolation procedures in cells lacking Gal80 protein, there is no nucleosome deposition on these regions, and the in vivo disrupted structure remains present in the nuclear chromatin, There fore, the nucleosome deposition process that operates in wild-type cells is dependent on Gal80 protein, defining another activity of this negative regulator.			LOHR, D (corresponding author), ARIZONA STATE UNIV,DEPT CHEM & BIOCHEM,TEMPE,AZ 85287, USA.				NATIONAL CANCER INSTITUTE [K04CA000911] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037788] Funding Source: NIH RePORTER; NCI NIH HHS [CA00911] Funding Source: Medline; NIGMS NIH HHS [GM37788] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BELTZ W, 1977, THESIS FLORIDA STATE; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; FEDOR M, 1988, MOL CELL BIOL, V9, P1721; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; LIU L, 1987, P NATL ACAD SCI USA, V89, P7024; LOHR D, 1993, P NATL ACAD SCI USA, V90, P10628, DOI 10.1073/pnas.90.22.10628; LOHR D, 1987, J BIOL CHEM, V262, P15589; LOHR D, 1984, NUCLEIC ACIDS RES, V12, P8457, DOI 10.1093/nar/12.22.8457; LOHR D, 1985, NUCLEIC ACIDS RES, V13, P8409, DOI 10.1093/nar/13.23.8409; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; LOHR D, 1988, YEAST PRACTICAL APPR, P125; LOHR DE, 1981, BIOCHEMISTRY-US, V20, P5966, DOI 10.1021/bi00524a007; MANN RK, 1992, EMBO J, V11, P3297, DOI 10.1002/j.1460-2075.1992.tb05408.x; NEDOSPASOV SA, 1980, BIOCHEM BIOPH RES CO, V92, P532, DOI 10.1016/0006-291X(80)90366-6; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; SELLECK SB, 1987, MOL CELL BIOL, V7, P3260, DOI 10.1128/MCB.7.9.3260; SHIMADA H, 1985, GENE, V39, P1; TORCHIA TE, 1984, MOL CELL BIOL, V4, P1521, DOI 10.1128/MCB.4.8.1521; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	32	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27671	27678		10.1074/jbc.270.46.27671	http://dx.doi.org/10.1074/jbc.270.46.27671			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499233	hybrid			2022-12-27	WOS:A1995TE73600044
J	DOUGHERTY, GJ; COOPER, DL; MEMORY, JF; CHIU, RK				DOUGHERTY, GJ; COOPER, DL; MEMORY, JF; CHIU, RK			LIGAND-BINDING SPECIFICITY OF ALTERNATIVELY SPLICED CD44 ISOFORMS - RECOGNITION AND BINDING OF HYALURONAN BY CD44R1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; PROTEOGLYCAN CORE; LINK PROTEINS; CELLS; MOLECULE; VARIANT; EXONS; CDNA; DISTINCT; ANTIGEN	CD44 species of widely differing molecular mass have been identified on various normal and/or transformed cells. Recent studies have demonstrated that much of this heterogeneity is produced as a result of the alternative splicing of a series of 10 exons present within the CD44 gene generating a large number of CD44 isoforms containing additional peptide sequences of varying length inserted into a single site within the extracellular domain of the molecule. At present, the effect of such insertions on the ligand binding specificity of CD44 re mains unclear. CD44H, the major CD44 isoform expressed by most resting cell types, has been shown to function as a receptor for the glycosaminoglycan hyaluronan. In contrast, CD44E, the major isoform expressed by the colon carcinoma cell line HT29, which contains a 132-amino acid insert, is unable to recognize and bind this ligand. In the present study we demonstrate that CD44R1, an isoform isolated from the myelomonocytic cell line KG1a, that differs from CD44E by just 3 amino acid substitutions, is fully capable of mediating the attachment of transfected COS7 cells to hyaluronancoated plastic. In order to confirm that such binding was directly mediated by the introduced CD44 species, chimeric proteins containing the entire extracellular domain of CD44H or CD44R1 fused in-frame to human bone/liver/kidney alkaline phosphatase were prepared and tested for their ability to bind hyaluronan-coated plastic. Both fusion proteins bound equally well to hyaluronan and in each case their attachment could be readily inhibited by monoclonal antibodies directed against the hyaluronan-binding domain of CD44. These data indicate that the 132-amino acid insert present within the extracellular domain of CD44R1 does not interfere with the hyaluronan binding function of the molecule. Since CD44E contains an identically sized insert but is unable to bind hyaluronan, it is likely that mutation of one or more of the 3 amino acid residues that differ between CD44E and CD44R1 is responsible for the altered functional activity of this particular molecule.	BRITISH COLUMBIA CANC AGCY,TERRY FOX LAB HEMATOL ONCOL,VANCOUVER V5Z 1L3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT PATHOL,VANCOUVER,BC,CANADA; UNIV PITTSBURGH,DEPT PATHOL,PITTSBURGH,PA 15281	British Columbia Cancer Agency; University of British Columbia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BIRCH M, 1991, CANCER RES, V51, P6660; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CANNISTRA SA, 1993, CANCER RES, V53, P3830; COOPER DL, 1992, BIOCHEM BIOPH RES CO, V182, P569, DOI 10.1016/0006-291X(92)91770-Q; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HAKOMORI S, 1986, HDB EXPT IMMUNOLOGY, V4; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; HE Q, 1992, J CELL BIOL, V119, P1711, DOI 10.1083/jcb.119.6.1711; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HERRLICH P, 1993, IMMUNOL TODAY, V14, P395, DOI 10.1016/0167-5699(93)90141-7; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JALKANEN S, 1988, J IMMUNOL, V141, P1615; KOEFFLER HP, 1980, BLOOD, V56, P265; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; LEE TH, 1993, J BIOL CHEM, V268, P6154; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; NOTTENBURG C, 1989, P NATL ACAD SCI USA, V86, P8521, DOI 10.1073/pnas.86.21.8521; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; RUDY W, 1993, CANCER RES, V53, P1262; SALMI M, 1993, J CELL BIOL, V122, P431, DOI 10.1083/jcb.122.2.431; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; SHTIVELMAN E, 1991, MOL CELL BIOL, V11, P5446, DOI 10.1128/MCB.11.11.5446; St John T, 1989, Reg Immunol, V2, P300; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TOLG C, 1993, NUCLEIC ACIDS RES, V21, P1225, DOI 10.1093/nar/21.5.1225; WEISS MJ, 1986, P NATL ACAD SCI USA, V83, P7182, DOI 10.1073/pnas.83.19.7182; WIRTH K, 1993, EUR J CANCER, V29A, P1172, DOI 10.1016/S0959-8049(05)80310-7; WOLFFE EJ, 1990, J BIOL CHEM, V265, P341	39	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9074	9078						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510702				2022-12-27	WOS:A1994NB41100069
J	MILNE, DM; CAMPBELL, DG; CAUDWELL, FB; MEEK, DW				MILNE, DM; CAMPBELL, DG; CAUDWELL, FB; MEEK, DW			PHOSPHORYLATION OF THE TUMOR-SUPPRESSOR PROTEIN P53 BY MITOGEN-ACTIVATED PROTEIN-KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; WILD-TYPE P53; MAP KINASE; TYROSINE PHOSPHORYLATION; NUCLEAR-LOCALIZATION; TRANSCRIPTION FACTOR; GENE-PRODUCT; CELL-CYCLE; MOUSE P53; 3T3 CELLS	The p53 tumor suppressor protein is tightly regulated in the cell and is phosphorylated at multiple sites by several different protein kinases. We have investigated the phosphorylation of p53 by mitogen activated protein (MAP) kinase, a protein kinase that plays a central role in mediating many mitogenic and differentiation signals. Recombinant wild-type mouse p53 was phosphorylated in vitro by activated recombinant p42-MAP kinase but not by inactive MAP kinase or by the activating protein, MAP kinase kinase. Phosphorylation of p53 by MAP kinase occurred at two N-terminal sites, threonine residues 73 and 83. Tryptic phosphopeptides of recombinant p53 phosphorylated in vitro by MAP kinase comigrated on two-dimensional maps with p53 from SV3T3 cells labeled in vivo with [P-32]orthophosphate, suggesting that MAP kinase targets a site in p53 that is phosphorylated in the cell. Following serum stimulation of quiescent C57MG cells, two p53 kinases, which were resolved by chromatography on Mono Q, were stimulated 15-20-fold within 5 min. Each of these kinase activities co-eluted with myelin basic protein kinase activity and could be inactivated following treatment with protein phosphatase 2A, a serine/threonine phosphatase, or leukocyte antigen receptor, a protein tyrosine phosphatase, suggesting that these activities were members of the MAP kinase family. The two kinase activities from the lysates targeted the same phosphorylation sites on p53 as the purified recombinant MAP kinase. These protein kinase activities were also stimulated following exposure of the cells to ultraviolet radiation, but with slightly delayed kinetics. Phorbol ester treatment of SV3T3 cells led to increased phosphorylation of the peptide containing the residues targeted by MAP kinase. The data suggest that p53 may be phosphorylated by MAP kinase physiologically and that this interaction may be involved in the cell's response to UV exposure, growth factor stimulation, or transformation by oncogenes.	UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND	University of Dundee			Campbell, David G/K-1874-2015	Campbell, David G/0000-0003-2278-2149				ADDISON C, 1990, ONCOGENE, V5, P423; AHN NG, 1991, J BIOL CHEM, V266, P4220; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN P, 1992, BIOCHEM SOC T, V20, P671, DOI 10.1042/bst0200671; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEMAGGIO AJ, 1992, P NATL ACAD SCI USA, V89, P7008, DOI 10.1073/pnas.89.15.7008; DENTP, 1992, SCIENCE, V257, P1404; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FISCELLA M, 1993, ONCOGENE, V8, P1519; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HAL PA, 1993, ONCOGENE, V8, P203; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MEITZ JA, 1992, EMBO J, V11, P5013; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1990, ONCOGENE, V5, P1683; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAGIMOV N, 1993, ONCOGENE, V8, P1183; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SETH A, 1992, J BIOL CHEM, V267, P24796; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SOUSSI T, 1990, ONCOGENE, V5, P945; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	74	178	182	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9253	9260						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510706				2022-12-27	WOS:A1994NB41100092
J	GOLD, MR; DURONIO, V; SAXENA, SP; SCHRADER, JW; AEBERSOLD, R				GOLD, MR; DURONIO, V; SAXENA, SP; SCHRADER, JW; AEBERSOLD, R			MULTIPLE CYTOKINES ACTIVATE PHOSPHATIDYLINOSITOL 3-KINASE IN HEMATOPOIETIC-CELLS - ASSOCIATION OF THE ENZYME WITH VARIOUS TYROSINE-PHOSPHORYLATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; KINASE-ACTIVITY; INSULIN STIMULATION; INTACT-CELLS; BOVINE BRAIN; C-KIT; RECEPTOR; INTERLEUKIN-3	Activation of phosphatidylinositol (PI) 3-kinase is a common sequel to tyrosine kinase activation and appears to be essential for tyrosine kinases to induce proliferation. Since multiple hemopoietic growth factors activate tyrosine kinases, we investigated whether these growth factors activate PI 3-kinase. We show that interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5 (IL-5), granulocyte-macrophage colony stimulating factor (GM-CSF), and steel factor (SLF) all activate PI 3-kinase. These cytokines increased the amount of PI 3-kinase activity that could be immunoprecipitated with anti-phosphotyrosine antibodies from the MC-9 mast cell line or from the hemopoietic progenitor cell line FDC-P1, Increases in this assay frequently correlate with PI 3-kinase activation in vivo, To determine directly whether these factors activate PI 3-kinase in vivo, we measured the levels of 3-phosphorylated inositol phospholipids in intact P-32-labeled MC-9 cells. IL-3, IL-4, IL-5, GM-CSF, and SLF all caused increased synthesis of the PI 3-kinase products phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate with a relative potency of SLF >> IL-3> IL-5, GM-CSF > IL-4. In contrast, IL-4 caused the largest increase in the in vitro anti-phosphotyrosine immune complex PI 3-kinase assay. Thus, the in vitro assay does not accurately reflect in vivo activation of PI 3-kinase. Cytokine treatment did not stimulate tyrosine phosphorylation of either the 85-kDa regulatory subunit or the 110-kDa catalytic subunit of PI 3-kinase and is therefore not required for activation of PI 3-kinase by these factors. Cytokine treatment did induce PI 3-kinase to associate with other tyrosine-phosphorylated proteins in a cytokine-specific manner. PI 3-kinase associated with c-kit after SLF stimulation, a 170-kDa protein after IL-4 stimulation, and a 70-kDa protein after treatment with IL 3 or GM-CSF. Thus, multiple hemopoietic growth factors that act through different types of receptors activate PI 3-kinase in vivo and induce factor-specific interactions of PI 3-kinase with other tyrosine-phosphorylated proteins.	UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT BIOCHEM & MOLEC BIOL, VANCOUVER V6T 1Z3, BC, CANADA	University of British Columbia; University of British Columbia; University of British Columbia				Gold, Michael/0000-0003-1222-3191				AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLARKLEWIS I, 1986, SCIENCE, V231, P134, DOI 10.1126/science.3079915; COREY SJ, 1992, BLOOD, V80, P150; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DURONIO V, 1992, J BIOL CHEM, V267, P21856; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOLD MR, 1992, J IMMUNOL, V148, P2012; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; IZUMI T, 1987, J BIOL CHEM, V262, P1282; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KELLER SR, 1991, J BIOL CHEM, V266, P12817; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LIPS DL, 1989, J BIOL CHEM, V264, P8759; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; NABEL G, 1981, NATURE, V291, P332, DOI 10.1038/291332a0; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OKUDA K, 1992, BLOOD, V79, P2889; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAUL WE, 1991, BLOOD, V77, P1859; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHIEVEN GL, 1992, J IMMUNOL, V149, P1676; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SKOLNIK RY, 1991, CELL, V65, P88; SUSA M, 1992, J BIOL CHEM, V267, P22951; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VELHAM MJ, 1992, J IMMUNOL, V149, P2772; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0	49	156	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5403	5412						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508938				2022-12-27	WOS:A1994MX57100105
J	HOLMES, CE; HECHT, SM				HOLMES, CE; HECHT, SM			FE-CENTER-DOT-BLEOMYCIN CLEAVES A TRANSFER-RNA PRECURSOR AND ITS TRANSFER DNA ANALOG AT THE SAME MAJOR SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC CLEAVAGE; STRAND SCISSION; DEOXYRIBONUCLEIC-ACID; ACTIVATED BLEOMYCIN; DEGRADATION; ANTIBIOTICS; TALISOMYCIN; CHEMISTRY	Previously, Fe.bleomycin (BLM) has been shown to mediate RNA cleavage in a fashion more highly selective than that of DNA. Because RNAs often assume secondary and tertiary structures not commonly encountered with DNAs, it was not clear whether the greater selectivity of RNA cleavage was a consequence of differences in the mononucleotide constituents of RNA and DNA, or of the three-dimensional structures of the individual substrates. Accordingly, we prepared a ''tDNA'' identical in sequence with Bacillus subtilis tRNA(His) precursor, the latter of which is known to be a good substrate for Fe(II).BLM A2 and which undergoes oxidative cleavage predominantly at U35. Remarkably, the tDNA underwent cleavage predominantly at T35. At higher concentrations of Fe(II).BLM A2, the tDNA was extensively degraded, while the tRNA(His) precursor was not. Competition experiments suggested that this was not due to more efficient binding of Fe.BLM to the tDNA; in fact the tRNA precursor appeared to be bound more efficiently. The lesser cleavage of the tRNA(His) may be due to limitations in the facility of chemical transformation following Fe.BLM binding, or else to the formation of RNA lesions that do not lead directly to RNA strand scission.	UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22901; UNIV VIRGINIA,DEPT BIOL,CHARLOTTESVILLE,VA 22901	University of Virginia; University of Virginia					NCI NIH HHS [CA53913] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA053913] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERRY DE, 1985, BIOCHEMISTRY-US, V24, P3207, DOI 10.1021/bi00334a020; CARTER BJ, 1990, J BIOL CHEM, V265, P7100; CARTER BJ, 1990, P NATL ACAD SCI USA, V87, P9373, DOI 10.1073/pnas.87.23.9373; CARTER BJ, 1991, NUCLEOS NUCLEOT, V10, P215, DOI 10.1080/07328319108046448; CARTER BJ, 1991, TETRAHEDRON, V47, P2463, DOI 10.1016/S0040-4020(01)81781-6; CHIEN M, 1977, BIOCHEMISTRY-US, V16, P3641, DOI 10.1021/bi00635a021; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P3608, DOI 10.1073/pnas.75.8.3608; DUFF RJ, 1993, J AM CHEM SOC, V115, P3350, DOI 10.1021/ja00061a052; GOLD B, 1988, J AM CHEM SOC, V110, P2347, DOI 10.1021/ja00215a080; GREEN CJ, 1988, J BIOL CHEM, V263, P652; HAIDLE CW, 1979, BLEOMYCIN CHEM BIOCH, P222; HECHT SM, 1986, ACCOUNTS CHEM RES, V19, P383, DOI 10.1021/ar00132a002; HERTZBERG RP, 1988, BIOCHEMISTRY-US, V27, P3164, DOI 10.1021/bi00409a007; HERTZBERG RP, 1985, BIOCHEMISTRY-US, V24, P5285, DOI 10.1021/bi00341a001; HOLMES CE, 1993, BIOCHEMISTRY-US, V32, P4293, DOI 10.1021/bi00067a019; HUTTENHOFER A, 1992, J BIOL CHEM, V267, P24471; KAHN AS, 1988, SCIENCE, V241, P74; KROSS J, 1982, BIOCHEMISTRY-US, V21, P4310, DOI 10.1021/bi00261a021; LONG EC, 1990, J AM CHEM SOC, V112, P5272, DOI 10.1021/ja00169a040; MAGLIOZZO RS, 1989, MOL PHARMACOL, V35, P428; MASCHARAK PK, 1983, P NATL ACAD SCI-BIOL, V80, P6795, DOI 10.1073/pnas.80.22.6795; MIRABELLI CK, 1982, CANCER RES, V42, P2779; MIRABELLI CK, 1983, BIOCHEMISTRY-US, V22, P300, DOI 10.1021/bi00271a011; NAGAI K, 1991, J BIOL CHEM, V266, P23994; PAQUETTE J, 1990, EUR J BIOCHEM, V189, P259, DOI 10.1111/j.1432-1033.1990.tb15485.x; PERREAULT JP, 1989, EUR J BIOCHEM, V186, P87, DOI 10.1111/j.1432-1033.1989.tb15181.x; Sambrook J, 1989, MOL CLONING LABORATO; Slick B. I., 1985, BLEOMYCIN CHEMOTHERA; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; SUGIYAMA H, 1988, BIOCHEMISTRY-US, V27, P58, DOI 10.1021/bi00401a011; TAKESHITA M, 1978, P NATL ACAD SCI USA, V75, P5983, DOI 10.1073/pnas.75.12.5983; UEDA K, 1985, J BIOL CHEM, V260, P5804; WILLIAMS LD, 1988, BIOCHEMISTRY-US, V27, P3004, DOI 10.1021/bi00408a051	34	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25909	25913						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503991				2022-12-27	WOS:A1993MK10000089
J	BELDENT, V; MICHAUD, A; BONNEFOY, C; CHAUVET, MT; CORVOL, P				BELDENT, V; MICHAUD, A; BONNEFOY, C; CHAUVET, MT; CORVOL, P			CELL-SURFACE LOCALIZATION OF PROTEOLYSIS OF HUMAN ENDOTHELIAL ANGIOTENSIN I-CONVERTING ENZYME - EFFECT OF THE AMINO-TERMINAL DOMAIN IN THE SOLUBILIZATION PROCESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ANCHORED GROWTH-FACTORS; FACTOR TNF RECEPTOR; GOLGI-COMPLEX; MEMBRANE-PROTEINS; PLASMA-MEMBRANE; FACTOR-ALPHA; BREFELDIN-A; CLEAVAGE; RELEASE	Angiotensin-converting enzyme (ACE) belongs to the type I class of ectoproteins and is solubilized by Chinese hamster ovary cells transfected with the full-length human ACE cDNA. ACE release in Chinese hamster ovary cells involves a proteolytic cleavage occurring in the carboxyl-terminal region, between Arg-1137 and Leu-1138, The subcellular localization of ACE proteolysis was established by pulse chase experiments, cell surface immunolabeling, and biotinylation of radiolabeled mature proteins, The proteolysis of ACE takes place primarily at the plasma membrane, The solubilization of ACE is less than 2% within 1 h, is increased 2.4-fold by phorbol esters, but is not influenced by ionophores. An ACE mutant lacking the transmembrane domain and the cytosolic part (ACE(Delta COOH)), is secreted at a faster rate without a carboxyl-terminal cleavage, and phorbol esters or ionophores have no effect on its rate of production in the medium, Therefore, the proteolysis of ACE is dependent on the presence of the membrane anchor and suggests that the secretase(s) involved is also membrane-associated, An ACE mutant lacking the aminoterminal domain (ACE(CF)) is secreted 10 fold faster compared with wild-type ACE, The solubilization of ACE(CF) occurs at the plasma membrane and is stimulated 2.7-fold by phorbol esters, and the cleavage site is localized between Arg-1227 and Val-1228. The amino-terminal domain of ACE slows down the proteolysis and seems to act as a ''conformational inhibitor'' of the proteolytic process, possibly via interactions with the ''stalk'' of ACE and the secretase(s) itself.	COLL FRANCE, INSERM, U36, F-75005 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France								ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; BELDENT V, 1993, J BIOL CHEM, V268, P26428; BOSENBERG MW, 1992, CELL, V71, P117; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CUSHMAN DW, 1971, BIOCHEM PHARMACOL, V20, P1637, DOI 10.1016/0006-2952(71)90292-9; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; EFTHIMIOPOULOS S, 1994, J NEUROSCI RES, V38, P81, DOI 10.1002/jnr.490380111; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; EVIN G, 1994, INT J EXP CLIN INVES, V1, P263; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HARANO T, 1994, J BIOL CHEM, V269, P20305; HOOPER NM, 1987, BIOCHEM J, V247, P85, DOI 10.1042/bj2470085; HOOPER NM, 1991, INT J BIOCHEM, V23, P641, DOI 10.1016/0020-711X(91)90032-I; HORIUCHI M, 1982, J CHROMATOGR, V233, P123, DOI 10.1016/S0378-4347(00)81738-7; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; HUBERT C, 1991, J BIOL CHEM, V266, P15377; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; KOO EH, 1994, J BIOL CHEM, V269, P17386; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATTION AL, 1989, FEBS LETT, V252, P99, DOI 10.1016/0014-5793(89)80897-X; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOTTAZ D, 1992, FEBS LETT, V313, P270, DOI 10.1016/0014-5793(92)81207-3; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; OPPONG SY, 1993, BIOCHEM J, V292, P597, DOI 10.1042/bj2920597; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PORTEU F, 1991, J BIOL CHEM, V266, P18846; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4450; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; ROBERTS SB, 1994, J BIOL CHEM, V269, P3111; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEN I, 1991, J BIOL CHEM, V266, P21985; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SKIDGEL RA, 1985, P NATL ACAD SCI USA, V82, P1025, DOI 10.1073/pnas.82.4.1025; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WEI L, 1991, J BIOL CHEM, V266, P9002; WEI L, 1991, J BIOL CHEM, V266, P5540	44	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28962	28969		10.1074/jbc.270.48.28962	http://dx.doi.org/10.1074/jbc.270.48.28962			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499427	hybrid			2022-12-27	WOS:A1995TH05600071
J	KOHLHUBER, F; HERMEKING, H; GRAESSMANN, A; EICK, D				KOHLHUBER, F; HERMEKING, H; GRAESSMANN, A; EICK, D			INDUCTION OF APOPTOSIS BY THE C-MYC HELIX-LOOP HELIX/LEUCINE ZIPPER DOMAIN IN MOUSE 3T3-L1 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; LEUCINE ZIPPER; TRANSCRIPTIONAL ACTIVATION; CELL-GROWTH; MAX; PROTEIN; SEQUENCE; TRANSFORMATION; DIMERIZATION; GENE	The cellular proto-oncogene c-myc is involved in cell proliferation and transformation but is also implicated in the induction of programmed cell death (apoptosis). The c-Myc protein is a transcriptional activator with a carboxyl-terminal basic region/helix-loop-helix (HLH)/leucine zipper (LZ) domain. It forms heterodimers with the HLH/LZ protein Max and transactivates gene expression after binding DNA E-box elements. We have studied the phenotype of dominant negative mutants of c-Myc and Max in microinjection experiments. Max mutants with a deleted or mutated basic region inhibited DNA synthesis in serum stimulated 3T3-L1 mouse fibroblasts. In contrast, mutants of c-Myc expressing only the basic reson/HLH/LZ or HLH/LZ domains rapidly induced apoptosis at low and high serum levels. Co expression of the HLH/LZ domains of c-Myc and Max failed to do so. We suggest that the c-Myc HLH/LZ domain induces apoptosis by specific interaction with cellular factors different to Max.	GSF MUNICH, FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT, INST KLIN MOLEK BIOL & TUMORGENET, D-81377 MUNICH, GERMANY; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; FREE UNIV BERLIN, INST MOLEK BIOL & BIOCHEM, D-14195 BERLIN, GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Cancer Research UK; Free University of Berlin								AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BILLAUD M, 1993, P NATL ACAD SCI USA, V90, P2739, DOI 10.1073/pnas.90.7.2739; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; COGLIATI T, 1993, ONCOGENE, V8, P1263; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DEUSCHLE U, 1989, P NATL ACAD SCI USA, V86, P5400, DOI 10.1073/pnas.86.14.5400; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; GREEN H, 1994, CELL, V74, P127; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; REDDY CD, 1992, ONCOGENE, V7, P2085; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAYLOR IM, 1990, MOL MICROBIOL, V4, P1259, DOI 10.1111/j.1365-2958.1990.tb00705.x; WYLLIE AH, 1987, ARCH TOXICOL, P3; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	55	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28797	28805		10.1074/jbc.270.48.28797	http://dx.doi.org/10.1074/jbc.270.48.28797			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499403	hybrid			2022-12-27	WOS:A1995TH05600047
J	HOWARD, MT; NELSON, WC; MATSON, SW				HOWARD, MT; NELSON, WC; MATSON, SW			STEPWISE ASSEMBLY OF A RELAXOSOME AT THE F PLASMID ORIGIN OF TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA HELICASE-I; INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; NICKING REACTION; GENE-PRODUCT; SEX FACTOR; ORIT; SITE; CONJUGATION; CATALYZES	A central step in the transfer of genetic information during bacterial conjugation of the Escherichia coli F plasmid involves the formation of a protein-DNA complex, called the relaxosome, at the origin of transfer. During conjugation, the relaxosome introduces a site- and strand-specific nick from which the physical transfer of a single strand of DNA is initiated. At least two F-encoded proteins, TraIp (tra gene product) and TraYp (traY gene product), and one host-encoded protein, integration host factor, are involved in this process. In this report, we use DNase I protection and electron microscopic techniques to investigate the mechanism of relaxosome formation. Our results show that TraYp and integration host factor form a protein-DNA complex that facilitates the binding of TraIp to assemble a relaxosome capable of introducing a site- and strand-specific nick at the origin of transfer. This nick is identical to that observed during conjugation.	UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULUM GENET & MOLEC BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Nelson, William C/E-9263-2016	Nelson, William C/0000-0002-1873-3929	NIGMS NIH HHS [GM16358, GM33476] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033476, F32GM016358] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMONEM M, 1983, P NATL ACAD SCI-BIOL, V80, P4659, DOI 10.1073/pnas.80.15.4659; EVERETT R, 1980, J MOL BIOL, V136, P129, DOI 10.1016/0022-2836(80)90309-5; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; FU FYH, 1991, J BACTERIOL, V173, P1012; IPPENIHLER KA, 1986, ANNU REV GENET, V20, P593, DOI 10.1146/annurev.ge.20.120186.003113; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; LAURENZIO LD, 1992, MOL MICROBIOL, V6, P2951; LUO Y, 1994, MOL MICROBIOL, V11, P459, DOI 10.1111/j.1365-2958.1994.tb00327.x; Maniatis T., 1982, MOL CLONING LABORATO, P86; MATSON SW, 1991, J BIOL CHEM, V266, P16232; MATSON SW, 1993, J BACTERIOL, V175, P2599, DOI 10.1128/JB.175.9.2599-2606.1993; NELSON WC, 1995, J BIOL CHEM, V270, P28374; NELSON WC, 1993, J BACTERIOL, V175, P2221, DOI 10.1128/JB.175.8.2221-2228.1993; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; REYGERS U, 1991, EMBO J, V10, P2689, DOI 10.1002/j.1460-2075.1991.tb07812.x; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN JA, 1994, J BIOL CHEM, V269, P26220; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; THOMPSON R, 1984, EMBO J, V3, P1175, DOI 10.1002/j.1460-2075.1984.tb01947.x; THOMPSON TL, 1989, J MOL BIOL, V207, P505, DOI 10.1016/0022-2836(89)90460-9; TRAXLER BA, 1987, J BACTERIOL, V169, P3251, DOI 10.1128/jb.169.7.3251-3259.1987; TRAXLER BA, 1988, J MOL BIOL, V204, P205, DOI 10.1016/0022-2836(88)90609-2; TSAI MM, 1990, J BACTERIOL, V172, P4603, DOI 10.1128/jb.172.8.4603-4609.1990; Wilkins B, 1993, BACTERIAL CONJUGATIO, P105; WILLETTS N, 1984, MICROBIOL REV, V48, P24, DOI 10.1128/MMBR.48.1.24-41.1984; WILLETTS N, 1987, ESCHERICHIA COLI SAL, P1110	27	61	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28381	28386						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499340				2022-12-27	WOS:A1995TG21000065
J	JACKSON, CE; ONEILL, DO; BANK, A				JACKSON, CE; ONEILL, DO; BANK, A			NUCLEAR FACTOR-BINDING SITES IN HUMAN BETA-GLOBIN IVS2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONTROL REGION; HEMATOPOIETIC-CELL LINES; HIGH-LEVEL EXPRESSION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; ERYTHROID-DIFFERENTIATION; RESTRICTED EXPRESSION; TRANSGENIC MICE; HOMEOBOX GENES; PROTEIN	The second intron of the human beta globin gene (beta IVS2) has been previously identified as a region required for proper expression of beta globin. To further characterize this region, we have footprinted the entire beta IVS2 and have analyzed regions of interest by electrophoretic mobility shift assay. Through these studies we have identified four utilized binding sites for the erythroid regulatory factor GATA-1, two sites bound by general transcription factor Oct-1, two sites bound by the nu clear matrix attachment DNA binding protein special A-T-rich binding protein 1, and a site bound by a potential homeobox protein. Additionally, we have found several factors displaying temporal or tissue specificity by electrophoretic mobility shift assay, which may be potentially involved in the regulation of beta globin expression. These proteins are not supershifted by antibodies to factors important in erythroid regulation such as GATA-1, NFE-2, or YY1, or by antibodies against more general transcription factors.	COLUMBIA UNIV COLL PHYS & SURG, DEPT GENET & DEV, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University					NHLBI NIH HHS [HL-28381, HL-48345] Funding Source: Medline; NIDDK NIH HHS [DK-25274] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048345, P60HL028381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK025274, R01DK025274] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANTONIOU M, 1988, EMBO J, V7, P377, DOI 10.1002/j.1460-2075.1988.tb02824.x; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BEHRINGER RR, 1987, P NATL ACAD SCI USA, V84, P7056, DOI 10.1073/pnas.84.20.7056; BORTELL R, 1992, P NATL ACAD SCI USA, V89, P6119, DOI 10.1073/pnas.89.13.6119; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; CUNNINGHAM JM, 1994, BLOOD, V84, P1298; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DONOVANPELUSO M, 1987, J BIOL CHEM, V262, P17051; DWORETZKY SI, 1992, P NATL ACAD SCI USA, V89, P4178, DOI 10.1073/pnas.89.9.4178; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GALSON DL, 1988, MOL CELL BIOL, V8, P381, DOI 10.1128/MCB.8.1.381; GEY GO, 1952, CANCER RES, V12, P264; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GROUDINE M, 1983, P NATL ACAD SCI-BIOL, V80, P7551, DOI 10.1073/pnas.80.24.7551; ISOMURA T, 1992, NUCLEIC ACIDS RES, V20, P5305, DOI 10.1093/nar/20.20.5305; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LAFLAMME S, 1987, J BIOL CHEM, V262, P4819; LAVELLE D, 1991, P NATL ACAD SCI USA, V88, P7318, DOI 10.1073/pnas.88.16.7318; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LAWRENCE HJ, 1994, ANN NY ACAD SCI, V718, P165; LLOYD JA, 1994, J BIOL CHEM, V269, P19385; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATHEWS CHE, 1991, BLOOD, V78, P2248; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; NAKAGOMI K, 1994, MOL CELL BIOL, V14, P1852, DOI 10.1128/MCB.14.3.1852; ONEILL D, 1991, P NATL ACAD SCI USA, V88, P8953, DOI 10.1073/pnas.88.20.8953; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SENGUPTA PK, 1994, BLOOD, V83, P1420; SHEN WF, 1989, P NATL ACAD SCI USA, V86, P8536, DOI 10.1073/pnas.86.21.8536; SHEN WF, 1989, ADV EXP MED BIOL, V271, P211; SHEN WF, 1992, EMBO J, V11, P983, DOI 10.1002/j.1460-2075.1992.tb05137.x; STAMATOYANNOPOU.G, 1987, MOL BASIS BLOOD DISE, P66; SUN JM, 1994, J CELL BIOCHEM, V55, P252, DOI 10.1002/jcb.240550212; TAKESHITA K, 1993, P NATL ACAD SCI USA, V90, P3535, DOI 10.1073/pnas.90.8.3535; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; TRUDEL M, 1987, GENE DEV, V1, P954, DOI 10.1101/gad.1.9.954; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VALLERGA A, 1991, BLOOD S, V78, P254; VANASSENDELFT GB, 1989, CELL, V56, P969, DOI 10.1016/0092-8674(89)90630-2; WAITZ W, 1991, ONCOGENE, V6, P29; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; 1991, PROGRAM MANUAL GCG P	58	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28448	28456						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499351				2022-12-27	WOS:A1995TG21000076
J	VANGOLEN, FA; LI, KW; DELANGE, RPJ; JESPERSEN, S; GERAERTS, WPM				VANGOLEN, FA; LI, KW; DELANGE, RPJ; JESPERSEN, S; GERAERTS, WPM			MUTUALLY EXCLUSIVE NEURONAL EXPRESSION OF PEPTIDES ENCODED BY THE FMRFA GENE UNDERLIES A DIFFERENTIAL CONTROL OF COPULATION IN LYMNAEA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNAIL LYMNAEA; NEUROPEPTIDES; STAGNALIS; BRAIN; COTRANSMISSION; PRECURSOR; BEHAVIOR	An innovative method, direct peptide profiling of small samples of nervous tissue by matrix-assisted laser desorption ionization mass spectrometry, in combination with peptide characterization, immunocytochemistry in conjunction with specific neuronal labeling by backfilling of the penis nerve, and bioassay of peptides was used to study the intrinsic neuronal expression patterns of distinct sets of related FMRFa peptides and their significance for the organization of male copulation behavior in the mollusk, Lymnaea stagnalis. Previous studies indicate that the sets of FMRFa-related and GDPFLRFa-related peptides are encoded by two alternatively spliced transcripts of the single FMRFa gene. Direct mass spectrometry revealed that both FMRFa-related and GDPFLRFa-related peptides are present in the penis nerve, the sole nerve that innervates the penis complex. Accordingly, authentic FMRFa, GDPFLRFa, and related peptides were purified from the penis complex. The loci of synthesis of FMRFa and related peptides could be traced to the right cerebral ventral lobe, those of GDPFLRFa and related peptides to the B group neurons in the right parietal ganglion and to a few unidentified neurons in the right pleural ganglion. Notwithstanding their related structures, the two sets of peptides have distinctly different actions on the penis retractor muscle.	VRIJE UNIV AMSTERDAM, FAC BIOL, NEUROSCI RES INST, GRAD SCH NEUROSCI AMSTERDAM, 1081 HV AMSTERDAM, NETHERLANDS; TNO, CTR STRUCT ELUCIDAT & INSTRUMENTAL ANAL, 3700 AJ ZEIST, NETHERLANDS	University of Amsterdam; Vrije Universiteit Amsterdam; Netherlands Organization Applied Science Research								BENJAMIN PR, 1981, COMP BIOCHEM PHYS A, V70, P293, DOI 10.1016/0300-9629(81)90182-1; BRIGHT K, 1993, J NEUROSCI, V13, P2719, DOI 10.1523/JNEUROSCI.13-06-02719.1993; DORNAN WA, 1989, NEUROSCI BIOBEHAV R, V13, P1, DOI 10.1016/S0149-7634(89)80046-6; EBBERINK RHM, 1987, PEPTIDES, V8, P515, DOI 10.1016/0196-9781(87)90018-0; FISHER JM, 1988, CELL, V54, P813, DOI 10.1016/S0092-8674(88)91131-2; GERAERTS WPM, 1991, CURRENT ASPECTS NEUR, V3, P255; HEILIG M, 1994, TRENDS NEUROSCI, V17, P80, DOI 10.1016/0166-2236(94)90079-5; HERBERT E, 1983, COLD SPRING HARB SYM, V48, P375, DOI 10.1101/SQB.1983.048.01.041; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; JIMENEZ CR, 1994, J NEUROCHEM, V62, P404; KELLETT E, 1994, J NEUROSCI, V14, P6564; KUPFERMANN I, 1991, PHYSIOL REV, V71, P683, DOI 10.1152/physrev.1991.71.3.683; LI KW, 1992, PEPTIDES, V13, P633, DOI 10.1016/0196-9781(92)90166-Z; LI KW, 1993, BIOCHEM BIOPH RES CO, V197, P1056, DOI 10.1006/bbrc.1993.2585; LI KW, 1994, MOL BRAIN RES, V25, P355, DOI 10.1016/0169-328X(94)90172-4; PRICE DA, 1989, BIOL BULL, V177, P198, DOI 10.2307/1541933; PRICE DA, 1987, ZOOL SCI, V4, P395; SANTAMA N, 1993, EUR J NEUROSCI, V5, P1003, DOI 10.1111/j.1460-9568.1993.tb00952.x; SANTAMA N, 1995, EUR J NEUROSCI, V7, P65, DOI 10.1111/j.1460-9568.1995.tb01021.x; SAUNDERS SE, 1992, J NEUROSCI, V12, P1033; SMIT AB, 1992, J NEUROSCI, V12, P1709; VANDUIVENBODEN YA, 1988, MALACOLOGIA, V28, P53; VANDUIVENBODEN YA, 1984, THESIS FREE U AMSTER; VANGOLEN FA, 1995, IN PRESS NEUROSCIENC; VANGOLEN FA, 1996, IN PRESS J NEUROCHEM; VANKESTEREN RE, 1995, J NEUROSCI, V15, P5989; WEISS KR, 1992, EXPERIENTIA, V48, P456, DOI 10.1007/BF01928164	27	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28487	28493						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499356	hybrid			2022-12-27	WOS:A1995TG21000081
J	LUNEBERG, J; MARTIN, I; NUSSLER, F; RUYSSCHAERT, JM; HERRMANN, A				LUNEBERG, J; MARTIN, I; NUSSLER, F; RUYSSCHAERT, JM; HERRMANN, A			STRUCTURE AND TOPOLOGY OF THE INFLUENZA-VIRUS FUSION PEPTIDE IN LIPID BILAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; TRANSFORM INFRARED-SPECTROSCOPY; ELECTRON-SPIN-RESONANCE; SECONDARY STRUCTURE; PHOSPHOLIPID-VESICLES; CONFORMATIONAL CHANGE; PROTEINS; ORIENTATION; FLUORESCENCE; LIPOSOMES	The secondary structure of a 20-amino acid length synthetic peptide corresponding to the N terminus of the second subunit of hemagglutinin (HA2) of influenza virus A/PR8/34 and its interaction with phospholipid bilayers are investigated using ESR, Fourier transform infrared (FTIR), and CD spectroscopy. N-terminal spin labeling of the peptide did not affect the secondary structure of the peptide either in solution or when bound to liposomes as revealed by FTIR and CD spectroscopy. ESR spectra show that the mobility of the labeled peptide is dramatically restricted in the presence of phosphatidylcholine liposomes, suggesting a strong binding to the lipid membranes, The N terminus of the peptide penetrates into the membrane and is located within the hydrophobic core, We find an oblique insertion of the peptide into the lipid bilayer with an angle of about 45 degrees between helix axis and membrane plane using FTIR spectroscopy, No gross changes of the peptide's orientation, motion, and secondary structure were observed between pH 7.4 and pH 5.0. A model of the insertion of the fusion sequence of HA2 into a lipid bilayer is presented taking into account recent investigations on the low pH conformation of HA2 (Bullough, P. A. Hughson, F. M., Skehel, J. J., and Wiley, D. C. (1994) Nature 371, 37-43).	HUMBOLDT UNIV BERLIN, INST BIOL BIOPHYS, FAK MATH NAT WISSENCH 1, D-10115 BERLIN, GERMANY; FREE UNIV BRUSSELS, CHIM PHYS MACROMOLEC INTERFACES LAB CP2062, B-1050 BRUSSELS, BELGIUM	Humboldt University of Berlin; Universite Libre de Bruxelles; Vrije Universiteit Brussel								ABRAHAM DJ, 1987, PROTEINS, V2, P130, DOI 10.1002/prot.340020207; ALTENBACH C, 1988, PROTEINS, V3, P230, DOI 10.1002/prot.340030404; [Anonymous], 1976, SPIN LABELING THEORY, DOI DOI 10.1016/B978-0-12-092350-2.50008-4; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1029, P267, DOI 10.1016/0005-2736(90)90163-I; BRUNNER J, 1989, FEBS LETT, V257, P369, DOI 10.1016/0014-5793(89)81574-1; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CABIAUX V, 1989, J BIOL CHEM, V264, P4928; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CLAGUE MJ, 1991, BIOCHEMISTRY-US, V30, P5491, DOI 10.1021/bi00236a023; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P594; EPAND RF, 1994, BIOCHEM BIOPH RES CO, V205, P1938, DOI 10.1006/bbrc.1994.2897; FRETTEN P, 1980, BIOCHIM BIOPHYS ACTA, V598, P247, DOI 10.1016/0005-2736(80)90003-6; Fringeli U P, 1981, Mol Biol Biochem Biophys, V31, P270; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; Harrick N.J., 1967, INTERNAL REFLECTION; HARTER C, 1989, J BIOL CHEM, V264, P6459; HARTER C, 1988, BIOCHEMISTRY-US, V17, P4108; HORTH M, 1991, EMBO J, V10, P2747, DOI 10.1002/j.1460-2075.1991.tb07823.x; ISHIGURO R, 1993, BIOCHEMISTRY-US, V32, P9792, DOI 10.1021/bi00088a034; JOHN E, 1988, BIOPHYS J, V54, P817, DOI 10.1016/S0006-3495(88)83019-4; KAUPPINEN JK, 1981, APPL OPTICS, V20, P1866, DOI 10.1364/AO.20.001866; KEITH A, 1974, CHEM PHYS LIPIDS, V13, P49, DOI 10.1016/0009-3084(74)90041-3; KORTE T, 1992, BIOSCIENCE REP, V12, P397, DOI 10.1007/BF01121503; LEAR JD, 1987, J BIOL CHEM, V262, P6500; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marsh D, 1981, Mol Biol Biochem Biophys, V31, P51; MARTIN I, 1993, BIOCHIM BIOPHYS ACTA, V1145, P124, DOI 10.1016/0005-2736(93)90389-H; MARTIN I, 1993, FEBS LETT, V333, P325, DOI 10.1016/0014-5793(93)80680-S; MARTIN I, 1994, J VIROL, V68, P1139, DOI 10.1128/JVI.68.2.1139-1148.1994; MARTIN I, 1991, BIOCHEM BIOPH RES CO, V175, P872, DOI 10.1016/0006-291X(91)91646-T; MIICK SM, 1993, BIOCHEMISTRY-US, V32, P8014, DOI 10.1021/bi00082a024; Perrin F, 1936, J PHYS-PARIS, V7, P1, DOI 10.1051/jphysrad:01936007010100; RAFALSKI M, 1991, BIOCHEMISTRY-US, V30, P10211, DOI 10.1021/bi00106a020; SCHOCH C, 1993, J BIOL CHEM, V268, P9267; TAILOR JW, 1987, METHOD ENZYMOL, V154, P473; TAKAHASHI S, 1990, BIOCHEMISTRY-US, V29, P6257, DOI 10.1021/bi00478a021; WHARTON SA, 1988, J GEN VIROL, V69, P1847, DOI 10.1099/0022-1317-69-8-1847; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WOODLE MC, 1989, METHOD ENZYMOL, V171, P193; YU YG, 1994, BIOCHEMISTRY-US, V33, P14221, DOI 10.1021/bi00251a034	47	121	123	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27606	27614						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499224				2022-12-27	WOS:A1995TE73600035
J	MACIEJEWSKI, PM; PETERSON, FC; ANDERSON, PJ; BROOKS, CL				MACIEJEWSKI, PM; PETERSON, FC; ANDERSON, PJ; BROOKS, CL			MUTATION OF SERINE-90 TO GLUTAMIC-ACID MIMICS PHOSPHORYLATION OF BOVINE PROLACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; ISOCITRATE DEHYDROGENASE; RECEPTOR; DESIGN; MUTAGENESIS; BINDING; DOMAIN; SITE	Phosphorylated prolactin has been identified and isolated from bovine pituitaries. The biological activity of this phosphoprotein is severely reduced in comparison with nonphosphorylated prolactin, The sites of phosphorylation are serines 26, 34, and 90, and the stoichiometry is 1:1:10, respectively, In this report, the phosphoserine residues have been individually replaced with glutamic acid in recombinant methionyl bovine prolactins in order to mimic phosphorylation at each site, Substitution of glutamic acid for serine at positions 26, 34, and 90 reduced protein helical contents by 10, 6, and 14%, respectively, UV absorbances for S26E and S34E bovine prolactins were blue-shifted, similar to the biological isolates of phosphorylated bovine prolactin, but the biological activities of the S26E and S34E mutants (ED(50) values of 16.3 and 18.8 pM, respectively) were similar to that of wild-type prolactin (ED(50) value of 18.6 pm) in the Nb2 rat lymphoma assay, S90E bovine prolactin had the greatest reduction in helical content but showed similar UV and fluorescent spectra to the wildtype bovine prolactin, The biological activity of S90E bovine prolactin (ED(50) value of 672 pm) was reduced to an activity similar to that of phosphorylated bovine prolactin, The data indicate that the phosphorylation of serine 90 is responsible for the reduction in biological activity.	OHIO STATE UNIV, DEPT VET BIOSCI, OHIO STATE BIOCHEM PROGRAM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT CHEM, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042604, K04DK001989] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42604, DK01989] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BROOKS CL, 1994, BIOL REPROD S1, V50, P17; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DEAN AM, 1990, SCIENCE, V249, P1044, DOI 10.1126/science.2204110; DEAN AM, 1989, J BIOL CHEM, V264, P20482; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1993, J BIOL CHEM, V268, P5376; GOFFIN V, 1994, J BIOL CHEM, V269, P32598; GOFFIN V, 1992, MOL ENDOCRINOL, V6, P1381, DOI 10.1210/me.6.9.1381; GOFFIN V, 1995, IN PRESS PROTEINS; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HO TWC, 1989, ENDOCRINOLOGY, V124, P1507, DOI 10.1210/endo-124-3-1507; HORSEMAN ND, 1994, ENDOCR REV, V15, P627, DOI 10.1210/er.15.5.627; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KIM BG, 1993, BIOCHEM J, V296, P41, DOI 10.1042/bj2960041; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; SASAVAGE NL, 1982, J BIOL CHEM, V257, P678; SINHA YN, 1995, ENDOCR REV, V16, P354, DOI 10.1210/er.16.3.354; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANAKA T, 1980, J CLIN ENDOCR METAB, V51, P1058, DOI 10.1210/jcem-51-5-1058; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; WALKER AM, 1994, TRENDS ENDOCRIN MET, V5, P195, DOI 10.1016/1043-2760(94)90077-9; WANG YF, 1993, ENDOCRINOLOGY, V133, P2156, DOI 10.1210/en.133.5.2156; WELLS JA, 1993, RECENT PROG HORM RES, V48, P253; WICKS JR, 1995, MOL CELL ENDOCRINOL, V112, P223, DOI 10.1016/0303-7207(95)03604-6	31	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27661	27665		10.1074/jbc.270.46.27661	http://dx.doi.org/10.1074/jbc.270.46.27661			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499231	hybrid			2022-12-27	WOS:A1995TE73600042
J	KISHIMOTO, M; HASHIRAMOTO, M; YONEZAWA, K; SHII, K; KAZUMI, T; KASUGA, M				KISHIMOTO, M; HASHIRAMOTO, M; YONEZAWA, K; SHII, K; KAZUMI, T; KASUGA, M			SUBSTITUTION OF GLUTAMINE FOR ARGININE-1131 - A NEWLY IDENTIFIED MUTATION IN THE CATALYTIC LOOP OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CELL-SURFACE; IMPAIRS TRANSPORT; ALPHA-SUBUNIT; GENE; RESISTANCE; PRORECEPTOR; BINDING; MUTANT; MUTAGENESIS	We studied a patient with severe insulin resistance and a remarkable decrease in the in vivo autophosphorylation of the insulin receptor. Using a polymerase chain reaction-single strand conformation polymorphism method and direct sequencing, we identified a heterozygous mutation substituting Gln for Arg1131 in the putative ''catalytic loop'' of the tyrosine kinase domain of the insulin receptor gene. The Gln113 mutant receptor was expressed by transfection in Chinese hamster ovary cells and compared with cells expressing the wild-type insulin receptor. Both mutant and wild-type receptors were expressed on the cell surface and displayed similar insulin-binding affinity. The Gln1131 mutation impaired the activity of the receptor tyrosine kinase and inhibited the ability of insulin to phosphorylate the endogenous substrate insulin receptor substrate-I. In addition, the Gln1131 mutant receptor exhibited diminished tyrosine-phosphorylated phosphatidylinositol 3-kinase and myelin basic protein kinase activities compared with the wild-type cells. It also demonstrated a defective mediation of the insulin signal stimulating 2-deoxy-D-glucose transport and thymidine incorporation, resistance to endocytosis, and insulin-induced down-regulation. Unlike a previously described mutation in the putative catalytic loop of the receptor that substituted Glu for Ala1135, the Gln1131 mutation retained proteolytic cleavage of the proreceptor into separate subunits. Our results demonstrate that a naturally occurring mutation (R1131Q) in the putative catalytic loop of the insulin receptor results in severe impairment of the tyrosine kinase function in our patient. In addition, our results indicate that Arg1131 is important for receptor-mediated insulin action in vivo and suggest that the amino acids constituting the catalytic loop of protein kinases may possess different modes in order to retain kinase function.	KOBE UNIV,SCH MED,DEPT INTERNAL MED 1,7-5-1 KUSUNOKI CHO,CHUO KU,KOBE 650,JAPAN; HYOGO MED CTR ADULTS,AKASHI 673,JAPAN	Kobe University								ACCILI D, 1989, EMBO J, V8, P2509, DOI 10.1002/j.1460-2075.1989.tb08388.x; ANDO A, 1992, J BIOL CHEM, V267, P12788; CAMA A, 1992, J BIOL CHEM, V267, P8383; CAMA A, 1993, J BIOL CHEM, V268, P8060; CAMA A, 1991, J CLIN ENDOCR METAB, V73, P894, DOI 10.1210/jcem-73-4-894; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; COCOZZA S, 1992, DIABETES, V41, P521, DOI 10.2337/diabetes.41.4.521; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; HAGINO H, 1994, DIABETES, V43, P274, DOI 10.2337/diabetes.43.2.274; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARI J, 1987, J BIOL CHEM, V262, P15341; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI T, 1991, J BIOL CHEM, V266, P21224; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; KADOWAKI T, 1990, P NATL ACAD SCI USA, V87, P655; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KASUGA M, 1982, J BIOL CHEM, V257, P392; KISHIMOTO M, 1992, J CLIN ENDOCR METAB, V74, P1027, DOI 10.1210/jc.74.5.1027; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOBAYASHI M, 1988, DIABETES, V37, P653, DOI 10.2337/diabetes.37.5.653; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUSARI J, 1991, J BIOL CHEM, V266, P5260; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAASSEN JA, 1991, BIOCHEMISTRY-US, V30, P10778, DOI 10.1021/bi00108a024; MASSAGUE J, 1980, P NATL ACAD SCI-BIOL, V77, P7137, DOI 10.1073/pnas.77.12.7137; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MOLLER DE, 1988, NEW ENGL J MED, V319, P1526, DOI 10.1056/NEJM198812083192306; MOLLER DE, 1990, J BIOL CHEM, V265, P14979; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MOLLER DE, 1990, MOL ENDOCRINOL, V4, P1183, DOI 10.1210/mend-4-8-1183; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEINO S, 1990, DIABETES, V39, P123, DOI 10.2337/diabetes.39.1.123; TAIRA M, 1989, SCIENCE, V245, P63, DOI 10.1126/science.2544997; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; TAYLOR SI, 1990, DIABETES CARE, V13, P257, DOI 10.2337/diacare.13.3.257; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDERVORM ER, 1992, J BIOL CHEM, V267, P66; YAMAMOTOHONDA R, 1990, J BIOL CHEM, V265, P14777; YONEZAWA K, 1992, J BIOL CHEM, V267, P440; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938	48	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11349	11355						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512563				2022-12-27	WOS:A1994NF96600057
J	FIELD, MC; MORAN, P; LI, WL; KELLER, GA; CARAS, IW				FIELD, MC; MORAN, P; LI, WL; KELLER, GA; CARAS, IW			RETENTION AND DEGRADATION OF PROTEINS CONTAINING AN UNCLEAVED GLYCOSYLPHOSPHATIDYLINOSITOL SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORED MEMBRANE-PROTEINS; ROUGH ENDOPLASMIC-RETICULUM; EXOCRINE PANCREATIC-CELLS; DECAY-ACCELERATING FACTOR; CLEAVAGE ATTACHMENT SITE; AUTOPHAGIC VACUOLE; SECRETORY PROTEINS; MOUSE FIBROBLASTS; PRE-GOLGI; BIOSYNTHESIS	Glycosylphosphatidylinositol (GPI) membrane anchor attachment is directed by a COOH-terminal signal that is proteolytically removed and replaced with a preformed GPI anchor in a coupled reaction. Failure to complete proteolytic cleavage and anchor addition results in the retention of an uncleaved precursor in a post-endoplasmic reticulum (ER) compartment. In this report, we address three issues: (i) the exact position of the transport block, (ii) the subsequent fate of the retained molecules, i.e. where are they degraded, and (iii) the mechanism whereby these proteins are selected for retention. Using decay accelerating factor (DAF), we provide evidence that failure to cleave the GPI signal totally prevents O-glycosylation, suggesting that the uncleaved polypeptides are not transported into the cis-Golgi complex. This implies that transport is blocked at the boundary between the ER-Golgi intermediate compartment and the Golgi stacks. The degradation of an intracellularly retained human growth hormone (hGH)-DAF fusion protein containing a nonfunctional GPI signal shows some features of ER degradation, i.e. the degradation is insensitive to leupeptin, chloroquine, and ammonium chloride, and is inhibited at 16 degrees C or after ATP depletion. However, morphological evidence points to a pathway resembling autophagy. To reconcile these observations, we suggest either that hGHDAF is degraded by two distinct pathways (ER degradation and autophagy) or that ER degradation takes place in an ER-associated vesicular compartment in a process resembling autophagy. Using as probes a soluble hGH receptor and an antibody recognizing only native hGH, we show that a significant fraction of the retained protein is correctly folded, ruling out general misfolding as the basis for retention. We also show that hGHDAF fusion proteins are present in high molecular weight, disulfide-linked aggregates in COS cells. We suggest a model for retention in which the uncleaved GPI signal drives the formation of large micelle-like aggregates that cannot be secreted.	GENENTECH INC,DEPT NEUROBIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PHARMACOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech			Field, Mark/AAD-6455-2021	Field, Mark/0000-0002-4866-2885; Caras, Ingrid/0000-0002-8902-808X				AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; ASCOLI M, 1979, BIOCHIM BIOPHYS ACTA, V586, P608, DOI 10.1016/0304-4165(79)90051-5; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CARAS IW, 1991, J CELL BIOL, V113, P77, DOI 10.1083/jcb.113.1.77; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEKKER J, 1990, J BIOL CHEM, V265, P18116; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; FATEMI SH, 1988, J BIOL CHEM, V263, P1288; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIELD MC, 1993, J BIOL CHEM, V268, P9570; FIELD MC, 1991, EMBO J, V10, P2731, DOI 10.1002/j.1460-2075.1991.tb07821.x; FIELD MC, 1993, CRC HDB LIPID MODIFI, P83; GERBER LD, 1992, J BIOL CHEM, V267, P12168; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; KARNOVSKY MJ, 1971, J CELL BIOL, V51, pA146; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; LOW MG, 1989, FASEB J, V3, P1601; MACHAMER CE, 1985, MOL CELL BIOL, V5, P3074, DOI 10.1128/MCB.5.11.3074; MASTERSON WJ, 1991, EMBO J, V10, P2041, DOI 10.1002/j.1460-2075.1991.tb07734.x; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; MORAN P, 1991, J BIOL CHEM, V266, P1250; NODA T, 1992, J CELL BIOL, V119, P85, DOI 10.1083/jcb.119.1.85; RABOUILLE C, 1993, J CELL BIOL, V120, P897, DOI 10.1083/jcb.120.4.897; REDDY P, 1989, J BIOL CHEM, V264, P17329; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHREIER H, 1994, J BIOL CHEM, V269, P9090; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; SELDEN RF, 1987, CURRENT PROTOCOLS MO; SELVARAJ P, 1987, J EXP MED, V166, P1011, DOI 10.1084/jem.166.4.1011; SINGH N, 1991, MOL CELL BIOL, V11, P2362, DOI 10.1128/MCB.11.5.2362; TOOZE J, 1989, J CELL BIOL, V109, P35, DOI 10.1083/jcb.109.1.35; TOOZE J, 1990, J CELL BIOL, V111, P329, DOI 10.1083/jcb.111.2.329	50	93	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10830	10837						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511608				2022-12-27	WOS:A1994NF01700095
J	HESS, MA; DUNCAN, RF				HESS, MA; DUNCAN, RF			RNA/PROTEIN INTERACTIONS IN THE 5'-UNTRANSLATED LEADER OF HSP70 MESSENGER-RNA IN DROSOPHILA LYSATES - LACK OF EVIDENCE FOR SPECIFIC PROTEIN-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA CAP; HEAT-SHOCK RESPONSE; PREFERENTIAL TRANSLATION; SELECTIVE TRANSLATION; UNTRANSLATED LEADER; INITIATION-FACTORS; C-MYC; CELLS; SEQUENCE; COMPLEX	We have investigated the hypothesis that preferential translation of the heat stress mRNAs requires the binding of a trans-acting protein factor. P-32-Labeled RNA probes covering the 5'-untranslated region (5'-UTR) of HSP70 mRNA were synthesized, and gel retardation and UV cross-linking assays performed to identify trans-acting sequence-specific RNA-binding factors. The results indicate that no HSP70 5'-UTR RNA-specific binding proteins exist. Reducing the ''stringency'' in the gel retardation binding analyses revealed several non-sequence-specific RNA-binding complexes. The proteins bind RNA more strongly than DNA, show minor preferences for specific sequences, but none binds more strongly to the HSP70 5'-UTR than to other non-heat stress RNAs. Ultraviolet cross-linking analysis identifies two principal HSP70 5'-UTR binding proteins, of approximately 50 and 70 kDa. The p50 binding activity is increased severalfold for all mRNAs in heat-stressed lysates, and its binding produces the primary gel-retarded complex. Further detailed analyses were performed to probe for any possible heat-influenced changes. RNA/protein interactions are not affected by capping. Neither the kinetics nor the salt sensitivity of protein binding is affected by heat. Binding analyses using partial or complete HSP70 5'-UTR give qualitatively similar conclusions. Binding analyses were also carried out with several ''normal'' 5'-UTRs to investigate whether a heat-induced repressor might be activated by heating. No normal mRNA specific heat-induced binding changes are detected. We conclude that heat-induced alterations in RNA-binding proteins do not mediate preferential translation of heat stress mRNAs or repression of nor mal mRNAs.	UNIV SO CALIF,SCH PHARM,DEPT MOLEC PHARMACOL & TOXICOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033	University of Southern California; University of Southern California					NIGMS NIH HHS [GM42644] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONNER JJ, 1984, CELL, V37, P979; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; GEHRKE L, 1983, BIOCHEMISTRY-US, V22, P5157, DOI 10.1021/bi00291a015; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; INGOLIA TD, 1980, CELL, V21, P669, DOI 10.1016/0092-8674(80)90430-4; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; JOSHIBARVE S, 1992, J BIOL CHEM, V267, P21038; KLEMENZ R, 1985, EMBO J, V4, P2053, DOI 10.1002/j.1460-2075.1985.tb03891.x; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAWSON TG, 1986, J BIOL CHEM, V261, P13979; LINDQUIST S, 1981, NATURE, V293, P311, DOI 10.1038/293311a0; LINDQUIST S, 1990, ENZYME, V44, P147, DOI 10.1159/000468754; LINDQUIST S, 1987, TRANSLATIONAL REGULA, P187; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MAROTO FG, 1988, J BIOL CHEM, V263, P15720; MCGARRY TJ, 1985, CELL, V42, P903, DOI 10.1016/0092-8674(85)90286-7; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; PANNIERS R, 1985, J BIOL CHEM, V260, P9648; PARKIN NT, 1989, ONCOGENE, V4, P815; PETERSEN NS, 1981, P NATL ACAD SCI-BIOL, V78, P1708, DOI 10.1073/pnas.78.3.1708; RYCHLIK W, 1986, J BIOL CHEM, V261, P71; SANDERS MM, 1986, J BIOL CHEM, V261, P2189; SHERMAN DR, 1989, TRENDS GENET, V5, P137; SONENBERG N, 1987, ADV VIRUS RES, V33, P175, DOI 10.1016/S0065-3527(08)60318-8; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; ZAPATA JM, 1991, J BIOL CHEM, V266, P16007; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	38	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10913	10922						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511613				2022-12-27	WOS:A1994NF01700106
J	POWERS, MF; SMITH, LL; BEAVIS, AD				POWERS, MF; SMITH, LL; BEAVIS, AD			ON THE RELATIONSHIP BETWEEN THE MITOCHONDRIAL INNER MEMBRANE ANION CHANNEL AND THE ADENINE-NUCLEOTIDE TRANSLOCASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; K+ FLUX; DIBUTYLCHLOROMETHYLTIN CHLORIDE; STRUCTURAL RELATIONSHIP; CATIONIC AMPHIPHILES; HEART MITOCHONDRIA; LIGHT-SCATTERING; CARRIER PROTEIN; INHIBITION; SEQUENCE	The mitochondrial inner membrane anion channel (IMAC) is a transport pathway which is believed to be involved in mitochondrial volume homeostasis. The protein, however, has not been identified. In this paper, we examine the relationship between IMAC and the adenine nucleotide translocator. Many inhibitors of the adenine nucleotide translocase are shown to block IMAC, including Cibacron blue 3GA, bromcresol green, alizarin red S, agaric acid, palmitoyl-CoA, and the fluorescein derivatives erythrosin B, erythrosin isothiocyanate, rose bengal, and eosin Y. The following evidence suggests that Cibacron blue, agaric acid, and palmitoyl-CoA inhibit by binding to a common site. 1) They all only partially block the transport of small anions such as Cl-, NO3-, and HCO3-, but completely block the transport of larger anions such as malonate. 2) They decrease the IC50 values of each other in a manner consistent with competitive binding. 3) N-Ethylmaleimide decreases their IC50 values by a similar extent. 4) Inhibition by all shows no dependence on matrix pH and only a small dependence on medium pH. It is suggested that these agents may selectively bind to an open state of IMAC and inhibit by decreasing its conductance. The physiological nucleotides CoA, NAD(+) NADH, NADP(+), NADH, and ATP do not inhibit; in fact, IMAC is shown to transport ATP. Despite these similarities between IMAC and the adenine nucleotide translocase, IMAC appears to be a separate entity, since some of the IC50 values differ by up to 8-fold, and carboxyatractyloside, the most selective inhibitor of the adenine nucleotide translocase, has no effect on IMAC. In addition, IMAC is also able to transport AMP, while the adenine nucleotide translocase does not.	MED COLL OHIO,DEPT PHARMACOL,TOLEDO,OH 43699						NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [S15HL047735] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47735] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONENKO Y N, 1991, Biophysical Journal, V59, p216A; AQUILA H, 1982, H-S Z PHYSIOL CHEM, V363, P345; AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; AUSTIN J, 1984, J BIOL CHEM, V259, P154; AZZI A, 1966, BIOCHIM BIOPHYS ACTA, V120, P466, DOI 10.1016/0926-6585(66)90316-5; AZZI A, 1967, BIOCHIM BIOPHYS ACTA, V131, P468, DOI 10.1016/0005-2728(67)90006-0; BABEL W, 1991, BIOCHIM BIOPHYS ACTA, V670, P176; BEAVIS AD, 1987, J BIOL CHEM, V262, P15085; BEAVIS AD, 1989, EUR J BIOCHEM, V185, P511, DOI 10.1111/j.1432-1033.1989.tb15143.x; BEAVIS AD, 1989, J BIOL CHEM, V264, P17148; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BEAVIS AD, 1992, J BIOL CHEM, V267, P3079; BEAVIS AD, 1993, J BIOL CHEM, V268, P997; BEAVIS AD, 1992, J BIOENERG BIOMEMBR, V24, P77, DOI 10.1007/BF00769534; BEAVIS AD, 1989, J BIOL CHEM, V264, P1508; BEAVIS AD, 1991, BIOCHIM BIOPHYS ACTA, V1063, P111, DOI 10.1016/0005-2736(91)90360-K; BEAVIS AD, 1988, J BIOL CHEM, V263, P7544; BEAVIS AD, 1994, MOL BIOL MITOCHONDRI, P137; BOOS KS, 1981, FEBS LETT, V127, P40, DOI 10.1016/0014-5793(81)80336-5; BRIERLEY GP, 1969, BIOCHEM BIOPH RES CO, V35, P396, DOI 10.1016/0006-291X(69)90512-9; BRIERLEY GP, 1970, BIOCHEMISTRY-US, V9, P697, DOI 10.1021/bi00806a001; BRIERLEY GP, 1970, BIOCHEMISTRY-US, V9, P677; CHAVEZ E, 1978, BIOCHEM BIOPH RES CO, V67, P272; DIWAN JJ, 1986, J BIOENERG BIOMEMBR, V18, P123, DOI 10.1007/BF00743481; DIWAN JJ, 1980, J BIOENERG BIOMEMBR, V12, P205, DOI 10.1007/BF00744684; DIWAN JJ, 1982, J BIOENERG BIOMEMBR, V14, P15, DOI 10.1007/BF00744076; DIWAN JJ, 1983, J BIOENERG BIOMEMBR, V15, P277, DOI 10.1007/BF00744525; GARLID KD, 1985, J BIOL CHEM, V260, P3434; GARLID KD, 1986, BIOCHIM BIOPHYS ACTA, V853, P187, DOI 10.1016/0304-4173(87)90001-2; GAUTHIER LM, 1979, BIOCHEM BIOPH RES CO, V87, P1072, DOI 10.1016/S0006-291X(79)80017-0; HALLESMITH SC, 1988, FEBS LETT, V236, P155, DOI 10.1016/0014-5793(88)80305-3; HARRIS EJ, 1973, FEBS LETT, V29, P339, DOI 10.1016/0014-5793(73)80054-7; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; MOREL F, 1974, FEBS LETT, V39, P133, DOI 10.1016/0014-5793(74)80035-9; MURRAY AG, 1988, EBEC REP, V5, P206; NESLUND GG, 1984, CURR TOP CELL REGUL, V24, P447; PETRESCU I, 1982, FEBS LETT, V141, P148, DOI 10.1016/0014-5793(82)80034-3; POWERS MF, 1990, BIOPHYS J, V57, pA179; POWERS MF, 1991, J BIOL CHEM, V266, P17250; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; Selwyn MJ, 1979, BIOCHEM SOC T, V7, P216, DOI 10.1042/bst0070216; SONE N, 1964, J BIOCHEM-TOKYO, V56, P151, DOI 10.1093/oxfordjournals.jbchem.a127972	43	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10614	10620						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511601				2022-12-27	WOS:A1994NF01700065
J	DONOHUE, PJ; ALBERTS, GF; HAMPTON, BS; WINKLES, JA				DONOHUE, PJ; ALBERTS, GF; HAMPTON, BS; WINKLES, JA			A DELAYED-EARLY GENE ACTIVATED BY FIBROBLAST GROWTH FACTOR-I ENCODES A PROTEIN RELATED TO ALDOSE REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MOUSE VAS-DEFERENS; MESSENGER-RNA; ALDEHYDE REDUCTASE; HEPARIN-BINDING; DIABETIC COMPLICATIONS; HYPERTONIC CONDITIONS; CULTURED-CELLS; OSMOTIC-STRESS; FACTOR-I	The addition of polypeptide mitogens to quiescent cell lines induces the expression of various gene products, some of which are likely to perform functions critical for cell cycle progression, DNA synthesis, and mitosis. We have used a differential display approach to identify fibroblast growth factor (FGF)-1-inducible genes in NIH-3T3 cells. One of these genes, termed FGF-regulated (FR)-1, encodes a 316-amino acid protein with similar to 82% amino acid sequence identity to an abundant protein expressed in mouse vas deferens and similar to 70% identity to human aldose reductase. The function of the vas deferens protein is unknown; however, aldose reductase is an NADPH-dependent monomeric oxidoreductase implicated in the pathogenesis of diabetic complications. FGF-1 induction of FR-1 mRNA expression is first detectable at 4 h after mitogen addition and is dependent on de novo RNA and protein synthesis. FGF-2 or phorbol ester treatment can also increase FR-1 mRNA levels; in contrast, whole blood serum or individual growth factors present in serum have only minimal effects on FR-1 mRNA expression. FR-1 mRNA is detectable in a number of mouse tissues but is most abundant in newborn liver and in adult intestine, ovary, and testis. These results raise the possibility that aldose reductase-related proteins may play a role in FGF-1- and FGF-2 stimulated mitogenesis.	AMER RED CROSS,HOLLAND LAB,DEPT MOLEC BIOL,ROCKVILLE,MD 20855	American Red Cross			Hampton, Brian/G-8427-2015	Hampton, Brian/0000-0003-4650-2869	NHLBI NIH HHS [HL-39727] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039727, R29HL039727] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGNASCO SM, 1987, P NATL ACAD SCI USA, V84, P1718, DOI 10.1073/pnas.84.6.1718; BHATNAGAR A, 1992, BIOCHEM MED METAB B, V48, P91, DOI 10.1016/0885-4505(92)90055-4; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BOHREN KM, 1991, J BIOL CHEM, V266, P24031; BURGESS WH, 1991, J CELL BIOCHEM, V45, P131, DOI 10.1002/jcb.240450203; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURGESS WH, 1994, REGULATION PROLIFERA; CARPER D, 1987, FEBS LETT, V220, P209, DOI 10.1016/0014-5793(87)80905-5; CARPER D, 1990, EXP EYE RES, V50, P743, DOI 10.1016/0014-4835(90)90124-D; CARPER DA, 1989, EXP EYE RES, V49, P377, DOI 10.1016/0014-4835(89)90048-1; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHOWDHURY K, 1987, CELL, V48, P771, DOI 10.1016/0092-8674(87)90074-2; Dixon HBF, 1986, J BIOL CHEM, V261, P13; GARCIAPEREZ A, 1989, J BIOL CHEM, V264, P16815; GRAHAM C, 1991, GENE, V107, P259, DOI 10.1016/0378-1119(91)90326-7; GRIMSHAW CE, 1989, ANAL BIOCHEM, V176, P66, DOI 10.1016/0003-2697(89)90273-X; HSU DKW, 1993, BIOCHEM BIOPH RES CO, V197, P1483, DOI 10.1006/bbrc.1993.2644; IWATA N, 1990, ARCH BIOCHEM BIOPHYS, V282, P70, DOI 10.1016/0003-9861(90)90088-G; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KANEKO M, 1990, EXP CELL RES, V188, P135, DOI 10.1016/0014-4827(90)90288-L; KAWASAKI N, 1989, BIOCHIM BIOPHYS ACTA, V996, P30, DOI 10.1016/0167-4838(89)90090-3; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; MARTINEZ A, 1991, MOL CELL ENDOCRINOL, V76, P191, DOI 10.1016/0303-7207(91)90273-U; MARTINEZ A, 1990, MOL CELL ENDOCRINOL, V72, P201, DOI 10.1016/0303-7207(90)90144-W; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; NELKI D, 1990, NUCLEIC ACIDS RES, V18, P3655, DOI 10.1093/nar/18.12.3655; NISHIMURA C, 1988, BIOCHEM BIOPH RES CO, V153, P1051, DOI 10.1016/S0006-291X(88)81335-4; NISHIMURA C, 1993, BIOCHEM PHARMACOL, V46, P21, DOI 10.1016/0006-2952(93)90343-U; PAILHOUX EA, 1990, J BIOL CHEM, V265, P19932; PETRASH JM, 1992, BIOCHEM BIOPH RES CO, V187, P201, DOI 10.1016/S0006-291X(05)81479-2; PETRASH JM, 1992, J BIOL CHEM, V267, P24833; PETRASH JM, 1989, CURR EYE RES, V8, P1021, DOI 10.3109/02713688908997394; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; TANIMOTO T, 1991, INT J BIOCHEM, V23, P421; TARAGNAT C, 1990, J ANDROL, V11, P279; TAUTZ D, 1983, ANAL BIOCHEM, V132, P14, DOI 10.1016/0003-2697(83)90419-0; TOMLINSON DR, 1992, PHARMACOL THERAPEUT, V54, P151, DOI 10.1016/0163-7258(92)90031-T; WARREN JC, 1993, BIOCHEMISTRY-US, V32, P1401, DOI 10.1021/bi00057a003; WERMUTH B, 1985, ENZYMOLOGY CARBONYL, V2, P209; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; WILUSZ J, 1989, NUCLEIC ACIDS RES, V17, P3899, DOI 10.1093/nar/17.10.3899; WINKLES JA, 1993, AM J PATHOL, V143, P518; WINKLES JA, 1991, CELL GROWTH DIFFER, V2, P531; YAMAOKA T, 1992, BIOCHEM BIOPH RES CO, V183, P327, DOI 10.1016/0006-291X(92)91647-9; YOSHITAKE Y, 1992, IN VITRO CELL DEV-AN, V28A, P419	48	98	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8604	8609						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510692				2022-12-27	WOS:A1994NB40900115
J	OKAMOTO, SI; MUKAIDA, N; YASUMOTO, K; RICE, N; ISHIKAWA, Y; HORIGUCHI, H; MURAKAMI, S; MATSUSHIMA, K				OKAMOTO, SI; MUKAIDA, N; YASUMOTO, K; RICE, N; ISHIKAWA, Y; HORIGUCHI, H; MURAKAMI, S; MATSUSHIMA, K			THE INTERLEUKIN-8 AP-1 AND KAPPA-B-LIKE SITES ARE GENETIC END TARGETS OF FK5O6-SENSITIVE PATHWAY ACCOMPANIED BY CALCIUM MOBILIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; PROTEIN-KINASE-C; CYCLOSPORINE-A; LYMPHOCYTES-T; HUMAN MONOCYTES; FACTOR BINDING; EXPRESSION; ENHANCER; REL; INTERFERON	FK506, an immunosuppressant, inhibits the production of several cytokines in T lymphocytes. We observed that FK506 suppressed the transcription of a chemotactic cytokine, interleukin-8 (IL-8) in a human T cell line, Jurkat cells, activated by phorbol 12-myristate 13-acetate (PMA) and calcium (Ca2+) ionophore (ionomycin). By deleted and mutated analysis of the IL-8 promoters, the AP-1 and kappa B-like sites were identified as the responsive elements for PMA and ionomycin. FK506 suppressed the transcriptions through the AP-1 or kappa B-like sites induced by PMA plus Ca2+-mobilizing agents, but not those induced by Ca2+-independent stimuli. In gel retardation analysis, FK506 had little effect on the binding to the AP-1 site of PMA/ionomyein-induced nuclear factors, which were recognized with anti-JunD or c-Fos antibody. In contrast, FK506 or EGTA (Ca2+ chelator) similarly affected the formation of kappa B-like site binding complexes, which were not recognized by any antibodies against the human Rel family proteins (c-Rel, p65, p50, and p49). Furthermore, we confirmed the previous report that FK506 suppressed the PMA/ionomycin-induced activation through authentic kappa B site of immunoglobulin (Ig) gene, to which NF-kappa B binding was also decreased by FK506, indicating that both IL-8 kappa B-like site and Ig kappa B Site are FK506-sensitive in spite of the difference of binding factors. Our results indicate that not only the reported IL-2 NF-AT and NFIL-2A sites and Ig kappa B site, but also the IL-8 AP-1 and kappa B-like sites are terminals of FK506-sensitive pathway involving Ca2+ mobilization.	KANAZAWA UNIV, CANC RES INST, DEPT PHARMACOL, KANAZAWA, ISHIKAWA 920, JAPAN; KANAZAWA UNIV, CANC RES INST, DEPT SURG, KANAZAWA, ISHIKAWA 920, JAPAN; KANAZAWA UNIV, CANC RES INST, DEPT BIOPHYS, KANAZAWA, ISHIKAWA 920, JAPAN; NCI, FREDERICK CANC RES & DEV CTR, ADV BIOSCI LABS, BASIC RES PROGRAM, FREDERICK, MD 21702 USA	Kanazawa University; Kanazawa University; Kanazawa University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851				ABATE C, 1991, ONCOGENE, V6, P2179; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BANERJI SS, 1991, MOL CELL BIOL, V11, P4074, DOI 10.1128/MCB.11.8.4074; BICKEL M, 1987, P NATL ACAD SCI USA, V84, P3274, DOI 10.1073/pnas.84.10.3274; BISHOP DK, 1992, J IMMUNOL, V148, P1049; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; BRABLETZ T, 1993, MOL CELL BIOL, V13, P1155, DOI 10.1128/MCB.13.2.1155; BROWNELL E, 1989, ONCOGENE, V4, P935; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLIOTT JF, 1984, SCIENCE, V226, P1439, DOI 10.1126/science.6334364; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GAWKRODGER DJ, 1986, CLIN EXP IMMUNOL, V66, P590; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANELLIPIPERNO A, 1990, J EXP MED, V172, P1869, DOI 10.1084/jem.172.6.1869; HAYRY P, 1988, ANN NY ACAD SCI, V532, P86; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; JAGELS MA, 1992, J IMMUNOL, V148, P1119; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KO YC, 1992, J IMMUNOL METHODS, V149, P227, DOI 10.1016/0022-1759(92)90254-Q; LARSEN CG, 1991, BIOCHEM BIOPH RES CO, V176, P1020, DOI 10.1016/0006-291X(91)90384-J; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MALEFYT RD, 1991, J EXP MED, V174, P1209; MATSUSHIMA K, 1992, CHEM IMMUNOL, V51, P236; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; MUKAIDA N, 1992, MICROBIOL IMMUNOL, V36, P773, DOI 10.1111/j.1348-0421.1992.tb02080.x; OLIVEIRA IC, 1992, P NATL ACAD SCI USA, V89, P9049, DOI 10.1073/pnas.89.19.9049; PALIOGIANNI F, 1993, J CLIN INVEST, V91, P1481, DOI 10.1172/JCI116353; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; REEM GH, 1983, SCIENCE, V221, P63, DOI 10.1126/science.6407112; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; SCHMIDT A, 1990, J VIROL, V64, P4037, DOI 10.1128/JVI.64.8.4037-4041.1990; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; STANDIFORD TJ, 1990, J IMMUNOL, V145, P1435; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; TOCCI MJ, 1989, J IMMUNOL, V143, P718; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; ZIPFEL PF, 1991, BIOCHEM BIOPH RES CO, V181, P179, DOI 10.1016/S0006-291X(05)81398-1	49	129	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8582	8589						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510691				2022-12-27	WOS:A1994NB40900112
J	GAGNON, Y; BRETON, R; PUTZER, H; PELCHAT, M; GRUNBERGMANAGO, M; LAPOINTE, J				GAGNON, Y; BRETON, R; PUTZER, H; PELCHAT, M; GRUNBERGMANAGO, M; LAPOINTE, J			CLUSTERING AND CO-TRANSCRIPTION OF THE BACILLUS-SUBTILIS GENES ENCODING THE AMINOACYL-TRANSFER-RNA SYNTHETASES SPECIFIC FOR GLUTAMATE AND FOR CYSTEINE AND THE FIRST ENZYME FOR CYSTEINE BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; SERINE ACETYLTRANSFERASE; REGULATORY SEQUENCE; OPERON; EXPRESSION; CLONING; CYSE; STEAROTHERMOPHILUS	The Bacillus subtilis cysE and cysS genes encoding, respectively, the serine acetyltransferase and the cysteinyl-tRNA synthetase were found downstream from the gltX gene encoding the glutamyl-tRNA synthetase. This gene organization is also conserved in Bacillus stearothermophilus where the cysE and cysS genes show high amino acid identity with those of B. subtilis. In both organisms the coding sequences of cysE and cysS overlap, suggesting a translational coupling. B. subtilis cysE and cysS were expressed in Escherichia coli using the inducible trc promoter; they functionally complement mutants of E. coli affected in those genes. Overproduction of B. subtilis CysRS in E. coli has a toxic effect on cell growth. Disruption of gltX and cysS by Campbell-type insertion is lethal for the cell, indicating that these genes code for an essential and unique function in B. subtilis. S1 mapping analysis shows that the transcription of gltX is under the control of a sigma A promoter located 43 base pairs upstream of the initiation codon. A T-box sequence and a rho-independent terminator known to regulate expression of other aminoacyl-tRNA synthetase genes and of some amino acid biosynthetic operons in Bacillus sp., were found between gltX and cysE. No sigma A promoter was detected upstream of cysE, which is consistent with the lethality of a Campbell-type insertion using a plasmid that interrupts transcription coming from the gltX promoter, and suggests that gltX, cysE, and cysS constitute an operon. This is the first case where genes implicated in the biosynthesis of an amino acid and its cognate aminoacyl-tRNA synthetase are shown to be co-transcribed.	UNIV LAVAL,FAC SCI & GENIE,DEPT BIOCHIM,QUEBEC CITY G1K 7P4,PQ,CANADA; INST BIOL PHYSICOCHIM,SERV BIOCHIM,F-75005 PARIS,FRANCE	Laval University			Putzer, Harald/GRY-6203-2022					AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; ANTONIEWSKI C, 1990, J BACTERIOL, V172, P86, DOI 10.1128/JB.172.1.86-93.1990; Ausubel FM, 1988, MOL REPROD DEV; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BOHMAN K, 1979, MOL GEN GENET, V176, P53, DOI 10.1007/BF00334295; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETON R, 1990, J BIOL CHEM, V265, P18248; BRETON R, 1990, THESIS U LAVAL; Brun Y V, 1991, DNA Seq, V1, P285, DOI 10.3109/10425179109020784; BURKHOLDER PR, 1947, AM J BOT, V34, P345, DOI 10.2307/2437147; CAMPBELL LL, 1955, ARCH BIOCHEM BIOPHYS, V54, P154, DOI 10.1016/0003-9861(55)90018-7; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P8275; DEBARBOUILLE M, 1990, J BACTERIOL, V172, P3966, DOI 10.1128/jb.172.7.3966-3973.1990; DENK D, 1987, J GEN MICROBIOL, V133, P515; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOWNIE JA, 1989, MOL MICROBIOL, V3, P1649, DOI 10.1111/j.1365-2958.1989.tb00150.x; ERANI G, 1990, NATURE, V347, P203; EVANS DJ, 1991, J BACTERIOL, V173, P5457, DOI 10.1128/jb.173.17.5457-5469.1991; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Glaser P, 1990, J DNA MAPPING SEQUEN, V1, P251; GRANDONI JA, 1992, J BACTERIOL, V174, P3212, DOI 10.1128/jb.174.10.3212-3219.1992; GRUNBERGMANAGO M, 1989, ESCHERICHIA COLI SAL, P1386; GRUNDY FJ, 1993, CELL, V74, P475, DOI 10.1016/0092-8674(93)80049-K; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARDY KG, 1985, DNA CLONING PRACTICA, V2, P1; HENKIN TM, 1992, J BACTERIOL, V174, P1299, DOI 10.1128/jb.174.4.1299-1306.1992; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; JOHNESMORTIMER MC, 1968, BIOCHEM J, V110, P589; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI CY, 1992, GENE, V119, P113, DOI 10.1016/0378-1119(92)90074-Y; LAPOINTE J, 1986, J BACTERIOL, V165, P88, DOI 10.1128/jb.165.1.88-93.1986; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEVEQUE F, 1990, NUCLEIC ACIDS RES, V18, P305, DOI 10.1093/nar/18.2.305; MCCARTHY JEG, 1990, MOL MICROBIOL, V4, P1233, DOI 10.1111/j.1365-2958.1990.tb00702.x; MECHULAM Y, 1991, NUCLEIC ACIDS RES, V19, P3673, DOI 10.1093/nar/19.13.3673; Miller J.H., 1972, EXPT MOL GENETICS; MORAN CP, 1982, MOL GEN GENET, V186, P339, DOI 10.1007/BF00729452; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; PUTZER H, 1992, EMBO J, V11, P3117, DOI 10.1002/j.1460-2075.1992.tb05384.x; PUTZER H, 1990, J BACTERIOL, V172, P4593, DOI 10.1128/jb.172.8.4593-4602.1990; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNETZ K, 1988, EMBO J, V7, P3271, DOI 10.1002/j.1460-2075.1988.tb03194.x; SWANSON R, 1988, SCIENCE, V242, P1548, DOI 10.1126/science.3144042; VANDERHORN PB, 1992, J BACTERIOL, V174, P3928, DOI 10.1128/jb.174.12.3928-3935.1992; VARY PS, 1988, GENETICS BIOTECHNOLO, V2, P403; VELLANOWETH RL, 1992, MOL MICROBIOL, V6, P1105, DOI 10.1111/j.1365-2958.1992.tb01548.x; Vellanoweth Robert Luis, 1993, P699; WILCOX M, 1968, P NATL ACAD SCI USA, V61, P229, DOI 10.1073/pnas.61.1.229; WILLIAMS JG, 1985, NUCLEIC ACID HYBRIDI, P139; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YANOFSKY C, 1984, MOL BIOL EVOL, V1, P143	52	59	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7473	7482						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510287				2022-12-27	WOS:A1994NA03200070
J	RIDGWELL, K; EYERS, SAC; MAWBY, WJ; ANSTEE, DJ; TANNER, MJA				RIDGWELL, K; EYERS, SAC; MAWBY, WJ; ANSTEE, DJ; TANNER, MJA			STUDIES ON THE GLYCOPROTEIN ASSOCIATED WITH RH (RHESUS) BLOOD-GROUP ANTIGEN EXPRESSION IN THE HUMAN RED-BLOOD-CELL MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; ENDO-BETA-GALACTOSIDASE; SOLID-PHASE SYNTHESIS; MONOCLONAL-ANTIBODIES; RH(D) POLYPEPTIDE; MOLECULAR-CLONING; PEPTIDE-SYNTHESIS; ANION TRANSPORT; MESSENGER-RNAS; PROTEIN	The blood group Rh antigens are associated with non-glycosylated 30-kDa erythrocyte membrane proteins (the Rh-30 polypeptides) and the Rh glycoprotein. We used antipeptide antibodies to study the Rh glycoprotein in human erythrocyte membranes. The Rh glycoprotein was present in Rh-null U+ve cells. However, the N-glycan chain of the Rh glycoprotein in Rh-null U+ve cells was smaller than in normal cells. In contrast, the N-glycan chain of the Rh glycoprotein was larger than normal in glycophorin B-deficient red cells. We suggest that this observation reflects a lower rate of movement of newly synthesized Rh glycoprotein through intracellular membranes to the cell surface in the absence of glycophorin B, and that in normal red cells glycophorin B facilitates the movement of the Rh protein complex to the cell surface. Our results provide evidence for the intracellular interaction of a least three proteins, the Rh glycoprotein, Rh-30 polypeptides, and glycophorin B during the biosynthesis and cell surface expression of the Rh complex. These observations are likely to be important for the successful design of expression systems for the blood group Rh antigens.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,ENGLAND; INT BLOOD GRP,REFERENCE LAB,BRISTOL BS10 5ND,ENGLAND	University of Bristol			Anstee, David/AAE-9231-2020					AGRE P, 1991, BLOOD, V78, P551, DOI 10.1182/blood.V78.3.551.bloodjournal783551; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; ANSTEE DJ, 1993, BAILLIERE CLIN HAEM, V6, P401, DOI 10.1016/S0950-3536(05)80152-0; ATHERTON E, 1981, J CHEM SOC PERK T 1, P538, DOI 10.1039/p19810000538; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; AVENT N, 1988, BIOCHEM J, V251, P499, DOI 10.1042/bj2510499; AVENT ND, 1990, BIOCHEM J, V271, P821, DOI 10.1042/bj2710821; AVENT ND, 1992, J BIOL CHEM, V267, P15134; AVENT ND, 1988, BIOCHEM J, V256, P1043, DOI 10.1042/bj2561043; BLOY C, 1988, BLOOD, V72, P661; BRUNS GAP, 1989, CYTOGENET CELL GENET, V51, P67, DOI 10.1159/000132781; CHERIFZAHAR B, 1991, HUM GENET, V86, P398, DOI 10.1007/BF00201843; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; DAHR W, 1987, BLUT, V55, P19, DOI 10.1007/BF00319637; DAHR W, 1987, BIOL CHEM H-S, V368, P659, DOI 10.1515/bchm3.1987.368.1.659; DAHR W, 1978, H-S Z PHYSIOL CHEM, V359, P1217, DOI 10.1515/bchm2.1978.359.2.1217; DAHR W, 1987, BLUT, V54, P13, DOI 10.1007/BF00326022; DRYLAND A, 1986, J CHEM SOC PERK T 1, P125, DOI 10.1039/p19860000125; EYERS SAC, 1994, J BIOL CHEM, V269, P6417; FUKUDA MN, 1979, J BIOL CHEM, V254, P5458; GAHMBERG CG, 1976, J BIOL CHEM, V251, P6108; GAHMBERG CG, 1983, EMBO J, V2, P223, DOI 10.1002/j.1460-2075.1983.tb01409.x; GROVES JD, 1992, J BIOL CHEM, V267, P22163; JARNEFELT J, 1978, J BIOL CHEM, V253, P8006; KAJII E, 1992, P JPN ACAD B-PHYS, V68, P51, DOI 10.2183/pjab.68.51; KITAMIKADO M, 1981, J BIOL CHEM, V256, P3906; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU JTY, 1983, J BIOL CHEM, V258, P5255; LEVANKIM C, 1992, P NATL ACAD SCI USA, V89, P10925, DOI 10.1073/pnas.89.22.10925; LEVANKIM C, 1992, BLOOD, V80, P1074; MACGEOCH C, 1992, CYTOGENET CELL GENET, V59, P261, DOI 10.1159/000133264; MALLINSON G, 1986, BIOCHEM J, V234, P649, DOI 10.1042/bj2340649; MALLINSON G, 1990, TRANSFUSION, V30, P222, DOI 10.1046/j.1537-2995.1990.30390194341.x; MOLLISON PL, 1987, BLOOD TRANSFUSION CL; MOORE S, 1982, NATURE, V295, P529, DOI 10.1038/295529a0; MOORE S, 1987, BIOCHEM J, V244, P735, DOI 10.1042/bj2440735; Race R. R, 1968, BLOOD GROUPS MAN; RIDGWELL K, 1992, BIOCHEM J, V287, P223, DOI 10.1042/bj2870223; RIDGWELL K, 1983, BIOCHEM J, V213, P267, DOI 10.1042/bj2130267; SABOORI AM, 1989, J CLIN INVEST, V83, P187, DOI 10.1172/JCI113857; SABOORI AM, 1988, P NATL ACAD SCI USA, V85, P4042, DOI 10.1073/pnas.85.11.4042; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT PJ, 1967, VOX SANG, V13, P18, DOI 10.1111/j.1423-0410.1967.tb03383.x; SUYAMA K, 1992, BLOOD, V79, P808; SUYAMA K, 1991, BLOOD, V77, P411; TANNER MJA, 1976, BIOCHEM J, V155, P701, DOI 10.1042/bj1550701; TARENTINO AL, 1987, METHOD ENZYMOL, V138, P770; VONDEMBORNE AEGK, 1990, BRIT J HAEMATOL, V75, P254; WAINWRIGHT SD, 1989, BIOCHEM J, V258, P211, DOI 10.1042/bj2580211	52	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6410	6416						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509803				2022-12-27	WOS:A1994MZ50300026
J	KAPUS, A; ROMANEK, R; GRINSTEIN, S				KAPUS, A; ROMANEK, R; GRINSTEIN, S			ARACHIDONIC-ACID STIMULATES THE PLASMA-MEMBRANE H+ CONDUCTANCE OF MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; PROTEIN-KINASE-C; HUMAN-NEUTROPHILS; NADPH-OXIDASE; SUPEROXIDE GENERATION; K+ CHANNEL; PHORBOL 12-MYRISTATE; PROTON CONDUCTANCE; POTASSIUM CHANNELS; INDUCED ACTIVATION	When activated, phagocytes undergo a large burst of metabolic acid production. Deleterious cytosolic acidification is prevented by extrusion of H+ (equivalents) through specific transport systems, including a recently described H+ conductive pathway. The conductance can be activated by cytosolic acidification and by depolarization, events known to occur during phagocyte activation. It is possible, however, that the conductance is also directly stimulated by agonists or second messengers. In this report, spectroscopic and electrophysiological determinations were used to assess the effects of arachidonic acid (AA), a potent phagocyte stimulant, on the plasmalemmal H+ conductance of murine macrophages. AA greatly enhanced the slowly activating H+ currents and the cytosolic alkalinization triggered by depolarizing pulses. The H+ current in AA-treated cells appeared at more negative potentials and its activation and deactivation became faster. The ionic selectivity, outward rectification, and pharmacological properties of the stimulated current were identical to those of the basal current, suggesting that AA acts by facilitating the activation of the endogenous H+ conductive pathway, rather than by exerting a protonophoric effect. Experiments using specific inhibitors suggested that the effects ofAA are not mediated by lipo- or cyclooxygenase. Comparison of the effects of a variety of fatty acids supported this conclusion. The order of potency to stimulate the conductance was: AA > palmitoleate approximate to palmitelaidate > Linoleate > oleate > elaidate. Saturated fatty acids were inactive. This sequence shows striking similarity with the ability of these lipids to stimulate the NADPH oxidase. The results indicate that, simultaneously with the activation of metabolic acid generation, phagocyte agonists also directly activate regulatory H+ extrusion, thereby favoring maintenance of intracellular pH in the physiological range.	HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,TORONTO M5G 1X8,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								ANDERSON MP, 1990, P NATL ACAD SCI USA, V87, P7334, DOI 10.1073/pnas.87.18.7334; BADWEY JA, 1981, J BIOL CHEM, V256, P2640; BADWEY JA, 1984, J BIOL CHEM, V259, P7870; BORREGAARD N, 1984, J CLIN INVEST, V74, P455, DOI 10.1172/JCI111442; BROMBERG Y, 1983, CELL IMMUNOL, V79, P240, DOI 10.1016/0008-8749(83)90067-9; BROMBERG Y, 1984, CELL IMMUNOL, V88, P212; BYERLY L, 1989, J PHYSIOL-LONDON, V413, P75, DOI 10.1113/jphysiol.1989.sp017642; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; DECOURSEY TE, 1991, BIOPHYS J, V60, P1243, DOI 10.1016/S0006-3495(91)82158-0; DECOURSEY TE, 1993, BIOPHYS J, V64, P96; DEMAUREX N, 1993, J PHYSIOL-LONDON, V466, P329; EGAN RW, 1984, PROSTAGLANDINS LEUKO, P593; FLOWER JR, 1984, PROSTAGLANDINS LEUKO, P583; GUTKNECHT J, 1987, J BIOENERG BIOMEMBR, V19, P427; GUTKNECHT J, 1988, J MEMBRANE BIOL, V106, P83, DOI 10.1007/BF01871769; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; HENDERSON LM, 1992, BIOCHEM J, V283, P171, DOI 10.1042/bj2830171; HENDERSON LM, 1988, BIOCHEM J, V255, P285; HENDERSON LM, 1988, BIOCHEM J, V251, P563, DOI 10.1042/bj2510563; HWANG TC, 1990, P NATL ACAD SCI USA, V87, P5706, DOI 10.1073/pnas.87.15.5706; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; KAPUS A, 1993, J GEN PHYSIOL, V102, P729, DOI 10.1085/jgp.102.4.729; KAPUS A, 1992, BIOCHEM J, V281, P697, DOI 10.1042/bj2810697; KAPUS A, 1993, BIOCHEM J, V292, P445, DOI 10.1042/bj2920445; KIM D, 1992, J GEN PHYSIOL, V100, P1021, DOI 10.1085/jgp.100.6.1021; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; LUKACS LG, 1993, AM J PHYSIOL, V265, pC3; NANDA A, 1993, P NATL ACAD SCI USA, V90, P760, DOI 10.1073/pnas.90.2.760; NANDA A, 1992, J BIOL CHEM, V267, P22740; NANDA A, 1991, P NATL ACAD SCI USA, V88, P10816, DOI 10.1073/pnas.88.23.10816; NANDA A, 1991, Cellular Physiology and Biochemistry, V1, P65, DOI 10.1159/000154595; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SEIFERT R, 1987, EUR J BIOCHEM, V162, P563, DOI 10.1111/j.1432-1033.1987.tb10676.x; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SHIMADA T, 1992, J GEN PHYSIOL, V100, P27, DOI 10.1085/jgp.100.1.27; SIMCHOWITZ L, 1985, J BIOL CHEM, V260, P3248; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; TANAKA T, 1987, BIOCHEM BIOPH RES CO, V144, P606, DOI 10.1016/S0006-291X(87)80009-8; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VOLPI M, 1985, BIOCHEM BIOPH RES CO, V128, P594, DOI 10.1016/0006-291X(85)90087-7; WANG WH, 1992, AM J PHYSIOL, V262, pF554, DOI 10.1152/ajprenal.1992.262.4.F554; WIELAND SJ, 1992, AM J PHYSIOL, V263, pC308, DOI 10.1152/ajpcell.1992.263.2.C308	47	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					4736	4745						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508928				2022-12-27	WOS:A1994MX57100010
J	BURGESS, JW; STANLEY, KK				BURGESS, JW; STANLEY, KK			17-ALPHA-ETHINYLESTRADIOL INCREASES TRANSCYTOSIS OF ASIALOGLYCOPROTEINS IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-MEDIATED ENDOCYTOSIS; IMMUNOELECTRON MICROSCOPIC VISUALIZATION; CARBOHYDRATE RECOGNITION SYSTEMS; LIPID-ACCUMULATION; CELLS; BINDING; PROTEIN; HEPATOCYTES; ESTROGEN	We have measured the hepatobiliary transcytosis of asialofetuin (ASF) and low density lipoprotein (LDL) in rats following treatment with 5 mg of 17alpha-ethinylestradiol/kg of body weight for 3 days. The rate of appearance of both ligands in bile was increased 5-fold in estradiol-treated rats compared with controls. In contrast, no increase was observed in the transcytosis of dimeric IgA. The majority of the ASF recovered from the bile of estradiol-treated rats was undegraded, indicating transcytic delivery rather than lysosomal discharge. No increase in the rate of endocytosis of ASF was observed. When transcytosis of I-125-LDL was measured in the presence of excess ASF the rate decreased by approximately 70%. Moreover, sialidase treatment of LDL in vitro increased the biliary appearance of LDL 2-fold in estradiol-treated rats, suggesting that the effect of estradiol on both ligands was mediated via the asialoglycoprotein receptor. We conclude that 17alpha-ethinylestradiol increases the transcytosis of ASF and LDL through mechanisms that alter the intracellular trafficking of the asialoglycoprotein receptor.	HEART RES INST, 145 MISSENDEN RD, CAMPERDOWN, NSW 2050, AUSTRALIA	University of Sydney; Heart Research Institute								BELCHER JD, 1987, P NATL ACAD SCI USA, V84, P6785, DOI 10.1073/pnas.84.19.6785; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BERTHOIS Y, 1989, BIOCHEM BIOPH RES CO, V159, P126, DOI 10.1016/0006-291X(89)92413-3; BOMSEL M, 1991, J CELL BIOL, V115, P195; BREITFELD PP, 1985, EUR J BIOCHEM, V150, P409, DOI 10.1111/j.1432-1033.1985.tb09035.x; BROWN MS, 1978, J SUPRAMOL STR CELL, V8, P223, DOI 10.1002/jss.400080302; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHAO Y, 1979, J BIOL CHEM, V254, P1360; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHUNG BH, 1980, J LIPID RES, V21, P284; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COOPER AD, 1987, J LIPID RES, V28, P59; DAVIS RA, 1978, ATHEROSCLEROSIS, V30, P293, DOI 10.1016/0021-9150(78)90122-3; DICKSON RB, 1986, CANCER RES, V46, P1707; DICZFALUSY E, 1969, FOETUS PLACENTA, P191; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; DUFOUR JF, 1992, HEPATOLOGY, V16, P997, DOI 10.1002/hep.1840160424; FALLON RJ, 1988, J BIOL CHEM, V263, P13159; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GEFFEN I, 1991, P NATL ACAD SCI USA, V88, P8425, DOI 10.1073/pnas.88.19.8425; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HARKES L, 1984, BIOCHEM J, V224, P21, DOI 10.1042/bj2240021; HAY RV, 1971, BIOCHEM BIOPH RES CO, V44, P1471, DOI 10.1016/S0006-291X(71)80251-6; HUBBARD AL, 1979, J CELL BIOL, V83, P65, DOI 10.1083/jcb.83.1.65; HUBBARD AL, 1979, J CELL BIOL, V83, P47, DOI 10.1083/jcb.83.1.47; HUFF KK, 1988, MOL ENDOCRINOL, V2, P200, DOI 10.1210/mend-2-3-200; KAETZEL CS, 1991, P NATL ACAD SCI USA, V88, P8796, DOI 10.1073/pnas.88.19.8796; KAWASAKI T, 1976, J BIOL CHEM, V251, P1296; KLEINHERENBRINKSTINS MF, 1990, LAB INVEST, V63, P73; KOLSET SO, 1979, EXP CELL RES, V122, P159, DOI 10.1016/0014-4827(79)90570-6; KOVANEN PT, 1979, J BIOL CHEM, V254, P1367; MUELLER SC, 1986, J CELL BIOL, V102, P932, DOI 10.1083/jcb.102.3.932; OREKHOV AN, 1989, BIOCHEM BIOPH RES CO, V162, P206, DOI 10.1016/0006-291X(89)91982-7; OREKHOV AN, 1991, ATHEROSCLEROSIS, V86, P153, DOI 10.1016/0021-9150(91)90211-K; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; Pittman R C, 1986, Methods Enzymol, V129, P612; RUDLING M, 1992, P NATL ACAD SCI USA, V89, P6983, DOI 10.1073/pnas.89.15.6983; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SNELTINGHAVINGA I, 1989, EUR J CELL BIOL, V48, P27; SOBENIN IA, 1991, ATHEROSCLEROSIS, V89, P151, DOI 10.1016/0021-9150(91)90055-8; SOLARI R, 1984, CELL, V36, P61, DOI 10.1016/0092-8674(84)90074-6; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; STEER CJ, 1980, J BIOL CHEM, V255, P3008; STOORVOGEL W, 1991, J BIOL CHEM, V266, P5438; TAKAHASHI T, 1985, BIOCHEM BIOPH RES CO, V126, P1054, DOI 10.1016/0006-291X(85)90292-X; TERTOV VV, 1989, BIOCHEM BIOPH RES CO, V163, P489, DOI 10.1016/0006-291X(89)92163-3; THIRION J, 1991, BIOL CELL, V71, P267, DOI 10.1016/0248-4900(91)90269-S; WADE DP, 1988, EUR J BIOCHEM, V174, P213, DOI 10.1111/j.1432-1033.1988.tb14084.x; WAN JS, 1992, J BIOL CHEM, V267, P13446; WESTWOOD SA, 1979, BIOCHIM BIOPHYS ACTA, V583, P454, DOI 10.1016/0304-4165(79)90062-X; WINDLER E, 1991, BIOCHEM J, V276, P79, DOI 10.1042/bj2760079	53	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3482	3488						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508915				2022-12-27	WOS:A1994MV63100055
J	LIN, JH; WU, XR; KREIBICH, G; SUN, TT				LIN, JH; WU, XR; KREIBICH, G; SUN, TT			PRECURSOR SEQUENCE, PROCESSING, AND UROTHELIUM-SPECIFIC EXPRESSION OF A MAJOR 15-KDA PROTEIN SUBUNIT OF ASYMMETRIC UNIT MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT URINARY-BLADDER; TRANSITIONAL EPITHELIAL-CELLS; AMINO-ACID-SEQUENCE; LUMINAL MEMBRANE; 3-DIMENSIONAL STRUCTURE; SECONDARY-STRUCTURE; PLASMA-MEMBRANE; GOLGI-APPARATUS; UROPLAKIN-I; SURFACE	The asymmetric unit membrane (AUM) is a highly specialized biomembrane elaborated by terminally differentiated urothelial cells. It contains quasi-crystalline arrays of 12-nm protein particles each of which is composed of six dumbbell-shaped subdomains. In this paper we describe the precursor sequence, processing and in vitro membrane insertion properties of bovine uroplakin II (UPII), a 15-kDa major protein component of AUM. The cDNA-deduced amino acid sequence revealed that UPII is synthesized as a precursor protein containing a cleavable signal peptide of approximately 26 amino acids, a long pro-sequence of approximately 59 residues harboring three potential N-glycosylation sites, and the mature polypeptide of 100 residues. In vitro translation of UPII mRNA demonstrated that UPII is indeed first synthesized as a 19-kDa precursor, which loses its signal peptide upon insertion into added microsomes; this process is accompanied by the acquisition of high mannose-type oligosaccarides giving rise to a 28-kDa precursor which is completely protected from the digestion by exogenous proteases. These results, together with the presence of a stretch of 25 hydrophobic amino acids at the C terminus, suggest that UPII protein is anchored to the lipid bilayer via its C-terminal membrane-spanning domain with its major N-terminal domain exposed luminally. The formation of the 15-kDa mature UPII requires the removal of the pro-sequence by a furin-like endoprotease. Since only mature UPII devoid of this pro-sequence can interact with 27-kDa uroplakin I, the proteolytic processing of UPII precursor may play an important role in regulating the assembly of AUM. Finally, we showed that genomic sequences cross-hybridizing with bovine UPII cDNA are present in many mammals suggesting that UPII performs a highly conserved function in the terminally differentiated cells of mammalian urinary bladder epithelium.	NYU, SCH MED,RONALD O PERELMAN DEPT DERMATOL, EPITHELIAL BIOL UNIT,566 1ST AVE, NEW YORK, NY 10016 USA; NYU, SCH MED, DEPT PHARMACOL, NEW YORK, NY 10016 USA; NYU, SCH MED, KAPLAN COMPREHENS CANC CTR, DEPT CELL BIOL, NEW YORK, NY 10016 USA	New York University; New York University; New York University			Sun, Tung-Tien/J-4425-2015	Sun, Tung-Tien/0000-0002-6841-1063; Wu, Xue-Ru/0000-0001-6058-6291	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039753] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39749] Funding Source: Medline; NIDDK NIH HHS [DK39753] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALROY J, 1982, ANAT RECORD, V203, P429, DOI 10.1002/ar.1092030402; ALROY J, 1980, ANAT RECORD, V197, P75, DOI 10.1002/ar.1091970107; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRISSON A, 1983, J MOL BIOL, V166, P21, DOI 10.1016/S0022-2836(83)80048-5; CARUTHERS JMS, 1980, J ULTRA MOL STRUCT R, V71, P288, DOI 10.1016/S0022-5320(80)90080-5; CARUTHERS JS, 1977, J CELL BIOL, V73, P382, DOI 10.1083/jcb.73.2.382; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLAUDIO T, 1989, J CELL BIOL, V108, P2277, DOI 10.1083/jcb.108.6.2277; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Gennis R., 1989, BIOMEMBRANE MOL STRU; HICKS RM, 1970, J CELL BIOL, V45, P542, DOI 10.1083/jcb.45.3.542; HICKS RM, 1969, NATURE, V224, P1304, DOI 10.1038/2241304a0; HICKS RM, 1966, J CELL BIOL, V30, P623, DOI 10.1083/jcb.30.3.623; HICKS RM, 1965, J CELL BIOL, V26, P25, DOI 10.1083/jcb.26.1.25; HICKS RM, 1975, BIOL REV, V50, P215, DOI 10.1111/j.1469-185X.1975.tb01057.x; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KETTERER B, 1973, BIOCHIM BIOPHYS ACTA, V311, P180, DOI 10.1016/0005-2736(73)90265-4; KNUTTON S, 1976, J CELL SCI, V22, P355; KOSS LG, 1969, LAB INVEST, V21, P154; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEWIS SA, 1984, J MEMBRANE BIOL, V82, P123, DOI 10.1007/BF01868937; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LONSDALEECCLES JD, 1981, BIOCHEM J, V197, P591, DOI 10.1042/bj1970591; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MINSKY BD, 1978, J CELL BIOL, V77, P685, DOI 10.1083/jcb.77.3.685; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; PAULI BU, 1983, PATHOLOGY BLADDER CA, P42; PORTER KR, 1967, PROTOPLASMA, V63, P262, DOI 10.1007/BF01248042; PORTER KR, 1963, INTRO FINE STRUCTURE; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROBERTSON JD, 1980, J CELL BIOL, V86, P514, DOI 10.1083/jcb.86.2.514; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; RYAN AM, 1993, IN PRESS MAMM GENOME; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIKAS SN, 1986, CELL TISSUE RES, V246, P109; SEVERS NJ, 1979, J ULTRA MOL STRUCT R, V69, P279, DOI 10.1016/S0022-5320(79)90117-5; STAEHELIN LA, 1972, J CELL BIOL, V53, P73, DOI 10.1083/jcb.53.1.73; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; STUBBS CD, 1979, BIOCHIM BIOPHYS ACTA, V558, P58, DOI 10.1016/0005-2736(79)90315-8; SURYA B, 1990, J CELL SCI, V97, P419; TAYLOR KA, 1984, J ULTRA MOL STRUCT R, V87, P23, DOI 10.1016/S0022-5320(84)90113-8; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; VERGARA J, 1974, J CELL BIOL, V61, P83, DOI 10.1083/jcb.61.1.83; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WARREN RC, 1970, NATURE, V227, P280, DOI 10.1038/227280b0; WU XR, 1993, J CELL SCI, V106, P31; WU XR, 1990, J BIOL CHEM, V265, P19170; YU J, 1990, J CELL BIOL, V111, P1207, DOI 10.1083/jcb.111.3.1207; YU YH, 1989, P NATL ACAD SCI USA, V86, P9931, DOI 10.1073/pnas.86.24.9931	65	74	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1775	1784						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507484				2022-12-27	WOS:A1994MR98800038
J	BOGOYEVITCH, MA; GLENNON, PE; ANDERSSON, MB; CLERK, A; LAZOU, A; MARSHALL, CJ; PARKER, PJ; SUGDEN, PH				BOGOYEVITCH, MA; GLENNON, PE; ANDERSSON, MB; CLERK, A; LAZOU, A; MARSHALL, CJ; PARKER, PJ; SUGDEN, PH			ENDOTHELIN-1 AND FIBROBLAST GROWTH-FACTORS STIMULATE THE MITOGEN-ACTIVATED PROTEIN-KINASE SIGNALING CASCADE IN CARDIAC MYOCYTES - THE POTENTIAL ROLE OF THE CASCADE IN THE INTEGRATION OF 2 SIGNALING PATHWAYS LEADING TO MYOCYTE HYPERTROPHY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MYOCARDIAL-CELLS; MAP KINASE; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; DIFFERENTIAL REGULATION; VENTRICULAR MYOCYTES; INDEPENDENT PATHWAYS; BIPHASIC ACTIVATION; SKELETAL-MUSCLE; MESANGIAL CELLS	Maximally effective concentrations of endothelin-1 (ET-1), acidic FGF (aFGF), or 12-O-tetradecanoylphorbol-13-acetate (TPA) activated mitogen-activated protein kinase (MAPK) by 3-4-fold in crude extracts of myocytes cultured from neonatal rat heart ventricles. Maximal activation was achieved after 5 min. Thereafter, MAPK activity stimulated by ET-1 or aFGF declined to control values within 1-2 h, whereas activation by TPA was more sustained. Two peaks of MAPK activity (a 42- and a 44-kDa MAPK) were resolved in cells exposed to ET-1 or aFGF by fast protein liquid chromatography on a Mono Q column. One major and one minor peak of MAPK kinase (MAPKK) was stimulated by ET-1 or aFGF. Cardiac myocytes expressed protein kinase C (PKC)-alpha, -delta, -epsilon, and -zeta as shown by immunoblotting. Exposure to 1 muM TPA for 24 h down-regulated PKC-alpha, -delta, and -epsilon, but not PKC-zeta. This maneuver wholly abolished the activation of MAPK on re-exposure to TPA but did not affect the response to aFGF. The effect of ET-1 was partially down-regulated. ET-1 stimulated phospho[H-3]inositide hydrolysis 18-fold, whereas aFGF stimulated by only 30%. Agonists which initially utilize dissimilar signaling pathways may therefore converge at the level of MAPKK/MAPK and this may be relevant to the hypertrophic response of the heart.	UNIV LONDON, NATL HEART & LUNG INST, DEPT CARDIAC MED, DOVEHOUSE ST, LONDON SW3 6LY, ENGLAND; UNIV LONDON, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Imperial College London; University of London; University of London; Institute of Cancer Research - UK; Cancer Research UK			Lazou, Antigone/L-3878-2014; Lazou, A./I-4511-2019; Parker, Peter j/D-5192-2013	Lazou, A./0000-0002-7889-9648; Clerk, Angela/0000-0002-5658-0708; parker, peter/0000-0002-6218-2933; Bogoyevitch, Marie/0000-0001-9745-3716	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CLEMENS MJ, 1992, J CELL SCI, V103, P881; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CRABOS M, 1992, BIOCHEM J, V288, P891, DOI 10.1042/bj2880891; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; FEDIDA D, 1993, PHYSIOL REV, V73, P469, DOI 10.1152/physrev.1993.73.2.469; FORCE T, 1991, J BIOL CHEM, V266, P6650; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GRANOT Y, 1993, J BIOL CHEM, V268, P9564; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; ISHIDA Y, 1992, FEBS LETT, V310, P41, DOI 10.1016/0014-5793(92)81142-9; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KRAMER BK, 1992, CIRCULATION, V85, P350, DOI 10.1161/01.CIR.85.1.350; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEIDELL RS, 1986, AM J PHYSIOL, V251, P1076; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; OTSU M, 1993, FEBS LETT, V320, P246, DOI 10.1016/0014-5793(93)80596-M; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEARS CJ, 1991, J CELL SCI, V100, P683; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SETH A, 1992, J BIOL CHEM, V267, P24796; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SIMPSON PC, 1989, ANNU REV PHYSIOL, V51, P189, DOI 10.1146/annurev.ph.51.030189.001201; SOKOLOVSKY M, 1991, TRENDS BIOCHEM SCI, V16, P261, DOI 10.1016/0968-0004(91)90100-A; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUGDEN PH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P327, DOI 10.1016/0167-4889(93)90225-E; SUZUKI T, 1990, FEBS LETT, V268, P149, DOI 10.1016/0014-5793(90)80995-U; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; TERZIC A, 1993, PHARMACOL REV, V45, P147; THORBURN A, 1993, J BIOL CHEM, V268, P2244; TOBE K, 1991, J BIOL CHEM, V266, P24793; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WAYS DK, 1992, J BIOL CHEM, V267, P4799; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	91	356	362	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1110	1119						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507104				2022-12-27	WOS:A1994MR22000054
J	HARRISON, ML; ISAACSON, CC; BURG, DL; GEAHLEN, RL; LOW, PS				HARRISON, ML; ISAACSON, CC; BURG, DL; GEAHLEN, RL; LOW, PS			PHOSPHORYLATION OF HUMAN ERYTHROCYTE BAND-3 BY ENDOGENOUS P72(SYK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; RED-CELL MEMBRANE; INSULIN-RECEPTOR KINASE; ANTIGEN RECEPTOR; PARTIAL-PURIFICATION; PHOSPHATASE-ACTIVITY; ACID-PHOSPHATASE; RAT ADIPOCYTES; BOVINE THYMUS; VANADATE	The anion transporter, band 3, is the major tyrosine kinase substrate in both red cell membranes and intact human erythrocytes. Using antibodies to various protein-tyrosine kinases, we found that p72syk and p56/53lyn are present in human red cells, while p56lck, pp60src, p59fyn, and p55blk are absent. Treatment of intact red cells with a combination of vanadate and hydrogen peroxide dramatically increased the tyrosine phosphorylation of band 3. This treatment increased the tyrosine kinase activity of p72syk and decreased the activity of p56/53lyn in immune complex kinase assays. Band 3 was found to be associated in immune complexes with p72syk but not with p56/53lyn. These findings suggest that p72syk is responsible, at least in part, for the tyrosine phosphorylation of band 3 in human erythrocytes.	PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus	HARRISON, ML (corresponding author), PURDUE UNIV,DEPT MED CHEM & PHARMACOGNOSY,W LAFAYETTE,IN 47907, USA.			Geahlen, Robert/0000-0001-8400-2924; Low, Philip/0000-0001-9042-5528	NCI NIH HHS [CA37372] Funding Source: Medline; NIGMS NIH HHS [GM40983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BOIVIN P, 1985, FEBS LETT, V186, P89, DOI 10.1016/0014-5793(85)81345-4; BOIVIN P, 1986, BIOCHIM BIOPHYS ACTA, V860, P243, DOI 10.1016/0005-2736(86)90520-1; BOIVIN P, 1986, BIOCHEM BIOPH RES CO, V134, P557, DOI 10.1016/S0006-291X(86)80456-9; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BURG DL, 1993, J BIOL CHEM, V268, P2304; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CLARI G, 1989, EUR J BIOCHEM, V179, P581, DOI 10.1111/j.1432-1033.1989.tb14586.x; CLARI G, 1987, BIOCHEM BIOPH RES CO, V142, P587, DOI 10.1016/0006-291X(87)90314-7; CLARI G, 1988, EUR J BIOCHEM, V175, P673, DOI 10.1111/j.1432-1033.1988.tb14243.x; CLARI G, 1986, BIOCHEM BIOPH RES CO, V137, P556; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; DEKOWSKI SA, 1983, J BIOL CHEM, V258, P2750; DONS RF, 1981, J BIOL CHEM, V256, P2982; ENGELMANN B, 1992, AM J HEMATOL, V39, P239, DOI 10.1002/ajh.2830390402; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FOULKES JG, 1985, CANCER CELL, V3, P329; GAMBHIR KK, 1978, DIABETES, V27, P701, DOI 10.2337/diabetes.27.7.701; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GRIGORESCU F, 1983, J BIOL CHEM, V258, P3708; HARRISON ML, 1991, J BIOL CHEM, V266, P4106; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HERZBERG V, 1980, NATURE, V286, P279, DOI 10.1038/286279a0; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IM JH, 1983, J BIOL CHEM, V258, P5021; KADOTA S, 1987, J BIOL CHEM, V262, P8252; KADOTA S, 1987, BIOCHEM BIOPH RES CO, V147, P259, DOI 10.1016/S0006-291X(87)80115-8; KLIMAN HJ, 1980, J BIOL CHEM, V255, P6314; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOW PS, 1987, J BIOL CHEM, V262, P4592; LOW PS, 1993, J BIOL CHEM, V268, P14627; MACARA IG, 1980, BIOCHIM BIOPHYS ACTA, V629, P95, DOI 10.1016/0304-4165(80)90268-8; MOHAMED AH, 1986, J BIOL CHEM, V261, P2804; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; PETERSON SW, 1983, J BIOL CHEM, V258, P9605; ROBINSON TJ, 1979, SCIENCE, V205, P200, DOI 10.1126/science.451590; SHIBAT, 1986, BIOCHEM BIOPH RES CO, V35, P720; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TUY FPD, 1983, NATURE, V305, P435; TUY FPD, 1985, BIOCHEM BIOPH RES CO, V126, P304; VARSHNEY GC, 1986, FEBS LETT, V205, P97, DOI 10.1016/0014-5793(86)80873-0; WANG QM, 1991, BIOCHEM J, V279, P567, DOI 10.1042/bj2790567; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893; WO YYP, 1992, J BIOL CHEM, V267, P10856; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YANNOUKAKOS D, 1991, BIOCHIM BIOPHYS ACTA, V1066, P70, DOI 10.1016/0005-2736(91)90252-4; YANNOUKAKOS D, 1991, BIOCHIM BIOPHYS ACTA, V1061, P253, DOI 10.1016/0005-2736(91)90291-F; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	54	131	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					955	959						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507112				2022-12-27	WOS:A1994MR22000030
J	YADAV, PNS; YADAV, JS; ARNOLD, E; MODAK, MJ				YADAV, PNS; YADAV, JS; ARNOLD, E; MODAK, MJ			A COMPUTER-ASSISTED ANALYSIS OF CONSERVED RESIDUES IN THE 3-DIMENSIONAL STRUCTURES OF THE POLYMERASE DOMAINS OF ESCHERICHIA-COLI DNA-POLYMERASE-I AND HIV-1 REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; KLENOW FRAGMENT; MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURE; BINDING DOMAIN; IDENTIFICATION; SITE; HETERODIMER; MUTAGENESIS; INHIBITOR	Using a computer-assisted molecular modeling protocol, we have completed the three-dimensional structures of HIV-1 reverse transcriptase and the Klenow fragment of DNA polymerase I based on the Calpha crystal coordinates of the individual enzymes. The two model-built structures were then used to compare the electrostatic potential contours and analyze the spatial positions of residues conserved in the catalytic domains of the two enzymes. In spite of rather weak sequence similarity and different folding patterns between the DNA-dependent DNA polymerase (pol I) and the RNA-dependent DNA polymerases (RT), we have noted the occurrence of identical or similar residues at common spatial positions in pol I and RT in a three-dimensional context. The homologous residues present at equivalent spatial positions in the Klenow fragment and the p66 subunit of HIV-1 RT may therefore imply their functional similarity. Furthermore, these conserved residues may represent a similar structure-function feature in all polymerases.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT BIOCHEM & MOLEC BIOL,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY,ACAD COMP CTR,NEWARK,NJ 07103; RUTGERS UNIV,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; RUTGERS UNIV,DEPT CHEM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University New Brunswick					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI027690, R01AI027690, R01AI026652] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-27690, AI-26652] Funding Source: Medline; NIGMS NIH HHS [GM-36307] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASU A, 1987, BIOCHEMISTRY-US, V26, P1704, DOI 10.1021/bi00380a032; BASU S, 1988, BIOCHEMISTRY-US, V27, P6710, DOI 10.1021/bi00418a011; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BOYER PL, 1992, J VIROL, V66, P7533, DOI 10.1128/JVI.66.12.7533-7537.1992; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KALLAM P, 1992, P NATL ACAD SCI USA, V89, P1934; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LOWE DM, 1991, FEBS LETT, V282, P231, DOI 10.1016/0014-5793(91)80484-K; MODAK MJ, 1976, BIOCHEMISTRY-US, V15, P3620, DOI 10.1021/bi00661a033; MOHAN PM, 1988, BIOCHEMISTRY-US, V27, P226, DOI 10.1021/bi00401a034; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; PANDEY VN, 1987, BIOCHEMISTRY-US, V26, P7744, DOI 10.1021/bi00398a031; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; RUSH J, 1990, J BIOL CHEM, V265, P4821; WINTERSBERGER U, 1988, TRENDS GENET, V3, P198; YADAV PNS, 1992, BIOCHEMISTRY-US, V31, P2879, DOI 10.1021/bi00126a006	28	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					716	720						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506263				2022-12-27	WOS:A1994MR21900112
J	JAYARAMAN, T; MARKS, AR				JAYARAMAN, T; MARKS, AR			RAPAMYCIN-FKBP12 BLOCKS PROLIFERATION, INDUCES DIFFERENTIATION, AND INHIBITS CDC2 KINASE-ACTIVITY IN A MYOGENIC CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; CYCLOSPORINE-A; RYANODINE RECEPTOR; GENE FAMILY; BC3H1 CELLS; ACTIVATION; FK506; TRANSCRIPTION; IMMUNOPHILIN; COMPLEXES	Rapamycin is a potent immunosuppressant that binds to the cytosolic protein, FKBP12, and blocks T cell activation. Here we report that rapamycin also blocks myogenic proliferation and induces differentiation, associated with a decrease in p34cdc2 activity and cyclin A levels. In yeast and mammals, rapamycin blocks cell cycle progression by causing G1 arrest, arguing for a conserved signaling pathway governing the G1 to S transition. p34cdc2 has been shown to play a role in both the transition from G1 to S and from G2 to M in yeast. In higher eukaryotes the role of p34cdc2 in G1 to S transition is less clear. Rapamycin and the structurally related macrolide antibiotic FK506 both bind to a cytosolic protein, the FK506-binding protein (FKBP12). We show that inhibition of myogenic proliferation is achieved at low doses of rapamycin (<1 ng/ml) and is competed by a molar excess of FK506, indicating specificity for FKBP12. The distinct FK506-calcineurin pathway did not affect myogenic proliferation, differentiation, or p34cdc2 kinase activity. Thus, the rapamycin-FKBP12 signaling pathway involves a specific and direct effect on p34cdc2 kinase activity at the G1 to S transition and identifies a regulatory step during myogenic differentiation.	CUNY MT SINAI SCH MED,MOLEC MED PROGRAM,BOX 1269,1 GUSTAVE L LEVY,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRENNAN TJ, 1990, J CELL BIOL, V110, P929, DOI 10.1083/jcb.110.4.929; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FORNWALD JA, 1982, NUCLEIC ACIDS RES, V10, P3861, DOI 10.1093/nar/10.13.3861; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LATHROP B, 1985, J CELL BIOL, V100, P1540, DOI 10.1083/jcb.100.5.1540; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARKS AR, 1991, J CELL BIOL, V114, P303, DOI 10.1083/jcb.114.2.303; MORICE WG, 1993, J BIOL CHEM, V268, P3734; MUNSON R, 1982, J CELL BIOL, V92, P350, DOI 10.1083/jcb.92.2.350; OLSON EN, 1983, J BIOL CHEM, V258, P2644; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHUBERT D, 1974, J CELL BIOL, V61, P398, DOI 10.1083/jcb.61.2.398; STRAUCH AR, 1986, J BIOL CHEM, V261, P849; TAUBMAN MB, 1989, J CELL BIOL, V108, P1799, DOI 10.1083/jcb.108.5.1799; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WICE B, 1987, J BIOL CHEM, V262, P1810	28	98	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25385	25388						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503980				2022-12-27	WOS:A1993MK10000019
J	GUDI, R; BOWKERKINLEY, MM; KEDISHVILI, NY; ZHAO, Y; POPOV, KM				GUDI, R; BOWKERKINLEY, MM; KEDISHVILI, NY; ZHAO, Y; POPOV, KM			DIVERSITY OF THE PYRUVATE-DEHYDROGENASE KINASE GENE FAMILY IN HUMANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COENZYME-A; PURIFICATION; MECHANISM; KIDNEY; HEART; MICROCOMPUTER; PHOSPHATASE; STIMULATION; OXIDATION; COMPLEX	Recent evidence from this laboratory indicates that at least two isoenzymic forms of pyruvate dehydrogenase kinase (PDK1 and PDK2) may be involved in the regulation of enzymatic activity of mammalian pyruvate dehydrogenase complex by phosphorylation (Popov, K. M., Kedishvili, N, Y,, Zhao, Y,, Gudi, R,, and Harris, R. A. (1994) J. Biol. Chem, 269, 29720-29724), The present study was undertaken to further explore the diversity of the pyruvate dehydrogenase kinase gene family, Here we report the deduced amino acid sequences of three isoenzymic forms of PDK found in humans, In terms of their primary structures, two isoenzymes identified in humans correspond to rat PDK1 and PDK2, whereas a third gene (PDK3) encodes for a new isoenzyme that shares 68% and 67% of amino acid identities with PDK1 and PDK2, respectively, PDK3 cDNA expressed in Escherichia coli directs the synthesis of a polypeptide with a molecular mass of approximately 45,000 Da that possesses catalytic activity toward kinase-depleted pyruvate dehydrogenase. PDK3 appears to have the highest specific activity among the three isoenzymes tested as recombinant proteins, Tissue distribution of all three isoenzymes of human PDK was characterized by Northern blot analysis. The highest amount of PDK2 mRNA was found in heart and skeletal muscle, the lowest amount in placenta and lung, Brain, kidney, pancreas, and liver expressed an intermediate amount of PDK2 (brain > kidney = pancreas > liver), The tissue distribution of PDK1 mRNA differs markedly from PDK2, The message for PDK1 was ex pressed predominantly in heart with only modest levels of expression in other tissues (skeletal muscle > liver > pancreas > brain > placenta = lung > kidney), In contrast to PDK1 and PDK2, which are expressed in all tissues tested, the message for PDK3 was found almost exclusively in heart and skeletal muscle, indicating that PDK3 may serve specialized functions characteristic of muscle tissues, In all tissues tested thus far, the level of expression of PDK2 mRNA was essentially higher than that of PDK1 and PDK3, consistent with the idea that PDK2 is a major isoenzyme responsible for regulation of pyruvate dehydrogenase in human tissues.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis				Kedishvili, Natalia/0000-0001-6917-4891	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051262, R01GM051262] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47844] Funding Source: Medline; NIGMS NIH HHS [GM 51262] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEHAL RH, 1993, ANNU REV NUTR, V13, P497, DOI 10.1146/annurev.nu.13.070193.002433; CATE RL, 1978, J BIOL CHEM, V253, P496; CATERSON ID, 1982, BIOCHEM J, V208, P53, DOI 10.1042/bj2080053; COOPER RH, 1974, BIOCHEM J, V143, P625, DOI 10.1042/bj1430625; DENTON RM, 1972, BIOCHEM J, V128, P161, DOI 10.1042/bj1280161; HANSFORD RG, 1976, J BIOL CHEM, V251, P5483; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HUCHO F, 1972, Archives of Biochemistry and Biophysics, V151, P328, DOI 10.1016/0003-9861(72)90504-8; KERBEY AL, 1976, BIOCHEM J, V154, P327, DOI 10.1042/bj1540327; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; LINN TC, 1969, P NATL ACAD SCI USA, V62, P227; Popov K M, 1991, Protein Expr Purif, V2, P278, DOI 10.1016/1046-5928(91)90084-V; POPOV KM, 1993, J BIOL CHEM, V268, P26602; POPOV KM, 1994, J BIOL CHEM, V269, P29720; POPOV KM, 1992, J BIOL CHEM, V267, P13129; PRATT ML, 1979, J BIOL CHEM, V254, P7191; PRIESTMAN DA, 1994, BIOCHEM J, V300, P659, DOI 10.1042/bj3000659; PRIESTMAN DA, 1992, FEBS LETT, V308, P83, DOI 10.1016/0014-5793(92)81056-R; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEPP LR, 1983, J BIOL CHEM, V258, P9454; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TEAGUE WM, 1982, BIOCHEMISTRY-US, V21, P5585, DOI 10.1021/bi00265a031; WIRTZ E, 1991, MOL BIOCHEM PARASIT, V47, P119, DOI 10.1016/0166-6851(91)90154-X	26	209	224	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28989	28994		10.1074/jbc.270.48.28989	http://dx.doi.org/10.1074/jbc.270.48.28989			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499431	hybrid			2022-12-27	WOS:A1995TH05600075
J	KEILER, KC; SAUER, RT				KEILER, KC; SAUER, RT			IDENTIFICATION OF ACTIVE-SITE RESIDUES OF THE TSP PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE	In a search for active-site residues of the Tsp protease, 20 positions were individually mutated to alanine, the mutant strains were assayed for growth defects in vivo, and the purified proteins were assayed for proteolytic activity in vitro. Alanine substitutions at three positions, Ser-430, Asp-441, and Lys-455, result in inactive proteases that have structures and substrate-binding properties similar to wild type, suggesting that the side chains at these positions participate in catalysis. Replacing Ser-430 with cysteine results in a partially active protease, which is inhibited by cysteine-modifying reagents. Replacing Asp-44l with asparagine does not significantly affect activity. However, other residues, including histidine and arginine, cannot functionally replace Lys-455. These data are consistent with a serine-lysine dyad mechanism, similar to those proposed for the LexA-like proteases, the type I signal peptidases, and the class A beta-lactamases.			KEILER, KC (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Sauer, Robert/0000-0002-1719-5399; Keiler, Kenneth/0000-0001-8753-335X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015706, R01AI015706, R01AI016892] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-16892, AI-15706] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Antonov V. K., 1993, CHEM PROTEOLYSIS; AZIZAN A, 1994, J BACTERIOL, V176, P6653, DOI 10.1128/JB.176.21.6653-6662.1994; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; Dunn BM., 1989, PROTEOLYTIC ENZYMES, P57; HARA H, 1991, J BACTERIOL, V173, P4799, DOI 10.1128/jb.173.15.4799-4813.1991; HIGAKI JN, 1989, BIOCHEMISTRY-US, V28, P9256, DOI 10.1021/bi00450a004; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; KEILER KC, 1995, PROTEIN SCI, V4, P1507, DOI 10.1002/pro.5560040808; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; LITTLE JW, 1993, J BACTERIOL, V175, P4943, DOI 10.1128/JB.175.16.4943-4950.1993; NAKATSUKA T, 1987, J AM CHEM SOC, V109, P3808, DOI 10.1021/ja00246a064; SCHAGGER H, 1991, ANAL BIOCHEM, V166, P368; SHESTAKOV SV, 1994, J BIOL CHEM, V269, P19354; SILBER KR, 1992, P NATL ACAD SCI USA, V89, P295, DOI 10.1073/pnas.89.1.295; SILBER KR, 1994, MOL GEN GENET, V242, P237, DOI 10.1007/BF00391018; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; 1991, PROGRAM MANUAL GCG P	21	62	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28864	28868		10.1074/jbc.270.48.28864	http://dx.doi.org/10.1074/jbc.270.48.28864			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499412	hybrid			2022-12-27	WOS:A1995TH05600056
J	NOESKEJUNGBLUT, C; HAENDLER, B; DONNER, P; ALAGON, A; POSSANI, L; SCHLEUNING, WD				NOESKEJUNGBLUT, C; HAENDLER, B; DONNER, P; ALAGON, A; POSSANI, L; SCHLEUNING, WD			TRIABIN, A HIGHLY POTENT EXOSITE INHIBITOR OF THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; HIRUDIN; PEPTIDE; THROMBOMODULIN; COAGULATION; KINETICS; BINDING; FORMS; VENOM	Triabin, a new thrombin inhibitor, has been purified from the saliva of Triatoma pallidipennis, a blood-sucking triatomine bug, It forms a noncovalent complex with thrombin at a molar ratio of 1:1, inhibits thrombin-induced platelet aggregation, and prolongs thrombin clotting time and activated partial thromboplastin time, However, it only minimally suppresses the amidolytic activity of thrombin, as measured by a chromogenic peptide substrate assay. It completely blocks trypsin-catalyzed cleavage of thrombin, probably via protection of the anion-binding exosite and inhibits the effect of thrombomodulin on thrombin in a dose-dependent fashion, These results indicate that the inhibitor is directed toward the anion-binding exosite of thrombin, The protein was partially sequenced and the information used to isolate cDNA clones from a T. pallidipennis salivary gland library. Four slightly polymorphic variants coding for mature proteins of 142 amino acids preceded by a putative leader sequence were obtained. The recombinant protein expressed in the periplasmic space of Escherichia coli has a biological activity similar to that of salivary triabin, as tested in a thrombin-induced platelet aggregation assay, In addition, recombinant triabin inhibits thrombin catalyzed hydrolysis of fibrinogen with a K-i of about 3 pM.	UNIV NACL AUTONOMA MEXICO,INST BIOTECHNOL,CUERNAVACA 62271,MORELOS,MEXICO	Universidad Nacional Autonoma de Mexico	NOESKEJUNGBLUT, C (corresponding author), SCHERING AG,RES LABS,MULLERSTR 170-178,D-13342 BERLIN,GERMANY.		Possani, Lourival D/J-2397-2013					BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN PJ, 1988, THROMB RES, V50, P273, DOI 10.1016/0049-3848(88)90228-9; CHURCH FC, 1991, J BIOL CHEM, V266, P11975; CLARKE JH, 1993, J BIOL CHEM, V268, P6309; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; DENNIS S, 1990, EUR J BIOCHEM, V188, P61, DOI 10.1111/j.1432-1033.1990.tb15371.x; DIXON M, 1972, BIOCHEM J, V129, P197, DOI 10.1042/bj1290197; DODT J, 1988, FEBS LETT, V229, P87, DOI 10.1016/0014-5793(88)80803-2; DUGGLEBY RG, 1981, ANAL BIOCHEM, V110, P9, DOI 10.1016/0003-2697(81)90104-4; FENTON JW, 1989, SEMIN THROMB HEMOST, V15, P265, DOI 10.1055/s-2007-1002718; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; FRIEDRICH T, 1993, J BIOL CHEM, V268, P16216; HAENDLER B, 1995, BIOCHEM J, V307, P465, DOI 10.1042/bj3070465; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; HOLLEMAN WH, 1976, J BIOL CHEM, V251, P1663; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARAGANORE JM, 1990, BIOCHEMISTRY-US, V29, P7095, DOI 10.1021/bi00482a021; MARKWARDT F, 1957, H-S Z PHYSIOL CHEM, V308, P147, DOI 10.1515/bchm2.1957.308.1.147; Markwardt F., 1970, METHOD ENZYMOL, V19, P924, DOI [10.1016/0076-6879(70)19082-3, DOI 10.1016/0076-6879(70)19082-3]; MAURER HR, 1971, DISC ELECTROPHORESIS, P44; NOESKEJUNGBLUT C, 1994, J BIOL CHEM, V269, P5050; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; TARR GE, 1986, METHODS PROTEIN MICR, P162; TUSZYNSKI GP, 1987, J BIOL CHEM, V262, P9718; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; ZINGALI RB, 1993, BIOCHEMISTRY-US, V32, P10794, DOI 10.1021/bi00091a034	35	122	127	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28629	28634		10.1074/jbc.270.48.28629	http://dx.doi.org/10.1074/jbc.270.48.28629			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499380	hybrid			2022-12-27	WOS:A1995TH05600024
J	ANAGUCHI, H; HIRAOKA, O; YAMASAKI, K; NAITO, S; OTA, Y				ANAGUCHI, H; HIRAOKA, O; YAMASAKI, K; NAITO, S; OTA, Y			LIGAND-BINDING CHARACTERISTICS OF THE CARBOXYL-TERMINAL DOMAIN OF THE CYTOKINE RECEPTOR HOMOLOGOUS REGION OF THE GRANULOCYTE-COLONY-STIMULATING FACTOR-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; SIGNAL TRANSDUCTION; EXTRACELLULAR DOMAIN; ESCHERICHIA-COLI; DRUG-THERAPY; PROTEIN; IDENTIFICATION; DETERMINANTS; DESIGN; MOTIF	The carboxyl-terminal domain (EC domain, roughly 100 amino acid residues) of the cytokine receptor homologous region in the receptor for murine granulocyte colony-stimulating factor was secreted as a maltose binding protein fusion into the Escherichia coli periplasm. The murine BC domain was prepared from the fusion protein by restriction protease factor Xa digestion and was purified to homogeneity. The purified BC domain specifically and stoichiometrically bound granulocyte colony-stimulating factor. This result indicates that the BC domain is also critical for ligand binding, as shown for the amino-terminal domain of the cytokine receptor homologous region (Hiraoka, O., Anaguchi, H., Yamasaki, K., Fukunaga, R., Nagata, S., and Ota, Y. (1994) J. Biol. Chem. 269, 22412-22419). The tertiary folding and the beta-sheet structure of the BC domain were confirmed by NMR spectroscopy. The disulfide bond pattern suggested from peptide mapping was Cys(224)-Cys(271) and Cys(242)-Cys(285). Disruption of the disulfide bonds suggested that both bonds are critical for maintaining the folding of the BC domain, although a BC domain lacking the second bond still retained ligand binding activity. Mutational analysis of the WSXWS sequence conserved in the cytokine receptor family suggested that this motif is critical for protein folding rather than for ligand binding.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN				Yamasaki, Kazuhiko/L-7108-2018	Yamasaki, Kazuhiko/0000-0003-0320-9697				ASAKURA A, 1994, BIOMED PHARMACOTHER, V48, P35, DOI 10.1016/0753-3322(94)90188-0; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEMETRI GD, 1991, BLOOD, V78, P2791; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; HIRAOKA H, 1995, IN PRESS J BIOL CHEM, V270; HIRAOKA O, 1994, J BIOL CHEM, V269, P22412; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P99; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P28; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; NAGATA S, 1990, HDB EXPT PHARM, V1, P699; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; ROZAKISADCOCK M, 1992, J BIOL CHEM, V267, P7428; SETO Y, 1992, J IMMUNOL, V148, P259; SOMERS W, 1994, NATURE, V327, P478; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P28; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619	30	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27845	27851		10.1074/jbc.270.46.27845	http://dx.doi.org/10.1074/jbc.270.46.27845			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499256	hybrid			2022-12-27	WOS:A1995TE73600067
J	AVRAHAM, S; LONDON, R; FU, YG; OTA, S; HIREGOWDARA, D; LI, JZ; JIANG, SX; PASZTOR, LN; WHITE, RA; GROOPMAN, JE; AVRAHAM, H				AVRAHAM, S; LONDON, R; FU, YG; OTA, S; HIREGOWDARA, D; LI, JZ; JIANG, SX; PASZTOR, LN; WHITE, RA; GROOPMAN, JE; AVRAHAM, H			IDENTIFICATION AND CHARACTERIZATION OF A NOVEL RELATED ADHESION FOCAL TYROSINE KINASE (RAFTK) FROM MEGAKARYOCYTES AND BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; C-KIT LIGAND; SIGNAL TRANSDUCTION; SHORT ARM; PROTEIN; PHOSPHORYLATION; GENE; SRC; PP125(FAK); RECEPTORS	We have isolated a cDNA encoding a novel human intracytoplasmic tyrosine kinase, termed RAFTK (for a related adhesion focal tyrosine kinase), In addition, we have cloned and characterized the murine homolog of the human RAFTK cDNA, Comparison of the deduced amino acid sequences of human RAFTK and murine Raftk cDNAs revealed 95% homology, indicating that RAFTK is highly conserved between these species, The RAFTK cDNA clone, encoding a polypeptide of 1009 amino acids, has closest homology (48% identity, 65% similarity) to the focal adhesion kinase (pp125(FAK)). Comparison of the deduced amino acid sequences also indicates that RAFTK, like pp125(FAK), lacks a transmembrane region, myristylation sites, and SH2 and SH3 domains, In addition, like pp125(FAK), RAFTK contains a kinase domain flanked by large N-terminal (426 residues) and C-terminal (331 residues) domains, and the C-terminal region contains a predicted proline-rich stretch of residues, In fetal tissues, RAFTK expression was abundant in brain, and low levels were observed in lung and liver. In adult tissues, it was less restricted, indicating that RAFTK expression is developmentally up-regulated, Expression of RAFTK was also observed in human CD34(+) marrow cells, primary bone marrow megakaryocytes, platelets, and various areas of brain, The human RAFTK gene was assigned to human chromosome 8 using genomic DNAs from human/rodent somatic cell hybrid lines, The mouse Raftk gene was mapped to chromosome 14, closely linked to gonadotropin-releasing hormone, Using specific antibodies for RAFTK, a similar to 123-kDa protein from the human megaIzaryocytic CMK cell line was immunoprecipitated. Treatment of the megakaryocytic CMK cells with thrombin caused a rapid induction of tyrosine phosphorylation of RAFTK protein, The structural features of RAFTK suggest that it is a member of the focal adhesion kinase gene family and may participate in signal transduction in human megakaryocytes and brain as well as in other cell types.	UNIV MISSOURI,SCH MED,CHILDRENS MERCY HOSP,GENET SECT,KANSAS CITY,MO 64108	Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City	AVRAHAM, S (corresponding author), HARVARD UNIV,DEACONESS HOSP,SCH MED,DEPT MED,DIV HEMATOL ONCOL,1 DEACONESS HOSP,BOSTON,MA 02215, USA.			Avraham, Hava/0000-0002-7545-3640	NHLBI NIH HHS [HL51456, HL46668] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046668, R01HL051456] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; AVRAHAM H, 1992, BLOOD, V79, P365; AVRAHAM H, 1992, BLOOD, V80, P1679; AVRAHAM H, 1993, STEM CELLS, V11, P499, DOI 10.1002/stem.5530110619; AVRAHAM H, 1992, INT J CELL CLONING, V10, P70, DOI 10.1002/stem.5530100203; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN PY, 1994, J BIOL CHEM, V269, P20567; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CRAMER EM, 1993, AM J PATHOL, V143, P1498; DEVOR BB, 1993, BIOCHEM BIOPH RES CO, V190, P1084, DOI 10.1006/bbrc.1993.1160; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAMAWY MM, 1994, J IMMUNOL, V153, P4655; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HEARNE CM, 1991, MAMM GENOME, V1, P273, DOI 10.1007/BF00352339; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HURST J, 1987, CYTOGENET CELL GENET, V45, P30, DOI 10.1159/000132421; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MANIATIS T, 1992, MOL CLONING; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SATO T, 1987, EXP HEMATOL, V15, P495; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SILVER J, 1985, J HERED, V76, P436, DOI 10.1093/oxfordjournals.jhered.a110140; TANAKA H, 1989, BRIT J HAEMATOL, V73, P18, DOI 10.1111/j.1365-2141.1989.tb00212.x; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VITTET D, 1993, BLOOD COAGUL FIBRIN, V4, P759, DOI 10.1097/00001721-199304050-00013; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WHITE RA, 1992, NAT GENET, V2, P80, DOI 10.1038/ng0992-80; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YANGFENG TL, 1986, SOMAT CELL MOLEC GEN, V12, P95, DOI 10.1007/BF01560732; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHANG C, 1994, J BIOL CHEM, V269, P25247	62	311	323	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27742	27751		10.1074/jbc.270.46.27742	http://dx.doi.org/10.1074/jbc.270.46.27742			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499242				2022-12-27	WOS:A1995TE73600053
J	RYAN, P; EDWARDS, CO				RYAN, P; EDWARDS, CO			SYSTEMATIC INTRODUCTION OF PROLINE IN A EUKARYOTIC SIGNAL SEQUENCE SUGGESTS ASYMMETRY WITHIN THE HYDROPHOBIC CORE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX VIRUS TYPE-1; GLYCOPROTEIN-GIII; PROTEIN LOCALIZATION; SECONDARY-STRUCTURE; ESCHERICHIA-COLI; MUTATION; PEPTIDE; GENE; EFFICIENCY; MUTANTS	The hydrophobic core or h region of both prokaryotic and eukaryotic signal sequences is the predominant structural domain that controls the efficiency of protein translocation across membranes, Characteristically, hy drophobic cores appear to assume alpha-helical conformations, and studies in prokaryotes have indicated that this conformation is necessary for efficient signal sequence function, To address the conformational constraints of a eukaryotic signal sequence, we have introduced a single proline in almost each position of the signal sequence hydrophobic core of glycoprotein C (gC) of the swine herpesvirus, pseudorabies virus, When the resulting mutant virus strains were used to infect cells, we found that substitution of proline at certain positions affected gC translocation greater than its introduction at other sites within the hydrophobic core, The observed positional effects did not completely correlate with reductions in overall hydrophobicity or linear position within the hydrophobic core. Rather, it appeared that one face of the gC signal sequence alpha-helix is far more sensitive to proline disruption than the other, potentially indicating a functional asymmetry.			RYAN, P (corresponding author), UNIV TENNESSEE,DEPT MICROBIOL & IMMUNOL,858 MADISON AVE,RM 201,MEMPHIS,TN 38163, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028520] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28520] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEDOUELLE H, 1980, NATURE, V285, P78, DOI 10.1038/285078a0; BIRD P, 1990, J BIOL CHEM, V265, P8420; BRUCH MD, 1990, J BIOL CHEM, V265, P3851; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; ENQUIST LW, 1988, J VIROL, V62, P3565, DOI 10.1128/JVI.62.10.3565-3573.1988; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P233, DOI 10.1007/BF00763167; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOLLAND TC, 1983, J VIROL, V46, P649, DOI 10.1128/JVI.46.2.649-652.1983; HOPP TP, 1981, P NATL ACAD SCI USA, V78, P3842; ROBBINS AK, 1989, J VIROL, V63, P250, DOI 10.1128/JVI.63.1.250-258.1989; ROBBINS AK, 1986, J VIROL, V58, P339, DOI 10.1128/JVI.58.2.339-347.1986; ROBBINS AK, 1986, J VIROL, V59, P635, DOI 10.1128/JVI.59.3.635-645.1986; RYAN JP, 1987, J VIROL, V61, P2962, DOI 10.1128/JVI.61.10.2962-2972.1987; RYAN P, 1993, VIRUS GENES, V7, P5, DOI 10.1007/BF01702345; TOMILO M, 1994, J BIOL CHEM, V269, P32016; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511	21	13	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27876	27879		10.1074/jbc.270.46.27876	http://dx.doi.org/10.1074/jbc.270.46.27876			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499261	hybrid			2022-12-27	WOS:A1995TE73600072
J	SHI, LB; SKACH, WR; VERKMAN, AS				SHI, LB; SKACH, WR; VERKMAN, AS			FUNCTIONAL INDEPENDENCE OF MONOMERIC CHIP28 WATER CHANNELS REVEALED BY EXPRESSION OF WILD-TYPE-MUTANT HETERODIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS OOCYTES; PROTEIN; RECONSTITUTION; MEMBRANE; CDNA; RNA	CHIP28 is a major water transporting protein in erythrocytes and kidney which forms tetramers in membranes (Verbavatz, J. M., Brown, D., Sabolic, I., Valenti, G., Ausiello, D. A., Van Hoek, A. N., Ma, T., and Verkman, A. S. (1993) J. Cell Biol. 123, 605-618). To determine whether CHIP28 monomers function independently, chimeric cDNA dimers were constructed which contained wild-type CHIP28 in series with either wild-type CHIP28, a non-water transporting CHIP28 mutant (C189W), or a functional but mercurial-insensitive CHIP28 mutant (C189S). Transcribed cRNAs were injected in Xenopus oocytes and plasma membrane expression was assayed by quantitative immunofluorescence. Water channel function was measured by osmotically induced swelling. CHIP28 homo- and heterodimers were targeted to the oocyte plasma membrane and functioned as water channels. Relative osmotic water permeability (P-f) values (normalized for plasma membrane expression of monomeric subunits) were: 1.0 (CHIP28 monomer), 0.0 (C189W), 1.07 (C189S), 1.10 (CHIP28-CHIP28 dimer) and 0.52 (CHIP28 C189W). The increase in oocyte P-f was linearly related to plasma membrane expression of wild-type CHIP28 and C189S subunits. HgCl2 (0.3 mM) inhibited channel-mediated P-f in oocytes expressing wild-type CHIP28 monomers and dimers by 85-90%, but did not inhibit P-f in oocytes expressing C189S. HgCl2 inhibited P-f in oocytes expressing CHIP28-C189S dimers by 44 +/- 7%, consistent with one mercurial-sensitive and one insensitive subunit in the heterodimer. These results indicate that despite their assembly in tetramers, monomeric CHIP28 subunits function independently as water channels.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CANC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [K11CA001614] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER; NCI NIH HHS [CA01614] Funding Source: Medline; NHLBI NIH HHS [HL42368] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; HASEGAWA H, 1993, AM J PHYSIOL, V264, pC237, DOI 10.1152/ajpcell.1993.264.1.C237; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; MA TH, 1993, J BIOL CHEM, V268, P22756; MA TH, 1994, AM J PHYSIOL, V266, pC189, DOI 10.1152/ajpcell.1994.266.1.C189; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; Skach W. R., 1993, Journal of the American Society of Nephrology, V4, P859; SMITH BL, 1991, J BIOL CHEM, V266, P6407; TYTGAT J, 1992, NATURE, V359, P420, DOI 10.1038/359420a0; VANHOEK AN, 1991, J BIOL CHEM, V266, P16633; VANHOEK AN, 1993, BIOCHEMISTRY-US, V32, P11847, DOI 10.1021/bi00095a013; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; VERKMAN AS, 1984, P NATL ACAD SCI-BIOL, V81, P150, DOI 10.1073/pnas.81.1.150; VERKMAN AS, 1993, WATER CHANNELS, P74; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZEN K, 1992, J CELL BIOL, V119, P99, DOI 10.1083/jcb.119.1.99; ZHANG R, 1990, J BIOL CHEM, V265, P15375; ZHANG RB, 1993, BIOCHEMISTRY-US, V32, P2938, DOI 10.1021/bi00063a002; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359	30	103	106	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10417	10422						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511600				2022-12-27	WOS:A1994NF01700037
J	MOCHIZUKIODA, N; NAKAJIMA, Y; NAKANISHI, S; ITO, S				MOCHIZUKIODA, N; NAKAJIMA, Y; NAKANISHI, S; ITO, S			CHARACTERIZATION OF THE SUBSTANCE-P RECEPTOR-MEDIATED CALCIUM INFLUX IN CDNA TRANSFECTED CHINESE-HAMSTER OVARY CELLS - A POSSIBLE ROLE OF INOSITOL 1,4,5-TRISPHOSPHATE IN CALCIUM INFLUX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; INTRACELLULAR CA2+ STORES; RAT TACHYKININ RECEPTORS; PLASMA-MEMBRANE; HUMAN PLATELETS; ION CHANNELS; CA-2+ ENTRY; ENDOTHELIAL-CELLS; SMOOTH-MUSCLE; RELEASE	In Chinese hamster ovary cells expressing the substance P (SP) receptor clone (CHO-SPR cells), we examined SP-stimulated [Ca2+]i changes by microscopic fluorescence analysis and electrophysiological recordings. In fura-2-loaded cells, SP (1 muM) induced a prolonged elevation of [Ca2+]i, which comprised a rapid and transient Ca2+ mobilization and a prolonged phase of Ca2+ entry, but thrombin (1 unit/ml) induced only transient elevation of [Ca2+]i. The formation of inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) was stimulated to 230% above the control by SP but 10% by thrombin 10 s after stimulation. In whole cell clamp recordings, SP induced a long lasting inward current, whereas thrombin did not evoke an inward current. G(qalpha) antibody applied intracellularly blocked the SP-induced current, but G(salpha) antibody did not block it. Furthermore, decavanadate and heparin, inhibitors of Ins(1,4,5)P3 binding to its receptor, suppressed the SP-induced current. In cell-attached patch, bath-applied SP activated channel currents carried by Ba2+, Ca2+, or Na+. In inside-out patches, Ins(1,4,5)P3, but neither inositol 1,3,4-trisphosphate nor inositol 1,3,4,5-tetrakisphosphate, activated channel currents carried by Ba2+, Ca2+, or Na+. The channel activity induced by Ins(1,4,5)P3 was abolished by heparin. These results demonstrate that SP induces Ca2+ entry through activation of cation channels and suggest that Ins(1,4,5)P3 may regulate both SP-induced Ca2+ mobilization and Ca2+ entry in CHO-SPR cells.	OSAKA BIOSCI INST,DEPT CELL BIOL,SUITA 565,JAPAN; KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN	Kyoto University								ADAMS DJ, 1989, FASEB J, V3, P2389, DOI 10.1096/fasebj.3.12.2477294; ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BENHAM CD, 1989, ION TRANSPORT, P197; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BREGESTOVSKI P, 1988, BRIT J PHARMACOL, V95, P429, DOI 10.1111/j.1476-5381.1988.tb11663.x; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; BYRON KL, 1992, J BIOL CHEM, V267, P108; FADOOL DA, 1992, NEURON, V9, P907, DOI 10.1016/0896-6273(92)90243-7; FELDER CC, 1992, P NATL ACAD SCI USA, V89, P509, DOI 10.1073/pnas.89.2.509; FOHR KJ, 1989, BIOCHEM J, V262, P83; FOHR KJ, 1991, CELL CALCIUM, V12, P735, DOI 10.1016/0143-4160(91)90042-D; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; INGI T, 1991, J PHARMACOL EXP THER, V259, P968; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; ISLAM MS, 1993, BIOCHEM J, V293, P423, DOI 10.1042/bj2930423; ITO S, 1991, J NEUROCHEM, V56, P531, DOI 10.1111/j.1471-4159.1991.tb08182.x; JACKOWSKI S, 1988, J BIOL CHEM, V263, P16830; KALINOSKI DL, 1992, BIOCHEM J, V281, P449, DOI 10.1042/bj2810449; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LIDOFSKY SD, 1993, J BIOL CHEM, V268, P14632; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MAHAUTSMITH MP, 1990, J BIOL CHEM, V265, P10479; MAHAUTSMITH MP, 1992, J BIOL CHEM, V267, P3060; MELDOLESI J, 1987, EXP CELL RES, V171, P271, DOI 10.1016/0014-4827(87)90161-3; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MILLIGAN G, 1989, BIOCHEM J, V260, P837, DOI 10.1042/bj2600837; MITSUHASHI T, 1989, J CLIN INVEST, V84, P635, DOI 10.1172/JCI114209; MOCHIZUKIODA N, 1993, REGUL PEPTIDES, V46, P450, DOI 10.1016/0167-0115(93)90116-P; MOCHIZUKIODA N, 1991, J NEUROCHEM, V56, P541, DOI 10.1111/j.1471-4159.1991.tb08183.x; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; Nakanishi S, 1990, Recent Prog Horm Res, V46, P59; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.ne.14.030191.001011; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PITTET D, 1989, J BIOL CHEM, V264, P7251; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SHENKER A, 1991, J BIOL CHEM, V266, P9309; STAUDERMAN KA, 1989, J BIOL CHEM, V264, P18349; TAYLOR CW, 1990, TRENDS PHARMACOL SCI, V11, P269, DOI 10.1016/0165-6147(90)90003-Q; TSUCHIDA K, 1990, EUR J BIOCHEM, V193, P751, DOI 10.1111/j.1432-1033.1990.tb19396.x; ZSCHAUER A, 1988, NATURE, V334, P703, DOI 10.1038/334703a0	51	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9651	9658						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511591				2022-12-27	WOS:A1994NE05300041
J	OTSU, K; NISHIDA, K; KIMURA, Y; KUZUYA, T; HORI, M; KAMADA, T; TADA, M				OTSU, K; NISHIDA, K; KIMURA, Y; KUZUYA, T; HORI, M; KAMADA, T; TADA, M			THE POINT MUTATION ARG(615)-]CYS IN THE CA2+ RELEASE CHANNEL OF SKELETAL SARCOPLASMIC-RETICULUM IS RESPONSIBLE FOR HYPERSENSITIVITY TO CAFFEINE AND HALOTHANE IN MALIGNANT HYPERTHERMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUSCLE RYANODINE RECEPTOR; SUSCEPTIBLE PIGS; CA-2+ RELEASE; CALCIUM; MECHANISM	Malignant hyperthermia (MH) is an autosomal dominant myopathy. Molecular genetic studies have shown that the alteration of Arg615 to Cys in the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum (ryanodine receptor) is cosegregated with porcine MH (Fujii, J., Otsu, K., Zorzato, F., de Leon, S., Khanna, V. K., Weiler, J. E., O'Brien, P. J., and MacLennan, D. H. (1991) Science 253, 448-451; Otsu, K., Khanna, V. K., Archibald, A., and MacLennan, D. H. (1991) Genomics 11, 744-750). Here, using the fluorescence calcium indicator indo-1, we determined the concentration of ionized cytosolic calcium in myoblastic cells transfected with either the wild-type or mutated ryanodine receptor cDNA. The cells expressing the mutant ryanodine receptor showed higher sensitivity to caffeine, which induces Ca2+ release from the sarcoplasmic reticulum through the ryanodine receptor. Exposure to clinical doses of halothane resulted in a rapid increase of [Ca2+]i in cells expressing the mutated ryanodine receptor, whereas no [Ca2+] changes were observed in cells expressing the wild-type ryanodine receptor. These results provide definite evidence that a single amino acid mutation, Arg615 --> Cys, in the ryanodine receptor is causative of MH.	OSAKA UNIV,SCH MED,DEPT MED 1,SUITA,OSAKA 565,JAPAN	Osaka University	OTSU, K (corresponding author), OSAKA UNIV,SCH MED,DEPT PATHOPHYSIOL,2-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN.							BANRANY M, 1985, BIOCHEMISTRY-US, V24, P7911; BRITT BA, 1987, MALIGNANT HYPERTHERM, P11; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENDO M, 1983, BIOMED RES-TOKYO, V4, P83, DOI 10.2220/biomedres.4.83; FILL M, 1990, BIOPHYS J, V57, P471, DOI 10.1016/S0006-3495(90)82563-7; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; GILLARD EF, 1991, GENOMICS, V11, P751, DOI 10.1016/0888-7543(91)90084-R; IAIZZO PA, 1988, PFLUG ARCH EUR J PHY, V411, P648, DOI 10.1007/BF00580861; LOPEZ JR, 1986, MUSCLE NERVE, V9, P85; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; OBRIEN PJ, 1986, CAN J VET RES, V50, P318; OHNISHI ST, 1983, FEBS LETT, V161, P103; OTSU K, 1991, GENOMICS, V11, P744, DOI 10.1016/0888-7543(91)90083-Q; OTSU K, 1990, J BIOL CHEM, V265, P13472; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0	15	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9413	9415						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511586				2022-12-27	WOS:A1994NE05300005
J	ROY, R; SCHAEFFER, L; HUMBERT, S; VERMEULEN, W; WEEDA, G; EGLY, JM				ROY, R; SCHAEFFER, L; HUMBERT, S; VERMEULEN, W; WEEDA, G; EGLY, JM			THE DNA-DEPENDENT ATPASE ACTIVITY ASSOCIATED WITH THE CLASS-II BASIC TRANSCRIPTION FACTOR BTF2/TFIIH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; MAJOR LATE PROMOTER; C-TERMINAL DOMAIN; INITIATION-FACTOR; HELICASE; COMPLEXES; INVITRO; PROTEIN; KINASE; PHOSPHORYLATION	BTF2/TFIIH from human, delta from rat, and factor b from yeast are multisubunit basal transcription factors that have been shown to be closely associated with a protein kinase capable of phosphorylating the carboxyl-terminal domain of the large subunit of RNA polymerase II (Lu, H., Zawel, L., Fischer, L., Egly, J. M., and Reinberg, D. (1992) Nature 358,641-645; Serizawa, H., Conaway, R. C., and Conaway, J. W. (1992) Proc. Natl. Acad. Sci. U.S.A. 89,7476-7480; Feaver, W. J., Gileadi, O., and Kornberg, R. D. (1991) Cell 67,1223-1230). We report here that a DNA-dependent ATPase and the previously characterized helicase (Schaeffer, L., Roy, R., Humbert, S., Moncollin, V., Vermeulen, W., Hoeijmakers, J., Chambon, P., and Egly, J. M. (1993) Science 260, 58-63) are both associated with BTF2 and reside with the p89 polypeptide subunit. The DNA requirement, the effect of Sarkosyl and staurosporine inhibitors, as well as nucleotide competition experiments, clearly distinguished ATPase/helicase from the carboxyl-terminal domain kinase. Using recombinant wild type or mutated p89/ERCC3 polypeptides and different forms of DNA template, we show the connection between ATPase and the helicase.	FAC MED STRASBOURG,INSERM,U184,CNRS,UPR 6520,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE; ERASMUS UNIV ROTTERDAM,CTR MED GENET,DEPT CELL BIOL & GENET,3000 DR ROTTERDAM,NETHERLANDS	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Erasmus University Rotterdam			Humbert, Sandrine/S-2981-2016; Vermeulen, Wim/W-8708-2019	Vermeulen, Wim/0000-0003-3616-734X; Humbert, Sandrine/0000-0002-9501-2658; schaeffer, laurent/0000-0001-6600-503X				ARIAS JA, 1989, J BIOL CHEM, V264, P3223; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CAI H, 1987, J BIOL CHEM, V262, P298; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DAHMUS ME, 1992, TRANSCRIPTIONAL REGU, P109; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLORES O, 1992, J BIOL CHEM, V267, P2786; GERARD M, 1991, J BIOL CHEM, V266, P20940; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1986, J BIOL CHEM, V261, P169; MIYAMOTO NG, 1984, NUCLEIC ACIDS RES, V12, P8779, DOI 10.1093/nar/12.23.8779; NAEGELI H, 1992, J BIOL CHEM, V267, P392; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	34	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9826	9832						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511595				2022-12-27	WOS:A1994NE05300068
J	COLE, H; REYNOLDS, TR; LOCKYER, JM; BUCK, GA; DENSON, T; SPENCE, JE; HYMES, J; WOLF, B				COLE, H; REYNOLDS, TR; LOCKYER, JM; BUCK, GA; DENSON, T; SPENCE, JE; HYMES, J; WOLF, B			HUMAN SERUM BIOTINIDASE - CDNA CLONING, SEQUENCE, AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENCY; PURIFICATION; PEPTIDES	Biotinidase (EC 3.5.1.12) catalyzes the hydrolysis of biocytin, the product of biotin-dependent carboxylase degradation, to biotin and lysine. Biotinidase deficiency is an inherited metabolic disorder of biotin recycling that is characterized by neurological and cutaneous abnormalities, and can be successfully treated with biotin supplementation. Sequences of tryptic peptides of the purified human serum enzyme were used to design oligonucleotide primers for polymerase chain reaction amplification from human hepatic total RNA to generate putative biotinidase cDNA fragments. Sequence analysis of a cDNA isolated from a human liver library by plaque hybridization with the largest cDNA probe revealed an open reading frame of 1629 bases encoding a protein of 543 amino acid residues, including 41 amino acids of a potential signal peptide. Comparison of the open reading frame with the known biotinidase tryptic peptides and recognition of the expressed protein encoded by this cDNA by monoclonal antibodies prepared against purified biotinidase demonstrated the identity of this cDNA. Southern analyses suggested that biotinidase is a single copy gene and revealed that human cDNA probes hybridized to genomic DNA from mammals, but not from chicken or yeast. Northern analysis indicated the presence of biotinidase mRNA in human heart, brain, placenta, liver lung, skeletal muscle, kidney, and pancreas.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT HUMAN GENET,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL IMMUNOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PEDIAT,RICHMOND,VA 23298; TULANE UNIV,SCH MED,DEPT MED,NEW ORLEANS,LA 70112	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Tulane University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033022] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33022] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAUHAN J, 1986, J BIOL CHEM, V261, P4268; CRAFT DV, 1985, BIOCHEMISTRY-US, V24, P2471, DOI 10.1021/bi00331a012; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GRIER RE, 1989, CLIN CHIM ACTA, V186, P397; HART PS, 1991, CLIN CHIM ACTA, V197, P257, DOI 10.1016/0009-8981(91)90146-4; HART PS, 1992, AM J HUM GENET, V50, P126; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LEE KB, 1990, APPL BIOCHEM BIOTECH, V23, P53, DOI 10.1007/BF02942052; OIZUMI J, 1989, BIOCHIMIE, V71, P1163, DOI 10.1016/0300-9084(89)90019-9; OIZUMI J, 1990, ARCH BIOCHEM BIOPHYS, V278, P381, DOI 10.1016/0003-9861(90)90274-3; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PISPA J, 1965, ANN MED EXP BIOL F S, V43, P1; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; SUCHY SF, 1985, NEUROLOGY, V35, P1510, DOI 10.1212/WNL.35.10.1510; WEINER DL, 1983, AM J HUM GENET, V34, pA56; WOLF B, 1986, J INHERIT METAB DIS, V9, P303, DOI 10.1007/BF01799736; WOLF B, 1983, J PEDIATR-US, V103, P233, DOI 10.1016/S0022-3476(83)80351-5; WOLF B, 1983, CLIN CHIM ACTA, V131, P273, DOI 10.1016/0009-8981(83)90096-7; WOLF B, 1987, CLIN CHIM ACTA, V164, P27, DOI 10.1016/0009-8981(87)90104-5; Wolf B., 1992, METABOLIC BASIS INHE, P2083; 1991, MOL GENETICS CUSTOME	25	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 4	1994	269	9					6566	6570						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MZ503	7509806				2022-12-27	WOS:A1994MZ50300048
J	TANG, YL; TAYLOR, KT; SOBIESKI, DA; MEDVED, ES; LIPSKY, RH				TANG, YL; TAYLOR, KT; SOBIESKI, DA; MEDVED, ES; LIPSKY, RH			IDENTIFICATION OF A HUMAN CD36 ISOFORM PRODUCED BY EXON SKIPPING - CONSERVATION OF EXON ORGANIZATION AND PRE-MESSENGER-RNA SPLICING PATTERNS WITH A CD36 GENE FAMILY MEMBER, CLA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IV CD36; MEMBRANE GLYCOPROTEIN; RECEPTOR; PROTEIN; ERYTHROCYTES; PLATELETS; ADHESION; ACID; RNA	During an examination of different cell types for CD36 mRNA splice variants, a partial cDNA from HEL cells was isolated and characterized. This CD36 cDNA had a 309-base pair deletion following the region encoding the first putative transmembrane domain of CD36. The open reading frame of the deleted CD36 cDNA was retained and was predicted to yield a protein lacking 103 amino acid residues. The presence of this variant was confirmed in RNA pools from placental tissue by a reverse transcriptase-coupled polymerase chain reaction assay. Comparison of the HEL CD36 cDNA with the genomic sequence revealed that the mRNA represented by this variant CD36 cDNA was produced by a pre-mRNA splicing reaction that excluded exons 4 and 5. Transient expression of the variant CD36 cDNA in COS-1 cells showed that CD36 immunoreactive protein was expressed on the cell surface but lacked an antigenic epitope defined by amino acid residues 41-143. This cell surface glycoprotein (M(r) approximate to 57,000) was of identical molecular weight as a CD36 isoform observed on the surface of HEL cells. The exclusion of exons during CD36 pre-mRNA processing appears to be conserved within one other CD36 gene family member, CLA-1.	AMER RED CROSS,DEPT CELL BIOL,JH HOLLAND LAB,ROCKVILLE,MD 20855	American Red Cross				Lipsky, Robert/0000-0001-7753-1473	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046447] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46447] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; CALVO D, 1993, J BIOL CHEM, V268, P18929; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FUJITA H, 1992, BIOCHEM BIOPH RES CO, V184, P604, DOI 10.1016/0006-291X(92)90632-U; GREENWALT DE, 1992, BLOOD, V80, P1105; HARLOW E, 1988, ANTIBODIES LABORATOR; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; INGALLS HM, 1986, P NATL ACAD SCI USA, V83, P4779, DOI 10.1073/pnas.83.13.4779; LEUNG LLK, 1992, J BIOL CHEM, V267, P18244; LIPSKY RH, 1987, CANCER RES, V47, P4900; LIPSKY RH, 1991, THROMB HAEMOSTASIS, V65, P456; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; NOGUCHI K, 1993, BIOCHEM BIOPH RES CO, V192, P88, DOI 10.1006/bbrc.1993.1385; OCKENHOUSE CF, 1991, P NATL ACAD SCI USA, V88, P3175, DOI 10.1073/pnas.88.8.3175; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TAYLOR KT, 1993, GENE, V133, P205, DOI 10.1016/0378-1119(93)90639-K; VEGA MA, 1991, J BIOL CHEM, V266, P16818; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432	25	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					6011	6015						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509795				2022-12-27	WOS:A1994MY84000081
J	BUSSOLINO, F; SILVAGNO, F; GARBARINO, G; COSTAMAGNA, C; SANAVIO, F; ARESE, M; SOLDI, R; AGLIETTA, M; PESCARMONA, G; CAMUSSI, G; BOSIA, A				BUSSOLINO, F; SILVAGNO, F; GARBARINO, G; COSTAMAGNA, C; SANAVIO, F; ARESE, M; SOLDI, R; AGLIETTA, M; PESCARMONA, G; CAMUSSI, G; BOSIA, A			HUMAN ENDOTHELIAL-CELLS ARE TARGETS FOR PLATELET-ACTIVATING-FACTOR (PAF) .3. ACTIVATION OF ALPHA-PROTEIN AND BETA-PROTEIN KINASE-C ISOZYMES IN ENDOTHELIAL-CELLS STIMULATED BY PAF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTOR; RAT-BRAIN; DIFFERENTIAL REGULATION; SELECTIVE INHIBITOR; SIGNAL TRANSDUCTION; POTENT INHIBITORS; HUMAN-NEUTROPHILS; LEUKEMIA-CELLS; F-ACTIN; EXPRESSION	We evaluated the role of the protein kinase C (PKC) and its isozymes in the activation of human endothelial cells (EC) stimulated by platelet-activating factor (PAF). Exposure of confluent EC to PAF resulted in a rapid and concentration-dependent redistribution of PKC from cytosol to plasma-membrane, rearrangement of cytoskeleton (i.e. decrease in F-actin content and redistribution of vinculin), and finally increase in the transendothelial flux of I-125-albumin. Stimulation of EC with oleylacetylglycerol or phorbol 12-myristate 13-acetate induced the modification of the cytoskeletal structures and the increase of I-125-albumin clearance. Inhibitors of PKC prevented the effects induced by PAF on the cytoskeleton and on the barrier function of the EC monolayer. Confluent EC expressed only alpha, beta, and epsilon PKC isoforms. Biochemical and immunochemical analysis showed that the time course of the PKC isozymes translocation from cytosol to the membrane fraction of EC stimulated by PAF was different: beta isoform was redistributed more quickly than alpha isoform. PAF did not induce translocation of PKC epsilon. These results suggest that activation of PKC alpha and beta is an important signal transduction pathway by which PAF activates endothelial monolayer and modify its function of barrier to macromolecules.	UNIV TURIN,INST INTERNAL MED,I-10126 TURIN,ITALY; UNIV TURIN,DEPT BIOL SCI & ONCOL,I-10126 TURIN,ITALY; UNIV NAPLES,DEPT BIOCHEM & BIOPHYS,I-80138 NAPLES,ITALY	University of Turin; University of Turin; University of Naples Federico II	BUSSOLINO, F (corresponding author), UNIV TURIN,DEPT GENET BIOL & MED CHEM,VIA SANTENA 5BIS,I-10126 TURIN,ITALY.		arese, marco/J-6119-2013; Camussi, Giovanni/J-7624-2016; Bussolino, Federico/AES-3951-2022; Bussolino, Federico/K-2500-2016	arese, marco/0000-0002-7384-9406; Camussi, Giovanni/0000-0003-2795-232X; AGLIETTA, Massimo/0000-0002-2255-7972; Bussolino, Federico/0000-0002-5348-1341; PESCARMONA, GIAN PIERO/0000-0003-2143-8901	Telethon [295] Funding Source: Medline	Telethon(Fondazione Telethon)		ANTONOV AS, 1986, P NATL ACAD SCI USA, V83, P9704, DOI 10.1073/pnas.83.24.9704; APGAR JR, 1991, J CELL BIOL, V112, P1157, DOI 10.1083/jcb.112.6.1157; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BELL RM, 1991, J BIOL CHEM, V266, P4661; BRATTON DL, 1992, J IMMUNOL, V148, P514; BROCK TA, 1986, AM J PHYSIOL, V250, P1086, DOI 10.1152/ajpheart.1986.250.6.H1086; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUSSOLINO F, 1988, J BIOL CHEM, V263, P11856; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; BUSSOLINO F, 1985, J IMMUNOL, V135, P2748; CAMUSSI G, 1983, J IMMUNOL, V131, P2397; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DHUMIERES S, 1986, EUR J PHARMACOL, V131, P13, DOI 10.1016/0014-2999(86)90510-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREIREMOAR J, 1991, J IMMUNOL, V147, P405; GANONG BR, 1986, P NATL ACAD SCI USA, V83, P1184, DOI 10.1073/pnas.83.5.1184; GODSON C, 1990, J BIOL CHEM, V265, P8369; GORDON J, 1991, VASCULAR ENDOTHELIUM; GRIGORIAN GY, 1987, CIRC RES, V61, P389, DOI 10.1161/01.RES.61.3.389; HANDLEY DA, 1984, IMMUNOPHARMACOLOGY, V8, P137, DOI 10.1016/0162-3109(84)90017-1; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HELLER R, 1992, J IMMUNOL, V149, P3682; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HUANG FL, 1989, J BIOL CHEM, V264, P4238; Huang K P, 1989, Adv Exp Med Biol, V255, P21; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; INAGAKI M, 1988, J BIOL CHEM, V263, P5970; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V118, P736, DOI 10.1016/0006-291X(84)91456-6; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P48; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KUIJPERS TW, 1992, J CELL BIOL, V117, P565, DOI 10.1083/jcb.117.3.565; LACASSE C, 1990, J LEUKOCYTE BIOL, V49, P245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LERNER R, 1988, BIOCHEM BIOPH RES CO, V153, P805, DOI 10.1016/S0006-291X(88)81167-7; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; LYNCH JJ, 1990, J CLIN INVEST, V85, P1991, DOI 10.1172/JCI114663; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; Maniatis T., 1982, MOL CLONING; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MATILLA P, 1991, FEBS LETT, V289, P86; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; MELLONI E, 1989, J BIOL CHEM, V264, P18414; MISCHAK H, 1991, J IMMUNOL, V147, P3981; MIYATA Y, 1989, J BIOL CHEM, V264, P15565; NIELSEN TB, 1989, TISSUE CELL, V21, P813, DOI 10.1016/0040-8166(89)90032-3; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OLIVER JA, 1990, J CELL PHYSIOL, V145, P536, DOI 10.1002/jcp.1041450321; ONO Y, 1986, FEBS LETT, V203, P111, DOI 10.1016/0014-5793(86)80724-4; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PARKI R, 1992, J CELL BIOL, V116, P1211; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PHATAK PD, 1988, J IMMUNOL, V141, P2929; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; PRESCOTT SM, 1984, P NATL ACAD SCI USA, V81, P3934; RENKONEN R, 1990, SCAND J IMMUNOL, V31, P523, DOI 10.1111/j.1365-3083.1990.tb02800.x; ROTROSEN D, 1986, J CELL BIOL, V103, P2379, DOI 10.1083/jcb.103.6.2379; RYAN US, 1988, NEW TRENDS LIPID MED, P144; SALARI H, 1992, BIOCHIM BIOPHYS ACTA, V1134, P81, DOI 10.1016/0167-4889(92)90030-F; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; Stein W., 1989, CELL SHAPE DETERMINA; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUSUMI A, 1993, J IMMUNOL, V150, P1746; UHING RJ, 1989, J BIOL CHEM, V264, P9224; WERTH DK, 1984, J BIOL CHEM, V259, P5264; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529	88	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2877	2886						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7507929				2022-12-27	WOS:A1994MV43200077
J	NUSSLER, AK; BILLIAR, TR; LIU, ZZ; MORRIS, SM				NUSSLER, AK; BILLIAR, TR; LIU, ZZ; MORRIS, SM			COINDUCTION OF NITRIC-OXIDE SYNTHASE AND ARGININOSUCCINATE SYNTHETASE IN A MURINE MACROPHAGE CELL-LINE - IMPLICATIONS FOR REGULATION OF NITRIC-OXIDE PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; NECROSIS FACTOR CACHECTIN; L-ARGININE; AMINO-ACID; METABOLISM; ENZYMES; NITRATE; UREA; CITRULLINE; TRANSPORT	In macrophages and other cell types, bacterial lipopolysaccharide and certain cytokines stimulate nitric oxide (NO) production via expression of the inducible isoform of nitric oxide synthase (NOS). Citrulline, which is the coproduct of NOS-catalyzed metabolism of arginine, can be recycled to arginine by the action of argininosuccinate synthetase and argininosuccinate lyase, which are present at high levels in hepatocytes and renal tubular cells but normally at very low levels in other cell types such as macrophages. The present study demonstrates that lipopolysaccharide and interferon-gamma, which induce NOS in the murine macrophage cell line RAW 264.7, also coinduce activity and mRNA for argininosuccinate synthetase, which is limiting for arginine synthesis. Argininosuccinate lyase activity and mRNA abundance are unaffected. Induction of argininosuccinate synthetase is not blocked by N(G)- monomethyl-L-arginine, a potent inhibitor of NOS, indicating that argininosuccinate synthetase induction is not the consequence of depleting cellular arginine levels by NOS. Because plasma levels of arginine are limiting for NO synthesis, enhanced cellular capacity to regenerate arginine from citrulline could play a significant role in regulating NO production, especially under conditions where the inducible isoform of NOS is expressed.	UNIV PITTSBURGH,SCH MED,DEPT SURG,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Nussler, Andreas/H-3557-2019; Morris, Sidney M/I-3440-2015	Nussler, Andreas/0000-0002-6666-6791; 	NIDDK NIH HHS [DK33144] Funding Source: Medline; NIGMS NIH HHS [GM37753, GM44100] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044100, R01GM037753, R29GM044100, R37GM044100] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBINA JE, 1988, AM J PHYSIOL, V254, pE459, DOI 10.1152/ajpendo.1988.254.4.E459; BEAUDET AL, 1986, ADV HUM GENET, V15, P161; BILLIAR TR, 1990, BIOCHEM BIOPH RES CO, V168, P1034, DOI 10.1016/0006-291X(90)91133-D; BILLIAR TR, 1989, J EXP MED, V169, P1467, DOI 10.1084/jem.169.4.1467; BOGLE RG, 1992, BIOCHEM J, V284, P15, DOI 10.1042/bj2840015; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BURCHETT SK, 1988, J IMMUNOL, V140, P3473; CAREY GP, 1987, J NUTR, V117, P1734, DOI 10.1093/jn/117.10.1734; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES GHA, 1980, JPEN-PARENTER ENTER, V4, P195, DOI 10.1177/0148607180004002195; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; CORBIN JL, 1974, ANAL BIOCHEM, V57, P310, DOI 10.1016/0003-2697(74)90080-3; CURRIE GA, 1979, BRIT J CANCER, V39, P613, DOI 10.1038/bjc.1979.112; DING AH, 1988, J IMMUNOL, V141, P2407; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GRANGER DL, 1988, J CLIN INVEST, V81, P1129, DOI 10.1172/JCI113427; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; HOFMANN F, 1978, Biochemical Society Transactions, V6, P990; IRR JD, 1978, SOMAT CELL GENET, V4, P111, DOI 10.1007/BF01546496; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; JACKSON MJ, 1988, J BIOL CHEM, V263, P16388; KATZ RA, 1983, J GEN VIROL, V64, P429, DOI 10.1099/0022-1317-64-2-429; LAMBERT MA, 1986, MOL CELL BIOL, V6, P1722, DOI 10.1128/MCB.6.5.1722; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MITCHELL JA, 1990, EUR J PHARMACOL, V182, P573, DOI 10.1016/0014-2999(90)90058-E; MORRIS SM, 1989, ARCH BIOCHEM BIOPHYS, V273, P230, DOI 10.1016/0003-9861(89)90183-5; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; OBRIEN WE, 1981, BIOCHEMISTRY-US, V20, P2056, DOI 10.1021/bi00510a049; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; RATNER S, 1973, ADV ENZYMOL RAMB, V39, P1; SATO H, 1992, J LEUKOCYTE BIOL, V52, P161, DOI 10.1002/jlb.52.2.161; SAX HC, 1988, J SURG RES, V45, P50, DOI 10.1016/0022-4804(88)90020-0; SCHIMKE RT, 1964, J BIOL CHEM, V239, P136; STUEHR DJ, 1987, CANCER RES, V47, P5590; SU TS, 1981, BIOCHEMISTRY-US, V20, P2956, DOI 10.1021/bi00513a037; WERNER ER, 1991, BIOCHEM J, V280, P709, DOI 10.1042/bj2800709; WU GY, 1992, BIOCHEM J, V281, P45, DOI 10.1042/bj2810045; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	46	203	205	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1257	1261						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507106				2022-12-27	WOS:A1994MR22000077
J	GARCIACALVO, M; KNAUS, HG; MCMANUS, OB; GIANGIACOMO, KM; KACZOROWSKI, GJ; GARCIA, ML				GARCIACALVO, M; KNAUS, HG; MCMANUS, OB; GIANGIACOMO, KM; KACZOROWSKI, GJ; GARCIA, ML			PURIFICATION AND RECONSTITUTION OF THE HIGH-CONDUCTANCE, CALCIUM-ACTIVATED POTASSIUM CHANNEL FROM TRACHEAL SMOOTH-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-ACTIVATED K+ CHANNEL; RAT-BRAIN; CHARYBDOTOXIN BLOCK; XENOPUS-OOCYTES; TEA BLOCKADE; BINDING-SITE; S4 REGION; VOLTAGE; PROTEIN; TETRAETHYLAMMONIUM	The high-conductance Ca2+-aetivated K+ (maxi-K) channel from bovine tracheal smooth muscle was purified to apparent homogeneity by a combination of conventional chromatographic techniques and sucrose density gradient centrifugation. Fractions with the highest specific activity for binding of monoiodotyrosine charybdotoxin, [I-125]ChTX, were enriched approximately 2000-fold over the initial digitonin-solubilized material up to a specific activity of 1 nmol/mg protein. Silver staining after SDS-polyacrylamide gel electrophoresis of the fractions from the last step of the purification indicates that binding activity is correlated with a major component of the preparation that displays an apparent molecular weight of 62,000. Labeling the same preparation with, I-125-Bolton-Hunter reagent reveals the existence of both 62 (alpha)- and 31 (beta)-kDa subunits, in an apparent stoichiometry of 1:1, comigrating with binding activity. The beta subunit is heavily glycosylated. Deglycosylation studies indicate that the beta subunit represents the protein to which [I-125]ChTX is covalently incorporated in the presence of the bifunctional cross-linking reagent disuccinimidyl suberate. Binding of [I-125]ChTX to the purified ChTX receptor displayed the same pharmacological profile that has been found previously for toxin binding to native membranes, including inhibition by iberiotoxin, limbatustoxin, tetraethylamonium, potassium, cesium, and barium. The purified preparation was reconstituted into liposomes which were then fused with artificial lipid bilayers. Single channels were readily observed with a conductance of 235 picosiemens in 150 mm KCl that displayed selectivity for potassium over chloride and that were blocked by ChTX. The open probability of these channels was increased by depolarizing membrane potentials and by raising the internal calcium concentration. These data suggest that the maxi-K channel purified from tracheal smooth muscle is composed of two subunits.	MERCK SHARP & DOHME LTD, DEPT MEMBRANE BIOCHEM & BIOPHYS, RAHWAY, NJ 07065 USA	Merck & Company								ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ANDERSON CS, 1988, J GEN PHYSIOL, V91, P317, DOI 10.1085/jgp.91.3.317; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; AUGUSTE P, 1989, FEBS LETT, V248, P150, DOI 10.1016/0014-5793(89)80451-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CECCHI X, 1987, BIOPHYS J, V52, P707, DOI 10.1016/S0006-3495(87)83265-4; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; FRANK RN, 1975, ARCH BIOCHEM BIOPHYS, V171, P1, DOI 10.1016/0003-9861(75)90001-6; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GARCIA ML, 1991, J BIOENERG BIOMEMBR, V23, P615, DOI 10.1007/BF00785814; GARCIACALVO M, 1991, BIOCHEMISTRY-US, V30, P11157, DOI 10.1021/bi00110a020; GIANGIACOMO KM, 1992, BIOCHEMISTRY-US, V31, P6719, DOI 10.1021/bi00144a011; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HUGUES M, 1982, BIOCHEM BIOPH RES CO, V107, P1577, DOI 10.1016/S0006-291X(82)80180-0; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; KNAUS HG, 1993, BIOPHYS J, V64, pA199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATORRE R, 1986, ION CHANNEL RECONSTI, P431; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOGOTHETIS DE, 1992, NEURON, V8, P531, DOI 10.1016/0896-6273(92)90281-H; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; MILLER C, 1988, NEURON, V1, P1003, DOI 10.1016/0896-6273(88)90157-2; MILLER C, 1987, BIOPHYS J, V52, P123, DOI 10.1016/S0006-3495(87)83196-X; NOVICK J, 1991, Biophysical Journal, V59, p78A; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PARCEJ DN, 1989, BIOCHEM J, V257, P899, DOI 10.1042/bj2570899; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; REHM H, 1989, BIOCHEMISTRY-US, V28, P6455, DOI 10.1021/bi00441a044; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SCHMIDANTOMARCHI H, 1984, EUR J BIOCHEM, V142, P1, DOI 10.1111/j.1432-1033.1984.tb08242.x; SCOTT VES, 1990, J BIOL CHEM, V265, P20094; SEAGAR MJ, 1986, BIOCHEMISTRY-US, V25, P4051, DOI 10.1021/bi00362a010; SLAUGHTER RS, 1989, BIOCHEMISTRY-US, V28, P3995, DOI 10.1021/bi00435a055; SLAUGHTER RS, 1989, J CELL BIOL, V107, pA143; STOSCHECK CM, 1987, ANAL BIOCHEM, V160, P301, DOI 10.1016/0003-2697(87)90051-0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TRIMMER JS, 1991, P NATL ACAD SCI USA, V88, P10764, DOI 10.1073/pnas.88.23.10764; VAZQUEZ J, 1989, J BIOL CHEM, V264, P20902; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	53	164	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					676	682						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506261				2022-12-27	WOS:A1994MR21900106
J	MAHON, TM; ONEILL, LAJ				MAHON, TM; ONEILL, LAJ			STUDIES INTO THE EFFECT OF THE TYROSINE KINASE INHIBITOR HERBIMYCIN-A ON NF-KAPPA-B ACTIVATION IN T-LYMPHOCYTES - EVIDENCE FOR COVALENT MODIFICATION OF THE P50 SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; PROTEIN; INTERLEUKIN-1; PHOSPHORYLATION; ALPHA; CELLS; MECHANISM; INVITRO	The tyrosine kinase inhibitor herbimycin A was found to block NF-kappa B stimulation in response to interleukin-1 and phorbol 12-myristate 13-acetate in EL4.NOB-1 thymoma cells and phorbol 12-myristate 13-acetate in Jurkat T lymphoma cells. The effect appeared not to involve inhibition of tyrosine kinase activation as neither interleukin-1 nor phorbol 12-myristate 13-acetate induced major changes in tyrosine phosphorylation in EL4.NOB-1 or Jurkat cells, respectively, Herbimycin A did not interfere with I kappa B-alpha degradation, and in unstimulated cells, it modified NF-kappa B prior to chemical dissociation with sodium deoxycholate. Because herbimycin A is thiol-reactive, we suspected that the target was the p50 subunit of NF-kappa B, which has a key thiol at cysteine 62, Herbimycin A inhibited DNA binding when added to nuclear extracts prepared from stimulated cells, which were shown to contain high levels of p50. Incubation of herbimycin A with a mercaptoethanol attenuated the effect, Herbimycin A was also shown to react directly with p50, blocking its ability to bind to the NF-kappa B consensus sequence. However, a mutant form of p50 in which cysteine 62 was mutated to serine was insensitive to herbimycin A. Finally, we demonstrated that the compound inhibited the expression of interleukin-2 (an NF-kappa B-regulated gene) in EL4.NOB-1 cells, These data therefore suggest that herbimycin A inhibits NF-kappa B by modifying the p50 subunit on cysteine 62 in the NF-kappa B complex, which blocks DNA binding and NF-kappa B driven gene expression. The results urge caution in the use of herbimycin A as a specific tyrosine kinase inhibitor and suggest that the development of agents that selectively modify p50 may have potential as a means of inhibiting NF-kappa B-dependent gene transcription.	TRINITY COLL DUBLIN, DEPT BIOCHEM, DUBLIN 2, IRELAND; TRINITY COLL DUBLIN, INST BIOTECHNOL, DUBLIN 2, IRELAND	Trinity College Dublin; Trinity College Dublin								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BEG AA, 1993, GENE DEV, V7, P1564; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN P, 1995, BBA-GENE STRUCT EXPR, V1260, P167, DOI 10.1016/0167-4781(94)00186-7; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHOUCHI H, 1994, BIOCHEM J, V303, P499; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; EICHER DM, 1994, J IMMUNOL, V152, P2710; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FUKAZAWA H, 1994, FEBS LETT, V340, P155, DOI 10.1016/0014-5793(94)80127-4; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; GELFAND EW, 1985, NATURE, V315, P419, DOI 10.1038/315419a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GUPTA S, 1994, J BIOL CHEM, V269, P17349; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HSI ED, 1989, J BIOL CHEM, V264, P10836; IWASAKI T, 1992, FEBS LETT, V298, P240, DOI 10.1016/0014-5793(92)80067-Q; JOSHIBARVE SS, 1993, J BIOL CHEM, V268, P18018; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KERR LD, 1991, J BIOL CHEM, V5, P1464; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK E, 1992, J BIOL CHEM, V267, P239; MARTIN M, 1989, EUR J BIOCHEM, V148, P1; MATHEWS JR, 1993, NUC ACID RES, V21, P1727; MIZEL S, 1990, IMMUNOL TODAY, V11, P357; MOYNAGH PN, 1993, BIOCHEM J, V294, P343, DOI 10.1042/bj2940343; MUNOZ E, 1992, EUR J IMMUNOL, V22, P1391, DOI 10.1002/eji.1830220610; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; ONEILL LAJ, 1992, KIDNEY INT, V41, P546, DOI 10.1038/ki.1992.78; ONEILL LAJ, 1995, BBA-MOL CELL RES, V1266, P31, DOI 10.1016/0167-4889(94)00217-3; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P390; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITZ LM, 1991, TRENDS CELL BIOL, V1, P130; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SONG L, 1993, IMMUNOLOGY, V80, P222; STANLEY JB, 1990, J IMMUNOL, V145, P2189; STRICKER K, 1993, EUR J IMMUNOL, V23, P1475, DOI 10.1002/eji.1830230712; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; YONEDA T, 1993, J CLIN INVEST, V91, P2791, DOI 10.1172/JCI116521	54	122	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28557	28564		10.1074/jbc.270.48.28557	http://dx.doi.org/10.1074/jbc.270.48.28557			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499370	Green Published, hybrid			2022-12-27	WOS:A1995TH05600014
J	OLSON, MW; WANG, YX; ELDER, RH; KAGUNI, LS				OLSON, MW; WANG, YX; ELDER, RH; KAGUNI, LS			SUBUNIT STRUCTURE OF MITOCHONDRIAL-DNA POLYMERASE FROM DROSOPHILA EMBRYOS - PHYSICAL AND IMMUNOLOGICAL STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3'->5' EXONUCLEASE; SUBSTRATE-SPECIFICITY; CATALYTIC SUBUNIT; FUNCTIONAL ROLES; XENOPUS-LAEVIS; GAMMA; PROTEINS; POLYMERIZATION; IDENTIFICATION; MELANOGASTER	The subunit structure of mitochondrial DNA polymerase from Drosophila embryos has been examined by a combination of physical and immunological methods. A highly specific rabbit antiserum directed against the native enzyme was developed and found to recognize specifically its two subunits in immunoblot and immunoprecipitation analyses. That and the potent inhibition by the rabbit antiserum of the DNA polymerase and 3' --> 5' exonuclease activities of the nearly homogeneous mitochondrial DNA polymerase provide strong evidence for the physical association of the 3' --> 5' exonuclease with the two subunit enzyme. An immunoprecipitation analysis of crude enzyme fractions showed that the two subunits of Drosophila mitochondrial DNA polymerase are intact, and an in situ gel proteolysis analysis showed that they are structurally distinct. Template-primer DNA binding studies demonstrated formation of a stable and discrete enzyme DNA complex in the absence of accessory proteins. Photochemical cross-linking of the complexes by UV light indicated that the alpha but not the beta subunit of mitochondrial DNA polymerase makes close contact with DNA, and limited digestion of the native enzyme with trypsin showed that an similar to 65-kDa proteolytic fragment of the alpha subunit retains the DNA binding function.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University					NIGMS NIH HHS [GM45295] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045295] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; FOURY F, 1989, J BIOL CHEM, V264, P20552; FOURY F, 1989, EMBO J, V11, P2717; FREEMONT P S, 1986, Proteins Structure Function and Genetics, V1, P66, DOI 10.1002/prot.340010111; GRAY H, 1992, J BIOL CHEM, V267, P5835; HACKER KJ, 1994, J BIOL CHEM, V269, P24209; HUBSCHER U, 1979, P NATL ACAD SCI USA, V76, P2316, DOI 10.1073/pnas.76.5.2316; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; ITO J, 1990, NUCLEIC ACIDS RES, V18, P6716, DOI 10.1093/nar/18.22.6716; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KAGUNI LS, 1989, P NATL ACAD SCI USA, V86, P6469, DOI 10.1073/pnas.86.17.6469; KAGUNI LS, 1988, CANC CELLS EUKARYOTI, P425; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; LISHWE MA, 1982, ANAL BIOCHEM, V127, P453; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; OLSON MW, 1992, J BIOL CHEM, V267, P23136; REEMS JA, 1994, J BIOL CHEM, V269, P33091; SANJANWALA B, 1989, P NATL ACAD SCI USA, V86, P4421, DOI 10.1073/pnas.86.12.4421; THOMMES P, 1995, J BIOL CHEM, V270, P21137, DOI 10.1074/jbc.270.36.21137; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WEISSBACH A, 1979, ARCH BIOCHEM BIOPHYS, V198, P386, DOI 10.1016/0003-9861(79)90511-3; WERNETTE CM, 1988, BIOCHEMISTRY-US, V27, P6046, DOI 10.1021/bi00416a033; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WILLIAMS AJ, 1993, J BIOL CHEM, V268, P24855; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P860, DOI 10.1074/jbc.270.2.860; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	31	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28932	28937		10.1074/jbc.270.48.28932	http://dx.doi.org/10.1074/jbc.270.48.28932			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499423	hybrid			2022-12-27	WOS:A1995TH05600067
J	THOMPSON, J; HU, HZ; SCHARFF, J; NEVILLE, DM				THOMPSON, J; HU, HZ; SCHARFF, J; NEVILLE, DM			ANTI-CD3 SINGLE-CHAIN IMMUNOTOXIN WITH A TRUNCATED DIPHTHERIA-TOXIN AVOIDS INHIBITION BY PREEXISTING ANTIBODIES IN HUMAN BLOOD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INACTIVATION; FRAGMENT-A; RECEPTOR; CELLS; INTERLEUKIN-2; CONSTRUCTION; LYMPHOCYTES; CONJUGATE; KINETICS; MUTANTS	Diphtheria toxin (DT) is often used in the construction of immunotoxins. One potential problem using DT-based immunotoxins is the pre-existing anti-DT antibodies present in human blood due to vaccination. The present study examined the effect of human serum with pre-existing anti-DT antibodies on the toxicity of UCHT1-CRM9, an immunotoxin directed against CD3 molecules on T-lymphocytes. Sera with detectable anti DT antibodies at 1:100 or greater dilutions inhibited the immunotoxin toxicity. Experiments with radiolabeled UCHT1-CRM9 indicate that anti-DT antibodies partially block its binding to the cell surface as well as inhibit the translocation from the endosome to the cytosol. The inhibitory effect could be adsorbed using a full-length DT mutant or B-subfragment. A C-terminal truncation mutant could not adsorb the inhibitory effect, suggesting that the last 150 amino acids contain the epitope(s) recognized by the inhibitory antibodies. Therefore, an anti-CD3 single-chain immunotoxin, sFv-DT390, was made with a truncated DT. The IC50 of sFv-DT390 was 4.8 x 10(-11) M, 1/16 the potency of the divalent UCHT1-CRM9. More importantly, sFv-DT390 toxicity was only slightly affected by the anti-DT antibodies in human sera.	NIMH, MOLEC BIOL LAB, BIOPHYS CHEM SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								CHANG TM, 1977, J BIOL CHEM, V252, P1505; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; ESWORTHY RS, 1984, J BIOL CHEM, V259, P1496; GIANNINI G, 1984, NUCLEIC ACIDS RES, V12, P4063, DOI 10.1093/nar/12.10.4063; GRIMONT F, 1981, NUCLEIC ACID TECHNIQ, P252; HIGASHI K, 1989, J GEN VIROL, V70, P3171, DOI 10.1099/0022-1317-70-12-3171; JOHNSON S, 1991, METHOD ENZYMOL, V203, P88; JOHNSON VG, 1989, J BIOL CHEM, V264, P17739; KNECHTLE SJ, 1995, 7TH C EUR SOC ORG TR; KREITMAN RJ, 1993, LEUKEMIA, V7, P553; LASKE DW, 1994, J NEUROSURG, V80, P520, DOI 10.3171/jns.1994.80.3.0520; LEMAISTRE CF, 1992, BLOOD, V79, P2547; Murphy J R, 1988, Cancer Treat Res, V37, P123; NEVILLE DM, 1992, P NATL ACAD SCI USA, V89, P2585, DOI 10.1073/pnas.89.7.2585; NEVILLE DM, 1987, ANN NY ACAD SCI, V507, P155, DOI 10.1111/j.1749-6632.1987.tb45798.x; NEVILLE DM, 1993, J CONTROL RELEASE, V24, P133, DOI 10.1016/0168-3659(93)90173-3; NEVILLE DM, 1989, J BIOL CHEM, V264, P14653; NICHOLLS PJ, 1993, J BIOL CHEM, V268, P5302; PELCHENMATTHEWS A, 1991, J EXP MED, V173, P575, DOI 10.1084/jem.173.3.575; PLATANIAS LC, 1994, LEUKEMIA LYMPHOMA, V14, P257, DOI 10.3109/10428199409049676; SHALABY MR, 1992, J EXP MED, V175, P217, DOI 10.1084/jem.175.1.217; WILLIAMS DP, 1990, J BIOL CHEM, V265, P11885; WILLIAMS DP, 1987, PROTEIN ENG, V1, P493, DOI 10.1093/protein/1.6.493; YOULE RJ, 1982, J BIOL CHEM, V257, P1598	24	41	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28037	28041						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499288				2022-12-27	WOS:A1995TG21000013
J	KURAS, R; BUSCHLEN, S; WOLLMAN, FA				KURAS, R; BUSCHLEN, S; WOLLMAN, FA			MATURATION OF PRE-APOCYTOCHROME-F IN-VIVO - A SITE-DIRECTED MUTAGENESIS STUDY IN CHLAMYDOMONAS-REINHARDTII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANE POLYPEPTIDES; SULFATE-POLYACRYLAMIDE GELS; CYTOCHROME-F; ELECTROPHORETIC TRANSFER; PHOTOSYSTEM-II; HEME LYASE; CHLOROPLAST; MITOCHONDRIAL; BIOSYNTHESIS; PROTEINS	The biosynthesis of cytochrome fis a multistep process which requires processing of the precursor protein and covalent ligation of a c-heme upon membrane insertion of the protein, The crystal structure of a soluble form of cytochrome f has revealed that one axial ligand of the c-heme is provided by the alpha-amino group of Tyr(1) generated upon cleavage of the signal sequence from the precursor protein (Martinet S. E., Huang D., Szczepaniak A., Cramer W, A., and Smith J, L, (1994) Structure 2, 95-105), We therefore investigated, by site-directed mutagenesis, the possible interplay between protein processing and heme attachment to cytochrome fin Chlamydomonas reinhardtii. These modifications were performed by chloroplast transformation using a petA gene encoding the full-length precursor protein and also a truncated version lacking the C-terminal membrane anchor, We first substituted the two cysteinyl residues responsible for covalent ligation of the c-heme, by a valine and a leucine, and showed that heme binding is not a prerequisite for cytochrome f processing, In another series of experiments, we replaced the consensus cleavage site for the thylakoid processing peptidase, AQA, by an LQL sequence, The resulting transformants were nonphototrophic and displayed delayed processing of the precursor form of cytochrome f, but nonetheless both the precursor and processed forms showed heme binding and assembled in cytochrome b(6)f complexes, Thus, pre apocytochrome f adopts a suitable conformation for the cysteinyl residues to be substrates of the heme lyase and pre-holocytochrome f folds in an assembly-competent conformation, In the last series of experiments, we compared the rates of synthesis and degradation of the Various forms of cytochrome fin the four types of transformants under study: (i) the C terminus membrane anchor apparently down-regulates the rate of synthesis of cytochrome f and (ii) degradation of misfolded forms of cytochrome f occurs by a proteolytic system intimately associated with the thylakoid membranes.	INST BIOL PHYSICOCHIM, SERV PHOTOSYNTHESE, CNRS, URA 1187, F-75005 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS)								ANDERSON CM, 1991, PLANT PHYSIOL, V96, P584, DOI 10.1104/pp.96.2.584; ATTEIA A, 1992, J BIOL CHEM, V267, P226; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUSCHLEN S, 1991, FEBS LETT, V284, P257, DOI 10.1016/0014-5793(91)80698-3; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; CRAMER WA, 1994, J BIOENERG BIOMEMBR, V26, P31, DOI 10.1007/BF00763218; CRAMER WA, 1991, CURR TOP BIOENERG, V16, P179; DELEPELAIRE P, 1983, PHOTOBIOCH PHOTOBIOP, V6, P279; DELEPELAIRE P, 1984, EMBO J, V3, P701, DOI 10.1002/j.1460-2075.1984.tb01872.x; DELEPELAIRE P, 1985, BIOCHIM BIOPHYS ACTA, V809, P277, DOI 10.1016/0005-2728(85)90071-4; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; GRAY JC, 1992, PHOTOSYNTH RES, V34, P359, DOI 10.1007/BF00029811; Gray JC, 1984, CHLOROPLAST BIOGENES, P137; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HOWE G, 1995, MOL GEN GENET, V246, P156, DOI 10.1007/BF00294678; HOWE G, 1994, PHOTOSYNTH RES, V40, P147, DOI 10.1007/BF00019332; HOWE G, 1992, EMBO J, V11, P2789, DOI 10.1002/j.1460-2075.1992.tb05346.x; JOHNSON EM, 1990, CURR GENET, V17, P529, DOI 10.1007/BF00313083; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURAS R, 1995, BIOCHEMISTRY-US, V34, P7468, DOI 10.1021/bi00022a021; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; PIERRE Y, 1995, IN PRESS J BIOL CHEM; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; SMITH TA, 1994, J CELL BIOL, V126, P365, DOI 10.1083/jcb.126.2.365; STURM NR, 1994, MOL CELL BIOL, V14, P6171, DOI 10.1128/MCB.14.9.6171; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALLON O, 1993, EUR J BIOCHEM, V215, P351, DOI 10.1111/j.1432-1033.1993.tb18041.x; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WILLEY DL, 1988, PHOTOSYNTH RES, V17, P125, DOI 10.1007/BF00047685	34	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27797	27803		10.1074/jbc.270.46.27797	http://dx.doi.org/10.1074/jbc.270.46.27797			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499249	hybrid			2022-12-27	WOS:A1995TE73600060
J	BANKA, CL; BLACK, AS; CURTISS, LK				BANKA, CL; BLACK, AS; CURTISS, LK			LOCALIZATION OF AN APOLIPOPROTEIN-A-I EPITOPE CRITICAL FOR LIPOPROTEIN-MEDIATED CHOLESTEROL EFFLUX FROM MONOCYTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; MONOCLONAL-ANTIBODIES; CELLULAR CHOLESTEROL; ACYLTRANSFERASE; LECITHIN; MACROPHAGES; BINDING; MEMBRANE; AII; METABOLISM	The inverse correlation between plasma high density lipoprotein (HDL) levels and the risk for cardiovascular disease has been attributed in part to the role of HDL in facilitating the transport of cholesterol to the liver for catabolism. One component of this reverse cholesterol transport is removal of excess cholesterol from peripheral cells. An immunochemical approach was employed to evaluate the role of human apolipoprotein (apo) A-I in cellular cholesterol efflux and to test the hypothesis that discrete structural domains of the molecule mediate this function. Two apoA-I-specific monoclonal antibodies (AI-11 and AI-14) inhibited in vitro cellular cholesterol efflux from THP-1 monocytic cells to HDL or apoA-I proteoliposomes by approximately 50%. Six other antibodies had no effect although three of these bound significant proportions of the apoA-I proteoliposomes. Antibody AI-11 binds apoA-I amino acid residues 96-111 (Banka, C. L., Bonnet, D. J., Black, A. S., Smith, R. S., and Curtiss, L. K, (1991) J. Biol. Chem. 266, 23886-23892). The AI-14 epitope was localized to residues 74-105. Therefore, the two antibodies that inhibited HDL promotion of cellular cholesterol efflux bound overlapping but distinct regions of the apoA-I molecule.			BANKA, CL (corresponding author), SCRIPPS RES INST, RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043815, R29HL050060] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50060, HL-43815] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANTHARAMAIAH GM, 1990, ARTERIOSCLEROSIS, V10, P95, DOI 10.1161/01.ATV.10.1.95; BADIMON JJ, 1992, CIRCULATION, V86, P86; BANKA CL, 1991, J LIPID RES, V32, P35; BANKA CL, 1991, J BIOL CHEM, V266, P23886; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; BURING JE, 1992, CIRCULATION, V85, P22, DOI 10.1161/01.CIR.85.1.22; CHEN CH, 1982, J LIPID RES, V23, P680; CURTISS LK, 1982, J BIOL CHEM, V257, P5213; CURTISS LK, 1983, J CLIN INVEST, V72, P1427, DOI 10.1172/JCI111099; CURTISS LK, 1988, J BIOL CHEM, V263, P13779; CURTISS LK, 1987, J CLIN INVEST, V80, P367, DOI 10.1172/JCI113081; CURTISS LK, 1990, ATHEROSCLER REV, P217; CURTISS LK, 1987, NIH872646 PUBL, P363; CURTISS LK, 1985, J BIOL CHEM, V260, P282; GAMBLE W, 1978, J LIPID RES, V19, P1068; GLOMSET JA, 1968, J LIPID RES, V9, P155; HARA H, 1991, J BIOL CHEM, V266, P3080; JJONAS A, 1990, J BIOL CHEM, V265, P22123; JJONAS A, 1993, J BIOL CHEM, V268, P1596; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KAWANO M, 1993, BIOCHEMISTRY-US, V32, P5025, DOI 10.1021/bi00070a008; KINOSHITA M, 1983, J BIOCHEM-TOKYO, V94, P615, DOI 10.1093/oxfordjournals.jbchem.a134395; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; MAHLBERG FH, 1991, J BIOL CHEM, V266, P19930; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; MENDEZ AJ, 1992, CIRCULATION, V86, P7; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MINNICH A, 1992, J BIOL CHEM, V267, P16553; OHTA T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P119, DOI 10.1016/0005-2760(92)90083-8; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; ROUSSEAUX J, 1980, MOL IMMUNOL, V17, P469, DOI 10.1016/0161-5890(80)90087-5; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; SEGREST JP, 1992, J LIPID RES, V33, P141; VONECKARDSTEIN A, 1990, J BIOL CHEM, V265, P8610; YOUNG SG, 1986, CLIN CHEM, V32, P1484	41	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10288	10297						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511599				2022-12-27	WOS:A1994NF01700020
J	HSU, HY; NICHOLSON, AC; HAJJAR, DP				HSU, HY; NICHOLSON, AC; HAJJAR, DP			BASIC FIBROBLAST GROWTH FACTOR-INDUCED LOW-DENSITY-LIPOPROTEIN RECEPTOR TRANSCRIPTION AND SURFACE EXPRESSION - SIGNAL-TRANSDUCTION PATHWAYS MEDIATED BY THE BFGF RECEPTOR TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; DEPENDENT PROTEIN-KINASE; CHOLESTEROL ESTER HYDROLASE; STEROL REGULATORY ELEMENT; CULTURED FIBROBLASTS; HAMSTER FIBROBLASTS; LIPID-ACCUMULATION; ENDOTHELIAL-CELLS; ADENYLATE-CYCLASE; MAMMALIAN-CELLS	Basic fibroblast growth factor (bFGF) has been implicated in the regulation of cell proliferation and cholesterol metabolism. In studies reported herein, we show bFGF increases low density lipoprotein (LDL) binding, uptake, and degradation in arterial smooth muscle cells in a dose-dependent manner. This increase was paralleled by an increase in LDL receptor mRNA steady state levels. To determine if bFGF activated transcription of the LDL receptor gene, we transiently transfected smooth muscle cells with a gene construct consisting of the 5'-upstream promoter region of the DNA from the human LDL receptor gene ligated to a plasmid containing the luciferase gene. We found that bFGF and a protein kinase C (PKC) activator, phorbol 12-myristate 13-acetate, significantly induced luciferase activity driven by the LDL receptor promoter, whereas 25-hydroxycholesterol reduced the luciferase activity in bFGF-stimulated cells. These findings show that bFGF and PKC are inducing LDL receptor gene transcription. We also evaluated potential signal transduction pathways induced by bFGF to establish the mechanism(s) leading to the activation of the LDL receptor gene. Activation of the activity of FGF receptor tyrosine kinase in smooth muscle cells by ligand binding resulted in tyrosine phosphorylation of one of the FGF receptors and a 90-kDa-protein as well as increased tyrosine phosphorylation of phospholipase C-gamma. Parallel observations were made in that increased PKC and protein kinase A activities occurred with bFGF as compared with control cells. Inhibitors of receptor tyrosine kinase and other protein kinases significantly reduced transcription and surface expression of LDL receptor. Finally, several key enzymes that are central to the regulation of LDL-cholesteryl ester metabolism were also studied in bFGF-stimulated cells. An increase in acyl-CoA:cholesterol acyltransferase activity and cholesterol esterification was observed with bFGF stimulation, but there was no effect on the lysosomal or cytoplasmic cholesteryl ester hydrolase activities. Our findings suggest potential signal transduction pathways activated by bFGF which play a role in regulating transcription and surface expression of the LDL receptor.	CORNELL UNIV,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT PATHOL,NEW YORK,NY 10021	Cornell University; Cornell University					NCRR NIH HHS [RR-00085] Funding Source: Medline; NHLBI NIH HHS [HL-46403, HL-07423] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000085] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046403, T32HL007423] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BAIRD A, 1990, NATURE, V348, P344, DOI 10.1038/348344a0; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHAIT A, 1988, BIOCHIM BIOPHYS ACTA, V960, P183, DOI 10.1016/0005-2760(88)90063-X; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JK, 1988, IN VITRO CELL DEV B, V24, P199; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5894; COLBRAN RJ, 1986, FEBS LETT, V201, P257, DOI 10.1016/0014-5793(86)80619-6; CORTON JM, 1992, EUR J BIOCHEM, V204, P203, DOI 10.1111/j.1432-1033.1992.tb16625.x; DAVIES PF, 1982, BIOCHIM BIOPHYS ACTA, V712, P26, DOI 10.1016/0005-2760(82)90080-7; DAVIS LG, 1986, BASIC METODS MOL BIO; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GHOSH S, 1989, LIPIDS, V24, P733, DOI 10.1007/BF02535213; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GROVE RI, 1991, J LIPID RES, V32, P1889; HAJJAR DP, 1980, AM J PATHOL, V100, P683; HAJJAR DP, 1982, J CLIN INVEST, V70, P479, DOI 10.1172/JCI110639; HAJJAR DP, 1991, AM J PATHOL, V139, P1195; HAJJAR DP, 1983, J LIPID RES, V24, P1176; HAJJAR DP, 1985, J BIOL CHEM, V260, P6124; HALEY NJ, 1980, J LIPID RES, V21, P961; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MAGNALDO I, 1989, CELL SIGNAL, V1, P507, DOI 10.1016/0898-6568(89)90035-1; MAGNALDO I, 1986, J BIOL CHEM, V261, P6916; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARSHALL PJ, 1985, ANAL BIOCHEM, V145, P192, DOI 10.1016/0003-2697(85)90347-1; MAZZONE T, 1990, J BIOL CHEM, V265, P5145; MAZZONE T, 1989, J BIOL CHEM, V264, P1787; MIDDLETON B, 1992, BIOCHEM J, V282, P853, DOI 10.1042/bj2820853; MOORBY CD, 1992, ATHEROSCLEROSIS, V97, P21, DOI 10.1016/0021-9150(92)90047-K; NANBERG E, 1990, J CELL PHYSIOL, V143, P232, DOI 10.1002/jcp.1041430206; NICHOLSON AC, 1992, J BIOL CHEM, V267, P25982; OSTLUND RE, 1991, JAMA-J AM MED ASSOC, V266, P1937, DOI 10.1001/jama.266.14.1937; OWEN CH, 1991, ARTERIOSCLER THROMB, V11, P1447; PARIS S, 1991, ANN NY ACAD SCI, V638, P139, DOI 10.1111/j.1749-6632.1991.tb49024.x; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PRESTA M, 1991, CELL REGUL, V2, P719, DOI 10.1091/mbc.2.9.719; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SMITH JR, 1988, J BIOL CHEM, V263, P18480; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; STOUT RW, 1983, ATHEROSCLEROSIS, V46, P13, DOI 10.1016/0021-9150(83)90159-4; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; SUGDEN PH, 1976, BIOCHEM J, V159, P423, DOI 10.1042/bj1590423; TAM SP, 1991, J BIOL CHEM, V266, P16764; THERET N, 1990, BIOCHEM BIOPH RES CO, V173, P1361, DOI 10.1016/S0006-291X(05)80938-6; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WANG XD, 1993, J BIOL CHEM, V268, P14497; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; ZWILLER J, 1991, ONCOGENE, V6, P219	65	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9213	9220						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510705				2022-12-27	WOS:A1994NB41100087
J	ITOH, H; IDE, H; ISHIKAWA, N; NAWA, Y				ITOH, H; IDE, H; ISHIKAWA, N; NAWA, Y			MAST-CELL PROTEASE INHIBITOR, TRYPSTATIN, IS A FRAGMENT OF INTER-ALPHA-TRYPSIN INHIBITOR LIGHT-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; PROTEINASE-INHIBITOR; CHYMOTRYPSIN-TYPE; SERINE PROTEASES; MESSENGER-RNA; RAT; ALPHA-1-MICROGLOBULIN; TRYPTASE; GENE; SEQUENCE	The mast cell protease inhibitor trypstatin was purified from rat peritoneal mast cells (Kido, H., Yokogoshi, Y., and Katunuma, N. (1988) J. Biol. Chem. 263, 18104-18107). We noticed that trypstatin could possibly be identical with the second half of inter-alpha-trypsin inhibitor light chain (M-LC), because only 5 amino acid residues of trypstatin are different from the sequence deduced from the recently reported rat ITI-LC mRNA. Southern blot analysis revealed that a 170-base pair probe corresponding to the second half of rat ITI-LC hybridized to the digested rat genomic DNAs only at single bands even in low stringency conditions. Similarly, a 170-base pair probe corresponding to the human counterpart, which differs by 10 deduced amino acids from the rat probe, also hybridized to the digested rat genomic DNAs only at single bands at the same positions and same conditions. These results suggest that rat trypstatin is genetically identical with rat ITI-LC. ITI-LC/trypstatin mRNA was not detected in rat peritoneal mast cells by RNA blot nor by reverse transcription-polymerase chain reaction analysis. Since trypstatin was purified from rat peritoneal mast cells and the cells were immunohistochemically positive with anti M-LC antibody, ITI-LC/trypstatin may be taken up into mast cell granules from the serum but may not be generated by mast cells themselves.	MIYAZAKI MED COLL,DEPT PARASITOL,MIYAZAKI 88916,JAPAN	University of Miyazaki			Nawa, Yukifumi/I-1147-2019	Nawa, Yukifumi/0000-0002-0206-5196				AKERSTROM B, 1990, TRENDS BIOCHEM SCI, V15, P240, DOI 10.1016/0968-0004(90)90037-C; ATKINS FM, 1987, ANN ALLERGY, V59, P44; CREIGHTON TE, 1987, J MOL BIOL, V194, P11, DOI 10.1016/0022-2836(87)90711-X; DIARRAMEHRPOUR M, 1990, EUR J BIOCHEM, V191, P131, DOI 10.1111/j.1432-1033.1990.tb19102.x; GALLI SJ, 1990, LAB INVEST, V62, P5; KASTERN W, 1986, J BIOL CHEM, V261, P5070; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; KIDO H, 1985, BIOCHEM BIOPH RES CO, V132, P613, DOI 10.1016/0006-291X(85)91177-5; KIDO H, 1988, J BIOL CHEM, V263, P18104; KIDO H, 1985, ARCH BIOCHEM BIOPHYS, V239, P436, DOI 10.1016/0003-9861(85)90709-X; KIDO H, 1986, J IMMUNOL, V136, P1061; LINDQVIST A, 1992, BIOCHIM BIOPHYS ACTA, V1130, P63, DOI 10.1016/0167-4781(92)90462-9; MCKEEHAN WL, 1986, J BIOL CHEM, V261, P5378; NAWA Y, 1979, CELL IMMUNOL, V42, P225, DOI 10.1016/0008-8749(79)90188-6; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; ODUM L, 1987, CLIN CHIM ACTA, V162, P189, DOI 10.1016/0009-8981(87)90450-5; ODUM L, 1989, APMIS, V97, P357, DOI 10.1111/j.1699-0463.1989.tb00800.x; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; SALIER JP, 1987, P NATL ACAD SCI USA, V84, P963; SALIER JP, 1987, 2ND P INT S PULM EMP, P159; Sambrook J, 1989, MOL CLONING LABORATO; SCHREITMULLER T, 1987, BIOL CHEM HOPPESEYLE, V368, P8272; SCHWARTZ LB, 1983, J IMMUNOL, V130, P1891; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; SJOBERG EM, 1992, ARCH BIOCHEM BIOPHYS, V295, P217, DOI 10.1016/0003-9861(92)90509-U; TAKAGI K, 1980, CLIN CHIM ACTA, V108, P277; TAVAKKOL A, 1991, BIOCHIM BIOPHYS ACTA, V1088, P47, DOI 10.1016/0167-4781(91)90152-C; YOSHIDA E, 1991, INFLAMMATION, V15, P71, DOI 10.1007/BF00917911; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	30	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3818	3822						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508921				2022-12-27	WOS:A1994MV63100100
J	MATZENBACH, B; MAULET, Y; SEFTON, L; COURTIER, B; AVNER, P; GUENET, JL; BETZ, H				MATZENBACH, B; MAULET, Y; SEFTON, L; COURTIER, B; AVNER, P; GUENET, JL; BETZ, H			STRUCTURAL-ANALYSIS OF MOUSE GLYCINE RECEPTOR ALPHA-SUBUNIT GENES - IDENTIFICATION AND CHROMOSOMAL LOCALIZATION OF A NOVEL VARIANT, ALPHA(4)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GATED ION CHANNELS; RAT SPINAL-CORD; FUNCTIONAL EXPRESSION; BETA-SUBUNIT; X-CHROMOSOME; BINDING SUBUNIT; MESSENGER-RNA; BRAIN; CLONING	The inhibitory glycine receptor is a ligand-gated ion channel protein that occurs in different developmentally regulated-isoforms in the mammalian central nervous system. Here, we have analyzed genomic clones covering the coding regions of the murine glycine receptor alpha1 and alpha2 subunit genes. Both genes contain eight intronic regions with precisely conserved boundaries. The same structure was also found for seven exons of a third homologous gene, alpha4, identified during screening. The predicted alpha4 polypeptide displays very high homology to the alpha2 subunit. Like the alpha2 gene, the alpha4 gene maps to the mouse X chromosome. Our data indicate that the genomic organization of glycine receptor alpha subunit genes is conserved during evolution.	MAX PLANCK INST BRAIN RES,DEPT NEUROCHEM,DEUTSCHORDENSTR 46,D-60528 FRANKFURT 71,GERMANY; UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,D-69120 HEIDELBERG,GERMANY; INST PASTEUR,UNITE GENET MOLEC MURINE,F-75724 PARIS 15,FRANCE; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Max Planck Society; Ruprecht Karls University Heidelberg; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Cancer Research UK			Maulet, Yves/AAC-3207-2019	Maulet, Yves/0000-0002-3162-0435				AKAGI H, 1991, FEBS LETT, V281, P160, DOI 10.1016/0014-5793(91)80383-E; AMAR L C, 1988, Genomics, V2, P220, DOI 10.1016/0888-7543(88)90006-7; Aprison MH, 1978, ADV NEUROCHEM, V3, P203; AVNER P, 1988, TRENDS GENET, V4, P18, DOI 10.1016/0168-9525(88)90123-0; AVNER P, 1987, P NATL ACAD SCI USA, V84, P5330, DOI 10.1073/pnas.84.15.5330; BECKER CM, 1988, EMBO J, V7, P3717, DOI 10.1002/j.1460-2075.1988.tb03255.x; BECKER CM, 1986, J NEUROSCI, V6, P1358; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BETZ H, 1992, Q REV BIOPHYS, V25, P381, DOI 10.1017/S0033583500004340; BETZ H, 1990, BIOCHEMISTRY-US, V29, P3591, DOI 10.1021/bi00467a001; BORMANN J, 1993, EMBO J, V12, P3729, DOI 10.1002/j.1460-2075.1993.tb06050.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROWN SDM, 1992, MAMM GENOME, V2, P5274; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COUTURIER S, 1990, J BIOL CHEM, V265, P17660; DERRY JMJ, 1991, GENOMICS, V10, P593, DOI 10.1016/0888-7543(91)90441-G; ECONS MJ, 1990, GENOMICS, V7, P439, DOI 10.1016/0888-7543(90)90180-3; FEINBERG A, 1984, ANAL BIOCHEM, V137, P66; FUJITA M, 1991, BRAIN RES, V560, P23, DOI 10.1016/0006-8993(91)91210-R; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GRAHAM D, 1985, BIOCHEMISTRY-US, V24, P990, DOI 10.1021/bi00325a027; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; HOCH W, 1989, NEURON, V3, P339, DOI 10.1016/0896-6273(89)90258-4; KUHSE J, 1990, NEURON, V5, P867, DOI 10.1016/0896-6273(90)90346-H; KUHSE J, 1991, FEBS LETT, V283, P73, DOI 10.1016/0014-5793(91)80557-J; KUHSE J, 1990, J BIOL CHEM, V265, P22317; LANGOSCH D, 1990, EUR J BIOCHEM, V194, P1, DOI 10.1111/j.1432-1033.1990.tb19419.x; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LASHAM A, 1991, J NEUROCHEM, V57, P352, DOI 10.1111/j.1471-4159.1991.tb02135.x; MALOSIO ML, 1991, J BIOL CHEM, V266, P2048; MALOSIO ML, 1991, EMBO J, V10, P2401, DOI 10.1002/j.1460-2075.1991.tb07779.x; NEF P, 1984, P NATL ACAD SCI-BIOL, V81, P7975, DOI 10.1073/pnas.81.24.7975; NODA M, 1983, NATURE, V305, P818, DOI 10.1038/305818a0; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1991, NEUROSCIENCE, V43, P381, DOI 10.1016/0306-4522(91)90302-5; SAWRUK E, 1988, FEBS LETT, V235, P40, DOI 10.1016/0014-5793(88)81230-4; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SCHMIEDEN V, 1992, EMBO J, V11, P2025, DOI 10.1002/j.1460-2075.1992.tb05259.x; SCHMIEDEN V, 1993, SCIENCE, V262, P256, DOI 10.1126/science.8211147; SCHRODER S, 1991, BIOCHEMISTRY-US, V30, P42, DOI 10.1021/bi00215a007; SIDDIQUE T, 1989, NUCLEIC ACIDS RES, V17, P1785, DOI 10.1093/nar/17.4.1785; SOMMER B, 1990, DNA CELL BIOL, V9, P561, DOI 10.1089/dna.1990.9.561; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; TAKAHASHI T, 1992, NEURON, V9, P1155, DOI 10.1016/0896-6273(92)90073-M; VANDENBERG RJ, 1992, NEURON, V9, P491, DOI 10.1016/0896-6273(92)90186-H; VANDENBERG RJ, 1992, P NATL ACAD SCI USA, V89, P1764; WADA K, 1988, SCIENCE, V240, P330, DOI 10.1126/science.2832952	53	116	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2607	2612						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7507926				2022-12-27	WOS:A1994MV43200040
J	HOTTIGER, M; PODUST, VN; THIMMIG, RL; MCHENRY, C; HUBSCHER, U				HOTTIGER, M; PODUST, VN; THIMMIG, RL; MCHENRY, C; HUBSCHER, U			STRAND DISPLACEMENT ACTIVITY OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE HETERODIMER AND ITS INDIVIDUAL SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-DELTA; CALF THYMUS; VIRAL-DNA; ENZYME; EXPRESSION; INFECTION; PROTEIN; BINDING; PRODUCT; EPSILON	By using a DNA substrate with defined gap size, we found that human immunodeficiency virus type 1 reverse transcriptase (HIV-RT) was able to perform strand displacement DNA synthesis. This activity was not affected first by calf thymus proliferating cell nuclear antigen and replication factor C and second by Escherichia coli single-stranded DNA-binding protein, which together allow DNA polymerase 8 to perform strand displacement DNA synthesis (Podust, V., and Hubscher, U. (1993) Nucleic Acids Res. 21, 841-846). 3'-Azido-2',3'-dideoxythymidine triphosphate inhibited displacement completely, indicating that DNA synthesis is required for this reaction. The HIV-RT p66 polypeptide alone could perform limited strand displacement DNA synthesis, whereas the HIV-RT p51 polypeptide was completely inactive, likely due to its inability to replicate extensively on a M13 DNA template. On the other hand the HIV-RT p51 polypeptide enhanced the strand displacement activity of the HIV-RT p66 subunit at a molar ratio of 4:1, mainly by chasing short products into longer ones. Furthermore, kinetic experiments after complementation of HIV-RT p66 with HIV-RT p5l indicated that HIV-RT p51 can restore rate and extent of strand displacement activity by HIV-RT p66 compared with the HIV-RT heterodimer p66/p5l, suggesting a function of the 51-kDa polypeptide.	UNIV ZURICH IRCHEL,DEPT VET BIOCHEM,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262	University of Zurich; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Hottiger, Michael O./J-7747-2013	Hottiger, Michael O./0000-0002-7323-2270	NIAID NIH HHS [R01 AI126600] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; BATHURST IC, 1990, BIOCHEM BIOPH RES CO, V171, P589, DOI 10.1016/0006-291X(90)91187-W; BOONE LR, 1981, J VIROL, V37, P117, DOI 10.1128/JVI.37.1.117-126.1981; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARNEAU P, 1991, J VIROL, V65, P2415, DOI 10.1128/JVI.65.5.2415-2421.1991; CULLMANN G, 1993, IN PRESS GENE AMST; DISTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; ELDIRANIDIAB R, 1992, FEBS LETT, V301, P23; HAFKEMEYER P, 1991, P NATL ACAD SCI USA, V88, P5262, DOI 10.1073/pnas.88.12.5262; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MCHENRY CS, 1989, MOL BIOL CHROMOSOME, P97; PFEIFFER P, 1983, CELL, V33, P781, DOI 10.1016/0092-8674(83)90020-X; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; PODUST VN, 1992, CHROMOSOMA, V102, P133; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROBINSON HL, 1990, J VIROL, V64, P4836, DOI 10.1128/JVI.64.10.4836-4841.1990; Sambrook J, 1989, MOL CLONING LABORATO; SHANK PR, 1978, J VIROL, V25, P104, DOI 10.1128/JVI.25.1.104-104.1978; SOENGAS MS, 1992, EMBO J, V11, P4227, DOI 10.1002/j.1460-2075.1992.tb05517.x; STARNES MC, 1988, J BIOL CHEM, V263, P5132; THIMMIG RL, 1993, J BIOL CHEM, V268, P16528; THOMMES P, 1992, J BIOL CHEM, V267, P6063; VARMUS H, 1985, RNA TUMOR VIRUSES MO, P369; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WEISER T, 1991, J BIOL CHEM, V266, P10420	30	52	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					986	991						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507115				2022-12-27	WOS:A1994MR22000035
J	CARTER, MS; DOSKOW, J; MORRIS, P; LI, SL; NHIM, RP; SANDSTEDT, S; WILKINSON, MF				CARTER, MS; DOSKOW, J; MORRIS, P; LI, SL; NHIM, RP; SANDSTEDT, S; WILKINSON, MF			A REGULATORY MECHANISM THAT DETECTS PREMATURE NONSENSE CODONS IN T-CELL RECEPTOR TRANSCRIPTS IN-VIVO IS REVERSED BY PROTEIN-SYNTHESIS INHIBITORS IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA MESSENGER-RNA; VARIABLE-REGION GENES; CHAIN GENES; TRANSLATION; MUTATIONS; EXPRESSION; STABILITY; ACCUMULATION; DIVERSITY; INDUCTION	Gene rearrangement during the ontogeny of T- and B-cells generates an enormous repertoire of T-cell receptor (TCR) and immunoglobulin (Ig) genes, Because of the error-prone nature of this rearrangement process, two thirds of rearranged TCR and Ig genes are expected to be out-of-frame and thus contain premature terminations codons (ptcs), We performed sequence analysis of reverse transcriptase-polymerase chain reaction products from fetal and adult thymus and found that newly transcribed TCR-beta pre-mRNAs (intron-bearing) are frequently derived from ptc-bearing genes but such transcripts rarely accumulate as mature (fully spliced) TCR-beta transcripts. Transfection studies in the SL12.4 T-cell line showed that the presence of a ptc in any of several TCR-beta exons triggered a decrease in mRNA levels, Ptc-bearing TCR-beta transcripts were selectively depressed in levels in a cell clone that contained both an in-frame and an out-of-frame gene, thus demonstrating the allelic specificity of this down-regulatory response, Protein synthesis inhibitors with different mechanism of action (anisomysin, cycloheximide, emetine, pactamycin, puromycin, and polio virus) all reversed the down-regulatory response, Ptc-bearing transcripts were induced within 0.5 h after cycloheximide treatment, The reversal by protein synthesis inhibitors was not restricted to lymphoid cells, as shown with TCR-beta and beta-globin constructs transfected in HeLa cells, Collectively, the data suggest that the ptc-mediated mRNA decay pathway requires an unstable protein, a ribosome, or a ribosome-like entity, Protein synthesis inhibitors may be useful tools toward elucidating the molecular mechanism of ptc-mediated mRNA decay, an enigmatic response that can occur in the nuclear fraction of mammalian cells.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT IMMUNOL,HOUSTON,TX 77030; OREGON HLTH SCI UNIV,MOLEC MICROBIOL & IMMUNOL GRAD PROGRAM,PORTLAND,OR 97201	University of Texas System; UTMD Anderson Cancer Center; Oregon Health & Science University			Li, Shulin/D-6478-2011; Sandstedt, Sara A/A-3001-2010		NIGMS NIH HHS [GM39586] Funding Source: Medline; PHS HHS [T32 ML07781] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039586, R29GM039586] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARKER GF, 1994, MOL CELL BIOL, V14, P1986, DOI 10.1128/MCB.14.3.1986; BARTH RK, 1985, NATURE, V316, P517, DOI 10.1038/316517a0; BASERGA SJ, 1992, P NATL ACAD SCI USA, V89, P2935, DOI 10.1073/pnas.89.7.2935; BAUMANN B, 1985, EMBO J, V4, P351, DOI 10.1002/j.1460-2075.1985.tb03636.x; BEHLKE MA, 1985, SCIENCE, V229, P566, DOI 10.1126/science.3875151; BELGRADER P, 1994, MOL CELL BIOL, V14, P6326, DOI 10.1128/MCB.14.9.6326; BELGRADER P, 1993, P NATL ACAD SCI USA, V90, P482, DOI 10.1073/pnas.90.2.482; BELGRADER P, 1994, MOL CELL BIOL, V14, P8219, DOI 10.1128/MCB.14.12.8219; CHENG J, 1990, Molecular and Cellular Biology, V10, P5215; CHENG J, 1994, MOL CELL BIOL, V14, P6317, DOI 10.1128/MCB.14.9.6317; CHENG J, 1993, MOL CELL BIOL, V13, P1892, DOI 10.1128/MCB.13.3.1892; CHORNEY MJ, 1990, MOL CELL BIOL, V10, P243, DOI 10.1128/MCB.10.1.243; CHOU HS, 1987, P NATL ACAD SCI USA, V84, P1992, DOI 10.1073/pnas.84.7.1992; CONNOR A, 1994, J BIOL CHEM, V269, P25178; CUI Y, 1995, GENE DEV, V9, P423, DOI 10.1101/gad.9.4.423; DAAR IO, 1988, MOL CELL BIOL, V8, P802, DOI 10.1128/MCB.8.2.802; ENSSLE J, 1993, P NATL ACAD SCI USA, V90, P10091, DOI 10.1073/pnas.90.21.10091; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; FIELDS BN, 1991, FUNDAMENTAL VIROLOGY, P409; GASCOIGNE NRJ, 1990, J BIOL CHEM, V265, P9296; GASCOIGNE NRJ, 1984, NATURE, V310, P387, DOI 10.1038/310387a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HE F, 1995, GENE DEV, V9, P437, DOI 10.1101/gad.9.4.437; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOOD L, 1985, CELL, V40, P225, DOI 10.1016/0092-8674(85)90133-3; JACK HM, 1989, EUR J IMMUNOL, V19, P843, DOI 10.1002/eji.1830190510; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P96; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; KUGLER W, 1995, NUCLEIC ACIDS RES, V23, P413, DOI 10.1093/nar/23.3.413; LEE NE, 1988, J IMMUNOL, V140, P1665; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LOZANO F, 1994, EMBO J, V13, P4617, DOI 10.1002/j.1460-2075.1994.tb06783.x; MACLEOD CL, 1984, CANCER RES, V44, P1784; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MAQUAT LE, 1995, RNA, V1, P453; MENON KP, 1994, CELL MOL BIOL, V40, P999; NAEGER LK, 1992, GENE DEV, V6, P1107, DOI 10.1101/gad.6.6.1107; PELTZ SW, 1994, PROG NUCLEIC ACID RE, V47, P271, DOI 10.1016/S0079-6603(08)60254-8; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; QIAN L, 1993, J IMMUNOL, V151, P6801; QIAN LA, 1993, MOL CELL BIOL, V13, P1686, DOI 10.1128/MCB.13.3.1686; SIMPSON SB, 1994, MOL CELL BIOL, V14, P1835, DOI 10.1128/MCB.14.3.1835; SINGER PA, 1986, P NATL ACAD SCI USA, V83, P7018, DOI 10.1073/pnas.83.18.7018; TUAILLON N, 1993, P NATL ACAD SCI USA, V90, P3720, DOI 10.1073/pnas.90.8.3720; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; WILKINSON M, 1990, NUCLEIC ACIDS RES, V19, P679; WILKINSON MF, 1988, EMBO J, V7, P101, DOI 10.1002/j.1460-2075.1988.tb02788.x; WILKINSON MF, 1988, EUR J IMMUNOL, V18, P873, DOI 10.1002/eji.1830180607; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796	53	253	259	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28995	29003		10.1074/jbc.270.48.28995	http://dx.doi.org/10.1074/jbc.270.48.28995			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499432	hybrid			2022-12-27	WOS:A1995TH05600076
J	CHUNG, CY; ZARDI, L; ERICKSON, HP				CHUNG, CY; ZARDI, L; ERICKSON, HP			BINDING OF TENASCIN-C TO SOLUBLE FIBRONECTIN AND MATRIX FIBRILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; HEXABRACHION TENASCIN; CELL-ADHESION; PROTEIN; LOCALIZATION; EXPRESSION; TISSUES; DOMAINS; TUMORS	The small splice variant of tenascin-C (TN) has eight fibronectin type III (FN3) domains. The major large splice variant has three (in chicken) or seven (in human) additional FN3 domains inserted between domains five and six, Chiquet-Ehrismann et al, (Chiquet-Ehrismann, R,, Matsuoka, Y,, Hofer, U,, Spring, J,, Bernasconi, C,, and Chiquet, M, (1991, Cell Regul. 2, 927-938) demonstrated that the small variant bound preferentially to fibronectin in enzyme-linked immunosorbent assay, and only the small variant was incorporated into the matrix by cultures of chicken fibroblasts. Here we have studied human TN, and confirmed that the small variant binds preferentially to purified fibronectin and to fibronectin-containing extracellular matrix. Thus this differential binding appears to be conserved across vertebrate species, Using bacterial expression proteins, we mapped the major binding site to the third FN3 domain of TN, Consistent with this mapping, a monoclonal antibody against an epitope in this domain did not stain TN segments bound to cell culture matrix fibrils, The enhanced binding of the small TN variant suggests the existence of another, weak binding site probably in FN3 domains 6-8, which is only positioned to bind fibronectin in the small splice variant. This binding of domains 6-8 may involve a third molecule present in matrix fibrils, as the enhanced binding of small TN was much more prominent to matrix fibrils than to purified fibronectin.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; IST NAZL RIC CANC,CELL BIOL LAB,I-16132 GENOA,ITALY	Duke University; University of Genoa; IRCCS AOU San Martino IST			Chung, Chang Y/G-7522-2012		NCI NIH HHS [R37 CA47056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA047056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUKHIL I, 1993, J BIOL CHEM, V268, P2542; AUKHIL I, 1990, MATRIX, V10, P98, DOI 10.1016/S0934-8832(11)80176-9; CHIQUET M, 1984, J CELL BIOL, V98, P1926, DOI 10.1083/jcb.98.6.1926; CHIQUETEHRISMAN.R, 1986, CELL, V47, P131; CHIQUETEHRISMANN R, 1991, CELL REGUL, V2, P927, DOI 10.1091/mbc.2.11.927; CHUANG CY, 1994, J CELL BIOL, V126, P539; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; ERICKSON HP, 1989, J MOL BIOL, V206, P465, DOI 10.1016/0022-2836(89)90494-4; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FAISSNER A, 1990, J NEUROCHEM, V54, P1004, DOI 10.1111/j.1471-4159.1990.tb02350.x; LIGHTNER VA, 1990, ANN NY ACAD SCI, V580, P260, DOI 10.1111/j.1749-6632.1990.tb17935.x; LIGHTNER VA, 1990, J CELL SCI, V95, P263; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; RIOU JF, 1990, DEV BIOL, V137, P305, DOI 10.1016/0012-1606(90)90256-I; RIOU JF, 1988, DEVELOPMENT, V104, P511; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	18	82	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					29012	29017		10.1074/jbc.270.48.29012	http://dx.doi.org/10.1074/jbc.270.48.29012			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499434	hybrid			2022-12-27	WOS:A1995TH05600078
J	HUANG, WB; BATEMAN, E				HUANG, WB; BATEMAN, E			CLONING, EXPRESSION, AND CHARACTERIZATION OF THE TATA-BINDING PROTEIN (TBP) PROMOTER-BINDING FACTOR, A TRANSCRIPTION ACTIVATOR OF THE ACANTHAMOEBA TBP GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-I; III PROMOTERS; FACTOR-TFIIB; DNA; COMPLEX; CASTELLANII; SEQUENCE; DOMAINS; GCN4; COMPONENTS	TATA-binding protein (TBP) gene promoter binding factor (TPBF) is a transactivator which binds to the TBP promoter element (TPE) sequence of the Acanthamoeba TBP gene promoter and stimulates transcription in vitro. We have isolated a cDNA clone encoding TPBF. TPBF is a polypeptide of 327 amino acids with a calculated molecular mass of 37 kDa. The predicted amino acid sequence of TPBF shows no significant homology to other proteins. TPBF has two potential coiled-coil regions, a basic region, a proline-rich region, a histidine-rich N terminus, and a nuclear targeting sequence. The recombinant protein has an apparent molecular mass of 50 kDa, identical with that of TPBF purified from Acanthamoeba. Recombinant TPBF is able to bind DNA and activate transcription with the same specificity as natural Acanthamoeba TPBF, demonstrating the authenticity of the clone. Mobility shift assays of co-translated TPBF polypeptides and chemical cross-linking demonstrate that TPBF is tetrameric in solution and when bound to DNA. Analyses of TPBF mutants show that Coiled-coil II is essential for DNA binding, but Coiled coil I and the basic region are also involved. TPBF is thus a novel DNA-binding protein with functional similarity to the tumor suppressor protein p53.	UNIV VERMONT,MARKEY CTR MOLEC GENET,DEPT MICROBIOL & MOLEC GENET,BURLINGTON,VT 05405	University of Vermont					NEI NIH HHS [EY 08706] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY008706, R01EY008706] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1988, MOL REPROD DEV; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BOULIKAS T, 1995, J CELL BIOL, V55, P32; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CRAIG D, 1992, NUCLEIC ACIDS RES, V20, P4987, DOI 10.1093/nar/20.19.4987; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAMMER JA, 1987, J CELL BIOL, V105, P913, DOI 10.1083/jcb.105.2.913; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hodges R. S., 1972, COLD SPRING HARB SYM, V37, P299; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; LEONE G, 1992, CELL, V71, P479, DOI 10.1016/0092-8674(92)90516-F; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU F, 1994, J BIOL CHEM, V269, P18541; LIU F, 1993, NUCLEIC ACIDS RES, V21, P4321, DOI 10.1093/nar/21.18.4321; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Matsudaira PT., 1993, PRACTICAL GUIDE PROT; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PARRY DAD, 1994, SCIENCE, V263, P488; PUGH BF, 1992, J BIOL CHEM, V267, P679; RADEBAUGH CA, 1994, MOL CELL BIOL, V14, P597, DOI 10.1128/MCB.14.1.597; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WONG JM, 1992, GENE, V117, P91, DOI 10.1016/0378-1119(92)90494-A; WONG JM, 1992, NUCLEIC ACIDS RES, V20, P4817, DOI 10.1093/nar/20.18.4817; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911	57	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28839	28847		10.1074/jbc.270.48.28839	http://dx.doi.org/10.1074/jbc.270.48.28839			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499409	hybrid			2022-12-27	WOS:A1995TH05600053
J	PFAFFINGER, PJ; DERUBEIS, D				PFAFFINGER, PJ; DERUBEIS, D			SHAKER K+ CHANNEL T1 DOMAIN SELF-TETRAMERIZES TO A STABLE STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL	The potassium channel T1 domain plays an important role in the regulated assembly of subunit proteins. We have examined the assembly properties of the Shaker channel T1 domain to determine if the domain can self-assemble, the number of subunits in a multimer, N-S and the mechanism of assembly, High pressure liquid chromatography (HPLC) size exclusion chromotography (SEC) separates T1 domain proteins into two peaks, By co-assembly assays, these peaks are identified to be a high molecular weight assembled form and a low molecular weight monomeric form, To determine the N, of the assembled protein peak on HPLC SEC, we first crosslinked the T1 domain proteins and then separated them on HPLC. Four evenly spaced bands co-migrate with the assembled protein peak; thus, the T1 domain assembles to form a tetramer, The absence of separate dimeric and trimeric peaks of assembled T1 domain protein suggests that the tetramer is the stable assembled state, most probably a closed ring structure.			PFAFFINGER, PJ (corresponding author), BAYLOR COLL MED,DIV NEUROSCI,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031583] Funding Source: NIH RePORTER; NICHD NIH HHS [P30 HD31583] Funding Source: Medline; NINDS NIH HHS [R01 NS31583] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATTALI B, 1993, J BIOL CHEM, V268, P24283; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BUTLER A, 1989, SCIENCE, V243, P943, DOI 10.1126/science.2493160; HOPKINS WF, 1994, J NEUROSCI, V14, P1385, DOI 10.1523/JNEUROSCI.14-03-01385.1994; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; TU LW, 1995, BIOPHYS J, V68, P147, DOI 10.1016/S0006-3495(95)80169-4; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0	15	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28595	28600		10.1074/jbc.270.48.28595	http://dx.doi.org/10.1074/jbc.270.48.28595			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499375	hybrid			2022-12-27	WOS:A1995TH05600019
J	ANDRESS, DL				ANDRESS, DL			HEPARIN MODULATES THE BINDING OF INSULIN-LIKE GROWTH-FACTOR (IGF) BINDING PROTEIN-5 TO A MEMBRANE-PROTEIN IN OSTEOBLASTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; RECEPTOR; BONE; IDENTIFICATION; MITOGENESIS; SURFACE	Osteoblast-like cells secrete insulin-like growth factor (IGF) binding protein-5 (IGFBP-5), which may act to enhance IGF-stimulated osteoblast function. We recently demonstrated that carboxyl-truncated IGFBP-5 (IGFBP-5(1-169)) binds to the osteoblast surface and stimulates mitogenesis by a pathway that is independent of IGF action, The present study was conducted to determine the mechanism of osteoblast binding of IGFBP-5, beginning with the assumption that cell surface glycosaminoglycans may mediate the binding of this heparin binding protein, Intact I-125-IGFBP-5 and I-125-IGFBP-5(1-169) exhibited one-site binding to mouse osteoblast monolayers with dissociation constants of 28 and 6 nM for intact I-125-IGFBP-5 and I-125-IGFBP-5(1-169), respectively. Osteoblast binding of intact I-125-IGFBP-5 was inhibited by low heparin concentrations, while I-125-IGFBP-5(1-169) binding was stimulated by heparin, Treatment of cells with heparinase or chlorate to decrease surface glycosaminoglycan density failed to reduce the binding of either form of IGFBP-5. In contrast, pretreatment of cells with IGFBP-5 caused down-regulation of I-125-IGFBP-5 binding. Cross-linking studies revealed that both intact I-125-IGFBP-5 and I-125-IGFBP-5(1-169) bind to proteins in Triton extracts of osteoblast membranes, which were absent in osteoblast derived matrix, Purification of membrane extracts by IGFBP-5 affinity chromatography revealed, 420-kDa band on reduced SDS-polyacrylamide gels, While the membrane protein internalized both forms of IGFBP-5,heparin treatment inhibited the internalization of intact I-125-IGFBP-5 but stimulated I-125-IGFBP-5(1-169) internalization. These data indicate that IGFBP-5 binds to and is internalized by an osteoblast membrane protein, which does not appear to be a proteoglycan. Glycosaminoglycans, however, modulate the binding and internalization of IGFBP-5 in a way that may preferentially favor the intracellular accumulation of the carboxyl-truncated form.	VET ADM MED CTR, RES SERV, SEATTLE, WA 98108 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98493 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle	ANDRESS, DL (corresponding author), VET ADM MED CTR, MED SERV, 1660 S COLUMBIAN WAY, SEATTLE, WA 98108 USA.							ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; ANDRESS DL, 1991, BIOCHEM BIOPH RES CO, V176, P213, DOI 10.1016/0006-291X(91)90911-P; ARAI T, 1994, ENDOCRINOLOGY, V135, P2358, DOI 10.1210/en.135.6.2358; ARAI T, 1994, J BIOL CHEM, V269, P20388; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BAR RS, 1987, BIOCHEM BIOPH RES CO, V148, P734, DOI 10.1016/0006-291X(87)90937-5; BAUTISTA CM, 1991, BIOCHEM BIOPH RES CO, V176, P756, DOI 10.1016/S0006-291X(05)80249-9; BOOTH BA, 1995, GROWTH REGULAT, V5, P1; CAMPBELL PG, 1992, ENDOCRINOLOGY, V130, P1401, DOI 10.1210/en.130.3.1401; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CONOVER CA, 1993, ENDOCRINOLOGY, V132, P2525, DOI 10.1210/en.132.6.2525; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; FIELDER PJ, 1993, ENDOCRINOLOGY, V133, P415, DOI 10.1210/en.133.1.415; FINKELSTEIN JS, 1994, NEW ENGL J MED, V331, P1618, DOI 10.1056/NEJM199412153312404; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HOWARD GA, 1981, P NATL ACAD SCI-BIOL, V78, P3204, DOI 10.1073/pnas.78.5.3204; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; KANZAKI S, 1994, ENDOCRINOLOGY, V134, P383, DOI 10.1210/en.134.1.383; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; LALOU C, 1994, ENDOCRINOLOGY, V135, P2318, DOI 10.1210/en.135.6.2318; LYLES KW, 1993, AM J PHYSIOL, V264, pE938, DOI 10.1152/ajpendo.1993.264.6.E938; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P143; MCCARTHY TL, 1994, J CELL PHYSIOL, V160, P163, DOI 10.1002/jcp.1041600119; MUELLER K, 1994, AM J PHYSIOL, V267, pE1; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAM TJ, 1994, ENDOCRINOLOGY, V135, P1385, DOI 10.1210/en.135.4.1385; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OH Y, 1993, J BIOL CHEM, V268, P26045; OH YM, 1993, J BIOL CHEM, V268, P14964; OKAZAKI R, 1994, ENDOCRINOLOGY, V134, P126, DOI 10.1210/en.134.1.126; PFEILSCHIFTER J, 1990, ENDOCRINOLOGY, V126, P703, DOI 10.1210/endo-126-2-703; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; ROSENBERG RD, 1977, SEMIN HEMATOL, V14, P427; SCHMID C, 1994, AM J PHYSIOL, V267, pE226, DOI 10.1152/ajpendo.1994.267.2.E226; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	40	106	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28289	28296						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499327				2022-12-27	WOS:A1995TG21000052
J	KADKHODAYAN, S; COULTER, ED; MARYNIAK, DM; BRYSON, TA; DAWSON, JH				KADKHODAYAN, S; COULTER, ED; MARYNIAK, DM; BRYSON, TA; DAWSON, JH			UNCOUPLING OXYGEN-TRANSFER AND ELECTRON-TRANSFER IN THE OXYGENATION OF CAMPHOR ANALOGS BY CYTOCHROME P450-CAM - DIRECT OBSERVATION OF AN INTERMOLECULAR ISOTOPE EFFECT FOR SUBSTRATE C-H ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; HYDROXYLATION; MECHANISM; REGIOSELECTIVITY; STEREOCHEMISTRY; REDUCTION; OXIDASE; IRON	The hydroxylation of (1R)-camphor by cytochrome P450-CAM involves almost complete coupling of electron to oxygen transfer. Modifications at C-5 of camphor, the normal site of hydroxylation by P450-CAM, lead to as much as 98% uncoupling of electron and oxygen transfer as well as to decreases in the rate of electron uptake (up to 10-fold) and the rate of oxygenated product formation (up to 210-fold). Two modes of uncoupling are seen: (a) two-electron uncoupling in which the decrease in oxygenated product formation is balanced by increases in H2O2 formation and (b) four-electron ''oxidase'' uncoupling where the NADH/O-2 ratio has changed from one to nearly two and relatively little H2O2 is formed, Both enantiomers of 5-methylenylcamphor are two-electron uncouplers, while (1R)- and (1S)-5,5-difluorocamphor and (1R)-9,9,9-d(3)-5,5-difluorocamphor are four-electron uncouplers. An intermolecular isotope effect of 11.7 is observed for oxygenation of C-9 in (1R)-5,5-difluorocamphor. With this substrate, the significant decrease in the rate of oxygenated product formation combined with the large isotope effect suggest that the rate-limiting step has switched from electron to oxygen transfer.	UNIV S CAROLINA, DEPT CHEM & BIOCHEM, COLUMBIA, SC 29208 USA; UNIV S CAROLINA, SCH MED, COLUMBIA, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia			Dawson, John/HDM-6702-2022	Dawson, John H/0000-0002-4902-4295				ATKINS WM, 1987, J AM CHEM SOC, V109, P3754, DOI 10.1021/ja00246a038; ATKINS WM, 1988, BIOCHEMISTRY-US, V27, P1610, DOI 10.1021/bi00405a033; ATKINS WM, 1989, J AM CHEM SOC, V111, P2715, DOI 10.1021/ja00189a057; ATKINS WM, 1988, J BIOL CHEM, V263, P18842; BREWER CB, 1988, J BIOL CHEM, V263, P791; CRULL GB, 1989, J BIOL CHEM, V264, P2649; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; DEMONTELLANO PRO, 1986, CYTOCHROME P450 STRU, P216; DEVOSS JJ, 1995, J AM CHEM SOC, V117, P4185, DOI 10.1021/ja00119a041; EBLE KS, 1984, J BIOL CHEM, V259, P4389; FRUETEL J, 1994, J AM CHEM SOC, V116, P11643, DOI 10.1021/ja00105a003; FRUETEL JA, 1992, J AM CHEM SOC, V114, P6987, DOI 10.1021/ja00044a006; GELB MH, 1982, BIOCHEMISTRY-US, V21, P370, DOI 10.1021/bi00531a026; GELB MH, 1992, BIOCHEM BIOPH RES CO, V189, P488; GERBER NC, 1992, J AM CHEM SOC, V114, P8742, DOI 10.1021/ja00048a081; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; GOULD PV, 1981, J BIOL CHEM, V256, P6686; GROVES JT, 1978, BIOCHEM BIOPH RES CO, V81, P154, DOI 10.1016/0006-291X(78)91643-1; GROVES JT, 1985, J CHEM EDUC, V62, P928, DOI 10.1021/ed062p928; Gunsalus I C, 1978, Methods Enzymol, V52, P166; Gunsalus I.C., 1974, MOL MECHANISMS OXYGE, P559; HAWKINS BK, 1992, FRONTIERS BIOTRANSFO, V7, P216; HJELMELAND LM, 1977, BIOCHEM BIOPH RES CO, V76, P541, DOI 10.1016/0006-291X(77)90758-6; JONES JP, 1993, J AM CHEM SOC, V115, P381, DOI 10.1021/ja00055a002; KADKHODAYAN S, 1992, THESIS U S CAROLINA; LEFEVER MR, 1994, BIOCHEM BIOPH RES CO, V201, P373, DOI 10.1006/bbrc.1994.1711; LOIDA PJ, 1993, BIOCHEMISTRY-US, V32, P11530, DOI 10.1021/bi00094a009; LOIDA PJ, 1995, J BIOL CHEM, V270, P5326, DOI 10.1074/jbc.270.10.5326; MARYNIAK DM, 1993, TETRAHEDRON, V49, P9373, DOI 10.1016/0040-4020(93)80022-L; MARYNIAK DM, 1992, THESIS U S CAROLINA; O'Keeffe D H, 1978, Methods Enzymol, V52, P151; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1985, J BIOL CHEM, V260, P6122; RAAG R, 1989, BIOCHEMISTRY-US, V28, P917, DOI 10.1021/bi00428a077; RAAG R, 1991, BIOCHEMISTRY-US, V30, P2674, DOI 10.1021/bi00224a016; ROBINSON J, 1970, ANAL BIOCHEM, V33, P390, DOI 10.1016/0003-2697(70)90310-6; SLIGAR SG, 1986, CYTOCHROME P450 STRU, P443; STAUDT H, 1974, EUR J BIOCHEM, V46, P99, DOI 10.1111/j.1432-1033.1974.tb03601.x; ULLAH AJH, 1990, J BIOL CHEM, V265, P1345; WATANABE Y, 1989, J AM CHEM SOC, V111, P410, DOI 10.1021/ja00183a083; WHITE RE, 1984, ARCH BIOCHEM BIOPHYS, V228, P493, DOI 10.1016/0003-9861(84)90015-8; WHITE RE, 1991, PHARMACOL THERAPEUT, V49, P21, DOI 10.1016/0163-7258(91)90020-M	43	88	88	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28042	28048						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499289				2022-12-27	WOS:A1995TG21000014
J	KHARITONOV, VG; SUNDQUIST, AR; SHARMA, VS				KHARITONOV, VG; SUNDQUIST, AR; SHARMA, VS			KINETICS OF NITROSATION OF THIOLS BY NITRIC-OXIDE IN THE PRESENCE OF OXYGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME-PROTEINS; HEMOGLOBIN; MECHANISM	Nitrosothiols are powerful vasodilators, They act by releasing nitric oxide, which activates the heme protein guanylate cyclase, We have studied the kinetics of nitrosothiol formation of glutathione, cysteine, N-acetylcysteine, human serum albumin, and bovine serum albumin upon reaction with nitric oxide (NO) in the presence of oxygen, These studies have been made at low pH as well as at physiological pH, At pH 7.0, contrary to published reports, nitric oxide by itself does not react with thiols to yield nitrosothiol. However, formation of nitrosothiols is observed in the presence of oxygen, For all thiols studied, the rates of nitrosothiol formation were first order in O-2 concentration and second order in NO concentration and at lower concentrations (<5 mM thiol) also depended on thiol concentrations, analysis of the kinetic data indicated that the rate-limiting step was the reaction of NO with oxygen, Analysis of the reaction products suggest that the main nitrosating species is N2O3: RSH + N2O3 --> RSNO + NO2- + H+. Rate constants for this reaction for glutathione and several other low molecular weight thiols are in the range of 3-1.5 x 10(5) M(-1) s(-1), and for human and bovine serum albumins 0.3 x 10(5) M(-1) s(-1) and 0.06 x 10(5) M(-1) s(-1), respectively, The data further indicate that the reaction rate of the nitrosating species N2O3 with thiols is competitive with its rate of hydrolysis. At physiological concentrations nitrosoglutathione formation represents a significant metabolic fate of N2O3, and at glutathione concentrations of 5 mM or higher almost all of N2O3 formed is consumed in nitrosation of glutathione. Implications of these results for in vivo nitrosation of thiols are discussed.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [T32AM007233] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048014, R01HL013581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48014, HL13581] Funding Source: Medline; NIADDK NIH HHS [AM07233] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BRACKMAN W, 1965, RECL TRAV CHIM PAY-B, V84, P357; BUTLER AR, 1993, CHEM SOC REV, V22, P233, DOI 10.1039/cs9932200233; BYLER DM, 1983, J AGR FOOD CHEM, V31, P523, DOI 10.1021/jf00117a015; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; GRATZEL M, 1970, BERICH BUNSEN GESELL, V74, P488; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; JOCELYN P, 1972, BIOCH SH GROUP, P143; KEANEY JF, 1993, J CLIN INVEST, V91, P1582, DOI 10.1172/JCI116364; KHARITONOV VG, 1994, J BIOL CHEM, V269, P5881; LICHT WR, 1988, CARCINOGENESIS, V9, P365, DOI 10.1093/carcin/9.3.365; MCANINLY J, 1993, J CHEM SOC CHEM COMM, P1758, DOI 10.1039/c39930001758; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOORE EG, 1976, J BIOL CHEM, V251, P2788; PADMAJA S, 1993, BIOCHEM BIOPH RES CO, V195, P539, DOI 10.1006/bbrc.1993.2079; PARK JW, 1993, BIOCHEM MOL BIOL INT, V30, P885; SHARMA VS, 1983, BIOCHEMISTRY-US, V22, P3897, DOI 10.1021/bi00285a026; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; WILLIAMS DLH, 1988, NITROSATION, P176; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; [No title captured]	24	320	327	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28158	28164						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499306				2022-12-27	WOS:A1995TG21000031
J	WINDISCH, JM; MARKSTEINER, R; SCHNEIDER, R				WINDISCH, JM; MARKSTEINER, R; SCHNEIDER, R			NERVE GROWTH-FACTOR BINDING-SITE ON TRKA MAPPED TO A SINGLE 24-AMINO ACID LEUCINE-RICH MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; NEUROTROPHIC FACTOR; FACTOR RECEPTORS; RIBONUCLEASE INHIBITOR; PROTOONCOGENE PRODUCT; CHICK-EMBRYO; NGF RECEPTOR; PC12 CELLS; REPEATS; ADHESION	The extracellular domains of the TrkA nerve growth factor (NGF) receptor and its homologs harbor a modular mosaic of potential ligand binding motifs, namely two immunoglobulin (Ig)-like modules and an LRM(3) cassette consisting of a tandem array of three leucine-rich motifs (LRMs) flanked by cysteine-rich clusters (Schneider, R., and Schweiger, M. (1991) Oncogene 6, 1807-1811). Identification of a structural motif capable of specifically recognizing the various neurotrophins was achieved by assessing their affinities to isolated recombinant modules of TrkA and TrkB. In both receptors the LRM(3) cassette alone could mediate the respective neurotrophin selectivities and affinities. Further tracking down of this NGF-binding site in TrkA strikingly revealed that a single LRM of 24 amino acids could bind NGF selectively with nanomolar affinity, Since this is the first example of a single LRM with a highly specific, well defined function, it might serve as a valuable tool to elucidate the general structural requirements of substrate recognition and high affinity binding in the large superfamily of LRM-containing proteins.	UNIV INNSBRUCK, INST BIOCHEM, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck								BARBACID M, 1993, ONCOGENE, V8, P2033; BARKER PA, 1992, MOL CELL BIOCHEM, V110, P1, DOI 10.1007/BF02385000; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; DECHANT G, 1993, DEVELOPMENT, V119, P545; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DRINKWATER CC, 1991, P ROY SOC B-BIOL SCI, V246, P307, DOI 10.1098/rspb.1991.0159; GOTZ R, 1994, NATURE, V372, P266, DOI 10.1038/372266a0; GOTZ R, 1992, EUR J BIOCHEM, V204, P745, DOI 10.1111/j.1432-1033.1992.tb16689.x; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P8537, DOI 10.1021/bi00423a006; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRANTZ DE, 1990, EMBO J, V9, P1969, DOI 10.1002/j.1460-2075.1990.tb08325.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LOEB DM, 1993, J NEUROSCI, V13, P2919; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROVELLI G, 1993, P NATL ACAD SCI USA, V90, P8717, DOI 10.1073/pnas.90.18.8717; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHNEIDER R, 1993, SCIENCE, V261, P1169, DOI 10.1126/science.8356450; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; SONNENFELD KH, 1985, J NEUROSCI, V5, P1717; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; SUTTER A, 1979, J BIOL CHEM, V254, P5972; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; ZE W, 1993, MOL CELL BIOL, V13, P5348, DOI 10.1128/MCB.13.9.5348	51	53	56	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28133	28138						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499302				2022-12-27	WOS:A1995TG21000027
J	LIN, RY; MOSS, SB; RUBIN, CS				LIN, RY; MOSS, SB; RUBIN, CS			CHARACTERIZATION OF S-AKAP84, A NOVEL DEVELOPMENTALLY-REGULATED A-KINASE ANCHOR PROTEIN OF MALE GERM-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-PROTEIN; CAENORHABDITIS-ELEGANS; SPERMATOGENIC CELLS; LEUCINE ZIPPER; II-BETA; SUBUNIT; SPERM; EXPRESSION; CLONING; LOCALIZATION	In mammalian spermatozoa, most of the type II alpha isoform of cAMP-dependent protein kinase (PKAII alpha) is anchored at the cytoplasmic surface of a specialized array of mitochondria in the flagellar cytoskeleton. This places the catalytic subunits of PKAII alpha in proximity with potential target substrates in the cytoskeleton. The mechanism by which PKAII alpha is anchored at the outer surface of germ cell mitochondria has not been elucidated. We now report the cloning of a cDNA that encodes a novel, germ cell A kinase anchor protein (AKAP) designated S-AKAP84. S-AKAP84 comprises 593 amino acids and contains a centrally located domain that avidly binds regulatory subunits (RII alpha and RII beta) of PKAII alpha and PKAII beta. The 3.2-kilobase S-AKAP84 mRNA and the cognate S-AKAP84 RII binding protein are expressed principally in the male germ cell lineage. Expression of S-AKAP84 is tightly regulated during development. The protein accumulates as spermatids undergo nuclear condensation and tail elongation. The timing of S-AKAP84 expression is correlated with the de novo accumulation of RII alpha and RII beta subunits and the migration of mitochondria from the cytoplasm (round spermatids) to the cytoskeleton (midpiece in elongating spermatids). Residues 1-30 at the NH2 terminus of S-AKAP84 constitute a putative signal/anchor sequence that may target the protein to the outer mitochondrial membrane, Immunofluorescence analysis demonstrated that S-AKAP84 is co-localized with mitochondria in the flagellum.	UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,DIV REPROD BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania	LIN, RY (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,ATRAN LABS,1300 MORRIS PK AVE,BRONX,NY 10461, USA.				NIGMS NIH HHS [GM22792] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; BELLVE AR, 1977, J HISTOCHEM CYTOCHEM, V25, P480, DOI 10.1177/25.7.893996; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BROKAW CJ, 1987, J CELL BIOCHEM, V35, P175, DOI 10.1002/jcb.240350302; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARRERA A, 1994, DEV BIOL, V165, P272, DOI 10.1006/dbio.1994.1252; Clermont Y., 1993, FRONT ENDOCRINOL, P332; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; HAHNE K, 1994, CELL, V79, P829, DOI 10.1016/0092-8674(94)90072-8; Hecht N. B., 1993, CELL MOL BIOL TESTIS, P400; HIRSCH AH, 1993, J BIOL CHEM, V267, P2131; HOROWITZ JA, 1984, J BIOL CHEM, V259, P832; HOROWITZ JA, 1988, J BIOL CHEM, V263, P2098; HU ED, 1990, J BIOL CHEM, V265, P5072; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAND M, 1994, J BIOL CHEM, V269, P9234; LANDMARK BF, 1993, J REPROD FERTIL, V99, P323, DOI 10.1530/jrf.0.0990323; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; LI Y, 1993, EXP CELL RES, V208, P170; LIEBERMAN SJ, 1988, J CELL BIOL, V107, P1809, DOI 10.1083/jcb.107.5.1809; LONNERBERG P, 1992, BIOL REPROD, V46, P1057, DOI 10.1095/biolreprod46.6.1057; LU XY, 1990, J BIOL CHEM, V265, P3293; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SUL HS, 1984, J BIOL CHEM, V259, P1201; TASH JS, 1982, BIOL REPROD, V26, P745, DOI 10.1095/biolreprod26.4.745; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	37	160	163	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27804	27811		10.1074/jbc.270.46.27804	http://dx.doi.org/10.1074/jbc.270.46.27804			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499250	hybrid			2022-12-27	WOS:A1995TE73600061
J	MARK, MR; SCADDEN, DT; WANG, ZG; GU, QM; GODDARD, A; GODOWSKI, PJ				MARK, MR; SCADDEN, DT; WANG, ZG; GU, QM; GODDARD, A; GODOWSKI, PJ			RSE, A NOVEL RECEPTOR-TYPE TYROSINE KINASE WITH HOMOLOGY TO AXL/UFO, IS EXPRESSED AT HIGH-LEVELS IN THE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; GENE; FAMILY; ENCODES; DOMAINS; PROTOONCOGENE; ONCOGENES; FEATURES	We have isolated cDNA clones that encode the human and murine forms of a novel receptor-type tyrosine kinase termed Rse. Sequence analysis indicates that human Rse contains 890 amino acids, with an extracellular region composed of two immunoglobulin-like domains followed by two fibronectin type III domains. Murine Rse contains 880 amino acids and shares 90% amino acid identity with its human counterpart. Rse is structurally similar to the receptor-type tyrosine kinase Axl/Ufo, and the two proteins have 35 and 63% sequence identity in their extracellular and intracellular domains, respectively. To study the synthesis and activation of this putative receptor-type tyrosine kinase, we constructed a version of Rse (termed gD-Rse, where go represents glycoprotein D) that contains an NH2-terminal epitope tag NM3T3 cells were engineered to express gD-Rse, which could be detected at the cell surface by fluorescence-activated cell sorting. Moreover, gD-Rse was rapidly phosphorylated on tyrosine residues upon incubation of the cells with an antibody directed against the epitope tag, suggesting that rse encodes an active tyrosine kinase. in the human tissues we examined, the highest level of expression of rse mRNA was observed in the brain; rse mRNA was also detected in the premegakaryocytopoietic cell lines CMK11-5 and Dami. The gene for rse was localized to human chromsome 15.	GENENTECH INC, DEPT CELL GENET, San Francisco, CA 94080 USA; GENENTECH INC, DEPT MOLEC BIOL, San Francisco, CA 94080 USA; HARVARD UNIV, NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA	Roche Holding; Genentech; Roche Holding; Genentech; Harvard University; Harvard Medical School								AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LASKY LA, 1984, DNA-J MOLEC CELL BIO, V3, P23, DOI 10.1089/dna.1.1984.3.23; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MCCLAIN DA, 1990, J BIOL CHEM, V265, P21363; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PABORSKY LR, 1990, PROTEIN ENG, V3, P547, DOI 10.1093/protein/3.6.547; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; SARUP JC, 1991, GROWTH REGULAT, V1, P72; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	125	151	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	1994	269	14					10720	10728						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF017	7511603				2022-12-27	WOS:A1994NF01700079
J	KROLL, TG; PETERS, BP; HUSTAD, CM; JONES, PA; KILLEN, PD; RUDDON, RW				KROLL, TG; PETERS, BP; HUSTAD, CM; JONES, PA; KILLEN, PD; RUDDON, RW			EXPRESSION OF LAMININ CHAINS DURING MYOGENIC DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE PROTEINS; CELL-BINDING SITE; A-CHAIN; EXTRACELLULAR-MATRIX; PARIETAL ENDODERM; MESSENGER-RNA; BASAL LAMINA; NEUROMUSCULAR-JUNCTION; MULTIDOMAIN PROTEIN; DEVELOPING KIDNEY	Expression of two Ae-related chains of the extracellular matrix glycoprotein laminin was induced as multi potent C3H10T1/2 mouse embryo fibroblasts differentiated into myoblasts and myofibers. C3H10T1/2 fibroblasts expressed the B1e (M(r) = 215,000) and B2e (M(r) = 205,000) laminin chains based on metabolic radiolabeling, immunoprecipitation, peptide mapping, and mRNA analysis. In contrast, myoblasts derived from C3H10T1/2 fibroblasts treated with DNA demethylating agents or transfected with the cDNA encoding MyoD expressed the Ae (M(r) = 400,000) and a novel Ae-related laminin chain (designated Ac3h, M(r) = 350,000) in addition to the B1e and B2e chains. Expression of the Ae and Ac3h chains paralleled the capacity for myofiber formation in six additional C3H10T1/2 myoblast clones with varied potentials for terminal differentiation and coincided with a switch in laminin isoforms from those of M(r) = 850,000 synthesized by C3H10T1/2 fibroblasts to those of M(r) = 900,000-950,000 synthesized by C3H10T1/2 myoblasts and myofibers. Cultures of mouse C2C12, mouse BC3H1, rat L6, and primary mouse myoblasts also synthesized the Ae, Ac3h, B1e, and B2e laminin chains. The results demonstrate that expression of the Ae and Ac3h laminin chains is associated with expression of MyoD and the mammalian myogenic differentiation program.	UNIV MICHIGAN,SCH MED,PROGRAM CELLULAR & MOLEC BIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198; N CAROLINA STATE UNIV,COLL VET MED,DEPT ANAT PHYSIOL SCI & RADIOL,RALEIGH,NC 27606; UNIV SO CALIFORNIA,KENNETH NORRIS JR COMPREHENS CANC CTR,LOS ANGELES,CA 90033	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Nebraska System; University of Nebraska Medical Center; University of North Carolina; North Carolina State University; University of Southern California					NCI NIH HHS [CA-49758, CA-41359, CA-36727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727, R01CA041359, R35CA049758] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAYNE EK, 1984, J CELL BIOL, V99, P1486, DOI 10.1083/jcb.99.4.1486; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BEDNARCZUK TA, 1991, BIOTECHNIQUES, V10, P478; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; CHIU AY, 1984, DEV BIOL, V103, P456, DOI 10.1016/0012-1606(84)90333-6; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOPER AR, 1983, DEV BIOL, V96, P467, DOI 10.1016/0012-1606(83)90183-5; COOPER AR, 1981, EUR J BIOCHEM, V119, P189, DOI 10.1111/j.1432-1033.1981.tb05593.x; DAVIS L, 1987, BASIC METHODS MOL BI, P130; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; EKBLOM M, 1990, CELL, V60, P337, DOI 10.1016/0092-8674(90)90748-4; ENGEL J, 1991, BIOCHEM SOC T, V19, P839, DOI 10.1042/bst0190839; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; ENGVALL E, 1992, EXP CELL RES, V198, P115, DOI 10.1016/0014-4827(92)90156-3; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORSBERG E, 1990, J BIOL CHEM, V265, P6376; FRENETTE GP, 1989, J BIOL CHEM, V264, P3078; FRENETTE GP, 1988, CANCER RES, V48, P5193; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; GEORGEWEINSTEIN M, 1993, DEV BIOL, V156, P209, DOI 10.1006/dbio.1993.1071; GODFREY EW, 1988, DEV BIOL, V130, P471, DOI 10.1016/0012-1606(88)90343-0; GREEN TL, 1992, J BIOL CHEM, V267, P2014; HAAPARANTA T, 1991, MATRIX, V11, P151, DOI 10.1016/S0934-8832(11)80153-8; HANTAI D, 1985, CELL BIOL INT REP, V9, P647, DOI 10.1016/0309-1651(85)90057-8; HARRINGTON MA, 1988, MOL CELL BIOL, V8, P4322, DOI 10.1128/MCB.8.10.4322; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HUSTAD CM, 1991, MOL CARCINOGEN, V4, P153, DOI 10.1002/mc.2940040211; JAFFREDO T, 1988, DEVELOPMENT, V103, P431; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; KLEIN G, 1990, DEVELOPMENT, V110, P823; KLEINMAN HK, 1987, DEV BIOL, V122, P373, DOI 10.1016/0012-1606(87)90302-2; Konigsberg I R, 1979, Methods Enzymol, V58, P511; KUCHEREREHRET A, 1990, DEVELOPMENT, V110, P1285; KUHL U, 1982, DEV BIOL, V93, P344, DOI 10.1016/0012-1606(82)90122-1; KULLUNKI P, 1992, J CELL BIOL, V119, P679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE GW, 1989, J CELL BIOL, V109, P1351, DOI 10.1083/jcb.109.3.1351; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; LIESI P, 1989, EXP NEUROL, V105, P86, DOI 10.1016/0014-4886(89)90175-1; LOREAL O, 1991, FEBS LETT, V290, P9, DOI 10.1016/0014-5793(91)81213-R; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MORITA A, 1985, BIOCHEM J, V229, P259, DOI 10.1042/bj2290259; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; NURCOMBE V, 1989, EUR J BIOCHEM, V180, P9, DOI 10.1111/j.1432-1033.1989.tb14608.x; OLWIN BB, 1985, DEV BIOL, V112, P359, DOI 10.1016/0012-1606(85)90407-5; OREAR JJ, 1992, J BIOL CHEM, V267, P20555; PAULSSON M, 1991, J BIOL CHEM, V266, P17545; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; PAULSSON M, 1989, J BIOL CHEM, V264; PETERS BP, 1985, J BIOL CHEM, V260, P4732; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SASSOON DA, 1993, DEV BIOL, V156, P11, DOI 10.1006/dbio.1993.1055; SCHUBERT D, 1974, J CELL BIOL, V61, P398, DOI 10.1083/jcb.61.2.398; SEEBACHER T, 1991, EXP CELL RES, V196, P66, DOI 10.1016/0014-4827(91)90456-5; SHULL JD, 1991, GENE, V104, P203, DOI 10.1016/0378-1119(91)90251-6; SIMO P, 1991, DEVELOPMENT, V112, P477; SKUBITZ APN, 1988, J BIOL CHEM, V263, P4861; SOLURSH M, 1988, DEVELOPMENT, V104, P41; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SOROKIN L, 1990, J CELL BIOL, V111, P1265, DOI 10.1083/jcb.111.3.1265; STREULI CH, 1990, J CELL BIOL, V110, P1405; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TOKIDA Y, 1990, J BIOL CHEM, V265, P18123; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WEWER UM, 1992, LAB INVEST, V66, P378; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	81	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1994	269	12					9270	9277						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB411	7510707				2022-12-27	WOS:A1994NB41100094
J	BEDNARCZYK, JL; SZABO, MC; WYGANT, JN; LAZAROVITS, AI; MCINTYRE, BW				BEDNARCZYK, JL; SZABO, MC; WYGANT, JN; LAZAROVITS, AI; MCINTYRE, BW			IDENTIFICATION OF A COMBINATORIAL EPITOPE EXPRESSED BY THE INTEGRIN ALPHA-4-BETA-1 HETERODIMER INVOLVED IN THE REGULATION OF CELL-ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; T-CELLS; RHEUMATOID-ARTHRITIS; LYMPHOCYTE ADHESION; MELANOMA ADHESION; ALPHA-SUBUNIT; BETA-SUBUNIT; VLA-4; FIBRONECTIN; RECEPTOR	The alpha 4 integrin subunit can associate with either the beta 1- or beta 7-integrin subunit to form two unique adhesion receptors alpha 4 beta 1 and alpha 4 beta 7. We developed a monoclonal antibody (mAb 19H8) that immunoprecipitated alpha 4 beta 1, induced homotypic leukocyte aggregation, and blocked the binding of cells to a synthetic peptide corresponding to the CS-1 peptide region of fibronectin. Aggregation cross-blocking analysis suggested that mAb 19H8 belonged to the group of mAbs that react with the B2 epitope of the alpha 4 subunit (alpha 4.B2 epitope); however, unlike the alpha 4.B2-specific mAb L25, mAb 19H8 did not immunoprecipitate alpha 4 beta 7. In addition, mAb 19H8 did not bind to beta 1-positive cells unless transfected with alpha 4 cDNA. These results indicated that mAb 19H8 was not specific for an individual alpha 4, beta 1, or beta 7 subunit but reacted with an epitope formed from the association of alpha 4 with beta 1. Separating the alpha 4 from the beta 1 subunit, by removing divalent cations or by treatment with high pH, disrupted mAb 19H8 binding. In contrast, the alpha 4-specific mAb L25 and the beta 1-specific mAb 18D3 could react with their respective subunits without subunit association. Therefore, mAb 19H8 defined a novel regulatory epitope expressed by the integrin alpha 4 beta 1.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT IMMUNOL, HOUSTON, TX 77030 USA; UNIV WESTERN ONTARIO, DEPT MED, LONDON N6A 5A5, ON, CANADA	University of Texas System; UTMD Anderson Cancer Center; Western University (University of Western Ontario)					NATIONAL CANCER INSTITUTE [R01CA062596] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 62596] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; ARROYO AG, 1993, J BIOL CHEM, V268, P9863; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BEDNARCZYK JL, 1990, J IMMUNOL, V144, P777; BEDNARCZYK JL, 1992, J BIOL CHEM, V267, P25274; BEDNARCZYK JL, 1992, CLIN EXP METASTAS, V10, P281; BEDNARCZYK JL, 1993, J CELL BIOCHEM, V51, P465, DOI 10.1002/jcb.2400510412; BEDNARCZYK JL, 1992, J LEUKOCYTE BIOL, V52, P456, DOI 10.1002/jlb.52.4.456; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BURKLY LC, 1991, EUR J IMMUNOL, V21, P2871, DOI 10.1002/eji.1830211132; CAIXIA S, 1991, CELL IMMUNOL, V138, P216, DOI 10.1016/0008-8749(91)90146-3; CAMPANERO MR, 1992, EUR J IMMUNOL, V22, P3111, DOI 10.1002/eji.1830221213; CAMPANERO MR, 1990, J CELL BIOL, V110, P2157, DOI 10.1083/jcb.110.6.2157; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DAVIS LS, 1990, J IMMUNOL, V145, P785; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; KAPPLER J, 1983, CELL, V35, P295, DOI 10.1016/0092-8674(83)90232-5; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFON A, 1991, J CLIN INVEST, V88, P546, DOI 10.1172/JCI115338; LAZAROVITS AI, 1984, J IMMUNOL, V133, P1857; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; MCINTYRE BW, 1989, J BIOL CHEM, V264, P13745; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOULD AP, 1990, J BIOL CHEM, V265, P4020; NEUHAUS H, 1991, J CELL BIOL, V115, P1149, DOI 10.1083/jcb.115.4.1149; PARKER CM, 1993, J BIOL CHEM, V268, P7028; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PODOLSKY DK, 1993, J CLIN INVEST, V92, P372, DOI 10.1172/JCI116575; POSTIGO AA, 1993, J IMMUNOL, V151, P2471; PULIDO R, 1991, J BIOL CHEM, V266, P10241; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANCHEZMADRID F, 1983, J EXP MED, V158, P586, DOI 10.1084/jem.158.2.586; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SCHWEIGHOFFER T, 1993, J IMMUNOL, V151, P717; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; TAKAHASHI H, 1992, EUR J IMMUNOL, V22, P2879, DOI 10.1002/eji.1830221119; UDAGAWA T, 1992, LYMPHOKINE CYTOK RES, V11, P193; VANDINTHERJANSSEN ACHM, 1991, J IMMUNOL, V147, P4207; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; WAYNER EA, 1992, J CELL BIOL, V116, P489, DOI 10.1083/jcb.116.2.489; WIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461; YABKOWITZ R, 1993, J IMMUNOL, V151, P149; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	58	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8348	8354						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510686				2022-12-27	WOS:A1994NB40900078
J	REDDY, VY; DESROCHERS, PE; PIZZO, SV; GONIAS, SL; SAHAKIAN, JA; LEVINE, RL; WEISS, SJ				REDDY, VY; DESROCHERS, PE; PIZZO, SV; GONIAS, SL; SAHAKIAN, JA; LEVINE, RL; WEISS, SJ			OXIDATIVE DISSOCIATION OF HUMAN ALPHA(2)-MACROGLOBULIN TETRAMERS INTO DYSFUNCTIONAL DIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-2-MACROGLOBULIN; METHIONINE RESIDUES; HALF-MOLECULES; ALPHA-1-PROTEINASE INHIBITOR; NUCLEOPHILIC MODIFICATION; CONFORMATIONAL CHANGE; ALPHA-MACROGLOBULINS; GLUTAMINE-SYNTHETASE; NEUTROPHIL ELASTASE; PROTEINASE-BINDING	Human alpha(2)-macroglobulin is a broad-spectrum, homotetrameric antiproteinase that can maximally bind up to two proteinase molecules in a ternary complex. Proteinases cleave the inhibitor within a peptide stretch termed the bait region and induce the emergence of internal thiol esters whose nucleophilic scission precede a major conformational change which entraps enzymes within molecular cages. In a previous study, leukocyte generated hypohalous acids and N-haloamines were identified as the first examples of physiologically relevant inactivators of the antiproteolytic activity of alpha(2)-macroglobulin (Reddy, V.Y., Pizzo, S. V., and Weiss, S. J. (1989) J. Biol. Chem. 264, 13801-13809), but the mechanisms whereby the oxidants damaged the inhibitor remained undefined. We now demonstrate that N-chloramines (RNCl) destroy the antiproteolytic activity of alpha(2)-macroglobulin in an unusual biphasic process that results in the formation of inactive alpha(2)-macroglobulin half-molecules. In the first phase, 8 eq of RNCl reacted with each alpha(2)-macroglobulin subunit to generate a partially oxidized antiproteinase containing 8 methionyl sulfoxide residues/monomer. Structure-function analyses demonstrated that the oxidized inhibitor retained its homotetrameric structure as well as its ability to entrap proteinases. In marked contrast, the oxidation of an additional 6 methionyl residues and a single tryptophanyl residue fractured the alpha(2)M homotetramer across its non-covalent axis into two pairs of disulfide-linked dimers. Despite the fact that the oxidized dimers displayed normal bait regions whose cleavage by proteinases initiated thiol ester scission, all antiproteolytic activity was lost. Furthermore, the oxidized dimers were unable to undergo the critical conformational changes normally associated with bait region cleavage or thiol ester scission. Together, these results demonstrate that chlorinated oxidants destroy the antiproteolytic activity of alpha(2)-macroglobulin by attacking a subset of methionyl and tryptophanyl residues whose oxidation mediates the dissociation of the native homotetramer into conformationally locked dimers.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; NHLBI,BIOCHEM LAB,BETHESDA,MD 20892	Duke University; Duke University; University of Virginia; University of Virginia; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Levine, Rodney L/D-9885-2011	Reddy, Vivek/0000-0002-5638-4993	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028024] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-28024] Funding Source: Medline; NIAID NIH HHS [AI-23870] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBINK JJ, 1991, ARTHRITIS RHEUM, V34, P1139, DOI 10.1002/art.1780340910; ALEXANDER NM, 1973, J BIOL CHEM, V249, P1946; BAKER MS, 1990, BIOCHEM BIOPH RES CO, V166, P993, DOI 10.1016/0006-291X(90)90909-7; BJORK I, 1985, BIOCHEM J, V231, P451; BROWER MS, 1982, J BIOL CHEM, V257, P9849; CALDWELL P, 1978, P NATL ACAD SCI USA, V75, P5349, DOI 10.1073/pnas.75.11.5349; CHAPMAN ML, 1989, J RHEUMATOL, V16, P15; CHRISTENSEN U, 1989, BIOCHEMISTRY-US, V28, P9324, DOI 10.1021/bi00450a012; CLARK RA, 1986, BIOCHEM BIOPH RES CO, V135, P451, DOI 10.1016/0006-291X(86)90015-X; CLIMENT I, 1989, ANAL BIOCHEM, V182, P226, DOI 10.1016/0003-2697(89)90584-8; CUNNINGHAM LW, 1990, BIOCHEMISTRY-US, V29, P1638, DOI 10.1021/bi00458a040; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DELAIN E, 1988, J BIOL CHEM, V263, P2981; DELALLOSA P, 1980, CAN J BIOCHEM CELL B, V58, P745, DOI 10.1139/o80-105; DESROCHERS PE, 1991, J CLIN INVEST, V87, P2258, DOI 10.1172/JCI115262; DESROCHERS PE, 1992, J BIOL CHEM, V267, P5005; DROZDZ R, 1988, ACTA BIOCHIM POL, V35, P277; DROZDZ R, 1988, BIOCHIM BIOPHYS ACTA, V957, P47, DOI 10.1016/0167-4838(88)90155-0; ENGHILD JJ, 1989, J BIOL CHEM, V264, P11428; GONIAS SL, 1989, J BIOL CHEM, V264, P9565; GONIAS SL, 1983, BIOCHEMISTRY-US, V22, P536, DOI 10.1021/bi00272a003; GONIAS SL, 1993, J BIOL CHEM, V302, P42; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JASIN HE, 1988, J CLIN INVEST, V81, P6, DOI 10.1172/JCI113310; KAN CC, 1985, P NATL ACAD SCI USA, V82, P2282, DOI 10.1073/pnas.82.8.2282; KNAUPER V, 1990, FEBS LETT, V263, P355, DOI 10.1016/0014-5793(90)81412-H; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON LJ, 1988, BIOCHEMISTRY-US, V27, P983, DOI 10.1021/bi00403a022; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1982, J CHROMATOGR, V236, P499; LEVINE RL, 1982, BIOCHEMISTRY-US, V21, P2600, DOI 10.1021/bi00540a004; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; LIU D, 1987, Biochemistry, V26, P5221, DOI 10.1021/bi00391a001; MAIER KL, 1992, EUR RESPIR J, V5, P651; MICHAELIS J, 1990, BIOCHEM J, V270, P809, DOI 10.1042/bj2700809; MONCINO MD, 1991, BIOCHEMISTRY-US, V30, P1545, DOI 10.1021/bi00220a015; OSSANNA PJ, 1986, J CLIN INVEST, V77, P1939, DOI 10.1172/JCI112523; POCHON F, 1987, BIOCHEM BIOPH RES CO, V149, P488, DOI 10.1016/0006-291X(87)90394-9; POCHON F, 1989, BIOCHIM BIOPHYS ACTA, V996, P132, DOI 10.1016/0167-4838(89)90105-2; POTEMPA J, 1991, J BIOL CHEM, V266, P21482; QUIGLEY JP, 1991, J BIOL CHEM, V266, P1942; REDDY VY, 1989, J BIOL CHEM, V264, P13801; ROCHE PA, 1988, BIOCHEMISTRY-US, V27, P7876, DOI 10.1021/bi00420a044; ROCHE PA, 1989, BIOCHEMISTRY-US, V28, P7629, DOI 10.1021/bi00445a019; ROCHE PA, 1987, BIOCHEMISTRY-US, V26, P486, DOI 10.1021/bi00376a021; ROSEMAN JE, 1987, J BIOL CHEM, V262, P2101; SHECHTER Y, 1975, BIOCHEMISTRY-US, V14, P4497, DOI 10.1021/bi00691a025; SHECHTER Y, 1976, BIOCHEMISTRY-US, V23, P5071; SILVERBERG M, 1977, BIOCHIM BIOPHYS ACTA, V494, P441, DOI 10.1016/0005-2795(77)90178-7; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; SPYCHER SE, 1987, J BIOL CHEM, V262, P14606; STELMASZYNSKA T, 1978, EUR J BIOCHEM, V92, P301, DOI 10.1111/j.1432-1033.1978.tb12748.x; STONE PJ, 1982, METHOD ENZYMOL, V82, P588; STRANDBERG L, 1991, J BIOL CHEM, V266, P13852; STRICKLAND DK, 1984, BIOCHEMISTRY-US, V23, P6679, DOI 10.1021/bi00321a061; STRICKLAND DK, 1984, BIOCHEMISTRY-US, V23, P3115, DOI 10.1021/bi00309a002; THOMAS D, 1988, BIOL CELL, V64, P39, DOI 10.1016/0248-4900(88)90091-3; Thomas E L, 1986, Methods Enzymol, V132, P569; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TYAGI SC, 1990, J BIOL CHEM, V266, P5279; VANLEUVEN F, 1982, BIOCHEM J, V203, P405, DOI 10.1042/bj2030405; VIRCA GD, 1984, J BIOL CHEM, V259, P8870; VIRCA GD, 1983, H-S Z PHYSIOL CHEM, V364, P1297, DOI 10.1515/bchm2.1983.364.2.1297; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; ZGLICZYNSKI JM, 1985, INT J BIOCHEM, V17, P393, DOI 10.1016/0020-711X(85)90216-2	68	95	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4683	4691						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508448				2022-12-27	WOS:A1994MW98900115
J	HUANG, L; YONEDA, M; KIMATA, K				HUANG, L; YONEDA, M; KIMATA, K			A SERUM-DERIVED HYALURONAN-ASSOCIATED PROTEIN (SHAP) IS THE HEAVY-CHAIN OF THE INTER-ALPHA-TRYPSIN INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-PROTEINASE INHIBITOR; SEQUENCE; CD44; PROTEOGLYCAN; FAMILY; RECEPTOR; DOMAINS; PLASMA; ACID; MOLECULE	We showed previously that hyaluronan (HA) synthesized by cultured fibroblasts firmly bound 85-kDa proteins. The proteins were derived from serum used for the culture and appeared to be covalently linked to HA (Yoneda, M., Suzuki, S., and Kimata, K. (1990) J. Biol. Chem. 265, 5247-5257). In these regards, we named this molecule SHAP (serum-derived HA associated proteins). Incubation of serum with exogenous HA under physiological conditions enabled us to prepare SHAP.HA complex without cell cultivation. The complex thus obtained from bovine or human serum was served for the characterization of SHAP. Digestion with HA-lyase and subsequent separation on SDS-polyacrylamide gel electrophoresis yielded two components, X and Y. Because of the block of their NH2 termini, peptides were obtained by the digestion of X and Y with V8 protease, separated on SDS-polyacrylamide gel electrophoresis and then subjected to the anaylsis. Peptides from X and Y showed a high degree of sequence similarity to the two heavy chains, HC2 and HC1, of human inter-alpha-trypsin inhibitor (ITI), respectively (over 80% with bovine SHAP and essentially 100% with human SHAP). Cross-reactivity with antibodies against ITI supported the findings. Direct digestion of the complex with V8 protease and the subsequent purification of the HA-resistant fragment complex were performed to identify the HA-binding domains. NH2-terminal sequences of the fragments suggested the participation of the COOH-terminal half of ITI with an amphipathic alpha helix structure in the HA binding.			HUANG, L (corresponding author), AICHI MED UNIV, INST MOLEC SCI MED, YAZAKO, NAGAKUTE, AICHI 48011, JAPAN.							ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; BIGNAMI A, 1993, J NEUROSCI RES, V34, P97, DOI 10.1002/jnr.490340110; BORK P, 1991, BIOCHEM J, V279, P908, DOI 10.1042/bj2790908; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CASTILLO GM, 1993, FEBS LETT, V318, P292, DOI 10.1016/0014-5793(93)80531-X; CHEN L, 1992, J BIOL CHEM, V267, P12380; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DIARRAMEHRPOUR M, 1992, BIOCHIM BIOPHYS ACTA, V1132, P114, DOI 10.1016/0167-4781(92)90065-8; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; ENGHILD JJ, 1993, J BIOL CHEM, V268, P8711; ENGHILD JJ, 1989, J BIOL CHEM, V264, P15975; GEBHARD W, 1989, EUR J BIOCHEM, V181, P571, DOI 10.1111/j.1432-1033.1989.tb14762.x; GEBHARD W, 1988, BIOL CHEM H-S, V369, P19; GEBHARD W, 1988, FEBS LETT, V229, P63, DOI 10.1016/0014-5793(88)80798-1; GEBHARD W, 1986, PROTEINASE INHIBITOR, P375; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HUTADILOK N, 1988, ANN RHEUM DIS, V47, P377, DOI 10.1136/ard.47.5.377; KIMATA K, 1974, J BIOL CHEM, V249, P1646; KNUDSON W, 1989, CIBA F SYMP, V143, P150; KUHN LA, 1990, P NATL ACAD SCI USA, V87, P8506, DOI 10.1073/pnas.87.21.8506; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; ODUM L, 1990, INT J BIOCHEM, V22, P925, DOI 10.1016/0020-711X(90)90197-B; ODUM L, 1992, INT J BIOCHEM, V24, P215, DOI 10.1016/0020-711X(92)90249-Z; PRATT CW, 1986, ARCH BIOCHEM BIOPHYS, V248, P587, DOI 10.1016/0003-9861(86)90512-6; PRATT CW, 1987, ARCH BIOCHEM BIOPHYS, V258, P591, DOI 10.1016/0003-9861(87)90381-X; REISINGER P, 1985, BIOL CHEM H-S, V366, P479, DOI 10.1515/bchm3.1985.366.1.479; ROUET P, 1992, BIOL CHEM H-S, V373, P1019, DOI 10.1515/bchm3.1992.373.2.1019; SALIER JP, 1980, ANAL BIOCHEM, V109, P273, DOI 10.1016/0003-2697(80)90649-1; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; SALIER JP, 1987, P NATL ACAD SCI USA, V84, P8272, DOI 10.1073/pnas.84.23.8272; Sandson J, 1965, Trans Assoc Am Physicians, V78, P304; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SHINOMURA T, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P35; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; UNDERHILL C, 1992, J CELL SCI, V103, P293; WANG HS, 1992, CONNECT TISSUE RES, V28, P29, DOI 10.3109/03008209209014226; WEIGEL PH, 1989, CIBA F SYMP, V143, P248; WEST DC, 1989, CIBA F SYMP, V143, P187; YONEDA M, 1990, J BIOL CHEM, V265, P5247; YONEDA M, 1991, CONNECT TISSUE, V22, P31; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	48	149	166	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26725	26730						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	7504674				2022-12-27	WOS:A1993MK42500104
J	VINITSKY, A; GRUBMEYER, C				VINITSKY, A; GRUBMEYER, C			A NEW PARADIGM FOR BIOCHEMICAL ENERGY COUPLING - SALMONELLA-TYPHIMURIUM NICOTINATE PHOSPHORIBOSYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PNCB GENE; INTERMEDIATE; SYNTHETASE; MECHANISM; SEQUENCE; ATP	The pncB gene of Salmonella typhimurium was used to develop an overexpression system for nicotinate phosphoribosyltransferase (NAPRTase, EC 2.4.2.11), which forms nicotinate mononucleotide (NAMN) and PP(i) from nicotinate and alpha-D-5-phosphoribosyl-1-pyrophosphate (PRPP). NAPRTase hydrolyzes ATP in 1:1 molar stoichiometry to NAMN synthesis. Hydrolysis of ATP alters the ratio of products/substrates for the reaction nicotinate + PRPP half arrow right over half arrow left NAMN + PP(i) from its equilibrium value of 0.67 to a steady-state value of 1100. The energy for the maintenance of this ratio must come from ATP hydrolysis. However, in contrast to other ATP-utilizing enzymes, when all ATP is hydrolyzed the unfavorable product/substrate ratio collapses. ATP/ADP exchange results suggest that the overall reaction involves a phosphoenzyme (E-P) arising from E. ATP. K(m) values for nicotinate and PRPP each decreased by 200-fold when ATP was present to phosphorylate the enzyme. PP(i) stimulated the ATPase activity of the enzyme to V(max) values, suggesting that PP(i) formation during catalysis provides a trigger for cleavage of the putative E-P in the overall reaction and regenerates the low affinity form of the enzyme. A model is presented in which alternation of high and low affinity forms of NAPRTase provides a ''steady-state'' coupling between ATP hydrolysis and NAMN formation.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,3400 N BROAD ST,PHILADELPHIA,PA 19140; NYU,DEPT BIOL,NEW YORK,NY 10003	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; New York University								AMES GFL, 1990, BACTERIA, V12, P225; ARMON T, 1990, J BIOL CHEM, V265, P20723; BHATIA MB, 1990, BIOCHEMISTRY-US, V29, P10480, DOI 10.1021/bi00498a009; CULLIS PM, 1992, BIOCHEMISTRY-US, V31, P9642, DOI 10.1021/bi00155a017; Davis R., 1980, ADV BACTERIAL GENETI; FERRO AM, 1987, PYRIDINE NUCLEOTID B, V2, P25; HANNA LS, 1983, J BIOL CHEM, V258, P9745; HONJO T, 1966, BIOCHEM BIOPH RES CO, V25, P199, DOI 10.1016/0006-291X(66)90580-8; IMSANDE J, 1961, J BIOL CHEM, V236, P525; IMSANDE J, 1964, BIOCHIM BIOPHYS ACTA, V85, P255, DOI 10.1016/0926-6569(64)90246-9; Jencks W P, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P75; KASAROV LB, 1973, BIOCHIM BIOPHYS ACTA, V320, P372, DOI 10.1016/0304-4165(73)90318-8; KOSAKA A, 1977, ARCH BIOCHEM BIOPHYS, V179, P334, DOI 10.1016/0003-9861(77)90119-9; KOSAKA A, 1971, J BIOL CHEM, V246, P3277; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MIDELFORT CF, 1976, J BIOL CHEM, V251, P5881; MUSICK WDL, 1981, CRC CR REV BIOCH MOL, V11, P1, DOI 10.3109/10409238109108698; NIEDEL J, 1973, J BIOL CHEM, V248, P3500; OGASAWAR.N, 1966, BIOCHIM BIOPHYS ACTA, V118, P422, DOI 10.1016/S0926-6593(66)80052-8; PACKMAN PM, 1967, J BIOL CHEM, V242, P2075; PREISS J, 1958, J BIOL CHEM, V233, P492; PURICH DL, 1983, CONT ENZYME KINETICS, P403; SMITH LD, 1969, J BIOL CHEM, V244, P68; STAHL N, 1987, BIOCHEMISTRY-US, V26, P7654, DOI 10.1021/bi00398a019; STITT BL, 1988, J BIOL CHEM, V263, P11130; TANFORD C, 1983, ANNU REV BIOCHEM, V52, P379, DOI 10.1146/annurev.bi.52.070183.002115; TREVORROW K, 1984, J BIOENERG BIOMEMBR, V16, P5359; VINITSKY A, 1991, J BACTERIOL, V173, P536, DOI 10.1128/jb.173.2.536-540.1991; VONDERSAAL W, 1985, J BIOL CHEM, V260, P4993; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WUBBOLTS MG, 1990, J BIOL CHEM, V265, P17665	33	41	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					26004	26010						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503993				2022-12-27	WOS:A1993MK10000101
J	ENGLISH, JM; VANDERBILT, CA; XU, SC; MARCUS, S; COBB, MH				ENGLISH, JM; VANDERBILT, CA; XU, SC; MARCUS, S; COBB, MH			ISOLATION OF MEK5 AND DIFFERENTIAL EXPRESSION OF ALTERNATIVELY SPLICED FORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-KINASE; MAP KINASE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; SCHIZOSACCHAROMYCES-POMBE; INVITRO; YEAST; IDENTIFICATION; INSULIN; FAMILY	The prototype mitogen-activated protein (MAP) kinase module is a three-kinase cascade consisting of the MAP kinase, extracellular signal-regulated protein kinase (ERK) 1 or ERK2, the MAP/ERK kinase (MEK) MEK1 or MEK2, and the MEK kinase, Raf-1 or B-Raf. This and other MAP kinase modules are thought to be critical signal transducers in major cellular events including proliferation, differentiation, and stress responses. To identify novel mammalian MAP kinase modules, polymerase chain reaction was used to isolate a new MEK family member, MEK5, from the rat. MEK5 is more closely related to MEK1 and MEK2 than to the other known mammalian MEKs, MKK3 and MKK4. MEK5 is thought to lie in an uncharacterized MAP kinase pathway, because MEK5 does not phosphorylate the ERK/MAP kinase family members ERK1, ERK2, ERK3, JNK/SAPK, or p38/HOG1, nor will Raf-1, c-Mos, or MEKK1 highly phosphorylate it. Alternative splicing results in a 50-kDa alpha and a 40-kDa beta isoform of MEK5. MEK5 beta is ubiquitously distributed and primarily cytosolic. MEK5 alpha is expressed most highly in liver and brain and is particulate. The 23 amino acids encoded by the 5' exon in the larger alpha isoform are similar to a sequence found in certain proteins believed to associate with the actin cytoskeleton; this alternatively spliced modular domain may lead to the differential subcellular localization of MEK5 alpha.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	ENGLISH, JM (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235, USA.			Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34128] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CAMPBELL JS, 1994, RECENT PROG HORM RES, V50, P131; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE HS, 1993, J BIOL CHEM, V268, P5255; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LUND PK, 1986, J BIOL CHEM, V261, P12459; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; NADINDAVIS SA, 1990, MOL CELL BIOL, V10, P549, DOI 10.1128/MCB.10.2.549; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RACKER E, 1974, J BIOL CHEM, V249, P662; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SANGER F, 1977, P NATL ACAD SCI USA, V7, P5463; SEGER R, 1992, J BIOL CHEM, V267, P25628; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; WARBRICK E, 1992, EMBO J, V10, P4291; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; YAN MH, 1994, NATURE, V372, P798; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZHOU G, 1995, J BIOL CHEM, V270, P12664; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	66	185	191	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28897	28902		10.1074/jbc.270.48.28897	http://dx.doi.org/10.1074/jbc.270.48.28897			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499418	hybrid			2022-12-27	WOS:A1995TH05600062
J	RUSTAEUS, S; LINDBERG, K; BOREN, J; OLOFSSON, SO				RUSTAEUS, S; LINDBERG, K; BOREN, J; OLOFSSON, SO			BREFELDIN-A REVERSIBLY INHIBITS THE ASSEMBLY OF APO-B CONTAINING LIPOPROTEINS IN MCA-RH7777 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEP G2 CELLS; ADP-RIBOSYLATION FACTOR; APOLIPOPROTEIN-B; ENDOPLASMIC-RETICULUM; GOLGI MEMBRANES; MESSENGER-RNA; INTRACELLULAR-TRANSPORT; SECRETORY PROTEINS; GUANINE-NUCLEOTIDE; RAT HEPATOCYTES	BFA inhibited in a dose dependent way the assembly of apoB-48 very low density lipoprotein (VLDL) but allowed a normal rate of biosynthesis of the apolipoprotein and of the assembly of the dense (''high density lipoprotein (HDL) like'') apoB-48 particle (apoB-48 HDL). The inhibition of the assembly of apoB-48 VLDL occurred at BFA levels that allowed a major secretion of both transferrin and apoB-48 HDL. The assembly of apoB-100 containing lipoproteins was also inhibited by BFA but could be reactivated by a 30-60 min chase in the absence of BFA, which agreed with the time that was estimated to be needed to restore the secretory pathway (approximately 60 min). Also the assembly of apoB-48 VLDL was reversible, Both apoB-48 and apoB-100 that was labeled in the presence of BFA assembled VLDL after removal of the BFA. Both apoB-100 and apoB-48 were associated with the membrane pellet of the microsomes. Virtually all (122 +/- 30%) of the membrane associated pulse-labeled apoB-48 remained in the membrane after a 180-min chase in the presence of BFA, compared to only 21 +/- 2% in normal cells (mean +/- S.D., n = 4). The corresponding figures for apoB-100 was 40 +/- 7% in BFA-treated cells and 9 +/- 7% in normal cells (mean +/- S.D., n = 4). Pulse-chase experiments with BFA offered conditions to selectively follow the turnover of membrane-associated apoB-100. Such experiments indicated that this apoB-100 pool is a precursor to VLDL.	GOTHENBURG UNIV,INST MED BIOCHEM & MICROBIOL,DEPT MED BIOCHEM,S-41390 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,WALLENBERG LAB,S-41390 GOTHENBURG,SWEDEN	University of Gothenburg; University of Gothenburg				Andersson, Karin/0000-0002-9475-3040				ALEXANDER CA, 1973, J CELL BIOL, V69, P241; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1986, J BIOL CHEM, V83, P5296; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; BRUNING A, 1992, J BIOL CHEM, V267, P7726; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DU EZ, 1994, J BIOL CHEM, V269, P24169; FAINARU M, 1977, METABOLISM, V26, P999, DOI 10.1016/0026-0495(77)90017-8; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GRETCH DG, 1995, FASEB J, V9, pA174; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; KANE JP, 1980, P NATL ACAD SCI-BIOL, V77, P2465, DOI 10.1073/pnas.77.5.2465; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LAU PP, 1991, J BIOL CHEM, V266, P20550; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; OLOFSSON SO, 1987, ATHEROSCLEROSIS, V68, P1, DOI 10.1016/0021-9150(87)90088-8; ORCI L, 1991, CELL, V64, P1183; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SATO R, 1990, J BIOL CHEM, V265, P11880; SCOTT J, 1989, MOL BIOL MED, V6, P65; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; TSAI SC, 1994, P NATL ACAD SCI USA, V91, P3063, DOI 10.1073/pnas.91.8.3063; WETTESTEN M, 1985, EUR J BIOCHEM, V149, P461, DOI 10.1111/j.1432-1033.1985.tb08947.x; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WINDMUELLER HG, 1985, J LIPID RES, V26, P70; YAN JP, 1994, J CELL BIOL, V126, P65, DOI 10.1083/jcb.126.1.65; YAO ZM, 1991, J BIOL CHEM, V266, P3300	43	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28879	28886		10.1074/jbc.270.48.28879	http://dx.doi.org/10.1074/jbc.270.48.28879			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499415	hybrid			2022-12-27	WOS:A1995TH05600059
J	TIKKANEN, K; HAATAJA, S; FRANCOISGERARD, C; FINNE, J				TIKKANEN, K; HAATAJA, S; FRANCOISGERARD, C; FINNE, J			PURIFICATION OF A GALACTOSYL-ALPHA-1-4-GALACTOSE-BINDING ADHESIN FROM THE GRAM-POSITIVE MENINGITIS-ASSOCIATED BACTERIUM STREPTOCOCCUS-SUIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIMBRIATED ESCHERICHIA-COLI; BINDING PROTEIN; POLYACRYLAMIDE GELS; GROUP-B; SPECIFICITY; STRAINS; PIGS; IDENTIFICATION; COAGGREGATION; ACTINOMYCES	Streptococcus suis causes meningitis, sepsis, and other serious infections in newborn and young pigs and in adult humans. The Gal alpha 1-4Gal-binding adhesin of S. suis was purified to homogeneity by ultrasonic treatment, fractional ammonium sulfate precipitation, and preparative polyacrylamide gel electrophoresis. Pigeon ovomucoid, a glycoprotein with Gal alpha 1-4Gal terminals, was used to detect the adhesin by blotting. The purified adhesin appeared as single band of an apparent size of 18 kDa and of a pI of 6.4; no disulfide bridges were present. The amount of adhesin as revealed by pigeon ovomucoid binding correlated with the hemagglutination activity of different S. suis strains. The purified adhesin bound to latex particles induced hemagglutination which was specifically inhibited with the same inhibitors as hemagglutination by the intact bacteria, thus demonstrating that the purified protein was the Gal alpha 1-4Gal-recognizing adhesin of S. suis. Two adhesin variants (P-N and P-O) with differing Gal alpha 1-4Gal binding specificity had the similar electrophoretic mobilities and the same N-terminal peptide sequences, indicating that they were closely related. This represents the first isolation of an adhesin with well defined cell surface carbohydrate binding activity from Gram-positive bacteria associated with meningitis.	UNIV KUOPIO, AI VIRTANEN INST, SF-70211 KUOPIO, FINLAND; UNIV TURKU, DEPT MED BIOCHEM, SF-20520 TURKU, FINLAND; CHU LIEGE, SERV IMMUNOHEMATOL, B-4000 LIEGE, BELGIUM	University of Eastern Finland; University of Turku; University of Liege	TIKKANEN, K (corresponding author), UNIV KUOPIO, DEPT BIOCHEM & BIOTECHNOL, POB 1627, SF-70211 KUOPIO, FINLAND.		Haataja, Sauli/AAR-5103-2020; Finne, Jukka/B-6881-2008	Finne, Jukka/0000-0002-8076-3344				ANDERSEN RN, 1993, INFECT IMMUN, V61, P981, DOI 10.1128/IAI.61.3.981-987.1993; ARENDS JP, 1988, REV INFECT DIS, V10, P131; BAGG J, 1982, J MED MICROBIOL, V15, P363, DOI 10.1099/00222615-15-3-363; Beachey, 1980, BACTERIAL ADHERENC B, V6, P1; BEACHEY EH, 1981, J INFECT DIS, V143, P325, DOI 10.1093/infdis/143.3.325; BERGE A, 1995, J BIOL CHEM, V270, P9862, DOI 10.1074/jbc.270.17.9862; BOYD B, 1993, J EXP MED, V177, P1745, DOI 10.1084/jem.177.6.1745; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CLIFTONHADLEY FA, 1983, AGR SOME DISEASES EM, P33; COLLETT MS, 1989, ADV VET SCI COMP MED, V33, P109; ELLIOTT SD, 1980, J HYG-CAMBRIDGE, V85, P275, DOI 10.1017/S0022172400063312; FRANCOISGERARD C, 1980, REV FR TRANSFUS IMMU, V23, P95, DOI 10.1016/S0338-4535(80)80050-X; FRANCOISGERARD C, 1979, BIOCHEM J, V177, P679, DOI 10.1042/bj1770679; GANESHKUMAR N, 1991, INFECT IMMUN, V59, P1093, DOI 10.1128/IAI.59.3.1093-1099.1991; GOLDHAR J, 1987, INFECT IMMUN, V55, P1837, DOI 10.1128/IAI.55.8.1837-1842.1987; HAATAJA S, 1993, J BIOL CHEM, V268, P4311; HAATAJA S, 1994, J BIOL CHEM, V269, P27466; HACKER J, 1993, INFECT IMMUN, V61, P544, DOI 10.1128/IAI.61.2.544-550.1993; HANSKI E, 1992, P NATL ACAD SCI USA, V89, P6172, DOI 10.1073/pnas.89.13.6172; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; KALLENIUS G, 1980, FEMS MICROBIOL LETT, V7, P297, DOI 10.1111/j.1574-6941.1980.tb01608.x; KORHONEN TK, 1985, INFECT IMMUN, V48, P486, DOI 10.1128/IAI.48.2.486-491.1985; KORHONEN TK, 1985, ENTEROBACTERIAL SURF, P301; KURL DN, 1989, INFECT IMMUN, V57, P384, DOI 10.1128/IAI.57.2.384-389.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPOLLA RJ, 1991, INFECT IMMUN, V59, P2677, DOI 10.1128/IAI.59.8.2677-2685.1991; LIUKKONEN J, 1992, J BIOL CHEM, V267, P21105; MOCH T, 1987, P NATL ACAD SCI USA, V84, P3462, DOI 10.1073/pnas.84.10.3462; MURRAY PA, 1986, INFECT IMMUN, V53, P359, DOI 10.1128/IAI.53.2.359-365.1986; NOWICKI B, 1986, MICROB PATHOGENESIS, V1, P335, DOI 10.1016/0882-4010(86)90066-5; Ofek I., 1990, CURR TOP MICROBIOL, V151, P91; PARKKINEN J, 1986, INFECT IMMUN, V54, P37, DOI 10.1128/IAI.54.1.37-42.1986; QUESSY S, 1995, INFECT IMMUN, V63, P1975, DOI 10.1128/IAI.63.5.1975-1979.1995; RUDEL T, 1995, NATURE, V373, P357, DOI 10.1038/373357a0; SANDFORD SE, 1992, DISEASES SWINE, P588; SIHVONEN L, 1988, ACTA VET SCAND, V29, P9; STINSON MW, 1982, INFECT IMMUN, V35, P335, DOI 10.1128/IAI.35.1.335-342.1982; TROTTIER S, 1991, REV INFECT DIS, V13, P1251; VAISANENRHEN V, 1984, INFECT IMMUN, V43, P149; VECHT U, 1985, VET QUART, V7, P315, DOI 10.1080/01652176.1985.9694005	41	27	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28874	28878		10.1074/jbc.270.48.28874	http://dx.doi.org/10.1074/jbc.270.48.28874			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499414	hybrid			2022-12-27	WOS:A1995TH05600058
J	CHEN, J; PARSONS, S; BRAUTIGAN, DL				CHEN, J; PARSONS, S; BRAUTIGAN, DL			TYROSINE PHOSPHORYLATION OF PROTEIN PHOSPHATASE 2A IN RESPONSE TO GROWTH-STIMULATION AND V-SRC TRANSFORMATION OF FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; OKADAIC ACID; T-ANTIGENS; B-SUBUNIT; TYPE-2A; MODULATION; COMPLEXES; DISTINCT; HEPARIN; FORM	The catalytic subunit of protein phosphatase 2A (PP2A) is inactivated by in vitro phosphorylation of Tyr(307) by receptor and nonreceptor protein tyrosine kinases (Chen, J., Martin, B. L., and Brautigan, D. L. (1992) Science 257, 1261-1264). Here we show the phosphorylation of PP2A in cells under different growth conditions. In lysates of nontransformed murine 10T1/2 fibroblasts, there were two forms of PP2A at 36 kDa detected after two-dimensional gel electrophoresis and immunoblotting with anti-PP2A peptide antibody. These two forms exactly comigrated with unphosphorylated purified PP2A and the PP2A P-32-labeled by in vitro phosphorylation with p60(v-src) kinase. The phosphorylated form of PP2A recovered from red blood cells or produced by in vitro phosphorylation was eliminated by incubation with tyrosine-specific phosphatase (PTP1B). Transformation of 10T1/2 cells by expression of p60(v-src) resulted in most of the PP2A in the cells being converted to a phosphorylated form that was reactive with anti phosphotyrosine antibody. Serum starvation of cells reduced the amount of phosphorylated PP2A, whereas serum stimulation of quiescent cells caused an increase to the same relative amount of phosphorylated PP2A as in src-transformed cells. Addition of epidermal growth factor to quiescent NeoR cells (10T1/2 fibroblasts overexpressing epidermal growth factor receptors) temporarily increased the level of phosphorylation of PP2A, with a peak at 5-15 min and a return to basal level within 60 min. The results show that PP2A is phosphorylated in intact cells, and the extent of this modification is increased by growth factors or cell transformation, providing evidence for a physiological mechanism of PP2A regulation.	BROWN UNIV,DIV BIOL & MED,BIOCHEM SECT,PROVIDENCE,RI 02912; UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908	Brown University; University of Virginia								BRAUTIGAN DL, 1991, P NATL ACAD SCI USA, V88, P6696, DOI 10.1073/pnas.88.15.6696; BRAUTIGAN DL, 1994, CELL CYCLE 93 REGULA; BRAUTIGAN DL, 1993, ADV PROT PHOSPHATASE, V7, P49; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHERNOFF J, 1983, J BIOL CHEM, V258, P7852; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CSORTOS C, 1990, BIOCHEM BIOPH RES CO, V169, P559, DOI 10.1016/0006-291X(90)90367-V; DAMUNI Z, 1993, P NATL ACAD SCI USA, V90, P2500; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; GUO H, 1993, J BIOL CHEM, V268, P11193; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HERMANN J, 1988, EUR J BIOCHEM, V173, P17, DOI 10.1111/j.1432-1033.1988.tb13961.x; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KIM YH, 1993, J BIOL CHEM, V268, P18513; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LUDLOW JW, 1992, ONCOGENE, V7, P1011; MARTIN BL, 1991, FEBS LETT, V285, P6, DOI 10.1016/0014-5793(91)80712-C; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; SELVA E, 1993, J BIOL CHEM, V268, P2250; SENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; UEMURA T, 1993, GENE DEV, V7, P429, DOI 10.1101/gad.7.3.429; USUI H, 1988, J BIOL CHEM, V263, P3752; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; WALKER F, 1993, J BIOL CHEM, V268, P19552; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521	34	246	253	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					7957	7962						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510677				2022-12-27	WOS:A1994NB40900022
J	DOMIN, J; HIGGINS, T; ROZENGURT, E				DOMIN, J; HIGGINS, T; ROZENGURT, E			PREFERENTIAL INHIBITION OF PLATELET-DERIVED GROWTH FACTOR-STIMULATED DNA-SYNTHESIS AND PROTEIN-TYROSINE PHOSPHORYLATION BY NORDIHYDROGUAIARETIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; SIMIAN SARCOMA-VIRUS; ARACHIDONIC-ACID; SIGNAL TRANSDUCTION; BIOLOGICAL-ACTIVITY; FACTOR RECEPTOR; KINASE-ACTIVITY; SH3 DOMAIN; BOMBESIN; VASOPRESSIN	Nordihydroguaiaretic acid (NDGA), a reportedly specific lipoxygenase inhibitor, was found to selectively inhibit platelet-derived growth factor (PDGF)-stimulated DNA synthesis in Swiss 3T3 cells. Maximal inhibition of PDGF-induced [H-3]thymidine incorporation (96%) was observed using 4 mu M NDGA (IC50 = 1.5 mu M). No effect of NDGA was observed upon DNA synthesis stimulated with either fetal bovine serum, bombesin, or epidermal growth factor (EGF) in the presence of insulin, or with the potent mitogen Pasteurella multocida toxin. The selective inhibition of PDGF-stimulated DNA synthesis by NDGA was also observed in diploid murine cells, rat, and human fibroblasts. Furthermore, 4 mu M NDGA also inhibited PDGF-stimulated anchorage-independent colony growth of rat-1 cells by 76%. Using Swiss 3T3 cells, we found that PDGF-stimulated arachidonic acid mobilization and prostaglandin E(2) production was abolished by NDGA in a dose-dependent manner. Inhibition of PDGF-stimulated arachidonic acid mobilization by NDGA could not, however, explain its potent inhibitory effect upon PDGF-stimulated DNA synthesis. Our results showed that NDGA also selectively inhibited PDGF receptor tyrosine phosphorylation in a dose-dependent manner in intact cells. Protein tyrosine phosphorylation stimulated by EGF or bombesin was not altered by NDGA treatment. Crucially, NDGA inhibited in vitro the tyrosine kinase activity of anti-phosphotyrosine and anti-PDGF receptor immunoprecipitates prepared from cultures stimulated with PDGF. This inhibition of receptor tyrosine phosphorylation in a cell-free system confirmed that NDGA acts directly at the level of the PDGF receptor tyrosine kinase domain. These results suggest that the potent and selective inhibitory effect of NDGA on PDGF-stimulated DNA synthesis results from its inhibitory action on tyrosine phosphorylation.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANG J, 1984, INFLAMMATION, V8, P143, DOI 10.1007/BF00916090; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; DOMIN J, 1993, J BIOL CHEM, V268, P8927; DOMIN J, 1992, J BIOL CHEM, V267, P15217; DUAN DSR, 1991, J BIOL CHEM, V266, P413; ENGSTROM U, 1992, J BIOL CHEM, V267, P16581; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GIL J, 1991, J CELL BIOL, V113, P943, DOI 10.1083/jcb.113.4.943; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HOSANG M, 1985, J CELL BIOCHEM, V29, P265, DOI 10.1002/jcb.240290310; JOHNSSON A, 1985, NATURE, V317, P438, DOI 10.1038/317438a0; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORN SJ, 1990, MOL PHARMACOL, V38, P524; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOPEZRIVAS A, 1984, EMBO J, V3, P939, DOI 10.1002/j.1460-2075.1984.tb01911.x; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACDONALD ML, 1988, J BIOL CHEM, V263, P1575; MCCORMICK DL, 1987, CANCER LETT, V37, P139, DOI 10.1016/0304-3835(87)90156-X; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; MIYAZAWA K, 1985, JPN J PHARMACOL, V38, P119; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NOAR Z, 1988, MOL ENDOCRINOL, V2, P1043; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; RONDEAU E, 1990, BIOCHIM BIOPHYS ACTA, V1055, P165, DOI 10.1016/0167-4889(90)90117-V; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROZENGURT E, 1991, CANCER CELL-MON REV, V3, P397; ROZENGURT E, 1990, P NATL ACAD SCI USA, V87, P123, DOI 10.1073/pnas.87.1.123; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1975, P NATL ACAD SCI USA, V72, P4492, DOI 10.1073/pnas.72.11.4492; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANWAUWE J, 1983, PROSTAGLANDINS, V26, P725, DOI 10.1016/0090-6980(83)90057-6; VASSBOTN FS, 1992, J BIOL CHEM, V267, P15635; WESTERMARK B, 1991, CANCER RES, V51, P5087; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	56	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 18	1994	269	11					8260	8267						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NB409	7510683				2022-12-27	WOS:A1994NB40900066
J	KING, SM; WITMAN, GB				KING, SM; WITMAN, GB			MULTIPLE SITES OF PHOSPHORYLATION WITHIN THE ALPHA-HEAVY-CHAIN OF CHLAMYDOMONAS OUTER ARM DYNEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-SITES; FLAGELLAR AXONEMES; MOLECULAR-WEIGHT; PARAMECIUM; PURIFICATION; REINHARDTII; PROTEINS; ATP; POLYPEPTIDE; TRANSPORT	We have examined the phosphorylation of the alpha dynein heavy chain (DHC) from the outer arm of the Chlamydomonas flagellum. Quantitative analysis indicates that this DHC is phosphorylated at a minimum of six sites. Using previously identified proteolytic and photocleavage sites (King, S. M., and Witman, G. B. (1988) J. Biol. Chem. 263, 9244-9255), we have mapped two regions that are phosphorylated in vivo. One is located in a 20-kDa section immediately N-terminal to the site of V1 photocleavage. Thus, this region is close to the ATP hydrolytic site and also to the predicted junction between the head and stem domains of the particle. The second encompasses the 90-kDa C-terminal region of the molecule, In this latter section, at least one site is found in an similar to 2-kDa region close to domains that are predicted to adopt a coiled-coil structure in those DHCs that have been sequenced. The alpha DHC also is specifically labeled by endogenous kinases in demembranated, washed axonemes, suggesting that at least one alpha DHC kinase is located close to, or is a component of, the outer arm in situ.	WORCESTER FDN EXPTL BIOL INC, CELL BIOL GRP, SHREWSBURY, MA 01545 USA	Worcester Foundation for Biomedical Research				Witman, George/0000-0002-9497-9218	NATIONAL CANCER INSTITUTE [P30CA012708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030626, R37GM030626] Funding Source: NIH RePORTER; NCI NIH HHS [CA12708] Funding Source: Medline; NIGMS NIH HHS [GM30626] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONINI NM, 1990, J CELL SCI, V95, P219; CHILCOTE TJ, 1990, J BIOL CHEM, V265, P17257; GIBBONS IR, 1991, NATURE, V352, P640, DOI 10.1038/352640a0; GOODENOUGH U, 1984, J MOL BIOL, V180, P1083, DOI 10.1016/0022-2836(84)90272-9; GOODENOUGH UW, 1982, J CELL BIOL, V95, P798, DOI 10.1083/jcb.95.3.798; HAMASAKI T, 1991, P NATL ACAD SCI USA, V88, P7918, DOI 10.1073/pnas.88.18.7918; JOHNSON KA, 1983, J CELL BIOL, V96, P669, DOI 10.1083/jcb.96.3.669; KAMIYA R, 1988, J CELL BIOL, V107, P2253, DOI 10.1083/jcb.107.6.2253; KINDLE KL, 1989, J CELL BIOL, V109, P2589, DOI 10.1083/jcb.109.6.2589; KING SM, 1986, METHOD ENZYMOL, V134, P291; KING SM, 1990, J BIOL CHEM, V265, P19807; KING SM, 1988, J BIOL CHEM, V263, P9244; KING SM, 1987, J BIOL CHEM, V262, P17596; KING SM, 1989, J BIOL CHEM, V264, P10210; King SM, 1989, CELL MOVEMENT DYNEIN, V1, P61; KOONCE MP, 1992, J CELL BIOL, V119, P1597, DOI 10.1083/jcb.119.6.1597; LARSEN J, 1991, J PROTOZOOL, V38, P55, DOI 10.1111/j.1550-7408.1991.tb04801.x; LEEEIFORD A, 1986, J BIOL CHEM, V261, P2337; Luck D.J.L., 1989, CELL MOVEMENT, V1, P49; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MIKAMI A, 1993, NEURON, V10, P787, DOI 10.1016/0896-6273(93)90195-W; MITCHELL DR, 1985, J CELL BIOL, V100, P1228, DOI 10.1083/jcb.100.4.1228; MITCHELL DR, 1994, IN PRESS J CELL SCI; MOCZ G, 1990, BIOCHEMISTRY-US, V29, P4839, DOI 10.1021/bi00472a013; OGAWA K, 1991, NATURE, V352, P643, DOI 10.1038/352643a0; PFISTER KK, 1982, CELL MOTIL CYTOSKEL, V2, P525, DOI 10.1002/cm.970020604; PFISTER KK, 1984, J BIOL CHEM, V259, P2072; PIPERNO G, 1991, J CELL BIOL, V112, P701, DOI 10.1083/jcb.112.4.701; PIPERNO G, 1981, CELL, V27, P331, DOI 10.1016/0092-8674(81)90416-5; PIPERNO G, 1979, J BIOL CHEM, V254, P3084; PORTER ME, 1983, J BIOL CHEM, V258, P6575; REMILLARD SP, 1982, J CELL BIOL, V93, P615, DOI 10.1083/jcb.93.3.615; SAKAKIBARA H, 1991, J CELL BIOL, V113, P615, DOI 10.1083/jcb.113.3.615; SAKAKIBARA H, 1993, J CELL BIOL, V122, P653, DOI 10.1083/jcb.122.3.653; SAKAKIBARA H, 1989, J CELL SCI, V92, P77; SCHROEDER CC, 1990, J CELL BIOL, V111, P2553, DOI 10.1083/jcb.111.6.2553; SEGAL RA, 1985, J CELL BIOL, V101, P1702, DOI 10.1083/jcb.101.5.1702; STEPHENS RE, 1992, J CELL SCI, V103, P999; WILKERSON CG, 1994, IN PRESS J CELL SCI; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; WITMAN GB, 1991, SERONO SYM, V75, P439; WITMAN GB, 1983, J SUBMICR CYTOL PATH, V15, P193; Witman George B., 1994, V13, P229	43	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	1994	269	7					5452	5457						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MX571	7508939				2022-12-27	WOS:A1994MX57100111
J	GREENBERG, S; CHANG, P; SILVERSTEIN, SC				GREENBERG, S; CHANG, P; SILVERSTEIN, SC			TYROSINE PHOSPHORYLATION OF THE GAMMA-SUBUNIT OF FC(GAMMA)-RECEPTORS, P72(SYK), AND PAXILLIN DURING FC-RECEPTOR-MEDIATED PHAGOCYTOSIS IN MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; SIGNAL TRANSDUCTION; MOUSE MACROPHAGES; CROSS-LINKING; PROTEIN; ACTIVATION; KINASE; ANTIGEN; INTEGRINS; IGG	Fc receptor-mediated phagocytosis in mouse macrophages occurs by a tyrosine kinase-dependent pathway (Greenberg, S., Chang, P., and Silverstein, S. C. (1993) J. Exp. Med. 177, 529-534). To identify proteins that are phosphorylated on tyrosine residues during phagocytosis, we used anti-phosphotyrosine antibodies to perform immunoblotting and immunoprecipitation of lysates derived from Fc receptor-stimulated macrophages. Proteins of 26, 30, 35, 37, 40, 43, 47, 56, 60, 68, 83, 116, and 150 kDa displayed enhanced tyrosine phosphorylation during Fc receptor-mediated phagocytosis. Tyrosine phosphorylation of these proteins was not a consequence of actin polymerization since treatment with cytochalasin D did not alter the pattern of Fc receptor-stimulated protein tyrosine phosphorylation. The 68-kDa tyrosine phosphoprotein was identified as paxillin, a cytoskeletal-associated tyrosine kinase substrate previously identified in fibroblasts and shown to localize to focal adhesions (Turner, C. E., Glenney, J. R., and Burridge, K. (1990) J. Cell Biol. 111, 1059-1068). Paxillin colocalized with F-actin beneath nascent phagosomes. In addition to the above proteins detected by anti-phosphotyrosine immunoblotting, the gamma subunit of FcRI and III was shown to undergo tyrosine phosphorylation during Fc receptor-mediated phagocytosis. Of several candidate tyrosine kinases that may be activated during Fc receptor stimulation, p72syk, but not p125FAK, displayed enhanced tyrosine phosphorylation during Fc receptor aggregation. The coordinated tyrosine phosphorylation of the gamma subunit of macrophage Fc receptors, the tyrosine kinase syk, and the cytoskeletal-associated protein, paxillin, may be important steps in integrating signals between Fc receptors and the underlying cytoskeleton.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL & CELLULAR BIOPHYS,ROVER LAB CELLULAR PHYSIOL,NEW YORK,NY 10032	Columbia University	GREENBERG, S (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,DIV PULM,P&S 9-503,630 W 168TH ST,NEW YORK,NY 10032, USA.				NHLBI NIH HHS [HL-02641] Funding Source: Medline; NIAID NIH HHS [AI-20516] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020516, R37AI020516] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARWAL A, 1993, J BIOL CHEM, V268, P15900; AMIGORENA S, 1992, NATURE, V358, P337, DOI 10.1038/358337a0; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BONNEROT C, 1992, EMBO J, V11, P2747, DOI 10.1002/j.1460-2075.1992.tb05340.x; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; BURRIDGE K, 1992, CELL, V71, P649; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; EINSPAHR KJ, 1991, P NATL ACAD SCI USA, V88, P6279, DOI 10.1073/pnas.88.14.6279; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; FINLAY BB, 1991, J CELL SCI, V99, P283; FUORTES M, 1993, J CELL BIOL, V120, P777, DOI 10.1083/jcb.120.3.777; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; GREENBERG S, 1990, J EXP MED, V172, P1853, DOI 10.1084/jem.172.6.1853; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HO MK, 1982, J IMMUNOL, V128, P2281; HUANG CK, 1990, BIOCHEM J, V269, P431, DOI 10.1042/bj2690431; HUANG MM, 1992, J BIOL CHEM, V267, P5467; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RANKIN BM, 1993, J IMMUNOL, V150, P605; RETH M, 1989, NATURE, V338, P384; SALCEDO TW, 1993, J EXP MED, V177, P1475, DOI 10.1084/jem.177.5.1475; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SCHOLL PR, 1992, J IMMUNOL, V149, P1751; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TING AT, 1991, J IMMUNOL, V147, P3122; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; UNKELESS JC, 1977, J EXP MED, V145, P931, DOI 10.1084/jem.145.4.931; WEINSHANK RL, 1988, J EXP MED, V167, P1909, DOI 10.1084/jem.167.6.1909; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WIRTHMUELLER U, 1992, J EXP MED, V175, P1381, DOI 10.1084/jem.175.5.1381; YOUNG VB, 1992, J CELL BIOL, V116, P197, DOI 10.1083/jcb.116.1.197; YU KT, 1991, J BIOL CHEM, V266, P22564; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195	50	217	219	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3897	3902						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508923				2022-12-27	WOS:A1994MV63100112
J	MAJUMDAR, MK; FENG, LJ; MEDLOCK, E; TOKSOZ, D; WILLIAMS, DA				MAJUMDAR, MK; FENG, LJ; MEDLOCK, E; TOKSOZ, D; WILLIAMS, DA			IDENTIFICATION AND MUTATION OF PRIMARY AND SECONDARY PROTEOLYTIC CLEAVAGE SITES IN MURINE STEM-CELL FACTOR CDNA YIELDS BIOLOGICALLY-ACTIVE, CELL-ASSOCIATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMORDIAL GERM-CELLS; GROWTH FACTOR-ALPHA; BONE-MARROW CULTURES; KIT-LIGAND; GENE-PRODUCT; SI-LOCUS; TRANSMEMBRANE; HEMATOPOIESIS; MOUSE; PRECURSOR	Phenotypic abnormalities of melanocytes, germ cells, and hematopoietic cells of Steel mice demonstrate the critical role of stem cell factor (SCF) in development. Production of SCF in the hematopoietic microenvironment as either a membrane-associated or soluble factor leads to pleiotropic effects on hematopoietic stem and progenitor cells and significant effects on the production of erythroid cells. Although the production of these two forms of SCF is highly regulated, the physiologic role(s) of membrane-associated and soluble SCF remain unclear. We have demonstrated that the generation of soluble murine SCF by murine stromal cells derived from the fetal hematopoietic microenvironment is dependent on two distinct proteolytic cleavage sites. The primary site in exon 6 is preferentially utilized in these cells. The secondary site located in exon 7 is utilized only in the absence of the primary site. Proteolytic processing at this secondary site appears to be species-specific, since the human protein sequence diverges at this site, and protein expressed from the hilman cDNA encoding this site in murine stromal cells remains largely membrane-associated. Site-directed mutagenesis of the murine SCF cDNA encoding both proteolytic cleavage sites leads to the generation of membrane-associated and biologically active SCF on murine stromal cells. These results suggest that the regulation of processing of the secondary proteolytic cleavage site could play a critical role in the function of membrane-associated SCF protein.	INDIANA UNIV, SCH MED, HERMAN B WELLS CTR PEDIAT RES, INDIANAPOLIS, IN 46202 USA; AMGEN INC, THOUSAND OAKS, CA 91359 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, BOSTON, MA 02115 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Amgen; Harvard University; Boston Children's Hospital; Harvard Medical School	MAJUMDAR, MK (corresponding author), INDIANA UNIV, SCH MED, HOWARD HUGHES MED INST, INDIANAPOLIS, IN 46202 USA.				NHLBI NIH HHS [R01 HL46528] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046528] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allen T D, 1981, Ciba Found Symp, V84, P38; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CASHMAN JD, 1990, BLOOD, V75, P96; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; DOVER GA, 1991, CELL, V65, P9, DOI 10.1016/0092-8674(91)90401-J; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN JJ, 1992, BIOTECHNIQUES, V12, P718; LONGLEY BJ, 1993, NEW ENGL J MED, V328, P1302, DOI 10.1056/NEJM199305063281803; LYMAN SD, 1992, AM J PEDIAT HEMATOL, V14, P1; MAJUMDAR MK, 1993, ANAL BIOCHEM, V208, P403, DOI 10.1006/abio.1993.1071; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MARZIALI G, 1993, DEV BIOL, V157, P182, DOI 10.1006/dbio.1993.1122; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6; MEDLOCK ES, 1992, J CELL PHYSIOL, V153, P498, DOI 10.1002/jcp.1041530309; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PAUL SR, 1991, BLOOD, V77, P1723; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; RETTENMIER CW, 1989, CURR TOP MICROBIOL, V149, P129; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TOKSOZ D, 1992, P NATL ACAD SCI USA, V89, P7350, DOI 10.1073/pnas.89.16.7350; TOKSOZ D, 1980, BLOOD, V55, P931; TRENTIN JJ, 1967, 21ST MD AND HOSP ANN, P713; WILLIAMS DA, 1993, BLOOD, V81, P3169; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	45	76	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1237	1242						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507105				2022-12-27	WOS:A1994MR22000074
J	DATTO, MB; YU, Y; WANG, XF				DATTO, MB; YU, Y; WANG, XF			FUNCTIONAL-ANALYSIS OF THE TRANSFORMING GROWTH-FACTOR-BETA RESPONSIVE ELEMENTS IN THE WAF1/CIP1/P21 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; GENE-EXPRESSION; TGF-BETA; TRANSCRIPTION; KINASES; CLONING; FAMILY; INHIBITION; CYCLINS; PRODUCT	The transforming growth factor beta s (TGF-beta s) are a group of multifunctional growth factors that inhibit cell cycle progression in many cell types, The TGF-beta-induced cell cycle arrest has been partially attributed to the regulatory effects of TGF-beta on both the levels and activities of the G(1) cyclins and their cyclin-dependent kinase partners. The ability of TGF-beta to inhibit the activity of these kinase complexes derives in part from its regulatory effects on the cyclin-dependent kinase inhibitors, p21/WAF1/Cip1, p27(Kipl), and p15, Upon treatment of cells with TGF-beta, these three inhibitors bind to and block the activities of specific cyclin-cyclin-dependent kinase complexes to cause cell cycle arrest. Little is known, however, on the mechanism through which TGF-beta activates these cyclin dependent kinase inhibitors. In the case of p21, TGF-beta treatment leads to an increase in p21 mRNA. This increase in p21 mRNA is partly due to transcriptional activation of the p21 promoter by TGF-beta. To further define the signaling path ways through which TGF-beta induces p21, we have performed a detailed functional analysis on the p21 promoter. Through both deletion and mutation analysis of the p21 promoter, we have defined a 10-base pair sequence that is required for the activation of the p21 promoter by TGF-beta. In addition, this sequence is sufficient to drive TGF-beta-mediated transcription from a previously nonresponsive promoter. Preliminary gel shift assays demonstrate that this TGF-beta responsive element binds specifically to several proteins in vitro. Two of these proteins are the transcription factors Sp-1 and Sp-3. These studies represent the initial steps toward defining the signaling pathways involved in TGF-beta-mediated transcriptional activation of p21.	DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Duke University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045746] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45746] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BAUKAMP P, 1988, J CELL BIOL, V106, P761; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GU Y, 1993, NATURE, V336, P707; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HARPER JW, 1993, CELL, V75, P805; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; NASMYTH K, 1994, NATURE, V336, P634; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	36	401	405	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28623	28628		10.1074/jbc.270.48.28623	http://dx.doi.org/10.1074/jbc.270.48.28623			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499379	hybrid			2022-12-27	WOS:A1995TH05600023
J	MURTHY, YVSN; MASSEY, V				MURTHY, YVSN; MASSEY, V			CHEMICAL MODIFICATION OF THE N-10 RIBITYL SIDE-CHAIN OF FLAVINS - EFFECTS ON PROPERTIES OF FLAVOPROTEIN DISULFIDE OXIDOREDUCTASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART LIPOAMIDE DEHYDROGENASE; GLUTATHIONE-REDUCTASE; PIG-HEART; AZOTOBACTER-VINELANDII; RESOLUTION; RECONSTITUTION; BINDING; OXIDASE; ENZYME; NMR	Three flavin derivatives modified at the 2'-position of the flavin N-10 ribityl side chain were synthesized: arabinoflavin, 2'-F-2'-deoxyarabinoflavin, and 2'-deoxyriboflavin, These were converted to the FAD level with FAD synthetase, Apoproteins of lipoamide dehydrogenase, glutathione reductase, and mercuric reductase, a family of flavoprotein oxidoreductases, were reconstituted with these flavins. Significant reduction of the catalytic activities was observed with the modified enzymes, During anaerobic reduction of the modified enzymes with substrate or dithiothreitol, decreased thermodynamic stability of the two-electron reduced enzyme forms (EH(2)) and the accumulation of the four-electron reduced forms (EH(4)) noted. This effect was more pronounced in case of arabino-FAD-reconstituted enzymes than with the other two. It was found that NAD(+) binding influences the interaction between the flavin and the reduced disulfide in the 2'-F-arabino-FAD-lipoamide dehydrogenase, presumably by altering the relative oxidation-reduction potentials, F-19 NMR data were obtained for different forms of the 2'-F-arabino-FAD-lipoamide dehydrogenase, which suggest marked conformational changes from one form to the other, The F-19 NMR data for the oxidized forms of all three 2'-F-arabino-FAD proteins suggest that the fluorine experiences very similar chemical environments at the active sites.	UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-11106] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECVAR J, 1982, J BIOL CHEM, V257, P5607; BRADY AH, 1971, J BIOL CHEM, V246, P5498; FOX B, 1982, J BIOL CHEM, V257, P2498; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; GATTI DL, 1994, SCIENCE, V266, P110, DOI 10.1126/science.7939628; Ghisla S, 1994, FLAVINS AND FLAVOPROTEINS 1993, P283; GHISLA S, 1986, BIOCHEM J, V239, P1; GREIG JP, 1978, BIOL MAGN RESON, V1, P139; JARDETZKY O, 1981, NMR MOL BIOL, P52; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KELLOGG RM, 1992, TETRAHEDRON, V48, P4147, DOI 10.1016/S0040-4020(01)92193-3; KIM JJ, 1988, P NATL ACAD SCI USA, V18, P331; KIM JJP, 1992, PROG CLIN BIOL RES, V375, P111; LINDON JC, 1980, PROG NUCL MAG RES SP, V14, P27, DOI 10.1016/0079-6565(80)80002-1; MACHEROUX P, 1990, BIOCHEMISTRY-US, V29, P2670, DOI 10.1021/bi00463a008; MANSTEIN DJ, 1986, BIOCHEMISTRY-US, V25, P6807, DOI 10.1021/bi00370a012; MASSEY V, 1962, J BIOL CHEM, V237, P2347; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; MASSEY V, 1960, BIOCHEM J, V77, P341, DOI 10.1042/bj0770341; MATTEVI A, 1991, J MOL BIOL, V220, P975, DOI 10.1016/0022-2836(91)90367-F; MATTHEWS RG, 1976, J BIOL CHEM, V251, P3956; MATTHEWS RG, 1979, J BIOL CHEM, V254, P4974; MATTHEWS RG, 1976, FLAVINS FLAVOPROTEIN, P464; MILES DW, 1968, BIOCHEMISTRY-US, V7, P2791, DOI 10.1021/bi00848a014; MILLER SM, 1995, BIOCHEMISTRY-US, V34, P13066, DOI 10.1021/bi00040a018; Miller SM, 1994, FLAVINS AND FLAVOPROTEINS 1993, P575; SCHREUDER HA, 1994, BIOCHEMISTRY-US, V33, P10161, DOI 10.1021/bi00199a044; SHERRY B, 1985, BIOCHEMISTRY-US, V24, P2594, DOI 10.1021/bi00332a002; SPENCER R, 1976, BIOCHEMISTRY-US, V15, P1043, DOI 10.1021/bi00650a015; Sykes B D, 1978, Methods Enzymol, V49, P270; SYKES BD, 1980, MAGNETIC RESONANCE B, V1, P171; THORPE C, 1976, J BIOL CHEM, V251, P3553; TISHLER M, 1947, J AM CHEM SOC, V69, P1487, DOI 10.1021/ja01198a068; VANBERKEL WJH, 1991, EUR J BIOCHEM, V197, P769; VANBERKEL WJH, 1994, PROTEIN SCI, V3, P2245, DOI 10.1002/pro.5560031210; WEBER G, 1950, BIOCHEM J, V47, P114, DOI 10.1042/bj0470114; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; [No title captured]	39	17	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28586	28594		10.1074/jbc.270.48.28586	http://dx.doi.org/10.1074/jbc.270.48.28586			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499374	hybrid			2022-12-27	WOS:A1995TH05600018
J	UITTENBOGAARD, MN; GIEBLER, HA; REISMAN, D; NYBORG, JK				UITTENBOGAARD, MN; GIEBLER, HA; REISMAN, D; NYBORG, JK			TRANSCRIPTIONAL REPRESSION OF P53 BY HUMAN T-CELL LEUKEMIA-VIRUS TYPE-I TAX PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HELIX-LOOP-HELIX; LONG TERMINAL REPEAT; WILD-TYPE P53; HTLV-I; DNA-SEQUENCES; GENE; EXPRESSION; LYMPHOMA; PROMOTER; BINDING	The human T-cell leukemia virus type I oncoprotein Tax transcriptionally deregulates a wide variety of viral and cellular genes. Tax deregulation of gene expression is mediated through interaction with a variety of structurally unrelated cellular transcription factors, as Tax does not bind DNA in a sequence-specific manner. Although most of these cellular transcription factors have been shown to mediate activation by Tax, we have recently demonstrated that members of the basic helix-loop-helix (bHLH) family of transcription factors, which play a critical role in progression through the cell cycle, mediate repression by Tax. In this report, we examined whether Tax might repress transcription of the tumor suppressor p53, as the p53 gene has recently been demonstrated to be regulated by the bHLH protein c-Myc. Furthermore, loss or inactivation of the p53 gene has been shown to be causally associated with oncogenic transformation. We show that Tax represses transcription of the p53 gene and that this repression is dependent upon the bHLH recognition element in the p53 promoter. Together, these results suggest that Tax may promote malignant transformation through repression of p53 transcription.	COLORADO STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,FT COLLINS,CO 80523; COLORADO STATE UNIV,DEPT MICROBIOL,FT COLLINS,CO 80523; UNIV S CAROLINA,DEPT BIOL SCI,COLUMBIA,SC 29208	Colorado State University; Colorado State University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia				Uittenbogaard, Martine/0000-0003-0371-3041	NCI NIH HHS [R01 CA55035, R29 CA59986] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA059986, R01CA055035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTMAN R, 1988, J VIROL, V62, P1339, DOI 10.1128/JVI.62.4.1339-1346.1988; BEIMLING P, 1988, ONCOGENE, V4, P511; BHATIA KG, 1992, CANCER RES, V52, P4273; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; FREBOURG T, 1962, P NATL ACAD SCI USA, V89, P6413; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3551; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REID RL, 1993, ONCOGENE, V8, P3029; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; REISMAN D, 1988, P NATL ACAD SCI USA, V85, P5146, DOI 10.1073/pnas.85.14.5146; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; UITTENBOGAARD MN, 1994, J BIOL CHEM, V269, P22466; WIMAN KG, 1991, ONCOGENE, V6, P1633	36	78	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28503	28506		10.1074/jbc.270.48.28503	http://dx.doi.org/10.1074/jbc.270.48.28503			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499359	hybrid			2022-12-27	WOS:A1995TH05600003
J	MIYOSHI, E; IHARA, Y; HAYASHI, N; FUSAMOTO, H; KAMADA, T; TANIGUCHI, N				MIYOSHI, E; IHARA, Y; HAYASHI, N; FUSAMOTO, H; KAMADA, T; TANIGUCHI, N			TRANSFECTION OF N-ACETYLGLUCOSAMINYLTRANSFERASE-III GENE SUPPRESSES EXPRESSION OF HEPATITIS-B VIRUS IN A HUMAN HEPATOMA-CELL LINE, HB611	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN EXPRESSION; CDNA CLONING; HBV-DNA; PROTEIN; SURFACE; OLIGOSACCHARIDES; REPLICATION; INHIBITION; TISSUES; SYSTEM	beta-D-mannoside beta-1,4-N-acetylglucosaminyltransferase III (GnT-III) catalyzes the addition of N-acetylglucosamine in beta 1-4 linkage to the beta-linked mannose of the trimannosyl core of N-linked oligosaccharides and forms a bisecting GlcNAc structure. Although the biological meaning of the bisecting GlcNAc structure remains unclear, it is known that the attachment of a bisecting GlcNAc inhibits further processing of oligosaccharides by other glycosyltransferases. To investigate whether or not structural changes of oligosaccharides affect secretion and gene expression of hepatitis B virus (HBV), we introduced the GnT-III gene into a human hepatoma cell line, HB611, which secreted HBV-related proteins into the medium. Positive transfectants were cloned by hygromycin resistant selection. Three clones have high activities of GnT-III and secreted lower levels of HBV-related proteins into the medium in comparison with other clones, These clones showed marked suppression of HBV-related mRNAs and an increased binding with E-PHA as judged by lectin blot. Expression of beta actin, alpha fetoprotein, albumin, and prealubmin was not correlated with GnT-III activity in all the seven clones. Treatment of these cells with tunicamycin or swainsonine resulted in enhanced expression of HBV-related mRNA, These results indicate that some glycoproteins whose oligosaccharide structures are changed by overexpression of GnT-III suppress HBV gene expression.	OSAKA UNIV, SCH MED, DEPT BIOCHEM, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT MED 1, SUITA, OSAKA 565, JAPAN	Osaka University; Osaka University			Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				BLOCK TM, 1994, P NATL ACAD SCI USA, V91, P2235, DOI 10.1073/pnas.91.6.2235; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu CM, 1987, GASTROENTEROLOGY, V92, P220, DOI 10.1016/0016-5085(87)90863-8; DUDLEY FJ, 1971, LANCET, V2, P1; FARZA H, 1994, MOL CARCINOGEN, V9, P185, DOI 10.1002/mc.2940090402; FELKNER RH, 1992, J VIROL, V66, P4258, DOI 10.1128/JVI.66.7.4258-4264.1992; FLEET GWJ, 1988, FEBS LETT, V237, P128, DOI 10.1016/0014-5793(88)80185-6; FUJIYAMA A, 1983, NUCLEIC ACIDS RES, V11, P4601, DOI 10.1093/nar/11.13.4601; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; ISHIBASHI K, 1989, CLIN CHIM ACTA, V185, P325, DOI 10.1016/0009-8981(89)90223-4; KORCZAK B, 1993, INT J CANCER, V53, P634, DOI 10.1002/ijc.2910530418; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MIYOSHI E, 1994, CANCER RES, V54, P1854; MIYOSHI E, 1995, J BIOL CHEM, V270, P6216, DOI 10.1074/jbc.270.11.6216; MIYOSHI E, 1992, INT J CANCER, V52, P137, DOI 10.1002/ijc.2910520124; MIYOSHI E, 1993, CANCER RES, V53, P3899; MIZUOCHI T, 1990, J BIOL CHEM, V265, P8519; NARASIMHAN S, 1982, J BIOL CHEM, V257, P235; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NISHIKAWA A, 1988, BIOCHEM BIOPH RES CO, V152, P107, DOI 10.1016/S0006-291X(88)80686-7; NISHIKAWA A, 1988, ANAL BIOCHEM, V170, P349, DOI 10.1016/0003-2697(88)90641-0; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SHIRAKI K, 1992, J GEN VIROL, V73, P1401, DOI 10.1099/0022-1317-73-6-1401; SUREAU C, 1986, CELL, V47, P37, DOI 10.1016/0092-8674(86)90364-8; TANIGUCHI N, 1989, METHOD ENZYMOL, V179, P397; TOWATA T, 1993, GASTROENTEROL JPN, V28, P242; TSURIMOTO T, 1987, P NATL ACAD SCI USA, V84, P444, DOI 10.1073/pnas.84.2.444; UEDA K, 1989, VIROLOGY, V169, P213, DOI 10.1016/0042-6822(89)90057-3; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754; YOSHIMURA M, 1995, INT J CANCER, V60, P443, DOI 10.1002/ijc.2910600404	33	39	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28311	28315						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499330				2022-12-27	WOS:A1995TG21000055
J	SEGER, R; BIENER, Y; FEINSTEIN, R; HANOCH, T; GAZIT, A; ZICK, Y				SEGER, R; BIENER, Y; FEINSTEIN, R; HANOCH, T; GAZIT, A; ZICK, Y			DIFFERENTIAL ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE AND S6 KINASE SIGNALING PATHWAYS BY 12-O-TETRADECANOYLPHORBOL-13-ACETATE (TPA) AND INSULIN - EVIDENCE FOR INVOLVEMENT OF A TPA-STIMULATED PROTEIN-TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULINOMIMETIC AGENTS H2O2; RECEPTOR KINASE; INTACT-CELLS; PHOSPHATIDYLINOSITOL 3'-KINASE; ANTIPROLIFERATIVE AGENTS; 3T3-L1 ADIPOCYTES; GLUCOSE-TRANSPORT; EGF RECEPTOR; MAP KINASE; PHOSPHORYLATION	AG-18, an inhibitor of protein-tyrosine kinases, was employed to study the role of tyrosine-phosphorylated proteins in insulin- and phorbol ester-induced signaling cascades. When incubated with Chinese hamster ovary cells overexpressing the insulin receptor, AG-18 reversibly inhibited insulin-induced tyrosine phosphorylation of insulin receptor substrate-1, with minimal effects either on receptor autophosphorylation or on phosphorylation of Shc64, Under these conditions, AG-18 inhibited insulin-stimulated phosphorylation of the ribosomal protein S6, while no inhibition of insulin-induced activation of mitogen-activated protein kinase (MAPK) kinase or MAPK was detected, In contrast, 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced activation of MAPK kinase and MAPK and phosphorylation of S6 were inhibited by AG-18, This correlated with inhibition of TPA-stimulated tyrosine phosphorylation of several proteins, the most prominent ones being pp114 and pp120. We conclude that Tyr-phosphorylated insulin receptor substrate-1 is the main upstream regulator of insulin-induced S6 phosphorylation by p70(s6k), whereas MAPK signaling seems to be activated in these cells primarily through the adaptor molecule She. In contrast, TPA induced S6 phosphorylation is mediated by the MAPK/p90(rsk) cascade, A key element of this TPA-stimulated signaling pathway is an AG-18-sensitive protein-tyrosine kinase.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT MEMBRANE RES, IL-76100 REHOVOT, ISRAEL; HEBREW UNIV JERUSALEM, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Hebrew University of Jerusalem			Zick, Yehiel/K-1479-2012					AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDO A, 1992, J BIOL CHEM, V267, P12788; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HEFFETZ D, 1992, BIOCHEM J, V288, P631, DOI 10.1042/bj2880631; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; Holm-Hansen O., 1978, METHOD ENZYMOL, V57, P73, DOI [10.1016/0076-6879(78)57010-9, DOI 10.1016/0076-6879(78)57010-9]; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LAWRENCE JC, 1992, ANNU REV PHYSIOL, V54, P177, DOI 10.1146/annurev.ph.54.030192.001141; LEVITZKI A, 1990, BIOCHEM PHARMACOL, V40, P913, DOI 10.1016/0006-2952(90)90474-Y; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; OFFERMANNS S, 1993, BIOCHEM J, V294, P545, DOI 10.1042/bj2940545; OGAWA W, 1994, J BIOL CHEM, V269, P29602; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; OSTROWSKI J, 1994, J BIOL CHEM, V269, P17626; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; PELECH SL, 1987, J BIOL CHEM, V262, P11598; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SCHECHTER Y, 1989, EMBO J, V8, P1671, DOI 10.1002/j.1460-2075.1989.tb03558.x; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SRINIVASAN M, 1994, J BIOL CHEM, V269, P16662; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUNG CK, 1994, J BIOL CHEM, V269, P12503; TERADA H, 1988, BIOCHIM BIOPHYS ACTA, V933, P193, DOI 10.1016/0005-2728(88)90070-9; THOMAS G, 1992, BIOCHEM SOC T, V20, P678, DOI 10.1042/bst0200678; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; YANG YC, 1993, FEBS LETT, V333, P287, DOI 10.1016/0014-5793(93)80672-H; ZICK Y, 1983, J BIOL CHEM, V258, P75	66	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28325	28330						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499332				2022-12-27	WOS:A1995TG21000057
J	YAMAGUCHI, M; HATEFI, Y				YAMAGUCHI, M; HATEFI, Y			PROTON-TRANSLOCATING NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE - RECONSTITUTION OF THE EXTRAMEMBRANOUS NUCLEOTIDE-BINDING DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ENZYME; SEQUENCE; CLEAVAGE; SITES	The nicotinamide nucleotide transhydrogenase of bovine mitochondria is a homodimer of monomer M(r) = 109,065. The monomer is composed of three domains, an NH2-terminal 430 residue long hydrophilic domain I that binds NAD(H), a central 400-residue-long hydrophobic domain II that is largely membrane intercalated and carries the enzyme's proton channel, and a COOH-terminal 200-residue-long hydrophilic domain III that binds NADP(H). Domains I and III protrude into the mitochondrial matrix, where they presumably come together to form the enzyme's catalytic site. The two-subunit transhydrogenase of Escherichia coli and the three-subunit transhydrogenase of Rhodospirillum rubrum have each the same overall tridomain hydropathy profile as the bovine enzyme. Domain I of the R. rubrum enzyme (the alpha 1 subunit) is water soluble and easily removed from the chromatophore membranes. We have isolated domain I of the bovine transhydrogenase after controlled trypsinolysis of the purified enzyme and have expressed in E. coli and purified therefrom domain III of this enzyme. This paper shows that an active bidomain transhydrogenase lacking domain II can be reconstituted by the combination of purified bovine domains I plus III or R. rubrum domain I plus bovine domain III.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV BIOCHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024887] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24887] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CLARKE DM, 1986, EUR J BIOCHEM, V158, P647, DOI 10.1111/j.1432-1033.1986.tb09802.x; DIGGLE C, 1995, EUR J BIOCHEM, V228, P719, DOI 10.1111/j.1432-1033.1995.0719m.x; FISHER R. R., 1982, PYRIDINE NUCLEOTIDE, P279; FISHER RR, 1971, J BIOL CHEM, V246, P4679; GLAVAS NA, 1995, BIOCHEMISTRY-US, V34, P7694, DOI 10.1021/bi00023a016; HATEFI Y, 1992, MOL MECHANISMS BIOEN, P265; HOU C, 1990, BIOCHIM BIOPHYS ACTA, V1018, P61, DOI 10.1016/0005-2728(90)90110-P; HUTTON M, 1994, EUR J BIOCHEM, V219, P1041, DOI 10.1111/j.1432-1033.1994.tb18587.x; KONINGS AWT, 1973, J BIOL CHEM, V248, P1045; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVER TM, 1991, EUR J BIOCHEM, V197, P247, DOI 10.1111/j.1432-1033.1991.tb15905.x; MOSBACH K, 1972, BIOCHEM J, V127, P625, DOI 10.1042/bj1270625; ORMEROD JG, 1961, ARCH BIOCHEM BIOPHYS, V94, P449, DOI 10.1016/0003-9861(61)90073-X; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PHELPS DC, 1984, BIOCHEMISTRY-US, V23, P4475, DOI 10.1021/bi00314a037; RYDSTROM J, 1972, EUR J BIOCHEM, V31, P496, DOI 10.1111/j.1432-1033.1972.tb02557.x; Rydstrom J., 1987, PYRIDINE NUCLEOTIDE, P433; WAKABAYASHI S, 1987, BIOCHEM INT, V15, P915; WILLIAMS R, 1994, MICROBIOL-UK, V140, P1595, DOI 10.1099/13500872-140-7-1595; WU LNY, 1981, J BIOL CHEM, V256, P7401; YAMAGUCHI M, 1993, J BIOL CHEM, V268, P17871; YAMAGUCHI M, 1991, J BIOL CHEM, V266, P5728; YAMAGUCHI M, 1994, J BIOENERG BIOMEMBR, V26, P435, DOI 10.1007/BF00762784; YAMAGUCHI M, 1988, J BIOL CHEM, V263, P2761; YAMAGUCHI M, 1990, BIOCHEMISTRY-US, V29, P4136, DOI 10.1021/bi00469a017; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P16653, DOI 10.1074/jbc.270.28.16653; YAMAGUCHI M, 1989, BIOCHEMISTRY-US, V28, P6050, DOI 10.1021/bi00440a049	27	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28165	28168						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499307				2022-12-27	WOS:A1995TG21000032
J	CHOW, G; KNUDSON, CB; HOMANDBERG, G; KNUDSON, W				CHOW, G; KNUDSON, CB; HOMANDBERG, G; KNUDSON, W			INCREASED EXPRESSION OF CD44 IN BOVINE ARTICULAR CHONDROCYTES BY CATABOLIC CELLULAR MEDIATORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE-HOMING RECEPTOR; FIBRONECTIN FRAGMENTS; CARTILAGE PROTEOGLYCANS; SULFATE PROTEOGLYCAN; ADHESION MOLECULE; HYALURONIC-ACID; CARCINOMA-CELLS; CORE PROTEIN; LINK-PROTEIN; MATRIX	Bovine articular chondrocytes cultured in alginate beads were used to study the effect of catabolic cellular mediators on CD44 expression. Treatment with either the 29-kDa fragment of fibronectin or interleukin-1 alpha results in a time- and dose-dependent inhibition of proteoglycan synthesis as well as a stimulation in the expression of CD44 mRNA level as determined by semiquantitative polymerase chain reaction following reverse transcription, No noticeable effect at 6 h was observed, By 24 h, the major CD44 product (CD44H) from fibronectin fragment-treated cultures showed an 8-fold increase; CD44H from interleukin-1 alpha-treated cultures showed a B-fold increase as compared to control cultures, In addition, a minor band, determined to be an isoform of CD44, was also shown to be up-regulated by both mediators. Stimulation of CD44 mRNA via interleukin-1 was also evident by in situ hybridization studies of bovine as well as human articular cartilage in organ culture, The increased in CD44 mRNA is matched by an increase at the protein level as determined by Western blot analysis, The Western blot reveals a doublet protein band at 80-90 kDa that corresponds to the molecular mass of CD44H, Cultures incubated with fibronectin fragments for 24 h had an 8.0-fold increase in CD44, while a 6.6-fold was observed for interleukin-1 alpha. Fluorescein conjugated hyaluronan binding and internalization studies indicate that the increase in CD44 protein, induced by interleukin-1 alpha, closely correlates with an increase in functional hyaluronan receptors present at the chondrocyte cell surface, Taken together these results indicate that conditions that up-regulate chondrocyte catabolism also up-regulate the expression of CD44, a cell surface hyaluronan receptor involved in hyaluronan endocytosis.	RUSH PRESBYTERIAN ST LUKES MED CTR,RUSH ARTHRITIS & ORTHOPED INST,DEPT BIOCHEM,CHICAGO,IL 60612; RUSH PRESBYTERIAN ST LUKES MED CTR,RUSH ARTHRITIS & ORTHOPED INST,DEPT PATHOL,CHICAGO,IL 60612	Rush University; Rush University					NIAMS NIH HHS [AR39507, P50 AR039239, R01 AR039507, AR39239] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039239, R29AR039507, R01AR039507] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; AYDELOTTE MB, 1988, CONNECT TISSUE RES, V18, P223, DOI 10.3109/03008208809016809; AYDELOTTE MB, 1988, ORTHOP T, V13, P247; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; BUCKWALTER JA, 1985, J ORTHOP RES, V3, P251, DOI 10.1002/jor.1100030301; BUCKWALTER JA, 1982, J BIOL CHEM, V257, P9830; CHANDRASEKHAR S, 1988, ARCH BIOCHEM BIOPHYS, V265, P294, DOI 10.1016/0003-9861(88)90131-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; CULTY M, 1992, J CELL BIOL, V116, P1055, DOI 10.1083/jcb.116.4.1055; EYRE DR, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P119; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HAMERMAN D, 1993, J AM GERIATR SOC, V41, P760, DOI 10.1111/j.1532-5415.1993.tb07469.x; HARDINGHAM TE, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P5; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HASCALL VC, 1977, J SUPRAMOL STR CELL, V7, P101, DOI 10.1002/jss.400070110; HASCALL VC, 1988, ISI ATLAS-BIOCHEM, V1, P189; Hauselmann H. J., 1992, ARTICULAR CARTILAGE, P701; HAUSELMANN HJ, 1992, MATRIX, V12, P116; HEINEGARD D, 1984, EXTRACELLULAR MATRIX, P277; HOMANDBERG GA, 1992, J BIOL CHEM, V267, P3597; HOMANDBERG GA, 1993, CLIN PHYSL, V10, P1; HUA Q, 1993, J CELL SCI, V106, P365; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; KNUDSON CB, 1987, DEV BIOL, V124, P82, DOI 10.1016/0012-1606(87)90462-3; KNUDSON W, 1993, P NATL ACAD SCI USA, V90, P4003, DOI 10.1073/pnas.90.9.4003; KNUDSON W, 1995, ORTHOP T, V20, P375; KRESSE H, 1987, ADV ENZYMOLOGY RELAT, P217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LOTZ M, 1995, J RHEUMATOL, V22, P104; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; MORALES TI, 1988, J BIOL CHEM, V263, P3632; MORT JS, 1993, MATRIX, V13, P95, DOI 10.1016/S0934-8832(11)80068-5; NEMEC RE, 1987, BIOCHEM BIOPH RES CO, V149, P249, DOI 10.1016/0006-291X(87)91632-9; NG KC, 1992, ARCH BIOCHEM BIOPHYS, V298, P70; PELLETIER JP, 1993, RHEUM DIS CLIN N AM, V19, P545; PITA JC, 1979, J BIOL CHEM, V254, P313; ROSENBERG LC, 1986, ARTICULAR CARTILAGE, P39; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SANDY JD, 1991, J BIOL CHEM, V266, P8198; SCREATON GR, 1993, J BIOL CHEM, V268, P12235; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P348; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TYLER JA, 1985, BIOCHEM J, V227, P869, DOI 10.1042/bj2270869; TYLER JA, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P251; XIE DL, 1992, J RHEUMATOL, V19, P1448; XIE DL, 1993, ARCH BIOCHEM BIOPHYS, V307, P110, DOI 10.1006/abbi.1993.1568; XIE DL, 1993, BIOCHIM BIOPHYS ACTA, V1182, P189, DOI 10.1016/0925-4439(93)90140-V	57	115	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27734	27741		10.1074/jbc.270.46.27734	http://dx.doi.org/10.1074/jbc.270.46.27734			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499241	hybrid			2022-12-27	WOS:A1995TE73600052
J	KNARR, G; GETHING, MJ; MODROW, S; BUCHNER, J				KNARR, G; GETHING, MJ; MODROW, S; BUCHNER, J			BIP BINDING SEQUENCES IN ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE BIP; PEPTIDE-BINDING; HEAVY-CHAINS; LIGHT-CHAINS; PROTEIN; IMMUNOGLOBULIN; ASSOCIATION; SPECIFICITY; TRANSPORT; RELEASE	During the process of folding and assembly of antibody molecules in the endoplasmic reticulum, immunoglobulin heavy and light chains associate transiently with BiP, a resident endoplasmic reticulum protein that is a member of the Hsp70 family of molecular chaperones. Dip is thought to recognize unfolded or unassembled polypeptides by binding extended sequences of approximately seven amino acids that include bulky hydrophobic residues not normally exposed on the surface of native proteins. We used a computer algorithm developed to predict BiP binding sites within protein primary sequences to identify sites within immunoglobulin chains that might mediate their association with BiP. Very few of the sequential heptapeptides in the heavy or light chain sequences were potential Dip binding sites. Analysis of the ability of synthetic heptapeptides corresponding to 24 potential sites in heavy chains to stimulate the ATPase activity of BiP indicated that at least half of them were authentic Dip binding sequences. These sequences were not confined to a single domain of the heavy chain but were distributed within both the V-H and C-H domains. interestingly, when the BiP binding sequences were mapped onto the three dimensional structure of the Fd antibody fragment, the majority involve residues that participate in contact sites between the heavy and light chains. Therefore, we suggest that in. vivo BiP chaperones the folding and assembly of antibody molecules by binding to hydrophobic surface regions on the isolated immunoglobulin chains that subsequently participate in interchain contacts.	UNIV REGENSBURG, INST BIOPHYS & PHYS BIOCHEM, D-93040 REGENSBURG, GERMANY; UNIV MELBOURNE, DEPT BIOCHEM & MOLEC BIOL, PARKVILLE, VIC 3052, AUSTRALIA; UNIV REGENSBURG, INST MED MIKROBIOL & HYG, D-93042 REGENSBURG, GERMANY	University of Regensburg; University of Melbourne; University of Regensburg			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				ATHERTON E, 1978, J CHEM SOC CHEM COMM, P537, DOI 10.1039/c39780000537; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P6922, DOI 10.1021/bi00242a016; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; DUL JL, 1990, P NATL ACAD SCI USA, V87, P8135, DOI 10.1073/pnas.87.20.8135; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; HAAS IG, 1991, CURR TOP MICROBIOL, V167, P71; HE XM, 1992, P NATL ACAD SCI USA, V89, P7154, DOI 10.1073/pnas.89.15.7154; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; KALOFF CR, 1995, IMMUNITY, V2, P629, DOI 10.1016/1074-7613(95)90007-1; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; LILIE H, 1995, FEBS LETT, V362, P43, DOI 10.1016/0014-5793(95)00203-L; LILIE H, 1994, J BIOL CHEM, V269, P14290; LILIE H, 1993, PROTEIN SCI, V2, P1490, DOI 10.1002/pro.5560020913; LILIE H, 1995, PROTEIN SCI, V4, P917; LILIE H, 1995, J MOL BIOL, V248, P190, DOI 10.1006/jmbi.1995.0211; MA J, 1990, MOL IMMUNOL, V27, P623, DOI 10.1016/0161-5890(90)90004-J; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; NAKAKI T, 1989, MOL CELL BIOL, V9, P2233, DOI 10.1128/MCB.9.5.2233; POUYSSEGUR J, 1977, CELL, V11, P941, DOI 10.1016/0092-8674(77)90305-1; SCHMIDT M, 1994, J BIOL CHEM, V269, P27964; SCHMIDT M, 1992, J BIOL CHEM, V267, P16829; WIECH H, 1993, J BIOL CHEM, V268, P7414; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; [No title captured]	36	95	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27589	27594		10.1074/jbc.270.46.27589	http://dx.doi.org/10.1074/jbc.270.46.27589			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499221	hybrid			2022-12-27	WOS:A1995TE73600032
J	HOSOMI, Y; SHII, K; OGAWA, W; MATSUBA, H; YOSHIDA, M; OKADA, Y; YOKONO, K; KASUGA, M; BABA, S; ROTH, RA				HOSOMI, Y; SHII, K; OGAWA, W; MATSUBA, H; YOSHIDA, M; OKADA, Y; YOKONO, K; KASUGA, M; BABA, S; ROTH, RA			CHARACTERIZATION OF A 60-KILODALTON SUBSTRATE OF THE INSULIN-RECEPTOR KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; RAT ADIPOCYTES; CELLS; PROTEIN; EXPRESSION; GAP	A 60-kDa tyrosine-phosphorylated protein has been observed after insulin treatment of cells in immunoprecipitations of the GTPase-activating protein of Ras (called GAP) as well as the phosphatidylinositol 3-kinase. In the present studies, these two 60-kDa proteins have been shown to differ by limited proteolytic digestions as well as by immunoprecipitation with a monoclonal antibody. This monoclonal antibody was also utilized to show that the 60-kDa GAP-associated protein was rapidly phosphorylated in intact cells after insulin stimulation and to associate with GAP only after insulin treatment of the cells. In addition, the 60-kDa protein was found to be phosphorylated in vitro by the insulin receptor. Finally, the 60-kDa protein immunoprecipitated by this antibody was found not to react with a polyclonal antibody directed against a 62-kDa tyrosine-phosphorylated GAP-associated protein previously observed in src-transformed cells. These studies indicate that insulin stimulates the tyrosine phosphorylation of at least two distinct 60-kDa proteins, one that becomes associated with GAP and appears to be a direct substrate of the insulin receptor kinase and another that associates with the phosphatidylinositol 3-kinase.	HYOGO INST CLIN RES,13-70 KITAOHJI CHO,AKASHI 673,JAPAN; STANFORD UNIV,MED CTR,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305; KOBE UNIV,SCH MED,DEPT INTERNAL MED 1,CHUO KU,KOBE 650,JAPAN	Stanford University; Kobe University			OGAWA, Wataru/AAQ-9586-2020		NIDDK NIH HHS [DK 41765] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041765] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; HAGINO H, 1994, DIABETES, V43, P274, DOI 10.2337/diabetes.43.2.274; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MOONEY RA, 1992, ENDOCRINOLOGY, V130, P1533, DOI 10.1210/en.130.3.1533; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; PORRAS A, 1992, J BIOL CHEM, V267, P21124; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTH RA, 1988, INSULIN INSULIN LIKE; SHII K, 1986, P NATL ACAD SCI USA, V83, P4147, DOI 10.1073/pnas.83.12.4147; SHII K, 1991, IGAKU NO AYUMI, V158, P221; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STEELEPERKINS G, 1990, J BIOL CHEM, V265, P9458; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUNG CK, 1992, BIOCHEM BIOPH RES CO, V189, P1024, DOI 10.1016/0006-291X(92)92306-I; TOBE K, 1993, J BIOL CHEM, V268, P11167; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; ZHANG B, 1992, J BIOL CHEM, V267, P18320	28	79	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1994	269	15					11498	11502						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NF966	7512567				2022-12-27	WOS:A1994NF96600077
J	NILSSON, L; EMILSSON, V				NILSSON, L; EMILSSON, V			FACTOR FOR INVERSION STIMULATION-DEPENDENT GROWTH-RATE REGULATION OF INDIVIDUAL TRANSFER-RNA SPECIES IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA; FIS PROTEIN; RECOMBINATIONAL ENHANCER; CODON USAGE; UPSTREAM ACTIVATION; FEEDBACK-REGULATION; GENE EXPRESSIVITY; RESPECTIVE CODONS; STRINGENT CONTROL; PROMOTER	We have studied the involvement of the factor for inversion stimulation (FIS) in the growth rate-dependent expression of the arginine, leucine, and methionine acceptor tRNA species. The concentration of individual tRNA species relative to 16 S rRNA was determined by blot hybridization using RNA preparations from bacteria with the fis gene deleted and from isogenic wild type bacteria. The RNA preparations were obtained from bacteria growing under steady state conditions in different media. The levels of tRNA1Leu, tRNA2Arg, tRNA4Arg, and tRNA5Arg decreased in the fis bacteria, relative to the wild type. The difference in levels increased with increasing growth rate. Surprisingly, tRNA3Leu, tRNA(f)Met, and tRNA(e)Met showed the opposite response, with an increase of the tRNA/16 S ratio in the fis bacteria. The tRNA2Leu, tRNA4Leu, tRNA5Leu, and tRNA3Arg had unaffected tRNA/16 S ratios in fis cells. We conclude that FIS, directly or indirectly, is involved in growth rate regulation of some tRNA species and that it affects the composition of the cellular tRNA pool.			NILSSON, L (corresponding author), UPPSALA UNIV, CTR BIOMED, DEPT MOLEC BIOL, S-75124 UPPSALA, SWEDEN.			Emilsson, Valur/0000-0001-9982-0524				BALL CA, 1992, J BACTERIOL, V174, P8043, DOI 10.1128/JB.174.24.8043-8056.1992; BAUER BF, 1988, GENE, V63, P123, DOI 10.1016/0378-1119(88)90551-3; BAUMANN S, 1991, HOPPESEYLERS Z PHYSL, V372, P631; BOSCH L, 1990, BIOCHIM BIOPHYS ACTA, V1050, P293, DOI 10.1016/0167-4781(90)90184-4; BREMER H, 1948, ESCHERICHIA COLI SAL, V2, P1527; CHAVANCY G, 1981, BIOCHIMIE, V63, P187, DOI 10.1016/S0300-9084(81)80192-7; COLE JR, 1987, J MOL BIOL, V198, P383, DOI 10.1016/0022-2836(87)90288-9; CONDON C, 1992, EMBO J, V11, P4175, DOI 10.1002/j.1460-2075.1992.tb05511.x; DUESTER G, 1982, CELL, V30, P855, DOI 10.1016/0092-8674(82)90290-2; EHRENBERG M, 1984, Q REV BIOPHYS, V17, P45, DOI 10.1017/S0033583500005254; EMILSSON V, 1990, EMBO J, V9, P4359, DOI 10.1002/j.1460-2075.1990.tb07885.x; EMILSSON V, 1993, J MOL BIOL, V230, P483, DOI 10.1006/jmbi.1993.1165; FILUTOWICZ M, 1992, J BACTERIOL, V174, P398, DOI 10.1128/jb.174.2.398-407.1992; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; FOURNIER MJ, 1985, MICROBIOL REV, V49, P379, DOI 10.1128/MMBR.49.4.379-397.1985; GAAL T, 1990, P NATL ACAD SCI USA, V87, P5533, DOI 10.1073/pnas.87.14.5533; GILLE H, 1991, NUCLEIC ACIDS RES, V19, P4167, DOI 10.1093/nar/19.15.4167; GOURSE RL, 1984, J BACTERIOL, V160, P1022, DOI 10.1128/JB.160.3.1022-1026.1984; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; GOUY M, 1982, NUCLEIC ACIDS RES, V10, P7055, DOI 10.1093/nar/10.22.7055; GRANTHAM R, 1981, NUCLEIC ACIDS RES, V9, pR43; GRANTHAM R, 1980, NUCLEIC ACIDS RES, V8, pR49, DOI 10.1093/nar/8.1.197-c; GRANTHAM R, 1980, NUCLEIC ACIDS RES, V10, P7055; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; GUYER MS, 1980, COLD SPRING HARB SYM, V45, P135, DOI 10.1101/SQB.1981.045.01.022; HENANDEZ VJ, 1990, J BIOL CHEM, V265, P11605; HSU LM, 1991, BIOCHEMISTRY-US, V30, P813, DOI 10.1021/bi00217a035; HSU LM, 1984, J MOL BIOL, V178, P509, DOI 10.1016/0022-2836(84)90236-5; HUBER HE, 1985, P NATL ACAD SCI USA, V82, P3776, DOI 10.1073/pnas.82.11.3776; HUBNER P, 1989, EMBO J, V8, P577, DOI 10.1002/j.1460-2075.1989.tb03412.x; IKEMURA T, 1982, COLD SPRING HARB SYM, V47, P1087, DOI 10.1101/SQB.1983.047.01.123; IKEMURA T, 1981, J MOL BIOL, V146, P1, DOI 10.1016/0022-2836(81)90363-6; IKEMURA T, 1981, J MOL BIOL, V151, P389, DOI 10.1016/0022-2836(81)90003-6; IKEMURA T, 1985, MOL BIOL EVOL, V2, P13; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; JINKSROBERTSON S, 1983, CELL, V33, P865, DOI 10.1016/0092-8674(83)90029-6; JOHNSON RC, 1988, P NATL ACAD SCI USA, V85, P3484, DOI 10.1073/pnas.85.10.3484; JOHNSON RC, 1985, CELL, V41, P781, DOI 10.1016/S0092-8674(85)80059-3; KAHMANN R, 1985, CELL, V41, P771, DOI 10.1016/S0092-8674(85)80058-1; KOMINE Y, 1990, J MOL BIOL, V96, P69; KURLAND CG, 1993, BIOCHEM SOC T, V21, P841, DOI 10.1042/bst0210841; LAZARUS LR, 1993, EMBO J, V12, P2483, DOI 10.1002/j.1460-2075.1993.tb05903.x; LINDAHL L, 1982, ADV GENET, V21, P53, DOI 10.1016/S0065-2660(08)60297-7; Maniatis T., 1982, MOL CLONING; NAGASE T, 1988, GENE, V67, P49; NAKAJIMA N, 1981, CELL, V23, P239, DOI 10.1016/0092-8674(81)90288-9; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NILSSON L, 1990, EMBO J, V9, P727, DOI 10.1002/j.1460-2075.1990.tb08166.x; NILSSON L, 1992, J BACTERIOL, V174, P921, DOI 10.1128/jb.174.3.921-929.1992; NINNEMANN O, 1992, EMBO J, V11, P1075, DOI 10.1002/j.1460-2075.1992.tb05146.x; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x; ROWLEY KB, 1993, J BACTERIOL, V175, P1309, DOI 10.1128/JB.175.5.1309-1315.1993; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; SARUBBI E, 1988, MOL GEN GENET, V213, P214, DOI 10.1007/BF00339584; SAXENA P, 1992, J BACTERIOL, V174, P1956, DOI 10.1128/jb.174.6.1956-1964.1992; SLANY RK, 1992, NUCLEIC ACIDS RES, V20, P4193, DOI 10.1093/nar/20.16.4193; TRAVERS AA, 1980, J BACTERIOL, V141, P973, DOI 10.1128/JB.141.2.973-976.1980; VERBEEK H, 1990, BIOCHIM BIOPHYS ACTA, V1050, P302, DOI 10.1016/0167-4781(90)90185-5	59	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9460	9465						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511587				2022-12-27	WOS:A1994NE05300013
J	ISHIZAKI, J; HANASAKI, K; HIGASHINO, K; KISHINO, J; KIKUCHI, N; OHARA, O; ARITA, H				ISHIZAKI, J; HANASAKI, K; HIGASHINO, K; KISHINO, J; KIKUCHI, N; OHARA, O; ARITA, H			MOLECULAR-CLONING OF PANCREATIC GROUP-I PHOSPHOLIPASE A(2) RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; MACROPHAGE MANNOSE RECEPTOR; BINDING-PROTEIN; RAT; DNA; RNA; POLYMERASE; EFFICIENT; SITES; LUNG	We have recently reported that mammalian pancreatic group I phospholipase A(2) (PLA(2)-I) has its specific receptor (PLA(2) receptor) on a variety of mammalian cells and that various biological responses are elicited by PLA(2)-I via this receptor. In this study, we cloned cDNAs encoding a protein corresponding to the bovine PLA(2) receptor purified from the corpora lutea on the basis of its partial amino acid sequences. The identity of a protein encoded by the cloned cDNA with the bovine PLA(2) receptor was verified by a transient expression experiment using COS-7 cells. Interestingly, the deduced primary structure of the PLA(2) receptor (1,463 amino acid residues) exhibits a close relatedness throughout the molecule to that of the macrophage mannose receptor, a unique member of Ca2+-dependent (C-type) animal lectin family, in spite of their functional diversity. Based on this sequence similarity between these two receptors, the domain organization of the PLA(2) receptor could be tentatively assigned as follows; 10 extracellular domains including 8 tandem repeats homologous to C-type carbohydrate-recognition domains (CRDs) and a single transmembrane region followed by a short cytoplasmic tail. The results of transient expression experiments for mutant PLA(2) receptors supported this assign ment and furthermore suggested the region responsible for PLA(2)-I binding corresponds to CRDs in the mannose receptor.	SHIONOGI & CO LTD,SHIONOGI RES LABS,FUKUSHIMA KU,OSAKA,JAPAN	Shionogi & Company Limited			Ohara, Osamu/G-5448-2015; Ohara, Osamu/A-9119-2012	Ohara, Osamu/0000-0002-3328-9571; 				BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; HANASAKI K, 1992, BIOCHIM BIOPHYS ACTA, V1127, P233, DOI 10.1016/0005-2760(92)90226-L; HARRIS N, 1992, BLOOD, V80, P2363; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; ISHIZAKI J, 1993, FEBS LETT, V324, P349, DOI 10.1016/0014-5793(93)80149-O; KANEMASA T, 1992, FEBS LETT, V303, P217, DOI 10.1016/0014-5793(92)80523-J; KANEMASA T, 1992, BIOCHIM BIOPHYS ACTA, V1125, P210, DOI 10.1016/0005-2760(92)90047-Y; KISHINO J, 1992, BIOCHEM BIOPH RES CO, V186, P1025, DOI 10.1016/0006-291X(92)90849-G; KORTESUO PT, 1993, INT J PANCREATOL, V13, P111; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LATHE R, 1984, DNA-J MOLEC CELL BIO, V3, P173, DOI 10.1089/dna.1984.3.173; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKATA T, 1989, BIOCHIM BIOPHYS ACTA, V1007, P124, DOI 10.1016/0167-4781(89)90141-3; Sambrook J, 1989, MOL CLONING LABORATO; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; STAHL PD, 1992, CURR OPIN IMMUNOL, V4, P49, DOI 10.1016/0952-7915(92)90123-V; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, BIOCHEM SOC T, V21, P468, DOI 10.1042/bst0210468; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	34	180	187	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5897	5904						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509792				2022-12-27	WOS:A1994MY84000065
J	TAKAHASHI, N; BREITMAN, TR				TAKAHASHI, N; BREITMAN, TR			RETINOYLATION OF VIMENTIN IN THE HUMAN MYELOID-LEUKEMIA CELL-LINE HL-60	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTOR; INTERMEDIATE FILAMENT PROTEINS; MAMMARY EPITHELIAL-CELLS; AVIAN MYOGENIC CELLS; GRANULOCYTIC DIFFERENTIATION; EPIDERMAL-KERATINOCYTES; NUCLEAR-ENVELOPE; GENE-EXPRESSION; HL-60 CELLS	Retinoylation (retinoic acid acylation) is a posttranslational modification of proteins occurring in many eukaryotic cell lines. The widespread occurrence of retinoylation suggests that it may play a role in many effects of retinoic acid (RA) on cells. The regulatory subunits of cyclic AMP dependent protein kinase are retinoylated in the human myeloid leukemia cell line HL60 (Takahashi, N., Liapi, C., Anderson, W. B., and Breitman, T R. (1991) Arch. Biochem. Biophys. 290, 293-302), and cytokeratins are retinoylated in normal human keratinocytes (Takahashi, N., Jetten, A. M., and Breitman, T R. (1991) Biochem. Biophys. Res. Commun. 180, 393-400), We show, in this study, that the intermediate filament protein vimentin is retinoylated in HL60 cells during a 24-h exposure to 100 nM [H-3]RA. We found that a retinoylated protein of M(r) 55,000 coeluted on anion exchange chromatography and comigrated on either one- or two-dimensional polyacrylamide gel electrophoresis with a protein that also was stained on immunoblots by an anti-vimentin antibody. About 50% of the [H-3]RA was released from this M(r) 55,000 retinoylated protein after hydrolysis with either NH2OH (1 M, pH 10) or CH3OH, 0.1 m KOH. These results indicated that a large fraction of the RA was bound to vimentin by an ester bond. Both the M(r) 55,000 retinoylated protein and immunoreactive vimentin were associated with cell nuclei isolated by two procedures. They were detached during exposure to a nonionic detergent buffer, suggesting that they are bound to the nuclear envelope. These results indicate that retinoylation is a new modification of vimentin that may be an early event in RA-induced differentiation of HL60 cells.			TAKAHASHI, N (corresponding author), NCI, DIV CANC TREATMENT,DEV THERAPEUT PROGRAM, BIOL CHEM LAB,BLDG 37, RM 5D-02, BETHESDA, MD 20892 USA.							BELGRADER P, 1991, J CELL SCI, V98, P281; BERKOWIT.DM, 1969, J CELL BIOL, V42, P851, DOI 10.1083/jcb.42.3.851; BERNAL SD, 1982, CANCER RES, V42, P5106; BERTOLERO F, 1984, EXP CELL RES, V155, P64, DOI 10.1016/0014-4827(84)90768-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREITMAN TR, 1980, EXP CELL RES, V126, P494, DOI 10.1016/0014-4827(80)90296-7; BREITMAN TR, 1981, BLOOD, V57, P1000; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHAN D, 1989, P NATL ACAD SCI USA, V86, P2747, DOI 10.1073/pnas.86.8.2747; CHOMIENNE C, 1990, BLOOD, V76, P1710; CLARKE R, 1993, BREAST CANCER RES TR, V24, P227, DOI 10.1007/BF01833263; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; CRETTAZ M, 1990, BIOCHEM J, V272, P391, DOI 10.1042/bj2720391; DAENEN S, 1986, BLOOD, V67, P559; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P1585, DOI 10.1093/nar/19.7.1585; DELLAGI K, 1983, EMBO J, V2, P1509, DOI 10.1002/j.1460-2075.1983.tb01615.x; DELLAGI K, 1984, LEUKEMIA RES, V8, P611, DOI 10.1016/0145-2126(84)90009-2; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DOMAGALA W, 1990, AM J PATHOL, V137, P1299; EVANS RM, 1988, FEBS LETT, V234, P73, DOI 10.1016/0014-5793(88)81306-1; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANS RM, 1984, J BIOL CHEM, V259, P5372; EVANS RM, 1982, CELL, V29, P43, DOI 10.1016/0092-8674(82)90088-5; FLYNN PJ, 1983, BLOOD, V62, P1211; FONTANA JA, 1986, CANCER-AM CANCER SOC, V57, P209, DOI 10.1002/1097-0142(19860115)57:2<209::AID-CNCR2820570204>3.0.CO;2-K; FRANKE WW, 1984, EXP CELL RES, V154, P567, DOI 10.1016/0014-4827(84)90181-2; GALLAGHER RE, 1985, LEUKEMIA RES, V9, P967, DOI 10.1016/0145-2126(85)90067-0; GARD DL, 1982, P NATL ACAD SCI-BIOL, V79, P6912, DOI 10.1073/pnas.79.22.6912; GARD DL, 1982, MOL CELL BIOL, V2, P1104, DOI 10.1128/MCB.2.9.1104; GEORGATOS SD, 1987, J CELL BIOL, V105, P117, DOI 10.1083/jcb.105.1.117; GEORGATOS SD, 1987, J CELL BIOL, V105, P105, DOI 10.1083/jcb.105.1.105; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V150, P1006, DOI 10.1016/0006-291X(88)90728-0; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUNT RC, 1990, J CELL PHYSIOL, V145, P187, DOI 10.1002/jcp.1041450202; IMAIZUMI M, 1987, CANCER RES, V47, P1434; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; ISAACS WB, 1989, J BIOL CHEM, V264, P17953; KEIDEL S, 1993, EUR J BIOCHEM, V212, P13, DOI 10.1111/j.1432-1033.1993.tb17627.x; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB NJC, 1989, J CELL BIOL, V108, P2409, DOI 10.1083/jcb.108.6.2409; LASZLO A, 1983, EXP CELL RES, V148, P221, DOI 10.1016/0014-4827(83)90201-X; LASZLO A, 1992, J CELL PHYSIOL, V151, P519, DOI 10.1002/jcp.1041510311; LEUNG MF, 1992, CANCER RES, V52, P949; LOCOCO F, 1991, BLOOD, V77, P1657; MORK C, 1990, DIFFERENTIATION, V43, P146; NELSON WJ, 1982, BIOCHEM BIOPH RES CO, V106, P1141, DOI 10.1016/0006-291X(82)91231-1; NGAI J, 1984, J CELL BIOL, V99, P306, DOI 10.1083/jcb.99.1.306; OCONNOR CM, 1981, CELL, V23, P135, DOI 10.1016/0092-8674(81)90278-6; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OSHIMA RG, 1981, J BIOL CHEM, V256, P8124; PAULINLEVASSEUR M, 1989, EUR J CELL BIOL, V50, P453; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PIEPER FR, 1992, EUR J BIOCHEM, V210, P509, DOI 10.1111/j.1432-1033.1992.tb17449.x; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; SARRIA AJ, 1992, J BIOL CHEM, V267, P19455; SARRIA AJ, 1990, J CELL BIOL, V111, P553, DOI 10.1083/jcb.111.2.553; SIEBERT PD, 1985, J BIOL CHEM, V260, P3868; SKALLI O, 1992, Trends in Cell Biology, V2, P308, DOI 10.1016/0962-8924(92)90121-3; SKALLI O, 1992, P NATL ACAD SCI USA, V89, P11959, DOI 10.1073/pnas.89.24.11959; SOMMERS CL, 1992, CANCER RES, V52, P5190; SOMMERS CL, 1989, CANCER RES, V49, P4258; TAIMI M, 1990, DIFFERENTIATION, V45, P55, DOI 10.1111/j.1432-0436.1990.tb00457.x; TAKAHASHI N, 1990, J BIOL CHEM, V265, P19158; TAKAHASHI N, 1991, ARCH BIOCHEM BIOPHYS, V285, P105, DOI 10.1016/0003-9861(91)90334-F; TAKAHASHI N, 1992, J STEROID BIOCHEM, V43, P489, DOI 10.1016/0960-0760(92)90235-B; TAKAHASHI N, 1991, BIOCHEM BIOPH RES CO, V180, P393, DOI 10.1016/S0006-291X(05)81306-3; TAKAHASHI N, 1989, IN VITRO CELL DEV B, V25, P1199; TAKAHASHI N, 1989, J BIOL CHEM, V264, P5159; TAKAHASHI N, 1991, ARCH BIOCHEM BIOPHYS, V290, P293, DOI 10.1016/0003-9861(91)90544-S; TAKAHASHI N, 1991, STATUS DIFFERENTIATI, V2, P255; TAKAHASHI N, 1984, VITAMIN A HLTH DISEA, P257; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TOKUI T, 1990, BIOCHEM BIOPH RES CO, V169, P896, DOI 10.1016/0006-291X(90)91977-Z; TSURU A, 1990, J CELL BIOL, V110, P1655, DOI 10.1083/jcb.110.5.1655; TUNG PS, 1993, J CELL PHYSIOL, V155, P139, DOI 10.1002/jcp.1041550118; VANMUIJEN GNP, 1987, LAB INVEST, V57, P359; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002	84	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1994	269	8					5913	5917						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MY840	7509793				2022-12-27	WOS:A1994MY84000067
J	GOPALAKRISHNAN, V; BENKOVIC, S				GOPALAKRISHNAN, V; BENKOVIC, S			EFFECT OF A THIOBENZIMIDAZOLONE DERIVATIVE ON DNA STRAND TRANSFER CATALYZED BY HIV-1 REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BINDING-SITE; INHIBITOR; AZT; SENSITIVITY; REPLICATION; POLYMERASE; ZIDOVUDINE; THERAPY; TARGET	Thiobenzimidazolone (TIBO) derivatives are known inhibitors of the DNA polymerase activity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). The effect of a TIBO derivative ((+)-S-4,5,6,7-tetrahydro-9-chloro-5-methyl-6-(3-methyl-2-butenyl)-imidazol[4,5,1-jk]1,4-benzodiazapine-2-thione) DNA strand transfer reaction catalyzed by HIV-1 RT (which is a function of both the DNA polymerase and RNase H activities) was investigated by delineating the effect of the drug on the constitutive DNA polymerase and RNase H activities. Single nucleotide incorporation on template-primer 1 was used to study the DNA polymerase activity of HIV-1 RT while template-primer 2 was used to study the effect of TIBO on the RNase H activity (polymerase independent). The drug was found to decrease the amplitude of the presteady-state burst when preequilibrated with the enzyme substrate complex besides decreasing the steady-state rate of single nucleotide incorporations. In the absence of preincubation, TIBO did not affect the burst amplitude but decreased the steady-state rate after the pre-transient phase. This suggested that binding of TIBO to RT was affected by the presence of template-primer and required dissociation of the enzyme from the template primer for effective binding. The polymerase-independent RNase H activity was activated in the presence of TIBO. The effect of TIBO on the overall process of DNA strand transfer is a balance between its inhibition of the polymerase activity and its activation of the RNase H activity.	PENN STATE UNIV, DEPT CHEM, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIGMS NIH HHS [GM13306-23] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARROLL SS, 1993, J BIOL CHEM, V268, P276; COHEN KA, 1991, J BIOL CHEM, V266, P14670; DARBY G, 1992, BIOCHEM SOC T, V20, P505, DOI 10.1042/bst0200505; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DECLERCQ E, 1993, MED RES REV, V13, P229, DOI 10.1002/med.2610130303; DEVREESE K, 1992, VIROLOGY, V188, P900, DOI 10.1016/0042-6822(92)90550-9; DUEWEKE TJ, 1992, J BIOL CHEM, V267, P27; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; JOHNSON KA, 1993, 22ND SSTEENB S PROT, P20; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106	25	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4110	4115						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508439				2022-12-27	WOS:A1994MW98900035
J	BARAK, LS; TIBERI, M; FREEDMAN, NJ; KWATRA, MM; LEFKOWITZ, RJ; CARON, MG				BARAK, LS; TIBERI, M; FREEDMAN, NJ; KWATRA, MM; LEFKOWITZ, RJ; CARON, MG			A HIGHLY CONSERVED TYROSINE RESIDUE IN G-PROTEIN-COUPLED RECEPTORS IS REQUIRED FOR AGONIST-MEDIATED BETA(2)-ADRENERGIC RECEPTOR SEQUESTRATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-2-ADRENERGIC RECEPTOR; DOWN-REGULATION; INTERNALIZATION; DESENSITIZATION; SEQUENCE; ENDOCYTOSIS; BINDING; SIGNAL; PATHWAYS; MEMBRANE	An aromatic residue, tyrosine 326 in the prototypical human beta2-adrenergic receptor, exists in a highly conserved sequence motif in virtually all members of the G protein-coupled receptor family. The potential role of this conserved aromatic amino acid residue in the cellular processes of sequestration (a rapid internalization of the surface receptor) and down-regulation (a slower loss of total cellular receptors) associated with agonist-mediated desensitization of the beta2-adrenergic receptor was assessed by replacing tyrosine residue 326 with an alanine residue (beta2AR-Y326A). This mutation completely abolishes agonist-mediated receptor sequestration without affecting the ability of the receptor to activate maximally adenylyl cyclase, to undergo rapid desensitization, and to down-regulate in response to agonist. The only other major change associated with the mutated receptor is a complete loss of the ability to resensitize following rapid desensitization. These results imply that this tyrosine residue, which is part of a highly conserved sequence motif in G protein-coupled receptors, may be responsible for their agonist-mediated sequestration and that sequestration and down-regulation of the receptor are dissociable phenomena. The lack of resensitization in the sequestration-defective beta2-adrenergic receptor mutant strongly suggests that the sequestration pathway is an important mechanism by which cells reestablish the normal responsiveness of G protein-coupled receptors following the removal of agonist.	DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University; Duke University			Kwatra, Madan/ABD-2008-2020; Lefkowitz, Robert/AAW-2649-2021		NIMH NIH HHS [MH44211] Funding Source: Medline; NINDS NIH HHS [NS19576] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH044211] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BURBACH JPH, 1992, EUR J PHARM-MOLEC PH, V227, P1, DOI 10.1016/0922-4106(92)90136-J; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; EASON MG, 1992, J BIOL CHEM, V267, P25473; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HERTEL C, 1985, J BIOL CHEM, V260, P2547; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MAHAN LC, 1985, P NATL ACAD SCI USA, V82, P129, DOI 10.1073/pnas.82.1.129; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEGISHI M, 1993, J BIOL CHEM, V268, P9517; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; WALDO GL, 1983, J BIOL CHEM, V258, P3900; YU SS, 1993, J BIOL CHEM, V268, P337	29	355	362	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2790	2795						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	7507928				2022-12-27	WOS:A1994MV43200065
J	CROOKSTON, KP; WEBB, DJ; WOLF, BB; GONIAS, SL				CROOKSTON, KP; WEBB, DJ; WOLF, BB; GONIAS, SL			CLASSIFICATION OF ALPHA(2)-MACROGLOBULIN-CYTOKINE INTERACTIONS BASED ON AFFINITY OF NONCOVALENT ASSOCIATION IN SOLUTION UNDER APPARENT EQUILIBRIUM CONDITIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; RECEPTOR-RELATED PROTEIN; ALPHA-MACROGLOBULIN; ALPHA-2-MACROGLOBULIN RECEPTOR; COVALENT BINDING; CYTOKINE BINDING; FAST FORMS; COMPLEXES; CLEARANCE; IDENTIFICATION	Alpha2-macroglobulin (alpha2M) binds numerous cytokines; however, since binding affinities have not been determined, it is difficult to compare various alpha2M-cytokine interaetions or predict whether alpha2M-cytokine complexes will form in the presence of other cytokine-binding macromolecules. In this investigation, we used a novel method to demonstrate that transforming growth factor-beta1 (TGF-beta1), TGF-beta2, nerve growth factor-beta (NGF-beta), platelet derived growth factor-BB (PDGF-BB), tumor necrosis factor-alpha (TNF-alpha), and basic fibroblast growth factor (bFGF) reversibly associate with alpha2M-methylamine to form noncovalent complexes. Apparent equilibrium was achieved in less than 15 min. Noncovalent alpha2M-cytokine complexes were converted into covalent complexes; however, this occurred slowly. Therefore, a rapid equilibrium assumption was applied and equilibrium dissociation constants were determined using a single binding site model. K(D) values for the binding of cytokines to alpha2M-methylamine varied by 2 orders of magnitude. The rank order of affinity was TGF-beta2 (13 +/- 2 nm) > TGF-beta1, NGF-beta > PDGF-BB greater-than-or-equal-to bFGF > TNF-alpha. Native alpha2M bound TGF-beta1, TGF-beta2, NGF-beta, PDGF-BB, and TNF-alpha. Interferon-gamma did not bind to native alpha2M or alpha2M-methylamine. Each cytokine bound native alpha2M with lower affinity than alpha2M-methylamine except for TGF-beta2 which bound both forms with equal affinity. In non-equilibrium systems, alpha2M-methylamine appeared to bind more TGF-beta2 due to the more rapid dissociation of TGF-beta2-native alpha2M complex. The classification of alpha2M-cytokine complexes according to binding affinity should predict which complexes are most likely to form in cell culture and under various conditions in vivo.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,BOX 214,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53462] Funding Source: Medline; NHLBI NIH HHS [HL-02272] Funding Source: Medline; NIGMS NIH HHS [GM 07267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELLA PM, 1979, BIOCHEM BIOPH RES CO, V87, P734, DOI 10.1016/0006-291X(79)92020-5; ASSOIAN RK, 1987, METHOD ENZYMOL, V146, P153; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BJORK I, 1982, BIOCHEM J, V207, P347; BONNER JC, 1992, J BIOL CHEM, V267, P12837; BONNER JC, 1990, J CELL PHYSIOL, V145, P1, DOI 10.1002/jcp.1041450102; BORTH W, 1989, J BIOL CHEM, V264, P5818; BORTH W, 1990, BLOOD, V75, P2388; BORTH W, 1990, J IMMUNOL, V145, P3747; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; CHU CT, 1991, BIOCHEMISTRY-US, V30, P1551, DOI 10.1021/bi00220a016; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DARLING TL, 1984, CELL CULTURE METHODS, V4, P79; DENNIS PA, 1989, J BIOL CHEM, V264, P7210; FEINMAN RD, 1983, ANN NY ACAD SCI, V421, P178, DOI 10.1111/j.1749-6632.1983.tb18108.x; GONIAS SL, 1989, J BIOL CHEM, V264, P9565; GONIAS SL, 1983, BIOCHEM J, V209, P99, DOI 10.1042/bj2090099; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; GONIAS SL, 1983, J BIOL CHEM, V258, P4682; GONIAS SL, 1992, EXP HEMATOL, V20, P302; HALL PK, 1978, BIOCHEM J, V173, P27, DOI 10.1042/bj1730027; HALL SW, 1992, BIOCHEM J, V281, P569, DOI 10.1042/bj2810569; HOWARD JB, 1981, P NATL ACAD SCI-BIOL, V78, P2235, DOI 10.1073/pnas.78.4.2235; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JAMES K, 1992, IMMUNOL LETT, V32, P49, DOI 10.1016/0165-2478(92)90198-W; KOO PH, 1989, J NEUROSCI RES, V22, P247, DOI 10.1002/jnr.490220304; KRUMMEN LA, 1993, ENDOCRINOLOGY, V132, P431, DOI 10.1210/en.132.1.431; LAMARRE J, 1991, BIOCHIM BIOPHYS ACTA, V1091, P197, DOI 10.1016/0167-4889(91)90062-3; LAMARRE J, 1991, LAB INVEST, V65, P3; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; LIEBL DJ, 1993, BIOCHEM BIOPH RES CO, V193, P1255, DOI 10.1006/bbrc.1993.1760; MATSUDA T, 1989, J IMMUNOL, V142, P148; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; PHILIP A, 1991, J BIOL CHEM, V266, P22290; PIZZO SV, 1984, RECEPTORS, V1, P177; RAINES EW, 1984, P NATL ACAD SCI-BIOL, V81, P3424, DOI 10.1073/pnas.81.11.3424; RONNE H, 1979, BIOCHEM BIOPH RES CO, V87, P330, DOI 10.1016/0006-291X(79)91683-8; SALVESEN GS, 1981, BIOCHEM J, V195, P453, DOI 10.1042/bj1950453; SALVESEN GS, 1980, BIOCHEM J, V187, P695, DOI 10.1042/bj1870695; SOKER S, 1993, J BIOL CHEM, V268, P7685; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; STOUFFER GA, 1993, J BIOL CHEM, V268, P18340; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STRICKLAND DK, 1988, BIOCHEMISTRY-US, V27, P1458, DOI 10.1021/bi00405a010; SWENSON RP, 1979, J BIOL CHEM, V254, P4452; TEODORESCU M, 1991, MOL IMMUNOL, V28, P323, DOI 10.1016/0161-5890(91)90144-9; VAUGHAN JM, 1993, ENDOCRINOLOGY, V132, P2038, DOI 10.1210/en.132.5.2038; WEBB DJ, 1992, ARCH BIOCHEM BIOPHYS, V292, P487, DOI 10.1016/0003-9861(92)90020-W; WOLLENBERG GK, 1991, AM J PATHOL, V138, P265	55	113	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1533	1540						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507109				2022-12-27	WOS:A1994MR22000115
J	JACQUES, PS; WOHRL, BM; HOWARD, KJ; LEGRICE, SFJ				JACQUES, PS; WOHRL, BM; HOWARD, KJ; LEGRICE, SFJ			MODULATION OF HIV-1 REVERSE-TRANSCRIPTASE FUNCTION IN SELECTIVELY DELETED P66/P51 HETERODIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; METAL CHELATE ADSORBENT; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DOMAIN-STRUCTURE; DNA-SYNTHESIS; TYPE-1; PRIMER; PURIFICATION; POLYMERASE	A contribution of the 51-kDa subunit of human immunodeficiency virus type-1 reverse transcriptase to activities of the parental heterodimer (p66/p51) was assessed in ''selectively deleted'' heterodimers whose p51 component contained C-terminal truncations of 13, 19, or 25 residues. Analyses included (i) efficiency of reconstitution into heterodimer, (ii) retention of polymerase and ribonuclease H (RNase H) function, and (iii) interaction with the HIV replication primer, tRNA(Lys,3). Our data suggest that these features of heterodimer reverse transcriptase can be modulated by the extent of the C-terminal p51 deletion. Severely impaired tRNA binding in a selectively deleted heterodimer whose 51-kDa subunit lacks 13 residues, despite retention of enzymatic functions, strengthens arguments for p51 involvement in tRNA binding.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DIV INFECT DIS,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031147] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 31147-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BAILLON JG, 1991, NEW BIOL, V3, P1015; BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; BASU A, 1992, BIOCHEMISTRY-US, V31, P616, DOI 10.1021/bi00117a045; BENARTZI H, 1992, P NATL ACAD SCI USA, V89, P927, DOI 10.1073/pnas.89.3.927; BENARTZI H, 1992, NUCLEIC ACIDS RES, V20, P5115, DOI 10.1093/nar/20.19.5115; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; BUCK HM, 1990, SCIENCE, V248, P208, DOI 10.1126/science.2326635; CHENG N, 1991, BIOCHEM BIOPH RES CO, V174, P785, DOI 10.1016/0006-291X(91)91486-V; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; HOWARD KJ, 1991, J BIOL CHEM, V266, P23003; HUBER HE, 1990, J BIOL CHEM, V265, P10565; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOHLSTAEDT LA, 1992, P NATL ACAD SCI USA, V89, P9652, DOI 10.1073/pnas.89.20.9652; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEDERER H, 1992, EMBO J, V11, P1131, DOI 10.1002/j.1460-2075.1992.tb05153.x; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LEGRICE SFJ, 1991, J VIROL, V65, P7004, DOI 10.1128/JVI.65.12.7004-7007.1991; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LEGRICE SFJ, 1989, J BIOL CHEM, V264, P14902; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; MULLER B, 1991, J BIOL CHEM, V266, P14709; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RICHTERCOOK NJ, 1992, J BIOL CHEM, V267, P12592; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SCHATZ O, 1990, ONCOGENESIS AIDS, P304; SOBOL RW, 1991, BIOCHEMISTRY-US, V30, P10623, DOI 10.1021/bi00108a004; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WEISS S, 1992, GENE, V111, P183, DOI 10.1016/0378-1119(92)90686-J; WOHRL BM, 1993, J BIOL CHEM, V268, P13617; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003	39	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1388	1393						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507107				2022-12-27	WOS:A1994MR22000096
J	BEDI, GS; WILLIAMS, T				BEDI, GS; WILLIAMS, T			PURIFICATION AND CHARACTERIZATION OF A COLLAGEN-DEGRADING PROTEASE FROM PORPHYROMONAS-GINGIVALIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLACK-PIGMENTED BACTEROIDES; TRYPSIN-LIKE PROTEASE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; EXTRACELLULAR VESICLES; BACTERICIDAL ACTIVITY; DEGRADATION; IMMUNOGLOBULIN; STRAINS; W50	A trypsin-like protease was purified from spent culture medium of oral pathogen Porphyromonas gingivalis by chromatography on columns of DEAE-Sepharose, gel filtration on Sephadex G-100, and chromatofocusing on PBE-94. Purified enzyme showed a single band on SDS-polyacrylamide gel electrophoresis with an estimated molecular weight of 55,000. Purified protease hydrolyzed type I, III, IV, and V collagen from human placenta, and type I collagen from rat tail and calf skin, but did not hydrolyze type II collagen from chicken sternal cartilage. The purified enzyme also hydrolyzed the C3 component of complement, fibrinogen, fibronectin, alpha1-antitrypsin, alpha2-macroglobulin, apotransferrin, and human serum albumin. The hydrolytic activity of the purified enzyme on chromogenic substrates was limited to substrates with arginine in the P-1 position, although synthetic peptides were also cleaved at Lys-X linkage. The enzyme was activated by reducing agents dithiothreitol, L-Cysteine, and glutathione and inhibited by cysteine protease inhibitors N-ethylmaleimide, iodoacetic acid, and iodoacetamide. The enzyme was also inhibited by trans-epoxysuccinyl-L-leucylamido(4-guanidino) butane (E-64), leupeptin, antipain, salivary histidine-rich protein (HRP-5), soybean trypsin inhibitor, and EDTA. Since the protease is able to degrade the connective tissue components of periodontal tissue as well as components of host defense mechanism, this enzyme may be a potent virulence factor of P. gingivalis involved in invasion and tissue destruction.			BEDI, GS (corresponding author), MAGAININ PHARMACEUT INC,5110 CAMPUS DR,PLYMOUTH MEETING,PA 19462, USA.							BIRKEDALHANSEN H, 1988, J PERIODONTAL RES, V23, P258, DOI 10.1111/j.1600-0765.1988.tb01369.x; CARLSSON J, 1984, J MED MICROBIOL, V18, P39, DOI 10.1099/00222615-18-1-39; CHEN ZX, 1992, J BIOL CHEM, V267, P18896; FRANDSEN EVG, 1987, INFECT IMMUN, V55, P631, DOI 10.1128/IAI.55.3.631-638.1987; FUZIMURA S, 1992, ORAL MICROBIOL IMMUN, V7, P212; GRENIER D, 1987, INFECT IMMUN, V55, P111, DOI 10.1128/IAI.55.1.111-117.1987; GRENIER D, 1992, INFECT IMMUN, V60, P1854, DOI 10.1128/IAI.60.5.1854-1857.1992; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUGHON BE, 1982, J CLIN MICROBIOL, V15, P345, DOI 10.1128/JCM.15.2.345-346.1982; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYRAND D, 1988, MICROBIOL REV, V52, P134, DOI 10.1128/MMBR.52.1.134-152.1988; Miller EJ, 1984, EXTRACELLULAR MATRIX, P41; MORTENSEN SB, 1984, INFECT IMMUN, V45, P550, DOI 10.1128/IAI.45.3.550-557.1984; ODELL EW, 1992, ARCH ORAL BIOL, V37, P597, DOI 10.1016/0003-9969(92)90121-N; Ono M, 1987, Oral Microbiol Immunol, V2, P77, DOI 10.1111/j.1399-302X.1987.tb00294.x; ROBERTSON PB, 1982, J PERIODONTAL RES, V17, P275, DOI 10.1111/j.1600-0765.1982.tb01154.x; SATO M, 1987, ARCH ORAL BIOL, V32, P235, DOI 10.1016/0003-9969(87)90016-1; SCOTT CF, 1993, J BIOL CHEM, V268, P7935; SCRAGG MA, 1991, ARCH ORAL BIOL, V36, P709, DOI 10.1016/0003-9969(91)90037-U; SLOTS J, 1979, J CLIN PERIODONTOL, V6, P351, DOI 10.1111/j.1600-051X.1979.tb01935.x; SLOTS J, 1986, J CLIN PERIODONTOL, V13, P570, DOI 10.1111/j.1600-051X.1986.tb00849.x; SLOTS J, 1979, J CLIN MICROBIOL, V10, P371, DOI 10.1128/JCM.10.3.371-373.1979; SMALLEY JW, 1989, ARCH ORAL BIOL, V34, P579, DOI 10.1016/0003-9969(89)90098-8; SMALLEY JW, 1987, J GEN MICROBIOL, V133, P2883; SOJAR HT, 1993, INFECT IMMUN, V61, P2369, DOI 10.1128/IAI.61.6.2369-2376.1993; SORSA T, 1987, J PERIODONTAL RES, V22, P375, DOI 10.1111/j.1600-0765.1987.tb01602.x; SUNDQVIST G, 1985, J MED MICROBIOL, V19, P85, DOI 10.1099/00222615-19-1-85; TODA K, 1984, J PERIODONTAL RES, V19, P372, DOI 10.1111/j.1600-0765.1984.tb01010.x; TSUTSUI H, 1987, INFECT IMMUN, V55, P420, DOI 10.1128/IAI.55.2.420-427.1987; VANWINKELHOFF AJ, 1988, J CLIN PERIODONTOL, V15, P145; VANWINKELHOFF AJ, 1986, A VAN LEEUW J MICROB, V52, P163, DOI 10.1007/BF00429320; YONEDA M, 1990, INFECT IMMUN, V58, P406, DOI 10.1128/IAI.58.2.406-411.1990; YOSHIMURA F, 1984, ARCH ORAL BIOL, V29, P559, DOI 10.1016/0003-9969(84)90078-5	34	82	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					599	606						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506259				2022-12-27	WOS:A1994MR21900095
J	PARK, S; JOVE, R				PARK, S; JOVE, R			TYROSINE PHOSPHORYLATION OF RAS GTPASE-ACTIVATING PROTEIN STABILIZES ITS ASSOCIATION WITH P62 AT MEMBRANES OF V-SRC TRANSFORMED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; P21 GTPASE; SIGNAL TRANSDUCTION; FACTOR RECEPTORS; SH2 DOMAINS; GAP; BINDING; KINASES; STIMULATION; REQUIREMENT	Ras GTPase-activating protein (GAP) regulates the activity of Ras proteins, which have key roles in signal transduction pathways downstream of oncogenic and receptor tyrosine kinases. Previous studies indicated that Tyr-457 of bovine GAP (Tyr-460 of human GAP) is the major site of phosphorylation by viral Src (v-Src) kinase and epidermal growth factor receptor. The finding that Tyr-457 in GAP is located immediately adjacent to Src homology 2 (SH2) and 3 (SH3) domains led us to investigate the possibility that this specific phosphorylation regulates protein-protein interactions involving GAP. For this purpose, we constructed a full-length GAP mutant containing a substitution of Phe-457 in place of Tyr-457. Both wild-type GAP and mutant GAP(F457) were tagged with the KT3 epitope at the carboxyl terminus and were expressed in v-Src transformed rat fibroblasts. In vivo phosphorylation analyses established that GAP(F457) was weakly phosphorylated on tyrosine and, as expected, lacked the phosphopeptide containing Tyr-457. Analysis of GAP-associated proteins in anti-KT3 immunoprecipitates showed that GAP stably associated with two major phosphoproteins, p62 and p190, which have been previously described. Significantly, association of p62 with GAP(F457) was reduced approximately 3-fold compared with wild-type GAP. Subcellular fractionation experiments further demonstrated that Tyr-457 phosphorylation of GAP stabilized its association with p62 at cell membranes. Based on these findings, we propose that one role of tyrosine phosphorylation in GAP is to enhance its association with p62 at membranes, which in turn may contribute to regulation of Ras signal transduction pathways.	UNIV MICHIGAN,SCH MED,CTR COMPREHENS CANC,DEPT MICROBIOL & IMMUNOL,6606 MED SCI 2,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan				Park, Soochul/0000-0002-7029-3414	NCI NIH HHS [CA55652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055652] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CHANG JH, 1993, ONCOGENE, V8, P959; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CORMACK B, 1988, CURRENT PROTOCOLS MO; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIBBS JB, 1990, ADP RIBOSYLATING TOX, P381; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HSIEH CL, 1989, SOMAT CELL MOLEC GEN, V15, P579, DOI 10.1007/BF01534919; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; LUO K, 1990, ONCOGENE, V5, P921; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MOLLOY CJ, 1992, MOL CELL BIOL, V12, P3903, DOI 10.1128/MCB.12.9.3903; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PARK S, 1992, J BIOL CHEM, V267, P11612; PARK S, 1992, J BIOL CHEM, V267, P17194; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	51	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25728	25734						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503985				2022-12-27	WOS:A1993MK10000066
J	PAVLIAK, V; NASHED, EM; POZSGAY, V; KOVAC, P; KARPAS, A; CHU, CY; SCHNEERSON, R; ROBBINS, JB; GLAUDEMANS, CPJ				PAVLIAK, V; NASHED, EM; POZSGAY, V; KOVAC, P; KARPAS, A; CHU, CY; SCHNEERSON, R; ROBBINS, JB; GLAUDEMANS, CPJ			BINDING OF THE O-ANTIGEN OF SHIGELLA-DYSENTERIAE TYPE-1 AND TYPE-26 RELATED SYNTHETIC FRAGMENTS TO A MONOCLONAL IGM ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-PNEUMONIAE; ENTERIC INFECTIONS; RURAL BANGLADESH; POLYSACCHARIDE; LIGANDS; LIPOPOLYSACCHARIDE; SPECIFICITY; DEXTRAN; SHIGELLA-DYSENTERIAE-1; VIRULENCE	Shigella dysenteriae type 1 possesses an O-antigen whose repeating unit is -->3-alpha-L-Rhap-(1-->3)-alpha-L-Rhap-(1-->2)-alpha-D-Galp-(1-->3)-alpha-D-GlcpNAc-(1-->, where Rhap is rhamnopyranosyl, Galp is galactopyranosyl, and Glcp is glucopyranosyl. Using ligand-induced protein fluorescence change, we have measured the affinities of a monoclonal murine IgM for 26 fragments of, or related to, the structure of the O-polysaccharide and of the IgM Fab for the intact O-specific bacterial polysaccharide. Synthetic saccharides used were methyl glycosides to ensure an anomerically defined pyranosyl ring conformation. The galactosyl residue is the only monosaccharide of the antigenic epitope that shows quantifiable binding: approximately 3.0 kcal/mol of binding free energy, depending on the structure and conformation of the fragment it is a part of. Addition of an alpha-(1-->2)-linked rhamnosyl residue increases the free energy of binding significantly. We propose this rhamnopyranosyl-alpha-(1-->2)-galactopyranosyl disaccharide to be the basic determinant of the Shigella O-polysaccharide. Further extension (by linkages as in the natural antigen) of this oligosaccharidic ligand toward the upstream end (in an oligo- (or poly-)saccharide, such as A-->B-->C-->D-->E-->m, where A, B, C, D, and E are sugars and m is any moiety, such as methyl, we define A as the glycosyl- or upstream terminus, and E as the glycoside- or downstream terminus) by rhamnosyl and N-acetylglucosaminyl moieties improves the binding only minimally. The antibody is quite specific for the rhamnosyl-alpha-(1-->2)-galactosyl sequence but less so for the nature of the attachment to the galactosyl residue on the downstream side. Measurements using IgM Fab and the intact O-specific polysaccharide show that the antibody can bind internal segments on the antigen chain. The free energy of binding of this antibody for the disaccharide determinant varies from -DELTAG of 4.7 to 5.1 kcal/mol, depending on its flanking residues.	NIDDKD, BETHESDA, MD 20892 USA; US FDA, CTR BIOL RES & REVIEW, BETHESDA, MD 20892 USA; NICHHD, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BENNETT LG, 1979, BIOCHEMISTRY-US, V18, P3337, DOI 10.1021/bi00582a021; BENNETT LG, 1979, CARBOHYD RES, V72, P315, DOI 10.1016/S0008-6215(00)83958-0; BENNETT LG, 1979, J IMMUNOL, V122, P2356; BHATTACHARJEE AK, 1983, MOL IMMUNOL, V20, P351, DOI 10.1016/0161-5890(83)90016-0; BHATTACHARJEE AK, 1984, REV INFECT DIS, V6, P619; BIDLACK JM, 1986, J IMMUNOL METHODS, V91, P157, DOI 10.1016/0022-1759(86)90473-4; BINNS MM, 1985, ZBL BAKT MIK HYG B, V181, P197; BLACK RE, 1980, J INFECT DIS, V142, P660, DOI 10.1093/infdis/142.5.660; BLACK RE, 1984, PEDIATRICS, V73, P799; CHEN LC, 1980, INT J EPIDEMIOL, V9, P25, DOI 10.1093/ije/9.1.25; CHU CY, 1991, INFECT IMMUN, V59, P4450, DOI 10.1128/IAI.59.12.4450-4458.1991; CHU CY, 1983, INFECT IMMUN, V40, P245, DOI 10.1128/IAI.40.1.245-256.1983; CISAR J, 1975, J EXP MED, V142, P435, DOI 10.1084/jem.142.2.435; COHEN D, 1988, J INFECT DIS, V157, P1068, DOI 10.1093/infdis/157.5.1068; DAHMEN J, 1985, CARBOHYD RES, V138, P17, DOI 10.1016/0008-6215(85)85219-8; DAS MK, 1979, MOL IMMUNOL, V16, P97, DOI 10.1016/0161-5890(79)90050-6; DMITRIEV BA, 1976, EUR J BIOCHEM, V66, P559, DOI 10.1111/j.1432-1033.1976.tb10582.x; DUPONT HL, 1989, J INFECT DIS, V159, P1126, DOI 10.1093/infdis/159.6.1126; EVANS ME, 1968, J ORG CHEM, V33, P1074, DOI 10.1021/jo01267a028; FELSEN J, 1945, BACILLARY DYSENTERY; FORMAL SB, 1989, REV INFECT DIS, V11, pS547; GLAUDEMANS CPJ, 1993, ACS SYM SER, V519, P72; GLAUDEMANS CPJ, 1988, ACS SYM SER, V374, P78; GLAUDEMANS CPJ, 1989, CARBOHYD RES, V190, P267, DOI 10.1016/0008-6215(89)84130-8; GLAUDEMANS CPJ, 1991, CHEM REV, V91, P25, DOI 10.1021/cr00001a002; GLAUDEMANS CPJ, 1977, IMMUNOCHEMISTRY, V14, P675, DOI 10.1016/0019-2791(77)90140-9; Glaudemans CPJ, 1980, METHODS CARBOHYDR CH, V8, P145; GORDON JE, 1965, AM J TROP MED HYG, V14, P404, DOI 10.4269/ajtmh.1965.14.404; JOLLEY ME, 1974, CARBOHYD RES, V33, P377, DOI 10.1016/S0008-6215(00)82819-0; KOVAC P, 1992, J ORG CHEM, V57, P2455, DOI 10.1021/jo00034a047; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levene PA, 1934, J BIOL CHEM, V105, P431; LEVINE MM, 1973, J INFECT DIS, V127, P261, DOI 10.1093/infdis/127.3.261; LEVINE MM, 1983, MICROBIOL REV, V47, P510, DOI 10.1128/MMBR.47.4.510-550.1983; LEVINE MM, 1990, LANCET, V335, P958, DOI 10.1016/0140-6736(90)91013-Z; LINDBERG AA, 1984, B WORLD HEALTH ORGAN, V62, P597; MATA LJ, 1967, TROP GEOGR MED, V19, P247; MICHON F, 1989, CARBOHYD RES, V194, P321, DOI 10.1016/0008-6215(89)85033-5; NASHED EM, 1990, J BIOL CHEM, V265, P20699; Orskov F., 1978, METHOD MICROBIOL, V2, P1; OUCHTERLONY O, 1968, HDB IMMUNODIFFUSION; PAVLIAK V, 1992, CARBOHYD RES, V229, P103, DOI 10.1016/S0008-6215(00)90483-X; POZSGAY V, 1987, CAN J CHEM, V65, P2764, DOI 10.1139/v87-459; POZSGAY V, 1992, BIOORG MED CHEM LETT, V2, P255; POZSGAY V, 1993, IN PRESS BIOORG MED; POZSGAY V, 1992, CARBOHYDRATES SYNTHE, P188; ROUSE DA, 1990, INFECT IMMUN, V58, P1445, DOI 10.1128/IAI.58.5.1445-1449.1990; SCRAGG JN, 1978, J PEDIATR-US, V93, P796, DOI 10.1016/S0022-3476(78)81081-6; SHARON J, 1982, MOL IMMUNOL, V19, P389, DOI 10.1016/0161-5890(82)90204-8; STANKER LH, 1985, J IMMUNOL METHODS, V76, P157, DOI 10.1016/0022-1759(85)90488-0; STOLL BJ, 1982, J INFECT DIS, V146, P177, DOI 10.1093/infdis/146.2.177; STREEFKERK DG, 1977, BIOCHEMISTRY-US, V16, P3760, DOI 10.1021/bi00636a005; STREEFKERK DG, 1977, J IMMUNOL, V120, P408; STURM S, 1986, MICROB PATHOGENESIS, V1, P307, DOI 10.1016/0882-4010(86)90056-2; TAYLOR DN, 1993, INFECT IMMUN, V61, P3678, DOI 10.1128/IAI.61.9.3678-3687.1993; WATANABE H, 1984, INFECT IMMUN, V43, P391, DOI 10.1128/IAI.43.1.391-396.1984; WATANABE H, 1984, INFECT IMMUN, V46, P55, DOI 10.1128/IAI.46.1.55-63.1984; ZIDOVETZKI R, 1980, BIOCHEMISTRY-US, V19, P2790, DOI 10.1021/bi00553a039; ZIEGLER T, 1990, CARBOHYD RES, V203, P253, DOI 10.1016/0008-6215(90)80022-U; ZIEGLER T, 1990, CARBOHYD RES, V204, P167, DOI 10.1016/0008-6215(90)84033-Q	60	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25797	25802						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503987				2022-12-27	WOS:A1993MK10000076
J	CHA, MK; KIM, HK; KIM, IH				CHA, MK; KIM, HK; KIM, IH			THIOREDOXIN-LINKED THIOL PEROXIDASE FROM PERIPLASMIC SPACE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE DISMUTASE; ANTIOXIDANT PROTEIN; OXIDATIVE DAMAGE; DNA; GLUTATHIONE; OVOTHIOL	Three different molecular masses (24, 22, and 20 kDa) of antioxidant proteins were purified in Escherichia coli. These proteins exhibited the preventive effects against the inactivation of glutamine synthetase activity and the cleavage of DNA by a metal-catalyzed oxidation system capable of generating reactive oxygen species. Their antioxidant activities were supported by a thiol-reducing equivalent such as dithiothreitol. Analysis of the amino-terminal amino acid sequences and the immunoblots between 24 and 22-kDa proteins indicates that the 24-kDa protein is an intact form of the 22-kDa protein that was previously identified 22-kDa subunit (AhpC) of E. coli alkyl hydroperoxide reductase (AhpC/AhpF). We isolated and sequenced an E. coli genomic DNA fragment that encodes 20-kDa protein. Comparison of the deduced amino acid sequence of the 20-kDa protein with that of AhpC revealed no sequence homology. A search of a data bank showed that the 20-kDa protein is a new type of antioxidant enzyme. The synthesis of this novel 20-kDa protein was increased in response to oxygen stress during growth. The 20-kDa protein resides mainly in the periplasmic space of E. coli, whereas the 24-kDa AhpC resides mainly in the matrix. The 20-kDa protein was functionally linked to the thioredoxin as an in vivo thiol-regenerating system and exerted a peroxidase activity. This 20-kDa protein is thus named ''thiol peroxidase,'' which could act as an antioxidant enzyme removing peroxides or H2O2 within the catalase- and peroxidase-deficient periplasmic space of E. coli.	PAI CHAI UNIV,DEPT BIOCHEM,TAEJON 302735,SOUTH KOREA	Pai Chai University			Kim, Il-Han/W-1401-2019					BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, BIOFACTORS, V4, P177; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7072; CHANCE B, 1955, METHOD ENZYMOL, V2, P764, DOI 10.1016/S0076-6879(55)02300-8; CLAYCAMP HG, 1987, BIOCHEM BIOPH RES CO, V144, P432, DOI 10.1016/S0006-291X(87)80528-4; Crapo J D, 1978, Methods Enzymol, V53, P382; FRIDOVICH I, 1976, ANN REV BIOCH, V44, P147; GREGORY EM, 1973, J BACTERIOL, V115, P987, DOI 10.1128/JB.115.3.987-991.1973; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HASSAN HM, 1977, J BACTERIOL, V129, P1574, DOI 10.1128/JB.129.3.1574-1583.1977; HEPPEL LA, 1967, SCIENCE, V156, P1451, DOI 10.1126/science.156.3781.1451; HOLLER TP, 1988, J AM CHEM SOC, V110, P4837, DOI 10.1021/ja00222a057; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; KEELE BB, 1970, J BIOL CHEM, V245, P6176; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM YS, 1993, BIOCHEM BIOPH RES CO, V192, P273, DOI 10.1006/bbrc.1993.1410; LIM YS, 1994, GENE, V140, P279, DOI 10.1016/0378-1119(94)90558-4; LIM YS, 1994, BIOCHEM BIOPH RES CO, V199, P199, DOI 10.1006/bbrc.1994.1214; MEAD JF, 1976, FREE RADICALS BIOLOG, V1, P51; RHEE SG, 1985, METHOD ENZYMOL, V113, P213; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLIWKOWSKI MX, 1985, ANAL BIOCHEM, V147, P369, DOI 10.1016/0003-2697(85)90284-2; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; Tappel A L, 1978, Methods Enzymol, V52, P506; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; TURNER E, 1988, SCIENCE, V242, P939, DOI 10.1126/science.3187533; YOST FJ, 1973, J BIOL CHEM, V248, P4905	32	126	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28635	28641		10.1074/jbc.270.48.28635	http://dx.doi.org/10.1074/jbc.270.48.28635			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499381	hybrid			2022-12-27	WOS:A1995TH05600025
J	KO, K; BUDD, D; WU, CB; SEIBERT, F; KOURTZ, L; KO, ZW				KO, K; BUDD, D; WU, CB; SEIBERT, F; KOURTZ, L; KO, ZW			ISOLATION AND CHARACTERIZATION OF A CDNA CLONE ENCODING A MEMBER OF THE COM44/CIM44 ENVELOPE COMPONENTS OF THE CHLOROPLAST PROTEIN IMPORT APPARATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; TRANSIT PEPTIDE; SPINACH-CHLOROPLASTS; CONTACT SITES; IDENTIFICATION; POLYPEPTIDES; LOCALIZATION; INNER; TRANSLOCATION; PRECURSORS	Many of the proteins in the chloroplast envelope play an important role in facilitating the biochemical and transport processes of the compartment, For the transport of proteins into the chloroplast, we have recently identified at least three different envelope proteins (Com44/Cim44, Com70, and Cim97) in close physical proximity to a partially translocated chimeric precursor protein (Wu, C., Seibert, F. S., and Ko, K. (1994) J. Biol. Chem, 269, 32264-32271), In this study we report the characterization of a cDNA clone encoding a member of the Com44/Cim44 envelope proteins, The combined data from nucleotide sequencing, and RNA and protein blot analyses indicate the existence of multiple forms of the 44-kDa envelope protein, Depending on the plant species examined, immunologically-related protein bands with molecular masses of 42 to 46 kDa were observed, Organelle subfractionation, protease treatment, and immunomicroscopic studies together provide an indication that the immunologically-related proteins may be present in both the outer and inner envelope membranes, Go-migration of the product synthesized from the cDNA insert with a 44-kDa immunoreactive band of the chloroplast envelope, and the in vitro import results, together suggest that the in vitro synthesized 44-kDa protein is targeted to the envelope membrane without any further processing.			KO, K (corresponding author), QUEENS UNIV, DEPT BIOL, KINGSTON, ON K7L 3N6, CANADA.							ALEFSEN H, 1994, J PLANT PHYSIOL, V144, P339, DOI 10.1016/S0176-1617(11)81196-X; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; CASHMORE AR, 1982, METHODS CHLOROPLAST, P387; CLINE K, 1981, P NATL ACAD SCI-BIOL, V78, P3595, DOI 10.1073/pnas.78.6.3595; CLINE K, 1985, J BIOL CHEM, V260, P3691; CORNWELL KL, 1987, PLANT PHYSIOL, V85, P780, DOI 10.1104/pp.85.3.780; DRESESWERRINGLOER U, 1991, EUR J BIOCHEM, V195, P361, DOI 10.1111/j.1432-1033.1991.tb15714.x; FISCHER K, 1994, PLANT MOL BIOL, V25, P167, DOI 10.1007/BF00023235; GIULIANO G, 1988, EMBO J, V7, P3635, DOI 10.1002/j.1460-2075.1988.tb03244.x; GRAY JC, 1995, TRENDS CELL BIOL, V5, P243, DOI 10.1016/S0962-8924(00)89018-2; HINZ G, 1988, EUR J BIOCHEM, V175, P649, DOI 10.1111/j.1432-1033.1988.tb14241.x; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; HOFFMAN NE, 1987, P NATL ACAD SCI USA, V84, P8844, DOI 10.1073/pnas.84.24.8844; HUNYH TV, 1985, DNA CLONING PRACTICA, V1, P49; JOYARD J, 1983, J BIOL CHEM, V258, P1; KADERBHAI MA, 1988, FEBS LETT, V232, P313, DOI 10.1016/0014-5793(88)80760-9; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; KO K, 1994, PLANT PHYSIOL, V104, P1087, DOI 10.1104/pp.104.3.1087; KO K, 1992, J BIOL CHEM, V267, P2986; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; Maniatis T., 1982, MOL CLONING; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; SEEDORF M, 1995, FEBS LETT, V367, P19, DOI 10.1016/0014-5793(95)00529-I; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SOLL J, 1992, PLANT J, V2, P253, DOI 10.1111/j.1365-313X.1992.00253.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WAN JX, 1995, J BIOL CHEM, V270, P16731, DOI 10.1074/jbc.270.28.16731; WU CB, 1993, J BIOL CHEM, V268, P19384; WU CB, 1994, J BIOL CHEM, V269, P32264	43	55	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28601	28608		10.1074/jbc.270.48.28601	http://dx.doi.org/10.1074/jbc.270.48.28601			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499376	hybrid			2022-12-27	WOS:A1995TH05600020
J	RIBAR, TJ; JAN, CR; AUGUSTINE, GJ; MEANS, AR				RIBAR, TJ; JAN, CR; AUGUSTINE, GJ; MEANS, AR			DEFECTIVE GLYCOLYSIS AND CALCIUM SIGNALING UNDERLIE IMPAIRED INSULIN-SECRETION IN A TRANSGENIC MOUSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; PATCH-CLAMP TECHNIQUES; ISLET CELLS; K+ CHANNELS; B-CELL; MICE; CALMODULIN; GLUCOSE; ELECTROPHYSIOLOGY; RELEASE	Pancreatic beta cells from mice that overexpress the Ca2+-binding protein calmodulin have a unique secretory defect that leads to chronic hyperglycemia. To further understand the molecular basis underlying this defect, we have studied signaling pathways in these beta cells, Measurements of cytosolic free Ca2+ concentration ([Ca2+](i)) using fura-2 or indo-1 revealed a markedly reduced response when glucose was the stimulant, However, eliciting membrane depolarization with 50 mM K+ or the addition of the ATP-sensitive K+ (K-ATP(+)) channel antagonist tolbutamide restored [Ca2+](i) transients to near normal levels. Electrophysiological analysis of the beta cell ion channels revealed that Ca2+ currents, delayed rectifier K+ currents, and K-ATP(+) channel currents were similar in transgenic and nontransgenic cells, suggesting that these ion channels were able to function normally. However, whereas K-ATP(+) channel currents in control cells were reduced by 50% by the presence of high glucose, those in transgenic cells were unaltered, Addition of tolbutamide inhibited this channel and enhanced the secretion of insulin in response to glucose for both control and transgenic cells, As these observations implicated a metabolic defect, glucose utilization, which is an indicator of glucose metabolism and ATP production in beta cells, was measured and found to be reduced by 40% in the transgenic cells. These data support the contention that excessive levels of calmodulin may compromise the ability of the beta cell. to metabolize glucose and to modulate the state of the K-ATP(+) channel, resulting in an inadequate control of the membrane potential, which collectively impair [Ca2+](i) and thus insulin secretion in response to glucose.	DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710	Duke University; Duke University			Augustine, George James/J-9228-2013		NIDDK NIH HHS [DK-43017] Funding Source: Medline; NINDS NIH HHS [NS-21624] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021624] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; ASHCROFT FM, 1987, J PHYSIOL-LONDON, V385, P517, DOI 10.1113/jphysiol.1987.sp016505; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BOKVIST K, 1990, J PHYSIOL-LONDON, V423, P327, DOI 10.1113/jphysiol.1990.sp018025; BROWN LJ, 1994, J BIOL CHEM, V269, P14363; DUKES ID, 1994, J BIOL CHEM, V269, P10979; EPSTEIN PN, 1989, CELL, V58, P1067, DOI 10.1016/0092-8674(89)90505-9; EPSTEIN PN, 1992, ENDOCRINOLOGY, V130, P1387, DOI 10.1210/en.130.3.1387; GILON P, 1992, J BIOL CHEM, V267, P20713; GOROIX MH, 1990, DIABETOLOGIA, V33, P654; GRODSKY GM, 1966, DIABETES, V15, P910, DOI 10.2337/diab.15.12.910; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; JONES PM, 1992, BIOCHEM J, V285, P973, DOI 10.1042/bj2850973; MCDERMOTT AM, 1993, CELL SIGNAL, V5, P229, DOI 10.1016/0898-6568(93)90014-D; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MISLER S, 1989, DIABETES, V38, P422, DOI 10.2337/diabetes.38.4.422; MISLER S, 1992, DIABETES, V41, P662, DOI 10.2337/diabetes.41.6.662; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; NORLING LL, 1994, CELL CALCIUM, V16, P137, DOI 10.1016/0143-4160(94)90008-6; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; RIBAR TJ, 1995, ENDOCRINOLOGY, V136, P106, DOI 10.1210/en.136.1.106; SAKMANN B, 1984, ANNU REV PHYSIOL, V46, P455, DOI 10.1146/annurev.ph.46.030184.002323; SENER A, 1987, BIOCHEM J, V246, P89, DOI 10.1042/bj2460089; SHIZURU JA, 1991, TRENDS ENDOCRIN MET, V2, P97, DOI 10.1016/S1043-2760(05)80004-9; SMOLEN P, 1993, BIOPHYS J, V64, P1668, DOI 10.1016/S0006-3495(93)81539-X; TAL M, 1992, P NATL ACAD SCI USA, V89, P5744, DOI 10.1073/pnas.89.13.5744; TSUURA Y, 1992, DIABETES, V41, P861, DOI 10.2337/diabetes.41.7.861; VALVERDE I, 1984, EXPERIENTIA, V40, P1061, DOI 10.1007/BF01971452; WOLLHEIM CB, 1987, BIOSCIENCE REP, V7, P443, DOI 10.1007/BF01362507	35	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28688	28695		10.1074/jbc.270.48.28688	http://dx.doi.org/10.1074/jbc.270.48.28688			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499389	hybrid			2022-12-27	WOS:A1995TH05600033
J	FUENTES, GM; RODRIGUEZRODRIGUEZ, L; FAY, PJ; BAMBARA, RA				FUENTES, GM; RODRIGUEZRODRIGUEZ, L; FAY, PJ; BAMBARA, RA			USE OF AN OLIGORIBONUCLEOTIDE CONTAINING THE POLYPURINE TRACT SEQUENCE AS A PRIMER BY HIV REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; PLUS-STRAND DNA; RNASE-H ACTIVITY; FEATURES IMPORTANT; INITIATION; INTEGRATION; REMOVAL	A primary site for initiation of plus strand DNA synthesis in human immunodeficiency virus (HIV) corresponds to a 19-nucleotide-long purine rich sequence located just upstream of the U3 region, designated the polypurine tract (PPT), The HIV reverse transcriptase (RT) uses its RNase H activity to cut the genomic RNA after minus strand DNA synthesis, A plus strand PPT primer is formed, extended, and then removed, In vitro, the HIV-RT recognizes this primer specifically, using it much more efficiently than other RNA primers, However, the PPT still primes significantly less efficiently than DNA primers, The 19-nucleotide PPT primer is partially resistant to degradation when compared with other oligoribonucleotides. Prior to initiation of DNA synthesis, several nucleotides are removed by the RT from the 3' ends of some of the PPT primers, Cleavage is enhanced in the absence of dNTPs. We suggest that DNA synthesis suppresses primer degradation, so that primer extension and cleavage occur in proper sequence, As a result of 3' end degradation, PPT elongation products contain 5'-RNA segments from 16 to 19 nucleotides in length, These shorter segments are also generated from a longer transcript containing the PPT sequence, indicating that they are not created as a result of binding of the RT to the 5' end of the PPT oligoribonucleotide. Full-length and shorter versions of the PPT primers are cleaved from the extended DNA by RT, These experiments show that HIV-RT has a specificity to generate a primer in the region of the PPT but that the ends of the primer are not well defined.	UNIV ROCHESTER, SCH MED & DENT, DEPT MICROBIOL & IMMUNOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT MED, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, CTR CANC, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester					NIAID NIH HHS [AI 01146] Funding Source: Medline; NIGMS NIH HHS [GM 49573, 1F 31 GM 17200-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573, F31GM017200] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; CHARNEAU P, 1991, J VIROL, V65, P2415, DOI 10.1128/JVI.65.5.2415-2421.1991; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DESTEFANO JJ, 1994, BBA-GENE STRUCT EXPR, V1219, P380, DOI 10.1016/0167-4781(94)90062-0; FEDEROFF OY, 1993, J MOL BIOL, V233, P509; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; HUBER HE, 1990, J BIOL CHEM, V265, P10565; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LUO GX, 1990, J VIROL, V64, P592, DOI 10.1128/JVI.64.2.592-597.1990; PULLEN KA, 1992, J VIROL, V66, P367, DOI 10.1128/JVI.66.1.367-373.1992; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; PULLEN KA, 1990, J VIROL, V64, P6274, DOI 10.1128/JVI.64.12.6274-6277.1990; RANDOLPH CA, 1994, J BIOL CHEM, V269, P19207; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; RATTRAY AJ, 1987, J VIROL, V61, P2843, DOI 10.1128/JVI.61.9.2843-2851.1987; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; SALAZAR M, 1993, BIOCHEMISTRY-US, V32, P739, DOI 10.1021/bi00054a002; Sambrook J, 1989, MOL CLONING LABORATO; SEN D, 1992, METHOD ENZYMOL, V211, P191; SMITH JK, 1984, J VIROL, V52, P314, DOI 10.1128/JVI.52.2.314-319.1984; WHITCOMB JM, 1992, ANNU REV CELL BIOL, V8, P275, DOI 10.1146/annurev.cb.08.110192.001423; WHORL B, 1990, BIOCHEMISTRY-US, V29, P10141	25	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28169	28176						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499308	hybrid			2022-12-27	WOS:A1995TG21000033
J	GUAGLIARDI, A; CERCHIA, L; ROSSI, M				GUAGLIARDI, A; CERCHIA, L; ROSSI, M			PREVENTION OF IN-VITRO PROTEIN THERMAL AGGREGATION BY THE SULFOLOBUS-SOLFATARICUS CHAPERONIN - EVIDENCE FOR NONEQUIVALENT BINDING SURFACES ON THE CHAPERONIN MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DENATURATION; COMPLEX; INVITRO; HSP60; GROEL; CELL	We have studied the effects of the Sulfolobus solfataricus chaperonin on the aggregation and inactivation upon heating of four model enzymes: chicken egg white lysozyme (one 14.4-kDa chain), yeast alpha-glucosidase (one 68.5-kDa chain), chicken liver malic enzyme (four 65-kDa subunits), and yeast alcohol dehydrogenase (four 37.5-kDa subunits). When the proteins were heated in the presence of an equimolar amount of chaperonin, 1) the aggregation was prevented in all solutions; 2) the inactivation profiles of the single-chain enzymes were comparable with those detected in the absence of the chaperonin, and enzyme activities were regained in the solutions heated in the presence of the chaperonin upon ATP hydrolysis (78 and 55% activity regains for lysozyme and alpha-glucosidase, respectively); 3) the inactivation of the tetrameric enzymes was completely prevented, whereas the activities decreased in the absence of the chaperonin. We demonstrate by gel filtration chromatography that the chaperonin interacted with the structures occurring during thermal denaturation of the model proteins and that the interaction with the single-chain proteins (but not that with the tetrameric proteins) was reversed upon ATP hydrolysis, The chaperonin had nonequivalent surfaces for the binding of the model proteins upon heating: the thermal denaturation intermediates of the single-chain proteins share Surfaces I, while the thermal denaturation intermediates of the tetrameric proteins share Surfaces II, ATP binding to the chaperonin induced a conformation that lacked Surfaces I and carried Surfaces II, These data support the concept that chaperonins protect native proteins against thermal aggregation by two mechanistically distinct strategies (an ATP-dependent strategy and an ATP-independent strategy), and provide the first evidence that a chaperonin molecule bears functionally specialized surfaces for the binding of the protein substrates.	CNR, IST BIOCHIM PROT & ENZIMOL, I-80125 NAPLES, ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	GUAGLIARDI, A (corresponding author), UNIV NAPLES, DIPARTIMENTO CHIM ORGAN & BIOL, VIA MEZZOCANNONE 16, I-80134 NAPLES, ITALY.			Cerchia, Laura/0000-0002-7633-7932				AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRANDSCH R, 1992, J BIOL CHEM, V267, P20844; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; DEMACARIO EC, 1994, TRENDS BIOTECHNOL, V12, P512, DOI 10.1016/0167-7799(94)90059-0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; GUAGLIARDI A, 1994, PROTEIN SCI, V3, P1436, DOI 10.1002/pro.5560030910; Halvorson H., 1966, METHODS ENZYMOL, V8, P559, DOI [10.1016/0076-6879(66)08101-1, DOI 10.1016/0076-6879(66)08101-1]; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HARTL FU, 1994, NATURE, V371, P557, DOI 10.1038/371557a0; HARTMAN DJ, 1993, P NATL ACAD SCI USA, V90, P2276, DOI 10.1073/pnas.90.6.2276; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; KNAPP S, 1994, J MOL BIOL, V242, P397; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCO S, 1994, FEBS LETT, V341, P152, DOI 10.1016/0014-5793(94)80447-8; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; NGUYEN VT, 1994, EUR J BIOCHEM, V220, P239; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; TSUGITA A, 1968, J BIOL CHEM, V243, P391; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425	34	56	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28126	28132						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499301				2022-12-27	WOS:A1995TG21000026
J	HU, CH; HARRIS, JE; DAVIE, EW; CHUNG, DW				HU, CH; HARRIS, JE; DAVIE, EW; CHUNG, DW			CHARACTERIZATION OF THE 5'-FLANKING REGION OF THE GENE FOR THE ALPHA-CHAIN OF HUMAN FIBRINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIOVASCULAR RISK FACTOR; NUCLEAR FACTOR; RESPONSE ELEMENTS; GAMMA-CHAIN; EXPRESSION; INTERLEUKIN-6; EVOLUTION; PROMOTERS; PROTEINS; BINDING	The 5'-flanking region of the gene coding for the alpha chain of human fibrinogen was isolated, sequenced, and characterized. The principal site of transcription initiation was determined by primer extension analysis and the RNase protection assay and shown to be at an adenine residue located 55 nucleotides upstream from the initiator methionine codon, or 13,399 nucleotides downstream from the polyadenylation site of the gene coding for the gamma chain. Transient expression of constructs con containing sequentially deleted 5'-flanking sequences of the alpha chain gene fused to the chloramphenicol acetyltransferase reporter gene showed that the promoter was liver-specific and inducible by interleukin 6 (IL-6). The shortest DNA fragment with significant promoter activity and full response to IL-6 stimulation encompassed the region from -217 to +1 base pairs (bp). Although six potential IL-6 responsive sequences homologous to the type II IL-6 responsive element were present, a single sequence of CTGGGA localized from -122 to -127 bp was shown to be a functional element in IL-6 induction, A hepatocyte nuclear factor 1 (HNF-1) binding site, present from -47 to -59 bp, in combination with other upstream elements, was essential for liver-specific expression of the gene. A functional CCAAT/enhancer binding protein site (C/EBP, -134 to -142 bp) was also identified within 217 bp from the transcription initiation site. An additional positive element (-1393 to -1133 bp) and a negative element (-1133 to -749 bp) were also found in the upstream region of the alpha-fibrinogen gene.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle			Sessum, Rachel/F-7312-2015	Sessum, Rachel/0000-0002-2444-7056	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16919] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ANDERSON GM, 1993, J BIOL CHEM, V268, P22650; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHUNG DW, 1990, ADV EXP MED BIOL, V281, P39; CLAVERIE JM, 1994, NATURE, V371, P752, DOI 10.1038/371752a0; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; CRABTREE GR, 1982, J BIOL CHEM, V257, P7277; CRABTREE GR, 1985, J MOL BIOL, V185, P1, DOI 10.1016/0022-2836(85)90179-2; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; ERNST E, 1990, J INTERN MED, V227, P365, DOI 10.1111/j.1365-2796.1990.tb00174.x; FEY GH, 1987, MOL BIOL MED, V4, P323; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG SM, 1993, J BIOL CHEM, V268, P8919; HUBER P, 1987, NUCLEIC ACIDS RES, V15, P1615, DOI 10.1093/nar/15.4.1615; HUBER P, 1990, J BIOL CHEM, V265, P5695; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KANT JA, 1985, P NATL ACAD SCI USA, V82, P2344, DOI 10.1073/pnas.82.8.2344; LIU ZY, 1995, J BIOL CHEM, V270, P7580, DOI 10.1074/jbc.270.13.7580; MANN EA, 1991, J BIOL CHEM, V266, P16931; MIAO CH, 1992, J BIOL CHEM, V267, P7395; RICHIE DG, 1983, ANN NY ACAD SCI, V408, P490; RIXON MW, 1985, BIOCHEMISTRY-US, V24, P2077, DOI 10.1021/bi00329a041; RIXON MW, 1983, BIOCHEMISTRY-US, V22, P3237, DOI 10.1021/bi00282a031; ROY SN, 1991, J BIOL CHEM, V266, P4758; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YU S, 1984, J BIOL CHEM, V259, P574; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	38	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28342	28349						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499335				2022-12-27	WOS:A1995TG21000060
J	KAMATA, T; PUZON, W; TAKADA, Y				KAMATA, T; PUZON, W; TAKADA, Y			IDENTIFICATION OF PUTATIVE LIGAND-BINDING SITES WITHIN I-DOMAIN OF INTEGRIN ALPHA-2-BETA-1 (VLA-2, CD49B/CD29)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION GLYCOPROTEIN; COMPLEMENT RECEPTOR TYPE-3; AMINO-ACID SEQUENCE; VONWILLEBRAND-FACTOR; COLLAGEN RECEPTOR; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; LAMININ RECEPTOR; VI COLLAGEN	Integrin alpha2beta1 is a cell surface adhesion receptor for collagen and echovirus 1. Here we localized the epitopes for anti-alpha2 monoclonal antibodies using interspecies (human/bovine) alpha2 chimeras with different lengths of human alpha2 sequence on the amino-terminal side and site-directed mutagenesis. The antibodies that block the collagen and/or echovirus 1 binding to human alpha2beta1 (6F1, RMAC11, 12F1, and AA10) recognizes a small region (residues 173-259) within the I domain. Asp-160 and Arg-242 are critical for binding of the two other function-inhibiting antibodies, P1H5 and 5E8, respectively. Notably, mutations of Asp-151 and Asp-254 block the binding of alpha2beta1 to collagen. These data suggest that the I domain (residues 140-359) is critically involved in the ligand/receptor interactions, and collagen and echovirus 1 binding sites are adjacent or overlapping within the I domain. The sequence of the residues 173-259 of alpha2 overlap with the peptide sequences (M11 and M20) that derive from von Willebrand factor A1 and A3 domains (homologous to the alpha2 I domain) and block von Willebrand factor/collagen interaction, suggesting that the epitope region of alpha2 (residues 173-259) may really be involved in ligand recognition.	Scripps Res Inst, DEPT VASC BIOL, CVB-2, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Scripps Research Institute				takada, yoshikazu/0000-0001-5481-9589	NIGMS NIH HHS [GM47157] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047157] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGRAVES WS, 1987, P NATL ACAD SCI USA, V84, P464, DOI 10.1073/pnas.84.2.464; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; BENTLEY DR, 1986, BIOCHEM J, V239, P339, DOI 10.1042/bj2390339; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BERGELSON JM, 1993, J CLIN INVEST, V92, P232, DOI 10.1172/JCI116555; BONALDO P, 1989, J BIOL CHEM, V264, P5575; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHEN FA, 1991, J EXP MED, V173, P1111, DOI 10.1084/jem.173.5.1111; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; COLLER BS, 1989, BLOOD, V74, P182; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; GOLDMAN R, 1992, EUR J IMMUNOL, V22, P1109, DOI 10.1002/eji.1830220502; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOLE JE, 1984, J BIOL CHEM, V259, P3407; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; OCONNELL PJ, 1991, IMMUNOL CELL BIOL, V69, P103, DOI 10.1038/icb.1991.16; PISCHEL KD, 1987, J IMMUNOL, V138, P226; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; ROTH GJ, 1986, BIOCHEMISTRY-US, V25, P8357, DOI 10.1021/bi00374a004; SANTORO SA, 1988, BIOCHEM BIOPH RES CO, V153, P217, DOI 10.1016/S0006-291X(88)81211-7; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1988, J CELL BIOCHEM, V37, P385, DOI 10.1002/jcb.240370406; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; YAMADA KM, 1990, CANCER RES, V50, P4485; YAMADA KM, 1991, J BIOL CHEM, V266, P12809	45	159	165	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 1	1994	269	13					9659	9663						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NE053	7511592				2022-12-27	WOS:A1994NE05300042
J	ALTENBERG, GA; VANOYE, CG; HAN, ES; DEITMER, JW; REUSS, L				ALTENBERG, GA; VANOYE, CG; HAN, ES; DEITMER, JW; REUSS, L			RELATIONSHIPS BETWEEN RHODAMINE-123 TRANSPORT, CELL-VOLUME, AND ION-CHANNEL FUNCTION OF P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; CHLORIDE CHANNELS; MEMBRANE; ATPASE; LINES	The P-glycoprotein (Pgp), a plasma membrane protein overexpressed in multidrug-resistant tumor cells, is thought to be both an ATPase that actively exports cytotoxic drugs and a Cl- channel activated by cell swelling. The partial reversal of multidrug resistance by Cl- transport blockers suggests a possible role for Cl- in Pgp mediated drug transport. We used multidrug-resistant Chinese hamster fibroblasts and human breast cancer cells expressing Pgp to study the roles of Cl- (and also Na+ and HCO3-/CO2) on Pgp-mediated efflux of the fluorescent dye rhodamine 123 (R123). In Pgp-expressing Chinese hamster fibroblasts, exposed to isosmotic solutions, the unidirectional efflux of R123 was not measurably changed by a similar to 60-min removal of Cl- (or by exposure to Na+-free, or nominally HCO3-/CO2-free medium); short term (2-3 min) ion substitutions were also ineffective. In human breast cancer cells transfected with human mdr1 cDNA, hyposmotic solutions activated a Cl- current but had no effect on the Pgp-mediated unidirectional efflux of R123. Additionally, in human breast cancer cells, the intracellular presence of R123 did not prevent activation of the Cl- current by hyposmotic solution. The lack of detectable effect of removal of Cl-, Na+, or HCO3- on Pgp-mediated R123 transport rules out direct coupling between substrate transport and transport of either of these ions by Pgp. The persistence of Pgp-mediated R123 efflux in osmotically swollen cells indicates that activation of the Pgp-associated Cl- current does not hinder the Pgp pump function. The lack of effect of R123 on swelling-activated Cl- current denotes that Pgp-mediated transport of organic substrates and Pgp-associated Cl- currents can occur at the same time in a single cell. These results underscore the dissociation between Pgp-mediated active drug transport and electrodiffusive Cl- transport.	UNIV TEXAS,MED BRANCH,DEPT PHYSIOL & BIOPHYS,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston				Altenberg, Guillermo/0000-0002-8932-740X	NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007205] Funding Source: NIH RePORTER; NCRR NIH HHS [RR07205] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTENBERG G, 1990, METHOD ENZYMOL, V192, P650; ALTENBERG GA, 1993, P NATL ACAD SCI USA, V90, P9735, DOI 10.1073/pnas.90.20.9735; ALTENBERG GA, 1994, IN PRESS CANCER RES; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; BECK WT, 1992, MOL CELLULAR BIOL MU, P215; COPELLO J, 1993, J GEN PHYSIOL, V102, P177, DOI 10.1085/jgp.102.2.177; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; FAIRCHILD CR, 1990, MOL PHARMACOL, V37, P801; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Higgins CF, 1993, CURR OPIN CELL BIOL, V5, P684, DOI 10.1016/0955-0674(93)90140-L; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HOWELL N, 1984, CANCER RES, V44, P4023; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; NAKAGAWA M, 1992, CANCER RES, V52, P6175; PON DJ, 1993, EUR J PHARM-MOLEC PH, V245, P119, DOI 10.1016/0922-4106(93)90119-T; RONINSON IB, 1984, NATURE, V309, P626, DOI 10.1038/309626a0; RONINSON IB, 1992, MOL CELLULAR BIOL MU, P91; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Shalinsky D. R., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P315; SOGNIER MA, 1992, BIOCHEM PHARMACOL, V44, P1859, DOI 10.1016/0006-2952(92)90082-T; TOTH K, 1992, AM J PATHOL, V140, P1009; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0	24	67	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7145	7149						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510282				2022-12-27	WOS:A1994NA03200019
J	MARKEN, JS; BAJORATH, J; EDWARDS, CP; FARR, AG; SCHIEVEN, GL; HELLSTROM, I; HELLSTROM, KE; ARUFFO, A				MARKEN, JS; BAJORATH, J; EDWARDS, CP; FARR, AG; SCHIEVEN, GL; HELLSTROM, I; HELLSTROM, KE; ARUFFO, A			MEMBRANE TOPOLOGY OF THE L6 ANTIGEN AND IDENTIFICATION OF THE PROTEIN EPITOPE RECOGNIZED BY THE L6 MONOCLONAL-ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-ASSOCIATED ANTIGEN; MOLECULAR-CLONING; ANTIPROLIFERATIVE ANTIBODY; CELL-SURFACE; CDNA; EXPRESSION; TAPA-1; SITE; FAMILY; TARGET	The murine monoclonal antibody (mAb) L6 recognizes an integral membrane glycoprotein that is highly expressed on lung, breast, colon, and ovarian carcinomas and is referred to as the L6 antigen. This antigen is an attractive target for therapeutic intervention due to its high level expression on malignant cells. We have previously reported the isolation of a cDNA encoding the human L6 antigen (H-L6). Here, we report the isolation of a cDNA clone encoding the murine L6 antigen (M-L6). This cDNA contains one long open reading frame, which encodes a 220-amino acid polypeptide that is 78% homologous to H-L6. This protein contains short NH2- and COOH-terminal hydrophilic domains and four hydrophobic regions, each long enough to span the plasma membrane. Each of these hydrophobic domains is separated by a hydrophilic domain, the longest of which contains one possible N-linked glycosylation site and is located between the third and fourth hydrophobic domains. We have previously demonstrated that the murine L6 mAb recognizes a protein epitope expressed on human tumor-derived cell lines. Now, using chimeric cDNA constructs encoding human-murine L6 antigen hybrids in conjunction with monoclonal antibody binding experiments, we show that the 42-residue hydrophilic domain of the L6 antigen, located between the third and fourth hydrophobic domains, is outside the cell and that residues in the NH2-terminal region of this domain are critical for the binding of the murine L6 mAb to H-L6.	UNIV WASHINGTON,DEPT BIOL STRUCT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	MARKEN, JS (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121, USA.		Bajorath, Jürgen/F-7493-2014					AMIOT M, 1990, J IMMUNOL, V145, P4322; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLASSON BJ, 1989, J EXP MED, V169, P1497, DOI 10.1084/jem.169.4.1497; DENARDO SJ, 1991, NUCL MED BIOL, V18, P621, DOI 10.1016/0883-2897(91)90032-G; DENARDO SJ, 1991, RADIOIMMUNOTHERAPY I, P227; FELL HP, 1992, J BIOL CHEM, V267, P15552; GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GOODMAN GE, 1990, J CLIN ONCOL, V8, P1083, DOI 10.1200/JCO.1990.8.6.1083; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HELLSTROM I, 1986, CANCER RES, V46, P3917; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOTTA H, 1988, CANCER RES, V48, P2955; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEVY S, 1991, J BIOL CHEM, V266, P14597; MARKEN JS, 1992, P NATL ACAD SCI USA, V89, P3503, DOI 10.1073/pnas.89.8.3503; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Sambrook J, 1989, MOL CLONING LABORATO; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; VAICKUS L, 1985, J IMMUNOL, V135, P1987; VANNOESEL CJM, 1993, IMMUNOL TODAY, V14, P8, DOI 10.1016/0167-5699(93)90316-D; WRIGHT MD, 1990, J IMMUNOL, V144, P3195	28	28	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7397	7401						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510285				2022-12-27	WOS:A1994NA03200058
J	MISAKI, Y; PRUIJN, GJM; VANDERKEMP, AWCM; VANVENROOIJ, WJ				MISAKI, Y; PRUIJN, GJM; VANDERKEMP, AWCM; VANVENROOIJ, WJ			THE 56K AUTOANTIGEN IS IDENTICAL TO HUMAN ANNEXIN-XI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDNA CLONING; PROTEIN; AUTOANTIBODIES; FAMILY; CELLS; LIPOCORTIN-1; SPECIFICITY; RECOGNITION; EXPRESSION; ANTIGEN	Anti-56K autoantibodies are present in sera from patients with various autoimmune diseases, predominantly in sera from patients with rheumatoid arthritis, systemic lupus erythematosus, or Sjogren's syndrome. To clarify the molecular structure of this autoantigen, we isolated a 2.0-kilobase pair cDNA clone considered to encode the full length 56K autoantigen. The longest open reading frame encodes a 505-amino acid polypeptide, with a predicted molecular mass of 54.4 kDa. The in vitro translated protein is recognized by all anti 56K positive patient sera tested. Antibodies affinity-purified using the bacterially expressed recombinant protein recognized the 56K autoantigen in a HeLa cell extract. cDNA sequencing revealed that the 56K cDNA shares a high degree of homology in both nucleotide (87%) and amino acid sequence (92.5%) with bovine annexin XI, indicating that the 56K cDNA encodes the human homologue of annexin XI, a member of the Ca2+-dependent phospholipid binding protein family. Anti-56K autoantibody exhibits both a cytoplasmic and a nuclear staining in immunofluorescence experiments. Patients' sera recognize preferentially the N-terminal region of the protein, which is specific for 56K/annexin XI and not shared by other annexins, indicating that the autoimmune response to 56K/annexin XI in these patients is specific for this annexin family member.	UNIV NIJMEGEN,DEPT BIOCHEM,6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen			Pruijn, Ger/D-6664-2012					BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CALABRETTA B, 1985, P NATL ACAD SCI USA, V82, P4463, DOI 10.1073/pnas.82.13.4463; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; FOLLI F, 1993, NEW ENGL J MED, V328, P546, DOI 10.1056/NEJM199302253280805; FURLONG J, 1992, NUCLEIC ACIDS RES, V20, P4668, DOI 10.1093/nar/20.17.4668; GOULDING NJ, 1989, ANN RHEUM DIS, V48, P843, DOI 10.1136/ard.48.10.843; GOULDING NJ, 1992, IMMUNOL TODAY, V13, P295, DOI 10.1016/0167-5699(92)90040-E; HABETS WJ, 1983, EMBO J, V2, P1625, DOI 10.1002/j.1460-2075.1983.tb01636.x; HIRATA F, 1981, P NATL ACAD SCI-BIOL, V78, P3190, DOI 10.1073/pnas.78.5.3190; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KRAUS M, 1992, J IMMUNOASSAY, V13, P411, DOI 10.1080/15321819208021241; MIZUTANI A, 1992, J BIOL CHEM, V267, P13498; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRUIJN GJM, 1992, MOL BIOL REP, V16, P267, DOI 10.1007/BF00419667; REICHLIN M, 1989, TXB RHEUMATOLOGY, P208; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SILLEKENS PTG, 1987, EMBO J, V6, P3841, DOI 10.1002/j.1460-2075.1987.tb02721.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUN J, 1992, FEBS LETT, V314, P425, DOI 10.1016/0014-5793(92)81519-R; TOKUMITSU H, 1992, J BIOL CHEM, V267, P8919; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWLE CA, 1992, J BIOL CHEM, V267, P5416; TOWLE CA, 1992, BIOCHIM BIOPHYS ACTA, V1131, P223, DOI 10.1016/0167-4781(92)90084-D; VANVENROOIJ WJ, 1989, CLIN EXP RHEUMATOL, V7, P277; VERHEIJEN R, 1992, MOL BIOL REP, V16, P49, DOI 10.1007/BF00788753; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	34	36	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4240	4246						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508441				2022-12-27	WOS:A1994MW98900054
J	NIKAIDO, H				NIKAIDO, H			PORINS AND SPECIFIC DIFFUSION CHANNELS IN BACTERIAL OUTER MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PORE-FORMING ACTIVITY; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; OMPF PORIN; INVITRO TRIMERIZATION; INTACT-CELLS; BINDING-SITE; PROTEIN; PERMEABILITY; TRANSPORT				NIKAIDO, H (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,229 STANLEY HALL,BERKELEY,CA 94720, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009644, R37AI009644] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-09644] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAUER K, 1989, J BIOL CHEM, V264, P16393; BELLIDO F, 1992, J BACTERIOL, V174, P5196, DOI 10.1128/JB.174.16.5196-5203.1992; BENSON SA, 1988, J MOL BIOL, V203, P961, DOI 10.1016/0022-2836(88)90121-0; BENZ R, 1987, J MEMBRANE BIOL, V100, P21, DOI 10.1007/BF02209137; BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; BUECHNER M, 1990, BIOCHIM BIOPHYS ACTA, V1024, P111, DOI 10.1016/0005-2736(90)90214-9; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DECOCK H, 1990, J BIOL CHEM, V265, P4646; DELCOUR AH, 1992, FEBS LETT, V304, P216, DOI 10.1016/0014-5793(92)80622-N; FREUNDLIEB S, 1988, J BIOL CHEM, V263, P314; GARAVITO RM, 1980, J CELL BIOL, V86, P327, DOI 10.1083/jcb.86.1.327; HANCOCK REW, 1990, MOL MICROBIOL, V4, P1069, DOI 10.1111/j.1365-2958.1990.tb00680.x; HANCOCK REW, 1992, J BACTERIOL, V174, P471, DOI 10.1128/jb.174.2.471-476.1992; HEINE HG, 1988, J BACTERIOL, V170, P1730, DOI 10.1128/jb.170.4.1730-1738.1988; JAP BK, 1991, NATURE, V350, P167, DOI 10.1038/350167a0; JEANTEUR D, 1991, MOL MICROBIOL, V5, P2153, DOI 10.1111/j.1365-2958.1991.tb02145.x; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; KILLMANN H, 1993, EMBO J, V12, P3007, DOI 10.1002/j.1460-2075.1993.tb05969.x; KLEBBA PE, 1990, J BIOL CHEM, V265, P6800; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; MAIER C, 1988, J BIOL CHEM, V263, P2493; MISRA R, 1988, J BACTERIOL, V170, P3611, DOI 10.1128/jb.170.8.3611-3617.1988; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; NIKAIDO H, 1993, MOL MICROBIOL, V8, P1025, DOI 10.1111/j.1365-2958.1993.tb01647.x; PLESIAT P, 1992, MOL MICROBIOL, V6, P1323, DOI 10.1111/j.1365-2958.1992.tb00853.x; RACHEL R, 1990, FEBS LETT, V262, P64, DOI 10.1016/0014-5793(90)80155-C; RUTZ JM, 1992, SCIENCE, V258, P471, DOI 10.1126/science.1411544; SCHIRMER T, 1993, PROTEIN SCI, V2, P1361, DOI 10.1002/pro.5560020820; SCHLAEPPI JM, 1985, J BIOL CHEM, V260, P9775; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SCHULEIN K, 1991, MOL MICROBIOL, V5, P2233, DOI 10.1111/j.1365-2958.1991.tb02153.x; Schulz GE, 1993, CURR OPIN CELL BIOL, V5, P701, DOI 10.1016/0955-0674(93)90143-E; SEN K, 1988, J BIOL CHEM, V263, P1182; SEN K, 1990, P NATL ACAD SCI USA, V87, P743, DOI 10.1073/pnas.87.2.743; SEN K, 1991, J BACTERIOL, V173, P926, DOI 10.1128/jb.173.2.926-928.1991; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; SUGAWARA E, 1992, J BIOL CHEM, V267, P2507; TODT JC, 1992, BIOCHEMISTRY-US, V31, P10471, DOI 10.1021/bi00158a009; TRIAS J, 1992, SCIENCE, V258, P1479, DOI 10.1126/science.1279810; TRIAS J, 1990, J BIOL CHEM, V265, P15680; TRIAS J, 1988, BIOCHIM BIOPHYS ACTA, V938, P493, DOI 10.1016/0005-2736(88)90148-4; TRIAS J, 1989, ANTIMICROB AGENTS CH, V33, P1201, DOI 10.1128/AAC.33.8.1202; VANDERLEY P, 1987, PHOSPHATE METABOLISM, P159; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; WEISS MS, 1992, J MOL BIOL, V227, P493, DOI 10.1016/0022-2836(92)90903-W	47	290	297	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3905	3908						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508433				2022-12-27	WOS:A1994MW98900001
J	OHMICHI, M; SAWADA, T; KANDA, Y; KOIKE, K; HIROTA, K; MIYAKE, A; SALTIEL, AR				OHMICHI, M; SAWADA, T; KANDA, Y; KOIKE, K; HIROTA, K; MIYAKE, A; SALTIEL, AR			THYROTROPIN-RELEASING-HORMONE STIMULATES MAP KINASE-ACTIVITY IN GH3 CELLS BY DIVERGENT PATHWAYS - EVIDENCE OF A ROLE FOR EARLY TYROSINE PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; MAMMOTROPIC PITUITARY-CELLS; SWISS 3T3 CELLS; PROLACTIN SECRETION; SIGNAL TRANSDUCTION; TRK PROTOONCOGENE; PHOSPHOLIPASE-C; INTACT-CELLS; RAS	Regulation of the mitogen-activated protein (MAP) kinase by thyrotropin-releasing hormone (TRH) in GH3 rat pituitary tumor cells was investigated. Both TRH and epidermal growth factor (EGF) acutely activated this enzyme, via tyrosine and serine/threonine phosphorylation. Down-regulation of cellular protein kinase C (PKC) only partly inhibited the phosphorylation of MAP kinase by TRH, suggesting both PKC-dependent and -independent pathways. Both TRH and EGF similarly increased the phosphorylation of raf-1, by a PKC-independent mechanism. Both TRH and EGF stimulated the formation of a ras-GTP complex. This activation of ras by growth factors is thought to involve the tyrosine phosphorylation of Shc. EGF stimulated the tyrosine phosphorylation of three Shc proteins and their subsequent association with its receptor. TRH stimulated the tyrosine phosphorylation of the 52-kDa Shc protein, although neither phorbol esters nor the calcium ionophore A23187 had any effect, indicating that this effect of TRH was not dependent on PKC. Both TRH and EGF induced the association of tyrosine phosphorylated Shc proteins with a fusion protein containing SH2 and SH3 domains of Grb2, another important component in ras activation. These results provide evidence that MAP kinase is acutely activated by TRH through a PKC-dependent pathway as well as a second pathway possibly involving tyrosine phosphorylation.	WARNER LAMBERT PARKE DAVIS,PHARMACEUT RES,DIV SIGNAL TRANSDUCT,2800 PLYMOUTH RD,ANN ARBOR,MI 48105; UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; OSAKA UNIV,SCH MED,DEPT OBSTET & GYNECOL,SUITA,OSAKA 565,JAPAN	Pfizer; University of Michigan System; University of Michigan; Osaka University			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				AHN NG, 1990, J BIOL CHEM, V265, P11487; ALTSCHULER LR, 1993, NEUROENDOCRINOLOGY, V57, P23, DOI 10.1159/000126337; ANDERSON NG, 1991, J BIOL CHEM, V266, P10131; ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; CAMORATTO AM, 1985, ENDOCRINOLOGY, V116, P1506, DOI 10.1210/endo-116-4-1506; CANONICO PL, 1983, NEUROENDOCRINOLOGY, V37, P212, DOI 10.1159/000123545; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DANNIES PS, 1976, NATURE, V261, P707, DOI 10.1038/261707a0; DRUMMOND AH, 1984, MOL PHARMACOL, V25, P201; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; JAISWAL RK, 1993, J BIOL CHEM, V268, P7055; KOLESNICK RN, 1984, AM J PHYSIOL, V246, pE458, DOI 10.1152/ajpendo.1984.246.5.E458; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KOVACINA KS, 1990, J BIOL CHEM, V265, P1215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUTZ MP, 1993, J BIOL CHEM, V268, P11119; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; MATSUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OHMICHI M, 1992, BIOCHEMISTRY-US, V31, P4034, DOI 10.1021/bi00131a019; OHMICHI M, 1993, BIOCHEMISTRY-US, V32, P4650, DOI 10.1021/bi00068a024; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OHMICHI M, 1990, NEUROENDOCRINOLOGY, V52, P75, DOI 10.1159/000125542; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REBECCHI MJ, 1983, BIOCHEM J, V216, P287, DOI 10.1042/bj2160287; REBECCHI MJ, 1983, J BIOL CHEM, V258, P227; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHONBRUNN A, 1980, J CELL BIOL, V85, P786, DOI 10.1083/jcb.85.3.786; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; TASHJIAN AH, 1971, BIOCHEM BIOPH RES CO, V43, P516, DOI 10.1016/0006-291X(71)90644-9; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TSAO H, 1990, J BIOL CHEM, V265, P15741; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAJIMA Y, 1984, J CELL PHYSIOL, V120, P249, DOI 10.1002/jcp.1041200220; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126	61	157	158	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3783	3788						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508919				2022-12-27	WOS:A1994MV63100095
J	WEI, XY; NEELY, A; LACERDA, AE; OLCESE, R; STEFANI, E; PEREZREYES, E; BIRNBAUMER, L				WEI, XY; NEELY, A; LACERDA, AE; OLCESE, R; STEFANI, E; PEREZREYES, E; BIRNBAUMER, L			MODIFICATION OF CA2+ CHANNEL ACTIVITY BY DELETIONS AT THE CARBOXYL-TERMINUS OF THE CARDIAC ALPHA(1) SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; SHAKER POTASSIUM CHANNEL; SKELETAL-MUSCLE; BETA-SUBUNIT; DIHYDROPYRIDINE RECEPTOR; FUNCTIONAL EXPRESSION; COMPLEMENTARY-DNA; VENTRICULAR MYOCYTES; GAMMA-SUBUNIT; ALPHA-1-SUBUNIT	Voltage-sensitive Ca2+ channels are multisubunit complexes that include, among others, a large alpha1 subunit, which by itself is sufficient to form a channel. Several alpha1 genes encoding L-, N-, and P-type Ca2+ channels have been cloned. These alpha1 genes share a high degree of sequence homology in the putative transmembrane regions, but vary substantially in the putative intracellular loops and the flanking amino and carboxyl termini. In the present study, we investigated the functional roles of the 665-amino acid long carboxyl terminus of a cardiac al by constructing deletion mutants. Expression in Xenopus oocytes of DELTAC1856, DELTAC1733, and DELTAC1700, which lack from 307 to 472 amino acids at the carboxyl terminus, led to inward Ba2+ currents that were 4- to 6-fold greater than observed with the 2171-amino acid long wild type alpha1. Ionic currents increased without a change in the amount of charge moved during voltage-dependent gating, suggesting that the increase in ionic currents was not due to an increase in the number of channels that were expressed. Single channel analysis revealed an unaltered unitary conductance. Thus, removal of up to 70% of the carboxyl terminus increased current density by facilitating the coupling between the voltage-dependent gating and channel opening, leading to an increased opening probability of the channel.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	WEI, XY (corresponding author), BAYLOR COLL MED, DEPT MOLEC PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA.		Neely, Alan/A-8715-2009	Neely, Alan/0000-0002-6007-2159	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046702, P01HL037044, R55HL046702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038970] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46702, HL-37044] Funding Source: Medline; NIAMS NIH HHS [AR38970] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALDRICH RW, 1983, NATURE, V306, P436, DOI 10.1038/306436a0; BEAM KG, 1992, NATURE, V360, P169, DOI 10.1038/360169a0; BOSSE E, 1990, FEBS LETT, V267, P153, DOI 10.1016/0014-5793(90)80312-7; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; HESCHELER J, 1988, J PHYSIOL-LONDON, V404, P259, DOI 10.1113/jphysiol.1988.sp017289; Hofmann F, 1990, Curr Top Cell Regul, V31, P223; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KLOCKNER U, 1992, PFLUG ARCH EUR J PHY, V420, P413, DOI 10.1007/BF00374479; LACERDA AE, 1989, J GEN PHYSIOL, V93, P1243, DOI 10.1085/jgp.93.6.1243; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; PATLAK J, 1982, J GEN PHYSIOL, V79, P333, DOI 10.1085/jgp.79.3.333; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; RAKOWSKI RF, 1993, J GEN PHYSIOL, V101, P117, DOI 10.1085/jgp.101.1.117; REGULLA S, 1991, EMBO J, V10, P45, DOI 10.1002/j.1460-2075.1991.tb07919.x; ROTMAN EI, 1992, J BIOL CHEM, V267, P16100; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1991, NATURE, V352, P800, DOI 10.1038/352800a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WEI XY, 1989, MOL PHARMACOL, V35, P541; WEI XY, 1991, J BIOL CHEM, V266, P21943; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	45	175	178	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1635	1640						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507480				2022-12-27	WOS:A1994MR98800017
J	DESTEFANO, JJ; BAMBARA, RA; FAY, PJ				DESTEFANO, JJ; BAMBARA, RA; FAY, PJ			THE MECHANISM OF HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE TRANSCRIPTASE-CATALYZED STRAND TRANSFER FROM INTERNAL REGIONS OF HETEROPOLYMERIC RNA TEMPLATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-RECOMBINATION; RETROVIRAL RECOMBINATION; RIBONUCLEASE H; GENOMES; ENDONUCLEASE; DISPLAYS	The mechanism of human immunodeficiency virus reverse transcriptase-catalyzed strand transfer synthesis (i.e. switching of the primer to a new template) from internal regions of natural sequence RNA was investigated. The system consisted of a 142-nucleotide RNA template (donor) primed with a specific 20-nucleotide DNA oligonucleotide used to initiate synthesis. DNA oligonucleotides with homology to internal regions of the donor were used as acceptor templates. In reactions performed in the absence of acceptor template, a prominent DNA synthesis product 75 nucleotides in length resulting from pausing DNA synthesis within the homology zone was observed. Prominent donor RNA degradation products of 47 or 54 nucleotides were also observed, in reactions with 80 or 150 mM KCl, respectively. The lengths indicated a potential 13- or 20-nucleotide long, respectively, complementary region between the DNA and RNAs. The 54-, but not the 47-, nucleotide RNA was susceptible to Escherichia coli RNase H, indicating that the DNA was annealed only to the 54-mer. When acceptor was added, a portion of the 75-nucleotide DNA was chased into transfer product at both salt concentrations, and a portion of the 54-mer RNA became resistant to E. coli RNase H. Evidently, this donor RNA was annealed to the 75-nucleotide long DNA but could be actively displaced by the acceptor. Overall, these observations support two mechanisms for transfer. In one, the pause site-specific DNA dissociates from the donor template before transferring. In the other, the acceptor actively displaces the DNA from the donor.	UNIV ROCHESTER,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester					NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER; NCI NIH HHS [CA 11198] Funding Source: Medline; NIGMS NIH HHS [GM 49573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; Hunter E, 1978, Curr Top Microbiol Immunol, V79, P295; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SKALKA AM, 1982, J CELL BIOCHEM, V19, P293, DOI 10.1002/jcb.240190311; STARNES MC, 1989, J BIOL CHEM, V264, P7073; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; VOGT PK, 1973, POSSIBLE EPISOMES EU, P35; VOLKMANN S, 1993, J BIOL CHEM, V268, P2674; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; XU H, 1987, P NATL ACAD SCI USA, V84, P8553, DOI 10.1073/pnas.84.23.8553; ZHANG JY, 1993, SCIENCE, V259, P234, DOI 10.1126/science.8421784	21	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					161	168						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506252				2022-12-27	WOS:A1994MR21900033
J	HWANG, S; LOPEZ, CA; HECK, DE; GARDNER, CR; LASKIN, DL; LASKIN, JD; DENHARDT, DT				HWANG, S; LOPEZ, CA; HECK, DE; GARDNER, CR; LASKIN, DL; LASKIN, JD; DENHARDT, DT			OSTEOPONTIN INHIBITS INDUCTION OF NITRIC-OXIDE SYNTHASE GENE-EXPRESSION BY INFLAMMATORY MEDIATORS IN MOUSE KIDNEY EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELAXING FACTOR; RAT; OSTEOCLASTS; MESSENGER	We report that osteopontin (OPN), a secreted, Arg-Gly-Asp-containing phosphoprotein expressed at high levels in the kidney, suppresses nitric oxide (NO) synthesis induced by the inflammatory mediators gamma-interferon and lipopolysaccharide in primary mouse kidney proximal tubule epithelial cells. Northern blot and immunofluorescence analyses of inducible nitric oxide synthase (iNOS) expression revealed that the inflammatory mediators increased iNOS mRNA and protein levels. Recombinant human OPN (purified from both mammalian cells and from Escherichia coli) inhibited this response by a process that was blocked by anti-OPN antiserum and by the peptide GRGDS, but not GRGES. The data suggest that inhibition of NO synthesis by OPN in these kidney cells is mediated by an integrin, possibly the alpha(v)beta3 integrin, which is known to be an OPN receptor. NO is believed to control blood flow through the glomerulus, regulating salt and water balance, and to be important as a defense against tumor cells and infecting microorganisms. The ability of OPN to inhibit the induction of iNOS suggests that OPN may be an important regulator of the NO signaling pathway and NO-mediated cytotoxic processes.	RUTGERS UNIV,DEPT BIOL SCI,NELSON BIOL LABS,PISCATAWAY,NJ 08855; RUTGERS UNIV,DEPT PHARMACOL & TOXICOL,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT ENVIRONM & COMMUNITY MED,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center				Laskin, Debra/0000-0003-1832-7311	NIA NIH HHS [AG07972] Funding Source: Medline; NIDCD NIH HHS [DC01295] Funding Source: Medline; NIEHS NIH HHS [ES04738] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001295] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BREZIS M, 1991, J CLIN INVEST, V88, P390, DOI 10.1172/JCI115316; BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169; CATTELL V, 1990, KIDNEY INT, V38, P1056, DOI 10.1038/ki.1990.312; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; COOK HT, 1991, AM J PATHOL, V139, P1047; DENHARDT DT, 1993, IN PRESS FASEB J; DING A, 1990, J IMMUNOL, V145, P940; ELLIGET KA, 1991, IN VITRO CELL DEV B, V27, P739; FLORES ME, 1992, EXP CELL RES, V201, P526, DOI 10.1016/0014-4827(92)90305-R; GIACHELLI CM, IN PRESS KIDNEY INT; GOUREAU O, 1993, P NATL ACAD SCI USA, V90, P4276, DOI 10.1073/pnas.90.9.4276; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HECK DE, 1992, J BIOL CHEM, V267, P21277; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; ISHII K, 1991, J PHARMACOL EXP THER, V256, P38; KHOKHA R, 1987, ANTICANCER RES, V7, P653; LOPEZ CA, 1993, LAB INVEST, V69, P355; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARKEWITZ BA, 1993, J CLIN INVEST, V91, P2138, DOI 10.1172/JCI116439; MCCALL TB, 1992, BIOCHEM BIOPH RES CO, V186, P680, DOI 10.1016/0006-291X(92)90800-Z; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NICOLSON AG, 1993, BIOCHEM BIOPH RES CO, V193, P1269, DOI 10.1006/bbrc.1993.1762; NORIS M, 1993, KIDNEY INT, V44, P445, DOI 10.1038/ki.1993.264; PUNJABI CJ, 1992, J IMMUNOL, V149, P2179; ROSS FP, 1993, J BIOL CHEM, V268, P9901; Sambrook J, 1989, MOL CLONING LABORATO; SCHINI VB, 1993, FASEB J, V7, pA243; STOOS BA, 1992, J CLIN INVEST, V89, P761, DOI 10.1172/JCI115653; WILCOX CS, 1992, P NATL ACAD SCI USA, V89, P11993, DOI 10.1073/pnas.89.24.11993; XUAN JW, IN PRESS J CELL BIOC; ZIMOLO Z, 1993, AM J PHYSIOL, V69, P355	32	168	178	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					711	715						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	7506262				2022-12-27	WOS:A1994MR21900111
J	BRADSHER, JN; TAN, SY; MCLAURY, HJ; CONAWAY, JW; CONAWAY, RC				BRADSHER, JN; TAN, SY; MCLAURY, HJ; CONAWAY, JW; CONAWAY, RC			RNA POLYMERASE-II TRANSCRIPTION FACTOR-SIII .2. FUNCTIONAL-PROPERTIES AND ROLE IN RNA CHAIN ELONGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR; FACTOR-EPSILON; FACTOR-DELTA; RAT-LIVER; PREINITIATION COMPLEX; FACTOR-ALPHA; CALF THYMUS; FACTOR-TAU; GENE; PURIFICATION	A novel transcription factor that stimulates synthesis of accurately initiated transcripts by mammalian RNA polymerase II has been identified and purified to apparent homogeneity from rat liver extracts (Bradsher, J. N., Jackson, K. W., Conaway, R. C., Conaway, J. W. (1993) J. Biol. Chem. 268, 25587-25593). This factor, which we designate SIII, has a native molecular mass of approximately 140 kDa and is composed of three polypeptides of 110, 18, and 15 kDa. In this report, we demonstrate that SIII stimulates promoter-specific transcription by increasing the overall rate of RNA chain elongation by RNA polymerase II. Results of pulse-chase experiments indicate that SIII does not need to be present during preinitiation complex formation or transcription initiation in order to stimulate promoter-specific transcription. In addition, SIII is able to stimulate the rate of RNA chain elongation by RNA polymerase II during transcription of double stranded oligo(dC)-tailed templates. Taken together, these findings indicate that the factor exerts its activity directly on the elongation complex.	OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,825 NE 13TH ST,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation				Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; EGLY JM, 1984, EMBO J, V3, P2363, DOI 10.1002/j.1460-2075.1984.tb02141.x; ERNST H, 1983, MOL CELL BIOL, V3, P2172, DOI 10.1128/MCB.3.12.2172; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1989, J BIOL CHEM, V264, P8913; GARRETT KP, 1992, J BIOL CHEM, V267, P23942; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KASH SF, 1993, MOL CELL BIOL, V13, P2718, DOI 10.1128/MCB.13.5.2718; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; PETERSON MG, 1991, NATURE, V354, P369; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SPENCER CA, 1990, ONCOGENE, V5, P777; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; UCKER DS, 1984, J BIOL CHEM, V259, P7416; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843	46	94	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25594	25603						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503981				2022-12-27	WOS:A1993MK10000048
J	GU, WG; POWELL, W; MOTE, J; REINES, D				GU, WG; POWELL, W; MOTE, J; REINES, D			NASCENT RNA CLEAVAGE BY ARRESTED RNA POLYMERASE-II DOES NOT REQUIRE UPSTREAM TRANSLOCATION OF THE ELONGATION COMPLEX ON DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-ALPHA; ESCHERICHIA-COLI; TRANSCRIPTION ELONGATION; TERNARY COMPLEXES; WHEAT-GERM; CALF THYMUS; FACTOR-SII; RAT-LIVER; AMANITIN; TERMINATION	Obstacles incurred by RNA polymerase II during primary transcript synthesis have been identified in vivo and in vitro. Transcription past these impediments requires SII, an RNA polymerase II-binding protein. SII also activates a nuclease in arrested elongation complexes and this nascent RNA shortening precedes transcriptional readthrough. Here we show that in the presence of SII and nucleotides, transcript cleavage is detected during SII-dependent elongation but not during SII-independent transcription. Thus, under typical transcription conditions, SII is necessary but insufficient to activate RNA cleavage. RNA cleavage could serve to move RNA polymerase II away from the transcriptional impediment and/or permit RNA polymerase II multiple attempts at RNA elongation. By mapping the positions of the 3'-ends of RNAs and the elongation complex on DNA, we demonstrate that upstream movement of RNA polymerase II is not required for limited RNA shortening (seven to nine nucleotides) and reactivation of an arrested complex. Arrested complexes become elongation competent after removal of no more than nine nucleotides from the nascent RNA's 3'-end. Further cleavage of nascent RNA, however, does result in ''backward'' translocation of the enzyme. We also show that one round of RNA cleavage is insufficient for full readthrough at an arrest site, consistent with a previously suggested mechanism of SII action.	EMORY UNIV,GRAD PROGRAM BIOCHEM & MOLEC BIOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University; Emory University			excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243; Powell, Wade H./0000-0002-3727-2822	NIGMS NIH HHS [GM-46331, R01 GM046331, GM-08367] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008367, R01GM046331] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENGAL E, 1989, J BIOL CHEM, V264, P18926; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P1; COCHETME.M, 1974, BIOCHIM BIOPHYS ACTA, V353, P160, DOI 10.1016/0005-2787(74)90182-8; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; DEMERCOYROL L, 1989, BIOCHEM J, V258, P165, DOI 10.1042/bj2580165; EILAT D, 1984, J IMMUNOL, V133, P489; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; GARIGLIO P, 1974, FEBS LETT, V44, P330, DOI 10.1016/0014-5793(74)81170-1; GRACHEV MA, 1986, FEBS LETT, V200, P287, DOI 10.1016/0014-5793(86)81154-1; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; JACOB ST, 1970, NATURE, V225, P60, DOI 10.1038/225060b0; JOB C, 1992, BIOCHEM J, V285, P85, DOI 10.1042/bj2850085; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; Maxam A M, 1980, Methods Enzymol, V65, P499; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; REINES D, 1991, J BIOL CHEM, V266, P10510; REINES D, 1993, IN PRESS TRANSCRIPTI; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; RICHARDSON JP, 1993, CRIT REV BIOCHEM MOL, V28, P1, DOI 10.3109/10409239309082571; RIVA M, 1987, J BIOL CHEM, V262, P14377; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SPARKOWSKI J, 1992, GENETICS, V130, P411; SPENCER CA, 1990, ONCOGENE, V5, P777; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; VAISIUS AC, 1982, BIOCHEMISTRY-US, V21, P3097, DOI 10.1021/bi00256a010; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WIEST DK, 1992, J BIOL CHEM, V267, P7733	49	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1993	268	34					25604	25616						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK100	7503982				2022-12-27	WOS:A1993MK10000049
J	MAUPINFURLOW, JA; FERRY, JG				MAUPINFURLOW, JA; FERRY, JG			A PROTEASOME FROM THE METHANOGENIC ARCHAEON METHANOSARCINA-THERMOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOPLASMA-ACIDOPHILUM PROTEASOMES; MULTICATALYTIC PROTEINASE; SEQUENCE-ANALYSIS; ALPHA-SUBUNIT; GENE; EXPRESSION; ALIGNMENT; CLONING; GROWTH; ACID	A 645-kDa proteasome was purified from Methanosarcina thermophila which had chymotrypsin like and peptidylglutamyl-peptide hydrolase activities and contained alpha (24-kDa) and beta (22-kDa) subunits. Processing of both subunits was suggested by comparison of N-terminal sequences with the sequences deduced from the alpha- and beta-encoding genes (psmA and psmB). Alignment of deduced sequences for the alpha and beta subunits revealed high similarity; however, the N-terminal sequence of the alpha subunit contained an additional 24 amino acids that were not present in the beta subunit. The alpha and beta subunits had high sequence identity with alpha- and beta-type subunits of proteasomes from eucaryotic organisms and the distantly related archaeon Thermoplasma acidophilum. The psmB gene was transcribed in vivo as a monocistronic message from a consensus archaeal promoter. The results suggest that proteasomes are more widespread in the Archaea than previously proposed. Southern blotting experiments suggested the presence of ubiquitin-like sequences in M. thermophila.	PENN STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park			Maupin-Furlow, Julie/AAW-4035-2020	Maupin-Furlow, Julie/0000-0001-6105-0923	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044661, F32GM015877] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44661-02, 1F32GM15877-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA K, 1994, FEBS LETT, V343, P85, DOI 10.1016/0014-5793(94)80612-8; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARRIGO AP, 1987, J MOL EVOL, V25, P141, DOI 10.1007/BF02101756; BALCH WE, 1979, MICROBIOL REV, V43, P260, DOI 10.1128/MMBR.43.2.260-296.1979; BARRETT AJ, 1980, BIOCHEM J, V187, P909, DOI 10.1042/bj1870909; COUX O, 1994, MOL GEN GENET, V245, P769, DOI 10.1007/BF00297284; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DEMARTINO GN, 1991, BIOCHIM BIOPHYS ACTA, V1079, P29, DOI 10.1016/0167-4838(91)90020-Z; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ECKER DJ, 1987, J BIOL CHEM, V262, P3524; ENENKEL C, 1994, FEBS LETT, V341, P193, DOI 10.1016/0014-5793(94)80455-9; FERRY JG, 1992, CRIT REV BIOCHEM MOL, V27, P473, DOI 10.3109/10409239209082570; GENSCHIK P, 1992, FEBS LETT, V309, P311, DOI 10.1016/0014-5793(92)80796-J; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GRIBSKOV M, 1988, COMPUT APPL BIOSCI, V4, P61; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; JABLONSKI PE, 1990, J BACTERIOL, V172, P1271, DOI 10.1128/jb.172.3.1271-1275.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1994, TRENDS BIOCHEM SCI, V19, P533, DOI 10.1016/0968-0004(94)90054-X; MARTINEK RG, 1964, CLIN CHEM, V10, P1087; NOTHWANG HG, 1994, BBA-GENE STRUCT EXPR, V1219, P361, DOI 10.1016/0167-4781(94)90060-4; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; PHILIPPS G, 1993, EMBL Z26405 ACC; PUHLER G, 1994, SYST APPL MICROBIOL, V16, P734; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RAYNAL M, 1994, EMBL Z29892 ACC; Reeve John N., 1993, P493; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SELDEN RF, 1987, CURRENT PROTOCOLS MO; SHIRATSUCHI A, 1993, EMBL X57210 ACC; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOWERS KR, 1984, CURR MICROBIOL, V11, P227, DOI 10.1007/BF01567165; SOWERS KR, 1988, J BACTERIOL, V170, P998, DOI 10.1128/jb.170.2.998-1002.1988; SOWERS KR, 1993, J BIOL CHEM, V268, P23172; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; TERLESKY KC, 1986, J BACTERIOL, V168, P1053, DOI 10.1128/jb.168.3.1053-1058.1986; WENZEL T, 1993, FEBS LETT, V326, P215, DOI 10.1016/0014-5793(93)81793-Y; WOLF S, 1993, FEBS LETT, V326, P42, DOI 10.1016/0014-5793(93)81757-Q; ZWICKL P, 1991, FEBS LETT, V278, P217, DOI 10.1016/0014-5793(91)80120-R; ZWICKL P, 1992, FEBS LETT, V312, P157, DOI 10.1016/0014-5793(92)80925-7; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004; ZWICKL P, 1994, STRUCT BIOL, V1, P765	48	60	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28617	28622		10.1074/jbc.270.48.28617	http://dx.doi.org/10.1074/jbc.270.48.28617			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499378	hybrid			2022-12-27	WOS:A1995TH05600022
J	MIMNAUGH, EG; WORLAND, PJ; WHITESELL, L; NECKERS, LM				MIMNAUGH, EG; WORLAND, PJ; WHITESELL, L; NECKERS, LM			POSSIBLE ROLE FOR SERINE/THREONINE PHOSPHORYLATION IN THE REGULATION OF THE HETEROPROTEIN COMPLEX BETWEEN THE HSP90 STRESS PROTEIN AND THE PP60(V-SRC) TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; HEAT-SHOCK PROTEIN; RSV-TRANSFORMED CELLS; 2 CELLULAR PROTEINS; OKADAIC ACID; RETINOBLASTOMA PROTEIN; STEROID-RECEPTORS; TUMOR PROMOTER; CASEIN KINASE; PP60SRC	The abundant, cytoplasmic 90-kDa heat-shock protein associates transiently with the Rous sarcoma virus oncogenic protein tyrosine kinase, pp60(v-src), directs its cellular trafficking and negatively regulates its kinase activity, Here we report that the serine/threonine phosphatase inhibitor, okadaic acid, destabilized the heat-shock protein 90-pp60(v-src) chaperone complex in v-src-transfected cells. Concomitant with complex destabilization by okadaic acid, phosphoserine was doubled and phosphothreonine was increased 20-fold in the heat-shock protein 90. Although phosphorylation of the total pool of immunoprecipitable pp60(v-src) was unchanged, okadaic acid slightly increased phosphoserine and phosphothreonine levels specifically in pp60(v-src) bound to heat-shock protein 90. The low level of tyrosine phosphorylation in the pp60(v-src) complexed with heat-shock protein 90 was further decreased by okadaic acid. Interestingly, okadaic acid-stabilized hyperphosphorylation of the heat-shock protein 90-pp60(v-src) complex lowered the level of pp60(v-src) in cell membranes, the functional location for pp60(v-src). We suggest that serine/threonine phosphorylation of heat-shock protein 90 and/or pp60(v-src) functions as a regulatory molecular trigger to release pp60(v-src) from the chaperone complex at the inner surface of cell membranes.	NCI, BIOL CHEM LAB, BETHESDA, MD 20892 USA; UNIV ARIZONA, HLTH SCI CTR, STEELE MEM CHILDRENS RES CTR, TUCSON, AZ 85724 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Arizona; University of Arizona Health Sciences	MIMNAUGH, EG (corresponding author), NCI, CLIN PHARMACOL BRANCH, BLDG 10, ROOM 12N226, BETHESDA, MD 20892 USA.							Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; DOUGHERTY JJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P74, DOI 10.1016/0167-4889(87)90067-X; GARBER EA, 1985, MOL CELL BIOL, V5, P2781, DOI 10.1128/MCB.5.10.2781; GOTTESMAN MM, 1984, MOL CELL BIOL, V4, P2639, DOI 10.1128/MCB.4.12.2639; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GUPTA RW, 1993, BIOCHEM BIOPH RES CO, V196, P320, DOI 10.1006/bbrc.1993.2251; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IANNOTTI AM, 1988, ARCH BIOCHEM BIOPHYS, V264, P54, DOI 10.1016/0003-9861(88)90569-3; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KRUEGER JG, 1983, CURR TOP MICROBIOL, V107, P51; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; OPPERMANN H, 1981, VIROLOGY, V113, P736, DOI 10.1016/0042-6822(81)90202-6; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PURCHIO AF, 1985, SCIENCE, V229, P1393, DOI 10.1126/science.2994221; RESH MD, 1985, MOL CELL BIOL, V5, P916, DOI 10.1128/MCB.5.5.916; SARTOR O, 1992, J BIOL CHEM, V267, P21044; SCHUH S, 1985, J BIOL CHEM, V260, P4292; SCHULTE TW, P AM ASSOC CANC RES, V36, P435; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; YATSUNAMI J, 1993, CANCER RES, V53, P239	43	78	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28654	28659		10.1074/jbc.270.48.28654	http://dx.doi.org/10.1074/jbc.270.48.28654			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499384	hybrid			2022-12-27	WOS:A1995TH05600028
J	MORTIMER, BC; BEVERIDGE, DJ; MARTINS, IJ; REDGRAVE, TG				MORTIMER, BC; BEVERIDGE, DJ; MARTINS, IJ; REDGRAVE, TG			INTRACELLULAR-LOCALIZATION AND METABOLISM OF CHYLOMICRON REMNANTS IN THE LIVERS OF LOW-DENSITY-LIPOPROTEIN RECEPTOR-DEFICIENT MICE AND APOE-DEFICIENT MICE - EVIDENCE FOR SLOW METABOLISM VIA AN ALTERNATIVE APOE-DEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID EMULSION MODELS; APOLIPOPROTEIN-E; PLASMA-LIPOPROTEINS; TRANSGENIC MICE; LDL-RECEPTOR; PROTEIN; RATS; HYPERCHOLESTEROLEMIA; CLEARANCE; LACTOFERRIN	The metabolism of chylomicron remnants in mice deficient in low density lipoprotein receptor (LDLr) or apolipoprotein E (apoE) was compared with that of control C57BL/6J mice. Mice were injected intravenously with chylomicron-like emulsions labeled with radioactive lipids. Blood samples were taken at fixed time intervals from the retro-orbital sinus, and clearance rates of the lipoproteins were assessed from the decline in plasma radioactivities. To follow the intracellular pathway of remnants in the liver, emulsions labeled with a fluorescent cholesteryl ester (BODIPY) were injected, and liver sections were processed and assayed by laser confocal microscopy, Catabolism of remnant cholesteryl esters was assessed by injecting emulsions labeled with cholesteryl[1-C-14]oleate and measuring the expired CO2 from each animal. In apoE-deficient mice, remnant removal from plasma was totally impeded, while the clearance of remnants in LDLr-deficient mice was similar to that in C57BL/6J control mice, The confocal micrographs of livers 20 min after injection of fluorescent chylomicron-like emulsions showed evenly distributed fluorescent particles in the hepatocytes from control mice. In contrast, the fluorescent particles were mainly located in sinusoidal spaces in LDLr deficient mice, Three hours after injection the livers from control mice showed few fluorescent particles, indicating that remnants have been catabolized, while the sections from LDLr-deficient mice were still highly fluorescent, Micrographs from apoE deficient mice showed no fluorescent particles in the liver at any time after injection, Measurement of expired radioactive CO2 after injection of emulsions labeled in the fatty acid moiety of cholesteryl oleate indicated that remnant metabolism was slower in the LDLr-deficient mice and essentially nil in the apoE-deficient mice, Control mice had expired 50% of the injected label by 3 h after injection. We conclude that under normal circumstances, chylomicron remnants are rapidly internalized by LDLr and catabolized in hepatocytes, with a critical requirement for apoE, When LDLr is absent, remnants are taken up by a second apoE-dependent pathway, first to the sinusoidal space of the liver, with subsequent slow endocytosis and slow catabolism. Hepatic clearance via this second pathway is increased by heparin, inhibited by lactoferrin, heparinase, and suramin, and down-regulated by feeding a high fat diet.			MORTIMER, BC (corresponding author), UNIV WESTERN AUSTRALIA,DEPT PHYSIOL,NEDLANDS,WA 6907,AUSTRALIA.			Martins, Ian/0000-0002-2390-1501				CALLOW MJ, 1993, BIOCHEM MOL BIOL INT, V29, P913; CHANG SY, 1994, BBA-LIPID LIPID MET, V1215, P205, DOI 10.1016/0005-2760(94)90112-0; CHOI SY, 1993, J BIOL CHEM, V268, P15804; COLETTE C, 1994, DIABETES NUTR METAB, V7, P295; DESILVA HV, 1993, BIOCHEM SOC T, V21, P483, DOI 10.1042/bst0210483; DIARD P, 1994, BIOCHEM J, V299, P889, DOI 10.1042/bj2990889; GODFREY P, 1962, ANAL BIOCHEM, V4, P310, DOI 10.1016/0003-2697(62)90092-1; HERZ J, 1995, P NATL ACAD SCI USA, V92, P4611, DOI 10.1073/pnas.92.10.4611; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; JI ZS, 1995, J LIPID RES, V36, P58; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KRASINSKI SD, 1990, METABOLISM, V39, P357, DOI 10.1016/0026-0495(90)90249-C; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MEILINGER M, 1995, FEBS LETT, V360, P70, DOI 10.1016/0014-5793(95)00082-K; MOKUNO H, 1994, J BIOL CHEM, V69, P13238; MORTIMER BC, 1994, ARTERIOSCLER THROMB, V14, P1542, DOI 10.1161/01.ATV.14.10.1542; MORTIMER BC, 1990, BIOCHIM BIOPHYS ACTA, V1046, P46, DOI 10.1016/0005-2760(90)90093-D; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; REDGRAVE TG, 1983, INT REV PHYSIOL, V28, P103; REDGRAVE TG, 1990, METABOLISM, V39, P1, DOI 10.1016/0026-0495(90)90140-8; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; REDGRAVE TG, 1985, BIOCHIM BIOPHYS ACTA, V835, P104, DOI 10.1016/0005-2760(85)90036-0; REDGRAVE TG, 1995, IN PRESS J LIPID RES; SHAFI S, 1994, J LIPID RES, V35, P709; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SULTAN F, 1989, BIOCHEM J, V258, P587, DOI 10.1042/bj2580587; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1995, P NATL ACAD SCI USA, P4537; YEN FT, 1994, BIOCHEMISTRY-US, V33, P1172, DOI 10.1021/bi00171a017; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	39	70	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28767	28776		10.1074/jbc.270.48.28767	http://dx.doi.org/10.1074/jbc.270.48.28767			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499399	hybrid			2022-12-27	WOS:A1995TH05600043
J	SAVAGE, B; BOTTINI, E; RUGGERI, ZM				SAVAGE, B; BOTTINI, E; RUGGERI, ZM			INTERACTION OF INTEGRIN ALPHA(IIB)BETA(3) WITH MULTIPLE FIBRINOGEN DOMAINS DURING PLATELET-ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; GAMMA-CHAIN; VONWILLEBRAND-FACTOR; GLANZMANN THROMBASTHENIA; STIMULATED PLATELETS; VITRONECTIN RECEPTOR; BINDING-SITE; ALPHA-CHAIN; AGGREGATION; COMPLEX	We have investigated how modulation of integrin alpha(IIb)beta(3) function influences the mechanisms that initiate platelet thrombus formation onto surface-bound fibrinogen and isolated fibrinogen domains, Under stationary conditions and with full activation of platelets blocked by prostaglandin E(1), the carboxyl-terminal gamma(400-411) sequence is necessary for establishing initial contact with the immobilized substrate. Molecules containing a single copy of this sequence, like the plasmin-generated fibrinogen fragment D, support platelet spreading, but the resulting attachment to the surface is loose and disrupted by minimal peeling force, In contrast, platelets adhere firmly to intact fibrinogen under the same conditions, suggesting that recognition of contact sites outside a single D domain can secure the firm interaction not supported by a single gamma(400-411) sequence. If platelets are activated, the gamma(400-411) sequence is no longer necessary to initiate the adhesion process but becomes sufficient, even as a single copy, to mediate stable surface attachment in the absence of shear stress, Under conditions of flow, however, intact fibrinogen but not fragment D can support adhesion, regardless of whether platelets have the potential to become activated or not, These results indicate the functional relevance of multiple fibrinogen domains during the initial stages of the platelet adhesion process.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NCRR NIH HHS [RR0833] Funding Source: Medline; NHLBI NIH HHS [HL-31950, HL-48728] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, P01HL031950] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1992, J BIOL CHEM, V267, P2775; ALEVRIADOU BR, 1993, BLOOD, V81, P1263; BENNETT JS, 1982, J BIOL CHEM, V257, P8049; CHEN CS, 1988, BIOCHEMISTRY-US, V27, P6121, DOI 10.1021/bi00416a044; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; COLLER BS, 1991, BLOOD, V78, P2603; COLLER BS, 1980, BLOOD, V55, P169; COLLER BS, 1991, BLOOD, V77, P75; DEMARCO L, 1986, J CLIN INVEST, V77, P1272, DOI 10.1172/JCI112430; DISE CA, 1982, J BIOL CHEM, V257, P4701; EDGECOMBE M, 1993, PLATELETS, V4, P141, DOI 10.3109/09537109309013210; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1994, J BIOL CHEM, V269, P226; GARTNER TK, 1993, THROMB RES, V71, P47; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GOGSTAD GO, 1982, BLOOD, V60, P663; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; KAZAL LA, 1963, P SOC EXP BIOL MED, V113, P989; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; LAM SCT, 1987, J BIOL CHEM, V262, P947; LAM SCT, 1989, J BIOL CHEM, V264, P3742; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MASSINI P, 1971, THROMB DIATH HAEMOST, V25, P13, DOI 10.1055/s-0038-1654275; MUSTARD JF, 1978, BLOOD, V52, P453; NACHMAN RL, 1982, J CLIN INVEST, V69, P263, DOI 10.1172/JCI110448; NIIYA K, 1987, BLOOD, V70, P475; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PACKHAM MA, 1987, BLOOD, V70, P647; PLOW EF, 1980, J BIOL CHEM, V255, P971; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; Ruggeri ZM, 1993, CURR OPIN CELL BIOL, V5, P898, DOI 10.1016/0955-0674(93)90041-N; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SMITH JW, 1990, J BIOL CHEM, V265, P12267	37	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	1995	270	48					28812	28817		10.1074/jbc.270.48.28812	http://dx.doi.org/10.1074/jbc.270.48.28812			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TH056	7499405	hybrid			2022-12-27	WOS:A1995TH05600049
J	BUSE, P; WOO, PL; ALEXANDER, DB; REZA, A; FIRESTONE, GL				BUSE, P; WOO, PL; ALEXANDER, DB; REZA, A; FIRESTONE, GL			GLUCOCORTICOID-INDUCED FUNCTIONAL POLARITY OF GROWTH-FACTOR RESPONSIVENESS REGULATES TIGHT JUNCTION DYNAMICS IN TRANSFORMED MAMMARY EPITHELIAL TUMOR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA; SUPPRESSOR PROTEIN; TGF-ALPHA; INVITRO; ASSOCIATION; MECHANISMS; DROSOPHILA; EXPRESSION; CANCER; MICE	The synthetic glucocorticoid, dexamethasone, induces the ''normal-like'' differentiated property of tight junction formation and suppresses growth of the Con8 mammary epithelial tumor cell line, derived from a 7,12-dimethylbenz(alpha)anthracene-induced rat mammary adenocarcinoma. Characterization of the transepithelial electrical resistance of Con8 mammary tumor cells cultured on permeable supports revealed that a novel response to dexamethasone is the generation of a polarized cell monolayer with respect to epidermal growth factor receptor responsiveness, Administration of transforming growth factor-alpha (TGF-alpha) to the basolateral, but not the apical, plasma membrane compartment disrupted the glucocorticoid-stimulated tight junction barrier, Confocal immunofluorescence microscopy revealed that dexamethasone caused the ZO-1 tight junction-associated protein to localize exclusively to the apical border of laterally adjacent membranes of the cell periphery, whereas basolateral administration of TGF-alpha caused the redistribution of ZO-1 back to disorganized aggregates along the cell periphery, In contrast, TGF-alpha was able to exert its mitogenic effects equally on both sides of the cell monolayer independent of its polarized disruption of tight junction formation, Our results represent the first evidence for a functional polarization of the epidermal growth factor receptor and strongly implicate the glucocorticoid-regulated formation of tight junctions in policing the polarized responsiveness of mammary cells to growth factors.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, CANC RES LAB, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley					NIDDK NIH HHS [DK-42799] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042799, R56DK042799] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ABBOTT LA, 1992, MECH DEVELOP, V37, P43, DOI 10.1016/0925-4773(92)90014-B; ALEXANDER DB, 1993, CANCER RES, V53, P1808; Anderson JM, 1993, CURR OPIN CELL BIOL, V5, P772, DOI 10.1016/0955-0674(93)90024-K; BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420; BUSE P, 1995, J BIOL CHEM, V270, P6505, DOI 10.1074/jbc.270.12.6505; CITI S, 1993, J CELL BIOL, V121, P485, DOI 10.1083/jcb.121.3.485; DEREN P, 1994, CARCINOGENESIS, V15, P1807; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; FULLER PJ, 1991, FASEB J, V5, P3092, DOI 10.1096/fasebj.5.15.1743440; GONZALEZ ML, 1990, AM J PHYSIOL, pC978; GOYA L, 1993, CANCER RES, V53, P1816; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; HSIEH JT, 1994, J BIOL CHEM, V269, P3711; IMAGAWA W, 1990, ENDOCR REV, V11, P494, DOI 10.1210/edrv-11-4-494; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383; LIU SC, 1987, MOL ENDOCRINOL, V1, P683, DOI 10.1210/mend-1-10-683; MADARA JL, 1988, CELL, V53, P497, DOI 10.1016/0092-8674(88)90562-4; MANDEL LJ, 1993, NATURE, V361, P552, DOI 10.1038/361552a0; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCROBERTS JA, 1992, AM J PHYSIOL, V262, pC207, DOI 10.1152/ajpcell.1992.262.1.C207; MEHTA PP, 1991, J MEMBRANE BIOL, V124, P207, DOI 10.1007/BF01994355; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARRY G, 1992, J CELL SCI, V101, P191; PAWSON T, 1993, PHILOS T R SOC B, V340, P279, DOI 10.1098/rstb.1993.0069; PITELKA DR, 1978, LACTATION COMPREHENS, P141; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Segaloff A, 1966, Recent Prog Horm Res, V22, P351; SINGER KL, 1994, J BIOL CHEM, V269, P16108; SJAASTAD MD, 1993, J CELL BIOL, V122, P589, DOI 10.1083/jcb.122.3.589; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; Vonderhaar B K, 1988, Cancer Treat Res, V40, P251; WEBSTER MK, 1990, J BIOL CHEM, V265, P4831; WEBSTER MK, 1991, CANCER RES, V51, P6031; WELSCH CW, 1985, CANCER RES, V45, P3415; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; ZETTL KS, 1992, P NATL ACAD SCI USA, V89, P9069, DOI 10.1073/pnas.89.19.9069; ZHANG ZY, 1993, J BIOL CHEM, V268, P5557	44	46	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28223	28227						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499317				2022-12-27	WOS:A1995TG21000042
J	MIZUGUCHI, J; HU, CH; CAO, ZY; LOEB, KR; CHUNG, DW; DAVIE, EW				MIZUGUCHI, J; HU, CH; CAO, ZY; LOEB, KR; CHUNG, DW; DAVIE, EW			CHARACTERIZATION OF THE 5'-FLANKING REGION OF THE GENE FOR THE GAMMA-CHAIN OF HUMAN FIBRINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; TRANSCRIPTION FACTOR; NUCLEAR FACTOR; EXPRESSION; PROTEINS; BINDING; ELEMENT; RAT; INTERLEUKIN-6; UPSTREAM	The 5'-flanking region of the gene coding for the gamma chain of human fibrinogen was characterized for its promoter activity, Reporter gene studies using chloramphenicol acetyltransferase as the indicator along with mutations in the DNA showed that a TATA-like sequence (-20 to -23 base pairs (bp)), a CAAT-like sequence (-54 to -57 bp), and an upstream stimulatory factor (USF) binding site (-66 to -77 bp) constitute a minimal promoter that mediates liver-specific expression of the gene. Electrophoretic gel mobility assays and antibody binding studies confirmed the interaction of USF with the binding site. An IL-6 responsive element with a sequence of CTGGAA located at -301 to -306 bp was shown to be a functional element in the IL-6 response. In contrast to the IL-6 responsive elements in the human alpha- and beta-fibrinogen genes, the element in the gene for the gamma chain of human fibrinogen was unaffected by the presence or elevated levels of the beta or delta isoforms of the CCAAT/enhancer binding proteins, A negative element with sequence homology to several silencer elements was also identified in the region of -348 to -390 bp of the gene for the gamma chain of human fibrinogen. A comparison of the regulatory elements in the genes coding for all three chains in fibrinogen is also presented.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle			Sessum, Rachel/F-7312-2015	Sessum, Rachel/0000-0002-2444-7056	NHLBI NIH HHS [HL16919] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON GM, 1993, J BIOL CHEM, V268, P22650; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; CHUNG DW, 1984, BIOCHEMISTRY-US, V23, P4232, DOI 10.1021/bi00313a033; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Haidaris P J, 1990, Blood Coagul Fibrinolysis, V1, P433, DOI 10.1097/00001721-199010000-00011; HANDAGAMA P, 1990, J CLIN INVEST, V86, P1364, DOI 10.1172/JCI114848; HANSEN LP, 1993, CURR OPIN GENET DEV, V3, P246, DOI 10.1016/0959-437X(93)90030-S; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HU CH, 1995, J BIOL CHEM, V270, P28342; KANT JA, 1985, P NATL ACAD SCI USA, V82, P2344, DOI 10.1073/pnas.82.8.2344; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; MIAO CH, 1992, J BIOL CHEM, V267, P7395; MORGAN JG, 1988, MOL CELL BIOL, V8, P2628, DOI 10.1128/MCB.8.6.2628; MOSESSON MW, 1972, J BIOL CHEM, V247, P5223; RIXON MW, 1985, BIOCHEMISTRY-US, V24, P2077, DOI 10.1021/bi00329a041; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1992, MOL CELL BIOL, V12, P2525, DOI 10.1128/MCB.12.6.2525; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; STRAUB PW, 1963, J CLIN INVEST, V42, P130, DOI 10.1172/JCI104690; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WOLFENSTEINTODEL C, 1981, BIOCHEMISTRY-US, V20, P6146, DOI 10.1021/bi00524a036	30	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28350	28356						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499336				2022-12-27	WOS:A1995TG21000061
J	TAKAHASHI, S; NAKAGAWA, T; BANNO, T; WATANABE, T; MURAKAMI, K; NAKAYAMA, K				TAKAHASHI, S; NAKAGAWA, T; BANNO, T; WATANABE, T; MURAKAMI, K; NAKAYAMA, K			LOCALIZATION OF FURIN TO THE TRANS-GOLGI NETWORK AND RECYCLING FROM THE CELL-SURFACE INVOLVES SER AND TYR RESIDUES WITHIN THE CYTOPLASMIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; FACTOR-II RECEPTOR; BREFELDIN-A; COMPLEX; TGN38; SPECIFICITY; EXPRESSION; SEQUENCE; PROTEIN; INTERNALIZATION	Furin is a membrane-associated endoprotease that catalyzes cleavage of precursor proteins at Arg-X-Lys/Arg-Arg sites. Although, at steady state, furin is predominantly found in the trans-Golgi network (TGN), it also cycles between the TGN and the cell surface. Recently, the cytoplasmic tail of furin has been shown to be sufficient for its localization to the TGN. Within the cytoplasmic domain, there are Ser residues, which we now show are sites for phosphorylation by casein kinase II in vitro, and a Tyr-containing sequence, both of which have been shown to be important for other TGN proteins to localize to this compartment. In the present study, we show by site-directed mutagenesis that these residues are important for TGN localization and recycling of furin. Mutation of the Ser residues abrogated the TGN localization. By contrast, mutation of the Tyr residue did not affect the TGN localization but impaired the internalization from the plasma membrane. These observations suggest that distinct cytoplasmic determinants are responsible for retention in the TGN and retrieval from the cell surface of furin.	UNIV TSUKUBA, INST BIOL SCI, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, INST APPL BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, INST BASIC MED SCI, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, CTR GENE EXPT, TSUKUBA, IBARAKI 305, JAPAN	University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba			Nakayama, Kazuhisa/ABF-2924-2020	Watanabe, Tsuyoshi/0000-0002-6094-7728; Nakayama, Kazuhisa/0000-0001-7701-7183				Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHAPMAN RE, 1994, EMBO J, V13, P2305, DOI 10.1002/j.1460-2075.1994.tb06514.x; CONIBEAR E, 1994, J CELL SCI, V107, P923; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HALBAN PA, 1994, BIOCHEM J, V299, P1; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JONES SM, 1993, J CELL BIOL, V122, P775, DOI 10.1083/jcb.122.4.775; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KORNER C, 1994, J BIOL CHEM, V269, P16529; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LADINSKY MS, 1994, J CELL BIOL, V127, P29, DOI 10.1083/jcb.127.1.29; LADINSKY MS, 1992, EUR J CELL BIOL, V59, P92; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; LUZIO JP, 1993, TRENDS BIOCHEM SCI, V18, P395, DOI 10.1016/0968-0004(93)90097-7; MAUXION F, 1995, EUR J CELL BIOL, V66, P119; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MERESSE S, 1990, J BIOL CHEM, V265, P18833; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; REAVES B, 1994, FEBS LETT, V351, P448, DOI 10.1016/0014-5793(94)00813-2; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SEIDAH NG, 1991, ENZYME, V45, P271, DOI 10.1159/000468901; Stanley Keith K., 1993, Trends in Cell Biology, V3, P252, DOI 10.1016/0962-8924(93)90046-4; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TORII S, 1995, J BIOL CHEM, V270, P11574, DOI 10.1074/jbc.270.19.11574; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; WONG SH, 1993, J BIOL CHEM, V268, P22853	41	118	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28397	28401						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499343				2022-12-27	WOS:A1995TG21000068
J	ISSE, N; OGAWA, Y; TAMURA, N; MASUZAKI, H; MORI, K; OKAZAKI, T; SATOH, N; SHIGEMOTO, M; YOSHIMASA, Y; NISHI, S; HOSODA, K; INAZAWA, J; NAKAO, K				ISSE, N; OGAWA, Y; TAMURA, N; MASUZAKI, H; MORI, K; OKAZAKI, T; SATOH, N; SHIGEMOTO, M; YOSHIMASA, Y; NISHI, S; HOSODA, K; INAZAWA, J; NAKAO, K			STRUCTURAL ORGANIZATION AND CHROMOSOMAL ASSIGNMENT OF THE HUMAN OBESE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; PROTEINS; MOUSE	The obese (ob) gene has been identified through a positional cloning approach; the mutation of this gene causes marked hereditary obesity and diabetes mellitus in mice, We report here the isolation and characterization of the human ob gene, Southern blot analysis demonstrated a single copy of the ob gene in the human genome, The human ob gene spanned similar to 20 kilobases (kb) and contained three exons separated by two introns, The first intron, similar to 10.6 kb in size, occurred in the 5'-untranslated region, 29 base pair (bp) upstream of the ATG start codon, The second intron of 2.3 kb in size was located at glutamine +49, By rapid amplification of 5'-cDNA ends, the transcription initiation sites were mapped 54 similar to 57 bp upstream of the ATG start codon, The 172-bp 5'-flanking region of the human ob gene contained a TATA box-like sequence and several cis-acting regulatory elements (three copies of GC boxes, an AP-2-binding site, and a CCAAT/enhancer-binding protein-binding site), By the fluorescence in situ hybridization technique, the ob gene was assigned to human chromosome 7q31.3. This study should establish the genetic basis for ob gene research in humans, thereby leading to the better understanding of the molecular mechanisms underlying the ob gene.	KYOTO UNIV, GRAD SCH MED, DEPT MED & CLIN SCI, SAKYO KU, KYOTO 606, JAPAN; KYOTO PREFECTURAL UNIV, DEPT HYG, KYOTO 606, JAPAN	Kyoto University; Kyoto Prefectural University			Mori, Kiyoshi/N-1267-2014	Mori, Kiyoshi/0000-0002-7285-8351; Okazaki, Taku/0000-0003-4790-1925				AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; ARIYAMA T, 1995, GENOMICS, V25, P114, DOI 10.1016/0888-7543(95)80116-4; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; FRIEDMAN JM, 1991, GENOMICS, V11, P1054, DOI 10.1016/0888-7543(91)90032-A; FUNAHASHI T, 1995, BIOCHEM BIOPH RES CO, V211, P469, DOI 10.1006/bbrc.1995.1837; INAZAWA J, 1991, GENOMICS, V10, P1075, DOI 10.1016/0888-7543(91)90202-P; INGALLS AM, 1950, J HERED, V41, P317, DOI 10.1093/oxfordjournals.jhered.a106073; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MASUZAKI H, 1995, DIABETES, V44, P855, DOI 10.2337/diabetes.44.7.855; MASUZAKI H, 1995, P JPN ACAD B-PHYS, V71, P148, DOI 10.2183/pjab.71.148; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OGAWA Y, 1995, J CLIN INVEST, V96, P1647, DOI 10.1172/JCI118204; OGAWA Y, 1994, J CLIN INVEST, V93, P1911, DOI 10.1172/JCI117182; OGAWA Y, 1995, GENOMICS, V27, P142, DOI 10.1006/geno.1995.1016; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKAHASHI E, 1990, HUM GENET, V86, P14; TAMURA N, 1994, J CLIN INVEST, V94, P1059, DOI 10.1172/JCI117420; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; ZHANG YY, 1995, NATURE, V374, P479, DOI 10.1038/374479a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	135	165	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27728	27733		10.1074/jbc.270.46.27728	http://dx.doi.org/10.1074/jbc.270.46.27728			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499240	hybrid			2022-12-27	WOS:A1995TE73600051
J	JACOB, KK; OUYANG, LH; STANLEY, FM				JACOB, KK; OUYANG, LH; STANLEY, FM			A CONSENSUS INSULIN-RESPONSE ELEMENT IS ACTIVATED BY AN ETS-RELATED TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-ACTING ELEMENTS; THYROID-HORMONE; PROLACTIN GENE; GROWTH-HORMONE; PROTEIN; BINDING; DNA; FOS; EXPRESSION; SRF	Insulin increases expression of somatostatin-chloramphenicol acetyltransferase (CAT) constructs 10-fold and thymidine kinase-CAT constructs 5-fold in GH4 cells. These responses are similar to our previously reported data on insulin-increased prolactin-CAT expression, They are also observed in HeLa cells and are thus not cell type specific, The evidence suggests that the insulin responsiveness of these genes is mediated by an Ets-related transcription factor, First, linker-scanning mutations and/or deletions of the prolactin, somatostatin, and thymidine kinase promoters suggest that their insulin responsiveness is mediated by the sequence CGGA, This sequence is identical with the response element of the Ets-related transcription factors, Second, CGGA-containing sequences placed at -88 in the Delta MTV-CAT reporter plasmid conferred insulin responsiveness to the mammary tumor virus promoter, Third, expression of the DNA-binding domain of c-Ets-a, which acts by blocking effects mediated by Ets-related transcription factors, inhibits the response of these promoters to insulin, Finally, the Ets-related proteins Sap and Elk-l bind to the prolactin, somatostatin, and thymidine kinase insulin response elements, An Ets-like element was found in all insulin-sensitive promoters examined and may serve a similar function in those promoters.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University	JACOB, KK (corresponding author), NYU,MED CTR,DEPT MED,NEW YORK,NY 10016, USA.			Stanley, Frederick/0000-0002-3684-2168	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043365] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43365] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CADILLA C, 1992, GENE, V118, P223, DOI 10.1016/0378-1119(92)90192-R; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DRUST DS, 1991, MOL ENDOCRINOL, V5, P1541, DOI 10.1210/mend-5-10-1541; FLUG F, 1987, J BIOL CHEM, V262, P6373; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; JACOB KK, 1994, J BIOL CHEM, V269, P25515; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; JONG MTC, 1994, MOL ENDOCRINOL, V8, P1320, DOI 10.1210/me.8.10.1320; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MEISLER MH, 1989, ANNU REV PHYSIOL, V51, P701, DOI 10.1146/annurev.physiol.51.1.701; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; NAZRIN N, 1990, P NATL ACAD SCI USA, V87, P5273; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PARK HY, 1993, MOL ENDOCRINOL, V7, P319, DOI 10.1210/me.7.3.319; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; PRAGER D, 1988, ENDOCRINOLOGY, V122, P2946, DOI 10.1210/endo-122-6-2946; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; STANLEY F, 1989, MOL ENDOCRINOL, V3, P1627, DOI 10.1210/mend-3-10-1627; STANLEY F, 1988, J BIOL CHEM, V263, P13443; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WEBER JL, 1984, MOL CELL BIOCHEM, V65, P171; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237	30	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27773	27779		10.1074/jbc.270.46.27773	http://dx.doi.org/10.1074/jbc.270.46.27773			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499246	hybrid			2022-12-27	WOS:A1995TE73600057
J	KVASSMAN, JO; LAWRENCE, DA; SHORE, JD				KVASSMAN, JO; LAWRENCE, DA; SHORE, JD			THE ACID STABILIZATION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 DEPENDS ON PROTONATION OF A SINGLE GROUP THAT AFFECTS LOOP INSERTION INTO BETA-SHEET-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL STABILITY; PROTEINASE-INHIBITORS; SERPINS; ANTITHROMBIN; TRANSITION; LATENT; ALPHA-1-ANTITRYPSIN; THROMBOSIS; SUBSTRATE; AFFINITY	The serpin plasminogen activator inhibitor-1 (PAI-1) spontaneously adopts an inactive or latent conformation by inserting the N-terminal part of the reactive center loop as strand 4 into the major beta-sheet (sheet A), To examine factors that may regulate reactive loop insertion in PAI-1, we determined the inactivation rate of the inhibitor in the pH range 4.5-13, Below pH 9, inactivation led primarily to latent PAI-1, and one predominant effect of pH on the corresponding rate constant could be observed, Protonation of a group exhibiting a pK(alpha) of 7.6 (25 degrees C, ionic strength = 0.15 M) reduced the rate of formation of latent PAI-1 by a factor of 35, from 0.17 h(-1) at pH 9 to about 0.005 h(-1) below pH 6. The ionization with a pK(alpha) 7.6 was found to have no effect on the rate by which PAI-1 inhibits trypsin and is therefore unlikely to change the flexibility of the loop or the orientation of the reactive center, The peptides Ac-TEASSSTA and Ac-TVASSSTA (cf. P14-P7 in the reactive loop of PAI-1) formed stable complexes with PAI-1 and converted the inhibitor to a substrate for tissue type plasminogen activator, We found that peptide binding and formation of latent PAI-1 are mutually exclusive events, similarly affected by the pK(alpha) 7.6 ionization. This is direct evidence that external peptides can substitute for strand 4 in beta-sheet A of PAI-1 and that the pR(alpha) 7.6 ionization regulates insertion of complementary, internal or external, strands into this position, A model that accounts for the observed pH effects is presented, and the identity of the ionizing group is discussed based on the structure of latent PAI-1, The group is tentatively identified as His-143 in helix F, located on top of sheet A.	AMER RED CROSS,DEPT BIOCHEM,ROCKVILLE,MD 20855	American Red Cross	KVASSMAN, JO (corresponding author), HENRY FORD HOSP,HLTH SCI CTR,DIV BIOCHEM RES,1 FORD PL,DETROIT,MI 48202, USA.			Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045930] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45930] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BJORK I, 1992, J BIOL CHEM, V267, P1976; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BRUCH M, 1988, J BIOL CHEM, V263, P16626; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CHMIELEWSKA J, 1988, BIOCHEM J, V251, P327, DOI 10.1042/bj2510327; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P3634, DOI 10.1021/bi00410a017; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; GOLDSMITH EJ, 1994, STRUCTURE, V2, P241, DOI 10.1016/S0969-2126(00)00025-3; GOLDSMITH EJ, 1991, PROTEINS, V9, P225, DOI 10.1002/prot.340090308; HEKMAN CM, 1988, BIOCHEMISTRY-US, V27, P2911, DOI 10.1021/bi00408a037; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; Kassell B., 1970, METHODS ENZYMOLOGY, VVolume 19, P844, DOI [10.1016/0076-6879(70)19074-4, DOI 10.1016/0076-6879(70)19074-4]; KVASSMAN J, 1993, THROMB HAEMOSTASIS, V69, P1328; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LINDAHL TL, 1989, THROMB HAEMOSTASIS, V62, P27; LIU W, 1986, BIOCHIM BIOPHYS ACTA, V870, P185, DOI 10.1016/0167-4838(86)90220-7; LOMAS DA, 1995, J BIOL CHEM, V270, P5282, DOI 10.1074/jbc.270.10.5282; MARSHALL CJ, 1993, PHILOS T ROY SOC B, V342, P101, DOI 10.1098/rstb.1993.0141; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHREUDER HA, 1994, STRUCT BIOL, V1, P48; SCHULZE AJ, 1991, EUR J BIOCHEM, V202, P1147, DOI 10.1111/j.1432-1033.1991.tb16483.x; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; SHORE JD, 1994, J BIOL CHEM, V270, P5395; VAUGHAN DE, 1993, BIOCHIM BIOPHYS ACTA, V1202, P221, DOI 10.1016/0167-4838(93)90008-F; YUNG BY, 1975, BIOCHEM BIOPH RES CO, V65, P927, DOI 10.1016/S0006-291X(75)80474-8	37	60	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27942	27947		10.1074/jbc.270.46.27942	http://dx.doi.org/10.1074/jbc.270.46.27942			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499270	hybrid			2022-12-27	WOS:A1995TE73600081
J	NEMETH, K; CHOLLET, A				NEMETH, K; CHOLLET, A			A SINGLE MUTATION OF THE NEUROKININ-2 (NK2) RECEPTOR PREVENTS AGONIST-INDUCED DESENSITIZATION - DIVERGENT CONFORMATIONAL REQUIREMENTS FOR NK2 RECEPTOR SIGNALING AND AGONIST-INDUCED DESENSITIZATION IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Receptor activation and agonist induced desensitization of the human neurokinin-2 (NK2) receptor expressed in Xenopus oocytes have been investigated, When neurokinin A (NKA) was applied repeatedly at 5-min intervals, the second and subsequent applications gave no responses. This desensitization was not observed with the specific agonists (Lys(3), Gly(8)-R-gamma-lactam-Leu(9))MCA(3-10) (GR64349) or (Nle(10))-NKA(4-10). However, in the presence of the protein kinase inhibitor staurosporine, stimulation with GR64349 or (Nle(10))-NKA(4-10) induced receptor desensitization. In contrast, the protein kinase C inhibitor Ro-31-8220 was not able to enhance GR64349-mediated desensitization. We created a mutation (F248S) in the third cytoplasmic loop of NK2 that impairs NKA-induced desensitization. In the presence of either staurosporine or Ro-31-8220, the mutant receptor was desensitized in response to NKA application but not to GR64349. Also, truncation mutants Delta 62 and Delta 87, lacking serine and threonine residues in the cytoplasmic COOH-terminal tail, were functionally active and were partially resistant to desensitization. These observations indicate that 1) there are different conformational requirements for NK2 receptor signaling and agonist-induced desensitization, 2) the third intracellular loop and the cytoplasmic tail of NK2 are functional domains important for agonist-induced desensitization, and 3) some agonists at the NK2 receptor cause much more desensitization than others and suggest that this might result from phosphorylation by receptor-specific kinases and other non-identified protein kinases.	GLAXO INST MOLEC BIOL SA, CH-1228 PLAN OVATES, SWITZERLAND	GlaxoSmithKline								ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; ARKINSTALL S, 1994, FEBS LETT, V338, P75, DOI 10.1016/0014-5793(94)80119-3; BHOGAL N, 1994, J BIOL CHEM, V269, P27269; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CHOLLET A, 1995, MEMBRANE PROTEIN MOD; EASON MG, 1994, MOL PHARMACOL, V45, P696; HAGA T, 1994, J NEUROCHEM, V63, P400; HAGAN RM, 1991, NEUROPEPTIDES, V19, P127, DOI 10.1016/0143-4179(91)90142-6; HUNYADY L, 1994, KIDNEY INT, V46, P1496, DOI 10.1038/ki.1994.428; IRELAND SJ, 1991, BRIT J PHARMACOL, V103, P1463, DOI 10.1111/j.1476-5381.1991.tb09812.x; JOSIAH SM, 1994, BIOCHEM BIOPH RES CO, V199, P626, DOI 10.1006/bbrc.1994.1274; KOBILKA BK, 1987, J BIOL CHEM, V262, P15796; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.ne.14.030191.001011; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; ROVERO P, 1989, NEUROPEPTIDES, V13, P263, DOI 10.1016/0143-4179(89)90080-2; SASAKAWA N, 1994, FEBS LETT, V347, P181, DOI 10.1016/0014-5793(94)00532-X; STUBBS CM, 1992, NEUROPEPTIDES, V22, P64; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939; ZOZYULA SA, 1990, PROTEIN ENG, V3, P453	25	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 17	1995	270	46					27601	27605		10.1074/jbc.270.46.27601	http://dx.doi.org/10.1074/jbc.270.46.27601			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TE736	7499223	hybrid			2022-12-27	WOS:A1995TE73600034
J	LU, B; ROTHNAGEL, JA; LONGLEY, MA; TSAI, SY; ROOP, DR				LU, B; ROTHNAGEL, JA; LONGLEY, MA; TSAI, SY; ROOP, DR			DIFFERENTIATION-SPECIFIC EXPRESSION OF HUMAN KERATIN-1 IS MEDIATED BY A COMPOSITE AP-1 STEROID-HORMONE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-18; MOUSE EPIDERMAL-CELLS; CULTURED HUMAN KERATINOCYTES; RETINOID X-RECEPTOR; THYROID-HORMONE; GENE-EXPRESSION; C-FOS; TERMINAL DIFFERENTIATION; TRANSCRIPTION FACTOR; CALCIUM REGULATION	Human keratin 1 (HK1) expression is associated with the loss of mitotic activity in epidermal keratinocytes and restricted to an intermediate stage of terminal differentiation. Recently, the control elements that mediate this differentiation-specific expression were identified (Huff, C. A, Yuspa, S. H., and Rosenthal, D. (1993) J. Biol. Chem. 268, 377-384). We now report the characterization of one of these elements. Footprint analysis on a 249-base pair fragment containing the calcium responsive element (CaRE) revealed two adjacent protected regions. The 5' most footprint contains an AP-1 consensus sequence while the 3' footprint encodes two inverted repeats of the canonical hormone response recognition sequence. Deletion of the AP-1 protected region abolished the calcium response in a reporter construct. Calcium activation of the reporter construct containing the intact CaRE was unaffected by the addition of thyroid hormone or estrogen. However, vitamin D-3 was able to suppress calcium induction by the CaRE, and this suppression could be abrogated by the coaddition of retinoic acid. These studies show that AP-1 factors bind to the 5' element to mediate the calcium response while members of the steroid hormone receptor superfamily interact with the 3' element to modulate the calcium response.	BAYLOR UNIV,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR UNIV,DEPT DERMATOL,HOUSTON,TX 77030	Baylor University; Baylor University			Rothnagel, Joe/A-4874-2010	Rothnagel, Joe/0000-0002-6710-3165	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025479] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25479] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASSELINEAU D, 1990, DIFFERENTIATION, V45, P221, DOI 10.1111/j.1432-0436.1990.tb00476.x; BIKLE DD, 1986, BIOCHEMISTRY-US, V25, P1545, DOI 10.1021/bi00355a013; BLUMENBERG M, 1992, J INVEST DERMATOL, V98, pS42, DOI 10.1111/1523-1747.ep12462194; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; CRIPE T P, 1990, New Biologist, V2, P450; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FISHER C, 1991, DEVELOPMENT, V111, P253; FISHER C, 1987, J INVEST DERMATOL, V88, P661, DOI 10.1111/1523-1747.ep12470281; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1981, CELL, V25, P617, DOI 10.1016/0092-8674(81)90169-0; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARPER JR, 1988, J INVEST DERMATOL, V91, P150, DOI 10.1111/1523-1747.ep12464396; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Higuchi R., 1989, PCR TECHNOLOGY, P61; HOGGARD N, 1991, MOL ENDOCRINOL, V5, P1748, DOI 10.1210/mend-5-11-1748; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HOSOMI J, 1983, ENDOCRINOLOGY, V113, P1950, DOI 10.1210/endo-113-6-1950; HUFF CA, 1993, J BIOL CHEM, V268, P377; HUITFELDT HS, 1991, CARCINOGENESIS, V12, P2063, DOI 10.1093/carcin/12.11.2063; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KIM YK, 1989, GENE, V77, P123, DOI 10.1016/0378-1119(89)90366-1; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENORMAND P, 1992, MOL CELL BIOL, V12, P2793, DOI 10.1128/MCB.12.6.2793; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MALMQVIST KG, 1984, NUCL INSTRUM METH B, V3, P611, DOI 10.1016/0168-583X(84)90447-6; MATSUMOTO K, 1990, BIOCHEM BIOPH RES CO, V166, P916, DOI 10.1016/0006-291X(90)90898-W; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; OFFORD EA, 1990, J VIROL, V64, P4792, DOI 10.1128/JVI.64.10.4792-4798.1990; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; PASTORCIC M, 1986, MOL CELL BIOL, V6, P2784, DOI 10.1128/MCB.6.8.2784; PRIBNOW D, 1992, MOL ENDOCRINOL, V6, P1003, DOI 10.1210/me.6.7.1003; REGNIER M, 1991, DIFFERENTIATION, V47, P173, DOI 10.1111/j.1432-0436.1991.tb00235.x; REGNIER M, 1986, J INVEST DERMATOL, V87, P472, DOI 10.1111/1523-1747.ep12455517; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROOP DR, 1983, P NATL ACAD SCI-BIOL, V80, P716, DOI 10.1073/pnas.80.3.716; ROOP DR, 1988, BIOL WOOL HAIR, P311; ROOP DR, 1989, PHARM RETINOIDS SKIN, P1; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROSENTHAL DS, 1991, CELL GROWTH DIFFER, V2, P107; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; ROTHNAGEL JA, 1987, J BIOL CHEM, V262, P15643; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHWEIZER J, 1984, CELL, V37, P159, DOI 10.1016/0092-8674(84)90311-8; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; STUMPF WE, 1984, CELL TISSUE RES, V238, P489; TAMAI Y, 1991, GENE, V104, P169, DOI 10.1016/0378-1119(91)90247-9; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VAHLQUIST A, 1987, UPSALA J MED SCI, V92, P253, DOI 10.3109/03009738709178695; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WOODCOCKMITCHELL J, 1982, J CELL BIOL, V95, P580, DOI 10.1083/jcb.95.2.580; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	69	90	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 11	1994	269	10					7443	7449						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NA032	7510286				2022-12-27	WOS:A1994NA03200066
J	LAUDANNA, C; CONSTANTIN, G; BARON, P; SCARPINI, E; SCARLATO, G; CABRINI, G; DECHECCHI, C; ROSSI, F; CASSATELLA, MA; BERTON, G				LAUDANNA, C; CONSTANTIN, G; BARON, P; SCARPINI, E; SCARLATO, G; CABRINI, G; DECHECCHI, C; ROSSI, F; CASSATELLA, MA; BERTON, G			SULFATIDES TRIGGER INCREASE OF CYTOSOLIC-FREE CALCIUM AND ENHANCED EXPRESSION OF TUMOR-NECROSIS-FACTOR-ALPHA AND INTERLEUKIN-8 MESSENGER-RNA IN HUMAN NEUTROPHILS - EVIDENCE FOR A ROLE OF L-SELECTIN AS A SIGNALING MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; FUNCTION-ASSOCIATED ANTIGEN-1; ENDOTHELIAL CELL RECOGNITION; LYMPHOCYTE HOMING RECEPTOR; CENTRAL-NERVOUS-SYSTEM; ADHESION MOLECULE-1; T-CELLS; RESPIRATORY BURST; GENE-EXPRESSION; ACTIVATION	Sulfatides have been established recently as ligands for L-selectin, and we investigated whether they trigger transmembrane signals through ligation of L-selectin. We found that sulfatides trigger the increase of cytosolic free calcium in neutrophils and that this effect was strictly dependent on sulfation of the galactose ring, as non-sulfated galactocerebrosides were not stimulatory. Chymotrypsin and phorbol 12-myristate 13-acetate treatment of neutrophils caused shedding of L-selectin, but not of class I major histocompatibility complex antigens or beta 2 integrins, and blunted the capability of neutrophils to respond to sulfatides with an increase of cytosolic free calcium. Four different anti-L-selectin antibodies (DREG-200, LAM1/3, LAM1/6, and LAM1/10), but not four control antibodies directed against different surface molecules of neutrophils, also triggered an increase of cytosolic free calcium. The anti-L-selectin antibodies were stimulatory both if used in a soluble form, after cross linking with anti-mouse F(ab')(2) fragments, and immobilized to protein A of Staphylococcus aureus through the Fc fragment. With immobilized antibodies, an increase of cytosolic free calcium was found also by plating neutrophils on antibodies bound to protein A-coated coverslips and monitoring the increase of cytosolic free calcium by fluorescence microscopy. Both sulfatides and anti-L-selectin antibody effects were not inhibited by pertussis toxin, thus indicating that a pertussis toxin-sensitive GTP-binding protein was not involved in signal transduction. Sulfatides also triggered an increase of tumor necrosis factor-alpha and interleukin-8 mRNAs in neutrophils. Also to act as stimuli of cytokine mRNA expression, sulfatides required sulfation of the galactose ring, as non-sulfated galactocerebrosides were not stimulatory, and depended on expression of L-selectin, as shedding of this molecules induced by chymotrypsin blunted their effects. These findings suggest that L-selectin can transduce signals activating selective cell function.	UNIV VERONA,INST GEN PATHOL,I-37134 VERONA,ITALY; UNIV MILAN,DINO FERRARI CTR,DEPT NEUROL,MILAN,ITALY; CYST FIBROSIS CTR,VERONA,ITALY	University of Verona; University of Milan			Cabrini, Giulio/K-4761-2016; Cassatella, M A/B-8037-2013; Scarpini, Elio/K-6547-2016	Cabrini, Giulio/0000-0003-2720-0742; Cassatella, M A/0000-0001-7824-1806; Constantin, Gabriela/0000-0001-8978-3539; Scarpini, Elio/0000-0002-6395-2119				BAZZONI F, 1991, J LEUKOCYTE BIOL, V50, P223, DOI 10.1002/jlb.50.3.223; BAZZONI F, 1991, J EXP MED, V173, P771, DOI 10.1084/jem.173.3.771; BERTON G, 1992, J CELL BIOL, V116, P1007, DOI 10.1083/jcb.116.4.1007; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CASSATELLA MA, 1992, J IMMUNOL, V148, P3216; CASSATELLA MA, 1989, J CLIN INVEST, V83, P1570, DOI 10.1172/JCI114054; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DAVIS LS, 1990, J IMMUNOL, V145, P785; DECHECCHI MC, 1993, J BIOL CHEM, V268, P11321; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALMANNN R, 1991, BIOCHEM BIOPH RES CO, V174, P236; HUANG K, 1991, J CLIN INVEST, V88, P1778, DOI 10.1172/JCI115498; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; IMAI Y, 1993, NATURE, V361, P555; JUNG TM, 1990, J IMMUNOL, V144, P3130; JUTILA MA, 1991, CELL IMMUNOL, V132, P201, DOI 10.1016/0008-8749(91)90019-8; KAKINUMA K, 1982, FEBS LETT, V145, P16, DOI 10.1016/0014-5793(82)81197-6; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; KUHLMAN P, 1991, J IMMUNOL, V146, P1773; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAUDANNA C, 1993, IMMUNOLOGY, V80, P273; LEDBETTER JA, 1985, J IMMUNOL, V135, P1819; LEMONNIER FA, 1982, J IMMUNOL METHODS, V54, P9, DOI 10.1016/0022-1759(82)90108-9; LEW DP, 1993, CURR OPIN HEMATOL, V1, P106; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LLOYD AR, 1992, IMMUNOL TODAY, V13, P169, DOI 10.1016/0167-5699(92)90121-M; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; MOY VT, 1992, J EXP MED, V175, P1, DOI 10.1084/jem.175.1.1; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; SPERTINI O, 1991, J IMMUNOL, V147, P942; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SUZUKI Y, 1993, BIOCHEM BIOPH RES CO, V190, P426, DOI 10.1006/bbrc.1993.1065; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WACHOLTZ MC, 1989, J EXP MED, V170, P431, DOI 10.1084/jem.170.2.431; WILLENBORG DO, 1988, J IMMUNOL, V140, P3401; WILLENBORG DO, 1989, FASEB J, V3, P1968, DOI 10.1096/fasebj.3.8.2721857; YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034	46	182	185	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4021	4026						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508438				2022-12-27	WOS:A1994MW98900021
J	LEEDS, FS; BRASS, EP				LEEDS, FS; BRASS, EP			HEPATIC COBALAMIN DEFICIENCY INDUCED BY HYDROXYCOBALAMIN[C-LACTAM] TREATMENT IN RATS IS ASSOCIATED WITH DECREASED MITOCHONDRIAL MESSENGER-RNA CONTENTS AND ACCUMULATION OF POLYCISTRONIC MITOCHONDRIAL RNAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; MAMMALIAN MITOCHONDRIA; METHYLMALONIC ACIDURIA; LIVER-MITOCHONDRIA; SKELETAL-MUSCLE; THYROID-HORMONE; TRANSCRIPTION; VITAMIN-B12; METHYLATION; DNA	Treatment of rats with hydroxycobalamin[c-lactam] (HCCL), a cobalamin antagonist, results in both increased hepatic mitochondrial content and the development of defects in mitochondrial ubiquinol:cytochrome c oxidoreductase and cytochrome c oxidase. The present study was designed to evaluate changes in hepatic mitochondrial RNA contents in response to HCCL treatment in rats. After 2 weeks of HCCL treatment, hepatic contents of the mature mitochondrial mRNAs (expressed normalized to 28 S rRNA) encoding subunit II of cytochrome c oxidase (CO II), subunit 1 of NADH dehydrogenase (ND1), and cytochrome b were reduced to values 40-60% of those observed in RNA from control liver tissue. In addition, HCCL induced a pronounced accumulation of high molecular weight RNA species which hybridized to mitochondrial probes and represented polycistronic RNA sequences. The polycistronic RNAs were products of the heavy strand of the mitochondrial genome, and major species demonstrated hybridization patterns consistent with identifications corresponding to the 12-16 S rRNA, 12-16 S-ND1, 16 S ND1, and CO II-ATP synthase subunit 6 regions of the mitochondrial genome. Maximal expression of the polycistronic mitochondrial RNA was observed after 2 weeks of HCCL treatment. Thus, HCCL treatment interferes with mitochondrial RNA processing and decreases the content of mature mitochondrial mRNAs. Altered expression of the mitochondrial genome may be responsible for the decreased electron transport chain activity known to result from HCCL administration.	CASE WESTERN RESERVE UNIV, DEPT MED, DIV CLIN PHARMACOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT PHARMACOL, DIV CLIN PHARMACOL, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University				Leeds, Frederic/0000-0002-8712-0915	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK036069, R01DK036069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36069] Funding Source: Medline; NIGMS NIH HHS [2 T32 GM07250] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; AW TY, 1989, ANNU REV NUTR, V9, P229, DOI 10.1146/annurev.nu.09.070189.001305; BONNETT R, 1957, J CHEM SOC, P1158, DOI 10.1039/jr9570001158; BRASS EP, 1990, BIOCHEM J, V266, P809; BRASS EP, 1992, BIOCHEM J, V288, P175, DOI 10.1042/bj2880175; CANATORE P, 1987, FEBS LETT, V213, P144; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; CHRISTMAN JK, 1993, CARCINOGENESIS, V14, P551, DOI 10.1093/carcin/14.4.551; CHUMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; COLEMAN WB, 1991, BIOCHIM BIOPHYS ACTA, V1058, P178, DOI 10.1016/S0005-2728(05)80235-X; DOI T, 1989, J NUTR SCI VITAMINOL, V35, P1, DOI 10.3177/jnsv.35.1; Dolphin D., 1971, METHOD ENZYMOL, V18, P34; DUBIN DT, 1978, J MOL BIOL, V121, P523, DOI 10.1016/0022-2836(78)90398-4; DUBIN DT, 1978, NUCLEIC ACIDS RES, V5, P4385, DOI 10.1093/nar/5.11.4385; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GAINES G, 1987, J BIOL CHEM, V262, P1907; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GROSSMAN LI, 1990, AM J HUM GENET, V46, P415; HARE JF, 1982, J BIOL CHEM, V257, P3575; HEDDI A, 1993, J BIOL CHEM, V268, P12156; HERRERA E, 1968, BIOCHIM BIOPHYS ACTA, V170, P244, DOI 10.1016/0304-4165(68)90004-4; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; KADOWAKI T, 1988, FEBS LETT, V233, P51, DOI 10.1016/0014-5793(88)81354-1; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KLIASHEVA RI, 1983, BIOL NAUKI, V10, P17; KRAHENBUHL S, 1990, J CLIN INVEST, V86, P2054, DOI 10.1172/JCI114942; KRAHENBUHL S, 1991, J BIOL CHEM, V266, P20998; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; METZ J, 1992, ANNU REV NUTR, V12, P59, DOI 10.1146/annurev.nu.12.070192.000423; MUTVEI A, 1989, EUR J BIOCHEM, V180, P235, DOI 10.1111/j.1432-1033.1989.tb14638.x; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; NARAYAN P, 1992, ADV ENZYMOL RAMB, V65, P255; NELSON BD, 1987, CURR TOP BIOENERG, V15, P221; PRINCE DL, 1986, MOL BIOL REP, V11, P51, DOI 10.1007/BF00417596; STABLER SP, 1991, J CLIN INVEST, V87, P1422, DOI 10.1172/JCI115148; TANDLER B, 1991, ANAT RECORD, V231, P1, DOI 10.1002/ar.1092310102; ULLU E, 1991, P NATL ACAD SCI USA, V88, P10074, DOI 10.1073/pnas.88.22.10074; VANITALLIE CM, 1988, MOL ENDOCRINOL, V2, P332, DOI 10.1210/mend-2-4-332; VANITALLIE CM, 1990, ENDOCRINOLOGY, V127, P55, DOI 10.1210/endo-127-1-55; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; WILSON SD, 1986, ARCH BIOCHEM BIOPHYS, V244, P248, DOI 10.1016/0003-9861(86)90114-1	45	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					3947	3951						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508436				2022-12-27	WOS:A1994MW98900010
J	WILCOX, DA; WAUTIER, JL; PIDARD, D; NEWMAN, PJ				WILCOX, DA; WAUTIER, JL; PIDARD, D; NEWMAN, PJ			A SINGLE AMINO-ACID SUBSTITUTION FLANKING THE 4TH CALCIUM-BINDING DOMAIN OF ALPHA(IIB) PREVENTS MATURATION OF THE ALPHA(IIB)BETA(3) INTEGRIN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; PLATELET GPIIB-IIIA; LEUKOCYTE ADHESION DEFICIENCY; GLANZMANNS THROMBASTHENIA; MONOCLONAL-ANTIBODY; FIBRINOGEN-BINDING; CROSSED-IMMUNOELECTROPHORESIS; HUMAN MEGAKARYOCYTES; CATION REGULATION; PLASMA-MEMBRANES	To define specific structural domains involved in the biosynthesis and processing of integrin subunits, we examined the biosynthesis of normal and mutated forms of the platelet-specific integrin alpha(IIb)beta(3). Platelet mRNA was isolated from a Glanzmann thrombasthenic patient who failed to express significant levels of the glycoprotein (GP) IIb-IIIa complex on the platelet surface, Sequence analysis of polymerase chain reaction amplified platelet GPIIb, mRNA revealed a Gly(418) --> Asp amino acid substitution in GPIIb. Gly(418) is a highly conserved residue that flanks the fourth calcium binding domain of GPIIb. Co-transfection of Asp(418) GPIIb) and GPIIIa plasmid constructs into COS-7 cells resulted in the accumulation of a pre-GPIIb-IIIa complex that failed to reach the cell surface, in effect recreating the thrombasthenic phenotype. Pulse chase and endoglycosidase studies demonstrated that the biosynthetic blockade occurred in a pre-Golgi compartment. Removal of the negatively charged carboxyl group of Asp(418) GPIIb, creating Ala(418) GPIIb, rescued intracellular transport and surface expression of the integrin complex. Mutagenesis of a homologous Gly within the integrin alpha subunit alpha(v), also resulted in the failure to express alpha(v) beta(3) on the cell surface. These results suggest that the presence of a small, uncharged amino acid 6-8 residues amino-terminal to the calcium coordination complex is crucial for the proper folding and maturation of integrin complexes.	BLOOD CTR SE WISCONSIN INC,BLOOD RES INST,MILWAUKEE,WI 53233; MED COLL WISCONSIN,DEPT CELLULAR BIOL,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT PHARMACOL,MILWAUKEE,WI 53226; HOP LARIBOISIERE,BIOL VASC & CELLULAIRE LAB,F-75010 PARIS,FRANCE; HOP ST LOUIS,INSERM,U353,F-75475 PARIS,FRANCE	Versiti Blood Center of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Wautier, Jean-Luc/T-9851-2019	WAUTIER, Jean-Luc/0000-0001-6826-2312; Pidard, Dominique/0000-0002-5732-3279	NHLBI NIH HHS [HL-44612] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044612] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNOUT MA, 1990, J CLIN INVEST, V85, P977; BAJT ML, 1992, J BIOL CHEM, V267, P22211; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BENNETT JS, 1982, J BIOL CHEM, V257, P8049; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BODARY SC, 1989, J BIOL CHEM, V264, P18859; BOGAERT T, 1987, CELL, V51, P929, DOI 10.1016/0092-8674(87)90580-0; BRAY PF, 1986, P NATL ACAD SCI USA, V83, P1480, DOI 10.1073/pnas.83.5.1480; BRAY PF, 1990, BLOOD, V75, P881; BURK CD, 1991, J CLIN INVEST, V87, P270, DOI 10.1172/JCI114982; CAEN J, 1972, CLIN HAEMATOL, V1, P383; CAEN JP, 1983, BLOOD, V62, P951; DUPERRAY A, 1987, J CELL BIOL, V104, P1665, DOI 10.1083/jcb.104.6.1665; DUPERRAY A, 1989, BLOOD, V74, P1603; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; FOURNIER DJ, 1989, THROMB HAEMOSTASIS, V62, P977; FUJIMURA K, 1983, J BIOL CHEM, V258, P247; GEORGE JN, 1990, BLOOD, V75, P1383; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; GOLDBERGER A, 1991, BLOOD, V78, P681; GULINO D, 1992, J BIOL CHEM, V267, P1001; HAGEN I, 1980, J CLIN INVEST, V65, P722, DOI 10.1172/JCI109719; HOLAHAN JR, 1981, BLOOD, V57, P174; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KATO A, 1992, BLOOD, V79, P3212; KIEFFER N, 1987, EUR J BIOCHEM, V164, P189, DOI 10.1111/j.1432-1033.1987.tb11010.x; KISHIMOTO TK, 1987, CELL, V50, P193, DOI 10.1016/0092-8674(87)90215-7; KOLODZIEJ MA, 1991, BLOOD, V78, P2344; KUNICKI TJ, 1981, BLOOD, V58, P1190; KUNICKI TJ, 1981, BLOOD, V58, P268; KUNICKI TJ, 1978, J CLIN INVEST, V61, P1225, DOI 10.1172/JCI109038; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LYMAN S, 1990, BLOOD, V75, P2343; MCEVER RP, 1982, BLOOD, V59, P80; MCEVER RP, 1983, J BIOL CHEM, V258, P5269; NEWMAN PJ, 1991, THROMB HAEMOSTASIS, V66, P111; NEWMAN PJ, 1991, P NATL ACAD SCI USA, V88, P3160, DOI 10.1073/pnas.88.8.3160; NEWMAN PJ, 1985, MOL IMMUNOL, V22, P719, DOI 10.1016/0161-5890(85)90103-8; NEWMAN PJ, 1985, BLOOD, V65, P227; NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656; NURDEN AT, 1987, J CLIN INVEST, V79, P962, DOI 10.1172/JCI112907; NURDEN AT, 1975, NATURE, V255, P720, DOI 10.1038/255720a0; NURDEN AT, 1974, BRIT J HAEMATOL, V28, P253, DOI 10.1111/j.1365-2141.1974.tb06660.x; OTOOLE TE, 1989, BLOOD, V74, P14; PHILLIPS DR, 1977, J CLIN INVEST, V60, P535, DOI 10.1172/JCI108805; PIDARD D, 1983, J BIOL CHEM, V258, P2582; RIFAT S, 1992, CLIN RES, V40, P210; ROSA JP, 1989, J BIOL CHEM, V264, P12596; SILVER SM, 1987, BLOOD, V69, P1031; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TSUJI T, 1986, J BIOCHEM-TOKYO, V100, P1387, DOI 10.1093/oxfordjournals.jbchem.a121845; WARDLAW AJ, 1990, J EXP MED, V172, P335, DOI 10.1084/jem.172.1.335; WILCOX DA, 1992, CIRCULATION, V86, P682	55	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 11	1994	269	6					4450	4457						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MW989	7508443				2022-12-27	WOS:A1994MW98900085
J	PENG, YL; SHIRANO, Y; OHTA, H; HIBINO, T; TANAKA, K; SHIBATA, D				PENG, YL; SHIRANO, Y; OHTA, H; HIBINO, T; TANAKA, K; SHIBATA, D			A NOVEL LIPOXYGENASE FROM RICE - PRIMARY STRUCTURE AND SPECIFIC EXPRESSION UPON INCOMPATIBLE INFECTION WITH RICE BLAST FUNGUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SATIVUM SEED LIPOXYGENASE; ESCHERICHIA-COLI; JASMONIC ACID; ACTIVE ENZYME; CDNA CLONING; LEAVES; SEQUENCE; GENE; MECHANISM; 5-LIPOXYGENASE	A novel lipoxygenase cDNA (3,007 base pairs) was isolated from rice leaves (Oryza sativa cv. Aichiasahi) which had been infected with an incompatible race of the rice blast fungus, Magnaporthe grisea. A single copy of the gene is present in the rice genome and encodes a protein of 923 residues with a molecular weight of 102,714. This gene product shares the least amino acid sequence homology among plant lipoxygenases identified to date. A novel feature of this gene product is a putative transit peptide sequence at the amino terminus, suggesting the enzyme is localized in chloroplasts. An active lipoxygenase was expressed from the cDNA in Escherichia coli and characterized. The lipoxygenase introduces molecular oxygen exclusively into the C-13 position of linoleic and linolenic acids. The gene is expressed at high levels 15 h after inoculation with an incompatible race of M. grisea, at a low level after inoculation with a compatible race of the pathogen, and is not expressed in mock-infected leaves. Gene expression begins at the same time that the pathogen begins to penetrate into leaf tissue. This novel lipoxygenase gene expression is a part of the early response of the host to pathogenic attack.	MITSUI PLANT BIOTECHNOL RES INST,TCI-A10,SENGEN 2-1-6,TSUKUBA,IBARAKI 305,JAPAN; KYOTO PREFECTURAL UNIV,DEPT AGR BIOCHEM,KYOTO 606,JAPAN	Kyoto Prefectural University			Ohta, Hiroyuki/B-1840-2014	Ohta, Hiroyuki/0000-0002-1068-3242				Axelrod B., 1981, METH ENZYMOL, V441, P451, DOI [10.1016/0076-6879(81)71055-3, DOI 10.1016/0076-6879(81)71055-3]; BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; CROFT KPC, 1990, PHYSIOL MOL PLANT P, V36, P49, DOI 10.1016/0885-5765(90)90091-B; EALING PM, 1989, BIOCHEM J, V264, P929, DOI 10.1042/bj2640929; EALING PM, 1988, BIOCHEM J, V253, P915, DOI 10.1042/bj2530915; FARMER EE, 1992, PLANT CELL, V4, P129, DOI 10.1105/tpc.4.2.129; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JOFUKU KD, 1988, PLANT MOL BIOL PRACT, P37; KATO T, 1992, PLANT PHYSIOL, V98, P324, DOI 10.1104/pp.98.1.324; KATO T, 1983, NATURWISSENSCHAFTEN, V70, P200, DOI 10.1007/BF01047565; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KOCH E, 1992, PLANT PHYSIOL, V99, P571, DOI 10.1104/pp.99.2.571; KODA Y, 1991, PHYTOCHEMISTRY, V30, P1435, DOI 10.1016/0031-9422(91)84180-Z; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LI WX, 1991, AGR BIOL CHEM TOKYO, V55, P1041, DOI 10.1080/00021369.1991.10870743; LOSEL DM, 1978, NEW PHYTOL, V80, P167, DOI 10.1111/j.1469-8137.1978.tb02277.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marston F. A. O., 1987, DNA CLONING, P59; MELAN MA, 1993, PLANT PHYSIOL, V101, P441, DOI 10.1104/pp.101.2.441; MINOR W, 1993, BIOCHEMISTRY-US, V32, P6320, DOI 10.1021/bi00076a003; OHTA H, 1991, PLANT PHYSIOL, V97, P94, DOI 10.1104/pp.97.1.94; OHTA H, 1992, EUR J BIOCHEM, V206, P331, DOI 10.1111/j.1432-1033.1992.tb16931.x; OHTA H, 1990, PLANT CELL PHYSIOL, V31, P1117; PEEVER TL, 1989, PLANT PHYSIOL, V90, P867, DOI 10.1104/pp.90.3.867; PENG YL, 1988, CAN J BOT, V66, P730, DOI 10.1139/b88-107; PENG YL, 1989, THESIS KYOTO U JAPAN; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBATA D, 1991, PLANT MOL BIOL, V16, P353, DOI 10.1007/BF00020569; SHIBATA D, 1987, J BIOL CHEM, V262, P10080; SHIBATA D, 1988, J BIOL CHEM, V263, P6816; SHIMURA M, 1983, AGR BIOL CHEM TOKYO, V47, P1983, DOI 10.1080/00021369.1983.10865897; SHIRANO Y, 1990, FEBS LETT, V271, P128, DOI 10.1016/0014-5793(90)80388-Y; SIEDOW JN, 1991, ANNU REV PLANT PHYS, V42, P145, DOI 10.1146/annurev.pp.42.060191.001045; YAMAMOTO H, 1986, J PHYTOPATHOL, V116, P329, DOI 10.1111/j.1439-0434.1986.tb00928.x; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; YENOFSKY RL, 1988, MOL GEN GENET, V211, P215, DOI 10.1007/BF00330597; 1994, IN PRESS PLANT MOL B, V12	41	145	170	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3755	3761						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508918				2022-12-27	WOS:A1994MV63100091
J	PLATANIAS, LC; SWEET, ME				PLATANIAS, LC; SWEET, ME			INTERFERON-ALPHA INDUCES RAPID TYROSINE PHOSPHORYLATION OF THE VAV PROTOONCOGENE PRODUCT IN HEMATOPOIETIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSCRIPTION FACTOR; PROTOONCOGENE PRODUCT; SH3 DOMAINS; GENE; DIFFERENTIATION; INDUCTION; RECEPTOR; PROTEINS; KINASE; ACID	The vav proto-oncogene product (p95vav) is specifically expressed in cells of the hematopoietic system, contains one Src homology 2 and two Src homology 3 domains, and is a substrate for receptor and non-receptor tyrosine kinases. Immunoblotting experiments using an anti-phosphotyrosine monoclonal antibody showed that interferon alpha (IFNalpha) induces rapid tyrosine phosphorylation of p95vav after binding to its cell surface receptor in the U-266 human myeloma cell line. The IFNalpha-induced tyrosine phosphorylation of p950vav was time- and dose-dependent, confirming the specificity of the process. IFNalpha-dependent tyrosine phosphorylation of p95vav was also observed in other hematopoietic cell lines of B-cell origin (Daudi), T-cell origin (MOLT-4), and promyelocytic origin (HL-60). Immunoprecipitation experiments performed with P-32-labeled U-266 cells and phosphoaminoacid analysis of the bands corresponding to p95vav showed that p95vav is phosphorylated on serine residues prior to IFNalpha stimulation of the cells. After IFNa stimulation significant amounts of phosphorylation of p95vav on tyrosine residues were detectable. Tyrosine phosphorylation of p95vav in U-266 and HL-60 cells was also induced by two other Type I IFNs, IFNbeta and EFNomega. Altogether these data suggest that the vav proto-oncogene product is a substrate for a Type I IFN-regulated tyrosine kinase(s) and may be involved in the signal transduction pathway of Type I IFNs in hematopoietic cells.	EDWARD HINES VET ADM MED CTR,MAYWOOD,IL	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital	PLATANIAS, LC (corresponding author), LOYOLA UNIV,DIV HEMATOL ONCOL,BLDG 54,RM 49,2160 S 1ST AVE,MAYWOOD,IL 60153, USA.							ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; COLAMONICI OR, 1992, BLOOD, V80, P744; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLAMONICI OR, 1994, IN PRESS J BIOL CHEM, V269; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GALLAND F, 1992, ONCOGENE, V7, P585; GULBINS E, 1993, SCIENCE, V260, P82; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HEMMI H, 1987, BLOOD, V69, P501; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARAN A, 1990, MOL CELL BIOL, V10, P4424, DOI 10.1128/MCB.10.8.4424; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1992, BLOOD S1, V80, pA247; PETSKA S, 1987, ANNU REV BIOCHEM, V56, P727; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; TOMIDA M, 1982, BIOCHEM BIOPH RES CO, V104, P30, DOI 10.1016/0006-291X(82)91936-2; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L	24	92	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 4	1994	269	5					3143	3146						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV631	7508909				2022-12-27	WOS:A1994MV63100006
J	IRMINGER, JC; VOLLENWEIDER, FM; NEERMANARBEZ, M; HALBAN, PA				IRMINGER, JC; VOLLENWEIDER, FM; NEERMANARBEZ, M; HALBAN, PA			HUMAN PROINSULIN CONVERSION IN THE REGULATED AND THE CONSTITUTIVE PATHWAYS OF TRANSFECTED ATT20 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RELATED PEPTIDES; PANCREATIC BETA-CELL; SECRETORY PATHWAY; SEQUENCE REQUIREMENTS; PRECURSOR CLEAVAGE; PROCESSING PROTEINASES; SUBTILISIN FAMILY; PLASMA-MEMBRANE; GOLGI-COMPLEX; ATT-20 CELLS	AtT20 (mouse pituitary corticotroph) cells were stably transfected with human proinsulin cDNA. Clone H12 displayed low basal release of insulin-like immunoreactivity (< 1% cell content/30 min) with 17-fold stimulation by isobutylmethylxanthine/forskolin. Clone H23, by contrast, showed higher basal release (2.8% cell content/30 min) and only 6-fold stimulation. To follow the kinetics of conversion and release of only newly synthesized proinsulin, cells were pulse-chased, and labeled proinsulin-related products were analyzed by high pressure liquid chromatography. In the cells of both clones, [H-3]proinsulin was converted to insulin with des-31,32-split proinsulin as the only detectable intermediate. While basal release of labeled products from H12 cells was low (3%/60 min), it was rapid and elevated from H23 cells (12.5% by 30 min and 24.8% by 60 min of chase) with [H-3]des-31,32-split proinsulin the predominant molecular form. Stimulation of [H-3] insulin release increased with time, reaching 3.8-fold by 90 min of chase, whereas that of [H-3]des-31,32-split proinsulin was approximately 1.5-fold regardless of the chase time. Rapid secretion of newly synthesized products that is insensitive to secretagogues is the hallmark of the constitutive pathway. Thus in H23 cells an unusually large amount of proinsulin is diverted to the constitutive pathway, where it is partially converted to des-31,32-split proinsulin before release.			IRMINGER, JC (corresponding author), UNIV GENEVA,MED CTR,LABS RECH LOUIS JEANTET,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND.			Neerman-Arbez, Marguerite/0000-0002-9351-4195	NIDDK NIH HHS [DK-35292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arvan Peter, 1992, Trends in Cell Biology, V2, P327; BAILYES EM, 1992, BIOCHEM J, V286, P223, DOI 10.1042/bj2860223; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRENNAN SO, 1991, J BIOL CHEM, V266, P21504; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; COHEN RM, 1986, METABOLISM, V35, P1137, DOI 10.1016/0026-0495(86)90027-2; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; FERBER S, 1991, MOL ENDOCRINOL, V5, P319, DOI 10.1210/mend-5-3-319; GIVEN BD, 1985, J CLIN INVEST, V76, P1398, DOI 10.1172/JCI112116; GOLD G, 1984, DIABETES, V33, P556, DOI 10.2337/diabetes.33.6.556; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GROSS D, 1988, FEBS LETT, V241, P205, DOI 10.1016/0014-5793(88)81062-7; GROSS DJ, 1989, J BIOL CHEM, V264, P21486; GROSS DJ, 1989, P NATL ACAD SCI USA, V86, P4107, DOI 10.1073/pnas.86.11.4107; GUMBINER B, 1982, CELL, V28, P51, DOI 10.1016/0092-8674(82)90374-9; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; HALBAN PA, 1991, DIABETOLOGIA, V34, P767, DOI 10.1007/BF00408349; HALBAN PA, 1980, J BIOL CHEM, V255, P6003; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Huttner WB, 1989, CURR OPIN CELL BIOL, V1, P648, DOI 10.1016/0955-0674(89)90029-X; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; KARRENBAUER A, 1990, CELL, V63, P259, DOI 10.1016/0092-8674(90)90159-C; KAWABATA S, 1992, J BIOL CHEM, V267, P10331; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDGERWOOD EC, 1992, BIOCHIM BIOPHYS ACTA, V1159, P9, DOI 10.1016/0167-4838(92)90068-O; LINDBERG I, 1991, MOL ENDOCRINOL, V5, P1361, DOI 10.1210/mend-5-10-1361; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MOORE HP, 1983, NATURE, V302, P434, DOI 10.1038/302434a0; MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; NAGAMATSU S, 1992, ENDOCRINOLOGY, V130, P748, DOI 10.1210/en.130.2.748; ORCI L, 1985, DIABETOLOGIA, V28, P528, DOI 10.1007/BF00281987; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; POWELL SK, 1988, J CELL BIOL, V106, P1843, DOI 10.1083/jcb.106.6.1843; REHEMTULLA A, 1992, BLOOD, V79, P2349; RHODES CJ, 1987, J CELL BIOL, V105, P145, DOI 10.1083/jcb.105.1.145; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SIZONENKO S, 1993, DIABETES, V42, P933, DOI 10.2337/diabetes.42.6.933; SIZONENKO SV, 1991, BIOCHEM J, V278, P621, DOI 10.1042/bj2780621; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; TAYLOR NA, 1992, BIOCHEM J, V286, P619, DOI 10.1042/bj2860619; Tooze S A, 1992, Semin Cell Biol, V3, P357, DOI 10.1016/1043-4682(92)90021-M; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VOLLENWEIDER F, 1992, J BIOL CHEM, V267, P14629; WATANABE T, 1992, J BIOL CHEM, V267, P8270	61	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1756	1762						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507483				2022-12-27	WOS:A1994MR98800035
J	PRESTON, GM; JUNG, JS; GUGGINO, WB; AGRE, P				PRESTON, GM; JUNG, JS; GUGGINO, WB; AGRE, P			MEMBRANE TOPOLOGY OF AQUAPORIN CHIP - ANALYSIS OF FUNCTIONAL EPITOPE-SCANNING MUTANTS BY VECTORIAL PROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR INTRINSIC PROTEIN; WATER CHANNELS; XENOPUS-OOCYTES; CDNA; IDENTIFICATION; RECONSTITUTION; PURIFICATION; EXPRESSION; TRANSPORT; DOMAIN	CHIP is the archetypal member of the aquaporins, a widely expressed family of membrane water channels. The NH2- and COOH-terminal halves of CHIP are sequence-related, and hydropathy analysis predicted six membrane-spanning domains with five connecting loops (A-E). Here, we determined the membrane topology of CHIP expressed in Xenopus oocytes using biologically active recombinant channels. CHIP is glycosylated at Asn-42, indicating loop A is exofacial. An epitope from the coronavirus E1 glycoprotein was inserted into CHIP and localized to the outer or inner leaflet of the membrane by alpha-chymotrypsin digestion of intact oocytes or inside-out membrane vesicles. The E1 epitope at Thr-120 was protease-sensitive in intact oocytes, indicating that loop C is exofacial. The E1 epitope at Lys-6, Arg-162, or Lys-267 was protease-sensitive in inside-out membrane vesicles, confirming the cytoplasmic location of the NH2 and COOH termini and loop D. Insertions into loops B and E did not produce active water channels, but their cleavage patterns were consistent with inner (loop B) and outer (loop E) leaflet locations. This study indicates that the functional CHIP molecule is a unique structure with two internal repeats oriented 180-degrees to each other within the membrane.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	PRESTON, GM (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, 725 N WOLFE ST, BALTIMORE, MD 21205 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033991, R37HL048268, R01HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032753, R37DK032753] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33991, HL48268] Funding Source: Medline; NIDDK NIH HHS [DK32753] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AERTS T, 1990, J BIOL CHEM, V265, P8675; AGRE P, 1993, AM J PHYSIOL, V265, pF463; AGRE P, 1993, AM J PHYSIOL, V265, pF461, DOI 10.1152/ajprenal.1993.265.3.F461; BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500; DAVIS JQ, 1984, J BIOL CHEM, V259, P1874; DEEN PMT, 1992, BIOCHEM BIOPH RES CO, V188, P1267, DOI 10.1016/0006-291X(92)91368-Z; DENKER BM, 1988, J BIOL CHEM, V263, P15634; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; HORWITZ J, 1987, BIOCHEMISTRY-US, V26, P8092, DOI 10.1021/bi00399a012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LU L, 1990, BIOPHYS J, V57, P1117, DOI 10.1016/S0006-3495(90)82632-1; MACEY RI, 1984, AM J PHYSIOL, V246, pC195, DOI 10.1152/ajpcell.1984.246.3.C195; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; MOON C, 1993, J BIOL CHEM, V268, P15772; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; NISHIMURA H, 1993, J BIOL CHEM, V268, P8514; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PLUTA AF, 1992, J CELL BIOL, V116, P1081, DOI 10.1083/jcb.116.5.1081; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; SMITH BL, 1991, J BIOL CHEM, V266, P6407; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VANHOEK AN, 1991, J BIOL CHEM, V266, P16633; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG R, 1990, J BIOL CHEM, V265, P15375; ZHANG RB, 1993, BIOCHEMISTRY-US, V32, P2938, DOI 10.1021/bi00063a002; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359	35	149	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1668	1673						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	7507481				2022-12-27	WOS:A1994MR98800022
J	GOELZ, S; KUMAR, R; POTVIN, B; SUNDARAM, S; BRICKELMAIER, M; STANLEY, P				GOELZ, S; KUMAR, R; POTVIN, B; SUNDARAM, S; BRICKELMAIER, M; STANLEY, P			DIFFERENTIAL EXPRESSION OF AN E-SELECTIN LIGAND [SLE(X)] BY 2 CHINESE-HAMSTER OVARY CELL-LINES TRANSFECTED WITH THE SAME ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE (ELFT)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; N-LINKED OLIGOSACCHARIDES; SIALYL-LEX DETERMINANT; MOLECULE E-SELECTIN; LEWIS-X; EMBRYONIC ANTIGEN; ENDOTHELIAL-CELLS; MYELOID CELLS; TYPE-2 CHAIN; P-SELECTIN	The mammalian cDNA encoding alpha(1,3)-fucosyltransferase (alpha(1,3)Fuc-T) termed ELAM-1 ligand fucosyltransferase (ELFT) or Fuc-TIV was previously cloned by three groups who reported different results from transfection studies Goelz et al. (Goelz, S. E., Hession, C., Goff, D., Griffiths, B., Tizard, R., Newman, B., Chi-Rosso, G., and Lobb, R. (1990) Cell 63, 1349-1356) found that Chinese hamster ovary (CHO) cells expressing the ELFT cDNA had alpha(1,3)Fuc-T activity and were able to bind to E-selectin. In contrast, Lowe et al. (Lowe, J. B., Kukowska-Latallo, J. F., Nair, R. P., Larsen, R. D., Marks, R. M., Macher, B. A., Kelly, R. J., and Ernst, L. K. (1991) J. Biol. Chem. 266, 17467-17477) and Kumar et al. (Kumar, R., Potvin, B., Muller, W. A., and Stanley, P. (1991) J. Biol. Chem. 266, 21777-21783) found no binding to E-selectin of CHO transfectants expressing the same alpha(1,3)Fuc-T gene; nor did the latter transfectants synthesize a known E-selectin ligand, sialylated Le(x) (SLe(x)), although they had substantial alpha(1,3)Fuc-T activity. We now show that these discrepant results were due to a difference between the parental CHO cell lines. Following transfection of ELFT cDNA into Pro-5 or dihydrofolate reductase (DHFR)- CHO cells, only the DHFR- transfectants expressed SLe(x) and bound to E-selectin. Indirect evidence from monoclonal antibody and lectin binding studies indicates that the range of carbohydrate structures synthesized by the Pro-5 and DHFR- CHO cell lines differs. Since DHFR-/ELFT transfectants expressed cell surface SLe(x) but transferred fucose poorly to sialylated substrates in vitro, ELFT may be able to fucosylate a complex carbohydrate missing from Pro-5 cells. Alternatively, either CHO line may have an activity (such as an alpha(2,3)-sialyltransferase), that modifies alpha(1,3)-fucosylated lactosamines.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461; BIOGEN INC,BOSTON,MA 02142	Yeshiva University; Albert Einstein College of Medicine; Biogen				Stanley, Pamela/0000-0001-5704-3747	PHS HHS [R37 30645, P01 13330, R01 30644] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARSOUM J, 1990, DNA CELL BIOL, V9, P293, DOI 10.1089/dna.1990.9.293; CHANDRASEKARAN EV, 1992, J BIOL CHEM, V267, P23806; DEVRIES T, 1992, HISTOCHEM J, V24, P761, DOI 10.1007/BF01046347; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; EASTON EW, 1993, BLOOD, V81, P2978; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FUKUSHI Y, 1984, J BIOL CHEM, V259, P4681; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; HANISCH FG, 1988, CARBOHYD RES, V178, P23, DOI 10.1016/0008-6215(88)80099-5; HANSSON GC, 1985, J BIOL CHEM, V260, P9388; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; JOHNSON PH, 1985, BIOCHEM SOC T, V13, P1119, DOI 10.1042/bst0131119; KANNAGI R, 1982, J BIOL CHEM, V257, P4865; KOJIMA N, 1992, BIOCHEM BIOPH RES CO, V182, P1288, DOI 10.1016/0006-291X(92)91872-N; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LARKIN M, 1992, J BIOL CHEM, V267, P13661; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEEUWENBERG JFM, 1991, EUR J IMMUNOL, V21, P3057, DOI 10.1002/eji.1830211225; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; Liener I.E., 1986, LECTINS; LOBB RR, 1991, J IMMUNOL, V147, P124; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; MACHER BA, 1988, J BIOL CHEM, V263, P10186; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; NGUYEN M, 1992, J BIOL CHEM, V267, P26157; PAREKH RB, 1992, J BIOCH TOKYO D, V16, P137; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POTVIN B, 1991, CELL REGUL, V2, P989, DOI 10.1091/mbc.2.12.989; POTVIN B, 1990, J BIOL CHEM, V265, P1615; RAY MK, 1991, J BIOL CHEM, V266, P22818; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; SINGHAL AK, 1990, CANCER RES, V50, P1375; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANLEY P, 1992, GLYCOBIOLOGY, V2, P99, DOI 10.1093/glycob/2.2.99; STANLEY P, 1975, SOMAT CELL GENET, V1, P3, DOI 10.1007/BF01538729; STANLEY P, 1983, SOMAT CELL GENET, V9, P593, DOI 10.1007/BF01574260; STANLEY P, 1988, J BIOL CHEM, V263, P11374; TETTEROO PAT, 1987, J BIOL CHEM, V262, P15984; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; Vestweber D, 1992, Semin Cell Biol, V3, P211; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003	56	58	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1033	1040						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	7507103				2022-12-27	WOS:A1994MR22000042
